<SEC-DOCUMENT>0001144204-13-022048.txt : 20130416
<SEC-HEADER>0001144204-13-022048.hdr.sgml : 20130416
<ACCEPTANCE-DATETIME>20130416143043
ACCESSION NUMBER:		0001144204-13-022048
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		27
CONFORMED PERIOD OF REPORT:	20121231
FILED AS OF DATE:		20130416
DATE AS OF CHANGE:		20130416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		13763569

	BUSINESS ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v337358_10k.htm
<DESCRIPTION>10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">x</FONT></TD>
    <TD STYLE="width: 93%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ANNUAL REPORT PURSUANT TO
    SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>For the fiscal year ended December 31,
2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 93%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TRANSITION REPORT PURSUANT
    TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>For the transition period from______________________
to____________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 1-12584</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="tlogo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name of small business issuer in its
charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13-3808303</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(State or other jurisdiction of incorporation
    or organization)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(IRS Employer Identification Number)</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>155 Gibbs Street, Suite 412</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Rockville, MD</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>20850</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Address of principal executive offices)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Zip Code)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Securities registered pursuant to Section
    12(b) of the Act:</B></FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Title of Class)</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common Stock, $0.001 par value per share</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NYSE MKT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>None</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp;&nbsp;Yes&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;No&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&nbsp;&nbsp;Yes
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> No&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.&nbsp;Yes&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">No&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of issuer&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every interactive
data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;No </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company.&nbsp;&nbsp;See the
definitions of &ldquo;large accelerated filer, &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in
Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%">&nbsp;</TD>
    <TD STYLE="width: 19%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 26%"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 27%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting company&nbsp;&nbsp; </FONT><FONT STYLE="font: 10pt Wingdings">x</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller reporting company) &nbsp;
    &nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;Yes&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;No&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate market value of the registrant&rsquo;s
common stock held by non-affiliates of the registrant as of June 30, 2012, was approximately $44,969,000 based on $1.98, the price
at which the registrant&rsquo;s common stock was last sold on that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of March 27, 2013, the issuer had 44,654,414 shares of
common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Documents incorporated by reference: None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 76%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART I.</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Business</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1A.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1B.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unresolved Staff Comments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 2.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Properties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 3.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Proceedings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 4.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mine Safety Disclosures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART II.</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 5.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Market for Registrant&rsquo;s Common Equity Related Stockholder
    Matters and Issuer Purchases of Equity Securities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 6.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Selected Financial Data</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 7.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management&rsquo;s Discussion and Analysis of Financial Condition
    and Results of Operations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 7A.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quantitative and Qualitative Disclosures About Market Risk</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 8.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial Statements and Supplementary Data</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Changes in and Discussions with Accountants on Accounting and Financial
    Disclosure</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">52</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9A.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controls and Procedures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">52</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9B.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">52</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART III.</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 10.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Directors, Executive Officers and Corporate Governance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 11.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive Compensation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">55</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 12.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Security Ownership of Certain Beneficial Owners and Management
    and Related Stockholder Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 13.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain Relationships and Related Transactions, and Director Independence</FONT></TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 14.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Accountant Fees and Services</FONT></TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART IV.</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 15.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibits and Financial Statement Schedules</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SIGNATURES</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GLOSSARY</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Most of the matters discussed within
this report include forward-looking statements on our current expectations and projections about future events. In some cases you
can identify forward-looking statements by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; and similar expressions. These statements are based on our current beliefs, expectations, and assumptions
and are subject to a number of risks and uncertainties, many of which are difficult to predict and generally beyond our control,
that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements.
Such risks and uncertainties include the risks noted under &ldquo;Item 1A Risk Factors.&rdquo; We do not undertake any obligation
to update any forward-looking statements. Unless the context requires otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our,&rdquo; and &ldquo;Synthetic Biologics,&rdquo; refer to Synthetic Biologics, Inc. and its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused
on the development of biologics for the prevention and treatment of serious infectious diseases. We are developing an oral enzyme
for the prevention of<I> C. difficile</I> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis
and <I>Acinetobacter</I> infections. In addition, we are developing a drug candidate for the treatment of relapsing-remitting multiple
sclerosis and cognitive dysfunction in multiple sclerosis, and have partnered the development of a treatment for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpgi1.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt"><I>Summary of Infectious Disease Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt">&bull;</TD><TD STYLE="text-align: justify"><B><I>Clostridium difficile (C. difficile)</I> infections:</B> In November 2012, we acquired a series of oral beta-lactamase
enzymes (P1A, P2A and P3A) and related assets targeting the prevention <I>of C. difficile</I> infections (CDI), the leading cause
of hospital acquired infections (HAI), that generally occurs secondary to treatment with intravenous antibiotics. The acquired
assets include a pre-Investigational New Drug (IND) package for P3A (SYN-004), Phase I and Phase II clinical data for P1A, manufacturing
processes and data, and a portfolio of issued and pending U.S. and international patents intended to support an IND and Biologic
License Application (BLA) with the FDA. Utilizing this portfolio of assets, we intend to develop a proprietary oral beta-lactamase
enzyme product candidate, SYN-004, previously known as IPSAT P3A. When co-administered with certain intravenous beta-lactam antibiotics,
it is expected that SYN-004 can degrade the antibiotic that is excreted in the gastrointestinal (GI) tract, thus preserving the
natural balance of the patient's microflora, and preventing opportunistic<I> </I>infections including CDI. Beta-lactam antibiotics
are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.
According to GlobalData, an estimated 8.7 million Americans were administered intravenous beta-lactam antibiotics in 2011.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>Pertussis:</B> In December 2012, in collaboration with Intrexon Corporation (Intrexon), we </FONT>initiated
development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more commonly known as whooping cough.
We are developing a mAb therapy, SYN-005, designed to target and neutralize the pertussis toxin, in order to reduce the mortality
rate in infants and potentially shorten the duration of chronic cough in afflicted adults. To further the development of this potential
therapy for Pertussis, we entered into an agreement with The University of Texas at Austin to license the rights to certain research
and pending patents related to pertussis antibodies. According to the World Health Organization, each year, <I>B. pertussis </I>infection
causes an estimated 294,000 deaths worldwide, primarily among young, unvaccinated children.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt">&bull;</TD><TD STYLE="text-align: justify"><B><I>Acinetobacter </I>infections:</B> In September 2012, in collaboration with Intrexon, we initiated efforts to develop
a mAb therapy for the treatment of <I>Acinetobacter</I> infections. Many strains of<I> Acinetobacter</I> are multidrug-resistant
and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected by natural disasters.
A treatment for <I>Acinetobacter</I> infections represents a multi-billion dollar market opportunity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><I>Summary of Multiple
Sclerosis Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt">&bull;</TD><TD STYLE="text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is being developed as an oral once-daily treatment for relapsing-remitting multiple sclerosis
(MS) in women. Patient enrollment is complete in this two-year, randomized, double-blind, placebo-controlled Phase II clinical
trial being conducted at 15 centers in the U.S. The primary endpoint is relapse rate at two years, with top-line results expected
in 1H 2014. This trial is supported by grants exceeding $8 million, which should be sufficient to fund the trial through completion.
Current sales of injectable disease-modifying therapies for MS are estimated at $8.9 billion annually.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.6pt; text-align: justify; text-indent: -13.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt"><FONT STYLE="color: black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">Trimesta<SUP>TM</SUP> is also being developed for the treatment of cognitive dysfunction in female
MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at University of
California, Los Angeles (UCLA). The primary endpoint is the effect on cognitive function as assessed by </FONT>Paced Auditory Serial
Addition Test (PASAT). <FONT STYLE="color: black">Patient enrollment is ongoing. The majority of the costs of this trial are being
funded by grants from foundations and charitable organizations and we have pledged approximately $500,000 to UCLA to partially
fund this trial payable over three years. An estimated 50-65% of MS patients are expected to develop disabilities due to cognitive
dysfunction and there is currently no approved treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.6pt; text-align: justify; text-indent: -13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-align: justify"><I>Summary of Fibromyalgia Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt"><FONT STYLE="color: black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">Effirma<SUP>TM</SUP> (flupirtine) is being developed for the treatment of fibromyalgia by Meda AB
(Meda), a multi-billion dollar international pharmaceutical company. On May 6, 2010, we entered into a sublicense agreement with
Meda covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. The sublicense
agreement provides that all ongoing and future development costs are to borne by Meda and we are entitled to receive certain payments
if milestones are achieved and royalties on sales. </FONT>According to Meda&rsquo;s 2012 Year-End Report filed in February 2013,
Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the treatment of fibromyalgia. Meda
also announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be conducted
at 25 clinics in the U.S. <FONT STYLE="color: black">Based on an estimated annual price of $1,200 per fibromyalgia patient, we
estimate that the total market potential in the U.S. is $6 billion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To prioritize our focus on the<FONT STYLE="color: black">
development of product candidates for the prevention and treatment of serious infectious diseases, we do not intend to pursue</FONT>
further development of our previously announced program for pulmonary arterial hypertension. However, we are currently in discussions
with Intrexon to substitute this program with an alternate program better suited to our current objectives and focus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to further prioritize our focus,
we have elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, we are
currently seeking development partners for our zinc-based intellectual property and assets including, AEN-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>Pipeline Programs and Therapeutic
Areas</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Infectious Disease Programs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are focused on the development of biologics
for the prevention and treatment of serious infectious diseases. Infectious disease outbreaks are increasing while intervention
options are declining due to widespread multidrug-resistant bacteria, increasing numbers of immuno-compromised patients (eg. the
elderly and cancer patients), and the isolation of new pathogens. <FONT STYLE="color: black">We are developing an oral enzyme for
the prevention of<I> C. difficile</I> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis
and <I>Acinetobacter</I> infections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>C. difficile Infections</I>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Agency for Healthcare
Research and Quality, aggregate costs associated with CDI-related stays in the hospital were $8.2 billion in the U.S. during 2009.
CDI is a rising global HAI problem in which the toxins produced by <I>C. difficile</I> bacteria result in diarrhea (<I>C. difficile</I>-associated
diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the lower GI tract) that can lead to death.
CDI is a major, unintended risk associated with the prophylactic or therapeutic use of intravenous antibiotics, which may alter
the natural balance of microflora that normally protect the GI tract, leading to <I>C. difficile</I> overgrowth and infection.
Other risk factors for CDI include hospitalization, prolonged length of stay, underlying illness, immune-compromising conditions
including the administration of chemotherapy, and advanced age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CDI is a widespread and often drug resistant
infectious disease, resulting in more than 337,000 hospitalizations and 30,000 deaths in the U.S. during 2009, according to the
U.S. Department of Health &amp; Human Services. CDI has surpassed methicillin-resistant staphylococcus aureus (MRSA) as the most
frequent infection acquired in the hospital. It has recently been reported by The Centers for Disease Control and Prevention that
the current number of CDI cases may be as high as 500,000 annually in the U.S. Controlling the spread of CDI has proven challenging,
as the <I>C. difficile</I> spores are easily transferred to patients via normal contact with healthcare personnel and other inanimate
objects. There is currently no vaccine or approved product for the prevention of <I>C. diff</I> infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>C. difficile: Acquisition of Clinical-Stage
Program</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2012, we acquired a series
of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention CDI, the leading cause of HAIs, that
generally occurs secondary to treatment with intravenous antibiotics. The acquired assets include a pre-IND package for P3A (SYN-004),
Phase I and Phase II clinical data for P1A, manufacturing processes and data, and a portfolio of issued and pending U.S. and international
patents intended to support an IND and BLA with the FDA. Utilizing this portfolio of assets, we intend to develop a proprietary
oral beta-lactamase enzyme product candidate, SYN-004, previously known as IPSAT P3A. When co-administered with certain intravenous
beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the GI tract, thus preserving
the natural balance of the patient's microflora, and preventing opportunistic<I> </I>infections including CDI. Beta-lactam antibiotics
are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.
According to GlobalData, an estimated 8.7 million Americans were administered intravenous beta-lactam antibiotics in 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>C. difficile: Oral Enzyme Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We acquired a series of oral beta-lactamase
enzymes (P1A, P2A and P3A). Beta-lactamase enzymes have the ability to degrade beta-lactam antibiotics that may be excreted into
the GI tract. P1A (the first generation candidate) showed acceptable safety and tolerability in a Phase I study. In addition, two
Phase II clinical studies demonstrated that P1A had the ability to preserve GI microflora in hospitalized patients treated with
intravenous ampicillin or the combination of piperacillin and tazobactam.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>C. difficile: Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compared to the first generation oral enzyme
candidate, P1A, we believe that SYN-004 (formerly P3A) will have activity against a broader spectrum of beta-lactam antibiotics,
including both penicillins and most cephalosporins. Due to the structural similarities between P1A and SYN-004 for the prevention
of CDI, along with previous discussions with the FDA, it is anticipated that certain preclinical data collected on P1A may be used
in support of an IND for our new product candidate, SYN-004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Monoclonal Antibodies:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Monoclonal Antibodies for Infectious
Diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acting as the body's army, antibodies are
proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such as viruses and
bacteria and their associated toxins. MAbs can also be designed and produced as therapeutic agents, utilizing protein engineering
and recombinant production technologies. The mAbs being developed under our collaboration with Intrexon are intended to supplement
a patient's own immune system by providing the means to specifically and rapidly neutralize and/or clear specific pathogens and
toxins of interest in a process known as &ldquo;passive immunity&rdquo;. Many pathogens that cause infectious diseases are innately
resistant to, or over time have developed increased resistance to, antibiotics and other drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Intrexon Collaboration: Monoclonal Antibodies
for Infectious Diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2012, we entered into a worldwide
exclusive channel collaboration with Intrexon through which we intend to develop a series of mAb therapies for the treatment of
certain infectious diseases not adequately addressed by existing therapies. Utilizing Intrexon&rsquo;s comprehensive suite of proprietary
technologies, including the mAbLogix&trade; platform for rapid discovery of fully human mAbs and the LEAP&trade; cell processing
station, our initial efforts will target three infectious disease indications. We also have the option to target an additional
five infectious disease indications under this collaboration. To date, we have initiated development of a mAb therapy for the treatment
of Pertussis and <I>Acinetobacter</I> infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(mAbLogix<SUP>TM</SUP> and LEAP<SUP>TM</SUP>
are registered trademarks of Intrexon Corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pertussis (Whooping Cough):</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Bordetella pertussis (B. pertussis)
</I>is a gram-negative bacterium that infects the upper respiratory tract, causing uncontrollable, violent coughing. Antibiotic
treatment does not have a major effect on the course of Pertussis, because while it can eliminate the <I>B. pertussis </I>bacteria
from the respiratory tract, it does not neutralize the pertussis toxin. Infants with Pertussis often require hospitalization in
pediatric intensive care units, frequently requiring mechanical ventilation. Pertussis in adults generally leads to a chronic cough
referred to as the "cough of 100 days." The incidence of Pertussis is increasing in association with exposure of unvaccinated
and under-vaccinated individuals including infants who are not yet fully vaccinated, exposure of individuals whose immunity has
diminished over time, as well as asymptomatic carriers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the World Health Organization,
each year, <I>B. pertussis </I>infection causes an estimated 294,000 deaths worldwide, primarily among young, unvaccinated children.
Recent news reports throughout the U.S. indicate that the pertussis vaccine introduced in the 1990s does not provide long-term
protection and, as a result, whooping cough cases are increasing to a 60-year high. There is no approved treatment for Pertussis,
and antibiotic treatment does not have a major effect on the course of Pertussis, because while it can eliminate the <I>B. pertussis
</I>bacteria from the respiratory tract, it does not neutralize the pertussis toxin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pertussis: Intrexon Collaboration and
The University of Texas at Austin Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2012, we initiated mAb development
for the treatment of Pertussis focusing on toxin neutralization pursuant to our August 2012 collaboration with Intrexon. Unlike
antibiotics, we are developing a mAb therapy, SYN-005, to target and neutralize the pertussis toxin, in order to reduce the mortality
rate in infants and potentially shorten the duration of chronic cough in afflicted adults. SYN-005 is currently in preclinical
studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To further the development of this potential
therapy for pertussis, we have entered into an agreement with The University of Texas at Austin to license the rights to certain
research and pending patents related to pertussis antibodies. These research efforts are being conducted at the Cockrell School
of Engineering in the laboratory of Assistant Professor, Jennifer A. Maynard, Ph.D., the Laurence E. McMakin, Jr. Centennial Faculty
Fellow in the McKetta Department of Chemical Engineering. Dr. Maynard brings to the project her expertise in defining the key neutralizing
epitopes of pertussis toxin to optimize the potential efficacy of antibody therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Acinetobacter Infections:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Acinetobacter baumanii</I> is a difficult
to treat pathogen due to its rapid and well-established development of resistance to most antibiotics, making it a multidrug-resistant
pathogen. In addition, as a biofilm-forming pathogen, <I>Acinetobacter baumanii</I> has the ability to survive up to twice as long
as non-biofilm-forming pathogens. In the U.S., <I>Acinetobacter</I> <I>baumanii</I> has been reported to be the cause of up to
2.6% of hospital acquired infections, 1.3% of bloodstream infections and 7% of ICU respiratory tract infections, and more than
half of the <I>Acinetobacter baumanii</I> isolates are multidrug-resistant. According to published articles, mortality rates as
high as 43% are reported in hospital and ICU settings. While <I>Acinetobacter baumanii</I> is a well-documented pathogen in the
hospital setting, this pathogen also poses an increasing danger to wounded servicemen and women in military treatment centers and
to those treated in trauma centers following natural disasters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A treatment for <I>Acinetobacter</I> infections
represents a multi-billion dollar market opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Acinetobacter: Intrexon Collaboration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2012, we initiated a mAb discovery
and development program for <I>Acinetobacter </I>infections pursuant to our August 2012 collaboration with Intrexon. Discovery
efforts for the development of a mAb are currently underway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Multiple Sclerosis Program</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Relapsing-Remitting MS in Women:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MS is a progressive neurological
disease in which the body loses the ability to transmit messages along central nervous system nerve cells, leading to pain,
loss of muscle control, paralysis, cognitive impairment and in some cases death. According to the National Multiple Sclerosis
Society (NMSS), more than 2.5 million people worldwide (approximately 400,000 patients in the U.S. of which approximately 70%
are women) have been diagnosed with MS. The diagnosis is typically made in young adults, ages 20 to 50. According to the
NMSS, approximately 85% of MS patients are initially diagnosed with the relapsing-remitting form, and 10-15% with other
progressive forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are ten FDA-approved
therapies for the treatment of relapsing-remitting MS: Betaseron<SUP>&reg;</SUP>, Rebif<SUP>&reg;</SUP>,
Avonex<SUP>&reg;</SUP>, Novantrone<SUP>&reg;</SUP>, Copaxone<SUP>&reg;</SUP>, Tysabri<SUP>&reg;</SUP>,
Gilenya<SUP>&reg;</SUP>, Extavia<SUP>&reg;</SUP>, Aubagio<SUP>&reg;</SUP> and Tecfidera<SUP>TM</SUP>. Many of these therapies
provide only a modest benefit for patients with relapsing-remitting MS. All of these drugs except Gilenya<SUP>&reg;</SUP> and
Tecfidera<SUP>TM</SUP> require frequent (daily, weekly &amp; monthly) injections (or infusions) on an ongoing basis and can
be associated with unpleasant side effects (such as flu-like symptoms) and high rates of non-compliance among users. Despite
the availability of therapies for the treatment of relapsing-remitting MS, the disease is highly underserved and exacts a
heavy personal and economic toll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current sales of injectable disease-modifying
therapies for MS are estimated at $8.9 billion annually.&nbsp; According to various reports, sales of oral disease-modifying therapies
for MS, such as Trimesta, if and when approved, are anticipated to grow from $500 million in 2010 to in excess of $5 billion annually
by 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Relapsing-Remitting MS: Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research has shown that pregnant women
with MS tend to experience a spontaneous reduction of disease symptoms during pregnancy, particularly in the third trimester. The
PRIMS (Pregnancy In MS) study, a landmark clinical study published in the <I>New England Journal of Medicine</I> followed 254 women
with MS during 269 pregnancies and for up to one year after delivery. The PRIMS study demonstrated that relapse rates were significantly
reduced by 71% (p &lt; 0.001) through the third trimester of pregnancy compared to pre-pregnancy-rates, and that relapse rates
increased by 120% (p &lt; 0.001) during the first three months after birth (post-partum) and then return to pre-pregnancy rates.
It has been hypothesized that the female hormone, estriol, produced by the placenta during pregnancy, plays a role in&nbsp;&ldquo;fetal
immune privilege&rdquo;, a process that prevents&nbsp;a mother&rsquo;s immune system from attacking and rejecting the fetus.&nbsp;The
maternal levels of estriol increase linearly through the third trimester of pregnancy until birth, whereupon it abruptly returns
to low circulating levels. The anti-autoimmune effects of estriol are thought to be responsible for the therapeutic effects of
pregnancy on MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rhonda Voskuhl, M.D., Director, UCLA MS
program, UCLA Department of Neurology, has found that plasma levels of estriol achieved during pregnancy have potent immunomodulatory
effects. She further postulated and tested in a pilot clinical study that oral doses of estriol may have a therapeutic benefit
when administered to non-pregnant female MS patients by, in essence, mimicking the spontaneous reduction&nbsp;in relapse rates
seen in MS patients during pregnancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estriol has been approved and marketed
for over 40 years throughout Europe and Asia for the oral treatment of post-menopausal symptoms. It has never been approved by
the U.S. FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Relapsing-Remitting MS: Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trimesta (oral estriol) is being developed
for the treatment of relapsing-remitting MS in women. An investigator-initiated, 10-patient, 22-month, single-agent, crossover
clinical trial to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female relapsing-remitting
MS patients was completed in the U.S. The total volume and number of gadolinium-enhancing lesions were measured by brain magnetic
resonance imaging (an established neuroimaging measure of disease activity in MS). Over the next three months of treatment with
Trimesta, the median total enhancing lesion volumes decreased by 79% (p = 0.02) and the number of lesions decreased by 82% (p =
0.09). They remained decreased during the next 3 months of treatment, with lesion volumes decreased by 82% (p = 0.01), and numbers
decreased by 82% (p =0.02). Following a six-month drug holiday during which the patients were not on any drug therapies, median
lesion volumes and numbers returned to near baseline pretreatment levels. Trimesta therapy was reinitiated during a four-month
retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion
volumes of 88% (p = 0.008) and a decrease in the number of lesions by 48% (p = 0.04) compared with original baseline scores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Phase II randomized, double-blind, placebo-controlled
clinical trial is currently underway at 15 centers in the U.S. under the direction of Lead Principal Investigator, Dr. Rhonda Voskuhl.
The purpose of this clinical trial is to evaluate whether 8 mg of oral Trimesta taken daily over a two year period will reduce
the rate of relapses in a large population of female patients with relapsing-remitting MS. Investigators are administering either
Trimesta or matching placebo, in addition to a standard of care, glatiramer acetate injections (Copaxone<SUP>&reg;</SUP>), an FDA-approved
therapy for MS, to women between the ages of 18 to 50 who have been recently diagnosed with relapsing-remitting MS. Relapse rates
at two years is the primary endpoint in this clinical trial being run under an investigator-initiated IND. As of January 23, 2012,
164 patients have been enrolled and enrollment has been closed. The patients will be dosed and monitored for two years with the
last patient scheduled to complete two years of therapy in January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With over $8 million in grant funding
to date, the ongoing Trimesta clinical trial should be funded to its completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cognitive Dysfunction in MS:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the NMSS and the Multiple
Sclerosis Society of Canada publication, <I>Hold that Thought! Cognition and MS</I>, it is fairly common for people with MS to
complain of cognitive difficulties, such as remembering things, finding the right words and the ability to concentrate. Among MS
patients, 50-65% have some degree of cognitive dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The major areas of cognition that may be
affected include complex attention and executive functions<I>.</I> Complex attention involves multitasking, the speed with which
information can be processed, learning and memory, and perceptual skills; executive functions include problem solving, organizational
skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of MS-related physical problems can
widely vary, not all people with MS will have cognitive dysfunction, and no two people will experience exactly the same type or
severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cognitive Dysfunction in MS: Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the investigator-initiated, 10-patient,
22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant 14% improvement from
baseline in the PASAT cognitive testing scores (p = 0.04) was observed in relapsing-remitting MS patients after six months of Trimesta
therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS.
The PASAT scores are expressed as a mean percent change from baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cognitive Dysfunction in MS: Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Trimesta (oral estriol) drug candidate
is also being developed for the treatment of cognitive dysfunction in female MS patients. This randomized, double-blind, placebo-controlled
Phase II clinical trial to evaluate Trimesta&rsquo;s potential neuroprotective and therapeutic effect on cognitive dysfunction
in female MS patients is currently enrolling relapsing-remitting or secondary-progressive female MS patients at UCLA. Up to 64
patients between the ages of 18 and 50 will be randomized 1:1 into the treatment and placebo groups. Dr. Voskuhl will administer
either oral Trimesta or a matching placebo, in addition to any FDA-approved MS treatment. Each patient will be dosed and monitored
for one year after being enrolled. The primary endpoint in this clinical trial being run under an investigator-initiated IND application
is expected to be improvement in PASAT cognitive testing scores versus matching placebo. We and a private foundation have pledged
to equally support this new clinical trial, and we will also provide Trimesta drug supply. The trial also received contributions
from several other supporters. Patient recruitment and enrollment into this trial is ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Fibromyalgia Program</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fibromyalgia is a chronic and debilitating
condition characterized by widespread pain and stiffness throughout the body, often accompanied by severe fatigue, insomnia and
alterations in mood. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 3-6% of the population
worldwide, including an estimated 10 million people in the U.S. There are presently three FDA products approved for the treatment
of fibromyalgia &ndash; Lyrica<SUP>&reg;</SUP>, Cymbalta<SUP>&reg;</SUP> and Savella<SUP>&reg;</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an estimated annual price of $1,200 per fibromyalgia
patient, we estimate that the total market potential in the U.S. is $6 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fibromyalgia</I>: <I>Meda Corporate
Partnership</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, we entered into a sublicense
agreement with Meda, a multi-billion dollar international pharmaceutical company, pursuant to which Meda assumed all future development
costs and may commercialize flupirtine, a molecular entity with a unique mode of action for the treatment fibromyalgia in the
U.S. As consideration for such sublicense, we received an up-front payment of $2.5 million and are entitled to milestone payments
of $5 million upon the FDA&rsquo;s acceptance of the New Drug Application (NDA) for flupirtine for fibromyalgia and $10 million
upon FDA approval of such NDA. Pursuant to the sublicense agreement, we will also receive a 7% royalty on net sales of flupirtine
for fibromyalgia in the U.S., Canada and Japan, with such royalties being shared equally with our licensor, McLean Hospital, a
Harvard teaching hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Flupirtine is approved and marketed by
Meda and its distributors in Europe and other countries for indications other than fibromyalgia and has been prescribed to millions
of patients worldwide. We believe that such substantial human experience with flupirtine should greatly assist the FDA in its evaluation
of the safety of flupirtine upon review of an NDA of flupirtine for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fibromyalgia</I>: <I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Effirma (flupirtine) drug candidate
for the treatment of fibromyalgia, has been partnered to Meda (see &ldquo;Fibromyalgia: Meda Corporate Partnership&rdquo; section
above). Effirma is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties. Effirma is
a non-opioid, non-NSAID, non-steroidal, analgesic. Preclinical data and clinical experience suggest that Effirma should also be
effective for neuropathic pain since it acts in the central nervous system via a mechanism of action distinguishable from most
marketed analgesics. Effirma is especially attractive because it operates through non-opiate pain pathways, exhibits no known abuse
potential, and lacks withdrawal effects. In addition, no tolerance to its antinocioceptive effects has been observed. One common
link between neuroprotection, nocioception and Effirma may be the N-methyl-D-aspartic acid glutamate system, a major receptor subtype
for the excitotoxic neurotransmitter, glutamate. Effirma has strong inhibitory actions on N-methyl-D-aspartic acid-mediated neurotransmission.
Flupirtine was originally developed by Asta Medica (subsequently acquired by Meda) and has been approved and is marketed by Meda
in Europe since 1984, as well as other countries, for the treatment of pain. It has never been approved by the FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Meda&rsquo;s 2012 Year-End
Report filed in February 2013, Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the
treatment of fibromyalgia. Meda also announced that the randomized, double-blind, placebo and active-controlled study of patients
with fibromyalgia will be conducted at 25 clinics in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our goal is to (a) obtain, maintain, and
enforce patent protection for our products, formulations, processes, methods, and other proprietary technologies, (b) preserve
our trade secrets, and (c) operate without infringing on the proprietary rights of other parties, worldwide. We seek, where appropriate,
the broadest intellectual property protection for product candidates, proprietary information, and proprietary technology through
a combination of contractual arrangements and patents. Below is a description of our license and development agreements relating
to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The University of Texas at Austin License
Agreement and Sponsored Research Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 19, 2012, we entered into a
Patent License Agreement (the &ldquo;Texas License Agreement&rdquo;) with The University of Texas at Austin (the &ldquo;University&rdquo;)
for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related
to pertussis antibodies developed in the lab of Dr. Jennifer A. Maynard, Assistant Professor of Chemical Engineering. The Texas
License Agreement provides that the University is entitled to payment of past patent expenses, an annual payment of $50,000 per
year commencing on the effective date through December 31, 2014 and a $25,000 payment on December 31, 2015 and milestone payments
of $50,000 upon commencement of Phase I Clinical Trials, $100,000 upon commencement of Phase III Clinical Trials, $250,000 upon
NDA submission in the United States, $100,000 upon European Medicines Agency approval and $100,000 upon regulatory approval in
an Asian country. In addition, the University is entitled to a running royalty upon Net Product Sales and Net Service Sales (as
defined in the Texas License Agreement). The License Agreement terminates upon the expiration of the patent rights (as defined
in the Texas License Agreement); provided, however that the Texas License Agreement is subject to early termination by us in our
discretion and by the University for a breach of the Texas License Agreement by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Texas License Agreement,
we also entered into a Sponsored Research Agreement (the &ldquo;Sponsored Research Agreement&rdquo;) with the University pursuant to which
the University will perform certain research work related to pertussis under the direction of Dr. Jennifer Maynard and we will
obtain certain rights to patents and technology developed during the course of such research. All inventions conceived during such
research shall be subject to the Texas License Agreement. The Sponsored Research Agreement may be renewed annually, in our sole discretion,
after the first year for two additional one year terms with a fixed fee for the first year of $303,287 and for the second and third
years, if renewed, a fixed fee of $316,438 and $328,758 respectively, all payable in quarterly installments. If renewed by us after
the first year for the remaining two years, the research shall be performed from the effective date of the Sponsored Research Agreement until
December 31, 2015; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the
parties, a default in the material obligations under the Sponsored Research Agreement which remain uncured for sixty days after receipt of
notice, automatically upon our bankruptcy or insolvency and by us in our sole discretion at any time after the one year anniversary
of the date of execution thereof upon no less than 90 days notice. Upon termination prior to December 31, 2014, we shall only be
responsible for payment of expenses that do not exceed the fixed annual amount and are incurred prior to the termination date and
non-cancellable expenses committed to be expended by the University prior to the termination date for the lesser of the remainder
of their appointment in the case of salaries and December 31, 2014. Upon a termination after December 31, 2014 or due to a breach
by the University, we shall only be responsible for all reasonable expenses that do not exceed the fixed annual amount and that
are incurred by the University prior to the termination date for services performed prior to the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Oral Enzyme for C. difficile Program
Acquisition Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">On
November 8, 2012, we entered into an Asset Purchase Agreement (the &ldquo;Prev Agreement&rdquo;) with Prev ABR LLC
(&ldquo;Prev&rdquo;), and subsequently closed the transaction o</FONT>n November 28, 2012. Pursuant to the Prev Agreement we
acquired the <I>C. difficile</I> program assets of Prev, including <FONT STYLE="color: black">pre-IND package for P3A
(SYN-004), Phase I and Phase II clinical data for P1A, manufacturing processes and data, and a portfolio of issued and
pending U.S. and international patents intended to support an IND and BLA with the FDA</FONT>. Pursuant to the Prev
Agreement, we paid Prev an initial cash payment of $100,000 upon execution of the Prev Agreement and at closing paid an
additional cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to Prev. In addition, upon the
achievement of the milestones set forth below, Prev may be entitled to receive additional consideration payable 50% in cash
and 50% in our stock, subject to Prev&rsquo;s option to receive the entire payment in shares of our stock, with the exception
of the first milestone payments to be paid in cash: (i) upon commencement of an IND; (ii) upon commencement of a Phase I
clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon commencement of a Phase III clinical trial;
(v) upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S. (as defined in the
Prev Agreement); and (vi) upon BLA approval in the U.S. and upon approval in territories outside the U.S. The future stock
issuances are subject to prior approval of the NYSE MKT, LLC. No royalties are payable to Prev under the Prev Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Prev Agreement also provides that Prev has
a right to the return to it of all assets acquired by us under the Prev Agreement if on or prior to the date that is (i) thirty (30)
months after the execution of the Prev Agreement, we have not initiated toxicology studies in non-rodent models or (ii) thirty six (36)
months have not filed an IND under the program related to the assets and such failure is not due to action or inaction of Prev
or breach of its representations or warranties or covenants or if there is a change of control as defined in the Prev Agreement and
after such change of control the assets are not further developed; provided however that such thirty (30) and thirty six (36) month
periods can be extended by us for an additional twelve (12) months upon payment of a cash milestone payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Infectious Disease Collaboration with
Intrexon</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2012, we expanded our relationship
with Intrexon and entered into a second Exclusive Channel Collaboration Agreement (the &ldquo;Second Channel Agreement&rdquo;)
with Intrexon that governs a &ldquo;channel collaboration&rdquo; arrangement in which we will use Intrexon&rsquo;s technology relating
to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a
series of monoclonal antibody therapies for the treatment of certain serious infectious diseases the &ldquo;Program&rdquo;) for
the treatment of eight specific target infectious disease indications (the &ldquo;Field&rdquo;). Initially, our development efforts
will target three infectious diseases within the Field. Within the first two years of the collaboration, we have the right to exchange
our initial three targets on a one-for-one basis with any of the other five targeted infectious diseases in the Field at no additional
cost. We also have the option, within such two year period, to choose to develop any or all of the other five target diseases in
the Field, upon payment of the additional consideration described below. Such license is exclusive with respect to any clinical
development, selling, offering for sale or other commercialization of our products within the Field (&ldquo;Synthetic Products&rdquo;),
and otherwise is non-exclusive. We may not sublicense the rights described without Intrexon&rsquo;s written consent. Under the
Second Channel Agreement, and subject to certain exceptions, we are responsible for, among other things, the performance of the
Program including the development, commercialization and manufacturing of products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain expense allocations
and other offsets provided in the Second Channel Agreement, we will pay Intrexon royalties on annual net sales of the Synthetic
Products, calculated on a Synthetic Product-by-Synthetic Product basis. We have likewise agreed to pay Intrexon a percentage of
quarterly revenue obtained from a sublicensor in the event of a sublicensing arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the first 18 months, we may not
terminate the Second Channel Agreement, except under limited circumstances. Following the first 18 months, we may voluntarily terminate
the Second Channel Agreement upon 90 days written notice to Intrexon.&nbsp; Intrexon may also terminate the Second Channel Agreement
if we elect not to pursue the development of a Program identified by Intrexon that is a &ldquo;Superior Therapy&rdquo; as defined
in the Second Channel Agreement upon 60 days notice unless we remedy the circumstances giving rise to the termination during such
notice period. Each party has the right to terminate the agreement upon 60 days notice if the other party commits a material breach
of the Second Channel Agreement, subject to certain cure periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon termination of the Second Channel
Agreement, we may continue to develop and commercialize any Synthetic Product that, at the time of termination satisfies one of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">is being commercialized by us,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">has received regulatory approval,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">is a subject of an application for regulatory approval that is pending before the applicable regulatory authority,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">is a subject of at least a Phase 2 or Phase 3 clinical trial if such termination is by Intrexon due to a material breach by
us of the Second Channel Agreement or by us upon 60 days notice after the first 18 months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our obligation to pay the royalties described
above with respect to these &ldquo;retained&rdquo; products will survive termination of the Second Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 16, 2012, we
issued 3,552,210 shares of our Common Stock as consideration in connection with the Second Channel Agreement and the
related Stock Issuance Agreement with Intrexon that we entered into on August 6, 2012 (the &ldquo;Second Stock Issuance
Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also agreed upon the filing of an Investigational
New Drug application with the U.S. Food and Drug Administration for a Synthetic Product, or alternatively the filing of the first
equivalent regulatory filing with a foreign regulatory agency (both as applicable, the &ldquo;IND Milestone Event&rdquo;), to pay
Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares of Common Stock (the &ldquo;IND Milestone
Shares&rdquo;) having a fair market value equaling two million dollars ($2M) where such fair market value is determined using published
market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public
announcement of attainment of the IND Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the first to occur of either first
commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both
as applicable, the &ldquo;Approval Milestone Event&rdquo;), we agreed to pay to Intrexon either (i) three million dollars ($3M)
in cash, or (ii) that number of shares of Common Stock (the &ldquo;Approval Milestone Shares&rdquo;) having a fair market value
equaling three million dollars ($3M) where such fair market value is determined using published market data of the share price
for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment
of the Approval Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also agreed that we will pay an optional
and varying fee whereby we remit a payment, in cash or equity at our sole discretion, to Intrexon calculated as a multiple of the
number of targets in excess of three (3) total that we desire to elect (the &ldquo;Field Expansion Fee&rdquo;). The Field Expansion
Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for
each target in excess of three (3) total that we elect, or (ii) that number of shares of Common Stock (the &ldquo;Field Expansion
Fee Shares&rdquo;) having a fair market value equaling two million dollars ($2M) for each such target that we elect in excess of
three where such fair market value is determined using published market data establishing the volume-weighted average price for
a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field Expansion Fee Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the transactions
contemplated by the Second Stock Issuance Agreement, and pursuant to the First Amendment to Registration Rights Agreement
(the &ldquo;First Amendment to Registration Rights Agreement&rdquo;) executed and delivered by the parties at the closing,
we agreed to file a &ldquo;resale&rdquo; registration statement registering the resale of certain of the shares issued
under the Second Stock Issuance Agreement. None of the shares to be issued under the Second Stock Issuance Agreement need to
be registered until<FONT STYLE="color: #1F497D"> </FONT>April 30, 2013. Under that agreement, we are obligated to use
our reasonable best efforts to cause the &ldquo;resale&rdquo; registration statement to be declared effective as promptly
as practicable after filing and to maintain the effectiveness of the registration statement until all securities therein
are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>DNA-Based Therapy Collaboration with
Intrexon</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, we entered into a
Channel Agreement with Intrexon (the &ldquo;Channel Agreement&rdquo;) that governs an &ldquo;exclusive channel collaboration&rdquo;
arrangement in which we intend to use Intrexon&rsquo;s technology directed towards the production of prostaglandin synthase (PGIS),
through the use of <I>in vivo</I> conditionally regulated embedded controllable bioreactors for the treatment of PAH. The Channel
Agreement establishes committees comprised of our and Intrexon representatives that will govern activities related to the PAH program
in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization
efforts and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Channel Agreement grants us a worldwide
license to use specified patents and other intellectual property of Intrexon in connection with the research, development, use,
importing, manufacture, sale, and offer for sale of products involving the production of PGIS through the use of an <I>in vivo</I>
conditionally regulated embedded controllable bioreactor for the treatment of PAH in humans. Such license is exclusive with respect
to any clinical development, selling, offering for sale or other commercialization of Products, and otherwise is non-exclusive.
We may not sublicense the rights described without Intrexon&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Channel Agreement, and subject
to certain exceptions, we are responsible for, among other things, the performance of the PAH program including the development,
commercialization and certain aspects of manufacturing products. Among other things, Intrexon is responsible for the costs of establishing
manufacturing capabilities and facilities for the bulk manufacture of products developed under the PAH program, certain other aspects
of manufacturing, costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and
maintenance of Intrexon&rsquo;s patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain expense allocations
and other offsets provided in the Channel Agreement, we will pay Intrexon 50% of the cumulative net quarterly profits derived from
the sale of products, calculated on a product-by-product basis. We have likewise agreed to pay Intrexon 50% of quarterly revenue
obtained from a sublicensor in the event of a sublicensing arrangement. During the first 18 months, neither we nor Intrexon may
terminate the Channel Agreement, except under limited circumstances. Following the first 18 months, we may voluntarily terminate
the Channel Agreement upon 90 days written notice to Intrexon. Following the first 18 months, Intrexon may also terminate the Channel
Agreement if we elect not to pursue the development of a PAH program identified by Intrexon that is a &ldquo;Superior Therapy&rdquo;
as defined in the Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon termination of the Channel Agreement,
we may continue to develop and commercialize any Product that, at the time of termination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: justify">is being commercialized by us,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: justify">has received regulatory approval,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: justify">is a subject of an application for regulatory approval that is pending before the applicable regulatory authority,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: justify">is the subject of at least an ongoing Phase II clinical trial (in the case of a termination by Intrexon due to our uncured
breach or a voluntary termination by us), or an ongoing Phase I clinical trial in the Field (as defined in the Channel Agreement)
(in the case of a termination by us due to an Intrexon uncured breach or a termination by Intrexon following an unconsented assignment
by us or our election not to pursue development of a Superior Therapy), or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">&bull;</TD><TD STYLE="text-align: justify">we have spent at least $4.5 million developing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will be obligated to pay 50% of net
profits or revenue with respect to these &ldquo;retained&rdquo; products, which will survive termination of the Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As consideration
for execution of the Channel Agreement, we entered into a Stock Purchase Agreement with Intrexon (the &ldquo;Stock
Purchase Agreement&rdquo;) pursuant to which we issued to Intrexon a number of shares of our common stock equal to 9.995% of
the number of shares of our common stock issued and outstanding following and giving effect to such issuance (the
&ldquo;First Tranche&rdquo;) at a purchase price equal to the $0.001 par value of such shares, which issuance was deemed paid
in consideration for the execution and delivery of the Channel Agreement. We also agreed to issue additional shares
of our common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored by us in the U.S., or
similar study as the parties may agree in a country other than the U.S. The program under this Channel Agreement is in the
discovery stage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Stock Purchase Agreement, Intrexon
is entitled, at its election, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) participate in our future securities
offerings that constitute &ldquo;Qualified Financings&rdquo; and purchase securities equal to 19.99% of the number of shares of
common stock or other securities sold in such offering. For this purpose, a &ldquo;Qualified Financing&rdquo; means a sale of our
common stock or equity securities convertible into our common stock in a public or private offering, raising gross proceeds of
at least $5 million, where the sale of shares is either registered under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), at the time of issuance or we agree to register the resale of such shares, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) without restriction, purchase an additional
number of shares of our common stock in the open market, or otherwise, that do not exceed an additional 10% of the number of shares
of common stock then issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Stock Purchase Agreement contains a
standstill provision pursuant to which, among other things, Intrexon has agreed that, for a period of three years, subject to certain
exceptions and unless invited in writing by us to do so, neither Intrexon nor its affiliates will, directly or indirectly: (i)
effect or seek, initiate, offer or propose to effect, or cause or participate in any acquisition of our securities or assets; any
tender or exchange offer, merger, consolidation or other business combination involving us; any recapitalization, restructuring,
liquidation, dissolution or other extraordinary transaction with respect to us; or any &ldquo;solicitation&rdquo; of &ldquo;proxies&rdquo;
or consents to vote any of our voting securities, or in any way advise or, assist any other person in doing so; (ii) form, join
or in any way participate in a &ldquo;group&rdquo; with respect to any of our securities; (iii) otherwise act to seek to control
or influence the management, Board of Directors or our policies; (iv) take any action reasonably expected to force us to make a
public announcement regarding any such matters; or (v) enter into any agreements, discussions or arrangements with any third party
with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the transactions
contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by us
to Intrexon, we agreed to file a &ldquo;resale&rdquo; registration statement registering the resale of the First Tranche
Shares within 120 days of the closing date of such issuance. The registration statement registering such shares was declared
effective on April 13, 2012, but is not currently valid due to certain issues regarding the failure of our prior auditor to
follow proper partner rotation. Intrexon has agreed not to require us to file a post effective registration statement on Form
S-1 with respect to the First Tranche Shares and instead has agreed to wait until we are once again S-3 eligible for
registration of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>McLean Hospital Exclusive License Agreement and Meda AB Sublicense
Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2005, as amended in 2007 and 2010, we
entered into an exclusive license agreement with the McLean Hospital, a Harvard University teaching hospital, relating to U.S.
Patent No. 6,610,324 and its foreign equivalents, entitled &ldquo;Flupirtine in the treatment of fibromyalgia and related conditions.&rdquo;
Pursuant to this agreement, we paid an upfront fee and back patent costs of approximately $62,000 and agreed to pay McLean royalties
on net sales of oral flupirtine equal to 3.5% of net sales of oral flupirtine for indications covered by the issued patents, reduced
to 1.75% if we have a license to other intellectual property covering those indications. In addition, we agreed to use our best
efforts to commercialize oral flupirtine for the therapeutic uses embodied in the patent applications. Furthermore, we agreed to
reimburse McLean Hospital all future patent costs and pay the following milestone payments: $150,000 upon the initiation of a pivotal
Phase III clinical trial of oral flupirtine; $300,000 upon the filing of an NDA for oral flupirtine; and $600,000 upon FDA approval
of oral flupirtine. The due diligence requirements of the exclusive license agreement were amended in April of 2010 and further
amended by a Non-Disturbance Agreement that was signed with McLean Hospital, Meda and us.&nbsp;The agreement remains in effect
until the later of (i) the date all issued patents and filed patent applications within the Patent Rights (as defined in the agreement)
expire or are abandoned and (ii) one year after the last Commercial Sale (as defined in the agreement) for which royalty is due
or ten years after expiration or abandonment date set forth in clause (i) above, whichever is earlier.&nbsp;We have the right to
terminate the agreement at any time upon 90 days notice. In addition, McLean may terminate the agreement (i) upon 10 days notice
for nonpayment unless payment is made within such 10 days, (ii) immediately upon written notice if we fail to maintain required
insurance or become insolvent, make an assignment for the benefit of creditors or petition for bankruptcy is filed for or against
us or (ii) if we, our affiliates or our sublicensees default in performance of their obligations under the agreement and such default
is not cured within 60 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective May 6, 2010, we entered into
a Sublicense Agreement with Meda AB of Sweden. Pursuant to this agreement, Meda has been granted an exclusive sublicense to all
of our patents covering the use of oral flupirtine for fibromyalgia. These patents have been issued in the U.S. and are pending
in Canada and Japan (the &ldquo;Territory&rdquo;). This agreement provides that Meda will assume all future development costs for
the commercialization of oral flupirtine for fibromyalgia. As consideration for this sublicense, we received an up-front payment
of $2.5 million upon execution of this agreement and are entitled to milestone payments of $5 million upon&nbsp;filing of an NDA
with the FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. This agreement also provides that we
are entitled to receive royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued
patent claims in the Territory. Pursuant to the terms of this agreement with our university licensor, we are obligated to share
half of the royalties we receive with the university licensor, McLean Hospital, and we were obligated to pay them $375,000 upon
receipt of an upfront payment, which we did pay in May 2010 when we received the payment from Meda. The agreement continues in
effect country by country until the earlier of the expiration of the Royalty Period (as defined in the agreement) or the termination
of the McLean license.&nbsp;Meda has the right to terminate the agreement at any time upon 90 days notice. In addition, a party
may terminate the agreement upon 30 days notice if the other party breached material obligations and such breach is not cured within
a period of time set forth in the agreement. The parties also have the right to terminate the agreement upon 60 days notice in
the event of the filing by a party of a bankruptcy petition, the filing of an involuntary petition not dismissed within 60 days,
a party proposes a written agreement of composition or extension of its debt, a party becomes Insolvent (as defined in the agreement),
liquidates, dissolves, ceases to conduct business or makes an assignment for the benefit of creditors.&nbsp;Upon a termination,
all licenses revert to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Regents of University of California License Agreement</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2005, we were granted an
exclusive worldwide license agreement with the Regents of the University of California (the &ldquo;Regents&rdquo;) relating
to issued U.S. Patent No. 6,936,599 and pending patent applications covering the uses of the drug candidate Trimesta (oral
estriol), which has been subsequently amended. Pursuant to this agreement, we paid an upfront license fee and reimbursed
patent expenses totaling approximately $61,000 and agreed to pay a license fee of $25,000 during 2006.&nbsp;We also agreed to
pay annual maintenance fees, milestone payments totaling $750,000 that are payable on filing an NDA, and on approval of an
NDA with the FDA, an additional $750,000 payable upon the first achievement of $50,000,000 in annual sales while covered by a
validly issued U.S. patent as well as royalties on net sales of Trimesta covered by the licensed patents. We may be permitted
to partially pay milestone payments in the form of equity.&nbsp;The duration of this agreement is from the effective date of
July 11, 2005 until the last-to-expire patent in Regent&rsquo;s Patent Rights, or until the last patent application licensed
under this agreement is abandoned and no patent in Regent&rsquo;s Patent Rights ever issues.&nbsp;We have the right to
terminate this agreement at any time and termination will be effective 90 days after the effective date of the termination
notice.&nbsp;The Regents may terminate the agreement with a written notice of default if we violate or fail to perform any
material term or covenant of this agreement including failure within three years from the successful completion of the
ongoing clinical trial of estriol for relapsing-remitting MS being conducted by Dr. Rhonda Voskuhl as principal investigator,
to initiate a Phase III clinical trial, or within 17 years of the effective date of the agreement to complete the
commercial sale of a product for human therapeutics for the treatment of autoimmune diseases, including MS.&nbsp;However, we
have 60 days after the effective date of the notice of default to repair the default.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>AEN-100 &ndash; Gastroretentive Zinc Acetate</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AEN-100 is the subject of U.S. and international
patent pending applications. On October 26, 2011, we received a final rejection letter with regard to U.S. patent application Ser.
No. 11/621,962. On February 15, 2012, we filed a Request for Continued Examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Manufacturing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We utilize contract manufacturing firms
to produce our investigational product Trimesta in accordance with &ldquo;current good manufacturing processes&rdquo; (cGMP) guidelines
outlined by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2012
and 2011, we incurred $12.3 million and $3.3 million, respectively, in research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competitive Environment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries
are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical
companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of these
companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources
significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships
and other types of joint ventures with larger, well established industry competitors that afford these companies potential research
and development and commercialization advantages in the therapeutic areas we are currently pursuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Academic research centers, governmental
agencies and other public and private research organizations are also conducting and financing research activities which may produce
products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent
protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our predecessor, Sheffield Pharmaceuticals,
Inc. was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics, Inc., a Delaware corporation formed
in 2001. After the merger, we changed our name to Pipex Pharmaceuticals, Inc., and in October 2008 we changed our name to Adeona
Pharmaceuticals, Inc. On October 15, 2009, we reincorporated in the State of Nevada. After reprioritizing our focus on the emerging
area of synthetic biologics and entering into our first collaboration with Intrexon, we amended our Articles of Incorporation to
change our name to Synthetic Biologics, Inc. on February 15, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 27, 2013, we employed approximately
fourteen individuals, eight of whom are full-time employees. A significant number of our management and professional employees
have had prior experience with pharmaceutical, biotechnology or medical product companies. None of our employees are covered by
collective bargaining agreements, and management considers relations with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 155 Gibbs Street, Suite 412, Rockville, Maryland 20850. We also maintain an administrative and finance office in Ann Arbor,
Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional information about Synthetic
Biologics is contained at our website, <U>www.syntheticbiologics.com</U>. Information on our website is not incorporated by reference
into this report. We make available on our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance
documents are also posted on our website: Code of Conduct, Code of Ethics for Financial Management and the Charters for the Audit
Committee, Compensation Committee and Nominations Committee of the Board of Directors. Our phone number is (734) 332-7800 and our
facsimile number is (734) 332-7878.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Risk Factors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investing in our common stock involves
a high degree of risk. In addition to the risks related to our business set forth in this Form 10-K and the other information included
and incorporated by reference in this Form 10-K, you should carefully consider the risks described below before purchasing our
common stock. Additional risks, uncertainties and other factors not presently known to us or that we currently deem immaterial
may also impair our business operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will need to raise additional capital to operate our
business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the exception of the three months
ended June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. We expect
to incur additional operating losses in the future and therefore our cumulative losses to increase. To date, other than the licensing
fee we received from Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the U.S., Canada
and Japan and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March 2012, we have generated very
minimal revenues. Inasmuch as our sole source of revenue (with the exception of the Meda licensing fee) has been our laboratory
revenue and our laboratory was sold recently, we do not expect to derive revenue from any source in the near future until we or
our partners successfully commercialize our products. As of December 31, 2012, our accumulated deficit totaled approximately $68.9
million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for our product
candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of products.
For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings,
cash on hand, licensing fees and grants. If our current cash, cash equivalents and short-term investments are not sufficient to
sustain our operations, we will need to seek additional sources of financing and such additional financing may not be available
on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete
planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities.
In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing efforts, and forego
licensing in attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity
or debt securities, which will have a dilutive effect on our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have not been able to sustain
profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than with respect to the three months
ended June 30, 2010, we have a history of losses and we have incurred&nbsp;and continue to incur substantial losses and negative
operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates, we may still incur
substantial losses for the foreseeable future and may not sustain profitability. We also expect to continue to incur significant
operating and capital expenditures and anticipate that our expenses will substantially increase in the foreseeable future as we
do the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">continue to undertake preclinical development and clinical trials for our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">expand our research activities with Intrexon relating to monoclonal antibodies for infectious diseases;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">seek regulatory approvals for our product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">develop our product candidates for commercialization;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">implement additional internal systems and infrastructure;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">lease additional or alternative office facilities; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 32.3pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">hire additional personnel, including members of our management team.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience negative cash flow for
the foreseeable future as we fund our technology development with capital expenditures. As a result, we will need to generate significant
revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability
in the future. Our failure to achieve or maintain profitability could negatively impact the value of our common stock and underlying
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our research and development efforts
may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must continue to explore opportunities
that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources
to research and development. A high rate of failure is inherent in the research and development of new products and technologies.
Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at
any point in the process, including after significant funds have been invested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of whether our clinical trials
are deemed to be successful, promising new product candidates may fail to reach the market or may only have limited commercial
success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory
approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture, the failure to establish
or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if we successfully
develop new products or enhancements, they may be quickly rendered obsolete by changing customer preferences, changing industry
standards, or competitors' innovations. Innovations may not be quickly accepted in the marketplace because of, among other things,
entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or
whether any of our products under development will be launched, whether we will be able to develop, license, or otherwise acquire
drug candidates or products, or whether any products will be commercially successful. Failure to launch successful new products
or new indications for existing products may cause our products to become obsolete, which may limit our ability to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The technology on which our channel
partnering arrangements with Intrexon is based on early stage technology.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have an exclusive channel collaboration
arrangement with Intrexon that contemplates the use of Intrexon&rsquo;s transgene engineering platform technology and regulatory
control technology for the<I> in vivo</I> cellular production of PGIS, a specific effector enzyme that regulates the production
of prostacyclin. Such technologies have a limited history of use in the design and development of human therapeutic product candidates
and may therefore involve unanticipated risks or delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2012, we announced an additional
exclusive channel collaboration with Intrexon relating to the design, production, testing and commercialization of monoclonal antibodies
for the treatment of certain infectious diseases. Although monoclonal antibody therapeutics are well established in the biotechnology
and pharmaceutical sectors, their use for the treatment of infectious disease is extremely limited. In order for monoclonal antibodies
to be effective for infectious diseases, they must not only properly target the organism of interest (or its toxins), but may also
need to overcome defenses and forms of resistance of such organisms. To accomplish this may require the use of more than one specific
monoclonal antibody, and mixtures of different monoclonal antibodies, which may create additional unforeseen complications, including
increased manufacturing complexity and expense. In order to be competitive, monoclonal antibodies will be required to be produced
at a low enough cost of goods in order to be profitably marketed. We have very limited development and manufacturing experience
in the field of monoclonal antibodies and infectious disease. We cannot assure that any monoclonal antibody candidates will provide
satisfactory in vitro and in vivo nonclinical results sufficient to warrant the expense of cGMP manufacture and clinical testing
in human clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DNA-based therapy has not yet been
proven to be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">The FDA has
not yet approved any human DNA-based therapy product for sale. The field of DNA-based therapy, also referred to as gene therapy
or gene transfer, is experimental and has not yet proven successful in many clinical trials. Clinical trials with DNA-based therapy
have encountered a multitude of significant technical problems in the past, including, unintended integration with host DNA, poor
levels of protein expression, transient protein expression, viral overload, immune reactions to either viral capsids utilized to
deliver DNA, DNA itself, proteins expressed or cells transfected with DNA. There can be no assurance that our preclinical animals
studies or human clinical trials will be successful or that we will receive the regulatory approvals necessary to initiate such
studies. To the extent that we utilize viral constructs or other systems to deliver our DNA-based therapies and the same or similar
delivery systems demonstrate unanticipated and/or unacceptable side effects in preclinical or clinical trials conducted by ourselves
or others we may be forced to, or elect to, discontinue development of such product candidates. We do not intend to pursue</FONT>
further development of our previously announced program for pulmonary arterial hypertension. However, we are currently in discussions
with Intrexon to substitute this program with an alternate program better suited to our current objectives and focus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not generate additional revenue
from our relationships with our corporate&nbsp;collaborators.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">On May 6, 2010,
we entered into a sublicense agreement with Meda AB whereby we may receive milestone payments totaling $17.5 million (including
an upfront payment of $2.5 million that has already been received), plus royalties on our flupirtine program. There can be no assurance
that Meda AB will successfully develop flupirtine for fibromyalgia in the U.S., Canada or Japan that would allow us to receive
such additional $15 million in milestone payments and royalties on sales in connection with such agreement. The successful achievement
of the various milestones set forth in the sublicense agreement is not within our control and we will be dependent upon Meda AB
for achievement of such milestones. </FONT>According to Meda&rsquo;s 2012 Year-End Report filed in February 2013, Meda has received
the go-ahead from the FDA to conduct a Phase II proof of concept study for the treatment of fibromyalgia. There can be no assurance
that Meda will initiate or successfully complete such planned study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have experienced several management
changes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have had significant changes in management
in the past few years. Jeffrey Riley was appointed Chief Executive Officer and President on February 3, 2012. Effective February
6, 2012, C. Evan Ballantyne was appointed Chief Financial Officer. James S. Kuo, M.D., served as Chief Executive Officer and President
from February 6, 2010 until February 3, 2012. Changes in our key positions, as well as additions of new personnel and departures
of existing personnel, can be disruptive, might lead to additional departures of existing personnel and could have a material adverse
effect on our business, operating results, financial results and internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to retain rights
licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need to
develop, manufacture, and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our own patent applications,
we also currently rely on licensing agreements with third party patent holders/licensors for our products. We have an exclusive
license agreement with the McLean Hospital relating to the use of flupirtine to treat fibromyalgia which was sublicensed to Meda
AB and an exclusive license agreement with the Regents of the University of California relating to our Trimesta technology. Each
of these agreements requires us or our sublicensee to use our best efforts to commercialize each of the technologies as well as
meet certain diligence requirements and timelines in order to keep the license agreement in effect. In the event we or our sublicensee
are not able to meet our diligence requirements, we may not be able to retain the rights granted under our agreements or renegotiate
our arrangement with these institutions on reasonable terms, or at all. Furthermore, we currently have very limited product development
capabilities, and limited marketing or sales capabilities. For us to research, develop, and test our product candidates, we would
need to contract with outside researchers, in most cases those parties that did the original research and from whom we have licensed
the technologies. Our exclusive channel collaboration agreements with Intrexon provide that Intrexon may terminate each such agreement
if we do not perform certain specified requirements, including developing therapies considered superior. Our agreement with The
University of Texas allows the Universtiy to terminate its agreement if we fail to comply with the terms of the agreement. Our
agreement with Prev provides Prev with the right to the return of the assets if we do not perform certain requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can give no assurances that any of our
issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection or
be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability, nor
does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur additional expenses
in connection with our exclusive channel collaboration arrangements with Intrexon and Prev.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our exclusive channel collaborations
with Intrexon, we are responsible for future research and development expenses of product candidates developed under each such
collaboration, the effect of which has and will continue to increase the level of our overall research and development expenses
going forward. Our agreement with Prev requires that we initiate certain studies and file an NDA within a certain amount of time,
each of which are costly and will require additional expenditures. Although all manufacturing, preclinical studies and human clinical
trials are expensive and difficult to design and implement, costs associated with the manufacturing, research and development of
biologic product candidates are generally greater in comparison to small molecule product candidates. We have added additional
personnel and expect to add additional personnel to support our exclusive channel collaborations with Intrexon, and research and
development of our biologic candidate, SYN-004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our biologic programs
are relatively new, we have only recently assumed development responsibility and costs associated with such programs.
In addition, because development activities in collaboration with Intrexon are determined pursuant to a joint steering
committees comprised of Intrexon and ourselves and we have limited experience, future development costs associated this
program may be difficult to anticipate and exceed our expectations. Our actual cash requirements may vary materially from our
current expectations for a number of other factors that may include, but are not limited to, unanticipated technical
challenges, changes in the focus and direction of our development activities or adjustments necessitated by changes in the
competitive landscape in which we operate. If we are unable to continue to financially support such collaborations due to our
own working capital constraints, we may be forced to delay our activities. If we are unable to obtain additional financing on
terms acceptable to us or at all, we may be forced to seek licensing partners or discontinue development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Developments by competitors may render
our products or technologies obsolete or non-competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Companies that currently sell or are developing
both generic and proprietary products to treat multiple sclerosis include: Abbott Biotherapeutics Corporation, Bayer Health Care,
Biogen Idec, Genzyme, GlaxoSmithKline Pharmaceuticals, Merck &amp; Co., Pfizer, Novartis, Sanofi and Teva Pharmaceuticals. Companies
that currently sell or are developing both generic and proprietary products to treat infectious diseases include: MedImmune, Pfizer,
Cubist, Optimer Pharmaceuticals, Symphogen, Merus, GlaxoSmithKline Pharmaceuticals and Merck &amp; Co.. Many of our competitors
have significant financial and human resources. The infectious disease market is highly competitive with many generic and proprietary
intravenous and oral formulations available to physicians and their patients. For our monoclonal antibodies, we currently do not
expect to be able to deliver our infectious disease candidates via the oral route and may thus be limited to the in-patient and/or
acute treatment setting. In addition, academic research centers may develop technologies that compete with our Trimesta and flupirtine
technologies. Should clinicians or regulatory authorities view these therapeutic regiments as more effective than our products,
this might delay or prevent us from obtaining regulatory approval for our products, or it might prevent us from obtaining favorable
reimbursement rates from payers, such as Medicare, Medicaid, hospitals and private insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We operate in a highly competitive
environment</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries,
including the monoclonal antibody industry, are characterized by rapidly evolving technology and intense competition. Our competitors
include major multi-national pharmaceutical companies and biotechnology companies developing both generic and proprietary therapies
to treat serious diseases. Many of these companies are well-established and possess technical, human, research and development,
financial, and sales and marketing resources significantly greater than ours. In addition, many of our potential competitors have
formed strategic collaborations, partnerships and other types of joint ventures with larger, well established industry competitors
that afford these companies potential research and development and commercialization advantages in the therapeutic areas we are
currently pursuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Academic research centers, governmental
agencies and other public and private research organizations are also conducting and financing research activities which may produce
products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent
protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competitors could develop and/or
gain FDA approval of our product candidates for a different indication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we do not have composition of matter
patent claims for flupirtine and estriol, others may obtain approvals for other uses of these products that are not covered by
our issued or pending patents. For example, the active ingredients in both Effirma (flurpirtine) and Trimesta (oral estriol) have
been approved for marketing in overseas countries for different uses. Other companies, including the original developers or licensees
or affiliates may seek to develop Effirma or Trimesta or their respective active ingredient(s) for other uses in the U.S. or any
country we are seeking approval for. We cannot provide any assurances that any other company may obtain FDA approval for products
that contain flupirtine and estriol in various formulations or delivery systems that might adversely affect our ability or the
ability of Meda to develop and market these products in the U.S. We are aware that other companies have intellectual property protection
using the active ingredients and have conducted clinical trials of flupirtine and estriol for different applications than what
we are developing. Many of these companies may have more resources than us. We cannot provide any assurances that our products
will be FDA-approved prior to our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product containing our active ingredients
is already marketed or if the FDA approves other products containing our active ingredients in the future to treat indications,
physicians may elect to prescribe and substitute a competitor&rsquo;s products to treat the diseases for which we are intending
to commercialize; this is commonly referred to as &ldquo;off-label&rdquo; use. While under FDA regulations a competitor is not
allowed to promote off-label uses of its product, the FDA does not regulate the practice of medicine and, as a result, cannot direct
physicians to select certain products for their patients. Consequently, we might be limited in our ability to prevent off-label
use of a competitor&rsquo;s product to treat the diseases we are intending to commercialize, even if we have issued method of use
patents for that indication. If we are not able to obtain and enforce our patents, if any, or otherwise receive orphan drug protection
in the case of ALS, a competitor could develop and commercialize similar products for the same indications that we are pursuing.
We cannot provide any assurances that a competitor will not obtain FDA approval for a product that contains the same active ingredients
as our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on method patents and patent
applications and various regulatory exclusivities to protect some of our product candidates and our ability to compete may be limited
or eliminated if we are not able to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitiveness may be
adversely affected if we are unable to protect our proprietary technologies. We do not have composition of matter patents for
Trimesta or Effirma, or their respective active ingredients estriol and flupirtine. We rely on issued patent and pending
patent applications for use of Trimesta to treat MS (issued U.S. Patent Nos. 6,936,599 and 8,372,826) and various other therapeutic
indications, which have been exclusively licensed to us. We have exclusively licensed an issued patent for the treatment of
fibromyalgia with flupirtine, which we have sublicensed to Meda AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our AEN-100 drug candidate (gastroretentive
zinc acetate) is the subject of U.S. and international pending patent applications, such as published U.S. patent application Ser.
No. 11/621,962 and corresponding international applications that claim priority to January 10, 2006 as well as additional patent
applications. On October 26, 2011, we received a final rejection letter with regard to U.S. patent application Ser. No. 11/621,962.
On February 15, 2012, we filed a Request for Continued Examination. Our inability to obtain patent protection could hinder our
partnering efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical
companies are uncertain and may involve complex legal and factual questions. We may incur significant expense in protecting our
intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other
infringement litigation by or against us could cause us to incur significant expense and divert the attention of our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Others may file patent applications or
obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in any
such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how they
will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another party
claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large sum if
we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign our
product, which may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets and proprietary
know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors,
current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors
or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade
secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop
similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may fail to retain or recruit
necessary personnel, and we may be unable to secure the services of consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 27, 2013, we employed approximately
fourteen individuals, eight of whom are full-time employees. <FONT STYLE="color: black">We have also engaged clinical consultants
to advise us on our clinical programs and regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory
authorities. We have been and will be required to retain additional consultants and employees in order to fulfill our obligations
under our exclusive channel collaborations with Intrexon and our development obligations under our agreement with Prev. Our future
performance will depend in part on our ability to successfully integrate newly hired officers into our management team and our
ability to develop an effective working relationship among senior management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of our directors,&nbsp;scientific
advisors, and consultants serve as officers, directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology
companies that might be developing competitive products to ours. Other than corporate opportunities, none of our directors are
obligated under any agreement or understanding with us to make any additional products or technologies available to us. Similarly,
we can give no assurances, and we do not expect and stockholders should not expect, that any biomedical or pharmaceutical product
or technology identified by any of our directors or affiliates in the future would be made available to us other than corporate
opportunities. We can give no assurances that any such other companies will not have interests that are in conflict with our interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Losing key personnel or failing to recruit
necessary additional personnel would impede our ability to attain our development objectives. There is intense competition for
qualified personnel in the drug and biologic development areas, and we may not be able to attract and retain the qualified personnel
we would need to develop our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on independent organizations, advisors,
and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval, clinical
management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may not always
be available to us on a timely basis when we need them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the parties we depend on for supplying
substance raw materials for our product candidates and certain manufacturing-related services do not timely supply these products
and services in sufficient quality or quantity, it may delay or impair our ability to develop, manufacture and market our product
candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on suppliers for the substance
raw materials of our product candidates and third parties for certain manufacturing-related services to produce material that meets
appropriate content, quality and stability standards and use in clinical trials of our products and, after approval, for commercial
distribution. We have not yet established cGMP manufacturers for our biologic and drug candidates. To succeed, clinical trials
require adequate supplies of study material, which may be difficult or uneconomical to procure or manufacture. We and our suppliers
and vendors may not be able to (i) produce our study material to appropriate standards for use in clinical studies, (ii) perform
under any definitive manufacturing, supply or service agreements with us, or (iii) remain in business for a sufficient time to
successfully produce and market our product candidates. If we do not maintain important manufacturing and service relationships,
we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilities which could delay or
impair our ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins,
if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreements with them on terms and
conditions favorable to us and, there could be a substantial delay before a new facility could be qualified and registered with
the FDA and foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If successful large-scale manufacturing
of DNA-based products is not possible, we or our collaborators may be unable to manufacture enough of our product candidates to
achieve regulatory approval or market our DNA-based products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Few companies to date have demonstrated
successful large-scale manufacturing of DNA-based products, including those that have had significantly more resources than us
and it is anticipated that significant challenges will be faced in the scale-up of our manufacturing process for commercial production.
There are a limited number of contract manufacturers qualified to perform large-scale manufacturing of DNA-based products. We or
our collaborators may be unable to manufacture commercial-scale quantities of DNA-based products or receive appropriate government
approvals on a timely basis or at all. Failure to successfully manufacture or obtain appropriate government approvals on a timely
basis or at all would prevent us from achieving our business objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical trials are very expensive,
time-consuming, and difficult to design and implement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are very expensive
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial
process is also time-consuming. We estimate that clinical trials of our product candidates would take at least several years to
complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or
repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">obtaining an IND application with the FDA to commence clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">identification of, and acceptable arrangements with, one or more clinical sites;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">obtaining IRB approval to commence clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">unforeseen safety issues;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">determination of dosing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">lack of effectiveness during clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">slower than expected rates of patient recruitment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">inability to monitor patients adequately during or after treatment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">inability or unwillingness of medical investigators to follow our clinical protocols; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">unwillingness of the FDA or IRBs to permit the clinical trials to be initiated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we, IRBs or the FDA may suspend our clinical trials
at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs or the FDA finds deficiencies
in our submissions or conduct of our trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The results of our clinical trials
may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily
predictive of future results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, long-term safety and efficacy
have not yet been demonstrated in clinical trials for any of our product candidates. Favorable results in our early studies or
trials may not be repeated in later studies or trials. Even if our clinical trials are initiated and completed as planned, we cannot
be certain that the results will support our product candidate claims. Success in preclinical testing and early clinical trials
does not ensure that later clinical trials will be successful. Furthermore, success of our predecessor with P1A, does not ensure
success of SYN-004. We cannot be sure that the results of later clinical trials would replicate the results of prior clinical trials
and preclinical testing nor that they would satisfy the requirements of the FDA or other regulatory agencies. Clinical trials may
fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Any such failure could cause
us or our sublicensee to abandon a product candidate and might delay development of other product candidates. Preclinical and clinical
results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization.
Any delay in, or termination of, our clinical trials would delay our obtaining FDA approval for the affected product candidate
and, ultimately, our ability to commercialize that product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on third parties, including
researchers and sublicensees, who are not under our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we have in-licensed some of our product
candidates, have sublicensed a product candidate and have collaboration agreements for the development of other product candidates,
we depend upon our sublicensee and independent investigators and scientific collaborators, such as universities and medical institutions
or private physician scientists, to advise us and to conduct our preclinical and clinical trials under agreements with us. These
collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs or
the timing of their procurement of clinical-trial data or their compliance with applicable regulatory guidelines. Should any of
these scientific inventors/advisors or those of our sublicensee become disabled or die unexpectedly, or should they fail to comply
with applicable regulatory guidelines, we or our sublicensee may be forced to scale back or terminate development of that program.
They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking those programs
ourselves. Failing to devote sufficient time and resources to our drug-development programs, or substandard performance and failure
to comply with regulatory guidelines, could result in delay of any FDA applications and our commercialization of the drug candidate
involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These collaborators may also have relationships
with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors could harm our competitive
position. For example, we are highly dependent on scientific collaborators for our Trimesta development program. Specifically,
all of the clinical trials have been conducted under investigator-sponsored IND applications, not corporate-sponsored INDs. We
have sometimes experienced difficulty in collecting data generated from these investigator-sponsored clinical trials for our programs.
We cannot provide any assurances that we will not experience any additional delays in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also highly dependent on government
and private grants to fund certain of our clinical trials for our product candidates. For example, Trimesta (oral estriol) has
received grants totaling over $8 million,&nbsp;predominantly from the Southern California Chapter of the NMSS and the National
Institutes of Health which funds a majority of the ongoing clinical trial in relapsing-remitting MS for women. Although we believe
that the grant funding received to date is sufficient to complete the current clinical trial based upon current cost estimates,
if we experience any additional unanticipated costs or require further clinical trials, and our scientific collaborator is unable
to maintain or receive additional grants, we might be forced to scale back or terminate the development of this product candidate.
We will also need to cross reference our IND with the inventor/IND holder for this program should we elect to file our own corporate
IND for our Trimesta (oral estriol) program. The on-going and future development and commercialization of Effirma (flupirtine)
for fibromyalgia is the responsibility of Meda AB and no assurance can be given that Meda will gain the FDA&rsquo;s acceptance
of the NDA or obtain NDA approval from the FDA of flupirtine for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to our product candidates
in collaboration with Intrexon, we are dependent upon Intrexon&rsquo;s synthetic biology facilities and capabilities as we have
no such facilities and capabilities of our own. We are also reliant on their vector engineering platform, gene expression switch
technology, monoclonal antibody discovery, production cell line development and know-how. If any of the foregoing were to become
inaccessible or terminated, it would be difficult for us to develop and commercialize our synthetic biologic product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may incur substantial costs as
a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated
with lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any other person files patent applications,
or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference
proceedings in the U.S. Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to
participate in interference proceedings involving our issued patents and pending applications of another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The intellectual property environment in
the area of DNA-based therapeutics is particularly complex, constantly evolving and highly fragmented. Other companies and institutions
have issued patents and have filed or will file patent applications that may issue into patents that cover or attempt to cover
genes, vectors, cell lines, and methods of making and using DNA and DNA-based therapy products used in, or similar to our product
candidate, and technologies. The same is true of the monoclonal antibody field in terms of methods of producing monoclonal antibodies
for human use. We have not conducted freedom-to-use patent searches on all aspects of our product candidates or potential product
candidates, and we may be unaware of relevant patents and patent applications of third parties. In addition, the freedom-to-use
patent searches that have been conducted may not have identified all relevant issued patents or pending patents. We cannot provide
assurance that our proposed products in this area will not ultimately be held to infringe one or more valid claims owned by third
parties which may exist or come to exist in the future or that in such case we will be able to obtain a license from such parties
on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot guarantee that the practice of
our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition
proceedings, either by opposing the validity of another&rsquo;s foreign patent or by persons opposing the validity of our foreign
patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also face frivolous litigation or
lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding
relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could distract management
from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect
on our ability to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we infringe the rights of others
we could be prevented from selling products or forced to pay damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our products, methods, processes, and
other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may
be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling
to offer us a license on commercially acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will seek to raise additional
funds in the future, which may be dilutive to stockholders or impose operational restrictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to seek to raise additional capital
in the future to help fund development of our proposed products. If we raise additional capital through the issuance of equity
or of debt securities, the percentage ownership of our current stockholders will be reduced. We may also enter into strategic transactions,
issue equity as part of license issue fees to our licensors, compensate consultants or settle outstanding payables using equity
that may be dilutive. Our stockholders may experience additional dilution in net book value per share and any additional equity
securities may have rights, preferences and privileges senior to those of the holders of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are substantially controlled by
our current officers, directors, and principal stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, our directors, executive officers,
and principal stockholders beneficially own a substantial number of shares of our common stock. As a result, they will be able
to exert substantial influence over the election of our Board of Directors and the vote on issues submitted to our stockholders.
Our executive officers and directors beneficially owned approximately 8.9 million shares of our common stock, including stock options
and warrants exercisable within 60 days of March 27, 2013. Randal J. Kirk indirectly beneficially owns approximately 9.8 million
shares of our common stock. Our executive officers, directors and principal stockholders together beneficially owned approximately
18.7 million shares of our common stock, including the stock options and warrants exercisable within 60 days of March 27, 2013.
Because our common stock has from time to time been &ldquo;thinly traded&rdquo;, the sale of a substantial number of shares by
our executive officers, directors and principal stockholders would have an adverse effect on the market for our stock and our share
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our shares of common stock are from
time to time thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to
raise money or otherwise desire to liquidate their shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has from time to time
been &ldquo;thinly-traded,&rdquo; meaning that the number of persons interested in purchasing our common stock at or near ask prices
at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the
fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others
in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons,
they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase
of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or
more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady
volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give
stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained,
or that current trading levels will be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We cannot assure you that the common stock will be liquid
or that it will remain listed on the NYSE MKT.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will be able
to maintain the continued listing standards of the NYSE MKT (formerly the NYSE Amex and the American Stock Exchange). The NYSE
MKT requires companies to meet certain continued listing criteria including certain minimum stockholders' equity&nbsp;and equity
prices per share&nbsp;as outlined in the NYSE MKT Exchange Company Guide. We may not be able to maintain such minimum stockholders'
equity or prices per share or may be required to effect a reverse stock split to maintain such minimum prices and/or issue additional
equity securities in exchange for cash or other assets, if available, to maintain certain minimum stockholders' equity required
by the NYSE MKT.&nbsp;If we are delisted from the NYSE MKT then our common stock will trade, if at all, only on the over-the-counter
market, such as the OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply
with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity
of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting
from the NYSE MKT could also have other negative results, including the potential loss of confidence by suppliers and employees,
the loss of institutional investor interest and fewer business development opportunities. In order to remain listed on NYSE MKT,
we are required to maintain a minimum stockholders&rsquo; equity of $6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be issuances of shares
of preferred stock in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we currently do not have preferred
shares outstanding, the Board of Directors could authorize the issuance of a series of preferred stock that would grant holders
preferred rights to our assets upon liquidation, the right to receive dividends before dividends would be declared to common stockholders,
and the right to the redemption of such shares, possibly together with a premium, prior to the redemption of the common stock.
To the extent that we do issue preferred stock, the rights of holders of common stock could be impaired thereby, including without
limitation, with respect to liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our failure to fulfill all of our registration requirements
may cause us to suffer liquidated damages, which may be very costly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the registration
rights agreement that we entered into with Intrexon and an affiliated entity, we are required to file a registration statement
with respect to securities issued to them within a certain time period and maintain the effectiveness of such registration statement.
The failure to do so could result in the payment of damages by us. There can be no assurance as to when the registration
statement will be declared effective or that we will be able to maintain the effectiveness of any registration statement, and therefore
there can be no assurance that we will not incur  damages with respect to such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATED TO OUR INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to government regulation,
compliance with which can be costly and difficult.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., the formulation, manufacturing,
packaging, storing, labeling, promotion, advertising, distribution and sale of our products are subject to regulation by various
governmental agencies, including (1) the FDA, (2) the Federal Trade Commission, or FTC, (3) the Consumer Product Safety Commission,
or CPSC, (4) the U.S. Department of Agriculture, or USDA. Our proposed activities may also be regulated by various agencies of
the states, localities and foreign countries in which our proposed products may be manufactured, distributed and sold. The FDA,
in particular, regulates the formulation, manufacture and labeling of over-the-counter, or OTC drugs, prescription drugs, conventional
foods, dietary supplements, and cosmetics such as those that we intend to distribute. FDA regulations require us and our suppliers
to meet relevant cGMP regulations for the preparation, packing, labeling, and storage of all drugs and foods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any products manufactured or distributed
by us pursuant to FDA approvals are subject to pervasive and continuing FDA regulation, including record-keeping requirements,
reporting of adverse experiences, submitting periodic reports, drug sampling and distribution requirements, manufacturing or labeling
changes, record-keeping requirements, and compliance with FDA promotion and advertising requirements. Drug manufacturers and their
subcontractors are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced
inspections for GMP compliance, imposing procedural and documentation requirements upon us and third-party manufacturers. Failure
to comply with these regulations could result, among other things, in suspension of regulatory approval, recalls, suspension of
production or injunctions, seizures, or civil or criminal sanctions. We cannot be certain that we or our present or future subcontractors
will be able to comply with these regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA regulates prescription drug labeling
and promotion activities. The FDA actively enforces regulations prohibiting the marketing of products for unapproved uses. The
FDA permits the promotion of drugs for unapproved uses in certain circumstances, subject to stringent requirements. We and our
product candidates are subject to a variety of state laws and regulations which may hinder our ability to market our products.
Whether or not FDA approval has been obtained, approval by foreign regulatory authorities must be obtained prior to commencing
clinical trials, and sales and marketing efforts in those countries. These approval procedures vary in complexity from country
to country, and the processes may be longer or shorter than that required for FDA approval. We may incur significant costs to comply
with these laws and regulations now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA, comparable foreign regulators
and state and local pharmacy regulators impose substantial requirements upon clinical development, manufacture and marketing of
pharmaceutical products. These and other entities regulate research and development and the testing, manufacture, quality control,
safety, effectiveness, labeling, storage, record keeping, approval, advertising, and promotion of our products. The drug approval
process required by the FDA under the Food, Drug, and Cosmetic Act generally involves:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">preclinical laboratory and animal tests;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">submission of an IND, prior to commencing human clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">adequate and well-controlled human clinical trials to establish safety and efficacy for intended use;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.9pt; text-indent: -33.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.9pt; text-indent: -33.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">submission to the FDA of an NDA or Biologics License Application (BLA); and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.7pt"></TD><TD STYLE="width: 33.2pt">&#9679;</TD><TD STYLE="text-align: justify">FDA review and approval of an NDA or BLA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The testing and approval process requires
substantial time, effort, and financial resources, and we cannot be certain that any approval will be granted on a timely basis,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical tests include laboratory evaluation
of the product candidate, its chemistry, formulation and stability, and animal studies to assess potential safety and efficacy.
Certain preclinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations
can, in some cases, lead to invalidation of the studies, requiring them to be replicated. In some cases, long-term preclinical
studies are conducted concurrently with clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will submit the preclinical test results,
together with manufacturing information and analytical data, to the FDA as part of an IND, which must become effective before we
begin human clinical trials. The IND automatically becomes effective 30 days after filing, unless the FDA raises questions about
conduct of the trials outlined in the IND and imposes a clinical hold, in which case, the IND sponsor and FDA must resolve the
matters before clinical trials can begin. It is possible that our submission may not result in FDA authorization to commence clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials must be supervised by qualified
investigators in accordance with good clinical practice (GCP) regulations, which include informed consent requirements. Each study
must be approved and monitored by the appropriate IRBs which are periodically informed of the study&rsquo;s progress, adverse events
and changes in research. Annual updates are submitted to the FDA and more frequently if certain serious adverse events occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials of drug candidates
typically have three sequential phases that may overlap:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase I:&nbsp;The drug is initially tested
in healthy human subjects or patients for safety, dosage tolerance, absorption, metabolism, distribution, and excretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase II:&nbsp;The drug is studied in a
limited patient population to identify possible adverse effects and safety risks, determine efficacy for specific diseases and
establish dosage tolerance and optimal dosage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase III:&nbsp;When Phase II evaluations
demonstrate that a dosage range is effective with an acceptable safety profile, Phase III&nbsp;trials to further evaluate dosage,
clinical efficacy and safety, are undertaken in an expanded patient population, often at geographically dispersed sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that we will successfully
complete Phase I, Phase II, or Phase III testing of our product candidates within any specific time period, if at all. Furthermore,
the FDA, an IRB or the IND sponsor may suspend clinical trials at any time on various grounds, including a finding that subjects
or patients are exposed to unacceptable health risk. Concurrent with these trials and studies, we also develop chemistry and physical
characteristics data and finalize a manufacturing process in accordance with good manufacturing practice (GMP) requirements. The
manufacturing process must conform to consistency and quality standards, and we must develop methods for testing the quality, purity,
and potency of the final products. Appropriate packaging is selected and tested, and chemistry stability studies are conducted
to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life. Results of the foregoing are submitted
to the FDA as part of a NDA (or BLA in case of biologic products) for marketing and commercial shipment approval. The FDA reviews
each NDA or BLA submitted and may request additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the FDA accepts the NDA or BLA for
filing, it begins its in-depth review. The FDA has substantial discretion in the approval process and may disagree with our interpretation
of the data submitted or identify new concerns. The process may be significantly extended by requests for new information or clarification
of information already submitted. As part of this review, the FDA may refer the application to an advisory committee, typically
a panel of clinicians. Manufacturing establishments often are inspected prior to NDA or BLA approval to assure compliance with
GMPs and with manufacturing commitments made in the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Submission of an NDA or BLA with clinical
data requires payment of a fee. In return, the FDA assigns a goal of ten months for issuing its &ldquo;complete response,&rdquo;
in which the FDA may approve or deny the NDA or BLA, or require additional clinical data. Even if these data are submitted, the
FDA may ultimately decide the NDA or BLA does not satisfy approval criteria. If the FDA approves the NDA or BLA, the product becomes
available for marketing. Product approval may be withdrawn if regulatory compliance is not maintained or safety problems occur.
The FDA may require post-marketing studies, also known as phase IV studies, as a condition of approval, and requires surveillance
programs to monitor approved products that have been commercialized. The agency has the power to require changes in labeling or
prohibit further marketing based on the results of post-marketing surveillance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Satisfaction of these and other regulatory
requirements typically takes several years, and the actual time required may vary substantially based upon the type, complexity
and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period
of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve
any of our products on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success
in later-stage clinical trials. Data obtained from preclinical and clinical activities are not always conclusive and may be susceptible
to varying interpretations that could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval,
the approval may be significantly limited to specific indications or uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after regulatory approval is obtained,
later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
of the product from the market. Delays in obtaining, or failures to obtain regulatory approvals would have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA&rsquo;s policies may change, and
additional government regulations may be enacted which could prevent or delay regulatory approval of our potential products. Increased
attention to the containment of health care costs worldwide could result in new government regulations materially adverse to our
business. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative
or administrative action, either in the U.S. or abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not have a guarantee of patent
term restoration and marketing exclusivity of the ingredients for our drugs even if we are granted FDA approval of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Drug Price Competition and Patent
Term Restoration Act of 1984 (Hatch-Waxman) permits the FDA to approve Abbreviated New Drug Applications (ANDAs) for generic versions
of innovator drugs, as well as NDAs with less original clinical data, and provides patent restoration and exclusivity protections
to innovator drug manufacturers. The ANDA process permits competitor companies to obtain marketing approval for drugs with the
same active ingredient and for the same uses as innovator drugs, but does not require the conduct and submission of clinical studies
demonstrating safety and efficacy. As a result, a competitor could copy any of our drugs and only need to submit data demonstrating
that the copy is bioequivalent to gain marketing approval from the FDA. Hatch-Waxman requires a competitor that submits an ANDA,
or otherwise relies on safety and efficacy data for one of our drugs, to notify us and/or our business partners of potential infringement
of our patent rights. We and/or our business partners may sue the company for patent infringement, which would result in a 30-month
stay of approval of the competitor&rsquo;s application. The discovery, trial and appeals process in such suits can take several
years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period,
the stay is lifted and the FDA may approve the application. Hatch-Waxman also allows competitors to market copies of innovator
products by submitting significantly less clinical data outside the ANDA context. Such applications, known as &ldquo;505(b)(2)
NDAs&rdquo; or &ldquo;paper NDAs,&rdquo; may rely on clinical investigations not conducted by or for the applicant and for which
the applicant has not obtained a right of reference or use and are subject to the ANDA notification procedures described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law also permits restoration of a portion
of a product&rsquo;s patent term that is lost during clinical development and NDA review, and provides statutory protection, known
as exclusivity, against FDA approval or acceptance of certain competitor applications. Restoration can return up to five years
of patent term for a patent covering a new product or its use to compensate for time lost during product development and regulatory
review. The restoration period is generally one-half the time between the effective date of an IND and submission of an NDA, plus
the time between NDA submission and its approval (subject to the five-year limit), and no extension can extend total patent life
beyond 14 years after the drug approval date. Applications for patent term extension are subject to U.S. Patent and Trademark Office
(USPTO) approval, in conjunction with FDA. Approval of these applications takes at least nine months, and there can be no guarantee
that it will be given at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hatch-Waxman also provides for differing
periods of statutory protection for new drugs approved under an NDA. Among the types of exclusivity are those for a &ldquo;new
molecular entity&rdquo; and those for a new formulation or indication for a previously-approved drug. If granted, marketing exclusivity
for the types of products that we are developing, which include only drugs with innovative changes to previously-approved products
using the same active ingredient, would prohibit the FDA from approving an ANDA or 505(b)(2) NDA relying on our safety and efficacy
data for three years. This three-year exclusivity, however, covers only the innovation associated with the original NDA. It does
not prohibit the FDA from approving applications for drugs with the same active ingredient but without our new innovative change.
These marketing exclusivity protections do not prohibit the FDA from approving a full NDA, even if it contains the innovative change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Unresolved Staff Comments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Properties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently rent approximately 1,000
square feet of office space in Rockville, Maryland for monthly rent of $3,002, and we rent approximately 1,600 square feet of
office space in Ann Arbor, Michigan for monthly rent of $2,633. We believe our current offices will be adequate for the
foreseeable future.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Legal Proceedings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Mine Safety Disclosures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has traded on the
NYSE MKT under the symbol &ldquo;SYN&rdquo; since February 16, 2012. Prior to this time, our common stock traded under the
symbol &ldquo;AEN&rdquo; since October 16, 2008. The following table states the range of the high and low sales prices of our
common stock for each of the calendar quarters during the years ended December 31, 2012 and December 31, 2011. These
quotations represent inter-dealer prices, without retail mark-up, markdown, or commission, and may not represent actual
transactions. The last price of our common stock as reported on the NYSE MKT on March 27, 2013 was $1.75 per share. As of
March 27, 2013, there were approximately 352 stockholders of record of our common stock. This number does not
include beneficial owners from whom shares are held by nominees in street name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">High</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Low</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>YEAR ENDED DECEMBER 31, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Fourth quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.43</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.51</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>YEAR ENDED DECEMBER 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Third quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">First quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid any cash dividends
on our common stock to date, and do not anticipate paying such cash dividends in the foreseeable future. Whether we declare and
pay dividends is determined by our Board of Directors at their discretion, subject to certain limitations imposed under Nevada
corporate law. The timing, amount and form of dividends, if any, will depend on, among other things, our results of operations,
financial condition, cash requirements and other factors deemed relevant by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Item 12 &ndash; Executive compensation for equity compensation
plan information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 26, 2012, we issued a performance
warrant as compensation for a consulting agreement that we had entered into for a financial communications program.&nbsp; The performance
warrant is exercisable for 250,000 shares of our common stock based on achievement of certain stock price milestones at an exercise
price equal to the market price of our common stock on the date of execution of the agreement. Upon initiation of the program,
50,000 of the performance warrants vested.&nbsp;&nbsp; The warrant was issued in reliance on the exemption from registration afforded
by Section 4(a)(2) of &nbsp;the Securities Act of 1933.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All other sales of unregistered
securities have been previously reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Selected Financial Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable because we are a smaller reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion of our financial
condition and results of operations should be read in conjunction with the audited financial statements and notes thereto for the
year ended December 31, 2012 found in this report. In addition to historical information, the following discussion contains forward-looking
statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements
by using words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;intends,&rdquo; or similar expressions. Our actual
results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including,
but not limited to, those set forth under &ldquo;Risk Factors&rdquo; in Part I, Item 1A of this Report.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused
on the development of biologics for the prevention and treatment of serious infectious diseases. We are developing an oral enzyme
for the prevention of<I> C. difficile</I> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis
and <I>Acinetobacter</I> infections. In addition, we are developing a drug candidate for the treatment of relapsing-remitting multiple
sclerosis and cognitive dysfunction in multiple sclerosis, and have partnered the development of a treatment for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tpgii1.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt"><I>Summary of Infectious Disease Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt">&bull;</TD><TD STYLE="text-align: justify"><B><I>Clostridium difficile (C. difficile)</I> infections:</B> In November 2012, we acquired a
series of oral beta-lactamase enzymes (P1A, P2A and P3A) and related assets targeting the prevention <I>of C. difficile</I> infections
(CDI), the leading cause of hospital acquired infections (HAI), that generally occurs secondary to treatment with intravenous antibiotics.
The acquired assets include a pre-Investigational New Drug (IND) package for P3A (SYN-004), Phase I and Phase II clinical data
for P1A, manufacturing processes and data, and a portfolio of issued and pending U.S. and international patents intended to support
an IND and Biologic License Application (BLA) with the FDA. Utilizing this portfolio of assets, we intend to develop a proprietary
oral beta-lactamase enzyme product candidate, SYN-004, previously known as IPSAT P3A. When co-administered with certain intravenous
beta-lactam antibiotics, it is expected that SYN-004 can degrade the antibiotic that is excreted in the gastrointestinal (GI) tract,
thus preserving the natural balance of the patient's microflora, and preventing opportunistic<I> </I>infections including CDI.
Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin
classes of antibiotics. According to GlobalData, an estimated 8.7 million Americans were administered intravenous beta-lactam antibiotics
in 2011.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: -33.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt"><FONT STYLE="color: black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black"><B>Pertussis:</B> In December 2012, in collaboration with Intrexon Corporation
(Intrexon), we </FONT>initiated development of a monoclonal antibody (mAb) therapy for the treatment of Pertussis infections, more
commonly known as whooping cough. We are developing a mAb therapy, SYN-005, designed to target and neutralize the pertussis toxin,
in order to reduce the mortality rate in infants and potentially shorten the duration of chronic cough in afflicted adults. To
further the development of this potential therapy for Pertussis, we entered into an agreement with The University of Texas at Austin
to license the rights to certain research and pending patents related to pertussis antibodies. According to the World Health Organization,
each year, <I>B. pertussis </I>infection causes an estimated 294,000 deaths worldwide, primarily among young, unvaccinated children.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: -33.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: -33.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.05pt"></TD><TD STYLE="width: 33.45pt">&bull;</TD><TD STYLE="text-align: justify"><B><I>Acinetobacter </I>infections:</B> In September 2012, in collaboration with Intrexon, we initiated
efforts to develop a mAb therapy for the treatment of <I>Acinetobacter</I> infections. Many strains of<I> Acinetobacter</I> are
multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those affected
by natural disasters. A treatment for <I>Acinetobacter</I> infections represents a multi-billion dollar market opportunity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: -33.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><I>Summary of Multiple
Sclerosis Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52pt"></TD><TD STYLE="width: 33.2pt">&bull;</TD><TD STYLE="text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is being developed as an oral once-daily treatment for
                                                                  relapsing-remitting multiple sclerosis (MS) in women. Patient enrollment is complete in this two-year, randomized,
                                                                  double-blind, placebo-controlled Phase II clinical trial being conducted at 15 centers in the U.S. The primary endpoint is
                                                                  relapse rate at two years, with top-line results expected in 1H 2014. This trial is supported by grants exceeding $8 million,
                                                                  which should be sufficient to fund the trial through completion. Current sales of injectable disease-modifying therapies for
                                                                  MS are estimated at $8.9 billion annually.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.2pt; text-align: justify; text-indent: -33.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52pt"></TD><TD STYLE="width: 33.2pt"><FONT STYLE="color: black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">Trimesta<SUP>TM</SUP> is also being developed for the treatment of
                                                                                                    cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical
                                                                                                    trial is being conducted at University of California, Los Angeles (UCLA). The primary endpoint is the effect on cognitive
                                                                                                    function as assessed by </FONT>Paced Auditory Serial Addition Test (PASAT). <FONT STYLE="color: black">Patient enrollment is
                                                                                                    ongoing. The majority of the costs of this trial are being funded by grants from foundations and charitable organizations and
                                                                                                    we have pledged approximately $500,000 to UCLA to partially fund this trial payable over three years. An estimated 50-65% of
                                                                                                    MS patients are expected to develop disabilities due to cognitive dysfunction and there is currently no approved
                                                                                                    treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.6pt; text-align: justify; text-indent: -13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-align: justify"><I>Summary of Fibromyalgia Program:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52.1pt"></TD><TD STYLE="width: 33.2pt"><FONT STYLE="color: black">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: black">Effirma<SUP>TM</SUP> (flupirtine) is being developed for the treatment
of fibromyalgia by Meda AB (Meda), a multi-billion dollar international pharmaceutical company. On May 6, 2010, we entered into
a sublicense agreement with Meda covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S.,
Canada and Japan. The sublicense agreement provides that all ongoing and future development costs are to borne by Meda and we are
entitled to receive certain payments if milestones are achieved and royalties on sales. </FONT>According to Meda&rsquo;s 2012 Year-End
Report filed in February 2013, Meda has received the go-ahead from the FDA to conduct a Phase II proof of concept study for the
treatment of fibromyalgia. Meda also announced that the randomized, double-blind, placebo and active-controlled study of patients
with fibromyalgia will be conducted at 25 clinics in the U.S. <FONT STYLE="color: black">Based on an estimated annual price of
$1,200 per fibromyalgia patient, we estimate that the total market potential in the U.S. is $6 billion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To prioritize our focus on the<FONT STYLE="color: black">
development of product candidates for the prevention and treatment of serious infectious diseases, we do not intend to pursue</FONT>
further development of our previously announced program for pulmonary arterial hypertension. However, we are currently in discussions
with Intrexon to substitute this program with an alternate program better suited to our current objectives and focus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to further prioritize our focus,
we have elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, we are
currently seeking development partners for our zinc-based intellectual property and assets including, AEN-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Recent Developments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 19, 2012, we entered into a
Patent License Agreement (the &ldquo;License Agreement&rdquo;) with The University of Texas at Austin (the &ldquo;University&rdquo;)
for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related
to Pertussis (more commonly known as whooping cough) antibodies developed in the lab of Dr. Jennifer A. Maynard, Assistant Professor
of Chemical Engineering. In connection with the License Agreement, we and the University also entered into a Sponsored Research
Agreement pursuant to which the University will perform certain research work related to pertussis under the direction of Dr. Jennifer
Maynard and we will obtain certain rights to patents and technology developed during the course of such research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2012, a closing was held
for the transaction contemplated by the Asset Purchase Agreement (the &ldquo;Prev Agreement&rdquo;) we entered into with Prev ABR
LLC (&ldquo;Prev&rdquo;), pursuant to which we acquired the<I> C. diff</I> program assets of Prev, including pre-Investigational
New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international
patents.&nbsp; Pursuant to the Prev Agreement, we paid Prev an initial cash payment of $100,000 upon execution of the Prev Agreement
and at closing paid an additional cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to Prev.
In addition, upon the achievement of the milestones set forth below, Prev may be entitled to receive additional consideration payable
50% in cash and 50% in our stock, subject to Prev&rsquo;s option to receive the entire payment in shares of our stock, with the
exception of the first milestone payments to be paid in cash: (i) upon commencement of an IND; (ii) upon commencement of a Phase
I clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon commencement of a Phase III clinical trial; (v)
upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement);
and (vi) upon BLA approval in the U.S. and upon approval in territories outside the-U.S.&nbsp; The future stock issuances are subject
to prior approval of the NYSE MKT, LLC. No royalties are payable to Prev under the Prev Agreement. The Prev Agreement also provides
that Prev has a right to the return to it of all assets acquired by us under the Prev Agreement if on or prior to the date that
is (i) thirty (30) months after the execution of the Prev Agreement, we have not initiated toxicology studies in non-rodent models
or (ii) thirty six (36) months have not filed an IND under the program related to the assets and such failure is not due to action
or inaction of Prev or breach of its representations or warranties or covenants or if there is a change of control as defined in
the Prev Agreement and after such change of control the assets are not further developed; provided however that such thirty (30)
and thirty six (36) month periods can be extended by us for an additional twelve (12) months upon payment of a cash milestone payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2012, we completed a private
placement (the &ldquo;October 2012 Private Placement&rdquo;) with certain accredited investors, pursuant to which we sold an aggregate
of 6,750,000 shares of our common stock at a price per share of $1.60 (the &ldquo;Common Shares&rdquo;) for aggregate gross proceeds
of $10.8 million and net proceeds of $10.1 million. In connection with the October 2012 Private Placement, we filed a registration
statement with the SEC which was declared effective on December 20, 2012 for the resale of our common stock owned by certain of
the purchasers in the October 2012 Private Placement. In connection with the October 2012 Private Placement, we also entered into
an agreement with a certain purchaser that is an affiliate of Intrexon (the &ldquo;Joinder Agreement&rdquo;) pursuant to which
such purchaser agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement with us entered
into in connection with the Second Channel Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Griffin Securities, Inc.
(&ldquo;Griffin&rdquo;) served as the placement agent for the October 2012 Private Placement. In consideration for services
rendered by Griffin in the October 2012 Private Placement, we  (i) paid to Griffin cash commissions equal to 6.0% of the
gross proceeds received in the October 2012 Private Placement, (ii) issued to Griffin, or its designee, the Agent Warrants,
which are five-year warrants to purchase 635,855 shares of our common stock with an exercise price of $1.60 per share; and
(iii) reimbursed Griffin for its reasonable actual out-of-pocket expenses incurred in connection with the October 2012
Private Placement, including reasonable legal fees and disbursements. The common stock underlying the Agent Warrants was
registered under the registration statement declared effective on December 20, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2012, we expanded our relationship
with Intrexon and entered into a Second Channel Agreement with Intrexon (the &ldquo;Second Channel Agreement&rdquo;) that governs
an &ldquo;exclusive channel collaboration&rdquo; arrangement in which we will use Intrexon&rsquo;s technology relating to the identification,
design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody
therapies for the treatment of certain serious infectious diseases (the &ldquo;Program&rdquo;). The Second Channel Agreement establishes
committees comprised of our and Intrexon representatives that will govern activities related to the Program in the areas of project
establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual
property. On October 16, 2012, a closing was held for the transaction contemplated by the Second Channel Agreement. Pursuant to
the terms of a Stock Issuance Agreement with Intrexon (the &ldquo;Second Stock Purchase Agreement&rdquo;), we issued 3,552,210
shares of our common stock, $0.001 par value, which issuance is also deemed paid in consideration for the execution and
delivery of the Second Channel Agreement, dated August 6, 2012, between ourselves and Intrexon. We also agreed to register the
shares issued to Intrexon in accordance with the First Amendment to Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2012, upon stockholder
approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common stock continues trade
on the NYSE MKT (formerly the NYSE Amex and American Stock Exchange), under the symbol &ldquo;SYN&rdquo;. Prior to this time and
since October 16, 2008, our name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE MKT stock exchange under the symbol
&ldquo;AEN&rdquo;. We are incorporated in the State of Nevada. We maintain principal executive offices at 155 Gibbs Street, Suite
412, Rockville, Maryland 20850, and we maintain an administrative and finance office in Ann Arbor, Michigan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2011, we announced that
the Board of Directors had taken several actions to prioritize our focus on our entry into the emerging field of synthetic biology.
In connection with the change in business focus on March 8, 2012, we entered into a Membership Interest Purchase Agreement, and
certain related agreements, pursuant to which we sold all of our interest in the Adeona Clinical Laboratory (the &ldquo;Lab&rdquo;)
to Hartlab, LLC, an entity controlled by the Lab&rsquo;s former owner, in consideration for (i) the immediate assignment of the
Lab&rsquo;s outstanding accounts receivable up through the date of closing, plus (ii) Seven Hundred Thousand Dollars ($700,000)
payable pursuant to the terms of a two-year non-recourse promissory note secured by all of the assets of the Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, we entered into a
Channel Agreement with Intrexon (the &ldquo;Initial Channel Agreement&rdquo;) that governs an &ldquo;exclusive channel collaboration&rdquo;
arrangement in which we initially intended to use Intrexon&rsquo;s technology directed towards the production of PGIS, through
the use of<I> in vivo</I> conditionally regulated embedded controllable bioreactors for the treatment of PAH. The Initial Channel
Agreement establishes committees comprised of our and Intrexon representatives that will govern activities related to the PAH program
in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization
efforts and intellectual property. As consideration for execution of the Initial Channel Agreement, we entered into a Stock
Purchase Agreement with Intrexon (the Initial Stock Purchase Agreement&rdquo;) pursuant to which we issued to Intrexon a number
of shares of our common stock equal to 9.995% of the number of shares of our common stock issued and outstanding following and
giving effect to such issuance (the &ldquo;First Tranche&rdquo;) at a purchase price equal to the $0.001 par value of such shares,
which issuance was deemed paid in consideration for the execution and delivery of the Initial Channel Agreement. We also
agreed to issue additional shares of our common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial
sponsored by us in the U.S., or similar study as the parties may agree in a country other than the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since our inception in January 2001, our
efforts and resources have been focused primarily on acquiring and developing our product candidates, our clinical trials, raising
capital and recruiting personnel. As of June 30, 2010, we emerged from the development stage after entering into a sublicense agreement
with Meda AB and receiving an up-front payment of $2.5 million.&nbsp;We consider this sublicense agreement to be an indication
that we commenced our principal operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have financed our operations
primarily through public and private sales of our common stock, and we expect to continue to seek to obtain the required capital
in a similar manner. We have incurred an accumulated deficit of $68.9 million through December 31, 2012. We cannot provide any
assurance that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the
required regulatory approvals, or complete additional corporate partnering or acquisition transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of our consolidated financial
statements in accordance with U.S. generally accepted accounting principles (GAAP)&nbsp;requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, net revenues and expenses, and related disclosures. We believe
our estimates and assumptions are reasonable; however, actual results and the timing of the recognition of such amounts could differ
from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are accounting policies that we believe
are significant to the presentation of our consolidated financial statements. The most significant accounting policies relate to
stock-based compensation, revenue recognition and accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Calculating stock-based compensation expense
requires the input of highly subjective assumptions. We apply the Black-Scholes option pricing model to determine the fair value
of our stock options. Inherent in this model are assumptions related to expected stock-price volatility, option life, risk-free
interest rate and dividend yield. We estimate the volatility of our common stock at the date of grant based on historical volatility.
We estimate the expected life of our option using the contractual term of the option.&nbsp;The risk-free interest rate is based
on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected life of the options. The
dividend rate is based on our historical rate, which we anticipate to remain at zero. The assumptions used in calculating the fair
value of stock options represent our best estimates, however these estimates involve inherent uncertainties and the application
of management judgment. As a result, if factors change and different assumptions are used, the stock-based compensation expense
could be materially different in the future. In addition, we are required to estimate the expected forfeiture rate and only recognize
expense for those stock options expected to vest over the service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We record revenue when all of the following
have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the
sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&nbsp;&nbsp;We recognize milestone
payments or upfront payments that have no contingencies as revenue when payment is received.&nbsp;&nbsp;Our primary streams of
revenue are license revenue and laboratory revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our licensing agreements may contain multiple
elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees
associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or
regulatory event specified in the agreement. When we have substantive continuing performance obligations under an arrangement,
revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under
the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on the elapsed time
compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent
payments received or due. When we have no substantive continuing performance obligations under an arrangement, we recognize revenue
as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense research and development costs
associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and
development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries,
stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development,
legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing
and enhancement of our product candidates.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Year Ended December 31, 2012 and
2011</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative
expenses increased to $5.0 million for the year ended December 31, 2012, from $2.6 million for the year ended December 31,
2011. This increase of 94% is primarily the result of additional employee costs, expanded investor relation activities and
outside legal fees related to various Securities and Exchange Commission issues related to Berman &amp; Company P.A.&rsquo;s
failure to follow proper partner rotation procedures. The charge relating to stock-based compensation expense was $1.5
million for the year ended December 31, 2012, compared to $919,000 for the year ended December 31, 2011. This increase is due
to stock options granted to new executive officers. The stock-based compensation for the year ended December 31, 2011
includes a charge of $398,000 relating to the modification of certain stock options, prior to expiration, held by a member of
the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Research and
development expenses increased to $12.3 million for the year ended December 31, 2012, from $3.3 million for the year ended December
31, 2011. This increase of 268% is primarily the result of recording the fair value ($7.8 million) of the common stock issued to
Intrexon as consideration for the Exclusive Channel Collaboration Agreement and the fair value ($1.2 million) of the common stock
issued for the acquisition of the</FONT><I> C. diff</I> program assets of Prev ABR LLC. These are non-cash charges. <FONT STYLE="color: black">The
charge relating to share-based compensation expense was $400,000 for the year ended December 31, 2012, compared to $54,000 for
the year ended December 31, 2011.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Income (Expense), net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $15,000 for the year ended
December 31, 2012, compared to other expense of $1.7 million for the year ended December 31, 2011. Other expense for the year ended
December 31, 2011, includes $1.7 million relating to the estimated fair value of the warrants associated with the January 2011
and April 2011 financings, adjusted for the change in their fair value at December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Loss</I> <I>from Continuing Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our  loss from continuing operations
for the year ended December 31, 2012, was $17.3 million, or $0.50 per common share, compared to $7.6 million, or $0.27 per common
share for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Income (Loss) from Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our income from discontinued operations
was $216,000, or $0.01 per common share for the year ended December 31, 2012, compared to a net loss of $523,000, or $0.02 per
common share for the year ended December 31, 2011. On March 8, 2012, we entered into a Membership Interest Purchase Agreement,
and certain related agreements, pursuant to which we sold all of our interest in the Lab to Hartlab, LLC. This resulted in the
classification of the Lab as discontinued operations.<I> See Note 3 - Discontinued Operations of Adeona Clinical Laboratory and
Note Receivable</I> for summarized statement of operations data for the years ended December 31, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have financed our operations since inception
primarily through proceeds from equity financings, corporate partnering license fees, laboratory revenues and miscellaneous equipment
sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2012, we completed a private
placement financing of 6,750,000 shares of our common stock, par value of $.001 per share, at a price per share of $1.60. We raised
gross proceeds of $10.8 million, before estimated offering expenses of $680,000, which includes placement agent fees. In addition
to the fee, the placement agent received warrants to purchase 635,855 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $10.0 million at December
31, 2012, an increase of $3.3 million from December 31, 2011. During the year ended December 31, 2012, the primary sources of cash
were net proceeds from the issuances of common stock in a private placement financing&nbsp;of $10.2 million and stock option exercises
of $127,000 and warrant exercises of $2.0 million.&nbsp;The primary use of cash during the year ended December 31, 2012 was for
working capital requirements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $6.7 million at December
31, 2011, an increase of $4 million from December 31, 2010. During the year ended December 31, 2011, the primary sources of cash
were net proceeds from the issuances of common stock to institutional investors&nbsp;of $7 million and stock option and warrant
exercises of $15,000.&nbsp;The primary use of cash during the year ended December 31, 2011 was for working capital requirements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 27, 2013, our cash balance
was approximately $8.7 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our continued operations will primarily
depend&nbsp;on whether we are able to generate revenues and profits through partnerships, joint ventures and/or raise additional
funds through various potential sources, such as license fees from a potential corporate partner, equity and debt financing. Such
additional funds may not become available on acceptable terms and there can be no assurance that any additional funding that we
do obtain will be sufficient to meet our needs in the long term. We will continue to fund operations from cash on hand and through
the similar sources of capital previously described. We can give no assurances that any additional capital that we are able to
obtain will be sufficient to meet our needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Current and Future Financing Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred an accumulated deficit
of $68.9 million through December 31, 2012. With the exception of the quarter ended June 30, 2010, we have incurred negative cash
flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection
with implementing our business strategy, including our planned product development efforts, our clinical trials, and our research
and discovery efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our current plans, we believe
that our cash will be sufficient to enable us to meet our planned operating needs for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, the actual amount of funds we
will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the progress of our research activities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the number and scope of our research programs;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the progress of our preclinical and clinical
development activities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the progress of the development efforts
of parties with whom we have entered into research and development agreements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to maintain current research
and development&nbsp;licensing arrangements&nbsp;and to establish new research and development and&nbsp;&nbsp;&nbsp;licensing &nbsp;&nbsp;arrangements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to achieve our milestones
under licensing arrangements;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs involved in prosecuting and
enforcing patent claims and other intellectual property rights;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs and timing of regulatory approvals;
and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 19pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">profitability of our clinical laboratory
diagnostic and microbiology services business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based our estimate on assumptions
that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential
sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek
to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not
have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we
need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other
securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able
to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit
our operations and our business, financial condition and results of operations would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>License and Contractual Agreement Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a table of our contractual obligations
for the years 2013 through 2017 as of December 31, 2012 <I>(in thousands)</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 22%; text-align: left">License Agreements</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">175</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Sponsored Research Agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Lease Agreements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">48</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">335</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">66</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">456</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional In-Licensed Programs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may enter into additional license agreements relating to
new product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Quantitative and Qualitative Disclosures About Market Risk</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable because we are a smaller reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Financial Statements and Supplemental Data</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reports of Independent Registered Public Accounting Firms</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Operations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Changes in Stockholders&rsquo; Equity</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">38</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Cash Flows</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">39</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes to Consolidated Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">40</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Report of Independent Registered Public
Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors and Stockholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Rockville, Maryland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have audited the
accompanying consolidated balance sheet of Synthetics Biologics, Inc. as of December 31, 2012 and the related consolidated
statements of operations, changes in stockholders&rsquo; equity, and cash flows for the year ended December 31, 2012. These
financial statements are the responsibility of Synthetic Biologic Inc.&rsquo;s management. Our responsibility is to express
an opinion on these financial statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">We conducted
our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatemen</FONT><FONT STYLE="color: Black">t. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. </FONT><FONT STYLE="color: black">Our audit included consideration of internal
control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for
our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the financial position of Synthetic Biologics, Inc. at December
31, 2012, and the results of its operations and its cash flows for the year ended December 31, 2012<B>,</B> in conformity with
accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ BDO USA, LLP</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boston, Massachusetts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 16, 2013</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><IMG SRC="image_002.jpg" ALT="" STYLE="height: 57px; width: 355px">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Synthetic Biologics, Inc. and Subsidiaries as of December 31, 2011 and 2010 and the related consolidated statements
of operations, stockholders&rsquo; equity and cash flows for the years ended December 31, 2011 and 2010. These consolidated financial
statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States).&nbsp; Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.&nbsp;
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&nbsp;
Our audits included the consideration of internal control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting.&nbsp; Accordingly, we express no such opinion. An audit includes examining, on a test
basis, evidence supporting the amounts and disclosures in the financial statements.&nbsp; An audit also includes assessing the
accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement
presentation.&nbsp; We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly in all material respects, the consolidated financial position of Synthetic Biologics,
Inc. and Subsidiaries as of December 31, 2011 and 2010, and the related consolidated statements of operations, stockholders&rsquo;
equity and cash flows for the years ended December 31, 2011 and 2010, in conformity with accounting principles generally accepted
in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="color: black">Berman &amp; Company, P.A.</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 35px; width: 178px"></P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">Boca Raton, Florida</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: black">May 11, 2012</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 56px; width: 251px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9,954</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6,678</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable &ndash; net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">405</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Assets of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.25in">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,122</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Long-term note receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Deposits and other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">13,423</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Liabilities and Stockholders' Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accrued liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Preferred stock,&nbsp;&nbsp;$0.001 par value; 10,000,000
    shares authorized, none&nbsp;&nbsp;issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Common stock,&nbsp;&nbsp;$0.001 par value; 100,000,000
    shares authorized, 44,444,230&nbsp;&nbsp;issued and 44,362,748 outstanding and 31,374,002&nbsp;&nbsp;issued and 31,292,520
    outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(68,941</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(51,873</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,028</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">13,423</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share and per
share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the years ended December
    31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,012</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,588</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Research and development</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Operating Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,928</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Loss from Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,299</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,928</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other Income (Expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,492</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(242</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income (expense)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total Other Income (Expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,698</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Loss from Continuing Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,284</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,626</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Income (Loss) from Discontinued Operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">216</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss and Comprehensive Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(17,068</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Net Income (Loss) Per Share&nbsp;&nbsp;- Basic and Dilutive:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt">Continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.50</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.27</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.01</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt">Net Income (Loss) Per Share</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.49</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.29</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 2.5pt">Weighted
    average number of shares outstanding during the period - Basic and Dilutive</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">34,896,592</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">27,710,428</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Changes in
Stockholders' Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands, except share amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="color: black; font-weight: bold; border-bottom: Black 1pt solid">Common Stock $0.001 Par Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; padding-bottom: 1pt">Additional Paid-</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; padding-bottom: 1pt">Accumulated</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; padding-bottom: 1pt">Total Stockholders'</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">in Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD STYLE="padding-bottom: 1pt; color: black; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 35%; color: black; font-weight: bold">Balance, December 31, 2010</TD><TD STYLE="width: 1%; color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; color: black; font-weight: bold; text-align: right">23,338,707</TD><TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; color: black; font-weight: bold; text-align: right">23</TD><TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; color: black; font-weight: bold; text-align: right">47,280</TD><TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; color: black; font-weight: bold; text-align: right">(43,724</TD><TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 10%; color: black; font-weight: bold; text-align: right">3,579</TD><TD STYLE="width: 1%; color: black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">&nbsp;</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">&nbsp;</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">973</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">973</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for employee compensation</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">73,585</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">94</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">94</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for exclusive channel collaboration agreement</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">3,123,558</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">3</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,684</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,687</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for consulting fees</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">171,796</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">165</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">165</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for stock options and warrants exercised</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">38,948</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">15</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">15</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Issuance of common stock , net of issuance costs of&nbsp;&nbsp;$539</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">4,545,926</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">5</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">6,956</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">6,961</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Warrant liability reclassified to stockholders' equity</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,734</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">-</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,734</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">)</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">(8,149</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; font-weight: bold">Balance, December 31, 2011</TD><TD STYLE="color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; text-align: right">31,292,520</TD><TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; text-align: right">31</TD><TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; text-align: right">58,901</TD><TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; text-align: right">(51,873</TD><TD STYLE="color: black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: black; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; text-align: right">7,059</TD><TD STYLE="color: black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,852</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,852</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for exclusive channel collaboration agreement</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">3,552,210</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">3</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">7,811</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">7,814</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for acquisition of program assets</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">625,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,168</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1,169</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Issuance of common stock for stock options and warrants exercised</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">2,143,018</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">2</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">2,080</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">2,082</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Issuance of common stock, net of issuance costs of $680</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">6,750,000</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">7</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">10,113</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">10,120</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">(17,068</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">)</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">(17,068</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2012</TD><TD STYLE="color: black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: right">44,362,748</TD><TD STYLE="padding-bottom: 2.5pt; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: right">44</TD><TD STYLE="padding-bottom: 2.5pt; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: right">81,925</TD><TD STYLE="padding-bottom: 2.5pt; color: black; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="color: black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: right">(68,941</TD><TD STYLE="padding-bottom: 2.5pt; color: black; font-weight: bold; text-align: left">)</TD><TD STYLE="color: black; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: black; font-weight: bold; text-align: right">13,028</TD><TD STYLE="padding-bottom: 2.5pt; color: black; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(In thousands)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(17,068</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(8,149</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">973</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock issued as compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock issued for consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock issued for exclusive channel collaboration agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,815</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,684</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock issued for acquisition of program assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Warrant expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,492</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Provision for uncollectible accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">442</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Gain on sale of discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(677</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Amortization of premium on investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Loss on sale of short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Loss on sale of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Impairment on loss of equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Gain on the settlement of accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(480</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,544</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">327</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deposits and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Assets of discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(181</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Liabilities of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,916</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,875</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Purchase of short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,370</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Proceeds from short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Proceeds from the sale of equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used In Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Proceeds from issuance of common stock for stock option and warrant exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,082</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of common stock for exclusive channel collaboration agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Proceeds from the issuance of common stock, net of issuance costs of $680 and $539, respectively</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10,120</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,961</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided By&nbsp;&nbsp;Financing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,979</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,029</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash at beginning of year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,678</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,649</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at end of year</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">9,954</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,678</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">Supplemental disclosures of non-cash investing
    and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Reclassification of warrant liability to additional paid-in-capital</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,734</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 39; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31, 2012 and 2011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Organization and Nature of Operations and Basis of Presentation</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Description of Business</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Synthetic Biologics&rdquo;) is a<FONT STYLE="color: black"> biotechnology company focused on the development of biologics
for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of<I>
C. difficile</I> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and <I>Acinetobacter</I>
infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis
and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 27%; border-bottom: black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Therapeutic
    Area</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 27%; border-bottom: black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Product
    Candidate</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Status</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relapsing-remitting
    MS</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trimesta</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(oral
        estriol)</FONT></P></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patients
    fully enrolled in Phase II clinical trial;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">dosing and monitoring underway</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cognitive
    dysfunction in MS</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trimesta</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(oral
        estriol)</FONT></P></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patient
    enrollment underway in Phase II</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">clinical trial</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>C.
    difficile</I> infection prevention</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYN-004</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">(monoclonal antibody)</FONT></FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Series
        of oral enzyme candidates; first generation candidate (formerly known as P1A) is in Phase II;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">next
        generation candidate, SYN-004, (formerly known as P3A) is in preclinical</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pertussis</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYN-005</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">(monoclonal antibody)</FONT></FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Preclinical;
    Collaborations with Intrexon and The University of Texas at Austin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Acinetobacter
    </I>infection</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYN-001</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">(monoclonal antibody)</FONT></FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Discovery;
    Collaboration with Intrexon</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fibromyalgia</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effirma</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">(oral flupirtine)</FONT></FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Partnered
    with Meda AB</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To prioritize the Company&rsquo;s focus
on the<FONT STYLE="color: black"> development of product candidates for the prevention and treatment of serious infectious diseases,
it does not intend to pursue</FONT> further development of the previously announced program for pulmonary arterial hypertension.
However, the Company is currently in discussions with Intrexon to substitute this program with an alternate program better suited
to its current objectives and focus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to further prioritize the Company&rsquo;s
focus, it has elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However,
the Company is currently seeking development partners for its zinc-based intellectual property and assets including, AEN-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basis of Presentation and Corporate
Structure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012, the Company
had seven subsidiaries, Pipex Therapeutics, Inc. (&ldquo;Pipex Therapeutics&rdquo;), Effective Pharmaceuticals, Inc.
(&ldquo;EPI&rdquo;), Solovax, Inc. (&ldquo;Solovax&rdquo;), CD4 Biosciences, Inc. (&ldquo;CD4&rdquo;), Epitope
Pharmaceuticals, Inc. (&ldquo;Epitope&rdquo;), Healthmine, Inc. (&ldquo;Healthmine&rdquo;) and Putney Drug Corp.
(&ldquo;Putney&rdquo;). As of December 31, 2012, Pipex Therapeutics, EPI, Healthmine and Putney are wholly owned and Solovax,
CD4 and Epitope are majority-owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, the
outstanding common stock of the Company is that of Synthetic Biologics, Inc. All statements of operations, stockholders&rsquo;
equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the
State of Delaware on January 8, 2001, except for EPI, which was incorporated in Delaware on December 12, 2000, Epitope which was
incorporated in Delaware in January of 2002, Putney which was incorporated in Delaware in November of 2006 and Healthmine which
was formed in Delaware in December of 2007.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2012, the Company sold all
of its interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s
former owner, in consideration for (i) the immediate assignment of the Lab&rsquo;s outstanding accounts receivable up through
the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all
the assets of the Lab. Accordingly, this business has been presented in the consolidated financial statements as discontinued
operations. This transaction is described in more detail in Note 3 &ndash; Discontinued Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Summary of Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All inter-company transactions and accounts
have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Emerging from the Development Stage</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the second quarter of 2010, the
Company emerged from the development stage.&nbsp;&nbsp;&nbsp;A development-stage enterprise is one in which planned principle
operations have not commenced or if its operations have commenced, there has been no significant revenue.&nbsp;On May 6, 2010, the Company entered into a Sublicense Agreement
(the &ldquo;Meda Agreement&rdquo;) with Meda&nbsp;AB of Sweden (&ldquo;Meda&rdquo;) and received an up-front payment of $2.5 million.
The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement
of principal operations, and therefore development-stage reporting was no longer required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and
assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates
and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property
and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability
and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected
future operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating
its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounts Receivable and Allowance
for Doubtful Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable were reported at realizable
value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded.
The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they
were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related
to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the
state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve
estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables
deemed uncollectible were charged against the allowance for doubtful accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records revenue when all of
the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation,
(3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&nbsp;&nbsp;The Company
recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&nbsp;&nbsp;For
the year ended December 31, 2012 and 2011, the Company&rsquo;s only stream of revenue was laboratory revenue.&nbsp;&nbsp;Laboratory
revenues are a component of discontinued operations for the years ended December 31, 2012 and 2011. See Note 3 &ndash; Discontinued
Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s licensing agreements
may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones
and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion
of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations
under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance
approach. Under the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on
the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the
amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under
an arrangement, it recognizes revenue as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2010, the Company entered into the
Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&nbsp; As consideration
for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment
was recorded as license revenue in 2010. Pursuant to the Company&rsquo;s license agreement with McLean Hospital, the Company paid
15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled
to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and
$10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of
7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and
Japan.&nbsp;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral
flupirtine for fibromyalgia. Pursuant to the terms of the Company&rsquo;s agreement with McLean Hospital, the Company is obligated
to pay half of all future royalties the Company receives.&nbsp;&nbsp;Future milestone payments will be recorded as revenue when
payment is received as there are no future deliverables, and it is non-refundable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Laboratory Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company primarily recognized revenue
for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including
Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts
from such payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintained a sales
allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this
allowance, the Company looked at several factors, the most significant of which was the average difference between the amount
charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average
adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior period multiplied by
the period&rsquo;s actual gross sales to determine the actual sales allowance for each period. See Note 3 - Discontinued
Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks and Uncertainties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's operations could be subject
to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business
failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases
in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may
not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast
and plan future business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash
and highly liquid short-term investments with original maturities of three months or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Classification of Marketable Securities
as Held to Maturity, Trading, and Available for Sale</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determines the appropriate
classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at
each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability
to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity
are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance
sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally
for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized
gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading,
are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax,
included in the determination of comprehensive income and reported in shareholders&rsquo; equity. At December 31, 2012 and 2011,
respectively, the Company had no debt and marketable equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2011,
the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds
and certificates of deposits as follows <I>(in thousands)</I> :</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 72%; text-align: justify">Purchase of short-term investments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 25%; text-align: right">(4,370</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Amortization of premium on investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Proceeds from short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Loss on sale of short-term investments</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Fair value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Property and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is recorded at
cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying
lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following
table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 49%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Asset&nbsp;Description</B></FONT></TD>
    <TD NOWRAP STYLE="width: 4%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 47%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Estimated&nbsp;Useful&nbsp;Life</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Office equipment and furniture</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3-5&nbsp;&nbsp;years</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Laboratory equipment</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7-10 years</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Manufacturing equipment</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10 years</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Leasehold improvements and fixtures</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lesser of estimated useful or life of
    lease</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense was approximately
$63,000 and $144,000 for the years ended December 31, 2012 and 2011, respectively. When assets are disposed of, the cost and accumulated
depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2012, the Company reviewed property
and equipment for impairment and determined that certain items were impaired due to obsolescence. As a result of this review,
the Company recorded an impairment loss of approximately $47,000. For the year ended December 31, 2011, there were no significant
events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Long-Lived Assets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company reviews its long-lived assets
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the
estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the
carrying value of the asset exceeds its fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill was not amortized, and was tested
for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying
value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available
and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was
assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC No. 350, &ldquo;Intangibles &ndash;
Goodwill and Others,&rdquo; requires a two-step approach to test goodwill for impairment for each reporting unit. The first step
tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the
impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the
goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities
to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit.
The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2011, in connection with
the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired.
See Note 3 &ndash; Discontinued Operations of Adeona Clinical Laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Derivative Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once determined, derivative liabilities
are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded
in results of operations as an adjustment to fair value of derivatives. In&nbsp;addition, the fair value of freestanding derivative
instruments such as warrants, are also valued using the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Income (Loss) per
Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net income (loss) per share is
computed by dividing net income (loss) by the weighted average number of common
shares outstanding. Diluted income (loss) per share is computed by dividing net income (loss) by the
weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent
shares were anti-dilutive, at December 31, 2012 and December 31, 2011, as such there is no separate computation for diluted
loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations
of net loss per common share for the year ended December 31, 2012 were 4,453,746 and 1,632,501, respectively, and for the
year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses research
and development costs associated with developmental products not yet approved by the FDA to research and development expense
as incurred.  Research and development  costs consist primarily of license fees (including upfront payments), milestone payments,
manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside
service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other
expenses relating to the design, development, testing and enhancement of the Company&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value accounting standards define
fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an
asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 1 inputs: Quoted
    prices (unadjusted)&nbsp;for identical assets or liabilities in active markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 2 inputs: Inputs,
    other than quoted prices included in Level 1 that are observable either directly or indirectly; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 3 inputs: Unobservable
    inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In many cases, a valuation technique used
to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant
input determines the placement of the entire fair value measurement in the hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of the Company&rsquo;s
short-term financial instruments, including cash and cash equivalents, accounts receivable, other current assets, accounts payable
and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include money
market accounts and mutual funds of $8.6 million and $5.0 million as of December 31, 2012 and December 31, 2011, respectively,
that are measured using Level 1 inputs.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Payment Arrangements</I></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, all forms of
stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are
measured at their fair value on the awards&rsquo; grant date typically using a Black-Scholes pricing model, based on the
estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for
services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based
payment, whichever is more readily determinable and are re-measured over the corresponding vesting period. The expense resulting
from stock-based payments is recorded in research and development expense or general and administrative expense in the
consolidated statement of operations, depending on the nature of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes
in accordance with accounting guidance now codified as FASB ASC Topic 740, &ldquo;<I>Income Taxes</I>,&rdquo; which requires that
the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts
and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse.
Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation
allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, accounting guidance now codified
as FASB ASC Topic 740-20, <I>&ldquo;Income Taxes &ndash; Intraperiod Tax Allocation&rdquo; </I>requires<I> </I>management to assess
the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities
who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex
tax laws of multiple jurisdictions. The accounting guidance prescribes a recognition threshold and measurement attribute for the
financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company records
the related interest expense and penalties, if any, as tax expense in the tax provision. At December 31, 2012 and 2011, respectively,
the Company did not record any liabilities for uncertain tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no accounting standards or
interpretations issued or recently adopted that are expected to have a material impact on the Company&rsquo;s financial position,
operations, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>3.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Discontinued Operations of Adeona Clinical Laboratory and Note
    Receivable</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2012, the Company sold all
of its interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s
former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&rsquo;s
outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year
promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are
due on March 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic
205-20 &ldquo;<I>Presentation of Financial Statements&mdash;Discontinued Operations</I>&rdquo; (ASC 205-20), the Company
determined that all the criteria for reporting a discontinued operation had been met. Accordingly, the Lab has been
classified as a discontinued operation and its results of operations, financial position and cash flows are separately
reported for all periods presented. The assets of the discontinued operations are presented separately under the caption
&ldquo;Assets of discontinued operations&rdquo; in the accompanying Consolidated Balance Sheets at December 31, 2012, and
December 31, 2011, and consist of the following <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Assets of discontinued operations:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt; padding-bottom: 1pt">Property and equipment, net</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid">-</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">23</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summarized statement of operations data for Adeona Clinical
Laboratory for the years ended December 31, 2012 and December 31, 2011 are as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Laboratory fees, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">115</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,169</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Cost of&nbsp; laboratory services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">975</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Impairment loss on goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">178</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total operating costs and expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">576</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(461</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(523</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Gain on sale of Adeona Clinical Laboratory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Income (loss) from discontinued operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">216</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(523</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>4.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Selected Balance Sheet Information</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Accounts receivable (in thousands)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: justify">Accounts receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">682</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Bad debt allowance - customer</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">405</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prepaid expenses and other current
assets (in thousands)</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: justify">Intrexon prepaid research and development expenses - See Note 10</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,412</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,509</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Intrexon prepaid research and development
expenses are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of
the remaining balance minus any amounts owed to Intrexon. The Company anticipates that the majority of the prepaid will be applied
to research and development goods and services during 2013.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Property and equipment (in thousands)&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: justify">Manufacturing equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">297</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Computer and office equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Laboratory equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">133</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(372</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">223</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">323</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Accrued liabilities (in thousands)&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: justify">Accrued vendor payments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5.</B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock-Based Compensation</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2001, the Company&rsquo;s Board
of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;). The total number of shares of stock with respect
to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during
any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate
upon the termination of the grantee&rsquo;s employment for any reason. Awards include options, restricted shares, stock appreciation
rights, performance shares and cash-based awards (the &ldquo;Awards&rdquo;). The 2001 Stock Plan contains certain anti-dilution
provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan
provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all
other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of December 31, 2012,
there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2007, the
Company&rsquo;s Board of Directors approved the 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;) for the
issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options,
stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards
to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by
stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the
compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the
Company&rsquo;s common stock on the date the option is granted. The total number of shares of stock with respect to which
stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any
one-year period under the 2007 plan shall not exceed 250,000. Options become exercisable over various periods from the date
of grant, and generally expire ten years after the grant date. As of December 31, 2012, there are 872,739 options issued and
outstanding under the 2007 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2010, the Board of Directors
and stockholders adopted the 2010 Stock Incentive Plan (&ldquo;2010 Stock Plan&rdquo;) for the issuance of up to 3,000,000 shares
of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend
equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors
and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined
by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&rsquo;s
common stock on the date the option is granted. Options become exercisable over various period from the date of grant, and generally
expire ten years after the grant date. As of December 31, 2012, there are 2,515,000 options issued and outstanding under the 2010
Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of an employee&rsquo;s termination,
the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial
grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has applied fair value accounting
for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date
of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2012
and 2011 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$1.69 - $2.47</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$0.49 - $2.22</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Expected dividends</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">0%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">0%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">108% - 174%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">175% - 188%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk fee interest rate</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">0.37% - 1.98%</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">1.30% - 3.58%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Expected life of option</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 - 10 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 - 7 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected forfeitures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">0%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">0%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based
compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements
have various terms as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">immediate vesting,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">half vesting immediately and the remainder over three years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">quarterly over three years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">annually over three years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">one-third immediate vesting and remaining annually over two years,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">one half immediate vesting with remaining vesting over nine months,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">one quarter immediate vesting with the remaining over three years</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">one quarter immediate vesting with the remaining over 33 months;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">monthly over three years.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2012, the Company granted 2,075,000
options to employees and consultants having an approximate fair value of $4.5 million based upon the Black-Scholes option pricing
model.&nbsp; During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of
$609,000 based upon the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation expense included
in general and administrative expenses and research and development expenses relating to stock options issued employees for the
years ended December 31, 2012 and 2011 were $1.4 million and $268,000, respectively. Stock-based compensation expense included
in general and administrative expenses and research and development expenses relating to stock options issued to consultants for
the years ended December 31, 2012 and 2011 were $216,000 and $705,000, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average&nbsp;Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; padding-bottom: 2.5pt">Balance &ndash; December 31, 2010</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,539,091</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.32</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.97
                                                                                          years</FONT></TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">1,028,000</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">557,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,333</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(93,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.59</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,979,010</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.01
                                                                               years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,075,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(374,851</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(225,413</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.37</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; December 31, 2012 &ndash; outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,453,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.78</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.43
                                                                               years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,308,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance &ndash; December 31, 2012 &ndash; exercisable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,891,877</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.71
                                                                               years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,160,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Grant date fair value of options granted &ndash; 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,467,984</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average grant date fair value &ndash; 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.15</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Grant date fair value of options granted &ndash; 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">609,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average grant date fair value &ndash; 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding and exercisable at December 31, 2012
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="11" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Outstanding</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="9" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Range&nbsp;of</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 14%; text-align: center">$0.09 - $2.00</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,162,362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.78</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">5.76 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">1,801,187</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">5.52 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">$2.01 - $3.00</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,212,227</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.15 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,011,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.14 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">$3.01 - $6.00</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,157</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.87</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.49 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">79,157</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.87</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.49 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.09 - $6.00</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,453,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.78</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.43 years</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,891,877</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.71 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding and exercisable at December 31, 2011
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="11" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Outstanding</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="9" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options&nbsp;Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Weighted</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Weighted&nbsp;Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">Range&nbsp;of</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">Average</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">Remaining</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 14%; text-align: center">$0.09 - $4.57</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,889,011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">6.11 years</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,364,608</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: right">5.72 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">$4.58 - $9.05</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.76 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.76 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">$0.09 - $9.05</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,979,010</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.34</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.01 years</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,454,607</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.46</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.62 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a summary of the Company&rsquo;s non-vested
stock options at December 31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Unvested</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Grant</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock&nbsp;Options</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date&nbsp;Fair&nbsp;Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%">Non-vested&nbsp;&ndash;&nbsp;December&nbsp;31,&nbsp;2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">524,403</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.82</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,075,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.21</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Vested/Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(891,332</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(146,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.79</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Non-vested &ndash; December 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,561,869</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.11</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average remaining period for vesting</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.09
                                                                               years</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012,
total unrecognized stock-based compensation expense related to stock options was $3.2 million, which is expected to be
expensed through September 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB&rsquo;s guidance for stock-based payments
requires cash flows from excess tax benefits to be classified as a part of cash flows from financing activities.&nbsp; Excess tax
benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to
stock compensation costs for such options.&nbsp; The Company did not record any excess tax benefits in 2012 or 2011.&nbsp; Cash
received from option exercises under the Company&rsquo;s stock-based compensation plans for the years ended December 31, 2012 and
2011 was $127,000 and $15,000, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock Warrants and Derivative Liabilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 25, 2012, the Company entered
into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants
to purchase 635,855 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price
of $1.60 and a life of five years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted
as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect
to equity. As of December 31, 2012, all the warrants were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2012, the Company
entered into a consulting agreement for a financial communications program, for a period of twelve months that began on
February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance
warrant exercisable for 250,000 shares of the Company&rsquo;s common stock based on achievement of certain stock price
milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable
for a period of two years from the date of issuance for an exercise price equal to the price ($2.20 per share) of
the Company&rsquo;s common stock on the date of execution (March 15, 2012). The expense recorded for the year ended December
31, 2012 approximated $63,000 and was estimated using the Monte Carlo valuation model. The assumptions used by the Company
are summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; color: black">Exercise price</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">2.20</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Expected dividends</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Expected volatility</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">110</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Risk free interest rate</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.26</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Expected life of warrant</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">2
                                                          years</FONT></TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2011, the Company
entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such
services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares
of the Company&rsquo;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of
issue at an exercise price equal to the price of the Company&rsquo;s common stock on the date of issue. The fair value of the
warrant approximated $200,000 and was measured using the Black-Scholes valuation model. All of this expense was recorded
in the year ended December 31, 2012. The assumptions used by the Company are summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; color: black">Exercise price</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">1.14</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Expected dividends</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Expected volatility</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">174</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Risk free interest rate</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.71</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Expected life of warrant</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">5
                                                          years</FONT></TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2011, the Company entered
into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants
to purchase 1,428,572 shares of common stock. Each warrant was exercisable&nbsp;for thirteen months&nbsp;at $2.00 per share and
subsequently exchanged for new warrants with substantially the same&nbsp;terms as the original warrants except that the expiration
date was extended for two months. The original warrants had an anti-dilution price protection feature; if the Company issues securities
at a price per share that is less than $2.00 per share, the warrant holders will be ratcheted down to the lower offering price.
However, the Company had instituted a floor price of $1.40 per share in connection with the price protection.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company entered
into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40
per share. Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid-in
capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2012, all of these warrants have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants were initially recorded as
liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair
value recorded as a warrant expense&nbsp;in the Company&rsquo;s statement of operations at each subsequent reporting period. On
April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000.
The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the
following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center">Remeasurement</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center">Commitment</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center">Date</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center; border-bottom: Black 1pt solid">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black">&nbsp;</TD><TD NOWRAP STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center; border-bottom: Black 1pt solid">April&nbsp;6,&nbsp;2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; color: black">Closing stock price</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">1.39</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">2.08</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Expected dividend rate</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0</TD><TD STYLE="color: black; text-align: left">%</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Expected stock price volatility</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">117.1</TD><TD STYLE="color: black; text-align: left">%</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">104.6</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left">Risk free interest rate</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.28</TD><TD STYLE="color: black; text-align: left">%</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.29</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left">Expected life (years)</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1.08</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.85</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 10, 2011, the Company entered
into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially
the same terms as the original warrants except that in the new warrants the expiration date was&nbsp;extended by two months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company entered into
a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase
844,391 shares of common stock. The warrant was initially exercisable&nbsp;for thirteen months&nbsp;at $2.0725 per share. The warrant
had an anti-dilution price protection feature; that provided if the Company issues securities at a price per share that is less
than $2.0725 per share,&nbsp;the&nbsp;exercise price of the warrant&nbsp;will be ratcheted down to the lower offering price.&nbsp;On
July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i)
the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was
extended for an additional&nbsp;three months to August 12, 2012,&nbsp;and (iv) the warrant&rsquo;s initial exercise date was changed
to January 2012. Due to this warrant exchange, the warrant liability was marked-to-market and reclassified to additional paid-in
capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2012, all of these warrants have
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrant is&nbsp;initially recorded
as a liability at&nbsp;its estimated fair value on the commitment date, which was $776,000 with subsequent changes in estimated
fair value recorded as a warrant expense&nbsp;in the Company&rsquo;s statement of operations at each subsequent period. On July
28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair
value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following
table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center">Remeasurement</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center">Commitment</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center">Date</TD><TD NOWRAP STYLE="color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center; border-bottom: Black 1pt solid">Date</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black">&nbsp;</TD><TD NOWRAP STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="color: black; text-align: center; border-bottom: Black 1pt solid">July&nbsp;28,&nbsp;2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; color: black">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; color: black; text-indent: -13.2pt; padding-left: 13.2pt">Closing stock price</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">2.08</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 10%; color: black; text-align: right">0.84</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; text-indent: -13.2pt; padding-left: 13.2pt">Expected dividend rate</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0</TD><TD STYLE="color: black; text-align: left">%</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left; text-indent: -13.2pt; padding-left: 13.2pt">Expected stock price volatility</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">112.1</TD><TD STYLE="color: black; text-align: left">%</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">105.6</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; text-indent: -13.2pt; padding-left: 13.2pt">Risk free interest rate</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.29</TD><TD STYLE="color: black; text-align: left">%</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">0.21</TD><TD STYLE="color: black; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; text-align: left; text-indent: -13.2pt; padding-left: 13.2pt">Expected life (years)</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1.08</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black">&nbsp;</TD>
    <TD STYLE="color: black; text-align: left">&nbsp;</TD><TD STYLE="color: black; text-align: right">1.04</TD><TD STYLE="color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the estimated fair value of
the warrant liabilities at December 31, 2011<I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.25in; padding-left: 0.25in">Balance at December 31, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; text-indent: -0.25in; padding-left: 0.25in">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,492</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Change in fair value of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in">Reclassification to additional
    paid-in capital</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in">Balance at December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of warrant activity for the
Company for the year ended December 31, 2011 and for the year ended December 31, 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted&nbsp;Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%">Balance at December 31, 2010</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,131,078</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.49</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,272,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(129,240</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2.08</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Balance as December 31, 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,259,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">985,855</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,768,167</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(844,373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.32</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Balance as December 31, 2012</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,632,501</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.99</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stock-based compensation expense included
in general and administrative expenses relating to warrants issued to consultants for the year ended December 31, 2012 was $271,000.
There was no stock-based compensation for warrants for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
<P STYLE="margin: 0">A summary of all outstanding and exercisable warrants as of December 31, 2012 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exercise</FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Price</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrants</FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Outstanding</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrants</FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exercisable</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted&nbsp;Average</FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Remaining</FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Contractual&nbsp;Life</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aggregate
    </FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intrinsic Value</FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.14</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.09 years</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18,182</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18,182</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.00 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">635,855</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">635,855</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.83 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">102,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">250,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.20 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.22</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">517,257</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">517,257</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.91 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.30</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61,207</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61,207</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.30 years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.75</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.13
    years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.99</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,632,501</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,432,501</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.80
    years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">172,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options of Subsidiary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012, Epitope, a
majority-owned subsidiary of Synthetic Biologics, has 50,000 stock options outstanding and 40,000 stock options exercisable.
These stock options have an exercise price of $0.001 and a remaining contractual life of 5.50 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Stockholders&rsquo;
                                                                                     Equity</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Year Ended December 31, 2011</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2011,
the Company issued 28,333 shares of common stock in connection with the exercise of stock options and warrants for proceeds of
$15,000 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company issued 73,585 shares of common
stock for employment service, having a fair value of $94,000 ($1.29 average per share) and 171,796 shares of common stock for
consulting services, having a fair value of $165,000 ($0.96 average per share), based on the quoted closing trading prices. The
Company also issued 3,123,558 shares of common stock as consideration for the Exclusive Channel Collaboration Agreement with Intrexon,
having a fair value of $1.7 million ($0.54 per share), based on the quoted closing trading price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2011, the Company sold
2,857,144 shares of common stock and warrants exercisable for&nbsp;1,428,572 shares of common stock&nbsp;for $4 million. Direct
offering costs were approximately $296,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company sold 1,688,782
shares of common stock and a warrant exercisable for 844,391 shares of common stock&nbsp;for $3.5 million. Direct offering costs
were approximately $243,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><I>Year Ended December
31, 2012</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">On October
31, 2012, the Company completed a private placement financing of </FONT>6,750,000 shares of the Company&rsquo;s common stock at
a closing price of $1.60 for gross proceeds of $10.8 million.&nbsp;&nbsp;The Company paid direct offering costs of $680,000.&nbsp;&nbsp;See
Note 5 regarding warrants granted with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">During the
year ended December 31, 2012, the Company issued 374,851 shares of common stock, in connection with the exercise of stock options,
for proceeds of approximately $127,000. The Company also issued 1,768,167 shares of common stock in connection with the exercise
of warrants, for proceeds of approximately $2.0 million.</FONT> The Company also issued 3,552,210 shares of common stock as consideration
for a second Exclusive Channel Collaboration Agreement with Intrexon, having a fair value of $7.8 million ($2.20 per share),
based on the quoted closing trading price. These shares are subject to the registration rights agreement as described in Note 7. In connection with
the private placement that was completed on October 31, 2012, the Company also entered into an agreement with NRM VII Holdings I,
LLC, an affiliate of Intrexon that acquired 3,125,000 shares of the Company&rsquo;s common stock in the private placement, pursuant
to which NRM VII Holdings I, LLC agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement
as described in Note 7. In addition, the Company issued 625,000 shares of common stock as consideration
for the acquisition of the <I>C. diff</I> program assets of Prev ABR LLC, having a fair value of $1.2 million ($1.87 per
share), based on the quoted closing trading price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>License,
                                                                                     Collaborative and Employment Agreements and
                                                                                     Commitments</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License and Collaborative
Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As described below, the Company has entered
into several license and collaborative agreements for the right to use research, technology and patents. Some of these license
and collaborative agreements may contain milestones.&nbsp; The specific timing of such milestones cannot be predicted and are
dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which
may never occur).&nbsp; Further, under the terms of certain licensing agreements, the Company may have the obligation to pay certain
milestones contingent upon the achievement of specific levels of sales.&nbsp; Due to the long-range nature of such commercial
milestone amounts, they are neither probable at this time nor predictable and consequently are not included in this disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On
December 19, 2012, the Company entered into a License Agreement with The University of Texas at Austin (the &ldquo;University&rdquo;)
for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related
to pertussis antibodies. The License Agreement provides that the University is entitled to payment of past patent expenses, an
annual payment of $50,000 per year commencing on the effective date through December 31, 2014 and a $25,000 payment on December
31, 2015 and milestone payments of $50,000 upon commencement of Phase I clinical trials, $100,000 upon commencement of Phase III
clinical trials, $250,000 upon NDA submission in the U.S., $100,000 upon European Medicines Agency approval and $100,000 upon
regulatory approval in an Asian country. In addition, the University is entitled to a running royalty upon net sales (as defined
in the License Agreement). The License Agreement terminates upon the expiration of the patent rights (as defined in the License
Agreement); provided, however that the License Agreement is subject to early termination by the Company in its discretion and
by the University for a breach of the License Agreement by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the License Agreement, the Company and the University also entered into a Sponsored
Research Agreement pursuant to which the University will perform certain research work related to pertussis. The Sponsored Research
Agreement may be renewed annually, in the sole discretion of the Company, after the first year for two additional one year terms
with a fixed fee for the first year of $303,287 and for the second and third years, if renewed, a fixed fee of $316,438 and $328,758
respectively, all payable in quarterly installments. If renewed by the Company after the first year for the remaining two years,
the research shall be performed from the effective date of the Sponsored Research Agreement until December 31, 2015; provided,
however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default
in the material obligations under the Research Agreement which remain uncured for sixty days after receipt of notice, automatically
upon the Company&rsquo;s bankruptcy or insolvency and by the Company in its sole discretion at any time after the one year anniversary
of the date of execution thereof upon no less than 90 days notice. Upon termination prior to December 31, 2014, the Company shall
only be responsible for payment of expenses that do not exceed the fixed annual amount and are incurred prior to the termination
date and non-cancellable expenses committed to be expended by the University prior to the termination date for the lesser of the
remainder of their appointment in the case of salaries and December 31, 2014. Upon a termination after December 31, 2014 or due
to a breach by the University, the Company shall only be responsible for all reasonable expenses that do not exceed the fixed annual
amount and that are incurred by the University prior to the termination date for services performed prior to the termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 28, 2012, a closing
was held for the transaction contemplated by the Prev Agreement the Company entered into with Prev ABR LLC
(&ldquo;Prev&rdquo;), pursuant to which it acquired the<I> C. diff</I> program assets of Prev, including pre-Investigational
New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and
international patents.&nbsp; Pursuant to the Prev Agreement, the Company paid Prev an initial cash payment of $100,000 upon
execution of the Prev Agreement and at closing paid an additional cash payment of $135,000 and issued 625,000 unregistered
shares of our common stock to Prev. See Note 6. In addition, upon the achievement of the milestones set forth below, Prev may
be entitled to receive additional consideration payable 50% in cash and 50% in our stock, subject to Prev&rsquo;s option to
receive the entire payment in shares of our stock, with the exception of the first milestone payments to be paid in cash: (i)
upon commencement of an IND; (ii) upon commencement of a Phase I clinical trial; (iii) upon commencement of a Phase II
clinical trial; (iv) upon commencement of a Phase III clinical trial; (v) upon Biologic License Application (BLA) filing in
the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi) upon BLA approval in the U.S.
and upon approval in territories outside the-U.S. The Prev Agreement also provides that Prev has a right to the return to it
of all assets acquired by the Company under the Prev Agreement if on or prior to the date that is (i) thirty (30) months
after the execution of the Prev Agreement, the Company has not initiated toxicology studies in non-rodent models or (ii)
thirty six (36) months have not filed an IND under the program related to the assets and such failure is not due to action or
inaction of Prev or breach of its representations or warranties or covenants or if there is a change of control as defined in
the Prev Agreement and after such change of control the assets are not further developed; provided however that such thirty
(30) and thirty six (36) month periods can be extended by the Company for an additional twelve (12) months upon payment of a
cash milestone payment.</P>


<!-- Field: Page; Sequence: 50; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2012, the Company
expanded its relationship with Intrexon and entered into the Second Channel Agreement with Intrexon that governs an
&ldquo;exclusive channel collaboration&rdquo; arrangement in which the Company will use Intrexon&rsquo;s technology relating
to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of
a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases. Pursuant to the terms of
the Second Stock Issuance Agreement with Intrexon, which was approved by the Company&rsquo;s stockholders on October 5, 2012,
the Company issued 3,552,210 shares of its common stock, $0.001 par value, which issuance is also deemed paid in
consideration for the execution and delivery of the Second Channel Agreement, dated August 6, 2012, between the Company and
Intrexon. The fair value of this transaction was $7.8 million and was charged to research and development expense for the
year ended December 31, 2012, in accordance with the Company&rsquo;s accounting policy. In connection with the transactions
contemplated by the Second Stock Issuance Agreement, and pursuant to the First Amendment to Registration Rights Agreement
(the &ldquo;First Amendment to Registration Rights Agreement&rdquo;) executed and delivered by the parties at the closing,
the Company agreed to file a &ldquo;resale&rdquo; registration statement registering the resale of certain of the shares
issued under the Second Stock Issuance Agreement. None of the shares to be issued under the Second Stock Issuance Agreement
need to be registered until April 30, 2013. Under that agreement, the Company is obligated to use its reasonable best efforts
to cause the &ldquo;resale&rdquo; registration statement to be declared effective as promptly as practicable after filing and
to maintain the effectiveness of the registration statement until all securities therein are sold or are otherwise can be
sold pursuant to Rule 144, without any restrictions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to certain expense allocations
and other offsets provided in the Second Channel Agreement, the Company will pay Intrexon royalties on annual net sales of the
Synthetic Products, calculated on a Synthetic Product-by-Synthetic Product basis. The Company has likewise agreed to pay Intrexon
a percentage of quarterly revenue obtained from a sublicensor in the event of a sublicensing arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also agreed upon the filing
of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product, or alternatively
the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the &ldquo;IND Milestone
Event&rdquo;), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares of Common Stock (the
&ldquo;IND Milestone Shares&rdquo;) having a fair market value equaling two million dollars ($2M) where such fair market value
is determined using published market data of the share price for Common Stock at the close of market on the business day immediately
preceding the date of public announcement of attainment of the IND Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the first to occur of either first
commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both
as applicable, the &ldquo;Approval Milestone Event&rdquo;), the Company agreed to pay to Intrexon either (i) three million dollars
($3M) in cash, or (ii) that number of shares of Common Stock (the &ldquo;Approval Milestone Shares&rdquo;) having a fair market
value equaling three million dollars ($3M) where such fair market value is determined using published market data of the share
price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment
of the Approval Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also agreed that it will pay
an optional and varying fee whereby the Company remits a payment, in cash or equity at our sole discretion, to Intrexon calculated
as a multiple of the number of targets in excess of three (3) total that the Company desires to elect (the &ldquo;Field Expansion
Fee&rdquo;). The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two
million dollars ($2M) in cash for each target in excess of three (3) total that the Company elects, or (ii) that number of shares
of Common Stock (the &ldquo;Field Expansion Fee Shares&rdquo;) having a fair market value equaling two million dollars ($2M) for
each such target that the Company elects in excess of three where such fair market value is determined using published market
data establishing the volume-weighted average price for a share of Common Stock over the thirty (30) day period immediately preceding
the date of the Field Expansion Fee Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, the
Company entered into the Initial Channel Agreement with Intrexon that governs an &ldquo;exclusive channel
collaboration&rdquo; arrangement in which the Company initially intended to use Intrexon&rsquo;s technology directed towards
the production of PGIS. As consideration for execution of the Initial Channel Agreement, the Company entered into the
Initial Stock Purchase Agreement with Intrexon pursuant to which the Company issued to Intrexon a number of shares of our
common stock equal to 9.995% of the number of shares of the Company&rsquo;s common stock issued and outstanding following and
giving effect to such issuance at a purchase price equal to the $0.001 par value of such shares, which issuance was deemed
paid in consideration for the execution and delivery of the Initial Channel Agreement. The Company also agreed to
issue additional shares of its common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial
sponsored by the Company in the U.S., or similar study as the parties may agree in a country other than the U.S. The program
under this Initial Channel Agreement is in the discovery stage. In connection with the transactions contemplated by the Stock
Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the
Company agreed to file a &ldquo;resale&rdquo; registration statement registering the resale of the First Tranche Shares
within 120 days of the closing date of such issuance. The registration statement registering such shares was declared
effective on April 13, 2012, but is not currently valid due to certain issues regarding the failure of the Company&rsquo;s
prior auditor to follow proper partner rotation. Intrexon has agreed not to require the Company to file a post effective
registration statement on Form S-1 with respect to the First Tranche Shares and instead has agreed to wait until the Company
is once again S-3 eligible for registration of such shares.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company paid Intrexon a prepayment
of research and development expenses of $2.5 million for research and development goods and services to be provided in the future
and has been recorded on the Company&rsquo;s balance sheet in prepaid expenses and other current assets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September&nbsp;of 2005, the Company
entered into a three-year research agreement with the University of Michigan. Pursuant to that agreement, the Company sponsored
research of approximately $460,000 per year.&nbsp;&nbsp;On March 20, 2008, the Company terminated the agreement.&nbsp;&nbsp;On
March 24, 2009, the Company entered into a payment plan with the University of Michigan to pay the outstanding balance of $197,000.&nbsp;&nbsp;The
Company agreed to pay $5,000 per month, the balance was paid in full July 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Employment Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 3, 2012, Dr. Kuo resigned
from his positions as President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered into a nine-month
consulting agreement with the Company (the &ldquo;Consulting Agreement&rdquo;). Pursuant to the Consulting Agreement, Dr. Kuo
will be entitled to a consulting fee of $17,000 per month and retain the right to exercise the stock options held by him that
have vested (324,999) as of the effective date of the Consulting Agreement for a period expiring on the date that is one year
from the effective date of the Consulting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 3, 2012, Jeffrey Riley
was appointed to serve as the Company&rsquo;s Chief Executive Officer and President. In connection with his appointment, Mr. Riley
entered into a three-year employment agreement with the Company (the &ldquo;Riley Employment Agreement&rdquo;). Pursuant to the
Riley Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary
performance and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of the Company&rsquo;s
common stock with an exercise price equal to the per share market price on the date of issue. These options will vest pro rata,
on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1.7 million
using a Black-Scholes valuation model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 6, 2012, C. Evan Ballantyne
was appointed the Company&rsquo;s Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year
employment agreement with the Company (the &ldquo;Ballantyne Employment Agreement&rdquo;). Pursuant to the Ballantyne Employment
Agreement, Mr. Ballantyne will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance
and transactional bonus payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock
with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly
basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1 million using a Black-Scholes
valuation model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Commitments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012, amounts due for
license and sponsored research agreements are as follows <I>(in thousands)</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Year&nbsp;Ending&nbsp;December&nbsp;31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 85%; text-align: left; padding-left: 17.3pt">2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">287</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 17.3pt">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 17.3pt">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 17.3pt">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 8.65pt; text-align: left">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">402</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Operating Lease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2012, the Company entered into
a one year operating lease for office space in Ann Arbor, Michigan.&nbsp; In March 2013, this lease was amended to extend the
term of the lease to December 31, 2014, for annual lease payments of $33,000. In March 2012, the Company also entered into a
one year operating lease that may be renewed for two additional terms of one year, for office space in Rockville, Maryland,
for annual lease payments of $35,000. The Maryland office lease may be terminated with 60 days written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the years ended December 31, 2012
and 2011, the Company recognized rent expense of $123,000 and $64,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Stock
                                                                                     Repurchase Program</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 3, 2009, the Company&rsquo;s
Board of Directors approved a Stock Repurchase Program authorizing the Company to repurchase, from time-to-time and through December
31, 2009, up to $1 million of its common stock, up to a maximum of four million shares at prices of up to $5 per share. As of
December 31, 2012, the Company had repurchased 81,482 shares for approximately $50,000 ($0.61 per share), based upon the quoted
closing trading price.&nbsp;&nbsp;These treasury shares are not included in the computation of earnings (loss) per share and are
deemed to be canceled and retired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Income
                                                                                     Taxes</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no income tax expense for the
years ended December 31, 2012 and 2011 due to the Company&rsquo;s net losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s tax
expense differs from the &ldquo;expected&rdquo; tax expense for the years ended December 31, 2012 (computed by applying the
Federal Corporate tax rate of 34% to loss before taxes and 3.96% for Michigan State Corporate taxes, the blended rate used was 37.96%) and December 31, 2011, (computed by applying the Federal Corporate tax rate of 32.13% to loss before taxes and 5.5%
for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2012</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2011</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Computed &ldquo;expected&rdquo; tax benefit
    - Federal</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right">(5,803</TD>
    <TD STYLE="width: 1%">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2,618</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Computed &ldquo;expected&rdquo; tax benefit - State</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(676</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(448</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Meals, entertainment and other</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-deductible stock-based compensation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">518</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">366</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Warrant expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">562</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Change in fair value of warrant expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">91</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Realized loss on debt securities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Change in valuation allowance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">5,956</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,035</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The effects of temporary differences that
gave rise to significant portions of deferred tax assets at December 31, 2012 and 2011 are as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Deferred&nbsp;tax&nbsp;assets:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2012</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2011</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 66%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock issued for services</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right">318</TD>
    <TD STYLE="width: 1%"></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">321</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bad debt &ndash; change in allowance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,099</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">205</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Stock issued for acquisition of program </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">527</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net operating loss carry-forward</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">14,964</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,425</FONT></TD>
    <TD></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total gross deferred tax assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16,908</TD>
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,951</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Less valuation allowance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">(16,908</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10,951</FONT></TD>
    <TD>)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2012, the Company
has a net operating loss carry-forward of approximately $39.7 million available to offset future taxable income expiring
through 2032. However, utilization of these net operating losses may be limited due to potential ownership changes under
Section 382 of the Internal Revenue Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The valuation allowance at December 31,
2011 was approximately $11.0 million. The net change in valuation allowance during the year ended December 31, 2012 was an increase
of approximately $6.0 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely
than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred
income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences
become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income,
and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough
uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full
valuation allowance as of December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 740-10 &ldquo;<I>Accounting
for Uncertain Tax Positions</I>&rdquo; prescribes a recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on de-recognition,
classification, interest and penalties, accounting in interim periods, disclosure, and transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December&nbsp;31, 2012
and 2011, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC
740-10. The Company&rsquo;s practice was and continues to be to recognize interest and penalty expenses related to uncertain tax
positions in income tax expense, which was zero for the years ended December&nbsp;31, 2012 and 2011. The Company files United States
federal and various state income tax returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is routinely subject to examinations
by taxing authorities in these various jurisdictions. The Company&rsquo;s U.S. tax matters for the years 2000 through 2012 remain
subject to examination by the Internal Revenue Service due to the Company&rsquo;s NOL carryforwards. The Company&rsquo;s U. S.
tax matters remain subject to examination by various state and local tax jurisdictions due to our NOL carryforwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0">The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December&nbsp;31,
2012 will significantly change within the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>10. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2012, the Company entered
into a consulting agreement with Dr. James Kuo, a director of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From January 2, 2012 through September
30, 2012, Steve H. Kanzer was engaged as the Company&rsquo;s Interim Director of its Biologics Division. In connection with his
appointment, Mr. Kanzer entered into a six month employment agreement with us on a full time basis (the &ldquo;Kanzer Employment
Agreement&rdquo;), which may be extended for an additional three (3) months upon consent of the parties. Pursuant to the Kanzer
Employment Agreement, Mr. Kanzer will be entitled to a base salary of $90,000 for the term, healthcare coverage pursuant to the
Company&rsquo;s healthcare insurance plan, reimbursement for certain relocation expenses and rent expense. The Kanzer Employment
Agreement also includes confidentiality obligations and inventions assignments by Mr. Kanzer.&nbsp; Mr. Kanzer is not entitled
to severance pay upon termination of his employment. On October 1, 2012, the Kanzer Employment Agreement was amended (the &ldquo;Amended
Kanzer Employment Agreement&rdquo;) and Mr. Kanzer is engaged as the Company Licensing Associate. In connection with this appointment,
Mr. Kanzer entered into a two year agreement with us on a part time basis (2.5 days per week). Pursuant to the Amended Kanzer
Employment Agreement, Mr. Kanzer will be entitled to a base salary of $150,000 for the term and healthcare coverage pursuant to
the Company&rsquo;s healthcare insurance plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2012, the Company
entered into an Exclusive Channel Agreement with Intrexon and issued 3,552,210 shares of common stock as consideration,
having a fair value of $7.8 million ($2.20 per share), based on the quoted closing trading price on October 5, 2012<FONT STYLE="color: black">. </FONT>In
November 2011, the Company entered into an Exclusive Channel Agreement with Intrexon and issued 3,123,558 shares of
common stock as consideration, having a fair value of $1.7 million ($0.54 per share), based on the quoted closing trading
price<FONT STYLE="color: black">. In connection with the November 2011 and August 2012 </FONT>Exclusive Channel Agreements,
the Company paid Intrexon approximately $2.9 million during 2012, including a prepayment of research and development expenses
of $2.5 million for research and development goods and services to be provided in the future which has been recorded on the
Company&rsquo;s balance sheet in prepaid expense as described in Note 4. In October 2012, the Company consummated the
Company&rsquo;s October 2012 Private Placement and entered into a stock purchase agreement with several investors, including
NRM VII Holdings I, LLC, an entity affiliated with Intrexon. Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority
of the outstanding capital of Intrexon Corporation, and controls NRM VII Holdings I, LLC. Mr. Kirk disclaims beneficial ownership
of the shares held by Intrexon Corporation and NRM VII Holdings I, LLC, except to the extent of any pecuniary interest therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.&nbsp;&nbsp;&nbsp;&nbsp; <I>Changes
In and Discussions with Accountants on Accounting and Financial Disclosures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2012, the Company was informed
by Berman &amp; Company, P.A. (&ldquo;Berman &amp; Company&rdquo;), its independent registered accounting firm at that time, that
during a regular Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) inspection of Berman &amp; Company, the PCAOB
issued a comment that the audit opinion included in the Company&rsquo;s Annual Report on Form 10-K for the year ended December
31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act
as the Company&rsquo;s named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after
the original engagement partner rotated off the account under the Securities and Exchange Commission&rsquo;s independence rules
as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9A.&nbsp;&nbsp; <I>Controls and
Procedures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disclosure Controls and Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted and maintains
disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed
in the reports filed under the Exchange Act, such as this Form 10-K, is collected, recorded, processed, summarized and reported
within the time periods specified in the rules of the SEC. The Company&rsquo;s disclosure controls and procedures are also designed
to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure.
As required under Exchange Act Rule 13a-15, the Company&rsquo;s management, including the Chief Executive Officer and Chief Financial
Officer, has conducted an evaluation of the effectiveness of disclosure controls and procedures as of the end of the period covered
by this Annual Report on Form 10-K. Based upon that evaluation, the Company&rsquo;s Chief Executive Officer and Chief Financial
Officer concluded that the Company&rsquo;s disclosure controls and procedures are effective to ensure that information required
to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed,
summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms, and that such information is accumulated
and communicated to the Company&rsquo;s management, including the Company&rsquo;s Chief Executive Officer and Chief Financial
Officer, as appropriate, to allow timely decisions regarding required disclosure.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Management&rsquo;s Report on Internal
Control Over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s management is responsible
for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15. The
Company&rsquo;s internal control over financial reporting is designed to provide reasonable assurance to the Company&rsquo;s management
and Board of Directors regarding the preparation and fair presentation of published financial statements.&nbsp;&nbsp;Management
conducted an assessment of the Company&rsquo;s internal control over financial reporting based on the framework and criteria established
by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework.&nbsp;&nbsp;Based
on the assessment, management concluded that, as of December 31, 2012, the Company&rsquo;s internal control over financial reporting
is effective based on those criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s management, including
its Chief Executive Officer and Chief Financial Officer, does not expect that the Company&rsquo;s disclosure controls and procedures
and its internal control processes will prevent all error and all fraud. A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of error or fraud, if any, within the Company have been detected. These inherent limitations
include the realities that judgments in decision-making can be faulty, and that the breakdowns can occur because of simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people,
or by management override of the control. The design of any system of controls also is based in part upon certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals
under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree
of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control
system, misstatements due to error or fraud may occur and may not be detected. However, these inherent limitations are known features
of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate,
this risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Changes in Internal Control</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There has been no change in our internal
control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal
quarter ended December 31, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Annual Report on Form 10-K does not
include an attestation report of the Company&rsquo;s registered public accounting firm regarding internal control over financial
reporting.&nbsp;&nbsp;Management&rsquo;s report was not subject to attestation by the Company&rsquo;s registered public accounting
firm pursuant to rules of the SEC that permit the Company to provide only management&rsquo;s report in this Annual Report
on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Other Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Directors, Executive Officers and Corporate Governance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Below is certain information regarding our directors and executive
officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Age</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 64%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey Riley</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C. Evan Ballantyne</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey J. Kraws &nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">48</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve H. Kanzer,&nbsp; C.P.A, J.D.</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Scott L. Tarriff</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey Wolf,&nbsp; J.D.</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeffrey Riley.</I></B> Mr. Riley,
a member of the Synthetic Biologics&rsquo; Board of Directors since March 2010 and Chairman of the Board from November 2011 to
May 2012, was appointed as the Company&rsquo;s President and Chief Executive Officer in February 2012. Since November 2009 until
January 2012, Mr. Riley served as the Managing Director of 526 Ventures, a life science-focused consulting firm with a commercial
and transactional focus, and from April 2009 until February 2012 he was the business officer of Ruga Corporation, a Stanford University
spin-out oncology drug discovery company focused on targeting tumor adaptive responses. From January 2005 until January 2010, Mr.
Riley was a member of the advisory board and a venture partner of Queensland Biocapital Fund, an Australia-based venture fund.
Mr. Riley has held senior corporate and commercial development positions with multiple venture-backed biotech companies. In these
positions, he was responsible for raising equity and negotiating alliances including in-licensing, out-licensing, distribution
agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. Mr. Riley's
pharmaceutical experience includes commercial management and mergers and acquisition roles for Pfizer and SmithKline Beecham. Additionally,
Mr. Riley served as CFO and VP Corporate Development for Nichols Institute Diagnostics, later acquired by Corning and spun out
as Quest Diagnostics. Mr. Riley&rsquo;s education includes: a B.S. degree from Boise State University, coursework at UCSF/Berkeley
in drug discovery/development and participation in a dual-degree graduate program, an M.B.A./M.I.M. sponsored by Arizona State
University and the Thunderbird School of Global Management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Riley brings to the Board extensive
knowledge of the pharmaceutical industry. Having served in senior corporate positions in biotech and pharmaceutical companies he
has a vast knowledge of the industry.&nbsp;&nbsp;His business experience provides him with a broad understanding of the operational,
financial and strategic issues facing public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>C. Evan Ballantyne.</I></B> Mr. Ballantyne
joined Synthetic Biologics as its Chief Financial Officer in February 2012. He also serves as the Company's Corporate Secretary
and Treasurer. From 2006 until its acquisition in April 2011, Mr. Ballantyne served as Executive Vice President and Chief Financial
Officer of Clinical Data, Inc., a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories, Inc. for
$1.3 billion. While at Clinical Data, he was instrumental in leading corporate financings totaling approximately $220 million as
well as a number of acquisition and divestitures totaling $116 million. Mr. Ballantyne has also served as Chief Financial Officer
of a number of private medical technology companies, including Avedro and ZymeQuest. Earlier in his career, he served as Vice President
and Chief Operating Officer for ACNielsen Europe Middle East &amp; Africa and held the Chief Financial Officer position as well
for two years. There, Mr. Ballantyne was responsible for all aspects of operations, strategic planning and finance in more than
45 countries for a corporation with 9,700 employees. He also helped lead the company's successful ISO certification process. He
began his career at the Dun &amp; Bradstreet Corporation where he held several senior financial positions. Mr. Ballantyne earned
a BA from the University of Western Ontario, and took a post-graduate degree in Business Administration with Honors from the University
of Windsor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeffrey J. Kraws.</I></B> Mr. Kraws
has been a director since January of 2006, and was appointed independent, non-executive Chairman of the Board in May 2012. Since
2003, Mr. Kraws has served Chief Executive Officer and co-founder of Crystal Research Associates, and since February 2012, he has
served as partner and co-founder of TopHat Capital, LLC. Well known and respected on Wall Street, Mr. Kraws has received some of
the most prestigious awards in the industry. Among other awards, he was given a &ldquo;5-Star Rating&rdquo; in 2001 by Zacks and
was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding
Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily
under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for
Ryan Beck &amp; Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal &amp; Co., LLC (prior
to its merger with Ryan Beck &amp; Company). Mr. Kraws served as managing director of the healthcare research group and senior
pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss
conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros
Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown &amp; Sons,
and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury
group at Bristol-Myers-Squibb Company. He holds an M.B.A. from Cornell University and a B.S. degree from State University of New
York-Buffalo. During 2006 through February of 2007, Mr. Kraws served as our Vice President of Business Development, on a part-time
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kraws brings a strong business background
to Synthetic Biologics, having worked as a pharmaceutical analyst for over 22 years. Mr. Kraws brings to the Board significant
strategic, business and financial experience related to the business and financial issues facing pharmaceutical companies. Mr.
Kraws has a broad understanding of the operational, financial and strategic issues facing pharmaceutical companies. Through his
services as the Company&rsquo;s Vice President of Business Development during 2006 and a part of 2007, he developed extensive knowledge
of Synthetic Biologics&rsquo; business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Steve H. Kanzer, C.P.A, J.D.</I></B>
Mr. Kanzer is a co-founder and served as our President from our inception in February of 2001 until May of 2006. Since October
2012, Mr. Kanzer has served as our Licensing Associate, and from January 2012 through September 2012, he served as our Interim
Director of our Biologics Division. Mr. Kanzer previously served as our Chief Executive Officer from September of 2004 until November
of 2008, Chairman of the Board until February 6, 2010 and currently serves as a director. Mr. Kanzer has also been a director and
officer of our subsidiaries, including Solovax, Inc., Effective Pharmaceuticals, Inc., Putney Drug Corp., Epitope Pharmaceuticals,
Inc. and CD4 Biosciences, Inc. Since December 2000, he has served as co-founder and Chairman of Accredited Ventures Inc. and Accredited
Equities Inc., a venture capital firm and investment bank, respectively, which both specialize in the biotechnology industry. Prior
to founding Accredited Ventures and Accredited Equities in December 2000, Mr. Kanzer served as Senior Managing Director-Head of
Venture Capital at Paramount Capital from 1991 until December of 2000. While at Paramount Capital, Mr. Kanzer was involved in the
formation and financing of a number of biotechnology companies and held various positions in these companies. Prior to joining
Paramount Capital in 1992, Mr. Kanzer was an attorney at the law firm of Skadden, Arps, Slate, Meagher &amp; Flom in New York where
he specialized in mergers and acquisitions. Mr. Kanzer received a J.D. from New York University School of Law in 1988 and a B.B.A.
in Accounting from Baruch College in 1985, where he was a Baruch Scholar. Mr. Kanzer is active in university-based pharmaceutical
technology licensing and has served as Co-Chair of the New York Chapter of the Licensing Executives Society.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Kanzer has been associated with the
Company since inception, and initiated and negotiated our synthetic biology collaborations with Intrexon and brings to the Board
extensive knowledge about our business operations and in particular our licenses and products. Mr. Kanzer also brings to the Board
significant executive leadership and operational experience. Mr. Kanzer&rsquo;s legal background provides him with a broad understanding
of the legal issues facing Synthetic Biologics, the financial markets and the financing opportunities available to Synthetic Biologics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Scott L. Tarriff.</I></B> Mr. Tarriff
has been a director since February 3, 2012. Since January 2007 he has served as a director and Chief Executive Officer of Eagle
Pharmaceuticals, Inc., a hospital specialty company. Eagle Pharmaceuticals, Inc. is focused on developing branded parenteral products
through the application of various in-licensed drug delivery technologies. Prior to forming Eagle Pharmaceuticals, Inc., Mr. Tarriff
was president and chief executive officer of Par Pharmaceutical Companies, Inc. Mr. Tarriff joined Par Pharmaceutical Companies,
Inc., in 1998 as executive vice president. Mr. Tarriff was named president and Chief Executive Officer of Par Pharmaceutical, Inc.,
the company&rsquo;s principal operating subsidiary, in 2001, and was elected to the company&rsquo;s Board of Directors in 2002.
In September 2003, he was appointed President and Chief Executive Officer of Par Pharmaceutical Companies, Inc. Mr. Tarriff joined
Par Pharmaceutical Companies, Inc. following a 12-year career at Bristol-Meyers Squibb. From 2009 until 2011, Mr. Tarriff served
as a director of Clinical Data, Inc. He received his M.B.A. from Rider College and his undergraduate degree from Pennsylvania State
University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Tarriff brings to our Board of Directors
significant knowledge of and experience in the pharmaceutical and medical industries. He has extensive business, managerial, executive
and leadership experience that further qualify him to serve as a member of the Board and a valuable understanding of the role played
by the Board of Directors acquired through service on the boards of many companies. He has had a long and successful career in
top executive leadership positions with leading, publicly traded pharmaceutical companies including Par Pharmaceuticals Companies,
Inc. and Bristol-Myers Squibb.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeffrey Wolf, J.D.</I> &nbsp;</B>
Mr. Wolf, a director since 2006, has substantial experience in creating, financing, nurturing and growing new ventures based upon
breakthrough research and technology. In August 2008, Mr. Wolf founded Heat Biologics, Inc., a company engaged in research and
development of drugs focused on combating cancer and other diseases. Since April 2010, Mr. Wolf has served as the Chief Executive
Officer of Heat Biologics, Inc. From 2006 until April 2010, Mr. Wolf served as the Chairman and Chief Executive Officer of GenerationOne,
a company that was focused on mobile-based collaborative care. Mr. Wolf is the founding partner of Seed-One Ventures, LLC, a venture
capital group formed in 1997 and focused on seed-stage technology-based investments. Mr. Wolf has been a founder of Elusys Therapeutics,
Inc., an antibody-based therapeutic company, Tyrx Pharma, Inc., a biopolymer-based company, Sensatex, Inc., a medical device company
and Generation Mobile, Inc. a telecommunications company. Prior to founding Seed-One Ventures, Mr. Wolf served as the Managing
Director of The Castle Group, Ltd., a biomedical venture capital firm. At both organizations, Mr. Wolf was responsible for supervising
the formation and funding of new technology, biomedical, and service oriented ventures. Mr. Wolf currently sits on the board of
Elusys Therapeutics and Netli, Inc. Mr. Wolf received an M.B.A. from Stanford Business School, a J.D. from New York University
School of Law and a B.A. with honors in Economics from the University of Chicago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Wolf has extensive knowledge of the
industry and in particular research and development. His legal and business background provide him with a broad understanding of
the legal, operational, financial and strategic issues facing Synthetic Biologics. Having served as a board member on other public
company boards, Mr. Wolf has an extensive understanding of the operational, financial and strategic issues facing public companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Directors&rsquo; Term of Office</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors will hold office until the next
annual meeting of stockholders and the election and qualification of their successors. Officers are elected annually by our Board
of Directors and serve at the discretion of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee is comprised of Mr.
Wolf and Mr. Tarriff. The Audit Committee is responsible for recommending our independent public accounting firm and reviewing
management&rsquo;s actions in matters relating to audit functions. The Committee reviews with our independent public accountants
the scope and results of the audit engagement and the system of internal controls and procedures. The Committee also reviews the
effectiveness of procedures intended to prevent violations of laws. The Committee also reviews, prior to publication, our reports
on Form 10-K and Form 10-Q. Our Board has determined that all audit committee members are independent under applicable SEC regulations.
Our Board of Directors has determined that both Mr. Wolf and Mr. Tarriff qualify as &ldquo;audit committee financial experts&rdquo;
as that term is used in Section 407 of Regulation S-K.&nbsp;&nbsp;Our Audit Committee charter is located on our website <FONT STYLE="color: windowtext"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Compensation Committee
consists of Mr. Wolf and Mr. Kraws. This committee performs several functions, including reviewing all forms of compensation
provided to our executive officers, directors, consultants and employees, including stock compensation. Our Board has
determined that all compensation committee members are independent under applicable SEC regulations. Our Compensation
Committee charter is located on our website <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nominations Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Nominations Committee consists
of Mr. Kraws and Mr. Wolf. This committee performs several functions, including identifying qualified individuals to become
members of the Board and recommending appointments to the Board and appointment of executive officers. The committee seeks
individuals who have an inquisitive and objective perspective, practical wisdom and mature judgment, and the talent and
expertise to understand, and provide sound and prudent guidance with respect to, our activities, operations and
interests.&nbsp;&nbsp;Candidates must also be individuals who have the highest personal and professional integrity, who have
demonstrated exceptional ability and judgment, and who are likely to be the most effective, in conjunction with the other
members of the Board, in collectively serving the long-term interests of stockholders. Our Board has determined that all
nominations committee members are independent under applicable SEC regulations. Our Nominations Committee charter is located
on our website <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 16(a) of the Securities Exchange
Act of 1934 requires our executive officers, directors and persons who beneficially own more than 10 percent of a registered class
of the Synthetic Biologics&rsquo; equity securities, to file with the SEC initial reports of ownership and reports of changes in
ownership of our common stock.&nbsp;&nbsp;Such officers, directors and persons are required by SEC regulation to furnish us with
copies of all Section 16(a) forms that they file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based solely on a review of the copies
of such forms that were received by us, or written representations from certain reporting persons that no Form 5s were required
for those persons, we are not aware of any failures to file reports or report transactions in a timely manner during the year ended
December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have long maintained a Code of Conduct
which is applicable to all of our directors, officers and employees.&nbsp;&nbsp;In addition, we have adopted a Code of Ethics for
Financial Management which applies to our Chief Executive Officer, Chief Financial Officer, Treasurer and Controller.&nbsp;&nbsp;Each
of these codes is posted on our website at www.syntheticbiologics.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Executive Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes all compensation
awarded to, earned by or paid to Jeffrey Riley, C. Evan Ballantyne and James S. Kuo, M.D., during the fiscal years ended December
31, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal&nbsp;Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Salary&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bonus&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options<BR> Awards($)&nbsp;&nbsp;(1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All&nbsp;Other<BR> Compensation<BR> ($)&nbsp;&nbsp;(2)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total&nbsp;($)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 28%; text-align: left">Jeffrey Riley, President and CEO (3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2012</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">314,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">52,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,716,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,089,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">C. Evan Ballantyne, CFO (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">267,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">44,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,044,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,362,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">James S. Kuo, M.D., President,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">37,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">CEO and CFO (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">199,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">211,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(1)</TD><TD STYLE="text-align: justify">Amount reflects the grant date fair value of the named executive officer&rsquo;s stock options,
calculated in accordance with FASB ASC Topic 718.&nbsp;&nbsp;For a discussion of the assumptions used in calculating these values,
see Note&nbsp;6 to our consolidated financial statements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(2)</TD><TD STYLE="text-align: justify">The all other compensation column is comprised of the portion of medical, dental and vision premiums
paid by us on behalf of our named executive officer. These benefits are offered to all full-time Synthetic Biologics employees.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(3)</TD><TD STYLE="text-align: justify">Mr. Riley was appointed as the Company&rsquo;s President and Chief Executive Officer on February
3, 2012.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(4)</TD><TD STYLE="text-align: justify">Mr. Ballantyne was appointed as the Company&rsquo;s Chief Financial Officer on February 6, 2012.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(5)</TD><TD STYLE="text-align: justify">Dr. Kuo resigned as our President, Chief Executive Officer and Chief Financial Officer on February
3, 2012.&nbsp;Dr. Kuo remained as a consultant to the Company until February 2013. Does not include $135,000 of consulting fees
paid to Dr. Kuo during the year ended December 31, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below reflects all outstanding
equity awards made to each of the named executive officers that are outstanding at&nbsp;December 31,&nbsp;2012. We currently grant
stock-based awards pursuant to our 2010 Stock Incentive Plan (the &ldquo;2010 Stock Plan&rdquo;) and have outstanding awards under
our 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;) and 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Grant&nbsp; &nbsp;<BR> Date&nbsp;(1)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Underlying<BR> Unexercised&nbsp;Options<BR> Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Underlying<BR> Unexercised&nbsp;Options<BR> Unexercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Exercise<BR> Price&nbsp;($)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR> Expiration<BR> Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 31%; text-align: left">Jeffrey Riley</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">02/03/12</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">208,333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">541,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">02/03/22</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/17/11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/17/18</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/05/11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/05/18</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/01/10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/01/20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">03/03/10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">03/03/20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">C. Evan Ballantyne</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/06/12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/06/22</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">James S. Kuo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/06/10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/06/20</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/22/09</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/22/19</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/02/08</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.53</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/02/18</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/02/07</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/02/17</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/07/07</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.87</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/07/17</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(1)</TD><TD STYLE="text-align: justify">Unless otherwise noted, options vest immediately on the date of grant.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(2)</TD><TD STYLE="text-align: justify">These options will vest pro rata, on a monthly basis, over thirty-six months.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(3)</TD><TD STYLE="text-align: justify">These options vest 12,500 shares immediately and the remainder in equal quarterly installments
for seven quarters commencing on February 17, 2012.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20pt">(4)</TD><TD STYLE="text-align: justify">These options vest 100,000 shares immediately and the remainder in equal monthly installments over
a three-year period beginning on the date of grant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3, 2012, Jeffrey Riley was
appointed to serve as our Chief Executive Officer and President, and on February 6, 2012, C. Evan Ballantyne was appointed to serve
as our Chief Financial Officer. On February 3, 2012, James S. Kuo, M.D., resigned as our Chief Executive Officer, President and
Chief Financial Officer. Dr. Kuo remained as a consultant to the Company until February 2013. The following are summaries of the
agreements that were executed in connection with these changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Jeffrey Riley Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with his appointment, Mr.
Riley entered into a three-year employment agreement with us (the &ldquo;Riley Employment Agreement&rdquo;). Pursuant to the Riley
Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary performance
and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of our common stock with
an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis,
over thirty-six months. The Riley Employment Agreement also includes confidentiality obligations and inventions assignments by
Mr. Riley.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Mr. Riley&rsquo;s employment is terminated
for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay, expense
reimbursement and any other entitlements accrued by him to the extent not previously paid (the &ldquo;Accrued Obligations&rdquo;);
<U>provided</U> , <U>however</U> , that if his employment is terminated (1) by us without Just Cause (as defined in the Riley Employment
Agreement) or by Mr. Riley for Good Reason (as defined in the Riley Employment Agreement) then in addition to paying the Accrued
Obligations, (x) we shall continue to pay his then current base salary and continue to provide benefits at least equal to those
which were provided at the time of termination for a period of six months and (y) he shall have the right to exercise any vested
options until the earlier of the expiration of the severance or the expiration of the term of the option, or (2) by reason of his
death or Disability (as defined in the Riley Employment Agreement), then in addition to paying the Accrued Obligations, he would
have the right to exercise any vested options until the expiration of the term of the option. In such event, if Mr. Riley commenced
employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provider
plan, the medical and other welfare benefits to be provided by us as described herein will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>C. Evan Ballantyne Employment Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 6, 2012, C. Evan Ballantyne
was appointed our Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year employment
agreement with us (the &ldquo;Ballantyne Employment Agreement&rdquo;). Pursuant to the Ballantyne Employment Agreement, Mr. Ballantyne
will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance and transactional bonus
payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock with an exercise price
equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six
months. The Ballantyne Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Ballantyne.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Mr. Ballantyne&rsquo;s employment is
terminated for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay,
expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &ldquo;Accrued Obligations&rdquo;);
<U>provided</U> , <U>however</U> , that if his employment is terminated (1) by us without Just Cause (as defined in the Ballantyne
Employment Agreement) or by Mr. Ballantyne for Good Reason (as defined in the Ballantyne Employment Agreement) then in addition
to paying the Accrued Obligations, (i) we shall continue to pay his then current base salary and continue to provide benefits at
least equal to those which were provided at the time of termination for a period of six months and (ii) he shall have the right
to exercise any vested options until the earlier of the expiration of the severance or the expiration of the term of the option,
or (2) by reason of his death or Disability (as defined in the Ballantyne Employment Agreement), then in addition to paying the
Accrued Obligations, he would have the right to exercise any vested options until the expiration of the term of the option. In
such event, if Mr. Ballantyne, commenced employment with another employer and becomes eligible to receive medical or other welfare
benefits under another employer-provider plan, the medical and other welfare benefits to be provided by us as described herein
will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dr. Kuo&rsquo;s Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective February 3, 2012, James S. Kuo,
M.D., resigned from his positions as our President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered
into a nine-month consulting agreement with us (the &ldquo;Consulting Agreement&rdquo;). Pursuant to the Consulting Agreement,
Dr. Kuo was entitled to a consulting fee of $16,666 per month during the term of the Consulting Agreement, receive health and dental
benefits for one year and retain the right to exercise the stock options held by him that have vested as of the effective date
of the Consulting Agreement for a period expiring on the date that is one (1) year from the effective date of the Consulting Agreement.
The Consulting Agreement also includes confidentiality obligations and inventions assignments by Dr. Kuo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2010, Dr. Kuo had entered into
a three-year employment agreement with us (the &ldquo;Kuo Employment Agreement&rdquo;).&nbsp;&nbsp;Pursuant to the Kuo Employment
Agreement, Dr. Kuo was entitled to an annual base salary of $199,000 and was eligible for discretionary performance and transactional
bonus payments.&nbsp;&nbsp;Additionally, Dr. Kuo was granted an initial stock option to purchase 400,000 shares of our common stock
(with an exercise price of $0.82, the fair market value on February 6, 2010, which is the date of grant).&nbsp;&nbsp;Of this stock
option grant, 300,000 shares vested prior to his resignation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information for the fiscal year
ended December 31, 2012 regarding the compensation of our directors who at December 31, 2012 were not also named executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Fees&nbsp;Earned&nbsp;or<BR STYLE="font-family: Times New Roman, Times, Serif"> Paid&nbsp;in&nbsp;Cash</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Option<BR STYLE="font-family: Times New Roman, Times, Serif">
    Awards(1) (3)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Other<BR STYLE="font-family: Times New Roman, Times, Serif"> Compensation</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 48%; text-align: left; font-family: Times New Roman, Times, Serif">Steve H. Kanzer</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">2,000</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif">2,000</TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">Jeffrey J. Kraws (2)</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">100,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">169,000</TD><TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">269,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">Scott Tarriff</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">14,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">57,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">71,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">Jeffrey Wolf</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">24,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">-</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">$</TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif">24,000</TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 20pt; text-align: left">(1)</TD><TD STYLE="text-align: justify">The amounts in the &ldquo;Option awards&rdquo; column reflect the dollar amounts of the
                                                                            grant                                                                             date fair value for
                                                                            the                                                                                                              financial
                                                                            statement reporting purposes for                                                                             stock
                                                                            options for the fiscal year ended December
                                                                            31, 2012 in accordance with ASC 718. The fair value of the options was determined using the Black-Scholes model.</TD>
</TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 20pt">(2)</TD><TD STYLE="text-align: justify">Mr. Kraws was appointed as our independent, non-executive Chairman of the Board in May
                                                          2012. Pursuant to his agreement he will receive annual
                                                          compensation                                                           of
                                                          $150,000 and received a
                                                          one-time grant of                                                           stock options
                                                          exercisable for an additional 100,000                                                                           shares of
                                                          our                                                           common
                                                          stock.</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">As of December 31, 2012, the following are the outstanding
aggregate number of option awards held by each of our directors who were not also named executive officers:</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Option<BR> Awards (#)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Steve H. Kanzer</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: right">304,391</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Jeffrey J. Kraws</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">387,105</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Scott Tarriff</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Jeffrey Wolf</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83,332</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-indent: -20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2007, director compensation for
independent members was approved at $2,000 per board meeting that they attend in person, $1,000 per telephonic board meeting and
$500 per committee meeting.&nbsp;&nbsp;In addition, we grant independent members of the Board of Directors upon appointment 25,000
stock options to purchase shares of our common stock at an exercise price equal to the fair market value of the our common stock
on the date of grant, and an additional 25,000 stock options each year.&nbsp;&nbsp;Directors who are employees, or who are compensated
for board service pursuant to a separate agreement or arrangement, do not receive additional compensation for attending board,
committee and stockholder meetings. We also reimburse directors for travel and other out-of-pocket expenses incurred in attending
Board of Director and committee meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Security Ownership of Certain Beneficial Owners</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information,
as of March 27, 2013, or as otherwise set forth below, with respect to the beneficial ownership of our common stock (i) all persons
know to us to be the beneficial owners of more than 5% of the outstanding shares of our common stock, (ii) each of our directors
and our executive officer named in the Summary Compensation Table, and (iii) all of our directors and our executive officer as
a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.2pt; text-align: center"><B>Principal&nbsp;Stockholders&nbsp;Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Owned (1)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name and Address of Beneficial Ownership (2)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage&nbsp;of<BR> Shares&nbsp;(3)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 0.4pt">Accredited Venture Capital, LLC (4)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">7,086,380</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">15.87</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Intrexon Corporation (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,675,768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.95</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">NRM VII Holding I, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">C. Evan Ballantyne (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177,083</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Steve H. Kanzer (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,766,017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.27</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Jeffrey J. Kraws (8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349,605</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Jeffrey Riley (9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468,733</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Scott L. Tarriff (10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Jeffrey Wolf (11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.4pt">Randal J. Kirk(12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,800,768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.95</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.4pt">All officers and directors as a group (6 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,869,770</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19.26</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* represents less than 1% of our common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(1)</TD><TD STYLE="text-align: justify">The address for each beneficial owner except Intrexon Corporation, NRM VII Holdings I, LLC and
Randal J. Kirk is 155 Gibbs Street, Suite 412, Rockville, Maryland 20850.The address for Intrexon Corporation and NRM VII Holdings
I, LLC is 20358 Seneca Meadows Pkwy, Germantown, Maryland 20876 and the address for Mr. Kirk is The Governor Tyler, 1881 Grove
Avenue, Radford, Virginia 24141.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(2)</TD><TD STYLE="text-align: justify">Beneficial ownership is determined in accordance with SEC rules and generally includes voting or
investment power with respect to securities. Except as indicated in the footnotes to the table, to the knowledge of the Company,
the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially
owned by them, subject to community property laws, where applicable. Pursuant to the rules of the SEC, the number of shares of
our common stock deemed outstanding includes shares issuable pursuant to options held by the respective person or group that are
currently exercisable or may be exercised within 60 days of March 27, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74pt; text-align: justify; text-indent: -38pt">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74pt; text-align: justify; text-indent: -38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(3)</TD><TD STYLE="text-align: justify">As of March 27, 2013, we had 44,654,414 shares of common stock outstanding.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(4)</TD><TD STYLE="text-align: justify">Consists of 7,086,380 shares of common stock issued to Accredited Venture Capital, LLC. Pharmainvestors,
LLC is the managing member of Accredited Venture Capital, LLC, and Mr. Kanzer is the managing member of Pharmainvestors, LLC. As
such, Mr. Kanzer may be considered to have control over the voting and disposition of the shares registered in the name of Accredited
Venture Capital, LLC, and therefore, such shares are also included in the shares listed as held by Mr. Kanzer. Mr. Kanzer disclaims
beneficial ownership of those shares, except to the extent of his pecuniary interest.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(5)</TD><TD STYLE="text-align: justify">Does not include additional shares that have not yet been earned but may in the future be earned
under the terms of agreements with Intrexon Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(6)</TD><TD STYLE="text-align: justify">Includes 177,083 shares issuable upon exercise of options held by Mr. Ballantyne that are exercisable
within the 60-day period following March 27, 2013. Does not include an additional 247,917 shares issuable upon exercise of options
held by Mr. Ballantyne that are not exercisable within the 60-day period following March 27, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(7)</TD><TD STYLE="text-align: justify">Includes 7,086,380 shares of common stock issued to Accredited Venture Capital, LLC and 304,391
shares issuable upon exercise of options held by Mr. Kanzer that are exercisable within the 60-day period following March 27, 2013.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(8)</TD><TD STYLE="text-align: justify">Includes 349,605 shares issuable upon exercise of options held by Mr. Kraws that are exercisable
within the 60-day period following March 27, 2013. Does not include an additional 37,500 shares issuable upon exercise of options
held by Mr. Kraws that are not exercisable within the 60-day period following March 27, 2013.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(9)</TD><TD STYLE="text-align: justify">Includes 458,333 shares issuable upon exercise of options held by Mr. Riley that are exercisable
within the 60-day period following March 27, 2012. Does not include an additional 450,000 shares issuable upon exercise of options
held by Mr. Riley that are not exercisable within the 60-day period following March 27, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(10)</TD><TD STYLE="text-align: justify">Includes 25,000 shares issuable upon exercise of options held by Mr. Tarriff that are exercisable
within the 60-day period following March 27, 2012.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(11)</TD><TD STYLE="text-align: justify">Includes 83,332 shares issuable upon exercise of options held by Mr. Wolf that are exercisable
within the 60-day period following March 27, 2012.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 38pt">(12)</TD><TD STYLE="text-align: justify">All such shares are held by Intrexon Corporation and NRM VII Holdings I, LLC. Mr. Kirk,
                                                              directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital of
                                                              Intrexon Corporation, and controls NRM VII Holdings I, LLC. Mr. Kirk disclaims beneficial ownership of the shares held by
                                                              Intrexon                                                               Corporation
                                                              and                                                                                                            NRM VII
                                                              Holdings I,                                                               LLC, except to the extent of any pecuniary
                                                              interest                                                               therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
about the securities authorized for issuance under our equity compensation plans for the fiscal year ended December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Plan&nbsp;Category</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> to&nbsp;be&nbsp;Issued&nbsp;Upon<BR> Exercise&nbsp;of<BR> Outstanding&nbsp;Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-<BR> Average<BR> Exercise&nbsp;Price&nbsp;of<BR> Outstanding<BR> Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Securities<BR> Remaining&nbsp;Available&nbsp;for<BR> Future&nbsp;Issuance&nbsp;Under<BR> Equity&nbsp;Compensation<BR> Plans</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Equity compensation plans approved by stockholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-left: 9pt">2001 Stock Incentive Plan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,066,007</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.38</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">60,190</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">2007 Stock Incentive Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">872,739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">2010 Stock Incentive Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,515,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">481,530</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by stockholder</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,453,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.78</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">824,821</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Certain Relationships and Related Transactions, and Director Independence</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our charter, our Audit Committee
shall review on an on-going basis for potential conflicts of interest, and approve if appropriate, all our &ldquo;Related Party
Transactions&rdquo; as required by Section 120 of the NYSE MKT Company Guide. For purposes of the Audit Committee Charter, &ldquo;Related
Party Transactions&rdquo; shall mean those transactions required to be disclosed pursuant to SEC Regulation S-K, Item 404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2012, we entered into a Consulting
Agreement with Dr. James Kuo. See Item 11- Executive Compensation for additional information regarding such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From January 2, 2012 through September
30, 2012, Steve H. Kanzer was engaged as our Interim Director of our Biologics Division. In connection with his appointment, Mr.
Kanzer entered into a six month employment agreement with us on a full time basis (the &ldquo;Kanzer Employment Agreement&rdquo;),
which may be extended for an additional three (3) months upon consent of the parties. Pursuant to the Kanzer Employment Agreement,
Mr. Kanzer will be entitled to a base salary of $90,000 for the term, healthcare coverage pursuant to our healthcare insurance
plan, reimbursement for certain relocation expenses and rent expense. The Kanzer Employment Agreement also includes confidentiality
obligations and inventions assignments by Mr. Kanzer.&nbsp; Mr. Kanzer is not entitled to severance pay upon termination of his
employment. On October 1, 2012, the Kanzer Employment Agreement was amended (the &ldquo;Amended Kanzer Employment Agreement&rdquo;)
and Mr. Kanzer is engaged as our Licensing Associate. In connection with this appointment, Mr. Kanzer entered into a two year agreement
with us on a part time basis (2.5 days per week). Pursuant to the Amended Kanzer Employment Agreement, Mr. Kanzer will be entitled
to a base salary of $150,000 for the term and healthcare coverage pursuant to our healthcare insurance plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2012, we entered into an Exclusive Channel Agreement with Intrexon and issued 3,552,210 shares
of common stock as consideration, having a fair value of $7.8 million ($2.20 per share), based on the quoted closing trading
price on October 5, 2012 (date <FONT STYLE="color: black">approved by our stockholders). In connection with the November 2011 and
August 2012 </FONT>Exclusive Channel Agreements, we paid Intrexon approximately $2.9 million during 2012, including a prepayment
of research and development expenses of $2.5 million. In October 2012, we consummated our October 2012 Private Placement and entered
into a stock purchase agreement with several investors, including NRM VII Holdings I, LLC, an entity affiliated with Intrexon.
Randal J. Kirk may be deemed to indirectly beneficially own all of such shares. See Item 7 - Management&rsquo;s Discussion and
Analysis of Financial Conditions and Results of Operations for additional information regarding such issuance and agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Principal Accountant Fees and Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 3, 2012, we dismissed Berman &amp;
Company, P.A. as our independent registered public accounting firm, and on July 9, 2012, we selected BDO USA, LLP as our new independent
registered public accounting firm responsible for auditing its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Independent Registered Public Accounting Firm Fees and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the
aggregate fees including expenses billed to us for the year ended December 31, 2012 by BDO USA, LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December&nbsp;31,<BR> 2012</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 82%; text-align: left; padding-bottom: 1pt">Audit Fees and Expenses(1)</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 15%; text-align: right; border-bottom: Black 1pt solid">123,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">123,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 20pt">(1)</TD><TD STYLE="text-align: justify">Audit fees and expenses were for professional services rendered for the audit and reviews of the
consolidated financial statements of the Company, professional services rendered for issuance of consents and assistance with review
of documents filed with the SEC.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee has adopted procedures
for pre-approving all audit and non-audit services provided by the independent registered public accounting firm, including the
fees and terms of such services. These procedures include reviewing detailed back-up documentation for audit and permitted non-audit
services. The documentation includes a description of, and a budgeted amount for, particular categories of non-audit services that
are recurring in nature and therefore anticipated at the time that the budget is submitted. Audit Committee approval is required
to exceed the pre-approved amount for a particular category of non-audit services and to engage the independent registered public
accounting firm for any non-audit services not included in those pre-approved amounts. For both types of pre-approval, the Audit
Committee considers whether such services are consistent with the rules on auditor independence promulgated by the SEC and the
PCAOB. The Audit Committee also considers whether the independent registered public accounting firm is best positioned to provide
the most effective and efficient service, based on such reasons as the auditor&rsquo;s familiarity with our business, people, culture,
accounting systems, risk profile, and whether the services enhance our ability to manage or control risks and improve audit quality.
The Audit Committee may form and delegate pre-approval authority to subcommittees consisting of one or more members of the Audit
Committee, and such subcommittees must report any pre-approval decisions to the Audit Committee at its next scheduled meeting.
All of the services provided by the independent registered public accounting firm were pre-approved by your Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. <I>Exhibits and Financial Statement Schedules and
Reports on Form 8-K</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)(1)</TD><TD>The following financial statements are included in this Annual
                                                              Report on Form 10-K for the fiscal years ended December 31, 2012 and 2011.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Independent Registered Public Accounting Firms</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Consolidated Balance Sheets as of
                                                              December 31, 2012 and 2011</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Consolidated Statements of Operations
                                                              for the years ended December 31, 2012 and 2011</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Consolidated Statements of changes
                                                              in Stockholders&rsquo; Equity for the years ended December 31, 2012 and
                                                              2011</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Consolidated Statements of Cash
                                                              Flows for the years ended December 31, 2012 and 2011</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">Notes to Consolidated Financial
                                                              Statements</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)(2)</TD><TD STYLE="text-align: justify">All financial statement schedules
                                                              have been omitted as the required information is either inapplicable
                                                              or included in the Consolidated Financial Statements or related
                                                              notes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)(3)</TD><TD STYLE="text-align: justify">The following exhibits are either
                                                              filed as part of this report or are incorporated herein by reference:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">Certificate of Incorporation, as amended
                                                           (Incorporated by reference to (i) Exhibit 3.1 of the Registrant&rsquo;s
                                                           Current Report on Form 8-K filed October 16, 2008, (ii) Exhibit 3.1
                                                           of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarterly
                                                           period ended June 30, 2001 filed August 14, 2001 and (iii) Exhibits
                                                           3.1, 4.1 and 4.2 of the Registrant&rsquo;s Quarterly Report on Form
                                                           10-Q for the quarterly period ended June 30, 1998 filed August 14,
                                                           1998)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify">Articles of Merger (Incorporated by
                                                           reference to Exhibit 3.1 of the Registrant&rsquo;s Current Report on
                                                           Form 8-K filed October 19, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify">Certificate of Merger filed with the
                                                           Secretary of State of Delaware (Incorporated by reference to Exhibit
                                                           3.2 of the Registrant&rsquo;s Current Report on Form 8-K filed October
                                                           19, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify">Articles of Incorporation filed with
                                                           the Nevada Secretary of State (Incorporated by reference to Exhibit
                                                           3.3 of the Registrant&rsquo;s Current Report on Form 8-K filed October
                                                           19, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify">By-Laws (Incorporated by reference
                                                           to (i) Exhibit 3.4 of the Registrant&rsquo;s Current Report on Form
                                                           8-K filed October 19, 2009 and (ii) Exhibit 3.1 of the Registrant&rsquo;s
                                                           Current Report on Form 8-K filed June 3, 2010. )</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify">Amended and Restated Bylaws Adopted
                                                           and Effective October 31, 2011 (Incorporated by reference to Exhibit
                                                           3.1 of the Registrant&rsquo;s Current Report on Form 8-K filed October
                                                           2, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify">Certificate of Amendment to Articles
                                                           of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&rsquo;s
                                                           Current Report on Form 8-K filed February 16, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">Form of Warrant Certificate (Incorporated
                                                           by reference to Exhibit 4.1 to the Registrant&rsquo;s Current Report
                                                           on Form 8-K filed December 1, 2006.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*4.2</TD><TD STYLE="text-align: justify">2001 Stock Incentive Plan (Incorporated
                                                            by reference to Exhibit 4.1 of the Registrant&rsquo;s Registration
                                                            Statement on Form S-8 filed January 18, 2008.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*4.3</TD><TD STYLE="text-align: justify">2007 Stock Incentive Plan (Incorporated
                                                            by reference to Exhibit 4.2 of the Registrant&rsquo;s Registration
                                                            Statement on Form S-8 filed January 18, 2008.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*4.4</TD><TD STYLE="text-align: justify">2010 Stock Incentive Plan (Incorporated
                                                            by reference to Exhibit 4.1 of the Registrant&rsquo;s Registration
                                                            Statement on Form S-8 filed November 29, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.5</TD><TD STYLE="text-align: justify">Form of Warrant Certificate issued
                                                           to Enclave Capital LLC (Incorporated by reference to Exhibit 4.1 of
                                                           the Registrant&rsquo;s Form 8-K filed July 6, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.6</TD><TD STYLE="text-align: justify">Form of Warrant to Purchase Common
                                                           Stock issued January 2011(Incorporated by reference to Exhibit 10.3
                                                           of the Registrant&rsquo;s Current Report on Form 8-K filed February
                                                           2, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.7</TD><TD STYLE="text-align: justify">Form of Warrant to Purchase Common
                                                           Stock issued April 2011(Incorporated by reference to Exhibit 10.3 of
                                                           the Registrant&rsquo;s Current Report on Form 8-K filed April 6, 2011.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.8</TD><TD STYLE="text-align: justify">Form of Exchange Warrant to Purchase
                                                           Common Stock issued in exchange of the Warrant issued April 2011 (Incorporated
                                                           by reference to Exhibit 4.1 of the Registrant&rsquo;s Quarterly Report
                                                           on Form 10-Q for the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.9</TD><TD STYLE="text-align: justify">Form of Exchange Warrant to Purchase
                                                           Common Stock issued in exchange of the Warrant issued February 2011
                                                           (Incorporated by reference to Exhibit 4.2 of the Registrant&rsquo;s
                                                           Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 filed
                                                           August 15, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.10</TD><TD STYLE="text-align: justify">Form of Warrant to Purchase Common
                                                            Stock issued February 2012 (Incorporated by reference to Exhibit 4.10
                                                            of the Registrant&rsquo;s Annual Report on Form 10-K for the year
                                                            ended December 3, 2011 filed March 30, 2012.)</TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.11</TD><TD STYLE="text-align: justify">Form of Warrant to Purchase Common
                                                            Stock issued to Griffin Securities, Inc. on October 30, 2012 (Incorporated
                                                            by reference to Exhibit 10.4 of the Registrant&rsquo;s Current Report
                                                            on Form 8-K filed October 31, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.12</TD><TD STYLE="text-align: justify">Form of Warrant Certificate issued
                                                            to Redington, Inc. (Incorporated by reference to Exhibit 4.13 of the
                                                            Registrant&rsquo;s Registration Statement on Form S-1 filed on December
                                                            13, 2012.)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">Unit Purchase Agreement (Incorporated
                                                            by reference to Exhibit 10.1 to the Registrant&rsquo;s Current Report
                                                            on Form 8-K filed December 1, 2006.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.2</TD><TD STYLE="text-align: justify">License Agreement between The Regents
                                                            of the University of California and Epitope Pharmaceuticals, Inc.
                                                            (Incorporated by reference to Exhibit 10.22 of the Registrant&rsquo;s
                                                            Quarterly Report on Form 10-Q for the quarterly period ended June
                                                            30, 2008 filed August 14, 2008.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.3</TD><TD STYLE="text-align: justify">Form of Director/Officer Indemnification
                                                             Agreement (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed January 6, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.4</TD><TD STYLE="text-align: justify">Warrant Cancellation and Registration
                                                             Rights Agreement between Accredited Adventures Capital LLC and Adeona
                                                             (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed January 20, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.5</TD><TD STYLE="text-align: justify">Stock Purchase Agreement with Neil
                                                            O. Colwell and Connie Colwell (Incorporated by reference to Exhibit
                                                            10.1 of the Registrant&rsquo;s Current Report on Form 8-K filed April
                                                            16, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.6</TD><TD STYLE="text-align: justify">Escrow Agreement Nayaran Torke (Incorporated
                                                            by reference to Exhibit 10.5 of the Registrant&rsquo;s Current Report
                                                            on Form 8-K filed July 16, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.7</TD><TD STYLE="text-align: justify">Consulting Agreement with Nayaran
                                                            Torke (Incorporated by reference to Exhibit 10.4 of the Registrant&rsquo;s
                                                            Current Report on Form 8-K filed July 16, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.8</TD><TD STYLE="text-align: justify">Purchase Agreement 1st Amendment HartLab
                                                            LLC (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                            Current Report on Form 8-K filed July 16, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.9</TD><TD STYLE="text-align: justify">Purchase Agreement 2nd Amendment Hartlab
                                                            LLC (Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s
                                                            Current Report on Form 8-K filed July 16, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.10</TD><TD STYLE="text-align: justify">Agreement and Plan of Reincorporation
                                                             Merger (Incorporated by reference to Exhibit 1.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed October 19, 2009.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.11</TD><TD STYLE="text-align: justify">Employment Agreement with James
                                                              S. Kuo, M.D., (Incorporated by reference to Exhibit 10.1 of the
                                                              Registrant&rsquo;s Current Report on Form 8-K filed February 9,
                                                              2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.12</TD><TD STYLE="text-align: justify">Separation Agreement with Max Lyons
                                                              (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                              Current Report on Form 8-K filed February 9, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.13</TD><TD STYLE="text-align: justify">Sublicense Agreement between Meda
                                                             AB, Adeona Pharamaceuticals, Inc. and Pipex Therapeutics, Inc. (Incorporated
                                                             by reference to Exhibit 10.1 of the Registrant&rsquo;s Current Report
                                                             on Form 8-K filed May 11, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.14</TD><TD STYLE="text-align: justify">Non-Disturbance Agreement among Pipex
                                                             Therapeutics, Inc., Mclean Hospital Corp and Meda AB (Incorporated
                                                             by reference to Exhibit 10.2 of the Registrant&rsquo;s Current Report
                                                             on Form 8-K filed May 11, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.15</TD><TD STYLE="text-align: justify">Placement Agent Agreement with Enclave
                                                             Capital LLC (Incorporated by reference to Exhibit 1.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed July 6, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.16</TD><TD STYLE="text-align: justify">Common Stock Purchase Agreement with
                                                             Seaside 88,LP (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed July 6, 2010.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.17</TD><TD STYLE="text-align: justify">Agreement with Chardan Capital Markets,
                                                             LLC (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed February 2, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.18</TD><TD STYLE="text-align: justify">Securities Purchase Agreement with
                                                             investors (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed February 2, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.19</TD><TD STYLE="text-align: justify">McLean Hospital Corporation Exclusive
                                                             License Agreement (Incorporated by reference to Exhibit 10.21 of
                                                             the Registrant&rsquo;s Annual Report on Form 10-K filed March 31,
                                                             2011)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.20</TD><TD STYLE="text-align: justify">Agreement with Chardan Capital Markets,
                                                             LLC (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed April 6, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.21</TD><TD STYLE="text-align: justify">Securities Purchase Agreement with
                                                             investors (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed April 6, 2011.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.22</TD><TD STYLE="text-align: justify">Exchange Agreement with respect to
                                                             Warrant issued April 2011(Incorporated by reference to Exhibit 10.1
                                                             of the Registrant&rsquo;s Quarterly Report on Form 10-Q for the quarter
                                                             ended June 30, 2011 filed August 15, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.23</TD><TD STYLE="text-align: justify">Exchange Agreement with respect to
                                                             Warrant issued February 2011(Incorporated by reference to Exhibit
                                                             10.2 of the Registrant&rsquo;s Quarterly Report on Form 10-Q for
                                                             the quarter ended June 30, 2011 filed August 15, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.24</TD><TD STYLE="text-align: justify">Exclusive Cannel Collaboration Agreement
                                                             with Intrexon Corporation (Incorporated by reference to Exhibit 10.1
                                                             of the Registrant&rsquo;s Current Report on Form 8-K filed November
                                                             21, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.25</TD><TD STYLE="text-align: justify">Stock Purchase Agreement with Intrexon
                                                             Corporation (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed November 21, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.26</TD><TD STYLE="text-align: justify">Registration Rights Agreement with
                                                             Intrexon Corporation (Incorporated by reference to Exhibit 10.3 of
                                                             the Registrant&rsquo;s Current Report on Form 8-K filed November
                                                             21, 2011.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.27</TD><TD STYLE="text-align: justify">Employment Agreement with Jeffrey
                                                              Riley (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                              Current Report on Form 8-K filed February 6, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.28</TD><TD STYLE="text-align: justify">Consulting Agreement with Dr. James
                                                             Kuo (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed February 6, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.29</TD><TD STYLE="text-align: justify">Employment Agreement with C. Evan
                                                              Ballantyne (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                              Current Report on Form 8-K filed February 7, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">*10.30</TD><TD STYLE="text-align: justify">Employment Agreement with Steve
                                                              H. Kanzer (Incorporated by reference to Exhibit 10.30 of the Registrant&rsquo;s
                                                              Annual Report on Form 10-K for the year ended December 3, 2011 filed
                                                              March 30, 2012.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.31</TD><TD STYLE="text-align: justify">Membership Interest Purchase Agreement
                                                             by and among Synthetic Biologics, Inc., Hartlab LLC, and Adeona Clinical
                                                             Laboratory, LLC, dated as of March 7, 2012 (Incorporated by reference
                                                             to Exhibit 10.1 of the Registrant&rsquo;s Current Report on Form
                                                             8-K filed March 12, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.32</TD><TD STYLE="text-align: justify">Pledge and Security Agreement between
                                                             Synthetic Biologics, Inc. and Hartlab, LLC dated as of March 7, 2012
                                                             (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed March 12, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.33</TD><TD STYLE="text-align: justify">Non-Recourse Promissory Note between
                                                             Synthetic Biologics, Inc. and Hartlab, LLC dated as of March 7, 2012
                                                             (Incorporated by reference to Exhibit 10.1 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed March 12, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.34</TD><TD STYLE="text-align: justify">Financial Advisory Agreement with
                                                             Griffin Securities, Inc. (Incorporated by reference to Exhibit 10.34
                                                             of the Registrant&rsquo;s Annual Report on Form 10-K for the year
                                                             ended December 3, 2011 filed March 30, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.35</TD><TD STYLE="text-align: justify">Exclusive Channel Collaboration Agreement
                                                             with Intrexon Corporation (Incorporated by reference to Exhibit 10.1
                                                             of the Registrant&rsquo;s Current Report on Form 8-K filed August
                                                             9, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.36</TD><TD STYLE="text-align: justify">Stock Purchase Agreement with Intrexon
                                                             Corporation (Incorporated by reference to Exhibit 10.2 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed August 9, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.37</TD><TD STYLE="text-align: justify">First Amendment to Registration Rights
                                                             Agreement between Synthetic Biologics, Inc. and Intrexon Corporation
                                                             (Incorporated by reference to Exhibit 10.3 of the Registrant&rsquo;s
                                                             Current Report on Form 8-K filed August 9, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.38</TD><TD STYLE="text-align: justify">Stock Purchase Agreement dated October
                                                             25, 2012 with investors (Incorporated by reference to Exhibit 10.1
                                                             of the Registrant&rsquo;s Current Report on Form 8-K filed October
                                                             31, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.39</TD><TD STYLE="text-align: justify">Registration Rights Agreement dated
                                                             October 25, 2012 with investors (Incorporated by reference to Exhibit
                                                             10.2 of the Registrant&rsquo;s Current Report on Form 8-K filed October
                                                             31, 2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.40</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Joinder
                                                                                                                           Agreement
                                                                                                                           by
                                                                                                                           and
                                                                                                                           among
                                                                                                                           Synthetic
                                                                                                                           Biologics,
                                                                                                                           Inc.,
                                                                                                                           NRM
                                                                                                                           VII
                                                                                                                           Holdings
                                                                                                                           I,
                                                                                                                           LLC
                                                                                                                           and
                                                                                                                           Intrexon
                                                                                                                           Corporation
                                                                                                                           (Incorporated
                                                                                                                           by
                                                                                                                           reference
                                                                                                                           to
                                                                                                                           Exhibit
                                                                                                                           10.3
                                                                                                                           of
                                                                                                                           the
                                                                                                                           Registrant&rsquo;s
                                                                                                                           Current
                                                                                                                           Report
                                                                                                                           on
                                                                                                                           Form
                                                                                                                           8-K
                                                                                                                           filed
                                                                                                                           October
                                                                                                                           31,
                                                                                                                           2012.)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.41</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Asset
                                                                                                                           Purchase
                                                                                                                           Agreement
                                                                                                                           dated
                                                                                                                           November
                                                                                                                           8,
                                                                                                                           2012
                                                                                                                           between
                                                                                                                           Synthetic
                                                                                                                           Biologics,
                                                                                                                           Inc.
                                                                                                                           and
                                                                                                                           Prev
                                                                                                                           ABR
                                                                                                                           LLC
                                                                                                                           (Incorporated
                                                                                                                           by
                                                                                                                           reference
                                                                                                                           to
                                                                                                                           Exhibit
                                                                                                                           10.1
                                                                                                                           of
                                                                                                                           the
                                                                                                                           Registrant&rsquo;s
                                                                                                                           Current
                                                                                                                           Report
                                                                                                                           on
                                                                                                                           Form
                                                                                                                           8-K
                                                                                                                           filed
                                                                                                                           November
                                                                                                                           13,
                                                                                                                           2012.)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*10.42</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment
                                                                                                                            to
                                                                                                                            Employment
                                                                                                                            Agreement
                                                                                                                            dated
                                                                                                                            October
                                                                                                                            1,
                                                                                                                            2012
                                                                                                                            with
                                                                                                                            Steve
                                                                                                                            H.
                                                                                                                            Kanzer
                                                                                                                            (Incorporated
                                                                                                                            by
                                                                                                                            reference
                                                                                                                            to
                                                                                                                            Exhibit
                                                                                                                            10.42
                                                                                                                            of
                                                                                                                            the
                                                                                                                            Registrant&rsquo;s
                                                                                                                            Registration
                                                                                                                            Statement
                                                                                                                            on
                                                                                                                            Form
                                                                                                                            S-1
                                                                                                                            filed
                                                                                                                            December
                                                                                                                            13,
                                                                                                                            2012.)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.43</TD><TD STYLE="text-align: justify">Patent License Agreement dated December
                                                             19, 2012 between Synthetic Biologics, Inc. and The University of
                                                             Texas at Austin (Incorporated by reference to Exhibit 10.1 of the
                                                             Registrant&rsquo;s Current Report on Form 8-K filed December 21,
                                                             2012.)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.44</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sponsored
                                                                                                                           Research
                                                                                                                           Agreement
                                                                                                                           dated
                                                                                                                           December
                                                                                                                           19,
                                                                                                                           2012
                                                                                                                           between
                                                                                                                           Synthetic
                                                                                                                           Biologics,
                                                                                                                           Inc.
                                                                                                                           and
                                                                                                                           The
                                                                                                                           University
                                                                                                                           of
                                                                                                                           Texas
                                                                                                                           at
                                                                                                                           Austin
                                                                                                                           (Incorporated
                                                                                                                           by
                                                                                                                           reference
                                                                                                                           to
                                                                                                                           Exhibit
                                                                                                                           10.2
                                                                                                                           of
                                                                                                                           the
                                                                                                                           Registrant&rsquo;s
                                                                                                                           Current
                                                                                                                           Report
                                                                                                                           on
                                                                                                                           Form
                                                                                                                           8-K
                                                                                                                           filed
                                                                                                                           December
                                                                                                                           21,
                                                                                                                           2012.)</FONT></TD></TR>                                                                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>10.45</TD><TD STYLE="text-align: justify">Exclusive License Agreement with The Regents of The University of California (1)</TD></TR>
<TR STYLE="vertical-align: top">
<TD> </TD><TD>10.46</TD><TD STYLE="text-align: justify">First Amendment to Exclusive License Agreement with The Regents of The University of California (1)</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>10.47</TD><TD STYLE="text-align: justify">Second Amendment to Exclusive License Agreement with The Regents of The University of
                             California                              (1)</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>10.48</TD><TD STYLE="text-align: justify">Third Amendment to Exclusive License Agreement with The Regents of The University of California (1)</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>10.49</TD><TD STYLE="text-align: justify">Fourth Amendment to Exclusive License Agreement with The Regents of The University of California (1)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21</TD><TD STYLE="text-align: justify">List of Subsidiaries <FONT STYLE="color: black">(Incorporated
                                                          by reference to Exhibit 10.34 of the Registrant&rsquo;s Annual Report
                                                          on Form 10-K filed March 30, 2012.)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.1</TD><TD STYLE="text-align: justify">Consent of Independent Registered Public Accounting
                                                            Firm (BDO USA, LLP) (1)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">23.2</TD><TD STYLE="text-align: justify">Consent of Independent Registered Public Accounting Firm (Berman &amp; Company, P.A.)
                                                                              (1)</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">31.1</TD><TD STYLE="text-align: justify">Certification of Jeffrey Riley, Chief
                                                            Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) (1)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">31.2</TD><TD STYLE="text-align: justify">Certification of C. Evan Ballantyne,
                                                            Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) (1)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">32.1</TD><TD STYLE="text-align: justify">Certification of Jeffrey Riley, Chief
                                                            Executive Officer pursuant to Section 1350 of the Sarbanes-Oxley Act
                                                            of 2002 (1)</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">32.2</TD><TD STYLE="text-align: justify">Certification C. Evan Ballantyne,
                                                            Chief Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley
                                                            Act of 2002 (1)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>**+101.INS XBRL Instance Document</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>**+101.SCH XBRL Taxonomy Extension
Schema Document</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>**+101.CAL XBRL Taxonomy Extension
Calculation Linkbase Document</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>**+101.DEF XBRL Taxonomy Extension
Definition Linkbase Document</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>**+101.LAB XBRL Taxonomy Extension
Label Linkbase Document</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>**+101.PRE XBRL Taxonomy Extension
Presentation Linkbase Document</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><B>(1) Filed herewith.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><B>* Management contract or
compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-indent: -13.5pt"><B>** As provided in Rule
406T of Regulation S-T, this information is deemed furnished and not filed for purposes of Sections 11 and 12 of the Securities
Act of 1933, as amended, and Section 18 of the Securities Exchange Act of 1934, as amended.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jeffrey
    Riley</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 31%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ C. Evan
    Ballantyne</FONT></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Principal Accounting Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1934,
this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jeffrey
    Riley</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jeffrey
    J. Kraws</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey J. Kraws</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Steve H.
    Kanzer</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Steve H. Kanzer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Scott L.
    Tarriff</FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Scott L. Tarriff</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Jeffrey Wolf</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jeffrey Wolf</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GLOSSARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>Term</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black"><B>Definition</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Adverse Event</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Any adverse change in
    health or &ldquo;side-effect&rdquo; that occurs in a person participating in a clinical trial, from the time they consent
    to joining the trial until a pre-specified period of time after their treatment has been completed.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Bioavailability</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">The quantity or fraction of the ingested dose that
    is absorbed by the body.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">BLA - Biologics License Application</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">An application in the
    U.S. through which biologic sponsors formally propose that the FDA approve a new biologic for sale and marketing.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Clinical Study/Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A research study that
    is conducted to find out if a treatment or procedure is safe and/or effective in humans.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Controlled Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A clinical study that
    compares patients receiving a specific treatment to patients receiving an alternate treatment for the condition of interest.
    The alternate treatment may be another active treatment, standard of care for the condition and/or a placebo (inactive)&nbsp;treatment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Double-blinded Study/Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Both the participant
    and the researcher are unaware of who is receiving the active treatment or the placebo.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Effirma (flupirtine)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Proposed tradename of
    Synthetic Biologics&rsquo; centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">FDA - Food &amp; Drug Administration</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">The U.S. government agency
    that ensures that medicines, medical devices, prescription medical foods and radiation-emitting consumer products are safe
    and effective. Authorized by Congress to enforce the Federal Food, Drug, and Cosmetic Act and several other public health
    laws, the agency monitors the manufacture, import, transport, storage, and sale of $1 trillion worth of goods annually.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">GMP - Good Manufacturing Practice</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Regulations that require
    that manufacturers, processors, and packagers of drugs, medical devices, some food, and blood take proactive steps to ensure
    that their products are consistently produced, pure, and stable. GMP regulations require a quality approach to manufacturing,
    enabling companies to minimize or eliminate instances of contamination, mix-ups, and errors.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Monoclonal Antibodies (mAbs)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Acting as the body's
    army, antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens,
    such as viruses and bacteria and their associated toxins.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">IND - Investigational New Drug</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">An application in the
    U.S. submitted to the FDA for a new drug or biologic that, if allowed, will be used in a clinical trial.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">IRB - Institutional Review Board</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A committee designated
    to formally approve, monitor, and review biomedical research at an institution involving human studies. Institutional Review
    Boards aim to protect the rights and welfare of the research subjects.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">NDA - New Drug Application</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">An application in the
    U.S. through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Open-label Clinical Study/Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A trial in which both
    the treating physician and the patient know they are receiving the experimental treatment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Phase I Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A Phase I trial represents
    an initial study in a small group of patients to primarily test for safety.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Phase II Clinical Trial</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A Phase II
    trial represents a study in a larger number of patients to assess the safety and efficacy of a product.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Phase III Clinical Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Phase III trials are
    initiated to establish safety and efficacy in an expanded patient population and at multiple clinical trial sites and are
    generally larger than trials in earlier phases of development.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Placebo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">An inactive pill or liquid.
    Many studies compare an active drug to a placebo to determine whether any changes seen during the study can be attributed
    to the active drug.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Principal Investigator</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">This is the study director
    who is ultimately responsible for the conduct of the study.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Prospective Clinical Study/Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A clinical study/trial
    in which participants are identified and then followed throughout the study going forward in time.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Protocol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">A clinical study/trial&rsquo;s
    plan - includes the schedule of tests, requirements for participation, procedures, and medications.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Randomized Study/Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Participants in a study
    are assigned by chance to either one or more of the active treatment group(s) or the placebo group.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Single-blinded Study/Trial</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">One party, either the
    participant or the researcher, does not know if the participant is taking the active treatment or the placebo.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Study/Trial Coordinator</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Staff member who is often
    the primary contact for research participants and coordinates their care and evaluations throughout the study.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Synthetic Biology</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic biology is an emerging
        field that combines molecular biology and automation to design, optimize and construct new biological systems and functions.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These technologies utilize a combination
        of automated processes including, DNA sequencing, computer-aided design, DNA synthesis, fabrication of modular transgenes
        and high throughput testing to create and optimize biologic products.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Trimesta (oral estriol)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Proposed tradename of
    Synthetic Biologics&rsquo; investigational oral drug for the treatment of relapsing- remitting MS and cognitive dysfunction
    in MS.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 68; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.45
<SEQUENCE>2
<FILENAME>v337358_ex10-45.htm
<DESCRIPTION>EXHIBIT 10.45
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #0E0F0E">Exhibit 10.45</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E0F0E">EXCLUSIVE LICENSE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">This Agreement is made
and is effective this 11th day of July 2005 (the &quot;Effective Date&quot;) between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
(&quot;The Regents&quot;), a California corporation having its corporate offices located at 1111 Franklin Street, Oakland, California
94607-5200, acting through its offices located at 10920 Wilshire Blvd, Suite 1200, Los Angeles, California 90024-1406, and General
Fiber, Inc (&quot;Licensee&quot;), a corporation having a principal place of business at 801 Brickell Avenue, 9<SUP>th</SUP> Floor,
Suite 942, Miami, FL 33131.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E0F0E">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">WHEREAS, a certain invention
(the &quot;Invention&quot;), generally characterized as &quot;Estriol for the treatment of autoimmune diseases &amp; the use of
estriol and other estranges, estrogens and estrogen receptor active compositions in the treatment of psoriasis &amp; other autoimmune
diseases&quot; (UCLA Case No. 1998-531 &amp; UCLA Case No. 2004-101) made in the course of research at the University of California,
Los Angeles and Irvine by Drs. Rhonda Voskuhl, Jenny Murase, and Gerald Weinstein), and claimed in Regents' Patent Rights as defined
below;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #0E0F0E">WHEREAS, Drs.
Voskuhl, Murase, </FONT><FONT STYLE="color: #212321">~</FONT><FONT STYLE="color: #0E0F0E">and Weinstein are an employees of The
Regents and as such are obligated to assign their right, title and interest in and to the Invention to The Regents; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">WHEREAS, the Invention
was developed with United States Government funds, and The Regents has elected title thereto and granted a royalty-free nonexclusive
license to the United States Government on 11-14-97, as required under 35 U.S.C. &sect;200-212;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">WHEREAS, Licensee and The
Regents entered into a Secrecy Agreement effective 10-20-03 and expiring on 10-20-08 to allow Licensee to evaluate its interest
in the Invention and, as a result of its evaluation, Licensee wishes to obtain certain rights from The Regents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">WHEREAS, Licensee is a
&quot;small business concern&quot; as defined in 15 U.S.C. &sect;632; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">WHEREAS, The Regents wishes
that Regents' Patent Rights be developed and utilized to the fullest extent so that the benefits can be enjoyed by the general
public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">The parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E0F0E">1. DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E0F0E">1.1
&#9;&quot;Regents' Patent Rights&quot; means The Regents interest in any of the patent applications listed in Appendix A attached
to this Agreement and assigned to The Regents (UCLA Case No. 1998-531 &amp; UCLA Case No. 2004-101); any continuing applications
thereof including divisions; but excluding continuations-in-part except to the extent of claims entirely supported in the specification
and entitled to the priority date of the parent application; any patents issuing on these applications including reissues and reexaminations;
and any corresponding foreign patents or patent applications; all of which will be automatically incorporated in and added to Appendix
A and made a part of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E0F0E"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2 &#9;&quot;Licensed
Product&quot; means any article, composition, apparatus, substance, chemical, or any other material covered by Regents' Patent
Rights or whose manufacture, use or sale would constitute an <FONT STYLE="color: #0D0E0D">infringement of any claim within Regents'
Patent Rights, or any service, article, composition, apparatus, chemical, substance, or any other material made, used, or sold
by or utilizing or practicing a Licensed Method. This definition of Licensed Product also includes a service either used by Licensee,
an Affiliate, or sublicensee or provided by Licensee, an Affiliate or sublicensee to its customers when such service requires the
use of Licensed Product or performance of Licensed Method. Additionally, for the avoidance of doubt, if such product is a component
of a larger unit such as a kit, composition of matter or combination, such kit, composition of matter or combination is deemed
to be the Licensed Product for purposes of this definition. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">1.3
&#9;&quot;Licensed Method&quot; means any process or method which is covered by Regents' Patent Rights or whose use or practice
would constitute an infringement of any claim within Regents' Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">1.4
&#9;The &quot;Field of Use&quot; means all fields for the first two years after the Effective Date of the Agreement. On the second
anniversary of the Effective Date of the Agreement Licensee will select fields of use and for each field will be required to meet
the diligence terms outlined in paragraph 6.3 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">1.5
&#9;&quot;Affiliate&quot; means any corporation or other business entity in which Licensee owns or controls, directly or indirectly,
at least 50% of the outstanding stock or other voting rights entitled to elect directors. In any country where the local law does
not permit foreign equity participation of at least 50%, then &quot;Affiliate&quot; means any company in which Licensee owns or
controls, directly or indirectly, the maximum percentage of outstanding stock or voting rights that is permitted by local law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">1.6
&#9;&quot;First Commercial Sale&quot; means the first sale of any Licensed Product by Licensee or any Affiliate or Sublicensee,
following approval of it's marketing by the appropriate governmental agency for the country in which the sale is to be made. When
governmental approval is not required, &quot;First Commercial Sale&quot; means the first sale in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">1.7
&#9;&quot;Final Sale&quot; means any sale, transfer, lease, exchange or other disposition or provision of a Licensed Product and/or
a Licensed Method to a Customer. A Final Sale shall be deemed to have occurred upon the earliest to occur of the following (as
applicable): (a) the transfer of title to such Licensed Product and/or Licensed Method to a Customer, (b) the shipment of such
Licensed Product to a Customer, (c) the provision of a Licensed Method to a Customer, (d) the provision of an invoice for such
Licensed Product or Licensed Method to a Customer, or (e) payment by the Customer for Licensed Products or Licensed Methods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0E0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #0D0E0D">1.8
&#9;&quot;Net Sales&quot; means the total of the gross amount invoiced or otherwise charged (whether consisting of cash or any
other forms of consideration) for the Final Sale of Licensed Products or Licensed Methods by Licensee, or by any Affiliate, Joint
Venture or Sublicensee to Customers, less the following deductions (to the extent included in and not already deducted from the
gross amount invoiced or otherwise charged) to the extent reasonable and customary: cash, trade or quantity discounts actually
granted to Customers; sales, use, tariff, import/export duties or other excise taxes imposed on particular sales (excepting value
added taxes or income taxes); transportation charges, including insurance to the extent actually paid by the Customer; and allowances
or credits to Customers because of rejections or returns. Where Licensee or any Affiliate, Joint Venture or Sublicensee is the
Customer, then Net Sales shall be based on the gross amount normally invoiced or otherwise charged to other Customers in an arms
length transaction for such Licensed Products or Licensed Methods. For the avoidance of doubt, if Licensee or any Affiliate, Joint
Venture or Sublicensee supplies (directly or indirectly) a Product that constitutes a 8-Jul-05 </FONT><FONT STYLE="color: #0E1111">Licensed
Product to any Affiliate, Joint Venture or Sublicensee and such Affiliate, Joint Venture or Sublicensee includes such Product in
another Product, then Net Sales shall be based on the total gross amount invoiced or otherwise charged for such other Product in
its entirety. If License pays a third party royalties in consideration for patent rights which are necessary in order to practice
Regents' Patent Rights then Licensee or Sublicensee, as the case may be may deduct .333% from the royalty rate due to The Regents
under this Agreement for every percentage point paid to third party in royalties, provided that in no event shall royalties or
other amounts due to The Regents in any reporting period be reduced to less than 50% of what would otherwise be due to The Regents.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">1.9
&#9;&quot;Sublicensee&quot; means any third party sublicensed by Licensee to make, have made, use, sell, offer for sale or importany
Licensed Product or to practice any Licensed Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">1.10
&#9;&quot;Sublicensing Income&quot; means income received by Licensee under or on account of Sublicenses. Sublicensing Income includes
income received by way of license issue fees, milestone payments, and the like but specifically excludes royalties on the sale
or distribution of Licensed Products or the practice of Licensed Methods. Not included in the definition of Sublicensing Income
is income received by Licensee as payment or reimbursement for research costs conducted by or for Licensee, including costs associated
with materials, equipment or clinical testing and amounts received in connection with the issuance of debt or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">1.11
&#9;&quot;Customer&quot; means any individual or entity that receives Licensed Products or Licensed Methods, provided however,
that Licensee or any Affiliate, Joint Venture or Sublicensee shall be deemed a Customer only if it receives Licensed Products or
Licensed Services for its own end-use and not resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1111">2. GRANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">2.1
&#9;Subject to the limitations set forth in this Agreement, The Regents hereby grants to Licensee an exclusive license (the &quot;License&quot;)
under Regents' Patent Rights, in jurisdictions where Regents' Patent Rights exist, to make, have made, use, sell, offer for sale
and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">2.2
&#9;The License is subject to all the applicable provisions of any license to the United States Government executed by The Regents
and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. &sect;&sect;200-212 and applicable
governmental implementing regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">2.3
&#9;The Regents expressly reserves the right to use Regents' Patent Rights and associated technology for educational and research
purposes including publication of research results and sharing research results with other non-profit institutions, and allowing
other non-profit research institutions to use Regents' Patent Rights and associated technology for the same purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1111">3. SUBLICENSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">3.1
&#9;The Regents also grants to Licensee the right to issue exclusive or nonexclusive sublicenses (&quot;Sublicenses&quot;) to third
parties to make, have made, use sell, offer for sale or import Licensed Products and to practice Licensed Methods in any jurisdiction
in which Licensee has exclusive rights under this Agreement. To the extent applicable, sublicenses must include all of the rights
of and obligations due to The Regents (and, if applicable, the U.S. Government under 35 U.S. C. &sect;&sect;201-212) contained
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">3.2
&#9;Licensee must pay to The Regents 25% of all Sublicensing Income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">3.3
&#9;On Net Sales of Licensed Products sold or disposed of by a Sublicensee, Licensee must pay to The Regents an earned royalty
in accordance with Article 5 (Royalties) as if these were Licensee's Net Sales. Any royalties received by Licensee in excess of
royalties due to The Regents under this Paragraph 3.3 belong to Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #090D0D">3.4
&#9;Licensee must provide to The Regents a copy of each Sublicense within 30 days of execution</FONT><FONT STYLE="color: #1D2327">,
</FONT><FONT STYLE="color: #090D0D">and a copy of all information submitted to Licensee by Sublicensees relevant to the computation
of the payments due to The Regents under this Article 3. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">3.5
&#9;If this Agreement is terminated for any reason, all outstanding Sublicenses, not in default, will be assigned by Licensee to
The Regents, at the option of The Regents. The Sublicenses will remain in full force and effect with The Regents as the licensor
or sublicensor instead of Licensee, but the duties of The Regents under the assigned Sublicenses will not be greater than the duties
of The Regents under this Agreement, and the rights of The Regents under the assigned Sublicenses will not be less than the rights
of The Regents under this Agreement, including all financial consideration and other rights of The Regents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0D">4. FEES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">4.1
&#9;In partial consideration for the License, Licensee will pay to The Regents a license issue fee of twenty thousand dollars ($20,000)
within 30 days of the Effective Date and twenty five thousand dollars ($25,000) on the first anniversary of this Agreement. This
fee is nonrefundable and is not an advance against royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">4.2
&#9;For each Licensed Product reaching the milestones indicated below, Licensee must make the following payments to The Regents
within 30 days of reaching the milestones:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #090D0D"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 97px">&nbsp;</TD>
    <TD STYLE="width: 47px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090D0D">4.2a</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090D0D">One hundred thousand dollars ($100,000) upon the NDA filing with the U.S. Food and Drug Administration which is covered by a validly issued U.S. patent.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090D0D">4</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #1D2327">.</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090D0D">2b</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090D0D">Six hundred fifty thousand dollars ($650,000) upon approval of an NDA with the U.S. Food and Drug Administration which is covered by a validly issued U.S. patent </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">4.3
&#9;Licensee must pay to The Regents a license maintenance fee of $ 5,000 beginning on the one-year anniversary date of the Effective
Date of this Agreement and continuing annually on each anniversary date of the Effective Date. The maintenance fee will not be
due and payable on any anniversary date of the Effective Date if on that date Licensee is commercially selling a Licensed Product
and paying an earned royalty to The Regents on the sales of that Licensed Product. The license maintenance fees are non-refundable
and are not an advance against royalties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">4.4
&#9;In the event that the Licensee is publicly traded, Licensee shall make, at The Regents' election, payment under sections 4.1,
4.2 &amp; 4.3 with Licensee's publicly traded equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0D">5. ROYALTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0D">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #090D0D">5.1
&#9;Licensee must pay to The Regents for sales by Licensee or its Affiliates an earned royalty of four percent (4%) of Net Sales
of Licensed Products or Licensed Methods unless reduced pursuant to Section </FONT><FONT STYLE="color: #1D2327">1</FONT><FONT STYLE="color: #090D0D">.8</FONT><FONT STYLE="color: #1D2327">.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #1D2327">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.2
&#9;Licensee must pay to The Regents a minimum annual royalty of $10,000 for the life of Regents' Patent Rights, beginning in the
year of the First Commercial Sale of Licensed Product. Licensee must pay the minimum annual royalty to The Regents by February
28 of each year. The minimum annual royalty will be credited against the earned royalty due and owing for the calendar year in
which the minimum payment was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1111"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.3
&#9;Paragraphs 1.1, 1.2, 1.3 and 1.4 define Regents' Patent Rights, Licensed Products, Licensed Methods and the Field of Use so
that royalties are payable on products covered by pending patent applications and issued patents. Royalties accrue for the duration
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.4
&#9;Licensee must pay royalties owed to The Regents on a quarterly basis. Licensee must pay the royalties within two months of
the end of the calendar quarter in which the royalties accrued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.5
&#9;All monies due The Regents must be paid in United States funds. When Licensed Products are sold for monies other than United
States dollars, the royalties will first be determined in the foreign currency of the country in which those Licensed Products
were sold and, second, converted into equivalent United States funds. Licensee must use the exchange rate established by the Bank
of America in San Francisco, California on the last day of the calendar quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.6
&#9;Any tax for the account of The Regents required to be withheld by Licensee under the laws of any foreign country must be promptly
paid by Licensee for and on behalf of The Regents to the appropriate governmental authority. Licensee will use its best efforts
to furnish The Regents with proof of payment of any tax. Licensee is responsible for all bank transfer charges. All payments made
by Licensee in fulfillment of The Regents' tax liability in any particular country will be credited against fees or royalties due
The Regents for that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.7
&#9;If at any time legal restrictions prevent the acquisition or prompt remittance of United States Dollars by Licensee with respect
to any country where a Licensed Product is sold, the Licensee shall pay royalties due to The Regents from Licensee's other sources
of United States Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.8
&#9;If any patent or any claim included in Regents' Patent Rights is held invalid or unenforceable in a final decision by a court
of competent jurisdiction from which no appeal has or can be taken, all obligation to pay royalties based on that patent or claim
or any claim patentably indistinct from it will cease as of the date of that final decision. Licensee will not, however, be relieved
from paying any royalties that accrued before that decision or that is based on another patent or claim not involved in that decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">5.9
&#9;No royalties will be collected or paid on Licensed Products sold to the United States Federal Government, or any agency of
the United States Government. The Licensee and its Sublicensee will reduce the amount charged for Licensed Products distributed
to the United States Government by the amount of the royalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1111"><B>6. DILIGENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1111">6.1
&#9;Upon the execution of this Agreement, Licensee must diligently proceed with the development, manufacture and sale (&quot;Commercialization&quot;)
of Licensed Products and must earnestly and diligently endeavor to market them within a reasonable time after execution of this
Agreement and in quantities sufficient to meet the market demands for them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1111">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D100F">6.2
&#9;Licensee must endeavor to obtain all necessary governmental approvals for the Commercialization of Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D100F">6.3
&#9;The Regents has the right and option to either terminate this Agreement, narrow the fields of use granted under paragraph 1.4
or reduce Licensee's exclusive license to a nonexclusive license if Licensee fails to perform any of the terms in this Paragraph
6.3. This right, if exercised by The Regents, supersedes the rights granted in Article 2 (Grant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D100F"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">6.3a &#9;Within
twenty-four months from the Effective Date of this Agreement, Licensee will file, cross-file or transfer an investigational new
drug application (IND) relating to the Licensed Product for each field of use selected under paragraph 1.4 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">6.3b &#9;Within
five years of the Effective Date of this Agreement, initiate Phase II clinical trials for a Licensed Product for each field of
use selected under paragraph 1.4 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">6.3c &#9;Within
eight years of the Effective Date of this Agreement, initiate Phase III clinical trials for a Licensed Products for each field
of use selected under paragraph 1.4 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">6.3d &#9;Within
fourteen years of the Effective Date of this Agreement complete a First Commercial Sale of a Licensed Product for each field of
use selected under paragraph 1.4 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D100F">6.4
&#9;Licensee has the sole discretion for making all decisions as to how to commercialize any Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D100F">7. PATENT FILING, PROSECUTION
AND MAINTENANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #0D100F">7.1
&#9;As long as Licensee is paying prosecution costs, The Regents will file, prosecute and maintain the patents and applications
comprising Regents' Patent Rights. These patents will be held in the name of The Regents and will be obtained with counsel of The
Regents' choice. The Regents must provide Licensee with copies of each patent application, office action, response to office action,
request for terminal disclaimer, and request for reissue or reexamination of any patent or patent application under Regents' Patent
Rights. The Regents will consider any comments or suggestions by Licensee</FONT><FONT STYLE="color: #303734">: </FONT><FONT STYLE="color: #0D100F">The
Regents is entitled to take action to preserve rights and minimize costs whether or not Licensee has commented. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D100F">7.2
&#9;Licensee will bear all costs incurred prior to and during the term of this Agreement in the preparation, filing, prosecution
and maintenance of patent applications and patents in Regents' Patent Rights. Prosecution includes interferences, oppositions and
any other inter parties matters originating in a patent office. Licensee must send payment to The Regents within 30 days of Licensee's
receipt of an invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt; color: #0D100F">7.3
&#9;Licensee has the right to request patent protection on the Invention in foreign countries if the rights are available. Licensee
must notify The Regents of its decision within eight months of the filing of the corresponding United States patent application.
This notice must be in writing and must identify the countries desired. The absence of this notice from Licensee to The Regents
will be considered an election not to secure foreign rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt; color: #0E1110">7.4
&#9;Eight months after the filing of the corresponding United States application, but not sooner, The Regents will have the right
to file patent applications at its own expense in any country which Licensee has not identified in written notice provided by 7.3.
These applications and resulting patents will not be subject to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt; color: #0E1110">7.5
&#9;Licensee's obligation to underwrite and to pay all United States and foreign patent costs will continue for as long as this
Agreement remains in effect. Licensee may terminate its obligations with respect to any given patent application or patent upon
three months written notice to The Regents. The Regents will use its best efforts to curtail patent costs chargeable to Licensee
under this Agreement after this notice is received from Licensee. The Regents may continue prosecution or maintenance of these
application(s) or patent(s) at its sole discretion and expense, and Licensee will have no further rights or licenses to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1110">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1110"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1110">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt; color: #0E1110">7.6
&#9;The Regents will use its best efforts to not allow any Regents' Patent Rights for which Licensee is licensed and is underwriting
the costs of to lapse or become abandoned without Licensee's authorization or reasonable notice, except for the filing of continuations,
divisionals, or the like which substitute for the lapsed application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt; color: #0E1110">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1110"><B>8. PATENT INFRINGEMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1110">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1110">8.1
&#9;In the event that The Regents (to the extent of the actual knowledge of the licensing professional responsible for the administration
of this Agreement) or the Licensee learns of infringement of potential commercial significance of any patent licensed under this
Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence
of such infringement available to it (the &quot;Infringement Notice&quot;). During the period in which, and in the jurisdiction
where, the Licensee has exclusive rights under this Agreement, neither The Regents nor the Licensee will notify a third party (including
the infringer) of infringement or put such third party on notice of the existence of any Patent Rights without first obtaining
consent of the other. If the Licensee puts such infringer on notice of the existence of any Patent Rights with respect to such
infringement without first obtaining the written consent of The Regents and if a declaratory judgment action is filed by such infringer
against The Regents, then Licensee's right to initiate a suit against such infringer for infringement under Paragraph 8.2 below
will terminate immediately without the obligation of The Regents to provide notice to the Licensee. Both The Regents and the Licensee
will use their diligent efforts to cooperate with each other to terminate such infringement without litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1110">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1110">8.2
&#9;If infringing activity of potential commercial significance by the infringer has not been abated within ninety (90) days following
the date the Infringement Notice takes effect, then the Licensee may institute suit for patent infringement against the infringer.
The Regents may voluntarily join such suit at its own expense, but may not thereafter commence suit against the infringer for the
acts of infringement that are the subject of the Licensee's suit or any judgment rendered in the suit. The Licensee may not join
The Regents in a suit initiated by Licensee without The Regents' prior written consent. If, in a suit initiated by the Licensee,
The Regents is involuntarily joined other than by the Licensee, then the Licensee will pay any costs incurred by The Regents arising
out of such suit, including but not limited to, any legal fees of counsel that The Regents selects and retains to represent it
in the suit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1110">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #0E1110">8.3
&#9;If, within a hundred and twenty (120) days following the date the Infringement Notice takes effect, infringing activity of
potential commercial significance by the infringer has not been abated and if the Licensee has not brought suit against the infringer,
then The Regents may institute such suit for patent infringement against the infringer. If The Regents institutes such suit, </FONT><FONT STYLE="color: #0E1010">then
the Licensee may not join such suit without The Regents consent and may not thereafter commence suit against the infringer for
acts of infringement that are subject to The Regents suit or any judgment rendered in that suit. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">8.4
&#9;Any recovery or settlement received in connection with any suit will first be shared by The Regents and the Licensee equally
to cover any litigation costs each incurred and next shall be paid to The Regents or the Licensee to cover any litigation costs
it incurred in excess of the litigation costs of the other. In any suit initiated by the Licensee, any recovery in excess of litigation
costs will be shared between Licensee and The Regents as follows: (a) for any recovery other than amounts paid for willful infringement:
(i) The Regents will receive fifteen percent (15%) of the recovery if The Regents was not a party in the litigation and did not
incur any litigation costs, (ii) The Regents will receive twenty-five percent (25%) if The Regents was party in the litigation,
but did not incur any litigation costs, including provisions of Paragraph 8.2 above, and (iii) The Regents will receive fifty percent
(50%) of the recovery if The Regents incurred any litigation costs in connection with the litigation; and (b) for any recovery
for willful infringement, The Regents will receive fifty percent (50%) of the recovery. In any suit initiated by The Regents, any
recovery in excess of litigation costs will belong to The Regents. The Regents and the Licensee agree to be bound by all determinations
of patent infringement, validity and enforceability (but no other issue) resolved by any adjudicated judgment in a suit brought
in compliance with this Article 8 (Patent Infringement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">8.5
&#9;Any agreement made by the Licensee for purposes of settling litigation or other dispute shall comply with the requirements
of Article 3 (Sublicenses) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">8.6
&#9;Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who
initiated the suit (unless such suit is being jointly prosecuted by the parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">8.7
&#9;Any litigation proceedings will be controlled by the party bringing the suit, except that The Regents may be represented by
counsel of its choice in any suit brought by the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1010">9. PROGRESS AND ROYALTY
REPORTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1010">9.1
&#9;Beginning January 31, 2006, Licensee must submit to The Regents semiannual progress reports covering Licensee's activities
related to the development and testing of all Licensed Products and the obtaining of the governmental approvals necessary for marketing.
These progress reports must be made for each Licensed Product until its First Commercial Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1010">9.2
&#9;The progress reports submitted under Paragraph 9.1 must include the following topics:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">9.2a Summary
of work completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">9.2b Key scientific
discoveries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">9.2c Summary
of work in progress.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">9.2d Current
schedule of anticipated events or milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">9.2e Market
plans for introduction of Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">9.2f A summary
of resources ( dollar value) spent in the reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; text-indent: 35.25pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt; color: #0E1010">9.3.
&#9;Licensee must notify The Regents if Licensee or any of its Sublicensees or Affiliates ceases to be a small entity (as defined
by the United States Patent and Trademark Office) under the provisions of 35 U.S.C. &sect;41(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt; color: #0E1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.1pt; color: #0D1010">9.4
&#9;Licensee must report the date of the First Commercial Sale in the royalty report immediately following that Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">9.5 &#9;After
the First Commercial Sale of each Licensed Product, Licensee must make quarterly royalty reports to The Regents by February 28,
May 31, August 31 and November 30 of each year (i.e., within two months from the end of each calendar quarter). Each royalty report
must cover Licensee's most recently completed calendar quarter and must show:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; color: #0D1010"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: 0.5in; color: #0D1010">9.5a Gross sales
and Net Sales of any Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: 0.5in; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: 0.5in; color: #0D1010">9.5b Number of
each type of Licensed Product sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: 0.5in; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: 0.5in; color: #0D1010">9.5c Royalties
payable to The Regents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt; text-indent: 0.5in; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; color: #0D1010">9.6 &#9;Licensee must state in its
royalty report if it had no sales of any Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010"><B>10. BOOKS AND RECORDS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.5pt; color: #0D1010">10.1 &#9;Licensee
must keep accurate books and records of all Licensed Products manufactured, used or sold. Licensee must preserve these books and
records for at least five years from the date of the royalty payment to which they pertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.5pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.5pt"><FONT STYLE="color: #0D1010">10.2 &#9;The
Regents' representatives or agents are entitled to inspect these books and records at reasonable times. The Regents will pay the
fees and expenses of these inspections. If an error </FONT><FONT STYLE="color: #BCBCBC">&middot; </FONT><FONT STYLE="color: #0D1010">favoring
Licensee of more than 5% of the total annual royalties is discovered, then Licensee will pay the fees and expenses of these inspections</FONT><FONT STYLE="color: #362C2C">.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010"><B>11. LIFE OF THE AGREEMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">11.1 &#9;Unless
otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement
is in force from the Effective Date recited on page one and remains in effect for the life of the last-to-expire patent in Regents'
Patent Rights, or until the last patent application licensed under this Agreement is abandoned and no patent in Regents' Patent
Rights ever issues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">11.2 &#9;Upon
termination of this Agreement, Licensee will have no further right to make, have made, use or sell any Licensed Product except
as provided in Article 14 (Disposition of Licensed Products on Hand Upon Termination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">11.3 &#9;Any
expiration or termination of this Agreement will not affect the rights and obligations set forth in the following Articles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.25pt 0pt 0; text-indent: 35.1pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 14</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 17</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 18</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 23</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Article 24</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Books and Records</P>

<P STYLE="color: #0D1010; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Disposition of Licensed
Products on Hand upon Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Use of Names and Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Warranties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Failure to Perform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">Governing Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D1010"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010"><B>12. TERMINATION BY THE
REGENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #090D0B">12.1
&#9;If Licensee violates or fails to perform any material term or covenant of this Agreement</FONT><FONT STYLE="color: #272929">,
</FONT><FONT STYLE="color: #090D0B">then The Regents may give written notice of the default (&quot;Notice of Default&quot;) to
Licensee. If Licensee does not repair the default within 60 days after the effective date of the Notice of Default, then The Regents
has the right to terminate this Agreement and the License by a second written notice (&quot;Notice of Termination&quot;) to Licensee.
If The Regents sends a Notice of Termination to Licensee, then this Agreement automatically terminates on the effective date of
this notice. Termination does not relieve Licensee of its obligation to pay any royalty or fees owing at the time of termination
and does not impair any accrued right of The Regents. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">13. TERMINATION BY LICENSEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">13.1
&#9;Licensee has the right at any time to terminate this Agreement in whole or with respect to any portion of Regents' Patent Rights
by giving written notice to The Regents. This notice of termination will be subject to Article 19 (Notices) and will be effective
90 days after the effective date of the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #090D0B">13.2
&#9;Any termination in accordance with Paragraph 13.1 does not relieve Licensee of any obligation or liability accrued prior to
termination</FONT><FONT STYLE="color: #3A3A3A">. </FONT><FONT STYLE="color: #090D0B">Nor does termination rescind anything done
by Licensee or any payments made to The Regents prior to the effective date of termination. Termination does not affect in any
manner any rights of The Regents arising under this Agreement prior to termination. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: #090D0B; margin-top: 0; margin-bottom: 0; text-align: center">14.
DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #090D0B">14.1
&#9;Upon termination of this Agreement, Licensee will have the right to dispose of all previously made or partially made Licensed
Products, but no more, within a period of six months. But Licensee must submit royalty reports on the sale of these Licensed Products
and must pay royalties at the rate and at the time provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">15. PATENTMARKING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #090D0B">15.1
&#9;Licensee must mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance
with the applicable patent marking laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">16. USE OF NAMES AND TRADEMARKS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #090D0B">16.1
&#9;Neither party is permitted to use any name, trade name</FONT><FONT STYLE="color: #272929">, </FONT><FONT STYLE="color: #090D0B">trademark
or other designation of the other party or its employees (including contraction, abbreviation or simulation of any of the foregoing)
in advertising</FONT><FONT STYLE="color: #272929">, </FONT><FONT STYLE="color: #090D0B">publicity or other promotional activity.
Unless required by law, Licensee is expressly prohibited from using the name &quot;The Regents of the University of California&quot;
or the name of any campus of the University of California. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">17. LIMITED WARRANTY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">17.1
&#9;The Regents warrants that it has the lawful right to grant this license to Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">17.2
&#9;This License and the associated Invention are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE REGENTS MAKE NO REPRESENTATION OR WARRANTY THAT ANY LICENSED PRODUCT WILL NOT INFRINGE
ANY PATENT OR OTHER PROPRIETARY RIGHT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">17.3
&#9;IN NO EVENT WILL THE REGENTS BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS
LICENSE OR THE USE OF THE INVENTION OR LICENSED PRODUCTS OR THE USE OR THE PRACTICE OF LICENSED METHODS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">17.4
&#9;Nothing in this Agreement will be construed as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #090D0B">17.4a &#9;A
warranty or representation by The Regents as to the validity or scope of any Regents' Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #090D0B">17.4b &#9;A
warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement
is or will be free from infringement of patents of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #090D0B">17.4c &#9;Obligate
The Regents to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article
8 (Patent Infringement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #090D0B">17.4d &#9;Conferring
by implication, estoppel or otherwise any license or rights under any patents of The Regents other than Regents' Patent Rights
as defined herein, regardless of whether such patents are dominant or subordinate to Regents' Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #090D0B">17.4e &#9;Obligate
The Regents to furnish any know-how not provided in Regents' Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090D0B"><B>18. INDEMNIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">18.1
&#9;Licensee will, and will require its Sublicensees to, indemnify, hold harmless and defend The Regents, its officers, employees,
and agents, the sponsors of the research that led to the invention, the inventors of the patents and patent applications in Regents'
Patent Rights and their respective employers from and against any and all liability, claims, suits, losses, damages, costs, fees
and expenses resulting from or arising out of exercise of this license or any sublicense. Indemnification indudes but is not limited
to products liability. If The Regents, in its sole discretion, believes that there will be a conflict of interest or it will not
otherwise be adequately represented by counsel chosen by Licensee to defend The Regents in accordance with this Paragraph 18.1,
then The Regents may retain counsel of its choice to represent it, and Licensee will pay all expenses for such representation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">18.2
&#9;For the first use of the Licensed Product for humans and thereafter, Licensee, at its sole cost and expense, must insure its
activities in connection with the work under this Agreement and obtain, keep in force and maintain Comprehensive or Commercial
Form General Liability Insurance (contractual liability included) with limits as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.6pt; text-align: justify; text-indent: 0.5in; color: #090D0B">18.2a
Each occurrence $5,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.6pt; text-align: justify; text-indent: 0.5in; color: #090D0B">18.2b
Products/completed operations aggregate $10,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; color: #090D0B">18.2c Personal
and advertising injury $5,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; color: #090D0B">18.2d General aggregate
(commercial form only) $10,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #090D0B"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #090D0B">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D100F">18.3
&#9;Licensee expressly understands, however, that the coverages and limits in Paragraph 18.2 do not in any way limit the Licensee's
liability. Licensee must furnish The Regents with certificates of insurance evidencing compliance with all requirements. Licensee's
insurance must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; color: #0D100F">18.3a &#9;Provide for 30-day advance
written notice to The Regents of any modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt; color: #0D100F">18.3b &#9;Indicate that The Regents
of the University of California is endorsed as an Insured under the coverages listed in Paragraph 18.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.35pt"><FONT STYLE="color: #0D100F">18.3c &#9;Include a
provision that the coverages will be primary and will not participate with nor will be excess over any valid and collective insurance
or program of self-insurance carried or maintained by The Regents</FONT><FONT STYLE="color: #2D2E2C">. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #0D100F">18.4 &#9;The Regents shall
notify Licensee in writing of any claim or suit brought against The Regents in respect of which The Regents intends to invoke the
provisions of this Article 18 (Indemnification). Licensee shall keep The Regents informed on a current basis of its defense of
any claims under this Article 18 (Indemnification).</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D100F"><B>19. NOTICES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.5pt; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #0D100F">19.1 &#9;Any notice or payment
required to be given to either party must be sent to the respective address given below and is effective: (a) on the date of delivery
if delivered in person, (b) five days after mailing if mailed by first-class certified mail, postage paid, or ( c) on the next
business day if sent by overnight delivery. Either party may change its designated address by written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; color: #0D100F"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">For Licensee: </FONT></TD>
    <TD STYLE="width: 73%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">GENERAL FIBER, INC. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">801 Brickell Avenue 9<SUP>th &nbsp;</SUP>Floor Suite 942 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">Miami, Florida </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">Attention: Nicholas Stergis </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">For The Regents: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">The Regents of the University of California University of California, Los Angeles Office of Intellectual Property Administration 10920 Wilshire Blvd., Suite 1200 Los Angeles, California 90095-1406 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D100F">Attention: Director </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D100F"><B>20. ASSIGNABILITY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #0D100F">20.1 &#9;This Agreement
is binding upon and inures to the benefit of The Regents, its successors and assigns. But it is personal to Licensee and assignable
by Licensee only with the written consent of The Regents. The consent of The Regents will not be required if the assignment is
in conjunction with the transfer of all or substantially all of the business of Licensee to which this license relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D100F"><B>21. LATE PAYMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D100F">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">21.1
&#9;For each royalty payment or fee not received by The Regents when due, Licensee must pay to The Regents a simple interest charge
of 10% per annum to be calculated from the date payment was due until it was actually received by The Regents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211"><B>22. WAIVER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E1211">&#9;22.1 &#9;The waiver
of any breach of any term of this Agreement does not waive any other breach of that or any other term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211"><B>23. FAILURE TO PERFORM
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">23.1
&#9;If either party takes legal action against the other because of a failure of performance due under this Agreement, then the
prevailing party is entitled to reasonable attorney's fees in addition to costs and necessary disbursements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211"><B>24. GOVERNING LAW </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">24.1
&#9;THIS AGREEMENT IS TO BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and
validity of any patent or patent application will be governed by the applicable laws of the country of the patent or patent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1211"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">25. GOVERNMENT APPROVAL
OR REGISTRATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">25.1
&#9;If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with
any governmental agency, Licensee will assume all legal obligations to do so. Licensee will notify The Regents if it becomes aware
that this Agreement is subject to a United States or foreign government reporting or approval requirement. Licensee will make all
necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting
or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">26. EXPORT CONTROL LAWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">26.1
&#9;Licensee must observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and related
technical data to foreign countries, including the International Traffic in Arms Regulations (IT AR) and the Export Administration
Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">27. PREFERENCE FOR UNITED
STATES INDUSTRY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">27.1
&#9;Because this Agreement grants an exclusive right to a particular use of the Invention, Licensee must manufacture in the United
States any products embodying this Invention or produced through the Invention's use to the extent required by 35 U.S.C. &sect;200-212.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">28. FORCE MAJEURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">28.1
&#9;The parties will be excused from any performance required under this Agreement if performance is impossible or unfeasible due
to any catastrophe or other major event beyond their reasonable control, including war, riot, or insurrection; lockouts or other
serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events abate, and in any event within
one year, the parties' respective obligations will resume.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0E1211">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010"><B>29. CONFIDENTIALITY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D1010">29.1
&#9;If either party discloses confidential information to the other party, the disclosing party will designate this information
as confidential by appropriate legend or instruction, and the receiving party will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">29.1a &#9;Use
the same degree of care to maintain the secrecy of the confidential information as it uses to maintain the secrecy of its own information
of like kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">29.1 b &#9;Use
the confidential information only to accomplish the purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">29.2
&#9;Neither party will disclose confidential information received from the other party except to its employees, customers, distributors
and other agents who are bound to it by similar obligations of confidence and only as required to accomplish the purposes of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">29.3
&#9;Neither party will have any confidentiality obligation with respect to the confidential information belonging to or disclosed
by the other party that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">29.3a &#9;The
receiving party can demonstrate by written records was previously known to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">29.3b &#9;The
receiving party lawfully obtained from sources under no obligation of confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">29.3c &#9;Is
or becomes publicly available other than through an act or omission of the receiving party or any of its employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">29.3d &#9;Is
required to be disclosed under the California Public Records Act, governmental audit requirement or other requirement of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.85pt; text-align: justify; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">29.4
&#9;The provisions of this Article 29 will continue III effect for five years after expiration or termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">29.5
&#9;The Regents is free to release to the inventors and senior administrators employed by The Regents the terms and conditions
of this Agreement. If such release is made, then The Regents shall give notice of the confidential nature and shall request that
the recipient not disclose such terms and conditions to others. If a third party inquires whether a license to Regents' Patent
Rights is available, then The Regents may disclose the existence of this Agreement and the extent of the grant in Article 2 (Grant)
to such third party, but will not disclose the name of Licensee or any other terms or conditions of this Agreement, except where
The Regents is required to release information under the California Public Records Act, a governmental audit requirement, or other
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010"><B>30. MISCELLANEOUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">30.1
&#9;The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of, or
to affect the meaning or interpretation of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">30.2
&#9;This Agreement is not binding upon the parties until it has been signed below on behalf of each party, in which event it becomes
effective as of the date recited on page one.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D1010">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0F0E">30.3
&#9;No amendment or modification of this Agreement will be valid or binding upon the parties unless made in writing and signed
by each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #0D0F0E">30.4
&#9;This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations
or understandings, either oral or written</FONT><FONT STYLE="color: #20202E">, </FONT><FONT STYLE="color: #0D0F0E">between the
parties relating to the subject matter hereof, except for the Secrecy Agreement dated <B>10-20-03, </B>which continues to the extent
it is not inconsistent with this Agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt"><FONT STYLE="color: #0D0F0E">30.5
&#9;If any part of this Agreement is for any reason found to be unenforceable</FONT><FONT STYLE="color: #20202E">, </FONT><FONT STYLE="color: #0D0F0E">all
other parts nevertheless remain enforceable as long as a party's rights under this Agreement are not materially affected</FONT><FONT STYLE="color: #20202E">.
</FONT><FONT STYLE="color: #0D0F0E">In lieu of the unenforceable provision, the parties will substitute or add as part of this
Agreement a provision that will be as similar as possible in economic and business objectives as was intended by the unenforceable
provision. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.6pt; color: #0D0F0E">Both
The Regents and Licensee have executed this Agreement in duplicate originals by their authorized officers on the dates written
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D0F0E"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E"><B>GENERAL FIBER, INC </B></FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E">By: <U>/s/ Nicholas Stergis</U></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E">By: <U>/s/ Emily Loughran</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E">Name: Nicholas Stergis</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E">Name: Emily Loughran</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E">Title: Chief Operating Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E">Title: Director of Licensing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Dated: July 11, 2005</TD>
    <TD STYLE="padding: 0; text-indent: 0">Dated: July 5, 2005</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D0F0E">APPENDIX A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">REGENTS&rsquo; PATENT RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0D0F0E">U.S. Patent Application No. 10/131,384 entitled
&ldquo;Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases,&rdquo; filed April 24, 2002, which was based on Provisional
ApplicationNo. 60/286,842 filed 4/25/01 (UCLA Case Nos 1998-531-1,2) by Dr. Voskuhl, and assigned to The Regents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0D0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. Patent Application No. 10/984,364 entitled &ldquo;The Use
of Estrial and Other Estranes, Estrogen and Estrogen Receptor Active Compositions in the Treatment of Psoriasis&hellip;,&rdquo;
filed November 8, 2004, (UCLA Case No. 2004-101-3) by Drs. Rhonda R. Voskuhl, Gerald D. Weinstein and Jenny E. Murase and assigned
to The Regents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">European Patent Application No. 02729034.5 based on PCT/US02/13407,
filed April 25, 2002 entitled &ldquo;Estriol Therapy for Multiple Sclerosis and Other Autoimmune Diseases&rdquo; by Dr. Rhonda
R. Voskuhl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #0D0F0E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D0F0E"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #0D0F0E">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090A0A">EXCLUSIVE LICENSE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #090A0A">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #090A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #090A0A"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 85%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 15%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ARTICLE PAGE NUMBER&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">RECITALS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">1 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">1. DEFINITIONS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">1 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">2. GRANT </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">3 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">3. SUBLICENSES</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">3 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">4. FEES </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">4 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">5. ROYALTIES </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">4 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">6. DILIGENCE </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">5 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">7. PATENT FILING, PROSECUTION AND MAINTENANCE </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">6 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">8. PATENT INFRINGEMENT </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">7 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">9. PROGRESS AND ROYALTY REPORTS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">8 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10. BOOKS AND RECORDS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">9 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">11. LIFE OF THE AGREEMENT</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">9 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">12. TERMINATION BY THE REGENTS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13. TERMINATION BY LICENSEE</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">14. DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">15. PATENT MARKING </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">16. USE OF NAMES AND TRADEMARKS</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">17. LIMITED WARRANTY </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">18. INDEMNIFICATION</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">11 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">19. NOTICES</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">12 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">20. ASSIGNABILITY </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">12 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">21. LATE PAYMENTS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">22. WAIVER </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">23. FAILURE TO PERFORM </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">24. GOVERNING LAWS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">25. GOVERNMENT APPROVAL OR REGISTRATION </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">26. EXPORT CONTROL LAWS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">27. PREFERENCE FOR UNITED STATES INDUSTRY </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">28. FORCE MAJEURE </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">29. CONFIDENTIALITY </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">14 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">30. MISCELLANEOUS </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">14 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCFFCC">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #090A0A">APPENDIX A </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #090A0A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; color: #090A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.46
<SEQUENCE>3
<FILENAME>v337358_ex10-46.htm
<DESCRIPTION>EXHIBIT 10.46
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #060A08">Exhibit 10.46</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #060A08">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #060A08"><B>First Amendment to the
License Agreement Between The Regents of the University of California and <BR>
General Fiber, Inc. UC Agreement Control No. 2006-04-0026
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #060A08">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #060A08">This First Amendment (&quot;First Amendment&quot;),
dated November 08, 2005 (the &quot;Effective Date&quot;), is made by and between The Regents of the University of California (&quot;The
Regents&quot;) and General Fiber, Inc. (&quot;Licensee&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #060A08">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #060A08"><B>RECITALS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #060A08">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #060A08"><B>WHEREAS, </B>The Regents has entered into
an existing Exclusive License Agreement with Licensee, dated July 11, 2005, relating to various inventions entitled, &quot;Estriol
for the treatment of autoimmune diseases &amp; the use of estriol and other estranges, estrogens and estrogen receptor active compositions
in the treatment of psoriasis &amp; other autoimmune diseases&quot; (UCLA Case No. 1998-531 &amp; UCLA Case No. 2004-101) developed
at The Regents (the &quot;License Agreement&quot;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #060A08">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; color: #060A08"><B>WHEREAS, </B>Licensee desires
to amend and clarify the License Agreement with The Regents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.75pt; color: #060A08">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #060A08"><B>NOW THEREFORE, </B>in consideration of the
foregoing premises and the mutual promises, covenants, and agreements hereinafter set forth, all parties to this First Amendment
mutually agree to amend the License Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #060A08">&nbsp;</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. Paraqraph 1.1 (&quot;Regents' Patent Rights&quot;)
is deleted and replaced with the following, which is amended to include <I>&quot;UC Case No. 2006-154&quot; </I>and <I>UC Case
No. 2006-155&quot; </I>in the parenthetical in the paragraph:</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #060A08">1.1 &quot;Regents' Patent Rights&quot;
means The Regents interest in any of the patent applications listed in Appendix A attached to this Agreement and assigned to The
Regents (UCLA Case No. 1998-531, UCLA Case No. 2004-101, UCLA Case No. 2006</FONT><FONT STYLE="color: #31312F">.. </FONT><FONT STYLE="color: #060A08">154
and UCLA Case No. 2006-155); any continuing applications thereof including divisions; but excluding continuations-in-part except
to the extent of claims entirel</FONT><FONT STYLE="color: #C2BDC3">'</FONT><FONT STYLE="color: #060A08">y supported in the specification
and entitled to the priority date of the parent application; any patents issuing on these applications including reissues and reexaminations;
and any corresponding foreign patents or patent applications; all of which will be automatically incorporated in and added to Appendix
A and made a part of this Agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. Appendix A (&quot;Regents' Patent Rights&quot;)
is deleted and replaced with the following, which is amended to include the patent applications filed under UC Case No. 2006-154
and UC Case No. 2006-155.</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #060A08">APPENDIX A REGENTS' PATENT
RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #060A08">&nbsp;</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Patent No. 6,936,599, which was based on U.S. Patent Application No. <I>10/131,834 </I>entitled &quot;Estriol Therapy for
Multiple Sclerosis and Other Autoimmune Diseases,&quot; Wed April 24, 2002, which was based on Provisional Application No. <I>60/286,842
</I>filed <I>4125/01 </I>(UCLA Case Nos. 1998-531-1,2) by Dr. Rhonda</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Voskuhl, and assigned to The Regents.</P>

<P STYLE="color: #060A08; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="color: #070B09; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>S. Patent Application No. <I>10/984,364 </I>entitled &quot;The Use of Estriol and Other Estranes, Estrogen and Estrogen
Receptor Active Compositions in the Treatment of Psoriasis ... ,&quot; filed November 8,2004, (UCLA Case No. 2004-101-3) by Drs.
Rhonda R. Voskuhl, Gerald D. Weinstein and Jenny E. Murase and assigned to The Regents.</P>

<P STYLE="color: #070B09; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="color: #070B09; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="color: #070B09; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">European Patent Application
No. 02729034.5 based on <I>PCT/US02/13407 </I>(UCLA Case No. 1998-531-2), filed April 25, 2002 entitled &quot;Estriol Therapy for
Multiple Sclerosis and Other Autoimmune Diseases&quot; by Dr. Rhonda R. Voskuhl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">Provisional Patent Application
entitled &quot;Method of treating post-partum diseases with estrogens, estranges, estriol, or estrogen receptor composition&quot;,
filed September 26, 2005 (UCLA Case No.2006154), invented by Dr. Rhonda Voskuhl and assigned to The Regents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: #070B09">Provisional
Patent Application entitled &quot;Method of treating of preventing a neurodegenerative disease with estrogens, estranges, estriol,
or estrogen receptor composition&quot;, filed September 26, 2005 (UCLA ~ase No.2006-155), invented by Dr</FONT><FONT STYLE="color: #202120">.
</FONT><FONT STYLE="color: #070B09">Rhonda Voskuhl and assigned to The Regents. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">3. Section 6.3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">Under Section 6.3 of the
License Agreement, the list of diligence items shall be expanded to include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">Section 6.3e: Licensee
will, within eighteen months from the Effective Date of this Amendment, conduct preclinical or clinical studies with one or more
of the compounds whQse utility is claimed in the patent application described in Appendix A above to test efficacy in at least
one disease other than multiple sclerosis,.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">The remainder of the due
diligence obligations shall remain in place for the patent applications under Appendix A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">4. In consideration for
this Amendment, Licensee will pay to The Regents a two thousand dollar ($2,000) amendment fee within thirty (30) days of the Effective
Date of this First Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">IN WITNESS WHEREOF, the
parties have executed this First Amendment to the License Agreement by their duly authorized representatives for good and valuable
consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #070B09"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E"><B>GENERAL FIBER, INC </B></FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #0D0F0E"><B>THE REGENTS OF THE UNIVERSITY </B></FONT><FONT STYLE="font-size: 10pt; color: #0D0F0E"><B>OF CALIFORNIA
</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0D0F0E">By: <U>/s/ Nicholas Stergis</U></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0D0F0E">By: <U>/s/ </U></FONT><U><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #080C0A">Claire T . Wake, Ph.D.</FONT></U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0D0F0E">Name: Nicholas Stergis</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0D0F0E">Name: </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #080C0A">Claire T . Wake, Ph.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0D0F0E">Title: Chief Operating Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #0D0F0E">Title: </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #080C0A">Assistant Director</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #212220">, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #080C0A">Licensing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt; color: #080C0A">Office of Intellectual Property Administration</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 233.5pt; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.47
<SEQUENCE>4
<FILENAME>v337358_ex10-47.htm
<DESCRIPTION>EXHIBIT 10.47
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.47</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Second Amendment to the License Agreement
Between the Regents of the University of California and <BR>
General Fiber, Inc. License Agreement Control No. 2006-04-0026 Effective
January 3, 2007 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Second Amendment (the &ldquo;Second Amendment&rdquo;) dated
January 3, 2007 is made by and between The <FONT STYLE="color: black">Regents of the University of California and General Fiber,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, The Regents has entered into an Exclusive License with
dated July 11, 2005, and a First Amendment to the License November 8. 2005 to various inventions entitled, &quot;Estriol for the
treatment of autoimmune diseases &amp; the use of estnol and other and f'ci-rr.rrpn actlVe in the treatment of &amp; other autoimmune
diseases&quot; 1998-531 &amp; UCLA Case No. 2004-1 at The Regents (the &quot;License Agreement&rsquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS, Licensee desires to amend and the License with The</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOW THEREFORE, in consideration of the foregoing premises and
the mutual promises, covenants, and agreements hereinafter set forth, all parties to this Second Amendment mutually agree to amend
the License Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">1<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT>In Paragraph 1.1 (&quot;Regents' Patent Rights&quot;), any reference to &quot;UC Case No. 2004101-3&quot; 1S amended to
exclude this case number (UC Case No. 2004-JOl-3). The remainder of the case numbers shall remain as part of the license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;Appendix
A Patent is hereby amended to remove any reference to UC Case No. 2004-101 and LLS. Patent Application No.1 entitled. &quot;The
Use of Estriol and Other Estranes. Estrogen and Estrogen Active Compositions in the treatment of Psoriasis:, filed November 8,
2004, invented by Drs. Rhonda Voskuhl, Gerald D. Weinstein and Jenny E. Murase and to the</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The remainder of the patents listed on A will remain of the
license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: windowtext">3. </FONT>Under Section 6.3
of the License Agreement, section 6.3e shall be deleted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. In consideration for this Second Amendment, Licensee will
pay to the a two thousand dollar ($2,000) amendment fee within thirty (30) of the Effective Date of this amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, the parties have executed this Second Amendment
to the License by their duly authorized for and valuable consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>GENERAL FIBER, INC. </B></FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;&nbsp;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">By: <U>/s/ Nicholas Stergis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">By: <U>/s/ Emily W. Loughran&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Name: Nicholas Stergis</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Name: Emily W. Loughran</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Title: Chief Operating Officer</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Title: Director of Licensing</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.48
<SEQUENCE>5
<FILENAME>v337358_ex10-48.htm
<DESCRIPTION>EXHIBIT 10.48
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.48</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THIRD AMENDMENT TO EXCLUSIVE LICENSE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UC Agreement Control No. 2006-04-0026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This third amendment (&quot;Third Amendment&quot;)
to the Exclusive License Agreement (&quot;Agreement&quot;), effective August 29, 2007 is made by and between The Regents of the
University of California, a California corporation (&quot;The Regents&quot;), and Putney Drug Corp, a Delaware company (&quot;Licensee&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BACKGROUND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">A. </FONT></TD>
    <TD STYLE="width: 90%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">The Regents and Licensee are parties to the Agreement, dated as of July <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>II, </B></FONT>2005. </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">B. </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">The Agreement was amended on November
8, 2005 (&quot;First Amendment&quot;) and on January 3, 2007 (&quot;Second Amendment&quot;);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify">I. Amend Paragraph I.l (&quot;Regents'
Patent Rights&quot;) to include UC Case No. 2007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">561.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.6pt; text-align: justify">2. In consideration for adding
UC Case No. 2007-561 to the Agreement, a milestone payment in the new Paragraph 4.5, which reads as follows, is added to the Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.6pt; text-align: justify">4.5 Licensee will pay The Regents,
in either cash or publicly traded equity, twenty thousand dollars ($20,000) upon issuance of the first US patent claiming priority
to the provisional filing (SN 60/933,030).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the parties have executed
this Third Amendment to the Agreement by their duly authorized representatives for good and valuable consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>PUTNEY DRUG CORP. </B></FONT></TD>
    <TD STYLE="width: 50%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">By: <U>/s/ Steve Kanzer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">By: <U>/s/ Emily Waldron Loughran&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Name: Steve Kanzer</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Name: Emily Waldron Loughran</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Title: President </FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">Title: Director of Licensing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Dated: August 30, 2007</TD>
    <TD STYLE="padding: 0; text-indent: 0">Dated: September 4, 2007</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.49
<SEQUENCE>6
<FILENAME>v337358_ex10-49.htm
<DESCRIPTION>EXHIBIT 10.49
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">Exhibit 10.49</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FOURTH AMENDMENT TO EXCLUSIVE LICENSE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UC Agreement Control No. 2006-04-0026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This fourth amendment (&ldquo;<B>Fourth
Amendment</B>&rdquo;) to the Exclusive License Agreement (&ldquo;<B>Agreement</B>&rdquo;), effective December 31, 2012 is made
by and between the Regents of the University of California, a California corporation (&ldquo;<B>The Regents</B>&rdquo;), and Putney
Drug Corp., a Delaware company (&ldquo;<B>Licensee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BACKGROUND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Regents and Licensee are parties to the Agreement, dated as of July 11, 2005.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The Agreement was amended on November 8, 2005 (&ldquo;<B>First Amendment</B>&rdquo;), on January
3, 2007 (&ldquo;<B>Second Amendment</B>&rdquo;) and on August 29, 2007 (&ldquo;<B>Third Amendment</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: black">1.</FONT></TD><TD STYLE="text-align: justify">Amend paragraph 1.4 to read as follows: &ldquo;1.4 The &lsquo;Field of Use&rsquo; <FONT STYLE="color: black">means
human therapeutics for the treatment of autoimmune diseases, including multiple sclerosis.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Amend paragraph 4.3 to increase the annual maintenance fee from &ldquo;$5,000&rdquo; to &ldquo;$10,000&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Amend paragraph 4.2 by adding a new subparagraph 4.2c to read &ldquo;seven hundred fifty thousand
dollars ($750,000) upon the first achievement of fifty million dollars ($50,000,000) in annual sales while covered by a validly
issued U.S. patent.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Amend paragraph 6.3c to replace &ldquo;Within eight years of the Effective Date of this Agreement,
initiate Phase III clinical trials&rdquo; with &ldquo;Within 3 years from the successful completion of the ongoing clinical trial
of estriol for relapsing-remitting multiple sclerosis being conducted by Dr. Rhonda Voskuhl as principal investigator, initiate
a Phase III clinical Trial&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">Amend paragraph 6.3d to replace &ldquo;fourteen (14) years&rdquo; with &ldquo;seventeen (17) years&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the parties have executed
this Fourth Amendment to the Agreement by their duly authorized representatives for good and valuable consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PUTNEY DRUG CORP.</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>THE REGENTS OF THE UNIVERSITY OF</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CALIFORNIA</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Jeff Riley</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Emily Waldron Loughran</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(signature)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(signature)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT>&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeff Riley</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT>&nbsp;</TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emily Waldron Loughran</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">CEO</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director of Licensing</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3/15/2013</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: Black 1pt solid; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3/25/2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>v337358_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 23.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Consent of Independent Registered
Public Accounting Firm</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rockville, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the
incorporation by reference in the Registration Statements on Form S-3 (No. 333-166750 and 333-156973) and Form
S-8 (No. and 333-170858 and 333-148764) of Synthetic Biologics, Inc. of our report dated April 16, 2013, relating to the 2012
consolidated financial statements, which appear in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>/s/ BDO USA, LLP</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BDO USA, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Boston, MA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 16, 2013</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>8
<FILENAME>v337358_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 23.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tlogo1.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public
Accounting Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the use of our report dated
May 11, 2012 on the financial statements of Synthetic Biologics, Inc. as of December 31, 2011, and the related statements of operations,
stockholders&rsquo; equity and cash flows for the year ended December 31, 2011, included herein on the registration statement
of Synthetic Biologics, Inc. on Forms S-3 and S-8, referenced herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.35in">(i)</TD><TD STYLE="text-align: justify">Registration Statement (Form
                                                                 S-8, No. 333-170858), which relates to the Registrant&rsquo;s
                                                                 2010 Stock Incentive Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.35in">(ii)</TD><TD STYLE="text-align: justify">Registration Statement (Form
                                                                  S-8, No. 333-148764), which relates to the Registrant&rsquo;s
                                                                  2001 Stock Incentive Plan and 2007 Stock Incentive Plan.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.35in">(iii)</TD><TD STYLE="text-align: justify">Registration Statement (Form
                                                                   S-3, No. 333-166750), which relates to an indeterminate amount
                                                                   of securities of the Registrant pursuant to which the Registrant
                                                                   has issued,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.35in">(iv)</TD><TD STYLE="text-align: justify">Registration Statement (Form
                                                                  S-3, No. 333-156973), which relates to the registration of 9,965,671
                                                                  shares of common stock on behalf of selling stockholders.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Berman &amp; Company, P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certified Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><img src="tsig.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boca Raton, Florida</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> April 16, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="tfooter.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>v337358_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">I, Jeffrey Riley, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Synthetic Biologics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I&nbsp;have&nbsp;disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the
registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>v337358_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">I, C. Evan Ballantyne, certify
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Synthetic Biologics, Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">The registrant's other certifying officer(s) and I have disclosed, based on&nbsp;our most recent
evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>v337358_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Pursuant to 18 U.S.C. &sect; 1350, as created by
Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &ldquo;Registrant&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">the accompanying Annual Report on Form 10-K of the&nbsp;Registrant for the year ended December
31, 2012 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the
Securities Exchange Act of 1934, as amended; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Registrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Jeffrey Riley</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>v337358_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Pursuant to 18 U.S.C. &sect; 1350, as created by
Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &ldquo;Registrant&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">the accompanying Annual Report on Form 10-K of the&nbsp;Registrant for the year ended December
31, 2012 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the
Securities Exchange Act of 1934, as amended; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Registrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: April 16, 2013</FONT></TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: C. Evan Ballantyne</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>13
<FILENAME>syn-20121231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 6.0.1.3 [03/29/2013 01:08:07 PM] by DataTracks -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.0.2.9 by DataTracks on Friday, April 12, 2013 04:05:57 PM -->
<xbrli:xbrl xmlns:syn="http://www.syntheticbiologics.com/20121231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="syn-20121231.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_FYE_31-Dec-2001_SubsequentEventTypeAxis_StockPlan2001Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">syn:StockPlan2001Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2001-01-01
</xbrli:startDate>
<xbrli:endDate>
2001-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_Custom_30-Sep-2005_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ResearchAndDevelopmentArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2005-09-01
</xbrli:startDate>
<xbrli:endDate>
2005-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20-Mar-2007_PlanNameAxis_StockPlan2007Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2007-03-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2009">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-01-01
</xbrli:startDate>
<xbrli:endDate>
2009-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2009">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_Custom_02-Jul-2010_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:CommonStockPurchaseAgreementWithSingleInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-06-25
</xbrli:startDate>
<xbrli:endDate>
2010-07-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02-Nov-2010_PlanNameAxis_StockPlan2010Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-11-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2010_LegalEntityAxis_McleanHospitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:McleanHospitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2010_LegalEntityAxis_MedaAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:MedaAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:StockPurchaseAgreementWithThreeInstitutionalInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-01-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jan-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-19
</xbrli:startDate>
<xbrli:endDate>
2011-01-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:CommonStockPurchaseAgreementWithSingleInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-19
</xbrli:startDate>
<xbrli:endDate>
2011-01-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06-Apr-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:CommonStockPurchaseAgreementWithInstitutionalInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-04-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:CommonStockPurchaseAgreementWithSingleInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:StockPurchaseAgreementWithThreeInstitutionalInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:CommonStockPurchaseAgreementWithInstitutionalInvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="syn:PeriodTypeAxis">syn:CommitmentDateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="syn:PeriodTypeAxis">syn:RemeasurementDateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_ConsultingAgreementForFinancialAdvisoryServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:ConsultingAgreementForFinancialAdvisoryServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-03-25
</xbrli:startDate>
<xbrli:endDate>
2011-04-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-07-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jul-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-06-29
</xbrli:startDate>
<xbrli:endDate>
2011-07-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="syn:PeriodTypeAxis">syn:CommitmentDateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-06-29
</xbrli:startDate>
<xbrli:endDate>
2011-07-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="syn:PeriodTypeAxis">syn:RemeasurementDateMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-06-29
</xbrli:startDate>
<xbrli:endDate>
2011-07-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Nov-2011_BusinessAcquisitionAxis_IntrexonMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_EmployeesAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syn:AdeonaClinicalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_OptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009457Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice458905Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009905Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009457Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009457Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice458905Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice458905Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009905Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009905Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_31-Dec-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009457Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice458905Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009905Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:LaboratoryEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_31-Dec-2011_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_MoneyMarketAccountsAndMutualFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">syn:MoneyMarketAccountsAndMutualFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02-Feb-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-02-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02-Feb-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-15
</xbrli:startDate>
<xbrli:endDate>
2012-02-02
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_DrKuoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis">syn:DrKuoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-02-01
</xbrli:startDate>
<xbrli:endDate>
2012-02-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_JeffreyRileyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis">syn:JeffreyRileyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-02-01
</xbrli:startDate>
<xbrli:endDate>
2012-02-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_CEvanBallantyneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis">syn:CEvanBallantyneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-02-01
</xbrli:startDate>
<xbrli:endDate>
2012-02-29
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15-Mar-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-03-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15-Mar-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-02-16
</xbrli:startDate>
<xbrli:endDate>
2012-03-15
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Aug-2012_BusinessAcquisitionAxis_IntrexonMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-10-25
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-25
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_Custom_31-Oct-2012_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_31-Oct-2012_RelatedPartyTransactionsByRelatedPartyAxis_MrKanzerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:MrKanzerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-10-01
</xbrli:startDate>
<xbrli:endDate>
2012-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MrKanzerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:MrKanzerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_EmployeesAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">syn:AdeonaClinicalLaboratoryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_OptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009200Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice201300Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice301600Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009200Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009200Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice201300Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice201300Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice301600Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice301600Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice13Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice375Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice14Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice330Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_LegalEntityAxis_EpitopeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:EpitopeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice222Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice220Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice220Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:LaboratoryEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_ManufacturingEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ManufacturingEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:LaboratoryEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009600Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009600Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009600Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInAnnArborMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:EntityByLocationAxis">syn:OfficeSpaceInAnnArborMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInRockvilleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:EntityByLocationAxis">syn:OfficeSpaceInRockvilleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_PhaseIClinicalTrialsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">syn:PhaseIClinicalTrialsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_PhaseIiiClinicalTrialsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">syn:PhaseIiiClinicalTrialsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_NdaSubmissionInUsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">syn:NdaSubmissionInUsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_EuropeanMedicinesAgencyApprovalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">syn:EuropeanMedicinesAgencyApprovalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_RegulatoryApprovalInAsianCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis">syn:RegulatoryApprovalInAsianCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_SubsequentEventTypeAxis_StockPlan2001Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">syn:StockPlan2001Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_PlanNameAxis_StockPlan2007Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_31-Dec-2012_PlanNameAxis_StockPlan2010Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:LaboratoryEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009200Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice201300Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice301600Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice13Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice375Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice14Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice330Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_LegalEntityAxis_EpitopeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:EpitopeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice222Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice220Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">syn:ExercisePrice220Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice009600Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_OperatingLossForwardPeriodAxis_TaxableIncomeExpiringThrough2032Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:OperatingLossForwardPeriodAxis">syn:TaxableIncomeExpiringThrough2032Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_As_Of_31-Dec-2012_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_MoneyMarketAccountsAndMutualFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">syn:MoneyMarketAccountsAndMutualFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInAnnArborMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:EntityByLocationAxis">syn:OfficeSpaceInAnnArborMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInRockvilleMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:EntityByLocationAxis">syn:OfficeSpaceInRockvilleMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AnnualPaymentEffectivePeriodAxis_December312014Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:AnnualPaymentEffectivePeriodAxis">syn:December312014Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_AnnualPaymentEffectivePeriodAxis_December312015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:AnnualPaymentEffectivePeriodAxis">syn:December312015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_QuarterlyInstallmentsPaymentPeriodAxis_FirstYearMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:FirstYearMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_QuarterlyInstallmentsPaymentPeriodAxis_SecondYearMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:SecondYearMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_QuarterlyInstallmentsPaymentPeriodAxis_ThirdYearMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:ThirdYearMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_AnnArborMichiganMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis">syn:AnnArborMichiganMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27-Mar-2013">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>XUI~\FVPYwivc444c555cT{h>6<HE<4GG1FH<:18F651FFH;1:=H5=G<6G96I -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_31-Dec-2012">Synthetic Biologics, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_FYE_31-Dec-2012">0000894158</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_FYE_31-Dec-2012">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_FYE_31-Dec-2012">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:TradingSymbol contextRef="Context_FYE_31-Dec-2012">syn</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_27-Mar-2013" unitRef="shares" decimals="0">44654414</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_FYE_31-Dec-2012">10-K</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_FYE_31-Dec-2012">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_FYE_31-Dec-2012">2012-12-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_FYE_31-Dec-2012">FY</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_FYE_31-Dec-2012">2012</dei:DocumentFiscalYearFocus>
<dei:EntityWellKnownSeasonedIssuer contextRef="Context_FYE_31-Dec-2012">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="Context_FYE_31-Dec-2012">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="Context_FYE_31-Dec-2012">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityPublicFloat contextRef="Context_As_Of_30-Jun-2012" unitRef="USD" decimals="0">44969000</dei:EntityPublicFloat>
<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2009" unitRef="USD" decimals="-3">2715000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">2649000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">6678000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">9954000</us-gaap:Cash>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">405000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">16000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">2509000</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">23000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7122000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">12463000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">323000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">223000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:NotesAndLoansReceivableNetNoncurrent>
<us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">700000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">31000</syn:DepositsAndOtherAssetsNoncurrent>
<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">37000</syn:DepositsAndOtherAssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7476000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">13423000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">388000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">395000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">29000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">417000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">395000</us-gaap:LiabilitiesCurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">417000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">395000</us-gaap:Liabilities>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Nov-2011_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD" decimals="-4">1700000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">31000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Aug-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD" decimals="-5">7800000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">44000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">58901000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">81925000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-51873000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">-68941000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">3579000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">23000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">47280000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-43724000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7059000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">31000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">58901000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-51873000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">13028000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">44000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">81925000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-68941000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7476000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">13423000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Nov-2011_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD_per_Share" decimals="2">0.54</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Aug-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD_per_Share" decimals="1">2.2</us-gaap:CommonStockParOrStatedValuePerShare>

<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Nov-2011_BusinessAcquisitionAxis_IntrexonMember" unitRef="shares" decimals="0">3123558</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">31374002</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Aug-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="shares" decimals="0">3552210</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">44444230</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">31292520</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">44362748</us-gaap:CommonStockSharesOutstanding>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">2588000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">539000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">5012000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">466000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_Custom_30-Sep-2005_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ResearchAndDevelopmentArrangementMember" unitRef="USD" decimals="-3">460000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">3340000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">12287000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">5928000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">17299000</us-gaap:OperatingExpenses>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-5928000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-17299000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<syn:WarrantExpenses contextRef="Context_Custom_06-Apr-2011" unitRef="USD" decimals="-3">716000</syn:WarrantExpenses>
<syn:WarrantExpenses contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1492000</syn:WarrantExpenses>
<syn:WarrantExpenses contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:WarrantExpenses>
<syn:WarrantExpenses contextRef="Context_FYE_31-Dec-2012_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="-3">776000</syn:WarrantExpenses>
<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">242000</syn:ChangeInFairValueOfWarrantLiability>
<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:ChangeInFairValueOfWarrantLiability>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">14000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">33000</us-gaap:InvestmentIncomeInterest>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">22000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-18000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-1698000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">15000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-7626000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-17284000</us-gaap:IncomeLossFromContinuingOperations>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-523000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">-523000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">216000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">216000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-8149000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-8149000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-17068000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-17068000</us-gaap:NetIncomeLoss>
<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">-0.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">-0.50</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">27710428</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">34896592</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2010_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">23338707</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">31292520</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">44362748</us-gaap:SharesOutstanding>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">973000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">1852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">94000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">94000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">73585</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1687000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">3000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1684000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">7814000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">3000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">7811000</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">3123558</syn:StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">3552210</syn:StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement>

<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1168000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>


<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">625000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="shares" decimals="0">3552210</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember" unitRef="shares" decimals="0">625000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">165000</syn:StockIssuedDuringPeriodValueConsultingFees>
<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">165000</syn:StockIssuedDuringPeriodValueConsultingFees>
<syn:StockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueConsultingFees>
<syn:StockIssuedDuringPeriodSharesConsultingFees contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">171796</syn:StockIssuedDuringPeriodSharesConsultingFees>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">15000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">15000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">2082000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">2000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">2080000</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">38948</syn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<syn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">2143018</syn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">6961000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">6956000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">10120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">10113000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_28-Jan-2011" unitRef="shares" decimals="0">2857144</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_06-Apr-2011" unitRef="shares" decimals="0">1688782</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">4545926</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_31-Oct-2012_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="0">6750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">6750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1734000</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">0</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1734000</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
<syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified>
<syn:StockIssuanceCost contextRef="Context_Custom_28-Jan-2011" unitRef="USD" decimals="-3">296000</syn:StockIssuanceCost>
<syn:StockIssuanceCost contextRef="Context_Custom_06-Apr-2011" unitRef="USD" decimals="-3">243000</syn:StockIssuanceCost>
<syn:StockIssuanceCost contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">539000</syn:StockIssuanceCost>
<syn:StockIssuanceCost contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">680000</syn:StockIssuanceCost>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">973000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">1851000</us-gaap:ShareBasedCompensation>
<syn:StockIssuedAsCompensation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">94000</syn:StockIssuedAsCompensation>
<syn:StockIssuedAsCompensation contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:StockIssuedAsCompensation>
<syn:StockIssuedForConsultingFees contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">165000</syn:StockIssuedForConsultingFees>
<syn:StockIssuedForConsultingFees contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:StockIssuedForConsultingFees>
<syn:IssueOfStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-1684000</syn:IssueOfStockForExclusiveChannelCollaborationAgreement>
<syn:IssueOfStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-7815000</syn:IssueOfStockForExclusiveChannelCollaborationAgreement>
<syn:StockIssuedForAcquisitionsOfProgramAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:StockIssuedForAcquisitionsOfProgramAssets>
<syn:StockIssuedForAcquisitionsOfProgramAssets contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-1169000</syn:StockIssuedForAcquisitionsOfProgramAssets>
<us-gaap:Depreciation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">144000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">63000</us-gaap:Depreciation>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">414000</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">442000</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">57000</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:AdjustmentForAmortization>
<us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-20000</us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments>
<us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments>
<us-gaap:GainLossOnDispositionOfProperty contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-6000</us-gaap:GainLossOnDispositionOfProperty>
<us-gaap:GainLossOnDispositionOfProperty contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnDispositionOfProperty>
<syn:EquipmentImpairmentLoss contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:EquipmentImpairmentLoss>
<syn:EquipmentImpairmentLoss contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">47000</syn:EquipmentImpairmentLoss>
<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">63000</us-gaap:GainLossOnSaleOfAccountsReceivable>
<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">480000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-14000</us-gaap:IncreaseDecreaseInAccountsReceivable>


<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-60000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">6000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">191000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>

<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">153000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">7000</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-181000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-29000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">24000</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2875000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-8916000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">4370000</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquireMarketableSecurities>
<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">4293000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
<us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">10000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-75000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-10000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<syn:ProceedsFromIssuanceOfCommonStockForStockOptionsExercises contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">15000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionsExercises>
<syn:ProceedsFromIssuanceOfCommonStockForStockOptionsExercises contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">2082000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionsExercises>
<syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">3000</syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement>
<syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement>
<syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="-5">2000000</syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">6961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">10120000</us-gaap:ProceedsFromIssuanceOfCommonStock>


<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">6979000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">12202000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">4029000</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">3276000</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
<syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">1734000</syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
<syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0.5in;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Organization and Nature of Operations and Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px 0pt 0.5in; text-indent: -0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;Synthetic Biologics, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Synthetic Biologics&amp;#8221;) is a&lt;font style="color: black;"&gt; biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of&lt;i&gt; C. difficile&lt;/i&gt; infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and &lt;i&gt;Acinetobacter&lt;/i&gt; infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="width: 27%; text-align: center; font-family: times new roman, times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Therapeutic Area&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 2%; text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 27%; text-align: center; font-family: times new roman, times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Product Candidate&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 2%; text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 42%; text-align: center; font-family: times new roman, times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Status&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Relapsing-remitting MS&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: times new roman, times, serif;"&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;Trimesta&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;(oral estriol)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Patients fully enrolled in Phase II clinical trial;&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;br  /&gt; &lt;font style="font-size: 10pt;"&gt;dosing and monitoring underway&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Cognitive dysfunction in MS&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: times new roman, times, serif;"&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;Trimesta&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;(oral estriol)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Patient enrollment underway in Phase II&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;br  /&gt; &lt;font style="font-size: 10pt;"&gt;clinical trial&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;i&gt;C. difficile&lt;/i&gt; infection prevention&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;SYN-004&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;br  /&gt; &lt;font style="font-size: 10pt;"&gt;(monoclonal antibody)&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: times new roman, times, serif;"&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;Series of oral enzyme candidates; first generation candidate (formerly known as P1A) is in Phase II;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;next generation candidate, SYN-004, (formerly known as P3A) is in preclinical&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Pertussis&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;SYN-005&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;br  /&gt; &lt;font style="font-size: 10pt;"&gt;(monoclonal antibody)&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Preclinical; Collaborations with Intrexon and The University of Texas at Austin&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;i&gt;Acinetobacter &lt;/i&gt;infection&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;SYN-001&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;br  /&gt; &lt;font style="font-size: 10pt;"&gt;(monoclonal antibody)&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Discovery; Collaboration with Intrexon&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-family: times new roman, times, serif; vertical-align: top;"&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Fibromyalgia&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Effirma&lt;/font&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&lt;br  /&gt; &lt;font style="font-size: 10pt;"&gt;(oral flupirtine)&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font-family: times new roman, times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: times new roman, times, serif;"&gt;&lt;font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Partnered with Meda AB&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;To prioritize the Company&amp;#8217;s focus on the&lt;font style="color: black;"&gt; development of product candidates for the prevention and treatment of serious infectious diseases, it does not intend to pursue&lt;/font&gt; further development of the previously announced program for pulmonary arterial hypertension. However, the Company is currently in discussions with Intrexon to substitute this program with an alternate program better suited to its current objectives and focus.&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;In order to further prioritize the Company&amp;#8217;s focus, it has elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, the Company is currently seeking development partners for its zinc-based intellectual property and assets including, AEN-100.&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Corporate Structure&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;As of December 31, 2012, the Company had seven subsidiaries, Pipex Therapeutics, Inc. (&amp;#8220;Pipex Therapeutics&amp;#8221;), Effective Pharmaceuticals, Inc. (&amp;#8220;EPI&amp;#8221;), Solovax, Inc. (&amp;#8220;Solovax&amp;#8221;), CD4 Biosciences, Inc. (&amp;#8220;CD4&amp;#8221;), Epitope Pharmaceuticals, Inc. (&amp;#8220;Epitope&amp;#8221;), Healthmine, Inc. (&amp;#8220;Healthmine&amp;#8221;) and Putney Drug Corp. (&amp;#8220;Putney&amp;#8221;). As of December 31, 2012, Pipex Therapeutics, EPI, Healthmine and Putney are wholly owned and Solovax, CD4 and Epitope are majority-owned.&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics, Inc. All statements of operations, stockholders&amp;#8217; equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January 8, 2001, except for EPI, which was incorporated in Delaware on December 12, 2000, Epitope which was incorporated in Delaware in January of 2002, Putney which was incorporated in Delaware in November of 2006 and Healthmine which was formed in Delaware in December of 2007.&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner, in consideration for (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all the assets of the Lab. Accordingly, this business has been presented in the consolidated financial statements as discontinued operations. This transaction is described in more detail in Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;All inter-company transactions and accounts have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Emerging from the Development Stage&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During the second quarter of 2010, the Company emerged from the development stage.&amp;#160;&amp;#160;&amp;#160;A development-stage enterprise is one in which planned principle operations have not commenced or if its operations have commenced, there has been no significant revenue.&amp;#160;On May 6, 2010, the Company entered into a Sublicense Agreement (the &amp;#8220;Meda Agreement&amp;#8221;) with Meda&amp;#160;AB of Sweden (&amp;#8220;Meda&amp;#8221;) and received an up-front payment of $2.5 million. The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement of principal operations, and therefore development-stage reporting was no longer required.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&amp;#160;&amp;#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&amp;#160;&amp;#160;For the year ended December 31, 2012 and 2011, the Company&amp;#8217;s only stream of revenue was laboratory revenue.&amp;#160;&amp;#160;Laboratory revenues are a component of discontinued operations for the years ended December 31, 2012 and 2011. See Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company&amp;#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&amp;#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&amp;#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&amp;#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&amp;#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&amp;#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&amp;#160;&amp;#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;i&gt;Laboratory Revenues&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which was the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior period multiplied by the period&amp;#8217;s actual gross sales to determine the actual sales allowance for each period. See Note 3 - Discontinued Operations of Adeona Clinical Laboratory.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Classification of Marketable Securities as Held to Maturity, Trading, and Available for Sale&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading, are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&amp;#8217; equity. At December 31, 2012 and 2011, respectively, the Company had no debt and marketable equity securities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows &lt;i&gt;(in thousands)&lt;/i&gt; :&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;December 31, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 72%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Purchase of short-term investments&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 25%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(4,370&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Amortization of premium on investments&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;57&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Proceeds from short-term investments&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,293&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Loss on sale of short-term investments&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;20&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Fair value&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 49%;" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;Asset&amp;#160;Description&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 4%;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 47%;" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;Estimated&amp;#160;Useful&amp;#160;Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Office equipment and furniture&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3-5&amp;#160;&amp;#160;years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Laboratory equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;7-10 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Manufacturing equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;10 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Leasehold improvements and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Lesser of estimated useful or life of lease&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Depreciation expense was approximately $63,000 and $144,000 for the years ended December 31, 2012 and 2011, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During 2012, the Company reviewed property and equipment for impairment and determined that certain items were impaired due to obsolescence. As a result of this review, the Company recorded an impairment loss of approximately $47,000. For the year ended December 31, 2011, there were no significant events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;ASC No. 350, &amp;#8220;Intangibles &amp;#8211; Goodwill and Others,&amp;#8221; requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. See Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In&amp;#160;addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option pricing model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive, at December 31, 2012 and December 31, 2011, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the year ended December 31, 2012 were 4,453,746 and 1,632,501, respectively, and for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&amp;#8217;s product candidates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Level 1 inputs: Quoted prices (unadjusted)&amp;#160;for identical assets or liabilities in active markets;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The carrying amounts of the Company&amp;#8217;s short-term financial instruments, including cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Cash and cash equivalents include money market accounts and mutual funds of $8.6 million and $5.0 million as of December 31, 2012 and December 31, 2011, respectively, that are measured using Level 1 inputs.&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&amp;#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable and are re-measured over the corresponding vesting period. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC Topic 740, &amp;#8220;&lt;i&gt;Income Taxes&lt;/i&gt;,&amp;#8221; which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In addition, accounting guidance now codified as FASB ASC Topic 740-20, &lt;i&gt;&amp;#8220;Income Taxes &amp;#8211; Intraperiod Tax Allocation&amp;#8221; &lt;/i&gt;requires&lt;i&gt; &lt;/i&gt;management to assess the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The accounting guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December 31, 2012 and 2011, respectively, the Company did not record any liabilities for uncertain tax positions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;There were no accounting standards or interpretations issued or recently adopted that are expected to have a material impact on the Company&amp;#8217;s financial position, operations, or cash flows.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In accordance with ASC Topic 205-20 &amp;#8220;&lt;i&gt;Presentation of Financial Statements&amp;#8212;Discontinued Operations&lt;/i&gt;&amp;#8221; (ASC 205-20), the Company determined that all the criteria for reporting a discontinued operation had been met. Accordingly, the Lab has been classified as a discontinued operation and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption &amp;#8220;Assets of discontinued operations&amp;#8221; in the accompanying Consolidated Balance Sheets at December 31, 2012, and December 31, 2011, and consist of the following &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Assets of discontinued operations:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;23&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total assets&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;23&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the years ended December 31, 2012 and December 31, 2011 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Laboratory fees, net&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;115&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,169&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Operating Costs and Expenses:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;466&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;539&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Cost of&amp;#160; laboratory services&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;110&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;975&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Impairment loss on goodwill&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;178&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total operating costs and expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;576&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,692&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(461&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(523&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Other Income:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Gain on sale of Adeona Clinical Laboratory&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;677&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Income (loss) from discontinued operations&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;216&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(523&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>

<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="width: 0.5in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During 2001, the Company&amp;#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of December 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On March 20, 2007, the Company&amp;#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of December 31, 2012, there are 872,739 options issued and outstanding under the 2007 Stock Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various period from the date of grant, and generally expire ten years after the grant date. As of December 31, 2012, there are 2,515,000 options issued and outstanding under the 2010 Stock Plan.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2012 and 2011 are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="3"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$1.69 - $2.47&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$0.49 - $2.22&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected dividends&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;108% - 174%&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;175% - 188%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Risk fee interest rate&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.37% - 1.98%&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.30% - 3.58%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected life of option&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5 - 10 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5 - 7 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected forfeitures&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 9%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 88%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;immediate vesting,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;half vesting immediately and the remainder over three years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;quarterly over three years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;annually over three years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;one-third immediate vesting and remaining annually over two years,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;one half immediate vesting with remaining vesting over nine months,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;one quarter immediate vesting with the remaining over three years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;one quarter immediate vesting with the remaining over 33 months; and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt symbol;; font-family:times new roman,times" size="2"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;monthly over three years.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.25in; margin: 0pt 0px 0pt 1in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During 2012, the Company granted 2,075,000 options to employees and consultants having an approximate fair value of $4.5 million based upon the Black-Scholes option pricing model.&amp;#160; During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued employees for the years ended December 31, 2012 and 2011 were $1.4 million and $268,000, respectively. Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to consultants for the years ended December 31, 2012 and 2011 were $216,000 and $705,000, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Average&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remaining&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Aggregate&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Average&amp;#160;Exercise&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Contractual&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Intrinsic&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Life&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Value&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt; width: 48%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance &amp;#8211; December 31, 2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,539,091&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.32&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 10%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;6.97 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,028,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;557,002&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.26&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercised&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(23,333&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.57&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(93,750&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.59&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance &amp;#8211; December 31, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,979,010&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.34&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;6.01 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,075,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercised&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(374,851&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.34&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(225,413&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.37&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance &amp;#8211; December 31, 2012 &amp;#8211; outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,453,746&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.78&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;6.43 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,308,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance &amp;#8211; December 31, 2012 &amp;#8211; exercisable&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,891,877&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.60&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;5.71 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,160,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Grant date fair value of options granted &amp;#8211; 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,467,984&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted average grant date fair value &amp;#8211; 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.15&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Grant date fair value of options granted &amp;#8211; 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;609,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted average grant date fair value &amp;#8211; 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.09&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0px;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The options outstanding and exercisable at December 31, 2012 are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&amp;#160;Outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&amp;#160;Exercisable&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Range&amp;#160;of&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remaining&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remaining&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Contractual&amp;#160;Life&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Contractual&amp;#160;Life&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 14%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$0.09 - $2.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,162,362&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.78&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.76 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,801,187&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.52 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$2.01 - $3.00&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,212,227&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.26&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;7.15 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,011,533&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.17&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;6.14 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$3.01 - $6.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;79,157&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4.87&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4.49 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;79,157&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4.87&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4.49 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$0.09 - $6.00&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,453,746&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.78&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;6.43 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,891,877&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.60&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.71 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The options outstanding and exercisable at December 31, 2011 are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&amp;#160;Outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&amp;#160;Exercisable&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Range&amp;#160;of&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remaining&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Average&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remaining&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Contractual&amp;#160;Life&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Contractual&amp;#160;Life&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 14%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$0.09 - $4.57&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,889,011&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.20&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;6.11 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,364,608&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.72 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$4.58 - $9.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;89,999&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.93&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.76 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;89,999&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.93&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.76 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$0.09 - $9.05&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,979,010&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.34&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;6.01 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,454,607&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.46&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5.62 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The following is a summary of the Company&amp;#8217;s non-vested stock options at December 31, 2012:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Unvested&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Grant&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Stock&amp;#160;Options&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Date&amp;#160;Fair&amp;#160;Value&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-vested&amp;#160;&amp;#8211;&amp;#160;December&amp;#160;31,&amp;#160;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;524,403&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.82&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,075,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Vested/Exercised&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(891,332&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.81&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Forfeited/Cancelled&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(146,202&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.79&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Non-vested &amp;#8211; December 31, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,561,869&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.11&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted average remaining period for vesting&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;2.09 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of December 31, 2012, total unrecognized stock-based compensation expense related to stock options was $3.2 million, which is expected to be expensed through September 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;FASB&amp;#8217;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from financing activities.&amp;#160; Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options.&amp;#160; The Company did not record any excess tax benefits in 2012 or 2011.&amp;#160; Cash received from option exercises under the Company&amp;#8217;s stock-based compensation plans for the years ended December 31, 2012 and 2011 was $127,000 and $15,000, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Stock Warrants and Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase 635,855 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.60 and a life of five years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of December 31, 2012, all the warrants were outstanding.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company&amp;#8217;s common stock based on achievement of certain stock price milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date of issuance for an exercise price equal to the price ($2.20 per share) of the Company&amp;#8217;s common stock on the date of execution (March 15, 2012). The expense recorded for the year ended December 31, 2012 approximated $63,000 and was estimated using the Monte Carlo valuation model. The assumptions used by the Company are summarized in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 87%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.20&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected dividends&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;110&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.26&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected life of warrant&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font style="font: 10pt times new roman, times, serif; color: black;; font-family:times new roman,times" size="2"&gt;2 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&amp;#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&amp;#8217;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. All of this expense was recorded in the year ended December 31, 2012. The assumptions used by the Company are summarized in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 87%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise price&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected dividends&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;174&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.71&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected life of warrant&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font style="font: 10pt times new roman, times, serif; color: black;; font-family:times new roman,times" size="2"&gt;5 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. Each warrant was exercisable&amp;#160;for thirteen months&amp;#160;at $2.00 per share and subsequently exchanged for new warrants with substantially the same&amp;#160;terms as the original warrants except that the expiration date was extended for two months. The original warrants had an anti-dilution price protection feature; if the Company issues securities at a price per share that is less than $2.00 per share, the warrant holders will be ratcheted down to the lower offering price. However, the Company had instituted a floor price of $1.40 per share in connection with the price protection.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40 per share. Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2012, all of these warrants have been exercised.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The warrants were initially recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&amp;#160;in the Company&amp;#8217;s statement of operations at each subsequent reporting period. On April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000. The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remeasurement&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Commitment&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;April&amp;#160;6,&amp;#160;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 74%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Closing stock price&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.39&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected dividend rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;117.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;104.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.28&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected life (years)&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.85&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date was&amp;#160;extended by two months.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrant was initially exercisable&amp;#160;for thirteen months&amp;#160;at $2.0725 per share. The warrant had an anti-dilution price protection feature; that provided if the Company issues securities at a price per share that is less than $2.0725 per share,&amp;#160;the&amp;#160;exercise price of the warrant&amp;#160;will be ratcheted down to the lower offering price.&amp;#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&amp;#160;three months to August 12, 2012,&amp;#160;and (iv) the warrant&amp;#8217;s initial exercise date was changed to January 2012. Due to this warrant exchange, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2012, all of these warrants have been exercised.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The warrant is&amp;#160;initially recorded as a liability at&amp;#160;its estimated fair value on the commitment date, which was $776,000 with subsequent changes in estimated fair value recorded as a warrant expense&amp;#160;in the Company&amp;#8217;s statement of operations at each subsequent period. On July 28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Remeasurement&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Commitment&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;July&amp;#160;28,&amp;#160;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-indent: -13.2pt; padding-left: 13.2pt; width: 74%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Closing stock price&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.84&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected dividend rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;112.1&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;105.6&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.29&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;0.21&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Expected life (years)&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.04&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The following table summarizes the estimated fair value of the warrant liabilities at December 31, 2011&lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-indent: -0.25in; padding-left: 0.25in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance at December 31, 2010&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 87%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Warrant liability&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,492&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Change in fair value of warrant liability&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;242&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Reclassification to additional paid-in capital&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(1,734&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance at December 31, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;A summary of warrant activity for the Company for the year ended December 31, 2011 and for the year ended December 31, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance at December 31, 2010&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,131,078&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3.49&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2,272,963&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.25&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercised&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(15,615&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.03&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(129,240&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2.08&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance as December 31, 2011&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3,259,186&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.95&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Granted&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;985,855&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.71&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Exercised&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(1,768,167&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.11&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(844,373&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3.32&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Balance as December 31, 2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,632,501&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1.99&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Stock-based compensation expense included in general and administrative expenses relating to warrants issued to consultants for the year ended December 31, 2012 was $271,000. There was no stock-based compensation for warrants for the year ended December 31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;!-- Field: /Page --&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0px;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;A summary of all outstanding and exercisable warrants as of December 31, 2012 is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Exercise&lt;/font&gt;&lt;br  /&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Price&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Warrants&lt;/font&gt;&lt;br  /&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Warrants&lt;/font&gt;&lt;br  /&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Exercisable&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;br  /&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Remaining&lt;/font&gt;&lt;br  /&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Contractual&amp;#160;Life&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Aggregate &lt;/font&gt;&lt;br  /&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Intrinsic Value&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1.14&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;100,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 17%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;100,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 20%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;4.09 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;62,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1.32&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;18,182&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;18,182&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.00 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;8,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1.60&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;635,855&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;635,855&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;4.83 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;102,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;2.20&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;250,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1.20 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;2.22&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;517,257&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;517,257&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.91 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.30&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;61,207&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;61,207&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.30 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.75&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;50,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.13 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1.99&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1,632,501&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;1,432,501&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;3.80 years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;172,000&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Options of Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of December 31, 2012, Epitope, a majority-owned subsidiary of Synthetic Biologics, has 50,000 stock options outstanding and 40,000 stock options exercisable. These stock options have an exercise price of $0.001 and a remaining contractual life of 5.50 years.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 0.5in;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Year Ended December 31, 2011&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the year ended December 31, 2011, the Company issued 28,333 shares of common stock in connection with the exercise of stock options and warrants for proceeds of $15,000 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company issued 73,585 shares of common stock for employment service, having a fair value of $94,000 ($1.29 average per share) and 171,796 shares of common stock for consulting services, having a fair value of $165,000 ($0.96 average per share), based on the quoted closing trading prices. The Company also issued 3,123,558 shares of common stock as consideration for the Exclusive Channel Collaboration Agreement with Intrexon, having a fair value of $1.7 million ($0.54 per share), based on the quoted closing trading price.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&amp;#160;1,428,572 shares of common stock&amp;#160;for $4 million. Direct offering costs were approximately $296,000.&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 6, 2011, the Company sold 1,688,782 shares of common stock and a warrant exercisable for 844,391 shares of common stock&amp;#160;for $3.5 million. Direct offering costs were approximately $243,000.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Year Ended December 31, 2012&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: black;"&gt;On October 31, 2012, the Company completed a private placement financing of &lt;/font&gt;6,750,000 shares of the Company&amp;#8217;s common stock at a closing price of $1.60 for gross proceeds of $10.8 million.&amp;#160;&amp;#160;The Company paid direct offering costs of $680,000.&amp;#160;&amp;#160;See Note 5 regarding warrants granted with this offering.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font style="color: black;"&gt;During the year ended December 31, 2012, the Company issued 374,851 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $127,000. The Company also issued 1,768,167 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $2.0 million.&lt;/font&gt; The Company also issued 3,552,210 shares of common stock as consideration for a second Exclusive Channel Collaboration Agreement with Intrexon, having a fair value of $7.8 million ($2.20 per share), based on the quoted closing trading price. These shares are subject to the registration rights agreement as described in Note 7. In connection with the private placement that was completed on October 31, 2012, the Company also entered into an agreement with NRM VII Holdings I, LLC, an affiliate of Intrexon that acquired 3,125,000 shares of the Company&amp;#8217;s common stock in the private placement, pursuant to which NRM VII Holdings I, LLC agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement as described in Note 7. In addition, the Company issued 625,000 shares of common stock as consideration for the acquisition of the &lt;i&gt;C. diff&lt;/i&gt; program assets of Prev ABR LLC, having a fair value of $1.2 million ($1.87 per share), based on the quoted closing trading price.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 0.5in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;License, Collaborative and Employment Agreements and Commitments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;i&gt;License and Collaborative Agreements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As described below, the Company has entered into several license and collaborative agreements for the right to use research, technology and patents. Some of these license and collaborative agreements may contain milestones.&amp;#160; The specific timing of such milestones cannot be predicted and are dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which may never occur).&amp;#160; Further, under the terms of certain licensing agreements, the Company may have the obligation to pay certain milestones contingent upon the achievement of specific levels of sales.&amp;#160; Due to the long-range nature of such commercial milestone amounts, they are neither probable at this time nor predictable and consequently are not included in this disclosure.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On December 19, 2012, the Company entered into a License Agreement with The University of Texas at Austin (the &amp;#8220;University&amp;#8221;) for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to pertussis antibodies. The License Agreement provides that the University is entitled to payment of past patent expenses, an annual payment of $50,000 per year commencing on the effective date through December 31, 2014 and a $25,000 payment on December 31, 2015 and milestone payments of $50,000 upon commencement of Phase I clinical trials, $100,000 upon commencement of Phase III clinical trials, $250,000 upon NDA submission in the U.S., $100,000 upon European Medicines Agency approval and $100,000 upon regulatory approval in an Asian country. In addition, the University is entitled to a running royalty upon net sales (as defined in the License Agreement). The License Agreement terminates upon the expiration of the patent rights (as defined in the License Agreement); provided, however that the License Agreement is subject to early termination by the Company in its discretion and by the University for a breach of the License Agreement by the Company.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In connection with the License Agreement, the Company and the University also entered into a Sponsored Research Agreement pursuant to which the University will perform certain research work related to pertussis. The Sponsored Research Agreement may be renewed annually, in the sole discretion of the Company, after the first year for two additional one year terms with a fixed fee for the first year of $303,287 and for the second and third years, if renewed, a fixed fee of $316,438 and $328,758 respectively, all payable in quarterly installments. If renewed by the Company after the first year for the remaining two years, the research shall be performed from the effective date of the Sponsored Research Agreement until December 31, 2015; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Research Agreement which remain uncured for sixty days after receipt of notice, automatically upon the Company&amp;#8217;s bankruptcy or insolvency and by the Company in its sole discretion at any time after the one year anniversary of the date of execution thereof upon no less than 90 days notice. Upon termination prior to December 31, 2014, the Company shall only be responsible for payment of expenses that do not exceed the fixed annual amount and are incurred prior to the termination date and non-cancellable expenses committed to be expended by the University prior to the termination date for the lesser of the remainder of their appointment in the case of salaries and December 31, 2014. Upon a termination after December 31, 2014 or due to a breach by the University, the Company shall only be responsible for all reasonable expenses that do not exceed the fixed annual amount and that are incurred by the University prior to the termination date for services performed prior to the termination date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On November 28, 2012, a closing was held for the transaction contemplated by the Prev Agreement the Company entered into with Prev ABR LLC (&amp;#8220;Prev&amp;#8221;), pursuant to which it acquired the&lt;i&gt; C. diff&lt;/i&gt; program assets of Prev, including pre-Investigational New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents.&amp;#160; Pursuant to the Prev Agreement, the Company paid Prev an initial cash payment of $100,000 upon execution of the Prev Agreement and at closing paid an additional cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to Prev. See Note 6. In addition, upon the achievement of the milestones set forth below, Prev may be entitled to receive additional consideration payable 50% in cash and 50% in our stock, subject to Prev&amp;#8217;s option to receive the entire payment in shares of our stock, with the exception of the first milestone payments to be paid in cash: (i) upon commencement of an IND; (ii) upon commencement of a Phase I clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon commencement of a Phase III clinical trial; (v) upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi) upon BLA approval in the U.S. and upon approval in territories outside the-U.S. The Prev Agreement also provides that Prev has a right to the return to it of all assets acquired by the Company under the Prev Agreement if on or prior to the date that is (i) thirty (30) months after the execution of the Prev Agreement, the Company has not initiated toxicology studies in non-rodent models or (ii) thirty six (36) months have not filed an IND under the program related to the assets and such failure is not due to action or inaction of Prev or breach of its representations or warranties or covenants or if there is a change of control as defined in the Prev Agreement and after such change of control the assets are not further developed; provided however that such thirty (30) and thirty six (36) month periods can be extended by the Company for an additional twelve (12) months upon payment of a cash milestone payment.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On August 6, 2012, the Company expanded its relationship with Intrexon and entered into the Second Channel Agreement with Intrexon that governs an &amp;#8220;exclusive channel collaboration&amp;#8221; arrangement in which the Company will use Intrexon&amp;#8217;s technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases. Pursuant to the terms of the Second Stock Issuance Agreement with Intrexon, which was approved by the Company&amp;#8217;s stockholders on October 5, 2012, the Company issued 3,552,210 shares of its common stock, $0.001 par value, which issuance is also deemed paid in consideration for the execution and delivery of the Second Channel Agreement, dated August 6, 2012, between the Company and Intrexon. The fair value of this transaction was $7.8 million and was charged to research and development expense for the year ended December 31, 2012, in accordance with the Company&amp;#8217;s accounting policy. In connection with the transactions contemplated by the Second Stock Issuance Agreement, and pursuant to the First Amendment to Registration Rights Agreement (the &amp;#8220;First Amendment to Registration Rights Agreement&amp;#8221;) executed and delivered by the parties at the closing, the Company agreed to file a &amp;#8220;resale&amp;#8221; registration statement registering the resale of certain of the shares issued under the Second Stock Issuance Agreement. None of the shares to be issued under the Second Stock Issuance Agreement need to be registered until April 30, 2013. Under that agreement, the Company is obligated to use its reasonable best efforts to cause the &amp;#8220;resale&amp;#8221; registration statement to be declared effective as promptly as practicable after filing and to maintain the effectiveness of the registration statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Subject to certain expense allocations and other offsets provided in the Second Channel Agreement, the Company will pay Intrexon royalties on annual net sales of the Synthetic Products, calculated on a Synthetic Product-by-Synthetic Product basis. The Company has likewise agreed to pay Intrexon a percentage of quarterly revenue obtained from a sublicensor in the event of a sublicensing arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company also agreed upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the &amp;#8220;IND Milestone Event&amp;#8221;), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares of Common Stock (the &amp;#8220;IND Milestone Shares&amp;#8221;) having a fair market value equaling two million dollars ($2M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the &amp;#8220;Approval Milestone Event&amp;#8221;), the Company agreed to pay to Intrexon either (i) three million dollars ($3M) in cash, or (ii) that number of shares of Common Stock (the &amp;#8220;Approval Milestone Shares&amp;#8221;) having a fair market value equaling three million dollars ($3M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company also agreed that it will pay an optional and varying fee whereby the Company remits a payment, in cash or equity at our sole discretion, to Intrexon calculated as a multiple of the number of targets in excess of three (3) total that the Company desires to elect (the &amp;#8220;Field Expansion Fee&amp;#8221;). The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for each target in excess of three (3) total that the Company elects, or (ii) that number of shares of Common Stock (the &amp;#8220;Field Expansion Fee Shares&amp;#8221;) having a fair market value equaling two million dollars ($2M) for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field Expansion Fee Closing.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On November 18, 2011, the Company entered into the Initial Channel Agreement with Intrexon that governs an &amp;#8220;exclusive channel collaboration&amp;#8221; arrangement in which the Company initially intended to use Intrexon&amp;#8217;s technology directed towards the production of PGIS. As consideration for execution of the Initial Channel Agreement, the Company entered into the Initial Stock Purchase Agreement with Intrexon pursuant to which the Company issued to Intrexon a number of shares of our common stock equal to 9.995% of the number of shares of the Company&amp;#8217;s common stock issued and outstanding following and giving effect to such issuance at a purchase price equal to the $0.001 par value of such shares, which issuance was deemed paid in consideration for the execution and delivery of the Initial Channel Agreement. The Company also agreed to issue additional shares of its common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored by the Company in the U.S., or similar study as the parties may agree in a country other than the U.S. The program under this Initial Channel Agreement is in the discovery stage. In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a &amp;#8220;resale&amp;#8221; registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance. The registration statement registering such shares was declared effective on April 13, 2012, but is not currently valid due to certain issues regarding the failure of the Company&amp;#8217;s prior auditor to follow proper partner rotation. Intrexon has agreed not to require the Company to file a post effective registration statement on Form S-1 with respect to the First Tranche Shares and instead has agreed to wait until the Company is once again S-3 eligible for registration of such shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company paid Intrexon a prepayment of research and development expenses of $2.5 million for research and development goods and services to be provided in the future and has been recorded on the Company&amp;#8217;s balance sheet in prepaid expenses and other current assets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;In September&amp;#160;of 2005, the Company entered into a three-year research agreement with the University of Michigan. Pursuant to that agreement, the Company sponsored research of approximately $460,000 per year.&amp;#160;&amp;#160;On March 20, 2008, the Company terminated the agreement.&amp;#160;&amp;#160;On March 24, 2009, the Company entered into a payment plan with the University of Michigan to pay the outstanding balance of $197,000.&amp;#160;&amp;#160;The Company agreed to pay $5,000 per month, the balance was paid in full July 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Effective February 3, 2012, Dr. Kuo resigned from his positions as President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered into a nine-month consulting agreement with the Company (the &amp;#8220;Consulting Agreement&amp;#8221;). Pursuant to the Consulting Agreement, Dr. Kuo will be entitled to a consulting fee of $17,000 per month and retain the right to exercise the stock options held by him that have vested (324,999) as of the effective date of the Consulting Agreement for a period expiring on the date that is one year from the effective date of the Consulting Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Effective February 3, 2012, Jeffrey Riley was appointed to serve as the Company&amp;#8217;s Chief Executive Officer and President. In connection with his appointment, Mr. Riley entered into a three-year employment agreement with the Company (the &amp;#8220;Riley Employment Agreement&amp;#8221;). Pursuant to the Riley Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of the Company&amp;#8217;s common stock with an exercise price equal to the per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1.7 million using a Black-Scholes valuation model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Effective February 6, 2012, C. Evan Ballantyne was appointed the Company&amp;#8217;s Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year employment agreement with the Company (the &amp;#8220;Ballantyne Employment Agreement&amp;#8221;). Pursuant to the Ballantyne Employment Agreement, Mr. Ballantyne will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1 million using a Black-Scholes valuation model.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of December 31, 2012, amounts due for license and sponsored research agreements are as follows &lt;i&gt;(in thousands)&lt;/i&gt;:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Year&amp;#160;Ending&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt; width: 85%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;287&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;60&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;35&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 17.3pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2016&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;10&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2017&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;10&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;402&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During 2012, the Company entered into a one year operating lease for office space in Ann Arbor, Michigan.&amp;#160; In March 2013, this lease was amended to extend the term of the lease to December 31, 2014, for annual lease payments of $33,000. In March 2012, the Company also entered into a one year operating lease that may be renewed for two additional terms of one year, for office space in Rockville, Maryland, for annual lease payments of $35,000. The Maryland office lease may be terminated with 60 days written notice.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During the years ended December 31, 2012 and 2011, the Company recognized rent expense of $123,000 and $64,000, respectively.&lt;/font&gt;&lt;/p&gt;</syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock>
<syn:StockRepurchaseProgramTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 0.5in;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stock Repurchase Program&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 3, 2009, the Company&amp;#8217;s Board of Directors approved a Stock Repurchase Program authorizing the Company to repurchase, from time-to-time and through December 31, 2009, up to $1 million of its common stock, up to a maximum of four million shares at prices of up to $5 per share. As of December 31, 2012, the Company had repurchased 81,482 shares for approximately $50,000 ($0.61 per share), based upon the quoted closing trading price.&amp;#160;&amp;#160;These treasury shares are not included in the computation of earnings (loss) per share and are deemed to be canceled and retired.&lt;/p&gt;</syn:StockRepurchaseProgramTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.5in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;There was no income tax expense for the years ended December 31, 2012 and 2011 due to the Company&amp;#8217;s net losses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company&amp;#8217;s tax expense differs from the &amp;#8220;expected&amp;#8221; tax expense for the years ended December 31, 2012 (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 3.96% for Michigan State Corporate taxes, the blended rate used was 37.96%) and December 31, 2011, (computed by applying the Federal Corporate tax rate of 32.13% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 66%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit - Federal&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(5,803&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;(2,618&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit - State&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(676&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;(448&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Meals, entertainment and other&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Non-deductible stock-based compensation&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;518&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;366&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Warrant expense&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;562&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Change in fair value of warrant expense&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;91&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Realized loss on debt securities&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;7&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;5,956&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;2,035&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The effects of temporary differences that gave rise to significant portions of deferred tax assets at December 31, 2012 and 2011 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;Deferred&amp;#160;tax&amp;#160;assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 66%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Stock issued for services&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;318&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;321&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Bad debt &amp;#8211; change in allowance&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,099&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;205&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Stock issued for acquisition of program &lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;527&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Net operating loss carry-forward&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;14,964&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;10,425&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Total gross deferred tax assets&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;16,908&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;10,951&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Less valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(16,908&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;(10,951&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;Net deferred tax assets&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;At December 31, 2012, the Company has a net operating loss carry-forward of approximately $39.7 million available to offset future taxable income expiring through 2032. However, utilization of these net operating losses may be limited due to potential ownership changes under Section 382 of the Internal Revenue Code.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The valuation allowance at December 31, 2011 was approximately $11.0 million. The net change in valuation allowance during the year ended December 31, 2012 was an increase of approximately $6.0 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;ASC 740-10 &amp;#8220;&lt;i&gt;Accounting for Uncertain Tax Positions&lt;/i&gt;&amp;#8221; prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;As of December&amp;#160;31, 2012 and 2011, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740-10. The Company&amp;#8217;s practice was and continues to be to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the years ended December&amp;#160;31, 2012 and 2011. The Company files United States federal and various state income tax returns.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company is routinely subject to examinations by taxing authorities in these various jurisdictions. The Company&amp;#8217;s U.S. tax matters for the years 2000 through 2012 remain subject to examination by the Internal Revenue Service due to the Company&amp;#8217;s NOL carryforwards. The Company&amp;#8217;s U. S. tax matters remain subject to examination by various state and local tax jurisdictions due to our NOL carryforwards.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px 0pt 24.45pt; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December&amp;#160;31, 2012 will significantly change within the next 12 months.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;All inter-company transactions and accounts have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
<syn:EmergingFromDevelopmentStagePolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Emerging from the Development Stage&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the second quarter of 2010, the Company emerged from the development stage.&amp;#160;&amp;#160;&amp;#160;A development-stage enterprise is one in which planned principle operations have not commenced or if its operations have commenced, there has been no significant revenue.&amp;#160;On May 6, 2010, the Company entered into a Sublicense Agreement (the &amp;#8220;Meda Agreement&amp;#8221;) with Meda&amp;#160;AB of Sweden (&amp;#8220;Meda&amp;#8221;) and received an up-front payment of $2.5 million. The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement of principal operations, and therefore development-stage reporting was no longer required.&lt;/p&gt;</syn:EmergingFromDevelopmentStagePolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts.&lt;/p&gt;</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&amp;#160;&amp;#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&amp;#160;&amp;#160;For the year ended December 31, 2012 and 2011, the Company&amp;#8217;s only stream of revenue was laboratory revenue.&amp;#160;&amp;#160;Laboratory revenues are a component of discontinued operations for the years ended December 31, 2012 and 2011. See Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&amp;#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&amp;#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&amp;#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&amp;#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&amp;#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&amp;#160;&amp;#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Laboratory Revenues&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which was the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior period multiplied by the period&amp;#8217;s actual gross sales to determine the actual sales allowance for each period. See Note 3 - Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<syn:RisksAndUncertaintiesPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.&lt;/p&gt;</syn:RisksAndUncertaintiesPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<syn:MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Classification of Marketable Securities as Held to Maturity, Trading, and Available for Sale&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading, are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&amp;#8217; equity. At December 31, 2012 and 2011, respectively, the Company had no debt and marketable equity securities.&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows &lt;i&gt;(in thousands)&lt;/i&gt; :&lt;/p&gt;&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;December 31, 2011&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: justify; width: 72%;"&gt;Purchase of short-term investments&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 25%;"&gt;(4,370&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;Amortization of premium on investments&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;57&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;Proceeds from short-term investments&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,293&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;Loss on sale of short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;20&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Fair value&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 49%;" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Asset&amp;#160;Description&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 4%;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 47%;" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Estimated&amp;#160;Useful&amp;#160;Life&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Office equipment and furniture&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3-5&amp;#160;&amp;#160;years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Laboratory equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;7-10 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Manufacturing equipment&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;10 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Leasehold improvements and fixtures&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Lesser of estimated useful or life of lease&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Depreciation expense was approximately $63,000 and $144,000 for the years ended December 31, 2012 and 2011, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During 2012, the Company reviewed property and equipment for impairment and determined that certain items were impaired due to obsolescence. As a result of this review, the Company recorded an impairment loss of approximately $47,000. For the year ended December 31, 2011, there were no significant events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;ASC No. 350, &amp;#8220;Intangibles &amp;#8211; Goodwill and Others,&amp;#8221; requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. See Note 3 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>

<us-gaap:DerivativesReportingOfDerivativeActivity contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In&amp;#160;addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option pricing model.&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Net Income (Loss) per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive, at December 31, 2012 and December 31, 2011, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the year ended December 31, 2012 were 4,453,746 and 1,632,501, respectively, and for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&amp;#8217;s product candidates.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Level 1 inputs: Quoted prices (unadjusted)&amp;#160;for identical assets or liabilities in active markets;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%;"&gt;&lt;font style="font: 10pt symbol;"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The carrying amounts of the Company&amp;#8217;s short-term financial instruments, including cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cash and cash equivalents include money market accounts and mutual funds of $8.6 million and $5.0 million as of December 31, 2012 and December 31, 2011, respectively, that are measured using Level 1 inputs.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<syn:StockBasedPaymentArrangementsPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&amp;#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.&lt;/p&gt;</syn:StockBasedPaymentArrangementsPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC Topic 740, &amp;#8220;&lt;i&gt;Income Taxes&lt;/i&gt;,&amp;#8221; which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In addition, accounting guidance now codified as FASB ASC Topic 740-20, &lt;i&gt;&amp;#8220;Income Taxes &amp;#8211; Intraperiod Tax Allocation&amp;#8221; &lt;/i&gt;requires&lt;i&gt; &lt;/i&gt;management to assess the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The accounting guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December 31, 2012 and 2011, respectively, the Company did not record any liabilities for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;There were no accounting standards or interpretations issued or recently adopted that are expected to have a material impact on the Company&amp;#8217;s financial position, operations, or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

<us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0in 0in 0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows &lt;i&gt;(in thousands)&lt;/i&gt; :&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0in 0in 0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 70%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="padding: 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p style="text-align: justify;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; padding-top: 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom" colspan="2" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;December 31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; padding-top: 0in;" valign="bottom" nowrap="nowrap"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="width: 72%; background: #ccffcc; padding: 0in;" valign="bottom" width="72%"&gt;
&lt;p style="text-align: justify;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Purchase of short-term investments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 25%; background: #ccffcc; padding: 0in;" valign="bottom" width="25%"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(4,370&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p style="text-align: justify;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Amortization of premium on investments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;57&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: white; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="background: #ccffcc; padding: 0in;" valign="bottom"&gt;
&lt;p style="text-align: justify;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Proceeds from short-term investments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;4,293&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="background: #ccffcc; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4;"&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom"&gt;
&lt;p style="text-align: justify;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Loss on sale of short-term investments&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; background: white; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; background: white; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;20&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 5; mso-yfti-lastrow: yes;"&gt;
&lt;td style="padding-bottom: 2.5pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom"&gt;
&lt;p style="text-align: justify;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Fair value&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; border-left: medium none; background: #ccffcc; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; border-left: medium none;
 background: #ccffcc; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom"&gt;
&lt;p align="right" style="text-align: right;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
<syn:EstimatedUsefulLifeOfAssetsTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0in 0in 0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0in 0in 0pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;table style="width: 70%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; width: 49%; border-top: medium none; border-right: medium none; padding: 0in;" valign="top" width="49%" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Asset&amp;#160;Description&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 4%; padding: 0in;" valign="top" width="4%" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; border-left: medium none; width: 47%; border-top: medium none; border-right: medium none; padding: 0in;" valign="top" width="47%" nowrap="nowrap"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&lt;b&gt;Estimated&amp;#160;Useful&amp;#160;Life&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Office equipment and furniture&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;3-5&amp;#160;&amp;#160;years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2;"&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Laboratory equipment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;7-10 years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 3;"&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Manufacturing equipment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;10 years&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 4; mso-yfti-lastrow: yes;"&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Leasehold improvements and fixtures&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding: 0in;" valign="top"&gt;
&lt;p align="center" style="text-align: center;" class="msonormal"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Lesser of estimated useful or life of lease&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</syn:EstimatedUsefulLifeOfAssetsTableTextBlock>
<syn:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;div&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The assets of the discontinued operations are presented separately under the caption &amp;#8220;Assets of discontinued operations&amp;#8221; in the accompanying Consolidated Balance Sheets at December 31, 2012, and December 31, 2011, and consist of the following &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/div&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Assets of discontinued operations:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;23&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total assets&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;23&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock>
<syn:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the years ended December 31, 2012 and December 31, 2011 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2012&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Laboratory fees, net&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;115&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,169&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Operating Costs and Expenses:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;466&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;539&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Cost of&amp;#160; laboratory services&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;110&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;975&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Impairment loss on goodwill&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;178&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Total operating costs and expenses&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;576&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;1,692&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Loss from discontinued operations&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(461&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(523&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Other Income:&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Gain on sale of Adeona Clinical Laboratory&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;677&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;Income (loss) from discontinued operations&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;216&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;(523&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock>
<us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Accounts receivable (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;682&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;692&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Bad debt allowance - customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(682&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(287&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;405&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
<us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Prepaid expenses and other current assets (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Intrexon prepaid research and development expenses&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;2,412&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Other receivables&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;17&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Prepaid expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;16&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,509&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;16&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Property and equipment (in thousands)&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Manufacturing equipment&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;297&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;Computer and office equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;35&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;133&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;136&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;465&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(242&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(372&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;223&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<syn:AccruedExpensesTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Accrued liabilities (in thousands)&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Accrued vendor payments&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Compensation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;28&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;29&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:AccruedExpensesTableTextBlock>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2012 and 2011 are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="3"&gt;Year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"&gt;2011&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Exercise price&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$1.69 - $2.47&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;$0.49 - $2.22&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 74%;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 12%;"&gt;0%&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 12%;"&gt;0%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;108% - 174%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;175% - 188%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Risk fee interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;0.37% - 1.98%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;1.30% - 3.58%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected life of option&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;5 - 10 years&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;5 - 7 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;0%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;0%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;During 2012, the Company granted 2,075,000 options to employees and consultants having an approximate fair value of $4.5 million based upon the Black-Scholes option pricing model.&amp;#160; During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.&lt;/p&gt;
&lt;table style="font: 10pt times new roman, times, serif; width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Remaining&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Aggregate&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Average&amp;#160;Exercise&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Contractual&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2"&gt;Intrinsic&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;Price&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;Life&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2"&gt;Value&lt;/td&gt;
&lt;td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt; width: 48%;"&gt;Balance &amp;#8211; December 31, 2010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;2,539,091&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right;"&gt;1.32&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 10%; border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;6.97 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; border-bottom: black 2.5pt double; text-align: right;"&gt;1,028,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;557,002&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.26&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(23,333&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.57&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(93,750&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;0.59&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,979,010&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.34&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;6.01 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,075,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.21&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(374,851&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.34&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(225,413&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.37&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2012 &amp;#8211; outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,453,746&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.78&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;6.43 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,308,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Balance &amp;#8211; December 31, 2012 &amp;#8211; exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,891,877&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.60&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;5.71 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,160,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;Grant date fair value of options granted &amp;#8211; 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,467,984&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average grant date fair value &amp;#8211; 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.15&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;Grant date fair value of options granted &amp;#8211; 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;609,000&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average grant date fair value &amp;#8211; 2011&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.09&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The options outstanding and exercisable at December 31, 2012 are as follows:&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap"&gt;Options&amp;#160;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap"&gt;Options&amp;#160;Exercisable&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 14%;"&gt;$0.09 - $2.00&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;2,162,362&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;1.78&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;5.76 years&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1,801,187&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1.14&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;5.52 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;$2.01 - $3.00&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,212,227&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.26&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;7.15 years&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,011,533&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.17&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;6.14 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;$3.01 - $6.00&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;79,157&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4.87&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4.49 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;79,157&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="border-bottom: black 1pt solid; text-align: right;"&gt;4.87&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;4.49 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;$0.09 - $6.00&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;4,453,746&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.78&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6.43 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,891,877&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.60&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5.71 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The options outstanding and exercisable at December 31, 2011 are as follows:&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap"&gt;Options&amp;#160;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap"&gt;Options&amp;#160;Exercisable&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;Average&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" nowrap="nowrap"&gt;Remaining&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; width: 14%;"&gt;$0.09 - $4.57&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;2,889,011&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%;"&gt;1.20&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;6.11 years&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;2,364,608&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%;"&gt;1.29&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 13%;"&gt;5.72 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 1pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom:
 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.76 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.76 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,979,010&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.34&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;6.01 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,454,607&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.46&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;5.62 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following is a summary of the Company&amp;#8217;s non-vested stock options at December 31, 2012:&lt;/p&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Unvested&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Grant&lt;/td&gt;
&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Stock&amp;#160;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Date&amp;#160;Fair&amp;#160;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 74%;"&gt;Non-vested&amp;#160;&amp;#8211;&amp;#160;December&amp;#160;31,&amp;#160;2011&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;524,403&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;0.82&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,075,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2.21&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Vested/Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(891,332&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.81&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Forfeited/Cancelled&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(146,202&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;1.79&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Non-vested &amp;#8211; December 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,561,869&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2.11&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;Weighted average remaining period for vesting&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;2.09 years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The assumptions used by the Company are summarized in the following table:&lt;/p&gt;&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="width: 87%; color: black;"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; color: black;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; color: black;"&gt;2.20&lt;/td&gt;&lt;td style="text-align: left; width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Expected dividends&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Expected volatility&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;110&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;0.26&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Expected life of warrant&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;&lt;font style="font: 10pt times new roman, times, serif; color: black;"&gt;2 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The assumptions used by the Company are summarized in the following table:&lt;/p&gt;&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="width: 87%; color: black;"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%; color: black;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; color: black;"&gt;1.14&lt;/td&gt;&lt;td style="text-align: left; width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Expected dividends&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Expected volatility&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;174&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;0.71&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: left; color: black;"&gt;Expected life of warrant&lt;/td&gt;&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; color: black;"&gt;&lt;font style="font: 10pt times new roman, times, serif; color: black;"&gt;5 years&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The following table summarizes the estimated fair value of the warrant liabilities at December 31, 2011&lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.25in; padding-left: 0.25in;"&gt;Balance at December 31, 2010&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 87%;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;1,492&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;242&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;Reclassification to additional paid-in capital&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(1,734&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in;"&gt;Balance at December 31, 2011&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
<syn:ScheduleOfWarrantActivityTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of warrant activity for the Company for the year ended December 31, 2011 and for the year ended December 31, 2012 is as follows:&lt;/p&gt;&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Weighted&amp;#160;Average&lt;/td&gt;&lt;td style="font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Number&amp;#160;of&amp;#160;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;Exercise&amp;#160;Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="width: 74%;"&gt;Balance at December 31, 2010&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;1,131,078&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%;"&gt;3.49&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,272,963&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.25&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(15,615&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.03&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(129,240&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;2.08&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td&gt;Balance as December 31, 2011&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,259,186&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.95&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;985,855&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.71&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,768,167&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.11&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1pt;"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(844,373&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;3.32&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;Balance as December 31, 2012&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1,632,501&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;1.99&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantActivityTableTextBlock>
<syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of all outstanding and exercisable warrants as of December 31, 2012 is as follows:&lt;/p&gt;&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Exercise&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Price&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Warrants&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Warrants&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Exercisable&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Weighted&amp;#160;Average&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Remaining&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Contractual&amp;#160;Life&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Aggregate &lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Intrinsic Value&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 17%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1.14&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 17%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;100,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 17%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;100,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; width: 20%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;4.09 years&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; width: 15%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;62,000&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1.32&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;18,182&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;18,182&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.00 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;8,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1.60&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;635,855&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;635,855&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;4.83 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;102,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;2.20&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;250,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;50,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1.20 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;2.22&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;517,257&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;517,257&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.91 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman,
 times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.30&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;61,207&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;61,207&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.30 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 1pt solid;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.75&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;50,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;50,000&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.13 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color: white; vertical-align: bottom;"&gt;&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1.99&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1,632,501&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;1,432,501&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;3.80 years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double; text-align: left;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;172,000&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock>
<syn:DueForLicenseAgreementsTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif; text-align: justify;"&gt;As of December 31, 2012, amounts due for license and sponsored research agreements are as follows &lt;i&gt;(in thousands)&lt;/i&gt;:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="font: 10pt times new roman, times, serif; width: 50%; border-collapse: collapse;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="font-weight: bold; text-align: left;"&gt;Year&amp;#160;Ending&amp;#160;December&amp;#160;31,&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 17.3pt; width: 85%; text-align: left;"&gt;2013&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right;"&gt;287&lt;/td&gt;
&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 17.3pt; text-align: left;"&gt;2014&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;60&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 17.3pt; text-align: left;"&gt;2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;35&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 17.3pt; text-align: left;"&gt;2016&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 17.3pt; padding-bottom: 1pt; text-align: left;"&gt;2017&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;10&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #ccffcc;"&gt;
&lt;td style="padding-left: 8.65pt; padding-bottom: 2.5pt; text-align: left;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;402&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:DueForLicenseAgreementsTableTextBlock>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s tax expense differs from the &amp;#8220;expected&amp;#8221; tax expense for the years ended December 31, 2012 (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 3.96% for Michigan State Corporate taxes, the blended rate used was 37.96%) and December 31, 2011, (computed by applying the Federal Corporate tax rate of 32.13% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 66%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit - Federal&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;(5,803&lt;/td&gt;
&lt;td style="width: 1%;"&gt;)&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;(2,618&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit - State&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(676&lt;/td&gt;
&lt;td&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;(448&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Meals, entertainment and other&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;5&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Non-deductible stock-based compensation&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;518&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;366&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Warrant expense&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;562&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Change in fair value of warrant expense&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;91&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Realized loss on debt securities&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;7&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;5,956&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;2,035&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The effects of temporary differences that gave rise to significant portions of deferred tax assets at December 31, 2012 and 2011 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Deferred&amp;#160;tax&amp;#160;assets:&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 66%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Stock issued for services&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;318&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; width: 14%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;321&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Bad debt &amp;#8211; change in allowance&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,099&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;205&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;Stock issued for acquisition of program&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;527&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Net operating loss carry-forward&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;14,964&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;10,425&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Total gross deferred tax assets&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;16,908&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;10,951&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Less valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(16,908&lt;/td&gt;
&lt;td&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;(10,951&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;Net deferred tax assets&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&amp;#160;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 2.25pt double; text-align: right;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:NotesPayable contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="0">700000</us-gaap:NotesPayable><us-gaap:NotesReceivableNet contextRef="Context_As_Of_08-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_AdeonaClinicalLaboratoryLlcMember_CreditFacilityAxis_CommercialPaperMember" unitRef="USD" decimals="0">700000</us-gaap:NotesReceivableNet>

<us-gaap:InvestmentsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:InvestmentsFairValueDisclosure>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember_RangeAxis_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_ManufacturingEquipmentMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember_RangeAxis_MinimumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="Context_FYE_31-Dec-2012">Lesser of estimated useful or life of lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:LicensesRevenue contextRef="Context_FYE_31-Dec-2010_LegalEntityAxis_McleanHospitalMember" unitRef="USD" decimals="0">-375000</us-gaap:LicensesRevenue>
<us-gaap:LicensesRevenue contextRef="Context_FYE_31-Dec-2010_LegalEntityAxis_MedaAgreementMember" unitRef="USD" decimals="-3">2500000</us-gaap:LicensesRevenue>
<syn:LicenseRevenuePercentage contextRef="Context_FYE_31-Dec-2010_LegalEntityAxis_McleanHospitalMember" unitRef="pure" decimals="2">0.15</syn:LicenseRevenuePercentage>
<syn:AdditionalMilestonePayments contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-6">5000000</syn:AdditionalMilestonePayments>
<us-gaap:MarketingExpense contextRef="Context_FYE_31-Dec-2010" unitRef="USD" decimals="-6">10000000</us-gaap:MarketingExpense>
<syn:RoyaltyRevenuePercentage contextRef="Context_FYE_31-Dec-2010" unitRef="pure" decimals="2">0.07</syn:RoyaltyRevenuePercentage>
<us-gaap:GoodwillImpairmentLoss contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="0">47000</us-gaap:GoodwillImpairmentLoss>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">3259186</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_31-Dec-2011_MajorTypesOfDebtAndEquitySecuritiesAxis_OptionMember" unitRef="shares" decimals="0">2979010</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">1632501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_31-Dec-2012_MajorTypesOfDebtAndEquitySecuritiesAxis_OptionMember" unitRef="shares" decimals="0">4453746</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">23000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet>
<syn:LaboratoryFeesNet contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">1169000</syn:LaboratoryFeesNet>
<syn:LaboratoryFeesNet contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">115000</syn:LaboratoryFeesNet>
<syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">975000</syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts>
<syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">110000</syn:DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts>
<syn:DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">178000</syn:DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill>
<syn:DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">0</syn:DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">1692000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">576000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">-523000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">-461000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
<us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="Context_FYE_31-Dec-2011_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
<us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="Context_FYE_31-Dec-2012_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_AdeonaClinicalLaboratoryMember" unitRef="USD" decimals="-3">677000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
<us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="Context_As_Of_08-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_AdeonaClinicalLaboratoryLlcMember_CreditFacilityAxis_CommercialPaperMember" unitRef="pure" decimals="3">0.057</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
<us-gaap:AccountsReceivableGrossCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">692000</us-gaap:AccountsReceivableGrossCurrent>
<us-gaap:AccountsReceivableGrossCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">682000</us-gaap:AccountsReceivableGrossCurrent>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">287000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">682000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<syn:PrepaidExpensesResearchAndDevelopment contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:PrepaidExpensesResearchAndDevelopment>
<syn:PrepaidExpensesResearchAndDevelopment contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">2412000</syn:PrepaidExpensesResearchAndDevelopment>
<us-gaap:OtherReceivablesGrossCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">17000</us-gaap:OtherReceivablesGrossCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">16000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">80000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">695000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="USD" decimals="-3">400000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember" unitRef="USD" decimals="-3">136000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2011_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember" unitRef="USD" decimals="-3">159000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">465000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="USD" decimals="-3">297000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember" unitRef="USD" decimals="-3">133000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31-Dec-2012_PropertyPlantAndEquipmentByTypeAxis_ComputerAndOfficeEquipmentMember" unitRef="USD" decimals="-3">35000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">372000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">242000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<syn:AccruedVendorPayments contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">1000</syn:AccruedVendorPayments>
<syn:AccruedVendorPayments contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:AccruedVendorPayments>
<syn:AccruedCompensation contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">28000</syn:AccruedCompensation>
<syn:AccruedCompensation contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:AccruedCompensation>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="Context_FYE_31-Dec-2011_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">2.22</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="Context_FYE_31-Dec-2011_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.49</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="Context_FYE_31-Dec-2012_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">2.47</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne contextRef="Context_FYE_31-Dec-2012_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.69</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="pure" decimals="3">1.171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="pure" decimals="3">1.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="pure" decimals="3">1.121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="pure" decimals="3">1.056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="2">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_31-Dec-2011_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_31-Dec-2011_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="2">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_31-Dec-2012_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_31-Dec-2012_RangeAxis_MinimumMember" unitRef="pure" decimals="2">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="pure" decimals="4">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="pure" decimals="4">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="pure" decimals="4">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="pure" decimals="4">0.0021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="4">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_31-Dec-2011_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_31-Dec-2011_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="4">0.0026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_31-Dec-2012_RangeAxis_MaximumMember" unitRef="pure" decimals="4">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_31-Dec-2012_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.0037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember">P1Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember">P10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember">P1Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember">P1Y15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_31-Dec-2011">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_31-Dec-2011_RangeAxis_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_31-Dec-2011_RangeAxis_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_31-Dec-2012">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_31-Dec-2012_RangeAxis_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_31-Dec-2012_RangeAxis_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="2">0.00</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="2">0.00</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_20-Mar-2007_PlanNameAxis_StockPlan2007Member" unitRef="shares" decimals="0">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_02-Nov-2010_PlanNameAxis_StockPlan2010Member" unitRef="shares" decimals="0">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2010" unitRef="shares" decimals="0">2539091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">2979010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member" unitRef="shares" decimals="0">2889011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member" unitRef="shares" decimals="0">89999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member" unitRef="shares" decimals="0">2979010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">4453746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_SubsequentEventTypeAxis_StockPlan2001Member" unitRef="shares" decimals="0">1066007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_PlanNameAxis_StockPlan2007Member" unitRef="shares" decimals="0">872739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_PlanNameAxis_StockPlan2010Member" unitRef="shares" decimals="0">2515000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member" unitRef="shares" decimals="0">2162362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member" unitRef="shares" decimals="0">2212227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member" unitRef="shares" decimals="0">79157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_LegalEntityAxis_EpitopeMember" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member" unitRef="shares" decimals="0">4453746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">557002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">2075000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">23333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">374851</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">93750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">225413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member" unitRef="shares" decimals="0">2364608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member" unitRef="shares" decimals="0">89999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member" unitRef="shares" decimals="0">2454607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">2891877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member" unitRef="shares" decimals="0">1801187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member" unitRef="shares" decimals="0">1011533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member" unitRef="shares" decimals="0">79157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_LegalEntityAxis_EpitopeMember" unitRef="shares" decimals="0">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member" unitRef="shares" decimals="0">2891877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2010" unitRef="USD_per_Share" decimals="2">1.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="2">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member" unitRef="USD_per_Share" decimals="2">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member" unitRef="USD_per_Share" decimals="2">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member" unitRef="USD_per_Share" decimals="2">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="2">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member" unitRef="USD_per_Share" decimals="2">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member" unitRef="USD_per_Share" decimals="2">2.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member" unitRef="USD_per_Share" decimals="2">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member" unitRef="USD_per_Share" decimals="2">1.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">1.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">2.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">0.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>


<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member" unitRef="USD_per_Share" decimals="2">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member" unitRef="USD_per_Share" decimals="2">5.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member" unitRef="USD_per_Share" decimals="2">1.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="2">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member" unitRef="USD_per_Share" decimals="2">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member" unitRef="USD_per_Share" decimals="2">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_LegalEntityAxis_EpitopeMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member" unitRef="USD_per_Share" decimals="2">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2010">P6Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2011">P6Y0M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member">P6Y1M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member">P2Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member">P6Y0M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2012">P6Y5M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member">P5Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member">P7Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member">P4Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2012_LegalEntityAxis_EpitopeMember">P5Y5M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member">P6Y5M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member">P5Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member">P2Y9M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2012">P5Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member">P5Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member">P6Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member">P4Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member">P5Y8M16D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">1028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="0">1308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="0">1160000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="0">609000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="0">4467984</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2011" unitRef="USD_per_Share" decimals="2">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">2.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>




<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">4.57</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009457Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.09</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">9.05</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice458905Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">4.58</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">9.05</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2011_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009905Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.09</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.09</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009200Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">2.00</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">2.01</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice201300Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">3.00</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">3.01</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice301600Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">6.00</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">6.00</syn:OptionsExercisePrice>
<syn:OptionsExercisePrice contextRef="Context_FYE_31-Dec-2012_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_RangeOfExercisePrice009600Member_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.09</syn:OptionsExercisePrice>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber contextRef="Context_As_Of_31-Dec-2011" unitRef="shares" decimals="0">524403</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">1561869</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">2075000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">-891332</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod contextRef="Context_FYE_31-Dec-2012" unitRef="shares" decimals="0">-146202</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.82</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="2">2.11</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">2.21</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">0.81</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">1.79</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_31-Dec-2012">P2Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="2">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<syn:WarrantsFairValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">0</syn:WarrantsFairValue>
<syn:WarrantsFairValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:WarrantsFairValue>
<syn:WarrantsFairValue contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:WarrantsFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_31-Dec-2010_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1131078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">3259186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1632501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">2272963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">985855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">15615</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1768167</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">1768167</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">129240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">844373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31-Dec-2010_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">3.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.03</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.11</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2011_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">3.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012" unitRef="USD_per_Share" decimals="2">1.99</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member" unitRef="USD_per_Share" decimals="2">1.14</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member" unitRef="USD_per_Share" decimals="2">1.32</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member" unitRef="USD_per_Share" decimals="2">3.75</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member" unitRef="USD_per_Share" decimals="2">1.60</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member" unitRef="USD_per_Share" decimals="2">3.30</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member" unitRef="USD_per_Share" decimals="2">2.22</syn:WarrantsExercisePrice>
<syn:WarrantsExercisePrice contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice220Member" unitRef="USD_per_Share" decimals="2">2.20</syn:WarrantsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">1632501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member" unitRef="shares" decimals="0">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member" unitRef="shares" decimals="0">18182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member" unitRef="shares" decimals="0">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member" unitRef="shares" decimals="0">635855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member" unitRef="shares" decimals="0">61207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member" unitRef="shares" decimals="0">517257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice220Member" unitRef="shares" decimals="0">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">1432501</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member" unitRef="shares" decimals="0">100000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member" unitRef="shares" decimals="0">18182</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member" unitRef="shares" decimals="0">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member" unitRef="shares" decimals="0">635855</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member" unitRef="shares" decimals="0">61207</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member" unitRef="shares" decimals="0">517257</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice220Member" unitRef="shares" decimals="0">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_Custom_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">P15M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">P15M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_Custom_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012">P3Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member">P4Y1M2D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member">P3Y1M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member">P4Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member">P3Y3M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member">P3Y10M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Context_FYE_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice220Member">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="0">172000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice1Member" unitRef="USD_per_Share" decimals="0">62000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice13Member" unitRef="USD_per_Share" decimals="0">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice375Member" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice14Member" unitRef="USD_per_Share" decimals="0">102000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice330Member" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="Context_As_Of_31-Dec-2012_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember_RangeAxis_ExercisePrice222Member" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_31-Dec-2001_SubsequentEventTypeAxis_StockPlan2001Member" unitRef="shares" decimals="0">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_EmployeesAndConsultantsMember" unitRef="shares" decimals="0">557002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_JeffreyRileyMember" unitRef="shares" decimals="0">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_CEvanBallantyneMember" unitRef="shares" decimals="0">425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_EmployeesAndConsultantsMember" unitRef="shares" decimals="0">2075000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="Context_FYE_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_EmployeesAndConsultantsMember" unitRef="USD" decimals="0">609000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue contextRef="Context_FYE_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_EmployeesAndConsultantsMember" unitRef="USD" decimals="-5">4500000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>

<syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="Context_As_Of_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" unitRef="shares" decimals="0">1428572</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>
<syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="Context_As_Of_06-Apr-2011" unitRef="shares" decimals="0">844391</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>
<syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="Context_As_Of_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" unitRef="shares" decimals="0">844391</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>
<syn:IssuanceOfWarrantsToPurchaseOfCommonStock contextRef="Context_As_Of_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">635855</syn:IssuanceOfWarrantsToPurchaseOfCommonStock>

<syn:WarrantsExercisePricePerShare contextRef="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_ConsultingAgreementForFinancialAdvisoryServicesMember" unitRef="USD_per_Share" decimals="2">1.40</syn:WarrantsExercisePricePerShare>
<syn:WarrantsExercisePricePerShare contextRef="Context_Custom_28-Jul-2011" unitRef="USD_per_Share" decimals="2">1.00</syn:WarrantsExercisePricePerShare>
<syn:WarrantsExercisePricePerShare contextRef="Context_Custom_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.60</syn:WarrantsExercisePricePerShare>
<syn:LifeOfWarrants contextRef="Context_Custom_02-Jul-2010_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">P5Y</syn:LifeOfWarrants>
<syn:WarrantsExpirationDate contextRef="Context_Custom_02-Jul-2010_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithSingleInvestorsMember">2015-12-31</syn:WarrantsExpirationDate>

<syn:WarrantsFloorPricePerShare contextRef="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" unitRef="USD_per_Share" decimals="2">1.40</syn:WarrantsFloorPricePerShare>
<syn:WarrantsFloorPricePerShare contextRef="Context_Custom_06-Apr-2011_StockPurchaseWarrantsAggreementsAxis_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" unitRef="USD_per_Share" decimals="2">1.00</syn:WarrantsFloorPricePerShare>
<invest:InvestmentWarrantsExpirationDate contextRef="Context_Custom_25-Oct-2012_StatementEquityComponentsAxis_WarrantMember">2017-10-25</invest:InvestmentWarrantsExpirationDate>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber contextRef="Context_As_Of_02-Feb-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">100000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber contextRef="Context_As_Of_15-Mar-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">250000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_15-Mar-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="0">50000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber>
<syn:IssuanceOfWarrantsExpensesRecognized contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">63000</syn:IssuanceOfWarrantsExpensesRecognized>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod contextRef="Context_Custom_02-Feb-2012_StatementEquityComponentsAxis_WarrantMember">P5Y</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod contextRef="Context_Custom_15-Mar-2012_StatementEquityComponentsAxis_WarrantMember">P2Y</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod>
<syn:WarrantsFairValue1 contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:WarrantsFairValue1>
<syn:WarrantsFairValue1 contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">200000</syn:WarrantsFairValue1>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="0">127000</us-gaap:ProceedsFromStockOptionsExercised>
<syn:FairValueOfStockIssuedDuringPeriodValueConsultingFees contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">165000</syn:FairValueOfStockIssuedDuringPeriodValueConsultingFees>
<syn:SaleOfStockForConsultingFeesPricePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="2">0.96</syn:SaleOfStockForConsultingFeesPricePerShare>
<syn:StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">28333</syn:StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants>
<syn:SaleOfStockForEmploymentServicePricePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USD_per_Share" decimals="2">1.29</syn:SaleOfStockForEmploymentServicePricePerShare>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_28-Jan-2011" unitRef="USD" decimals="-6">4000000</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_Custom_06-Apr-2011" unitRef="USD" decimals="-5">3500000</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="0">15000</us-gaap:ProceedsFromIssuanceOfWarrants>

<syn:StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised contextRef="Context_FYE_31-Dec-2011" unitRef="shares" decimals="0">10615</syn:StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised>
<syn:SaleOfStockForChannelAgreementPricePerShare contextRef="Context_As_Of_31-Dec-2011_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD_per_Share" decimals="2">0.54</syn:SaleOfStockForChannelAgreementPricePerShare>
<syn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="Context_Custom_28-Jan-2011" unitRef="shares" decimals="0">1428572</syn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
<syn:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="Context_Custom_06-Apr-2011" unitRef="shares" decimals="0">844391</syn:StockIssuedDuringPeriodSharesStockWarrantsExercised>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_Custom_31-Oct-2012_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="-5">10800000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<us-gaap:NoninterestExpenseOfferingCost contextRef="Context_Custom_31-Oct-2012_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">680000</us-gaap:NoninterestExpenseOfferingCost>
<us-gaap:OtherCommitmentDueInNextTwelveMonths contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">287000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
<us-gaap:OtherCommitmentDueInSecondYear contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">60000</us-gaap:OtherCommitmentDueInSecondYear>
<us-gaap:OtherCommitmentDueInSecondYear contextRef="Context_As_Of_31-Dec-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_AnnArborMichiganMember" unitRef="USD" decimals="0">33000</us-gaap:OtherCommitmentDueInSecondYear>
<us-gaap:OtherCommitmentDueInThirdYear contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">35000</us-gaap:OtherCommitmentDueInThirdYear>
<us-gaap:OtherCommitmentDueInFourthYear contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">10000</us-gaap:OtherCommitmentDueInFourthYear>
<us-gaap:OtherCommitmentDueInFifthYear contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">10000</us-gaap:OtherCommitmentDueInFifthYear>
<us-gaap:OtherCommitmentDueInFourthAndFifthYear contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">402000</us-gaap:OtherCommitmentDueInFourthAndFifthYear>

<us-gaap:LineOfCreditFacilityPeriodicPayment contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="0">197000</us-gaap:LineOfCreditFacilityPeriodicPayment>
<us-gaap:LineOfCreditFacilityPeriodicPaymentInterest contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="0">5000</us-gaap:LineOfCreditFacilityPeriodicPaymentInterest>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_DrKuoMember" unitRef="shares" decimals="0">324999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_JeffreyRileyMember" unitRef="USD" decimals="-5">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_CEvanBallantyneMember" unitRef="USD" decimals="-5">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue>
<syn:ConsultingFees contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_DrKuoMember" unitRef="USD" decimals="0">17000</syn:ConsultingFees>
<us-gaap:OfficersCompensation contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_JeffreyRileyMember" unitRef="USD" decimals="0">348000</us-gaap:OfficersCompensation>
<us-gaap:OfficersCompensation contextRef="Context_Custom_29-Feb-2012_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_CEvanBallantyneMember" unitRef="USD" decimals="0">298000</us-gaap:OfficersCompensation>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="0">64000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="0">123000</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseExpirationDate1 contextRef="Context_FYE_31-Dec-2012">2013-05-31</us-gaap:LeaseExpirationDate1>
<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="Context_FYE_31-Dec-2009" unitRef="USD" decimals="-6">1000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
<us-gaap:SubsidiaryOrEquityMethodInvesteePricePerShare contextRef="Context_As_Of_31-Dec-2009" unitRef="USD_per_Share" decimals="0">5</us-gaap:SubsidiaryOrEquityMethodInvesteePricePerShare>
<us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased contextRef="Context_As_Of_31-Dec-2012" unitRef="shares" decimals="0">81482</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
<us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="0">50000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount>
<us-gaap:PreferredStockRedemptionPricePerShare contextRef="Context_As_Of_31-Dec-2012" unitRef="USD_per_Share" decimals="2">0.61</us-gaap:PreferredStockRedemptionPricePerShare>
<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-2618000</us-gaap:CurrentFederalTaxExpenseBenefit>
<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-5803000</us-gaap:CurrentFederalTaxExpenseBenefit>
<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-448000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">-676000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">5000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">5000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">366000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">518000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
<syn:WarrantExpensesForIncomeTax contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">562000</syn:WarrantExpensesForIncomeTax>
<syn:WarrantExpensesForIncomeTax contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:WarrantExpensesForIncomeTax>
<syn:ChangeInFairValueOfWarrantExpenses contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">91000</syn:ChangeInFairValueOfWarrantExpenses>
<syn:ChangeInFairValueOfWarrantExpenses contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:ChangeInFairValueOfWarrantExpenses>
<syn:RealizedLossOnDebtSecurities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7000</syn:RealizedLossOnDebtSecurities>
<syn:RealizedLossOnDebtSecurities contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:RealizedLossOnDebtSecurities>
<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">2035000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">5956000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
<syn:DeferredTaxAssetsStocksIssuedForServices contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">321000</syn:DeferredTaxAssetsStocksIssuedForServices>
<syn:DeferredTaxAssetsStocksIssuedForServices contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">318000</syn:DeferredTaxAssetsStocksIssuedForServices>
<syn:DeferredTaxAssetsBadDebts contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">205000</syn:DeferredTaxAssetsBadDebts>
<syn:DeferredTaxAssetsBadDebts contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">1099000</syn:DeferredTaxAssetsBadDebts>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">10425000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">14964000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">10951000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">16908000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:ValuationAllowanceAmount contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">10951000</us-gaap:ValuationAllowanceAmount>
<us-gaap:ValuationAllowanceAmount contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">16908000</us-gaap:ValuationAllowanceAmount>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="4">0.3213</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="3">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="4">0.0396</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="Context_FYE_31-Dec-2011" unitRef="pure" decimals="4">0.3763</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="Context_FYE_31-Dec-2012" unitRef="pure" decimals="4">0.3796</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31-Dec-2012_OperatingLossForwardPeriodAxis_TaxableIncomeExpiringThrough2032Member" unitRef="USD" decimals="-5">39700000</us-gaap:OperatingLossCarryforwards>


<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">-327000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">2544000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram>
<syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">527000</syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;10. Related Party Transactions&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In February 2012, the Company entered into a consulting agreement with Dr. James Kuo, a director of the Company.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;From January 2, 2012 through September 30, 2012, Steve H. Kanzer was engaged as the Company&amp;#8217;s Interim Director of its Biologics Division. In connection with his appointment, Mr. Kanzer entered into a six month employment agreement with us on a full time basis (the &amp;#8220;Kanzer Employment Agreement&amp;#8221;), which may be extended for an additional three (3) months upon consent of the parties. Pursuant to the Kanzer Employment Agreement, Mr. Kanzer will be entitled to a base salary of $90,000 for the term, healthcare coverage pursuant to the Company&amp;#8217;s healthcare insurance plan, reimbursement for certain relocation expenses and rent expense. The Kanzer Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Kanzer.&amp;#160; Mr. Kanzer is not entitled to severance pay upon termination of his employment. On October 1, 2012, the Kanzer Employment Agreement was amended (the &amp;#8220;Amended Kanzer Employment Agreement&amp;#8221;) and Mr. Kanzer is engaged as the Company Licensing Associate. In connection with this appointment, Mr. Kanzer entered into a two year agreement with us on a part time basis (2.5 days per week). Pursuant to the Amended Kanzer Employment Agreement, Mr. Kanzer will be entitled to a base salary of $150,000 for the term and healthcare coverage pursuant to the Company&amp;#8217;s healthcare insurance plans.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In August 2012, the Company entered into an Exclusive Channel Agreement with Intrexon and issued 3,552,210 shares of common stock as consideration, having a fair value of $7.8 million ($2.20 per share), based on the quoted closing trading price on October 5, 2012&lt;font style="color: black;"&gt;. &lt;/font&gt;In November 2011, the Company entered into an Exclusive Channel Agreement with Intrexon and issued 3,123,558 shares of common stock as consideration, having a fair value of $1.7 million ($0.54 per share), based on the quoted closing trading price&lt;font style="color: black;"&gt;. In connection with the November 2011 and August 2012 &lt;/font&gt;Exclusive Channel Agreements, the Company paid Intrexon approximately $2.9 million during 2012, including a prepayment of research and development expenses of $2.5 million for research and development goods and services to be provided in the future which has been recorded on the Company&amp;#8217;s balance sheet in prepaid expense as described in Note 4. In October 2012, the Company consummated the Company&amp;#8217;s October 2012 Private Placement and entered into a stock purchase agreement with several investors, including NRM VII Holdings I, LLC, an entity affiliated with Intrexon. Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital of Intrexon Corporation, and controls NRM VII Holdings I, LLC. Mr. Kirk disclaims beneficial ownership of the shares held by Intrexon Corporation and NRM VII Holdings I, LLC, except to the extent of any pecuniary interest therein.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<syn:EmploymentAgreementDescrption contextRef="Context_Custom_31-Oct-2012_RelatedPartyTransactionsByRelatedPartyAxis_MrKanzerMember">Mr. Kanzer entered into a two year agreement with us on a part time basis (2.5 days per week).</syn:EmploymentAgreementDescrption>
<syn:EmploymentAgreementDescrption contextRef="Context_9ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MrKanzerMember">Mr. Kanzer entered into a six month employment agreement with us on a full time basis (the "Kanzer Employment Agreement"), which may be extended for an additional three (3) months upon consent of the parties.</syn:EmploymentAgreementDescrption>




<us-gaap:NoninterestExpenseDirectorsFees contextRef="Context_Custom_31-Oct-2012_RelatedPartyTransactionsByRelatedPartyAxis_MrKanzerMember" unitRef="USD" decimals="0">150000</us-gaap:NoninterestExpenseDirectorsFees>
<us-gaap:NoninterestExpenseDirectorsFees contextRef="Context_9ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_MrKanzerMember" unitRef="USD" decimals="0">90000</us-gaap:NoninterestExpenseDirectorsFees>
<us-gaap:CostsAndExpensesRelatedParty contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-5">2900000</us-gaap:CostsAndExpensesRelatedParty>
<us-gaap:CostsAndExpensesRelatedParty contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-5">2500000</us-gaap:CostsAndExpensesRelatedParty>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2011_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_MoneyMarketAccountsAndMutualFundsMember" unitRef="USD" decimals="-5">5000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2012_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_MoneyMarketAccountsAndMutualFundsMember" unitRef="USD" decimals="-5">8600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<syn:OperatingLeaseLeasingTerm contextRef="Context_FYE_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInAnnArborMember">extend the term of the lease to December 31, 2014</syn:OperatingLeaseLeasingTerm>
<syn:OperatingLeaseLeasingTerm contextRef="Context_FYE_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInRockvilleMember">one year operating lease that may be renewed for two additional terms of one year</syn:OperatingLeaseLeasingTerm>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInAnnArborMember" unitRef="USD" decimals="0">33000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31-Dec-2012_EntityByLocationAxis_OfficeSpaceInRockvilleMember" unitRef="USD" decimals="0">35000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31-Dec-2012_AnnualPaymentEffectivePeriodAxis_December312014Member" unitRef="USD" decimals="0">50000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31-Dec-2012_AnnualPaymentEffectivePeriodAxis_December312015Member" unitRef="USD" decimals="0">25000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="USD_per_Share" decimals="2">1.39</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice contextRef="Context_Custom_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="USD_per_Share" decimals="2">2.08</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_CommitmentDateMember" unitRef="USD_per_Share" decimals="2">2.08</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice contextRef="Context_Custom_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember_PeriodTypeAxis_RemeasurementDateMember" unitRef="USD_per_Share" decimals="2">0.84</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-5">3200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="Context_As_Of_06-Apr-2011_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="-5">1500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="Context_As_Of_28-Jul-2011_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">253000</us-gaap:DerivativeFairValueOfDerivativeLiability>
<syn:IncreaseInFairValueOfWarrantLiability contextRef="Context_Custom_06-Apr-2011" unitRef="USD" decimals="0">765000</syn:IncreaseInFairValueOfWarrantLiability>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice contextRef="Context_Custom_06-Apr-2011" unitRef="USD_per_Share" decimals="4">2.0725</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice>
<syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod contextRef="Context_Custom_06-Apr-2011">P13M</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod>
<syn:AntiDilutionPriceProtectionWarrantsPricePerShare contextRef="Context_Custom_06-Apr-2011" unitRef="USD_per_Share" decimals="4">2.0725</syn:AntiDilutionPriceProtectionWarrantsPricePerShare>
<syn:DecreaseInFairValueOfWarrantLiability contextRef="Context_Custom_28-Jul-2011" unitRef="USD" decimals="0">523000</syn:DecreaseInFairValueOfWarrantLiability>
<syn:MilestonePayment contextRef="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_PhaseIClinicalTrialsMember" unitRef="USD" decimals="0">50000</syn:MilestonePayment>
<syn:MilestonePayment contextRef="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_PhaseIiiClinicalTrialsMember" unitRef="USD" decimals="0">100000</syn:MilestonePayment>
<syn:MilestonePayment contextRef="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_NdaSubmissionInUsMember" unitRef="USD" decimals="0">250000</syn:MilestonePayment>
<syn:MilestonePayment contextRef="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_EuropeanMedicinesAgencyApprovalMember" unitRef="USD" decimals="0">100000</syn:MilestonePayment>
<syn:MilestonePayment contextRef="Context_FYE_31-Dec-2012_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_RegulatoryApprovalInAsianCountryMember" unitRef="USD" decimals="0">100000</syn:MilestonePayment>
<syn:ResearchAgreementFixedFee contextRef="Context_As_Of_31-Dec-2012_QuarterlyInstallmentsPaymentPeriodAxis_FirstYearMember" unitRef="USD" decimals="0">303287</syn:ResearchAgreementFixedFee>
<syn:ResearchAgreementFixedFee contextRef="Context_As_Of_31-Dec-2012_QuarterlyInstallmentsPaymentPeriodAxis_SecondYearMember" unitRef="USD" decimals="0">316438</syn:ResearchAgreementFixedFee>
<syn:ResearchAgreementFixedFee contextRef="Context_As_Of_31-Dec-2012_QuarterlyInstallmentsPaymentPeriodAxis_ThirdYearMember" unitRef="USD" decimals="0">328758</syn:ResearchAgreementFixedFee>
<syn:CashPaymentForLicenseAgreement contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember" unitRef="USD" decimals="0">100000</syn:CashPaymentForLicenseAgreement>
<syn:AdditionalCashPaymentForLicenseAgreement contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember" unitRef="USD" decimals="0">135000</syn:AdditionalCashPaymentForLicenseAgreement>
<syn:UnregisteredSharesIssuedToLicenseAgreement contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember" unitRef="shares" decimals="0">625000</syn:UnregisteredSharesIssuedToLicenseAgreement>
<syn:AdditionalConsiderationPayable contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember">50% in cash and 50% in our stock</syn:AdditionalConsiderationPayable>
<syn:PartialConsiderationForExecution contextRef="Context_12ME_31-Dec-2011_BusinessAcquisitionAxis_IntrexonMember">Intrexon a number of shares of our common stock equal to 9.995% of the number of shares of our common stock issued</syn:PartialConsiderationForExecution>
<us-gaap:EquityIssuancePerShareAmount contextRef="Context_FYE_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:EquityIssuancePerShareAmount>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 0.5in;"&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;Selected Balance Sheet Information&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Accounts receivable (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;682&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;692&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Bad debt allowance - customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(682&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(287&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;405&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Prepaid expenses and other current assets (in thousands)&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Intrexon prepaid research and development expenses - See Note 10&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;2,412&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left;"&gt;Other receivables&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;17&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Prepaid expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;16&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;2,509&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;16&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Intrexon prepaid research and development expenses are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon. The Company anticipates that the majority of the prepaid will be applied to research and development goods and services during 2013.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Property and equipment (in thousands)&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Manufacturing equipment&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;297&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;Computer and office equipment&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;35&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;133&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;136&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;465&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;Less accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(242&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;(372&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;223&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Accrued liabilities (in thousands)&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 74%;"&gt;Accrued vendor payments&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%;"&gt;1&lt;/td&gt;
&lt;td style="text-align: left; width: 1%;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1pt;"&gt;Compensation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right;"&gt;28&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right;"&gt;29&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
<syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</syn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_31-Dec-2012_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<syn:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="Context_FYE_31-Dec-2012">&lt;div&gt;&lt;font size="2" style="font-family:times new roman,times"&gt;On April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000. The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/font&gt;&lt;/div&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Remeasurement&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Commitment&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;April&amp;#160;6,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 74%; color: black;"&gt;Closing stock price&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;1.39&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;2.08&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;Expected dividend rate&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;Expected stock price volatility&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;117.1&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;104.6&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0.28&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0.29&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; color: black;"&gt;Expected life (years)&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;1.08&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0.85&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On July 28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table align="center" style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Remeasurement&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Commitment&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td style="color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;Date&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"&gt;July&amp;#160;28,&amp;#160;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-indent: -13.2pt; padding-left: 13.2pt; width: 74%; color: black;"&gt;Closing stock price&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;2.08&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; color: black;"&gt;0.84&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;Expected dividend rate&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;Expected stock price volatility&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;112.1&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;105.6&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0.29&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;0.21&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"&gt;Expected life (years)&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;1.08&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; color: black;"&gt;1.04&lt;/td&gt;
&lt;td style="text-align: left; color: black;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;</syn:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
<syn:StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement contextRef="Context_FYE_31-Dec-2011_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-5">1700000</syn:StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement>
<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">680000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">539000</us-gaap:PaymentsOfStockIssuanceCosts>
<xbrli:context id="Context_0ME_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="syn:StockPurchaseWarrantsAggreementsAxis">syn:StockPurchaseAgreementWithThreeInstitutionalInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-19</xbrli:startDate><xbrli:endDate>2011-01-28</xbrli:endDate></xbrli:period></xbrli:context>
	<syn:WarrantsExercisePricePerShare contextRef="Context_0ME_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" unitRef="USD_per_Share" decimals="2">2.00</syn:WarrantsExercisePricePerShare>
<syn:WarrantsFloorPricePerShare contextRef="Context_0ME_28-Jan-2011_StockPurchaseWarrantsAggreementsAxis_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" unitRef="USD_per_Share" decimals="2">1.40</syn:WarrantsFloorPricePerShare>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_Custom_31-Oct-2012_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="0">3125000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>

<us-gaap:RegistrationPaymentArrangementTerm contextRef="Context_FYE_31-Dec-2012">In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a "resale" registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance.</us-gaap:RegistrationPaymentArrangementTerm>
<xbrli:context id="Context_12ME_31-Dec-2012_RegistrationPaymentArrangementByArrangementAxis_IndMilestoneEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">syn:IndMilestoneEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:RegistrationPaymentArrangementSettlementAlternatives contextRef="Context_12ME_31-Dec-2012_RegistrationPaymentArrangementByArrangementAxis_IndMilestoneEventMember">The Company also agreed upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the "IND Milestone Event"), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares of Common Stock (the "IND Milestone Shares") having a fair market value equaling two million dollars ($2M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event.</us-gaap:RegistrationPaymentArrangementSettlementAlternatives>
<xbrli:context id="Context_12ME_31-Dec-2012_RegistrationPaymentArrangementByArrangementAxis_ApprovalMilestoneEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">syn:ApprovalMilestoneEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:RegistrationPaymentArrangementSettlementAlternatives contextRef="Context_12ME_31-Dec-2012_RegistrationPaymentArrangementByArrangementAxis_ApprovalMilestoneEventMember">Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the "Approval Milestone Event"), the Company agreed to pay to Intrexon either (i) three million dollars ($3M) in cash, or (ii) that number of shares of Common Stock (the "Approval Milestone Shares") having a fair market value equaling three million dollars ($3M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.</us-gaap:RegistrationPaymentArrangementSettlementAlternatives>
<xbrli:context id="Context_12ME_31-Dec-2012_RegistrationPaymentArrangementByArrangementAxis_FieldExpansionFeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RegistrationPaymentArrangementByArrangementAxis">syn:FieldExpansionFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:RegistrationPaymentArrangementSettlementAlternatives contextRef="Context_12ME_31-Dec-2012_RegistrationPaymentArrangementByArrangementAxis_FieldExpansionFeeMember">The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for each target in excess of three (3) total that the Company elects, or (ii) that number of shares of Common Stock (the "Field Expansion Fee Shares") having a fair market value equaling two million dollars ($2M) for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field Expansion Fee Closing.</us-gaap:RegistrationPaymentArrangementSettlementAlternatives>
<syn:GainLossOnSaleOfDiscontinuedOperations contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">677000</syn:GainLossOnSaleOfDiscontinuedOperations>
<syn:GainLossOnSaleOfDiscontinuedOperations contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</syn:GainLossOnSaleOfDiscontinuedOperations>
<us-gaap:OtherReceivablesGrossCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:OtherReceivablesGrossCurrent>
<xbrli:context id="Context_12ME_31-Dec-2011_BusinessAcquisitionAxis_IntrexonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">1169000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<xbrli:context id="Context_As_Of_31-Dec-2011_BusinessAcquisitionAxis_IntrexonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure contextRef="Context_As_Of_31-Dec-2011_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD" decimals="-5">1700000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
<xbrli:context id="Context_As_Of_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure contextRef="Context_As_Of_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD" decimals="-5">7800000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
<xbrli:context id="Context_As_Of_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure contextRef="Context_As_Of_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember" unitRef="USD" decimals="-5">1200000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
<syn:SaleOfStockForChannelAgreementPricePerShare contextRef="Context_As_Of_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD_per_Share" decimals="2">2.20</syn:SaleOfStockForChannelAgreementPricePerShare>
<syn:SaleOfStockForChannelAgreementPricePerShare contextRef="Context_As_Of_31-Dec-2012_BusinessAcquisitionAxis_PrevAbrLlcMember" unitRef="USD_per_Share" decimals="2">1.87</syn:SaleOfStockForChannelAgreementPricePerShare>
<syn:CommonStockClosingPricePerShare contextRef="Context_Custom_31-Oct-2012_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD_per_Share" decimals="2">1.60</syn:CommonStockClosingPricePerShare>
<xbrli:context id="Context_As_Of_08-Mar-2012_RelatedPartyTransactionsByRelatedPartyAxis_AdeonaClinicalLaboratoryLlcMember_CreditFacilityAxis_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:AdeonaClinicalLaboratoryLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-03-08</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:UnrecognizedTaxBenefits contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:UnrecognizedTaxBenefits>
<us-gaap:UnrecognizedTaxBenefits contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:UnrecognizedTaxBenefits>
<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
<syn:WarrantsExercisablePricePerShare contextRef="Context_Custom_15-Mar-2012_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.20</syn:WarrantsExercisablePricePerShare>















<xbrli:context id="Context_25ME_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_25ME_31-Dec-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD" decimals="-5">7800000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="Context_FYE_31-Dec-2012" unitRef="USD" decimals="0">127000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions contextRef="Context_FYE_31-Dec-2011" unitRef="USD" decimals="0">15000</us-gaap:EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions>
<xbrli:context id="Context_12ME_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_12ME_31-Dec-2012_StatementEquityComponentsAxis_WarrantMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">271000</us-gaap:AllocatedShareBasedCompensationExpense>
<xbrli:context id="Context_12ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_EmployeeMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_12ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_EmployeeMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-5">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
<xbrli:context id="Context_12ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_12ME_31-Dec-2012_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">216000</us-gaap:AllocatedShareBasedCompensationExpense>
<xbrli:context id="Context_12ME_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_EmployeeMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_12ME_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_EmployeeMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">268000</us-gaap:AllocatedShareBasedCompensationExpense>
<xbrli:context id="Context_12ME_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_12ME_31-Dec-2011_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">705000</us-gaap:AllocatedShareBasedCompensationExpense>
<xbrli:context id="Context_As_Of_31-Jan-2012_BusinessAcquisitionAxis_IntrexonMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:IntrexonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-01-31</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Jan-2012_BusinessAcquisitionAxis_IntrexonMember" unitRef="USD" decimals="-5">2500000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2012" unitRef="USD" decimals="-3">2509000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">16000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>syn-20121231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.2.9 by DataTracks on Friday, April 12, 2013 04:05:57 PM -->
<schema targetNamespace="http://www.syntheticbiologics.com/20121231" elementFormDefault="qualified" xmlns:syn="http://www.syntheticbiologics.com/20121231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:country="http://xbrl.sec.gov/country/2012-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2012-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2012-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
<link:definition>005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
<link:definition>006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation" id="OrganizationAndNatureOfOperationsAndBasisOfPresentation">
<link:definition>009 - Disclosure - Organization and Nature of Operations and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
<link:definition>011 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation" id="SelectedBalanceSheetInformation">
<link:definition>012 - Disclosure - Selected Balance Sheet Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>013 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>014 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments" id="LicenseCollaborativeAndEmploymentAgreementsAndCommitments">
<link:definition>015 - Disclosure - License, Collaborative and Employment Agreements and Commitments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockRepurchaseProgram" id="StockRepurchaseProgram">
<link:definition>016 - Disclosure - Stock Repurchase Program</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>017 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>018 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables">
<link:definition>021 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables" id="SelectedBalanceSheetInformationTables">
<link:definition>022 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>023 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables" id="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables">
<link:definition>024 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>025 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual" id="OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual">
<link:definition>026 - Disclosure - Organization and Nature of Operations and Basis of Presentation (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>027 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
<link:definition>028 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
<link:definition>030 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1">
<link:definition>031 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual">
<link:definition>032 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails" id="SelectedBalanceSheetInformationDetails">
<link:definition>033 - Disclosure - Selected Balance Sheet Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1" id="SelectedBalanceSheetInformationDetails1">
<link:definition>034 - Disclosure - Selected Balance Sheet Information (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2" id="SelectedBalanceSheetInformationDetails2">
<link:definition>035 - Disclosure - Selected Balance Sheet Information (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3" id="SelectedBalanceSheetInformationDetails3">
<link:definition>036 - Disclosure - Selected Balance Sheet Information (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
<link:definition>037 - Disclosure - Stock-Based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails1" id="StockBasedCompensationDetails1">
<link:definition>038 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails2" id="StockBasedCompensationDetails2">
<link:definition>039 - Disclosure - Stock-Based Compensation (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails3" id="StockBasedCompensationDetails3">
<link:definition>040 - Disclosure - Stock-Based Compensation (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails4" id="StockBasedCompensationDetails4">
<link:definition>041 - Disclosure - Stock-Based Compensation (Details 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails5" id="StockBasedCompensationDetails5">
<link:definition>042 - Disclosure - Stock-Based Compensation (Details 5)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails6" id="StockBasedCompensationDetails6">
<link:definition>043 - Disclosure - Stock-Based Compensation (Details 6)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails7" id="StockBasedCompensationDetails7">
<link:definition>044 - Disclosure - Stock-Based Compensation (Details 7)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails8" id="StockBasedCompensationDetails8">
<link:definition>045 - Disclosure - Stock-Based Compensation (Details 8)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetailsTextual" id="StockBasedCompensationDetailsTextual">
<link:definition>046 - Disclosure - Stock-Based Compensation (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
<link:definition>047 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails" id="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails">
<link:definition>048 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual" id="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual">
<link:definition>049 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/StockRepurchaseProgramDetailsTextual" id="StockRepurchaseProgramDetailsTextual">
<link:definition>050 - Disclosure - Stock Repurchase Program (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>051 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
<link:definition>052 - Disclosure - Income Taxes (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
<link:definition>053 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
<link:definition>054 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="syn-20121231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="syn-20121231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="syn-20121231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="syn-20121231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:roleType roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical"><link:definition>008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="syn_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DepositsAndOtherAssetsNoncurrent" id="syn_DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BalanceSheetParentheticalAbstract" id="syn_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantExpenses" id="syn_WarrantExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfWarrantLiability" id="syn_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" id="syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" id="syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueLicenseFees" id="syn_StockIssuedDuringPeriodValueLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesLicenseFees" id="syn_StockIssuedDuringPeriodSharesLicenseFees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueConsultingFees" id="syn_StockIssuedDuringPeriodValueConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesConsultingFees" id="syn_StockIssuedDuringPeriodSharesConsultingFees" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" id="syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" id="syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" id="syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuanceCost" id="syn_StockIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedAsCompensation" id="syn_StockIssuedAsCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedForConsultingFees" id="syn_StockIssuedForConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssueOfStockForExclusiveChannelCollaborationAgreement" id="syn_IssueOfStockForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedForAcquisitionsOfProgramAssets" id="syn_StockIssuedForAcquisitionsOfProgramAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquipmentImpairmentLoss" id="syn_EquipmentImpairmentLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInDepositsAndOtherAssets" id="syn_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" id="syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" id="syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" id="syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" id="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" id="syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" id="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" id="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockRepurchaseProgramAbstract" id="syn_StockRepurchaseProgramAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockRepurchaseProgramTextBlock" id="syn_StockRepurchaseProgramTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmergingFromDevelopmentStagePolicyTextBlock" id="syn_EmergingFromDevelopmentStagePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RisksAndUncertaintiesPolicyTextBlock" id="syn_RisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" id="syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BeneficialConversionFeaturePolicyTextBlock" id="syn_BeneficialConversionFeaturePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OriginalIssueDiscountPolicyTextBlock" id="syn_OriginalIssueDiscountPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockBasedPaymentArrangementsPolicyTextBlock" id="syn_StockBasedPaymentArrangementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EstimatedUsefulLifeOfAssetsTableTextBlock" id="syn_EstimatedUsefulLifeOfAssetsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" id="syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" id="syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedExpensesTableTextBlock" id="syn_AccruedExpensesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfWarrantActivityTableTextBlock" id="syn_ScheduleOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" id="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DueForLicenseAgreementsTableTextBlock" id="syn_DueForLicenseAgreementsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfficeEquipmentAndFurnitureMember" id="syn_OfficeEquipmentAndFurnitureMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaboratoryEquipmentMember" id="syn_LaboratoryEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManufacturingEquipmentMember" id="syn_ManufacturingEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="McleanHospitalMember" id="syn_McleanHospitalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MedaAgreementMember" id="syn_MedaAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MoneyMarketAccountsAndMutualFundsMember" id="syn_MoneyMarketAccountsAndMutualFundsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseRevenuePercentage" id="syn_LicenseRevenuePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalMilestonePayments" id="syn_AdditionalMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyRevenuePercentage" id="syn_RoyaltyRevenuePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdeonaClinicalLaboratoryMember" id="syn_AdeonaClinicalLaboratoryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LaboratoryFeesNet" id="syn_LaboratoryFeesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" id="syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" id="syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" id="syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdeonaClinicalLaboratoryLlcMember" id="syn_AdeonaClinicalLaboratoryLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PrepaidExpensesResearchAndDevelopment" id="syn_PrepaidExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ComputerAndOfficeEquipmentMember" id="syn_ComputerAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedVendorPayments" id="syn_AccruedVendorPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedCompensation" id="syn_AccruedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" id="syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice009200Member" id="syn_RangeOfExercisePrice009200Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice201300Member" id="syn_RangeOfExercisePrice201300Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice301600Member" id="syn_RangeOfExercisePrice301600Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice009600Member" id="syn_RangeOfExercisePrice009600Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice009457Member" id="syn_RangeOfExercisePrice009457Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice458905Member" id="syn_RangeOfExercisePrice458905Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RangeOfExercisePrice009905Member" id="syn_RangeOfExercisePrice009905Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsExercisePrice" id="syn_OptionsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PeriodTypeAxis" id="syn_PeriodTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="PeriodTypeDomain" id="syn_PeriodTypeDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommitmentDateMember" id="syn_CommitmentDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RemeasurementDateMember" id="syn_RemeasurementDateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsFairValue" id="syn_WarrantsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPurchaseWarrantsAbstract" id="syn_StockPurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice1Member" id="syn_ExercisePrice1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice13Member" id="syn_ExercisePrice13Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice14Member" id="syn_ExercisePrice14Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice220Member" id="syn_ExercisePrice220Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice222Member" id="syn_ExercisePrice222Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice330Member" id="syn_ExercisePrice330Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice375Member" id="syn_ExercisePrice375Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExercisePrice199Member" id="syn_ExercisePrice199Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsExercisePrice" id="syn_WarrantsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPlan2007Member" id="syn_StockPlan2007Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPlan2010Member" id="syn_StockPlan2010Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockOptionsAndStockAppreciationRightsSarsMember" id="syn_StockOptionsAndStockAppreciationRightsSarsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesAndConsultantsMember" id="syn_EmployeesAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPurchaseWarrantsAggreementsAxis" id="syn_StockPurchaseWarrantsAggreementsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="StockPurchaseWarrantsAggreementsDomain" id="syn_StockPurchaseWarrantsAggreementsDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseAgreementWithSingleInvestorsMember" id="syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" id="syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" id="syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingAgreementForFinancialAdvisoryServicesMember" id="syn_ConsultingAgreementForFinancialAdvisoryServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CdfourBiosciencesIncMember" id="syn_CdfourBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EpitopeMember" id="syn_EpitopeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockPlan2001Member" id="syn_StockPlan2001Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfWarrantsToPurchaseOfCommonStock" id="syn_IssuanceOfWarrantsToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsExercisePricePerShare" id="syn_WarrantsExercisePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LifeOfWarrants" id="syn_LifeOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsExpirationDate" id="syn_WarrantsExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsFloorPricePerShare" id="syn_WarrantsFloorPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfWarrantsExpensesRecognized" id="syn_IssuanceOfWarrantsExpensesRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsFairValue1" id="syn_WarrantsFairValue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncreaseInFairValueOfWarrantLiability" id="syn_IncreaseInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AntiDilutionPriceProtectionWarrantsPricePerShare" id="syn_AntiDilutionPriceProtectionWarrantsPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DecreaseInFairValueOfWarrantLiability" id="syn_DecreaseInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IntrexonMember" id="syn_IntrexonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PrevAbrLlcMember" id="syn_PrevAbrLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfStockIssuedDuringPeriodValueConsultingFees" id="syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SaleOfStockForConsultingFeesPricePerShare" id="syn_SaleOfStockForConsultingFeesPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" id="syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SaleOfStockForEmploymentServicePricePerShare" id="syn_SaleOfStockForEmploymentServicePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" id="syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SaleOfStockForChannelAgreementPricePerShare" id="syn_SaleOfStockForChannelAgreementPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DrKuoMember" id="syn_DrKuoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="JeffreyRileyMember" id="syn_JeffreyRileyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CEvanBallantyneMember" id="syn_CEvanBallantyneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnArborMichiganMember" id="syn_AnnArborMichiganMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RockvilleMarylandMember" id="syn_RockvilleMarylandMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfficeSpaceInAnnArborMember" id="syn_OfficeSpaceInAnnArborMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfficeSpaceInRockvilleMember" id="syn_OfficeSpaceInRockvilleMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualPaymentEffectivePeriodAxis" id="syn_AnnualPaymentEffectivePeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AnnualPaymentEffectivePeriodDomain" id="syn_AnnualPaymentEffectivePeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="December312014Member" id="syn_December312014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="December312015Member" id="syn_December312015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseIClinicalTrialsMember" id="syn_PhaseIClinicalTrialsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PhaseIiiClinicalTrialsMember" id="syn_PhaseIiiClinicalTrialsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NdaSubmissionInUsMember" id="syn_NdaSubmissionInUsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EuropeanMedicinesAgencyApprovalMember" id="syn_EuropeanMedicinesAgencyApprovalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RegulatoryApprovalInAsianCountryMember" id="syn_RegulatoryApprovalInAsianCountryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="QuarterlyInstallmentsPaymentPeriodAxis" id="syn_QuarterlyInstallmentsPaymentPeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="QuarterlyInstallmentsPaymentPeriodDomain" id="syn_QuarterlyInstallmentsPaymentPeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FirstYearMember" id="syn_FirstYearMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SecondYearMember" id="syn_SecondYearMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ThirdYearMember" id="syn_ThirdYearMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultingFees" id="syn_ConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OperatingLeaseLeasingTerm" id="syn_OperatingLeaseLeasingTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AnnualPaymentForPastPatentExpenses" id="syn_AnnualPaymentForPastPatentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MilestonePayment" id="syn_MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ResearchAgreementFixedFee" id="syn_ResearchAgreementFixedFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashPaymentForLicenseAgreement" id="syn_CashPaymentForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalCashPaymentForLicenseAgreement" id="syn_AdditionalCashPaymentForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnregisteredSharesIssuedToLicenseAgreement" id="syn_UnregisteredSharesIssuedToLicenseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdditionalConsiderationPayable" id="syn_AdditionalConsiderationPayable" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PartialConsiderationForExecution" id="syn_PartialConsiderationForExecution" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantExpensesForIncomeTax" id="syn_WarrantExpensesForIncomeTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ChangeInFairValueOfWarrantExpenses" id="syn_ChangeInFairValueOfWarrantExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RealizedLossOnDebtSecurities" id="syn_RealizedLossOnDebtSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DeferredTaxAssetsStocksIssuedForServices" id="syn_DeferredTaxAssetsStocksIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DeferredTaxAssetsBadDebts" id="syn_DeferredTaxAssetsBadDebts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" id="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OperatingLossForwardPeriodAxis" id="syn_OperatingLossForwardPeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="OperatingLossForwardPeriodDomain" id="syn_OperatingLossForwardPeriodDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TaxableIncomeExpiringThrough2032Member" id="syn_TaxableIncomeExpiringThrough2032Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BoardOfDirectorsAndOfficersMember" id="syn_BoardOfDirectorsAndOfficersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MrKanzerMember" id="syn_MrKanzerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmploymentAgreementDescrption" id="syn_EmploymentAgreementDescrption" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" id="syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>
<element name="StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" id="syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="credit"/>
<element name="IndMilestoneEventMember" id="syn_IndMilestoneEventMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="ApprovalMilestoneEventMember" id="syn_ApprovalMilestoneEventMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="FieldExpansionFeeMember" id="syn_FieldExpansionFeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="GainLossOnSaleOfDiscontinuedOperations" id="syn_GainLossOnSaleOfDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true" xbrli:balance="credit"/>
<element name="CommonStockClosingPricePerShare" id="syn_CommonStockClosingPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>
<element name="WarrantsExercisablePricePerShare" id="syn_WarrantsExercisablePricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" nillable="true"/>



<element name="EmployeeMember" id="syn_EmployeeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="ConsultantMember" id="syn_ConsultantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
<element name="GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" id="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="true" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>syn-20121231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.2.9 by DataTracks on Friday, April 12, 2013 04:05:58 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_syn_WarrantExpenses" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" order="20" use="optional" weight="1"/></calculationLink>




<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedAsCompensation" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedForConsultingFees" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForAcquisitionsOfProgramAssets" xlink:label="loc_syn_StockIssuedForAcquisitionsOfProgramAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedForAcquisitionsOfProgramAssets" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_WarrantExpenses" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" order="110" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="120" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" order="130" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfProperty" order="140" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_EquipmentImpairmentLoss" order="150" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" order="160" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="170" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="180" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivables"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivables" order="190" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" order="200" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" order="210" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="220" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="230" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" order="240" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RecoveryOfDirectCosts" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GainLossOnSaleOfDiscontinuedOperations" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperations"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_GainLossOnSaleOfDiscontinuedOperations" order="250" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="260" use="optional" weight="1"/>
</calculationLink>



<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails3" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_syn_AccruedVendorPayments" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedCompensation" xlink:label="loc_syn_AccruedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_syn_AccruedCompensation" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear" order="50" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetails1" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1"/>
<calculationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="loc_syn_DeferredTaxAssetsStocksIssuedForServices"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_syn_DeferredTaxAssetsStocksIssuedForServices" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsBadDebts" xlink:label="loc_syn_DeferredTaxAssetsBadDebts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_syn_DeferredTaxAssetsBadDebts" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceAmount" xlink:label="loc_us-gaap_ValuationAllowanceAmount"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_ValuationAllowanceAmount" order="20" use="optional" weight="-1"/></calculationLink>

</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>syn-20121231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.2.9 by DataTracks on Friday, April 12, 2013 04:05:58 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails3" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails1" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails2" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails2"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails3" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails3"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails4" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails4"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails5" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails5"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails6" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails6"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails7" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails7"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails8" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails8"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockRepurchaseProgramDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockRepurchaseProgramDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetails" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetails1" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/RelatedPartyTransactionsDetailsTextual"/>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_14" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_15" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityPublicFloat_16" order="150" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Cash_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_PreferredStockValue_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommonStockValue_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquity_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_syn_WarrantExpenses_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_20" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_RetainedEarningsMember_5" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_CommonStockMember_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_12" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_13" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_14" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_15" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueLicenseFees_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueLicenseFees_16" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_17" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueConsultingFees_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueConsultingFees_18" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_19" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_20" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_21" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:label="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_24" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_25" order="190" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuanceCost_2" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedAsCompensation_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedForConsultingFees_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForAcquisitionsOfProgramAssets" xlink:label="loc_syn_StockIssuedForAcquisitionsOfProgramAssets_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedForAcquisitionsOfProgramAssets_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_WarrantExpenses_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_12" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_13" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_14" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_AdjustmentForAmortization_15" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_16" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnDispositionOfProperty_17" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_EquipmentImpairmentLoss_18" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_19" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivables_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivables_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_25" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_26" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_27" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_28" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_31" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_32" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_34" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_35" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises_37" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_38" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_39" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_40" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_41" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_42" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Cash_43" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_44" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_44" xlink:to="loc_us-gaap_InterestPaid_45" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_44" xlink:to="loc_us-gaap_IncomeTaxesPaid_46" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_47" xlink:to="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_48" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GainLossOnSaleOfDiscontinuedOperations" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperations"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_GainLossOnSaleOfDiscontinuedOperations" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetIncomeLoss" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NotesPayable_2" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentForAmortization_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeEquipmentAndFurnitureMember" xlink:label="loc_syn_OfficeEquipmentAndFurnitureMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_OfficeEquipmentAndFurnitureMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_LaboratoryEquipmentMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ManufacturingEquipmentMember" xlink:label="loc_syn_ManufacturingEquipmentMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_ManufacturingEquipmentMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_12" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_McleanHospitalMember" xlink:label="loc_syn_McleanHospitalMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_syn_McleanHospitalMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MedaAgreementMember" xlink:label="loc_syn_MedaAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_syn_MedaAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaap_OptionMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7" xlink:to="loc_us-gaap_OptionMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MoneyMarketAccountsAndMutualFundsMember" xlink:label="loc_syn_MoneyMarketAccountsAndMutualFundsMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13" xlink:to="loc_syn_MoneyMarketAccountsAndMutualFundsMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LicensesRevenue_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LicenseRevenuePercentage" xlink:label="loc_syn_LicenseRevenuePercentage_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_LicenseRevenuePercentage_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalMilestonePayments" xlink:label="loc_syn_AdditionalMilestonePayments_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AdditionalMilestonePayments_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_MarketingExpense_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RoyaltyRevenuePercentage" xlink:label="loc_syn_RoyaltyRevenuePercentage_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_RoyaltyRevenuePercentage_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Depreciation_20" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_21" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_22" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdeonaClinicalLaboratoryMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3" xlink:to="loc_syn_AdeonaClinicalLaboratoryMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_LaboratoryFeesNet_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" xlink:label="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_12" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_12" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_14" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_CreditFacilityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2" xlink:to="loc_us-gaap_CreditFacilityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2" xlink:to="loc_us-gaap_CreditFacilityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3" xlink:to="loc_us-gaap_CommercialPaperMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdeonaClinicalLaboratoryLlcMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryLlcMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_syn_AdeonaClinicalLaboratoryLlcMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaap_NotesReceivableNet_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NotesReceivableNet_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_9" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_5" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_EquipmentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_ComputerAndOfficeEquipmentMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_LaboratoryEquipmentMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AccruedVendorPayments_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedCompensation" xlink:label="loc_syn_AccruedCompensation_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AccruedCompensation_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_11" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_11" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_12" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_13" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_14" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_16" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xlink:label="loc_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties_18" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties_19" order="180" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009200Member" xlink:label="loc_syn_RangeOfExercisePrice009200Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009200Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice201300Member" xlink:label="loc_syn_RangeOfExercisePrice201300Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice201300Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice301600Member" xlink:label="loc_syn_RangeOfExercisePrice301600Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice301600Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009600Member" xlink:label="loc_syn_RangeOfExercisePrice009600Member_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009600Member_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009457Member" xlink:label="loc_syn_RangeOfExercisePrice009457Member_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009457Member_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice458905Member" xlink:label="loc_syn_RangeOfExercisePrice458905Member_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice458905Member_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009905Member" xlink:label="loc_syn_RangeOfExercisePrice009905Member_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009905Member_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_11" xlink:to="loc_us-gaap_RangeMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_11" xlink:to="loc_us-gaap_RangeMember_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_12" xlink:to="loc_us-gaap_MaximumMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_12" xlink:to="loc_us-gaap_MinimumMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OptionsExercisePrice" xlink:label="loc_syn_OptionsExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_OptionsExercisePrice_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_21" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_10" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeAxis" xlink:label="loc_syn_PeriodTypeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_PeriodTypeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeDomain" xlink:label="loc_syn_PeriodTypeDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_syn_PeriodTypeAxis_5" xlink:to="loc_syn_PeriodTypeDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeDomain" xlink:label="loc_syn_PeriodTypeDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_syn_PeriodTypeAxis_5" xlink:to="loc_syn_PeriodTypeDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommitmentDateMember" xlink:label="loc_syn_CommitmentDateMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_PeriodTypeDomain_6" xlink:to="loc_syn_CommitmentDateMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RemeasurementDateMember" xlink:label="loc_syn_RemeasurementDateMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_PeriodTypeDomain_6" xlink:to="loc_syn_RemeasurementDateMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails6">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue" xlink:label="loc_syn_WarrantsFairValue_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsFairValue_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantExpenses_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_5" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails7">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_11" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails8">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice1Member_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice13Member" xlink:label="loc_syn_ExercisePrice13Member_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice13Member_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice14Member_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice220Member_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice222Member_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice330Member_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice375Member_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice199Member_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsExercisePrice_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_19" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_syn_StockPlan2007Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_syn_StockPlan2010Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:label="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_syn_EmployeesAndConsultantsMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsAxis" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis_12" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis_12" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:label="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_16" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:label="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_17" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CdfourBiosciencesIncMember" xlink:label="loc_syn_CdfourBiosciencesIncMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_syn_CdfourBiosciencesIncMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EpitopeMember" xlink:label="loc_syn_EpitopeMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_syn_EpitopeMember_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22" xlink:to="loc_us-gaap_EquityComponentDomain_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_23_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22" xlink:to="loc_us-gaap_EquityComponentDomain_23_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_23" xlink:to="loc_us-gaap_WarrantMember_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_25" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_26_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_26_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_26" xlink:to="loc_syn_StockPlan2001Member_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_26" xlink:to="loc_us-gaap_SubsequentEventMember_28" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_29" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_31" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_32" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisePricePerShare" xlink:label="loc_syn_WarrantsExercisePricePerShare_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsExercisePricePerShare_33" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LifeOfWarrants" xlink:label="loc_syn_LifeOfWarrants_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_LifeOfWarrants_34" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExpirationDate" xlink:label="loc_syn_WarrantsExpirationDate_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsExpirationDate_35" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_36" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFloorPricePerShare" xlink:label="loc_syn_WarrantsFloorPricePerShare_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsFloorPricePerShare_37" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantExpenses_38" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_39" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_41" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_42" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_43" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_44" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_45" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_46" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_47" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_48" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssuanceOfWarrantsExpensesRecognized" xlink:label="loc_syn_IssuanceOfWarrantsExpensesRecognized_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_IssuanceOfWarrantsExpensesRecognized_49" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_50" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue1" xlink:label="loc_syn_WarrantsFairValue1_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsFairValue1_51" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_52" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_53" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseInFairValueOfWarrantLiability" xlink:label="loc_syn_IncreaseInFairValueOfWarrantLiability_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_IncreaseInFairValueOfWarrantLiability_54" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice_55" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod_56" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xlink:label="loc_syn_AntiDilutionPriceProtectionWarrantsPricePerShare_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AntiDilutionPriceProtectionWarrantsPricePerShare_57" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DecreaseInFairValueOfWarrantLiability" xlink:label="loc_syn_DecreaseInFairValueOfWarrantLiability_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_DecreaseInFairValueOfWarrantLiability_58" order="300" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantsExercisablePricePerShare" order="310" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" order="330" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmployeeMember" xlink:label="loc_syn_EmployeeMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_syn_EmployeeMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultantMember" xlink:label="loc_syn_ConsultantMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_syn_ConsultantMember" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" xlink:to="loc_us-gaap_PrivatePlacementMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" xlink:to="loc_syn_IntrexonMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" xlink:to="loc_syn_PrevAbrLlcMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuanceCost_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_17" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees_18" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForConsultingFeesPricePerShare" xlink:label="loc_syn_SaleOfStockForConsultingFeesPricePerShare_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_SaleOfStockForConsultingFeesPricePerShare_19" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants_20" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_21" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_22" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForEmploymentServicePricePerShare" xlink:label="loc_syn_SaleOfStockForEmploymentServicePricePerShare_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_SaleOfStockForEmploymentServicePricePerShare_23" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_24" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised_25" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_26" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForChannelAgreementPricePerShare" xlink:label="loc_syn_SaleOfStockForChannelAgreementPricePerShare_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_SaleOfStockForChannelAgreementPricePerShare_27" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised_28" order="160" use="optional"/>


<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_30" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_31" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_32" order="200" use="optional"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_35" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaap_NoninterestExpenseOfferingCost_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NoninterestExpenseOfferingCost_36" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" order="250" use="optional"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockClosingPricePerShare" xlink:label="loc_syn_CommonStockClosingPricePerShare"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_CommonStockClosingPricePerShare" order="270" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear_7" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
















<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12" xlink:to="loc_us-gaap_EquityComponentDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12" xlink:to="loc_us-gaap_EquityComponentDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13" xlink:to="loc_us-gaap_WarrantMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" xlink:to="loc_syn_IntrexonMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" xlink:to="loc_syn_PrevAbrLlcMember_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" xlink:to="loc_us-gaap_PrivatePlacementMember_18" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityByLocationAxis" xlink:label="loc_dei_EntityByLocationAxis_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityByLocationAxis_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LocationDomain" xlink:label="loc_dei_LocationDomain_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityByLocationAxis_22" xlink:to="loc_dei_LocationDomain_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LocationDomain" xlink:label="loc_dei_LocationDomain_23_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityByLocationAxis_22" xlink:to="loc_dei_LocationDomain_23_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeSpaceInAnnArborMember" xlink:label="loc_syn_OfficeSpaceInAnnArborMember_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_LocationDomain_23" xlink:to="loc_syn_OfficeSpaceInAnnArborMember_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeSpaceInRockvilleMember" xlink:label="loc_syn_OfficeSpaceInRockvilleMember_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_LocationDomain_23" xlink:to="loc_syn_OfficeSpaceInRockvilleMember_25" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodAxis" xlink:label="loc_syn_AnnualPaymentEffectivePeriodAxis_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_AnnualPaymentEffectivePeriodAxis_26" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodDomain" xlink:label="loc_syn_AnnualPaymentEffectivePeriodDomain_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_syn_AnnualPaymentEffectivePeriodAxis_26" xlink:to="loc_syn_AnnualPaymentEffectivePeriodDomain_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodDomain" xlink:label="loc_syn_AnnualPaymentEffectivePeriodDomain_27_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_syn_AnnualPaymentEffectivePeriodAxis_26" xlink:to="loc_syn_AnnualPaymentEffectivePeriodDomain_27_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_December312014Member" xlink:label="loc_syn_December312014Member_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AnnualPaymentEffectivePeriodDomain_27" xlink:to="loc_syn_December312014Member_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_December312015Member" xlink:label="loc_syn_December312015Member_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_AnnualPaymentEffectivePeriodDomain_27" xlink:to="loc_syn_December312015Member_29" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PhaseIClinicalTrialsMember" xlink:label="loc_syn_PhaseIClinicalTrialsMember_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_PhaseIClinicalTrialsMember_32" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PhaseIiiClinicalTrialsMember" xlink:label="loc_syn_PhaseIiiClinicalTrialsMember_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_PhaseIiiClinicalTrialsMember_33" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_NdaSubmissionInUsMember" xlink:label="loc_syn_NdaSubmissionInUsMember_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_NdaSubmissionInUsMember_34" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EuropeanMedicinesAgencyApprovalMember" xlink:label="loc_syn_EuropeanMedicinesAgencyApprovalMember_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_EuropeanMedicinesAgencyApprovalMember_35" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RegulatoryApprovalInAsianCountryMember" xlink:label="loc_syn_RegulatoryApprovalInAsianCountryMember_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_RegulatoryApprovalInAsianCountryMember_36" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37" xlink:to="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37" xlink:to="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FirstYearMember" xlink:label="loc_syn_FirstYearMember_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" xlink:to="loc_syn_FirstYearMember_39" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SecondYearMember" xlink:label="loc_syn_SecondYearMember_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" xlink:to="loc_syn_SecondYearMember_40" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ThirdYearMember" xlink:label="loc_syn_ThirdYearMember_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" xlink:to="loc_syn_ThirdYearMember_41" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_42" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_43" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_44" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_45" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue_46" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultingFees" xlink:label="loc_syn_ConsultingFees_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ConsultingFees_47" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OfficersCompensation_48" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_49" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LeaseAndRentalExpense_50" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LeaseExpirationDate1_51" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_52" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLeaseLeasingTerm" xlink:label="loc_syn_OperatingLeaseLeasingTerm_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_OperatingLeaseLeasingTerm_53" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_54" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentForPastPatentExpenses" xlink:label="loc_syn_AnnualPaymentForPastPatentExpenses_55"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AnnualPaymentForPastPatentExpenses_55" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MilestonePayment" xlink:label="loc_syn_MilestonePayment_56"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_MilestonePayment_56" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ResearchAgreementFixedFee" xlink:label="loc_syn_ResearchAgreementFixedFee_57"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ResearchAgreementFixedFee_57" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CashPaymentForLicenseAgreement" xlink:label="loc_syn_CashPaymentForLicenseAgreement_58"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_CashPaymentForLicenseAgreement_58" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalCashPaymentForLicenseAgreement" xlink:label="loc_syn_AdditionalCashPaymentForLicenseAgreement_59"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AdditionalCashPaymentForLicenseAgreement_59" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:label="loc_syn_UnregisteredSharesIssuedToLicenseAgreement_60"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_UnregisteredSharesIssuedToLicenseAgreement_60" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalConsiderationPayable" xlink:label="loc_syn_AdditionalConsiderationPayable_61"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_AdditionalConsiderationPayable_61" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_62"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_62" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount_63"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityIssuancePerShareAmount_63" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PartialConsiderationForExecution" xlink:label="loc_syn_PartialConsiderationForExecution_64"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_PartialConsiderationForExecution_64" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_65"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_65" order="240" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementSettlementAlternatives" xlink:label="loc_us-gaap_RegistrationPaymentArrangementSettlementAlternatives"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RegistrationPaymentArrangementSettlementAlternatives" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IndMilestoneEventMember" xlink:label="loc_syn_IndMilestoneEventMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="loc_syn_IndMilestoneEventMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ApprovalMilestoneEventMember" xlink:label="loc_syn_ApprovalMilestoneEventMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="loc_syn_ApprovalMilestoneEventMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FieldExpansionFeeMember" xlink:label="loc_syn_FieldExpansionFeeMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="loc_syn_FieldExpansionFeeMember" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="loc_us-gaap_RegistrationPaymentArrangementTerm"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RegistrationPaymentArrangementTerm" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain_Default" order="1"/>










<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" order="110" use="optional"/>






<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DrKuoMember" xlink:label="loc_syn_DrKuoMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_syn_DrKuoMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_JeffreyRileyMember" xlink:label="loc_syn_JeffreyRileyMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_syn_JeffreyRileyMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CEvanBallantyneMember" xlink:label="loc_syn_CEvanBallantyneMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_syn_CEvanBallantyneMember" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnArborMichiganMember" xlink:label="loc_syn_AnnArborMichiganMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_syn_AnnArborMichiganMember" order="3" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RockvilleMarylandMember" xlink:label="loc_syn_RockvilleMarylandMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_syn_RockvilleMarylandMember" order="4" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockRepurchaseProgramDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_6" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpensesForIncomeTax" xlink:label="loc_syn_WarrantExpensesForIncomeTax_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WarrantExpensesForIncomeTax_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantExpenses" xlink:label="loc_syn_ChangeInFairValueOfWarrantExpenses_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_ChangeInFairValueOfWarrantExpenses_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RealizedLossOnDebtSecurities" xlink:label="loc_syn_RealizedLossOnDebtSecurities_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_RealizedLossOnDebtSecurities_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="loc_syn_DeferredTaxAssetsStocksIssuedForServices_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_syn_DeferredTaxAssetsStocksIssuedForServices_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsBadDebts" xlink:label="loc_syn_DeferredTaxAssetsBadDebts_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_syn_DeferredTaxAssetsBadDebts_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceAmount" xlink:label="loc_us-gaap_ValuationAllowanceAmount_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceAmount_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_9" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodAxis" xlink:label="loc_syn_OperatingLossForwardPeriodAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_OperatingLossForwardPeriodAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodDomain" xlink:label="loc_syn_OperatingLossForwardPeriodDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_syn_OperatingLossForwardPeriodAxis_2" xlink:to="loc_syn_OperatingLossForwardPeriodDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodDomain" xlink:label="loc_syn_OperatingLossForwardPeriodDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_syn_OperatingLossForwardPeriodAxis_2" xlink:to="loc_syn_OperatingLossForwardPeriodDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_TaxableIncomeExpiringThrough2032Member" xlink:label="loc_syn_TaxableIncomeExpiringThrough2032Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_syn_OperatingLossForwardPeriodDomain_3" xlink:to="loc_syn_TaxableIncomeExpiringThrough2032Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceAmount" xlink:label="loc_us-gaap_ValuationAllowanceAmount_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceAmount_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_10" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="100" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BoardOfDirectorsAndOfficersMember" xlink:label="loc_syn_BoardOfDirectorsAndOfficersMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_BoardOfDirectorsAndOfficersMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MrKanzerMember" xlink:label="loc_syn_MrKanzerMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_syn_MrKanzerMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" xlink:to="loc_syn_IntrexonMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmploymentAgreementDescrption" xlink:label="loc_syn_EmploymentAgreementDescrption_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_EmploymentAgreementDescrption_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockValue_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_22" order="90" use="optional"/>
</definitionLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"/>
<definitionLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="1" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>syn-20121231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.2.9 by DataTracks on Friday, April 12, 2013 04:05:58 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DocumentAndEntityInformationAbstract" xlink:to="lab_syn_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-Known Seasoned Issuer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at beginning of year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at end of year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable - net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets Of Disposal Group, Including Discontinued Operation, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets of discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Notes, Loans and Financing Receivable, Net, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Long-term note receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_syn_DepositsAndOtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 28,127,644 issued and 28,209,126 outstanding and 23,420,189 issued and 23,338,707 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 44,444,230 issued and 44,362,748 outstanding and 31,374,002 issued and 31,292,520 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance, December 31, 2009</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BalanceSheetParentheticalAbstract" xlink:to="lab_syn_BalanceSheetParentheticalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares, issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating costs and expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">The amount of expenses incurred for warrant during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantExpenses" xlink:to="lab_syn_WarrantExpenses"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ChangeInFairValueOfWarrantLiability" xlink:to="lab_syn_ChangeInFairValueOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Expense, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) From Continuing Operations Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Loss from Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Gain (loss) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net Loss from Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net Loss from Continuing Operations</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xml:lang="en-US">Loss from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Gain (loss) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) from Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (loss) from discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Loss from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss and Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Continuing Operations, Per Basic and Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Continuing operations (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Per Basic and Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Discontinued operations (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Loss Per Share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Income (Loss) Per Share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Basic and Dilutive (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Warrant liability reclassified to stockholders equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Value, Share-Based Compensation, Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Issuance of common stock for employee compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Stock Issued During Period, Shares, Share-Based Compensation, Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US">Issuance of common stock for employee compensation (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock Issued During Period Value For Exclusive Channel Collaboration Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Issuance of common stock for exclusive channel collaboration agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Value of stock issued during the period For Exclusive Channel Collaboration Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock Issued During Period Shares For Exclusive Channel Collaboration Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Issuance of common stock for exclusive channel collaboration agreement (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Number of shares issued during the period For Exclusive Channel Collaboration Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of common stock for acquisition of program assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock issued for acqusition of program assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issuance of common stock for acquisition of program assets (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueLicenseFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueLicenseFees" xml:lang="en-US">Stock Issued During Period Value License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueLicenseFees" xml:lang="en-US">Issuance of common stock for license fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueLicenseFees" xml:lang="en-US">Value of stock issued during the period as a result of license fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueLicenseFees" xlink:to="lab_syn_StockIssuedDuringPeriodValueLicenseFees"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesLicenseFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesLicenseFees" xml:lang="en-US">Stock Issued During Period Shares License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesLicenseFees" xml:lang="en-US">Issuance of common stock for license fees (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesLicenseFees" xml:lang="en-US">Number of shares issued during the period as a result of license fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:to="lab_syn_StockIssuedDuringPeriodSharesLicenseFees"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueConsultingFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Stock Issued During Period Value Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Issuance of common stock for consulting fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Value of stock issued during the period as a result of consulting fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueConsultingFees" xlink:to="lab_syn_StockIssuedDuringPeriodValueConsultingFees"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesConsultingFees" xml:lang="en-US">Stock Issued During Period Shares Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesConsultingFees" xml:lang="en-US">Issuance of common stock for consulting fees (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesConsultingFees" xml:lang="en-US">Number of shares issued during the period as a result of consulting fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:to="lab_syn_StockIssuedDuringPeriodSharesConsultingFees"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Stock Issued During Period Value Stock Options and Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Issuance of common stock for stock options and warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xml:lang="en-US">Value stock issued during the period as a result of the stock options and warrants exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="lab_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Options and Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Issuance of common stock for stock options and warrants exercised (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xml:lang="en-US">Number of share options and warrants exercised during the current period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:label="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xml:lang="en-US">Adjustments To Additional Paid In Capital Warrants Liability Reclassified</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xml:lang="en-US">Warrant liability reclassified to stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xml:lang="en-US">Increase in additional paid in capital due to warrants liability reclassified to stockholders equity during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:to="lab_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuanceCost" xml:lang="en-US">Stock Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuanceCost" xml:lang="en-US">Stock Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuanceCost" xml:lang="en-US">Stock Issuance Cost during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuanceCost" xlink:to="lab_syn_StockIssuanceCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">Stock Issued As Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">Stock issued as compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">The noncash expense that accounts for the value of stock options distributed as compensation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedAsCompensation" xlink:to="lab_syn_StockIssuedAsCompensation"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">Stock Issued For Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">Stock issued for consulting fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForConsultingFees" xlink:to="lab_syn_StockIssuedForConsultingFees"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Issue Of Stock For Exclusive Channel Collaboration Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock issued for exclusive channel collaboration agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock issued for exclusive channel collaboration agreement during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Stock issued for exclusive channel collaboration agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_IssueOfStockForExclusiveChannelCollaborationAgreement"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForAcquisitionsOfProgramAssets" xlink:label="loc_syn_StockIssuedForAcquisitionsOfProgramAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForAcquisitionsOfProgramAssets" xml:lang="en-US">Stock Issued For Acquisitions Of Program Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedForAcquisitionsOfProgramAssets" xml:lang="en-US">Issuance of common stock for acquisition of program assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForAcquisitionsOfProgramAssets" xml:lang="en-US">The value of stock granted for acquisition of program assets.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_StockIssuedForAcquisitionsOfProgramAssets" xml:lang="en-US">Stock issued for acquisition of program assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForAcquisitionsOfProgramAssets" xlink:to="lab_syn_StockIssuedForAcquisitionsOfProgramAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision For Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for uncollectible accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization of premium on investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Held-To-Maturity Securities, Sold Security, Realized Gain (Loss), Excluding Other Than Temporary Impairments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Loss on sale of short-term investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xml:lang="en-US">Loss on sale of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfProperty" xml:lang="en-US">Gain (Loss) On Disposition Of Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfProperty" xml:lang="en-US">(Gain) loss on sale of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfProperty" xml:lang="en-US">Loss on sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfProperty" xlink:to="lab_us-gaap_GainLossOnDispositionOfProperty"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Equipment Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment on loss of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment loss on equipment during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_EquipmentImpairmentLoss" xml:lang="en-US">Impairment loss on equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EquipmentImpairmentLoss" xlink:to="lab_syn_EquipmentImpairmentLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain (Loss) On Sale Of Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain on the settlement of accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain on the settlement of accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:to="lab_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) In Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivables"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivables" xml:lang="en-US">Increase (Decrease) In Notes Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivables" xml:lang="en-US">Note receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivables" xml:lang="en-US">Note receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesReceivables"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease In Deposits and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Increase Decrease In Assets Of Disposal Group Including Discontinued Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Assets of discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">The increase (decrease) during the reporting period in assets of discontinued operations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Increase Decrease In Liabilities Of Disposal Group Including Discontinued Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Liabilities of discontinued operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">The increase (decrease) during the reporting period in liabilities of discontinued operations.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Liabilities of discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments To Acquire Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchase of short-term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchase of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds From Sale, Maturity and Collection Of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from short-term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xml:lang="en-US">Proceeds from short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of capital equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds From Sale Of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Stock Options Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xml:lang="en-US">Proceeds from issuance of common stock for stock option and warrant exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for stock option exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Exclusive Channel Collaboration Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Proceeds from issuance of common stock for exclusive channel collaboration agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Note receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xml:lang="en-US">The cash inflow from the additional capital contribution for exclusive channel collaboration agreement to the entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds From Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from the issuance of common stock, net of issuance costs of $680 and $539, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Recovery Of Direct Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Cash paid as direct offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Cash paid as direct offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash Period Increase Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification Of Derivative Liability To Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of warrant liability to additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of warrant liability to additional paid-in-capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">No authoritative reference available.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of warrant liability to additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:to="lab_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis Of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xml:lang="en-US">Disclosure Of License Collaborative and Employment Agreements and Commitments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xml:lang="en-US">Disclosure Of License Collaborative and Employment Agreements and Commitments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:to="lab_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xlink:label="loc_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xml:lang="en-US">License Collaborative and Employment Agreements and Commitments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xml:lang="en-US">License Collaborative and Employment Agreements and Commitments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xml:lang="en-US">The entire disclosure of license, collaborative and employment agreement and commitments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xlink:to="lab_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockRepurchaseProgramAbstract" xlink:label="loc_syn_StockRepurchaseProgramAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockRepurchaseProgramAbstract" xml:lang="en-US">Stock Repurchase Program [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockRepurchaseProgramAbstract" xml:lang="en-US">Stock Repurchase Program [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockRepurchaseProgramAbstract" xlink:to="lab_syn_StockRepurchaseProgramAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockRepurchaseProgramTextBlock" xlink:label="loc_syn_StockRepurchaseProgramTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockRepurchaseProgramTextBlock" xml:lang="en-US">Stock Repurchase Program [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockRepurchaseProgramTextBlock" xml:lang="en-US">Stock Repurchase Program [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockRepurchaseProgramTextBlock" xml:lang="en-US">The entire disclosure of stock repurchase program.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockRepurchaseProgramTextBlock" xlink:to="lab_syn_StockRepurchaseProgramTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmergingFromDevelopmentStagePolicyTextBlock" xlink:label="loc_syn_EmergingFromDevelopmentStagePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmergingFromDevelopmentStagePolicyTextBlock" xml:lang="en-US">Emerging From Development Stage [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_EmergingFromDevelopmentStagePolicyTextBlock" xml:lang="en-US">Emerging From Development Stage [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_EmergingFromDevelopmentStagePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for emerging from development stage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmergingFromDevelopmentStagePolicyTextBlock" xlink:to="lab_syn_EmergingFromDevelopmentStagePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use Of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy" xml:lang="en-US">Premiums Receivable, Allowance For Doubtful Accounts, Estimation Methodology, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy" xml:lang="en-US">Premiums Receivable, Allowance for Doubtful Accounts, Estimation Methodology, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy" xlink:to="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_syn_RisksAndUncertaintiesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RisksAndUncertaintiesPolicyTextBlock" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_RisksAndUncertaintiesPolicyTextBlock" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_RisksAndUncertaintiesPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy regarding risk and uncertainties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_syn_RisksAndUncertaintiesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" xlink:label="loc_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" xml:lang="en-US">Marketable Securities Held To Maturity Trading Available For Sale Securities Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" xml:lang="en-US">Marketable Securities Held To Maturity Trading Available For Sale Securities Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for investments in debt securities (which may include mandatorily redeemable preferred shares or preferred shares redeemable at the investing Company's option) that are classified as held-to-maturity. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of held-to-maturity securities are other than temporary, and how the fair values of such securities are determined, This policy also may describe the entity's accounting treatment for transfers between investment categories and how the fair values of such securities are determined,This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" xlink:to="lab_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment Or Disposal Of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BeneficialConversionFeaturePolicyTextBlock" xlink:label="loc_syn_BeneficialConversionFeaturePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BeneficialConversionFeaturePolicyTextBlock" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_BeneficialConversionFeaturePolicyTextBlock" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_BeneficialConversionFeaturePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy regarding beneficial conversion feature.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BeneficialConversionFeaturePolicyTextBlock" xlink:to="lab_syn_BeneficialConversionFeaturePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xml:lang="en-US">Derivatives, Reporting Of Derivative Activity [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xml:lang="en-US">Derivatives, Reporting of Derivative Activity [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="lab_us-gaap_DerivativesReportingOfDerivativeActivity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OriginalIssueDiscountPolicyTextBlock" xlink:label="loc_syn_OriginalIssueDiscountPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OriginalIssueDiscountPolicyTextBlock" xml:lang="en-US">Original Issue Discount [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_OriginalIssueDiscountPolicyTextBlock" xml:lang="en-US">Original Issue Discount [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_OriginalIssueDiscountPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for issue of debt on discount to debt holder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OriginalIssueDiscountPolicyTextBlock" xlink:to="lab_syn_OriginalIssueDiscountPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockBasedPaymentArrangementsPolicyTextBlock" xlink:label="loc_syn_StockBasedPaymentArrangementsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockBasedPaymentArrangementsPolicyTextBlock" xml:lang="en-US">Stock Based Payment Arrangements [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockBasedPaymentArrangementsPolicyTextBlock" xml:lang="en-US">Stock Based Payment Arrangements [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockBasedPaymentArrangementsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy regarding stock based payment arrangements for various stocks.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockBasedPaymentArrangementsPolicyTextBlock" xlink:to="lab_syn_StockBasedPaymentArrangementsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xml:lang="en-US">Held-To-Maturity Securities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xml:lang="en-US">Held-to-maturity Securities [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EstimatedUsefulLifeOfAssetsTableTextBlock" xlink:label="loc_syn_EstimatedUsefulLifeOfAssetsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EstimatedUsefulLifeOfAssetsTableTextBlock" xml:lang="en-US">Estimated Useful Life Of Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_EstimatedUsefulLifeOfAssetsTableTextBlock" xml:lang="en-US">Estimated Useful Life Of Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_EstimatedUsefulLifeOfAssetsTableTextBlock" xml:lang="en-US">Tabular disclosure of estimated useful life of assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EstimatedUsefulLifeOfAssetsTableTextBlock" xlink:to="lab_syn_EstimatedUsefulLifeOfAssetsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" xlink:label="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Schedule Of Disposal Groups Including Discontinued Operations Balance Sheet and Additional Disclosures [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Disposal Groups Including Discontinued Operations Balance Sheet and Additional Disclosures [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">The tabular disclosure of disposal groups, which may include the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" xlink:to="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xlink:label="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Schedule Of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Schedule of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xml:lang="en-US">Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xlink:to="lab_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule Of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule Of Other Current Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="loc_syn_AccruedExpensesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedExpensesTableTextBlock" xml:lang="en-US">Accrued Expenses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AccruedExpensesTableTextBlock" xml:lang="en-US">Accrued Expenses [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedExpensesTableTextBlock" xml:lang="en-US">Tabular disclosure of accrued expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedExpensesTableTextBlock" xlink:to="lab_syn_AccruedExpensesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options and Warrants Vested and Expected To Vest Outstanding and Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding and Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested and Expected To Vest Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested and Expected To Vest Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to share based compensation arrangement by share based payment award non vested stock options and expected to vest outstanding and exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule Of Derivative Liabilities At Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfWarrantActivityTableTextBlock" xml:lang="en-US">Tabular disclosure of warrant activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfWarrantActivityTableTextBlock" xlink:to="lab_syn_ScheduleOfWarrantActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xml:lang="en-US">Tabular disclosure relates to warrant outstanding and exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:to="lab_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DueForLicenseAgreementsTableTextBlock" xlink:label="loc_syn_DueForLicenseAgreementsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DueForLicenseAgreementsTableTextBlock" xml:lang="en-US">Due For License Agreements [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DueForLicenseAgreementsTableTextBlock" xml:lang="en-US">Due For License Agreements [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DueForLicenseAgreementsTableTextBlock" xml:lang="en-US">Tabular disclosure of license agreements due.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DueForLicenseAgreementsTableTextBlock" xlink:to="lab_syn_DueForLicenseAgreementsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule Of Components Of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeEquipmentAndFurnitureMember" xlink:label="loc_syn_OfficeEquipmentAndFurnitureMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OfficeEquipmentAndFurnitureMember" xml:lang="en-US">Office Equipment and Furniture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OfficeEquipmentAndFurnitureMember" xlink:to="lab_syn_OfficeEquipmentAndFurnitureMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_LaboratoryEquipmentMember" xml:lang="en-US">Laboratory equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LaboratoryEquipmentMember" xlink:to="lab_syn_LaboratoryEquipmentMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ManufacturingEquipmentMember" xlink:label="loc_syn_ManufacturingEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ManufacturingEquipmentMember" xml:lang="en-US">Manufacturing Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ManufacturingEquipmentMember" xml:lang="en-US">Manufacturing equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ManufacturingEquipmentMember" xlink:to="lab_syn_ManufacturingEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Leasehold improvements and fixtures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_McleanHospitalMember" xlink:label="loc_syn_McleanHospitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_McleanHospitalMember" xml:lang="en-US">Mclean Hospital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_McleanHospitalMember" xlink:to="lab_syn_McleanHospitalMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MedaAgreementMember" xlink:label="loc_syn_MedaAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_MedaAgreementMember" xml:lang="en-US">Meda Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_MedaAgreementMember" xlink:to="lab_syn_MedaAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types Of Debt and Equity Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types Of Debt and Equity Securities [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaap_OptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionMember" xml:lang="en-US">Options Held [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionMember" xlink:to="lab_us-gaap_OptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MoneyMarketAccountsAndMutualFundsMember" xlink:label="loc_syn_MoneyMarketAccountsAndMutualFundsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_MoneyMarketAccountsAndMutualFundsMember" xml:lang="en-US">Money Market Accounts and Mutual Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_MoneyMarketAccountsAndMutualFundsMember" xlink:to="lab_syn_MoneyMarketAccountsAndMutualFundsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">Licenses Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">License revenue, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">License revenue, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue" xlink:to="lab_us-gaap_LicensesRevenue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LicenseRevenuePercentage" xlink:label="loc_syn_LicenseRevenuePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LicenseRevenuePercentage" xml:lang="en-US">License Revenue Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_LicenseRevenuePercentage" xml:lang="en-US">License Revenue Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_LicenseRevenuePercentage" xml:lang="en-US">The percentage of license revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LicenseRevenuePercentage" xlink:to="lab_syn_LicenseRevenuePercentage"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalMilestonePayments" xlink:label="loc_syn_AdditionalMilestonePayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdditionalMilestonePayments" xml:lang="en-US">Additional Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AdditionalMilestonePayments" xml:lang="en-US">Additional Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AdditionalMilestonePayments" xml:lang="en-US">The amount of additional milestone payment for revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdditionalMilestonePayments" xlink:to="lab_syn_AdditionalMilestonePayments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketingExpense" xml:lang="en-US">Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MarketingExpense" xml:lang="en-US">Marketing Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingExpense" xlink:to="lab_us-gaap_MarketingExpense"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RoyaltyRevenuePercentage" xlink:label="loc_syn_RoyaltyRevenuePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RoyaltyRevenuePercentage" xml:lang="en-US">Royalty Revenue Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_RoyaltyRevenuePercentage" xml:lang="en-US">Royalty Revenue Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_RoyaltyRevenuePercentage" xml:lang="en-US">The net royalty revenue percentage from sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RoyaltyRevenuePercentage" xlink:to="lab_syn_RoyaltyRevenuePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Impairment loss on goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, At Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Assets Of Disposal Group, Including Discontinued Operation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xml:lang="en-US">Assets of discontinued operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xml:lang="en-US">Disposal Group Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdeonaClinicalLaboratoryMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdeonaClinicalLaboratoryMember" xml:lang="en-US">Adeona Clinical Laboratory [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdeonaClinicalLaboratoryMember" xlink:to="lab_syn_AdeonaClinicalLaboratoryMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LaboratoryFeesNet" xml:lang="en-US">Laboratory Fees Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_LaboratoryFeesNet" xml:lang="en-US">Laboratory fees, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_LaboratoryFeesNet" xml:lang="en-US">The amount of expense provided in the period for laboratory costs incurred on or before the balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LaboratoryFeesNet" xlink:to="lab_syn_LaboratoryFeesNet"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xml:lang="en-US">Disposal Group Including Discontinued Operation Laboratory Services Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xml:lang="en-US">Cost of laboratory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xml:lang="en-US">Total costs related to laboratory services rendered by an entity during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:to="lab_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xml:lang="en-US">Disposal Group Including Discontinued Operation Impairment Loss On Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xml:lang="en-US">Impairment loss on goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xml:lang="en-US">The amount impairment loss on goodwill provided by the entity during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xlink:to="lab_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Total operating costs and expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Total operating costs and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Loss from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" xlink:label="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" xml:lang="en-US">Discontinued Operation Income Loss Of Discountinued Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" xml:lang="en-US">Other Income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" xlink:to="lab_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Discontinued Operation, Gain (Loss) On Disposal Of Discontinued Operation, Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xml:lang="en-US">Gain on sale of Adeona Clinical Laboratory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party Transactions, by Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdeonaClinicalLaboratoryLlcMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdeonaClinicalLaboratoryLlcMember" xml:lang="en-US">Adeona Clinical Laboratory, Llc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdeonaClinicalLaboratoryLlcMember" xlink:to="lab_syn_AdeonaClinicalLaboratoryLlcMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureTextBlockSupplementAbstract" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockSupplementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_us-gaap_AccountsReceivableGrossCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance For Doubtful Accounts Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Bad debt allowance - customer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Bad debt allowance - customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Prepaid Expenses Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Intrexon prepaid research and development expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_PrepaidExpensesResearchAndDevelopment" xml:lang="en-US">Sum of the amounts paid in advance for research and development expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PrepaidExpensesResearchAndDevelopment" xlink:to="lab_syn_PrepaidExpensesResearchAndDevelopment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xml:lang="en-US">Other Receivables, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherReceivablesGrossCurrent" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesGrossCurrent" xlink:to="lab_us-gaap_OtherReceivablesGrossCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Manufacturing equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ComputerAndOfficeEquipmentMember" xml:lang="en-US">Computer and Office Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ComputerAndOfficeEquipmentMember" xlink:to="lab_syn_ComputerAndOfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedVendorPayments" xml:lang="en-US">Accrued Vendor Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AccruedVendorPayments" xml:lang="en-US">Accrued vendor payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedVendorPayments" xml:lang="en-US">Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedVendorPayments" xlink:to="lab_syn_AccruedVendorPayments"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedCompensation" xlink:label="loc_syn_AccruedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AccruedCompensation" xml:lang="en-US">Accrued Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AccruedCompensation" xml:lang="en-US">Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AccruedCompensation" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to compensation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AccruedCompensation" xlink:to="lab_syn_AccruedCompensation"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Exercise Price One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xml:lang="en-US">Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk fee interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of option (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">Expected forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xml:lang="en-US">The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options Outstanding, Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding,Begining Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options Outstanding,Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Number of Options, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock for options exercised (in shares)</label>
<label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Number of Options Outstanding, Forfeited or expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Number of Options, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Options Exercisable, options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options, Balance exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per Share, Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per Share, Balance outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per Share, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per Share, Excercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures and Expirations In Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price per Share, Forfeited or expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited or expired, Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Contractual Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Balance outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value Outstanding,Begining Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value Outstanding,Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value Excisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Grant date fair value of options granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xlink:label="loc_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xml:lang="en-US">Share Basedcompensation Arrangement By Share Based Payment Award Options Outstanding Held By Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xml:lang="en-US">Outstanding options held by related parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xml:lang="en-US">Change in the options outstanding held by related parties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xlink:to="lab_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Held By Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xml:lang="en-US">Exercisable Options Held By Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xml:lang="en-US">Change in the options Exercisable held by related parties.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009200Member" xlink:label="loc_syn_RangeOfExercisePrice009200Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice009200Member" xml:lang="en-US">Range Of Exercise Price 009200 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_RangeOfExercisePrice009200Member" xml:lang="en-US">Range Of Exercise Price 0.09-2.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice009200Member" xlink:to="lab_syn_RangeOfExercisePrice009200Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice201300Member" xlink:label="loc_syn_RangeOfExercisePrice201300Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice201300Member" xml:lang="en-US">Range Of Exercise Price 201300 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_RangeOfExercisePrice201300Member" xml:lang="en-US">Range Of Exercise Price 2.01-3.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice201300Member" xlink:to="lab_syn_RangeOfExercisePrice201300Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice301600Member" xlink:label="loc_syn_RangeOfExercisePrice301600Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice301600Member" xml:lang="en-US">Range Of Exercise Price 301600 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_RangeOfExercisePrice301600Member" xml:lang="en-US">Range Of Exercise Price 3.01- 6.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice301600Member" xlink:to="lab_syn_RangeOfExercisePrice301600Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009600Member" xlink:label="loc_syn_RangeOfExercisePrice009600Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice009600Member" xml:lang="en-US">Range Of Exercise Price 009600 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_RangeOfExercisePrice009600Member" xml:lang="en-US">Range Of Exercise Price 0.09-6.00 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice009600Member" xlink:to="lab_syn_RangeOfExercisePrice009600Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009457Member" xlink:label="loc_syn_RangeOfExercisePrice009457Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice009457Member" xml:lang="en-US">Range Of Exercise Price 009457 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_RangeOfExercisePrice009457Member" xml:lang="en-US">Range Of Exercise Price 0.09-4.57 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice009457Member" xlink:to="lab_syn_RangeOfExercisePrice009457Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice458905Member" xlink:label="loc_syn_RangeOfExercisePrice458905Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice458905Member" xml:lang="en-US">Range Of Exercise Price 458905 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_RangeOfExercisePrice458905Member" xml:lang="en-US">Range Of Exercise Price 4.58-9.05 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice458905Member" xlink:to="lab_syn_RangeOfExercisePrice458905Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009905Member" xlink:label="loc_syn_RangeOfExercisePrice009905Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RangeOfExercisePrice009905Member" xml:lang="en-US">Range Of Exercise Price 009905 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_RangeOfExercisePrice009905Member" xml:lang="en-US">Range Of Exercise Price 0.09-9.05 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RangeOfExercisePrice009905Member" xlink:to="lab_syn_RangeOfExercisePrice009905Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OptionsExercisePrice" xlink:label="loc_syn_OptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OptionsExercisePrice" xml:lang="en-US">Options Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_OptionsExercisePrice" xml:lang="en-US">Range of Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_OptionsExercisePrice" xml:lang="en-US">Exercise price of the options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OptionsExercisePrice" xlink:to="lab_syn_OptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xml:lang="en-US">Non-vested December</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xml:lang="en-US">Non-vested - December</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xml:lang="en-US">Stock Options, Non-vested - December 31, 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xml:lang="en-US">Stock Options, Non-vested - December 31, 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xml:lang="en-US">The number of non-vested equity-based payment instruments, including stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xml:lang="en-US">Stock Options, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xml:lang="en-US">The number of grants made during the period including stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xml:lang="en-US">Stock Options, Vested/Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xml:lang="en-US">The number of equity-based payment instruments, including stock (or unit) options, that vested during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Forfeited In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xml:lang="en-US">Stock Options, Forfeited/Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xml:lang="en-US">The number of equity-based payment instruments, including stock (or unit) options, that were forfeited during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Non Vested Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Non-vested - December</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested - December 31, 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Non-vested - December 31, 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">The weighted average fair value of nonvested awards on equity-based plans including option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grants In Period Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">The weighted average fair value at grant date for nonvested equity-based awards issued during the period including stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Option Vested In Period Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested/Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">The weighted average fair value as of grant date pertaining to an equity-based award plan including stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Forfeitures Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited/Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans including stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Stock Options, Weighted average remaining period for vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Closing stock price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeAxis" xlink:label="loc_syn_PeriodTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PeriodTypeAxis" xml:lang="en-US">Period Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_PeriodTypeAxis" xml:lang="en-US">Period Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PeriodTypeAxis" xlink:to="lab_syn_PeriodTypeAxis"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeDomain" xlink:label="loc_syn_PeriodTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PeriodTypeDomain" xml:lang="en-US">Period Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_PeriodTypeDomain" xml:lang="en-US">Period Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PeriodTypeDomain" xlink:to="lab_syn_PeriodTypeDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommitmentDateMember" xlink:label="loc_syn_CommitmentDateMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CommitmentDateMember" xml:lang="en-US">Commitment Date [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CommitmentDateMember" xlink:to="lab_syn_CommitmentDateMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RemeasurementDateMember" xlink:label="loc_syn_RemeasurementDateMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RemeasurementDateMember" xml:lang="en-US">Remeasurement Date [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RemeasurementDateMember" xlink:to="lab_syn_RemeasurementDateMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Closing Stock Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xml:lang="en-US">Closing stock price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xml:lang="en-US">Closing stock price of share-based payment award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue" xlink:label="loc_syn_WarrantsFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsFairValue" xml:lang="en-US">Warrants Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_WarrantsFairValue" xml:lang="en-US">Warrants Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsFairValue" xml:lang="en-US">Warrants Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_syn_WarrantsFairValue" xml:lang="en-US">Balance at December 31, 2010</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_syn_WarrantsFairValue" xml:lang="en-US">Balance at December 31, 2011</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsFairValue" xml:lang="en-US">The fair value of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsFairValue" xlink:to="lab_syn_WarrantsFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, By Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Warrants, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Warrants, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Number of share warrants exercised during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xml:lang="en-US">Number of Warrants, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeited In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Warrants, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Warrants, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Warrants, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Range of Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAbstract" xlink:to="lab_syn_StockPurchaseWarrantsAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice1Member" xml:lang="en-US">Exercise Price 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice1Member" xml:lang="en-US">Exercise Price 1.14 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice1Member" xlink:to="lab_syn_ExercisePrice1Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice13Member" xlink:label="loc_syn_ExercisePrice13Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice13Member" xml:lang="en-US">Exercise Price 13 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice13Member" xml:lang="en-US">Exercise Price 1.32 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice13Member" xlink:to="lab_syn_ExercisePrice13Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 14 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ExercisePrice14Member" xml:lang="en-US">Exercise Price 1.60 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice14Member" xlink:to="lab_syn_ExercisePrice14Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice220Member" xml:lang="en-US">Exercise Price 220 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice220Member" xml:lang="en-US">Exercise Price 2.20 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice220Member" xlink:to="lab_syn_ExercisePrice220Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice222Member" xml:lang="en-US">Exercise Price 2 22 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice222Member" xml:lang="en-US">Exercise Price 2.22 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice222Member" xlink:to="lab_syn_ExercisePrice222Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice330Member" xml:lang="en-US">Exercise Price 3 30 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice330Member" xml:lang="en-US">Exercise Price 3.30 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice330Member" xlink:to="lab_syn_ExercisePrice330Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice375Member" xml:lang="en-US">Exercise Price 3 75 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice375Member" xml:lang="en-US">Exercise Price 3.75 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice375Member" xlink:to="lab_syn_ExercisePrice375Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ExercisePrice199Member" xml:lang="en-US">Exercise Price 199 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ExercisePrice199Member" xml:lang="en-US">Exercise Price 1.99 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ExercisePrice199Member" xlink:to="lab_syn_ExercisePrice199Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisePrice" xml:lang="en-US">Exercise price of the warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisePrice" xlink:to="lab_syn_WarrantsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Warrants Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Warrants Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xml:lang="en-US">The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2007Member" xml:lang="en-US">Stock Plan 2007 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2007Member" xml:lang="en-US">2007 Stock Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2007Member" xlink:to="lab_syn_StockPlan2007Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2010Member" xml:lang="en-US">Stock Plan 2010 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2010Member" xml:lang="en-US">2010 Stock Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2010Member" xlink:to="lab_syn_StockPlan2010Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:label="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockOptionsAndStockAppreciationRightsSarsMember" xml:lang="en-US">Stock Options and Stock Appreciation Rights Sars [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:to="lab_syn_StockOptionsAndStockAppreciationRightsSarsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmployeesAndConsultantsMember" xml:lang="en-US">Employees and Consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeesAndConsultantsMember" xlink:to="lab_syn_EmployeesAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsAxis" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsAxis" xml:lang="en-US">Stock Purchase Warrants Aggreements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsAxis" xml:lang="en-US">Stock Purchase Warrants Aggreements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis" xlink:to="lab_syn_StockPurchaseWarrantsAggreementsAxis"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsDomain" xml:lang="en-US">Stock Purchase Warrants Aggreements [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsDomain" xml:lang="en-US">Stock Purchase Warrants Aggreements [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockPurchaseWarrantsAggreementsDomain" xml:lang="en-US">stock purchase aggrements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain" xlink:to="lab_syn_StockPurchaseWarrantsAggreementsDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xml:lang="en-US">Common Stock Purchase Agreement With Single Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:to="lab_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:label="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xml:lang="en-US">Stock Purchase Agreement With Three Institutional Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:to="lab_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xml:lang="en-US">Common Stock Purchase Agreement With Institutional Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:to="lab_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:label="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xml:lang="en-US">Consulting Agreement For Financial Advisory Services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:to="lab_syn_ConsultingAgreementForFinancialAdvisoryServicesMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CdfourBiosciencesIncMember" xlink:label="loc_syn_CdfourBiosciencesIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CdfourBiosciencesIncMember" xml:lang="en-US">Cdfour Biosciences Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CdfourBiosciencesIncMember" xlink:to="lab_syn_CdfourBiosciencesIncMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EpitopeMember" xlink:label="loc_syn_EpitopeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EpitopeMember" xml:lang="en-US">Epitope [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EpitopeMember" xlink:to="lab_syn_EpitopeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPlan2001Member" xml:lang="en-US">Stock Plan 2001 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPlan2001Member" xml:lang="en-US">2001 Stock Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPlan2001Member" xlink:to="lab_syn_StockPlan2001Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Issuance Of Warrants To Purchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Issuance Of Warrants To Purchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants issued to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:to="lab_syn_IssuanceOfWarrantsToPurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisePricePerShare" xlink:label="loc_syn_WarrantsExercisePricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExercisePricePerShare" xml:lang="en-US">Warrants Exercise Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExercisePricePerShare" xml:lang="en-US">Warrants Exercise Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisePricePerShare" xml:lang="en-US">per share amount of the warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisePricePerShare" xlink:to="lab_syn_WarrantsExercisePricePerShare"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LifeOfWarrants" xlink:label="loc_syn_LifeOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_LifeOfWarrants" xml:lang="en-US">Life Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_LifeOfWarrants" xml:lang="en-US">Life Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_LifeOfWarrants" xml:lang="en-US">Life of the warrant issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_LifeOfWarrants" xlink:to="lab_syn_LifeOfWarrants"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExpirationDate" xlink:label="loc_syn_WarrantsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsExpirationDate" xml:lang="en-US">Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsExpirationDate" xml:lang="en-US">Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExpirationDate" xml:lang="en-US">Expiration date of the warrant issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExpirationDate" xlink:to="lab_syn_WarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class Of Warrant Or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFloorPricePerShare" xlink:label="loc_syn_WarrantsFloorPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsFloorPricePerShare" xml:lang="en-US">Warrants Floor Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsFloorPricePerShare" xml:lang="en-US">Warrants Floor Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsFloorPricePerShare" xml:lang="en-US">Floor price per share amount of the warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsFloorPricePerShare" xlink:to="lab_syn_WarrantsFloorPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_invest_InvestmentWarrantsExpirationDate" xml:lang="en-US">Investment Warrants Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentWarrantsExpirationDate" xlink:to="lab_invest_InvestmentWarrantsExpirationDate"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xml:lang="en-US">The number of exercisable share warrants that may be converted as of the balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">As of the balance sheet date, the number of Warrants into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssuanceOfWarrantsExpensesRecognized" xlink:label="loc_syn_IssuanceOfWarrantsExpensesRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IssuanceOfWarrantsExpensesRecognized" xml:lang="en-US">Issuance Of Warrants Expenses Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IssuanceOfWarrantsExpensesRecognized" xml:lang="en-US">Issunance Of Warrants Expenses Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IssuanceOfWarrantsExpensesRecognized" xml:lang="en-US">Expenses recognized from issuance of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IssuanceOfWarrantsExpensesRecognized" xlink:to="lab_syn_IssuanceOfWarrantsExpensesRecognized"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xml:lang="en-US">Exercisable term of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue1" xlink:label="loc_syn_WarrantsFairValue1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantsFairValue1" xml:lang="en-US">Warrants Fair Value 1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantsFairValue1" xml:lang="en-US">Warrants Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsFairValue1" xml:lang="en-US">Fair value of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsFairValue1" xlink:to="lab_syn_WarrantsFairValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseInFairValueOfWarrantLiability" xlink:label="loc_syn_IncreaseInFairValueOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseInFairValueOfWarrantLiability" xml:lang="en-US">Increase In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseInFairValueOfWarrantLiability" xml:lang="en-US">The increase during the period in the fair value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseInFairValueOfWarrantLiability" xml:lang="en-US">Increase In Fair Value Of Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseInFairValueOfWarrantLiability" xlink:to="lab_syn_IncreaseInFairValueOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Warrant Exercisable Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xml:lang="en-US">Exercisable perice of warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Warrant Exercisable Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Warrant Exercisable Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xml:lang="en-US">Exercisable period of warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Warrant Exercisable Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xlink:to="lab_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xlink:label="loc_syn_AntiDilutionPriceProtectionWarrantsPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xml:lang="en-US">Anti Dilution Price Protection Warrants Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xml:lang="en-US">Per share value of anti dilution price protection for warrants.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xml:lang="en-US">Anti Dilution Price Protection Warrants Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xlink:to="lab_syn_AntiDilutionPriceProtectionWarrantsPricePerShare"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DecreaseInFairValueOfWarrantLiability" xlink:label="loc_syn_DecreaseInFairValueOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DecreaseInFairValueOfWarrantLiability" xml:lang="en-US">Decrease In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DecreaseInFairValueOfWarrantLiability" xml:lang="en-US">The decrease during the period in the fair value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DecreaseInFairValueOfWarrantLiability" xml:lang="en-US">Decrease In Fair Value Of Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DecreaseInFairValueOfWarrantLiability" xlink:to="lab_syn_DecreaseInFairValueOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale Of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale Of Stock, Name Of Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IntrexonMember" xml:lang="en-US">Intrexon [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IntrexonMember" xlink:to="lab_syn_IntrexonMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PrevAbrLlcMember" xml:lang="en-US">Prev Abr Llc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PrevAbrLlcMember" xlink:to="lab_syn_PrevAbrLlcMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds From Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Fair Value Of Stock Issued During Period Value Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Fair Value Of Stock Issued During Period Value Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xml:lang="en-US">Fair value of stock issued during the period as a result of consulting fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xlink:to="lab_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForConsultingFeesPricePerShare" xlink:label="loc_syn_SaleOfStockForConsultingFeesPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_SaleOfStockForConsultingFeesPricePerShare" xml:lang="en-US">Sale Of Stock For Consulting Fees Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_SaleOfStockForConsultingFeesPricePerShare" xml:lang="en-US">Sale Of Stock For Consulting Fees Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_SaleOfStockForConsultingFeesPricePerShare" xml:lang="en-US">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold for consulting service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_SaleOfStockForConsultingFeesPricePerShare" xlink:to="lab_syn_SaleOfStockForConsultingFeesPricePerShare"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xml:lang="en-US">Stock Issued During Period Shares For Exercise Of Stock Options and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xml:lang="en-US">Stock Issued During Period Shares For Exercise Of Stock Options And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xml:lang="en-US">Number of shares issued during the period in connection with the exercise of stock options and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xlink:to="lab_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForEmploymentServicePricePerShare" xlink:label="loc_syn_SaleOfStockForEmploymentServicePricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_SaleOfStockForEmploymentServicePricePerShare" xml:lang="en-US">Sale Of Stock For Employment Service Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_SaleOfStockForEmploymentServicePricePerShare" xml:lang="en-US">Sale Of Stock For Employment Service Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_SaleOfStockForEmploymentServicePricePerShare" xml:lang="en-US">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold for Employment service.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_SaleOfStockForEmploymentServicePricePerShare" xlink:to="lab_syn_SaleOfStockForEmploymentServicePricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds From Issuance Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Cashless Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Cashless Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xml:lang="en-US">Number of cashless stock warrants exercised during the current period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xlink:to="lab_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForChannelAgreementPricePerShare" xlink:label="loc_syn_SaleOfStockForChannelAgreementPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_SaleOfStockForChannelAgreementPricePerShare" xml:lang="en-US">Sale Of Stock For Channel Agreement Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_SaleOfStockForChannelAgreementPricePerShare" xml:lang="en-US">Sale Of Stock For Channel Agreement Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_SaleOfStockForChannelAgreementPricePerShare" xml:lang="en-US">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold for Channel Agreement with Intrexon.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_SaleOfStockForChannelAgreementPricePerShare" xlink:to="lab_syn_SaleOfStockForChannelAgreementPricePerShare"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xml:lang="en-US">Number of stock warrants exercised during the current period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="lab_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds From Issuance Of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaap_NoninterestExpenseOfferingCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestExpenseOfferingCost" xml:lang="en-US">Noninterest Expense Offering Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoninterestExpenseOfferingCost" xml:lang="en-US">Noninterest Expense Offering Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestExpenseOfferingCost" xlink:to="lab_us-gaap_NoninterestExpenseOfferingCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xml:lang="en-US">Other Commitment, Due In Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xml:lang="en-US">2013</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xml:lang="en-US">Other Commitment, Due In Second Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xml:lang="en-US">2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:to="lab_us-gaap_OtherCommitmentDueInSecondYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">Other Commitment, Due In Third Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_us-gaap_OtherCommitmentDueInThirdYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Other Commitment, Due In Fourth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFourthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xml:lang="en-US">Other Commitment, Due In Fifth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xml:lang="en-US">2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFifthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xml:lang="en-US">Other Commitment, Due In Fourth and Fifth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFourthAndFifthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xml:lang="en-US">Deferred Bonus and Profit Sharing Plan By Title Of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xml:lang="en-US">Deferred Bonus and Profit Sharing Plan by Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DrKuoMember" xlink:label="loc_syn_DrKuoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DrKuoMember" xml:lang="en-US">Dr Kuo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DrKuoMember" xml:lang="en-US">Dr.Kuo [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DrKuoMember" xlink:to="lab_syn_DrKuoMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_JeffreyRileyMember" xlink:label="loc_syn_JeffreyRileyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_JeffreyRileyMember" xml:lang="en-US">Jeffrey Riley [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_JeffreyRileyMember" xlink:to="lab_syn_JeffreyRileyMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CEvanBallantyneMember" xlink:label="loc_syn_CEvanBallantyneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CEvanBallantyneMember" xml:lang="en-US">C Evan Ballantyne [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_CEvanBallantyneMember" xml:lang="en-US">C. Evan Ballantyne [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CEvanBallantyneMember" xlink:to="lab_syn_CEvanBallantyneMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnArborMichiganMember" xlink:label="loc_syn_AnnArborMichiganMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AnnArborMichiganMember" xml:lang="en-US">Ann Arbor, Michigan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AnnArborMichiganMember" xlink:to="lab_syn_AnnArborMichiganMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RockvilleMarylandMember" xlink:label="loc_syn_RockvilleMarylandMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RockvilleMarylandMember" xml:lang="en-US">Rockville, Maryland [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RockvilleMarylandMember" xlink:to="lab_syn_RockvilleMarylandMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category Of Item Purchased [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xml:lang="en-US">Category of Item Purchased [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-Term Purchase Commitment, Category Of Item Purchased [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xml:lang="en-US">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xml:lang="en-US">Research and Development Arrangement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityByLocationAxis" xlink:label="loc_dei_EntityByLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityByLocationAxis" xml:lang="en-US">Entity By Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityByLocationAxis" xml:lang="en-US">Entity by Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityByLocationAxis" xlink:to="lab_dei_EntityByLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LocationDomain" xlink:label="loc_dei_LocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocationDomain" xml:lang="en-US">Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_LocationDomain" xml:lang="en-US">Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocationDomain" xlink:to="lab_dei_LocationDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeSpaceInAnnArborMember" xlink:label="loc_syn_OfficeSpaceInAnnArborMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OfficeSpaceInAnnArborMember" xml:lang="en-US">Office Space In Ann Arbor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OfficeSpaceInAnnArborMember" xlink:to="lab_syn_OfficeSpaceInAnnArborMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeSpaceInRockvilleMember" xlink:label="loc_syn_OfficeSpaceInRockvilleMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OfficeSpaceInRockvilleMember" xml:lang="en-US">Office Space In Rockville [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OfficeSpaceInRockvilleMember" xlink:to="lab_syn_OfficeSpaceInRockvilleMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodAxis" xlink:label="loc_syn_AnnualPaymentEffectivePeriodAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AnnualPaymentEffectivePeriodAxis" xml:lang="en-US">Annual Payment Effective Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AnnualPaymentEffectivePeriodAxis" xml:lang="en-US">Annual Payment Effective Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AnnualPaymentEffectivePeriodAxis" xlink:to="lab_syn_AnnualPaymentEffectivePeriodAxis"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodDomain" xlink:label="loc_syn_AnnualPaymentEffectivePeriodDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AnnualPaymentEffectivePeriodDomain" xml:lang="en-US">Annual Payment Effective Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AnnualPaymentEffectivePeriodDomain" xml:lang="en-US">Annual Payment Effective Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AnnualPaymentEffectivePeriodDomain" xlink:to="lab_syn_AnnualPaymentEffectivePeriodDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_December312014Member" xlink:label="loc_syn_December312014Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_December312014Member" xml:lang="en-US">December 31, 2014 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_December312014Member" xlink:to="lab_syn_December312014Member"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_December312015Member" xlink:label="loc_syn_December312015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_December312015Member" xml:lang="en-US">December 31, 2015 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_December312015Member" xlink:to="lab_syn_December312015Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xml:lang="en-US">Collaborative Arrangements and Non-Collaborative Arrangements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PhaseIClinicalTrialsMember" xlink:label="loc_syn_PhaseIClinicalTrialsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PhaseIClinicalTrialsMember" xml:lang="en-US">Phase I Clinical Trials [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PhaseIClinicalTrialsMember" xlink:to="lab_syn_PhaseIClinicalTrialsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PhaseIiiClinicalTrialsMember" xlink:label="loc_syn_PhaseIiiClinicalTrialsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PhaseIiiClinicalTrialsMember" xml:lang="en-US">Phase Iii Clinical Trials [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PhaseIiiClinicalTrialsMember" xlink:to="lab_syn_PhaseIiiClinicalTrialsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_NdaSubmissionInUsMember" xlink:label="loc_syn_NdaSubmissionInUsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_NdaSubmissionInUsMember" xml:lang="en-US">Nda Submission In Us [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_NdaSubmissionInUsMember" xlink:to="lab_syn_NdaSubmissionInUsMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EuropeanMedicinesAgencyApprovalMember" xlink:label="loc_syn_EuropeanMedicinesAgencyApprovalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EuropeanMedicinesAgencyApprovalMember" xml:lang="en-US">European Medicines Agency Approval [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EuropeanMedicinesAgencyApprovalMember" xlink:to="lab_syn_EuropeanMedicinesAgencyApprovalMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RegulatoryApprovalInAsianCountryMember" xlink:label="loc_syn_RegulatoryApprovalInAsianCountryMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RegulatoryApprovalInAsianCountryMember" xml:lang="en-US">Regulatory Approval In Asian Country [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RegulatoryApprovalInAsianCountryMember" xlink:to="lab_syn_RegulatoryApprovalInAsianCountryMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_QuarterlyInstallmentsPaymentPeriodAxis" xml:lang="en-US">Quarterly Installments Payment Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_QuarterlyInstallmentsPaymentPeriodAxis" xml:lang="en-US">Quarterly Installments Payment Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:to="lab_syn_QuarterlyInstallmentsPaymentPeriodAxis"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_QuarterlyInstallmentsPaymentPeriodDomain" xml:lang="en-US">Quarterly Installments Payment Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_QuarterlyInstallmentsPaymentPeriodDomain" xml:lang="en-US">Quarterly Installments Payment Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:to="lab_syn_QuarterlyInstallmentsPaymentPeriodDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FirstYearMember" xlink:label="loc_syn_FirstYearMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_FirstYearMember" xml:lang="en-US">First Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_FirstYearMember" xlink:to="lab_syn_FirstYearMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SecondYearMember" xlink:label="loc_syn_SecondYearMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_SecondYearMember" xml:lang="en-US">Second Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_SecondYearMember" xlink:to="lab_syn_SecondYearMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ThirdYearMember" xlink:label="loc_syn_ThirdYearMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ThirdYearMember" xml:lang="en-US">Third Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ThirdYearMember" xlink:to="lab_syn_ThirdYearMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xml:lang="en-US">Line Of Credit Facility, Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPayment" xml:lang="en-US">Line of Credit Facility, Periodic Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPayment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xml:lang="en-US">Line Of Credit Facility, Periodic Payment, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested In Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultingFees" xlink:label="loc_syn_ConsultingFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ConsultingFees" xml:lang="en-US">Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ConsultingFees" xml:lang="en-US">Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ConsultingFees" xml:lang="en-US">The amount of expense in the period for consulting fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ConsultingFees" xlink:to="lab_syn_ConsultingFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due In Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLeaseLeasingTerm" xlink:label="loc_syn_OperatingLeaseLeasingTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OperatingLeaseLeasingTerm" xml:lang="en-US">Operating Lease Leasing Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_OperatingLeaseLeasingTerm" xml:lang="en-US">The period at which the operating lease arrangements made.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_OperatingLeaseLeasingTerm" xml:lang="en-US">Operating Lease Leasing Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OperatingLeaseLeasingTerm" xlink:to="lab_syn_OperatingLeaseLeasingTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentForPastPatentExpenses" xlink:label="loc_syn_AnnualPaymentForPastPatentExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AnnualPaymentForPastPatentExpenses" xml:lang="en-US">Annual Payment For Past Patent Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AnnualPaymentForPastPatentExpenses" xml:lang="en-US">The amount annual payment represents the License Agreement provides that the University is entitled to payment of past patent expenses.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AnnualPaymentForPastPatentExpenses" xml:lang="en-US">Annual Payment For Past Patent Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AnnualPaymentForPastPatentExpenses" xlink:to="lab_syn_AnnualPaymentForPastPatentExpenses"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MilestonePayment" xlink:label="loc_syn_MilestonePayment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_MilestonePayment" xml:lang="en-US">A Milestone Payment is an Authority payment made to a Contractor which is linked to the Contractor delivering a service or commodity such that, should the Agreement be terminated at the point of payment.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_MilestonePayment" xlink:to="lab_syn_MilestonePayment"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ResearchAgreementFixedFee" xlink:label="loc_syn_ResearchAgreementFixedFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ResearchAgreementFixedFee" xml:lang="en-US">Research Agreement Fixed Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ResearchAgreementFixedFee" xml:lang="en-US">The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ResearchAgreementFixedFee" xml:lang="en-US">Research Agreement Fixed Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ResearchAgreementFixedFee" xlink:to="lab_syn_ResearchAgreementFixedFee"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CashPaymentForLicenseAgreement" xlink:label="loc_syn_CashPaymentForLicenseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_CashPaymentForLicenseAgreement" xml:lang="en-US">Cash Payment For License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_CashPaymentForLicenseAgreement" xml:lang="en-US">The amount of initial cash payment upon execution of the license Agreement during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_CashPaymentForLicenseAgreement" xml:lang="en-US">Cash Payment For License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CashPaymentForLicenseAgreement" xlink:to="lab_syn_CashPaymentForLicenseAgreement"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalCashPaymentForLicenseAgreement" xlink:label="loc_syn_AdditionalCashPaymentForLicenseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdditionalCashPaymentForLicenseAgreement" xml:lang="en-US">Additional Cash Payment For License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AdditionalCashPaymentForLicenseAgreement" xml:lang="en-US">The amount of additional cash payment for license agreement.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AdditionalCashPaymentForLicenseAgreement" xml:lang="en-US">Additional Cash Payment For License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdditionalCashPaymentForLicenseAgreement" xlink:to="lab_syn_AdditionalCashPaymentForLicenseAgreement"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:label="loc_syn_UnregisteredSharesIssuedToLicenseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_UnregisteredSharesIssuedToLicenseAgreement" xml:lang="en-US">Unregistered Shares Issued To License Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_UnregisteredSharesIssuedToLicenseAgreement" xml:lang="en-US">The number of shares issued during the period for license agreement.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_UnregisteredSharesIssuedToLicenseAgreement" xml:lang="en-US">Unregistered Shares Issued To License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:to="lab_syn_UnregisteredSharesIssuedToLicenseAgreement"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalConsiderationPayable" xlink:label="loc_syn_AdditionalConsiderationPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_AdditionalConsiderationPayable" xml:lang="en-US">Additional Consideration Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_AdditionalConsiderationPayable" xml:lang="en-US">Description related to additional consideration payable.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_AdditionalConsiderationPayable" xml:lang="en-US">Additional Consideration Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_AdditionalConsiderationPayable" xlink:to="lab_syn_AdditionalConsiderationPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityIssuancePerShareAmount" xml:lang="en-US">Equity Issuance, Per Share Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityIssuancePerShareAmount" xml:lang="en-US">Equity Issuance, Per Share Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityIssuancePerShareAmount" xlink:to="lab_us-gaap_EquityIssuancePerShareAmount"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PartialConsiderationForExecution" xlink:label="loc_syn_PartialConsiderationForExecution_1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_PartialConsiderationForExecution" xml:lang="en-US">Partial Consideration For Execution</label>

<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_PartialConsiderationForExecution" xml:lang="en-US">Partial Consideration For The Execution</label>
<label xlink:type="resource" xlink:label="lab_syn_PartialConsiderationForExecution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xml:lang="en-US">Partial Consideration For The Execution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_PartialConsiderationForExecution_1" xlink:to="lab_syn_PartialConsiderationForExecution"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_PartialConsiderationForExecution" xml:lang="en-US">Description related to partial consideration for the execution and delivery of the Initial Channel Agreement.</label>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments For Repurchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare" xml:lang="en-US">Subsidiary Or Equity Method Investee, Price-Per-Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare" xml:lang="en-US">Subsidiary or Equity Method Investee, Price-Per-Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xml:lang="en-US">Stock Repurchase Program, Remaining Number Of Shares Authorized To Be Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xml:lang="en-US">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Computed ''expected" tax benefit - Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Computed "expected" tax benefit - State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xml:lang="en-US">Income Tax Reconciliation, Nondeductible Expense, Meals and Entertainment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xml:lang="en-US">Meals, entertainment and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Income Tax Reconciliation, Nondeductible Expense, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US">Non-deductible stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpensesForIncomeTax" xlink:label="loc_syn_WarrantExpensesForIncomeTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantExpensesForIncomeTax" xml:lang="en-US">Warrant Expenses For Income Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantExpensesForIncomeTax" xml:lang="en-US">Warrant expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantExpensesForIncomeTax" xml:lang="en-US">The amount of expenses incurred for warrants during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantExpensesForIncomeTax" xlink:to="lab_syn_WarrantExpensesForIncomeTax"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantExpenses" xlink:label="loc_syn_ChangeInFairValueOfWarrantExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ChangeInFairValueOfWarrantExpenses" xml:lang="en-US">Change In Fair Value Of Warrant Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ChangeInFairValueOfWarrantExpenses" xml:lang="en-US">Change in fair value of warrant expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ChangeInFairValueOfWarrantExpenses" xml:lang="en-US">The increase (decrease) during the period in the carrying value of derivative instruments reported as expenses that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ChangeInFairValueOfWarrantExpenses" xlink:to="lab_syn_ChangeInFairValueOfWarrantExpenses"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RealizedLossOnDebtSecurities" xlink:label="loc_syn_RealizedLossOnDebtSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_RealizedLossOnDebtSecurities" xml:lang="en-US">Realized Loss On Debt Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_RealizedLossOnDebtSecurities" xml:lang="en-US">Realized loss on debt securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_RealizedLossOnDebtSecurities" xml:lang="en-US">The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_RealizedLossOnDebtSecurities" xlink:to="lab_syn_RealizedLossOnDebtSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Change In Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Expected tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Expected tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components Of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="loc_syn_DeferredTaxAssetsStocksIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DeferredTaxAssetsStocksIssuedForServices" xml:lang="en-US">Deferred Tax Assets Stocks Issued For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DeferredTaxAssetsStocksIssuedForServices" xml:lang="en-US">Stock issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DeferredTaxAssetsStocksIssuedForServices" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stocks issued for services.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_DeferredTaxAssetsStocksIssuedForServices" xml:lang="en-US">Stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DeferredTaxAssetsStocksIssuedForServices" xlink:to="lab_syn_DeferredTaxAssetsStocksIssuedForServices"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsBadDebts" xlink:label="loc_syn_DeferredTaxAssetsBadDebts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DeferredTaxAssetsBadDebts" xml:lang="en-US">Deferred Tax Assets Bad Debts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DeferredTaxAssetsBadDebts" xml:lang="en-US">Bad debt - change in allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DeferredTaxAssetsBadDebts" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from bad debts.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_DeferredTaxAssetsBadDebts" xml:lang="en-US">Bad debt - change in allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DeferredTaxAssetsBadDebts" xlink:to="lab_syn_DeferredTaxAssetsBadDebts"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xml:lang="en-US">Deferred Tax Assets Stock Issued For Acquisition Of Program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xml:lang="en-US">Stock issued for acquisition of program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Stock issued for acquisition of program.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xml:lang="en-US">Stock issued for acquisition of program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xml:lang="en-US">Stock issued for acquisition of program</label>
<label xlink:type="resource" xlink:label="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Stock issued for acquisition of program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:to="lab_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry-forward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry-forward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry-forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total gross deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total gross deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total gross deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total gross deferred tax assets</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xml:lang="en-US">Total gross deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceAmount" xlink:label="loc_us-gaap_ValuationAllowanceAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceAmount" xml:lang="en-US">Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceAmount" xml:lang="en-US">Less valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceAmount" xml:lang="en-US">Less valuation allowance</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_ValuationAllowanceAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Less valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceAmount" xlink:to="lab_us-gaap_ValuationAllowanceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodAxis" xlink:label="loc_syn_OperatingLossForwardPeriodAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OperatingLossForwardPeriodAxis" xml:lang="en-US">Operating Loss Forward Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_OperatingLossForwardPeriodAxis" xml:lang="en-US">Operating Loss Forward Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OperatingLossForwardPeriodAxis" xlink:to="lab_syn_OperatingLossForwardPeriodAxis"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodDomain" xlink:label="loc_syn_OperatingLossForwardPeriodDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_OperatingLossForwardPeriodDomain" xml:lang="en-US">Operating Loss Forward Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_OperatingLossForwardPeriodDomain" xml:lang="en-US">Operating Loss Forward Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_OperatingLossForwardPeriodDomain" xml:lang="en-US">Type of operating loss forward period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_OperatingLossForwardPeriodDomain" xlink:to="lab_syn_OperatingLossForwardPeriodDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_TaxableIncomeExpiringThrough2032Member" xlink:label="loc_syn_TaxableIncomeExpiringThrough2032Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_TaxableIncomeExpiringThrough2032Member" xml:lang="en-US">Taxable Income Expiring Through 2032 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_TaxableIncomeExpiringThrough2032Member" xlink:to="lab_syn_TaxableIncomeExpiringThrough2032Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, At Federal Statutory Income Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Enacted Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xml:lang="en-US">Title Of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BoardOfDirectorsAndOfficersMember" xlink:label="loc_syn_BoardOfDirectorsAndOfficersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BoardOfDirectorsAndOfficersMember" xml:lang="en-US">Board Of Directors and Officers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BoardOfDirectorsAndOfficersMember" xlink:to="lab_syn_BoardOfDirectorsAndOfficersMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MrKanzerMember" xlink:label="loc_syn_MrKanzerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_MrKanzerMember" xml:lang="en-US">Mr Kanzer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_MrKanzerMember" xlink:to="lab_syn_MrKanzerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xml:lang="en-US">Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs, By Report Line [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xml:lang="en-US">Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs, Report Line [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-Based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmploymentAgreementDescrption" xlink:label="loc_syn_EmploymentAgreementDescrption"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_EmploymentAgreementDescrption" xml:lang="en-US">Employment Agreement Descrption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_EmploymentAgreementDescrption" xml:lang="en-US">The description explains about the employment agreement between the company and related party during the period.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_EmploymentAgreementDescrption" xml:lang="en-US">Employment Agreement Descrption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmploymentAgreementDescrption" xlink:to="lab_syn_EmploymentAgreementDescrption"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestExpenseDirectorsFees" xml:lang="en-US">Noninterest Expense Directors Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NoninterestExpenseDirectorsFees" xml:lang="en-US">Noninterest Expense Directors Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestExpenseDirectorsFees" xlink:to="lab_us-gaap_NoninterestExpenseDirectorsFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_1"/>
<label xlink:type="resource" xlink:label="lab_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_1" xlink:to="lab_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</label>

<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement_1"/>
<label xlink:type="resource" xlink:label="lab_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Stock Issued During Period Fair Value For Exclusive Channel Collaboration Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement_1" xlink:to="lab_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" xml:lang="en-US">Fair Value of stock issued during the period For Exclusive Channel Collaboration Agreement.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="loc_us-gaap_RegistrationPaymentArrangementTerm"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_RegistrationPaymentArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Registration Payment Arrangement, Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementTerm" xlink:to="lab_us-gaap_RegistrationPaymentArrangementTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementSettlementAlternatives" xlink:label="loc_us-gaap_RegistrationPaymentArrangementSettlementAlternatives"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_RegistrationPaymentArrangementSettlementAlternatives" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Registration Payment Arrangement, Settlement Alternatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementSettlementAlternatives" xlink:to="lab_us-gaap_RegistrationPaymentArrangementSettlementAlternatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Registration Payment Arrangement by Arrangement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="lab_us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Registration Payment Arrangement, Arrangement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="lab_us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IndMilestoneEventMember" xlink:label="loc_syn_IndMilestoneEventMember"/>
<label xlink:type="resource" xlink:label="lab_syn_IndMilestoneEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Ind Milestone Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IndMilestoneEventMember" xlink:to="lab_syn_IndMilestoneEventMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ApprovalMilestoneEventMember" xlink:label="loc_syn_ApprovalMilestoneEventMember"/>
<label xlink:type="resource" xlink:label="lab_syn_ApprovalMilestoneEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Approval Milestone Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ApprovalMilestoneEventMember" xlink:to="lab_syn_ApprovalMilestoneEventMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FieldExpansionFeeMember" xlink:label="loc_syn_FieldExpansionFeeMember"/>
<label xlink:type="resource" xlink:label="lab_syn_FieldExpansionFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Field Expansion Fee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_FieldExpansionFeeMember" xlink:to="lab_syn_FieldExpansionFeeMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GainLossOnSaleOfDiscontinuedOperations" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperations_1"/>
<label xlink:type="resource" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Gain Loss On Sale Of Discontinued Operations</label>
<label xlink:type="resource" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Gain on sale of discontinued operations</label>
<label xlink:type="resource" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Gain on sale of discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_GainLossOnSaleOfDiscontinuedOperations_1" xlink:to="lab_syn_GainLossOnSaleOfDiscontinuedOperations"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_GainLossOnSaleOfDiscontinuedOperations" xml:lang="en-US">Gain loss on sale of discontinued operations during the period.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Equity Issued in Business Combination, Fair Value Disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockClosingPricePerShare" xlink:label="loc_syn_CommonStockClosingPricePerShare_1"/>
<label xlink:type="resource" xlink:label="lab_syn_CommonStockClosingPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Common Stock Closing Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_CommonStockClosingPricePerShare_1" xlink:to="lab_syn_CommonStockClosingPricePerShare"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_CommonStockClosingPricePerShare" xml:lang="en-US">Common stock closing price per share.</label>

<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaap_NotesReceivableNet"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Financing Receivable, Net, Total</label>

<label xlink:type="resource" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Notes Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Liability for Uncertain Tax Positions, Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare_1"/>
<label xlink:type="resource" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Warrants Exercisable Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantsExercisablePricePerShare_1" xlink:to="lab_syn_WarrantsExercisablePricePerShare"/><label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WarrantsExercisablePricePerShare" xml:lang="en-US">Warrants exercisable price per share.</label>













<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmployeeMember" xlink:label="loc_syn_EmployeeMember"/>
<label xlink:type="resource" xlink:label="lab_syn_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Employee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_EmployeeMember" xlink:to="lab_syn_EmployeeMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultantMember" xlink:label="loc_syn_ConsultantMember"/>
<label xlink:type="resource" xlink:label="lab_syn_ConsultantMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Consultant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ConsultantMember" xlink:to="lab_syn_ConsultantMember"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:label="lab_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">General And Administrative Expenses And Research And Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:to="lab_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>syn-20121231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.0.2.9 by DataTracks on Friday, April 12, 2013 04:05:58 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#OrganizationAndNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensation" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensation"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockholdersEquity" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitments" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockRepurchaseProgram" roleURI="http://www.syntheticbiologics.com/role/StockRepurchaseProgram"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxes" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#RelatedPartyTransactions" roleURI="http://www.syntheticbiologics.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationTables" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationTables" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesTables" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails1" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails2" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#SelectedBalanceSheetInformationDetails3" roleURI="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails1" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails2" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails2"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails3" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails3"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails4" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails4"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails5" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails5"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails6" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails6"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails7" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails7"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetails8" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails8"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockBasedCompensationDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockBasedCompensationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#StockRepurchaseProgramDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/StockRepurchaseProgramDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetails" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetails1" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.syntheticbiologics.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_14" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityVoluntaryFilers_15" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCurrentReportingStatus_16" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityPublicFloat_17" order="140" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Cash_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_StockholdersEquityAbstract_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_PreferredStockValue_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockValue_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquity_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_OperatingExpenses_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_syn_WarrantExpenses_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_NetIncomeLoss_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueLicenseFees_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodValueLicenseFees_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesLicenseFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodSharesLicenseFees_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodValueConsultingFees_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodValueConsultingFees_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified" xlink:label="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified_25" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_NetIncomeLoss_26" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_StockholdersEquity_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_SharesOutstanding_28" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_StockIssuanceCost_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensation_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedAsCompensation_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedForConsultingFees_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssueOfStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_IssueOfStockForExclusiveChannelCollaborationAgreement_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedForAcquisitionsOfProgramAssets" xlink:label="loc_syn_StockIssuedForAcquisitionsOfProgramAssets_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedForAcquisitionsOfProgramAssets_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_WarrantExpenses_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_Depreciation_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_AdjustmentForAmortization_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnDispositionOfProperty" xlink:label="loc_us-gaap_GainLossOnDispositionOfProperty_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_GainLossOnDispositionOfProperty_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EquipmentImpairmentLoss" xlink:label="loc_syn_EquipmentImpairmentLoss_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_EquipmentImpairmentLoss_19" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_20" order="150" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivables_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivables_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_40" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_41" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_43" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Cash_44" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Cash_45" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_46" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_46" xlink:to="loc_us-gaap_InterestPaid_47" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_46" xlink:to="loc_us-gaap_IncomeTaxesPaid_48" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_49" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_49" xlink:to="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_50" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GainLossOnSaleOfDiscontinuedOperations" xlink:label="loc_syn_GainLossOnSaleOfDiscontinuedOperations"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_GainLossOnSaleOfDiscontinuedOperations" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xlink:label="loc_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0" xlink:to="loc_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockRepurchaseProgram">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockRepurchaseProgramAbstract" xlink:label="loc_syn_StockRepurchaseProgramAbstract_0"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockRepurchaseProgramTextBlock" xlink:label="loc_syn_StockRepurchaseProgramTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockRepurchaseProgramAbstract_0" xlink:to="loc_syn_StockRepurchaseProgramTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmergingFromDevelopmentStagePolicyTextBlock" xlink:label="loc_syn_EmergingFromDevelopmentStagePolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_EmergingFromDevelopmentStagePolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_syn_RisksAndUncertaintiesPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_RisksAndUncertaintiesPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock" xlink:label="loc_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BeneficialConversionFeaturePolicyTextBlock" xlink:label="loc_syn_BeneficialConversionFeaturePolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_BeneficialConversionFeaturePolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesReportingOfDerivativeActivity_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OriginalIssueDiscountPolicyTextBlock" xlink:label="loc_syn_OriginalIssueDiscountPolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_OriginalIssueDiscountPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockBasedPaymentArrangementsPolicyTextBlock" xlink:label="loc_syn_StockBasedPaymentArrangementsPolicyTextBlock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_StockBasedPaymentArrangementsPolicyTextBlock_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_20" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_21" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_22" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EstimatedUsefulLifeOfAssetsTableTextBlock" xlink:label="loc_syn_EstimatedUsefulLifeOfAssetsTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_syn_EstimatedUsefulLifeOfAssetsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock" xlink:label="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock" xlink:label="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="loc_syn_AccruedExpensesTableTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_syn_AccruedExpensesTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_1" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_3" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock_4" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_6" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantActivityTableTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_syn_ScheduleOfWarrantActivityTableTextBlock_7" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_8" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" order="60" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DueForLicenseAgreementsTableTextBlock" xlink:label="loc_syn_DueForLicenseAgreementsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0" xlink:to="loc_syn_DueForLicenseAgreementsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NotesPayable_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AdjustmentForAmortization_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeEquipmentAndFurnitureMember" xlink:label="loc_syn_OfficeEquipmentAndFurnitureMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_OfficeEquipmentAndFurnitureMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_LaboratoryEquipmentMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ManufacturingEquipmentMember" xlink:label="loc_syn_ManufacturingEquipmentMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_ManufacturingEquipmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_McleanHospitalMember" xlink:label="loc_syn_McleanHospitalMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_syn_McleanHospitalMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MedaAgreementMember" xlink:label="loc_syn_MedaAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_syn_MedaAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaap_OptionMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_7" xlink:to="loc_us-gaap_OptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_12" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MoneyMarketAccountsAndMutualFundsMember" xlink:label="loc_syn_MoneyMarketAccountsAndMutualFundsMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13" xlink:to="loc_syn_MoneyMarketAccountsAndMutualFundsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_LicensesRevenue_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LicenseRevenuePercentage" xlink:label="loc_syn_LicenseRevenuePercentage_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_syn_LicenseRevenuePercentage_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalMilestonePayments" xlink:label="loc_syn_AdditionalMilestonePayments_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_syn_AdditionalMilestonePayments_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_MarketingExpense_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RoyaltyRevenuePercentage" xlink:label="loc_syn_RoyaltyRevenuePercentage_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_syn_RoyaltyRevenuePercentage_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_Depreciation_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_23" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_24" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdeonaClinicalLaboratoryMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3" xlink:to="loc_syn_AdeonaClinicalLaboratoryMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryFeesNet" xlink:label="loc_syn_LaboratoryFeesNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_syn_LaboratoryFeesNet_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill" xlink:label="loc_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract" xlink:label="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_13" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract_13" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_CreditFacilityAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2" xlink:to="loc_us-gaap_CreditFacilityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3" xlink:to="loc_us-gaap_CommercialPaperMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdeonaClinicalLaboratoryLlcMember" xlink:label="loc_syn_AdeonaClinicalLaboratoryLlcMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_syn_AdeonaClinicalLaboratoryLlcMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NotesReceivableNet" xlink:label="loc_us-gaap_NotesReceivableNet_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NotesReceivableNet_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrepaidExpensesResearchAndDevelopment" xlink:label="loc_syn_PrepaidExpensesResearchAndDevelopment_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_PrepaidExpensesResearchAndDevelopment_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesGrossCurrent" xlink:label="loc_us-gaap_OtherReceivablesGrossCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherReceivablesGrossCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockSupplementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockSupplementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_EquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ComputerAndOfficeEquipmentMember" xlink:label="loc_syn_ComputerAndOfficeEquipmentMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_ComputerAndOfficeEquipmentMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LaboratoryEquipmentMember" xlink:label="loc_syn_LaboratoryEquipmentMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_syn_LaboratoryEquipmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedVendorPayments" xlink:label="loc_syn_AccruedVendorPayments_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_AccruedVendorPayments_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AccruedCompensation" xlink:label="loc_syn_AccruedCompensation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_AccruedCompensation_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_11" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_12" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_14" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_15" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_16" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_17" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_19" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_20" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_21" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties" xlink:label="loc_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedcompensationArrangementByShareBasedPaymentAwardOptionsOutstandingHeldByRelatedParties_22" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableHeldByRelatedParties_23" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009200Member" xlink:label="loc_syn_RangeOfExercisePrice009200Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009200Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice201300Member" xlink:label="loc_syn_RangeOfExercisePrice201300Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice201300Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice301600Member" xlink:label="loc_syn_RangeOfExercisePrice301600Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice301600Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009600Member" xlink:label="loc_syn_RangeOfExercisePrice009600Member_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009600Member_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009457Member" xlink:label="loc_syn_RangeOfExercisePrice009457Member_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009457Member_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice458905Member" xlink:label="loc_syn_RangeOfExercisePrice458905Member_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice458905Member_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RangeOfExercisePrice009905Member" xlink:label="loc_syn_RangeOfExercisePrice009905Member_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_syn_RangeOfExercisePrice009905Member_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_11" xlink:to="loc_us-gaap_RangeMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_12" xlink:to="loc_us-gaap_MaximumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_12" xlink:to="loc_us-gaap_MinimumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OptionsExercisePrice" xlink:label="loc_syn_OptionsExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_syn_OptionsExercisePrice_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue_11" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue_12" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_13" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeAxis" xlink:label="loc_syn_PeriodTypeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_PeriodTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PeriodTypeDomain" xlink:label="loc_syn_PeriodTypeDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_PeriodTypeAxis_5" xlink:to="loc_syn_PeriodTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommitmentDateMember" xlink:label="loc_syn_CommitmentDateMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_PeriodTypeDomain_6" xlink:to="loc_syn_CommitmentDateMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RemeasurementDateMember" xlink:label="loc_syn_RemeasurementDateMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_PeriodTypeDomain_6" xlink:to="loc_syn_RemeasurementDateMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails6">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue" xlink:label="loc_syn_WarrantsFairValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_WarrantsFairValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_WarrantExpenses_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue" xlink:label="loc_syn_WarrantsFairValue_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_WarrantsFairValue_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails7">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetails8">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice1Member" xlink:label="loc_syn_ExercisePrice1Member_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice1Member_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice13Member" xlink:label="loc_syn_ExercisePrice13Member_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice13Member_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice14Member" xlink:label="loc_syn_ExercisePrice14Member_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice14Member_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice220Member" xlink:label="loc_syn_ExercisePrice220Member_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice220Member_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice222Member" xlink:label="loc_syn_ExercisePrice222Member_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice222Member_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice330Member" xlink:label="loc_syn_ExercisePrice330Member_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice330Member_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice375Member" xlink:label="loc_syn_ExercisePrice375Member_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice375Member_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ExercisePrice199Member" xlink:label="loc_syn_ExercisePrice199Member_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_syn_ExercisePrice199Member_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisePrice" xlink:label="loc_syn_WarrantsExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_syn_WarrantsExercisePrice_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockBasedCompensationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2007Member" xlink:label="loc_syn_StockPlan2007Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_syn_StockPlan2007Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2010Member" xlink:label="loc_syn_StockPlan2010Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_syn_StockPlan2010Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockOptionsAndStockAppreciationRightsSarsMember" xlink:label="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_syn_StockOptionsAndStockAppreciationRightsSarsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmployeesAndConsultantsMember" xlink:label="loc_syn_EmployeesAndConsultantsMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_syn_EmployeesAndConsultantsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsAxis" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsAxis_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseWarrantsAggreementsDomain" xlink:label="loc_syn_StockPurchaseWarrantsAggreementsDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsAxis_12" xlink:to="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockPurchaseAgreementWithSingleInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_CommonStockPurchaseAgreementWithSingleInvestorsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember" xlink:label="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_StockPurchaseAgreementWithThreeInstitutionalInvestorsMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember" xlink:label="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_CommonStockPurchaseAgreementWithInstitutionalInvestorsMember_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultingAgreementForFinancialAdvisoryServicesMember" xlink:label="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAggreementsDomain_13" xlink:to="loc_syn_ConsultingAgreementForFinancialAdvisoryServicesMember_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_18" xlink:to="loc_dei_EntityDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CdfourBiosciencesIncMember" xlink:label="loc_syn_CdfourBiosciencesIncMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_syn_CdfourBiosciencesIncMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EpitopeMember" xlink:label="loc_syn_EpitopeMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_syn_EpitopeMember_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_22" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_22" xlink:to="loc_us-gaap_EquityComponentDomain_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_23" xlink:to="loc_us-gaap_WarrantMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockPlan2001Member" xlink:label="loc_syn_StockPlan2001Member_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_26" xlink:to="loc_syn_StockPlan2001Member_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_26" xlink:to="loc_us-gaap_SubsequentEventMember_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssuanceOfWarrantsToPurchaseOfCommonStock" xlink:label="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_IssuanceOfWarrantsToPurchaseOfCommonStock_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisePricePerShare" xlink:label="loc_syn_WarrantsExercisePricePerShare_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_WarrantsExercisePricePerShare_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_LifeOfWarrants" xlink:label="loc_syn_LifeOfWarrants_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_LifeOfWarrants_35" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExpirationDate" xlink:label="loc_syn_WarrantsExpirationDate_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_WarrantsExpirationDate_36" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_37" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFloorPricePerShare" xlink:label="loc_syn_WarrantsFloorPricePerShare_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_WarrantsFloorPricePerShare_38" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_WarrantExpenses_39" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_40" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_41" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_42" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_43" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_44" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_45" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd#invest_InvestmentWarrantsExpirationDate" xlink:label="loc_invest_InvestmentWarrantsExpirationDate_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_invest_InvestmentWarrantsExpirationDate_46" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_47" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber_48" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_49" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IssuanceOfWarrantsExpensesRecognized" xlink:label="loc_syn_IssuanceOfWarrantsExpensesRecognized_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_IssuanceOfWarrantsExpensesRecognized_50" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod_51" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsFairValue1" xlink:label="loc_syn_WarrantsFairValue1_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_WarrantsFairValue1_52" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_53" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_54" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IncreaseInFairValueOfWarrantLiability" xlink:label="loc_syn_IncreaseInFairValueOfWarrantLiability_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_IncreaseInFairValueOfWarrantLiability_55" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice_56" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod_57" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AntiDilutionPriceProtectionWarrantsPricePerShare" xlink:label="loc_syn_AntiDilutionPriceProtectionWarrantsPricePerShare_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_AntiDilutionPriceProtectionWarrantsPricePerShare_58" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DecreaseInFairValueOfWarrantLiability" xlink:label="loc_syn_DecreaseInFairValueOfWarrantLiability_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_DecreaseInFairValueOfWarrantLiability_59" order="310" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantsExercisablePricePerShare" xlink:label="loc_syn_WarrantsExercisablePricePerShare"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_syn_WarrantsExercisablePricePerShare" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense" order="320" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_29" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions" order="330" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmployeeMember" xlink:label="loc_syn_EmployeeMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_syn_EmployeeMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultantMember" xlink:label="loc_syn_ConsultantMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_syn_ConsultantMember" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:to="loc_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" order="0" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7" xlink:to="loc_us-gaap_PrivatePlacementMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" xlink:to="loc_syn_IntrexonMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10" xlink:to="loc_syn_PrevAbrLlcMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuanceCost" xlink:label="loc_syn_StockIssuanceCost_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuanceCost_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesConsultingFees" xlink:label="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuedDuringPeriodSharesConsultingFees_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees" xlink:label="loc_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForConsultingFeesPricePerShare" xlink:label="loc_syn_SaleOfStockForConsultingFeesPricePerShare_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_SaleOfStockForConsultingFeesPricePerShare_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForEmploymentServicePricePerShare" xlink:label="loc_syn_SaleOfStockForEmploymentServicePricePerShare_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_SaleOfStockForEmploymentServicePricePerShare_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement_27" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SaleOfStockForChannelAgreementPricePerShare" xlink:label="loc_syn_SaleOfStockForChannelAgreementPricePerShare_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_SaleOfStockForChannelAgreementPricePerShare_28" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised_29" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>


<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_31" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_32" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_33" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_36" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:label="loc_us-gaap_NoninterestExpenseOfferingCost_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_NoninterestExpenseOfferingCost_37" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" xlink:label="loc_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement" order="100" use="optional"/>






<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CommonStockClosingPricePerShare" xlink:label="loc_syn_CommonStockClosingPricePerShare"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_13" xlink:to="loc_syn_CommonStockClosingPricePerShare" order="20" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInFourthAndFifthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthAndFifthYear_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DrKuoMember" xlink:label="loc_syn_DrKuoMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_DrKuoMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_JeffreyRileyMember" xlink:label="loc_syn_JeffreyRileyMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_JeffreyRileyMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CEvanBallantyneMember" xlink:label="loc_syn_CEvanBallantyneMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_CEvanBallantyneMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnArborMichiganMember" xlink:label="loc_syn_AnnArborMichiganMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_AnnArborMichiganMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RockvilleMarylandMember" xlink:label="loc_syn_RockvilleMarylandMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_RockvilleMarylandMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_10" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_12" xlink:to="loc_us-gaap_EquityComponentDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13" xlink:to="loc_us-gaap_WarrantMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17" xlink:to="loc_us-gaap_PrivatePlacementMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" xlink:to="loc_syn_IntrexonMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PrevAbrLlcMember" xlink:label="loc_syn_PrevAbrLlcMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_19" xlink:to="loc_syn_PrevAbrLlcMember_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityByLocationAxis" xlink:label="loc_dei_EntityByLocationAxis_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityByLocationAxis_22" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_LocationDomain" xlink:label="loc_dei_LocationDomain_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityByLocationAxis_22" xlink:to="loc_dei_LocationDomain_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeSpaceInAnnArborMember" xlink:label="loc_syn_OfficeSpaceInAnnArborMember_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LocationDomain_23" xlink:to="loc_syn_OfficeSpaceInAnnArborMember_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OfficeSpaceInRockvilleMember" xlink:label="loc_syn_OfficeSpaceInRockvilleMember_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LocationDomain_23" xlink:to="loc_syn_OfficeSpaceInRockvilleMember_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodAxis" xlink:label="loc_syn_AnnualPaymentEffectivePeriodAxis_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_AnnualPaymentEffectivePeriodAxis_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentEffectivePeriodDomain" xlink:label="loc_syn_AnnualPaymentEffectivePeriodDomain_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AnnualPaymentEffectivePeriodAxis_26" xlink:to="loc_syn_AnnualPaymentEffectivePeriodDomain_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_December312014Member" xlink:label="loc_syn_December312014Member_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AnnualPaymentEffectivePeriodDomain_27" xlink:to="loc_syn_December312014Member_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_December312015Member" xlink:label="loc_syn_December312015Member_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_AnnualPaymentEffectivePeriodDomain_27" xlink:to="loc_syn_December312015Member_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis_30" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PhaseIClinicalTrialsMember" xlink:label="loc_syn_PhaseIClinicalTrialsMember_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_PhaseIClinicalTrialsMember_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PhaseIiiClinicalTrialsMember" xlink:label="loc_syn_PhaseIiiClinicalTrialsMember_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_PhaseIiiClinicalTrialsMember_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_NdaSubmissionInUsMember" xlink:label="loc_syn_NdaSubmissionInUsMember_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_NdaSubmissionInUsMember_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EuropeanMedicinesAgencyApprovalMember" xlink:label="loc_syn_EuropeanMedicinesAgencyApprovalMember_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_EuropeanMedicinesAgencyApprovalMember_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RegulatoryApprovalInAsianCountryMember" xlink:label="loc_syn_RegulatoryApprovalInAsianCountryMember_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember_31" xlink:to="loc_syn_RegulatoryApprovalInAsianCountryMember_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodAxis_37" xlink:to="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FirstYearMember" xlink:label="loc_syn_FirstYearMember_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" xlink:to="loc_syn_FirstYearMember_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_SecondYearMember" xlink:label="loc_syn_SecondYearMember_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" xlink:to="loc_syn_SecondYearMember_40" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ThirdYearMember" xlink:label="loc_syn_ThirdYearMember_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_QuarterlyInstallmentsPaymentPeriodDomain_38" xlink:to="loc_syn_ThirdYearMember_41" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_42" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_43" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPayment" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPayment_44" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentInterest" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest_45" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_46" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue_47" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ConsultingFees" xlink:label="loc_syn_ConsultingFees_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_ConsultingFees_48" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_OfficersCompensation_49" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_LeaseAndRentalExpense_51" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_LeaseExpirationDate1_52" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_53" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLeaseLeasingTerm" xlink:label="loc_syn_OperatingLeaseLeasingTerm_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_OperatingLeaseLeasingTerm_54" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_55" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AnnualPaymentForPastPatentExpenses" xlink:label="loc_syn_AnnualPaymentForPastPatentExpenses_56"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_AnnualPaymentForPastPatentExpenses_56" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MilestonePayment" xlink:label="loc_syn_MilestonePayment_57"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_MilestonePayment_57" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ResearchAgreementFixedFee" xlink:label="loc_syn_ResearchAgreementFixedFee_58"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_ResearchAgreementFixedFee_58" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_CashPaymentForLicenseAgreement" xlink:label="loc_syn_CashPaymentForLicenseAgreement_59"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_CashPaymentForLicenseAgreement_59" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalCashPaymentForLicenseAgreement" xlink:label="loc_syn_AdditionalCashPaymentForLicenseAgreement_60"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_AdditionalCashPaymentForLicenseAgreement_60" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:label="loc_syn_UnregisteredSharesIssuedToLicenseAgreement_61"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_UnregisteredSharesIssuedToLicenseAgreement_61" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_AdditionalConsiderationPayable" xlink:label="loc_syn_AdditionalConsiderationPayable_62"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_AdditionalConsiderationPayable_62" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_63"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_63" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaap_EquityIssuancePerShareAmount_64"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_EquityIssuancePerShareAmount_64" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_PartialConsiderationForExecution" xlink:label="loc_syn_PartialConsiderationForExecution_65"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_syn_PartialConsiderationForExecution_65" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherCommitmentDueInSecondYear" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_66"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_66" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementSettlementAlternatives" xlink:label="loc_us-gaap_RegistrationPaymentArrangementSettlementAlternatives"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_RegistrationPaymentArrangementSettlementAlternatives" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:label="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:label="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementByArrangementAxis" xlink:to="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IndMilestoneEventMember" xlink:label="loc_syn_IndMilestoneEventMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="loc_syn_IndMilestoneEventMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ApprovalMilestoneEventMember" xlink:label="loc_syn_ApprovalMilestoneEventMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="loc_syn_ApprovalMilestoneEventMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_FieldExpansionFeeMember" xlink:label="loc_syn_FieldExpansionFeeMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RegistrationPaymentArrangementArrangementDomain" xlink:to="loc_syn_FieldExpansionFeeMember" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RegistrationPaymentArrangementTerm" xlink:label="loc_us-gaap_RegistrationPaymentArrangementTerm"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_RegistrationPaymentArrangementTerm" order="270" use="optional"/>
























<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="280" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/StockRepurchaseProgramDetailsTextual">
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_StockRepurchaseProgramAbstract" xlink:label="loc_syn_StockRepurchaseProgramAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockRepurchaseProgramAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_WarrantExpensesForIncomeTax" xlink:label="loc_syn_WarrantExpensesForIncomeTax_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_WarrantExpensesForIncomeTax_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_ChangeInFairValueOfWarrantExpenses" xlink:label="loc_syn_ChangeInFairValueOfWarrantExpenses_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_ChangeInFairValueOfWarrantExpenses_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_RealizedLossOnDebtSecurities" xlink:label="loc_syn_RealizedLossOnDebtSecurities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_RealizedLossOnDebtSecurities_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="loc_syn_DeferredTaxAssetsStocksIssuedForServices_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3" xlink:to="loc_syn_DeferredTaxAssetsStocksIssuedForServices_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsBadDebts" xlink:label="loc_syn_DeferredTaxAssetsBadDebts_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3" xlink:to="loc_syn_DeferredTaxAssetsBadDebts_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3" xlink:to="loc_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceAmount" xlink:label="loc_us-gaap_ValuationAllowanceAmount_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_ValuationAllowanceAmount_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodAxis" xlink:label="loc_syn_OperatingLossForwardPeriodAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_syn_OperatingLossForwardPeriodAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_OperatingLossForwardPeriodDomain" xlink:label="loc_syn_OperatingLossForwardPeriodDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_OperatingLossForwardPeriodAxis_2" xlink:to="loc_syn_OperatingLossForwardPeriodDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_TaxableIncomeExpiringThrough2032Member" xlink:label="loc_syn_TaxableIncomeExpiringThrough2032Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_OperatingLossForwardPeriodDomain_3" xlink:to="loc_syn_TaxableIncomeExpiringThrough2032Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceAmount" xlink:label="loc_us-gaap_ValuationAllowanceAmount_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ValuationAllowanceAmount_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="90" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_BoardOfDirectorsAndOfficersMember" xlink:label="loc_syn_BoardOfDirectorsAndOfficersMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_syn_BoardOfDirectorsAndOfficersMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5" xlink:to="loc_us-gaap_RelatedPartyDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_MrKanzerMember" xlink:label="loc_syn_MrKanzerMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6" xlink:to="loc_syn_MrKanzerMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_IntrexonMember" xlink:label="loc_syn_IntrexonMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9" xlink:to="loc_syn_IntrexonMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis_11" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain_12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="syn-20121231.xsd#syn_EmploymentAgreementDescrption" xlink:label="loc_syn_EmploymentAgreementDescrption_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_syn_EmploymentAgreementDescrption_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaap_NoninterestExpenseDirectorsFees_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_NoninterestExpenseDirectorsFees_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_CommonStockSharesIssued_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_CommonStockValue_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_14" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<roleRef xlink:type="simple" xlink:href="syn-20121231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"/>
<presentationLink xlink:type="extended" xlink:role="http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="loc_us-gaap_StatementTable" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementLineItems" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="0" use="optional"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MP``+"``Y`6,!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`.`U+QKXDCU.\5-<U!0)G``G(`&XU5_X3GQ-_P!![4?^
M_P"U!\:^(V.XZ[J.XC'_`!\-_C41\7:^7#?VYJ6X$L#]I?K^==I\*/$FIWWC
MVVM[_5+VYB>"15CEF9E)QD<$_6O?@<#GJ*7<,X[T9HR*,BC-&0#BBC.:"0*"
M<#)H!!Z49I:*3(S2TF1QSUHR*-PHW"DW#UI0P)QGF@G%&11GBD#J3P:7-&X>
MM)N&,YXI<BC(HR*,YHR.U`.>E+29%+17R-XCB2+Q/JD48VHEY,JCK@!S4NC>
M$M:\0Q2RZ18M=)"P60HZC:3TR"13H/"&LW3%+6T%RZY)2WFCE88Z_*K$UD2P
MO"S+(K(ZG:RL,$'T(KLOA#_R4C3OI)_Z`:]6\=QM_P`)CX9B2ZOH(+^X:*Y6
M&Y>-)%`!&0".?>M+PE+?)XBU_3GN);K3;.2(6TTS[V5F7+)NZMC(Z],UEZ[:
MBX^+&GV+7=Y#;7.GO+*D-T\89U)P>#[#\JZK1M&CTU+R);VZNX9Y=P6>8RF(
M%0"H8DG'4^V:X;PUH9UN?Q-&^I:I;W5E?R06LB7TF(4`RHP3@C.>#VKJ_A]J
M]_K7@^UO-4P]SN>,RJ,"4*Q`?\<5BZ1XMD'Q0UK2+IY!:7#JEHS-E5E2-=Z`
M]B1SCU^M;WCG7)-#\)WD]MDW<BF*W`ZER.OX#+?A4W@R^?4/!FCW4KM))):1
M[W;JS`8)_,&N7\;>*;W2O%-C<6I;^S-*=!J9!./WW"@_0#=^(KOII0;21T;C
MRRP(^G!KSWP/XTN[(6.C^*25FO(A+87KME+A#R%8_P!\9Q_D9U/',!;6?#,B
MO-&LVI);S".9DWH5)P0#R,BNT/`KC_%VI,GB/P_IEU--;:;?O*LSQN4,D@`V
M1[AR`2>W7BM;1]"_L:^O&@GF:TG5#'!)*TGE,,AB"Q.`>./8UM'I7):AJ,VN
M>,'\.VEU+;6]I;BXO98&Q(Q8X2,-_#QR2.>E6KSP783V31VLU[:W`!\NXCO)
M=R-V8Y;!YJEJFK7FFP^'O#ZW!.KZCMBEN.I547,L@_VO3W/M6D_A/3S:>6DE
M\DN2PN1=R>:&/\6<\_0\5F^#M=OYM5U/P]K3"2_TS:1<J,?:(F^ZQ'9L8S]:
MH:#XMF/Q,UK1KMF-I/+BQ=C\N^-1YB*3WYS@>A]:W/'>N2Z)X5NIK52][*AC
MME7[VX@DL/\`=4%OPJ?PE/\`VKX+TJ>9V<S6B!V)(+?+@G/7/O7(^'=-FU3P
M7J%]_:NHV^H07%R([C[6Y"A&.T,K$@J,=Q70:3XFE'PY@U_5T59A:>=(H&`Y
MZ+Q_M<?G57X>:KJ4UOJ.DZ^Q.JV$^Z0YSE)!O7'L,D>PQ4OCR[U>T72#H#*;
MXW3%8F;"S*(V8QGUR!Q[UI>&?$]GXHTPW-KF.:,[+FVDXD@?NK#^58WAK3HK
MG4O%ED9KI8A=+#&PN'W1#8&^4Y^7!.:C\):W)H\&I:%X@G<WFD*]Q]H=BQN;
M?)(DR<Y/8CZ5K>$]*D\N;6;XS"\U%S.(9)&(MXV^[&!G`..3[DUT@KS[^SH[
M[XL:E9W4MRUJNGI<1Q)<R((W+`%@`PP>M;7@JYO2VL:?>3R746GWK007,AR[
MI@-M8]RN<9KIBV#7#:5XJN9?B)<VMPQ&F7RM%8%FR&E@.),>F23_`-\BNZ!S
M2U\B^(@Z>)=4#DLXO)@6(ZG>:[OX,R#_`(J5-WSG3RP'KC//ZC\Z\[L+^YTN
M_AO;.5H;B!@Z.AP0:[OXR1VK:[IM]#&L=Q?6*3W"KW)Z'\N/PJA\(?\`DI&G
M?23_`-`->G?$2VAO?'_@ZVNHUE@DFD#QMR&'%36]J?"OQ/T_2]&=ETS4[>26
M>RW%EA91_K!GID@#\ZB\4:=:ZK\8-#M;ZU^TP/I\A9"Q`&"W)Q77Z%H^F:`M
MQ8Z6/+#2^>\7F%BA8`=^0/EXS[UYSX:T6]UVS\9K8:K=VEX^I3(%60>6^"<!
MAC(R,C(/\J[3P)X@M]6TA;'[,MC?Z;BWN;$#'E%>`5']TXXKDK?3I]2\':OK
M-FN_4K36[C4+4XP?D8!E..N54BMC2-0'CZZN=:C1ET^RM&@M%<8!G=/WK_\`
M`00GXFI?A;?I'\,;268@1V0F$A!S@*S-S^!K*T[P=J7BGPQ=7<^N7%LNNEKJ
M6U-M&R\_<!8@L,*%Z$=*Z'P)K;:WX+03_P#'W9JUG<#/\:#&?Q&#5;3-`L?%
M_P`,M*L]0B*_Z.OE2+]^)EX#J?PKG)]6U*+7_#GAWQ#O;4K+5(Y([@#]W>0[
M6`DSV89`(]Z]:/*UY])86'BWQ?XDTG6MYGMUA%E\VTQ1E<[X_P#:W]3[`5AZ
MWJ6H12V7A+7YPE\+N)K35O-\L/`&R6;!X;`VX/4G\:]<)^3(/XUYV9%\*_%B
MZN[\I'8Z_`BQ7+_*L<J`#83[X_45Z!)(L4332.$C52S,3PH'<FO/O%TJ0^)O
M"7BY&WZ5&3'-*1@1K*/D<^@^;G\*]`5P\2NCJR$9#`Y!&.N:XWPI$=5\>>(/
M$,8+63K'9VTAZ2;`-Y7U7(ZUB#1[C6?!%_JEAE-6M=7N;^UDSR2LA!7/H5&/
M3@5K:%<_\)TUQK80I;0V9M;)7&-LS)^^<#ZD*#[&M'X6S--\.]*WC#1J\1'I
MM=A_2L[P)I5KJ_A.YBOEDEB:_N@\7FLJ./-)PP!P?QJSXRC?6-0TKPQ93_93
M.3=SND88QQ18V\'CE]HQ[5@:U_:/@?QKI&L7>ISZA;:@?LE[(T"1X4<(3M&.
M"V?PQ76^)F(\1>%0/NF_?('_`%PDK.\5Z#=Z;J/_``E7AN/.I0KB[M%SMO8^
MX('\0Z@^U)\.M9M]>N?$.H6T3QQS7JG$@PP/EJ""/8@U!\0]-@G\1^%;AR4:
M6^%K,5ZRQGYMC>JY7I[UVLU[;VUS#!-<1QSW!(BC9@&DP,G`[U94Y4$UP=K;
MK<_&368G:15.EQ',<A1OO#N.:Z^"*PT2&"T@:*W65R(T9_FD<\GKRS'DGO5'
MQ=JSZ-X;N[JW)-T0(;=0,DRN=J<?4Y_"N%\1>#M4\/>%[*_M]8EN7T$K<Q6_
MV9%'7,AW`;CP23GTKT>UU>TNM+MM02>-;:Y171W8`'=C`R>_.*O!LC_ZU?)/
MBC/_``E>L9_Y_IO_`$-J[;X+%3?Z^DCA(SIK;B%RP&1R/IGI]*P-$TCPQ=:M
M#%?>()(K4N,[[,IO&>A8,0OUI?B#I.NV.M&YUQ4=;C`MYX3F$Q@?*J'L`,<5
M9^$/_)1]/_W9/_0#7K_B3X?W7B35_MUQJJH(>+2,0G]UT/4..<]QSTI^E>"-
M4TDR36^MP"ZE&V2=[+S9"O8;G<G'M535OAK>ZWJ46HWNOD7L:A1+%:E"`,\#
M#\`Y/2KVD>"M4T3[0;+7U5KA@TKR6AD=\#`RS.3P*KZ+\/M1T"YN)].\0^6]
MR<R;K(,&YSDC?R??K1?_``]OM1U$:A)KBPWI4*\]M9^4T@'9B'Y'%2:'X%U/
MP[8FUTSQ$4C>0R.KV2NISZ`MQ[\\U<L?"^K:99BSL=9M;>V!)$<>FJ%Y.3_'
MWS6'#\*)8+>>VCUUDM9VW20):[$;U!`?IV^E;]AX=UW3;""SMO$40A@0)&&T
M]20HZ#.^LF'X<7MM<7L]KKP@EO@PN#%9[1)N.22`^,]>?<U>T;PCK&A6"V=A
MX@2.W0Y5&LMX7V&7X'M4EWX6U:_N+:>[UJUFEM7\R!VTU<QMZ@[ZM?V7XA_Z
M&*#_`,%R_P#Q=8>N?#NY\07$5S>ZVBWD.`ES!9".4+GID/TZ_G3!\-'%K<6K
M:I;2Q7.&E\_3Q*[,.C%V<MD=N:M:)X+UC0(#!8^*&$&<B.2Q5PN.RY;@>PJW
MJ?AG4]8L&M-0UFUN(V/*R:8C#IP<%NO?-<__`,*B.TQ?\)%=FUP,6IC_`'77
M."N_D>U=')X?U>6S-G-K5J]H4\LP-IBE2N,;<%JQ3\+O+!CMM=N8K9CDVICS
M`1Z;`PXZ]^];\6B:Q!;K;Q:Y#%"J;%2+3T4*/08;CBJNC^$K[0+-[73M;6*-
MG9\&S#!23G@%JEL_#VL:?:K;6FNVT$"YVQIIJ@#)R?X^Y)-0:=X/O-&MVBTK
M65M8I`2Z"UW*6/\`$`7X-1Z/X*O]`21=,UU(8Y6#NGV/<"W][ESR>Y[U*WA&
M\76CJL&LA;UD,9D:T#90]5QNP!GG%.U3PQJFMZ?+8ZCKEO/:RXW1MIZ\X.0?
MO^H!JI+X!N+JUM89];D=K)@;5Q!CRL>GS=>V<]*VH]-UH1J'U]&(ZG[$@S_X
M]Z55L_#5]I\EW)::K;PR74AED,=@H#/TR?FY./IFJNJ>#+K6I;>;4=826>U)
M:%Q9A1&V000`W7CK5B]\+7E_=Z?>3ZT6N+#<T#?8TVAF7!)!_P`:M#3=<,:C
M_A((]_<_8%P?3`W50'@MTUI]7CU1DOW/SS+`OS@?PD9QC@<>U37GAO4;]K22
MXU:VEN+60R1R2:<C;&]5^;@XJ#5/!]UKDML]]K"2_9V#Q_Z(!M8'AAAN"/6K
M<^BZ]<020S>(8'BD4HZG3EY!&"/OUFP_#]HM'.F1ZC`]EN#F"2R#H&!R"H+_
M`"_Y]:[.-66-58@L``2!C/X5\C^($V>(=34G)%W*,D=?G-=S\&8@9?$<N3E=
M-9?SY_I7FN>E>P>$KM?%GP>UK2M2`/\`92;H)C_"`"R?D01]#7*_"+_DH^F_
M[LG_`*`:^E1TI:***********YSQE?7%GI$$=K</:R7=Y#:F>,`F)7;!89X!
MQQGWKG=7\37_`(1N(]*T^?\`MN;=),WGAI)8T4*?*)3^+DD,P``Q2/XK\27?
MB"WALX]/BL!JS6)5PWFL%3>=W8<'MW'I678^)]8EN;":XNC]E?["HCCF)/[R
M1]Q8_P`1PA!_+UJ_IGQ#UG5PL=KIUK&]Y,D=E-*LHAP=Y*N>[`(.5XY]JLQ:
MQ?R?":VO[JXNC=/(B2R6Y_>X,^TA??'%,B\0ZSX=M;A+R*::(PWEW:_;6'GB
M*)4*A]O<DMUY`QTJM+XKUNW_`+59FB:SGN9K>U8!O/AD^S^8N/X=H*_7-7+3
MQ+K+W$ECI4,-W=M<2L6O)CL6..*(E01T)+X&>G>K/Q'UZYTK3+*.RO!9W4S-
M-N/.1&A;9QV9MJY]Z7_A-;UX]0U*&TM7TBRCPY\QEF9_*$F1Q@KDA?7O27'B
MC7[:V@A:STS^T&@FO),2.8O(C53QW#DN!SZ$]Z)O'DBVD%U!:(T,T\B(&)SM
M%MYP/U)X-5!XK\0SMHOF#38OM5Y")!'O*M%)"T@!ST(VGGUQ[TR'XAW\D<\`
MM]/ENQ<01120NY@'F'')ZM@_Q+P>U#^,/$2W#.EK:3/!97#26D(8[Y8YO+W`
M]<=\=<`]\5N0>)+N7P2^KF32C<@D+(LK_9S\V,GC>#C^#&[/'6L:S\>ZIJ"6
MKV]K9*!;-/=>8)!G;-Y1"#J/7YJL:=XAU35?&FGY,,.D3"]2&.,DO(8F5=TF
M>/<`>IS3K._FGN]3UF\UB6TBL-4EM1;E@898D`&P*?XSUR.<U`/&VN+';036
M.GI=WTMK]G*NYC2*??C?WW#9SCCFI;/QKJ-QJ&G0SVMG!!<+AI)2ZB=]S*RQ
M-TRI4?*W)SQ5>?QCJ&I+IZ6P6"61K.8K&22WF^9E3_L@H/?K4.B>.]6,/AQ-
M1^PS-J31K(4#B7YV<*V!\JXVCKUYQTJ-O'.OW,5HJ0Z?;2W%S:LA4LP,,LK1
M[6ST;*Y)'8^M=1X9\0WNJZEJ5M?V]M;-;.0D`9A,@W$`N",$$`$,O'.*Z7-?
M)'B<?\59K`Y_X_9NO^^U=S\'[JPL!K9U/4+6SBNH!;H99`I).<D`]AFN.O?"
MTUI<R1QWVFW$2D[9H[M-K#UY.1]*U)/$-MX?\'W.@:1,+FXU!@U_=!<(`.D<
M>>2/5CZ\5+\(C_Q<?3OI)_Z`:^EJ6BBBBBBBBBBBJ.KZ3::UIDME>HS0R8/R
M,592#D$$=""`:PI/A[HLUJD,HNW<,S2SFX82W&[&Y9&'W@<#CVXQ5X^%-+X*
MQRHPO?MX9)&!64C!(QVP,8Z4R/P?H\8B'V8GR?)V;G)QY1)3\BQ^M5?^$!TA
M89(X3>0LTJR1R)<,'@VDD+&?X5^9N/\`:-:-OX;TZWT"#1TC?['"59%,AW95
MMP);KUYI->\,V'B-(UOQ,"BNH:&4H65QAE)'53@9'M55/!6DI?3702X_?9)B
M,[>6K%-A<+_>V\9I+SP1I-VC`_:H6>1G9X9V1FW*JNI(_A8(`16PVEV?VQ+P
MP`SQP&W1B2=L9()`'3G`_*L:+P-H\,X<1S-`(]AMFE)A8[-F\K_>V?+GT]Z2
M7P-I<UDL#27P968FX6Y;S7#`*R,W=2JJ,>@%22>#-*FOFN76X.5(6#SF$49,
M?EDJO8E>,^U32^%-+FMX(6A<+"8BA60@CRU*J/IM)!]0352S\!Z/:*`INY-K
M1LAEN6;;Y9R@'L.@'I5F;PCI<R$;9T8F9M\<S*P,KAV(([A@"/3%+'X5T^+1
M'TP><8Y)?/DF,I\YY=P;S"_][(!S[5';^#-)LQ((8Y@9(VC8M,S$AI/,;DYZ
MMSGZT^R\):=8:U_:<!N1*#*8XVF)CB\P@OM7H,D9I6\):4^KG4&BD+F4W'DM
M*?)\TC;YFSINQQGWJ.R\&:59A2!<S2)-'*DD\Q=D\O.Q03T5<G`]Z&\':2;J
M"X\J7]RRN(_.;RV96+(S+G!*ECBH['P/HUA,98HIG;S$E02S%A'L+%%4=E&X
M\4R+P'H\%Q;21B['V9UDB3[0VQ65BR';WV[F`]B:G/@S2/)$:QRH$CCC5EE(
M91&Y=2#V(8U9TGPS8:1?3W-L;AI)00!-*SB)2Q8JF>@+'-;&!7R1XI'_`!5F
ML'_I^F_]#:LNBBNR^$B;_B/IOS$;=YX[_(:^F$Y6G44TCFG4444444444444
M44444444444444444444445S$O\`KY?]]OYTRBBK%C_Q^Q_C_*N@7[M.HHHH
<HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHK_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`0$`2`!(``#_VP!#``,"`@("`@,"`@(#`P,#!`8$!`0$
M!`@&!@4&"0@*"@D("0D*#`\,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_
MVP!#`0,#`P0#!`@$!`@0"PD+$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0
M$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!#_P``1"``C`+(#`2(``A$!`Q$!_\0`
M&@`!``(#`0````````````````<(`P4&!/_$`"X0``$$`00"`00!`@<`````
M``(!`P0%!@`'$1(($R$4(C$R%2-!"18D0U%2<?_$`!0!`0``````````````
M``````#_Q``4$0$`````````````````````_]H`#`,!``(1`Q$`/P"YN\?E
MJ]MUO13;#81M?+SO++>J<M$B1;=B`K2"2(C9'(1&^Q(J*GWI\?GCXYF3;O.*
MO<K!J//*9B2Q#O(3<L&)(='F%)/N:-/^P%V%>.4Y%>%5.%U3N'F%;63=N_*W
M.;&%20+'<W.7;%THY>Q:AFFMF(O]0B5>/11Q2Z`G5PB;(>/P5E_&.JO*C8+"
M&,D5Y+*35!82&WS$W&%DD4A&3(41%)M'4!5^?D/V+]E"3]---`TTTT#3330-
M---!I<NPK#=P*5S&\\Q*ER2H=,''(%O`:F1C,5Y$E:=$A547Y1>/C7OJ:FJH
M*J%1459$KJVNCMQ(<.(R++$9AL4%MIML400`11!041$1$1$UP.^.]]1LI1UD
MH\:NLIO\AL`JZ+'*1E'9]E().Q=454$&FP13<=-4`$1.5Y(47;;-;FUV\^UF
M,[J5-;)KX>3U[=@Q%DD).M`?/`DH_'/Q_;0=GK`D*$DTK%(C*2R:1@G_`%I[
M%;155`4OSU155>/QRJZSZ:!IIIH&FFF@::::!IIIH&FFF@J[YA;5;5[HW6QN
MT&X-?)+&;3,)ZO54-YR)&)EBALGD,E9ZJ"MNBRJ*BHB"3O/PJZB:Q\D=R,8\
M3]I<RM-R,KJHC^Z!X;>9;7U<2VL9M`T]91V9?5Z.\#A%Z(G=T6B,S$E$34T`
MK:[K^/.S^^5E166[.%Q,F''&IC=?%FD11@62K/L<)I%02-$8!!5>>J$?'[:Z
M*TVVV_N\$/;"WPVHEXDY$""5,]$`HGH#CH"-JG"(*B*BJ?****G"HBZ"IF=^
M3M1M-M))R6#N5N-"L<MR6+BT6]W'J&XO\42,+*DV80/IV2]:1S4A;1A!<=5@
M`!`553M]N?*!VD\/(._&4VTO/9<BUEUU48A#@3+M'KIV)5H;8(#+#IL%&-P>
M!Z)W4D3JNI&+Q2\?$DX0_%VNI8C.WCTZ3C\.*SZHL=V8`C(,V1X!U2Z"OWH7
MW"B_E$774UNSFU-.-HU6;=X_'CW-E'N)T48#?T[T]A05J5Z53UH\)-MDCB"A
M=@`N>114"/\`!/,;9?.<[J-JOY.739K907Y,BDL6Q%VNDLR3CG!D.`1-C*]C
M+RBVA*I`WW3[2!2P^4WDZQXYL8HL>HA6\JYL''K",].;8<C4L5M7)TL!(D(R
M;'IU%!5%4N%5/SKOY.R.TDP\C>D[?4KCV6RFIUR^L=/=+DM"HM/JY^PNMH2]
M#%4(%7D51?G4?;D^%6QN[5BUD&XM++R>ZAXN>+0IMW+<E^AE7#=&0H=A[2!-
MPOZO*$J?'/\`?021;;BPYF/Y1)VQ=H\PO\8%6GJD+IJ,(RO4+HL/O\&D=2`Q
M+L0K\+SQKW[<9M7;E[>8ON/419,6!E=+"NXK$E!1YIF2P#P`?55'L@FB+PJI
MRB\*NJ^X7X`8'AN/?2UFZ&?5F0VE:S5Y+=44]J`MW%"*$?Z<XZMN-MM"(+ZB
M'_4M(9<2%55);)XY05>)X]5XM1Q_16TT)BOAM<\^MAH$!L>?[\"*)H*U;K;D
MYEB?G;M#ALC)KJLQC*ZQ^+$AH\`U=BX$2U<GB\*IR4@'FZ#U%RBBCKHCRCII
MJTVJJ^7&Q6[.\><UL7#\6QVVH+3";K$I,^YGHRF.R9TJ$ZEHRR@$;SS8PDZ"
M*A]_15,41>9YVDVRKMH<$K\#JLAR"ZCUXKQ,O+)R=*<)?DN7'%54'GE4%/M'
MGA$1-!&F#.6N?>4V[5C;3_7&V[KZO$L=%MIM7(1SH;-A/DBI@2=G%.""<\IQ
M&X453\[2XSO9+PWVRQ?!9<NS:JJB(%=75\**_:V/TS+#KKDEQED2=]0-L/..
M/=4`>J_CX36:_P!G-P*7<B_W0V4W"I:&=F(00R*LR*B=M8$EV,(LMS&49E1G
M&7TCHC:IW('$;;11%4[ZB[.O!S*]P]U:_>/(_(::YD+F,R<1N'&\7B``5L@C
M]@U2(7,$^CTH4<D+,-/>ORJ"B:"2-[/,383Q_8Q*9N-E_HC9F\VE>[$:61TB
MFV9I-,17NL=.H`I`)DA.M_;PJDG4UF_>UMMLH?D)$R0?\D-53]N].-HD-IEC
MNCP$WQW]H&V;:MHBEW%11%7XU@;\?-L&LKQ#+FZ/J_@^/GC--$3K](S!5650
M59Z]54?0WU5..O'PGXXB;R0V2JL`\1][L:VOJKZ>>6,V5LW3M/.2T;FS'>[H
M0V/]H",R+U-IQRJJ@JJKR';L^6>V5EX^/^1-&S:RZE#D0X=0<=&K279!(*,W
M`&/RI)(=>%!!O]E0Q7CA=8:/S.\>IM+AL[(]PZS&K'-<13-(=99.J+C5>C2N
M.JXXB>M"#H\/';DE9=Z(2`7&L'PEV6N-GL1VCR5<BM*W%[!W(&IG\H_!F2KE
M[VD=B\;*@7O1Q]PQY_150>.J==1AC7^&'ME&J,LQ'+,GGSL8O:T:FJ@15=25
M2-,V,R3&>8E/NN\.(S+1LQ1M&U)7EZJ+I#H+@5N48S<V$FII\BK)TZ%'C2Y,
M:-+;==88D(:L.F`JJB#B-N*!*G!="XYX76SU"&.^*.+X-9P[K;C<C/,6G1L<
M9Q9U^-,B35EPF#,HGN2?&D(1Q_:8MDB)P"H)=A1$UG\;Z0\<M]X:9J_O+F!'
MW!-84JWL')CRH=+5&^`F:\H`RBDH@)P(\*@HB)H)HU2;;_>O)MU_._(8N%Y!
ME\JBPZZ?PRVJPB/!21ZZ+6R#D2WB5$:69_,*RRVO)&K*$J(@*JZLAC]9NY'W
MZR^TN;!MW;F91584L=70(V;%LWOJE043L*$)-<JJ\+U3C\+IM]L'@FWV,YMB
MD=J3:PMP\@N<BR!)ZB7U<BR)?>"H`BB!Z^K:(B<]13E>?G00]YZ>4`[,;=-X
M/A-M8P\_SF$^6.SXE<_*9AML]2=DF3(&OX40%!$U[N@I"@=BU+/C5O93;_;/
MT>X-4-B$DV0A6S4ZO>B$S9M-@DMH?8V`NH#JD"N-(K?83%%Y$A'VXEL#M=@V
M;P-P<7H'(=O58DSA$(EENN@Q4-2%D"RB&2JJ^Q>5,E4EZHG/QI`V.Q:IO/YR
MIO,F@*64R<O=B1;=QJ*]-D1T9=;-H>!-@N%=5I?CVF9_DET$B::::!IIIH&F
MFF@::::!IIIH&FFF@::::!IIIH&FFF@:K_X>6,ZTJMW)-C*<D.AO!ET83<+E
?4::F^ML/_!`!%/\`A!33306`TTTT#3330----!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MP``+"``X`/L!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/9J*YWQ)J5YINH:;(K/'IK3+'<O&JLY=F547!Y"DDY(
MYZ5DG7M8LXM5^V-_IEM=P@1M$IB6*23`VLIR3MZEN016OKNHWNDWUI-;HUU:
ML'%Q;J!OVJ,ET[EA_=[C..:YW4?$>IPZ7%J=AJZ7%I*)D@;R$Q-*LA*)G&?F
M0,O'.X#N:WO#UY?:O:7%T;])+:2)([=TC7APO[Q\8Y^8XQ_LFJ$=SK,NEVLD
M>L'S);\PQ,]M&//CW8R1V&%<@CL133XT*:C'=/;W:V!M9'>/Y#MVSB,29SGN
M>/2KNNWU_:ZG&T=Q/%8*$+R6ZQR%&9L9D1OFV$<97IS447CN!K`74FGW2`Q/
M.5#JQ"K)Y8Z'J6I6\;H)IHO[+OPT%J;F;>%7R^&(4\]]AY]Q5C7+J^EL[!K8
MO$9"9+B&"=%G9-N<1D\$@X)Z9%41XXMUT)Y5::2:.%B)'15:0K")-VS/&0>G
MKGM5B;QDUM<10'2[B2::X:%%B="65`I9SSP`&'%1>(-2N-+OKJYMK^1A#;%I
M;=B"BYP$P.H(`=R>N!Z5#'J%[!J%M;IJ,LULNKBW21B#YT;0E]K-CG#<9'XU
MJZ_K&JZ9?:7#INDOJ$5U-LN958XMUR/F/YD_A63XQU#4+75X%T^YFC$5C+<.
M%E5$RKI@D$?,<;AM[U83QS%,UOLM'"W1*VY>4+E@V,2`C,9STSU/'6KVF^)X
M]2UQ]-$*AEB,AECF$BY4J&7([_.*YSPYXBO$%U-=7$LH:&22WCN)LK.5G9,J
M1]W`V@KUY%7;7QS<7T@\JQACC:&(KYTY!61V9<,`.$!0@GKG`Q4]KXRFGN8A
M+8QQ6_FQQ2R>?DJ7#!6"XY7*]>,@T_Q%J$]Q-HRZ5/YJWC2[$CNC")@(R5PX
M![X-6/#6K02M>6;Z@L]REU,JQM-YCA5P"/7`.>M95]?W`'B);?4/W86.2SE-
MVP02;2&CW=FRN=HR.GO4.IZ_K<5[*GV>\M(/[+=HV8(<R?N_WA(.>-V",<<F
MK.F7%QJ$&CDSRPS_`&MQ^YNG>&2)"6)!/WP1@9/J?2NU7[HSUIU%%%5I;"VG
MNH[B6&-YH_N.R`E?H>U1G1[`P/`;.W,,C^8\9C&&;.<D=SFLCQ3J#Z5=Z0\,
M=N99[AH1+)`TK1@HS':%YR=H%96G>*[>)KNW\0V,=E]ED\Q0L.Z*,A%D(W=-
MXW$\#-:/_"6Z1I\B6*V]S`Z[MT*6I'D`%<E@.`/G4YZ<YJ;3M6T>]>.VL[9F
M%I,886%N2B,-RDJPX`&&&>/UK/OA&6UB2RTFSF6V9;>0&W5BX($DC$9&X<K\
MN1DC-%KKMOJNMKMM(B$00P7DD`/G3&(2[<YR@`.<'.>QXJ:TE0C1&>PL?)U2
M!TG$4?`=E$AQZH2&R#WP:QI?$<=IK5Y;KI=NX0M:6"?9PHF;<J;4<_>^^^X=
ML>]65\2V4FIZ'H\MM;R(^Y9VGA$9@=5?`5.0#E2.I`&/6IK_`,2:*OB*"T^Q
MVDL,EN[33F'<Q41E@J#'S`@'/Y5F/XTM;BQLY?[.LC/<ZGY1+)N2-%D5`Y..
M7VD8'^%;>B:E9Z[XGUC-C9AK4(J2A`9G4AE;<<<?=QCT^M)X>U>R\0:1=2V^
MC&Q73IG2!)X0-C*N0ZC''6JVA^+)5T^WN-7:^?[3Y:AI+)855C@$J<_,I+#'
M4]:U;/6=-UN[E5+&6:2UN/LDC20*3%)DDCGL,`YZ<BJFJ&ZE&M_V;#;^;`8D
M(:)#G@.[DL.3@X`/'%5-%\0K?:I$8(!%9R(MM#=-"@:>X:(2?.HP5`7L."<\
M]*M:->SW%CX>DN([=UODD69%A"C?M+!@.P^4Y'N*R[S7=0;6+Z"&!5MCYB1N
ML22%HTD02[%QDLH+$JW!XQFKVDZC/J(T>X:ZA6*>)WF@E@12\2;E20#[P)^4
MXZ<G%6I;J1M0T;^SPT&GW<<D,:M;J/*<(2A"$!AT)/;&!WJ#2[^Y":5.MV)H
MKS4)(3,T"(TT81\$X`Q\R9'KFK>A374FKZI8ZD$>2"198U4(8E1BQ3``!#X`
MR#D]#WKHS$I<,0-PX!QR!0(5!&%4;>!@=*>.!2T4444AZ5S^MWNC+J=C'JDQ
M2ZMI%GM_F9<,VY0>.N>1CW]ZS'D\*7]Q,DV^22>0W$D+B3YF*K'DK_NNO'OG
MM4:_\(S>I-]B,ES=?8I5+F20ED*J_P`[9SR-F">>,#I46A^(?#UEIEI+._V2
M\N1'-);X?"R.H8E%/\!+$\<<U8N=5\.R2SSS2WOE7AS(B1R!',;>42=HSR2%
M()P<"I&U3PO:7:Z@P,+SPD[A&ZJ=JL#\HXWA58=,X&*GM-1T<36"6D=UYMN&
M@@M5C;,2D+EBIY``*_,>S57DU+PO+%//-;2;'R[%X7`QN)+KV4;D/(P<J/:K
MRW.BM!]J&5BT>5E5CG".P*DXZL3N[]<YI+K7M+6ZM)KQ+F.:$X4/$086D!4*
MX'0L`<#Z>M5;#4/#VK,FFP)<$W-Q]M59$=`9.)<Y]>0V*L66O64_CC4M(CM+
MA;V.WCDFG8?NW`Z`?]]]>_-/N?%>G12W%O=+.1&9%D*Q,RJJE58L>P^<5EIJ
M.E8N#J-H/L>GR-#!`MN6-O$CA=Y(/*LR#''\(KF[;Q,\6M3365GHZVTD<LB;
M4Q-'(@;83S\QR6ZXX#=.*Z&+7-#NQ"VI0W9O=0CB\^W,#X+*H^<J.@Q(!G.,
M8]*G3Q-X?ENH;Z+3KG[1<1@I(+7YBF[R@>OJ=H/7'M4D&N:!9+:R6T5Q'%#9
M/+;1I&=OEDC<%7/WN@_/%3I?Z->74T0TV5[J4M]HC,&&4*0"6YZ'CIUJG-XA
M\.^9!K,VF.+F.*(Q32P*KI$Y(5E)/3[W`YZU=@US2)1>ZJMN?M5M.;)B5'FN
MV0%4`G@,2`,XJK<^(M&TNU1;G298H+!L!?+1A!.4+A``?O$$\CCGK5O1/$&G
M3WYL;:PGL99R\N)(@HD8!6;)!/S`.AY]<=JZ;-%+2`YI:Y/3?&23WFH_;6M8
M[6S+EY8W8^4%D*`."/O-C(QGH:M7GC/2+:ZC@-W&7)^;.Y0J[2Q(.,$@*>/K
MZ5)-XOT2S607-^D'E.D3^8C##.H91C'/!'TH3QGH,_EA-2B)FC,L8P070'&1
MQSSP/7M6=>C0==T_3KCQ-!;^9*91;+*K*0`2QQW'RH"<U!JMWX?LKZ\U2.Q@
MEU2!3)')M8DRI$^,\<#:N,]*BL8_"\&@0ZI:6BQB_81LT._)E^8E6Z'`);.>
M./84>'5\.7-AHMPA\J^E4+"%ED\Q"J\Q`GG8!Q@\5G7L]O!KU[:G3$N8XI?L
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M9=[J4<_P_<.`>IIUD/#OB*ZN8K>"6222)GF#1R1JRR$`YS@9)0>_RFL8:CI%
MRVLRV=G;-)8X:W9G<^<&DYWCT\Q<XY'0^U6])T>SOFDUJRTO3DBFFFC>%U.[
M;DI(^[.`QP<C'(XSFLS[?!:>&X]4FTJT2<)&UD1)(JN67+1Y^\0JH/;.!70O
M9:;-#I":7:6H^U1#R)G!(BB7$@P,\_-M.,U1>V\.Z+,]IJFG6INO*>60VL#%
M?*SC<PS\I.<8YZ'%++JOAM9'N3ITR2`>9Y@B.[S'<ILQG);,1)'3"U7":+#X
M,N'ATN2_.FO]E!N(=K22Y\L\9Z`G![=:GMKKPVSPV2:2\QO9/+WI;_+*&&?,
M)SPI\LX_W*74'T:T\46NF'3[5H9(S;W!,;%MS*Q1<]#D;@<\_.H'6FW.N:#9
M0-<Z98_\3&*-3$!%\T9D55RW/``$8(Z]*U$\59T[4+DVDS"SM_/W!=JMDMA>
MIY`4$]N:DGU2ZT>:U749$NTN5^[!'M9&RHR!GYE^;\.*J7/C.UGB2'31.\L\
M;^3-Y8*;E.,=>2<@CZBI$\80VRNUY;7`B3!:Y2+$*[BVT')R#P`3TR173(^Y
M%(Z$9YZUAR^#--D3!:Y#?+\PDY)60NI.>"06;GT.*J6'@[%Y?S:A<>:)[EIX
MC'PR@J5*GCIM.,<\Y/>K</@S3+;4H[^$W"S1C"_OB1C8J=#ZA5_*N6\[0AIU
MK<)#<PW=U=PZ:+9+DKB2)\*V<=%&&SWR/6M34%\'SZ=;:;>:C;F*R+)&?M.'
M3^$@MU[X]^*JVTGAN^U35[:ZG01Q>7)YANF/VF,Q+EC[<\XZ]:U[2V\/:Q8/
M:V-XD\%O*\S^3/\`<9PV[+#H"&;CWK/T6]\.0/<:LC?8#'<26A,DP*N.''3C
M!'S`#I5EKOPK'I]Q'+J=L;?4;B2Y9VGZR#!8J?X=I48],5+8WNCSWOFF\,^R
M0)$\LY<2$IUVXX`#=?>H+;_A%S,MM9Z@4EF)B*1S,K.&9FVGVRS8^O'6HS)H
MFE:_=17.RTAM#;M$3*WEM)L(4;<8!55&/KFM2]\3:+9R/*TT)N$9H2P0\,HW
M%68#@#(R>@R*S6B\+:C'(LLBB3$D18RD.0\GS`'N"XQFK.G1^';LQPVTY<E'
MNUA>1AL23[QP>@(8\'IFJ$MAX?O+N.QM85G2_,DD^]W"A5RQ<?[69,J>G)(J
MU83M)9-J2V\2:9?Q?OIWN&$Z0JI"N>,=.PY&:KSZCX0OC;E;QY6BBCMHQ#O)
MVEE900!GJ@.?8^]5H-1TDWUZEUML-/B0SR`S.(W>10SLG`'`D7\6Z5L:;<Z?
M)K>GV6F_O8+:P;;(2Q")\@4`G@M@C/?&/6L70M3LKO3K*/4;9+&TMP9+*X29
M\QN/,W+N(Z[%+>F#]*B;4]+M;NX:VAC\\7#QS*\DF);=07:4\_,P/<9QG&.E
M;UKI^B:D))A`5E@*O+)')(L8<%F.U^`<,SYQZD&L^PUK3M:TJX6)H[>UCU+A
M(!YYN@3YHP!G#-G)&"0`:N6MYX<L)E>VA9`LI6.;8Q7&-I93T\L;MN1QDX[T
MD^O>&9(5#N\JS3I=`)'(2).&5C_=(`SCT&:SWT_P6NY3I+*/.DBD*1.,F,G+
M-@\KN4X)ZD>U6#J/A>+3)A%!<+:2V[12"..11Y:;>",\9\P8/<'K6C;>"M-1
MYAF>2RGC5&L[AO,5<$%0I;YE`('R@XS4\/@CP_;L&ATN!=K%U'.%8]2!G`)X
MZ>@J6[\,6=P-D?[F&0H)XT4$3*IRJG/0`\\8S6OM/K^E+C/6C%,E!9&4':2"
M,^E<5KF@Z5I*6DETTX-U-;VTER'`*LH(1L$<%B`"5P>!3=/T;04,EFU[*(=)
M9+1GD9(T+9$@!/&YAA<GO@56N]#\.6&@SFWU'[6MDGVF*)9XV8%`O/3YO]6H
MYX%;H?1CH<RIJMM;PZ@3,TGF1C=G`8#MVVUEZW::=9ZE'#9V2M_:$2R;8[E+
M>,!/W:E01RQ$O;K@4RPT#0FCFOIKR2S^VPR)+!+<(0%9B-RDC*YZC'KS2ZEI
MFE)<K+:75SG6)FM9%AN5P8V7!=>#\J[.E3W6G:78Z=#=6L]Q?JU_$%=+@$AS
M+G[V.0&/*^V.U79;;0KZ:>634XY/M$^65;A0"_E&/:,?[.XX]1FJ*6WAVZM>
M=3_T>Y#8G$Z*)AM7<#QQ@!.N,\=:?=:-X;CNXTN=3D1[,&YVM<A55?,;[QQC
M`9V&,_RJ^MMI&BV]UY^H,T=S`6=)9%)=0F"PX!)*J.>G%9>CI+;WMK+I\2SR
MW.G[UBEG^5(LKM+-M_NJJ@`==V?6I6T_1UT86&L7;Z?"0S&PEO$`@W$@`$=5
M!^[GCD<=JK:O-H,=H&-RTI:6)!.+E4!==T0#$#Y5`WDD#'!Q5;4-.T*'29I-
M2O!+=V,0N%B@F8*`57RQG'S_`.I7D@^I&*LW'E>&-6M[J"UGN+J]MV:6(WGW
M-SIN$:;<,=S9[=*CUS_A&_[(T'39KMYM-,NQ9A<E3&K1N`S$#)!Y'.!ZU%ID
M'AW4K`QWGF0E9FB54N7D.':08!`SM;.XYXY'I6M<Q:=HKVV@1M=>1J,A5O\`
M2>8`Q8@`'G#-N'YTM]8^'+J^CO&N)8)UE6-&MF>,*R9S]T8QAB"W3'&:AMK3
MPJK1K!=OM7+B%Y7P$,@PFTCA=^TA>.W45%9P^#4BD2VN&E2ZWI)(997W;8P6
M.[M\A'(]@*BC3P5/?M<1W5PTQ0SM$)9P#@NV2IXS_K./KQ6Q8V6@ZQ)/]E25
MBJ_OE_>(N)(U&T@\'Y0O';V-='#&L42QH,(@"J,YP!Q4E%%%%(0>V,^]96L:
M$FM"*.YD;R(]Y,8`PS%2H;)Z%<DC'>LE_`EM++"TMQ)+%%*DODS(KAV";27S
M]XGKGU-1GX=V`MS%%+(G8'RT((P05(QRI+$D>].7X>Z<L]W(S%S=D,_F1JQ4
M[LG:3]T'T'3-;<^C17&J+>38<)#Y21.H*J=P;</?('Y5B0?#VQCL?LEQ<3W,
M.0P6;:2K?*.#CIM7&.P)IVH>`X;\N/[0NHHVE,IC0)C.7..1]WYR,=QBKEMX
M4AM=,@LTN9ML5]]N+84%GWE]N`,!<FJX\#62W".DTJJH3*J%!RH89!QD9#L#
MZYJ-_`5J]F]O]MN@KQF-N$Y&Q$Z8QG]VIH'@&T$44375Q+'$RMB8(^\J[L"V
M1\Q_>-U]!4^M>$TU/[0\;XDN(TC=&QM^3(5NF1C<QP.":T+C1O,O$N[69K6X
M2+R-\:@AH\Y"E3QP<X],U1M_!UI!=7$\DMQ<O<2QS.TQ5F+(5(^;&<94<=*K
M-X'A,EL@FE>%0_F,[_/_`,M"NWC'65LD^@I%^']FMNT/VV^"-N!(9`Q5DVE<
M[>F.GIT%;2:0B:HM\99F=+86RH6&U1G)8?[1P/R%8]K\/]-M`P\^^F1U*,DT
MP8%2,$=,@8XX[9]34EAX'LM,O4NK2YODE0D#,P(V$_<P1]WCI5V]\,6=_)/+
M<!VGEE2439'F1;,%0C8RHRO3W/K4">$+2-(T2XO-B1/`%,HP8F_Y9GC[H[=_
M<TDG@W3YM0AO9#<&XBD\S>),;VR""1T[`8Z<43^"["4IY<EW"$`"B*7:!A%4
M=O1%/U'-)'X+T]89HW>[E,WWY'FW,>'`Y_[:-6CI6CQZ4\S1RSRM-MW-,^X_
-*,`=/3OUK2HHHK__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tfooter.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tfooter.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`6P%W`P$1``(1`0,1`?_$`'D```(#``,!`0$`````
M```````(!@<)`P0%`@H!`0$`````````````````````$```!P$``00!`@0#
M!P0#`0`!`@,$!08'"`D`$1(3%"$5,2(6%S(C&$%1<5(S)`IAD:&R@9(E0Q$!
M`````````````````````/_:``P#`0`"$0,1`#\`_?QZ`]`>@/0'H#T!Z`]`
M>@/0'H#T!Z`]`>@/0'H#T!Z`]`>@/0'H#T!Z`]`>@/0'H#T!Z`]`>@/0'H#T
M!Z`]`>@/0'H.L\70:M5W+I5%!LW3.NX7<K$;H((I%$ZBRJZ@@FDFD0HF$PB`
M``?Q]!TVSUFY01>MW39T@Z32,S=I*HJM795C`#<$'20F(N!SB'L)1'W]!W4Q
M$P_(P&#^;V$AQ#_+.!1_4GN'Z@8#?[/0=CT!Z`]`>@/0'H(K9)!=A$6*08_)
MP[AHE](),P-\?R7#2.7>-V@'_0"$<*I%`X_J/L/M^GH/SB<A]T=(WO-NVM%>
M]#WOH'K.B8OJ]XH'!1^4;#E`46T0TY,M*$G0WKQ)6T;=!.'B$9'&?LTS,UW#
MSV*83&`H!?O%74&HW[@3IW2X_MAEN?2F+PMT?W"4W+GN7YZC.?[U4,^9W"5S
M[0<JFEHNSFK;0$5E#3+D6_WME2K)$`J8E$-2\;M-DWSF3,+VK;$8>V:=DD/-
M?U9242EBV%@L$$DNG8*V@]_*(=DB]6^Q$BH+$40]@']!^7H,+^3_`"D[QM/*
M?0..[Q)RV)=AYGGV\6S%MR"HM6=&ZCH&*Z/=J+*:OES%^*D$:6B)&N)L9J"!
M99RR.8KHH&24$"!9^N:]VH6[9CFU0Z/EJ6[[.\?"URY:GY2L5)Z2*[8QJ%J%
MMM%*E@7)]CQIKE*L::Y&PD]D`:R+A$3"@5(0J7E#MCN/K3E/BYS#ZU"0G0O4
M/54I)6QW`UJMR<;F/+^!SSMEM;*40-(*I_NT\9BBR3,8A%$'SPZ1/<4O?T&P
MOD"D;K5\"L6F5KIIWRO!Y<RL]RN=P8U.N6Q_86:-6E6-;K;(EDD&\8S<.K>[
M8*%)_,J[%+Z"@7[/D`(7T/-=]9YP[0]PN_5A\RVR$YZSBL$SRN957&LCK/8F
MJ/&-5H=<M"=G?@SJS%UH5HA8=VV9BL`"HZ<JF032`!#L]@^1FHRV$=Q89F^E
M;CD/4/)F505PTC0J-DUGD&%/F64/2KA8SP5GDJG,TR54<,II5$K(1,X=)"H=
MJF<A`-Z!U>+.^,#ZZ2>T;.++H;[3,WSC)[=H,+I>7:!EEA=P5^KR;V`NT;'7
MRMUHUCA+(HU5,5]')J-1,?V`?U*'H,@>B.U=&IW2W15%Z-[#V_QP:-5]*AV/
M(4S;LVA;7PCHF;6*N1K&GO+]:BUEXPL4K/6MM)+R/Y5E@G<:G\B%;J%8J_(-
M%%O,9QU37V]5[19[6JV3E^^US+=3OCG$]+D<_E;;89IK5HIW7+=!5R3@9%G9
M+(Z$C<B3C[02**HD*B'S]!+YKRT\:5>]8CFDS?K.QG=T;U!U`JSM$ML(ZJ;;
M19U[6\Z6T6.EX>/DZ@E=9IFH@R5>()$(@!72WP;""HA"F'FHXBE)O?(*)MMV
ME'.!YMM&G.WA:+8VT3H-8YY9SA]E6SF77CR1]D4I4E7%6IUA,DB[74+^.*A`
M$P`T^,],2O47'C'J#"*)=HF8TC*;1=<DS[9JS*42PN+(W@I+^CHZ<BY%!J=&
M!L<VT;G1>(G5:O&2Q'+991!4IO08=<;=N1L5:J9=>H>R.J,;Z0S?.=(D^O.1
MNH<UDH2N7]G3F+^2L=JP>N,Z)%*R3:@`45F2L$\D3FCP*#H@J&]S!IYT9Y-L
M&HF4;7(T32Y"&T&N\4)]I4.;?X_H5OJZF6VE"/BZCH8-6D>P:6I!K,3D:,G#
M(.TGS!LZ34<$2*I\P#SH_P`K67..EAY@99CMMU"LX_6=FO/1U;J<>SP&!J4K
M28*WNYU_/N9?\J+1:P<^D\7;&3.+9,P^XB)1$0DW(?E+Y9\A$_HV5\YWRU,[
M_6*2WN@EFJG+PYE\_MP+157TFHR4K&IPTHU4=F!=)JHH5P0P%%9,A#`(@@\]
M-[CQ#T;W#IM0W;6=ZQOG;QR/=-UIEKUF:V1*1ZA:2TI-U1S"K-H^,BJ@[E:=
M!2:\@R:)*HI)D;$.0@*%.(7UBE=VS`>ULHP<_0^J:U0^M^,-+UFVW*URT98(
MZ"Z"RB7S*'L.B9@W*P`:]':`AK:$BI&&']N:&9(E0((+'*F%H>%[1=@TSD.S
MRFZ:M:=IT"K=5=8YPIH-P1C$)J4K^?[39JM7V[IO`(-8=LFSB8Y),A4B`4A0
M]@_3]`!3_(#Y]J9P?Y#</X(D,!NF@O=/2SR1LVCQDTR:MZY&:9)R4)$+P,,J
M@;]_<Q+IA]CM-99L4B1@$HF-[!Z!H?.9<KMGGC)WS0J!9+]5[I39K#W$._R]
MZ\979=*<V_-*O.0L,JT(=59W/5^P.VJ0"3W%94GZ`/H$)X][W2YLZ$Z=R/:;
M;TK5<I99?B]ZYRPCJR.<_P"I"Z7^_2LG#VR)PI1_',G>H4R<LS0R+-%)9TY:
M/@<$$J;<A3>@TCC_`"LX3(RSG-V].UE3IXMZ>4?_`$B_T\"^\D-&59Q>W%C5
MK:*XH1]+-4&+EX2175*BJ5N<A#&4]BB'+LWE8PWFU7,DMWH^R9A%:+(Y757\
MG:*8JU;9U;=GG;K7<^K5I*1RL]=.GCFAR!W[ED1RUBFH-'#I1--\V,H"T>>W
M1E\CYKYOU)E:]:@8Y/M7":':C8Q*6!E;+%FNE.)YK<8!E'P/W/+$,TWC6GTI
M()'<@HG_`-N('/\`$0]?A?JN8H7`E$V)XMN?4L-K6_Z!!<OUIT#.0VV&RZ7N
M;Z&HE0VVRS@5>M567H:,0^_=I&<7;-V+040<J@H4P`$UJ/E\I.LWCD"I8=@^
MJ:ZIU/.=!5BU+5J<HZ:.`->;+S4Z+IUJT!^\L*$#-UR%D[>BLBZAWCH'S3XB
MS_)471*8/N6\QF6P#O/+):L(WFJX/O);ZAS3T-+MJJQJ6Y35`ITS?%8N)J2L
MX-_H32YU^M.E*](V:,BXZ91*4Z"X@H03!:7*GDNJ'2FH4?'I3#M@P2VZUA1>
MDL91T\:?+%T/(TIE"OR\HFG2+/8U:?*0\HZ316CIO\)_\5"J)IG3$#>@BGG%
MLENI?BTZWNE%MMJI%KI=#B[=7;)39IW!V"#F*Y;*_+PKUI),3?F&;G>,")+M
M_B)'":IB*#]7S`0QPUBF9#5V50L-=YS\@F`V.7[BX.;PJ=[VG8#1FH3MWDK#
M+RS;/X62T"7:LLX(5J\5L!'RY&JYH\R()D$J2:H?KL*=1-PLD5-50YEB#]HF
M*8`*<P^PF`HB"1$2#[`4Q0$P#[A[_P`?08>X/0WN2>5?I;%?V#:LZS#=.5YG
M3:V[L6T2&B5_9K!6]6K\;IVHU2/>V2QR>43M.5U]G"H1R;>*349*`L#<"IH*
MF!)>=>N8#QG$\P+74Z=LF<)X'L^+2F)85>]-LVRP*.4;!68O/,DO\5H=@F+2
MJ5IH^APD[8+&U+(J#"1J!@^H#)@4X*'AW5VZ]6^-NI&H5ADNZ-U7\H^DN]&P
M:#>VO-C=$9;'7"2NDM6J]9)U]7Y6B4*DTIVUD?J]E&A6R:*+E,A%1]`TB4;A
MW0'B9G;5KN7[MD]SPWH[3,SS[E:-U'5,^O.1=,7^WPU%SK#Y&PQTZPLEK2=S
MU\CI)J999=B!)HHH&!-(@%#],7/^=S&1XCC.63]KE[[,YKF%'HDM=)U59Q.6
MN4J];80CZSRZ[I15PN[EUH\5CJ*'.J<ZHB8PB(B(7/Z`]`>@/0'H#T$,MC>Q
M.H.7;4N1K\%;7#202KDQ9H5S/PD=+'3^*;N2@F4W7W\NT$XA\TT7K8YR_I\R
M_P`?09R4+CKH**U32^K+OO&.77M&>R8_/V5VZ+PJUU;!,PS!*PQ5]=PDEDJ.
MRRMSM,W8;3%(NWSYW:D#%*R039D:D%<KH/N&X8TJ`P;L6'0UC*W_`%?W`:1E
MM9VF2PYP.4`[<T*O8VTC8C%DKV294JL%E4*D@DTD+.^^<NX7?+BN555N<&YP
M#-;UCW.659/8KI7K=>\ZS6$I[N]L:<M5ZE+V"%C1BV4ZWHI9Z5=1L4HN5(?P
M$Y0R@)E$A%2>X&*&,BG'G%73O#\/XR+GWM@M^WVB6?4[:TO_`#OI.>UC7*5H
MU@UR[:):5H'/4-+OMNKT-&N+8^AYF+<.E#NH\#H+JIG$?8'-V_D7!O(CP'0,
M7S?=V,M7ZD>B%R+J/&;*SF)VJV'*99*F6BQYQ<*A.QZ#"PSD#'S-><F;//H;
M?N*Q!!0$@)Z#GX9\7&1\0[KT;N-"L+R38;@YKY*+GZD<C'53":P5JE(W6M4F
M-;+EBF"%\O:KB9=G9LF'VKKB"I5C^ZI@9KL3E]MUIGE`S.3GVL17:UT#@^R6
M9@]B#3D;<JYBVFP.AOZ'(,R2,;]#2WA!@R.M\E2)`?Y&2.`>WH.KU'S$GTI8
MN8)"6N)8JM<^](5G?I2GKP[R18:$O6J/H]8@(!ZZ82D6ZCCP5JMS"9:.A*LW
M*K&%*L@M]A3I!FYV7X[+7:*WY!6$3UG0\3RWR)O\H+*-+-C\[<K]3]QK,;1*
MG$NJ3,Q.I5P+`PL32BIF&""+5=IF%54JX))G*`750\XR[*?)!&7ZS]HX0\U>
M8XTSKE]#F`SNM1.P3TG7)V-MW]UFU?+I+VP*Q4P>%,9%J$#]35F*IC.C%*8P
M!`]"Y-<:A>-[X6LO<D);<>WVN7[5;?S[<JVGIO6F>TZ^S",;<#TS4+A;)^*H
MF6&D[&=K7$7-0.[8`J8D4]`&Y1;!2O57#5-LG,79I(/M?),XY_M72F1;C%7Y
M3.7.DIX9L.0W&FPU^BM&FH30086B'>7V`;@Y8J-8L\`J=P#M4R)3_4#@:'PK
M4G_0YNZ$.B?[=R$_C=$K'1+Y6K9++9[H=&S=DJ^@YZ"FKM"693+T#IOG"QGT
M<]42!FX#V$%`(J`+-R5P1S-;LTZ%QC".V7VK<FW:+WVA2F4UJ(QYS=,SK_2T
M=9EK55)/4'%+=Z8-6C'5F=R%:,X.W45_D.LY?H%$#`_G+E'@7_"->QI[TO%;
M!"5[)[;@S_H_*',53'!XF'C9>CK6"O2\/*3T!!7>F1K;XK.V2RR*,DS%4H`!
M?@`4`W\>2F_T6HP/3?5SSJ'-:K2;16<PFHFJ9[79R>C;O3UZ*I;[IH,$UD%[
M3.PK,Q5H]6'&)05>%.9Z5[\O8`H7.O$A7P?:9EVO=L3>OVZQ>..Q>/\`;U-G
M6\ZJ-BSSFRVS<0A4+BA7X5N:3<V)E&U5.-_='Y#,W[E`3E(0X*)F"[([QQ93
M)]/WRU5[I&8FJ9,<W-^7=YY?!3.UV\W5GV35FA$5F9"OP\;?*0\G,_:Q;P@-
MW+8!%0JS;ZDER@`3/@+END<GO]-PC/>PI;;TLNKD!0H'*9J'P1.W<^TQ-`SS
M.X^UO<_H4%I%LG211@3*^LD@Y*Z13*)FY5?D<P4KS%P2I+_WC2N/D(MG8'->
MB3^[UG2,A2JF0M*?9+WHZ,G4+U&:!H=(KG]9W9Q2(J74CB-'<J(1+AHW3.)`
M9?CE!D.3>!;#S4W.[LG2^D]#W//LR>XCS7;M=K-#(]PS(&S*,:L*R#^EU>K/
M=`E7"T)%J3$G,*N',L:*0$OTF^T3!2F!GP7PQY#$XATMUNE,N=KUO9=1S^S6
MK,;!&O;'<+G+.M)TF";FI,;-0SA]^?*JN8Z.$S=\HD;ZFY'`E]O0:!9C.<K]
M9Q=$Z/SN/R[8TXTZ@9]J"U.8R5BK"J!RJ.FT7+6.#:6NK/V[@H?:@<K99!<H
ME.4IRB`!XO:/*]<[4P6T\ZW>^:)GE1M\K4)B5F\R4JC&V@O1[5`WF`:,G]OK
M-JB$E`M%>:.3"1L)Q*W^`&`#&]P2&]>'G"MO^%EZ?U'9NC-^B:S3JAFG1EF9
MY?3M+PV+J-K5O%=_L^7.LTJ->@GS>T**NEG<BPD5W*:YVSEPJB!$2@JFS<[>
M.>ETJ,[VN?;&]T30VO1C&<8]S4B/9.=>N6DU^-E,::YS&4*IX;+U'0*,E'/W
M\4\9,:3(,'Q!7.Z4,"(J$#UNB>*.$];S3(.N>C^P>FK)4)RFYG4:G:[77(4=
M$UF3C]@F][SV1J6?*<^EU^$TUY95E/>.I,3$N7-?BTB*,_P&R@@#B]Y99RWT
MOKW$^`:EUIH>+;)7M`_O[A>2YK,U9K8]/F,^8(#'V:\U2TT&[*&K=6*1TFS7
M7)%)_DN7B::QG"8E2"OH#C7C#<;5V#G6*;#K&;S<3T[EFA[EFU)E82+J68]'
MT9%G:8^Y5;--$IMBIR,?LS)P1U+-18OJ]/J)&<E1!VG]H!7S#$/'OQ1L.*9S
M#[AL66ZCGFTS%VBS0U/FKG`!_K9LD9"R&*:7=!R>WT.F43?=#I1'#521D(J1
M"60^MK(M$CHMS!%JAF7C#G-/A>4H/J/3YZH(3VK(<VX"NC..^>,JV)>M76)T
M0V"[:]S`U.T+1*3&VN;*TK#NYV9"LJ`Y1:1K8C8R*(3/"<FX`W33*[0L1WK;
M7'3O'O(MHYO!*UP.H8GH2&,:G(GCV]TFZ]:L_P`D<3K=U:F"2C"=KOXB8KH@
M#9P0#@(A)>SZMRMDOCAH_%WD(WKH&PYA,4/.Z/IO0%>I>KRMDN1<^L5*>3EJ
MT*]9[1[K"9M4IV813!\M8'[<[J)%=$%G9P56,$>\F-LX<GZ_@'/W0DOUX[+D
M.K8E?ZK:.>,QWF4)4KDBT:5W-;M=M>K%'>TQ$J)+0F06_P"[J/Q._`RB/\X%
M$'-Y:/S!CNBZ=QK1-?V'1-UBZQ$[=ID?M=LV2ZWYS4KNY+!0<\QOFAL&L!^Q
ME>K@T;1\&]!./6]R"@BH40]`M7/S?DW<M4Z/Q;/I+LZUW>+KURJLAU1<7&Q0
MU<85EI>(!M9:1SCT>X_"K0H0-YCD4GK"'6^Q\]KYRR(N`9^X`_V%<Q9MSS%6
MH:8K:[3<+T^BY.]:!J-HEKY?KD_AV0-(U&7L5E6?O48:*;I#^#'LA3C&:JBA
MF[<@'5^048W\;G.BN:NLTD#:0Y69[=IN^U>]5VXRN7:A0[QKLFYF+,:F7G,0
MI$JG%KI/#-5D#JJ`\:%!-[]P@7T$K5X+P(,PQ[)XUC:&%>QS=LXZ*A'[FUS=
MJO=JUW+;C%W2+LVBWZ[24W9KY+2[Z$;)/%Y1RX>'9)I(%4*BBF0@/$@`_(HB
M90X"8PI_("%!(I$TDQ*;Z!!(PJ"'R+[_`.P?T]!WO0'H#T!Z`]`>@^1(0W^(
MI1_00_4`']!_B'_Y]!\`BD4#`5,@?,"@;V*`?("A[%^7M_$0#]/0`H(C[^Z9
M!^0@(^Y0_40/]G_W_7_CZ#@6*;Y^Y2B(_(A4_B(&$H"/N<X$.'P)["'\?X^@
M_)WA/.Z7:'1/D0K^20>*T'*,R\IM'VQ;HBJ,HB/VN&F\KJV43%OI=&=5I)"=
MCG-FEX.2:+OWROX**#QZ4J2IUSF*$/\`&IV'O7'/-/'C65AN?[OQUO/6W;F)
MUF*I']5M>@JO=FNN=&Z;$OI?\RP.:=9XZ4D<^D6:#:&8(B1*19"?Y*&#Y`T=
MH\S&[U[$Z9OE<SK#[E4>C>=]TW;):5!.K2_M^#3>21"5M;U[IL8^84*O79>"
M$S%U)QI(\Z=@(8J0"W$A`"L-*\X76G,.*5+4>A\<YTT&1W3BMOU#@\1S@ZOI
MX^NV"5O^9T$('69JXV>;8*U.KH:DG)S,E&"C^.DQ63-\?U.`:,<Y=*=P$SRA
M(=5RO"L5=[#U/!Y@:VTO9U[#`Z!C=BS^<L#$M:BZZ5FV0W][98U)%G%>XL7$
M`51Q\#*)G,8.GV=8YY]Y2/%-F%H?R$%C[U'I[2X]=LY`:S>M_IM(K;2@U*:8
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MG^)BTNS/?SB5R1B:[+"\K-5LTA.II/$HZ)C8`S!^L[,0_P!C0ICG#W4'V#'?
M7K+V=S[3.I.5KUO><7'3-]<^-WG"Q]\<YUB&I.29'RKHNBWS,D&D]7:[\(R$
MTF`)9)U)\]<N!5=PLFU5.8I4VIO0-]NVB=R)\';OR'E>2)[-D?/=_P!MQC3]
MQYN<4_G5:U\TU/%(C2JBM1HVOIJ04+^;+6(:M9G$#];AVE`ORH&35>&$`?;P
MO]";-(>,GQ[0$KS[J%IGK#SM(2)=!=S,2_HS*$JDG*1=8=VBWNU4I=G9+:DB
MD+.)%NLN5F`'47$P?J&>'%E]\AU&\F_66CW_`(DGG&^;!P4^T^V,K1L$>6/<
M:-2K;8"9%1L]B"N%8>*S-1HVBJXY39(MW`S+E63<J'^TY?0?/!U0\A.=[%Y%
M]]J?'5Q7Z3F&,L\D6>O=(T":@Y#I.]9!C%E;I.:W$P9EX:LB^DC/8R+CE&C*
M.@10CRIE.D"HA7GC&CN]ZL]\PT!E7+U@';+;N&4FODGL_2M2<;FRO-FH,6_U
M`$[A(UF8BY:,EH)TN[K1A^I%FLX(B!2F0]_0:?\`_CD/[03@JUP,EE%ARZ%J
M_7O3\)"Q]IN+.[6%ZQ+J4Z,BC,RZ**2KA_57Q@CWK]0QQE7;5=?V+\_U",Y?
MAGFE;>;_`$?8]#V,KOQHN(N:0K&<J7MTZIPP#JL1[*M,H#-8U-LTCM`BK)&E
M5>/W7V?(IESB)A<@!`]GS.RLQ)=0^';/:'/YQ";-+]=7>UYTYV21F%\G/+5+
M,7()M[S2ZD]C[#:1L:DF#>)%LNV*W>@/NJ'R$!!6N@?(MV-Q!.Y[F>P=`X4I
ML&/U_![ET'G.=Y/4:[E=XKFQ;Y:*I8K1:+)+D1MM59GHY(TE=2JR0*-UTG;B
M95.4H"(7]3N]]ZDO+=)\46KL;)4\4<VZPW#.;2SS*CD<:'(PL!6EI_AAE9E4
M%F!-9SG]V_J"4>E.G*GBWS5(H`L!BF#3"M:YHVD<&:OIK71<TU._R65[Z]J%
MXQ.O6NMTN0DV,';U*6U@(BWNG=C_`'2,6:(-W1U52D.[2.)`*`@'H,_-)I7.
M>C>-?B"\6;L:3Y2+D&9PFV4"Y5RS5!Q*V'5$\ODF$ZA_3=J3E5M'6KU^EWCH
MT8W;.%U)%(A!`0_3T"!S]\['W>+X;W/H;HQWRSL>5>.?9.E,0>1=$C(:D:_T
M(>7-'5XNBY]=FSUM^\S^0Q]>D/Z8:_&72_?Y5JU*0`$@`[>HWVVZ9VS_`./S
M<];JC>D]`V&@=(6W6:2=!BG/5-U9L;H1%&<P+9+_`+",-96[\K5`PE*=RDL1
M+W.DI[`T>15IX'FSZ^L]1(J%./Q/S_`:FNB?_P#FAKJ5TE9#/TGP``)+37]N
M4WQ@./R4!N'L(@'MZ#)_NVD:D'DWMFXT'031$[&=$\`46R^/PC:9,AVODE$N
M:<U!]%+N46[B(/<\UO-_<+PJBHE9136C.W#TI@41$`YZWSSTG+]19'PA#Z?D
MFH\8\7=?7;OC1M[AH:WM=5Q%NTG-'L]1YPNUF_+6SB5N"DAH,@@NUBVWWMX:
M-^;CX"H5/T#Z<1]MX]U'MO8'1N)I(:QO\M4RPE`P9FREZ1/5_%<HF%86L,]'
MO%FK+2#J]WU&TN5)(&*JT@$6V^KXB)#F'T'F^8EO<=NX%4R2?T0^(=:.Y6$U
M.C<Y9T<^L0V[V.IVY3^A\2O\2,21E?<VGY=:+4G_`)))-45FHNE"@W2$HA>'
M7.ESMPTCQL<26V/CX^P="7-MKF]QU>9S"E89U/FFMP%QDZ>U.``/XDQJ<A#'
M9J.%E"I(PI@.01.D/H*VH=_JAO/_`-+-RS;8'<3XX\JAGPD1EU$&,I#:\_ML
MW#O5W#$T8G)-*\J5V9-NH8_XYP,(?9^@!S<"5G(:1WCJU:XFT;7KSRE+8_JV
MA;Q%V.X7J[XG4^JM!W*G6FK1>3O+F<6%<F'-;E;DYFXB&*5FW(NS,L`*"4H!
MNT*28^WN0H^WR]O<`_3Y>_R]O]WO\A_]_0?T"$*'L!0`/<3>WM_M-^HC_P`1
M'T'R"291$03(`C[>X@4/U]O?V]_]_P#B'T`"*1?B!4R@!1`Q?8/;V,4GUE$/
M;_<3]/\`AZ#D]`>@/0'H#T!Z`]`>@/01.W6RNT>$D[3;['#56LP:)'LS.SS]
MK&Q,6Q$Q$!=24D]40:1C4%U`**JA_C[B`?[0]`J^<UCB+GN9TJ<S%+#LME=%
MN+%KJ;V`EXF)<VF\6%H]G8A*U(_N!2JV.79R#ATW^TGVK-53&(/P]!7%,IWC
M6@HZC0M);<PQ\-C2DUT)GL7$2-=4&@I3$LDUG-<KC+\]0\6VE)5VF1692$45
M5%`$#?(_H/91R/QVQKZ_LHRJ<\,W6V15PIM]CHQ]!,E;M`5IPM+WZLK,F3TI
M4XB!<_)S*-6Q&Z3?]3+%]A_4%3ZG7Y1Y\:<%+U''N7G^#:A=GG+LA-V5@U=4
M^K<\:'2;799*+H#Q(7E;0@IF6BVZSM-8OXKEN!A$P*%)Z!PJM`^/[&:'0EJT
MUYHI.7N[4A>LQ?INZ22OK7**8!6D[769&0471/88>-?&8D=)'%=FBX%(AR?,
MQ?0>;T7_`*,-BL%(B]9V*CP%XY@O%?Z(K,G":)7ZY<LZ>UYJ#;]\E7QP=KQ5
M0GF5@!L^15*1O(-EDRB/Z%$`Y\AM7C]@]-FY'%[CSBSU327#=G,J4NUU9S:;
M4[?NCOR1)0_=%5?C+/!!86Z)$OS#@`^QQ`!`/4S>'X/RW2=%E<M+SQ1=/3B+
M-*Z4K3G=;A)UI7H63;2=VD9&*9K)(Q46SF@!Q-&2333*M['<C\_YO05_!99P
M!K?/&L\M8K.9>PQFV1+R0U>JX)?XBOI1D'8I,):Q3,D^K[UT>(CK6:/72>N/
M\+]%5P03F*8Y@"U&F^<7PN6*51YK7/O]JZ[#Q.;.H:0M576HT=#+-$H*OT^0
M9R2JD6Z;OF+4C=%NHF/Y``)2D,7T%=UZ<\:45@DA"5J=Y.3YRU]>:;/F+:=H
MJ]!T)TW,W3EBO7BSI1"2?0ZJR)!%0YA8`9'X&2^)/8+3K4MR/#D><=U26QV'
MD9:G3K<^#0,Q')R<C19B)]I91]`,%@EB,9.#F"*.W`_)4R;G[0.(*%.8)=6I
M'G_`8_.<!K,S0,R:MX=A4LIRII*,H]8L6R`J36(K<&Z<_FN_I$PBB3V^P0]Q
M#Y![^@AM<U+C2<Z"N[VK:)B\WT?3**G3=#_`N$(\T6N4:/<+3Q(.:3)(&.PB
M47K!5RN!BE]E$OF<?Y`]@\*I]*<'56>O-JJ.]<[1=BU:::WJ]2<5I%8,\NTO
M!5F!H3*T/S%E3_FK,ZC3X^.,JDG]8)LBE]Q,4P^@M^DU+":"?3^@J+&TR#+L
M:##2M3TN$<E7CKNE4:N6.B;C*RZ+I9BY8Q519_4DLF4A11)\C"8?YO0))XY>
M_?&YU6&L9/X_+?`S$9E5KL%@OD'7JI8JM%#-WNQ/I>Q7*%?V%FT865A8[#(+
M.3O69UD5E5#"`_K[>@<G0NC,RQN6N;?7;]GF946DTVDVN7N]WOM=A"Q)+S9+
MA7&*$^PD'C=U78AT[JXH1\@X^*#]8RJ2)CG;+`4%`ZNZHX3KN%7KMIZ\PK?Y
M3CJ,D;+7+''O:U<IK/['+.V-?11CY!D5Z^KX+.Y%+Y&+\1*F!SE_4/EZ"&Y0
M]YAFY7+)KN70.&-5[1U2M.$Z;+-:C3X24>95;4R6&JT*OQUK?3SV=:Q<8J<@
MN5`3*_`#*D3(`&`0PA[<\T:U`U64L?'G,F*6NCTO4+#,QTF&!PMR<WG7):UW
M'"4M3E]%34AXS,'.A[#EIH>'<-?S;/.L(8[TR'X@I*>@T!P;S1M+1TKSS3]>
M?X)S3SGI?$5[T37JY=GD97'.:=49_NTKC5USR$MKQVSB[35OWR*=)'+^*45"
ME*K\S`<P`&E];9^,G&)?(^7OW[F`ECB1E]$PO++S(9_:;C"(W69=V5U)9C%6
M,LC,Q$=+2\HHZ:%9&2.(*`*?R3]O8.Q.>0'Q<W-BNXM/5?&=PC<SNC*#!S-W
MW,[$QI.B(,IYZTCD`?N'9("XJ,*G**IIM_BY33CEQ#_IF]@GU*[`X$W2^0K7
M..@>9--TX]1/9JRI7K=1[#<R4Z/1=R?[I"R#55W+$B&1'"[M?Z52_B)JF4.4
MH',)@JRH]<>-/#:QT%N4)TIBL'5Y3=&/^H707M_CGK.%UV\H1\+7HBQS+YP*
MT)$KL&0)PZ)_@Q(D*ID1`IC^X616>Y^`-%H4KT]7N@N?9"C4:TJ9[*ZX^G*T
MP-7K`X>*0C&K+V&8%I*0[J?<R7_8I?("OFKLATBG36]Q"HY_RI^+[**O3K$X
MZ0Q.MUC=5;M:JXK%MD$&N@N("T?TKH=HD6,1&`Y>'2L*2J#M^Z3^"JC5?YJ&
M!)02A>+?KWBJGZW5\0AM5R2"T#0Q@DHB'@4X1BPDI&RQ)9NHPTI.QR"40E9+
MA!J_DP\>LJ#I\B43HD.`#Z"3Y-TGS7T'H=]@LMLM:O6CXP[6AK!),HD'+V$,
M[D92LR:M9L[QF'[@R:2T4\8/SL53)(N0,DL)?80]!&XKLCD:U:Y9\RC=5SF6
MTO%H:\3D](N$F:C*EP-80@E-(_:;FY3/$(-ZB@^8HV$$'@*ME!2!<@"'Q*%:
MK^1KQZPE+TK<)#:<TK<-G<S3JIH%HF(A.(M46XT144*(E*M7T>VL+B(N_P`1
M-%N3@9L^)_,F)BAZ#GP[R/<`:9<(G(\)VS+W5YM%MG8(E%@6JM=6;W1I&.)Q
MY#RK$(MF6'L]C@H]>08HNB)K2J+159'["IF,`:,HF/\`,X*&]Q,=0Q?Y@^(D
M`P`0$RA[^_Q((?(??_$/_L':]`>@/0'H#T!Z"OI_3*+5)B$K]JNU.K4W95%$
MZS$SUI@H22L#A`Y4UV<1&R+].1EG)#G`/@U25'W]@'V$?03(ZJIBG%+Y"*?\
MXD+\/M.8HD$B10,`E*FJ4IP-\OYBC[_P]O0<2CHZ1OA]H"8I$CG^1V_N":JA
MTTU#%,9$H$54`2E$#B(B4/T]Q]!Z91]P`1`0]P]_8?T$/_0?81#W]!_?0'H%
M-Z$@\.ZEI&_\;6:S9U=IJSY3(0VC9":SP<A;X2!O44JA5YVR5-G)ELE=BEY#
MZG31XX;D17%(!3.(A[>@Q4\?GADZ0YVZ$@-SZGZF9=#15IS$CC;<[3C(L]2E
M-LSBNH8=@4Y`QRE4C_S("`P>7E#/7;I5!P$\5)7ZU@]UR`L-._\`'0WBF="Y
M/IB'7SA[GM7U"\X_/9N>'KR#5UXU4[XWV[/.?6J"5/5>3]G2UU@5K-KO'Z20
MP;M,C99L#0C94)YLOAST[JC=-"Z%Y0[:SZEX8GO\7I//T3CHT2WQ$.\T:NFS
M_N>)MML@(&2*\)<(])6+80Z+]ZV:O"G<N"%6_P`L@.ST3SUL-5A.8\X",XAK
MF3\Z=BY7%<HY+H6K36;M=6Q^"R]]4Z[2[%+S]'M<7([P]M:BCIM%QD6]!ZBB
M)@."Z@F`,^;[X*-PF]8A=@GJ)A&\4B[6GIB>TGBR6Z:W3G''L:<;1.T%W6V6
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MZ`!ZD%X?>JYG'><J17IOF+*HF/\`&!H?&6W;!C6@RKYY=+FYDX"1S*X%9#ED
M=#:G2XUC3"D?FE7390C>=DBH)E*0!6#QMXZ*AT.7L%JLX7Q8+Z?D':W`42E"
M8%US6+A0KB]SC0&#*:E]TL;''HQQ@U-9-(@Y3B\C)Y-@F<Y1.82@F<(?<^+[
MCU3GE]I/(^U>.&ZO^@[5U+H736/X3T=0RNLP_O\`T+-Z14ZCENQ06*:U=4J`
M5?+BV6S-T82K&LDZ8?F=-ND9-0&^P3QN>03%=XJG05(D.=\TME>YA_HR\5NO
M[!JUKQ'=MPK&%9YGV>6*[8[,Y_&MJ<^B)VM'CWUJ@I-M(.Z]',P,Q_(57$`N
M"6YKZ:P+HW;]UL\OQ].YAV!&8Z&JZ)K=\F\NLW+VQPU)#+I(,`-+UFS1UYA)
MI224=0C%S(5Q^H_$A/R5#&]@"G:/XZN@<TRCE"G[W-\XM*'XYI_9=<;=3RVD
MR5;MO0:"V>:G2X:,WB%G\R:L,NJ<DTOJ+NZ2:ECL"3AO"&]RG*Z^UL"4<S>"
MKJFG[?P7LEF;<>VJ@XWPMIG-FJ!5;K9;&TL5@NEGV>=H>G4T7F1%B+LTD(BY
MP9ESKJ-#-1%<$CK)H)&7#]"OCHYUV#GWA#(.5^F4LVG;3FM*D<LDT\^D)V=J
M%ESU%:0C(1-RYLC.'?K3TE7'()ODP3*@"GN!`^(@`!`?'KPIXX^-KOTRAPM3
M*Q3[:[T:.JV^14%;[%97E+L#6'CK!#4$T=8):6_IV'29SX/DFY`(`@['V,8J
M20)A0_E#X/Z,[`K?8E*QB%Y^D$>E./,MP:&G]5N=WK4G5M`S'=;7>Q4GX:J5
M24+.U:3IUW=N8YY]Y7$5,,@*#9VT?KBF"\=#>+3I'3%.MGE)BN=JQ$]&\#<Z
MX$:(?VZP0\-![#A]XB[G*2<XDVS$C>4I$O'MEFX28)E?H@F03L_8PE($"U[Q
MYZ)3\FZMR31MNYGB^*.SM=R;8;CU9JFPL:;JV"S)252#D:!7IB4I`5K5V*DM
M6T(NFRSZR00Q:3_Z$61A`2J!G?VQX4*/EV[V^>IOD$RG`>8NB;S4NA\$8ZEV
M3"X%-8AME1>R-@>:K5HVXTF[/>D86"L-M<S44@TL=5!@,TL7[Q.L1WZ!T+!Q
M-3^,EN6-0C^I^'MRSQ]PY=N6)FQ]L]`5W*D=SD].T"S:3;]ZHM\6:76,M;9(
MEQ.H:+1.NH\07*G^Z-_;\DX3;#/$R[YNVG1M?:J\1;?S%J2>?[56^AN@+7;I
M>WXC<J]3HRN1C2O5MO(?VLTC,8V/;)MZM*+S<.]ADWA5"JN?K`JP3WG[P\;7
MEF`<J9M*$P6-M>,>4FS]I70*V^F%8Q'''L=J#:%J]:>KUM%Y*VV%6N[$@(/`
M0:MDB*_!P<2$,J"19SR".?[IBN5PG7WC6<:ABG;O>VB0=">;S#_W'6SGKBBO
M82KU^0HT9&18W#4J[</D,O4YDLDS5B2D3!0$_K(`,%>_!OU);\VZ4:$U+)XF
M^=,,>*4+`C-3%\U&#JW^F/16=@NJL3)Z,SL3\[*\1:'W146Q:1437U"IM6:"
M*2?VB#8]"^+?HBX=1;7V+BVFY%7]*=:+ROT/CV9WNOS4KGC_`%'GS+-KS69K
MFFRT<Y0>)5JW,M@56;RS-F#QJ\8-70('%`R9@HWH&D][O/)SQ22QUC%[1;+M
MRUU9F-\O4)A^XN.=,\K6HSU>4CJ_*VB.1M<5)Z2T2@E7*9Y=_7V$VV3<MQ38
MF=(',$`[(\3TAE^6I76W=@4?,^9>4E,3U?-Y*XU34WZ=55QYTO+66IRE&IVE
M?TUHKN_S[E5RE,RT+9+"P2^J.C4"D#[/0/SQEPKKF4SUSV_(^A,^I>;])V/(
M-37J-%Q>\5^AWJLN)25N5OL3?([GI+V(Q/0M:I5D;QC]S%H-!_-;%?N6?Y2A
MVP!$\^\6_0D)S5L?C]LO0F6H<66:,TZ'R>:HN5W2`Z4JS+2K6]OT'"2MV3U$
ME;00S*S+)(&74CUU[0Q0(1X**AUA4"O+;XOI7L*$VEU9.Q<@F=A3SK`N2KG+
M8_C;)S!4!+F/4H+5)V.O4>31E;/-:?.R\4W2(=\^;)P;-=1)!HJ4WR$+WLGB
M\ULW0&A;/2^C*K%,M.\A'.W:\_".\F=.IRMU?),S3SJZ957;0M='+9TKI3.-
M;H#*!'H'8,W+I$45#*D53#33.^D<:TM_-Q%0O+$TQ7M*N>1R4).LY.GRZ]\S
MMT=*Y0<!%VB+B'=L/#B8AE'D8BY8*HJ$.BX4()3F"U+?=JY0:O/7.[66MTZH
MUIFK*S]MM<S'U^M0,2C["N^F9>6<LV,:@W`0`QUU$R>XA_-[_H(+OBW<',W0
M5LDJ1E>H-IBW1G[BN>K3U:MM)L$M'1J;<ZT[4(F\P=7D+M4U$W)%49:(3?1Z
MR0B<BQB>YB@UBBJP?JF`&.!0]B&-\45BA[?(Y#$354*8#F`!#V'V#_9Z"F+]
MNE`RNZ912KW:Q@9G9)6>KM`:/8&==-IR7K$-_4$PD^G8R)7@JX)8P!.D>278
M)J`003^PX"4`M"OV6'M$1&6"N3$?/P,ND5:,EHAXS?L9%(5C)*+M'K=4S==%
M!1,Y#?#W'W+^GZ^@DGH/S`>7S2E(+M""M-9Y7H772G*_`FX[#H%6L$T#*?I4
M;>+I`4N'FDF+B,D1LD:FR=.9`S%@*$@LBT/\%T_8/8)9RKU7KG,0>.GQK<T4
M=;L>07QJM;_TGT(_?OJ]G^0\T[1=+M.TMS"2KF3>&:OF?S<QM;9O5'PJL8))
MB8OW+@ND"H2'F,Z'Z^CUZ@OSSSW`<]7CI;GC/47=TONM5&V)P.DZ[8V\51EK
MC7'\1",]\IT3EBUEDVS8XQIF4BU:J)?$RQE`:NX^8'HYE&#7:]4\"I=Y8>4.
M`X6F:W<%;?'FS3,3,G$V>VWJ6EY8D4XG)VHL#R+"1;@E$KLC?(A1,'R]!!97
MSL=BW&J;+TO@W"$!/\4TO4\SQ/(]0T30G=6GMTO%NZ#AL3?S='6CT).*EJ+(
MI2AUFKI)L08YRFF"YG)%!*4+W9>7[I,NSZ-49?G3.B9%Q[#V2,[DU=E;GR$'
M%Z?"8HKJP4?"):5DVK>>F333^,@TF#YJNN\.NLZ!5%-'X"$A\8&S:)T-V!Y(
M=VT\F:$ME1:<V9E&T;)_QY5E781;)":@2%>7@[EV[O-@26G4FKIR0R;`[HAR
MMB)$#X>@HG)O_(*C=*ACFF\HIU`OK_:>UJ4TS2;N8N;11<VY2R]E9Z[:+]7D
ME&]@>6;4-.?-85@V9-$_R/R@*U(JHFJ80JO"_)!M+C2*MH"=4YLQBR]&>3/8
M,?Z?5=6B\69(V5\G<^,(Z:82%=L=E>+4;9&",$W;*MXOZ6B[IBR6,04W+@%@
MOOP(]1:QHM6OW/&IYYE=.:Q=6A.E\YE\YF'1W\_2>BK%/V2/:Z14))P9>#N1
M&@IO_BS(FS,S<)B)?G[^X+?T[W1UOI\[>+/FP\YV&*YN\A^NQN+U";9V-LE(
M4CBSFNX[=I$KI\E'R0R;%U:W</\`BQ"R`(E*^;D`#?`X$$&QY_\`,-T'V'U#
M@&)<S<[YY*YQ_9[!=5[0TR[6EZS;9=+[[CC38X[/\O29RS9:R6*MP;]L=;[V
MSLK@CSV`$!;'$X>7Y!J&\VKRZ<Q9[5\MHFQSM-X,Z8EIBI:1-,8:KLX[8+,R
MSN"M*ZKN,EB/%ZDM".5U&B9$GJS5?_(53-[F]!5/ARPJ9R7JOJ3CSK:UU[<=
M;XCR/"J1S'*6>%1)&,^=-'8V6S6^QTJL2:[Q=.$D[LNUCG3MX9Y)D1CT4E'(
MD$I?0-!O-@Q_(^?[=S/XU:2MI5NZ[V._(6VIX9=/I_HFDMY^JUOK[1J',/U5
MXRI+5"NNU8N++%G(T872:;*%]UOO``SLQS6V$7S7R#Q)JA[-C.38OY/)SE/H
MBGZ2^/(RB&7U]E;=*YAS;6;^RDHMDDTT&(_IQZ^F3'*S?RC$K<2B*OZ!J3Y`
M*_C<1OG#M]SN`S]768JT:=*/PJL?`@]G.9$LTLC[8%+$5FR6C7M"!*/3,DN]
M$J",B5-1N87!0#T&(7C,K+FEW;P8Z)9\<Y]A:QJ,ETW:<RU'*)7[NBY!79*?
MT5;&U0UN$2,2/F,I/&3P%4>H(`>.E85HF*@%%1,P:A^=/3/,I09;E`OBKI3B
MP5B2N\C_`'K?PU;@K2]/*%?0+.H,+N6PHK+0N;'07=E>.6A2F4'[!5-[((^P
M.9Y::C,:/XN-[RRR.*]`:1M.:UC*V+TWNI`0VMW^3KL8VDVCDA1=$1B+$<ZK
M=5/V5*"11*(&'W`/SL=W=+;]N/B2W+B#0II:%V'@U2`HODCT1DV4B@M-#RC0
M*<VQV(SN6F2KMQM_3=2=1DHW<N3N$0182J#M)0%"_(-K9;NGMFT])SV3\Z9!
MS'"<_99>$,HG;KOEFL%6L:@U_-0G9^W5Y*$N,8T+%L+`8(UM%?M?YCIFV6=D
M5^GX>P9[5?S*>3V29YUIMFR_BQIEMMY;D^P+`SA6VLNW=:R:O=`-,0C8QO8G
MMM39#-Z8+W]P9O%TS,XY`@_,AA]Q$*O@/(GN?">K>0'L:M93F&Y\X[[Y`]C4
M=YK6)B9_U!+4#G#"F$'>=XJLLQDY"BL\QKCFC%_+&3:%56^\X(JE]TBJ`T5:
M\H'EKT9[Q76$\7X7R20[NOLU7\PE+!8='M\]3JS"8E%['(S%FHT%=3+JO:V`
M/8I<0<%0=&!HY*1L5R1,`UI\A>Q:]4\AKV!\\,:G<>N.E'B5$SZHO;`RJ3?^
ME$4V;G=M/*YD&LTLP@*G2U7(D<"BI]3MXV`/DH'OZ#\Z-FL[O$/`[Y!.$N@:
MW$Q6D\D:LXP6%I^AV2-OCAKG'06EQT[@$_%W-)%%K.VIVQL[PL=)'1:F3D6@
M&_D-[#Z#7W@YSG#?K7R&4OH1.F,-2Q70L?R?(:]HQH%12K\;1V.TYSAS.D25
MI2^R0KLY;T[6[=G;JJ>\R#D%O94/0(KU1EO.]SZ,\3&;\#T[(K%$P?3/D`UB
M`HEG<OGF7*3185.-NU]C8MK(KED\F)?)-T,>W:>\*Z(()MR?40"@$8Z.Y1U7
M2\8KGAVY[JMJZ*J',.;.=.Z=ND=O]?P^&J^Y:0XM5LY\HL(]DH*Z$&`S6W_9
M96M320:,B1\2V0<`*2P%,#S6WJG;^@?`IKVM9L[GY;J2H<V:3DNQC6S,)^Z0
MNTY"D\R_H!^Q91J`&3EE'U<E)MDF@FF](T=-ED0^PQ`]!>B-D\8T_P".W))"
MV0>4N.<YK*\2_IVO51:'E[L1PZ>50*=`U]G6G*UX=6AA9$&HG*V.9TF9NJ*W
MQ!)7T&;E:\G7DFO>67OJ;&R<J2>0:)MO,V%<P<\V1RXN6IU>P6_8WV.V-EJ\
MG1YAG-Q+&W-V'YZ:TL`/DQ#W;)I$*;YA#W7ELZCSR?BICHW;<LC:_P`M]6]]
M0>ZM<ZIA(='HVA\[8M3[/G>8P<3)/'4I#6><E]3^F.,0%075B$E7`'.FHJ4)
M5*]^>7EWD>'=&5[4N!TJ?U%TI@&7YOGD7'3%[5KJFWYB:15H<I-52>=2$1+4
MF02>3$FTD%G,LL\8?CIKMV2PHIAH1Y6ZSL=PC_'KG4+HD#4S&[&SO0-0?_T5
M"VA>\CB=8DM$3956K37Y+8BLW9X;Y)H*`LB1(X%6*H4/800[1_)GWD7G9QTG
ME$CC/[OIN#S6P-\/O-7C)*)YVGXOI7*L>Q/$AG*J$9;'UYZ+IE\>.7Z-F_-_
M#FH1=&)*@FF)`#;>[;C;N2..(31^E+?3-$VN+@ZO`JOX6-99Y6M+W.\O&E>J
M%>KL&^>$"&:6"WS#=(4@44=-F0*KC]@D-[A@KS6_Z#\>?575F4ZNIB^(77N3
MEJT]1Y$NI?&^IO[+USB5?FCZ9;[`+I"*%1I*PBJ3O\8`_%6%D(`8QQ,40BV1
M_P#D(V#1ZYBN26#0:9E^DZ+@7-\?:N@[-GKR(JT)K&X/3N+[M%=:3K%M0/Z#
MSJGPKL[#\PIH22N#QO'F(=N!RB"PX;WM+4:F:;=,?TM+6K!!X3YE^F[5L-MS
M&I.[BGT-3^BJU6,EN33\>`:1M!<O\OL+%R_@H4R4)^*L@`H%,B)0#8/N>_RL
M5Q5XP+?O6P1=_P`2LG1W)#SL+2)Z,C8!GIM4G8I2:2DI>$KT?^,%8_K$C=:4
M:-4TT0:(?YA1(!@]!??:&IU#:I+D.0XUU#'KCLU*V9AKS&^U20B=`K=`PZJ4
M>P2>NR5Q-1W[N1A:Y>,W=NZVP*8R*KN0ET440^9A.0,6,?\`_)&L*:'/U+TV
M_4Q2YR''?]17ZYV.A/*O1]*Z@WO5,QJN02$,$/7FI&V98A5Y"8EKHO&.&S,Y
M169`<[I!,Q0\5'O31]B>H:A?MJ2W70./W/E2MV07EGD,;29%TZJ^?0M.P6.8
MY\UI3.B7N:F&K9>>3%PBJBI$.RIJ`HO[@`-]DN_>0W6](W]KSCT/F5(M/,_&
M_$VF5WE6RXHPB:)H<I>J3%['N9VS@R+9_6!N[IFK6V\@T-],2O*_))-,4?0:
M8<T]Y7JU^,K4_))IT?-2%/\`[7[]U=G>>&@86!O$'B%"KUKMU7H$FHP:(Q4M
M.KP]54_#DA2]W":Z!U_F)C"(/PZY5Y]?;38>B7N90KK9[;FQ<?LMZ6=3!GTW
MF1#.#EI<A'?N002\*"CI0WP%K\OF;Y?+W_7T"<W/Q5\H-HB`D\2H#/&-7R3,
MY;/,!T"#G[NI%9^LE(6>U9^I8*HWL[.,O5<RBZV5>4B(^5!RV;&5.D0/K_E]
M`H_`GAU<X!3+AD'3[W+]GYW86W-](RC'XE[<K+%5O>J(M/FLO2#N4M$57Y:#
MONC#(-SNH9BXD(R.52.B@LJD(^@?28\67"]HSB,RZS8;$62G,MHCN@EVD_*S
M<M)S>F1:JYXV5LDZ^?*3<\Q8-7`M$63I<[=%D`-R$*E[E$%?Z,Y8Y5\<W'72
MVNXKRRPOE.H=I@>L[SD+C2IV$K;57&KPTV0)JBQ<[-#4ZFCGTE$.9YI#QS=L
MB]72^GXJF.FGZ"ANIE/%#FG)NF>9:7P*L[!&[[E%2LAXI.=?,C[?+:O%Q=0B
MVK:D2-C:4T=#LL/+-V<N\%L9^E'1)OC\?I4,8-,.0.6N5^4:3'.\`QS/L)=:
MA4*/8;G&5Z4=?DRK>"K2"<*22<STHZ<RS.N,78,P<A[B4A?<QA$/0<#;A#Q\
M/=J-NR/._/[C>UM-:ZTOHC6-AU[HIIR$$A%DLHO4'BCI5^WA&X'31,F#<#$_
M(^K[/=7T"E<AYQQ]W#5+WI-YY&P&`=T7M[KYUGBL`[--.KA)PMLLF%6SH1;Z
M4X5VI8=6B:TNB_.)7#;V2*)53F2*<`T,HF#<V9;='>J9S1LMIE_L--J>7/KG
M`C&1LF[H5+%=M3Z:9<'`IJL*_P#<*+1,A`4'V`IA_3V]`I/3]6X;\?&!]1=3
MON:Z])NKT^E+=>:K3X;]WN>^ZWH$.OFS.K1#([ETD-GT=&2"'.F@5LU5*Y$5
M0$"B8H=SC3#O'I;Z-S_W?A6%Y9FEBOV(T!S2+5&N`C)"#K0T15@QIIUR2P0;
MF9I4,Y<0S@YTE7#8C4Z)C_!,OQ!M&F'\WR>]+=2L:M3Y3>F.=AF[C4(Z6<OI
M]GGCQ<D@G`+),YE2(0AU'`"N"AVX'^7S$J@!\A]!%]CYZY#W21:7K5Z50;%8
M6D2W81U\9V=6L662KL?+MI%**"VTZQU^>F*XVG&28BQ7=*M16`2"0?D8HA#L
M"SKF0!RK=*WB-8PVXPE,T;+,H;24M"Q$XSS:=T96:EV5=CJ_/N:Q(5W39R)9
MSY%TRKNG(KHJKF!<P^@G]BP_D.]&V"#MM#Q*UAH,_6GFSQ,K^P2?[S8H)F@-
M1?W!HY=+"UM$>T;I"R75(@X*0@?6<?;W]!%\;YMY"S/,K2[P/-L]=4>Q4^SP
M*KZ&G)&XQL[60&0<R=/;V.6G+*Y95E20*L5=FW<)-B+>X@B`AZ!%O%+#<G6G
MG^O=ML>:,#Y9M=R=ZM7*\$-;G4XSKV:9OHM@S5)]!2-S59-L^B9)W57)W32'
M;LVI3.!$1.=8PF#5V?V7*JM-+UZY:5GE9M3"FR5Z?P4S<H6/?LZ-`E%27MID
M'#M)\-<;-_=91T<@)HIB`G^(&'T"ZWG>.;]4@XT;XA3;KS-.4^IZ2PV=]9X!
MYGKRZK7IG%T*HQY8^7_<CVV3=F3DF!B%!-5,OL4PG_D]!:5[YYYDU.*O4)H.
M7YG:HK3YZ,?Z2RDVT<LQOUEJR"S&%&V),UDD[!+PK)``;HNA4.BF7]"^Z8>P
M475:QXWM!*7K^O,>>+"V8V9[6T]O-+PKR$5M5!47R!\T4L;J15@Y2?A58Q>#
M%4?N76%$4OD8??T%PV+%>4*A1GR=GSO&H++(O,F.<N23+"$BJRWRM.Q%LT;2
MW)GYTHA*FIV-4':;<3"D9P/^`/?V$$9?Q?/['M1MR9RWB?/+:;T[.IS?.RY^
M6K[.3@9/`[A+0%0=TFN5]BX5:*6C8'3ENLH"39.+_`CS+.?=0R!3A7E,C7EJ
MT+4(#QJ<^<B5B`XQUJQ9\WO&U-[&=>Q;B]K=4=Z]4,I>5>+L3NBU0U96CH24
MF2G(K^[H*-@:BDW$P@[U*MV86Z(Q/I/K/)J9S=TG%)3^<U^*T>QP:MDJ\LZ?
M':6&N9W:VLDW;VJJV99F#I!9L0Q'C,4S*%`"^P!XVJ9WXUI\;A8=F9<R/T=_
MMN?M;G)V>QU]2/U&XP2YASEM,*KS`,)J9BG<08T40X"<IT#"F4!*)O09Z[_I
M^:]-;=B>-0F#\J16VZ$VZ$D:_H>[WR(M;&-YIYTMS#/H:T,D\YL"DA-S>G7.
MWJJP46[<>S6.:R2K@R3@@D$-4(#-^6:MH^.%L<'SU#](YED;YG26=42@*W/U
MW/$@36LJ^?5I-5@[B*"$@HHJH!&X(%`0^0^X>_H%G\?NT4S:NG_)P&>4G)FE
M+IF_9M60UW-6"";_`&*T_P!N#J6T]VG&;UTA8IVF&.W8INDQ(!$EOA[?RB/H
M,Q^)?(CH%$WZ5H,MA'/N2\P:YY%>XN:&D5FD5/,-#/)81"2=D>]/W%L8'T=,
MU2?+55(JPR*QDD&2Q3.7!R@00$'RZY;<9<8\V:GV9SOG_-L#I-9KU9TNG6QG
M!P4W7@AKGJ-2K4[>8.MQ\BTBD8YXUGG'_P#3CDFZ*"ACF`X%^PI@J>P:WS-C
M_36`U+GFL<>16.[7D>L=B:8^B*Y6J_!WW7,DD85GEMU8[3&+I52(?PVI3)&Y
MB/C'6347,HE\1`X"&GU=@N7+=(5Z#NV:<[--PM]:C]>M>=DB<WNEHC+-:JO&
MQ%@G$%DHU^>8.HU$\>:62`22#1+Y?(Z1Q]P1WN_6,:\76(49KS-R9E\S9K;N
M$7I2F<5"G0<3$TNG0DU`,=YZ778M&!&T>YSJHV1!L+TGT*)K2J)/L!'[0]`R
M&T(<VN.C.4-_W+H"NUIPT3DFO,&17"=K,-$V;1]*K!H7^IJV1V[)*3]K7K,F
M9LW1(51%(5!,0?F(#Z"W$K'QA`V/3ZP:7YP:V2I/JI:-IA1"B-Y*NKIR*;O/
MI2YL"HB+)PSL'UGBS.P*9)^?[4?9R?W$)E+7?F_78V'82UDQC1XYRS>:7`Q-
M@?4NUL4F-!?F;OKY'QTJ+]%%*ER8"DI)$(`L'(B45$S>X%"N[!KW"-UU&M5B
MP7?F*W;:87%+I\)-R.:SFC&_=6@O758K2<F9S-IMYAD8R@LFYBHNDS"/Q.!A
M]PK2Q[OXUG6?ZS/Z#*\MQF38)>67,^G3&CU>BQ=$J-FJQ8"Q1V:_DV.)3A7,
M7"*65L9NU1^31H_$Y2%*HFI\0F<;JWCX;.H*A1EPY-:.]&EG]/K=1BU<S14M
MLE?XT+*O6FD(@W33E7&@1$>#Y9H9(0E2)_,"K?$#`$$MG1?C?O,#3W6D:'@7
M](T/<+=C>;M]#DH6`JZ.VT$R=6FZK4X&1.T@)UW%MGQ4DB)(+)`10#$*4!`1
M#Q<8\5',?./4=@Z:YG+;>>7&AE%79\9RUU787$M>?,VLVUAW=IIJE><NHLT(
M\G7#E-O%O&C0ZR@?-$/8/<'D7P+"W3*/C76,90ZCHB%+6X>/<YU3UV4/7"/3
M29*]%-588R#"")**&=`T2*5N#@YE`+\A]_02<N>41%!-!"EU--!N#DK9LG6X
M1-NW*](";XB*1&)"$*\('^;_`,_^W]/T]!5>OX3':-7GT15IL,JE)\L-!V>X
M4F"A&]JL="B_=%U17<X+'\YK"NF)S(%`#&!`AO\`+`H_P#UB8%E1,"'FE&K-
M6^)_VJ-BP4I)$I(M3.%*HO3'5?,V(4/^R<5]8R)P'V^?O[C[_P`!"\O0<!&Z
M9#'$H?HH/\Q?8OQ$OL;^3X_'V^/S.8W^\1']1]!_10()S'$3^YRE*;V.8H?$
M@_(I0$H@8H`81']!#W]Q]_T]!RE*!0`H?P#_`-`#_P""@`>@0KR+U30="YV<
MYSGV/2NX-[OIF,5S5<\AIJ(@'MAP"7U"LMN@&1'LS<J&W5*]R$LNV^HDB0[A
M18B)B'34,'H/S=]D^&+K%YRGVWSIDE`/K6+9S=(.X^)S%X2R4V$=YA8MBT"J
MZ3N*EW2N5CBJVK!XZ,8_@Z@=R]<O46T@_*)%DG1!3"UZ1P?V/H.R=GZ-U)S=
MO.G:O9<CUK,N7K#8-UR6`YB@<[G,KA8*J4NOT6GW+^Y->L,G.)*-WS&44?07
M_:?N/S*X/[>@]3)?$]O?/&TQ6RY=SI6G5LHU?\?5-HR!=C_9H.RRL10+7!=@
M:_=9]9.?M06MG/2;-DLY%!TJ[A2)HM2G)_T@7JN>);N5AS=,6W'LEF>3NOL]
MQ+?J?;K73M-ID)>>L]4W#>J/?K-%UJQQTY<*Y#XS"9[%SK>J?ORT4]_?YPJJ
M[-K])EE`?SF;Q/TJ/UGC>Q77GC8HW,\<Q339BWPV[:)GUD?RFZSMZ93=5F=&
MIN=V-YG[N]Q3QJK)QBT,W3C8\7'L9R<X_64-%]VR_1NH.Q<[R_2L=OS/C;+,
MJF-5;ZU!:2WIR-OZ+G7IJC"T9\E3KG%:;'L:73I"2?BNB@DU&3,V'[C$(8A@
MRLK/C)W73JG0^/\`:\DFU>7.1_)C*Z;A<_?]&A)8;]PU9,CUAT;/E!K-AL-E
MG'D-JMD0B%6\TS;NUZVX!O\`8=$'7R#/\WBJ\EN"\Z*U+ES%82*E]>YGYZH_
M6$'G.]9W0-H925&U6\7"YY]0F;JHSU$"T3E`MK!BW=2,JK'(1[#X-Q%%4K1(
M'A?>'61F7')\WD_,[?(J_A'"O1<&WSC6--C-:FXGI2Y*H-,>KMLBY"8G:!/)
M14X]<W`%F;5E',)ANDJF8HI$0]!',8XJ[%Q$C+/]4X[YWTFSUGGK`X_AK>;G
ML-$4HO*>W9MCB44_H-1"7J`7^.N=GV:O*6MRY@8URPE`?`FZ<'18>_H*RH?B
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MGURQOO%->9?GQGIL0RHCJP<PK_E;O59=O`94YCWZQWBY9$T\HFO^Z/D?QA:J
M$$7HASUGQ\>3:L]'9K*43(,(I_/F9]T=L=#OHFQ;I/VA]>+3NM#DZQGW1:K9
MQ2Y1U&JTA*;5<,*PB()K2_VHG%FA];P053./$;VM%V/D2N:YP'C&K<UU#DNA
MX_J?-`]9MJ1FT!LB-]4EI_HZ:9Q.9KO'.S./K=S+M_#B=T0)1>/2E7*!#BH&
M^/DIQ'1;E3N;)R@U.E7/.<(LDY)W'!+MHD-1:3H,A*4$M%Q_\V7MK!Y7[4PS
MNVO_`-Q3CI`S)=\FG_E*%6^!3@J/C!P'-LAZXZXU.4EVJK_G#G/EGC"P[>[E
MX=*C6BXP+F\ZQOC!M:GS9L"Z%'L,Q`1()K/"NF$8S:(+ID4(E\08C#<8ZJX<
ML/7S/$<Q@.K<SZ5Z8N'56(NI?3H#,UJ#8=R?,I73Z-H\LC59A8E(B+"Y=2T+
M*,FDV_68.C-56X*(I?,%`M_BPZ(Z8[<SO;_(E2Z#UKG:6$U2!A8"M:C(5+,^
M8MF:P[U7096JYR6K1D[H$/<K&LFJ@[<2*"AFIA(Z;K$`A"A"8?PU2&0X)X^(
M&0R#F2R,.?MMV;:NPT]3F(:MUVU`_J.O5W)KS/V&0J%U3MZ>.1%Q9$CHIX#:
M-1;IBD59F0QE4P1;//%_&]=\J;1@>2.>.;3V)G7#N4Y"RTW,KO6M6Y]J=RUW
MLS;]5V*(8:S$T*SNZ]>%J+'K%.U9QYEX96=,B!3-U4'*@,TT\=_2D5U;VU-O
MZC@-MZLN^8W*;Y/VFS=:(#>TL!G;'6X-GC,-A:>4+6^(IKRC0C^I25EDG$A'
MPZRQ0C2!]BH$#2;Q1<];;RA(=CU_=ZWS5B=ZZ5VYWN>*8-BVKDMY:I4`SR'K
M1:\$/)5"GR`M*N>`0^UXU:.4W2@.%CD1`"@H%?X1X[K!D7CEZ[I_0>>\QU#J
M[6*]VG)VK<I6W+3U"L*NP2NB7:"O6F727I]=&@U1+^I$&\\DW:_0,?#D<*?,
MX@BB&4%;\4_6"&6NI?H&]\&ZIDVA8AP?SIS35X7HF=I&;-J3C5S=V^<P6B7F
M>H,HC;:ELZ?_`'HJ(JO#SGT']F9B`F0H7=H_@M[,7K&ITF@3O+C"@;)CMAAU
M,\DI*:K5/QG0[MT=3-KG*)D#&K9HS:L\L,PI#1B0RK8KA83K`#=,%1,`:X^/
MOE7H/EZ][L?=ZSSO=*M.Z1HNHTGIFMV*:/M2];N+JOH5C([%4)6@IA5Z9D5/
MC58-FJA9GJ:S*,9`5LW]E`*$=T;QR275E\[*T;LAL64=Z!`6'GWE6L9=T+LM
M7JU9YP4K3(\,31&-51HK(MXO>E*.Y26259V)LS;`@B15PDF<#@O>&\*>0J#V
MZGWKI.J\A[35I;ES(><Y9[(7ZTS$USE)9J[D$YO2\5JLYBCJ$N#VV,RQ\@LQ
M,O752RC(IA=&)^GH(36/&;W!!8_AF:3%)Y(G)'ECJN*VXUF<Z=>!D^ZJPVO6
MKVDZ?1TL]R)X^I=F8R-H@;-^*8EN8+6&*^21FI$VQT0@VR>&/L.RQTY+8[J'
M/.3:'KW/G=55VC2',+;YZPU6S]@:V^VU_B^-%^<='1>3#(R!H->>DBJJLXW[
MWC:&(]>*F*%SQ7B!TV/?FT%O_IT::TSZ-\?FF5R;=5QR\BJ]DG(M7@X&T5`K
MZ*B8:RJOK4NW>.2`9V*;U44SNW`@'UE!?F_B#\@455^A<HAKCR(MDV[M/(/%
M13V4B+>>ST*6ZYN;6>@]N7,PBUD+_HCC,WTS32()&@RP#.4<.C+2Z:GX?H+P
MK_A6L94]$G[.YY]>W:S:SX_+K"+QM.7B&L?%\<5"J!:'\E)Q!(:Q.9JP:>A-
MR3`BKE?_`+<J22[H4E!02"QJOXP]]&-Q^F7Z8PT39'T'I.WT;7:8]M</>6C7
M1M%=R=[IEII3QJO3=.K^K4,S=&:1D2E2;.D"`4CD4R.`#>]LF0B@"F<IRB)A
M-\#&`HK&*(JJ"81.=4YA``$AC&^`%#_=Z#TO0?)R%.42&`1*;]!`!$/_`)*(
M"'H/CZOU$1.<1]_<H_R@)`_Y2_$H`)?_`$'W]!]"0HF^?Z_+V`/?W'^'N`B`
M`/N``/M^OH/OT!Z`]`>@XC(IG.10Q"B=/W%,XE#Y$$Q1*82F]O<!,4?;_AZ#
M%'SLT*QZ5Q?"T?'6J[CKF;Z!QN*XSE&LZ]K;^(Z&C9)Q>DI,9=N=%JBT#,JE
M83.2.0,T53)[*>P@7XAF/TQY&?\`6?H/BRSS-7,BYYW1ZQR9AWM:$0EJ^>)V
MZ)@)27BL'?%%HUF73Z+F(1S,S)&1CI`W!`BIA`QB^@:N]?\`D!@G2]VVG%N"
MMLV[FG*9IK3ZMNK:[0-`@-@MRNET[*%:]6(:QUI5\V*]F[6X5BU?M<_N*,2X
M]B(G^)?02VC^;=Q9-78Y9NW'JV-U!75=EYXM=V7W>CZ'&Q&QY+B+G>+'62-6
M-7@&S^H&S),4EYK[RI)2+@&@D^:9CB"!\4^9QCQ)ROBO*>N\K:Y+=%2F:TZS
M\SY]#W)G:GO2T1J<[8)B):-YV.K3Q#,Y*M5<A'SJ/E3/W;:-.@M\CE5`0#7/
M`_)OO.U=<U+D>Q\"7S')Z1Y[A>D[I:+QN-)7"B4"9LB5-%!*L1=647M,^QGG
MB`?B"X:'42.93]!3$/09I]ZXF;H/RP[W*5WA:O\`D)ALX\?V-YW=*"XW".R,
M^4:!JFI[8ZA;9"&F(YT5[;'U0KXF*]8'0D(]J8#)K_+X@`3/F?I3/.0MKZRY
MGY*JR6E[A=]6GY"&PZ]7Y6#K&/Y;QSA5!H6BO).VO0EY44$96.0CXK[/;]U>
M+*N/L220,4P2&^>=G1IVKZB]K?`>DDR^B<W9QOE^O4AT+!Y7=H&IZG-?T3%M
MJ[#LZV[L*-G:VX%EFQTG2)EHEL9XD<OV$+Z"KNV.ZJQ?^PO'X%EK]<C.">:.
MK.@IYYT[)Z9(2NNVG5>*N7]H>ZK7EJ*\9,79ZG7[(*35\_<.7CJ5E([W3]S*
MD*<-BN(>X;=USJ_3N?VG%6F3,\%DLP3@ONOL?;K/.Q^FT.+OT,ZLD0U28N*Q
M.,X6;12>LS)&_!=%4;&6443-[!E+SYO^D<ROO(7T)SS@L1T>[Z:\MMAPVDPI
M]GC\J8,Q@H"'IK&=>-9^(EP-`1=N<N$Y`K4A#@V4.^.42)B7T#6Y-Y=]7U""
M\>-E)R:SA:YV?+:'`7Z[36OQD-0<IO.=WVVY\XHL#95H!\6T7*P-*9(S,0T6
M3:H2R+(\>@L#Q9,P`F9O,Q?;!5*OT%8,`SZH7"N\`;'U+CIU>B)1C04F&K=$
MH81E%:O=9CH@C6UEFRU>'<.7BB(K5]R=PDF<@/!,`/)6/+U$0^VR7-&OXY`U
MW8FCGD*M4R.K>QU.QQ6JVKJJ*%=Z:A'%BU'^GZ7]:ZSM=,%DC-P`/D!Q`WH%
MU@_-ENDKG\PR@N-2:[T1=.F>J\OY]RG++2\:1LGC?+]V3S<-(U.1EQ>+5F4D
M+RY;Q8($,DT.X?HK$,DFBN/H-:>C^KIG!<>Q2>;9<XE-?Z.T/,\-RO-9*;:I
MQD/JVFPDS9&D9;IV.$4C5ZC0M>E'CQ9H(*/2QXMVYB*+$4`,:I_JC;N\N]..
MN7I[':1_9#'NA^EWO2+TPNIFD7G2^39%K&U69J!99-X*]=1D'R,U&J'.=RE(
M%,T54,*1A$&RQ6-H'6_D@\B6>[]5&-F9\NO\+@,5Q:XH@:FQL)HE"M;R^[_`
MU4KHL3/S>F*/?V9],"T%TV1C_P`(5OBO\1"C=%Z#JGC>UNU<:^,#`%NB--T^
MPMM5L^`-KO&0&"\L1T23/:K;(XCM=XFI35K\W>!)"R^XC9A)+'='25%<6Q@\
MS4/,7V##UGI0['C?+,PLF(;WF7+M7?W7?(ZYQ-OW;5IV#/6:TFE7H2)8H,H&
MFR:B<LY7<IBC)IG3(!`)[""JZOT%J_6,7SA36E`J3LFX^1CHZ6V[#[1T-=;7
MD&HYQQ#EY[?*FJ3Q^;]L@LVEK!42*OJZ"+=@\D6Q/M2,FX44]`SO._E;(M2,
M=E,+Y+S7.,1@LJ-U1W2C#R+*`8X[GFF5/9=5-8L[".<,6MIM#=W059609KLG
MJLL$J;Z@;*)G.(>MQ+IVA])^974-8VB.H-%LN>>.7&$,\S6A2)WTK!U+>M'M
M.GHPNC.I)ZNZE;\QAWC)XLI&I-6"2;\I!*!OYA!"#\=:CW=VCY+);%LKSRDJ
M0GD5R'\#ML=-1:6/&B<]UZMV&V-<WHJ,.O/R]FT)604839OW5"&.'L55JH!3
M@(6[U=YJ"ZKQAOF(VJH9'%:3H/-7>\#>*U5]&.Y12I,+KLOQOAEEHRKDRYWK
MW4+_`#Q0)&NTU%W+>+?+(_2@9(1!;9KH#>J]E7+W!'6&1<_96;AWH?F"QQ-]
MP^WNWV,5=ACO*=ZUV*HFA2%R<%;-+:$BM$H/6\6)$$6,@04O950B9`UF\7_9
M=KW:M9_FG+\!S_2<-P=Y1JOMM:T2ZZ)8]7D+;I7[KI&B(9$_E[6,BTA*,YF_
M=H>?0DPF"K@5NJBFD!?07EY:&%GZ+H\#PG1&^FR$;N$+;;#T%,XLQ;2^DYSE
M$#7Y,]!D&$1^_5]RU:7#:B0+19([E(DA!H2B(E/\CB4%DYA\I][M_/'%?.D/
M(4%EWY<X+5<DU`_1[U\UJ%0TKDPL93]77T).FRL'*HV>^3ZB*\1&-797":*Y
MU#E.FF(G"T+KY4=5IV1[3UNO6\4FN>L=G;7EP9<P<6-+H>WZ;69*,IL;;49=
M&Z/Z55LEL5\?F6.F^C!DF<*0#JF46.'L%=R/F`V+!^HW&'=,U7!5\+SBR2;7
M;.J\XE;(E2XN"0Y@T3<'U=J-+<3,_,.+52+=36L5(BNHJ"D?-,0^@'7R4$*4
MNWFWZ^>Y[`;;C_/G/26:27#M@[QD4+_8[Z[M\9E=?T"9J\1"/VU=EH]HC(Z=
M!HMQ@W*A#(-W;-X9=,R?UE*$FI_F8T-YJ6_4JPZCS:PG+YT33L5Y7S^WG=UY
M+'8:!R"*T;:;WLCJ.G&,U;Z_4FDB8R;<BS)2:D"E09*IIB)?00%GYS^BY_"J
MEO.=QG'=NH%4YDU_H/<EWCS4&\VT=Y1T*7%Z_0:W'LK,HG5K)N,),QLI#_NG
MY(1ZPN".TSIF1]PNC4?)MU)\/)1)9;=^:W3GGK:,]RC$,[M3%%C=(2CQ>=T#
M1=^VU_7Y"]0JVLLJC%:(DM&-6JK=)ZG"NUTA$BI$B!OUE%C2NM`S^T&F8BP'
ML5.@9_\`?H-A)P47-JR,8@JI)QD'+&/)QC%T*GVHH.#G51*;V'^'OZ"SBH@4
MX'$YC&#W``'V`H`/O^H$``*!OU_C_$0]!S>@/0'H#T!Z`]`>@/0'H*2USG[.
M=MG,BL-\:RSN1P_16^K9Z,?,/(QO'7EI!3%::R[U%H8G[B"$)8'S<$E!^L4W
M2@"`_+T%"7_QR\I:(KGCN0HCJNR67[W/]-U*4I4PYJSQ#:[2"Q+!=)`(XI6L
ML\E$7"B9R.$CIE24,4@%#^`5[6_$GP_5F-C@XS-)DU.LMMA;HIGCN^7-WG<'
M-0FKP.WI#5:<O-GB:^V?:?664FX*B7[#F2,D4Y$5%"&"13WBVX@MM<0JMNQ2
M'LT*34MPV=XVE7\LH,GHG1498(+6)EZHF^3440L5=LSJ.*V`02;,0232`OU%
M'T$73\1W$C;-ZEF["A62-1H5]K^CTN[L+U8D--K%DJD"%1KG[)>?RC3$=%Q%
M-(G#IM$A*B:.2(F<#B7Y>@:3.^5,3RW2)K7:A5E&^CV//:1EDY;9*5E9F8?T
M?/5Y1[6H<[J2>.#E!.2EUG+@X?S.5A`3^_L7V#R:3R#C^>=):UU754++'ZON
M,#4J[IBAK$\7K%@CZ)&?M-/,6N*@+1@ZKK-5R5L=(0`OYK@1*85/<H+]H?B5
MX,TFUVG0)G%&D/H=[M]ZN5ZT"I6"PU>XW)]IQF']P(BPSL5)(O'=7MC:+00=
MQQ13;BD0?@!#G.<P6S8.".4;:CL+.>R:&?QV[9[E.5Z5%G</TF$QGV+-WK;-
M:PV1;NDE8V/KQ'ICI@D<HG4*43?+X^@6J<\(GC*M%EN%MM7,\):)JZ6S4+N^
M-8+5>9*-B;)M;*18ZO(UF#4LI86OJW@LJNJ\_';E`SDP*A["4/0,SS/P-RIR
M'(VV?P?+654MNA1]8CM$O#R8L-AN=]2IH*%K2EIGYV6?+R*T650P$,!2"8!'
MY>_N/H/-R3Q[<LXO".("GT%5PP5W*S](-@L4U)SIXS8[DHNI9K=&&=+@+127
M!R<BJ`>Z/UC\0*'M[^@C%&\87%V87.M7;.<B;5%S3E7,A6JNRL5K?Y['6%24
ML4VRM8429G9&OC9(>7N$JX9N4TDOH4D%3E`%`(<@=-7Q4<`JT)_FW^FVDIU:
M3RB3PQXW35FQ>&R2;T5UK,U1&[]:56<L825T-\O*+$0,F(+JB"8ID`A"!UZK
MXG_']3;S'Z/!<W4M.X0+3(&%2F7YI66>4ECA+==OF3.GNY*0=/H)O!?DG.H"
M2OR=G'_.$X``>@C`>'?Q])J1RK+#OV91C=-5O"ZU?O.@P3J9D-O:*M]4B)M]
M&VE!\^JUP<'(Z<1_V$1*\136)\5`,8P.)J/-F.;)GT)F.@T]K+U*K2T#/U%N
MV<OXR0J4_5TEF]<G*W+LG:<G%2\.S<*(HKIJ@<$U#E'W`Y@$%IRGAJIY+TRP
MU^E*P]9S2@80XQC',@@FLB@RK#JU716Z:+>[`NZ<N7,Y9;-**_0=TNH=840$
M3&$QO?T%P;3Q;SYO,T6W7:G+1^A$CF\,GIU'F96BZ*6";JK'"`5M5;=L7SZ#
M62<JIG:NOO2`JHF(!%`(<H5])^,SA29_M::1YRI2[G&ON+G\H1Y:FLY'D<2$
M1,+%G9]G8F\U>!4EX%DY]YY>3'[FY#?X@]_03:Y\(\C:#2KCG5RPFCV"DZ'L
MP=#WB`?-I$&MGVTDXE9":1)*M9)LZ/8PG$2N!.4Y4A,'M\/C_+Z!;8_QIY''
M=44O6F,158+%LIRW9JMF^#UR)=LV(Z-TO*H!NVG6IZ=ZHK*.I^KHJ1R"!?;Z
MDWBQP,'\I0"P83Q4^/:NRT'/P7+6=QDK7<O>8Q#JME;.#-#,'\)8:XYJ#J+-
M81C9..4@+9(L_FY25<%0=J$*H4!``">X%X^N.^7+HOHF`X33\VO#JEM<\=VV
M,4GY2RO:8RDE95G77LU8IN8>NXMD[5$4"',)D2@4A3`D4A"A8F&<I<_\SQEY
MA<'S2$S6(TR[SVCWZ/A5Y9RA:;O:5A7LEDD_W:2D%#2<T<?\\Q#$*/Q+[%``
M]O04LIXP_'^I$2<$;DS&#1DT32498BE6(H]=M]=F6UDT%`LL9P$JV).V-DD^
M+]:P?A.2F4:`@8YC"%K*\;<OKTB+SMWA^=RE0AY*1F64+/0"-B:FEY>/<1,G
M*2"DXH_>3,B[BG9VXK/%7"A$_B!3!]9/B'AU7A#D*BZG$;;2L"H%4U2"K+2G
M1=S@8]Q&R*%;8_4#*.6;M7:<:_%F1$I$5G*"SA,@?$IP*(AZ"]8[+:+$W6QZ
M1'UR.:7^W1D)!V6VH)JDF)B#K2SM:OQ#MP98_P`F$0=^L9!,/8I%%3G]O<YO
M<*0<\+\BNRNA<\^YDX=/=!?ZPZDW%=25EW&FROX7[K>%I8%"21I^6_;D/RU@
M5*+D$P!3Y![AZ#O%XKY53<:>Y2P7,DE-I1=-]533K+8C6[I2"R+B1_>&)3@R
M_(>N6Z:AUDDTE?L(4PF$0]_0=R-XZY?B8JOP;+"\T+$5BU2EXAV*]89O4DK?
M-QJL+,6)V=]^2M+2DG#+&;+J/#+_`&)>P&`0*4`#NM>3><V5:DZ8TQZA(526
MSAACKV`3@&P1Z^41DA)2S+/%DQ$3GJS:4FGRZ;4#%3*9V?\`3V]O8(N]X2XV
MD9)]-/\`F;%WTU)VN'O$A,/J#`O)-[::_'(1$/*NWSAHHZ<&91;9-`$3'%N=
M,H`<AO03:&Y=YYKT#)U>$Q3*8NN33698RT%'Y_5V<3(LK#,)3TXW>LD(TB+P
MDI+(IN%?N^P`73(<@%^!0`(W;^*^3+_)SDW=>=LALLQ99:!FI^4E:-!+OY1_
M6(<M?@3NG0-2+&280A"M?J]P150#X*$,7]/0,BSC6C`B"31(J*#9LBU;MTR)
MD011;IE11*DF0A2I`D@4"%`OL`$``]O0=[T!Z`]`>@/0'H#T!Z`]`>@/0'H#
MT!Z`]`>@/0<*_P#@_P#V_P#H;T'F,/?]RD_^O[?1%^WV?'Z/^BO[_C^W\WO_
M`,_O_M]O0>SZ`]`>@/0'H#T!Z#Y/_@/[^WM\3?Q]_;^`_P`?;]?;_AZ#ST_C
M]G_^OM]RG\?M^?O\A]OX?S?C?\OO^GO_`!]!Z7H#T!Z#HA\?M'_'\?L4]OE]
MGM\OK-\OK]O\SY>W\??^7V_P_KZ#MI_],GM[>WP+_A]_C_`/X>_Z^W_'T'WZ
@`]`>@/0'H#T!Z`]`>@/0'H#T!Z`]`>@/0'H#T!Z#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,0#Y`P$1``(1`0,1`?_$`+@```$$`P$!`0$`````
M``````D`!P@*!`4&`P$""P$!`0$``04!`0````````````$"`P0%!@<("0H0
M```&`0,#`@0"!`<+#0````$"`P0%!@<`$0@A$@DQ$R(4%0I!43(C%A=A<8&1
MP1A80K+4M=5VEK9W.1IB,T,D-%24M)4V5H>7$0`"`0,#`@0&`0,!"0``````
M`0(1`P0A,042!D%1$P=A<8$B,@B1H;$44L'1X6)R(Q46"?_:``P#`0`"$0,1
M`#\`OF7&[U>@PZL[:Y9O%L$Q["&5-NNY6V$2H-$"_K'"QMO0H=/QV#5C%R=(
M[D;2W(NI\M'%EDPC\>8VGYY#WRI&DW@^PB"(G`IG`-4"F4[2E'?;OZ[;:Y?2
M456;)U/:*;9I+/GSE'!6)TG'<9`L5356$(9]'V8J<LZ;()@*RSM!4HHM%5C@
M)B)B7<I=@$3#UU\F]\>\WO3V=W5=XRSV+?Y#@)3:Q[V->4Y3A%5;F](PD]U%
MQ5-JMGT?VO[:^RG/]O6<O,[R>%S_`*:=^W=QFK<)M_C#5RDELY5=7JJ(V%;Y
MH1II=E`Y,P_E3%S]\J*"3V4A?J\`14B*BZQUY:/["MT")I&'N$@^FN7M/]I^
M`YKN'#[4[FX/G>#YW.OQL6HY&/*5J5V;I&/JI**J_'4QSGZ]9./Q5_F^TNX.
M$YK`Q[;G*-N[Z5[I^%J=>I_"I)R@Y/Q[E*)+.8]N,#;HP>X#+PS])R=`Q#F3
M,5VUW([:'!0HALJ0@B/IKZQS,#,X^Z[.9;G;N)[23W^#V?T/0O(<5R7%7?0Y
M*Q<LW7X2C3XZ/9_0[W72H[>+0"T!$+FKS9PAP0PX]S'FV5=IQYG98:KUB%13
M>6>YV1P@LLT@X)BHJD!SG(B)UEC"":"0"<V_0HJ-Z+<%:N5^YXS+,/9&<QMP
M;>26.V#A0JDK(R5JF7:"!/07TO7HTL&W7*4HB<-A`GX[;:WT?$@3'@YYS\6<
MX&-KH%7QK(4?DY$5":LU,Q-9["S^@Y27A&2[US%U.WH-^U%^)$!W060$Y`'?
M<W4-9:H4;SA5]P!1N3?*"(XP91P3-\?;+8GLS5H:4L5I92:),BPSA5N:E2K4
M&+-1@]>KM%D4#B.QG`$)M\8#I1M50#7\E>0-`XLX/R+GG)C\K*IXZKKR:=)%
M423=2STI/;BX.-!0?UDC,R!TT$BAOL)^X0V*.HM=``LXR>?*T\G(7/MOK?#^
M;A:+QXQ)8\KW:S2%^9*M/;C"">#JK44XDJ9Y^?V$0)W?J4RB<P"&M.+0.V\>
M7GXQCS=SU&8"MF)'V$9^VPJ[RA2\K;8^<B[+/-")N%:L(IM61FDDZ9]YVW4P
M+')V`'<8-1Q:56`OG,+D*EQ/XSY?Y$+5A:YIXKK)+$>L-WR<8O,@:4CHSY4D
M@JDL1L8/G^_N$H_H[?COJ``DP^Y!BWG%VQ\DAXN3"24!FFOX@_94+XP46<GG
M:PC8RS8/RQ8II)MP5]KVA((F$-P'6^C6E0,.3[JV*4_1X>3GIOUR/'%_`1_N
MH@/35Z%YDJ>*_P!UG$($5,;AY.B*29CB4,C,!W[2B80W"&$/PT]/R8J2LSI]
MPNPPOE/#^-1XRRT_^]?'&#L@IRR=Y8,R0Y,RL(EZ2-4;*1QSN3P7U/M,<!*"
MO9T`-]8Z?MK\2ED6+>A)QD=(^V*02#!H]]H3=WM@[;IK^WW!L`B3W-M_QU``
M&S+YTV.)/(`;@R;CS)S2Y<L8^Q?^\).YLFS837HE?.$N$*>/.N!([Z[U2]S=
M3V^@AOK2C55`R_+7[C"/XN<D\R\>U>+TO;SXDN3^IGLZ%\CX]*:%D!?^O$8*
M1BJC4I]_T!,80T46]01P_P"*SB/['D]_^B,?\C:WZ?Q)4==E]S)$O,&6/,_]
M5*:3+7\J53&8P0WUD91T>SUFTV()4KKZ2`$(T+6Q2%,2B)A5WW#;;6>C6E2C
M7$^ZLBE!-V\/)P=OQ_>/'!N&_3;NB"ZOI_$E3'<?=:1#=-50W#N<,*1#&V#(
M\>._:7NV[@AA#8=M.CXH5);\J_N#8_C->,1TT_&B6MHY3P;B7,Q7R-X81H0Y
M,I(O%B01T58Y4SA2)^4^)4.TJF_0`UGI=*E#/\D^8^#^)&"0S]G:RDJM65CX
MU6,BD`*^L-BFY1@1ZTK5:C"G24E)14HCT`2D*4HF.8H>N05FKS]TI:GUBD$L
M+\0%)6JL53&!U;+!*R$X9B0X[.WK2K-OEH@5D@`W8J8P)[["8?77)T+QW($.
M\??W`''_`)B7Z`PODJGR&!<KVE8&%2&3EVTQ1;=,#T+"QTZ!6ZL5,N3AVH-G
M)3>Z;H!P-L`X:HRE@+4`*;,,F^RSGUQ7G;A;Z#7'013)H!A]E))`Q`<N`)N`
M%6>+*?$;]("]/375P^RW6.YQO66H22C4J$I,$RBXAB@W$C=+YE9-,H*++>V4
M3B)]NX2@([`'Y?PZZ:3;>IR':ZR#'<-6SM,R3INBY2,!BF272(L00,42F#M.
M4P?$0P@/Y@.N&[CV+\H3O6X3E;EU1<HI],EM*-4Z->#6IR6[MVS+JM2E%OR;
M7]B$F2^$%(DY=6_X1F9/`V543"Y:62E+*-(:1<@/?[5@KQ##'2#98VX'W3$=
MAZ!KS/![KR%#_$YF"S,![J?YQ7_++<\^XOW!SHV%QO<=N/(\.]'&XDYQ7G">
MZ?EJ<KC+EG<*!>X_!7+N(8TR[2"I&=+R?'E]F@Y$.=3VFJ7N;F3@IEUT^`YO
M9.<>T!`W37)R/;N/DXCY7MZ3NX2_*#_.WYZ;M+^3JN8[+P\[CGW#V9<ED<<J
MNY9>MVS35U_U17CXKY!#"B!@`P"!@$-P$!`0$!Z@("&X"`AZ:\./69]T!5:^
MYZP#E[(&,>/^8Z5!S=EQ]B:4N,?D!K"-EGRE9-:D8CZ3;'K-N!U0CR&C3M55
M^P01%0NX@!AWW"G5J"-GCE\]?$_!''O&?&S-N`):IHT2O,ZO(72BPD-9JY9R
M(F43<3T]`E(2?^IO@4%1UWIK=QQ-L(AMI*+;T(2MX;<+?%-R1YC(\PN'G*&P
M_O$JN2!RXCA>&60K3:O*N-_G(M.FR[5C,(UIVH<_N$(F9,.X0]-M)2=.EHI"
MK[AS@#*X4RK"<_L(-'<+`7.P1*>5%($#MEJ3E!@=`]9R`W,@(?)(V)1L1)=0
MH`!'R1#".ZNK!ZT(R`O.3RC9W\FN.^*W&.&J\JE88TE=CKU$QBI3FS#G!T<(
M"(DV[9N4H)0A4!!R5)0-DG#E8P_"0HZ*/2NI[@LR1_!6M\!?"YR/Q6V(V>Y$
MG\"W:XY>LI$]E)N^2U<*:00(<_ZPL9!@`-6I!'8I""(?I:S7JD4I#X9PIF.2
MPS?.6V*G#I%OQ<NN+5K&[AQ7)8*LO91=OJ[=$#H["$9$RL.FFX,'Z'O`8?@`
M=<CHWTLA<2NG/F!Y_P#@IY.9!7<,VV6J9B]A3LTUU`2)GC[DRGJR(S35L&PD
MAK4V`'C80#M+WG3WW3'7&U25"D=OM@*53KU@CE3$7:IUNX12&6:.\;QUG@XR
M>8H.B4I,".4&THV=(I.`#IW@`&V_'5GN1'(_<_XZQ[0:/Q-/1:)3J<=_<K\D
M]4JU:AH`[U).MIJII.SQ3-J9RFFH/<4#]P%'J&I%T=2A>?#IA##%J\:G%6;L
MV)<:V":D:5-JR,O-4>M2<F^5_;6S)`H\?O8U=TZ4!%,I=SF-L4H!^&CT=`5>
M//6K$4WRP+.6[!%A`U"F\>)!.,BFJ#5NTB:^QAI$[*.9HD2;H$(U:&*DF4`*
M`[```&M1KTNFY`Y\/]S5P4CHB*CU:7FT5&,:Q9JB6L,1#W&S5)%3M$7Y>X`.
M0>NP;ZSTR*5O;AR$I?*SS)4#D'CQI,Q],R5RCP1)P32P-DVLPBC'R--A5P?(
M)&.1,YW4<<0`!'X!*/KK:KTZD.BYC7JD8P\WV6,C9+:@^Q[2>6*=DNC(8TLR
M5W78Y4QWZ)H=1-8DD`E,7=(2&`_Y:0_$%A(_F^\+0G./[K&9NXYA[_ZN,8'=
MN8?BV&#`2]WKMTUBDOB4*GPTRCPEYSX6>Y2P3B6D.L<$NTA77;.?Q/7X$5+-
M7F#-15VI$.XDI5%&[.;`B2XE$P`<Y0';?6=5\P5R_N@L>T&@.>'Q*+2*C2RR
M(9:^H?LM7(>O_/@V1JYFX/!BFC3YKV#+'$G?W=O<.VV^MP_(!PO$C@["UG\;
M?$.;L>(\93TS)XH9N9&6F*+69.2?N#RLJ4R[Y\\C%G+I8Q2``F.<1V#6'N"K
ME]Q*Q91WDQB(V.:-8Z.880PFR8L6+=)HS9M&\U9DF[5JU0(F@W;HI@!2$(4"
ME`-@#7)#5-$9O?/'E:YYXYU8;XNLI)5"LXTHF%J96H_W#BQ)=,N1\"[E;$LU
MW`BCU%M--FX&$.[VFP``AN.D-FP7)N(_";`'%/!E*Q/0\;5-,L?7HXMHG7\#
M&R$[;;`NP;?6Y>=DWC==V\5?NRF-[9C>TF78I2@'KQE!#\XOM\*/R-Y#M<^X
M`RE%\9W#D(Z8L5;@J@#V-=7N*DROVUPA4VSMFC`NE4R%!5-`I4Q4(!R@7KJI
MM;`*#_5WY<_VJF?^A1/\(U`<QD:CS-9Y+)JQ3)19I?$%9*,,':FB+M),%'Z/
MNJ&*D3Y55'N$!$/@'?74>I"..YS:C&*;;>R2\7X?-O8PU]U?/^@06K2IYF!C
MGRJ1T'!D$TG21P'X7*(`13L.7X5$CF#N*8HB40'UUT=N[:R(1OX\X7+$U52C
M)2C)>::;37R9I--56IT6N0HM`+0$?N1_'^G\BL=R%*M2"H*)D5>0K]H#<CUC
M)IHG!N*"ZI!.F0ZG;OVG3'N`!WZ:[OPW-Y/"93R,=*:<:2@]I+_?Y/4\G[4[
MES.V>4CF8S7I3:C<4JN+BWJVD]6MUH_D#T\<'-:G6RP2W$"ZY5D;;G:C'MRC
M6`L$6>,GZ_5:5,A6QK5@6<E(J]L<>5$K@YBG<@HW5*8%C`'3Q[+[U[7[CYG_
M`!^%C*QE>FW=M25'&[&35R--55;Z:-:H][^]GL3W=VCQ5OW%>!;M]FY?H=&1
M:GUV;[R;?JPO6J?C;FFXT:BU.+3B@Q8>G\.NJ1\P@"O+AY=<E^.?)^/<?1W'
M&OY7HN3J%(3:=CL-G>PK5Q*L95>-FJR#-."E&CL$6"K=4X'/\15]A+MUU4J[
M`ZF'XB^'OR.XBKN;BXUPJP=W.NLIJ;DL<V5KCNR5.6<M2GE8V;9UQ]#(LI*+
M>B<BGSC+<QB=P@(#N-K),%2'(^/ZWPW\JU2I/"#*\CDEA2\NX]:T*U0TFA+O
MS.YYVV)8*(\F(<`869.,164;.#ID%%8O0Q=P'6OR59$/Z#G+VD57(_%O/M-N
M\(RL%;FL3W9.3BGR8+-U3-H!X]:JE_NDG#1XW3514+L=-0A3%$!`!UQE*2/V
MV>.:7>>?<Q-VN$:S<CC3#T_:Z4J\W53A+$M.Q<']821'X#OD(UVJFD<W5/O$
M0ZCOKEG6E/`B+C7DNW_J`<O/]A%]_P`4*_EMZ#K$/R12MG]K]3*SD;'/.R@W
M2):3]2N,=B^NV*%?IE69R41+UZV,GS5=,X"42JH+F`!]2CU#KJSW^A$"AYJX
M3S1XGN0/([CI77KMS@_DC07T/7%Y(558RY8M>3;:8@CK'W*G^V%!EF0LU%0#
MO#8X_H+!JQ2:UW`='[5HH$PYRP(&X]N4Z87<?^332!^(`(CTU)[A'-_=6?\`
ML;B)_GKD+_5=/2/XLH97PJ?[K_B3_F--?Z\6G4E^3!4[\][-K(^7U2-?(D<L
M)*#XX1S]JIO[;IB_3@VCQLIL(#[;ALL8AMNNQM:7X,A;.@/$)XUWD#!NW/$7
M%ZKAU#Q:ZRAD9O=155D@HH<VTP!1,8YA$>@;ZQ5E*<N>L7X_PMYRX'%V+*M'
M4K']1Y68"9UNKQ)50CHENZ6HS]RDU!=558"JO72B@[F-L8P[=-<BU@0\.5\9
MCZ:\Z>28C+00A\727+MLRR`6S.B,:X:JK*G"2+-O5%FR;6/[`+[AS*$``]1#
M2/X@M#&XW?;]E,8!C^%P"4P@/;D^*$N_=U[!+;Q*)=_RW#;6*2^)0BO#EOPE
MJ-0G,:\*)G$!JA#RY[)8:SB>UL+&UC9:?22;C)2)&TI)KM5I%*+*4HG,4#`C
MT#IK+KX@K:_=8?\`:^&/_P!P?^6JFMPW##Q^'/\`W8W#7_9"P_QO+ZR]P5*?
MN,^GD^9#^6&\,_Q=)RSB&_\`-K=OQ(SH_/;AJ\X,YI85Y:1<8NK5\G4C#MC@
M)@$50C4,B8DC8-N[K;IV("FF[>,(AJY*&^YDEQ[0'M'9&E*>(+;W$#R-<6.4
M>#J?D>!S'C^"F#5V._;>G6BV0L!9:=8&S%$LS'R\;,.V3DJ#=T4PD<E*9NJ3
M82G'KMAIK<H`CR6^<[.$+ROJ^"?'=>*5;J^R2C:?8)E&ILKRTM^49^<29M8B
MIR`+@F_:Q;<2I'4;B=)594>TP]@ZU&*I5D"S_3_+M_\`-<:_Z$17^%:=*\RA
M2\J5Q[8*9/E@8UF]N"$%-(5-9T<K<64M*,%&!54W@E,9J`E5^(P!Z!KQSNBQ
MR.7VUGX/$J,N2O8EVW;3=(]4XN*J]:+7>ATN="]<P[L,>GKR@U&NFK7F!RJ&
M5LQ<=;;&XXR>\FZQ8([Y0S<AWZBM:O,6AV`HI%/G0"Q<.3E`2B(E`X"&X@'X
M_EU;O^ZWL/W):P;]_.Q\2%R,IV8W'*Q?MIIR]/JK!IJJ3I5/='@V#R^9Q]R/
M&\OU6\N"HG7[;B\T]FPN>,<XT#*;5,8*71;312%^<KDBLDWF&JFP=P`@82E=
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M[:E5.+;HZIT:3T>OU/Z&,+L_L_W(_P#G9;O]G9CYWMC_`-05[#R8Q4I2G849
MPBE&J5RRU*#4=='0O7$,4Y"G(8IR'`#D.40,4Y3!W%,4Q>ABF`=P$/4-?3"=
M=3^>IQE%N,JJ2='7=$4.87"K`'.7%RF*L^5/ZY%MW(R5=GXU?Z9;*A-`D=).
M6K4XD0SF/<=IME2!NDN3X5"F#1.FJ(5T;-]K7%HSL@.-N8=SKU4>*F`L;-5=
MN[E0:CMLBZ>0SV)9NS@&X"8R/7\0UMRKND`E?`3P8<6^#]UB\ONI.Q9JS-#)
M*?0K7=R,"0U2>+D42<2%6KC-NFU:29TC]I7:PJN$P_0,4>NLMU`8B]U-O>Z3
M;J2\=+LFENK4W6G+QL4AG+1";CG$<JY0!4#I"LBFX$Q0,`E[@Z]-0`A?'7X6
M\6>.W,MES)2<PY`O\I9*.[HZT1:F->;1[9H[EF<L9ZBI%,&SD7)%&8$`!,)>
MTP]-]:<F]P%#Y"8=C.0>$,I81FI=]`Q.4:7-TN0F8M-NK(1C6::F:JO&2;LB
MK8SA$IMR@<IB[^H:B='5`@AXS_%ACWQHMLK-J'DVYY%+E56J*R)K<TA6HQ8U
M1K(M6P,@B&;7O!T61,)^_?82AMMHVVZL#F>0_P`<^'/(OBZ#H&2W\M4IZH3R
M<_3<A5="/-9J^HJ4$9>-2-(-G+=Q$S38I071.40$Z9#AL)=$VM@<IXV/&A0_
M&U5<G56C9&MV1&^3;+$V5^ZMK6':KQJ\3$A%)MF81#1HF9%5,.XPG`3=WH.V
MC;>X-?Y*O&!0/)1#8MAKWDFY8[2Q;+SLO'+5)K#.E)-2=CBQRR+T)AF[*5-!
M,O<42;#OZZ)M`ECQ%XX0?$;CGB_CI6K#+6N$QA#.X:/L$ZDS1EI))W,24P99
MXFP20:%4(K)&('80H=I0_'4>NH!F\T_"!B?FCRL3Y5VG,^1:=8DT,>(!6*^P
MKB\((8\,Q,R,*LC'KO=W_P`B'N_'T[A[=M6NE`&TC618V.CXY,YE$X]DU9$4
M.``90C5!-`IS`78`,8J>X[?CJ`"#EGP;8ERQSD-SBD<U9'BK:;)]$R<-*8Q]
M;/6_GZ*G!$9QOS"\>>2^4>_0R"H/N=X=X]HATU5)I4\`-'R@^W;PGR@Y!Y:Y
M`V#/^5:U,99MCVUR5?AHVJ*Q46X>[=[5DH\BUG1T"[=!.8QOX=$VM@,%_P`*
M[QV_M+9E_P#2:7_D?2K\P%#\:GB?QQXU9+*TE0\GW7(9\K-:TUD4[:SA&I(L
MM:/)';F9#$,V@G,X&2-W^YW?HAMMJ5;W!E>2WQ58\\E:N)5+WD^ZXZ'$W[5?
M30J+.$=?51M2<:FX^>&89N^P&P1I1)[?;OW#O^&E:;`FIQ3X^0O%/COB?CQ7
M9Z4M$)BBK(U:.GYI)HC*RC=%TZ=`Y?),4T6A%A,Z$!["`&P!H`87/;P@XGYZ
M\BT>15PS/D6C3:53J=3"OUEA7'$49O4WDB\;.C*R<>Y=^^Z-(F*?X^T`*&P:
MM6M@$WSMQ7PKR9PJXP+G"GL+W17$6P8$3?IE2DXM]&L@9L;!!2210=0LZT`.
MY)P@8ARB(AU*(@,!6YR-]K)07ED<N\2<I+E5:NX4[BPUOK;"QR35$PF$6Q)>
M/5B3O")%$"D,N0YA`-S;CK?6Z48",\`?!=Q<X/V^+RV_DIW-N9H=$P0=JNZ$
M<2"J+Q0.U20J=8:-B,V4H!>B;Q457*0&'L,7??66Z_(!M]0"U*(#798PWCG-
ME97JF1JVRG8U3XVK@Y01E8IT`"";V(DTR_-1[M(1W`Q!VW`-P'7C/=/:';W>
M?&RXON'&AD8KV;2ZX/\`U0EO%_+3S3.AY#C,+E++Q\V"G#^J?@T]TP2V4>#/
M(/$RYYO"-A-EFLL?<7:0DK(C!9)AD2&`Q&\7+HBFVFBI`.Q0,8JQ^WJ&OC?O
M#]7.:XC*?*]AY,KJBZQCU>E?A\(RC3J^C3?D>N>2[3YK!7J<5<]>PMHM]-U>
M5)>/^T99KS^Y"X.<A!9%9VR!59@"!XO+5.DD^WVMB^VA/(ID(HF7T`P&,(AK
MM''>XWOIV))8/*J[D6;>G3E6G*5%X*>C^NK/&+G>'=?!OT[\+C2TI=@_#REN
M.G4O+TI/6.LUIZSP]&%G9J.BW5@D[@^CX^+;O'*:*[]W[Q`(BFW3,)A[AV_/
M7L/A/V)[RY+/Q^-O\5A6O6NQA*[*Y<C&"DZ.4JJB26NYRXGNORU_.LX4L7'2
MNW8Q<W*244WK)^"HB'7.CE3R)F9++,0TD+NCABV3J[6`:UU%0:Y,0C-NC&,@
M3M$=[J8Q,XFU!RJ@10/<%3KZB&OW$]E>Q_;/.X+B^<X>_P`7G]PV<=2G=C=A
M<<;DOOE]B;^Z%7%-K2FA^3?[&>\'[*\OW[SO;7(?^8X3VNS>2E"Q'TY0C=Q[
M25J+MW4M;=]0]5Q4J2<M?%#^>*CA[R;!_$Y8Y1,*O#8ZKL"XB,5X\G*+77=[
MF6#PY'$1(6><D63J49UVNM#]L2UW(J`"!M^T"Z]!_L#E>TW)=PW\GM[C\3+[
MOOSC_DYW2I*/1IT6ZZ.;:^^7PWJ?J3^HW+?L5VM[7<?VESO<'.<;[:X=N3Q.
M+_R;MN,_5I)W;MN+73%U;C!NDJ[4+"Y"E(0I"%*0A"@4A"@!2E*4-BE*4-@*
M4H!L`!Z:^>5\-CZ2;E)N4FW)NK;WU\P8O-FU9'2Y"<;L>5"9R&G7[51,Y3M@
MK>/<J5C$3^7D:Q^[\D#(.K/:BC'J)Q1I=<"(`/>85^[80*.J0?#@#D2X90XK
M8YM&0+$^M%U26M-=L\M)$;B_&7JUJF(!TR=OV8%8SCB.-'^P:1;A[#\4_?3^
M$X:`F9H"+-*N5GD.7F>*,]G';FIUO$N$)N"@%#$%G%RMAE,E(S3]N4"@<%I)
M.);E4$1$!!$NV@)3:`@QS.NEIBIGCAC>,ODKBNH9BRX-3R!D*"<)1LVPB&4&
MZE8^L1,^Z26:UY_<Y!$&9'1BB<H`($#N'0'CQ2LMB8YAY+84#(\YEW'6+'>-
M9"G7*RR*,_/P4G=H::=63'4G9VR:2,X-<&):N4NX/?;)OO;4W^`=`3MT!#//
M&2+#3N3O#RL-K::O4Z\NLWIW&-6>-649/?L_2X=_!IOU'0D`YF#U<ZB12F`>
MXP^N@)B-7;5\W3=,G+=XU6+W(N6JR;ANJ7<2]R:R1CIJ%W`0W`1ZZ`R-`!TO
M5PM]R-S9R=8^1MXP]:^.=LM$)BK'T%8X^#J\=%4VOH3%3EK+5GS91Q<_WLN3
M$[A,<"*(.2HH!W%`=`%$P]9YZZXGQE<;5'!$6:U4&I6&P18)*(%83$S`L9"1
M:E;J_K4"I.US@!#?$0.@]0T`X^@`6Y$S=<DJSG3D/;\PYAJM@Q3R.M]`2HF/
MK%48^LXJH5$N,?7J\:VXXLJK9S>`R'$*D=.%4S^ZN#TID-BIAN`;R!DTYF#A
M9A(3&2EHF.DDS'3]HXD?,T71!.EN;VC"57J7<>T>F@-J/H/\0Z`C#Q'N-EO&
M+9F9MDT[GI1#+F9X-%Z],4ZR<57\EV2(AV!1(4H`A'1S1-%,-MP(0-]`2?T`
M-G*$M+91Y:9"PY;\X7/"%!QI@NH7^H(T>S,Z1(VV?MDU8V5CMLC./F[@):-H
M"4$T1*S(`))JO^]7U(`@2_X\V,ELPMCJ>3R".5TWU;9^UD@T.$`>ZI-P%LG8
ME(HOZMNI)D2!0PD_5J&,)R_"8-`//H`)O(+*63*;G',609;,5U<8NQG<\<L&
M"^&KS5Q-AE#>*7L=;RI@N?!":OR%G2?%44>L#G.#14/;#O2$-/D`ROUZ/_[X
M'_AEM2J!O=4'P>FX_D&@->X>'0*)BH&/MZ``")C?CL7T`1_ET`S-[N+)5J:.
MG<2SE\CS#L9G^SD1-LC=VP")F\HY]D0V]=PUQ7\3&R[?IY5NW<M^4XJ2_AIH
MX[MFU>CT7HQG#RDDU_#&@;\=^,-^4^<G.)F/V+A<P**_6L<5=DH8P;#^M!DD
M8INH=0$!`0UV"]V;VI=EU7./PW)^5J"_LD=IN=N\#>?5<P\=O_HBO[(D!4\0
M8GJ56<TJL8RI,#3WA_==U:-K46A7W)Q`0%1:)!L+%4X@;J(D$1UW[A[%GMZ2
MGP,5A33JG9_[3K\X49RWN"X7(P9<7DXF-<XV6]J=N$[;^<))Q?\``YS1HV8M
MF[)F@FV:-44V[9NB4")(((D`B221`Z$33(4```Z``;:ZFY<G>N2NW6Y79-MM
MZMM[MOS9W"S9M8]F./8BH6(148Q2HDEHDEX)+9&1K!RC7Y&PIB/+QX=3*&.*
M=?%:_P#.A!KVB"82R\062*@61+'+ND3K-"/BM4P6*0P`I[9>[?8-`=C5ZK6:
M3`1E5IT!#U:M0K8K.(@(".:1,1&M2"(E091[%)%JW3[C".Q2AN(B(]1T!O\`
M0&G;UZ":S<E96T/&M[#,,H^-E9M%F@G*24?$G=J1C)Z]*0'#EK'G?KBB0YA*
MF*I^T`[AW`W&@.2O%"I62ZX^J&0*M!7&L2/MB\@[#&MI2/541-WH+@@Z34*D
MZ;G^))4G:HF;J4P#UT!AX]QGC[%%?+5L;4ZOTFO@Z7?GBZ]'-X]!S(.NSYF1
M>F1*"K^1<@F4%'"YE%C@4`$P@`:`[G0#;9%P[BO+J$2VRACZI7U&`<N7D&2T
MPC&7&(=/$2-W;B-.[24.R5<H)E(H*8E$Y0`!W`-`=55ZK7*3`QM6J,+'5VN0
MZ`MHN%B6R;..8-Q4.J*+5LD`)I)BHH8VP!ZCH#?Z`9FY<=L%9#MT??;SB6AV
MJXQ@,0:V*;KD>^DC%BU07BRO%E41"2)&+@!VP.05!N8-T^T=`/*``4`*4```
M````#8``.@``!T``#0'W0#'V_C1Q]O\`;#7F[8;QU:K8JFV2<S<[5HJ2=/P9
M`4K$\F5RW40E%V!2%!NHX(JH@!0!,Q0`-`/6W00:H(M6R2:#9LBF@W01(5-)
M%!$A4TDDDR@!2)IIE`"@'0`#0'KH#40E?@ZTS4CZ]$1T(P5?/Y-5G%LT&392
M1E7:K^2>G1;D33,Z?O5SJK'$.Y10XF$1$=`;?0#3Y,P1AO,QXA3*F-*??%H$
M7'T=Q9(5I(.H])WV`\:(.E"`X!@^]LOOMQ,*"W:'>0VP:`<R/CH^(8,HJ*8M
M(R,C6C=C'QT>V19L6#)HD5!JS9M&Y$T&S5LB0")ID*4I"@````&@,S0#,6?C
MK@FZ75ED6V8EH5@O#`[%1"RRE<CG4FHI&*"M%JO55$1))*Q:P][8SDJIFYNJ
M8E'0#S;!^0?S!H#[H!:`\C^O\G](Z`P`_P"D_E_IT!^P_P"<#^(/[[0&>7T_
MF_O0T!^M`+0"T`M`+0"T`M`+0"T`M`+0"T`M`+0"T`M`+0"T`M`+0"T`M`+0
("T`M`+0'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P'L`P$1``(1`0,1`?_$`(T```$$`@,!`0``````
M```````'"`D*`@8!!0L#!`$!`````````````````````!````8"`0,"!`,%
M`P<&#P```0(#!`4&!P@1`!()(1,Q(A0*03(546$C%A=Q@1F10F)7&-B9L4,F
MMG@Y\-%2<I(S)#2T)975)U@:$0$`````````````````````_]H`#`,!``(1
M`Q$`/P"(C>_[@/RR8ZW.V5H%&VPGJK4J=EFUURNP<3"P:$1%0L;(&2:(-TU6
M)UC'*5,"\F[A'D>..@:,/W(GF5Y'G<JWE'D>2_H]=#@?Q#C]+]..@X__`*1/
M,K_^YEO_`/I%=_\`MG0?(_W$7F*7D#S@[J9&*[5B$88[5-O#A#H-C+G<%D&T
M65H#-";4$W:=V0I5SI`!1'@`Z#3YCS\>8*752=K;WYP9*%J9ZR)(J?-&H';G
M#@90[1J4B`V4!0$?U(2_5<CZ#^T.NKOGA\O\(V*Q:[^[#R"*$TUL/U%AN3F?
M>F,Q)[!6:CV1`[H\&J58!69`845CAW"0>@M@?:@^0[=#=S9K=*&VMV/R/F^$
MB\04VXUNMW2Q+2$)6)A_?EXQ^YJD0H!6]>;K,A(04&Q2IE+V<``]!>G;!_"*
M(#W`/J4PB8QQ+P`%%4QOF,J(!\W/X]!^CH#H#H#H#H#H#H#H#H#H#H#H#H#H
M#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H
M#H#H#H#H#H#H#H#H#H#H/$9\JU6L-#\C^Z%6LS08^<@L_P!W2?-%1*NFFX4=
M@Y2+[I>0-WM7!3EX'CM$.@CN-SR/(\CR/(\\\CSZCS^//0<=!SW&X[>XW;W=
MW;R/'=QQW<?#NX_'H#N'U]1]1[A]1]1]?4?W^O0<]QO3YC>@\AZCZ"''`A^P
M?3H+?GV8ZZY?)!EU$JRQ45M;K#[R153E26]JQPIDO=3`P$5]LQA$O<`]HCR'
M07DO*=Y/3>+#'T9G7(.L66<QX$=KQ]>M&0\36/'J"M"M<P^%K7V-HKUNL,)*
M%83:@>TV?-BJH`Z.1!3A11,!!JM>\]]*J^-\.YUVQTVVAU.UDSPYK1<>[+7Q
M&E6W%16>1HUQ8,>N;4XHEBEYRKHV&O`185'+4J")A5`#BFGW=!/C#R#67CF<
MJR=IR,?+,VK^-?-EDSMGD>Y13<L9!H9$QTDVSUHJ54@F,(GY_NZ"OYF;SH7/
M#'D!>>.9SX_,Y91S[)U&2R!C.,QA?,8R*-[I[:+FI]A8"#,V*+0BD5:]6))9
MRDH8RZ2B`$!,1,/`..POY4[M?]ML3:DY>T#VLU>L.9J?>[92KSEYUCIW19U/
M'C5BO9(AC(U*RS)W,Q'_`*RV!T@3M6;@J@)R`50HB"C>3OR)6+QHXB3V,L6N
M-XS;@B$78QN0IO&ECKS:X4N4F7+IO'OC5NQ.F(/*V@=$H.'8G*5M[@";TZ"/
M=?S^7W%N*J9L;M)XQ]O<.ZOWP*J^C<YQ!ZAD*OUFN69L9_%6:YP$!*J6**AW
M<6HFJ*J:!S*J'*0"]QB\A/9K]GO$VT&**)GK!MVB,@8LR174)ZJVB'6,=)\U
M54,15!XU,4%(V1CERF0<-5@(X;."'34*!B\`""^0'>K&GCWPY3<V9;BIQ_1[
M1G#%N%Y.2@EHM`]14R?*.HIK<I4TLY:-35^O+-@5>@!_<!`3"4!$..@>9%O&
MCQM'NHYT@\C7S9-XP?,72+U@_:N4?J&SQJY;J+)JM'J*H+)'`PE.40[1$.@_
M'=+?7,?5"T7JX2[6`J=.@):SV2;?*D09Q,'!L5Y*4D'*R@E(FBT9MSG,(CP`
M!T#3?'YNOCOR%:Q4K:C%3*2CZ7=9BYPC*/E0`KQH]I-JEZC*"<0X`Z:KV(.8
MG^B8!#H'JJ`(D,`"8!X'@2_F`?PX^/01TZW^23!NS&Y.X>EM+5<H9-T[D*:S
MLSE5ZR7C;DWLD0U>S<A52-UU%5&]-FGB<9)>X4!2=*%+^("(2+G'@AQX[N"F
M'MY`O/H/IW"(`7G]O/IT$:N*?)CKSDK>O8'QZ&E'=7V&P>VK<]%UNVNXY@&7
MH67@0GYB6QGP\$SU&F(=I'K4_#@B9O?[!2Y,`26=!!7MEY;LL:L[SZ_:0.-,
M;3DJS;2RRS3"]LJV4:7%Q\Q$1,Y-MIES/*3;QJW@I!I7H125%NJ8O#=0I!$#
MCP`3G-E%%6Z"JR!FJRB*2BK8YTU3MU#D*8Z!E43'24,D81*)BB)1$.0$0Z#[
M=!$YD3R666>SAD[7G2/5O(6Z5ZPK-I5C-EOK=QHV-<(XFO96[=^\QK8LG7V5
MCHV1R$QBS@LYC(XKE1FHJ5-S[9QXZ#;-"_(%.[?7+8/$62]<<BZQ9NUIG:Q%
M9(QU?9>N3Z3F-N\:O,U.PUZ<K;YXWDX^2C&XG*H7@APX[>0$!Z"31,PF(4P\
M`)@[O3N^!O4OH8`,`]H^H?@/08'^40-R</G#Y2"'\0P@'`#S\`X#]W[>@CDV
M[\D.*-6\B5/",+1LK[)[)76(/8Z]K=KM4E;[D7^7R+BU&V7!R1PUKV.JL1R4
M2)OIERU1<J`)$^[CH$J<[=^2U*LGMC/Q9RCA%4[EU'5I;:O!9;@>)2:*/62C
MZ."Q?3FF%TS`D,>B<[E%R4Q.TW`#T';^.WR@4_?RT9WQ"KA#->NF?M6#4YGG
MG$V9(=A%3-6GKTM9TX1"'DHYZ_8S+*3+47+@B_)2BV<(F``[O0%OVPW@IFML
MG5\;0E%OVP&Q5_:N7E$U^PVP;2F09J&1*J20M<J9TZ;1-1ID6JD";B3D5D$1
M$X`GW&'CH$/F-LO(16<<U;)$GXTK!8SN@CW]PQQ2\^8L?Y*J$*9)9R](C$N9
MQ")LD^R:`F4C1LY$YEE>P_:)3#T"KZ+>1_6CR"T^T3N#K3),KCCV:<5S)N'+
MU%FJV7\33+)^M'J-+QC^05)+QZ*CA)0B;OM,W5*F/!NXI@Z!Q&R6;(;6[`&8
M<^6**FIFOXCHUAO,K#PZS1.7D(^MM#.5VD29XLD@5=R0@F3$YN!^'Q$.@SU>
MV!QUM=@/$^R6)Y4\QCW,E)AKE5W:@'(J5J^0!-\R<(J%*HB^BY5%9HX(8.2+
MH'#X=`O*PG`@>WQW"8H?^D/:`AR(!\IA`1_<`]`P+5;?;$^VV9]R<,8T^K-+
MZ;97A,1VJ5,Z;N6UAFG-=;2DXO"F24416C8&QJ.HP5!,`*G;"8!$!Z#GR([N
M_P"'SKO9]F;'ABZY?QE0TQ>Y()0K-2(:>K$(JJ@T9R+2,NDU"EG5'$DY*FHD
MT.<Y$^3!SQQT#%9_S373&^`ZEM?G+QS[44'6&^TVMY+BLSU.;Q7EZ.JV-[DT
MC'U5M>0*OCJW2UHJZ3EK,MU3D.W4$I%B_'UX"5_6W8O#NV^&J5L/K]D)ED7%
M.1(DKZKSD.N0Z:*P'.WD(N59F_CQM@@GQ#H.VCCL<-%TS)*$`Q>@;[MUY&\`
M:99EU$P;E>77&W[A95;8MI)6+EH@6".8A&A+=9S/'"!&M5_7G"#)9<HC[:BX
M"/IZ]!(`4QO453^R<X=OS"`&3'O*57V^?S)B<2@4WKQST#*][]WL6^/[",7L
M%FIM+AC9/)=%QY;):&*5PXJC:]/E(\MB=)&43!>,C'9"*.S%]4V_>8`Y#H'3
M52W5>^UJNW:DV:,M5-M48RFJ[8X.0;R4%8(>50*NSD8Y\U442?HN43AV&(;^
M&/H/KT"`;BYUR7K=@>\9QQKAU[G57'<)-W&V42,LD75IT:;58.3F+)*07ZTJ
MBA.SA$HTA&L>02G7,8`+R(AT#.=?_)/D[.GCI+Y!(74:^O(E]'3-UKF%:W>*
M3(9.LF,Z\#TSZS19G4FG#$GSECE3HPIU@<'2#M#^(/'0*5XO?)9CORC:^S6Q
M&,Z19<8PD5DFQX\=T:\RL"\OD4^KJ37ZM]9XVN/9-O!_J1W`_1I*G*8_MF^/
M'0?;R5^08/'SA>CY1:8@LN<K'D?-=.P74\:U6;A8*RS-LNH/"Q#>-:RSA-24
M5^I9@!DD`,J#8YEQ#VB"8`>-@JU9ANF/(FQ9OQ8RPU>Y(J+B0H3*Y1=\2ADU
M4B*@T<6&$,:,7=H&,)%!1,9(3%^41`>@6D@@8A1`>X!#T$!Y`?[Q^/00Q^7?
MRTE\3-/Q_DR[Z_6O+F/\I6UEC"KRU,N-6BG;?);Z/D[`WA)^%G'K5^C#+5R`
M>JE?MBJ@5P0B1P`%`-T&H9,\O60=1(BH7+R&:.96UEQ%;[%6JDRS94+[CK.F
M-JJ]M2IF[0<D2%"G'DG2&`E2%4'3M`$C$2-P;D!`0FX@Y:.GX:*G8=^UE(>;
MCF4O$2;%0JS*0BY)LD]CWK1<HB5=L[:+D4(<!X,4P#T':]`U3=7;7&>B^M64
MMK,PI6)SCC#\3"RUH:U9DE)3BJ$_;8"G1Q(Z/650(Y<*RUA1`0$Y0*D!S"(=
MO0.#I5IAKS4ZW=:X^2DJ_;8&'L<*]06270<QDS'MY!FLDJ@=5$P'1<!R)3&#
MGGUZ#:.@.@\7_P`\2@_XP_D,[3&.([)6PH$^0R!N&<:0P")1``4+\!_S@^`^
MO012-$6JWME6*9-,P@412("B@E*9,RJ8"<J?U#@!,!DR)B!C?D,(`/<`6T;K
M]N)J52?'Q"^3&0\E-P'7"5Q7"9(;=FI2"EV6>6=Y%Q<%4$H)'.+B.6G23K\[
M1T'U8%1^G,<H*$`3`$2>&=1_&=L#>:KBFC[_`.6<5WFYV.'KD3)[/:M5O'V-
M?KI=0J":SJ[8[SSEE2!2*Y-V`>3:,6Q3&(!S@)NT`ZKR7^(/:WQ:7V!A\\0-
M=L6-;ZX<)8RS;CER[FL;W0C!;ZEU'GE)%HS4KUN0BRE=+1[E$!%+W3("X115
M5($3"Y1*J;^&*0&'O*GVF*!2G#O+V=XB84Q*(=HB/J'KT%O/[,C_`+R3+/\`
MV;K)_P!8H3H+4_W9DB=EX9<UMOYG0@22N3<$,OTLS$KM>X>UDV"?A`(+F6)^
MGF;*M"R!U0`W<BR,F("!^@B?VJW9T_W(\$FH/CFQ9G7'%UVXRK0M'L'1E';R
MT?`M\>Y#C&=4):I>XA(QS>+C8:JL*\_17,T52['"B:::@%4*DL%U77_&HX<P
MCBG%)Y=:P*XYQ[5*<I.NU`5=RJD%#-62KY8X"H(_4K)"8H]YN2\#ST%-;=S8
M'#.K_P!W!@+,NP%^@L98JKNE+B.L-RLJBR<+&+63%>>H&&0=@@BX.K^H3$@B
M@0G8("=0/V=!9>P!Y(O'5N+FZ'QKKYG3&&<,TP5*N=TAB5R"?3TG3Z/'O*I"
MW)TG:E80J=::2;^0C4SE6>-1DC=H%!8$#>V#!?NC8E.9\->PWN/WS((Z?QS-
M-ACWJ+89(S*>[P9/>\4DW;!0AQ%5%/N.)2`;UX]`7K%ETQ/.>!^IVG:9VW5P
M\]\>@-\O+/7B[OZFC?TM>Q4BS17]Y5=ZN_C68(HHE/[W=VD#YN"]`@?VO>N.
M5=;_`!.XH:Y;5DV,KEZRV7-E4JLJR(S>TV@W06C6K,7/8P8?5%L",2>=3,H9
M=<$)9,IC@0I"$!MWW4]2N>Q&%M&](,>OI3^=]MMHUH*M1C!FYD(>2E*/4_U5
MJ\F$VA#N2LX]6:+\X`((D546-\B1AZ!S7VY>[N1MI=.+3@[.0*&V,T5O`ZSY
M:ER`';.L*[^K,*1,_4EC6C)[((14"NT$6Z8(F0:)'$1.<W0;5YY\J7RWX(IO
MC>P$[7=;(^0V0L./(=HP$%G]6PW2H16YY<M+I%#DR+>2A(DL,G[X%27/)J%(
M83)\=`U'[1*^GG?%S*8O&1:/E,$['9?IBC!%,J;Z,)/2Q+LF$F8!Y%=PM/'5
M(`>H)J`'PZ">S>+9ZN:9ZDY]V3LJA5&F)\;6*R1+!9R5LM.V?Z!=&K5UBH?N
M%>1F9U9%!(A0,<QC``!^/045X'$V6O#-O;XC?(?=+`]GI/R,0LO&[M(,II^A
M&K7_`&)MG\Y23)\SEC/5V4/4HW),*L@D#EPFH\J:AA,D':94/1526[R%]LP^
MV=`AD5CB4WN=_=V'+QR!^X@`8`X]?W=!1OVY\8&6=V=]_*SL[J#DRT8>WTTV
MS-KI,X!EHJ6_2&%MBY3"SR7EZ<JJL"I6K^?=M0.S<G`S958HMEDCI&-T$M/@
MU\U9_(37++K/LQ7Y#$?D$UVB'J.9:1+0SFML+K$5R0;UF1OD6R>"4(:?923A
M$DU$'*C].Z6!9L46J@@W#3O*I6&J'FK\!=W34EU)21RGG^IJE,T0+!A'0^,G
M\J5=LX*<'AI9=6P*_4D,'M$132,4>1/R%F,`````^```!Z<>@?N```.@Z9ZJ
M;L5'Z@&X\'1.?DPBW)ZG7,"A5D$TS@W+W%.(B*//>;Y0$.@I>>#;>.B8'\G'
MDA\?=YR9!W2!V7VRS'LAKUL!)RS`\)F:<-,*5FYP[.;*C&0=IGI&-KR90".,
M=L9['/P3[@2^8+4%_L^H&I]OM^=LKWG#>O=GSHM4:[:\E92R-7<>(9`>X^A%
MF%2KQY2U6!C#J/H"`<&*B@T*111$_(]QO7H'/5:PPMLKT/9JY-1=B@9UBE)P
M\["2+*7B):.=@*K1_&2<<HJR>LG")@,FHF8Q1*(>HCT&J9?R5"88Q5E',%E;
MN7%9Q3CVYY+L2<>4%)!6'HE8E;3+)-4Q*(&<J1L08B8?B<P!T%9C[8:ZO]KZ
M7O5Y"\EOB6G->S6STI$OI^1C"(2,!C6F1Z04O&L.Y$#`UJT2W=@LDS1,#=!<
MQA`H'$PB%J;M*!![C=AE!+P<_P`3B`B8H'+P!?A\O^D`=`WY/$.(L391S-LZ
MVA4:]<<B8ZK#++=C9LS*)RU<P\-JE8B2=DCXY21?RL;&VAZF'>9111!-))$I
M>P>@K9_;:9GG-\L^^4SR*904![EF\YRJ>#ZRB@HL,)3<(T^#6L%-IU=2=((O
M&\<R3>E`#*@#A7M`RPF.(CT%LM4>XO<3U$HF$I$OE,<@`/`=_(=G8H'(\?'M
MXZ"DSYK*4^\:?E^\=ODJP))RE"BMILJ0V'-IXVN=C.L7&+9S-,K\R]L\"V^F
M:2I[52[4JL)5DU`"2BB.!_C]AA";_P"X$NZ,%X?MMVD<V<N%LH4BO8O@7;5R
M#1*.=Y%LL`QCI>2=',#@D2W3/RY!(JJHD-P!3``]!$A]M=FC+6H>7<[^%K:B
M6=.K_BN$ALZZ]RX.4UJK/8ZLT1#25MAJ2[>),)B0C`4E@DFA?9^G31:/!*('
M]!"P#Y1=QRZ9Z<WG(];*:4S#D5U!82UPK29BINK;G_,;D*EB]DQ9K*%<O/T>
M1=C,N44!!46,:X[?XG:`A6V^UWQ'E?47?ORW:89:E8JR63&DAC2TRUL0(N5]
M:9F9G;4@O/-_J)-ZNG#RC$Z"Y$5@,Y244'W3]QNT`FS^XN8*._#5NVDV,U1%
M#'+1Z?WW2#(ADFMBB5UB)G551*JX4(40(D`B=4X@4I3"/`@MNO.1\'8O\.FM
M]UV+G("&PC7?'9@(V5%K`]0;,5J=(Z\TQE+Q*R9G;559W/LW(LFK9,Y7#MRX
M(BB!E%"`(,'^V#UCREKCXV6:^4(:=JA<X9;NN:<=4N>>.E'M=QE9WA$J8N%>
M<-DE*FRLL0V)*%:*K*.>YV)UP25,9$@0R^4/7NW^6F=\I6\6/I*84?>+F8J.
M&]04(&Q*3D#8I'"D@GDK8"T1T8U,TXF)QTW&/22(8I$ED>\/?4`0(%NSQM;/
M+;F:':K[-R"K5W-96P_6Y*V.&B*"+56Y11'%7OAHQMW=S9J-SK[T03/Z%*3@
M`$`Z!A'W"]0I^1]'<:XYR+$6":QE?]T-7J#?8^JF*%D=U2Y6A_`.7->=G-V(
MNF3N3;KJ*G*<$DD53=IN``0A>PSF79C[9+9>.U5VJ?VK-/B%S5;'C37O/P,'
M5@E-?Y"5<&='@9UNT254CDV;IV4).(,(E60+]='=_"J`!;"VAM4';]*-B+91
M)Q.S0EBUPR?.5RRU"1C3A*-)/'<LI!OJ^_>&=0[E9T4Q104.`MP5#YR^@AT#
M*OM]2%3\0FEA>#@=3'LFN85$R)J&44M4X=8ROM@!#*G44Y.8/0QN1Z"&3.4-
M,>`3RYU?8^D&9,/'CY/\@MZ=G2KGBTXVM8(S$_E"OD+%"M(EVE#M2>ZZ,_*J
M9%(RC59PB)Q$`/T$K>%6KOR!>3;).R%D>QMCU-\?3X<,ZKQK59*1J-]V9L]<
M3>9:S<T=D4/&V%W0JW.I5Z)5`%46[ATY71."J13`$[7:7@`$I?3C@.`X#CX<
M>GX#T&705'?O'!I8^.[`A+*#_P#F(VX^/`Q^HV35%BE/#2K\$JI+&3-ZM`J(
MR($]#"*XDX#GH)3/-'9<>M?%=M!2;R#6PO\`*6)6N-L>8Y!RR=VK(64;4\JT
M7C>KT:LIK-I*S6%2WF:N44&YE5R`B8XE$`,4@/"\<>%+OKCH;J/@K),H]F;]
MBW`N.JC;I"1*X(_4G8VOM"OT'A'3I\X3<,ECB@8IUE!**?'</'0/*6."9P,)
M@#M()Q$YQ(FDD7T54$`]#CP8.`'X=!71\RE--Y#MB=:O#K#VF1AH7)F-<R;7
M['*P\X2#DX;'F-H1S1\&B^5-&223Z$G<[V=DY=M$R+.O8B.\$O@J0-?^V.VO
MGLJZ46/4;(Z*T;FG06^RV!+5'RLDNO*/ZQ'NWYJE*_1/&J#QHT:MT#,^3&6*
M8R//<`_+T%E!OQP<"F.)2G$@=XB8>[D3F$IS?,8O)^`_LZ#]'0>*CYGX)S5_
M*SOM"N9%Y,*QFQES16E'S!&-7<G.LV5,HZ:-!%%J82J]I?;'^(!>?QZ"+H5E
M>!)[IQ)V>T`<B`"D4_N%)V\_E[_FX_;T'H>YQDFS[[-3&CJ+>,WH-\?XU9N7
M#1TFM].[;9:4C)%L<Z`A[3QJJ4R"I!^8H]Q3?CT'GFF'DQP.!DB^A!`B7M@@
M8I@$!%/GN^;MY'G@>>@]!6-R*PW/^T'N%QV/3:7&UZ_-)&JT.YW"7%U8(VU8
MUO<6UHMDB)YT+:09S1(2SI0B31-8Q7+),&@]R:QR=!Y[ZP<'#UY[DTC<_O,F
M41Y^4GJ'/[_[1^/06]/LR/\`O),L_P#9NLG_`%BA.@LJ_>%"(>),_`B'.PN)
M@']X>_+#P/\`>4.@<[B_QZ:X;U>#?53%V4,=8Y&SVOQ\8`_E')LK7H9O8:+=
MX[!T`^J]Q9VGZ0LG&*0\CR9=<BI3_1G7()NU0P"#9/M+=DLY9IT1RYBO,]FF
M;PTU:SE(8>QM<)QR[DG4A2DX9"30B&\P[*920C*X[.=LU#W%?8;]B?(````,
M>W-85.7^\&U(A;OC2,RO79S6FIPKJL3$0QG(YHYE:9FME'VITPD6[EL)*@_6
M3D?=$O<B+?O`2B7D`MB5;2?4G&6P3#:*@83Q[CK-'].K!B`]WI[)M4?UJDVN
M;@+.Z@)J+B?H(J=<GF:PV6;KND5G#3M4!$2@NJ!@@F^[U,=/P\6`A16+[FRN
M"R.0-P4JIO\`I0J(_P`+A(P"=,@F#C@#E_;QT#-<Y>#DF8_$)JYDO264S%6M
MA<9XCQAGZ$P;?<Z6;+^&LI.F=;:6B<I/\B6RTS&+XL]C<][E@W8M6S;WU"-'
M0=HJ!T$WOA:\K5!\GFM$>_=(LJ#M#AI"/J.S&$_I5H5Q4K3''>1K2=AHMZDU
M<-ZC8/TT52I$3!2.=%48*@'L@90&4>3.4E;QY\/"'A]E-21?Z?M<QY\E(MRM
M[=948%8SE3^L8)$$.^SO/TKVSAV=I6Z10$WP`0;UN/D*%\,7G-Q7N*[9P]$T
MO\DM,-BK92Q!%.D:]4LIU-9%^2_OUFIE`:SSU4K9Z[!%NH=5BW<``#W"7H'F
M>'']3WLV,VK\Q>08>>;PV5K)*ZU:31=C:MBM('5'%\NFF-TJ";U!.<C"Y2N8
M.7K\JBA?:>E60(3VDR'.$>WVB[VP46*\F&ML^2JJO\=;:/[*^7C)([Q^:9=1
M[:GOQ;I>X@HO7BDJY3-'/L)=ZPJ!W#QVE!V_G5BY'?':303P[5Z\WBBPV;KC
M)[$[#S>/"0[B:A\38>;J/F*1',WW,V,FWFP3DF2RC9T4CAL0XIJ"!45`;'Y,
MOMZ\B6O2G+MG9>4+R#[#VW7NK26<\8XQV6R;#9#QL>UXO@9"6!O'Q#&$A%H^
MT.ZHW>QT:\;NRE:+N2B<#$[B=!-SX5M[FOD$\=^`,YR("AD",A$<8Y=CUDW'
MNLLFX]`U;L3PAUA]&=C69A)-`%104VSHA%#"J!@Z!!/'C<BH>77S68X&/!,K
MBVZO9"&4]X>`]O%KFN&:&*(<`*@#W_$.WM$/QZ!`/,WX=;7FFRP?D>\=<B;#
M7D9UX60N$6I5TT(^-V&9USW7K6K3C5048AQ<UF2RJ+1VL11O+(KF8O@,F9)1
M$(DZAY0L5^3SR<>"C(QV,]C';?$V8\]8>V>UUL$:\198_EXS%TFJTM<&ZD8=
M-0[2VS:TDFDFJY!\R,R%LJD!DQ76"^H3\A/02_*7Y3``"'H'H(%Y*`A^[TZ"
M#K[BK+^1L&>(+;.]8QL$E6+,LACNG/YF-;>^[0IV0<G4ZF7M-@<[9^HP5>4B
M:>H%<$`HMU%/<`2B'/0))ESQ1Z5>3CQKZD1>)$V>'GU*PCC6Z:A["4B$AX_(
M>.DAK32?K7OR$:VCU"UR8G7*;F69(BBJJ\)[R0I+E'@*_NR_DMVGD](L[^$[
MR+81+(;^6)]C[`.O>5[9&K.*EG.&LUO8PP9G4M<IQ"QUEJ$41-T$JT6%-QW=
M@D(X`Z9@O(Z<X'3U@U6U_P!>RN@?+XAQ53Z1)/BJG62?S</$MTIY\V44`JAF
M;V:%PJAW`!@1.4!`!].@V_/.-FV:\.YAPD_F%H!AF+%-]Q>ZFV:1'+^$;9!J
MDS4GLPT06'Z<R\<VEO>1(IP155/M'X\]!4M^U\R]/ZM7#<+PY;`HQU%RUKIE
MVSW'':,X^C8E_=ZY/2I(V73@$G*J:UND'"[=.025C^]']-7`P%,4HG$+CW\9
M0%%T0!(`*J7V3]R8+J%()$/<]3>TD4!$P]H_``_'D`!(;/;,:Y)G\G:[)W9(
MMY'%$9,76KL2G&4@<?Y;6M=+K=I^I48K1Z"TDYJTP1H05#*][43+)`D*8F"H
MI]K8A/:>[">2;QF9UBOY%SI6\MQ688:"EI%!"6M=:*R-7OU&LG,=%"QQ188C
M22,Y:)]OT[DIQY(8`*%TL_<8I%$U"$;IG4.)4DBD*<@B/\-<%NX"E`_)A$H<
MB(>G05!_-G5"[[^8'Q':/XV;,;).Z\W^0VCV'!\1Y*UBIXO/8\:V4C>^1A(T
MC5DC8H?&RK!N*YU!4<3C='M*F)NX'C?<S24>GI?K/CY6&^OBK[Y`]2(1RR(B
MC^FFB(RZ>\M&.V(`/US.0(JFD1(I1*';QQZ!T#>_N0]9LCX<5U9\O&I<>S@,
MO:#V^&0R.C!,F<:E,X&^L1<K)SR#)-J>QUVKF;@T7CUC'1+$/7*92"`@406?
M43-5.\RWDKB=N*,W<6C3#0O"%5A<4EL+%%2!FMQ\Y1#*XW2RQ":C%(KR>Q+0
MEVD.X45(FHQD%3';_(N(]`VO2\)W$OW6'D>QRX68.V68,#5#(RBI'!VZZ3-2
MOU.U1"*34>`?G:A/G17/Z^V8H<>@]!)W]QP(AX:-V.!X_P#Q_&!_<-GA@$/[
MPZ!8]'-3]9<F:/Z(9&R)@'$][O9=,=2G_P#-%JI,#-3BSR(PC1%HM920D63A
M4RS%5LF9$X\BF8H"'P#H-V\IVW45HKH/L-GUE+,H"V5RC2%3Q"DHD"CF5RU9
MVZM=HM?KD<1=JI)3H2"WOMTN\"C]*)A`2$$.@A3T;^W^RI5=7L?%L?E/\@^(
M[7F:I.\JYPQ;AS)E*BL+O;]F5FG-7Y9E3IK'[Y)RM)I29$7R[OZA519,X]WM
M]A0!@GV^6>)OQY>63<3PP9-O5TM-'6GYF#UK?W:5E70P;G%JMGR##5N*@S))
M5^O#D;&]Y=3,FLT;MD'$FP(9$G:X+P$W/W&I@1U)U/.9+WA/Y/=&051,<4BG
M*2\RR@)"JGVBH4>..3<@7GGX@'02^[1:Q88W#PS=L!9\I<)>L>7J-DHQ[&2;
M85U8Y?VS`QL4$^$HFA+-!O!!9NY3,50AR<`/`B'04GH7;S+7V^,AL!XG-U7U
MIRMIE=,*Y:L>E>R;"J.B6`JMTK<@Z0QZLH5^YAUV7\P>\T=,DU`492:R3KA%
MFY[.@LW>!"=+8_$5I#(%8H1Z9<4)1YDT"$1^H&.EY1@+U8$P`%',C[`KK&]1
M.H81'GGH--^X@Q-$97\/&Z2,F6/44Q]CI?,$2M(,D7I49G'CE.7CUX_W>X&$
MD':8J*Y/G(81X^/0;)X$Z94:)X?=%8BI2"4E%/L1'LLE--7#%4SR=M%NL$[-
M?4N80B:3Y_'R+H[`O/<NDBV*FJ83$'H)<F\LS<.))"-D6SU2-6)'OT6KIJ[)
M%R0)IJ%:/46RJJ[%P9%5(QTC@4Q4U"'[?F$>@V),W<0IOVE#G\P>H>@_G`#?
M']O04ZOO0`!/0[48R8=AAWJJ*@F+Z")_Z,Y@^?G_`,KY0_R=!9XJNHNKC"YU
MW-;/7[$3?+C1->9:9(3HE>_G)K+V%LR4G)-O/"Q%^@_E5&R9EUBG!10Q`$1Y
M#H'&J+)(J_2$431$B154D$^WW@)W]IU@0!4#*M2F-P8>WT-T'X)=ZPC&4K+2
M+M)!C#1SES(+&63,5O'))'>/5G@++D233*DAW`(]IBD*/`^O04\]#-0<E^67
M,&Z?E0B-\MJ]:ZUG#,%YP/KR_P!?%:O4WTKK%BEPS@H&35>W"F2S^N!+SC!5
M7Z:+435!V115==9PHKV@B6',*37@R\_^):Y<-C<M9HP1Y,<=3$59<H9KG4).
M[3N8Q='39R64[,V914)*2I+FF=5!?V@6^G?D[S&.`F$+PRBBY#)^P8JP@0Y5
MTD_9,8#%$2B8B93)#W)+\%'D>.T1Y]>.@X_4$/=[/>4^'P[2]W'N]O/'/'9[
MO\+\O?W^G[^@\9#SNJIJ>83R'*IB)T1V3MR8'*/"8JD1CRJ$,4?0P`H0?7\>
M.>@B-'XC\/B/P^'Q_#]W0>A;0<9V?.?V<5-H.O>+[Q<+*^-.&/4H1,]HL4S-
M0VS\_P#SG.QK1@F+@8]Q82N%D&H%%1%F/'`@3GH*158THVUN-H<T6OZNYVF+
MDU<J,W,*3&MN;NT5R*E;E!VNYBD6*!$G1P()C*<&,("(]OKT$SWD/V=OVD.A
M6._`Q#1SJ/L-0EX;,.[=MD$%D6LIDBX)5[*E?Q#447;<0"$QRU4A7,O(I*G!
MS+M?:0_@D6[@K7.``%3=HF$@]IB=P<#V&*`EY#D0_*/X>G06^?LR`+_B.9=-
MP!3%UNL'!A#N-ZV.)Y.7G@O:'``(?B(!^_H)\ON.W&Q.[C2+\>.*]<-D)FKU
M6QT[+-ZON/,*N\CM[JR</BPU3-5)U%\SA8F.AY:055D4CG^O4,FDD0OM'4,`
M1YXNS-YA*Q@R/\?*[K<]OB*E8\BL'225.\?T2GG&IXL9PQ:LA`UZ[S4N2">O
M7,2Z08)O5S"9-H5,@&[S'.`3(Z=[25/QK:Y5O7C7WQ">3V)QO2)49&V3\_BR
M'>V.4E;(J1S-7*S/W$NNM,R4H_<$_P#9FI1,0IP(F!2D'H(/-UJ?Y5<F^41'
MR>ZX:O[R4C-E1+7J5B&BJZR0_P!+4,7M:U,Q;^`M\A-RJL!<RS,;+3(.R!VG
M72=^V!B"0HB#R:AFOS`7_9G6*];K8FW:R[C77&\R^9F^"<.:11N)$KA:5:59
M*5692SSS.TJLYEG5W<^==HW64*"9^\3$,)@$`4CS8Y#VZ\H>L-1UTI'C0\A]
M'I2&3X*\9&9KX@J1+=80KS-__+B5=D9B<5B(Q",?OU570F[C.0.4@``%'D'$
M>-S=K>+4O53&&O6=_&-O]D5QC1&1J-=LE3P75:T-<QI"11E:<VFVC2?.G8;$
ML])],Z6:=I`$_O&#M`0$(V=CL1;`-]UU?)MXU=%?)AK%LM<(E\M>ZJ\UYIT_
M@_(SV;KL@RD9Z:JTS8VIU7-F36:]Z!T2MT'Y`D!`%@.`@GZJ/FZR]Y*M:=Z;
M[IYM)-9&PK3HNBPT5)8#I=!Q@C6WY3+7:I+NI2:4"#DK(M)/W9IPZIFK1T)$
MDB]@AVA)]Y)\CVCRF:V7?5K/GB'\G>,V4=;8:>Q]DNH8\HMPE8JRUYPJ"DS$
MH$G!1&*<M4SM%!4Y^K;N!,4?V@\K77>6TZRX,Q3K[B_Q#>2F,H>'J'7:!6P6
MQ%64WKEM`1Z3`)EZFE.`W5EY]=%1_(*\@!GBQA$!$W/05Q-6<6>2O03=C8O8
M[4S1[R,(T_9*[.W=Z@\@8$Q7*1\C6W=@DK.FJM#I6`\DS?5Z3G'`,S-CIJ*)
M"8IA$#"7H';:WV?R:4WR;-/(]L]IMN[FF<D\76O"DA1*EJ]$4QG1\=K`Y<TH
MM65+85&SF52D#`:4.7M4<BI\QA*0.`G4L7E*R7-PDM#27B!\D\LPF(J7AWL2
MOAF#,UDV,BT70<1SHJE@,@#=^542&[^"``\B/'/05O\`Q94GR)^*S)5@+B/4
M#R.W'6C*K^S6O)F#K]KA3'<NPM+2+!I3Y&HV6)LZ[.%D9%9P)'7M`*)T6B0.
M``?4`7'2O,?DJP1OML/N)D'3O<2WMMKY^$9Y>Q$EJT*$W78V@L5?Y:AJ59V<
MV2,.\80ABE5%0WL&$YA$PF[>@GF2\K>7$0*5+Q'^2M,I>_M*7$4-VE!0_N'`
M`&Q"``)QY_=^'IT$+>2L54N]>37"WD_I_B9\H>(LSXJN#BR7F%KF'*D[IN=G
M;BFO:FSEYF,&Q('JL_%DEUS.7R1#*28$`5"]X]_035#Y9,MD4]D/$OY,!$"&
MY`,-1/8`%$0*)%?Y@]L1,'^D''[.@1[/.]MDV7PYD?`64_#]Y)IO'F6JC,T:
MV-'.)*]\L?,,U&YET?<GA`KEJ"H+(K?E*L0.1`0Y`*UNL]3\[OCQG&N#M(Z)
MO?):@N'$TZBFVQ&IM>O[W'*"SYXM$1U<HZEC4-'/'+A;W9!5F[(S$IB^V3T'
MH%!NFFUXVCA<F./(;H7Y?MI=F,B,(EW6MOHK'E0IBN!74,LNJRI.#L6MK,W;
M1%+3>*>ZX3D"F*[$?00`._H%2T-V#\Z>CELK%"D]0O)7LSJ3!.GK3^0<O8SQ
M:[RQ&P+9LNTATZ[D;]8<KQ[(RJI%Q8F,J)!3,7W.#%Z"P9$>63.+YN5>>\/_
M`))H5RG)RC86Q<95R8.5LQ<.$XM^FJQG2$52E&Q2J=O_`#`J=IA,(<]!#YY2
M\/,-\;=0,[M_%[Y4,,;:T"L14[C//VOE6H;*WIO&$B9:!I-W5?6!G%HNH@W:
ML19R8#,TA,D)C<B7H&K5S8O[J_&CB$QE1\6[&93@?KG:89`S5KMAV0LR9%V"
M+A1M*6YY,-$1&.<."(E=J$!JL(+>SW@4.`>IXQ,C[;Z926P>9]G]&_*/LQME
MM).4][F2\R.&J>M%Q##'#"5AJE3*C(1=B+'.ZA"-I)<S,&Z:212N3``>G/0=
MAO=BV4\CN2\<9[HF@WE`TUW-PVBS1QSLU3J35*K+&8B#A9I5[5^IV%"(G(@K
MD/;.Y7[U6*)A+VJ)'$G0(`GLW]T;1X.)J-UP?F":A%S&:JY,Q]@;`-^R<SA(
M]M(10?6P?ZZTCG-AEEEVSTSD2]Q/9'L*/<8.@?=H]>?]AJJ7>V5[Q?\`E$R[
MG++U@82N?MA<I8]AI[-F8+6"9%W+U\FI/*#"4EFY.HHSCV0I,&XG,0I.X2CT
M"$>6A_NOOA,ZR26,-+-X\9(:P[!5[(D3")XDHLTG-WR*>-54[O*3$W-_2.L>
M0,2X(0$6Q#*.UA7[.!2Z"3#)&Y66\A:]W'%>;_%WNOE)A>*.]Q[D9K`8WK"[
M6T?S='RT/+O(JM+3)1+%)_2'5`1'AN51N)AY6#H&F^.[-)_&_JM0]5L.^)WR
M=2=;J#B1EIFY3&$JJTLEYM,Y)K24Q:+"A'SH)K/%2G3;IB("=)DV01*'\(H`
M#9[Y2MQ\K^3;_%+P?K3NWA7(=7Q(?&*&),J:YX_&L6"J-:VW0F8%U/EG5)^6
M4M+MHBLFN`?6,UB@@W'@H=`M'DSV!VJ\@6ELMJQ%^/G?[$Z>71KL=EFTCKXP
MLSMO7H=['2%DC*M"+6`IF#B8?H<,W3HX&*V`1'@X<`&Y>/W='=K4_6VCZZYJ
M\?\`Y`\[HXBB(RAXSO<+KU&TR;+BRKQ;:&I\#;8U:>4CY"8@8EBBV(NV'^*F
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MTY1V%OG%(:$K3!LY$%$E`.9S(@5/CV^.0D]UL\BFY*F.82N9V\<6YD[EB#@X
MU6UVZ.Q=!TJL61ZX43;(_IK>2F3IJ2S0@@>0]HI6X*]YD@%+@`!%M_;'#>0?
M5K*&"]@/%-O-)5IU&1#NN2T'2JBYR94[7,(1LI&V+&*:DK[YI*M.%40DT!53
M:J>RNV6`Y2FZ#N=$,PY4T3TOQ/K?#>/G?;(,1@"BLHHLQ*4>E,+=:%'LBX64
M3B:U&2QP>N&*CH0%-(X&(D'<;GX]`E?D1SMM-Y!M.LCZVT31S?O7J$R;)1=+
MR=-RN'*Q*7*=Q@\*+FS055@GLR9!)";(8K9=\J<GM$`Q0Y,/0=_XN<H;:::Z
MZPFGMQTAW*R1"X*CW5?Q[<;%C[']&0=5=O-S+E%@A-14P>*LCA1=^"C0Y2E5
M3:"`*F$P&$0;AH67;30S8?R+;`WWQN[MV&N[C;!DO./*-CVX5K+B%$K:))63
M8MUZL69(K"RLO,V!\9T]1'Z9JR39M1]$B]!+VX\DF;V<9`RJGB_WM61L4>K)
MM&3.I5=W,1:;4!!9E98U*:*I`20F+PDW6$3KAZE$>@AX\P6O>T'F*H>O]'7U
MLVYP5C/'-KDLFR-4=TC&3V=/>@@Y2!JUCF#R<L$R0L;&RCUM^F("*9OK?=6[
M?:+T$D6$=\=Y\;XJJ$%L=X\MNLAY&_7DZI_,N.:MC-VUD(UN=DP8VRR0E1E_
MTRGLGK107+@@F4*W,!B!Z%YZ!HF2I_(T;Y/*QOFKI?Y;W]JK.'T\1NL24**J
M]BUTG(V1$RC>=7<M[&B1NY;]W<^8)("FJ[`%E#@(=O0*+O[M%NGG_7F=Q)AW
M3[?S`1\G,)>B7.V5+"%(R-=F=;DV94)48I-:=0+""\C7!VZ;\#=Z8J&,EPHD
M'0:KX_MF\_:#:D8>U)G_`!I[]Y3)A^#7C8&[TW"$/$MY>O3,B\LL5_,$<6<2
M9M[@R1E_9DRH]Y`=D/R85.\1!J_EV_G_`,J>,,/U,_CK\FN#+U@W)Q<I4/)<
M5@"!GYR&E"),_?;QH'LI#-SNW#%%7N#D"JH$,)?0.@5G8^Q[L;)Z+V'3[97`
M'D??9`EUZA8X_8K6;&]9I]E?Q,`6/L4)!6N+9SS2/7L:JT$L$R@)R(JO721.
M`-VEZ":G^:<@?X=/UW\N;9_U*_V??Y8_3_TJ"_VR_P"8/T']`_G#]/[_`-"_
MK)V__._I>?:^L]./PZ#R</-K96-R\M&_=CC47+=C*;'74[=&1;_2.42(_1,P
M4=H@8Q$CG.@(E#D1]?41YZ"*D?B//[?_``^'IT'H&4?+&1Z-]F=5+M1+]8L?
MW6+E[1`1MKHDHYIUA8QC#:ZX,&\>VFZF:(D&*ZL>W("BH*`LX$1%8YS*'$P4
M_P#%_E4\CF&;"A:J#N]LRV?D78K>W8<O7*ZQRIX]R5V1%Y#W.5L$6J@=0!`_
M:B'N%'M-R'IT%U70RX:D?=(ZI9%Q!N7C>N4??;7N+^J0SSCZ/CH6R2T;9FZL
M97,FM46HL5;!'1$@P1:3L/(`+0HJ-P;*%%<PHA1KWXTKREX^MJ,L:K9A(T6M
M..IHA&,]&D<#$6VJR;<DE5K7!JK)HG-'3T0[35[3D*HB<#)'`IR&*`6,_LT"
MG1\DV76Q^!*76ZQ%.4>#E'BPPH@'J`_*/N#Z!Z#ST'IZ>TGV>WV@!.T2=I1$
MI0*;T$``HAV^G[/AT`5),A`3*0`3*``4GQ(4"CW%`I!Y*4"C\./AQT&0D*(\
MB'KQQSR(<<#R''`^@^OQ^/08>PER`]O)B]W:83&$P=X=IN#=W(`(?A^WU^/0
M<D233`0(0I0-QW^GJ<0("8"H(^IS=A0#D>1X`.@X,@B8I2BF7M)QVE]0``#\
M``!#Y?W?#H`44AYY(`]Q>P>>1^7CCM#D?0!_'CX]!R"28<<$*''(@(!P/S?F
MY'XF[A'D>?B/KT&)D$C%4*8@"57GW"B)NT>0[1$`YX*/'[./7U^/09%12(/)
M2!SP4O(\B/!``"^HB(^G'^7H,"MD"#W$3`@^OY>2@'<(F-P`"`!WF,(FX_,/
MJ/(]!D*")C`<R93&`"E+W!R4H%$PE$I!Y(4P"8?4`YZ#($R!QP4`XXX`.0`.
M/AV@'`%^/X?'H`4R#P(E`1`PF`3>HE,(<")1'D2^G[.@X!%(HF$$R<G-W&'M
M`1,/KZB(\B/`"(!^P.@Y]I/@`[0X#X`/J'QY#^W@?A^SH,N`_?\`Y1_\?0?+
MZ=$>.2=PEX$IC&,8Y>`('R',83%Y`@<\"'=QZ\]!\2B0O/=W=_>!>0X,HD"H
M\E)W]GHD`!R(\^G01^&\I7CZ6V.2U);;58F<Y_6LI*@VQ^A8B*N3W-1!58*6
MI(E`84+$Y33%,K07`J>\8J8E]TQ"G!_)N0("@E`$_P"-[JJ/<*9D!!,#*"D!
M#"=0_;P7T,4"@/`\<=!KL_:*U4F[22M4Y!U2.DI)C!1RT](LXE&0FY(_TL3$
MH'<J)(N'[I3T023%4RH^A2\]`W:^;KZJXR@,Y7'(6:ZA2Z[K?9:Y0<VS<ZJN
MP;T>V6Y""<5"#D5%FH?5REA/9&8,`;D7!95?VB?.)@`%"POL?A/8I.^CA#(D
M!D:/Q??'V+;^\K3A=9O6KY$1C&7E*ZY6,BFF#V/:RC85?;,9,ACBF80,0P=`
MKZKA)DS<R$DJ0J#%!9Q(.3HG!,$$$#*J*G2`HG!%%-,3&$Y3>@<E'H$PPUG3
M$6P^/&F6L-7N"R'0'#^QQB5A@GOU+`LA7))S"6%FZ.(@=NZB7K14JB"A0,4.
MTW;ZE'H&>X;\MWCISWETV!\1[4XTMF63.9*.8U,SQY%/921A'+9B]C8EU.,H
MF,DY%-97GZ9NL<ZG`B0H^O02*.EVS-!Q(/%T$6[-%R\.X?\`#8C)LBD*SQPY
M=J"`M&J:9!,<1```H?B`=`F&)\W8JS;C6+S#B>Z1%ZQA-K3HL+C7W1W\2]/7
MY>1K\V5-=$@&!M'2T4N!U`*"8%1$P^GJ()IC'<[6#,]RJ..L69AI]UO5_P`5
MO\YTZOP3EPK(3F($)U.IJW^)7*V%%S6'-I=`W;N3"5-<Q3]@&]HW`.B(/*)3
MJ`0ZG`!]2':!`.`BGP0Q0`1`!`>`$1]1Z!OF3]J,`X:REAS"F2\JUBE90V`E
M7$%ARH32X!,9!FF:J*;MG")&.'>JB=5-$Q3=@"JL4"CZ\=`O?HH0Q13*BF9P
ME[P_4%7(010;&(50/<!-(WJ"9>PP"!A*<`'D1Z#,QA,HHH+<#F,4R(E`Z9@4
M[##RB(KB@(*%)^;U,3^_GD`Y3HAW))@4A2`8Y!3,<%$P+W$3,H8R;8@BD!B<
MAW`4>WX]`=Z:IA30["=Y?;$"A['ME,F`>PH8B:@INB*"(@4>WG\/RCT'PE'+
M2)8O963=,F3"-;N'[J3?>VU81T:R14<KNGCA3O(DE'-T3J'4,*9"E`QA$`]>
M@ZRMS<-:82(L5:D8R?K$XU^LBIB'<LI>)E6CT/=:RK-\Q4<-',<X^)12$4_7
MN[A]>@[I(YQ,5-(A5BE#N$W:F=+O32!N(E.FH?V05Y^4I2!\J9@X]>@UQ6S5
M*+LT)57UBA(^V6!E(.JW6GC]DE8)V.A0*G)KQ[)VN5_($9%,F+@Q"C[(&*!Q
MXXX#:#)^R(KE323*!R>^(IE+\A/F$PF.9(A2(_YA@[Q_9T')$S&(0QTR'X%0
MR!"HE[2_."J0B!#G0,`]H'*81+P<`Z#XD,)EU$S`50J:9.\G*2H@*0?PE0/R
M"ITA6`Q>T4Q$%2F$/PZ!),WYXQ)KG2'.5<X7B(QO0FLK7JP>P61R9K'+S-ME
MVT-68A(JQB**RTM..TD44RIBH<YP*'QZ#L<RYDQAKSC:W9DS=>*WCC&5+8I2
M-JN-E=)QL-$HG.DV1674.H55P\D7ZK=!LW3(HX57.1,@&$X!T"6ZO;FZQ[KU
M:Q7'5_,51R]"5.>;P-J5KCA9%[!30LTW_P!%.1#I-&:C5EV+@IT0503]T..T
MPEYZ!T/*@B8@&`WN)B?VS&`AR")A[%!6]%?:*/R``)B8!Z#$QB"L0!2,"ATP
M#N`>Q<P#P54Q?<[%S)M^0_S!#U`0]>@!$H+^XHG[8)&]U)3L%,.#%*"J:AQX
M.4HF$#?-VE,8>!`1#GH$EN&=L0XZR)C;$UVR+5:WD7,!+&?'%0DY%HPD[,G4
M6`24]]`T75*H8C-H(F`W`$$Y1*'<8!Z#=JI882W0#.RU:=A+;!R*;P\78:ZZ
M;2#*701=KMW0,'[=99DH5)PD*!UB.%$_=2$/3@2@&UBIW@0K<Q_;*1$YE"_*
ME[7("42*]B@'[R`/PY]/B(>@B&M)7*M/++(4QK8(-U;XB/93<G6D9-@\G8F)
MDU54(V7>Q)%P?MV"[E(Q$3F*4%5`$I!$0Z#9&J)CI!]47E3N(MR'NE#N$>X.
MWO(DH41``[B"`\<]HB(=!^KZ5MV]GL)=G9[?9V%]OL[>SM]OCLX[/E^'Y?3X
M=!XL'FA@V5=\K&^T2UCOT5O'[&7-`D26:E[`W9]WTBQ2C,V1HSG)4IEU#"`.
M&R9B<]H'$``1"*XP`!C`'P`P@']@#_:/_+T'H89DAFT/]F;CE!LVCD".Z;CZ
M64+!M2,DC.)3,BT@X<R1!#A>1<.7!C.E0`#+*&YY'XB'GI&,8!$.\!X'T,7G
M@/\`S!$`,4/[..@F.\!VP61<`>6/2B2H$T]CBY*S92,(71@G(*-HJQT7+4^R
MIUAB)YB)OII5LU:R8O&B:I3`C(MT%R<*ID,`3M?>K0="9[>:I6>,2BD,DRV!
MIB)M:B;HQWB]787*:/57<A&D/[9%VSA]()%7.0QSI]A1$2II@0$2^S0[?\2G
M+0E`Q>=;;&(@(\^O\PP?(@/Q[1_#GUZ#T^>@.@.@.@.@.@.@.@.@.@.@.@.@
M.@.@.@.@.@3O(CF4C\?9!?1"*KZ8;4ZV/8=D0PMUG$@WK\@K',#+)C_"]QP0
MI2'Y[P$0'GH*LWC7J?CJ'PBXHS;O%2\>T]FGL-.7_+UZDF]R-=(;:@-EI(]0
M,>X5ABAD!M-MK,$.P,2*748*->XKA0R!WO`,!TOV>\D&;O(A4]GZ]<MJYVE6
M3R$Y3UXR="7W,]%@]`?Z(_ISMI5Z7A[#-OL$!<7>4*RRBQ5%Y'MW;XBS$#**
MJJ+N4S`P^S:OYLV8TQUTVMR#OKO)8+9DCRJVW`\/1;%G&[6''M#K<3FB6K,%
M;L9QDDRDG%>N\*@R.=LZ.](F00!-NB'MBF(.\\@&);EEC+.X%!NFSV?Y2!P_
MY=O'IBRHU^/L=@B$(V,M6%:O7Y.U2]G=?60]CN$VL9K*F60(52)FF1W7MI@^
M%,`_!FW=+96N8VVLPQ6LN;1/D\Y_<"Y\U\D9;7RP*P^S37"6.<?4%ZMBK`EO
MD7#F)I3P\@LV]D@%;&=D1.!![5W!#`H.$"^1399GISXW]M]DMNM?GC6B^0+(
MCO*..-D:E);!WZ,Q"#9GBJIY>R+C:1MB3M"FIR)8ZQ0\BZ5EW:P&(J=LH(&*
M$V_VW42YA_$16H.0D%9>6C,B[#1,M+./J2.9.3CK/(QSR36.Y5=.@7D5FXK&
M4.8YQ$P]YCFY$0BUT.U`VJ\B.K_CJJ]GURP7K=K_`*K[;(YYF]EALJT_GC.#
M7!N4LB(46J4BL+4]G)P<-*2:'T\ZZG)=R,HF5N\:$2*4$>@_3KUN?LY9*OXK
M9&R9KL]Q_P!H3R3>3C%V41->;99*]:L?PK*\%JU::2,[+(/9>KT\C),L2V<J
M+H)%+PFV5^5+H&K^/:NY>U+Q-XO-E:'GO9^X-=QM[<]ZOWO65YF5:?UGCL77
M>.R\W&WUW#[-HY+6;!2WD",J`.E&[@A2'4.DCW)J]!L>'MHLS:G8EQF7&ETA
M8B[X>^W]V`R4QJ!XMS)/JO?V^Q<)5J]=9%P+E>O6!M7Q7?)QC0"*)HN6:BCH
M[E$W80+%GBJU&SCJA-R9\K>0C+>UZ.9]>\390E\,9_R&CE*\XRR/*.GA[?>J
M%.R/Z;96N&K`*A8V/9%8HM&[YH<"BHIR/05O?.;EN"RQOQLUE:L,]C7V1?&O
M2=;&.O63,<XWOMLQ=A'+<1E",RSGZ2N-BK+9S3:VL^QVP;MP>6%P5JV3446,
MU,9)-4H2@4R?SWY"=O=V-D:EOMFK3NC:4Y9UJK^O%3DK)%P6LC[%-DI57O63
M9+/V/'*K6MY,0R;"V1\:'?/'R)XX'+`R+@4TB%Z#/33(>P.Q6:M@O)A9]W,I
M4JMXQVJV!PQ3M,I*P1=CP7E/#E`I4T>NXEI&/SR5<9N,X2<Q61?M9YLBZDUD
M2+)II*%,*W0-@U9S%L_CMKXL?(#9MI]F\N6CRKYISIC+-."K)99*?PK0:I=8
M'(,MC<F-\8J.#,<9.\./Z0S46E(Y1$H-P7,[0<E*83`I"NXVV4''^!UNCEO)
MKUYG/6+R)R.<#R-I?2SRZS6+L'EL5/G;I(,&S6.F9VL6N.)]`^40,5,5C%(`
M*'[A!M&JE1S?>M/<=9?R#O-O%?Y;?CQ[>1UWEBL77.C^;IE4D\&U^K6>GS6)
MH5Y$&5I#OW)E>-=&25.5[%+J(J%Y/W`#;("9?8G\0OCV@:OO1OS_`%*0TGSS
ML33-4M6I"<2O@V&5FW2-7RA>\EP#JNQE/U9PG^E*H(UN7^N([4=*JI)NQ(9,
MH/8K.8=S?)3FOQS:\94V6V9URQ[FK1^[W][DK728E,.63*E]KF,<'6A>T$MB
M30&,\G$VY8[E8\:).PSMPU$R2:AD!!$]=?ZN;(;$>$+8&S;%96L^P2^C&XKI
MA;K+DE(E!>W/"Z%GK=*6O7MQB#E0K^><MG5N5=*K@\!D0'`*]AQ.#Y/!M:,S
M5O;26QGM-N!NE&[:2>&K))9RU&W'*TLV+,H64]J?S,9FS0.XL)4L$WPS7X51
M$K^/9-5G!@7*IW$;!V@"0><_:#(>`MK[IFO#&T6Y5DOVOZ>I4@_P?AQ^ZQ_I
MGKA7IG*8(S4GN/,OU)**R'-9S3=%9UYDG'@9DDDJNX!5$"$Z#]-BM.?\O;;>
M3K8*2VXVMJZVH.V&D=8P]BFC9BDZ[@`(.\WG#5+M\!:,9M2IURTLY.OVA4CA
M-5L0BAQ(Z$1=*+'.#'/)$YR[NSC#<W=/(NRV;H^LZX^5[#^LV,=78Z__`*/K
M\IB>GY2K=<9+V*@,&*$+9\DEL+M23:S"@J.2<"0P&$`-T%A#S]OW2(>)*ND?
MKMJ]=O,GI]"7:#5=F;P=MKZ!;G,'A[-'B(LIZ&&1BVKCZ=T15'WVZ1NWO(40
M#2?*EEK5O764V6CM6[5!8C\F&R4/JA@7)-UQH>;8W;'^)\J9F:8_J649Z-2:
M)T=>S0D'8Y1)DJ!V]@(DX:J`K[*+<X!%'MW>MP=`,,>0O2BE[S;090B\/9S\
M<,GCC8#)U[?S^RL#6-K;&G'92IYLE^R#I2NF<LQ%DH;^(U,L"*?:`]`N.<H7
M?7%2>^VH.HV8]M<^T7!^SVH5IR@XG,\)3FY#_7#-F.LB3.9J%K'E^W'(ZB[J
MI/4=@Y;,TE$'3-L9R1DF8ZB:0@JVLVVDDB7Q6TW$.ZNPV;J%/>2'.>&LM1^Q
M\;9*;G^CL?Z*7.W0VL.R8SYW4C=;YBVPR#`BKLZJB2CD42AV)E(!08)1<CY)
MV]2\?,G,Y`OUSN<KC+S'8UR!?9>T*)9%@X^GHV=I(/J78)19S*QTM!H-VC2-
M,Q,98C-4Z:0%*8P`#9*6^M6#/"UJ8%"VX\AW\]N=-=G]JZQKWJ]<YVO!CFST
MN_+1`YBS!E(L_%#1-2<>MH)1HI3T$#J/YV=6<(]ZG!2`_';7+FW&Q4/B/,T3
MNIG_`%_#&/@BU_\`('(5/!5W=TNOY%V@=7"X'9R5I,_2E"2-+6`%$)B)6(8D
ML@#9)RH";?M,'2:[5O:_*F_GDJV`UYS->8W;B]^*G5O+>/HJZW,D+B!WDK.5
M5;J.JW(-)I%RW&JU5RV7-5.YP@G#RRYN5NT#"(3$>!&URC6GYWQ?>]AMW;UE
MVL(XDG,CX)\A?U,OG'#%[DX*R,+Y8*'>E%A99!U]R18HT%*VK'@=LP)&*<K*
M_4E,(6$?=/V_G+W>W^PG/=W=GO?G[?I^?7]O_)T'C!>=Y$&_F$\A*)5%U2EV
M/MW"CE=5RN)3-8TP$,NL8ZIRI@/:3D1$I0`/PZ")L$2F*(@1510W8)"E$.0$
M>WN!0O'/*ACAV@'J/0>GI$Z99XVG^U'Q=K=CFERB^9I/7RDW"H4>6;G@):Q!
M`7-&UMXE`DCW@C(S$&4Z[$IP(#H!3(`D%0#%#S:K3KUG*F3+^OV["N6JW/,"
M"9W%36.KC$OF9@6,W$SAJ^AP6%$%B"4%"_PSC^4P]!.5X=]7:=JYDZH^3?R`
M326!-?\`620<9,Q)0KI&M4LN;)Y9JOMGKE3QGCZ8!":<LX^>5:N!DU&Z:!5B
M)@DJ`]RA`CT\KOD8O7D[W/OVT5LKC2DQCM!C4,=4A!1-XI5,?5H7#>O1\J_(
M4$Y.?<$6.X?KE`J1W2QP3*5,"AT$Z/V99A/Y)<LF$`Y'6ZR<\!QS_P!(H3U'
M]X]!Z?O0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0?%5NBN0Z2R9%4E4SI+
M(G*!T5DE"B0Z:R1@$BI#%$0$!`0$!XZ"!^*\`>ID/L&IE!MDS8!7!`9J<;*J
M:/O<A+O=8S[&KRRTT3*CBJJ(G>K*%>+=Q8TZIX\GR@!`*';T&XT_P8:=T7;^
M$VQAYC+#B#IV3+-G;&NL\A=WBNNV-\^WE$[.Y98K%)[0*VDIYF1N0K$>63=9
MHFH0@"4``-LDO"EJ)):9LM)_KLJ,Z!#9UDMCZY=8^Y*M,H5C*\Q=G%[D)NO6
M=F@@O$M5)ET<`11`I02'XB8`-T&\V?Q1:U7-U>E[4_R5/OLD;,X0VGL<R\MS
MI&3_`*I8$K%3J]7DOJFQD5'#*:BJF0KX#`85W;A10?G[1`-"R[X6M0LC8_S;
M4:^;(6)+7F#:(^[#/+N+[,I"9(QMLN2-;1#'(>/GY2?3Q8,4TS.%&JH';NG2
MZBJA1-P(`DEX\"6M<QBO!&/<4YSV?P'=L'SN59(^?\;9*<AFC)!\^@HMG>*O
MEIFV[]208Y2>K*.7PI@0J9E!*GP7@`"1'232'#&B6L-7U6PF-J7QO6B6,$7%
MMECS-BDW5F7.,R]>.CIH)I`=4P\))D(F7M`0#U]04'5G6+&FGN$ZSK_B$EA+
M0*A)VF8A@M$X]LLJ1[<K9,W>>,YFI,ZKE9LM/3K@Z13#_`*8"%X*4H`$:-)\
M$^I]$V5J&Q,=D+8EY'X[S7>,]XQP7(Y2D'.%<?9.R;$N8^ZS56JY4>QF:QO'
M2KER?N`QS]I!-V%`.@^.LW@FU?UARI7+_!97V2OE4QK=[UDO"^%<@Y.D)?#^
M'LHY&9RD;;;W5:FD5LV?6:0C)M1%)1X"X)GX4+\X<]`LZ?B"U(428-K$UNUK
M@TM4\G:8.:Y/V%16,F,/99MR5WGV[HZ*'U+2V,YMLB=I)I'(LU5;D.7@Q>>@
MV'0CQ?8[T7N>0\AM,X[![$7JY5>NXRK5HV'ORMXF,98/I;Q5_3L-TY44T$R5
M6O2*RBY%UBG=K*&^=0>.@7NB:,:VXLHFR6/JI354X';BY9!O&>'$]+2-DD[E
M8LEP@0$\HZDYE9VX0C$8X@(LF8#],S((E3(4##T$<DMX&];7&1<:6*`S%L/3
M,9PU5U^KF=\`UF[]F(=L"ZKP=7A,,OL]1+I)PM-KUYO4(SO(D)$WZ+8$UP,4
MXAT#B(?Q0ZZP.V"FTL7:<N)Q+F\2N:?]FP]W=?[,[;.D[%OH"1S<TQL+8&:%
MU=Q#]PD8I!]GEPH84^3CT"=84\*NN6"-@:EFZ!R?L%9<;XKF+_:<#:LW+(SB
M<UYP#;\HQDM%7>VXRJCIL=[%OW32>>?1D,L8&!UA,W`@@'0:O@WP:Z[89R37
M<G6+.6TF;7N.F^:X'#=2RIEZ1EZ=A7&&;(=S!7+'-%AX]NU1;,&L=(J>T]4$
MTDLK[:BJIS)E$`=GAGQMZQX9Q=@'$\/`3L]4=><79DQ536EAL$J_%_5L_1D3
M&909V1%13M>ISL;$($3Y$!:%,<$^`,/0,#E/MY-8/Y;Q56JEL'MSC5KBZO9.
MQ4WEJ3EM2,G[+KAE.7//.-9)B7*P,\#$=:>K'3AVZ0E<-D%5$@4[3FY!V^OO
MB-UHUPR7KQF"D364WEUUUQ-:<-UEU:[B^F(R4IMGB86".E*0SLRD<R?1S&OL
M_:.T(CWF1[C@8QA$0_%3_#UJQ3\?ZF8Z:O<I.('3_P#KTRH!EKS)-5+#6=D(
M*5KV5:A=5&/TZTS6Y9E)`+5`3A]*JBF<@]Q0'H.FTV\0>'-1,SLLX/\`.&Q&
MR=YH=.F<7ZY*;$7P+VUUHQ7/F`9FB8F[VB2[5"19D(T<.WJBSM5H0$A/V]!K
MNW_A,U9W3R9FC(&4;KL+6([8*IT&M9AQGC+*\]4,9Y&G<3NY%?%=VO%=BSD2
MLL[25YGW&23H3MDS(@/9Z#R"M0_BRUQK45LLTA)7)02FTEZP9=LFV"3N#FQS
MCB:P))X_E:S]`ZEP5`_ZK)X^34DCF`53?4+%*)2E3``:[GSP):V;`9?R;D%]
MG39NA8YRMEBM9_N6N="R$2,P/)Y^J\NTE#94>5-PR=&6M$HNR("B8&*W3#DZ
M9"G'NZ"3'<73W#>\>&EL-9G0L2,.G:JKD&GVND3[FH9`QW?J7)(3E1NE$M+$
M"R$)88V21'A5(2BJBJ=(X"0Y@Z!D--\,.N=9Q3LG1[/D[8C*65MK$\??U<VF
MR1DY]/;"*GQ#,-IW"#R'N;E'MKQL0NXAB$<#4A`4%N!ENX3&'H.IJ?A)UL:X
M`RYB+*V2<Y9]ON?+QC3(6:ME\P6Y&P9QO,[B&=9SF.FRL^HA]#"0=7,P(B@S
M9I)(E`1,("<>[H%RV.\7&O6R,SDBXSTOE2B9#NV1<-YCB,C8LO<W3[YCO+.#
MH6R0-/NM`EV2X?I4HC`VEP@HB)5&ZG<)A+SZ]`WB:\&FJ[G7J/P15,A9ZHU[
M9[(O=O`VKB,C.G>S+W8FPLOT7(5\D+_)H+*GDKO5E?H'Q"E*0W<FH4`4;D$`
M4O7CPU:@:V1NO+2MHW^W#K>AL"C4W^1K<XLCR4/LJ"A\D2DTF=--!63*Z<JG
M8KD(15H9=02&`1Y`&R/_`+>C55>FP6-66<]PZ]0:W`Y1QO*5*N9QFXN&M&N&
M5K,VN\YK$X12*+EEB!"UL$7R#9`Y5%%B*^X8P'$!!U$/X@M:H>D.J&[GLES4
M6KHW$>/])W*6@ZL@&$(":L,Q`BF[03173FX5U9!0*J`_^[MTBFY`.@UJX^%[
M5&^2B+J9LN;&4'*Z@H:2WJFP.2YJO061\6196AZH^MJ$.HW7<62L+LP78+@H
M0B:@B<2B8QN0630GQJX_T<D,@6UOFG.FQN1K]#4JDIY.V$MJ5QN54Q3C=*21
MHV**M)),V8,*=7U)5R<$P`3+G.4R@F$H#T$DGTZ7;V]OIW^Y\1Y[O=][X_'M
M]S\/AT'C!>>7_OBO(9_VC[7_`/!1G01*H/7#<Z*B1@!1NK[R*@AR9-8!3$BH
M#SZF2%(!+SR`=`_ECY6O)!&1[:)CMT,_L(IDU;,648ROLHSCV+)F4I&C-DS;
M'2;M&C8J90(DF4I"E*``'`<=!U,SY._(!8WY96R;89@L<J1-)$LI8;$$Y)>P
M@':BV,^E6SMT=JD'Y4C&%,OX`'0--O&4<CY-ETY_(UZMM\FD2KIMY.W6&6L+
MQJW<JG75:,E91VZ^@9"JH8P(H>VF01^4`Z#13G,<0$P\B!2E^`!\I"@4H>@`
M'H4/[^@MG_9P3,A'^4:UQ;:(F'S";UQR"$I),(X'4;#EC'\(\9C,/3&*9@$B
MO_!;`0#&66^7C@!$`]2-)3W"B;L$@<\%[A#D0[2CR)0'D@\CP(#P("'0?3H#
MH#H,#CP'/<!/4/F$.0^(!Q\0]1YZ#+GUXY#X<\?C_;\?AT'/0'0'0'0'0'0'
M0'0'0'0'0'0'0?$6Z0\_+\>>>!$!,(F[N3&#@P\#\/7TZ#+VB?L'C\0^/(=W
M<`"(^H@4WJ'KZ<]!B")?\XQSAV\"!A#CGGGN]``>[]_/0<&;HG,0XD#N3$!*
M(``#\H]Q0'T]0*<`,`?M#GH#Z=(2F*<O>!^SN[N/7L$#%YX`.0[O7^T>@Y!$
M`$1[U!Y.!@`3!P4`_P";)P`=J?[N@R]L/7@Q_F'D?F^(^G/]G(!QT'`(D``*
M`<%+W?)\2CW?'D!YYXZ##Z9/L[![C%$IBF]0*)RF_`PD`H_+^''''0?3VB`!
M"]OHGV]H"(F`.WCM$>[GD2\`(#\>0Z`*D0A1*4."CS\H"(`'</)N./Q,/J/[
M^@")$((B7XB'`?#Y2AZ@0O`!P4!'H.%42+%X-W`(=W:8H\"43%$@B`#R41[3
M#\0$.@X!NB`B8$R@(B`B(``"(A[?`^GPX]HO^0.@"H)EY$O<'<<RAOF$>3FX
M$3>O/:/I^'`!T&(-DP'D!4X#_P!6'>(@D/!@,9/GD0,8#CSR(]!F5$A.>P!)
MW#R;MX#NX$!]0XX$>/3D?40Z#$&Z0$[!`Q@[N\>3#W'/SSWG,'`F-S_=T')D
M"&[1'N[BF[@,`^O///J'':/'X>G(?AT'((D#TXY+^!#?,4!Y$>[UY$3<C^WH
M`$2_B)C`''!1'T*(!QR''`\CSZ_OZ#CV"?-^;M.``)`'M+R`\]P=O!NX?Q'G
MH`$$P4%7@14,7L,;GU$H"!@`0#@H\"'QXYZ#$S5(X"!@$0'@>/E#M4`PF]XO
M!0$%A$WJ/X_CT&0($^7\PB4!#D1_-R(#R;\!,`ASS\>@!0(;\PF,'*9@`P@8
M"F3.)P.7D!$#"8?4>>@P!J3C@QU5!X$.5#`8>#=GN%X[>T04[/7D!^(\<=!F
M+=(>.X@&X#CU`!`2]P&X,7CL'U#]G0<E03)R)`$O<(&'YC#R("8?\X1XY[AY
MXZ##Z9,!,8.X!,8#CZ@(=X#SW`40$I3"'("(!R("/09&1*;GDQNX0``/R'<4
M/3D"B(#Z#^/0<&;)&.53@0.43&*8H\"!C$%+N_'D03,(!SZ!R/IT&0HD$2CZ
M@)1$0$./@;U,4>0'Y3#ZC^_H,2MTR?EY#\WH'``(&#@"B''J4@>A>?AT&94B
M$,8Y0'N,4A3#R/J"?=V@!?REX[A^`!ST'TZ#R2_-+HMEC(_E7WMO$+DW3.+B
M[)L%9W["-O>_VDV+[<S16:1H$1L-#R1GBKWBL/T>/XC:0CFRH?'CMX$0B[_P
MV\Y?ZX?'_P#\3WQV_P"\YT!_AMYR_P!<'C__`.)[X[?]YSH#_#;SE_K@\?\`
M_P`3WQV_[SG0'^&WG+_7!X__`/B>^.W_`'G.@/\`#;SE_K@\?_\`Q/?';_O.
M=!:5^TWU,R-@C?S)5GN%YUAM#![@2P1C9GA?<35S8*SHNE9ABH5RXJ6"<P7Z
MRM(L"$,4[E=J1`AQ#YP,/0>BPR[/9$"`'RFX,(=OS'[""8P@`B<!Y'CY_G]/
M7H/U]`=`=!\E02$O\82]G(?G$`*)OP]1X]>>@S`"\_AW=H?LY[>?3^[GH,N@
M.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@
=.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@.@_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tpgi1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpgi1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!`P*C`P$1``(1`0,1`?_$`0$```$#!0$!`0``````
M```````&!P@!`@0%"0,*"P$!``(#`0$!``````````````,$`0(%!@<($```
M!@$#`0(%"PL+#@@&$`<!`@,$!08'`!$($B$3,1086`E!46$B%1875Y?7F'&1
MH;'14M/4EM8:@3+2(Y.5U5:W.!G!0F(SE+4V=K8G=RAX"G*24R15-T=(-"4F
M1L:(\.&"HK)#8X-4-85FIF>':/%DA*2EQ<<1``$"`P0#"P8)"@4%``,!`0$"
M`P`1!"$Q$@5!41-A<9'1(E*2%%05!H&AL>$R4\%"HM(CDU4'%_!B<C-S-)0E
M-1:"LF,D=/'"XD,V@T1DTT7_V@`,`P$``A$#$0`_`/IGEL@<K[QFSDK&57DZ
M?&M0QKF4]`JE68X1QE;0:PZ6/*!9S*NIVQ%&4>.59&RK]IMMB`4.W;7IJH9#
M0T%"WU=3]>ZRI2DXE`2!E._19='FZ1.?5K]<Z@CJ;=0$INU&,_?F5Y[DC]&S
M"_['5'K66?9JNFKYT6>IYQN>:#?F5Y[DC]&S"_['3K66?9B^FKCAU+.-SS0;
M\RO/<D?HV87_`&.G6LL^S5=-7SHSU+.1?+@$&_,KSW)'Z-F%_P!CIUK+/LU7
M35\Z,=3SC<\T&_,KSW)'Z-F%_P!CIUK+/LU735\Z'4\XW/-!OS*\]R1^C9A?
M]CIUK+/LU735\Z'4\XW/-!OS*\]R1^C9A?\`8Z=:RS[-5TU?.AU/.-SS0;\R
MO/<D?HV87_8Z=:RS[-5TU?.AU/.-SS0;\RO/<D?HV87_`&.LBJRTW98OIJXX
M=2SG<\T&_,KSW)'Z-F%_V.L=;RS[-5TU?.@:+.1?+@$&_,KSW)'Z-F%_V.G6
MLL^S5=-7SH=3SC<\T&_,KSW)'Z-F%_V.G6LL^S5=-7SH=3SC<\T&_,KSW)'Z
M-F%_V.G6LL^S5=-7SH=3SC<\T&_,OSWI$/8\FS"_W-.M97]F*Z:N.'4LS^-7
M):/,PBSS>6&GRQ?>;-!#&`,.9SA\-^S'1L:/#.>.&'4ACV-H"9,YEFW=`8'#
MUK[G)@FF<`2$!'J[=A#I4#.55S#S_=A^B_/5OZXYN8=Y43[+/>0.U_-'%#LB
M',H@B4.;<B`;B(!Y-F%NP##U`'ZT/!OMKEIK,K4D*&6JD?SU?.CJ+H<W0HI2
MX'$CXTARMVZ*!Y9AA``YNR0B(@``'&O#`B(CL``'9VB(CK<566$R&6+)_35Q
MQCJ69WJS!+9TIPCD[EVB+SI\ST]A4YMRA`'P"?C3ADH#L.P["(!OL/9HJJRU
M`FO*U@3E:M0MU6F^,)HLQ7[&9H.\D'T"+.KF5V?Z[DCVCV#Y-N%^T1W`-NSM
MW$-:&MRD6'+B"/\`45\Z,]1SG7B&N0MW;M,8[U[R\C6+V3D^=SF-C8YLN]?R
M#_CMA!JQ8LVR1EW+MVY<"B@V:-D2B910YRD3+VF';6Z:O*U6)RQ1.XM1^&-#
ME^8BU69)3N2%FY:-$49ON7TDR9247SJ7DXV0;(O6$G'\=<(OHU^T<$(JW=Q[
M]J91L]:.$CE.FJF82'(8IBB8I@'6#5Y4"0<L4"#(\M5AU&VP[AMC<4&9R!&9
M),[N2+=ZRWR1E;\R^P?+<D=A[2CY-N%]C!OL`E';80$>SZNM>NY3<<N/35\Z
M,=2SC20-V0LW8!#F:4P%-S<DP-L!ND>-6&0'8>T!VVWV$/`.L]<RK[-5;^>K
MCC;J&:2F,P"I:,(MW+M-T4WYE#V>6Y(]O9V<;<+[_:UJY698EM2N[56`GVU:
MOTHB<HLXV:N4$V'E2%EE_DOAH;;?.;$'F/"^.V_,Q99ADB&R[)R$DKQPPX#J
M-4QW'4R08ILVY2^+K>Z1K$H54Y^U,$RB7<?!UVVLJJ<K%5W8>0`3-:C+4+3R
M9Z!9%6N&8TN=4](,Q&%=/;R1>1?8(=W_`%R_/>D?HUX8URS5Y6+3EBNFKCB[
MU+,OM)/1'%'J"7-`Q>L.;4H)-A$3AQIPUT``!N(B8"F```-2MNY<XL([K<$_
MSE\<8ZGF'VHC@3Q1I8^?Y72Z\LUB.>Z,LZ@'H1L\WC>/^"7J\%(BDFN$;-MV
MJ[A:)DA15*<$%P*KW9BF$I2F*.K2F\I1^LRXIWUJ'I,.I9C?WHF7Z(XHN?3O
M*^+>1$?+<]TXE]8'WN7`-)+`6"&"\[*=PHZ&,AVKM5!:4D"M43JBBW[U4$B&
M/T])1$,+3E:&2\C+5*2-(6HCA!@:',01/-$@G\T6^:-H/EE`.P<WY$=PW#_5
MKPQOX0`0$/"`@8=MO4$=4>N940",L5(W<M5N];&W4,SF1WD)B_DBS?LLC72L
MQRU@8Q_-3O/((2&C&RCN2F)CCW@R*B8QJD'4H[DI)^LW9,FB0=ISJ*$*`>KO
ML`S,.Y94.;).6*)ESU'X8P:+,1?F:1_A'%&8BXYB.447+?G(^6;N44G+=9+C
MEA-9NNV7(55!P@HEU$5062,!B'`PE,40$-2.JREI)PY:2H&1`6J8WQ.8\L8Z
MAF0,SF:9_HCBCW*3F>8>DO-N3,.PCL'&K#(CL'A';;?L]75=-3EJO8RM9WE+
M/H,9-%F($SF:0-U(XHL_UR_!Y;TCOZWDUX8W^MMK7K>5_9BKY>VJ_5??&30Y
MD+3F29?HCB@WYE^>_([^'8>-F&`';M#<-_9`?K:QUS*OLU735QPZAF=_>2;?
MS1Q17_7,\]Z1^C7ACP".P#]01[-#6Y2!,Y:9?M%?.@*#,R9#,A/]$<45$.9I
M0`P\W),`'?81XV88*'9MOVB&P[;ZV369`2E-1EBL2_8.-4K=1G*W1KBPUE&9
MO)7_`#(8TB<L(GP2G";A;ER=LLI:82N>D#:SDQ19=&O72,BN/F#WSRJSSB/;
M2J,-/(-S'-&2:L8[2<%05$%.X5(?;8P:OUK-)0I;6_EJL#@)3RU7#R[L<YAG
M,'E+2G,TD),O9'P",:^S_-*I4.\VYKS4=O753IMHLS9HOQNPVD@[<0,#(RJ#
M195+]L10<KM"E.8H"8"[].P]NH\O[JKZQ-(<L/*!/MJT>6-<P:S*CHE5?>0,
MC+V1Q1;CZ?YHVR@4.WNN:KUJ[MM*JMF=-$>-V&#H-'$]!L9A5J@H<@*J(MCO
MA3(8WMC%(`CVB.H*AW*V*ERG&6JY"I>VKCB6GILU>I6WT5`J,:9SD!AW+O+"
MNWYE>>Y(_1LPO^QU'UK+#=EB^FKCB;J.<FT2EO"#?F5Y[DC]&S"_['6.M99]
MFJZ:OG1CJ><;GF@WYE>>Y(_1LPO^QTZUEGV:KIJ^=#J><;GF@WYE>>Y(_1LP
MO^QTZUEGV:KIJ^=#J><;GF@WYE>>Y(_1LPO^QTZUEGV:KIJ^=#J><;GF@WYE
M>>Y(_1LPO^QTZUEGV:KIJ^=#J><;GF@WYE>>Y(_1LPO^QTZUEGV:KIJ^=#J>
M<;GFBWIYEB<!'F[)=([^U\FS"VV_2(`([E'?I'8P>#M`/4W#4R'LJ<JF:7NT
M_32^.K2=^(ETN9HI7JM5?LU-?$PBR6BZV&GP/D#FUE7#6.<D2G,Y:)D;E7$I
MEY&L>..'5V;-<[QXV,BV5<`"YTMFP&#J[>W;4M><KHJUVC[L5]$LI]M6CRQ%
M0MYE6T;57WD/I$!7LC3Y(=K?F7Y[DC]&S"_W-5.M99]FJZ:OG1:ZEF^A86.=
M(<K=NTP;\RO/<D?HV87_`&.G6LL^S5=-7SH=3SC<\T&_,KSW)'Z-F%_V.G6L
ML^S5=-7SH=3SC<\T4WYE^>](_1KPQIUK+/LQ?35QPZEF/VDD'5A%FY=!_KE^
M>](_1KPQK/6LL`F<L7+]-7'&109F;LR'1'%!_KE^>](_1KPQIUO+/LQ?35QQ
MCJ68W]YIE^B.**[\R_/>D?HV88UCK65_9BNFKCAU',]&8I4=6$6[EVFZ#JYE
M>>Y(_1LPO^QTZUEGV8OIJXXSU'.=S@$-MF6[\U\:X@RID6.YG.9.0H..KG<F
M,:[XXX<0:2#NM5Z0F&[)RL@0RR*#I5F!#F(`F*41$.W5JB.5UE8U2'+52<6$
M^VK2=^*E:WF])1NU2EA`;058I"R0O\D+6'<<SG\1$R1^;3]%62BHN1733XUX
M7Z"JO(]LY.!1V`1`@J=.X^$`]3P:T<=RIJL>H^[3]#/XZM'EB1NES)RD9J^\
MQ-Z5F$:M4HVF_,OSWI$?8\FS#&H.M97]F*Z:N.)NI9G\6O2Z>;A'*W+H-^97
MGN2/T;,+_L=.M99]F+Z:N.,]1SF^S@$&_,KSW)'Z-F%_V.G6LL^S5=-7SHQU
M/.-SS0;\RO/<D?HV87_8Z=:RS[-5TU?.AU/.-SS0;\RO/<D?HV87_8Z=:RS[
M-5TU?.AU/.-SS0;\RO/<D?HV87_8Z=:RS[-5TU?.AU/.-SS0?ZY0_P#?<D=O
M5`>-F%Q`?8$-MAUHJORM#K39RU4G'`GVU63_`,434V7YJY4)#CX83:9R!G8;
M+O+Y(:;&E[YJW2>S+'.^9:[$,<99D<?,'"''+#RZLDP9U&FV(CYV"Q0!NN=>
MR*$%-/<@`D4P"&X@'8S.GRO+5)0,M/*$[%GX#'#R969U3=2PK,AB14F7)%TB
M)70[._,OSW9$?_5LPO\`<'7*ZUE?V8KIJXXZW4LU^)5"HW)`2W;M,&_,KSW)
M'Z-F%_V.G6LL^S%]-7'#J6<;GF@WYE>>Y(_1LPO^QTZUEGV:KIJ^=&319R+Y
M<`@WYE>>Y(_1LPO^QTZUEGV:KIJ^=&.IYQN>:#?F5Y[DC]&S"_['3K66?9JN
MFKYT.IYQN>:#?F5Y[DC]&S"_['3K66?9JNFKYT.IYQN>:#?F5Y[DC]&S"_['
M3K66?9JNFKYT.IYQN>:&IM]\YKU_*N%*(AS*7<L\F?"E[H2*O''#I'47[PJB
MRL;+Q)(A.Y7]T5W8I*]Y^L(4!+VZZ3+.5.T9K#EIF"1[:M'ECGO*S5JL32KK
M`P2D'#A!OTW:8=;?F7ZO-R2'ZO&W"_W/!KF"LRM5HRU4I\]7SHZ2J#-D&27@
M^)>U(#R2EH@WYE^>[(A['DV88^YK/6LL^S%]-7'&!0YJ?:K0R>9A!ENW:8I_
MKE^>](_1KPQK/6\K^S%=-7'&.I9E]I)Z(XHKOS+\]R1'V?)LPO\`<UCK66?9
MJNFKYT.I9O\`%=#HY\@)^;R0;\RO/<D?HV87_8Z=:RS[-5TU?.AU/.-SS0;\
MRO/<D?HV87_8Z=:RS[-5TU?.AU/.-SS0;\RO/<D?HV87_8Z=:RS[-5TU?.AU
M/.-SS0B,F6GFC1L>7>[-N9SR2<5&KS-F1C5^.6&VR$BI"L5I`&3AR@0Z[=)W
MW'=F4(`J$`VY>T-=3+%>&*O,D9>YEBMHM,SRU7RWX@S)C,J;*U9AWA@*#(IP
MBS<NT71V?]T%O6+_`/4ONA_\]ZW@_6Z\K(>>/03/FCD72/\`KNYI_P"T\X_D
M8P_KL9W^[9;_`,9?^:.=E?ZZM_;I]!AS)>:A:^Q4E+!,P\!%HG236E)V480T
M:BHN<$T$U9"2<-6B2BZ@])"F.`G-V!N.N.E"UF2$E1W`3Z(Z*UH;&)Q02G62
M`.$P@)?.&&8)NQ<R66,=))2EB@*?'&;V^%E/&K7;'*C*KP()P[J052?SKU(R
M3<%`(4YBB`#N&VNE3Y1F[ZW$,A;"VDXEXTE$D[N("6NW1%1S-J&D"5K4A86K
M""E05(WZ"8=+M]4-A_K@]8VPB8OK[AM]7LUS%*`44%25*3>H$$<(LCJK%0MA
M-0LS85=N<4`@(=@]@AL(@/9V"&X#V^N';]36F-$PG$,1N$Q,[PT^2(`"H32)
MB`2B`@`@(";]:`AL)NW;L`?#V]GU=9Q)Y5HY,I[D[IZIZ)PPJF$R.(W;N]!L
M(]@`(CZP=HAN.W:'A#MUH'6B2`M,P0#:+";@;;)Z-<;%MP2FE5HF+#:!>1K`
MTZH-AVWV'80$0'U!`.T1`?`(`&MU$(,ED).[9Z8P$J(Q`$IUZ(H(@4!,<0*0
M`W,8P])2E]41,/8`:PE25K#39"G57)!F3O`6GR1B1""Z?U2;SH&^;AY818Y'
MH7PB!B0+9!FR:-2]_@48'Q!LAZ7[JC">^=./VW&&++`+85C"7]N#8`V$-=)F
MAS)NB5G=.XE-&E1;()`F1:;SJ,HA->VS5"@"%=;*0JXV)-@GJ%EYA:@&X`)>
MT!#<!#M`0W'M#;U`US4ELI4\V04&U1!F`3K-P\L7:ANI0XE%1:ZL32-)&B6O
MR1K6\S#.Y%]#M)B(=S$45N>4AVLHQ<RT61X4#M#R<8BX.^CRNR&`4A63("@"
M`EW`=2K;<;0''$J2VJXD$`[Q-A\D5$N-K4M*%)*F_:`()3^D![/EE&RV$=A#
MMWWVV]78`$=O7V`=1J4E'MD)W[/3&<29RF)G=BG@$"CV&'<0*/880#??8/".
MVW;K*>4G$FU.L6CAC<@I,E6&#_VP_5#L$/J@.L`@B8M$""#(WQ&SDI_W<O\`
M:MP__P#`M&O1Y'^XU>]\$<7,?WEK?B2RGZ\?U/M!KS3?L".S$>N6R[AIQ6Y*
M.FCI=BZ;8)RHNW>M53(.6BJ=+F#D7053$JI%B"'M>DQ3";8`$-]>I\+V^)::
M5HDF.9F9`H*XFXTA'EE'"W$[#D9QOXV7_EEBJFSV`J(SX@8=;LHF]9%:Y2:9
MCSD_M=6<.LX,*FM8+:VJD.^JTDJVZ5SMG2P.0`4$^[`P?2:FDRKQ%F;^09F$
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M^3Y5G6*G02T'"!*<@)V6@$62EHCGU.9YIFN4_2N`*4`1,@$S$YR-MM\+NA<N
M[/AG%%NI[G(]5H\+C/T4V`LOX7CI]O7&;D<H2%>GXM=S&K2Z7C-H[QXSCD"Q
MG4LB54P;);F-JFOPCEF9YJIT-J/>V?S589`)3[2N:++S(1W>^\VRO*=GBD<I
M$T:,6+FZ[]$X>7&W(;.N9LTH4I7DKCW`,;C[#_%*RNX&ST&CS4UG:S9VIL;.
M66<8*6:6B%8Z.:2;PK*+:PB>P2!B@L"A1[H:-?D%#EV6IS*MRM#LUX>1ROC2
M^+.Z-*+,LQS%*DK=0ES"3:H`BPF<ISLA<>BMF,C3.%\D.\BYVD\O2K'.N7*Z
M$#.,X5*P4-:LY"LD.Z</WS-Z[G#-[F1NFY;,G0$:1J*8-V0=R40#B?>`IB@K
MZ`Y7EJ$,%F142))F)7W;N_%SP>FJ[AJQF&9...%]-@!,[1OV;MT=-AUX"J_=
MG/T#Z(]HY["MXQ&7(W\Z;BE_BIR?_P`G<6:]8/\`YG._^1E_^9,<E[_ZEO\`
MXI]$2:'LW'UNWU/4[?5`0UX[,3*B=,P.3IWX[%GQO9CYB.5CJ9K7)OF1F-NK
M7X_X'>1G&)X:[L<W62I9[KU;>5G'IINK85Q,5VE3[ZG:D'QDGHO/;B"AR%(K
MN(:_2%/2TU7E+890X:E5"`E83-O%R3-2P)"XZ=-NB/C&8)S,9ZIQI0%"%<H:
M2+;!YHE@^Y&7ZHY(SO3:%-8PP<XS'Z1EOAM_G"0QU6&[.@UM;",!=#S5H:+K
M1\59L@6-5O[G,W=@<;$.84S]9$R%+P*C(VZ^G54U-.*NN8'):/QYD)\P)5Y(
MM*SMX#J">0%$<HV)$C.TFS1KC1)YKOV2LI\36N0;/7\PNL%>D6RWC2KY;IT)
M&UZ)R]"U[C[/S:+]O%P;EU`$GF+J7/%OS1ZGB2SA,HE(`@.\B\ARN@RI=,A]
M5+55"4IZO\4E:@DA1N$A;;*V)JO,:ZLK6'J@XFJ<%0`MG@25"6NT:(46)^;'
M(&1<<:LH36;<392C^3RN:`M'&V)J<#!R7'YC1:K;+)#R+BTQ4F[NHHU1W6T8
MZ?6FD03.=R840*;IVKN>"\I8HE91@*:B@4DH6;$D.'"J2B)&PZ"8N4_B7.WW
M#G-.XDM5R58T`@J&R$Q-(,Q:-($1^9<I>3N;^,W++)UUO\;D3%4!P]/<):E7
M?C[CVO49IF>U30JGHT4T?GDYO(N/J976J:[21=@=K)`L0%P,HF`!.KP[DF35
MK;3JW*9U(4YMD3-B!.4P/CW2GNQ39S+,\XHW*UQ:0MI8D)B=]V_$^<)9SRAD
M[D5:JBIG+&V&J)@F4PE0HW`CZEU#WR9FC[EBV*LCZP1TY(2L78X8'LG*`W@4
M8-%5JD5H!%$U.HQ3\;Q!D3.4T:LQH*0K9S))<54BWE"Y*[)@JF9`D:;#'H,I
MS2JK74FL6B?LR)&*W3*<Y:[(;/TI5N)D"WXRXN,E\PBD6CY"SI<E\&T^[WNU
M1TS$PDE4,`MY6.H;9>9BH1WDAX=\LLJ0&BGN>4I]^H!U<^[NB:ILMV^)`+KN
M`XB`)&TWZ@+-V.?XWKG&@<J;2I21)=@G=O;\,]E#TC&8I3!/$V5QM<7>.KED
MK"&4I6[JP>+XG+5V=Y^P\K$T4<;S$#:%V<=4:K.78[@TC+K$[]F(I@/03J'5
M[*?!M`BK>VZ-JWUTK2!;,E*@2F0,R$S,A?KB+./$=144S%`VH)4*1,YV?&%A
MG*7EC89TY<\YJ3?X+"U3EZT?(&,N-&+LNWJ2GFF`JU#Y*OMP:NW=F2M+G(][
MI49%XX@'+`[`ZM0,=\57K<"<A!2#6,M\*>&JG**JL2TL_P"Z4E0PGDR!O`39
MNSE&V9>)<R8S>FR_:)V;=,E0,Q*TRL,Y>2%CFSE3R\@WO+N_5'(]+I%9XJ17
M&:YFQ6[Q]7+D6V.,H4VJ2MUHSZ^"\;*L:RFX?.CHO&@+OE%13!-9-`"IFCH_
M#7ABIJF,B:I=NFLI*V8F`!LF0H`S'QB;K"2!(Q,WFF9/YB:HU"F4M`$*3,XI
MV2LU0N</9-N%!YC>D+N64>14D_Q?B"HT7(R>'IEC"),CU23Q>O<VJU6;JOS2
M\/'T=B@+!4\:W(E-+KIK/OV[IWK/9=E&?9!D65LT)IE%K!R18I5*J8!LL*<5
M@)G(Q)EN<OY=F55XF=JE5#B6MF`JPIVLP9;\K8E?P&I%AK/'"`N=Z8'99-S[
M8+-R(R25P!?'4K%EF2/88Z(=F#VQAK=4/'L2`(FZ"H[`.VP!XSQC5U68^(WG
MG!]$VVAI(&@-@B/3>'LO3E>2ML"Y:UNG_P#(08D)FG_J6S'_`**,C?Y&S>N7
MD?\`54#3A,6LT!%),BPF#"G_`%(X7_T2XW_R+@]5*\CO%X:2NS=WM<3TEE*D
MFZ4*AE<Z7(3"E>C[E4)"Q(*.$5J\PM$`\GD5F@F!VBK#MY%2125:"005*9,!
M2$!ZMNW64TN;4ZA5--N(:]DDI4!;ND`:8M-U!""67$$"]`4DJ.[A!G+=E&!5
M\BT&[RUW@:?;X.RSF-+$%1R!%1#PCEY4+.=@E*$@IU+VIF4H,<N1QW0@;=(V
M^^X#K;,:!>5+1UE29O(#DYB1"B18?)%5C,*6N"G&9)"5%)!L.(6F_?A8^`-Q
M[`]KVCX/;!N7<?`'4'@]?5`N-I]I21Y1%P-N*]E*CO`F*B`AN(AL`>$1[`#P
M?=#Z^LA22H)!!4JX3M.\-/DC!0L(+A2=FF\R,AOFX>6`0$.T0$-O#N&VW9OZ
MOL:V^*I?Q$F1.@'=.CRQJ`3(BXQ3UO9\'L]H!]LP?7#6I6A*@E1`4;@2)G>&
MGR0-@)-R;]S?U>6*[#ZW_L\&MT@JEA!,S(2MMU;^Y?&`01,6B*AX0]@=A]@>
MD=;V$4TNUI],1/?KU_\`$5Z(C+PT_FJX(_Q$0_OM*ZZWB/\`KU9^W5%')/Z/
M3?LDP_,W;*E63M$K-;*M6E7X'%@E8K'"P2KX$S%(H+).6?-#NP3.<`,*8&Z1
M$`'M$-<I++RDXDH64G2$DCAE'04ZT@R6I(.Z0/3"@V';J\)=@-U!VEZ3``E,
M!@[!*8#!L/@'?LU$KD**5V*%X-A&^#=Y8F2A2@"D$@W2$Y[VN#8>SL\/8'LC
MMOL'KCMV_4UJ%)4`4D%)N,[#O:XU^,4_&%XTC?&CRPE++?:32Y&H1%NM$179
M3(%@&IT=A*.BMG-ILP,'4J:#B"&*(+OB1C%=<P;ALFD8?8UTLLR[,<V)P+!0
MF^1G+?E=Y8H.YA0,2VZ%(G=B$I[TP)^2,>@9$HN5:K'WC&UKA;O3I91^E%V:
MNO`?Q#T\7(.HN1(@Y`I#'.RD&2J*@`78JB9@W';6N:T.89*>ZLV<3*\3(&]>
M8Z%!6+S-!50`H;D;P0.$Q1;(]$0R&SQ(O;(9#)LE5'EZCJ,HZ*-B>4V.DT8=
M]94&)3=1XIM*.$T#G'HZ5%``0\(Z.4%>UE*<U4XFV^T6#3IU10%?0+<[K"%<
MFZPWPL_J=O@[/5[1Z0^IN;L^KKGX\2-HR0J8FDBT'>(OCH85@8P#+>,)-2^T
MI&],\8+6B&3R,^JKR\,J4+DWN^ZJ$?*)0KVR(L^ZV"(;RJI6XJF,'[8<O9L.
M^NK497F5/EC>:%4T.$!4C.^^(^ODN;!5CAT'VI:Y7^:&NY6_S7.2/^@C+'^0
MTWK7)_ZK3?MD^F.=G7])J?V*O1#QU?\`P6J_^+5?_O.QU&_;FU9Y?3%Q@';-
M&1_=!Z!%9NQURLMTWEFL5?K3-90447=BFXN":K+%(*@HHN99VS056!,!,)2F
M$P%#?;;59ME]V99;<<EH2E2O\H,3I=80I*GUH0V3>I02.$D1HW62*"RM=.I#
MFXUTELR%$3D_18`LBFL_ML)6F[%W/2\!W`*M9*.BFTDW.LJFJ)0*N00W`==!
M64YLFC76K5@HT2*DJL-ID!(VSG*(7,SQU*:1KE-KG:#,66WBR%KN'KAZGJAZ
MH;A]<-<G&@@D*$DWVBS?U>6+"FUI`4I*@DW$@@'>.F#81#<.T.SM#P=H@`?7
M$=:[5J<L29[XC46W6Q40$`W$!``\(CX`]3M];M#4D8!!L!$XP4Y*-5?N8I*2
MCE95DW;NWL4D^:J2C-H[,<K1V[CB+&>-6KLR9@244(4B@E$"B.PZW4TZE(6I
M*@@W$@@'>-QC`6@J*005"\3$QOC1&;]T/ZNHU_J5_HCTB-V_WAO?/H,1MP!_
MA=RJ_P!IB=_DPQ7KT'B']92_\8?!'!R#]55?\I7HB0,K,0\"Q4DYZ8B8&,1.
MFFM)S<FQB(Y)18W0BFJ_D5VS1,ZQ^P@&.`F'L#<=<5IEY]6%A"UJU)25'@`,
M=M:T-C$XI*4ZR0!PF$K*Y1QQ"(TQ>1O=2;H9&LJ-,H#HLVU>LKC;7#=Z[1KU
M>>QAGK60DCMHUPH)"']J"!@'M[-7J7*,VJMIU;$ULDXEA0*3AUR,C(:3<-,5
MG,THZ0HQE*BZ9)(,Q,7W6:87NPCN``([`(CZNP!X1';LV#U]<HNME4L:5'G`
M@A7Z)%A&]..FZFI+:7GC-I7L[G%%.D1W``'</"&W@^KZV@4DG"",6K3%8D`8
MC8G7%`[1V#M'U@[?5Z?4_LNSZO9HE:%$A)!(OD9RW]7EC?"H@&1D;K+][7&O
M<2\0S=D8/):*9OU&3J338.Y)DV?*1C#;Q^339KKIN3QS'<._7`HHH[^W,&ID
MLO+0'$(66R9`A)()U`@2)W!;$2G6DJPJ4D*E.1(!EKE'NR>LI)HVD(UZSDH]
MZB1RRD(]TW?,7C90-TW#1XU45;.FZ@=I3IF,4P>`=:K0MM10X"E8O!!!&^#:
M(V2I*AB204ZQ;$=LH?SC>)7U>1O\E\1KOT/]`KOT(H5']3H?VIB0TC(QT0R<
M2<O(Q\1&-"=Z[DI5\UC8YHGUE)WCI\]50:-DQ.<"]1SE#J$`\(AK@T[#SS#*
M64+6HMID$I)GO2!G%]]UI%2[M%)3](;R!Z3")FLN8KKL-"V*8R)4&L!8[5#4
M:"FT9UA)1,O<;"])'P=9CW\4J];.)F3>J%231ZP'K,&^VX:ZF7Y-FM=4.4P2
MM"VT8@E0(5(>T<)$Y#292$4EYHW1_2L*2M+A")I(4)Z!,3MW+X<,0'?;LW#;
M<"CU`';M^N#L,!A\`AX=_7UQV]JX2%<MR9%ELY&6C>BXTDRE(XM(T@[HT0;"
M&^X"&WAW#P;@(AOZVX!O]36I<;29*4D'?$9*D@R)$XMW#?;<-_6W#?L';P?5
MUL5)$@2)FZV_>C)!38JP[L8;B2C6CME'NY*.:2$D#DT;'NG[1N^D2LD@6>FC
MV:RQ'+XK)$P'6%(IP2(/4;8.W4J67EB:$+4`96))MU6"^-5+;0<*U)"I3D2`
M9:Y&,1I8JY(&C2Q]BK[\TT@[<PI6,Y%O#3+:/-T2#F(*V=JC*-V!^Q<Z'>$1
M'L.)1T6TZVE2W$*2A)`42"`DFX$D2!.B=\82ZTI24I4DJ7/"`02J5^$3MEIE
M=IAM^0W_`%#9F_T8W7^\#[77\,`CQ.T#?A^"*&?VY296QUG_`#6UQ^..AQ1R
M:I'_`%W<T_\`:><?R,8?UU\[_=LM_P",O_-'.RO]=6_MT^@PL+U0J-DJKR52
MR-3JQ?*H\(5V[K=PA(ZPP;AY'`=W&NUHR4;N6BCE@[3*HB<2]1#AN`ZJY=45
M5,\%4A.V+C0LOEM4$\9W(WS6EIJO+GFZH3;")RW8^<VIXMI,;Z./A[8J'"57
M&^1<@\T\8UZ6R?6JI7"6U?Q3/>16%=</7:C1,L\K7"I)F8I.^^02$A=R"4-M
M?;J[-*ZH\;9XNL;:JJ`MLE25$$*3@`."9Y1G893CYQ4Y2TSD3"\L&!WK)Q6:
M,)^&'GRYR!Y+X>QWFS&41FJX6*+Q_P`\8C!TAGN]V2O5FYTO#]CQC&7PJ=JR
MBWHT[!TPKFSOBM"V)6$6(Q;*"0I$RF)T<S)?#^25M2K,GZ5FGR5M.)+`'*6J
M<E2;'*.@R%L3U6>YS29<&IG!<3JWS&VQ]E#DUDLW"O&\ERR7)'99SOR1HLQE
M#!UWK60)JRXUI-"B+55X62R&[H<'7+'=H!XBNU-.M8@GM5.\(4ZYS]&491X=
M6_7YA14*`H-M]7#B<&R6"K&J2I%(59P1&<RJUL4:%5:VDO+6.09SD!8J6_IA
ML\/<R,RVGE)*P$3F/(KZEV2G<PHR2Q]D7(-/LMKJ,YB*I3\A49QSC:M8YJWP
M'RS25A168-E9:75DF1A64`-S'/M4>'\EJ<L9#[#*,Y4ZB81(A^7.4"0H)W+L
M1G$+&?9C19PNE9J'':,-+"W5S&RG=A)TFW3H$68!Y=Y^?-L03N,N15XY4Y&M
MG#7-&0L]8BL4)#24/B;(M`IR+W%[MK%PU?AGT!)V&?*9L=%PY57L0%%<IA36
M2`+>;>&,F4P^C-,NI:5QNH9P;(I*G005*4N5O))`&H&6B)\LSUS*UTYI*ZKK
MB_3OE2G4J"&2%`!*5$2DN^^V4:7%W)'EI8<`<GK5!\EFF0I1CQ*D,F(Q%<RS
M#Y0S#CC+;&=@S*3D36Z[B&BN<31"<1(.VSFMNS22C5=$IB'/W2AM5LSR[(W*
M\4U/2-.$I`!5("4@`!.\@Z1O:8CR?-_$*:0K74(+)421B$Q;I$](UPM>37()
MSRAI_-*`Q-FVW6_%=5]'[B/(;2/Q\_,I7I;(S*Z/5KTW46&+6]U"NX@`;3PL
MS@*0MA1%9%5)8I>CX>R6DR#/<OS"HRZFV^W?PJ,@`G981;H!5,`F4S=&<VS)
M[-LES'+&ZEYI*V&9AL$A2@];=>H"\7@6QLK;GO(^.&\Q(<?,OV',S6M>B\K]
MZJ=U>A7LAS`SKG.S.N6J[D>15>CC3SC&,(J_3;M03\72+%`0Z:ITQ4/Q<ER:
MFK\F4[F3#:*WK#V%A4@VH8U$3)D)GSB4;9K75V79I6H:J7%4BJ5I.WMV@.``
MI3*T@;FF<=1>+M]Q@RPI=KG`\L[+RGHU3<2-DLN4;G.PMDD*N$93V$]8JX-@
M@X"MM7#!@W3,]\762.NP47,W5.)@UX/,6JFOSQK**O+V<OIJF32DM#Z(I03)
MQ1EA!5,@DFV0CUF1=6R?PZG-:.O?S!^E;VH4[/:!:["TE)Y1"9`R`TQR#XL9
M'NE+Y18'Y77G#^5L>UWFO=,ATK*F2[JA6D\?VQKF":1L?%EI57T799":1+6H
MF#:Q2/N@P9%!!RH*0F`1V^G9W1Y3F&7L^'G%MN(HB$)PD&Q.D2T$Z;8\/EJL
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M\SS[/&*)FH6YM'`;2DS%ALM&J.M'`;)UUS)PZP)DK(LR-BN]FJ#H]BGSM4&:
M\R\BK%-PB4B[;MD&R)7SEE&I"N8$DQ46ZCF*!C"&OF/BNAI<M\05-%1)**5M
M0P@B1$TI-V^8^BY!7O9GE#%=4&;SB3/R*(^"%5R4_P"[E_M6X?\`_@6C6<C_
M`'&KWO@C&8_O+6_$EE/UX_\`N0_5$``/KCKS+9`;!)$IR\NK?W([82I1DD$D
M"=@T:][=AF9'+_':U7*8X]RV3,362_RT9(1D]AM]::U*V&1CW#+>4AY6HJ.U
M7+I):-7-XPU43,(HF$%$^GJUZ:CRG-T,=[4:'&BV/:*5)2=W$1+RSCEUF:Y.
MZXG)EJ07G!:)I*B=-DYPN)/'%(E:83&LM2*X^Q_[F,H5.B24`P=U7W#B?%S1
MT26`70/&FCHT&B0HI=V*:0)%V+L`!KEM56:-5.VHUA-8Z5+G.6(SFI2><`9S
M(G+3%I_+Z%ZGZO7MJ72LA*)!).'0D*U$BX&4]$:>_P"&L3Y3+`IY0Q9C[(9:
M^N1Y6RWFFP=H&'=#T"#B&-.,WHLA4`A=RI;$/L43`80`=04N:U5!3KHZ*OJ6
MZBH423)0"E*,U83<JVZ4[+HF?R9BO8-76Y?3N-,)`2+"H)38,0O%E\Y6Q';,
M&2N'2EMMD9E^G5.V6_CVECIA)$E<*O[],49KG%;W!I+2L`WJ\RJ>/G1'NW*<
M>`I,D]CN.Z+N<?8T8\4Y3E`6XZ4I7<3-(5KOE,ZY1YE*/#.:9I(TYY`$Y)F$
MRUV6#5"PS=`<5<=06.;/F;%^,S0T5-UC">-'<MC".MH5MWD%4*I7Z;7B-X>1
M/!UZ1,?Q8P$!)F@0=SG(37,R\9S6)6K*\SJ0D(*E2G((TJ)T('.-D7\QILJI
M%H3FB,141@!%^J4[_)#K26#\/R4W2[3-XAQW(6'&K1M&8^L3^F0#B7HK.-(5
M-@TJ<NYCUG$&WBDDB@W*W.7Q<"`*8EV#:DNOKZ.@;REFMJSM#R))40O]&5BA
MK(G'47DU,W6JS5[+J=(*""3($"5IMW(R:!5,4,%)^[XLK>/6Y\ER7NW9[?CU
MA`%+?9:/7=-/=:9GJX04;*^9N@73.LHHJ<JO>%,8!`2AG,JC,*BD3E6<+^E0
M09$VS%UAC2@I:!AH*R=!2PH6$"PC<(L(WH7QBB41`P"40$0$!`0$!#P@(#V@
M(;Z\_4\JG<`M4$*]$3NI4EHJ4"$R-ODB,F1OYTW%+_%3D_\`Y.XLUZP?_,YV
M=&WR_P!*8Y#W_P!4W_Q3Z(?BVW*J8]K<Q=;O8H>I5.M-/=*P66POD8R$A8\%
M")"^D7[@2H-6R:QR@8YQ*4!,`;B(@`\)BBJZ]\4=&QUBJ7<V02%;BK/9.DW1
MU''FF6]N\1L1I)`&].Z>Y?$:\?L.#'(:[R&7\7L.,N9LDPLHS=RN0ZQ'T"YW
M:+FD6B#6.?OIE)%W.M7B;$B:3913I+TAL0PF*`%]/75WBUBA:HJQ^HR_+0K"
M6V@O9+/,"AR29Z!JNCC-TF39K6A30"W46D)DI0&L@3(&Z8?.7PQBF=B+I"6+
M%M#G('(LVE9;_%S=/A)*+N5B(W09(S]I:OF*Z$S-)H-4B$=K;N"E2(`']J&W
M,ILPJ*=\/4V95"7T**0;1)4CR=Q4I\F_<B[4>'\JK6>K(:2X5IQ!*I85)!!G
M;9ALONGIC)B\08RA65'B(7&5)B([&,BI+X[BXJHPL>RHDNY:KQR\I4V35@DW
M@9)TQ>*H'6;D(=1-4Q3";K-OQ!6TV9%]NMS"H<JDJ!,IJ(D01,"9'ECMMJIZ
M9#3HH*4--`I"IIE:"FPW:81,M@?`L"URC94:)0\82]_J=GB\C93JL+6Z%<S0
MDM&O49N6?7EM'MGC%PV36%R+I53I362*H??8=^^CQ!G%2^PWEM2Y5AI0`IUS
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MUCD86%5<N8:'D)M))-XZC(I=RJHW0.;NTA.82@&XZYVUKZ"C71N.I3)04<1`
MM(.$6Z2+1KT1(RC+GW45"D$.E6``B1\@\D0,Y'>C4Q'GR=@K!&RJV(U(>/N+
M"4@J]C+%MOILZXO\BWF+/:UJA?*O+0L-D:4>MR"I86::<B8@%*)^P!U[7PWX
MXS'(*1JN65$L+)1A)G,@B8(MNU:(YGB+P;0Y@'76$R44#1[1F)I&M6F5^F42
M'BN)7']CCO%&.K+BNHY+A\,5F'J=`F\JUF"O=FB8Z&0;I-E"SL[%KJ@Z5,@1
M4XD`B?>["4I0`I0\^/$F>-=<;57*8I:YTNG`KXRS+"H`WVV`VSNBX?#^4.;!
MJFI$/.-,)Q%8`2-R9LQ:Q.<H<J2Q%C*82NC><QM2Y1'(3>%;9!;OZO%+)71M
M7D$F\`C;456AR3B$*W23*T*X`Q&Q2E[L`V#7.9S9G)7V:M%95JJZ=2TS"5&2
MG$A)!D+"!;+5'4'56V^J]4;;-WT<B3OX?-#:YPXHX=SW"V%E<*HVB)BT0<+3
M)^_U2*@XC(#^BP\W%S*E"4MSB'?R"=3G%(I-L_:E,'?-3&3*)!`@DZN09IFN
M0OM-HJW'Z<%YT8YR079:[`3+?LC@5>298^TXSLR5J6A2A*U*4DS)%X`G:38-
M,.)+9.H-4R5CO"TE)*QEXR/7[1.42ODAI`63Z!H#6."Q*%E$6WN7'>Y+9ZW*
M1)=1(ZI0$$R#TCJI3T&=9IE=1GS3GL.G$)CXQ,IVST&4=+-\RI*?-6\A::5)
MQE)29&T`7BRT6WBR/'-._P`"V8]_BGR-[/\`YFS?9^IJ;(SCKF'3^L4A4]\&
M*V9(J&Z/9O*Q(3[-LY#3%^#!VPOA(=^WX*L9[=@C_P"9T#Z@=H_J=NJN8%CO
M-"5))?Z\D@RN$M.J-O\`_CDZ/5'S=V/R;W&)^7D5`MZ8\](`?GKEDF`4:.V(
MOR*:SR>7X92L/&CJ$0]\2-&:L47XNCNCEBRM2K=1A$Y-?;:EZLI:YQ[.%%WP
MZY2`81,@JMM&@Z!KG'SA&PV3KV5%*?$H60E<Q/92%D[[YQ(K+V>,Q5E+EP`\
MA8?%:E1YKQU<F$3W:KX<MEMJD-@*N3]@QWBK+,S2;-6J[:7,^<7J0R[<32A/
M^;E7(!M0=3RU#C`KJ%JJH7*0%K$,6!14H`*3>`)#5?$*7*ONWK25C:AXART6
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MA1;0ENQ*E&Y..^9D(],;\G^54[*W#$<=9K=;LG<"\/\`*J:S6[7:"\7S=DAE
M*2\%QL:6)LFT23G2O:Z8DX=NCT`Y5;%+M[78>;6>%_#M`NF8;6DY-G1VBBH@
M27/E`DV"2K`#'3IO$.=5R7J'9ENKI4E`D#(A`DD@[HMAB:GRPY1$XY\GK^TY
M45^Z*0W'&NWX@,<R0.3\IXQRXXOM49K2#>&B<58_1Q?7WT?-.&*]7D3NSM%"
M`5,Q@ZS%ZV8Y5DC&;4ZT9<VIBF;4`M:98@!9[7DD1?>(\_19[GCF65**M?T[
MSP"IG0+)\`B57)?*W(KAHK4VS/,&6<W$Y28,E\78T?W9:)D5ZCRZF;)#NZQ.
M03>!A(QC`Q;V`MK@J"`IB#5.((0QS;=8\3PUE=!XI;IJZE:11"@S=Q;R#R9H
MP7B<I@RO%AG'J,T>S'+':=FG<2MIT)M200;!I%D=E*1!R]9IU1KE@GY"UV"`
MK4##SUGEEO&).Q3<=$MFLO.2"W0F"CN4D$E%CB``'4?8.S7RVK>I:BJ0]1(+
M=(K,%%*2)$#:'1Y_+'KT(6WR'+7!1F?`88SAI_-5P1_B(A_?:5U>\1_UZL_;
MJB#)/Z/3?LDQSNY]XXE\L\Y./-"@,/XKS3,SW$[D4SCZKF*:+`U",6=3-?9%
MNQ7WO>LC@9FL*NP6;$;H)KG$H]"Z1B@;7T?PC74E'X,Z[6S46JPF2;580J=U
MMA%DY71XCQ9056:5Z6:)00X++3*V,[$%2Y!8KS*TXY^4%D*T,>*O!G%N2D:5
M67;`L+E_*;64OL4WAIA><C9&PFI\N1N@Q5;HK(N7I&[8#K)BB!-1U5929K34
MV;=1I\5?6K:4"4A26\1PK6+TB4C,@"+;#%1E]74Y:K,*B5#1I>24S*2X4@J0
M@BQ1!LD)F(I<?N7?,V5HN5\CQ^9ZSEV\!Q:RCD"6PJYR+#Y`R%3<KPJD<X@Y
M*O84AL34N1Q"PJCARY0=5U[)29'8)`!3+'((ZZ&:^'O#3=91973,AEE+]JL.
M%,M)Q'DE)-H58/-'G\FSS-*RFS#,T.8JE35B9S43+F^U/6)3G#QM;33[=,^C
MTF*KRUM_+%RXY;5:4LT_;Y6!FW5"M<SQTMLA*4]DYA*[7RQC<[LHN/<AQW[B
M,4#H,(=6PU6TUK--F:,VHJ?*VS8@LD36`;%`"\D6S$[XN+50+I\M.65]1F;J
M3-:7P1@)O%MV$V">J$]@B^9XR^VX@XV9\C\HXMC;UQHY>Y#N4MC?WI1DW89_
M&N:GC"L.D1?5UY%Q+EDCW""KELU*L9H"B("4RXJA9SJEI\G2BM[OI\T<)2#U
M@@$8@!.2K;`9C=MBO0KJ\S4JAHJZJ::3,VA03,6R!-FB4:AKRVY-.*+CK*5<
MGW%OR@\]%7=<EB5O68J57E[]%YPAZD[OZ<6UCQ>/9.(K*CA^=HDKXHJH01,@
M<!$IIQX9R--0G+WVT%H*$@J02NWV#.0DJX[\9[QSJ77E*4%+L-\P#83Y+X46
M7^2L94,*8LC,1<[LQYD+D>\R99?,3[+N.<?0E(G8;%4;87E"L^9O@>M1XY*2
M>K%=Q5;:1RC]9\H9FJN4H`4>=E&4-YM7YAF&>4#&74%%4):8IF1B)2I>&8;3
M(E-MJA8`)FR)LTK:C+\O0:/,'W%@\F4R"=`TWF%]PAR?<<R\D^)&2LAS'N_=
M[7Z-2ZN+!-F:H,EYAW&<A4H4L@Z:MD&R)7SEM&D4<&(FF!U3&,)"&$P:A\6,
M4+.15&69<@MM-U4P")3`-XUC=%D=7)G,P7G[&8YHK$\Y3$$ZB1*1U'<CJ#RM
M_FN\D/\`03E?_(>;U\TRC^JT_P"V3Z8]?F_]*J/V*O1#Q5C_``8J_P#BW7_[
MS,M#9G55/68ZS'*<:2FT]2'H$<O/2:P"UHO7H_X%MC2D9D=R7)RP-VN+\E2#
M:)HMR4^"RQ'-#V"1>0UC;-6@ID,J)SL5P`Q"`!1$VY?>>`'V:/*\PJ:IU=/3
M)02IQ,YIY0D1*V^0,M!CY]XP:J'Z7+:6C:0_7=;,FERD;#[0-PO,SIB*E8XH
M9+Q7F/@G@*9R_*8QN,A4N=5W5F,)/&S@<;P%GDJW9V&,,;3%TC7XLX2O-W2#
M0CX6(*`3O>X(B*A5->JI?$E*K*:D-T3=90*4@%YV6.6-,E6Z],<->3U`SBG<
MKJQRB>2E?T34]G^K582+!N;MD,KF#F]G8.-/'QZ?/&0J;E5;`^9KTYO+._4K
M%50R'.XYR78*+`ME6Z^-+K*Y9R2Z95Y$[FLM%(=JX;JG<&6!14PE4'AVA-57
M/"@IU9<^6Y@83,GE"V<@!*_1=?%"I\1U_4:5ENL?<=:<4,"@H"1LF9[EL2T2
MY1Y+3Y;\=FMBSA+V6.R77,&-8W!&';?5HZ2KMIN.*D+/9'&;<+3%*<V*T4>V
M2\AXRC982;33@TQ3(*0"CMKE_P!N9/F%&XAVA:IRVXDXR`"0%7`V:K8Z_>N9
MT]8VTRXE0<:43A,Y&4]$)#@ER7Y/98Y$4P,A9SJKL;6ZR\TS!QXG\H0LC;J@
M>`]TB5QI3\&1F*8"P8@6J3^+1(X7>3TBA)-E!5,<QE2%&KXOHO#]#E"D4+<J
MO"D!8!EIF,5QG9(7QOX1S&N?SM+%4H8<1,IZM,MR)UXS!,OI->6P>T!<.+W&
M(JH=)"J!M8+_`+$,4HF$I"F`>D-Q#8-<O/R3X0H=PB>Y88]-EHEX@KE:"J8W
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MZT^EV84O:C","3:22#,"9E'CW<BS?+*6FPN!3.)12`9RL$85_P"3V7*-A];&
MLYGK*XS]=YH\BL$5_-3S)%'Q"Y=U#%]<B[#7H_+F6Y#&MY*G,KJ39TV#-A#I
MN)QP0K?K(0A2#M0>%*)%:V:6AIAE*,NIEMHFF2%N8]HF0N4))FF\$VWQ;S7Q
M)G=)1MTR"HA4[IZ/^L:53F-F)7'G!C(M[Y)V)L%DQE6G%UQIBFV5&HYUO=S=
MY@DZ4WR$M2;31)6)SG4WL;">*R,!%.HM\D=-=P<I!4*.M7\I;(JZ6GR^G17*
M6G`ZJ00E(!Q#'<)V7FT71LSG.9(72U54L+H$H5M&@9J4;,)PWF5NB%Y"<F.4
M-GYP35:=9JJ5$/`<KG&+F_'^ZY2BJ\VG<)-GY8UB6KX''%;ZV6&>L$,Y"1:V
MM*R%3!<HD.1%`J@%W?R+(:/(77':9M%:JE45+;D0M9,[5"RRX)OE$67>(_$%
M?XC"=J&\M!DA!,BE.K"92MMB5/+'N/+=H?4*?5_1X<U.D5.@#]R"<.!_#X"=
MH=7J=NN-X2*U>$*-"9R;S8$CFIPIM.H;ILCO^(VCWX'`DR50FV5A.-6FZ>Y$
MC/1]]'D-<2N[Z>['`F/Q)T;='0,6`E$G3[7I$/!MKR?C)07XHK%@S079@W@C
M"+0=/DCTF0692RG2$VC5"NRA_.-XE?5Y&_R7Q&HJ(@>'Z]1]D(`)T`FX$Z)Z
M->B+%1_4Z']J88'TL`%'@%G@AT4')51QV06[HQ2-5P')M.*5!P8Y%`*@Y,82
M''80Z=^P=M=/[O4,*S^D-14OL%EN9"0<*3*=IT'7.V.9XQJ*FDHUN4],P\I;
MZQ-1&+1HOD-$<ZLR<6,@X@QY(VR8B<<<<_A]YQ<)"T+$&%)`EJIV*%:P\D(!
M>[H'D("`K3VZ6AZ\!ZHFA&IM040(5<%1ZRA]!R[Q4Y69A5UF6M-NU>79?6H+
MSQPJ>#JS)M!605D"P`$F4?/'\B=.5,U2WUTCZLWIEEEN<DI`M7(:#>3<#?"V
MR=R,RSB.I\@\1SV?,R3IJ+S>K^&*=FB8R!0<7V.%J$_B>/R*+',N:'>.+/"5
M6M)2;HR2+IO"&=N#]TT2*0JAMJ^6Y5E#>8Y?F[3*&Z9ZB2I;2`%8%E`Q@I!$
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M%XCA.T3-*4@7SX1*)&,\SISQ'L:Y?^W"Q($V@2&@VQ/WDV")><O`<1``Z8?E
M^"0JCNH4@8JCBB`&.8QQ`"EV$=QWV[=<GP2A]&3N-/*Q/]:G,6XK;QK&[='I
M_$Q2]GJ'&[4=5E,6@&5Q.O<B"G"+Q;WS>B,[KN-PX^<X.YZ!3W`IK4@!^[Z?
M``F'8=O".L^,<3OAGQ"RB:G55M,0D6DX5"<@+3+3*[3'+R`;///#SBQA0WUO
M$38$3!EB)L3/1.4]$=F>1/\`U$9H]7?&=U$!#M`0&!?"`@/J@(:\KD9!\93%
MTS'L:ZS*"3=9'67\UM>>XXZO%')JD?\`7=S3_P!IYQ_(QA_76SM2>K9;:+*9
M?^:.9EBDAZMF1^O3Z##O[>N`#V#MN&^PB`E`P;[AN&_U!\&N(ETMN(>:<2A:
M%3M('DB^YLW0&B1A49&W1&`$3$%:MV(1$2#)FJ1PS9!&,`9,W22AED'C9F5N
M5N@]17.8Y52%*<#B([^'>6IKEU=1UNKJU(.&0P*F?++1$*J6BI5=7,ELWB5H
MG%1BXLY'R9XR,.C*&,:604CF2K>6,H5-,YI1!5`Z3\RB:12B*H''I*`>`H;1
M)K&V7D5+5=4E;9G9,GS1*GJ@:<888:<VJ9':2``%MDXM0B(AL1B1M$1+<L9W
MH1A4(M@D2+[WJZO<TB:!08`)3=(]ST=90V-N&^I'ZX5ZGE/5M6"\`#/%HGQQ
MLU@IJ1*$4E'-F9%J;<6K@C43],K-CBYV+?0T<B6R1DS%2T@Q8,6DTNC/1+J$
MDG))4C872;]2,=G3*MN)MOUW47VNK&7USV6*:<HZIQPL3]LZY>S/>ME%:KIJ
M+,J0IK&&6U.Z$$:.=*Z^R$YB'$U-PCCNE8SH[1PG!4.K0E/AY&3%D[LCR&KK
M8&L02=FT&+->4<M4@V!0P%`-_:E*'9K?-LZJ<YK$5-94NM*$Y8)F>N<OABQ1
M]5H*3J%+3LN-:<9`EO3A>-HJ*8F<'81,3'J/5!5?KQ\6R8KOUC`<#KO56B*0
MO%C`<=S*]8CN;[X=:E="HI6Y6U)?`Y)MLB)L)IB6VZ.CPN&9M3O11")B6:0(
ML8F'8)>*@Q[ME$1K4@L`455\0Z&S9),K$5%1-W(`"76)C=.YC;QUN9+"DA[,
M:E?)LO,A.Z-W&*!!!<9:0HVR;((WS+3%6D7$L.Z%E$Q;04&81R`M(UBV[B/Z
MC'%@D**"?=LQ4.8W=!LGU&$W3U=NJZ*]-6>KKKJK9RG,SE.".K($F*=A:=:Y
M3GY=$",7$-F1XQK#Q+.,5[[OXQI&,6D:X!P&RQ5X]%`K-8B_;UE,02J;B!@$
M-3(S"K<20W4K4A)P@N&1LW]&J-5,LN*QJ0TTK4B4M_?CT481RR*#9>.CEFC4
MZ*C1FHR;':M#MS`9L9F@=,Z;51H)0[DQ`*9';V@EU`IVGVVV>JW6ZZ0M1[,A
M=N3UQ@=2GU9Y,QKE9;NW10(Z-*T48)QL:C'K%7!>/1CV2<<X!R8PN`7C@0%D
MJ5P8YA4`4]E.H>K??;655+"GS4.9A4&O('+F;A<)[@B5;.7MM=64`JCOPC6;
M[(\DX:#38MXL(&"&*9K%<-(HT+&&C&K@AC'(X;,#-19MW!#G$04(0I@$PCON
M(B.37@/EX5U4JM($UVR.JVZP602:,4@HJ.DI^J"<L<@JTS,P=V<92#9LT2(W
M9M6[-LGU=TV:()-FZ?68RBG=HHD(F3O%3F,;8.TQA$>T1'1=2M]6UJ'2Z\;U
MJ/*.BV>H6>2#26V&PT`V@#XJ2,(TV1''DI_W<O\`:MP__P#`M&O19'^X5BOB
MI1B4=238%'4DFP$V1RLQ4.LM6B^))N.^%)R#94&[D[5RFV<&`PD0=*-E"-EC
ME(!CF*BX,4VP`.^VP]F^N%E;]+2%!S!.)(JP<,K0)SF1JEICMOAY[&FC=2TY
MU/#,D"V5V_N1PYXE7K&V'\$N\!Y*PC?Y#FI2[?G&SO(AOABV+V>]90,]N,Y`
MY1JV:$JB^KC!6?A')$6$R=_NW[TI2IF`0*;Z[G]/6YGGE+59?7L)\+*2DK9#
MB?9(!PD3^"/G-#5Y?09.XQ64+SGB=((0\&U$8AIQ2UQ"?'V2>1#K$W-(:]8\
MV-&,CQ4QW=ZY&M7G*"6E*?E\<JQ$?8&4%9LY`I;']_B(EV9O+*5_NH=R':@D
M"93`'JE-Y,,QRL--9>JF:IJQ&)2VA)*IX`J1LQ:`KE&/.,U.9JR[-34/UR:I
MVJHU2"5VE(&,ILM"3>1,")89BB>0.&4^:M!Q#>>25BK9\(\5,CN)J2L=PO\`
M>8EU:[F\C^0D_C*;D4W;UK95:4@Z<+QT3L+,1,9!!+H3*'EJ!ZFK**B=JF*%
M#K+RAA4I`L!D"03,"0L.D&/1YBU44M=6M4M37+:?9!Q)2L@DB<@0)$VW0R*A
MI&%<\S[1QSD^3#BDS]F]'HACVZ7E'+B61;#6TLIGCKJWC9RWM6F0)VI-C>,M
MU1>@<`:&.F?=KT;]M_NZIR>B:S!YA90\N:0M)PC$96`V#5N1Y^BH&5.UW5G,
MP94ME,B4+&(R$Y3`F9Z(WN>2VFX9<ML?D%YR6E<\0WI&L7/8RGHQN3'G'R(X
MNQN0*HGCZQQ[!"/<8N")*BJFL#])0)?W04.50_==Z`3TBDTN7U[67#+V\>0J
M;$W$!2EE5J1,S*R/BBW<C6H0*BORY>8JS!U+=YV:R$ZIF5EL*6EVS+]^Y_(5
MY^;-=.KEZRCR>Q?E2C/K5R5?+MJ7[T+8%-FIFR3H1^#JNQFU&2#VLC3P:R#%
M%-/O5SB`*'YS2,A3X?%;C:%?EJD)93B1B5,R)0F>(A-Y,B)>6)5KK,PKG:)]
M[,!2!"K2AP)-ALG*5MT,W36V1,<<),#TG&[[,E"AXCD1>*SS+3G$N32:-)?M
M0L2N/XH&V/TVV28G&LIWS)9\M2%`8K2BB:CHPJJK[VWZS+JK/GGLR9H'&RDR
M6E;9OOE,X2=4XCK:>N:RC+6LHJ*Y"T-R*2E?),KE"5GECMOP']^8\8Z>:[9'
MDLKO/=VYD@;G,0&1:](NJ:2Q/!J\8HAEEA&9$E&L)'&!JUD95+QI^U335,8^
M_4/Q[Q>G+^N/*R=$F2A5UUVY'T[PZY7G)<&<+G48383;.6HPKLC?SIN*/^*G
M)_\`R>Q9J=:%CPOGB2#/;Y?HW4QET@>*VB39U4^B&[])*P?RW!/E#&Q;!]+2
M+O%[M%I&Q;)S)2+U3W:B#BV9Q[-%P[=KG3*;8B9#FVW';LUZ+[OG6V/&S#KR
M@AHM2F3(3D;)FR>Y'/\`$R%O>%%LL'Z?;SW0)WRU;L<Z,C6&/S%?5\R\4:5>
MJ_'X=X#YZJ67\IQ>+KQB,EGN,Q1H\,:XZ@R2=>J\[;K?7K"Q6DTUFJ"QF@`!
M2+;@3?U>2OC)Z!ICQ/4,51<S<J:94M)P)F3-229I3+2;-V/+U#536*??\/I=
MI%-T)#JTI(+IPRD@_&43H%L.5"RT[QEE/1U92N%BY(6:BW/&F39'.DA(N\L9
M;?/<NY!Q10W5386:HQR4V[CB+SC%VWC&0,46C!?O1`J9S*&'@*;.>4.:FF1E
M](ZG/TN-XUMHQ-`$%2<1$TFZ8LMC;+FAE+65*K':]Y1R9Q#DD+.%95/"J0.%
M6F1D8YXY5R_F9#"O&^F6NU9SC9"Q8;Y'S\H=YD;+>/+#CB[N,]3L-3<M9-5H
MD99[Y9XNC5DJK<8B3;EC"-DMDECF$Q`]KEE!D]=FE2YE=)0DH:3C*2V0XI(^
M*9\JVV\F/.NUH734C;=14M)#RIH=!0!.<L6*4MR=YCK_`,R:'-W7T=$!7\..
MIG-]>BXO`UFG4X.1EK5/YKQ%59RMS%X:Q;V5=O)FS*6^#9BZZ%5EEW2!3%W,
M;VIOF7A?.VW?$E135C5+2E.T"5DI2H*D<-\I6RCW'B)G-F_#R'&"7#B;Y*>4
M5(Q#%("_DPSN?\Z8CR/CZJ3?&^N97HF,6>5L,5GEE;L381R5B;)%?X]BA9%V
MM6C9..J%?MSUI`2W=DD/<(CQS',G0]V?9<`'NY5EU735;M5XBJJ6KJR%;)*W
M$$!)OE-5XT3LBCF*\KJ*5IFF;KZ#+9#:%AM>U4Y\6Q(GA)]HW`7PSD,GE2T0
M5%KE,O/*&/XWV_TC5.JF';=-S^38/*[C`$KC6:0O:#VSV-)'(:&-CW`R[:.=
M36QR'$QTS$.1,Q;E0Y2L4U6XVQ0*<53%(`4B9)6@V`&^0T:HY@H,W<3A#U1W
M3H40K;XM`*?:D=,>M'JF6\>V7&ETC<E\FYQ_2_2A2O'2$@;C>\@6BM$XU+R,
MBBLSGH"6[UK9HE<'@J^[\D5PL'2D4CDJ9"%U=9[JS+/:]FKIZ#JRVJ<H,T24
ML-D$IUJ!)F!<=$;-C-<IJ6:NA<J'3M)+VJ5!*$$&:IFR8(`!W3#:\=[Y>+1D
MO"84/(?*>TY\9\W\SPEYB)J7R9*X&:<58NYWMM--'[F51'&(Q$0H")$3^,'E
M4'R9D?:))-B%DKJ'(Z=>RSM-,S3BUI*%)!+FI0!F$RG/1=%3*NO+K55^3UE8
M]5+JSM4NA090V4F:VE$82O%(6&<B8<;CY/93F<O\>"M+/RL<<LU\YY'0YG5.
M^&R@3",!A\BEM*#9.+L+-+$49"L")0P5M6#.+PZ@]1A`P].HGG1U!QJMH\J[
MMVU.65)6V7"H.`J*@#.03:2188LT%'44R7G\KJ<P5FCE02ZAY"TM8-!;*A(G
M%JT1E<?\PY/G3\%</R8<@RY`Q;?N5<'R(<6B!R>PATGIJCE!:D15HN$T@WB;
M@+@Z35S'$(X?)-B))B`D."9=9;9I$UV:/*1EVP76DM@.-VC`.4FVW5,;T3U-
M3F:TA2NM-O-VS;0J:IV2,A;*,'C;&<@*9%<'+_7KOR#L>2<YX/Y7L,C0^3+=
M=[14@LE)I\G(X:8O*M92JP]/=1L\T;@T5.DDX>"8YE#K&.;JKLKR*L:J$YFW
M3MO-X=B$E.%1).+$1JD)162G/J0/U5`Z^I-505"7MH%!8D$X`@$3*E358+3*
M-)PH*>>Y1\)[,>1Y.6:^-<(Y]:<CI'.+'*2U=K.<WT)"K6*&K3V^L$XF(=KK
M%,5=K#+#%&;HM3)AWHGWDS*J6GPQ44]2C+6`K#LDTZVRM8`(.T"3BF+,,[;3
M*.EX89IT>*:"I9>KW2G*T)>54(6E#:Y6)0I8`F;<0%UDX[J9J_ZELQ_Z*,C_
M`.1LWKY5D#;G7Z9&$XU!20)6E5^$#296R%L>XS)2302!$\1],6X3';"6%_4V
MQ+C8=_#_`.9D'ZGJZI5?TF9NM!01-9DHF0FFPB=TP;"-$2TJFS2)0Z06B+1K
MA<-H2$9/5)-I"PK226[T%Y-E#QS.36[_`&!<RL@W;)NU#N.G]M,8PBH(B)MQ
M'?4%=55684_4LQK74X%<G`24X1NBR<XWH$9?0/FJRVD8((DK'(&>Y.V4HN<0
ML&[(ND[@8%VF[<%>O$G4)%N$GCTA.Z3>NB+-5".':27M2J'`QRE``WV`NVS-
M6R*@!>85*4I:"1.>B<155-05;18J66FRIPKDB4K9:M-D93AG'.UV;MW&1;QW
M'J%6CG3V/;/',<J4"AWD>NY3458J;D+VI"0?:AON`:Q35#"4J_WU29K.N+*G
M&5)2EFF86A"0F:Y3LW]$6%CXTCUQ)IQD8E)NTRHNI5&/9I2SE$O3T(N9(B`/
M'"(=V7VISB7VH;`&P;:9@^W6,(HWLPJ.J-F83,Z;39NQ'2HH:.M7F*VD)?<2
M$E*+1("0NBJ+-FV<NGC1HS:.GQDSOW35HW0=R!D4^Y04?NTTP<O%$$O:E,H8
MPE*(@&VXZB?J<J6A`K:NI<HQ8R@3);5I41HFJV<;TZLMIG77TMVO"1L\D81(
M"`23?)(P,&DE*'!2513AXTJ$JIUB<322`-01?;G$3?MI3B!A$0[1U.]6[9OJ
M]3F3ZEZ3,R(E9Y0)#R1&TVPP@-LTU,ML3D52F9F=OEAMLEX/HV6K5ANV7,LP
MZ<8-NRN1:3#LY$K2NN+C[D+0T?+V.+\66]US039RJHR3!1(B+A03^VV`-6LN
MS2JRRG73TM1M&5@@*)MD=<4*VA:KG4.*"&]D;$I(PC>AWR^$`#U^P/#L'2/9
MN/:.H"EU0IE+FI1JTVWSMCH+4%.J5_\`R'T1&?AH`^2K@C_$1#^^TKKH^)%I
M&?U@)`.W5%+)%H[HIK1^J&F)('8L5'2;U1BT4?(IG11>G;HF>H(J=(JH(.Q3
M%RB@H)`$Y"G`IQ`!,`[!KGLUE8Q2.4;3R0TZ2;Q9.+A:RU^=4\CZ=LR&LRTB
M*@U:`Y4>E9M2/542M5'Q&J!7RC1,QC)-%7@)^,KMD1.82)J&,0HF,/3VCK1%
M16H2$!Y$@)7C1&N'+5<LHD3;Y3'DTC8V/>.Y!A&QS*0?G(H_D&3!HR?OCIF,
M)%'KUJD@Z=JEZC;&4,<0$1-X1$1C;>2_-.9UU2M&H3(&X-P:(GIBW3'%EU)1
MMKG>2D$[OEO,>3:%@F8)%:0,(S*@\&1;D91$<T(WDCD[I620(V;)$2D56_[6
M=<H`J8@["(AV:VJ'6J@2KZZJ<0+KS(:(S2E%$2I-)1E1-LBG3?'HVC(MIW`M
M8J);F;(.&K4Z,7'HG:M7BG?/&S4R3<AFJ+Q7VZQ4Q*50^QC`(@&HZBIIJ@SS
M#,*AR5UI,I71$M.64?ZI$YZA._>BYK'1;(Z"C:*BVYVS4S!N=M',FAF\>=0%
M#1[<S9ND9NQ$X`84B"4@G`#"'4&^LU-4Q6+#B\PJ)I((M.BV-`WEBC+`+=8L
M\NY&-[@P`-0CP@($L<5X203CDX2+)'I2*9A,6018@T\32?%$1_;BD!;M'VV_
M@-9B6J]69"MJ]HNPV&<C$^)"U&B724B6$#V@4Z-1TG5NQDHQT8V,DHVBXMJJ
M@@HU06:QS%LJBV66!PLV;J(-TS-FZSD3*'(02E,H83B`FV'6M2^Q6N!Q=>^I
M0-Q)D=P[\0)1EP(*$25.S?AC>5O\USDC_H(RQ_D--ZZ63*2O-Z9*2"HO)D!O
MQ6SE:.Z:FT?J5:=R'BJ_^"U7_P`6J_\`WG8ZCJ249E6OR);!4)Z)SNW]R+K!
M7MFMDH)<ZH)&=U@MC:*M6;@Z"KEBS<KM%.^9N'#1!==DOL8G?LU52'.U7%,Y
MB]XF)3]!A+OL.VHR_64S&R9?1U%X2<1B$Y7R(WY1IU>E%0FJ?DNJ2;%3G;;`
MHT:+.$':C1H=XU*LFV>*-4%'C8B_1WQ&[HQ!<()K`0`.4A@*<``#`.P;:+J:
MCJRJ=ZHP98J6,)/*E,$2&_*-%T[2*@9@D-N.HN0HB1G9\,XP_<.",W:LU("#
M4:Q_?#'MC0L69M'BX$YG(L6RC51)H9T*AN]%,"BIN(FW$1$<,UJ6D[.GS"H%
M,;TS-NJS<B=Q"7FB^:2CVHT33.W<CV)%1)'99!.'BDY%-N1FE)%C&1)!)@F0
M$RQR3Y-$KI./*0-BHE.!"AV``!V:Q4U@=9V?7:J4QSHBI7%4SVU%'27$7ITQ
M1*+BT'SF5;Q46A*O"=VZE$(UBC).4RE3(FFY?HMR.W*:14R@4%3GVZ2^MK?:
M,JIPA56\Z9B25SEOVZM$'6T;4U(8IVEFR:""JW19;+7'N1HT376=I-&J;QP1
M)-R\(V0*]<$0Z@23</`(#E=)(##T$,82$W$2@`F'?+E77+9#+SR%48/LXA.8
MN,N&)&Z2G:_W06G:&R4Q.W<CW^Z']758D+:6$6G"+K?C")VE)-0W(B\^@Q&S
M`'^%W*K_`&F)W^3#%>O0^(^0Y2E=@ZL+[-4<'(%)#55,C]Z5Z(D6X:,WB?=/
MF+)^F4Y%4TG[1!ZBFND<JB3@J#E-1+OD5"`8AMNHI@`0$!UQJ>KK&,747DMX
MARID"8T".I4,4=5A-1)009B*KMFKHR!W+5JY.U<%=LSNFJ#DS-V0#%([:"NF
MH9N[3(82E4()3@4PAOL(AJ%3S:5%;U0MITWE!]K?EJB1:\N<;2T6[$;D8AH6
M$.15)6$A5VZ[WW36:K1+!9LK*]0*!**I*(&!21!0.KOQ_;=P#VW8&I6:QIN>
M"NJ3/?\`@C5`I4SZNPRO7CD);T_/%"PD$4[!4D'"IK11E#QK@D1'E7CC*G.H
MH:.5!L`QYU#*&$3(]`F$QA-OU#OBKKQ4TYH%5M5LW#,FV5FN)65I8J4U::2C
MQH!`M3.V/<8V+._++*Q44M+II=PG,JQC$\NDVZ#$%JC)B@+Q%L)#B'04X%V'
M;;4S+M6RPG*Z.M4JA*9KVBI6BZ4]R*SS&5O5:JNLIFDU2C-);D1+\Z6F>N+U
M6+!=4'#A@Q<.2MUV9'+AFW6<%9NMO&FA%U$SK%:.BALHD!N@_8(@(@&T":YM
MI"Z0U+K(G\2Y6[,61,[U1<MN,4A9N#5%Z#=%J@BU;(H-VS9(B#9LU01;-FZ"
M8;)H(-VY$T44DP_6E*4``.P.S55L,-@[-]3P)G-1M&YO1ELTR$R8DE,_/$<\
MG_SC^)/_``N1W\E\/KT=.E3G@[.4M@J*ETA`%L\*R52UX1:=6F*=2M'>5%:/
MUIB1;IJT>H';/F;1\W.)!4;/VJ#UH?NC]XGWC1TFJW4,F?VQ1,41*;M#80`=
M4$5=515]144SB0AU5EMXPCE#6#KBX\UE]95O-5202EPD'1O3@<M&;LJ1';)F
M\*@Z(]0*\:-G9$G:6PH.B)N$E$R.D!WZ%"@4X;CL(:K-OUC:<(>3+$3>--L0
M?RYSE*1(BR[0(QUXB&=@^*YAH=PG)KIN9%%>)CET)!RAW?B[E\BLV4(]=-@1
M(!%%>LQ>@-0BJ6Q4&H75OI=-X1,CR2\\1E:%KZLW2TZZ<7*7*9TF<XL]Q8/_
M`)I_XB@S`P=*/F'5#QIA8/5U>_7>LC&;&,T>.%PZSJD$J@F[=]]Q&PWFC86Z
M\JOJ@M^\6Z`!:/)&U1198^&D/-(2IBX)EAG.=FOCCU7BXMT^1E',7&.9-IU`
MQDW4<R=23%,XJ"HFR?.$%'35-05CB($,41$YNWMUI35`I:-=(Y7U*Z-T&P3,
M@=R+;:*=RH77)IJ4J0>25%(49;AM,9*S=HX51779,EG#8IRMG2S9!5VV*L3N
MW`-G2B9ED`<IF$JH$,7O"[`;<"@`5*(466RZM7U`0+A;8-4HB==H:IQ52\TE
M#RS,A(L!U",9&+BFPM#-HJ*;&8$528&;1C%N9@BN(F708&1;IF8HKG'J4*B)
M"J#L)@$0#705F%8E>S:?Q-/6E1-MO.U'7.(]GEA^)9#5\AO^H;,_K?!C=?7[
M`]P'W9V[CV:ZWAEM8\4-"_DWBT&R\17SY31R@I;(P@"0G='6?\UM<3CCI\4<
M.S9_Q!C?D%S-@;G;'$/,*<DW#[Q).HWR;`6QL1XF:$5!W7*O*QY>I9JH'2*_
M>!T@(E`#!KVU;E%2_DV7/Y?L^MEE4\<I8<1G?INCS67US%+55Y7)2NL`2TW&
M%3Y8/',/#D!Z'_Z<Y9_,;7(3X>\2/32>IR%MZ8O.>(*!H8G4!*2=,'E@\<_C
M`>_)QEG\QM93X8\0*5A1U(J&HI@/$%"H32@$0#S!XY_&`\^3G+(?^@VLJ\->
M)61,"CM_1C(SZB]W%/+!XY_&`\^3G+/YC:C[C\3:J3Y,:J\19>CVT@3UQ7RP
M..GQ@//DYRS^8VMDY!XH7[(I#T8RCQ#0.3V:`J6J*#S!XYAX<@//DYRS^8VB
MLA\4)]H4@Z,;G/:,7MP>6#QS^,!Y\G66?S&UKW'XFU4GR8T5XAH$V*0!!Y87
M'/XP'GR<Y8_,;6P\.^(W+5=2!W2F"?$%`JU*`1!Y8/',?^T!Y\G.6?ZE&U@^
M'_$C7)3U,C<*8U5XCRY!DM(!@\L'CG\8#SY.<L_F-K*?#_BA=J4TAZ,93XAH
M%B:$@B*^6#QS^,!Z'_Z<99_,74G]K^)UC$I-(#_AC;O^B]W!Y8/'/XP'GR<9
M9_,73^U/$NJC^3&._P"B]W%!Y@\<_C!>?)SEG\QM1J\/^)FC@`H[/T8P?$67
M@R*0#!Y8/'+XP7GR<Y9_,;6O<?B;52?)C']QY=S1$>N0?*K`TP.!O<V\N'`0
M_)K%,W(B:AY.;F;Q+!*QB]<@5Y3&WC)TQ<)`5%$5%U!-[4HAOMV,O\-9T[EV
M=8I%UW*VT#!+"5A9)2G60+XJ5GB"@VK)"/-$A1YA\<C#U?""\[?_`,N<L^#;
M;U*.8/K"(:Y2\B\18I-=6+>%,BHIQ6`7[L7G/$>7!9!2)QD>65Q[[KN0R+)`
ME[78@8]RX!"]`[@)2EHX``]7;V[]O;H,HS<6+("].&Z>YN:HG3FN7+2%X1:)
MQ4W,WCZ)RG^$N4`Q#`<!#'V6PV-L8H[`%&`I0$ANG8`V`/!MV[Y[HS76J.>O
M-LJQD$"<X\D^8W'9("`ED5^F5,1$A28[RV4A1,)C'$"%HQ2%ZS&$1V`.WM]?
M>3^WZ\VE5L2CQ%ER1A`$A%1YD\>1/WALCR1E.I0W4;'^70_MNX*![6D%V`X&
M$!^K[`:QW)G(NQ2WHG[[R<VG#%_EF<>N@$_A'?\`=E_6D''66>DFX"!P(0**
M"9`/OV])0W^OJ/\`M7.+^L#I#CAWWDWYL6!S*X]`D*`Y(DSHC^N34QYEPY3;
MF`X]752.WJ,&X^`1'U=3?V]7<^'?63?FQ=Y9?'GO$U?A&DA52*)"'''^7Q,!
M!_K.OWE`ITCN.^Q@WZA]?6#X>KI&2XQWWDXMY,_RW(\C<Q..ASF4/D-^=0X@
M)S'QUEHPF'P;B)J,(B(^N(B/J>``USGO#.9J94E*B5%)EORB$^(\OD>2)Q'>
M_P#*G`KSDGQGF6UY<*1D%5^1I)9<U#R:@HU/+P.-TXX$VJU+!X]\:48J@/<I
MG*ET!W@E`Y=_3N^&<U=\/YLI!4I"ZBAPD6SP*3CE;\61GJBO4Y_0_P!RH."S
MJA_RQ(<.8G',H@8F0GR9RF`P'3QUEHIP,7M*/4%%[.D1$0'P@(]@AK@-^'\V
M:<#C3A#J3,'4>&)U9]ECR2TL)P*$CO&/<>9O'LXE$^2))0Q0$"G5Q]EXYB]0
M#N!3&I(F(`]FX!MN(!J9>2YB\X%54UOZ%:O+%AK/\II62RT$R(T1:GS*X](]
M8IY(D2F4`04,7'>60,<3`)1.(%HI"B<0'PB`]@`'@#;6YR',T<IA2"\!8%2P
M^6(T^(\NQ6@2B-6:G?H\.0MBC[=EE63G[-'5]6HEG(R(Y'5"1D*@L[\>-5)]
MQ3XB"&QUP'9CJ`S?`X0*90^Q0ZAWZF3U'C7+:9Q+(I$/`\GV>$3!T:1;'.JG
M?#M2=M4)2NXRTF']K_*CBW58:&KE;MWN'`5V,CX6!AXW&656T?#Q,4V191D;
M'MRT42-V;!FW(FD0-^DI0^KKF=S9Y4N+.8"GQN'$5IE.8M%NZ8O.>(:!TH6B
M266A()NW+HW0\S>/IEDUQR5)=XD)NZ'X/<O;)]9`(;H`](/T[AV[AV[]H[ZP
MG(<PJ`7752<38`=(X8S_`''EVH1Y&YB\=CB<QLC2/6H42&4^#W+G6)!VZB"(
MT80Z#=(;@&P"```[@`;/[?KN?&/[CRZ_"(N+S(X\E.4X9)D^H@)D#_-_EW^U
MI'`Y$A`:.("D!@#<H;%';M`=93DF8L.)?;5-23."L^RNH0IAP`(6)6PWF,LY
M<.<.UAY3<<69Y6JU(6FT75W%)4G-;Y!2SW.8<3]DE0-*5)\JF>1EW2BW=@;N
MDS'V(4H``!FNRC-,Y>#]4HI4D63B*FS/)LL8ZO3X2F<[(<4_,KCRH0B:F1Y`
MZ:90*0@X\RWT%*7P!T!1MAV]G?MW]<=;JR7,5MADJY*;KHE_N/+]($7>6;Q\
MV*4<DR)BE("92&Q[EP4P(!Q.!2IA1RD3Z3"(@)=AW$1W[1U%_;U=SO1&?[CR
M[FQY*<Q^/"AEC'R/(CXP7I6Z<>Y<]OL("43;T@=Q((`(`.Y0$`';<-9_M^NY
M\;HS_*G/;`$M<5'F3QZ$@I&R1)F3$I"=!\>Y;,4"I]J8%(-&[LI4Q[2@!>D!
M]3L#4#WARO,L*H+S_*V[$!)G#;9>Y;\?9#$N5HYC?'*SR1QAD!DT1/C[*;?O
M7;JI2[9JEWSBD(MDN]<+$*)U#D3(`[F$`W$.GX>\.9D/$&6K"CA;K<2OS4X"
M)FVZ9BM5^(:`TBB$3MBF'N6_'R/Q!B6-?7UTD]C<7X]8O$BX]RFL5-VTJ$.W
M<IE6;TM9NN0BR8@!R&$AMMRB)1`1YJ_#OB!A;K;6RGUI\D.2GRG"4D3T$6B)
M&O$67BG;FB7)AQ?+!XY?&"\^3G+/YC:T[C\3:J3Y,;?W'EW-$'EA<<OC!>?)
MSEG\QM;#PYXB<$U]2!W2F']QY=S1YX/+"XY?&"\^3G+/YC:P?#_B1ODIZF1N
M%,/[CR[FB#RPN.7Q@O/DYRS^8VLCPWXB<Y2NI`[I3#^X\NYH\\'EA<<OC!>?
M)SEC\QM9_MCQ!KHN%,/[CR[FCSP>6%QR^,%Y\G.6/S&T_MCQ!KHN%,/[CR[F
MCSP>6#QR^,%Y\G.6?S&UJ<A\2H.%/4Y#=3#^X\NYH@'F%QS`!VR"[`0`1`38
MXRSL`[>KM1M^W?L\.X[!ZNMSX8SEQ-.XJ6+K2<6'V1:+K;HL+\0Y?RGB@;+J
MI$]$[;)ZXCWQ.Y48&KW&O#$',W=TSE8NFIM'[4M#R<]*@X+*R9A3*[84QRR<
M`!3@/4F<Q1W]?<`Z_B#P_P")1GE4&A3%O;*D52G+=W8XF4>),M1E;"5I`4&Q
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MS`4YQQS]"1=Y=NI.8PQDR+CFQJ#E!H#E^_ITNU:("Z>TM!FW!9=4I>M4Y$R[
M[F,`;CKK9!X?\3G.Z0+%,$%],\,IRGHW=4<_-?$F6KRQ]"$@J+2I#79#J5OE
M[QW1K==26O[HJB5?@TC%)CO*Y^@R42R3.43DHYDS"!RCVE$0$/5URO[9SE"J
MM39Y8JU2Q>S>;[;HZ[7B'+REMT(&RZJ!/1.0LGKW(W'E@\<OC!>?)SEG\QM1
M]Q>)M5)\F(?[CR[FB#RPN.7Q@O/DYRS^8VLC(/$BSA4*,`_HP_N/+N:(/+"X
MY?&"\^3G+/YC:R?#?B)`Q)ZD3OIA_<>7<T>>#RP>.7Q@O/DYRS^8VM>X_$VJ
MD^3#^X\NYH@\L'CE\8+SY.<L_F-IW'XFU4GR8?W'EW-$'E@\<_C`>?)SEG\Q
MM.X_$VJD^3&#XDRT7@17RP>.?Q@//DXRR/\`Z#:PYX>\0/,+0]L<,A^KE.\:
MM$6*/Q'EJZI`2E)OW=!A@<)<JL`Q=HY)KO;P[02F^0DO,QJA:'DUR5U'K8XQ
MJS(N)6M+45:'%RQ5**2Y4U2].XAL)1'O9]X=SMMRE53X"HTH_62E*>B>GX(X
MV4>(*!+%3B1+_=J]!A_?+!XY?&"\^3G+/YC:X7<?B;52?)CI?W'EW-$'EA<<
MOC!>?)SEG\QM;#P]XC<L5U,2UE,/[CR[FCSP>6%QR^,%Y\G.6?S&T/A[Q&U[
M'4S/44P_N/+N://!Y8/'+XP7GR<Y9_,;6O<?B;52?)A_<>7<T0>6#QR^,%Y\
MG.6?S&T[C\3:J3Y,/[CR[FB#RPN.7Q@O/DYRS^8VMAX=\1N":NI`C64P_N/+
MN://!Y87'+XP7GR<Y9_,;6#X?\2-\E/4R-PIA_<>7<T0P61.56`7F?.,$NWO
M+I1A!?#Y[JK^\3)J)VONMCN*9Q_0T6I9';[QERF)/V@I^ZVZE.DH@(]NCR#.
M%Y)6(J"@/K1)(1*1WI:=<4GO$-`K,:124`I0X2=P:SJA_1Y@\<_C`>?)SEG\
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M@-`R>U(X>.H5XBW04=/*2FU;%.H<-U%#$3+X3&*7<==7PWX<S1/B9I;RI'#;
M*Z[1N:HHYGGM(<M40V;3JW8[V])O8_P7Z?"'Z[Z_@UXR7^:/3V>:(I\52B:^
M<U=A/OY6LT([&-ZF&<,%#?8=Q[/4\`:NYOM5,T2'5+".KF6$R,L1EY+XY.64
MS;-16/*!)<?G+R7P[N<LW5;`M<KE@M45>K">W7>&Q]6:_CRJR%TM,U:9QG*R
M#%@R@V!R+'3%E"N5%%1,4B94]Q'M#52ARQZN6M-*XI"FT%:BM4AA$@;[-(BY
M5UM+1)0M;+C@6L(``F9D$@RGN1A4/D5B*^X];9-1MB-1JYY^4I\D7)('QS,5
MF[P<LO!35'M$5;%(U>%M<7,-5&ZC-3VYS@`IBH0Q3#`_25*U%E:U!*;<3=D_
M*-$;.*I`A"BG"M1L23(^F/=MGC'Q+UEFBSDH6K*8<A\=S]KLMGD(N&J7N7E!
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M*\[SQ,S2N.'Z<PZ!WW1NZZ$3=YTCT[[:V-&H)*R7\`TS,A!JH2DAMC9A2M"C
M:=[<C;2]OJ-?5:H6&UP,(X?"B5BC-3S"+6>&<O&\<W(T2D'391P=>1=I($*0
M#"994A`#J.4!UZL,(6%/!!,@<1OU;\;.*QN%#Z4EU*9R2923K/EG;&"ED*A+
M*S[=M>JBLM4W2+*UHI6F)55J[UP?NV[2QII/3F@G+A3VI".@2.<W8`"/9K?J
M1-YJ#/=,5^M!`&P+(;-O*-O_`$C`;Y3QG)>YR,;D>BR3J;EY2MP*+"YP+L\W
M984@J2U=B2HR1CR4Y%%#=TT1`[AN':<A=:KHUD%J=2@2GBF1?NQE#[3Z\*\"
MG@+D'1O:X:0G*C$["U5ZCW"QM,>VZY77(5'I->NTK#1;^X/<</$FLO+PBK:9
M?,@A)#ODS,!=*-7+L52)]RFONCK=O(*H-*<0]5N-(`*E!1.'%<#JC1=30H=2
MRL!+JR0D$R)E?*W_`*QZU'E+B3(0U!UC>R-LCP-IO=GQV[L5/DX=]'4^>J,?
M:GLLK<$W4NQD8V-55J3ANV50;N3.5#IK$(+0_C)=7<FJ&E85NU(4$@R*B+")
M@[Q%L9;?I'1-M.(8B+#<189VV6P\\??J'+)RZT1>JM)HU]!%S/GC;1%OR03=
MRP]U6Z\R9H\6"+1<1?\`SE,R_04[?]L*(D]MJ,4@;`2I3ZB389DSBZVX\$D,
MI:P)UVD;\75.^T:^MEWM%O=6NK-JN5LZ=U&TQ=D:MG)T2N"-W#F&>/4$%CMS
M@<"F,!A((#MMK=REV,@[MTDZR8PW5//3V6P5*^5LHC!S%`Q%>*OME?;<S,%@
M81.)@$#!:2F(`F\`"'K;#KH964(;J4A3OZI8M)OY-GZ.N*-8E+C[)<;FHK3:
M+IVVC>B9A$E!(78ZXAMX15/N/U=<EMMI2`H*?D=9,XZ6TJ!8A+6'1._RQ42B
M`["<^_LF4$?K[ZWV".<]THWDA7*6@XM,KO)!W9_445_=3A]C6-DSI6]/?,:E
M=4#)"6L.B8MENQ3H/_RBO[J?6VP1SGN$Q&:BH!D0S/>@Z3;[=ZIN/;MWJG@#
MPZB(:"L$W\7EC?:591C"6<&N#I-_RBO[JIK51I4F2G'@=]49+E6!,I9EO0=!
M_P#E%?W4^I]@CG/<)B/K%1J9X(KT'_Y17]U/J/`QSWN$QMM:KFLP=!_5.J(>
MJ'>G'?\`4W[=9*&4`J4IX`6WF!<JB""EJ1U7^3=B%^6PWYL\,O;*;^\'EH43
M=0[CO#8=$I=^T0$-]^S77R]`[@JR2_@2MJ9)M&)2I8CJ/Q=V.4^$'.V7&T34
MEM8F;0#)-A^'7$T>Z5^^6_=3ZY6Q;YSW"8ZVUJ^:SP0=TK]\M^ZGTV+?.>X3
M#:U?-9X(.Z5^_6_=3Z;%OG/<)AM:KFL\$6])_P#E%>W_`.54UHA##@*FUO$#
M=,"Y5@8BEF6]!T'_`.45_=5-;[%OG/<)C4/U*C(!F>]!T'^_6_=5-8V34IXG
MI;YC?'6<UG@@Z#_\HK^ZJ:U;0PZ)MK=(WS&"[5)$REF6]!T'_P"45_=5-;[!
ML?&>X3&G6*C4SP17H4^_5_=5-`RV;E/<)C)?J09$,SWH.A3[]7]U4T++8O4]
MPF,I>JE7)9X(`34'P'6_=5--BWSGN$QG:58^*SP17NE?OEOW4^FQ;YSW"8;6
MKYK/!!W2OWRW[J?38M\Y[A,-K5\UG@AEN1X&3X^YS$QU>KX&\I"7=0QMMJ/.
M;&`!W`1*;;PAJWEJ$)S%H)4\3B3I_.%WYVJ*.8K)I5&I0DB1]G>,YQX<:MS<
M=<!F[U81-A/%`C^V'`.H:%`";8"AL&XCN/LCK2M:0:UXK4^#M#I,KSY]>[$U
M&XHTR!2I1@"1[6\##W`4X^!1;]T4^YJMLV>>]PF+!<JQ>EF#H/\`?K?NBFL;
M-GGO<)AM:K4Q!T'^_6_=%--FSSWN$PVM5J8@Z#_?K?NBFFS9Y[W"8;6JU,0=
M!_OUOW1339L\][A,-K5:F(.@_P!^M^Z*:;-GGO<)AM:K4Q%-C?\`**_NBGW-
M9V37.>X3&0NK-H2S%BA>HH@)E1``$=@.?J,8`'M'MV,38?5]71O9A(DIZQZ4
MS.>]^CYH@JDA5(YC1])(DRNNT1$#T?Y3EX8\=BE,;8N/6I0_;#AV!)20%\`[
M=A=M=3/BRK.*A4ZDS<.N=^G=^"44LLZTG+F$LH:"-F+#*8U>:7EG$P^@_P!^
MK^HHIM^I[&N5LV><]PF.D':L"T,3@Z#_`'ZW[HIILV>>]PF,[6JU,0=!_OUO
MW1339L\][A,-K5:F(.@_WZW[HIILV>>]PF&UJM3$'0?[];]T4TV;//>X3#:U
M6IB#H/\`?K?NBFFS9Y[W"8;6JU,0=!_OUOW1339L\][A,-K5:F(.A3[]7]51
M339LBW$]PF,%VJE8&(C#S:*J'#7ED(B.WDVYNWW44\'P;63?U>S70R13"<XI
M58JD`5#9T\X1S<P75JH'DN)9*"VJ8%Y$H?.C;^\NH^V4#_R7K^^YS]74,.R'
MJW`?`._U=4WBV7GYE_":@@$SG?<-R+=$D)H6MFB2PE,IW7"^V%5L;_E%?W13
M[FM-DUSGN$Q9*ZL6E+,5Z#_?K?NBFL;-GGO<)C&UJM3$'0?[];]T4TV;//>X
M3#:U6IB#H/\`?K?NBFFS9Y[W"8;6JU,0=!_OUOW1339L\][A,-K5:F(KT*>H
M=0?^$HIMILV-*WN$QHMVKER4L3B@@<H;F.8H>H8#J#L/U_6UJM+*&U$*J#9H
M)G?H@P:A;H#R6RG\V4YRT[D1$XM=9KGS*#K4#HY93Y2E`Q@`"_!#ATW];[)O
MLZ[.;[-8I05/64HUR]HW;FKRQRLH2MHU:FD)"E5:[57'=%IB7?2?_E%?W537
M(*&!>M[A,=@.59N2S!TG_P"46[?_`)17[FL8:?GO6G68SCK.:S"-I>0J'DB%
M]\>/KS6[Q``]=QJDQ5+$QGXY&28.#M'\:Y=QCARBUD6+I,R2R"@E524*)3%`
MP;:WJF$42L-67VS*?*Q"PW'RQ$S5/5"-HQU=:)RF)$3%\+'I-_RJO;VA^VG]
M76$--.)"T*>*#<9F-E/U*2`H,@G<BX$U!\!U1_\`G3Z;)DDI"WL0OM,;;2KY
MK/!%>Z5^^6_=3ZSL6^<]PF&UJ^:SP0=TK]\M^ZGTV+?.>X3#:U?-9X(AMFLA
M@Y=<(^KO##MR8W$3G$=AQ=$[!X0]7P:M-)2EA8!=(LTSX?\`MW8I/!2ZA"GD
M`K`7:FX#"/.;HF3W9Q[2BJ4/6[PX?8`=4D(:<&(*>OUF+:5/($F4("/SKX.Z
M5^^6_=3ZWV+?.>X3&VUJ^:SP0=TK]\M^ZGTV+?.>X3#:U?-9X(.Z5^^6_=3Z
M;%OG/<)AM:OFL\$'=*_?+?NI]-BWSGN$PVM7S6>"#NE?OEOW4^FQ;YSW"8;6
MKYK/!!W2OWRW[J?38M\Y[A,-K5\UG@A@^50&+QEY!^$PAAG).Q3"8P;^]*5[
M1`P[#KIY,EE.>4X*WIXDS$S*4Q:/SHY^:EH9:X74&ZW5Y-R<.WO_`)(;ZKR_
MS1T+/-$7^)_^'O-3V>6TZ'UL-X9VUT\Y_5Y?_P`3_O5%2E_6._IF,SF)A.VY
MSA<&5ZKR-H@D*QR,I%ZM=EI-F9U*VUBI0U9O+!_-P$N[*LH#Y%_,-4A20267
M426.`$Z>HQ8<MS-O*U/..!*@ZPIL`@D$J*3:!O1IF%&JM2TE*BG`\E<P9&P&
MX^6.9EYX.\B"5/%-?>5"VY%A,/Y*Y/L9M"F6K`3G(F:(_+;II*4?D//FY&PM
MRQO*7B0CCNHJQIO"Q<J@Z=+.H\4VH^*F[%-F>7EEPKPA]024S!D`F<T\F5FD
M3)ML,>>J\JS)VK1RE=603:"+S*VTFW18!9"_F^)W(>LU>W15(Q^]GH=Y2>#=
M.(PL,S@^]Y2=53#D/DB.R4TJLCDV,##J^3JJ:PQJ3.0F8U")<H^,':DZ^[`L
M9S6E=:;:<`"4;4R$Y361*<K96<,H+RK,`MY3:E'$A`%O-G._R0PT'@?(F/'_
M`!<QC?N+L;GNWP^*?2`2"&)[';L/G&$AKWFS'CZJ2Q95PQKN)%SLH:SMD'J4
M:UCBQZ#I88]J8R96JDZJK+G:9[9K#:RILBPS,IXKKM=OPQ#24]<RMEMYLNJ2
M53NY$[C;9;N3NA_<=\5,ZXLR;Q\&)QY[YY"K8EQ5CS-N6;5,XFMM'E(NB8HL
M5?.OC5M-F;Y\IF2J_-R!(QFJP%.!F&!A7?%!4QC$H,5E.M.%U4DH5,``Z2)S
ME9;+3%ZKRRN#NT:4J2A:+"-R5Q'GG+5"&5X`Y)D\%VZ'M&(ZE(Y7C_1YX&P7
MBJ1D9.HOI&MYBH$YDJP3[&$G%'ZB%:7B920@W2<RBHW0.HF44EA[DP!=K<YH
ME5#:*=/T>V6M6Z"``FZZ^^<88RNJ-,XNH5)P)`3/?F2+Y7;_`)X:>C.*R_\`
M2#3+NZMH>9DEN6.58#'HURQXB<9<I.0)7':U-3OMDHTK53YW#'E?@8UP9)PX
MD#5UJZ.UD$&ZS,S<I%<[3KH=G3V++8F.5*P]&=NCE2CD43;Z\P2X\Z-FE:@#
M9BF;Y_'EI$^3.[3'2A7B18'?(S#5WO4[9L\P6-\-YOBXS)V8&V,I"UU+)%YM
MV*GM3-'P51JE(A^J*A:W)*-7J429=L8@%47!10@FY#=:PC+4TI`+HJDJ.L)"
M97W?#'I3EU4<R<J-H2TJD*`3SB39+SW1SDK?H\\V,<+YIH4[0LCNLJ2_'>WX
MA+8)J_\`&QIBC,$M9,@UZ>=R$2ACJJU;)KY>;/'*RA9&]NB/8U1PLW`RZC@Z
M^NN]G#'6ENTZ$E@KQ"PS%DK)W2%EFY*.73^'JPTR$NK(<"2#:-<[91)[*'`$
MYY[D[8<68-H$+*62=X=3&#9&);4R!=PCK%%HK\ADF3KJQ7#-2FR;>/B@%5<G
MB:\KW)"]2^Q0U19S1KD!TS2G&#9KNWY:O)%M&2K9?4\E9"RA,O(+;M<;>/XL
MY,@<OXJR3,X*K^2(VM\P>8%SEV2DCCI6=@\;9ZF57U#R''FM+YHS7:P3Q(KU
MY&HN2S"`J`=%LHN7I"=.:-"C?ITK*%+9:`E.U2#RKM=TSY=$1,4%0:EAY]$R
MA]TDR%B56)OG=>-(W+XU..^*65JFGB:KM\&P5.;8EY6<DL@3EQ@Y3'#*'OU&
MR=0.1#'']NBF4+()V$%8I?(L3#*,9)H@_:")N[*9FF*P9&9TH=6XM6(*8;3*
M1-J<,QYO+%KNY]=.IAOD$NK(59:%$R,1DS%Q9G^.7%Z$E&V.JC0&<=P-I6$L
MPNXV4K$7'.\T.LX80?(&N<LF9_%RC)CO8%U;#,)O8)HFNMX^H9FLJ0\]-F-#
M5UBG70$IVQ4!;8G`1(;YE8+=-\<BJIZO+:5+*7BI>&2COJF"?(;S.Z5T3D]%
M^M3BT7,C"`A(E"TH9KDI?)=KJ,MBRQ8WN-LL51K4BDZQY/8:A:]0E(J`@"LH
M]ZQ:M2J,)(BX+F454,<>3FZP\X@MS*```#.8`UXK9_!'?R-LH0O$0HJ),Q+"
M3IEALD+K+-4/OS($!4XIB'GGX*^W:M5LOL%3^S5_VQ=?!2MI)O"A\,341_M9
M/J:YK'ZE.]%PWQSXSCE[EQ3>1>,\78^+QQ-1\OI9"<UF4NT+E!S98!'&56A;
M#.A/C`65E%R2TJK(JD:`W20!%,@"H)S;@/4H:/(*ND==>#QK4JP@)E)2B2"!
M,62U\$<.MKZUBN;:92#2D'$HSLPB9NOW//&IBN>U8MZ6++Y`-;A6,5W&GYIN
M7>7C%$G&R^0J[B['+"\NK+CQ^I;&_N5#PO4NF<9%@I[KGV(V,FD!7*FZ,N=F
M60F3B%!)3,322<(!W9V7WQ:=K"T-HJQH@D'6`,4^"V-<;TFV(TV3N25QUR%0
M9LJ/7<M+JN,)V%`I<'6$JX)9U,H=\"2&.&"[90KDBQDILO0)DX]1,.\'<9)4
M+D4JGB<*`)CVQ\7?B$9TV5*3@,T(Q&RY)N5O0[3_`)MXAC,OL,0N7=A=.U+9
M7,=2=ZC:^DXQO$Y(NL.SL-2HC^Q*2:,DE/3$1(-E"&2CUF*:CU!%=R@LH4@T
MNXWRV:LJD^)V3MD#*<M4]V-T5P<=#+<C3$"T76V[_FAI+/Z0^*3PXTS1C'"&
M;\BU64R=C>AU]X2GQ\$VN$/D.YIU-&Y4Y1]8#^ZC!LN!TDFCOQ!\+]5LBY1:
M)N.^3N4645+J\%75TZ3A)M!$I"XR!M/!83$=1GJK-DRM0)`^"'KF.65<A\F4
MG$]DJ.6J3*Y(>1$!6K5,TN*:U9.VV>NNYZ'JJTHM-R"_N^B@Q<)'73CW<,$@
MW.U%V*H"F-<9?R"[M`4"^4S<=Z)5YF4.BG6V0\H@`6:?+#*R&0>9T`P!C&LI
MFYOY^@S46UE'^/(,CBF9*<7#(!H2RR*$&V@XUW7(ZBU-N"K(Y#J+2,BQ'JZ'
M/3JV6**2CB`(-EIM$A\)\QC"36XDS;,IVV"RWBCHM"N';N)CW#U,4WBL<P6>
M)F3[HR;I5HD=TF=(=N[.FX$Y1+X2B&VN%4_NZ_T#Z(ZH]KRQ#W+/\]GAE_B1
MRR_O)AO7HZ/_`.;S7]K2?YHY:?Z@-]?H$3>UPXZ<&D(L4'I3,;U@WV]?V/"'
MAUHXM+:"M9DD?"91D"9E$$+=G#D==<L98H7&NJ8@<Q&"/>S%7&8S#)6YO[][
M]9*PVN_O%I@5%#:LH1-9DF'C4Y(>.I`ZD`*FQ4(W5.;H&A9:81M24[6X"VR<
MI[]DY7QRDUKSU2I-(`Y3HGB,[C*<O7=&DQ_S_IM^9T5"(QOF&7M-KP[6LUSM
M>J%&/<6]#K4^ZM<,M'6";8OF+5Q+,K929"*21;$4=O7`)*)-A1,J=&1[P^:>
M0>4$DJD)F4[KK#H(,*;,Q6XA3HF$WFRS<MEJT1A#S>+<Y?$\9CN$F("0F.4U
M4P-E:JY+K;9C::Q&6;%5UR9'NHXU>LLW`JN)>.AF#AL\2=O6X(**)J)IK`)2
M8[G#"%.*5.314)$D$3"3H&DRB)69%2TH9M474I-PD##I9[YE8SX[ST;7;FVM
MLM)'J[Z_V1O3Z\A/!1\<QS\8Q[?;@8\M&F80"+PJ@$(T!](N"MESHM%2(*B6
M*ARAUUDANR:[YRGN#7$^8Y@B@K$,JM"T7;L)2P<X*T@EG8:+0,FY+^`BK6:<
MFYVJU=H>B2L[`U")N9:6TLSB93<HRZL+.-G`+K-$&2[<5#-EG"B0I'R<L"G$
M,K<`4XJ0F=-OFL,M=T3IK5X5XFCC""0++3PQJJGSJCK,7$\$XQ5F*`R1ES$@
MY?94]2A(RK>ETT'R4(\MMVF6=B+&157CYEXW42.=8CM^P5(=%#OCG12G5D*F
MVR\A8+0=V<Y_'YNN<N*>F*]+F3C[!VC*DU0Y129`A.N^4IV7S-\HT,-Z0N@Q
M-!H<S;4KI=72F&<6Y>R[?<;8JER4+%E8R9'@X@+?>X][8I26J$/.BW<NB1Z*
M\S)1\<@=PY#N"=^;0Y*M3_5UJD[.0$[SJ%DB?ALB-&;MNH4M(DE`FHZA$C^.
M67+/EE]R"3L*,.DTQAR&N>*JNI#MG"'CE8K];I,U'/))1P\=`[E5EK(L"BJ0
M)(G3*GTD*.^]>HH!0E`))6M`41JG.R+='4]:0742+4Y`C3$E]5XN0:0ACN2I
M#J<?LXE(&YC8:RD4/6#JH\X`#MZNQMM6LOEWBUCY+94D%6KEI^"9BAF1E2J4
MD8G`DD)UV1\]M._WB[B=A6H4_#]@PQR%E9W%U+I5#F).$C\<JQ#^3K%4AXMZ
MZC#OKXT>&8K+MQ%(54TSF*(")2CV:^BC[J?$]6XNLHBA=*ZK$E1,IC6!A,MV
M>F/`_B9DS'^VJ&'-NWR2$VR\X_Z0I/TGKAM\1')K][,5_.1K;\(O&6IKI'YD
M9_$OPVNU;+P/Z/$J#])ZX;?$1R:_>S%?SD:?A'XRU-=(_,A^)'AGW3O1/'!^
MD]<-OB(Y-?O9BOYR-/PC\9:FND?F0_$CPS[IWHGC@_2>N&WQ$<FOWLQ7\Y&G
MX1^,M372/S(?B1X9]T[T3QP?I/7#;XB.37[V8K^<C3\(_&6IKI'YD/Q(\,^Z
M=Z)XX/TGKAM\1')K][,5_.1I^$?C+4UTC\R'XD>&?=.]$\<'Z3WPV^(CDU^]
MF*_G(T_"+QEJ:Z1^9#\3_#R>2EAZ0_-]<>2O^\[\-SE$H8(Y,CU#V_\`BW%Y
M1V\`_P#:,)=MO6'M]35AG[E_':DI=&P#>T!F5CV=-D@9>>*U1]X_A=VG<&![
M;$'DV@SEP0Q_&/\`WBCBEA+`.*\467#'(65GJ+5D(.5D(.-QN>(<NTW;M<QX
M]1_D!H\4;]"Y0`5$DS;@/9ML(VLX^Z?Q<]FC[K2F7&U.$A0)`4-<L,:4'WE9
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M.RL&KI^4ZHI)**=V4>DIAV#5[+?NE\7MYBPXX64(2\@E149)`()/L:(JU_WC
M>&G*)YL,O$J;4+`1HUSAQ*[_`+S/P[AH&$B%L&<E%58N)C(]19&,QF*:JK%B
MW:JJ)]YD)(P)**)").H"B)=A$I1[`TJON8\=8W'QL5-%TD'$)E.N4B9'A$*+
M[Q?"Z*)O`AXN(2.3:3,#?E&[_2>^&WQ$<FOWKQ7\Y&JGX1>,M372/S(L_B?X
M>5R5,/2/YOK@_2>N&WQ$<FOWLQ7\Y&GX1^,M372/S(S^)'AGW3O1/'!^D]<-
MOB(Y-?O9BOYR-/PC\9:FND?F0_$CPS[IWHGC@_2>N&WQ$<FOWLQ7\Y&GX1^,
MM372/S(?B1X9]T[T3QP?I/7#;XB.37[V8K^<C3\(_&6IKI'YD/Q(\,^Z=Z)X
MX/TGKAM\1')K][,5_.1I^$?C+4UTC\R'XD>&?=.]$\<`?[SUPV#M^`GDT'_V
M7BT?L%R2&^L+^Y_QLME:D!H!*9DXI2$Q;:D1C\2O#*5I.S>2)WR.K?AC,-?[
MQ3Q0QQ8,^2LKACD.];96S7)9,A$HZ-QR91A#O:+0JNDQE1>7ULFG*D>U9PH8
MJ!ET024)LH)NH`ZN:_='XO'50E;"SU46`W6DRGA,[_/'(R?[QO#[?6=LR^G:
M5"E@&V8.D2-D/H'^\]\-P_[">30?_9F+/G(US!]T7C$WAKI'YD=@_>9X;1[#
M+Q_P\9@+_O/?#<3EZL$\F>G<0,(1F,#"`#MOL4,C%`PB'LA]74BON<\8[!50
M"P$H*9C'(F9L`FCAB,?>;X?<?2@LOI00J:I2`LLG;.VX2CY),:<PL\\?,TW?
M+O'')]PQ>O:[W:[6I%LGA%82=CK!8Y.:;QMUJ"XNZQ/@DW?E35(LBH!3@(IG
M`=C:_2>9^#,MSZBILIS=AA56FE0E2TR24'"!,FPG<E./CE'XCJ\MJE'+"\A@
MO+5A49@@F8E;PQ]/W"[_`'E2EV<L/2>;5%3QQ-B"+,,R8W9/Y7'[L_61N5U:
MZ887UEJ@*]0&.LR/)(%'<>Z2('9^??%7W*9AE;ZG\A<-2A$^0F](W3.7''V#
M)?O+8>0&\T;#9F!C)`'`+>`1].^+LKXSS33XW(&)+[4LD4F83*I&V>ESL?8(
M=R/04ZB`NXY=<B#M#K`%4%.A9(WM3E*;LU\>J*9ZD>4Q4I**A)DH$2,Q9'TV
MGJ:>K9%13+"VE"<Q=#B:AB:#2$0RS=_.[X1_4Y*_R816K+?[NY_A],0K_6I\
MOH$3++X/U=<ZF]@_I&)S\$7:L1B#2$&D(-(0:0@TA$>>5?\`-GY"?Z',E?Y)
M2^K.5?UYC?3Z1'.SS^EN?H\4.M^9^H_G1>XHC!Q/_P`/.:?^UO/?R-X9UTLY
M_5Y?_P`3_O5%6E_6._IGTQ,M7]:'_"#P>KV#V:XKBBE!*4XERL&[%].G>CF9
MR7YAYVPYD',L/CS$V/[W3<!X2H6?+\]LUYDZK8I2M6:R9!A96GTQFT@)=@K;
M`8T4SIDY?JMXXHB9-<VYR"3J4>2LNT#3]0YAJ'72G#*<I)G,D62G9*VW<CSR
MLTJT5#C3*,>!,Y3E>0+.'@CV8<P\S0-JD<>Y5QI0(2[QV=.-=!4+3+C+V&MA
M0>2AILL+*"^E*[#/CW>J+5]XW=H%2]SW:B2:B*A2*]!0RYIM.-A14,*B9V>P
M9'AG$O>U8V1MF9)*DB8(/M`G7.R7E]+)94Y,99GLDM'M"]P:W/XX?>D0H$:Q
M?R$DK4[3(83Q_0):HSMP118N%]D'[]9UXH0BR::H!L(AN)>E14"2RXIV<OH;
M1*8VBB!INLMBM7U[CQ:72I$P7<4Y@<E`._ILW;[)QIB<M\YX\K5%R;DZ`AK?
MDA/@*YS=(5ZEWZPP>,;*\?92Q/"1(.*U*P#-K$W:2CK6<Z\D"8MV!C*-6Y#M
MS=80G*Z=Y\M!9!VI3Y)$SLG,"6_$7?3[#<U(Q'!BTV6@:=T[T+ZX\E,Z/\CT
M?%N38>O8YN=%Y8<>4K$KB:X34_4[AB'+5)RU.,J]*.9>%KTN>1;/J6HVE6:J
M`M'9VJ+A#]K5Z";C)TMTR:I*IMNI<P$R!Q(*1=,D7[D;'Q`Z%8%M<F:9RML,
MR;R+1YYWRC;\->94KR<R2N\>X))4*_<,=O[S2,C,J#E6*D(^!8S45'L:7D*\
M7W%],J-BL-FA7[>29#5I26CNZ:.$A.8$DUU*&9T#K%(I:W`DA8$@03;ID"9>
M6)LDKJ>KKL&S'LDSE\)'HLAR<@<R+?CCD)/X[L]6JU9Q97*))W"-L-B/=&UV
MS`I#8_F;W.I8<<I5@<63;ZN#"K,G<&\FVL\<J2KU-`&I2&/(WE:32M/4ZL>,
M<H#XAQ2`5IM$E3E(`RT1,]G38K%TKG(6E4DS^,)7@W672)G#6V/.O(V0;<2L
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M\JM8!C4W[U8&:)2=)EPB1EE,_@4IR162!9=+2=\[\7',ZK65*0MCE)`)MU_E
MIA"YPYGY)2K_`#*JT_7HN@L,88DOMIQ]&1]KR#C_`#M<H2NM89=ODBH6-2F$
MI#NHR[68!1-Y7I*4D(!<449!$JR@D)(C*Y%*&CB2=.B=LP?6(-YXAT[-?)J!
M\6V<C*1G*4CN&<2,QOR(N=ZY(7CC_?J93*;48Z*D"4]A:7MO1R1E6&9Q,`\6
MOU<1DJDWQI<Z#(DDW#9TWC9=U+QQD2&?MTP4,!-7J13#.W224F=HE($&4KY@
MQ<;JT/U!I'4`N#T$3GJEY8FY#UV'@&2$=!13"'C6@*^*1\6T;1[!OWRAU%Q1
M9-$T&Z(K*J&,82D`3&,(CX1UR2\^OE`6;L=%MM+3G)`"(B-S(#I/Q3`?4YGX
M*_\`2GUM7<M*BBH*O:V:_P#MB&K,WFS^</AB:J/]K)]35!C]2G>BT;X8/(.%
MSWG+.),HJ33ABOB)KE%M'1"+)LLWFPRC7(^LO#O'2JZ:C085"/!=("%/WQCB
M!M@`-6:>J72M20W-9>!-HN"B0?+.W3%6IIPXF:?:M\XD88![P6C7V.<$X\^$
M2<3;X,PEE?"T?+'@XLSJQ,,KXT;XV=SL@V*\*FP>P35N#M)!(YDEU?:'$I0`
MP]/OIYBJ<JDMA:W'@X0)7I7C`MT3LWHYSF4;=(2XL@!*D^10EKU&-G,\,FTO
M#6R"&[2Z#>U\.(7A\L[+%QJCEG"PJ=B3)>TR'="BXG'9;$<#LS`5L44BCUB`
MB`:(S>H*FWRG"YUE3JA.XDG5HEJG&4Y8$NO\U3`0DZY"6N_?X81,5P`A8#/:
M^;X>5I8FF+!5[E98JQ8,Q5;[F:X5BGPM1"4I.8;`V<7.@1TJC6V+I9JBFZ.@
M[*J=HLV!8Q0W7F.)O!;.W20+3.T"P^7@B*CR78I.-<B=$I^2>CR1IF/H^9IO
M`9C(OF4S:\95LV*;NSL%/Q+2:/3ZU=</7<M^KMRD<80LL%;MMNL<X!4[#('5
M9K2S-%)(`0%,IM!F@`2D-B021>29$2O-PU;ML3'+C.<A.<[A+@NBU_Z._P!U
MN1L/R*E\E-I&?C,ET?+3I%QB>BN;0_MU1I36E.X6/RF]=N[Q6,4S""*KTE99
MG*W9/7"A@653,9,<*S0]3V*425@*;SI,[1<3NSB-G)L==UBH7R<4[AHWK0-R
M4HZ7E8-R[""8[AT__&'\)0V`?UWA`O9]0=<7&^;"+/)'=LC(!(B8'Z`$.H`W
M#<1#VI=@V`?!V:UJ?W=?Z!]$!>(A/EG^>SPR_P`2.67]Y,-Z]'1__-YK^UI/
M\T<M/]0&^OT")O:X<=.#2$6*$!0AB"(@!@VW*(E-Z_88-A`=:.(#B2@W&,I.
M$SB$]XXMY%/E"_Y$PAG^=PHGF)G74LJP:5`J-^:R,M6((*K'7"E.K"Z9*TJY
M*UE-!HX<*$E&*WB;946?>)J&5Z(JQLT!P8RV;!Y9QQ>Y@W4+J*=TIV@DI,MR
M4[;O)Q0E?(*J;&CY%QU6K9::S6;[QJH'&EN+%1NK,5VOT%W?WS6T!+JN`6FI
MZ;=7M4TFDJ1-!V!#@(CWQP+:[[>?>0[4-_JUJ4)FPSE99.Z0E$3&2=30XFG<
M/T@D>/?A'8?]';&XLE(J8]^T0L]9\@:-R!68T;$5%Q-30EJ/B6P8C;UJ(IE1
M=#'0,7*1D]X\X<`+EX=XF83G."NQ(ZC-WGP6<)#>S*9E4[U8M-M_`+(WH<C:
M9FX\Y]*%A0LE[-UUGKM,+?DGP;@\\Y.KV76TE2XVWQE(#',T3(>#<8YU@9>J
MH3KBQQZD+#Y#*5.H6F*DGSLJ+]NHHBLBZ$CELOW:0IPL5BDT^P42GEXIS-DM
MZ^?FC>HRPN50JL6)0&&T`V'2,5QW1;'F^X1FL&9;'E:RW\#1TSCBZXM95FI8
MZIU$GCU6ZU9I4U8J^W^OK@\R7"51@V,K`,WS!$(MP<INM3H#>1-<`4(4FQ#@
M7.9-HG9(W3B*HR5?6A5-/$\@IPRE(*O,[)RT0J,4<4[%09"NS-FR<O?9VL<=
M''&]M)J4^*JJ$G6&]E;S4%-R$=&S$BF68C8QFBR5!,Q$G9P4<;)=X"9-%9F^
M4[/"-GUG:2\AXXG&4AMM:DN$O*;P72L&]IW89I/T=+V(J"6/*CGBX5N@VO"F
M*,%YSKZ-1K+Y]E*L8GKRE2CI2O3[Q\#O%T_8JJY5CI%9J1^0[;NS(D1<)@N-
MQWQ`^NH2Z605M.%:5`Z52L-MH$IB<5&,@0W3*:VAQ.)PJLT`S_+UQ,O"6%VN
M&5LJA'RCB19Y/RK/955:KMD&Y(%W.P56@/>^Q.BNL9Y'Q[6K)F(LH!%3F5,`
ME`"AOSJJN<KE)6\G"M*`G1:!O;\=&@H$Y>@M-JFT3,#5N#<A]=58Z$&D(9/D
MB82<?LXG`-^C#N3S#MX>DM(FS"`>#P].K%"H)KVR;2%),M?*$4<R;4[1K0BP
MD$3U3!CYWJ9_NYO%K-=1J&7Y_-O(&)G,HTREWV7C89WCKW(825HJL1*.V,8#
MZDN7H,6JS@2)]\H=02@'481[=?7:?[[?%67)50T*&&V&CA`PSWK9\4>`9^Z_
M*1-]3ZRXZ<2IB=NYN0J/T7SB+\?W)3^Z\7_F%JQ^/7C;_0Z,3?AGE'O5='UP
M?HOG$7X_N2G]UXO_`#"T_'KQM_H=&'X9Y1[U71]<'Z+YQ%^/[DI_=>+_`,PM
M/QZ\;?Z'1A^&>4>]5T?7!^B^<1?C^Y*?W7B_\PM/QZ\;?Z'1A^&>4>]5T?7!
M^B^<1?C^Y*?W7B_\PM/QZ\;?Z'1A^&>4>]5T?7!^B^<1?C^Y*?W7B_\`,+3\
M>O&W^AT8?AGE'O5='UP?HOG$7X_N2G]UXO\`S"T_'KQM_H=&'X9Y1[U71]<>
M*_\`NP7$4B8]WGSDGWA1#JZGF+Q`2;^V`H>\(`(80_KAWV\.PZYCWWV>+'*U
M"W$-E*U2)'LSW1,'@$5ZS[LLG%.7&W%8TBVR&1XS?[NEQ;SA@7%V6)[-O(&)
MFKU6$IR2C89UCHL4T<J/';<R3$KZDNG96X$0#8%%5#;B([^H'H,Q^^_QC05S
MM$R&4M-+*0"F9`&[IC6B^[?*7J5MTNJFI(-T/I^B^<1?C^Y*?W7B_P#,+5+\
M>O&W^AT8M?AGE'O5='UP?HOG$7X_N2G]UXO_`#"T_'KQM_H=&'X9Y1[U71]<
M'Z+YQ%^/[DI_=>+_`,PM/QZ\;?Z'1A^&>4>]5T?7!^B^<1?C^Y*?W7B_\PM/
MQZ\;?Z'1A^&>4>]5T?7!^B^<1?C^Y*?W7B_\PM/QZ\;?Z'1A^&>4>]5T?7!^
MB^<1?C^Y*?W7B_\`,+3\>O&W^AT8?AGE'O5='UP?HOG$7X_N2G]UXO\`S"T_
M'KQM_H=&'X9Y1[U71]<'Z+YQ%^/[DI_=>+_S"T_'KQM_H=&'X9Y1[U71]<-#
MR!_W<+BMA_!&:<L0V<>0DG,8RQ1D'($3&RSK'(Q<A)4^J2L^Q920,J0W>"P=
M.8\J:W=*)J=V8>DP&V'5JB^_'QE65C5(Z&%-.N)20$R)"B`0#H,05/W:9.FG
M6HNJD$GXNY#A5G_=DN)4S7X:4>9ZY&D<R41&2"@-GF-01(H^CVSM0A"J4(QA
M3(HJ(%W'<2[;]O;K@C[[?%+.8NAM"`EMPI!-TQHE,GS2C-)]V&4)8"PXJ2DZ
MM<;L/]U]XB#X,_<E/[KQA^86NI^/7C;_`$.C$WX9Y1[U71]<5_1?.(OQ_<E/
M[KQ?^86GX]>-O]#HP_#/*/>JZ/K@_1?.(OQ_<E/[KQ?^86GX]>-O]#HP_#/*
M/>JZ/K@_1?.(OQ_<E/[KQ?\`F%I^/7C;_0Z,/PSRCWJNCZX/T7SB+\?W)3^Z
M\7_F%I^/7C;_`$.C#\,\H]ZKH^N#]%\XB_']R4_NO%_YA:?CUXV_T.C#\,\H
M]ZKH^N*#_NOW$,G:.?.29O8\<QB&_P"J%"$=4\P^_CQDY1N-N-M.)4)22`#>
M+9D@1HO[L,H7).V4"3S?7#'8>_W=#BUDFQYZB)'-W(%DTQ3F9_C2%4CW..P7
M?QK*CT6T^.RIG5)6*I)"[M:J1A1!)'NDB;$`W4(].H^_#Q33IIBPTRV]U8`D
MB<QB.Z=0\^B45J7[N,E=4X&WB0A92;#81>#/X)B'R_1?.(OQ_<E/[KQ?^86H
M/QZ\;?Z'1BY^&>4>]5T?7%OZ,!Q"*8H&S]R5V$P`80=XO#8-_!O[P3#V_4'5
M:K^_;Q?4-"G?;9<;4M-PE*1O-HLWIF*U3]UN3.I!+ZTD&R2=?Y;D?(]0.)V;
MLZ9MNN&>.V-;KE:3K%ZL]4!U$QR1H^)CX2PR,,VE+C8UA8UFME619=9U';EL
MEOOT@/80?OF9>*<@H6Z7.<[4,;E,@X4JN.$$BR9-]D?(T9%4OYBO+V6UJ;"I
M!4M&NV/IVX7?[M1`Q!8>[<V[V-NE0[E^3#6*Y-U&5-FH8"JE9W'(`^*3T\*>
M_0HE$HL41#J*#A0AA$?B?BG[ZZNH+M+X/;ZLT;%E=I5S2)W2$[X^FY+]U&5-
M/)J<Y*W9R(`58-^W\M<?4%B'#>+<$4QACO#V.Z?C&DQ6PL:S28%A`1)53)D(
ML\718ID,^DG()@*SIP*CE<P;J',/;KX<[45U6\JIS!W:U"S,G5'U>FIJ2C:%
M-1-;)A%@NMW;R>&V'0UI%B#2$0RS=_.[X1_4Y*_R816K+?[NY_A],0K_`%J?
M+Z!$RR^#]77.IO8/Z1B<_!%VK$8@TA!I"#2$&D(-(1'GE7_-GY"?Z',E?Y)2
M^K.5?UYC?3Z1'.SS^EN?H\4.M^9^H_G1>XHB/Q?LE=B<B<U&TK/0T8X'EC,J
ME0D)1BS5%-3#F'"E5*FX<)G%,QDS!U;;=0"'A`==C-Z=Y;&7K0DE/5-%OQU1
MS:.KIU/5"<0!;=D9V2-\IF^)>FN]+$-@M]6'M_C!$_C>N1U9_F+Z)XHO]:IA
M_P"Q'2''#-V['''*]O,D/[7[T99WES'\/BW(2Q[HHU]\5$@'=C?1,"H1E.MR
M,2-'5MD#@NV!%R;Q@0,H8"D`NY5F24I0AM>%))%ET_)%<#+PLN!QO&H2/*%T
M:B\X<XP9("\&MR=8D'61/@[/9Y-ED&1@YDSS$KM\_P`;R\%-05EC96ISM/?2
M*RS-_%K,WA%3=0J&$`VPVK,D&>S6+]&N_1IC+G4'4X7'&Y3'QAH$AP1H*9QQ
MX@X_)%$JT)4698>2RA+M!?Y!E9Y1>3S2PC8S*3Z55GK3)JSCFZ-(AOXX=Z9<
MPJ%,H42J**&-LJIS9"2EM"Y*PST>R9IT:#:(CV66BP.-RMTC2)'A$,[E#AOQ
MPF\'V/$N,Y>MU=_(8FF<*5J>M>2[-?$JWCJ?N-;NDI3P3M%REGJ]:,^K*"35
MJ"H%CT"%0;=RW`4]3T3]<W6!]]M>`!1NG,D$?";8C5298L$)4DS$KQK!^"'C
MJG'?B334VON*S@3/&N2:]ELDS/93L=MLBM[J$*[KE2DG]HM5PF;#*1]6K[]5
ME'1SARK&LVIN[20(4`#5;;9LM*6G&U[)&(`;BC,RLTRMC9%/ES22$K0F9!M(
MO%U^J<;3%V$.,6&)J3FL<NF,":1;O6C>$5R[:IJF5UE)2HS<@QI-%GKG)TZB
M,GDH;O3I0[%DG_6``$]KJ5\UE2G`XE93*_#;Y;)F,4C=!2+4ZVML+-W*''%9
MO"G&*QY/2R[8%XR<MZ!Q<-F\OE>QR5(:21JT]IRDXQQB\N"N.&5A5JTDX8G?
MI11'AT%S@901,(ZW:<KFVBVE"PG]&_RRNB*HR[*ZQ_K2W$[7<-GF,)JC\9.'
MF.SP1ZLQ@6_O5M$=;JJ26RQ:;*WK$C#0-HJ\+'5QI9;I+M8.IPT#=)1LTA&I
M$H=N1X<2-BF`HEB2[F0!!;<$]7_2-^KT24[,K04WVD>@FZ/"!XN</*W!SU4C
M4&'O1L(0:2M0DLTW>9J<"RK=N87N%BJ/69B^/H3'\*QM44V=%9PB#!L;Q=-(
MQ!1(5,-E*K7.4MM>+]'U1$U2Y>PJ32V]F?SAYK84&2<`<2\M7I'(U\CZS-6@
M64#&S!VV29N"@;G&U:45F:Q'9'J$!;(NIY+85V37.JR1GF4BFV$YBI@4@B76
M$"K0F02L`?FFSS1=<3ESJL;CC>+](<<:F9XS<1+)+Y!FK(W8V)WDVOVRJV9"
MP9ENDU$M8"^.(]Y=(VFP4G>G4+CM&TNHIL=Z,`WC3KBB7J';??;:UZ+$)7(;
MGJB$4V4I7M0MO'^D..%;`8@XUUK*CK,\<^8JY"6+-E9R,WENT62%KQK.FQ1L
MBU.IMAN,G3J6ZGT8Y$CQ6*8,U%R%$IC"4Q@'0JKW$;-2%[/>XA%A(HDN;=*D
M[37,;VN'Z+>*4```W"K?E!$_C>HA3/BP-KE^B>*)C4T\[5H!_2''$,>8ENJC
ME;BSXO9ZZOW7,K!SA7NIR*4%-NB%I%5<X%=CTHI@(=1A[`WU:RVFJ<%3]$Y(
M-J^*?S=R*E354H<:FZT#B'QAN[L3,2N]+!,@&M]7`>D.P;!$;]O:'@>"'@U0
M8IZC8I^C7=S3Q1<54TT_UB.D(O\`?Q2OXX5;\H(G\;U+U>H]VOHGBC7K--[Q
M'2''![^*5_'"K?E!$_C>G5ZCW:^B>*'6:;WB.D..#W\4K^.%6_*")_&].KU'
MNU]$\4.LTWO$=(<<'OXI7\<*M^4$3^-Z=7J/=KZ)XH=9IO>(Z0XX/?Q2OXX5
M;\H(G\;TZO4>[7T3Q0ZS3>\1TAQP>_BE?QPJWY01/XWIU>H]VOHGBAUFF]XC
MI#C@]_%*_CA5OR@B?QO3J]1[M?1/%#K--[Q'2''%!O%*$!`+A5MQ`0#_`,H(
MG\;U$_2U*V5H2VO$4D7'5&154P,RXB7Z0XXA7EFV54>:O#58MFKQD4:-RO,N
MN6;BQ10!2%PZ5,%E`=="9E1(;I`1W-TCMX!UVZ-+G]OYBU@<QNNTV'DFW`KE
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M(F0H.]S'.8P``>J(ZEHJ:I.9-2:<-H^*><-R(:JJI13*)=;`W5#4=V/+C5<:
M@AQXP,DXM5:052PMBE)1-6>BB*)JIT.`*HF<@O-RG3-V"`]H#J-ZGJ.N/_1K
M_6'XIXHD:J:;8HDXV>2/C#CA[O?Q2OXX5;\H(G\;UCJ]1[M?1/%&W6:;WB.D
M..#W\4K^.%6_*")_&].KU'NU]$\4.LTWO$=(<<'OXI7\<*M^4$3^-Z=7J/=K
MZ)XH=9IO>(Z0XX/?Q2OXX5;\H(G\;TZO4>[7T3Q0ZS3>\1TAQP>_BE?QPJWY
M01/XWIU>H]VOHGBAUFF]XCI#C@]_%*_CA5OR@B?QO3J]1[M?1/%#K--[Q'2'
M'![^*5_'"K?E!$_C>G5ZCW:^B>*'6:;WB.D..,9>Z4T2G$+=5]A*.P^^")`!
M_P#[OV-1J9?)1)M=CHGR3NQ#4OTYI'/I&[C\82NUSE$1^`5NJ;/AOQ[1=VBN
MM5B4!N4Z+B;C4%2&]TY+L.DJY*<@AMX!`!#7<\0,OKSJI4&UR+I^*>**^65-
M,,O9&T;_`%8^,..)@^_BE?QPJWY01/XWKC]7J/=KZ)XHO=9IO>(Z0XX/?Q2O
MXX5;\H(G\;TZO4>[7T3Q0ZS3>\1TAQP>_BE?QPJWY01/XWIU>H]VOHGBAUFF
M]XCI#C@]_%*_CA5OR@B?QO3J]1[M?1/%#K--[Q'2''![^*5_'"K?E!$_C>G5
MZCW:^B>*'6:;WB.D..#W\4K^.%6_*")_&].KU'NU]$\4.LTWO$=(<<'OXI7\
M<*M^4$3^-Z=7J/=KZ)XH=9IO>(Z0XX/?Q2OXX5;\H(G\;TZO4>[7T3Q0ZS3>
M\1TAQQ&'FS<*BYX<<KT6]JK;A9;C?FQ))%&=BU%55#XXL92)IID="<ZAS"``
M`!N(CL';KI9,P^,WI3LU_O#?Q3SAN14S"KI4T+Q4ZV!LU?&&H[L/;0[I30IE
M2ZK;6`VK-?`0-/Q)3>UB&93;@+O<.D0$/U-<1RGJ%U3ZDMN2-43[)NBS3U%.
MFF;;4XWCV8,L0ND/RG="Q"[TD/!;ZM^4$3^-ZL]7J/=KZ)XHVZS3>\1TAQP>
M_BE?QPJWY01/XWIU>H]VOHGBAUFF]XCI#C@]_%*_CA5OR@B?QO3J]1[M?1/%
M#K--[Q'2''![^*5_'"K?E!$_C>G5ZCW:^B>*'6:;WB.D..#W\4K^.%6_*")_
M&].KU'NU]$\4.LTWO$=(<<'OXI7\<*M^4$3^-Z=7J/=KZ)XH=9IO>(Z0XXL/
M=Z68`VM]7$=_`%@B=_`/_P#-ZB?IZC8J&S7/]$ZQ`5%.7$R<1?SAJ.[$1.+5
MOJ;:Z\R/&;/76X+\KIYP@*TW&)@N@?$6'2%62$[H.\2%1(Y=P[.HHAZFNIF-
M/43IOHW/W4?%/.,<C*'Z<&J5M&R#5KN4-,MV)?>_BE?QPJWY01/XWJAU>H]V
MOHGBCK]9IO>(Z0XX\E+K2QV$MOJ^^^_^$,3X=P'_`.E^QJ"II:U3)2RVO:3&
M@Z##;4RR#C09;HXX;N@U[`>*X0U9QJSQ;0:\>0>RSB(J2U8@6+V6DG*KN0E9
M%&/50]TI-\Z5,HLX<=XLJ<PB8PB.IJMO-JUX././E"4``'$=\6W"ZZ(P]1-F
M24-"9OF@0XY+O2R^&WU;U-O_`"@B?4__`*O4;5)4HF"VO@-L2=:IO>(Z0LB[
MW\4K^.%6_*")_&]2]7J/=KZ)XH=9IO>(Z0XX/?Q2OXX5;\H(G\;TZO4>[7T3
MQ0ZS3>\1TAQP>_BE?QPJWY01/XWIU>H]VOHGBAUFF]XCI#CB'.:K?4UN6W"A
M=*SUY5!`.2??KIS4:=%#KQC%%)WZI7(D2ZQ[`ZA#?5ANGJ`PY]&Y\7XIU[T0
M+JZ0/)!=;!D?C#<W8F*%WI90V&WU<!\/;8(G\;U18I:E*2"VN>(Z#%@U--[Q
M'2''%??Q2OXX5;\H(G\;U-U>H]VOHGBC'6:;WB.D..#W\4K^.%6_*")_&].K
MU'NU]$\4.LTWO$=(<<'OXI7\<*M^4$3^-Z=7J/=KZ)XH=9IO>(Z0XX/?Q2OX
MX5;\H(G\;TZO4>[7T3Q0ZS3>\1TAQP>_BE?QPJWY01/XWIU>H]VOHGBAUFF]
MXCI#C@]_%*_CA5OR@B?QO3J]1[M?1/%#K--[Q'2''#`\I+?4G'&W/R#>TUM=
M=QA_(Z2"*4[%**K*J526*FDDF5V)E%#F$`*4`$1$=@#5G*::I.>L$-N2FGXI
MUB.?G-32KRUQ*76YX><-S=A^-A]8?\$-O`/A];ZNJGSHZO%'.?#?&?CEEC*O
M-*T94P5B?(EB)RIE(LDY<:%7+)+A'-\08@<H,@>R;!PZ\40<.%%"I]724YS&
M`-Q$==;,,RS"C1E[-,Z6U+8(3(F7M*.BZ<K=X1PZ?+Z9Q=7UI"5M*>"I3E<)
M3],+FK<?O1C7FT66CTG$'#>WW2F**(VRI5BJ8HG;+6U4E2H+)34)&).I&..B
MN8"*`JF7NU!`IMC"`#5<SCQ"TG$NI7(&5F,V\,;MY3DCJ<2*=!3/G>N')+P:
MX1F$H!Q.X][F'I*4</TT#&'MWV+[C]0@&WK:B3GV?+,A4N#?QCX8W[ERC13H
M/^+UQ4W!GA*43%'B9Q\ZBF`HE##U,$=Q+U?]$;;=';OX-OJ#J49QGY,NM*X5
M<<:*RC)D>U3"W=]<(Q#C'Z.IQ8+)5$^/G&$MBJ#VL1MDB5L6TEJZB9&Z-#/J
MFP6\9B$4UGD^T3,=LDB90Z@`/9N`AK96:^)$`$U#A"KI8C=?IC4Y;D0$RP@;
MZI1DUWB?Z/JX.+4SK/&KCE+N:/:'%,MJ3/#U2ZH*U-(R-F',&_%6"3`KY&,E
MVJP@43%Z%R;"(CMIWMXA21.I5;=:KCB9K*\KD=@V&]=I,_/HA4%X,\).@Y_)
M/X^"4@['$^(*4'3N&Y=P]R0$`,'L?6'?;0YUGX,NLK'3XXV5E&6+(#K8<.B9
ME+SQZ*\&.%!#D3/Q,X^&.<#"4I<0TLX])=NHW_U3X`UA6=9\@`FJ49F5A4?A
MNW8U5DF4)25FF3)(G8JWR#3"7IO$GT?F1*Y%V^D<;.-ECK,R+TL9-1>)J4JQ
M>C'2+R(?=RH>'(81;2<<N@;L[%$Q#V=2KS7Q$TM3;E0H+3>"5>:V-:7+\K?I
MTU%(C`PJT7VZ)WQEV#AYP'J<#,6>S<9>-L+7*]%2LY.SDIBBD-(R(B(1JL]E
MI"0=*Q)4FS5@T;'44,80`I2ZC;SKQ`ZYLD5#F/\`Q\<9=RK*0WMGVT.`&4\4
MI;DIQJZ1Q4]'SD>I0=[I/&/CS.U2R,2R4)+IX4K3$K]D<YTRKE9RE>8R#<#'
M3$`!9%,WJ[;"`ZV.;^(0O9JJ5A>Z5<<81DV3.#$BG24G3B]<*HG!_A$81Z>)
MG'X!*<I.W#M.+N<VW24-X</#N&P]@#OV"(:V.:^(1?5*X5<<;*R3*$&1IDS_
M`$O7'B]X7<%HT$AD>+W'!@"[MI'H"]Q51VP.)!^H5)C'M^^BR>,/GJIP*BB3
MJ45-V%`1`=:)SCQ"M9;34K*DB9]N7#.(UY5DJ`"NG0`3+VAQQH:_Q.]'Y;GM
MFCZWQKXY3#ZF65Q3;4U98AIZBL%:&D;&3#B%?`:$+T/48N8:KB!>HH)K%[=^
MS16<Y^V`5U*I*NM7QQ;;R>A/):"4`?%G=IUPIPX-<)!#LXG<?#[")>S$%+$Q
MCAON4H>Y`=0[AMV=F_JZ=\9_VI7"KCB$Y/E*SB6TA:N=BE/SQ%;E7PVXCUX>
M-'N!QEP7#EG>6^%J_,>YV+Z@S"4@Y`UE%_#R!$HHH.XQZ9`@JH'ZDE>@.H!V
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M$HJ8=PL/B@\,O),2Q0(/5HD9!<6YU"F%`5U!)TB8PCU*3,\].1U:A4JV++K1
M(F;"M1PRMG,V3(B@[DV4+SAMY-,,8;6@F>X+);T[8EOY!?"SS3.._P`DE*_@
MC7,[ZS[M2N%7'%_N3*.S#A]<'D%\+/-,X[_))2OX(T[ZS[M2N%7'#N3*.S#A
M]<'D%\+/-,X[_))2OX(T[ZS[M2N%7'#N3*.S#A]<4\@SA7OMY)G'??\`T24K
M[?N1IWUG_:E<*N.,=R93V4</KBOD%\+/-,X[_))2OX(T[ZS[M2N%7'&>Y,H[
M,.'UP>07PL\TSCO\DE*_@C3OK/NU*X5<<.Y,H[,.'UP>07PL\TSCO\DE*_@C
M3OK/NU*X5<<.Y,H[,.'UP>07PL\TSCO\DE*_@C3OK/NU*X5<<.Y,H[,.'UQ0
M>!G"P/#Q,X[_`"24K^"-:JSW/$":JI4O\7'#N3*.S#A]<4#@;PK'P<3.._R2
M4K^"-83GV>+L35+^5QQCN7*.S#A]<7>07PL\TSCO\DE*_@C6_?6?=J5PJXXS
MW)E'9AP^N#R"^%GFF<=_DDI7\$:=]9]VI7"KCAW)E'9AP^N#R"^%GFF<=_DD
MI7\$:=]9]VI7"KCAW)E'9AP^N&DS[PAX=0>#,S2\7Q9P#'2D9B?(\A&R#'%=
M-;/&+]G3)IPS>-7"4251!RU<)E.F<H@8AR@("`@`ZLY?G>>#,FB:I0((YW.&
MLW:QIBM69-DR:96*E!$M>YOQX\>^$/#J;P+@^6E>+6`9*4E,.XOD)&0>XJIK
MEX^?/*/!KNGCQPK$BHX=.5U#'44,(G.<1,81$1'451G6>==?**I4MH></0>#
M4+(E9R7*-@B5,)81IU@;L/#Y!?"SS3.._P`DE*_@C4??6?=J5PJXXD[DRCLP
MX?7!Y!?"SS3.._R24K^"-.^L^[4KA5QP[DRCLPX?7!Y!?"SS3.._R24K^"-.
M^L^[4KA5QP[DRCLPX?7!Y!?"SS3.._R24K^"-.^L^[4KA5QP[DRCLPX?7!Y!
M?"SS3.._R24K^"-.^L^[4KA5QP[DRCLPX?7!Y!?"SS3.._R24K^"-.^L^[4K
MA5QP[DRCLPX?7!Y!?"SS3.._R24K^"-.^L^[4KA5QP[DRCLPX?7%BG!'A84A
MR&XG<>1)T]I0Q)2NW80,`;^Y'J&`!#UMM:ISC.0$XZE>,O`Z9<$_:LOC2HR?
M)Q1K"J9)1(V3B*W!WA=Q'MG$K`]ALG&3!-@GI6C(.I.9F,7U"0E)!R:2D0,X
M?/G,6HY=KF```3J&,80``WV`-=G/LXSY.<U*>M*F'3.U7FD8JY=DN3FA9(IA
M+9C3ZXE9Y!?"SS3.._R24K^"-<COK/NU*X5<<7>Y,H[,.'UP>07PL\TSCO\`
M))2OX(T[ZS[M2N%7'#N3*.S#A]<'D%\+/-,X[_))2OX(T[ZS[M2N%7'#N3*.
MS#A]<'D%\+/-,X[_`"24K^"-.^L^[4KA5QP[DRCLPX?7!Y!?"SS3.._R24K^
M"-.^L^[4KA5QP[DRCLPX?7!Y!?"SS3.._P`DE*_@C3OK/NU*X5<<.Y,H[,.'
MUP>07PL\TSCO\DE*_@C3OK/NU*X5<<.Y,H[,.'UP>07PL\TSCO\`))2OX(T[
MZS[M2N%7'#N3*.S#A]<1RYA<)^(-;XF<GK!`\7\"PL[!<?LP3$++Q>+:<RDH
MJ5C:!/O(^1CWJ$41=H]9.T2*)*$$#D.4!`0$-=/),ZS_`+XI?]TK]>C2KG#=
MBAFF192O+GT"E29M*^-N;\//3^#/#)[4ZNY<\5./CAPO6X%199;$U+4.J<\.
MR$YU!-$]1U3FW$3#VB/:.XCOKDKSK.$U%0DU*L76E73`G/3(_P#2+S&3926F
MW13)EL`F<[92]GUPI0X&<*Q\'$SCO\DE*#__`%&M^^L^[4KA5QP[DRCLHX?7
M%?(+X6>:9QW^22E?P1IWUGW:E<*N.,]R91V8</K@\@OA9YIG'?Y)*5_!&G?6
M?=J5PJXX=R91V8</K@\@OA9YIG'?Y)*5_!&G?6?=J5PJXX=R91V8</K@\@OA
M9YIG'?Y)*5_!&G?6?=J5PJXX=R91V8</K@\@OA9YIG'?Y)*5_!&G?6?=J5PJ
MXX=R91V8</KB@\#N%A?^Z;QW#?P#\$=*$/U0]R.W4;V<YV6E8ZI1$M:M>_&S
M>390EQ/^V`,[Y[AB+/&WA=Q'GK=RT;2_&3!,JA7N3\Y!P:$AC"H.DH>%2Q7B
M9^G%1A%8LQ&,<F^?KK%13`J8*+',`;F'78S7.\[)I2FJ7/JHOG/VCI!$_P#I
MJCCY3DV3_P"Z0FF$A5+TZM,2G\@OA9YIG'?Y)*5_!&N7WUGW:E<*N..MW)E'
M9AP^N+#\#N%90[>)W'DNX_UN(Z2._J=O_BCUQUJK/,];25JJE81NJXXW;R?+
M@K`RT&U'=G.7ECP0X+\)5Q,4G%#CT82B._7B*E%#L,)1$HC$`!@Z@\.ME9UG
MZ7"V:E04`#>K3=(SMC493EKZ`X6P\F9%\I$7Z8R`X&\*S;[<3./'9Z^(Z4'U
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M%4J6^KCBR<ERF?[L.'UP>07PL\TSCO\`))2OX(T[ZS[M2N%7'#N3*.S#A]<'
MD%\+/-,X[_))2OX(T[ZS[M2N%7'#N3*.S#A]<'D%\+/-,X[_`"24K^"-.^L^
M[4KA5QP[DRCLPX?7!Y!?"SS3.._R24K^"-.^L^[4KA5QP[DRCLPX?7!Y!?"S
MS3.._P`DE*_@C3OK/NU*X5<<.Y,H[,.'UP>07PL\TSCO\DE*_@C3OK/NU*X5
M<<.Y,H[,.'UPRG)'A/P]KW'S.,Y"<7<"Q,S#XGO\C%2D=BRG-)"-DF-8DG#-
M\R=HQ15VSEJY2*=,Y#`8IB@(#J]E&=9R,]8/6E8IIUSO`OG:):(Y^:Y)DZ,O
M<4NE3AE._P!<3W[P_P!^;_!+O/"/Z_[_`/X7LZXUORH]+9YHA%B!A/2K;TA\
M55'@1UKE.0N0XVK2!EC-R,+(_P"/F*6T$\.X(8IVY6THHD?O`$!)MOV;;ZZU
M>E*:C*G7;6DL3.]C(/FG'.2V'$5*53EB-U^F(B15UB6G"F,QC@3#F7\=\EL-
MX2KM:MON7@:Q1%^Q>DVG*9&9[8U*_P`Y5T*]9,@VV%;S,I$GAW\FI.O6Y'I>
M\4[L1W,UUSC[A0:1:R0"93G[,QN61RV0SU,-L!T+!MY,B")SX;X9'(]]N]:A
M9R'P@_Y-7CCK=,ZX=@,9URZ3?)J*R#=5H_$V2[+F^MUJ?&)E.7"-""9B8)TN
MYCF;LK241<D#NXWQD2WZ.G8J6G2\$)?0RHB1$IX@`3H%A-YWK8IUKRJ-*2VI
MR2E2$P1.R<A_TA74&A63(]`Q[7H3./)2UURE<->2D]*6:NWC.M*DWW).NY9C
M&\=`VY>S/6^13W;&DV+QBRA9A5%=PFR,5=HJW$Z&J2A3,-);=`ZSMD[V`I$[
M9ZXLTB:ZI25R.!+9),[U6RE9O61J<J0-SRE"/;9FMAG%S7ZAD?T;F3+$%4^%
MN!?0\6]QU'!FVR0-?QJJPG>\A9J4.O*IQ+=9S&.B"L!$ED^HMI#Z:5*4T^S4
MI>U29D78N0;=RZZ8CG5Z$5BDI<#J7&E-D809&:3CN-O*`GJAUKS><]8>4RCG
M*DQF9+U'TSE1D?','CE)C=)TMCQWE?CYBN%Q58F=>>%<O)B!IN;F48LO(]V?
MW/9OIA54Y-G)BPH%*^A=.LI%1LTD$R`"P;4SU%/HBV\JM83]$E1;!(&LB5A\
MD()_5^3=-Y+4?'5GS7>Z^I3`XUQ.);*_K?)N]Q^0X5.$@ELW"]?X^E?@/EWU
MPNP3C.7/>&ZSN'CSM'391!`B0ZP\J@11-E`*GR%XB)2G/DWVW6V0IT/O/`5"
MU)4)2%ML[[K.&43QYP/7K&T<=PM3_,\9@!:RWTF5W^#0R5[ZB6@E50/A]K.K
MX>;KY&;4YS8Q="H9H)62DJFP2>B+=0Q#<[+B7RI*`G:I<21BD!(3GPQT\R;J
M*5HJ1,TZFU),ID@FZS>G;'.2C+9WQIAWBSC6"?YAAU>7])F.-Q&4ZG-1MNQ#
MD"!S;<L@S&3Y1`_<^]"V27'^7M+I\[330[R4A&(E-[8A@[]2BCJJVHJW2,2%
MS`3:%)*92\BI1P$9AF+%'2T#+9V2FI*)$B%8K_*G2;(R,I5NRW&%Y[8K66SY
MEY&0Q)E:>C[:B\Y.TP]5?0EMBTZ+AA[19]NRH-AE$VHJ)1$I1E!3GX9HL$HR
M4*L5=:JQ5MM5C;^!"6D`#1;?;\-NFR-WVE.@4K9=)7RC,$`&<O+=HT0[^:K1
M>L.CG+#E7#D4X?VUAPM=<>W$(QS'D@J53@K/6H;,+@,D@,^6%5CO$W`6$9*3
M1?.&SDASE7(<-J6%#[B:AS#@FL&T`WDIL\HE'<JBJAI.KL8R_A219IN-ODC=
MQE9S;!Y&;9?@K/G)_<9OG'R1Q>C6;'8[B_Q4QPFO5,LNJ,S]X#PIJI'4A"W0
ML.[939D"K$76!-%YXLHFV"=3=,D)0HIM80J>G$;Q/7K$5F7:\H6ZXA4MLN0%
MHP@V>2([S].I60>/N/+#<"<V9V\4+,7&.[<L5K1(<I6CB"LJ%S<Q^4G=3A8=
MS%F5D:PX=.'`EHK5>-CHTC-VV*4Y4E`G8>2P\[A#1:4A24V@SF)#_H8K5+2Z
MQ"%G:AT*!(D1(`F?EWH=ZWRUS8W"P)91F^1D+Q:<<M,AL[-+8[^&DEO"J(<>
M,2N<(L%G^/V:^6(_$TA;AE3OG,08G7/%23>J%*=R4='44[K"%-A'6$H$Q8`3
MB,Y6W@2LX+(V2R\E]:BIW9*ND/S=.Y.$2TI7(B]U9-2\73E-#*TO@QG+(%`)
M'VB^4NS3ES@\TV]7CQ*9&+73,%Y_+[#&#>(56B'W4Y?**"63:KGZTB[U"Z%#
MTFA,%Q,[!(#",4K;IS\\;T](YU=(>4H.!)W_`&C*>[+S2B?&>9"9E\<<$9:Q
M@J6PRO);B[)3Y7#8S)<DV^@9MU+E79&(F9FL$@JIU)"4HIFW*(!MMKDT^':U
M>#V,*Y;W)E';PA*&$C<^&.AJ(!W9.SU-<EC]2G>CH&^(19:Y5WG&V9:YA]GQ
MDRM>7=[&S'H=HK-ZP=%P%C:T^#C9ZUNNXMF2(2;A!@6<CL)7[5`7"B8@B"@&
M()K[65,U5&NN0H%*%@*%N*:B0)"XVC7..2]7+;S$9?([9:<23\65]IT'R0H(
MWF%B&QSM2:4F_8^N57D&5[=7&WQ>2JGW-*-1*;'79XBO$D56<V7_`,4/14>J
M,%#%BT2=\YV3.4=:BCD)8#99:-,Y1;15L*Y)4,6GR7QL$^=?#HZ2BH<E<-"F
MWG8JKK*DOU>40)/32!5XMB5<'O0H1\0W[6N'_-Q-V"<!`0U)U"KNP*'DC5O,
M<N<.%#[4P9>T!#F/>0V$8W)L;A=_E"E,\LS+0K^)QTXL$:G;I!JHW7=H*-H4
MSGQLYW+-LJLBF)05603,HF4Q`ZM1=6?V9=PG9C3*-T5E,M[8)6-I#,7?T@O$
M*A525NDKFZER,!`Y"K&+YUU79F.G!A;A:Y-6,9,I(&;LQ&[=D#1TX=+=0IIM
MF3@Y1.*)RA*FAJ5N;()Y<B;=0MB*HS*@IFMJMY"D3ER3BM-FB''7Y*X2E[G%
MXKK.8L>KY7L$*TG*S1SV1@::F6$I#DGHIV6+15-(*-W<(<'Q4R`#H6.ZY2&3
M#<8%,NIMD2-,M$3IJ6EN%F<G-1LGO1%EUS1O=<C@-9J!7W4K,T.;G*8G!6>3
M\0FKXSN=TKT)0W9I"#(YCPE("@2LLH]Z5>X09KE%,QD@$W2%`"E1QHFFR\<V
M<_0-^.<*QW&D%*Y'<.N4=$H-^>3B&,@<.D7T>Q?`3J$P$*]9HN@(`C[;<@JB
M';X=M^SP!P:G]W7^@?1'9%XB'>6?Y[/#+_$CEE_>3#>O1T?_`,WFO[6D_P`T
M<M/]0&^OT")O:X<=.#2$6G.!"B8=]@V#L[1[1`H?9'6"96QD"9E$.LD<K5JS
MD*WX_P`<85RYG26QM$0<SE1QCDU&C(^@H6&/6F8B((M?K;4PN%UD*^V,_"&B
M`>/4FJJ!E`3,Y1`W0:R]QT)*EM("U2&)1$^`&0T3-GDCGNYBPT5"2U8!;A$Q
MZ8441S0XQ2$+0YA?-%*B`R33(_(52CK+,LJ]//:C*1LK+(2[J$E%FTA'-FK6
M#>D<G733(V79JI*"50O2,;E%4M.%I:2%`RW]Z,TV8TM2T7D*DE(M"K#P1HWW
M,7%4X7$3[%5BA,JP.5\VL<'!.TVRQCEK5I][3;5;U7DRD5)RL!V+:K"0S0X(
MKG!TDJ7=+M&1K+:IUIQU`&%I!6J9MPBRS7&$9E1N`%M6*:PBS6?@UF':O^?\
M+X==UB(ROE&F8_D;>\/'U=&Z6*)@%K"[34;)JEC22#I`RZ*"SU%-1;8$4U%2
M%,8#&*`TZ9MVL9#["%%!$[K1OC1%M]YBF4E#SB`M5PG;"4O/+SCCCMYDF'LV
M6:>WL^)*3*9"OM0;34<ZM4%5XE@VD7+QQ#$=`N58Z#]L!$A$JG4Z1Z@*50IA
MD8I:BI=0RTA1<6O"+-,5:O,J&A;4[4N)2A"<1WH3$1S8XU7.HX_LM5S'2E%<
MJQ"<SC:#?S\=$SUS,H=RQ"+BH]VMWYWC2=;G8NQ*4Z;1RF8J@[``C.O+*QIQ
M3;[2P$KPF8LQ:@?/O71LWF-$Y3=;;<2IK9X[#;ANG+?,9,#S#P@2O8?<Y'R+
MCC&ENS)4ZW9:Q3)/(]7EEWXV$C5)).#GF+AO%V6'-)NRM&LH@4C)\N&R)A'V
MH0.4JVBI(2<2;[+]P;NYY8LEUH-!X*24%`5?;(PO,+Y?+EN1S&V2B7,.3$F8
M[/AY;QEVB\"<=UJ(K,TI86P)-VYF#9VG9BHE;G%4Q!0$W6(&``/T[E,4!V0*
MT!8'YIN,0T]4U4E0:GR3(S$K1#Z:@BS!I"&1Y)^VX_9S('A'#643>QL%'G>S
MZNIZ)"NO-K%V)*=V94#\$4J[E,J;N(05;D@(YM8=]+KZ-[&^)<4T"[\KZ'7K
MC2L88[J]I@7D3=U'<-/P=/AXZ5C7*C6K.&IUV3UN=,PIJ')U%'81UZQK[OO&
M=?4/NT>7ON-ART@#2)B\B\6[T>>5XT\+43+2:NM9;4I%@),[)`W`W&R'*_IK
M?1:^>-CK]Z+]^:&KB?NL^\18FC**Q0W$@^A41_B%X+^T:?A5\V#^FM]%IYXV
M.?WHOOYH:V_"G[Q_L:NZ`XX?B#X+^T:?Y7S8/Z:WT6GGC8Y_>B^_FAI^%/WC
M_8U=T!QP_$'P7]HT_P`KYL']-;Z+3SQL<_O1??S0T_"G[Q_L:NZ`XX?B#X+^
MT:?Y7S8/Z:WT6GGC8Y_>B^_FAI^%/WC_`&-7=`<</Q!\%_:-/\KYL']-;Z+3
MSQL<_O1??S0T_"G[Q_L:NZ`XX?B#X+^T:?Y7S8/Z:WT6GGC8Y_>B^_FAI^%/
MWC_8U=T!QP_$'P7]HT_ROFQC+>FJ]%L8#;<QL>")O:[%A,@G'<1``[$Z<8=A
M'LW\&XZ@_"_[P5N);[JJ@M#@)!`%V^J(ZGQ]X,ZJM/>-/RDF5I/H$XC;PT]+
MGZ.'&?%_"U$O7*RAURW5BFH1L]!O(J[*.HQ^5^^6.V7.UJSAL90I%2C[0Y@V
M'PZ[.<_=E]X-9FC]33Y/6J96X2#@%HZ45\O\?>#6J)IM>8T^,(`/M?-B3?\`
M36^BT\\;'/[T7W\T-<W\*?O'^QJ[H#CBY^(/@O[1I_E?-@_IK?1:>>-CG]Z+
M[^:&GX4_>/\`8U=T!QP_$'P7]HT_ROFP?TUOHM//&QS^]%]_-#3\*?O'^QJ[
MH#CA^(/@O[1I_E?-@_IK?1:>>-CG]Z+[^:&GX4_>/]C5W0''#\0?!?VC3_*^
M;!_36^BT\\;'/[T7W\T-/PI^\?[&KN@..'X@^"_M&G^5\V#^FM]%IYXV.?WH
MOOYH:?A3]X_V-7=`<</Q!\%_:-/\KYL']-;Z+3SQL<_O1??S0T_"G[Q_L:NZ
M`XX?B#X+^T:?Y7S8/Z:WT6GGC8Y_>B^_FAI^%/WC_8U=T!QP_$'P7]HT_P`K
MYL,!RM]+]Z-C('&#D71:=RRH,[;;G@S*U5K$(UB;N1S,6"?H\Y%PT6W4<55!
MN1=_(NDTB"H<A`,<.HP!VZO97]U_WAL9G3O.Y/6AI#R%$X!8`H$_&U16K/'_
M`(,72.(3F-/B*%`>UJ_1AUZEZ9ST7\96*Y'/N8./6[QE`PK-T@>$R`!D7#:,
M:H+)F$:>`>T43$-P[!\(#KC.?==]X"ZUY*,JJE*4^5@``V>0W[D3TOW@>#.J
M(2,QI^2@3M(NWQ.%,7TUGHM`#;RQ\=>'_HB^_FCJU^%/WC_8U=T!QQM^(/@O
M[1I_E?-B[^FM]%IYXV.?WHOOYH:S^%/WC_8U=T!QP_$'P7]HT_ROFP?TUOHM
M//&QS^]%]_-#3\*?O'^QJ[H#CA^(/@O[1I_E?-@_IK?1:>>-CG]Z+[^:&GX4
M_>/]C5W0''#\0?!?VC3_`"OFP?TUOHM//&QS^]%]_-#3\*?O'^QJ[H#CA^(/
M@O[1I_E?-@_IK?1:>>-CG]Z+[^:&GX4_>/\`8U=T!QP_$'P7]HT_ROFQ8?TU
MGHM3`'^N/CKP_P#0]^'U!]:H#J)[[J?O%V12K**Q,]*D@#7KC'X@^"\05WC3
MV'6K41S8C1QY]+MZ-^G6KE`^LO*VAQ32]<BYBZ5-PO$7DR<U6'6-,8PB$NV,
MC5%`*@I*P+Q#I/T*`=`VY=A*(W:K[L_']26=AE-8HML!*I)2;9G4J[=BA0>-
M_"%,7RYF--)Q]2Q(J-AE*?)OB37]-;Z+3SQL<_O1??S0U7_"G[Q_L:NZ`XXZ
M'X@^"_M&G^5\V+#>FL]%J(E_UQL==@_]#WX?5`?4IX[>#U=<S,?N[\<T&R36
MY95,[1=F),IX;2!(G<OE%FG\:>%JLJ735K*PVFV4[)W:-S1'QV\>_3.\Q.)>
M4+LE2<CDS1@UYDJ\RD=C'*;B2GX,:W)6N4?L5:79UU#6VG$6:."BW23549)$
M$`,V'8=_T!FGW5Y'F^54]0U-C,@PD&0`FH`3Q>6X[YCX[DWCW.<IJ7V'@ERG
M4\2#.<A,RE\(CZM.$7ISN&/+<8JI6*R*\?\`,DD5NB&/,IR#%K$2LBH/=>+4
MS(10:5B?!=0`%)%<S)Z<#AL@.X:^%^)?N_\`$GAT!YYD/,*G+8S<(`/QA($3
MGNC=CZWD'C'*<YQ)+A;=$I[224S.HSCM$W<I.BB=+J$GM1*?;VBI#E`Q%$C@
M(E43,`]A@$0'7A1/"%$$$Z#>-^/5MNH=)P6I&G0=T'2(R-(E@TA$,LV[!RZX
M2>I_.4_DPBM3MCZ%9T##Z8@7^M3_`(O0(F44`V]355"PL33KBP?@B_6\8@TA
M!I"#2$&D(-(1'GE7_-GY"?Z',E?Y)2^K.5?UYC?3Z1'.SS^EN?H\4.M^9^H_
MG1>XHBUQ7*4]XYJ%.4#E-RWG0$#``@(!AO#0!N`@("`>SJ_G*E8*#`9$4AOW
M%&(*(J#SN&7MF>];'IG[D,PP5D:L^^62D34MA@KDAF6R5B'IS.:E9R-PM'T&
M6<N(NR.K)%'A).-93ZI4&(,W*<H=Q[==MW`=[BCRYW,Z45#:DI27$HD209JG
M(V`V"5ML4:S.44M>JG4@X4M%1L&@B[=A*1-HP9SM)-T#(6&<EU6?Q:K2LCQD
M-DY-]CJ\-8'($/8FM+R/2[#C>ZJS\&VGV+&48+MS/V$FV[M=L]:I=70;6H9J
M,EY:'4K2X<!*#,3G:DS`N/DU1JV[09XT5/MK`:.)((D9Z#8=4-K5>9V`\,&9
MX4QCQRSNC4ZUEF]\=ZHYI%"A7M5LF<Z@I-S$K1HB0D;NG,R,S:48Q])&L4H1
M*),<JQI*31=%6*6S4Y%5.I2Z\ZV#LDN^T9X%"R=EXND/)$2,_986FG;:<P*4
M4B0%X_Q:8D'1>8F+LBMZHJQK-\BWUAQOF3)*D18H2*:2E7+@FX1%"R34+$1M
M./FJ-NC;1,^+I)MEG3-P""BA7'1W9CT:G*7DH0<0]L)!!G:0"#O$$1T$5[;Q
M7LVE%:$S-@W;+[S*(@6OTA%W@75EO%(Q)9<L423C^"S_`![3(A.JU^YQ$5RO
M]\JDD]GWDY:HR*7DP!!@V8-DW)D$I!0$U5"MCJ.4>RC(654P<74-M/!MY2L9
M,B&2`0D@'E?I2&HZ(Y*<[J%.K;%*\H)";@G2/TH>9#FBRJUGR#`V>KY,R!.N
M<_0N&,<XMJ%!K;>VP=F=\=ZWFU>HRDLZR$K7)LR3<[Q9Q.N7,:P9+J]P<0;H
M`\5I*RATA"FGF2E3(=/*58E2L(!Y-YE.5HE;,QNO-VPH)JF'4+^+8FVRWXWD
MA,N_2"4]&U1E[DW$M5,&Q7''*F1;O!6:NH,\EU[)N/LV5##SVD2;8LFX9(3;
M"?EW,8=HFX4:N'ID54W)FX@J,XR5U3!2D'K)="01[!!1BG.4]T'5.+",U2I_
M"HI#"62LI58HR,K!<>&'RP/E_"W+QXCDJOU=U'WC`EBG:FK%V26J,W,4B4NE
M8AWCY5I)XXN=[QY+(V>H/&_=NFLB\41(95N84%?&$]<NJI:G+2*;&%%U.+$"
M2+R)&8!L(-DHLT54UF#0K&D2:$P`H2-F],>>$I#<_,53M1R!?&&/,N.*I2+@
M3'=9DVT/4))SE3(#FZ'QXTHE%A8J[OY^+MKVWI$;E8V5K7UB-U".U`(T`RQ9
M.[:EB2:AUG$JV\V#6>3+@G%=C/6:HJ+##RBA6'V4VG<Y7%"`L/.).A9%FYK*
M50M^(L5U;CFUR1,4.ZPE73R8UR"\SF7%<+')NH*W3E4>-[.=VU28BC)'9&47
M(LJY1(4_3=.3FJI0IAY+BU.X0I!.``)Q$DD`@C39PQ$[G*D5&*J06I(]A4L9
MY4@0`9%)T6SOLC?0OI%,/V:.J2-4QGENYWBY9,L^($<6TYOC*UVB*N]3I3/)
M#MK,SL#DQ_C7W%<49TE)(R3>><,"I`9-15-8ATBQNY$\AMQ>U;4TTA"BH*5(
MA1($II!)!O!`-HE%I.>T[H::0A>)U2@`0+"F4R;3('6)W0LXSG9B>2N+.*-2
M,KL*3,66ZT.F9O<UB*4Q?>+[CN.LTC:Z957$=8WMS7D&A*A+H-'"\.VCI-W'
MJHLG"YQ2!2$Y(\&E.XTDH0E13B.+"JXW2TB=LQ,1`G/6$DH4VODJ(G(2F+Y6
MSA%1G-B&R1`\?LB56)O&.*5E+-3&F,5+94:7<5,ATQUB^_7D'D))T7)<\A5(
MUP2M`=9=05YAD[:F9.(LBBICI;#*W4E38(44IG,&RV4KY:3O:C%A.<,*;#@D
M"='QN")!<:N1E6Y,4P;U4*1>*O4G+E!>J3%P1IP-;I$.45%6U@@C5"W6L&2:
M?<F2<,9+Q"88+`";IHD?LU5KF5T)DLI5HL)LW#,#S3$66*AJJ&,)(GK&KRP@
MN8X`!^*8```'EGX+'8.SPC:A'ZXCK.7>S4S]VO\`[85(DZV!H4/AB:J/]K)]
M37.8_4IWHMF^(S90PO9+GGCC]D^(<P:$%BR.SDTL:#Q=TE*NE<E4Z)@(,\2D
M@R7;K`W>L3F="HJB8B8@).L1$-='+GT4+*F>44K>2L^194?5'.JJ0O5!JFY!
MT,J2"=92`/)$0EN#&24<*\6\<1CW'L?*86XV\AL2VPS5W)M(E[<LNX@1I$7*
M09F]?*JYC#V<5G4@NLD@N*:@J@FJH(EUU^^&55U14+0=B[4)6!(3"4NXY7RG
MALW]R*G=)-*VB<JE+2DJ(-A4I!23O8CP1L9S@Q:'M9N$4P9XP;OYOT<%6X@0
MRXI+(D8W^$&VJKO.^2KQE6M(%S+LU$U$@%P)T.H6P"F3>-><$O%:<6SZRIP#
M\U4Y)ONMNN@O**8-2;IV"]LP"39,B6H>>\Z82K'@?D)ER*E+Q+D9W6@V3*V.
M\UIR"W(O+U*1I-MH]'J];38K8/@ZU(4;(;B/E:D16/D7$G'"=F],W=('*B'>
MY.<)ZL&DB2@DI]A))!5/VIS`.J5XG&M/DJ&ZOK"R<-\@3892NW-&Y&MA>'7)
MN+Q;D&EPR.*ZE`0URP3<\$86<97NF0:?7Y+$F3DL@V:+9Y'F\7Q%PH-#N+5F
MW:1<#XK8&L"J0ZB)@1.+8)AFF7]:VR]J9H()D`3-,IR"I3&NS>B"FRZLI:4L
M(IZ11"IC$I1%Y/,.N[7"@M7$_E/?N3E"RE:;'5U,?U/...,P,HIOFC(2$75:
MW`T!2NSV/(S#D;0HRBVNUM;2^=O$[E*/A?OF:W<>+M"@0B>O7\K9RTL4R7#5
MJ04J*D)D9GV@K$2!*S#*4[8F.7UM17"IJU("`00$DZ-%H'#'5`(2)V`!BHT0
MWWV%DW$-Q[_<0`4A`-_&E?W0WWP[^7V?YRH[LU:A&<FBF@F)$R$3+ML!4R@4
MH`4H%*`%````*4-@]8-:U/[NO]`^B-A>(A1EG^>SPR_Q(Y9?WDPWKT='_P#-
MYK^UI/\`-'+3_4!OK]`B;VN''3@TA'DN3O45$]BFZRB7I,(E*(#V"`B4!$.S
M6#/1?#"E7)7/"=40&L&)N3>,LOYNNN!(K#%VK.?7U/M;IGD^YW"DR6-,B5NE
M1^.7\RFE7:3<TK[4I>`A(]WX@"T.Z1=H+)@N)%R'1OA.65*4==+R5H,^2`09
M6B]0EJTC3N1R>JUK`<12[/`N[$3/RR!AK*EP6R;BZGY#B,;7>H-KLZX<8PP#
MCW)DK'">90R#4;-E:V6N>?,UH>60@*W8IF\MUFI43/S,E"]8MU1;)`ITW\Z1
M5U3;E2@[!#A,A82"D)MMOD!YXHLY(ZFF<0ZI/6%@`2GA%LYW`^:$IAKA!G6N
M6B*N=VE*XD^-RTQ;GB0CY/,N1LVV%O4*+Q\LV(W\<\R1>:C7YBQV5S.2:+E!
M(S1JP09&,DF).Z(!I:C.*1(4BD"L*Z=;9FE*;5$&X$R%FN*V6>'ZFA=VKBTJ
M^E"I3)L%]XOU>F%AS$X59$S;EWX1:QW5MK5HPD[P9<J&YY!Y3X^I-HE>R.9\
MTM[J8UJUK+<X.9;RB[22AWJ+83`W;J(N"CUE"GEV;=3RE-$I(%2ES$%`!0N`
M,IRE*5AEI,29IX>76YLWF+2Y(2C"021NV2!$97DC9E3RIE9"JK4[&>%\AX_R
M16[.S99)MU[3R5:+5C>)H-/NKO&]@H[!KBVY5XL>4TS*P]@<FGT&Y"N$3K*&
M63QU]A:65++B7FGTKFD">$8L0G,3M(*0181?*+!R=7TP(0XEQA2`%$RQ$BTV
M'1,&6N%;B#C5EAE:J!>\I16,8J?I_#)QQE4:52PRMJ23L;6UQ[E&PP\O+4ZM
M/6<'8X*&06=I=T15!<P(&\9*D5<=W\S1B4EEQU;)JMK)0`G9>9$V^:#>6U"J
M15(ZVPV.K;,%!)MT"U(Y-DYWST1&1IP%Y&5[&,_B2&5P?/Q6;N+F!>/N4+78
MYRS-Y7%$AB2I250F)>C12-(D4LC5Z0;2RDC%L'#FNF93!.^.H8%!,2W4YQ1U
M"MOA6E]MTK18)*)(,E6V2E*XSBJK)<Q0T&J=Q$BR$'$39(Z)`V1T:XWX<L>'
MSYU]\+V+?$R3GRV9-KJD<Z=NW"=9F:M1H*/2FSNF3($YSQBLKG7*EWJ6QRB"
M@B(@7EYO6,YC4M52`0XBF0VJ>DIG=;==YX[664CE&P6W2DK*B;(DMKF1T8-(
M0R?)`W1@#.1_O<-92#P`/:-'G!#L'L$.S5O+W`C,&-:74*\@4(HYB)TCR3\=
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MC7E'8*[^+5#\,/$?VLS_``K?'!^BY\I/.7X]?D]DC\1T_&O*.P5W\6J'X8>(
M_M9G^%;XX/T7/E)YR_'K\GLD?B.GXUY1V"N_BU0_##Q']K,_PK?'%I_]UTY1
M](;\G>/Z8%'J'NZWD8#```([%.+(>PQMM]P'LW]780RG[[\E*@BIRAY31,@>
MM+Q$[ME_EE&KOW99^RT7VLV:V@%N*E;P^21)\T-EA;_=RN2&<L54;+,)R&P;
M$1%[@TIMC%2\%?U9%BB=9=L"#M1FS,V45*9N([DV#8?`&K5?][^44%:Y1]0K
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MXX/T7/E)YR_'K\GLD?B.GXUY1V"N_BU0_##Q']K,_P`*WQP?HN?*3SE^/7Y/
M9(_$=/QKRCL%=_%JA^&'B/[69_A6^.&^RU_NW/)/#^*LE98F.1&"96'QE0K=
MD"4B8N#R`C(R<?3X!_8'C!@JZ8^+)O'C>/,FF93V@','5V;ZMY?]\>3U5<S3
M'+ZPAQQ*9&K5+E$"VRZV(WONV\1T[*WAFS)*$DVTK>@3UPL(;_=AN3\O$QTH
MWY+X`20E&+62105KF1C'31?H$=(D4.#+85`16*!Q#LZM]5%??9DE+4O(8REY
M+>,H)ZTYB!GHLE&S'W8^('V14/9LUM"`1AI6Y6Z[1Z(V/Z+GRD\Y?CU^3V2/
MQ'3\:\H[!7?Q:HV_##Q']K,_PK?'!^BY\I/.7X]?D]DC\1T_&O*.P5W\6J'X
M8>(_M9G^%;XX/T7/E)YR_'K\GLD?B.GXUY1V"N_BU0_##Q']K,_PK?'!^BY\
MI/.7X]?D]DC\1T_&O*.P5W\6J'X8>(_M9G^%;XX/T7/E)YR_'K\GLD?B.GXU
MY1V"N_BU0_##Q']K,_PK?'!^BY\I/.7X]?D]DC\1T_&O*.P5W\6J'X8>(_M9
MG^%;XXJ'^ZZ<I"]H<F./8>IN%>R1O]3_`,!]C6#]]N2(25.9;5.)&A54N0W;
M`;8?ACXC!`[V9F?_`.5OCAL,=_[N1R0R5*Y4B8SD-@N/5Q1DI]C*94?P60#)
MRDLQK%5M!I..!NT-T,%&5K12`B@%4!5)01W`0,,[_P!\N3,8/Y74-EQ&,%%6
MN<ID2,Q%:G^[O/ZHN!O-FOHW"@SI6[Q?*VZ'._1<^4GG+\>OR>R1^(ZA_&O*
M.P5W\6J+/X8>(_M9G^%;XXJ7_==>4H"`!R8X]@(CZE>R0/9ZO9XD'K^OK9/W
M\4-&94]"^`X0#M'=KO8<7LG6=,5W_NJSMZ0?S%EXB9`V>REKM0%8MXREHCYN
M92G3##(,UC>,:/K-9HVWS5+9L:_'/I*0L,M"2[N&.6%AV:*\BY4=N&AA11(F
M942B'9ON&OM[E72,Y<WF=4\T@.M)<PXK0")RU3&F/G#=,Z\\:>G27%!:DF5L
MB#*W<.B.[?"?_=Z>4O(LD9;^0SXG&'&*YD'9H><CT9S,4ZR5)WA1CZ:*Q(ZH
ME73$0!>76!RF)@-XF?;7R7/_`+Y,MRMM;61M%_,#-,UI3LQY9DGR#?CWN4_=
MO79I+O)P-4$P2$DA9.B0D!YX^T_BIQEI?$?#M?PG0)R_V&L5OK%E)Y'O,Y?+
M"J94I`5*5_-+'2B8\IB?M+!BDW8M@$023*`CK\T5U8]F5:[F-2$IJ'E8E!/L
M@_FW61]QR^D&7T;=`V9L-)DDGVB/SMV)(:JQ<@TA$,LW?SNN$GU.2G\F$5JP
MV?H'!I.'TQ"O]:G>5Z!$RR>#]75)E!0D@ZR8G/P1=J6,0:0@TA!I"#2$&D(C
MSRK_`)L_(3_0YDK_`"2E]6<J_KS&^GTB.=GG]+<_1XH=;\S]1_.B]Q1%SBIO
M[^^:FW;_`*VTYN/J>VPWAGU?7U8ST+4Q0.)4$I33R,YV@J5=+>BI0N)4\^&R
M%*0[(@'RQN\_\6(;D!+HR\W:I>".CA7/>$2H13=BJ083/\75XF?FQ,]06'W6
M@$*H@=D3;N#'44!4I@VVB8S-JG8+#2B!,&XWBZ-:V@-4^E]*9$6&T6CAOA?T
MO"D;3<H6C**$N\=R=HQ=C'%SF-40:IL6T;B^0N<A%R:*B:171WTD:[+E<%,<
M4B@@GW92[GWKOUR'Z4,K5RPO%.1E?O0;HG&G5*0GZ-2`F4QH\L-C$<2(*'>P
M#Y*V3+E2`Y5Y"Y7HD7;1_0ZM&08RZQ3NHJ]#8#(UJ,0O"YD5"#XT8Z"768P"
M<#6WLZVO)!&#8);N-R3,&Z,#+DS;446H65&ZTF&XF^!Z:S&%)2LW7S'$Y'O>
M1K25LE?A*;)/9RC<G+U\(5\I9V=@A9)C%FBYYNU]RI1N4KUJ1N/5UBH8`-9P
ME#>!9"I%)M!L*;B-,*W+15KQ-EUFPCD%(F")6V\$8!_1\0"%(E:?"96N,$\7
MJ'%2MU^U-HRMO9.M27$,RKC'-E2C9.-=P\LYEI`Q%)1HY2,S53()$R$`PCJ1
M?B%PA8`:4E3+R9*293=OT7:=<P-V*"/#P9GL7JB:L,YE)]F[3PPC\K<-[_\`
M"#0;9CO*=EBK+8.32F=LA9":1=(,_IJ\=Q6EL%(NXFI3+!Q"66*L$NTCO'8\
MS94Y0D5^[%-),ITYVL[IG62FH0$K33(:3@Q6E),RHV$7V$>6).Y7MJ'2M3DE
M3.+#9O"<I'5="F=>C?QS,5!S5+-=[A/'E\69`H-FL#M&N^[5BM>2LP5[.MAR
MN\*:#/"ELR>1:V@N@P!D,0#;_FYD#)`!!C1XCJVCA"DAH*!%AF)(*)7<TZXD
M5DE.Z\7WTJ+NQ4V)$2Y1Q3-NN)+\=L&.<$U";K;ZU1-S>S4XM+J243BW&>)8
MY!`6+5DWCR5S%]=KT8X!($#'.Y<]^Y.940`Q2`4A>;45K3[H=Q&8$K2HG3KW
MXNT-.[2TZ6%I!`!]G"D6G0!(1&1_Z/1G-6')MVG\T6UW?KXYHLE!7&OU#&M%
M?4N?QA?AR/0+<]CZK4V4/DFZP$X1-J,G/-W"SB)*9H8`(JJ)KK>?%NGZH4MK
M9F3-0456C#(&1D-(E*VV.<K(DJJC5I6ZVYJ24@7SF;;3NG1(:(W-VX#1V5(^
M?-EO,5WR%:K+BYCCJ0M;^$H\:=J_A,LM,R5FV1%=:5Q2L,QK=JC&J2$4JT<Q
MZS%#NG(+"HJ<YC.TT[0IV9(8"RJ0G>1A)X(Q5Y"W65'6W\:ZG"$S)3<#,6`R
M\T*O''#9&BRV(+$^R"E-S^([=DFWLEH#%^,,60DPYR)0#X[,Q>5G&E:KT41"
M$BU3N4UQ!1XN[./6J"(%1+77F:-B^RVHX70F4YF129WRUQ9;R]U+K+JDI^B*
MC8$B>*RP"0L_+3&D@N#2%?LT0LTS%=U,94>^7K*V)L2'BZB2)QMDZ_HVX7]G
M;6H(`]HL[&O25[EGD-&22J[-BX=AW@."(($)*,W1L%-D_2J;2B=LI)EHEID+
M=R41JRMS$I20+5E0N!$]T6V1H*3Z/N-J<O&6=]E>>FK6USA#YWD96)IN/L>P
MLC9X'&EOQDP(C1J57(ZJ1KYZRN*TC)R:2(OI2012%P8R1"I%F/B!>R%/-.R#
M>"T$J(G.TD73N%P%@C(R6G"^L%*NL[A2!8)"0!U7ZS;?#R<<>+I<`6/)]N=W
MU_?[/EJ5A96URAZG2<=Q2KFO1[N/92)*9CJ"@JNO:)0KY0\K,J)>/R)@2*<0
M303(6C75[%6RAM/)*";YF\SO-ODN$7&:=YI144V;DA&BYCCNKQ4#8>SF?@KM
M]3L"U#]H-398XTI%04J^(K0?S8S5;3:M'`98AI%E^[$TDU``A0V'L#7,9?9#
M21BT:CQ1:4')^R>$<<7]Z'K#]C4O6&>=YCQ1CZ3F'A''!W@#X2C]C3K#/.\Q
MXH?2<P\(XX.\+]Z/V-.L,\[S'BA])S#PCCBG>%^\^UIUAGG>8\4/I.8>$<<'
M>%^\^UIUAGG>8\4/I.8>$<<5[PH>`HA];3K#/.\QXH?2<P\(XX.]#UA^QIUA
MGG>8\4/I.8>$<<4%0!`0V'M#;U/5UHXXTZVIM*N4H$7'3Y(#:`SP'A''$)LM
MCT\VN%_K&HO+0X#_`,&%PX40V\.^X:[=)6,#(*]HDS><IY67;-1)GORLCG*0
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MWE$?4\`4:=U/0/,JS%N2M6@\X;D5*Y#JZ94DF>^-6_%G&<P%XZ8"`2[_`.9+
M$WK?Q"@/7U&^\RFM?!5;M-1XHF92XEA')^*-(U#=A[^\+]Y]K6G6&>=YCQ1+
M])S#PCC@[POWGVM.L,\[S'BA])S#PCC@[POWGVM.L,\[S'BA])S#PCC@[POW
MGVM.L,\[S'BA])S#PCC@[POWGVM.L,\[S'BA])S#PCC@[POWGVM.L,\[S'BA
M])S#PCC@[POWGVM.L,\[S'BA])S#PCCC'5'J`X%#M$H[!];]30.M.!"P>2'@
M+C?;$52APT;@";2#I&J(A>C],!>&7'C<-_\`-^W];_I.2UV?$%2PK.:E<["Z
MJ5AURBOEJ74T#*2DS#8TCCB8O>%^\^UKC=89YWF/%%WZ3F'A''!WA?O/M:=8
M9YWF/%#Z3F'A''!WA?O/M:=89YWF/%#Z3F'A''!WA?O/M:=89YWF/%#Z3F'A
M''!WA?O/M:=89YWF/%#Z3F'A''!WA?O/M:=89YWF/%#Z3F'A''!WA?O/M:=8
M9YWF/%#Z3F'A''!WA?O/M:=89YWF/%#Z3F'A''$7N;I@'AIRSV#;_5LS=ZWQ
M;V375R.I8&<TI*K!4-Z#SA%+,5+10/**#8VK2-6_#Y440+3*B(]H>]BO%_\`
M=>X[$=M<MYYERHJ"E5@J5&XZXMTZ7$TS;13;LP;QH%T*_O"_>?:UCK#/.\QX
MHV^DYAX1QP=X7[S[6G6&>=YCQ0^DYAX1QP=X7[S[6G6&>=YCQ0^DYAX1QP=X
M7[S[6G6&>=YCQ0^DYAX1QP=X7[S[6G6&>=YCQ0^DYAX1QP=X7[S[6G6&>=YC
MQ0^DYAX1QQ:<Y1#P;`':([?J>IV^KK1UYE3*@%:-1UB"4N%Q,TR`)TC4=V(@
M<5AZ;IS,W#??EG8-OD@PUKK9HZT@TV)5O51H/.,<C*4.)-4<-]6N5HNLB8/>
M%^\^UKF=89YWF/%'7^DYAX1QQ8<XCL)``!#M[>P![0'U.W;LUJMUA:98K0H&
MXZ#&`'-H%%!PR.D3M\L0@XP^CTXJ<2):R6C$F*H-&_6V=F[!/Y/LI"6?(L@\
ML$D\E9%!&R2:!G$%%&=/E`(RC@:M0)L`D,(`.NUFWBC,LV#;3U033MH"0GE`
M``2NT^6.%E_AK+,IQ+H&)/.+*EE6$VDS$K;/-$WD^[)U""92B<>HW24H=1O5
M,.P!N(^OKBI>:%JEDD[AXH[HVH$BB[41'KWH>L/V-;=89YWF/%&?I.8>$<<'
M>AZP_8TZPSSO,>*'TG,/"..#O0]8?L:=89YWF/%#Z3F'A''$-,V'WY=<(^P>
MWREMO!ZF,(G[>^K32VU,K4#99KUQ"L.;5/)/QM(U"6G3$R@4``VV'58OL@R*
MK=XQ.=IH2>$<<5[T/6'[&L=89YWF/%&/I.8>$<<'>AZP_8TZPSSO,>*'TG,/
M"..#O0]8?L:=89YWF/%#Z3F'A''!WH>L/V-.L,\[S'BA])S#PCC@[T/6'[&G
M6&>=YCQ0^DYAX1QP=Z'K#]C3K#/.\QXH?2<P\(XXC]RJ`1XS\@]@\.&LE&^H
M'O1EA^UJ[E+C1SU@XM*=!UC<CGYPEUW+G$)29X=8XX=;\S]:3'RHOR]$<TL3
M<;F.5\O<TK"XS1R/H1R<I)./]QL69FL5$KABH8BQ$X\;-#19!;&D%3.=CK_K
MSIE*0>PH"/=S*J%/3T"4MMK4:4GE`\]6H\'ECS]-E25O59+CB-J_BY"I&P2E
M=#^^0W$>=!S<^D[=/P6N9WDYV>FX%<<6>Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.
M\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJBT>
M#L0'_>@YN>K_`-YVZ>I]5+6%9FXE)4*:F,A=)7'#N1K34U4OVGJBGD/1'A\I
M_F[MV=OE.73;M]GNM$9FXM`4::F!.@A7'#N1K14U?UGJBTW!^&`.KRGN;AA*
M`C_.<N>_U`W2]71S-ELME?5:9>X`J?I$.XV3:JIJA_\`D]4:@.'5;%1-'RH>
M;7>JB<$R%Y16T1.=,2E42*&P"95,3!N4/!N&@S5YQ`6FDIQ,7259OVF-59/3
MIOJJJW_4]4>!^(E/*9,H<KN:!@5%4A#ARKL_=F41`W?)%.)@(HJB)1`Y2B8R
M>PB8``-]91F%2I<E4E.$2ODJ6]?&!E-(58>MU.(Z-IZHVI>%4&9-58.3_-T$
MD2"<ZA^3UQ(0"E3[P3=9B`4"`3MZA'IV]7PZU;S53JE)33TW)5*Y7'$QR%M(
MFJIJA_\`D]44;<+(!V!A0Y1<VE.DQ"F`G*&WG$HJ$!0H&`I1$@BF.^P[#MVA
MN&LO9D\RK":6G-FI7'$2<F:5:FHJRG7M!Q1FEX.Q!@W\I_FX';MV\G;I^"UA
M.9N*$S34P\BN.,]R(TU%6/\`\GJB[R&XCSH.;GTG;I^"UMWDYV>FX%<<9[D;
M[15_6>J#R&XCSH.;GTG;I^"T[R<[/3<"N.'<C?:*OZSU0>0W$>=!S<^D[=/P
M6G>3G9Z;@5QP[D;[15_6>J(H<I^(4375.-P!R$Y=S`S/+##E?.>>Y$7&6-')
MR/OD'W5AP6`A8R<9F1`$'2?[8D4QMM]]=/*LX6EJI2::E,VE#V23*:=,Q^6F
M*=7D32G65=9JPH+!]O?W+]W1JB5I.#T2<I3CR>YME$P;B4.3UV,`#ZNPF2`1
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MR(`!'RH.;G9V_P`YRZ?@M:KS5;:2X::F(2)W*T>6'<;9LZQ5_6>J(D9/XA1;
M3EWQ/@0Y#<O'19^D\FS*S#[D5<'%@B?<>+Q,NDG7Y82%6BF\CXZ(/2$#_G()
M)`8=B`&NU35[BLAK7!3TF%EUB?)5,XU$"V=PG=(1SW,F:<S=M\5%7-*%ID5V
M7"T:CKOG99$N/(;B/.@YN?2=NGX+7'[R<[/3<"N..AW(WVBK^L]4'D-Q'G0<
MW/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(W
MVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@
MM.\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@
M\AN(\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>F
MX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L]4'D-Q'G0<
MW/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(W
MVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@
MM.\G.STW`KCAW(WVBK^L]4--GGA?$0V$,R2OE(\RY,8W%.19`C&7Y)W-]%NS
MLJ?,N0:R+`Y"HOF#KN^A9(^Y5$Q$H^'5O+<W<:S)H]6I3)23:DGXPW?RU&*]
M7D3*Z50-35W'X^YO<,68`X8Q,Y@G"LJ/)'F5&#(8BQF_\1B.2=S81C3QVE0C
MD6L?'D(9%BR;&4$B21!$I$P`H#L``$55FJUUKQZO3?K#H5I,]?Y;ET2M9(WL
M$#K-7[(^/N;T.YY#<1YT'-SZ3MT_!:A[R<[/3<"N.-^Y&^T5?UGJ@\AN(\Z#
MFY])VZ?@M.\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&
M^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\
M%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L]4
M'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJCP7X0Q0$.0.3W-H2[>VWY.W
M4.SU=NE(!W_5\'K#VZV&:+1@_P!M2XBZ![*KCNSNW)>6(ZG)V^I.)ZS5RD?C
MV^B(N\(>'D9:>)V"IY7D7R_@U9.CMW)XJL<B;?"P+(1D9`HI1D4@F*+%M[7<
M$R^U*(CKK^(,Q=&=5.*GI2K:F=BN.*F69(UW>R!45<@V/C^J)4^0W$>=!S<^
MD[=/P6N-WDYV>FX%<<7^Y&^T5?UGJ@\AN(\Z#FY])RZ?@M.\G.STW`KCAW(W
MVBK^L]4>/D0P_2)O*?YN=F__`'GKGMV#MX>ZVU%WI5;,JZG3;70FV9&N<Y6Q
MMW$B<NL5<_T_5'J'!R($`'RH.;G;_P#N=NGX+4HS)R5M-3`[RN.->Y&^T5?U
MGJBOD-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G
M.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(
M\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L]41UY>\-8JN\4>3,\3D=S%F#PN`<O
M2Q(FP<C+?+P,F>/H,^[(PFHI=,$).)=G1!-RW/[59$QB#V#KJY'F:TYS2*ZO
M2S%0WH5SANQ0S3(6W,N?;ZS5\II0]O<WH>.F\*8IY4ZLX-R9YJ(G6K<"(D;<
MF;JDB0%(EF;I23[LP)D+OL`!V:Y3N;KV[Z%4U*5"I4)R5K.[9Y]^+S&3-*9;
M>%15`;`)ECW!;=?^4H4_D-Q'G0<W/I.W3\%IWDYV>FX%<<9[D;[15_6>J#R&
MXCSH.;GTG;I^"T[R<[/3<"N.'<C?:*OZSU0>0W$>=!S<^D[=/P6G>3G9Z;@5
MQP[D;[15_6>J#R&XCSH.;GTG;I^"T[R<[/3<"N.'<C?:*OZSU0>0W$>=!S<^
MD[=/P6G>3G9Z;@5QP[D;[15_6>J#R&XCSH.;GTG;I^"T[R<[/3<"N.'<C?:*
MOZSU1:/!^)3]L')_FV(^`-^3MT_`CZFM5YHM+:E&FIKM2M>_&49.VEQ)ZQ5S
MGS]P[@B+W'#A[%SMLY7-C<B.7T4$!R9FH4BT+R,N+!>6(CBW%+WW3G5$TQ&3
MF53R!DSN5/;BBDD3]:0-=C-LW6X*1/5J62:42Y)'QCN_#''RC)FO]VD5%7/K
M:IDKMF`-,HE'Y#<1YT'-SZ3MT_!:Y/>3G9Z;@5QQU^Y&^T5?UGJBPW!Z'*)0
M\I_FX/5OM_K.W3?L]CNNW6#F3V(!-+3%.DVV>?3&1D:#:*BKE^T]44+P?AS"
M(>4_S<`2@&^_)VZ;]N_J=U[&G>3V(@TM-@T&VWSZ('(T"WK%7+]IZH]/(;B/
M.@YN?2=NGX+6>\G.STW`KCC'<C?:*OZSU0>0W$>=!S<^D[=/P6G>3G9Z;@5Q
MP[D;[15_6>J#R&XCSH.;GTG;I^"T[R<[/3<"N.'<C?:*OZSU0>0W$>=!S<^D
M[=/P6G>3G9Z;@5QP[D;[15_6>J(K9:X?Q<7R>XAP1>0W+E\2P>4'WDK)<A;@
M\GHGW-QQ%N2>]^4.!58@'@FZ'/0`]^F`%-V!J\SFJQ2N)ZM2Z/BDZ;+9Q6<R
M)HOH5UFLLG_[-RW19/3KNB5`<'8@W;Y3_-L/4[.3ET_`AKGIS93@*DTU,!.5
MRN.+)R1OM%7=[SU17R&XCSH.;GTG;I^"UMWDYV>FX%<<.Y&^T5?UGJ@\AN(\
MZ#FY])VZ?@M.\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W3\%IWDYV>FX%<<.
MY&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L]4'D-Q'G0<W/I.W
M3\%IWDYV>FX%<<.Y&^T5?UGJ@\AN(\Z#FY])VZ?@M.\G.STW`KCAW(WVBK^L
M]4,MR,X;Q$#@'-DSY1?,69]Q\67R2"*G>1]QD8:1.QK<DY*SE8]1,J;^.="E
MT+(G$2*IF$I@$!$-=+)LY6C/*<"FI9A23[)E?JG?N^:.=F^1LHRUPFHJR)3]
MOU1T=[S^P)_@GWGZT/\`B?\``]C7#M^5'J.*(N<3_P##SFG_`+6T[_(WAG73
MSG]7E_\`Q/\`O5%2E_6._IGTQ,_7(B[!I"#2$,WR#N<UCG">6<A5N+7G+%0\
M:7VY04(W*LJI+S%9J\G,QD?XNW$%G!7+UFF4Q"^V,01`-Q$`&S28#4(0X0`H
M@6^>*>8J6C+GEHGB2F=D0GXM5;CC7Z[C?-3W-\%DG.ELI%;G+GEV6S8[?/+C
M+Y/;L&QDUJP-U-4&%>?622!A7HAO')LV)R-T&9/&";FVK!*H4`DI;!L&Y^5L
M5LKJVW*!N2PXYAFJ6B=MOHWQ"_YB9UL&/K?B'%\'E"IX*9WFNY:R3=<QW&-A
MIL*U2L.1U6</X2IP=D=-(&7MUBE;@S`?&>^\6C&SM1-$ZO=F)=RRDVJ5OE.-
M"%)&$3$RHG2+A9?%+/*EW`BD8FEQ<SBL(2!N63)U61R?;6[*$EQR4L$//,('
M,$SQ9D\L&R/'5..2N#;+'I%N298VKL:V22=2"M1:V.H0*15$2=:[8@-%DE04
M;=6NJTU3(?4VMHJ3M)RQ7)0F9G+3B$IFS7',<75)HF2M1#P&$V7J6J7D`29Z
M]6N-M+<8F-+O>2ZW[X:7D2`Q38.,?#+&-0L6$\6Q=5;W3/DO4K+FFUQ["#BX
MPS"ROZ=>1<2SQJH5[*%$Q':BI$"`::H>IU43.%*6P^EQPVS("584B[XTI[E\
M%TKS#CC@45/-+2@62F5#%KT&S=W(D7/YLO\`F'CQ=<AH9?QO+0&;9'X%J)Q7
M1I=6DBUB)R)G&-P14W5RF5)PMQF9\\<+M:>9N$THX5%SM444A;`HKRS34S=6
M&6D'"E(*E735*9(&K0-Z.NOK[M%MUN`J-PEHXX:.8Y$9JJUWN]:P&>*@93-N
M2^1.4E;Z\F<117N5C#`=@J?&/&D-!I9LM-;J#F`4D:4J]EW#4DH_81HD%!IU
MN2JEO/T-.EH.U"TXTI0"D`VJ4G&3,;A&@1Q59EF26.J4R5(^F4K$9>R2`!(^
M>.ZV*C74^.Z>.258!?(7O<A/?PK4Q>C53VT8ED:PGK(R12R(U\\L*IF?C`=]
MW`EZNW7F*A25.G`))CVR%+4T@NR+F`3EKAPM0QM!I"#2$0HYE_V[BK_MGX*_
M]*=6LM]FH_9K_P"V*M1^M;_2'PQ--'^UD^IKGL?J4[T6S?#-Y@Y`8LP/&14I
MDZR#!ISTFYB8*/80MEM=AG7C)BXE)!*#JE-A+%:)@8V+;'<NA;LU$VK<HJ*F
M(0-]6T-+<05H$PF^('*FG:<2TXL!2H3Y>5&#QA;38#7B/3BZ5*TF#LZIV\H#
MF-E\DM:Z\Q_'DC?<[W3DW-S;VV.&-!HBX*[%STD$3)J@34,U!D0@R(GY/5IC
M(J*8H4O&.22.#CCPBN6O'^;A+98XK)$&^AZ+EI'!-O<MPD%%:]EYS8HJIMJ)
M*,08^/-I=S8)MHW3,*?BYQ7*<J@DW,$[U#6T[J6GVRD*0%`GFFXRU&*S694+
M[;:V'`H..8-Y0,I>:Z%SEC-6.L(UMG:LF3Q:_%R4NTKT2BC'S$_-SMA?IKKL
MX&MUBM1LS9;-,KMFBRWBS!HX6*W055$H)IG,$5.TJK)#'*E/S7WV"+#K[=.R
M7J@X):+YPS4[SIXOUJHTZ]RV4X@U4O\`&S,U4Y.&CK+9U9&#K*A6]KGGD16H
M&6FJ_`4YV<J$R^DF[-K$.![IX=!3<H6$9?5*,BD@[LO)>1?HUZ(H]^9.1-+T
M]Y)AS;CR)P]0"XN/;;S!QA,V6.%J6)C(N%94M_L%B9$D89G731"#XKIL_8JD
M5*[,)&92*IB=4H*$ZJ@:?*7E%"L+-^]KW+8O%]H%E,Q-\33P3A(P_+O"4_G&
M;XYQ-C6>9=KD.C-S55)&28.8]DHM))G5<[L^\;-4B1Y%`>+$3CW!7C8K9PNH
ML4FKJ\MJ6LO3FRQ++EF25Z"=0W8IHS2E<J30((.8)$U-Z0-<XDV;]:;Z@_:U
MR:G]W7^@?1'3%XB$66?Y[/#+_$CEE_>3#>O1T?\`\WFO[6D_S1RT_P!0&^OT
M")O:X<=.*&'8!'P[>IK!L$Q:8R!,RA'W:^U/'-6GKM>)Z(JU3J\:O+V"PS\B
MVBHF)CF_3WKIX]=F(BDF!CE*&X[G.8"E`3"`#I2*75E00@XAHOG9.(7GFJ<8
MG520!:=4-3A_E)AC.LK,0..;0K(6&OM6,A-5J;K]II5ICXB4[\(J=5JMY@:U
M8U*_*':J$;2";4[)95,Z951.0Q0M.TU2TRT^I!V;A-N@2OW]44*3.*&L66VU
M$+!LFDB<2".KT%WZ!,;<`Z`[!'<=MP$>SLW]7;5=PJ2F:!BM$=(+23)1D=V&
M[Q?E>GY@JXW"CNG3V#)9+G4E%GC%U&N$Y[']MFJ1:69FCQ))?H8V.`<HE4`.
MA8I`4((D,41D=0MI00H<HB<1-5"'4E:?9!E#C=?K%W'U@'[NVM$XC[0E$P4A
M2I`Q03]/A#;MV[1]7UO!K3$X5X4I)&N<%+0CVC(7>6*"J`=FV_8`]G;V#MMZ
MFWJZPIY"#A7/%J`)]$9(.'$F13ORBO>?V(AV[=O9_4UNVM+A(3.8U@CTQ@D)
M$UD`</HBG>#]X/3]]N&W@WUJE;A44E!$HP%)*"O0!PQ<4W5Z@AV`/U]^S[&I
M9<,92<2`O7HB_6(S#)<D_P";WG7;M$<-91#Z]'G0_4U+0B>9-`7S3_G$5ZLX
M:52KY<1A#<<,B4=AQ]P4S>7&H-7;7"^*F[IJZM4"W<MUT:'`D51604?@JDHF
M<!`2F`!`0\&C[3J*Q[:)(^D,MV-6:EI;*-FI)Y(GRA99#T?"AC[^/%)_+"O?
MC^M,)U'@C?;#\WI"#X4,??QXI/Y85[\?TPG4>"&V'YO2$'PH8^_CQ2?RPKWX
M_IA.H\$-L/S>D(/A0Q]_'BD_EA7OQ_3"=1X(;8?F](0?"AC[^/%)_+"O?C^F
M$ZCP0VP_-Z0@^%#'W\>*3^6%>_'],)U'@AMA^;TA!\*&/OX\4G\L*]^/Z83J
M/!#;#\WI",9?)N/Q(H(7BE"(E-L'OPKH!N`;E`3#(@`=0AM^KK125%UML)5+
M&%3EJT:XC?7CHW0,.*1^,/3</+$2^`V0J/'\.>/;9Y<:BT=)4!N1=LZM,&V<
M(*!)R74FJBL](H0Y1#M`0`0'L$-PUVL^.USFI6D*D73>)&*F5/'NU@J"0K9B
M8Q`R\NF)>_"AC[^/%)_+"O?C^N1A.H\$7]L/S>D(/A0Q]_'BD_EA7OQ_3"=1
MX(;8?F](1\OGI#O3+9\X.>D0G*53!IF:./"V.L93SS'<DY:(G824DA)C8']3
MOU>*L]C)%X9$G4@\(_9]10$$2[B.OMG@S[L<G\6>%5YFXIYG/`LA#A,T2!E+
M!?OVQ\JS_P`<5>4^*$4R/I*20F`182-=MW_6.K_"STRG#'FF6+KU8N)\7Y8>
MD;)*XERPYCZU/N7JH"51"I3*C@U=NY"K$,4A6+@7AB@!C-D]]@\+XH\!^(?"
M3F'-&B6I3"D<H$>2T&5LMV^/8Y/XQRC.#(*#2]2B/5\$=+7F0J?&.56,M9ZS
M$R"'3WT?*62%8/D>L.I,5FCIXDND"A.TO44-P'<->-E/V)GR<<>F<?9;,BM'
M2`C>NIV.9M%9!VZ:MF""`.5WSEVV;,T6XAU"LHZ743;E1Z.WK$P%$!`0$0$-
M9+9T6F)24I25K("`)SC5Q=XJ<XN9K!V.OS3I-/OE&T/.Q4FNFD)N@%#HLG2Z
MI""<=MQ+T[^KJ%YQ+!&UQ`$RG(RF8@;J&7C)E25G<(,N`P2=WJT&L1O.V&O0
M;A0@JIH3,]%QBZB(&$O?)HO7**BB74&W44!+OV;[ZU:>14(4M@*5A5ANE,C=
M.B-W'F&K'%I2=T@1';F5*L9GA3RO?Q[EN[8K<;,VBW>M'*#QFZ3'&UC,"S9T
MV45062'?;J*80UULI46LWI<8,]NW,:?:&B*68/#NU]U`F`TJ5HML.GX8=/&]
M[J#^N4J+C[/69&0<5FO%291]DA'SU10L.S$Y$F;9ZHZ6[HA1,82DV``$?!VZ
MY50V4//.JF":DJE(ZXM4JU;%MB0L:!/*!E8-%YW[H7\S:X"NF2]WI>)A$EQ`
MK=Q,RL?%(.%1`1%%N=\X0!94H!N)2[B`=HZWY93C0DJ&F6B,K?:;5)TA(UD@
M1?&V:&FFPO(:2C9ED4QTSO(F29R30BI-A,D+EFHLCWA2CN)>KJ#U0V[=1*J&
M4/*862'$I"O9-Q,K(E00Z)L$+.X?AMC5GR'2DW9H]2V59*1*X\3-'*6:#(_*
M\$P)@T,T.^!<K@53`7H$H'W[-M^S4R9K$TA4MT2C13J$'"LI!WXW$C8HF';'
M>RS]A%,TSD(9Y)OVL>S**@]*?4Z=J)($,H;L*!C`)A[`WUOLS*8MC13Z46JD
M$ZR9#SQC1%NKM@4.G`S4/.=S_P"$GAI>/E2-1$O40KD6+A?N3*!^M`VV_J:@
M4ZE"L"IA>]\-T2(6AP8D*24[A!C!EL@TV"?'C9BT5F*?I](J,I2R0D:\(11,
M5$E#-7KY!P!%"[=(B4`$!W#LUDBHF,+9*3IG$9J:=!P.+2E>HD3],;E[,L6T
M:2557;DCS)E<&>J.FZ3-)J=(RH.U7BBA6Q&O=[#W@FZ-AWWVUHX0H]7,PM1D
M+)V^3>@X\EM*7C[(.L"R1TW1#'B3;JS(WSF,VC+!!2BSGE-89%%*-F8Y\NJR
M#$V'4#.DT&SA591J50@@*H%[L!\(]@Z[-<@K33JM&&G`M$M)M&Y'+REQG;U+
M3:TK4IY2[-V5F[OW1+Z4NM7@E$4IVP0,(JY3,JW2F)R*C%%TR"4JATDWKI$Z
MA2&.`")0$-Q\.N?LUZ!,1UW7V&9!U:4DZR!Z3$(_239OMV)^`G)3-F%[:C"W
M2A8[-9Z;;8KW(G$&LBUL,(B59$CE*2B7J"R9U45"J$5()#&`0$==7PK14&>>
M)*;):[:=6=<"7`GDG"=1C@^)\R=R_P`.U.94AM;2)$:9J`O\L<*N$_\`O*]:
M=A&4WG)1%JU)K]RR#,^*8QT_JRPE*!0>V^@"L[FH100+U*N(L[Q#M$0;)!KZ
M[XK^Y+,<M<=J/#2]OEC8GLU6+0#<`;E3W)71XO(/O'8=":+-4E+P`..8D<6Y
MN2MCZA,09PQ1GVH,[_AF_5/)=+D"D,SLE-G&<Y&F,<@'%JY.T,96.D4=]E6K
M@B3A(>PY"CKXB_3NTSRF*A*T.I-H4".#7Y(^G4U72UC8=I'$K3ID;H=;?58$
MF<Q*46(KK:$&D(AEF[^=WPC^IR5_DPBM66_W=S_#Z8A7^M3Y?0(F67P?JZYU
M-[!_2,3GX(NU8C$&D(-(0:0@TA!I"(\\J_YL_(3_`$.9*_R2E]6<J_KS&^GT
MB.=GG]+<_1XH=;\S]1_.B]Q1%WBD.U[YJ^QRWG?Y&L,ZZ.=G"U0*U49_SJBE
MEZ]J_4)NP.RWYV_#"]N_)JC8QO=UKV2)BGTNGTC']!NLG<YNXH-5V:E^N\_1
M8QO.0"L8F6#@UY>(12;29WBB;EPNHD*28("H>JQ1N5-.EYJ96HRP@?#Z1H@_
MF#5-5=7>L3AGBGYI1'S,7I(\+4NEXKL>,I>KY0DLQY<3P_4&[N<M54KK2>8%
M57M:MJF&&/;?/5XU?;%2`K96'%RZ5=H"4I6YE'"=FFRE]\N;2;8;;Q6BU6@`
M#=USD!.*];G5'1E@`XP\[@G=ALG,Z[I:(?N`YC\;;*ID9&*R_1UAQ'%2,WD9
MPK,"TCJW#P[]Q$RTR:6?-FL9+P<9+M5&B[U@LZ;)N2]T8X*B4@T^H9B%H2IE
M02X2`;[A.P2O.J+CN8T#8<5M4D-I!X3*&O:>D5XKSM^Q5CBO7I6Q368S69K3
M'<?6K3[D^Z=:?0<8O#3BKV#:.X21DW<^D5J#A`J0D**BIT4E$5%9D935+HCF
MJDR;:J$-&VV;I(!%ELL)U6R$],1*S.BZ\G+E$':-E6^!H_(PUU/S?PAH]'QQ
M:;Q$<:<)36;@C,D$@JY%U66BY.<B[&H@UO+FQP%-CF[EK$6)1+NK%)HLT&SY
M0>E<BI#&-BIHLQ16NM+"UM(<*$S209``S(,R">:;1*(J4Y:I@U-&$MS40H"6
M@RO`&[Y8>>\YYX?73*E;PCD&R8DLN782XMHZN4JVP\?99:O79_`,YZ)+&.92
M%>QL#9)BMR2:S`Q7""S](YR-Q6,14A)6V:UE)+16@%),P#<-=HNGY#$1JJ`N
MA-2I(<^*#;/7O0GN3=.P)30Q5;\G9+C\*42NW*LO&]>C86JP]?R7;\<1TC/8
MD@;*^2K+^U23'')XMR_A(%BZ;M73E,$3(KE$J!J^3UM8M*Z@C&I:5)T\D*F%
M;\]9NW[8GKC2*2VETAL!84-.*4(?$]_XD8TJM-(^Y`P.7;#R!R5,9<J-\N;:
M'DK?D_)#R9AJ6_G*["5FL,(Z!?4I16/A2MF,:R]PVR`$6*ET.%`C?9S)*6EI
M2I385@E:`F9Q7VZ[HB<J<O=+X2L`RVG`)2'!ZH5]<S!P1/8[XM5)/`[*RQ%[
MJB^19B(I\-&R#F\NKPG3JE8Y&71KK3WTOT,CRA8]&<0</4F,HOT&<I*F-J:H
MI,X024)4$CDS,YW3-AW-&J,M9GEKK;2<8&)`,O*1\$;+*U^X14]`S',9<'>*
M8GN24"VA[)0X6PJ46^SL0VOIV]<B$:U+NHV<<UY^A,O58Y'J1:J$<N3IA[?4
M-*UFM2225*.YI\\7'EY:VU@7A2L&>L\$.)-\R^,].M=:HM@S)0X^QW%I396M
ML5)=1492(R(JLWI$V#UHU=QK>#M#AOW3.0<.$F:RQB)BJ"AR%/*:&KP;3`<.
M(C@O\HU1"<WHK`5`$#7#=MO2`8;L\W?ZGCUXVFK=BW-]`PO=HFV.Y*B,T'=T
MM58JZLQ!S+^OR+.95;/K&9NR8?M+F0D&QD?VE)1-R:566524I(23C3B&]&6\
MTHUKPXI`:8=6.Y@\=9:]6[&D;E>FOKW165CD+17&TDNHY8MZ:B5>YE:NQ8EB
MYI[4$1$THU8KN73#80733$!`*W4ZL`%;93.5\]-VC3HBYUA@A2D*!0!8=>O@
MC;X:Y28)Y!+2[;#F3*GD)S`-(E_,(UN0<.1:1T\BNM#2J8NF3/QZ'D0:+)IO
M$`4;>,(J("<%DSD+JZPXS,.`@B(Z6LIZE`.()7J_*4-5S)$3*<4Q$-A'F?@K
MLWWV_P`*?5]76^6&;=0?]-?_`&PJ9;5N1F,0^&)J(_VLGU-4&/U*=Z+1OCG[
MSAKZ,NSH$Q%5GDDMDVHS5GE<69*XQP\#/7#'%C>0*42LC9H:RR#>NRM)N;!Z
M+1\UDVKN-6*@'?':J%16#K96X$%3:\!:4JT*NE/1IF+Q*.1G%,A80^V%AY*3
M[-\Y>2PW&&D:<?\`)%UY*\+,O95JJR<^AA1S-\FT:LN@&-76<\91T.YPJ_FT
M"F5*\DZA-7ZV'B#HJJIE/TF]L5LV,6RJLV-,]2-R5-:@E6I)-HENV:?3%5JF
MQNM5)24R2"1.]6O\AZ(BK<N+N<:Q'U*V4+&4_(JY2YB+M.0-(;F:-W9:/3>;
MLYFK$N?$T%G"3=PA"T8[R/?'3,=RK$2S,P$-XB!`Z[F;LU:TIJW`4M4Z4I,K
M9A`21?9:`=^?E\X<IJZ9FE<HFE)4JL6HB<["LD&[=X(FIF>C9^H66./^>+1)
M3?)2IXQREE!TXI&*,615=N]-J62\83]3AI&.@O?B^'(BU<E54$73A([5Z1H\
M56(@8@*`'#IW6!2NT[*0VXXD<HF8GBG=(2GIMMCU68LU(?;==*G6TGV$B1&Z
M#,DD1&?&U/S-@&YVG-=AXWY.N\?GRA<A(^,QK18RLV&T8LL5]SY:LK5*DWMB
M-A2BH9C=*W:DC2+YLNO&QT@S41=G_M9S=.JK:6H"&T.I&S6@DGXV%,IZ3/?C
MEY>G,Z7$'6$J2H&4D@$3-@.Y*_CA%S/$+FK2ZWQK4B&&%,CNL5>1K1X5D\F\
MB%L&-H+&,U6IO(XG0C(ES7GL')7)HJZF)5!8SMQ$1S)%%+_FZ91G7FV6.KJD
M@*2T^'3*:935[.[8+A(6DDVQO599F5(JE4@AQ3!`N4"1IU@#7IL$M,=@(?C)
MAR%R@_S;'46O1V59AD1I*W!HS$LJL*AI,[Y=-WWA5".I`)=9%=;]>LW*DF?<
MJ*0$\PNLK7,M1D[CA.6(5B2C4;.+5KCOIR^A;K%9BVV!F"Q)2]8WHD$;]:;Z
M@_:U1J?W=?Z!]$7!>(A%EG^>SPR_Q(Y9?WDPWKT='_\`-YK^UI/\T<M/]0&^
MOT")O:X<=.*"&X"'@W]700B''-C']TO>(HT:+7??Q,4'+N$<NN,>%6CF[K(D
M'BS)M>N=@J$<>8<M(<\O(1,8HHP3>*I-EWZ"*1SD*?J"[E[[=*Z3(C$E0G.4
ML0E/R1RJ]FJ2RIZG(4\""`1.<KQ?J)X!$$N34!F'E:TRK?J'A+,V,_>]Q6R#
MAV%;W)DSHF6,B7+)F1\9V5*-J<)&3\A,1\-0XJD+.22*ZS4#OGW2U`Y4EE0N
M9;4IH0A#ZMLT'"HBX6I(!T[D]<A%#,&\XS"F*&T);``^+RB018#.RRWAA!9B
MX]9&KW*?&K+">")JJ47&.1N.DC1[W0*4ZL19"AJW.&?9N7L^59O*[1U0!8,W
M;])["-*\\5GVKA1RX,X%911O9HJBD"7&:B1"TJ,Y@`&7)LE;;=:)14K&,S6M
M#S2%)4B0D+<4["<5DI:L)GK$2^H>+,YQ?`K.^/*BTDZ)F^QV+F&]QL+QRA#2
M;>3O.9\IV#'TNV?'7*E&!-QLPT<-'!E$^Z(X3.8R>PB6K65-._F:'TI_VZ0F
MR^X"8NTQUZ.BJDY4XRYR7E`F>J(.XRXM7:1HT=6'%4SC'4VS\E^,3_(&-)G&
M@X#@X>MU!C="Y*L\8RK68K],V!M.I/V+6UR9'+9M,`W1Z1<B*Z@755E.ZZ5A
M(3A:6!-05,F1`]E,MRPRCSU/E]>B@PXUE:JA$YHPR%H)EB)(W;-X1N<D8`=-
MX''V%+7QIRY:L95WEEG*>K]KH=:>W2RXKX_Q5SBK+1J9CU9K8FTK58O)4THW
M10==Z/N;6V;TB()J&;`6I25B<"JP84.!.'`?CFT%1LNN,M<=6KI7"MO+E!2T
ME6+&+DRN$IFV^<SHLA<V_'F4I[/?(+CY`M[`_P`?8QIN6^7]*+'R@F]TLA\D
ML7V6@47%(($>@Y8NJWDH+K/-&ZO2B0KR/.3]842W$FCIZ!&8H*>MN.!M25)!
MY*3B*@;+P`");T5UT[U=F*\FJROJ;3>T2M)*9J,DX3N`$D6P@'O!0S.J6Y**
MQ=D,\PZ]'K3YJ%;+W>[+'=\VX%G84FUI4*O:E"N<Y1@&9)IRBAQ712V3*J!!
M/JL[7[:6+`I(=)L2!R=4]6H7B-J+)F4.NH80[B2T.4I9(G.^1TQOUL'9]D>9
MS&_WD^86RGPB8CM^/,A5/%,/:(N+QM$4&L(VS'5CRROE6!''5=D+0C.M[%"#
M77!WX/BN&_C:JB8HR.U=(EA*4-@J*2%6B^=\I<!G'/8I<W8KBNI6HTX4,*0F
MR6F:L5G`?)'=QN?O$R*;"'6DD?I'PAUEZ]A]D-]M>>(Y15H,>ZGB`7<"+M49
M&D(97D>8"X`S@(^#X'LG;CV]@>\F;W'8`$1V#4^769NPI5C06DD_XTQ3S!91
M0N%(Q+PF0UV&/@$M/H9/2.Y*L4ID6D<:%[!3;W[FVVJS:>0L3L22L!.PT:_B
MWX,Y*ZM7[7QIHJ0_=K)IJE$=C%`=?JMKQ_\`=I2LHIW"VE]`DHEG'B(TSLWM
M._'P&J\'^-7ZA=2RE:F7#-(#NSPC5*1GOV;T:#^@O]*)YJ#KY3,,_G[J3\1O
MNRY[/\-ZXK_V7XY]TY_$_P#C!_07^E$\U!U\IF&?S]T_$;[LN>S_``WKA_9?
MCGW3G\3_`.,']!?Z43S4'7RF89_/W3\1ONRY[/\`#>N']E^.?=.?Q/\`XP?T
M%_I1/-0=?*9AG\_=/Q&^[+GL_P`-ZX?V7XY]TY_$_P#C!_07^E$\U!U\IF&?
MS]T_$;[LN>S_``WKA_9?CGW3G\3_`.,']!?Z43S4'7RF89_/W3\1ONRY[/\`
M#>N']E^.?=.?Q/\`XP?T%_I1/-0=?*9AG\_=/Q&^[+GL_P`-ZX?V7XY]TY_$
M_P#C!_07>E%#81XI+`41`-QR=AG<-Q[=P]_G:/L:E5]Y_P!UC3"5A3)>V@1^
M[73TSGYH#P%XX6;0X&U7CK'JA)T3T-?I&<GT^O9!HW&A>P5&V1Y):`F29#Q*
MR"08***(D<>)R%V;/FW4HB8.E5,A]@WVV$-25GWA?=HS5.-+=94L*()ZK?N^
MU#^R/&K?(::<V8L'^XT=&%9_07^E$\U!U\IF&?S]U6_$;[LN>S_#>N']E^.?
M=.?Q/_C!_07^E$\U!U\IF&?S]UC\1ONRY[/\-ZX?V7XY]TY_$_\`C$$>0?&S
M,O%+)#C#V>*4:@9"9PL38UZV:9@)XR4-/D75BGGC]9DY>*,#P&J@B0JPG()/
M;``Z^A9%FWA_/,N8JO#V(4[KA04AL@`@R)_(>6.%5Y5FU'F#U'F@0FI9;"P2
MN9((G*[S^6/;CYQES]RGNB%'X]8IN&2[,DND9=Q7F!TX.M]*W0$C9+:X.V@:
MT@W5(7]M<.4^DP>U$3``#SLU\4^%_"U,JH<<;<="B,#PVL[YRGZ)61KX?RC.
M\Q6>I4ZQ/\[X91TKRKZ#KTKTA=7+J>Q6;.$J2*K+=;(C?+E'E4GZ+2%8)MH5
M.5O-JA[0_)4D2^YH*.&Y2#XOLB)T03.;Y]0_>C]V=2RM-,EJF)"K.K8[3/=T
MF/7O_=]XH<=2I2'!)0/[SJ(/-\T?97S8Q#DG*GHY<U8)H=8-8,HV[CXSH\#5
MDY*+9F?V7W%AV2D<$G(.FL0AW;A`Y>\5732'HWZMA#7YSR#,,NI?$[;U:0:)
MMW&J8GR1/1IT61]E\1-9@YX=+5&C_=J2$WZ9C<WXX@^@G]'1S'X;\H\FW_D5
MA17&U2LF$GM0AYH;?1+$1U/K7&M2B;#Q:IV*;>I"+"/6/WATR)!T[=6X[:^F
M_>MXW\'YSDU.YX>P;8.`JPL%)E(C0;;3'B/`&4>(,IS=\9R%;#!R2;O3&P]/
M%Z.KF-S'Y'XCOO'7"BF2ZK5L)#5)N32M]$@/$+`-SL$M[EF:6NQ0KU<WN>\2
M4[Q%-1+8^W5N`AJ7[J_&GA+*,DJ:'Q"E!<>7B!+,R+`)3,Y?!?$7C?)O$F95
M27LFQ%"3.0TRME..G&.,2W_!?H1I[#>4X$:KD+'_``>S%7;973/XV5&(EDZ+
M>%CLSR$0\?13H01<DW,BNHGV_KO6\'3YCECWWALYC32&6)KVE73`2%I)LLG8
M#99JCUU715BO!*Z*J!16+I5),C:"1KCY_?1->BJYXX"YT\;\XY8X_K5'&-87
ML<A.6L]XQQ*^(M9[']BC(Y08Z$M4A+K>,.WR("":*@E!3<P%`!$/J_CKQMX+
MS/PN]EV6;(9FM\@28PDVS]J=EWY3CP'@W(,XILZ&95O6!3(;"0%+)$M>Z):(
MZ]>G\X7\E.9^,^.-=XWXR4R=+4/(UPG+2Q3L=4KIHJ-EZRTC6#L5+9-0K9T5
M1TF8O2B=0Y1#<0`.W7A/NIS[PSD68ON^(\);PI"048Q,$GV=,Y[ET>L^\/+<
M]S*C8:R1!Q$G$H&T7:/)KA]?0A<9,X\1>&#S%7(&A&QW>AS/?+66`/.0$\<*
M_-,ZXG&R'CM5DIF-`KM1BL`)@L*I1+N8H;AOP?O)\3Y1FOB=S,LL2$T*PE,D
MM2E(WV&7FCJ^$**OH\NZKFA5MRDVW&Z/GYRAZ)+T@5@](];N0,3QT6>8ID>9
M)<JL[7[_`'&20KT4N5V=E";"*7MJ4Z4H0R8J]R+8'&P=/=]79KZP]XV\"N^#
M6<H!;[W-,D$!F1Q)2)\NW5?*V/EH\*>(V<^>S1M;YHTO"0*B0052NGH!CZ/O
M3+\>LP\K."E\P_@FE#?<@S-WQG*QE="8@H(SR/@+0WD9=P#ZR/XF,2%FS2$X
ME46*8_@*!A[-?+ONS\0Y'DOBA.99X4JRU`<09HQB:A)/)TVZ8^H>-\KJ<UR`
MT=&%JJ%%*I).%5DS?$&?]W]X,\H>&`\GPY(8G/C(V0G.-#5+KL]/L(RQ:ZVM
M2<N8H5.<F@;`V&2;[]_W0F$WM>KI';N?>UXA\.Y]F#:O#I1L,!,DM;.Z6F=L
M<+[M\AJ,IH7%5X>368I26O%9YHY_^F:]%OSFY2\\\GYAP=@1:^X\GZ9C6'B[
M&2YX[ABKOJ_2FT9*HF8V.TQ4HF#9X0Y.HZ)"&VW*(@(B'K?N\\5^`J#P1446
M>!*LV4%8"4DWS(MPF7"(Y?BGPQXHS3Q$WF.7J**%LB:;\4O*)<!CZ3\U8BR+
M:_1JW'!5?K8R.5)GB*7&4=51DHQJ9Q=3XQ;5\(<)1T[2ATCA+)BD"QURH;AU
M=YT]NOBN2YE04GB9G,GS_L15@^SB$@9REI$H^AYG35E1D:V&`!5EG#(F4C(6
MSCYT?0)<"^5O';FAD:_Y>Q`-*J=)QU>L-V25/::7*A&9&<_!Y:6U9!M!3LBZ
M<BK`ODG'C")#L]C]/>]0"77V3[V_&/@_Q!E-.UD"T"I;(4I*6=G).$B^>O1+
M=CYW]WF1^*LKS9U><MCJA!`5CG,XKI2U:9Q([T]OH_N7/-'-''^S\<<.*9+@
MZ-BZT0%E?EME)KI8V6E+4TD&C3NK;8(1=T99H@*G4B54@>`1`=<?[J?%OA'(
M:=T^(2@K?4`G$WM+A;9HMBUX^RCQ'F=<1E*5!MM`-ELR2=[1#IWG#>2>/7^[
MFY(PMEZKGI>1J)Q\M3"T5I21BY48QT_RL>6;)^Z$([D(EQUQ[]$^Z*ZH!U;"
M("&VN7EN;97FOWPL"@,J-50%I*6B.2`!=.^>CRQ9SANJIONM?16@BJ2VD*G^
MT$?#60ACJ(HI%%5PNJ1!LBF4QUG"ZA@(FB@F0!.HHH80``+N81'8`$1`!_75
M349,\]UO,'7&D"8$SA297XA\;199+RQ^?E-+KZM*:$*6ZE"9@62G=KCZ$_1<
M^C`]**K;J_F7'=XN'!NC29V;MS:K,H[1L%XA>HJZ:;;""RR1;0S=)%+T>^%)
MBVZ3`8@G+V&^&_>-XY\#9@WU!QAFJJ6@I+:VY-RG*>,R.(SE(@S$?3_#/A[Q
MRR\EQM:J:B)&($8L6]:)2$?=-48J:AH&-CK%8U+9--6+-&3L*L6RA32[Y)N0
MCN0&*CA%BP\<<`944DOVM,3=)?:@&OS3M-J\M:1)O%8)SLWX^\,MEII*5'$N
M5INF=ZV4*;6\20:0B&6;OYW?"/ZG)7^3"*U9;_=W/\/IB%?ZU/E]`B99?!^K
MKG4WL'](Q.?@B[5B,0:0@TA!I"#2$&D(CSRK_FS\A/\`0YDK_)*7U9RK^O,;
MZ?2(YV>?TMS]'BAUOS/U'\Z+W%$7.*F_O[YK;;>VY:S?:(^MAK#(>IOJQG;^
M-FA2)"5,4VF0]HV^>Z.?EDNL5909KV]H\@ANN1'%RWY<RC>K9&R=:1AK?3.+
M540CIE*365[_``'R2D,WVA200;QCQHM&V&MNP8LB]1A.]W*L5-/934M#FPHJ
M8-MELN`FW%*])3J.N<0YCE"ZM_K"I`2E+UQ23XNW.6RM*W9":@V,%,\O87D&
MLV*>4;2J56C^+Y<"2,2!@8';%MR\\EX^F?K,V%GL8RH*^TUJC.6VDA+I1A#>
M`2,].*T62$15&3*JI'!-25XIXC.Z4YZXBE1O1GW>M8[L5">.<?A8JCCZ.H^)
M,JR&5^162QETJWDJEY%@65JPYD!^\H6,*M/+X_C4YYC7'+X%U!4,V,BF4$C]
MM7B-*ZQ-6C]7,DIY*0)I(F"/:-IO$<\^%ZA;"V3+EX;9ZC.)B*T+DU/92P%F
M:WI82;66BN<KUV[TRNSN0#U]MC7);:CI(O:O:Y*H!(6B]5]S3>].@_C(9B\3
M>E2!1OXMWJO+1F&RRQ[*D+3LG:AIS%8"-D5\F0-N(+-L[-1G*.PK*ZDYDUF6
MR3M&FU)(Q6*"@+9RW+C/?B+D!PCY!T3'CBA4ZP85FOA,XKPW&/*TA>`N!O>@
MA`RN1M[GCA&,@'B=P9OX;)3H5J_*FADAD&J"_C(`91,.G69^U7("GSA6FH<=
M!3(S*PD2,Y2EAL-LYFP:>?39!6T:G2U+"\9X9W6DV:[]RZ'I3X?VADQR"QC)
M>O*DL/)GB?F*OR$D5^,N6E\=*U@ZMOHJ=7;QZPEMLRGBEZHV,D*C</=`O6JG
MU'`O).>-.$;,I.%M:""K".7I%ELO/%RER5:`L5:0N:DJ%LI2!M\YX87'.>$R
M/,/^(*^+*Y"V.SUKEG6[4DC9VLZ>I,6L9B;,:2SJT2M<C9B3JT8=1ZFV3E0;
M+D9OG+<PIK"/<J19$NF80]3OK26U-*M!$[3.P6@G<F(QFM-7%QI=*PEU239R
MBF5NX(1^!^)=UH>0:UD^_2U,>SCZO\JI&\L:DWE4&T+>>3&5*3?5FF/EI*+;
MN3UZM15678JO716KQ^Z5%R=`H*G*3HU.<-NTHI6PA*$.H4)JOPIERM1.YHW;
M8A:R*I!+X0G&XR4*`/LS)G(Z;#N1'[#_`*-R2JU'O&,;\SK$C')8-NN%*/E6
M-S-R$N]N796&59R$7--L69'=NL=XE79.Z[&/G:$`Z?)JRC),[8S='V@[OYXX
M_5FHQI#:E8BBP"8LO%ILTG69P8\/J9HTTVR07$)PA>*W7=*5F_'O-\!<Q2]7
MP]<)^PT^^9^@+)G&Y9J2890SK@JB9`L6<@KJ4L]JE^Q.),A025,84N)CX]H\
M8N6KR-3625*D?NU-1JS=K:%3"6VVBE("9A0&'?%YWHA.0Y@B3SDGGBHS!5*P
M[MI,..YX031<;9JHE<2Q]6F^2^.7'/"]/BFSNX2<33GN&']TE)%LM*V-"2M#
MJK"I:&X1JJZ[E^H=`3K@FIMJ,YHHH0E2TE2%J7>+U`3BP_D+RR<"$A*T)!ML
MF"#+S0K[3QOR[.6'*S1"0Q][P[IRSP'RCK,BY?6E.X,5L<R^)5;Q2)^#3KCB
M!*DZBL8F/%/D)`YUU7H).4$")"N;5K,4M+2L*2<+.SE,7&_TQ,[E%6MM39;3
M-3F.>+3;HEJAO83AEF\L/2<7S=CQ(3%N#)CD#8L8V6#);"Y,O$MF2LY/K,`P
MR##/(%M7ZPSK[3*[I6:>1[^36GG+1)046^ZA3;+S-*ZA;Z2D%82")B0PR'_:
M#IE%=>2Y@NG;ITD)0W,S!OF2?)?$B\#<;+#BW(.'K4_D*XK'8ZX7TCC')LXM
M!ZDN[M=2GXF:=3D<!V39N%8<)1ZH(@IT."J*?VH@"8=<ZHK4N%0*D8BX53Q"
M=HN]<=*FRY3:4[1(*PC";=V=D;7F..ZG%0.P0#F=@KM`?`/_`)4]@AMV#MK;
M+4*4BI4"B6S6;]')\^Y"J+B'FD!(PX@+]^)FIJ=!0]J(]FW8`[?7VURVP^EL
M)^BL'.]4=0-J(F9`Q<*@"(CTC_Q1^YK<]8^+L@?TO5#8S]J1BG>?V(_\4WU-
M0%FI)GB;Z1XH;$;G#'D(!OO[;?<-_:F\`=0;>QV&U)LERD0WTSQ1H6'"E"<0
MY"I[^YN1Z=?9ML;_`(H^IX/4ULV*AL2.S/\`B]42;*9FJ1BO6'WH_P#%'M^Q
MJ,L+)G)OIGBC79NZ%"*`8`_K1]G8HAO]7L[=9V*YSDWTSQ0#;OQE`QZ]_P#V
M!OK#]S4GT_\`I]+U1G9'6.&`5MP$.D>WL\`^K^IK5Q#SB"A6S"2"+%3/!*V,
M%M21B$B1NQ"K+8;<V>&7JA[P^6:FX>N6&PX40V_4UV,OJ@YX?KFTBUYQB_1L
MU'TR\F[''7M&\W;:D,*TK5.=UB='EB:O?_V!OK#]S7)^G_T^EZH[.R.L<,'?
M_P!@;ZP_<T^G_P!/I>J&R.L<,4%8!#]8/UA'^II]/_I]+U0+2M!$>(](B!ND
MVX;[>U'U0$!]3UM9Q50$OHND>*)`%A,K(J`E#MZ1WVVWZ1W^UK!-6;BT/\1X
MHP4K.D17J#??I'_B#O\`7UF=3*1V<_TCQ1ILW9VJ!1J@Z_6`0[=^P@^KVCZG
MJZQ.IG_ZND>*,I92FP!,M_SP=?;OL/\`Q1^WMN&L'K)(P[,)!G+$;?-&5-A5
MX&+7"?CZU`1<[.65C#QS2>LH,2V*8:1K9K)SQ8I`6D.$T^12*YE/<=F8R+7O
MC&\72.8I-@,("4*E:YJ+9:`L3B,@==WP1KL1/$``O29Z-4;\3`/]:/AW_6#]
MSV=;IVJ?9#0_QGYL"TH?JR$G3IG%PJ;[>U'L\'M!_5]3U=1A-2%%1+9!T8O5
M#93]O"3'IW_]B;ZP_<UO]/\`Z?2]4-D=8X8._P#[`WUA^YK'T_\`I]+U0V1U
MCAAD^1YNKCWG3;LVPYE#P[@.P4><W$`$.T-AU;H0ZNL0VO9X5$"Q6M0W//'/
MS)MP4QV<L4CZ(\.-79QTP#U!N(X2Q./M0-X/>%`>';4-2AQ%4XA`:D%D6JF;
M#+58-6N^-Z:G<>IT%]1F$BXRT"?GG#V[E^]-]8^H9/\`-8X?5$W4D:U=*#<O
MWIOK'TD_S6.'U0ZDC6KI0;E^]-]8^DG^:QP^J'4D:U=*#<OWIOK'TD_S6.'U
M0ZDC6KI0;E^]-]8^DG^:QP^J'4D:U=*#<OWIOK'TD_S6.'U0ZDC6KI0;E^]-
M]8^DG^:QP^J'4D:U=*/(X#L8"^J!S;#N`[&*(;@<?UI@UAE#J;5[(S?G9<!\
M)B&H:+5&ZE()!!MQ6W1$/T?X;\,>._J_YOFH>$W_`$E)>MV:[&?[49S4R2Q^
MM.FR_19=\,XHY52DY8P%E14&@"<7E^&)@^U#U#?^_P!<B3_-8X?5'4%$@B]7
M2@W+]Z;ZQ])/\UCA]4.I(UJZ4<9N1GH9\"\PN9DORGY#VVVV.M^]"D5:&PO7
MS*UJ%>+TYN]07E;;:FCDT[*,Y([WVK%F9B)0)^V+'W$@?1LK^\CQ-D7AMO(,
MD6U3+;=4L.B2E$J,Y82!*1W3'DZWP!DF99ZYG=<E3BW&TH*"HX;!*<P9W;D=
M4L5XDQEA"GQ^/\14.J8YI44F1./K--K[&`BD!*FFF=PH@P23%X\7[L!476%1
M90>TQS#VZ\#5U69UU4:FM<2ZLSG-9O-YNUZ)2CU3&7L4:`W1)0V@62$KAP3\
ML..!@#U#?6-JOA='LI8'E]42=4$YXE=*#J#M]KX?6((:A>IE.G$`TE>O%ZHD
M#;T^4H$:HIN'9MU!MZ@%-MJ5`JFQA3L,.BVZ)`D_&PE6N`=A$-@'P^J4PZV2
MJL`DLLD;A(XXT*'4CZ-0`\AB,G-H!#AGRS#8`_U;<W>`#`/_`%;V/V/#KHY&
ME:<WI0VEH3J&_C3^,+[(YN8"HZ@\5$*5LU2T6RA\:+N%,J(F#VWO7K_M0ZMN
MD(=CX0`/UVJ3AJ^L5&(LD]85*5P''$]'M%430*4R*4SX(50B`B([#V_V!OLB
M&VH\+@5C"6MIKQ'BBULZ@'DK`3H$A%0$`V[#=@;=@&#[NF*L*IDLX=\QMLU&
MU9!5%!$!V]J(@`;;"01^SZFH'6:EX<LLST$&1'FTQC9*NFG9Z19;%PF`0VV'
M;L_K!]3]36[;);3A0AGI?^,"VN])`/#`!P#U#?6-_P"WK)%:JQ2F<&J?P^J&
MQ%X"0?)%IMA'?8>SP>T$=OU=:BG($@EL#],_-C4MU/Q7`!O"`^RA>G;8H"`F
MW`P=G;X!#U1'61UBF25,[(2%V*R_7*(WJ5+Z=F^,0.HRE9?$0N+'M;GS++MV
M!RSG@`O:8=@P_AL`'UQ`0]774S%MP!A*@TI*V`JTRLF1(B1MCFY45+VZ&D[,
MH?4F95BF!IME*>JV)?;AV>U'L_L3!];UM<9-*XAPK;V0U`F8&]9'92ET7D$Z
M=V(M\TN/Y^57&#,/'9.SA3#9<JY:HI:U(H\T$"V/+Q4D\?EB@>1Y9!0C6..!
M$C+I%.<0`QMMP'TOAS.:W(,YI\Z;2PMZF7B`G($R(M,C=/5'+SW+!G&5.Y4H
MA#;H`)`!E(@W6:M<1>X9^B&X9\*FL7,4BBEO^5&R")G>8LHMFUGN/C@=*BKF
ML-%44X"B)F5WZ"Q;5!<I-BG64$!$W1\4>-O%/BCDU=2A+(4HI2FP)Q2F++[M
M,<O*O!^498O:LMIVV%(*K+<,Y&6B.HFX;@.QA'8`$1*81'8-O".O&=74I(VH
M;4L"_&>*/3E#U@2H!(T1ZE6Z?ZTP_J&^YJ1*7TV?1R_2]4-D;YB<7=__`&!O
MK#]S6WT_^GTO5#9'6.&`5]P$.DW;[`_<T^G_`-/I>J&R.L<,0TS4;?ESPD\`
M#_K+;`/8([8OB=^P0WVU;:+O5U@X)V?&W;-'#J$4GL:'T)`!$E:=P2B9'>;#
MVAOZOM=Q#Z^VJ+:'T)(&S-O.E\$6TH6I,U2!WXO[_P#L#?6'[FM_I_\`3Z7J
MC;9'6.&#O_[`WUA^YI]/_I]+U0V1UCA@[_\`L#?6'[FGT_\`I]+U0V1UCA@[
M_P#L#?6'[FGT_P#I]+U0V1UCA@[_`/L#?6'[FGT_^GTO5#9'6.&#O_[`WUA^
MYI]/_I]+U0V1UCAB/W*L^W&;D(;;P89R4;;M`?\`!*6]</!VZZ>3LJ5GE.J:
M!-21?IF/-NQR\X;=<RYQ(`NUP[/YGZJ_.B[+T1S?PY2.0M@R[S2?XRSQ3\=5
MX.4TJBK7IS!J&1'9WQ<0X@,I(%GAR-5!3370$A/%_%C=`I]0G$3"&O19@[EB
M&*!NMI0\#2$GEE-N,R/LJ]?DCSF5,.]>KUH=*0:B["#HW8D2.*^9`AL/++''
MT4T/GLUR0/#H45#+TV_ZA^9'953U2A+K!'^!,4^"OF5ZG+3'`?\`JIMQ^WFO
M65*R,2+-$$*U[0F?R!$?5*T>Q5*2?V:3!\%?,KU>6F./U.*3</L_#7K<O9*M
M!0]1X]4W39Y,,8-+F)L-8KZI''%!Q9S*#8/*UQN&_P!]Q3;_`&/\]>M0YX:0
M@(70"?[4V^3!$:Z7-TVLU95KFVD1;\%O,CSNL9=G;_-3;?7_`.NW60]DB`=C
M1E"3J=-OR!&.KYS=UJW]FF`,6\RNW?EOC/\`5XI(#]K-@:B2_P"'5$EZDVA_
M:2E\@QNW3YP)[5X*U<A(]$7EQ=S([>GEMC?UA[OBHV_]]_GK-J9#WAP`[.@D
M?VI^!$3(8KP<3CTAJ"$\,XI\%7,G<1#EKCKM'<>KBFV/];_/478-9VGAW&%F
M@!LE^M-N[/!$"*+,D*4>NK(4J<MDBS<B@XMYDAX>6N./7[.*;<`^J/\`GK'4
M<\@F2F@203[T_,C5RGS('][4;/=H@+BSF0/:7EKC<>SS4VYOK;9L#PAK.+P_
M<:!,_P!H?F1NQ3YB%%:ZM13=+9I'EG%?@JYE>=IC@?\`U4FWSU#K.+P]V`?6
M'YD;)ILS3/\`WJK_`'2..#X*^9?J<M<<?11;?/6&F+P]V`?6'YD9ZMF7;5?5
M(XX/@JYE^=IC?Z*+;YZ]8Q>'NP#ZP_,AU;,>V*^J1QQ7X*^97G9XV'_U46_S
MVZ3\._9X^L/_`/G$J6*L"2Z@J5KP)$1(Y6XWY6,UN-?NUR>H$N9WRTPRSARM
M>-:$*6*GERV;Q*:=@3+KT99LQ2*<!9B*(+]0?MI.D-=3*W\B0U4I%`);-1$G
ME"7LZ`B_=T:HY5=35:JAJ50H<M/Q$[OFW-/DB6I,6\R3%`Q>6V.=C!N&W%1O
MML/U,UAKD-N9)@'^R'UA^9'0-)5DSZR>@F+O@KYE^=MCKZ*:'SV:WQY)V,?6
M'YD8ZG6=I/03!\%?,OSML=?130^>S3'DG8Q]8?F0ZG6=I/03!\%?,OSML=?1
M30^>S3'DG8Q]8?F0ZG6=I/03!\%?,OSML=?130^>S3'DG8Q]8?F0ZG6=I/03
M!\%?,OSML=?130^>S3'DG8Q]8?F0ZG6=I/03!\%?,OSML=?130^>S3'DG8Q]
M8?F0ZG6=I/03!\%?,OSML=?130^>S3'DG8Q]8?F0ZG6=I/03`.*^90`(^5MC
MKZ*:'SV:;3)?BT8"M!VA^9&JJ2L"2>LF[F)B(V4\<\JT^87$AF\Y-4)W/.Z-
MRB4A)M+C8BU:0K=M$XG]UT7,)\+BX2ZLJ19$J2OC#;Q7NC]BO>])>K0/Y=W#
M5(533.T;F=H9$8E62PV:9F9G.Z.=44U4K/F5;<RV"P!@3?)-L].]HE$N?@KY
ME^=MCKZ*:'SV:Y6/).QCZP_,CI]3K.TGH)@^"OF7YVV.OHIH?/9ICR3L8^L/
MS(=3K.TGH)BTV+>912B8W+?')0#PB;BH@`!V[=O^>S4;M3D##9==HP$"_P"D
M/S(RFBJR9=9/03%OP7<R?"'+O&NW@$1XJ(AL/K#_`)[-9#^0A&T7120?]0_,
MB)='F05R7YHUX$Q4,6\RAVVY<8W-OZI>*J`[_4_SV>IK<.9$I.)-'R?VA^9&
M$T>9E7*?DWKPIB_X*^9?G;8Z^BFA\]FFTR/L8^L/S(EZG6=I/03%!Q9S)#M'
MEOCDH>N/%-#;[&;-1.U.0M)Q*HQ*<OUA^9&11UA__9/03'G\&',?J$H<N\;"
M(>IY*:&_A`.T/AMW_K@^OJ5#V0K3,48/_P"3_P`(KJ9K0Y@ZP92YB8N+B[F2
M;P<N<<&[-_:\4T/!Z^_PV["&M=OD)5A%&)_M#\R-T4U8K_\`8/03%38MYE!M
MORXQP7<?Z[BFAV^P&V;/#K)>R%/M48^L_P#"-S15Y]BH)_P)BI<6<R1\'+G&
MX^#?IXIH=F_@_P"VWU=%.9+*:*(?6'YD9ZG6"^I,_P!!,5^"OF5YVV.A_P#5
M30^>S6$N9-\:B'UA^9#J=9VD]!,'P5\R_.VQU]%-#Y[-;8\D[&/K#\R'4ZSM
M)Z"8:+/^,>7+;!N97,MRKQ](1C?$^25I*/0XOH1SE_')TN:.]9-Y$,RN3,%7
M:("0%@34%,1`P%,(;:MY<]DB,P;)H0H3'_M(^,-(1=N:8JUU+5BE4.LG3\1.
MH_E/1?%G'S&G+MW@;"2\7RJQ['1RN'\9+,(Y7C"A)+1[):E0BK1BK(#F-H9^
MJU;G*0RXI)]Z(=707<2A%5.Y(JM>)H@/I#_["?\`MB6GI*PTZ!U@V)'Q$ZA^
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MHC88R%><:D)YS'M@D)$"H+2XY=C#/U"B`_M@H)"(#VEW[1[>?N9(G.JE'4A(
M.F7TA^;%++*"L[O9_P!VL#9CXB3YXE<&*^9?G;8Z^BFA\]FN-M,D[&/K#\R.
MB*.L`EUD]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9&>IUG:3T$P?!7S+\[?'GT5
M&_SUZTQ9-V1/3/S8=4K>U*Z"8/@KYE^=MCKZ*:'SV:WQY)V,?6'YD.IUG:3T
M$P?!7S+\[;'7T4T/GLTQY)V,?6'YD.IUG:3T$P?!7S+\[;'7T4T/GLTQY)V,
M?6'YD.IUG:3T$P?!7S+\[;'7T4T/GLTQY)V,?6'YD.IUG:3T$P?!7S+\[;'7
MT4T/GLTVF2=C'UA^9`T=81+K)Z"8CGR^QERT9<3>3CN?Y24.:@FV`,OKS,*S
MXS-X1U+125!GCR$:VF/A@D!BG#YH4Z1'((+=P)@/T&Z=AZV1NY'WS2`T0/\`
MN&__`&$?&'YD<S-:.M;RU]8JE$!I5F!(T:X>&E8QYB'J-5%ORNQTW05K<`H@
M@?BP@NHV2/$L1(W.M\,Z/>F1`=A,)"=0]O2&^VN4Z]DR:BH`HAAZRH?K3KTC
M#:=V+E+35:6&Z;;F6R!GA3JNE"K^"OF7YVV.OHIH?/9K&/).QCZP_,B?J=9V
MD]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9#J=9VD]!,'P5\R_.VQU]%-#Y[-,>2
M=C'UA^9#J=9VD]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9#J=9VD]!,'P5\R_.V
MQU]%-#Y[-,>2=C'UA^9#J=9VD]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9#J=9V
MD]!,4'%O,LNV_+;'0^P/%-#;[&;-1O+R0LJ`H@3+WAUC\R-FZ:K2ZG%4**9W
M8$ZC$6>-V..5[NX<LB0_)ZAQ:[/DU.-9M5SQI0E2R\P&+\4K*2S4GPO,C1#4
M[-9%`&@F<=(HBIW@]YL'7S1S)":574A;2B]PD^T=.'<CBY/2U?\`NP:@XNMJ
MF<"=6K1$I_@KYE^=MCKZ*:'SV:YF/).QCZP_,CL=3K.TGH)B@XJYE^=OCL/J
M<4V_SUCK!7DNBC'3/S8U-%6'_P#:4-YM,`8JYE^=OCL?J\4V_P`]8:!>2Z:,
M=,_-@**L%]4H[[:8K\%?,OSML=?130^>S6<>2=C'UA^9&W4ZSM)Z"8/@KYE^
M=MCKZ*:'SV:8\D[&/K#\R'4ZSM)Z"8/@KYE^=MCKZ*:'SV:8\D[&/K#\R'4Z
MSM)Z"8/@KYE^=MCKZ*:'SV:8\D[&/K#\R'4ZSM)Z"8B=E_&_*U#E%P_;R')V
MB/IMT'(88&72XV(LFL)W&-XM24\=B`RZX";]TFFR2?[>V\7,'7^V;].K2'LE
M31/N"BM0`1]*H7G]&S=UQ3=I*T5*#UDRDKXB=0G/7/S7Q*\F+>99B[^5KCHN
M_J%XIH`'ZH?#9X=4FG<D6VE9H@%*$_UAT_X(N]5K%6]9(W,"8N^"OF7YVV.O
MHIH?/9K?'DG8Q]8?F1CJ=9VD]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9#J=9VD
M]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9#J=9VD]!,'P5\R_.VQU]%-#Y[-,>2=
MC'UA^9#J=9VD]!,'P5\R_.VQU]%-#Y[-,>2=C'UA^9#J=9VD]!,'P5\R_.VQ
MV'U.*;?Y[--IDG8Q]8?F0ZI6=I/03#)\D\;<MF?'S-SN<Y38_EXAIBJ^N).,
M;\8&\8YD8]*M21WK%"3'+\B$>J[;%,F5;Q=84Q-U`0VVVKF2N9.KQ`RDT0PS
M2!](9VF5^&[<\D4\SIZKNUP%\S_03'0?<GW@_P""6_ZX?UGWG@\/LZXLO\T=
MSBB+O$\/_+WFM[/+6;^QAO#/9]G71SQ.-K+Q.7^T/^8QS<O92R_4K!)+CLSN
M:+(F;T^SKA[#\XQU)P=/LZ;#\XPG!T^SIL/SC"<>2H;``]@B'@W]?L#6CB`T
M`X>5)0%NZ91A2RE!E891P=;Y4Y`0^6L\99AU.2=@IV#N2&?W>3E;!:ZR[XVN
M./&-*1)RJN/Z14G\DZL".1R331BE'K,F#3Q=P*BJ[E1L"J9_9I:HE;.C"6PI
MQE'*ERL:M),Y2&K3'C7G<R;+E5-P[-PV?%*=0O,]>Y*R'7J_/?E#+T%[..^/
M<2PG+%9^.,3C29M5/S1BG',B;/5_:TF0JDA*7^`0F+'-8_9/V\F:6A45HZ3:
MK>T00,78U<Y/EB:A;;;BL*4+*O9)FBZ4K)'2+Q%QG-\T>IDNNM)2X5I`'*`(
M4+[;=Z,Z;Y+\M,,63FI9,@2F$[C3L#4G!,C#5:&A[E!IL[)?H]BF[7:2<E,/
M'9(-T95RN\(\577`Y$!1,F0%2G+RG*WF:131J#45"724@)(!0I0`$M<@8D:K
M\VZU5LNMM%JG4@)/*FH*3B-^K3*'FS7RTS54Y_/-:QAC*%LOP/WG"L`_LRD+
M=[PG4J=D7'[^YVJ^VJ@T`5;S:FM9>MV[0K*"3,Z*@\!TH`I(J`--O)*<-L./
MK6`\A:A=RBE90`DV#1IE;.+1S!UQMQ3&Q2IM0!QDC0"39H$_,8US;E_D>6RO
MC.MN(_&##"N3L>5J3J>56B.2I"!S);;+3[#.2L+B;(#"/)4:M,5]W#=+>$LP
M,9:5;=:K8X'3[L3.7,X5(2'E+!-V'DBP<H3)\HLNC954H(6MU=/8UB!!,IVZ
M2?1;;#8<<^5N54FO#.MR52A:AAG+>&L0OV^1+\\RU?WMRR#=X^<\<QU"95.$
MI%0MU@SQ[,6Z=O.5U91=&*V6!4FQMJG*J1+3JBMP52%$8#($`7%5U^X#**M/
MF=0MUE*$MKIG$)45I)E,DS`-U@E?KCKV7<0'?L[1#ZVO/I9)G,F^/1&0NBO3
M[.MMA^<8Q.#I]G38?G&$X.GV=-A^<83B%/,H/V[BH/\`^\_!0?Y4ZZ>5J*6J
MA/\`I+'^6*-4@*?:5^</AB::0;ID[?4UR6V\:`N9$XO760A;EE'&F.EH)OD#
M(M$HJ]IDPA*NC<K=7ZPM9)HW0!8B!3FY%B>8E#"H4`;MP45]L'M>T-2"F6H8
MD3*!?9=&I<;20E1`6;A.^,H,AT,6+23"[5$T8_L2U08R);)#BP>VUO(.XE>K
MM'8/!;N;$A*L%VQV)#&<E<(J)B3K(8`P:5[:)2D'`1.>GR1"JL822E1$P97_
M`)6[D>43DC'T_&5B:@;W3)N'N[M9A2Y:)M$)(QEO?MT)%RX95=^S?+-;`[0;
M1#M0Z30ZQRD:K&$`!,XEU--4H40L2`.[/RQD5+:[&B%'?C'O&5,:XOC6DSD[
M(E$QS$/Y!.(8RM[M]?J$:]E5RG.WC&CZPR$>U<R"Y$S&(B0YE#`41`-@UNW3
M+6-/D$XE<<2VZ&R1(C28\[#EG%]1G*M6K9DF@5BQ7A4$*5!6&Y5V%F;>X,HD
MD5&KQ4E)-GU@5,JN0H%:)K")CE#PB&@I'RUBD=KJT?E**YJV@]@FG9ZYB-:&
M<\+&OJN*4\O8O5RF@=5)3&9+_5#9`(LC'&EU$34T)8;&58D407(E%L`@W#O!
M]IVZE%"X0%\O9DRG*SANC<5+:U%M!!<%XG:-=E\)-UR.Q^R)CQ19Q.O$\IG:
MEHR\#1,@6)I/@]9N9-N#=]"5I\R9JA%-%7:A'*B)DFR1UC@"1!.&R<KKL=0E
M:0`RJ5^B<B3NS,K(B&941("5&9NLB0)@[![?4'[6JJT;%!=!)*03+>MBX>4,
M.N(2Y:'_`%VN&0__`'%Y9$_4&%PX;?ZXZ]%1I!\/9BO2VNG`W<:C/@G9')4G
M:9JATWI"T^8<43;Z?9UY_8?G&.M.#I]G38?G&$XU%@`Y8*9,DJ9)4D6^425)
MMU)JIME%$SEW`0ZB'*`AV:F89;#R=IRF\0F#<;=,0U"%NL*;;)2X181?..`W
M'_DYG:0XILN/4YE2RS?)[,,5CNPX=RC-+MG-V+B3.=:E;M:\C%60:E!TO@EI
M4+:R3=&3$J)V46"FW?)@I[=_+LN.8MYBML#*4!6-"39C`PI$C<%*4D[TX\A3
MYO4O4SU"ZM:<Q!`1(&T3F3Y`#^5STX]YD\A&6!*Q+5"+H%\-@/AIAKD-GZTY
MDLEB:7;)9;I4+#8UXNG.JZS&,BYU6$I#]=S-29%F:DDY20!L4H**ARZK)Z;K
M1;<4I.T=4AL)EA$C:53(LM$M,=AG,:M%))8"G$I!,YVV^:'=1YL9L<9(7?$Q
MWC9/`S#DAA3CRY66E[2GEIRZSO1\9V"!LQ&1VY:O&I5&<R2V0?,U!65?(`<4
MC(&2*+B#N.AV2FTN+-8EI2]&'DSF/*+C+?$41G=:'INM(%+B`F,15;<97:+;
M=Z$LEZ0C+,!6JOFZY8PQ\]P3EJM9TL&+X2I6.='+4*&&ZI;[S&EOJLFV/5'B
M5VKM(=%<#'E2&`>KHI*^-AUF"%O(6G4K3BFXV4SG=RC+7>(W/B'"E*RB253E
M?H_+1&!DC.7(2D6?BU?<X+X_8QYY3-V19*JX'F[H=A8:7`\2,F9")5[8RLZI
M23[^,FH8IV+LI18.EB$6*@W.3I&9FGHPE33*5KJ+KA(6RF)<&N9$:.YE5LD5
M-0V@4ZA9+%BF1,3W++-$9D]SEY&8VIDS,WO&^$YBP6?CFPY%XBC:5:[>2*:L
M5K[CBFO*%D64EV:RCAR">4(]1M/1J23-PJBX*#0H$)UY5E-$\I)FZA(=P+)"
M;#(FR6FPS!MB09RM*%8&QM2V%)'*`-H$C/TBR<*6Q<R\ZTN)RA1[K!8?C,Z4
MC+5!H%:2J]=S3DFMWUGDG&KC)<,QJ>/Z;&/,D3ERA6$>\0?(]ZU8^+-#OQ60
M((-M:#)\N6]M&B\Y2!!4989C"9$DFP"<K3HT3C`SFOV80M++=2I83)6*V8F,
M(%I,87%+D3<N0'(/%UUF$Y"K1]TX5W6Q3V/&[Z<1K;*[U3DLC0'<VG`S:3)^
MTD%$HI<J7CK<D@U;+@W6]N4X"S&F13L!&S6E:72)D2LP)(&_;/RQ+DSSKU0M
MQ;R%A38.%))D<:AI),K)1U>VW`/4[-<-:,>F4>C!@Z?9U'L/SC"<,?R6'IX^
M9S#U\,Y3'<>P`Z:/.>KX/`.KV6(#=>W,DIQ)_P`PBCF))IB$^U;Z(\.-!Q)Q
MTP$`B4!^!+$_A[/_`#!@/7$-05FR=K7L*I$.&<]TDB7D,6*5#J:=&-,^2/9W
M`->[#W][[)?U#%_9:K[(<],2+4M)D&UG@BO>_4_XQ?V6FR'/3&NT<]VOS0=[
M]3_C%_9:;(<],-HY[M?F@[WZG_&+^RTV0YZ8;1SW:_-!WOU/^,7]EILASTPV
MCGNU^:#O?J?\8O[+39#GIAM'/=K\T4[WV2?\8/V6FQ3SQ$J<1$RA?FC'74$"
M',(=0"78.GPB(^``W'8>W4B"VH(27$<EX6S\V_%*N=P4;@2VX52.C<B(?H_C
M[<,>._:7MQ\U'M,'JR4EO_7>IKJ^($AW.JES&FUU5UU\[/1$63E:\K86IM84
M6DV:19<8F+WOLE_XQ?V6N-LASTQ=+BP9;-?FBG>]OA)_Q@_9:;%//$2C%*>!
M?FCBKR?]-9A[AKS1F>+6?Z'9(JF$IE%M,3F6I@I9D(US;&K]5VSM=,210F"1
MK%1H7I=QQWBHD,/4W[-]?1LJ^[#.,]\)(\696ZRNG+JD*0527R3\6VTG1='@
MLP\?9?E/B1W),Q9>33-MI7M`)WB9$HZHX>SQB3D!26.1,+9&IV3*:_(F*<]4
M9EM*M45E"E-XF_024\=B)%/J]NV=IHN$_`8@#KY_799F&7U)9K6UTZ1[T821
MK%UF['KZ/,*;,T!S+EI6@B=I].J'@#80W`=_J;#ZF^HMA^<8NSBO3[.FP_.,
M)P=/LZ;#\XPG!T^SIL/SC"<1<YOA_J:<L^W_`+MF;OY-[)KJY$U@SJD7,V5#
M?^<11S-`=R]]!L!:4/,8?&A^VIM0'_[L5X/_`/#L?N:Y=2LJJ:A!TU2O3$],
M@%EI[3L@)<$++I]G6-A^<8GG!T^SIL/SC"<'3[.FP_.,)P=/LZ;#\XPG!T^S
MIL/SC"<'3[.FP_.,)QYJ!V!]7^H.L*1LVU*G.SX1&)_2)WSZ#$0.*G;=.9O^
MUG8/Y(,-:Z^:C:)I4W2IA_F/''&R?VZO_EK^")A]/LZY.P_.,=J<'3[.FP_.
M,)P=/LZ;#\XPG!T^SIL/SC"<'3[.FP_.,)P=/LZ;#\XPG!T^SIL/SC"<0QS<
M0!Y=\(QW'L#DM_[[%T2`_:U>83AHGVM"\-OEBJZD*>2=Q7H`B9A"[!X=<YM.
MT0)F6'D\$6A8)1=T^SK?8?G&$X.GV=-A^<83@Z?9TV'YQA.#I]G38?G&$X.G
MV=-A^<83@Z?9TV'YQA.(^\JQ_P!6?D&'_P"362@__"4MKHY,=GG[!%MJ/,1'
M.S@[/+'"-(G#J;_Y'[ZA^=%Z?HB,'$__``\YI_[6\]_(WAG73SG]7E__`!/^
M]45*7]8[^F?3$S#GZ`#P=H@`;^#P"/\`4UQ5J(D$^T3*+P`M)N`G#(XZSE7L
MBV'(T,R*VCF=%R%8L;QLF_DV2)[K-4J*A'MZ=5^,.H5XI&5"5F#1CI78X>--
M%C#TI@432N-NM)$TDK-LMPW1"AU+I.R(P#3NB+<J<@*#BFHQ=QDY-M.Q\U,T
MF)BVM;?Q$B_D4+Y=JS0(N>8)*2;5)Y7H^<MK,[UVF<Q$6YA,'6?I(:2EI:FK
M64(3(I$[=R*M=F-/ER4+J3-*U81+7Q0LCY/QL-4->E,AT4M)1$Q5KE[[8`*F
MF=-V9@H4]C&0]QRB1^F9`0%8!!4!(/M@VU`XWC!94%:#=Y=,3AYE8"E*&'1(
MCTW0A6C+`N-H*8<>[U"K-8S+;96TOU9RSPQ*_?[7?4$599VR4G9$\=,+6EJ4
M@F;MQ.BNF/M$^@P@.X2^I\5#>+$E(3(SE(72E;^5D96Y2.-EHD83?:(9NL<;
M.%N)7#2DP+&FU>1FKO29R"J\MDV9>R/OOQT[]]U"CJE"6:X/W46VJ[M8L@SA
MHQ)!B7VJ@MA)MO9+]>5*4)34F1L-QOX=<5DMT:$)#9Y*53O%XNC'D*OQ1O\`
M.9.R;E*LU^HRTY%V_CQ>WF4++$5V*R-1*?-%B7)I&");EJG8(#QF6(6-?/FQ
M9=FDZ!/_`)J*O="8=S&E92TVXL%`.$B\6SG.5\_)K!B8KIG'7'B<!<(Q`$`&
M0EIA.2W%S@)CVM+8_GRTFD1F0)N%MRJ4SFRS5BV7&>K\6O6HF<)<7F08^]3C
MI&%DSL%%2OU1<MU"I+BH4"`$2:O/,"4NK4ZAI)2DJ$Y`DJ(L``M)-T57:'**
MH8%I23BG?(^FV')D^,O$NB3%>RY.5JI5`V-J]"P%=G)BV/Z_0ZC%0T,>IU]T
MA6GD\SQS'R\;"/3,&DF=B$@DBIW::X;ZU%9FR254Z\$[Y:S*=]N@<$;]U94E
M*DJ91RVP@SG[(_*^$_!\=N%-;N>$9F);4-"T5:O0+'!,4IDM^X8.H2KM':=7
MDJM25[:I7K@^KK&06"/E18/7S1(X=TN7I*(;J?S.H!75**UDVD@^>4;L4V6T
M2$-,)2VVA,@`1HW[3$O4K965?%P1LD`L9Y,/*^T!.78*&=3\>#HS^#;E*Y$R
MTPQ*Q6%9J7==($3]10Z#;55)J`K"`)^6+>W9PXY\B&6R)RGPQC^IW.SEO-8N
M2U$/%)6.L46RUFR6N,/+6V&I13OH-O.)N&*$?.3J!'1EQ2[D.H.T^Q!D;H\S
M=6&T)3B5.4PH7;MT5W*^C907G%?0C403P",BV\AZC6HVB6.->1%TI]PRO`XD
MD;749R)EX6IS=D>.X&-?2[QJ^605:HW(C6(=))F[]LY>)BH4I2GVF;HZLN!M
M2>5@4HBT&S4#N1E%;2O)VC*IM$R!F#Z(?]NJ*R15!`2B/4`@)1*("4PE'VHB
M(AX/7'5&G6XXUB=`"\2A9N*(]`BRE04,2;HA=S+_`+=Q5_VS\%?^E.NCEOLU
M'[-?_;%:H_6M_I#X8FFC_:R?4USV/U*=Z+9OCD1S_<P%,RM3\K51TTGN0->Q
MQ-UBGX)N>%+!E>B<BZM.VV/E'&.H20CH1<E"R,YGH=$C>9:/2F:D72/),W3(
M$Q)W<O4VJE73.";2E$E4Y%)`/"+;O+'!S-+J:UJH;/*2``)3!M\QW;(RXW`Z
MA.;&2%G+>49XLC\4*\JJ[CT\<HO6X+D_EIG8\59"L3283%2.>2;6JUH[DK-(
M`,WDYYV^)[9SU:NEVD3E=*ZDSKQ4[-<R);%,L*@)3G:02;++HK.9?M:AQU2E
M24"J6C$93EY8AAQQQQDO#$KZ-G'L32+(KC'(\C7\^5I5S7I=*`PSEIOQ7R16
M<OT:VF2:BO4H6\V*;C["Q*NFCO)NY=,@=X)2FM5SN75K=2_/"\A2DI`E)20K
MD*Z,P92F9&*U.S6Y?F+;#'+HU6DJG-)-]TANZ8EGE.6FJ/G['>3^<M)Q_+TM
MSQ_S%CBLN\>4C(.4\=Q-]E[?2Y12$.PF*E*3<1;<BTMHLS:F.U(E()-%&J*O
M4(I*<BE%.^U*DQ*=QB8)`LE;I%DXZ2^L)J=OF>%*`"!@!NME/$%6RU2\D07A
M<>R&/<&9APMG3&MH?<A<P<5>.5+XRLUJ!.6V;4DHBFR\3"T*N6I*&E6=5F\2
M9%>H/YE)9ZU&-`2/#K&(7O2=1=31G.@4'_8A1GO6SU3&JPZXX2:2JZ@IA7[T
M2):2;;A*<CI-HNE$VBBG2^6\2QP]>;1>LBY#S4R7Y(8=GL*Q:\#1:]*8W90%
M[RG7LP#C>!M5;8L?>S'*QRB]@DHR5%Z9LBV'Q@#I\LU2%TJ6%)$D&85,S,B9
M`B<M-M@.['7:9=H,V4\RHK6Y84J$P)BTS$CZ?)IF]1L*62!5QK%2M@([JV$)
M>`4QVDA$F0DY.+98GF<?S2UK<&."1'LE-6!R\12;%,1N@W2)UF[TW1`:U14^
MLJFI\S5N6SD-R8TSBTBD(4DX4V$:#$NS?K3?4'[6N14_NZ_T#Z([0O$0BRS_
M`#V>&7^)'++^\F&]>CH__F\U_:TG^:.6G^H#?7Z!$WM<..G!I",9ZT1?M'+)
MP!A;NT%&ZY2F$AC)+$$BA0,':7J(80W#M#6R%%"@H7B,I5A,Q#`1'%C`-7D\
M?6&&Q[#1<OB7&LSA_'DP55X=_4L9V'W/";J,>_=.EG!HZ1-%MQ.=<RK@HI^U
M4*!U`-LJJJ0VM(62A9!*3=/1^6Y%<TE,I\5.!.V2"`=PSGZ3#)NN-?!&^-JW
MU1>+;!'X&AH+&[1.*O\`UQU6K<"\3&N8_P`@-XFT$96:#C9-#J;1-H*_0*X,
M<2I=9S[S-+S!IK"^I:EJ,P2+1^B9`^47Q46SESZYX[1>`I,O+ZXR,AS?#.H1
M,?:;=;\9H0N3>0M&GF%B6N+9>#G<_P!.1AVM:G0D8R34BVDW5V]*9D7W%&/:
M`Q(+HA0W$;#8KU3+`.U"%3)!GA^-,;WEB<]V):V3TMG,:1?HW.*&?@6?"7&>
M8Y&6>XG8X[G\C6K.=!=7.UR<9\&Q&</5(.[Y.GV3*8O,K2:/5,EM9=+O3,F$
M8O+.BG\>0`HE44W4UF**12D+)0"A1_Q$@6:P1'/IW,H>7L\(#G*`G98`)F=V
MF'MJ_&_A/A`M#5BHG'M33<SSZ1QPI9[\Y?%F)>QU!Y1U6-95N-GD!GHU>CSR
ML:SBD3+QS5BYZ&K=,I@WI*<S"7T2BA6DI!G9;J,K;=\1933Y?BFI6).HD2\E
MTX;"YX:X)\:(&5IA*/`-W.79W%E!EJ%'VM[,VYQ!6K)\-7Z2TB8F>MXSU5Q3
M5[O+(N/$8<S6)9@DIW38QP[L;;7>V8I6TMPKPI4NVRT"1-@$U2TZHK52\KI=
MF5$I"G`FPBW3(C5,<,H?F\\=^,>80=.[Q$5RSN<ISU9N8R#:WR$;)66S8[KC
MBOP%AJ<S69^-E&3ZOU=TLT45AW"/6R653<=::AP-5HZJMI$86G%H<M!.L&1D
M9B4K`=^)JO+:&J>VCZ$N-&4@=!NF)2-UD.#C+CGA/$3V!?XUH,34W-7I,ECJ
MO*1B\@9**I$S;E+U)5]H@Y>.&P,G=K6,\$PE,H!QZ2F`@`76CN85M8I2:IQ3
M@Q8K=<@F>_(`>2+=/EM#0\JD:2V2)63NF3*^Z9)\L/H'9V:ABU!I"&2Y))D4
MP!F\IQ$"CAW*!1V_LJ1-EV[=_"`ZM9=-.9,K3:X%IL-QY0-O_6.=FI'47,9(
M;P&T7BPW1^??;?2E^DMH5GF*12.2N5X*F5$\=7*I"L*I4W#"*@(B'CV<7'LU
MW%(=+*MVK5(I"F.H<Y@#<QA'MU^HZ#[N?`U?3IK,R<IFJMRU22XI(!-^$!0D
M-^V<?G[^Z/%Y?=9HG7Q3-KPIF`21*RTCR660G?Z7CTJWG5YC_(ZE_-]JY^%W
MW;]II/KG/GQ.GQ1XX2);5P_X4\4']+QZ5;SJ\Q_D=2OF^T_"[[M^TTGUSGSX
MS_=/CCWJ^@GB@_I>/2K>=7F/\CJ5\WVGX7?=OVFD^N<^?#^Z?''O5]!/%!_2
M\>E6\ZO,?Y'4KYOM/PN^[?M-)]<Y\^']T^./>KZ">*#^EX]*MYU>8_R.I7S?
M:?A=]V_::3ZYSY\/[I\<>]7T$\4']+QZ5;SJ\Q_D=2OF^T_"[[M^TTGUSGSX
M?W3XX]ZOH)XH/Z7CTJWG5YC_`".I?S?Z?A=]V_::3ZYSY\:'Q-XX)GMG!_A3
MQ1:;TNOI5A+V\J\R`7P]04^F%[>W;8?>!TB/L>KJ(_=]]U3"TL+*5U`6""'2
M4J\A/L^?=B)7BSQTRE0<<66U:<-ODLA+4;THOI*<>5&`I-$Y*Y6@J?6F!8RO
MQ$?5*BX9L&":BBA4$'#BC.EUR@JH8>HZAQW';?8``+U9]V_W=UM4Y5O/4C3K
MBL11M5C"3HEBLE!KQ+XV#20V^[@E9R4W<$*O^EX]*MYU>8_R.I7S?:K?A=]V
M_::3ZYSY\6!XI\<`2VJ^@GB@_I>/2K>=7F/\CJ7\W^GX7?=OVFD^N7\^(SXF
M\<^_=Z*>*(19WSKFOD7D)QDS/]UGL@9&<0T3!N;'96#",E5(6*(K[D,SM(V,
MB&96S<C@XIF*@43=8B(F]3V^3>&\FR:C9:RQ*%90PLJP!:E)62;2HDDD$[HC
MS%=F]9F5>ZNH=>->Z@((4$R``ER;/+IBF".0.<N-MV:77`&3KIC6WK+I(":H
M2"Q$K"8VY$HR;K@D=1-J05`>@&KMJY*;P`7?;6V?9-X4SFE+'BL-OH,Y$R"D
M@W`%,I2%T,JSC.<L5_+E.X@=-H\T?H!^BVY0>D"Y"8S"7YB\88_%[-O',SUC
M*IW2U+F<C`<$A!PZPG((.IJO]Z@IU^/=^T:+B`=TV`HAM^.?&&49!D^8FDR*
MN0^W/XUI`WTA(U#7'Z0\-YEFV89>*G-VD-.2LPA0!Z1,=>@[0#U/8];7DX]+
M!I"#2$1;YO\`\S3EG_LUYM_DXLFNGDO]8I?^0W_F$5*_]R=_9J]!A\*%_@;4
M?\6:[_>=EKB/?OE1_P`L^DQ8I?W)O]!/H$+35B-X-(0:0@TA!I"#2$>:O@#Z
MO]0=1/\`ZE6\/2(Q_P"Q.^?08A]Q4_PUYF_[6=@_D@PUKJYC?3?\4?YC''R?
MVJO_`):_@B8NN?'9@TA!I"#2$&D(-(0:0B&6;OYW?"/ZG)7^3"*U9;_=W/\`
M#Z8A7^M3Y?0(F67P?JZYU-[!_2,3GX(NU8C$&D(-(0:0@TA!I"(\\J_YL_(3
M_0YDK_)*7U9RK^O,;Z?2(YV>?TMS]'BAUOS/U'\Z+W%$8.*'^'G-3V.6T[O^
MKAO#.WU]=+.?U>7_`/$_[U15I?UCOZ9B9*X=1.SP[B(>K_6F_J:XBOUK9-V/
MX#%I[$6'`F\H,<3SX@RK:,4V]GAF,8/N1/'OF[R>2!F_FF=?7<4;D7+71:;D
MEGKXY$T$3XTS'%6)L13_`,)5B$BH@90$@UZM>842:[;NIG3+80)7R4DI/_:0
M=^/)4U#F#F6]60O#5(?42=:2)?#9O1HFOH_<D)X_R?BN6I#"?H-(F\&83X\1
M$A/0;H)OC/7>2-=SMD1[*MGJI"PIDXM1&&,R7,FZ?(U9(")G(JWW.9U3%0<I
M6PAQ1*ERG?A"`!N7G?,3L9-7F8J5)=0!).*V5I)WB8<2V<2[Y5,@S5LJ>`*W
MD?$E=Y:3&78K`+-_CZ"BK37+3QIIF-T[U5*]97,=CQI9J7DIG)/"1LN:/!8K
MAP\2,#@43'K(KVELE#H`<V83BD9S!F9D&<S=/5%A_*ZXK!9*-F%3EN;QL\ET
M-6QX99FI<="/)[C+1L\PUCP_R`H$/A):Y4PM>XURV8LO6+(U?B(1U>@C:\ZH
M["JS;2#EWL$`R+(8I,D<S7:F(!9'ZZF6W]')"DJ29R(Q`)`\Y&GU143EV8-N
MA+TE(4%`2E9P[_\`TOAN7'&;(MGON=,"QN)ZME3(<9C3@+CM_P`F9">K3.7P
MW-T&DL)27O39*P)IWER@08)21C%(4RS][)@DB[311W<AN]4L):8>;L)+A*=!
MY5FK7IG$##==M7V93"<`!TCDS/HD")7;LHEA6N&4_.9EK]ARWB>K6RB1.6O2
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M*Z(.Y"X@YDM3W*,+'<7\<QK_`#BUX_.L>Y,CK=32L>':>-"099BI,4U4H>VD
M0I4U$.IV"/3V:S23E)95-P#9,IEU+K5=2H*"Z20G%B'.G=N<,<6HR^N=4I3>
M&T`">@@\/!*%;8L1<B:K:T&B^(6J^,\:\NN07*YWEI"Y1+@)BEY'QOF)S%1T
M-0X94V0'%JA9J\A'R;4$FYSE3(JP.Y[T2MI6GJ%QY+@/*P(3+1B!`)GJTQ7J
M*7,&Z8TYD0%*,],C=9KCGOQ=Q>WS-B7+F)H6L43(&7LA<;,%LVLCCV[84FJC
M%8LJ^6:U,RF.,CN<>T^EN:WDJ75EI)X<+,YE)F3;-%$U5@6;&!:_5UV![:L$
MI80XH_&O*2)B>@:A8"9VB*.7TBBD4KH*GRG3(IEBGHTZR;9:HZ)9DPPIC5IG
MF@U2I5REUOD9RIX:M\&UJJEC(R.6DH`^)GV1)IE5XI-%&NJQ3/&<J_=J=PF9
MPFQ,X.`D$3C5I,P(6V\X9K:;<!G;.<Y`Z[[-4=A5*XT\JF2$A,TR"=T6^>^.
MQ3<-D@[=P$ZH@.P@(@90XAON`>O^KKS"5(4,2/9)/IM\\=YI.!L),_R,0NYE
M#^W\50__`'G8*']7>TAJYEWL5!_,7_VQ3JW"E]I(N*Q\,332V[L@>Q_5USV/
MU*=Z.A?;'@HS(H83"JX#<XG`"*B0I1$-A`"E``$#!X=]_#J9'T<PG29QHXA+
MI!5>G5'D6-0+N'4ML.^Y>\V((B(COT%*!2F`1\)0`=NSP:UPG&5S-HE+0-T;
ML9PINE&0+8H@4!46]J``(]?:?8`#]L[-E-P#U=]`F4K39&\]P14S<ABE+U*%
MZ0$H"0XD$0,7I'?;L'L\'9V#VAK`0![$T[T:*2%>U;'@#!$"G()US`<.DVZF
MVX>L(%`H"&WKAL&MI&4IF`0D.[8>UJT<$`,$R@F4%G(%1$>[`%>P`$NVQ@Z=
MC[;B(;[CN.LVREK@M"7'=JJ_5HX(R^@/7'['W-0AA`,[8WLU1<;]:;Z@_:UB
MI_=U_H'T0%XB$66?Y[/#+_$CEE_>3#>O1T?_`,WFO[6D_P`T<M/]0&^OT")O
M:X<=.#2$&D(U4ZBY7AY)%DFDJ\4:+%:)N.OQ8[GI'N"N@3_;#-15V[T"^V%/
M<`[=M;MA)6,7LSC"E*2DJ1:K"9;\C'SRU_@ORDL4!G%A=\4-6*^0^/U*QE-P
MIY3CW7J5:;G!9\K-WGVU(K&(JW5"16-4J@60&&4LKE]-J(F,@X.V5,)%O1OY
MM3A3+BPG`T3=.9Y,@3,FV<K@!N1XG*<HK":A3Y4'5RE.4O:F96:MT[]L2;RO
MPTMC.QY3G<=8"I5JHD=R>XO9OHN(608_KL?:Z[0<;Q--RVSK$78?<^J5JP21
MFI"G2D3QK>5*S`%%=C]8QT6<49245"UA9IW4XA/VE&:#O"T;FN4=.IRNL2D*
MIL!.V;)!`(PB>*__`*'2(3MHXJ9:89&;9(?\9Z_FRKPO+SD7FH,8/[/CMNL_
MJF1,+46ET>8BF=L>A4W%@93T6X0!B]7;)H))J*"H7]H[S6CS.E5E[U.5J#JP
MV`3,VI4LJ-EMQ$HTK<HJS7M/4P1LP%E7E"9#5>(0#3A7G.JX\:5Z>XZTG/#F
MY\597"->A'MPJ;.&XMW">O\`D:WA%,'%W(B\=8\B8V_1+/W8K2*TNG[TD"(,
M^[[@Z>7*RF)FV2DA85IY0``MEO:9Q&,LS%H3=PJ24D`"5A).N=F]([L*R=X>
M9P:W-*(>X3JF5Y@_(7B7F!CRIF[15$+%7J7AV+Q!7KE4TXZ9!7(9K$P5HLJZ
M:M6Y2Q#UA+K*&<^."=LMLUF#:"2E6%*FUI($[<1)&YJB-&6NOO-MO)FG:`SL
MLD#Y;?\`K#O\0L6RZ?*C.D-(%C76).),U>*!@)PQ<$7)'R/)*0ALTY)@#MA)
MM&O<:,'<?`H%*)^E@ZZ-R^V3+KF3E(*!DL)'6'#-9WA+SFV)<C16.5=2NK4<
M#:L"!HE.?#K]$=9R)E('M=]M@#M'?L#P=NO.!(!)&F/5E1(D8OUM&(-(0R7)
M/^;YG0=]A+AO*)@'UA"CSH@/Z@ZFHE$5[:1I(_S"*M:VERF4%7>HQI^-$7''
MX\X&4.R:G.KA/$@G%1NBH(B%"@=S;G(8PF-OVB(B(Z//O&K>!6HR<UP;I:0L
MH&R;]D?%$/I[D1?_`$>R_N-M^"UKM7><KA,;=4I/=-\`@]R(O_H]E_<;;\%I
MM7><KA,.J4GNF^`0>Y$7_P!'LO[C;?@M-J[SE<)AU2D]TWP"#W(B_P#H]E_<
M;;\%IM7><KA,.J4GNF^`0>Y$7_T>R_N-M^"TVKO.5PF'5*3W3?`(/<B+_P"C
MV7]QMOP6FU=YRN$PZI2>Z;X!![D1?_1[+^XVWX+3:N\Y7"8=4I/=-\`C#=1$
M8=,Q#,&8E*('*`-6P=)B^`2B"7M1#?L$.T/4'?4*UOA]IX.."3@$I\DBV\&(
MJRGIE4:YMHDD661$?T?\>P6X:<>#*LFBAO@^;>V.U;F'8).2V#<4Q[.W7=S]
M;B,ZJ4A:C)TWF(,NIJ5="THM-S*!\41,3W(B_P#H]E_<;;\%KD;5WG*X3%SJ
ME)[IO@$6FB8P`[(YD/;_`/0VWX+3:N\Y7"8=4I/=-\`CY=/2(^AIY!<]_2)S
MF2HN9J^)./:6.\8UU]D.2($Y8).1AF4H2;84^BL5FRKI=D"Z8&</W#!GW@^T
M,K[8`^P>$OO)I/!_A=RF45O5BE*.%5J1,Z[)3OTG<CY?GW@FJS;Q(BK2AMND
M`%J!(W>6.K/"[T1G#'A82.FZ-CX;QE1FBD9?,>3RLK+>"O`3Z5%:\0[1.%I2
M(B8P%3BV[<X%``,JH(=0^"SSQCGGB%6*K=P-FY*)@2-NDDGRQ[:@\*Y/EWZI
MLJ5K5(_`(Z=E:)%WVZQZ@#?J$!\'J[[;[CZOKZ\DJFIUO;=2$EW7'H%)2IK9
M"Q&Y&5J:-H-(0:0B+?-_^9IRS_V:\V_R<6373R7^L4O_`"&_\PBI7_N3O[-7
MH,/A0O\``RH_XLUW^\[+7$>_?*C_`)9])BQ2_N3?Z"?0(6F^_@U8C>#2$&D(
M-(0:0@TA'FKX`^K_`%!U$_\`J5;P](C'_L3OGT&(?<5/\->9O^UG8/Y(,-:Z
MN8WTW_%'^8QQ\G]JK_Y:_@B8NN?'9@TA!I"#2$&D(-(0:0B&6;=AY=<)/_64
M_DPBM3MGZ%8T'#Z8@7^M3O*]`B911#;PAJJA`0"$ZXL'X(OUO&(-(0:0@TA!
MI"#2$1YY5_S9^0G^AS)7^24OJSE7]>8WT^D1SL\_I;GZ/%#K?F?J/YT7N*.;
M^'9?E$SRWS21P_1\'6"L>5/*F6?9"R#>*Q-A)#B'$0+H$CH#']F9"S*W!$Q%
M?&.HQQ.`D`.D==_-4T(I\N4^5@]4,Y2YZI2GYXXN7O52ZFL20G"A^2;-!$[;
M8D-[XN?(AL.*N*>W^F7*?S.:Y"DY0H24IZ7^'CCI[2JU)X#QQ@-Y#G8U=.GC
M?$G%%-P^$IG:A<R91`S@Y``I#K&##0'5.1,H%*)A$2D``#8-;SRG#@Q/2'Z/
M'$02^%EP`!1$M,O3&=[X>?'Q5\4_EFRG\SFL?RGG/?(XXWQ56YY^.#WP\^/B
MKXJ?++E,?MX>+K$LI/QGOD\<9"JK4//QQYDLW/-3<"8OXH*"&W4!<SY2$2[^
M#?;#YA#?;6JF\G6G"I3^'?3QQD+J@<4DS\O'&,WD.=+1=RZ;8?XEH.7@(E=N
M$LP90(NZ*V`Q6X.%BX;!1<$"G$"=8FZ0'8-@UO/*L(3C>PB[V>.-$]80I2PE
M.)5]D9GO@Y[_`!5<4_EFRI\SNL8<HG/$]/\`P\<2;6KNDF6\>.-&[-S4<R;&
M7?85X>+S,<`A&2CS*V1W$E'E5,)3%CGSC#)G3(%3J#N"1B]0CV^'60<J$^6^
M9Z\)^&(SMU'%A1,:A&\"P<^`_P"RKBH/J]N9LJ>K_P#H^;0]U&]3WR8WQU6I
M/!ZXK[X>?'Q5<4_EERG\SFG\IYSWR..,%=4="?/QQ::P<]S%$IL5<4Q`0V'_
M`#S93^9WP@.@[I!F%/3_`,/'`KJB,)"2-X\<::+)S9@Q7&%PCQ`AP=NCOGA8
MO*V1X\CUZH&QWCPK3"R(.G1@\*A]SCZHZD+N6J$BMXC_``\<1I2\DS2E$][U
MQE+.^<[ATF]7P_Q.5=HF`Z#A3,>4CJMS@D=#K;F-AT#(',BH8@F()1$IA`1V
M$0&+#E$B,3\E7^SQQD)?Q[22<7Y;L;$MAY\$*!0Q7Q4V#<>W,N4_5$1'_L='
MU1UHTUD[#8:0I_"->$[L2%RJ)M">`\<1-Y63W,]5;C2%DQOQN:'+RRPT>%]Q
M\K9&>E7L1??-[EMI47>+&0LX94.KOET077((`!43@(B'7RMG*%,U*E+=!V2B
M+K?9F3NC5=''KWJT5+(0E'MIU[LM.GX(ED6Q<]@_M>*^*G3V@41S+E,!$N_9
MN'P.CL/ZH_5'7);&5)0$XG;-6&7GCKA=5*T)GO'CB[WR<^?BKXI_++E/YG-;
M_P`JYSWR..,XZK4GS\<'ODY\_%7Q3^67*?S.:?RKG/?(XX8ZK4GS\<'ODY\_
M%7Q3^67*?S.:?RKG/?(XX8ZK4GS\<'ODY\_%7Q3^67*?S.:?RKG/?(XX8ZK4
MGS\<'ODY\_%7Q3^67*?S.:?RKG/?(XX8ZK4GS\<'ODY\_%7Q3^67*?S.:?RK
MG/?(XX8ZK4GS\<'ODY\_%7Q3^67*?S.:?RKG/?(XX8ZK4GS\<4]\?/D?#BOB
MIMZNV9,I#V>K_P!CQ=84C*'$EM2GI*$OBZ8P7*L)*@$3`W>.(EY2FN9OE?<2
MU'N.^-J5E)2N3WO>8-<JY(6AW:"D/BCW;7EI!7%23MDNT(FW!LFDBL585%.L
MR7243=>D5EPR"L;Q+FZZSC$A<A1PR,[[+=[?CDN.UB,\:9"4;!32U3MGBD)Z
M;KHEI[X^?7Q5\4_EDRD'VL/&UR?Y3SGODQU\=5J3Y^.*^^3GS\5?%/Y9<I_,
MYI_*N<]\CCACJM2?/QP>^3GS\5?%/Y9<I_,YI_*N<]\CCACJM2?/QQ0;'SY'
ML'%?%/Y9<I_,YI_*N<]\B&.J&A/`>.+??#SX#P8JXI_+-E3YG=#W4H24IXC_
M``0+E41*2>`\<5]\//CXJ^*GRS93^9W6FSR8Z7?D\<8"JH:!Y^.#WP\^/BKX
MJ?++E,?_`/CQ=-GDXM"G@?\`#QP"ZJZ2?/QQ8-EYZ!V&Q?Q1+V].PYFRD`[[
M;[?]4'AV#ZVA1DZA(J?EY..,XZH:$^?CBOO@Y['#_JJXJ"40[/\`/+E0-P]?
M_J?$>W1+>3H.)*GY_P"'CAM*H$*`1,;GKC$;2'.IFJX6:XAXFMU7:JB[HZ68
M<H$%PNJ)1466Z<.)]ZL?H#<YMS"``&^P:F4O*U`)*WI#]&(FDOM%6!*9K5B.
M^?+&62T<]3B)$\7\4#F)V&*7,V4=R[#MV@&'Q'L'LUI_*N<]\F)<54="?/QQ
MZ>^/GU\5?%/Y9<I_,YI_*N<]\CCACJM2?/QP>^3GS\5?%/Y9<I_,YI_*N<]\
MCCACJM2?/QPT>?K%SD-@S,Y9S&/&%O$GQ/D8DDO&9=R8[D48XU-F@?*L&KG$
MK-NY>IMQ,*2:BJ29S@`&.4.W5O+6\I<S)K$MT)Q"WDS]H2NT3O-\4<P?K6Z9
M10E!LU'5OQ9Q^G^<*>!\(D@<8\87,03#^,0C'$GEW)K615CPI4)X@H^;-\2.
MVZ#P[3H%4B:JA"*"(%,8H`8T-4C*D5KPQ.RVAYNLWSB:E=K54Z"M*`<(T;F_
M#O\`ODY\_%7Q3^67*?S.:B_E7.>^1QQ8QU6I/GXX/?)SY^*OBG\LN4_F<T_E
M7.>^1QPQU6I/GXX/?)SY^*OBG\LN4_F<T_E7.>^1QPQU6I/GXX/?)SY^*OBG
M\LN4_F<T_E7.>^1QPQU6I/GXX/?)SY^*OBG\LN4_F<T_E7.>^1QPQU6I/GXX
M/?)SY^*OBG\LN4_F<T_E7.>^1QPQU6I/GXX/?)SY^*OBG\LN4_F<T_E7.>^1
MQPQU6I/GXX\UK#SS[HYAQ9Q5ZND=RAF3*0_6'X'OZGL>KHAO+'"F:W+'1H%V
MN8T[D5:QRL%&X0E$Y;O'$6.#\[S70XEX'3J6-^-4A7BT9`(MY/Y6R1&3"[8)
M*1Z3R#%CBJ19M7!MMQ*FLJ7;8>H-^D.QX@.5G.ZDE3H.U/-^&(LJ75=VL3"9
M[,:#QQ*OWR<^?BKXI_++E/YG-<?^5<Y[Y''%_'5:D^?C@]\G/GXJ^*?RRY3^
M9S3^5<Y[Y''#'5:D^?CBWWP\^/BKXJ?+-E3YG=1AG)0<0+T]W"?,3#:54I23
MP'CBH6+GR'@Q5Q3^67*?S.:D_E7.>^1QPQU6I/`>.*^^3GS\5?%/Y9<I_,YI
M_*N<]\CCACJM2?/QP>^3GS\5?%/Y9<I_,YI_*N<]\CCACJM2?/QP>^3GS\5?
M%/Y9<I_,YI_*N<]\CCACJM2?/QP>^3GS\5?%/Y9<I_,YI_*N<]\CCACJM2?/
MQQ'3E_/<W5N)_)M.S8UXS,JXIQ_S`G//(7+.2I"8:0QJ!/A)N8IB\Q0P:O9%
M!D)SH(J+(IJ*%`ICE`=PZF1C*3G-+-3W[PWS><(I9BY5C+WR`F>R5H.K?AYZ
M9/\`.H*A5Q:8OXLG;^]N!!N*^8,H)K&($0R`HK)DQ&L1(YO5*4QP+]\;PCRG
M6<LZU4%2G)BH4;):[[[#N71M0OUJJ%HJ2B>$#S;\*,+'SY#P8KXI_++E/YG-
M9_E7.>^3QQ;QU6I/`>.*^^3GS\5?%/Y9<I_,YI_*N<]\CCACJM2?/QP>^3GS
M\5?%/Y9<I_,YI_*N<]\CCACJM2?/QP>^3GS\5?%/Y9<I_,YI_*N<]\CCACJM
M2?/QP>^3GS\5?%/Y9<I_,YI_*N<]\CCACJM2?/QP>^3GS\5?%/Y9<I_,YI_*
MN<]\CCACJM2?/QQ4+%SV,(`IBSBH!?7#,F4A[?D=#U-:.IRM32@E3MVG#*_<
M,8"ZK:)L3>=>H[L17XW3O-=&X<M/<#&W&ITNIR=G%)X)/+.1VJ+::^"W%!%&
MT4=KBIVH\C?$2-SE56(W5[PYRBF`%*8W8S9&4I%(4J=D:1/-G/$?((XF2+K"
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M?&\7[J>[3Y7%:+J/%)IL+;N47'?*[E/W10`XW&F\I53+4%O8N3H3KT:_@CGU
M#^8)JD)2EO!(^BW3H$HE::P\]@$!)BOBH(;`.YLR93`=_J?`Z.J>'*TV*4[/
M>3\,7DNU:DS4$3\O'![Y.?/Q5\4_EERG\SFG\JYSWR..-L=5J3Y^.#WR<^?B
MKXI_++E/YG-/Y5SGOD<<,=5J3Y^.#WR<^?BKXI_++E/YG-/Y5SGOD<<,=5J3
MY^.#WR<^?BKXI_++E/YG-/Y5SGOD<<,=5J3Y^.#WR<^?BKXI_++E/YG-/Y5S
MGOD<<,=5J3Y^.*>^/GU\5?%/Y9,I#]O#Q=/Y3SGODPQU6I/GXX9/DC8.;I^/
MN;26'&/&9M!J8LOA)MS#Y:R4\E&\4:M219%>.:/,4-&KE\BU$YDDU%4DSG``
M,<@#U!TLF8RHYY3J4IS#B3J!OL&]NQQ,XJ*]67N)*48;M-T]^^.A6R?KF_P3
MV\`?VOU_UWZ[_P!F^N%\Z/1\41;XH!O?.:F_J\MIT/K8;PSMKIYQ8W0:NJ?]
MZHI424H>?*;U.3/HB9O07V?KZY,XZ$]Z*&*4OA$=:.+*4E=DA?&09Z!$!>>/
M*<V`J-7JA1\A8YH&:\P+V:*QQ.Y.D(=C5ZPRJ$"XL=MNTJWGWT9'29(AH@BP
M8LU%B%>S$FS1']K%42];(:#O"K2JJF:&5H2+;;!(CA.H3,>=S_/4Y;1XJ=(5
M5*5(:A*\G<T#6;!'E!\Q+7=H+"$?A_%HYAR#D+!6/\\W1HE<X'']8IU)NK-%
MG'NU)^892I9"?L=C;OTHB,1;E3<)L%U%G39(A3&D>RM;"5OKEU7;*;2;[4@$
MW:)$6ZS%Q>8$AI#<ML6PM8LL"KKX9U/F[;:J_N"54Q[=,UR5GM7*RYU^.E;3
M0Z=`43%?&*PUW'<L]6L;:``&-.L5F0D/<H[M.4EU'XBBH<Z(@HVW9RG;-%Q2
M@@I*!*5I*YR'DLGH$YQ5JL^;96AMM!6I0429V`)M\]LM9L$S&RL7I/*BA>\?
M8\HV,[)>K5::]A:Q6BK,IABTN];3SG'0TW7X:L5%&+EG-_G:G79Q*4L`>,14
M?&Q@@L+PQNI,D:<L;QE%2\&3RL,Q,*PV$ST"8LOC=6=+V>.F8+RC?(RPSN$M
M)CVI_-W-;AUD<MGPE`RRLKR8MW'WC5!TC(<>Y>Y%E*&@^;6\UJDY6#9,*M7Z
MT-2F95[.#WQ2-"`U29*.4R>-2U.54`#?5ZT6MA2YHNGH&M7YOGBHQG.;[)UR
MIH9$.8426+=TF=WYUWP)Z>YHYBO%LP)`8QQ1,MLBERER2KF8<4#;:>$,=KQ]
MK`PDJV?94>1BT<PQ^YO5LAG*4P@P(_7,0C8&A5#J)%U:RVG2E94\'6P$26$D
M<I6C"+9Q*]FM:O9!MK8NJ!*DF2I@:0;M?!&TF?23N7.-W&4<:X/LE_K=7PU1
M<OY6!Y<*K3'..QR01T%.H4<,FWD&]YN\JHS[\R+<[1JG&K(KD756<(-3UV\@
MJF7%(S"K0A:G2$`(!Y(O)(T`S$SIT2MB>ISM:,(HZ8OI")J4%2D9W2-YWH<R
MT\Q\D(1&:;?0L$)6;&N"V>3(JWY%G\GUVG,G.0L6U9_-6N`K]=<0LI)S%8@I
MQG[C.I?O43#)E5*BU521.KK=G+Z--:Q2U-6!M3S)\DW3EIW!=I,:+S3,EY<]
M5,T<G&TV`J%ITV'\CHAA'_I*[KBFFXCK&7\2Q4[R6M6(H;+%OQ?1[JBEXS!R
M[E./A&E`15K;^4LN2KR\;NC15230$401,5W)HEZ%5+#V2$*744[F++]LIM"B
M)3*93GN`$6[MT1L>(`=G2U+13F.Q2M:09@!5WH-D31Q7R+M.6\N9'I$#B:6C
M,?8JLI:1:LH3]BB&9'=U&CTZY*UNN4]H@\E9%:)/;?$91RJN@W9.FPE3,X$Y
M@1Y>94RLO90]B2HJ$Y"VR<A;NQTJ.M-6HJ2)(!E(BV8OB6A2@(;]NJC;@<0%
M@2!UQT2=Z*]!?9^OK><8GO1"KF4``MQ5V\\_!0?Y4ZL9<.34G\Q?_;%.J2"Z
MT2+<0^&)HI$`4R"._@]?5&GL92-R+I,K+(L4.FE^N,``)@(7?<1$P[[%`/"(
MCMK)%05<D##&CCJ&A-RXQC^-MQZQ!4VR9^[.(IG`I5`*!N@1,4``VPAV:F2A
MP@3E.`.(8@H!)W!'H+A$I>LYP3)N!>I0#)@!C;;`(G`H`(@(?7UC"K6(%U(O
ME!WZ("!1/L81Z0`2GW$=]MMNGU^SZNLVZA&-NB<K(\Q<IE'VQQ*(^U`ADU"B
M8P@(AT]10$VX`/@];4>V3MNKX3M)3W)1F2MICQ)V$M0],'CC;O.[%78P_P!:
M)3@._2!_`)0'L*8/_P".FU^EV&'Z24X$R1MRM.QWA%4GC1995NDY1.X0(DHL
M@4X"LDFOWG<**)?KRIK=R?H,(;&Z1V\`ZDF=0C&W0=49HD``$>WL`?5U$\M2
M&5+3+$$DC@C?VK#*1B$N6NWFUPP$?ZVC<LR!]087#8_;'77HJ9H>'\P>MVC+
MM/AM]XKE3&F\RU1RR`YF:'%>TD+`WI#BB;?07V?KZYDXZD]Z#H+[/U])PGO1
M@2JIVD7(NT!`%FS%VX2$P=1041044)U%[=PZB^#6"%J(2B0)4G@F)^:<:.+*
M6U*$IA)]$<5L(<Z\_6KB5*(VV1J<CRZL#O'</BQXWJR,97I^/Y"02MOQKD)S
M5F[M5%:%Q_76%@]UBD,FFN>I.!,!.^$`]C7Y;DR/%(32!S^V"6Q*9*YS`6`O
M3,D!._N1Y&AS?-7,EVSB4.9JMTI0D#"")ZMQ(,S#H4WGYD9'#=%M*N*7^8IB
MF<7,4<@^35F@YVL4)O6HB]5^1ES+TZN2B2Q;=:GD76I26&'068-D6J221'9U
MUTTM<ZKR12*AQMDA*%5SK+8,R<*+9>3DB9M))T".FG-:UFDVU;382`)F=@W)
M:8<U/G?*JY&4KZ6$Y]?%+7-V,L!N\SIVZN`W/<<R4VDVJA/HZ@G;EL3N"\8O
MC!G*KJJ-S,#+$42(Z+WQ4(59*ZMD[%8ZP&U.2E/DH/+O,IQJCQ`T;5(DV%!,
M]U4Y;LK+XTS3TBC9!K'7FWX@L=/P3=H7+4YBG*P6:O3\I<6V(*[8+=*%G,<L
MT&LI2??C5ZE)/Z^*CY\+M%`A70,E52)A"K*U'`G:I2L.(2KDS]K1,V;Y%HB5
MK.TU$A3-8UD$@3T"^R\;D_7&EN?*C-->N/&NR92H3K`M$L-ES!.W2#1N%7R6
MK;\:T_C/?<JIC(K040T<UJ<K4M`)'=,45%`%PD4B+ITD8QBW6<LHW6Z@,O8W
MVU)`&&4IJPF>N=GDG.5@@_FU13("ZFGP()OQ3T3NC-E/2$6JJ5"R6B_<;[74
MG!<,1^?L8UME>Z=9I7(M!=6RH5!U"2;ANA'L*%D2+<WZ'76C5COF0E>`4C\W
M=+"2LC)W74H4VM,MK@5,2T$[EEEX^&(D^(&Q[;?Q0H6SO(OE<=PVPIISG)9*
MA3,I25\Q37<?9`Q)D*HT>R4Z]YNI4#4!;9"JJ-RI\^WR<G#NTGPO(E;N%8QA
M$/I)-\FH0B:S<AG>M$Y4X_5M"G7BIG$*(`29S29&R\>4RB9_/&J>G><<;(6W
MA%^E5PX.#3&!QQY9S'(W.>,I6NK/87%F0.'EARH%(=A"R`L;]!9X;XY?/PL,
M>V%63;MTF;MLW416*T=MA(OW!#F#4E5EO4<OF_;7)JE-JNEA"$J$A_BM.F-Z
M7,'*JNV4I4YID."RV:E*29G_``W1TJ`@"`#V]O;X?7UQY[T=>>]!T%]GZ^DX
M3WH9+DF4`X]YSV^)O*/A]FC3NMZ,8LQ;\G^812S`_P"V5=<?1'EQFZ?)SP%O
M\2.)O\@8#6CEE8_^TB>F/^W1=[`]`A\-B>N/V?N:3B:>]'@L;I`>[W$0*80#
M;PF`IA`-Q\&XAJ,.$J6@"U*`0=TSXHPH+P%:2+!=*^./D[Z:?BEC3EYE;B)G
MMY+87G<=V2)@HC)-A1+(XTM!9FOP<XV4D9N.*9W2G2)ICN3^/H`Q]IUBZ+^M
M#VJON^\25&1,YQE\G$.(Q&203P'>-QCQO]]Y.G-596Z"AQ)D2;I_EOQUHK]I
MK=LC(Z=JL_#V6!EVJ;V)FX"29S$-*,U0**;N.E8]5PQ>MS@8-CIJ&*._AUXM
MY3E&0U5(4')R-DI'=&BV/7MNMO@.LN(+1%DI&%&4I1#?ZOV];VB^)9G2(KT%
M]GZ^DXQ/>@Z"^S]?2<)[T8J_84X>L4?ZFH5(2"B4[7P3%>J/^T<WCZ(B'Z/L
M`'AEQX`?B_;_`-\Y+7=S](;SFI0GV0Z8ARL_R]G]F/1$QN@OL_7UR)Q>GO0=
M!?9^OI.$]Z#H+[/U])PGO0=!?9^OI.$]Z#H+[/U])PGO0=!?9^OI.$]Z#H+[
M/U])PGO0=!?9^OI.$]Z(N\W@`.&G+/;S;,W?R;V372R:2LVIDFXOH_S"*F86
MT+H_TU>@P^%"_P`"ZB'J>]FO?9AV6N&YR*NH`NZV8EI`!1-RYB?0(6707V?K
MZM3B:>]!T%]GZ^DX3WH.@OL_7TG">]!T%]GZ^DX3WH.@OL_7TG">]!T%]GZ^
MDX3WHL.4``-M^T?7]@=0U`Q,*!W/2(Q/Z1.^?08A_P`50`;IS,W\[.P?R08:
MUU,P$E4Q_P#Y1_F,<?)SRJO_`):_@B8?07V?KZHSCLSWH.@OL_7TG">]!T%]
MGZ^DX3WH.@OL_7TG">]!T%]GZ^DX3WH.@OL_7TG">]!T%]GZ^DX3WHAKFP`#
MEUPD#_:4_DPBM2HM;5Y/3%9U(4\DG4KT")DE*`AN.H$\D2BS<`!%>@OL_7UM
M.$]Z#H+[/U])PGO0=!?9^OI.$]Z#H+[/U])PGO0=!?9^OI.$]Z#H+[/U])PG
MO1'SE5_-GY!^QAO)0?\`X2E@U/E0GG[!MO3Z1',SI*498X4Z1/T0ZWYGZT^=
M'0GZ(C!Q/_P\YI_[6\]_(WAG72SG]7E__$_[U14I?UCOZ9],3/UR(NQ02@;P
M^I]S;6%)"TE"O9(MC()$,4;`6/7V4[7EZP0`6FUV6JUVC$]](L)Z(@*G6)"6
MEVT5589ZT.V@R3$S,*NY(Y3'5?."(BH;I12(2TBKJ&J=-*VK"R@S$K#.4K2+
M39K,4C04BEJ6M`*E2G.T6&=@-@MU7Z89>I\'L:8\GL<6.B6?+E+>XZH]>QL+
M2`R$HVB[Y0J;9IRV4NI9$;&BU3S4?5I6ROBM3M#Q[@S5P9NLJJ@(DUN<TJ@P
MBB7RV`XI8!`L40`3.^T`6761J<K8=K#5)FEQ:`E=ID4I,TB5H$IFZ1USA-5'
MC'Q_=MLGXQ@U+\=W$8AD^-MS6>N)ED\3I^3I.8RE830,\]@FD=.3]G=WA1=]
M+1PNDTUB$1,5)5`Q=9>JWRI+N$X@9V:Y`7;PL]<5Q14S3CC#:@$R`(-MDR;)
MVWD^;4(QIO&^#<(9YI%EC[OFRH6O,LQ`QK3$6/I*U3F/,@3V,J7`U%O<+U4J
MS6IAQ!Q-2IK.):2DDJ_C(,$D6GCI5#"`FW=J\PJJ,J*,26;`2D3&,SE.^TW:
M=44PSE>7OAO$H..D$24J7)LM3.5D[9B-VIPAQNK!-("*O6;*RI6\MW'-E`L=
M<R"5O9,8VR_%L87.'HC][!2!`IUC"VRAW$?)HRB9CO#=)R]VEW>HS%XR4MM&
MU4B1Y(E(66C6-!L-\7%Y6DH"5OK+)ML400=PBW_I?#;77B1Q<K[))HA?<MX\
M7Q/ABZ#:(C&F3K*2]6+$UWM<A;<H3-Q8LV4_>+A(Y2M4*X-(22`#,.WS?NF*
MJ3@-QL&NJNKJ;PI+2G`KV18H"0E*4I#1Y8&DR\.IP+5M$MR]HGDDVWST\4*N
M3X-<=+XXA[="CDJ`I<@RP9-#CBMVN;JF-I9;!Y*\_P`12=@IKM@21&0KL'$L
MF"C-RJD@LV3`CE`SE$BB=1WQ!7TS((:"W!,`E(4H!1MM.[P:X(R.C2#-2DXB
M%$!2@+!(6`PL1X88L=)9OBALV7%*-GY#(IK7C0N1'Q:'#S675PD;]:*G#I,&
M[N$GY^1.HZ`RSQVW:KKK&;H)`LH4V[>;5.U9JU-)#C24R)0DFS7,6[ITQLK*
MZ9;2Z1+C@;<%HQJTZK9B>Y&P9<1X)K=:QD%GDS.T9:X6I4RDVR489(;LB9D@
M:!(2,G54<LH,8-#W8=QCN;?%%>,+#J+MGBJ"HF2Z2%D?SERHIQ2/%`82ZIP)
M"0)*7+$0;Q.0LG*RR(FL@1251JJ=:^L*:2V25%4TIGA!"I@RF;?AA_<78KK>
M+XNQ,8).0,K:\@7?),\\DGWCKV0L]\FUYJ9=*+$30*1JD98K9JAL(-F:"2("
M($`=4*AWK92I9F$@`;PNB_34B:5&"<U8BJ>Z;X=````V#_V?7UI?%J<XKI"(
M4<R_[=Q5_P!L_!7_`*4ZM9;[-1^S7_VQ5J/UK?Z0^&)IH_VLGU-<]C]2G>BV
M;XC]REJ5EO>`\FTVF9!98LMUG@@AJW>I*1=Q#"(EWSYHBV9NY>.=,I:);V/J
M&,.Y8JD?H%>"=MNN"8#<84<8G:(J5S2'V<#EV_+T1R!D+9;J#@YED_CY4WV+
M\K\<\YRW&#)V)[!G&U9CQ-)2F>3T&O)S]3O5CE9IQ9(FI7.WURT117+=H_8E
M"3CEF[99RN0>_34M.U4*%8X'&%4X<3(82".5(V`VR*3PQY:O>=52-G+FU-/]
M8V9))4")RLF2-T&-W?F=NXJ9PNMOB,@7^U8PX]<7<`X_SE&3UHG)M"=QYDEY
MFIC;,ZJQCYY(-&][IF0HR/GY!^4H*C!!(MP,"*:)4[E!14>8T%.@%*:ZHJ%`
M$F0D,.%.JT$VV;M\:UM569=65"\*G*-E@&0'QI6F=]^B%C*YZRQ4_1KU%_7*
MKE)HX#A[C*SN>3S6=H[JK0II>)K+:TROC\G=U,DGM43`OWCPD@,$LU35*5<5
MQ`O4%-O+:0YNJC6M.R2ZI,IFT))]._$CM;4)RH5:6EAU209[\C#9Y)85O%^<
MC<<L8Y"NZ7%+(%ZX:L\M'^&.[SJ%4D,E2.<2RL"PR?-6F4ME0+F9*G59.128
MRK8[E)V0R1D3OA.I*RPCJ/7^0G,^7AY(M2G#*2)83>;</HB9:5/5HI6%'NN0
MQ"9O-_*/*'#&5E2&79\2.=->I^8<FPN.N/.=[(SQ!(PV2Y->3D86.IN,YR7Q
MN]R'+/)2[S%.I.3K#+HBT1DR.#&;"Q75.@F9`9J)NG<S:D<>;25NM''9($R5
M;(6`V`V2$[8H5M31(RBJ::K%AIET!(D#AM')!D2H3,K23*.PE3J+\N8+MDLC
MN.7K]IQKBZJ,2M79W3T)*H362).1<+B4AF?B:B%N;`B8BIS&.57J*78!/XVH
M4IM0PZ8]93,MK&(@XK-)A]#?K3?4'[6HJG]W7^@?1%\7B(199_GL\,O\2.67
M]Y,-Z]'1_P#S>:_M:3_-'+3_`%`;Z_0(F]KAQTX-(1A23;QV/>LQ$X%=MEFQ
MA3,4J@$7(*1^@QP,4IN@P["(#K*5!!"S<(P0%`I-Q$HAG6.$&$:/9,.W>*AY
MT;)@C"TK@BB2;ZR.'0I4:63\7`\PW(W2;S5DCVSMZ@RD#ID5:(R;PI"]+@X:
MN-9HMEH,)5]"%A<I3.(2D9FW0++HI=TT12VA*2G98L,B;,0(.G43?.6B$=)>
MC^PB^AZQ`-I++,!!PV**E@VU0M7R"_AHW,6*:,5T%;IN7$46)E;,UCV\B\0,
MZ9C&OEFKY=N98R"G=EG5GF8N?K@"O;+=3R1,+6)+(E*^0L,P"`1(Q",MH7$J
M6A:Y)D""M1!MT@DB'#LF"L'Q)5QL$B[K*5VY&8GRY'-7,^UAD'N7J2RI\3CN
M`KK1=FF/N>Z0QVP33BD^L[H4E.D2]0@$+699BA2EL`X]DM!F`>0H26+1I!OL
M(G>(A7E]'AV96$A2TD?I6X9<-VF(\53`?#UCD9"D&E\I65&8G<_8LH&&<@2E
MY6QA29&6JJLWG2.Q3#OX:,20C96J6=9-*3,]D&J+5VY9Q*R)161+)2UE:EHU
M+"9!#B5*)2#:"<)F9V3T7'5&.J96P\FB=GM"E6$A2AH$Y`'49_#9#R5_A/C&
M(3J"M@M.7,E$I#NP'@`RGD5]<&[:OV3&\[B-W3WB3M@S0&L-Z-87:"8%(D^7
M75\8=NG*X`;6S^;5:\:FT(2ETS5A2E,R#B!&D6Z!9N08R=A"CMG%KU8EDR'#
MP:8;6?XE<:\4TB4:Y#N67K!`W!CC7C[!35UO<Y<)2D569R36%J!BF@NVT0<8
MB`>WI&*37=NT7KU5!%`';TR:!!2A8J:QU*DM`C!-<AI,I$GR'SQ;ZG0,CE*$
MB,-IWC(<$/1D;B3CG)%DL-PDI;(E2NT_?J-DE"YTBU(P$[5;EC^BRV,X-]5%
M7$=)-&*$A29UZQ>HK(O".2.3*E!-0I#$@:S-]AE*DHL&),B)V&TS!L(B5_*V
M7TXUK]H@S!D9INE*Z%'A;B9B[",W5YZG>^T[^H8QL&*(I2Q6EU83K5:SY*=Y
M4EE95T]3%[*SRMK>'/X\JJ*ID#"0P&-N<3V9/UZE%X$$KQFR0F0!8!=8!9$C
M5*AE6T!FK`$^0$D>F)4AJ")X-(0RG(XH&P'G`INT@X;RCU!X-_\`R(G/5[-N
MP=7,O0E=>P+E*>0F>X5#X8H5YPT[KBK6T,K5+=`GZ(^"2Q>G`])!BF<?8SI?
M(*O0E-Q^G%TZJ1*V)L0R"L;`5^%C8Z,8J2$C4G3]\HU:HE*9590ZIQ#<YA'7
MZP:^ZW[OZHE=,RAQT!.T)J'1RR)W8[(_/:?O`\:X`IH$,DG#]&BX&0^+&E_I
M_P#THOG+5GY&L*?F5J?\(_!?96OXEW__`$C/X@^.-WZI'S8M'T_WI0^T1Y*U
MD>SM_P`S>%O4W\`%I?:/;ZGAU$_]U?@:E:VC](VI"C*76709[^TG!7C7QF\V
M7A5J8?%A3L&E`IUVH,C?',_-F;\A\D\H6_->6K`UMF0K\];/[3/-(F(@VLF[
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M9H2I=.XV5)'M<%FY'1PH[E`?J_;VUYQM14@*-\=\B1E%VMXQ&&X\"G_!'^IK
M1=[?[4?#%>J_<W-X^B(A>CZ_F9<>/]'S?^^<CKN^(OZY5?MC$&6?T]G]F(F3
MKBQ?@TA!I"#2$&D(-(0:0@TA$6^;_P#,TY9_[->;?Y.+)KIY+_6*7_D-_P"8
M14K_`-R=_9J]!A\*%_@;4?\`%FN_WG9:XCW[Y4?\L^DQ8I?W)O\`03Z!"TU8
MC>#2$&D(-(0:0@TA'FKX`^K_`%!U$_\`J5;P](C'_L3OGT&(?<5/\->9O^UG
M8/Y(,-:ZN8WTW_%'^8QQ\G]JK_Y:_@B8NN?'9@TA!I"#2$&D(-(0:0B&6;OY
MW7"3ZG)7^3"*U8;'T#ATC#Z8A7^M3O*]`B99?!^KJBRM2TDJOQ&)S\$7:FC$
M&D(-(0:0@TA!I"(\\J_YL_(3_0YDK_)*7U9RK^O,;Z?2(YV>?TMS]'BAUOS/
MU'\Z+W%$7^*`[7SFF(^=O/?R-X9UTLY]C+_^)_WJBK2_K'?TSZ8FAKD1=@TA
M!I"/-3;;8?9$/9VUD*"3;I@DR6!I,<>\IX8O&2.0MRB;%7\DN\2V'F?A*>?*
MQ4M:H2"E,30_#NS0MJ$TC"R,>;W@+9'[B.F$2*%;.'2PH*E$R@[^@8<;53$D
MIVJ63*<O:F)>64Y1YE66+.8/./8BVI22+3=;.XQ'^7XG9/ER8S>T['MM;94Q
M/2_204G"=ZLKR=.XQ\".0SCQ,(M.RDL1$J(03M3WN+O3'(HV*4QU#$(`EN,Y
MG3T[:Z<J2JG<4TI0`3:4SQ#6+[9$6712JLF+RTK2DE20H`S59.[3P;M\)K'N
M$\G0N+)9=6N\D[#BJ1R9QZ>Y]P:C@O).%YJ8IU?87=MDD]8AYO+N1KKE>=E)
MN3@W-O-!ND&<^SC!\7%\HHLGJJ]4TKZ\36!M20K"9A4]4^3(>>^)*>@JJ<82
MEQ;)(Q"WR@6S\XA=VK!%;C;_`'>]8TXNYDJ#F\>C]R)2,)R"L'=).R4C),2I
MEY%G6+6^0L5@<8^L$_4+%'%@FDFJ0XE719I`F[1,@G.:U2J1"%.(+B7IFQ(!
M3A%PD)VSF=_1&BZ6F2\7VZ=<\$A:L\K%IY5EF_HC#GL89<D+.[))XTS[(\A5
M9KBHMQGS'$+VLN-,6XWKU2Q63),=;K$VG$JM4%HZ;C[=[[(N704D+(F_1(B#
MH#I=SLY44"]D&`A#`0K:B0)4LJ401.9]G"``0!*X6QL#7)2I%8A:GE$%LV@!
M$A99*XSM().N'OQ%@BT4[,>,,P,ZODUC=;)S4Y:1>2)67F[<_9I<=[&KF^3Q
MTSDH60E'4(PQ^ZFVM:>PXD;II)/77>I&ZESB>KF-2P1LVMF6PP@`I`]NW$9R
MG.=_DBW0452IQ-0Z%)4%F<Y^S9+3+7*R>LW1V*(0!#VW:.X^J(>KOZFVO-J2
MVX<0$X],L)49[D>@``!L'@^O]O60D)$A=&H$K!%=9C,&D(A1S+_MW%7_`&S\
M%?\`I3JUEOLU'[-?_;%6H_6M_I#X8FDB(=V0/5V_JZH,?J4[T6S?"?M],J60
M*W+TZ]5F"N%3GVHLIRM6:+9S<%+M!.17Q:2BI%%PR>(@JF4X%4(8`,4!#M`!
MU.E2D&:;#&BDI6)*$Q"6B<+8B@*8RQS!8SH\-C^-79.HZD1=9B&%38O(Z60G
MF#YI7VK1**0?LYQJD\37*D"I721%0-UE`P9+BRXITJ)6I.$F>BZ7!&%--J;2
MT0-FE4P-1UQOGF/Z1(.[&^?U2">O+A"MZW;73N-;.%[/7FJ4D@U@;`JLF<\Q
M#-T9EV4C5P*B)2NE0`H=X?<'7!@(4H;,S3:;#K$8#38"QA$G!)6F8W9QDL:5
M48NNL:A&UJ$85*,AVU=CJNSC6C:NLJ^S:%8M8-K"(I$C48=NR("1&Q4@1!,`
M+T[=FM9JVI>F=J=,S&Q0@M;`@;("Z5D-Y#<;^/U=HDSBZ!PIBV&QK8UG+FP4
M"+HU<8TR=</.[\9<3%9;1R</)KJ]R3VZR)S!W9-A#H+M,:E\G$5JQ;\0-4=,
MR)-(`'E^&,2:XP<<+'1H#&-@P1B2;QQ5''CE8H,KC^KOZ;7GG0NF+N%K3J,5
MAXQT=-TJ!E$42',"AMQ'J'?":A]*TNI6H.($@0;0-0@NCI%M+94V@M+,U"0M
M.N'1J=.J=#KT34:36X6I56!9IQ\)7*Y&M(>#AV"1CG291D6P209,6B9U3"5-
M(A2`)AV#MU"OZ0S7:8G0A+8D@2$*,WZTWU!^UJ"I_=U_H'T1N+Q$(LM#_KM<
M,0]>D<LMOU(/#>O1T?\`\WFO[2D_S1RT_P!0&^OT")O:X<=.#2$&L$`B1NA&
MGGQ4)"RAT$`<KD9+G;MC+@V*Z<$()D&PN1$/%@<*@!.\_P#B^KJ]366FVPXG
M1;?&KBL+:C*=ALCYL*EBCDQ,UGDDQ:XHS'C)KDW!=#2F:C6*7E''98W,+//]
M;<VAG6KG:\GWJS9.NU;HKQ\8;HS3B4I5F45DRN"D_:?1ON,)>:<*T+2DFRR[
M#83(66Z+8\1ES3S":AEUM?+M`.*TXA8#,FZV=FK?D'F_BPRC7.0*\&#,B7_`
M>->8/&3*5/ID4A=[\^&D3M"BXS/,QCZ,/,O;394#61P9U*-&2BZP/!<KIIBH
M*F\F7UJ>4DK0AU5.Z"3A`*C[.B0LF(L5V6LU:`C8J4A#S:Q(KF0)E1L4"9$#
M2(P+[B>>DL@,)_+F#\^9(PQ$<P^3MD>UNFQ5OEI8<3V?`>/:Y0W18"%E8^R2
M]!>V=NJ@2.9F/WKI`YA04!%74M/4(8H*BG2X@/N-M2GAE,+65`3$K`09[T9=
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M$M4K2?+*+^6OOU5=4LK210M+PH%NO7>;-9CK4DF5(A2E`0`I"E[1W'8H``;C
MX!'7"))OCO);0CV1'IK$;P:0ADN2?\WS.H^K\#.4@_4&C3N^IJ)2N\&D_%Q)
M/EQ"*]6E*J98(L*2#O$&8ALN.>'L12>`,&2$GBS&\A(/L-8K=/'SVC5AT\>.
MG%%@E%W+ITM%'7<+K*&$QCG,)C".XCJ5^MJU5KZBZY/:<X_EO:HA8H*%%,VV
MEEO`E(D,(,N$<.N\P]/P'85^)_%WR?U/^"=:=;J_>N=(\<2=1HO<M=!/%&,M
MA#"X;_YH,7=.P;A\'U2'</;=0;>Y`B.X!JN]5U*TK&T<*T)"ARC9?N[D;-T5
M(%&;36##=A3?P1\EW);T'O(WF-Z1;D7=()G4^/W&N1NE=&'O<BS8&4G(UK1J
MLRDC8XQW`G:F?`20;JD%P[4CF9E^H0,J8!`?T!E7WI9;D?A2DI6GW7L]2T)M
M&13*9D2M4U77B=DKA'R*N\!UF8>(77)!N@4J8DD)'D`E'=;A/Z(+AGPN2C9^
MI8^)D;*S/I[[+^5`9V:V).0)TJN*PP,W3@*4@8QS]!(]N1P!1`#KJ"&X_,?$
M?CSQ+XG=4<P66:8R`9;4=F`+C>;57JMOT1]`RGP?E&1@;-M*ZH6E9F3;N$R$
MMZ.II&J"8[E)L/4)]Q.<P]0AL(B)C"([@&O$EI!45$6G=/HNCTT[)62WA&1X
M-;@`"0NC$&LPC#<>!3_@C_4UHN]O]J/ABO5?N;F\?1$0O1]?S,N/'^CYO_?.
M1UW?$7]<JOVQB#+/Z>S^S$3)UQ8OP:0@TA!I"#2$&D(-(0:0B+?-_P#F:<L_
M]FO-O\G%DUT\E_K%+_R&_P#,(J5_[D[^S5Z##WT+_`RH_P"+->_O.RUQ'OWR
MH_Y9])BQ2_N3?Z"?0(6@"`^#5B-XKI"#2$&D(-(0:0CS5\`?5_J#J)_]2K>'
MI$8_]B=\^@Q#[BI_AKS-_P!K.P?R08:UU<QOIO\`BC_,8X^3^U5_\M?P1,77
M/CLP:0@TA!I"#2$&D(-(1#'-H@/+KA((?_N4_DPBM3MSV2QH.'TQ`O\`6IWE
M>@1,LHAML/A'59*4I$DW3BP?@B_6T8@TA!I"#2$&D(-(1'GE7_-GY"?Z',E?
MY)2^K.5?UYC?3Z1'.SS^EN?H\4.M^9^H_G1>XH@;2)O/F%LF\FTFW%7)N1Z]
MD//+_(=3ME0O&$HZ,E(%[CG'5;+WK"VY'@)UHZ1DJTY`Q56J8B4"B&X=H]&H
M0Q6-L)<?P*;:PBSV;22G>MG\,<FD54-.NK(+B"LR'HT0['E$Y[\QK.WRB<;O
MG?U6[MINV>;U1>ZV[[D\,'E%9[\QK.WRB<;OG?T[MI>V>;U0ZV[[D\,'E%9[
M\QK.WRB<;OG?T[MI>V>;U0ZV[[D\,4'D1GH?#P9SL.V__:+QN]7P_P#:_K!R
MRD,IU=HW#Q0ZV[.>Q,QNQB#GK-QA$P\$,XB(E,41^$3C@'M3#U&#LS"'A-V_
M5[=95EU,KVJSS'BC*JMY1FIDDQ<GGW."7:GP2SF0?7#(O'`1`-MM@WS".P=/
M9]3LU$,GH0215VG<,8ZV[[DP#GW.!BB4>".<1*81$P#D/C>(")NP=P','JAK
M;NJCNZWYC&PK7TB26C+R10^>LW*J=\IP0SB=40*`J#D/C?U&`@F$H&$,P!U`
M'4/A]?4B<OIT`A-9('</%&AJ7",)8LG.*!GG-I3BH'!#.76;8#'^$7CB)C``
M]0`8WPQ;F`!]?6ARND-AJ[#N&-UUK[B@I;)*@)`V6"+PS[G`I@,7@CG$HE-U
M%$,A\;PV-OOU!_GA'8=PUE.64B$X$UG)WCQ1DUU0;VCYHR`Y$Y[#P<&<[?*)
MQN^=_1.64B1)-79O'BC3K;ON3PQ7RBL]^8UG;Y1.-WSOZSW;2]L\WJAUMWW)
MX8/**SWYC6=OE$XW?._IW;2]L\WJAUMWW)X8/**SWYC6=OE$XW?._IW;2]L\
MWJAUMWW)X8C[GJZ\E<I+86&%X39E:%QQR`QME29"1R)QRW=P-1"7"1;1X(Y>
M,)Y,XR112(<2$-T&W,&X:OT%)EU.V\':L%2T$#DDVF6H761S*]^N<?94PTH(
M2H%5HM`G8;//#_)\A\]E*`>0UG?LW#MR)QN`?#ZH?"_MKG)RRE2D)ZY8-SU1
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M&AJJX\8!0Z8E!0@D`X]0%Z=*Q1LT%11KK!A>P3&$G$4&:9V:-$KM,XK/O5:J
MQMUADA(49VW@V'1$A_**SWYC6=OE$XW?._KF]VTO;/-ZHZ?6W?<GA@\HK/?F
M-9V^43C=\[^G=M+VSS>J'6W?<GA@\HK/?F-9V^43C=\[^G=M+VSS>J'6W?<G
MABTW(?/)PZ3\%\ZG*.VY39$XW"`["`AN'PP!X!#?6%972+&%579O'BC/6WO<
MF,8<]9N$YCCP0SB)C`4IA'(G'`1,!0Z2@.^81W`H#K"LKI%D%59,BZP\4.MN
MX@O8G$--D4'/.;3`4IN"&<3%+V@4<B<<1`!#P#M\,6V^LHRRE0<2:R1WCQ1M
MUZH]T?-Q0?#SFW<1\A#./:7H'?(G'`>HH&Z@`P#F(=]C>#?P?JCK564T:U8U
M5<U;QB/K+F'!L#@G/RP#GG-H]._!#.(]/84!R)QPV+]0/AAV`>S[`>L&LIRN
MD3[-9+R&,)J%I]EB4Q%#9XS:<``W!#.8@4=R_P"<;CD`E'LW$I@S$!B[[>H.
MLG+*4RG67&8L-\;HK'FI!MD@#>C4P.6LHU9S8GM;]'QE^#>6Z=6L]I=1EWXT
M-'%AL3AA'1:TW,*I9>`\A)J1D0U;BLIU'[ALF3?I(4`W.7TQE.LNW#Q1&A]3
M0.!@C$J9W2=,*/RBL]^8UG;Y1.-WSOZU[MI>V>;U1OUMWW)X8/**SWYC6=OE
M$XW?._IW;2]L\WJAUMWW)X8/**SWYC6=OE$XW?._IW;2]L\WJAUMWW)X8;S+
M67^1-[Q=D>D1G"'-K:3N-!N55CW+W(G'#Q-N^L%=D(AFJ[Z,O&4!L1P]*902
M@8P$*.P"/9JQ14-"S6(?=JQ@21.PZP=`OLLBGF%15N4:FV&E!XW2EJBS$66^
M1%"Q7C*CR?!_-SB3IF.J-4Y)9ID3CCXFK(UNL1D,^49G/E\IU&IW3(PIB8I3
M"381`-^D-*B@HW*EQYNKDA:IBPW<$34U54IIFTNLDNA,COB'&\HK/?F-9V^4
M3C=\[^HN[:7MGF]43=;=]R>&*#R(SR8!`W!C.H[@(?\`6+QO`=A`0[!+F$!#
ML'6O==',JZW:H2-AM'!NQGK;ON3'F7D%G4GZW@KG4!WW`?A%XXB(#L`;AOF+
ML\&L]V4F$(ZWR0)7?#*<9-:^1(M&7DCT#D1GHH;!P9SL`?Z1>-X^'ZN8!UA.
M5TB!)-79O$^F->M.BYD\,5\HK/?F-9V^43C=\[^MN[:7MGF]4.MN^Y/#!Y16
M>_,:SM\HG&[YW].[:7MGF]4.MN^Y/#!Y16>_,:SM\HG&[YW].[:7MGF]4.MN
M^Y/#'BMR'SV=,P$X,YUZO`.V1.-NYO7`1-F'L$`'?LV\&VMAEM'MFU*JQLTF
M9Y)E/6;)GR17??J'Z9Q#;1"K1?Z(8KB]=^2V%./V*<567A/F21GZ/5DH26>P
M^1N.IHQP[3>O%S*,CNLM(.#H&(N783ID,'@$!VW&]FK%'6YB]5-UG(6LD6'3
MY(CRYZH9H6FG&25I0`=^'[\HK/?F-9V^43C=\[^N?W;2]L\WJBYUMWW)X8/*
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M)&]#CUO/&?H6O040XX.9T6<1L-%1JZI,A<;>Z.NR8-VJITQ^&`#=)CI#MV>#
MU`\`5'LLH%UCSS=4-DM94+#?.\:9[]FY%RGJ:IBD:;=:45R`OW(WH<B<]AX.
M#.=OE%XW?._K3NZF[9YCQ18ZV[[D\,5\HK/?F-9V^43C=\[^G=M+VSS>J'6W
M?<GA@\HK/?F-9V^43C=\[^G=M+VSS>J'6W?<GA@\HK/?F-9V^43C=\[^G=M+
MVSS>J'6W?<GA@\HK/?F-9V^43C=\[^G=M+VSS>J'6W?<GA@\HK/?F-9V^43C
M=\[^G=M+VSS>J'6W?<GAB@\BL]>KP8SJ/U<B<;QV^MF$NG=U&+%U8*3K!C"J
ME]5J&3B&[##X6OG)+'=CY`2LIPES.Y;93S?)Y)@B,LB<=A4:PSRB4&L$;R'?
MY<(5-^#ZKKF,5,54P(8FQM]RA?JZ.B>::E6#&E.'V38+;+KMR_R1SJ-U]BH=
M`8(0M17Y2;3^7!#\^45GOS&L[?*)QN^=_5#NVE[9YO5'2ZV[[D\,'E%9[\QK
M.WRB<;OG?T[MI>V>;U0ZV[[D\,'E%9[\QK.WRB<;OG?T[MI>V>;U0ZV[[D\,
M'E%9[\QK.WRB<;OG?T[MI>V>;U0ZV[[D\,'E%9[\QK.WRB<;OG?T[MI>V>;U
M0ZV[[D\,'E%9[\QK.WRB<;OG?T[MI>V>;U0ZV[[D\,4'D5GOP>0WG7]7(?&X
M?_\`L`:R,MINU^8\40.UKZ56,F[7#`Y!N_)6V9TX[Y,8<)LS(PN)?A>]\#1Q
MD3CMX^\]_M,85Z&&+*GEXS=7N'S8QG'>F)T)["3K$>D+#=#1H;(55B9U@_EO
M15-76.5"9,J"0#IUV:M'GW(?X>1&>MP'R&<ZA]3(G&\`[/8^&$VH%9?2$\FK
M`&X#Q1T15/I$E-$F*^45GOS&L[?*)QN^=_6O=M+VSS>J'6W?<GA@\HK/?F-9
MV^43C=\[^G=M+VSS>J'6W?<GA@\HK/?F-9V^43C=\[^G=M+VSS>J'6W?<GA@
M\HK/?F-9V^43C=\[^G=M+VSS>J'6W?<GA@\HK/?F-9V^43C=\[^G=M+VSS>J
M'6W?<GA@\HK/?F-9V^43C=\[^G=M+VSS>J'6W?<GAAL<T96Y$Y'Q%DV@1'"'
M-+24N]&M-28NW^1..Q6#1Y8(9[%(.GYVN75W)6C=5T!U!3(8_2`[`(]FI\N8
MI:?-FZIUX;-$K9&1D=6LQR<QJ*RLH7&FV53F1?N[T3X]S7'K%_P?]S?"'_A'
MK>'];[/@USL0^5.._+T1YVBQUNFPSRQ6B6CH"%CR"J]E91XW8LVR92G.8RKA
MRHF0!Z2CL4!$YQ]J4!$0#4*J4U1"4^V/1JC13C%,G&LA"2;[K8I7[%!69JC(
MP4FREH]REWK9['O6[UJL4`()A36;+*D$Q.L`,&^Y3;@(`("`;+I6D"1`Q")D
MX2G:MN8DG=C$NEXI..8%U:K_`&RMT>L,5$4GUDMT]&5N!9'<J`BV([F)EXRC
MVQG*Y@(F!U`$YQ``[=812!TX6D8E:K8B=J&V0"\K"DF0.[&XBY*.FF#*6AWK
M23BI1FUD(R3CGB+Z.D6#U$CEH^CWK515J\9NFZI5$U4SF(<A@$!$!U$&DXRV
MMO"1OQ*`)8TK*DF-/#W:I3ZBB4)/Q,R9-U+L1&,DF3X@O*^^4C+`U(9NY4ZE
MX&32,V?%\+1QLFKTF$`';8,\T0F8592@/ZX!]3P[AX?U=-@SS1"9C43LQ%5Z
M)D9R:?-HF'B&#R3E9.0<I,XZ-C6"!G3Z1?O'*B;9HR9-4C**J*&*4A"B81V`
M=:FD2X1@`$15#^Q9*R;8T./<@4S*=1AKY09UI:J=8VOCL!8HPZBD9+LRJJMQ
M=,53@F95`5T#%W$H;[;AV"`CD4J&[%@$QLT[M6DK2;Q"UV)]Z;L\/A^[K.P:
MYHC?$J$K:;G5*86&/:9IC`I6&PP=1A%9)<K=.3M%F?%C:]`-#&-NK*3+XP)-
MT@[5#]@=NLAAGFB(G%K!D";H5!0+MVE$>WP]OW=8+#4_9$9:6LIM)G.+MB?>
MF[?J_=TV#7-$28CKBO03;?I'ZFX[_;TV#7-$,1UQ38GWAOL_=TV#7-$,1UQ<
M!""&^WV1^[IL&N:(8CKB@ID\/3O]3??[>M33,$S*1.,XE73BFQ/O!_4[`^P.
MMM@US1&,1UQ4"D$=ND0]7MW^[IL&N:(8CKA"0F1J%8Y-2&@[;`2<L5[;6!(M
MI*M%))1Y0YA"OW1N@P[\';@U5G7*;-^*9#%:N5")J"4QR@.BJ*W$/9\L5VJI
M*W"W.9!C/A;G5K#.VJKP\RT?6"DN8UG;(ANMU/J^ZF8].7B$)-'?J;JR<2L1
MRB`_KT#E-X!#4G5VA>D'\M^#-4%K*29D$QMDI)@N_7C$GR!I!NV2>+,0<HF=
MI,UU5$4'2C8JPKD;+JHG*102@0YBF`!$0$`B-&)Z(L[=N-KL3[TV_P"K]W4F
MP:U",8C'BY6;-$CK.#D22(110ZJBA4TR$2(*BAU%%#D(F1,A1,8PB!2@`B(@
M`:"G:)EAO@5$"<X:S'6;\29=8-I+&.0JQ>63ILN_;K5J8:R)EXQO)O88\ND@
MFJ#E6&/+QR[9-X4@MEE4C%3.;;4CE"FF_6H-NN(*:J0\)3!5#JK*-FZ"SEPH
MFW0;I*++KKJ%21122(*BJJJJABIII)D*)C&,(``!N/9J,,-3]F)^",1BZ92+
M9!XS62=MG"::Z#A!0JR*R*I>M)9%5,QDU4E2#N4Q1$I@'<!$-0OTS`=3)(OW
M8VQK%@-D9_23?;I-]GL^KVZFV#7-$:XE142D#PE'ZX_=TV#7-$,1UP=!-M^D
M?J=N_P!O38-<T0Q'7&#(OX^)9.)&2=-X]BU("CAX]<I-&K<@F*3K7<N54D$2
M=1@#<Q@#<?#K55.VH22`#&%+*1B-T:N/L]>E)>4@&$LP>S4&G&JS<2V>MUY&
M&3F6Z[N(/*L$US.XXDJV;**-A6(0%B$$Q-P[=:IHL!Q*D4Q&E\+5A%\*$"D$
M=ND?L]GV=2;!KFB)<2HN$A`_K1'Z@C]W38-<T0Q'7%NQ/O3?9^[IL&N:(8CK
M@V)V>U$-QV]7[NFP:YHC,U'3#>'RECPMC?U$]N@T;-&S4-6WL&XE&C612G['
M$.Y^OPI&SM=$[B4FX-@L\:H)]:JK9(Z@!TE$0RNC2IE10D!0'EBD,Q9+XI__
M`&$RC<)7.JGMQ*$,RT"Y*5I2X(UM142RBU91DV\,O.)-Q[5(]O*/$FYU`'8J
MJA2^$=1,4H33I4X)J)OBR7AME,?'2`>&-T]D8YDX8LW#ULW>R0K@P9J.4DW;
MWQ5,JSH6K8ZI57)6J9@,H)`-W8&`3;`.^ID4[)O2(DV@3[<9I=OUPF$0\.^X
M[;;>R/JZ@;::)4"D7QJIY`3/1#-3'(+"L`G$K3N1JK&)3^1E<10@NI1`3RV3
M6[MRP=TF-31,JH]GF+MFL1PDD!@;]R<5!*!#"%@T+3K9DD>>*":_Z64[(><A
M"E'80$=Q[/#]O?U-56:9*`0L3MLCHE<[K(O$I`_K1'ZF_P!W4^P:YHC&(ZXI
ML3P=)M_U?NZ;!KFB&(ZX2=ON-:HL0K/VN6:P$&BZBF2LK)+%;,$GTW+,H*'9
MJ.%#`0CF5F9-NU0*.W>++$*`[CK'4PX9HD!**]54AAL$F1)A1E5(*9C_`+8`
M%'82FW*<##M[40$0V'MV]@>S4:&F0YU<@%R4^&)ENA#>U/LRC35:U5JZQ`3M
M6EFD]$>Z,S$>Z$>N#AL$G7I=[`SC`5"CL#F)FHYPU7)X4UT3D'M*.IUTB&E8
M%)Y4:,5":AL.MGD'X+(40%(([=([^SO]W6NP:YHB7$=<7=V3UOLC]W38-<T0
MQ'7%.Z3'81+X!W#M'P^OX="PT1(I$C`*(G+3`)"!_6C]0-_NZP*=E(PA(D(8
MC`!2#X"C]<?NZSL&N:(8CKAKY#,>(XF^,<6264,?Q^2Y0A%8S';ZZUQG>I--
M=%9R@I'5)Q)I3[TBK9LHHF*;<P'(F80W`!UOU56'&&>1KME$.V80>KK=D^JZ
MVT0HX:Y5:P2T_7H>PQ$A/U0T>2SPC*58NY>NFED5',22<CFSE9W$J2;9(RK<
MJY$S+)@(D`0`=M33%("BT)&-:>I2I103,B$^7+.-5(Q*;;W>NO(E:W#CU*29
M3<>^CCWL)H:V-/.^9NEVJ-E)80\0,T4.19-Y^TG`JGM=8J&#35(I769*4)VS
MNE/UQLPZS5JZPR[-D62!LF(64C88")D86'D91@SEK&9^2`BW#YLA(S2D6S&0
MDDXIBLNFZD%&#`HK+`B0XII`)C;!IL&N:(GFJ"?L-?JL4]G;)*,(*%C&RCR2
MEY9ZWCHR.:)"`*.GT@\60:-&Q1,`"=0Y2@(^'P:;!KFB,8CKC=;)]/4`=FW4
M`@(CN&W5N&P]O9IL&>:(35#5V+-.(JG<(3']IR;0:W?+(5LI6Z5/72MQ%LL*
M;Q=5LT/!5V0E&\M+%=.$%$TNX1/WATS%+N("&MTT+KR2:9DJ;E:H3L&OR16?
MJ:9@SJ'<"]1,I[GEA55*Y56\1[V4J<RRGF$;.S=8D'+!7O4V=AK<@O$6"&<;
M;"E(0THU4;N$S!NFLF8H^#59RD2RH-NB85KW8E8?14(VC4I0J.[2ZO[6("(^
MR'ZOAU**=D``)$A$I4I4@3.47&*4`'8!WV\("/9^KOH6F$B:@)1HLKPG"3.$
MA(WFF0\DK$2UH@H^4;F@".(QY,1[9ZD>V2#B(JQ56J[HBZ9[++M%6D>!B@+U
MRD=)'K.4Q0P:5"B'$CD"(T52)AE7ZTPK2="@=1?UFYB["(@("41*("'_``@U
MML&>:(FF8].[)ZWV1^[IL&N:(8CK@[LGK?9'[NFP:YHAB.N#NR>M]D?NZ;!K
MFB&(ZXH*28]@EW_5'[NM54S"Q)201&0M0N,`))AX"@'A\&X>';?P>OMK8,-`
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M<H=@[AX?#Z_A\.M@A"1)(D(`E((%@-\>FMXQ#1YTP[4<^8NM.)[RW<N:Q;6A
M&DBFT=JLG!116(Z9N$5T?;@HS?(IK`4?:G%,"F`2B8!D:JTT2]LHR%W#%#,:
M+K[`9.A0/!.$+"XEL.#\(Q6->-K&FMI.FQ+*'I3')LS:UJL+0KY-9Z6>D8-!
M]8S&(@HL*'=%.!5#%*.R>X!JI9>7MB9SB=#::>G2TF0(_+1#&\T(5O,X6Q8^
MR8M?H3(U/N]=N$#:,$X:L?(6#K.5(ZJ3K!=25QF,!.O[)CN8;2[]@'N@U0.4
M'"1@=,W`)KDO4#[C"UA$L*T%)ME9,&_<E..=7L)JFTX[2A4Q9.V1%QE?NQ%(
M,P<FX=@A6K5C+,])NN3:_P`&INIU[%]0M#O&6/21.0V37D#%%FX87=:QHV;U
MP$C2T0\>$<G:.BH)`[!-0Q>DY2Y>LAU#H6!BQ3-OYL@;]4],<Y%=FU,DLBGD
M#()(%@UG<T'ANA-3-"R@3,F*<OK1V<SWQF_](O2\:O6[S)Y*3$768S$6R\?&
M%_A(!9*L1V.+3!QI@\<F4BP4@V:,TW*QP1:`7*JC+&Z-Q*4-ES$U;(3E:%R-
MXGN2C**?-^N-+QN%*T.33,R!`FFRZ\\$2#]&O\-2D7D=[EG)V8KD_=1E$-*U
M7+&+,ST/WF9),SF5+NG!V',-VN*EC1=NCHI.4*P=&IL@;)&8D`5U`"OG+U(J
MM2BG0A"<(N"9&?Z(`X1BUQMDG731*5F)>4O:$"15.0-LS/U1#J6@L_Y-Q;E^
MG29.8DK;I_C'R'8<I:_D%7)$31W690&-<XH@>/!RG:P2K21>%D6Z*%',>)?U
MHQ4I/O'1RE-T:.HRZG<2_4(9*4K3A3A!FF1"\8TZ)3MG=%6L8>K6%M4BZI*M
M.-2K]&'<URCH%R!@[?CGCCA^LTQWG96F0=NQA%9I?XZG+Y:,[)89;QLB:Q+0
M<ZP=RF5)&0;V(8Q&05C%%YXD1XR5L(&+N7C43E149LXK#3AHF:`L)PW:`>3+
M?LGNQT:DO)RQI#"E)6@`+(/*/EU[\1SQU&<A;9+8V/-3?*TN/ZK3^6%[H$%(
MVRRT?(%TBH7(>-W/&^NYIE7ID'KBU.ZXM*EC65B4!X]9]'NNBX,1V0>BZ[2L
MMN;5%.7RX+4I!`$I$)T2G?*S5$3S6:EE!84LIPDSQ&>Y/=E#'8%<<E,@II!=
M:SFI>K1O*S@_>ZQ#9`0SY97E642L-K4S(9*P9Y@H:XO&-94C&03"C%%*KLG1
M1<1Y$VJVY]*Q67N-I6`VE>!8Y*0!H*;M-]IMBOEJLYGAJ`I0Q@VDDZ9W_P#2
M)'\B5N33GFI4VD3DG*^/\8$0PPMBT*)B7,.2*A9'QK-**YCB[K*T&[0F*H%5
MU'IMFRZE\CWK9M%KE<QIR+)J@;"#EB\H"0$FKVJR53$Y<G"+1/78#*_3*)'D
MYR<WPM%::?9),M$[9V77_!"3A4LV4*-3R-<ICEYD-A=Z)S?>Y.H4-:,B/)=)
MA3\BMG6`H+&<5$^).L=6]U75E6D&_BBM7\HT5,HJ=QW:1DK2W::IDS1"C2AL
MH(*DI"B2)*Q$^T`;9&P:(RDN-L'KW7#435[!5*6BXWPCXVPYVIV+N/+.D9(Y
M!V&;Y,$O7&B:5R4;+<3/8PRI=;23(T7D""CLS-6N0D:_BK'[*U13*;>)*.';
M9E'K"<_8`:.MTE;UEQ>R;=9"#]&`$E(&$B2;,1,B=^*S%774]92J9VRZ1[&F
M3I).(&\SX!N>9=1^),UV?)%:7L>7^7\16+SR.Y74JX,(C)=[KT1'85KC2TO\
M*I1"K,J8TZ.>S4-'J,9]BHVE9`KHS8'IVJH-R[UV8Y<X4T]/3TX0&&AB"!,K
MP)VA)O,R3?I&N)::CS,MEY;[VW+CG(Q&0&(X0!HT>2&H9/N:<QD'C2K>,G9Z
MHJ!<8<;',&M$8AS#=VEMMK20=H9RC,KJ46V5G'%7GI9-JV2DSWV*<MT&;DSF
M/,FY34`=MMD=/1+:PH6\HJ&(R!'-E,$]$C=B%1\0KJF@X%MTZ")D3Y5ML][=
MB</+^4M"62,*#-O^2S/`:L-DDMH4XR-\D.+8?+1'E0)C)M<5,3IJWM&G&A/=
MH4#!M"J20)>Z0]V*._#H-BW3+20AQT&]=MEITZ?/*.U7MU%34-.TKBTTZ;3A
M,@=^6B(87"\<L77)G/Z5-B.0]8K2...4L-W+Z0S=9X]21A<7D<82LM41D(%I
M@B`=V.R-@=5Y"F*.IL%1.VE%57!^D.LV<J%$C:X-KR#8E-V+E"<RHV7SEN".
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M8^HS2$C$1<Q[GG?S2RJ[$0>JN5!Q3OY,\*<5&SV:JE6*0`Y$IB1%LIS$]`NN
ME$;;6>!&)1=VNS$K3[4Q.?DGY9;\*%Q)YZKV%*G*L<I<M,ME1S;,2-7HT=B;
MEUB2=L[=.KUI)MC^1OEAG\@YIKK1&?<.7D7(W!9>EO7RCEF\*5BW1,GJKJE1
M7E#K;3*)&T!,K#8<(`!LOE(QNIY#&7ARG.8/.8M*E$STVSG(1TKE'".6,>\R
M:U$6S*-K/U7"EKQRI_<1.GV@<.0Q).C8GL=30C)-\Q92+L@.ERN7+E*==/&X
M*@5,B1.`Q4,TV8(#H24A23:)B4]1W(].]CJV5=7)22DW66RB"88USG1L15C'
MN/GF?*VFEQ)X05]I+,):X2ERK=JEN2)0R['15AG!F)%E8*YCUZ=-RU,)RQ,,
MD1,42-4BD#N+J,O<S1=4\$*I2XZ0D@89858)C](B.$BFS5.7-TZ`4U(PS4+#
M[0G;?=.%#E2E9&?YKR9A.L2O*+(U%LO'JZX]8^Z%MS]7J[CHK;#TI[BR:V0Y
M&14Q;F%6^6M-NV<OE9%&]L9=R9-0ZT<"Q2Z,5E(VTPZZTS(.)*N0DXAB!,[+
M+)B5QU06W7.U#[#;KHFVH)Y1&$R(!'ED=<-UEB_S6*.$W".G420S_!C:)=G5
MKA4[!:.0M"S1*GJ6)K6[G(`TW7JA>^0T#"U>YQZ+M$L9$*L5&+1!N*B,8L0Q
MMJ=NGJ<VJ7RALL<HH&%.%()Y,DF0NL&HVVD14SYZJHLEIV2\ZBH&'&O$0HV6
MDJ%L)FI2O(F;O'&,*OR3S9.8F^#?`RF.,I5W&O(;+4+EBXHVJ91S\ID28976
M#@X"0<2#4C!=/)T:X0CXPX'8@W6053"RNHRQNF=:-.V*A14+0F8G8F1(,I"T
M8"+;YF):GO).9TRJ5UQ5%L$J5:2#9:3H/EAUUH+F+7*]-73'5TSW/Y5R33N=
MB2-?O$[/3]-KKZM9`[_CFVKU1G$F=<JDJVKQE"0+DA6JTTBKLY573!(4:]/5
M9345+;3K;2:9M:,1";2+E8B+3/S7ZXS5MYHQ2.NMN.EYQ)P<JXSLEJ^&Z,'#
M=1SY;8#$]5G,W<IY;']HY.I)6V14J/(;!%PKE)9\?LAO9BOOK3EFW6S+3FES
MF2F<4+AY[H-(]I)+`VC%R$,GJ!Y[+@MXLH;V@3)(L(Q8A:!*5T^*+=(SFREL
M;=3FS/M6GFF_RQ'>\Q_)[-L?S1Q[,4[DC'TRP\?<ON$*5/VC/LH[7R92<H5U
M>D0T38;<QA*"ZDK#3BO5FT?CPRD!*1RZ3=SXVX3Z]=2G5E-%4,UCH:6H+$T%
M*"DI*3B&&9G(W$VC1:(Y-2K/7TO4C`7@F.5,S$E`WZ)BPRB3EDD,D-G-I<5H
MG*]#CBM+<1??/+0C++X9])B`^,LG+7,8!5\B?-XV,N0O>VC:A8==E;1ZJH!T
M&`1+S:9-*75.A31J2%E*5R+<\0D)$2]DDBR4Q':J'EEI"5-K0VD#$INQ9,M8
MME._<A-2%7Y/7&G+KC?.7E<CJ?QUY;7G$C-.RW"K7Z9F(C*$<OQ;2RUXBW/+
M6'(9*.0PH0LLHH]DVWM9=NNL#@AI'*BG9Q*=12&:A/"D&4TVX=$IWRL!NBBM
M+CP2BE76)=F+5+,I`V@[\3AY1S.2`P3AZ6%SEUM`NKGC)YR,7PDUMI<KL\=+
M5B44LGO794,AL@-DAO7N866+``$NE%F<^+AN!M<W+L"JM:P&I;->$.2PS-UA
MY,P)RG9'7S#KC:&FV"K:!22J5Y2+^$WQ"RZW;/2/(OC6QQ3%<IV^.H^8XZI'
MLE\=\B)(;3C"RSBC/(Q[O6S0)\613N!AW14)Y>_.%+@58Z+AH"'=BH;I,4K!
MHG$5BZ<$%2AA",6(#DIF+<)U)Y.N.=F-1G3E6AVB;4&;`0)ROM,A9,16)A>7
M]6QTI;*I;N2UDR3D?"7+-S:8:SS<Y8"UNSU?+];#$3:C5RT-1KE&N[7'$E*H
MP)")(J3/0B=SXV9(B@;+?RMUY--@:2TET$*`D2,-H4=(G;N1`VG-VOI2MU3I
M3(I),A;?+1&%C>(R&RR+)6+%,3R8/4K%RDP$]BY?D#$9'2M4Q3HCC!DR/DE+
M3(9!:(7LV/(V](LD5UY@PJ(O!!/<""@0</\`4&PD/;(.%M6((E*>(8;M.&9L
MUQ&ZUF*GFW&4$.[1/*E:0$G3J!E^5D-/6'N:(PMXR*SJ7-"WY&;\-$:ADY:\
MFRO79)EG23S=0ULF,<23S6'D+&VKM?8&>2:S"B-UFRT,S*6``'1Q4+*\K+"I
M"`64M!TX9`&:<%F(63,]>F^R#_>[3CT@X7UM`3G<0HGDF\"1],;7&-9S59+!
MQ"R7EAER+=R>/,M\LZ+3Y`77(\ON?%VB/KKS`JU[C[&=')CO'%AD6*[=Q-7%
MN8%(XJ3277%$"E`[498BCJVF4-;56PPG"G$DA2L>&^0(E=?&E$<X754:7MHH
M-A\N`DD*FE.SQ3OD9WZ+HE7Z-I7D0ZD;J^SGDC+D[9%ZE5D[[1LDXES!2H:J
M9<]TWZEE<5:W9.N=JJ5@;JE*LV[BBIM:L+-)!PDDD)BE&IG#E"IQMJE;;2$)
MF2D)Y4P)3P@3W,4SK,7?#B<R6A]^N4HXL6`*F0G#.Z=VBZ&'J^);Q=<7<(;C
MCYI?#95Q?%<U7:Z\/:;3`UR)SLT9WE)H3(S6(DV<&JK8,IIJ,71)0!(_;+K-
M5@.BH=,=Z:J%*E^G**?`LHD5H23*P'"2"0`+3*T7WQ4:HJFMH*6J:<6%I#F,
MA1$S.R<KY2EO61[UIQGZP4R>B<>V/F]#UNPL>*L'D*>RR;(,1DF%S;*<@JJQ
MS>MBY:Z-%YJ+K+;%[A][N'@TSTUHCW1X[8`7$,U;E+3-+JG4T[E6`O"V@)PE
M&$R4<.G$;)\JP1:ITYFIX)8+BFPCE3)EBGH\GY70Y^3\5YM^$BY&KF6N5\+6
M*?FCB3C2FMJ[D:\R$7\$5@KM<A<X3CAQ)$E4[C(N6DDZ-)V"2,]=Q+QJ#M!9
MJ[!14^$5^5HRZFV;3+CKS2EN$I!4E>-02D*T```D:9QMU;-EK<QN.)(6`!B/
MLRM_ZPR.9(_EU#QM,IK+*')"IXUK=TY0U:MWR)H^>LUY%5G(;+*".!C7`V+[
ME5+]9(L,>*.#1,E9%96N294`"4!83I*#9H^Z$TSZG$H6_@2;<("9@XI8@;C(
M<GE6V63BN\QG:%X6EN%O7,DW\7DA^[MCK,=LJ?*.VV>5S1<)\N<N.U6H%-DW
MED)30HD1(<5+9:[)4,8M535\%E+4WFG;V0`CL8_N7;=%5-(JY3TW*JD"V*6G
M0V6MC-2L*9E1*K"J^P2D(L)H:Q=*:JJ6X7PJQ!)E(2T:S;#K\=)_+TSR3RCB
MRTV:U2%(XOR%W:%FI&:<N&V2%N0-C8Y&Q(UF%U'"IIU?$>+%%XTW?;=RJX04
M`!'I$M6OI:"FIF*[$`\[?K!%A!._<-424M5753CM+AFVBP67C09:+-,0\@*_
MR>A:AF&BKNL\TV0M-^EE,&2N+VEAA8NLXUG>:JRV5WTTQ:,GA&67GT5-FE&T
MK(E.U=4]T0T<4A4)`%.\^NCV@JZ;JJT84S2X!,D-@3$]!,_9ERKXJ4E-FJV>
MI$K9&(R4DRD"J<+FU!EFDR#JBWVP\RYCC;4.0>;(4L]BR3S!:\V/(E?'6,)S
M"C)Y=*:=UF*RX\]^$U:D4WR2[EN+]LS;/UQ:)B4*3M115235%NG;K%(3R0E*
M6P02%20!))(`)\T60WF-$OJH4ZZRDF2E$J49VB9TRG+R0GIB3Y\5Z+QQ'KR6
M:G\_+XIQER"O$@@@>33C)_CDA/JWG`\D:!(XA(ZV\@8A>KIOHQD!2OY(LH9`
M#AU;;-')#4+)"<,RD#1)4I*E^:9ZK(@J'\Y2R,(4%&W3,2G9Y8V=VK/*JVU!
M];G-^Y,URRMN)>9\_5ZL4RT6V!(PSC:\KR%TQ7CRP1D:BK[I36/::Z:0R577
M,JU71271<-54R@`1*JLLIW5,);:4@K`"BD3PX0#*>M4S/5=&2C,JA+#^T=04
MH!6`HB9Q:==FB'_](+<,PQ^'<:-:#!Y7DYZPNI,TW-8QF<V0RU<F4:*X?P9)
MF+X\1DKD^0/.6,WBT:D?Q:OH/2E&5/W'00U;+&Z/K2C680R#<0+1.V4R!8(M
M9^]F`0SW9B+JA:$SEY90WF$+IGA3D7@5>_K\@+2^L.!<:!DV/F8G*E"QUBNQ
M&PVWD;3/294&!,#9#):+VH9%XT6!K<X2?5!-`IHY(Z:6:U5"A#XIDH+*7%85
M2!)3/DR-XL\T9I49@I]GK"UAPH&),[`96B6FV%O9>-%\S9RQS7(/)6NU#%+&
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MIC_'ZD;D:_9"CH"S"S!!PHY<.'KHJZ@][T=`OTN:5R,P6Z5I2I258@+$A)EY
M!=ZXJ4;-9EE-U`M#:*`(E;,DB<]TVF.E?+8<@DN&%E:<^R%$Q24%R/-9IO'5
M?<6B7A''P'SXU&4:P1""VF9UC9NY4AV2PAX[)%21(`J'*&O,4KC-JE)"@)7[
MAMX1ICT5>Q4/M@4ZU(4`?9,M%G!$8J-,9IE/1X9T22A,SAD>*CK]#X^G;2[R
MY+W_`"`H5M%&C[E4H',[4F::LSEI-=9)O#RY5U6B[=46JRK$[8VKR4T*<R%0
MH@TRC:FS"+#9(6:HY5&[F2\M#"PKK(E-1)F9$3M-MHG"BAJ]G1IR,^$I2[9Z
M=Q<AS5M./AITA8K&MB5EQX6P:\>H.4*/W!*W[B!D-JDHVG1`RZ,A_P`W2<%3
M,J@>1=31.49I$MM!X->UA&(J%Y)O\V_&U,BM1FQJ5N.&E4JQ)5-(&B0NCRSQ
MQCO'(3E7E&*\<@:=B.=P7QQB[399G&;BQVN7<5+*>6K4I"8HN[J>C8&C62)+
MXL+UT=E*.6R;U!=`J2J:9];T=<**@;2@D/8E2D9>T,-HTV62C2JRWO',U*<`
M4VF5XG<9V:K=,-A3:?F_&=CFL@5,>0$H>Z9P](`K/XO8S\G&U)S4_$\BV[%:
ME3K\@P&HUB=LERC&*D+93H&</',F8AU7+<Z2)-GJJDK`&2EH+2$240)S%A*C
M?+78!*W7%9"*VE0\JF*RXE*R$3LL$TR&Z2=<1OJ5VY.N,%95?6&6Y1PD4VS!
MBF=H57;Q?-*?G+6Q?8SEG%NQX.09."9<GJE77=]:)I*S"#92#93R":1FON0Y
M.F?HN4].,Q"5*HRULB#+9@#1BD#A*I&:?C'3:)1`W4YRJA74N8Q4)3-*+>4=
M6OX(D;1I'E3/\TZJ\O=VSECB""9HKFL8P-C3+%VH\OBASB6)=6>OWG(U=NC3
MCM&VAC>5I-O+2,I"C8D)%HD#$YT%D@+S:AW*V\F#24H74+<*<7)G.>]BNE+E
M89:)Q<IV,VJ,\+SZUMTZ6@=GB.$V6V3E?N3AX>15%N$IR$O,O&5"Q2L:\FO1
MJN&TDPAGSIF[;4/E#DJ?NAD7B*)D54ZC!OT7LCL;I9-EB*J]!#@8>>P4;`I,
MK1=%BI8=16)>F;)>B.I3<0$A>D.DO4I[7L#;VQNS8.SLUS%DA_#HE'=:)*)F
M,K4D;P:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@
MTA!I"&^R-DJJXOB868MSETU93]WI&/HLS1FN].M:,AV6.J-6:*$;E.9!N[G)
M9!-1<VR:!3"<X@4HCK*6!4'`0#*VW<B"HJD4C>U7<3+RF%VD<BA2B`>$N_;L
M/@'8>T!$/#J$.I#QIQ>!.)4D.H#N@PW]SR73J-/X\K5C=*MIC*%EE:K3T4F2
MSA)W+PM0L5WDP>.DB"WBVK:N5AXJ*RYB$,8I2`/4<`&VTR\ZE1:$PD6^4R'G
MC1PL(D79`3LA.7+-V(,?UM[;;A=ZG"5B-F:_6I&87E6#F/8SUI?L8F!AWAV2
MKH6SN1>RB!"E4`H$(IWIQ*B!E`TILOKE/+`1,E-DA;??O1H:ZB;'*<Y.^85A
M+=2G"BC$LS6E3)1ZDL=$)6),`1K1-,Z\AW97!A\0:-UDS'7$.Z3*H01,`&*(
MPHI*QI:BI')5*\?EK@*ZB4J:')*3I!^$1Z(W*GJHH/&DW`N6KJ.-+)/&DK%K
MM3PS<!*M+@Y1<F0&):F`0.X`PH$]4P:F4U5>TI'*NW8)J*0"27"!N$\<6A=*
M;XT]:DF8-1]%M4G\HV1DXM1U%,EDN_1?2:`.0<QS-1("F*JL1-,P&*(#L(#H
M6:I4L2)ZI\,#44:K2Y,[_KC90D_`6)!T[AG\;)HQKQ9B[4CWC*0*U?($(=9H
MNHS67*W>(@8.M(XE5)N'44-PWB=IWE+"G!A<`L.F6YN1E+E*&U%N1&G?C2FN
ME+%:;3]U()5:OD(>P%))1)CPB9@$_P#X]*#KO(<"ICU_\Z!+]K'J\`"(8ZJX
M`1B,C?NF(6JQ@@A:L(G<#Q0U>4N3>+<2-VCN>+*3+%]C'+.76KZJ-HN:8NJM
MAF)@9NW>+//=5LV<R:[.?;"P(0QD7)P.!E4^G<;+=%4NLG!RK0+=VX1GKC*'
M@EM4TRW].N'*5R-3$63UP>1CS/(^L+7%>!*\C5;$6"*R]T0=^XQ7?CI"KI``
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MAX60!FHY5:2#J4D42`DH4IR%,*AP*F0YPVIJ.N<<4E"";)@`72%XW(U>?HD!
M#FTPS5?.T[\;1GDRDN$;8\<.V\1$U64814E8)PS2&KLBI)1$5-,WL/./ETHR
M4B5FDRW3*Z(KW1G'4D`]1!U713U.`)<0%+$[Q;?PQ8<J*4J*5.3&^9<4;ES;
M*FS=QK)Q)1#5Q+*H(1J+A_&ME7ZL@0YF:3-!=PDJ\/($04%$$BG%8$C]'5TF
MVT4S7+)+*<*$'E;L1"IIZ8!L2PK]F%<V2;&02.F@D4ABE,``FGMV``!^M`0[
M`*&VWJ!K<<M(*A+<BRC$E(3,QK)J5A:^P/(R[F.BV"*R2:CZ0=LHUD@=PH5%
M(5';U1!!(551*0H=748Y@*`"(@&MV&MHK#3G$O5:9'5(3B&I>;ID;58!WY>D
MPU^/\VX\R/4ZS=(IP6*B;A)V&'K2%F5C(F7EI.LV.7K4DT91QY!91XN:0AEE
M$2H&6.=`2J"!=Q`)54BDK*%CZ0&VR-$55&ML*QR21.4Y"V%!.Y'J,*UD5UQ/
M*KPLE7XB6B()%.>GHMS:)-A$QGNC"QRKB08H&5?$54.H0I2-"'6']K((ZTZF
MF4L-F]9`OT1O7/RQFKWRDMY5Y!FLE8&;8[F?0X3T($JS33(DL*SR.%_XXV23
M25*<3*)E`I!`PB`"7>#8K2`$TSV`&R0L\EOHB4U-&/\`V6_I1O8>:@+"@JZA
M7L;+-2*+-U74<Z9OVY7#=44'3119HJL0KELLET*)B/40Q=C``AMK*V7T\HK/
M">"-*2L15)*6;$#5ZHPQE:M".VD/WL)$2$VL_=1\0"\;'OIMP"AWLHX81_>(
MKR;D3JG67,F0Y]S"<^PCN,"VJRIITUC:.5,7B?GX_)&4NT:/94!O6?\`6,=I
M<JQ(.GC!G(1;MVS;E=.F;:0C'#E%LJHJB5RY;(N#K-VRJR"A`44*!#&(8`'<
MI@"795TI8$RC/7$ZXTXY-HBKB%;1,DRLI9^<6A`>515G9(^+?)PDE/F7L3Z)
M7<MX-DJPB5`*NY,0AE1(3<3'+J=MFJ4B50C`0;K1&I?92J=@)TB4_-&DN=<P
M7F6N/(K(U6Q?DZJU]\63?1MRC*A<X*%?M8\724D\;RQ9%A%.DXM83E55!(X(
M'W`>['<=%G-&7D[$%()$Y$BPQ`\G*JE!148'$:E#$//.%,PF\=5V!KJ,0ZIT
M)5SHQT14$XYY`Q=<6;G3*A%1E9%NLA%K)&;-P*W0:[[D3V(40#4I36*,R)J\
MI/ETQ*%4"!A24A(3*0NEJ&B6Y&+9LDU*LH'%WWDH]1=Q;16"@$49NQ)EDIF-
M@4GON"R5/)C','LLB9TOW?0V1$3G$-@`=4M5*22$`$WF5]D84[0D`%0(%UOP
M1NVEMJTF[=1K22BWDFT`IG<4W?1[F2;M_&#-RN5V*+E1RDV\91,3J,4`!0AB
M#[<!+H&7T''LP#N<<;]9I)>V9;_KC'C+?2;`=<L',UZP&C5`1>#"2<9,A'*'
M$X$2=#'KN?$Q.=,W2"G1N)!]8=M32U0Y3R3RK02#,;T_@@*FC18');QXC'B%
M\HSB.5EB3U<=QB#IPR7D4)J%=QR#QJ7J>M5WZ+U5H@Y:$`163.<#I@`]0`&V
M^@I'"L*D%KW8=9I!:%^>$]><P8[QSCV>R5-R+(:Y!5N;MX$C'44X?S["`@'=
MD>)U9L=\@C89)Q$LE#-TVZAN_$`Z3=(]83-T3KJ]G@`WA=Q"-':JG2C$A<U`
MC3Z[859;K6"U"-O#MZSB*Z_BHN63?33R.B&[-K,I-G#(KYT]=(L6BRGC1"[&
M5V%00*`B(AN4VM*M@E,UC1$H?86WM'"!N_!.!W<:JQ!D#J4AV@R2C-*.(ZDH
MQJ=^M(BH2/18ING2*CU:1,D8K<J(',N)1`@#MK5=-4+'*:4J7-L(\XLC":RC
M:,PN_=]<-]&\@\43TA,P]<L*-LE:UD=EBNTQ=;;FEWM5NKMLU>^*V-NVZCQD
M>S;OD3+/C`+1,RG1WG>%.0NJ:&H`!0RXV93!7.7DF;]Z'7Z-=K2@5Z=<+0F0
MZ$J5<_OCKG_,UF;5R56:A2J-G,J<4HIJN`OMTEYCH,+4AA`[DI![L#;:W%+4
MD_[@6:+(SUIE5KBI2W91AJ9)HS)]/M99\SJYZW-L:^J^LYFM;CI.1?0;.=13
MKTG+KLVLTFE'/P*H*!C]VJ11,0ZB&`"V%V%+:W#HPZ.*,"HHU&:EV[JH]I7(
ME#A22JTG.P#4T)#N+%,$5DX@KV+K[9`[I:;>LSO/'FT0"(&-XP8@)F]01W#?
M1NGJ77`TTRXA2S\87D:M)(C"JN@8:54XQA0+3/7";I.<L:Y";0,I2)$;%6[1
M22Y#@[A&M#&J;VN'7:I`HI-J`DW92H%=E5,R<`DY21`QE"$Z1#4RZ6OIWE,.
MH(=3(6WVZ],]R-&ZO+WZ=+S2QL5`RD;-VP6;\;=C8\6P$,M+0KFE1<#-R$K8
M7DC%/:ZR@I.4?.#.9Z<<R35=.,?OG#DIE7CGO#G,IN94W4(CJ*HI*RJ;(*)N
M"XD$D#<TB"*JC8`IV,.`Z!*7%OPJ).;K\;'NYJ57CFD6Q:`\<RSIU'MX]NR$
MHJ^,*2#A=-J@V[LP&$YCE3$IR^V[0U48-4XLX&T[9'()TG3*=\M,HV#R:.;Y
M,D$^3BAG[CR/QW4,@X>Q>DRF+;:<VC,.JLVJ):](L8ZJP:+!69O-A>2$]%)(
MU)J:3;D*HR\>=NCJ[H-U2)K'3NIR_,$4*ZY#<F6UA)`%F(V\,1MYE2+K4T3B
MP'W4;1,S\6[TB%.TS11G-TR52U^^BY+$\7196XS$P$=%UUM'9!8S3^!6:3#M
MZFFL1%&#7*Z%4J`(G$H`)NK?1##A;"W!(K'"!KWC$ZJII*BALS"3(^F%BK<J
M@DZB(U66ADE["3>!;+2,6@I.$%,JIAAFZCHJLJ0J1P,/BQ5?:B!O`(".^PJ$
M"32>0/-^0C0U-*NUU7*WX0"V0L44O)==QW'1D8WNV8;%/'>^]QC""HI8*_13
M6-Q(WT[1PE(-WKRHP)$FBSA-555-%-,-DR@)<KI'76=K4`E"=!M%^B=E^J(F
MJVF14;"GEB.D2GKMT_EN0Y3ZQUZ,EV\&YDHEM./&IW;&&.^8(S#YDWW\8=,H
MQ1PF]<M6QA-UJ$3$A1`=Q\.JFSVG+33N+`LQ`3$6EO4J%2>7)>_&M2OU)78+
M2Z%@KSF.;.EV*\BWFX5PR0>MB`H\9KO$'ZK9N[:D[54CG`Y-MS``"`C,FG?E
M)+6'<4+?+$9J*,7+LW_7&@MN6:#1*+,9#EI1B%;BX"6M"0L'L4Y=6)C!5]U8
M5TJHEX\FA/OEHIBH9NF@H;OA#VH].Y@PW2UCSNR;0`J<K!;;KC+CU'2M;9YS
MD.6B9]$SZ(K7<L4NPQCN:2\:@XAE[V#+RUH:)0$<H>VUR%LT0+22?+%8OQ\2
MG4$5#)*'*5X!T0$QRCK#M+6I?33E.)5MLID2U;L:M/T`IE5&-.S2+9_#&KQO
MF_&N3JG4;?`/48UI>S3"=:B[*I%PM@DSP,W)0$@FVB32"ZSQ4'<6J<I6_?"*
M1BF-TB;8+3]"\PXJGJ0=H@R(-NB(::NRZJ:15,KY"Q-,K+#JCWJ^;L.72/M,
MI6KK49.*I-GF:7;9$LO%M6$!8X&44B9*,DW+Q=LDW%.52.B10P]TN<H]T8X#
MOJ&JH<QHE-MEM6R=2%"8/LD3!`-X(NC5G,\MJGU(0X"ZE1!,[9C=AP/?-7$9
M-I"FDHQM,OVBS^/B3O6"4E(,$1`'#Z/8]^#M\R1'85%4B'3+N&XAJ$TKQ^-Y
M+8L=::;F!KW+=W=A2%11$"&[E,!ZN]#<A.HJA@-N??8?VSVX[C[(ZWE(!.A-
MWJB=(2"5I`!4+2-._KC72=?@9HC1.8A8J53823*98DD8]H](SEXQ7OXZ4:E<
MI*%0D(]<.M!8NRB1PZBB`]NB#LQA;Y*3JLOOX8V(!.(VJ&F-J9-,P`!DR&`O
MZT!*4>GLV]KN'9V:`!/LV1D$BZ+101$W6**0G[/;BF03=@[A[;;?L'6N%.H1
MBZZ#N$=@#N4M@`"@'=DV``'<``-NP`$-;2&(J^,=.F,84RE(2$5[I+<1[M/<
M=]QZ"[COL`[CMV[[:S,F_1```S%ABGBZ';^TI=H``_M9.T`$!`![.T`$-:%*
M2""!(W[N_`)2DX@`%18+-H)1(+9`2")A$HI)B`B81,81`2]HF,(B/KZP&T!>
MT`&.4IRMEJGJ@0#:1;%Q6S<G3T((DZ3&,4"ID*!3&WZC!L`;"._AUG`DRF!8
M9C<.O?W8VF9XOC2E.+Q33-OU)D'?P[E*._9MV[AV]FMP2+C&I2E7M`&+@*`;
M```&W@V#6LA.>F,@`717680:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@
MTA!I"#2$&D(-(0:0@TA!I"(V<H,<V?)E.H$154&3AY`<@>/F09,K]ZFP23K6
M.LMU6Y699)50AP6>)0D,L*"(``K*])`$.K?5RB>2RM:E"<VU#RF.?F-&JM;;
M:3>'4JX)PZU[K\Y<*C)055OD_C&:D"(`PN]7C:M*SL'W+I)511A'72!LU8<F
M=(I&2,#MBN4"*"(`!P*(<]MO"2\?:4?-%MYHS33IF`!.S@B,^>\-7ZXJ\;R1
M$D6VN,9S>1U[G:K"XAH>6E1L7&[*N,6$VHQBHZ.ACR4Q;+<R.Y1:-FS=%)14
MY$RII]&NK05K%'C-09)4$R\BPH^81RJ_+W*@LH"E<E9)M-LQ*(#R?H\9:'Q*
M[I]-PQB)TCY-?$6.DZ8=:O,8*]YWP-E8UUO:L\X=Q+R.4E[)5CKQ2-C>)K'5
M3>'36-XOU%UT49XPM6-MPE0=63(W)4"`+-1D9:Q.^*YR?!5KF`4%"0)VVSGI
MN.[Y+H7V2.$%COE#Y;O:_0*;0\B9DOF&YNLA%R]=BI=7$E#I>#B6;!PW9K`3
M["JP<M(T26BBI)LG,.IUH.%FZB!^R!.:(2\R%$JPI(MTGG$:3JTQFKH74,.&
ME0G$HZ)6#4#*ST0TSK@?DQSCC$T'2,;FHQJ-<LB9<LM<O>7ZY<)+(\)8IZG*
M2?%V<EJ'7:E48+&&7`A32TFFR;*1<>[CV7M5SN'HDLL9TTVMYMP)45(2!)/L
MRQ24`<5HG*^W3.0B@YE>8U265LH*0@J)!,YSE82D)G<=%FY&W\B_,SL+/%J8
MMQG6;0R@>7ZDQR!:7*)4O/)$_(2KW>-HE1MC)E%MYR-9UU[:&!I128>.6;!Q
M7FWN4!T#$[F)K-:.G455!Y)4B0-P"3:1ZK])B[W94U#K27DX2D*M$A.<KP+=
M&F>Y+3-_BSQQ2P!><HK5BHU2B8ZL^,N.L/$P]-39Q[5S?J)!7>'OLT^AF:#=
M$TD^)(19#R2P&7D2H`*AS=T`ZYU=6T54VTLJFM+RAJ$B9I%GHT1:I\O73EXM
M3Q$ID+[DR)EOQ#B`XF96B\.JXY>\9L,/K72[M1;1>+:>\5G_`%XH*M9+DKA.
M5_(#HU9--,??&@LG+&):3NVHS2(-52&9"=;5^MK:-ZM=73&31D,,@,)P@7#5
MN:Y[L<_8YL2`^RC$%7V<H3W!9/3.9LU61D*<0<QK46V,HRC4RE&M^/N>+>"Q
M/!V2.7K.)'?)"NXWA\<8\AG[9HS@U&1Y2H/Y&54CDDHN/>R"Q4`,ETG/JQF%
M*S(.JD04'?"9S]/F@:?,YG`A(M5=*R=PL^"S>C&F.+?(>0Y8QN4%JK1&M.KS
M^RE:VRNJXK@IB9J=@XW36,HR-LSE"B)9ILMO;WZ12\>+(64*X#%!HJV9=\VW
M).,VR]EDN.+L,I"V04%`[UWEUQ%U3,EU`4I`-DK9&SRV_!""HO![,K'&K6/+
M@;#%#4I.(..^/[EC>!OL<\JO+29Q7DFMW^\NKQ)Q]=:-V#"?A(=>):KSS5XZ
M<+R"Z3T?<XO6IL<VR[$6E+*E*6I22;T!29)E.^1ML\@G$[^5Y@XH*0V`D)`,
MI`&TZ@-%EL_@#XXZX=2[N]XJMMUPOBFJTB'S%R!RQ'844=0]IJ&&WE[QICNH
MT!C$QS./0JTE*.;94G\Z]]QVX,HU_*G.W,*Q>^/3=JDHFEE1,TI!5;,R))W=
M-D[=<66LO6!].F2L2C*RR=UTAJG(`:A$7(3@=R'E*QR#2ON&L2/)B[5#"JD#
M16AL*1=%MN1,1YL>Y&G%(6-I6.*XR@J]::DLI&Q<I:5)FR%2=F0?N0)U%-<3
MFU(&$-8U!X+45&9G(I(E>+/9,A99%/NZM;JU.)0%,%("00")S!-]VFV),VSC
M'DAS:9J^EP%C3(U(7S_$9/#C'8[/4&%=L%;6XGX^PM&)@:4B7^/$IO$EU@G8
ML6;YL+)9D47#50BHMP&M45E&XRTVEPI>;1(K$[3B49F5IL/Y2BS3TE>*AY]3
M8+3JN2DRL``%DP0#,:I;AAOY#T>]U=8YFHZPT_&]FR%!\7JCCW$DF:8._2Q;
MD=AGG(^3S0E#GIQN68KT;0H"PPT=&S1"M7)THTI"=VF'0$U9G+*CM*?DM%9)
ME9B&$)MT6D3(^&,4F6/,TJ6JFU\(E,VR.*=FJRR8CISDC`<AD^;;V!OGSD+C
M(B48G'#!8LO,%6H!4Z3E9<9)Q'RM-L2JDFMWW2=4%BD,F0A0(``(CP:7,=KM
M)--J0%$`E,[!J,Q'532MA(Q.N!4K0%&^&EY082MMDI6!6T138WDE&XBR-&35
MOQIEJQP35/*D7[R;/4&E@L4Q.0BU2D;)49F;;S1$WC$K5=5`YDP36*B`VLO?
M"5K6L;%2A84B[=LMMW(@KVJEYM**-(=*93!T^4@CACFNIZ/'+;EO@YC:J(6<
MA*ECU>B*4G&N;:S18K#,\3.MXR4G-PE@M>.[#/RE9D*W88U$5Z\:,GFYX5-(
M$S%,F*/8J<T9$RR$SQ3Q%,RKD@3-TB93MG'&H\JS,&50B9E<"`$F9U@S&X)0
M]X\5LT+VW/Z<%C>DUFJWS*V,+H@^G;%09ZZ6^?KO*ZG9;LU@9WJ#J$+<6-%5
MI,$^<$@+:YE';&753:1RB3(@`-%^IHMDG$N2I6WC09>7=$;*H\RVA2&TW[FO
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M4<*A7G,#EFJ8\/B&1Q;:)&=G7+^-G*%:;?-1=@7<(O2EK;]BX>J)*M'A`2,5
M8+U)FR1E:<N3A"@HSLM,Y2M!`X0=R44JW)7*K,U9@@J2UA$@E4D@C24RMWA*
M&)S!Q&L&,,-7+(5>QQ%,KJ7%//U'+<M06Z3N^7<,X7EM8L6L'!HM,)NY`SAT
M2*]PJHNWARE.3NC$%1,>I15U.]F(0X!LRM$I@2&$6V76CAX(RZQF8RX$)&.5
MLK[=W\I1Y<.L6+WREQ<]CS%H55Y`\E[7D/(=C&GT'&-)M[68XI9"Q-7W.+82
MDPE?B'+"N/YV,9R#<K8.Y?KNU^^4$RA219DNG8J$N+62E$B!-1-BIG%BUQEF
MDS)]A:"F14DB=@O$K)70I9ST>%UB,/QU&QE4*E2%7G&OC'6,F0]+L4)5#92R
M7B#*[>Z7Z`G9Q:NS4?+2%NJRKEFWGIAC(MUSK%3>$,VZP".CS9I%4Y6/)"TK
MQX<0Q!.))`(%EQU>2#V3..4;-*@D.-%.(@R)D9F9T^6&^NOHY[Y,4[&#%OC2
M]2%)C(7,43.X</R)Q4TL],LF3;C`V!O>6MP>8@>X]0C5F$2LW7:5I@TD(<RB
M1V"ZYS+%+OWZD@S2SM)IM"#*0!$O:G.V\D@Z9Q@Y(M1*3CP2-F*VVZV7H`\D
M2NE^'DTXK/)%VRI%15R=E/D;@2U5^YO7S%U99#$V+)/C/)RD9-6Q\U&5;@W>
M8RF7!&)@(#UT"2QD^MP`EY[N;(-0@$F021+1-4[9#?XHNM4&SI%TQ`VBA8=(
M\ODAF,I<1['CJEY*RW6<<0R=]<AZ1FS9`FZ.@=YDBXUO.\7>W6(8=-Y#)HV6
MRN`64B!"-(L)8M5$#$*4Q-QNL5E/5U":>H.&F46P=S">4=RS3INCG.Y=64C!
M?IQBJ$8B!?/$``-W7*X1N_1S5]!?"G)5A1,8LJMD>TG8-%+3/T"D4C$-PL26
M,2U2FQ41$8ZKM61<PU9]RTR6)'Q5591P^44[TQW)TDV=%E%2V$*G2`$7J)`G
M,^T2=[4(NY":ARD=<J6T]:&B0WM4-YA+@5E\X/H_-&,J,WIM@S]Q>R/.X_>K
MX=&L.8?$U/OT)?3'IF'Z#2,>*MEYV1CA:-#,G+V18%1]T7"RB9TBPNYG0M,[
M-@C;;-29Z>4I)!MT@`VZ+A%6BRVMJ'UJJD@4^,&0E*P$2&'7,;]YC(R)P<RP
MO096EL<'XDRU#O<8<M<14"JVFTQ,+7<`.LHYHN=ZQCD"JIR,),-&38M(EXZ-
M6;PZ*$G%FCT$$S>+=\9*R,T:PHPS22Z@D@>U).$@ZYWRMF;93B'NW.4.N)#8
M-,&E2-EAF"#<;)3&C?T&;W('#URMU&XU.FF,ZCG>-P_*-'N0,$7B;A(BO7LR
M^-WE,82J#VTQ\I4'\O19]R$DS1DDO%E2=X=,Y'!4-<FGJ&6UUC;JBE:W1A5*
MU-LY#2)[E\=2K9KGNI/H;!0EM6,6`$D"1TBPW$@QSSG.)&3UI>.PPK@G&>1)
M]YQ"0JL3:9ZRNV=8XRS-TY`93LL`OCJ;FH%P]ET</PTPU9M1BCL9L21;$&J:
M35;]IZRJUAMD.TZU)4'9D`GE)PB^6@G1=*^.*S35:JA;-0@85-R!LL45:-V7
MEB5T)Q0N-8R7>%H;%V/8V.DN:V'.1Y<JQ+ZKQ4[<Z-#U.&C[;$3<.QC$9]O-
MUJR1+Q^1%=11N^5E#JH""IEA-37FJ:ADK=<5@+)0E))("IWVF5UEUVY9'2I\
ML73%+`'*2Z%S!&(I%DM<M,B93T:89Z,]&M'#0XB*DL*XD7MB/$'D+0K`]52@
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M=)H2J,O/KULS5LU68,Q%,O=66,PI$4@^D67I`@DFPA4R4FX3MF1;.^*%;E.9
MU=7R4`,I,RD2D0;.4-,I63WXTT/PQS23"=&I+3%F-:$_I_%.O8:L-%96N&2J
M61;32\YXXO-FCI23JD40K6L9ZJ-*>HOGBK4SE`902/BJCWN]9S,67JA;K:RL
MEPJF2219("9),Q;N6V1;725R&4,MM)0$HE(`2)F";I2!\MH$X7=3X8/;/<J3
M9,D8"Q73,3+\@KGEF4XW(.ZQ;Z30(5QQV^"F(.>&CHY&@3=@ME\:%E'[*.;J
M,&IU2+"91QWRFC>;"GIUM!7TRT@!6FPSOO\`+.-4Y;4O5&W=3@2DF21*4CO2
M!X/)#A6#CCDHG$+C#C=[2*CDZ8P58J%8L@X8LEG9)U')]>J45:X@*7[M2[1]
M7'0PSF9CY:.3E$C1:SB+216%,.@Y*B*MI"W%F04X#;I$Q?\`E+<CIUB*ERE2
M&4A2$J&(66RWP1P@[T87'[B++4S)>"LD73&6,HL:4PY32K:`BRP4^;":F8LF
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MK=(0`U55(D$UH2M::-71W#-=15F"!QN4V:Y?:IY7^[Q$$`$"4@$D`&6N<YQ5
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M(1QV\KJ:8DU1M>6#+0`)BR1`TZ+])C>Y$X29-&FNJ;$X'Q%E^MN,?\N\7T"F
M6FTP\)6<#CE7,UIO&,\A5A"2@YME'-T:;),XQ5K#-TI6,%FB@B;Q;OC)PMYQ
ME[@2ZTX4$J25%/QI"1!ENVVV>6)D9=F#+?5E(2XA`.'%;*9F#;/7*R4.-8.+
MN5#RJ4_(XHHF:H)KF;&5TD<-W"RPS2"O<)`<0J;@QU.R2TY%S-<),4#(42M(
M1[21;JI.VQ#+H=#D$`U&K,*)]U"VG5(=;*N4"9@E9,[+;C%EO+LP;I74.-A2
M'OBV:I2MF-'JB/5GX/<H5JAQNI<5CS%;-+%D!005F*W*XS]T*58*KR#E,CSL
M1[^KOCB;R2O5$:4L@E`!47D"Z.[%PG)J@55/;I.YME514/U*UJ4I3A-L^:!Y
M"3.<Y[D<YO*\S0BE0AM"44Z$I($@#+TPLLD<%<@3$9<(BM8<JR%7;\O<CYQ=
M0U`M^+:)+9UQ]DJ%MZ=<8O5K/0['78BPX@G+60J<?86JS5RD14[)RBH9/IT_
MN*@=J$-+<"G4T+21C!6$J0)$@3!MT$2E9.=L=!638G"XE`2%.*4<,DDXI2$Y
M:)3MG>;H>;%7%C)>-\[8`L%8QC$1M8I.,Z?3[O>[UD>FY?F&%7K=3LK!G5:9
M(R5"A\EU^_0TS.)M?'XAXQK$K&`H#MF95-'IYSU50*HUNJ6,9F;B+2;YW2EK
MM'EB2FHJ^DKT8DXFK+Y&SRZ?3'7Q(.E)(N^_2F0-]Q'?8H!ON/:.^N*"")BX
MQZ,WQZ:S&(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D
M(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(1'GDIEN\X8Q9:,CT;%T=E92
ME1DW9K+7Y#(3?'9F]2K5>DY^9E(^3<UBT)2$FBFP*FBR%%(%A5ZN^)TB`RLT
MS54O9/*PIUR)MG+1+7%:JJ5TC8=;3B5.5X%ENOT1N\%Y`O61Z%"VK(F-HW%T
M_.($E&=6BKVAD9N6O/VK5]"R2UB;5NKHE=OVSC=1KXL/BY@`.\/ON$:T,LN%
MII4U#?$2M+?=1M7!))\OGLAK.6/(?(O'NF(7NEX2C<M5YC)1L;:C/\IL<<O8
M5W8+36Z;60C63JGVHTZ61FK#LN;J:@U10$_[:)@*$K%&S6KV;QE(3%A-ODW(
MJYA6.430=;3B)5*\#T@SMU0V]2YLUN'S'+80SY%0V'LD@QQ0$778Z=G,D1+B
M>RLYL#*,BI*[1%+B:[7VRTG$-V4>YD_<Y&0=.P02#O2@4\R\KK%-!VE$V#.1
MEJOW;-5L5*?-"ZXINO`3A`E;.T[HA_*9R<PM?L@6#%55M[*3O5="<%]$IQ\^
MU9//>P^0C+,6N620A&57N"M8D'*;>4)$O'QHY<W=N.[-V:A%%5-<JH%AE+R^
M<3T1T&*JE6X$,D$F^$E<>3D94XOEY*K4IX_+Q*@F$U((%EVJ`W@CS$L;E0&\
M><S%0(0Z;>2!CU*@X`5""IMTCT:T50E]QN4P5$REIC1%0TJI>#A(2V$VSU@F
MZ,B)YC<?I?);/#(W1NURLY<Q$2K45X2R&3866:J#>^1=4D+6:!+3F5BD:LX\
M=9LU7Y'+UNFH9!,XIG`L[V4**$K<2<$ISW/3$3><Y:I9;2KE@R\IC$H/,'$5
MOHHW.4L$##*1E>H%BM#&*?2]E91#7*<_(5G'YXR2][4(]LS>TSD:JU:G;,0.
M9R4R9DRB41UKW9L>1A-MH\G#*+**N@?:54!5B+]%\6*<X.+K=ED.1<Y/AF<?
MBUD67NTD_B;-'Q+*"&SI4T]BAI9W7TH^Z5MO:ER,5I"$4DFB#DY2*J$,8-.[
MZQ1&P3[1EOF4_0(JMYIE[X44JL29:8RQYA80D79X:NSKF7LQL?O\B-H9_4\A
M5U!G"HUV5M#%*VS4K2DXVB2<O#0R[Q&/E#(2RK!,72315/IZM#E;RABJ`9SE
MH_*^)NNT-V+TPWM)Y_8'M=]E<8R8S=:LL1"8/E%I-S5K@]Q_)O\`/#*-4JD=
M!7T:LRA'2!I67:,T7CKQ))^=R4Z`"4BX([5&1KIJ,9@L?0J6I(M!M3*=GET>
M4Q6:SG+G<P5E85],EL+TW*G*WR:XD#*Y[Q%7J9><AS=KC8RH8ZLTI2[E,&;2
M*Z,=;8F290SVO,VS:/5?6"8--2*+%)O'HNEG#]0&R13K@9,(4Y:EQU*$`FI4
M`1KD;MR+*:MN2GFC]$E12=\7Q%'(?/;'Q9+C[#89;-+[(YYRM+XY[^QQ&5JM
M'T;WGL#OKFWML?&8RGK16;HU[QN@UBY=C&$*9P#ITLV9$.X#KM9/5,)=4_-*
MTI!T6@W2ME+=%^_'.JL\;;<;`M#JL,+C-?(S->*LLT/'M.XZU?(=>R2YF&%8
MN\GGR.H9@DZQ4).ZV]&;@76-[`,4RB8>'7[EQXXJ5TH!0$J0&Z@Y[-%1/)-2
M52JYVC"3ID)&<O-9%Y]YZF=ZNZ/]K*8,QJF=V%36N;W&BTIN58O(T9T,9NF5
MQ=R\A[/%LU'V1)<U<I3Z,D)RO1369I]HLR"D>SL#8ZD$NZ(5,'?4HF4V5Y77
MJ5B0GDD3NU7W3X+X)S;+4)"4KL$;,_,OCJBYH[?W\F,3(XQI*=*H5*[+5J3]
MV[0^I==.^MK>L*U>MM[39XU5E$K2CMDA*K=`-#K%43,;!H74<AU/+%^YY(D%
M>RX,2#-!NA8T'D-B[)TW;H"C32\Z^HK]S'61=.#L["&2>-)"2B'X0UAEX&-K
M]M;1TM#NFCEQ$.GS=L\;J(JG(H7ITZJ4BZ0C`J$5$W4W-&V&"O7I%^-%+H]N
MNJ$S:K2E1YJAQ$_7X?'F0T;)XMD2U^]*NV:'BIBIQ[BQTUX[1='1F(\KF-=B
MT40;KJN3H(JSTV4U"W)(%JIFTV:SIBH<[RNTJ5)4[0)P^.:L[QV*L).,OP-1
MELBOI-M66V.\?,2*UBRY!M5W>Q\73:DS3L$>BZ@9*9?RB95?'6Q#L4P4.NF7
MNS@$+-*JJ?-.3)0)!ML$K]-T7:FM32L"I3,MD`CRW<,:NN<J\,V"DUN[GL3:
M*9S^#%.0YV;UL_4<Q.,8Y%A[XY=X9M'+%[VMR$@1JY;E#QKOP$"I#L.V%4)2
MHMJ$RE13Y1^4XU37)4D+T*$^&&_RESVX]XMK>5YM]-3-G?8;HRUZM-?J=2M\
MRH9J6*AIE&!C9]*NC475I]S;)'+N6`/P<1S9ZFX>%00`ZA5+E&8UV8(:18@F
M0&LF[A\^B*U9G679<C$M5HCU/S@P='-)JRVF8;U6C,(7$DK'S,Q%WAI:73_,
M*]G8U*$F,>/:*RLD#)3,E5UFL8ELY<R*NX`BENCWSN=<RFW%,V3&B\WW18%?
M0%./%9?I\D2)Q=E.C9DIL=D#'LRE.U244?-V<GXI(1:Z;V)DGD+,1<C$SC*,
MG(28AI>/6:NV;UNW=-G"1DU$RF*(!54V**25:8WHZU-:"I/LB%G)RT;#1[V6
MD%FZ$?&,W4C(/3&)W;%BQ;JNGCQ82`<W=H-TCG-L`CL`ZW`),DWF+)4$I*C[
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M.@DIS'["XRUE+(,YR&@DV./#E1O[B%MTQ#1]1M8410W3-%BWSU2,.`E<%(8-
MM0+H:\B6&T\-O'%A.8Y<\HI"K6;3Y(;S$G.'#F8\GV2IUB9;$AFLMCJKT>7>
MQ=PA).XV^Z4JY7YY6W-?M%9@7M7<L*W4SO&8O2)%DVR@*(B.Y`-/699F#+"'
M<,KSH(D+)S&_QQ6H\VRUYYQM*IF8UWG\O+#R6+E#A"K8J9YOL-WCV&,GTRA7
MF%M&/GGK5[,/+&YJ#!C'LF,.ZFWZLI9FIF;3N&IP=J"3N1."B8GH-T68N.;(
M`$ZK(M&OH$#:J59KMC4)<O>/I[C'4)Q?6T=:Y.-0DFS*;KUN@F+4SNJ'O*$+
M,6.8K;.MP%P]YA#2:D"]=H3:3,ICG:%`HZF&6U8Y;@!;\F],:Q.R=T8&:42S
M@;5RSHC0'YP<;24=CD8URD%*E*3BM<C%DL>Y,7GI>50A4+&J>#I:=)&Z3T(6
MN.22/NJT8+18L#E<`X%$P'UOU1P&XSC8US,OI%21"G1Y98"=72G4%I=6KJ?R
M&RKSZEKM8.T+UBQEMD0O8*HT9WM&!4H:<O8H5HLY9,%Y-)^X2)N1$=PWT72/
MJ22V+0)DD:!?/>C`K*%1"`J9)D!;YH1Q.>/%A6K&NC#(YY.MC:UZ-'O8:B9*
MEW5@N#-D^?R<%4(6+I;N;NB\$RBG)Y-:(;/&\8#94'2B1DS%#/=>:8L)$B+3
M=8-WA\L1.9CEK:0I2A(FS?C04?F]ANR9ON.&9:?C86TM[I5ZOCM$6UC<I7-G
M<L45+*<"]D9CW#"NU26FFTX]0CHYZ[1>2*<<8R!#G*HF2V]D]3U=*W4R:EBT
M:)@\&Y=IB#OJA"@&3-TF6F)QHB0P`)0+TF*4P;`&PAL&W@]8-<9M.S=4WJCK
MI.-L.:X]>DOWI?K!ZN^_U]]3[FB,[NF`2$';<A1V\&Y0';ZG9V::):(S,P=!
M/O"]O]B'W-8``NLC$`D(.VY"CMX-RAV=FW9V=G9K,(.DNVW27;UM@V^MI(0N
MN@Z"=OM2]N^_M0[=_#OV>KI"*"F0?"0@_5*'U/6];2,S,'=I[[]!-QV[>DN_
MM1$2]NWJ"([:Q(3G(3A,P`0@>`A`V'?L*'A]?P>'63;?"9B[I+X>D/K!K$A&
M)Q02E';<I1V[0W`!V'P=GZF@`%T8(!O@Z2_>E^L&L!"`)`"6]&9F#H*&_M2]
MNV_8';MX-^SMVUD)2+@(3,'27P=)=@\'8'U?MZ81J$(IT$[0Z"=H``^U#M`/
M``]G@#3"F<Y"<I>2$5`A`\!"AX/`4`\`;!ZGJ!I(2E*R,S,7:S&(-(0:0@TA
M!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(
M-(0:0@TA!I"#2$&D(-(0:0ANLNT;X3L5Y)QL$D$*;(5"N%'"9\4\>]R1ME=D
MH$),67?M?'08#(=[W7>I]YT=/47?<-D/BG6ETZ"(KU+6U:P;L:.;Q!5+?BR-
MQ%=4G4[7&T!7822!C*3U6<R85UJR2073DJS+Q<W'=XX8D4Z4'9>SVAA,41`=
MEOX)O<X^FV-'Z#;LH2?BD>82T2,)G+^!HS)."U,&P4NI48E$V-THJ2<)/K,M
M'QV.KK5+6T9+&E)4).24>-ZN#45W#M18!5[TYE#`(&T0ZFD=ZR=,QP@\<3*9
M!9#)T0B[_P`7S7:Q9CL!+F6,/E:<XS32;<T!XV$$;CM=T+EXNHI[JH>Z9;4*
M(H`/2CXD)N\V5'VNI&LT2V6PDVH"@/\`%$;E*'`L2]N4_)#5<=^!\'Q^RM9+
MO$+XGD81RYR*[K<FTPVC"YO3^$JTJ6F2BKGEXEN?(V>(AUEC-D"MX:.7=()H
M>-**F1*(WZK,W*EM`7,2&NPV2NBEEV4)RVJ75`SQ#CXXV68.'][O]IS&--S5
M&4G&_)2&K4'G:J2>-R6NR.F=>JR5$=KXUM?OLA&E2>VFD()Q[PTA&S)$#)@X
M;%25WWA:JL`!`F4W6Z[8C<RI[KKM6VJ3;^'$)<V<I<)G="P-Q,1]\<Q.-KF1
MNWD>4^/.2+>."OBH+)M0<7U7&J%)%T:6ZW!GJ58*Y"0,4!3!3NQ1-T]9M7:I
M2@,5^`IX8M4]%2M_J!RL04K?$Y0T]:]'TA7Y;BN_-E)TY8X"K:-<O\*A64V;
M+-2%5L,C=\3J21S3#A6N!CJ^2SB22*7QSQD5CIB)`'JU89S@T[;C=DUSD=*9
MB1EOB*M7E(>*"FP)$B-=L]$-_CWT8D5C^FVV@1=EQ1'Q;^,J=<J]QKF#&\!E
MEQ7:QE:L9-(AE&]$NSPM[>JDJZ+`PM6<0@N;9VX255+L.:K.'*Q>U).].P;U
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MIDD**976663T61?HZ*66M(/M8`?+&VQQQ0GZO=ZCE"WY,8VB_MLN9)S'D!>$
MIAZK6K'-WW$\;B%C"5F%5LL\^KD%5ZY!,#)B[>RKIVLB<ZJH&4`22O9@7&^K
MRDC`$@3U$F-*?+$MO"JG-R9)/F_(Z9[D.YEW!S++5HQ=.2,VI&QF/G.23242
MW:"=Q8&.1\863&KMJWDBND1B%F"-B,Z*KW2XG%/HV+OU!7IZCJF_,'@5BBQ6
M4G74X9Z".D,)B!U(]%S#UO$MLPB_LF)&U*N=<I>++3/8ZP*PQ_DJ[87K;]5W
M/P-WN)+E.>Z%XNC4B#=:79-H]LP.*[MHR3=JD51Z+V?*??-09XYD@$V`RE8)
M"Z.&CPZEA.Q!Y`U"TB_\M$;"\^CHR%?G.%4)[D=[H0&(HG%4,E%/*9:&R)V^
M'<F)7.!DZ["5[*=?HD78KA68V-B)]Y)PLWUJ1R;EB1GU"B&:?.DTVT.$%3L[
M=Q0D1.4^"4:U/A[K2F5XK&9:Q.6]9O\`PQ)#!W&.WXIR/F.[RV3(=W#9,.O[
MET2@4V5HU1B)!Q/34RXOTK`2EWN4"MD^02DTFSZ0B&D*RD`;]^Y9JN%#*!3=
MKP[LL0GL4@6Z0-%UT=9FEV"'6P?URB;KIQ%*I^C(N$'%YA4E^1"5AN>1J/CR
MKQ-Q?TVZ2CU.PXMRX.8*[>KT2UY@M*]CE)V>321F&42M7HY1(IA:(M1.'39>
M\2I4X%`)2$K)`T":2F0LN`.[%.@R`42BX3,J%O#.V)E9NXSN.0:6%X^_9"L4
M1#8SG'-YLC?&,I;<93%IR&C5G5?KDW!6VL6UM:*=#UUU,R+HC(CIV=<5TB*+
M#W1C*4:>J%*5.(ER]8G8;;MV+M;2]>3LC/"-5ENC@X=[1$I[Z-Z[0=8E*3BW
MD<:L5I_0>0&&&B5WQ^[R;,Q&',[6=C>CPC6>EKY'23^W5&U)O$VTL_.\3<1K
MWNU&W?(D6'JJSQIVN;KW:,*=1@)(.$**0!.0N"@!,1RNY<T3-+5>4MV@`@&0
MT#1:+KH6UJX"6*Y6#*:DEF2,K=,R3A2T8@?P-!Q_(5V3LRMBI,-3HRV977=W
MV7J>0)NB)Q1E(AVG"QDH"*WBSEZNW3(F$#&<&D>V^$8@YB$_BVSD+#+5%VMR
M05S>!:K<,B==DIF%NVX>VR4N$?D*\Y4A)>V&E>*$[8#5VA/8&`?O^,DOD&25
M-%Q<E=+$\BDKJ%X(791TY,P,TZNI;O`*G455%04!<K%\JTQ;%&!6A>D`>82A
MV:WQ?I"6-[]BW([*!RC4+_E[)V5I.%L=>1/$"?(&1)/(+")<QKAT]1>J5MV^
M(0CDPE[U1$%>@@CTAJ:I17C3[8$AY)QL*!/410&VZ?#/X8V5=XQX@QM3\A5O
M!E/K6!I+(E<>P;ZUXSK\7!S3%\I%R<="6!#ND`;N9.LKRAW+/O2B4BOL".MF
MZZM6M+N8`+*%`RT&1NUVW1A5!04K:F4S"E)(TZ1*(>X']'3.XFDT9ZQ9A8VR
M8-F#"N57QV%5N2;=TIAZG7JH&9&>W_*^2[*>0MWOR\?=.3R!F[=TFH5!L1-0
M"DO5^?H?^C32$`H6F=EF,I,[`!R<-EFDQS\NR9.6)PS!.))T_%!&G?ASF7"V
MQP<G7W]>RK&-TDHOEG5K@TE:.ZD$YNI\GLCN,GD3@3-+?&#7[+29P&Z'CBP/
MV\@U(H46R)SD.G33785`Z`0>C=&YRU6%0:6$.E)`5*[$)3\D(U#@9=VSAM7T
M<[QH8LGH+C#!9,J1\8%/99]#C'%PC>*5JER+<DB50UVD(%'Q_P`8821FK,!*
MU,FN(N!G[V0)$)&,8Y&9LQDD^GRQ5&39DIT;2MQ,\G$D`<K"`)3_`#CP3C%>
M>CRFK)"KXZNF<@D,15.%S3%88@H#'K6"NU17S0C+-G$A=[DO9Y6/O9J8QFG#
M=BBA%1"3XA^M_P",*@!]83F^%16D#&2F=]N&Z+AR28"2HX1.7EOA,YBXAY^?
MXQSO8BY2BL@<CLA2''^7QI8J/08_&T5C>Y8<E%HR(LK%C8+M93.V!8N=>.Y,
M'$@=PL@9RW1*9,Z*!+%%FU,BI;VX_P!L,<Q,W*'&`8K5F2U"J98IR-OR2+.:
M>*<3"F..4%)8KP?BVM285N`PA?<*6J),I'#(*23+"M@B9=*+6)XTQ[AS8AB-
ME'0B<4U53*BF<1$!YNU6TXYL_P!4X#Y)VQUA3MOH:4^)5+5V^`1\)A@'/`&-
M1Y'7G.D1)XB6)?+0\R&X<7/!K.YY5JUV=4)*C]W4LCN[@Q8-*>H+1%X=DXAW
M#HH&<-4G2:#@0+:[V4:040F$@`6&P@&=HE?Y8YZ\E2*OKY/*MT:560T[WT8\
MU,5BJ(63)&*K5/4>]VBSU*DVK"UALO'*LURX4V%I\Y3:UBF<S`_LU<8'<0A)
MAMXG9$FC"1652:M462AFVK#>>E#:F$B2E)`)%BK+K9>2_5JBDKPXE52FH*B0
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MN*J#0J8\KY$"S*@(ELKFEF>$<`(@R!T"0)J]WUGW=S7"AI*@00P4;\S.?GBO
MW6'`$V2"TKW\,Q\,302+ML'AV*`;^OMMKDH.-Y3LI`QUD#`V&]4>VIXS!I"#
M2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:
M0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2
M$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@#^J/@^K]O2$&D(-(
M0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"
M#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0
M:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#
32$&D(-(0:0@TA!I"#2$&D(__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tpgii1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tpgii1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`$``J$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^D3PEXW_:
MS^)>I_%77K7]KGQ1X)TO1_CS\;O`F@^%]'^#'P0U>PTCP[X#^)&O^&=!M5U/
MQ!X6O=7U"9-,L+=;BZO+EYII09'+.68=G]F_:W_Z/C\=_P#AA?V>/_F+KF/@
M#_R#OC-_V=5^U'_ZNGQ9Z5Z_KOB7PUX5M([_`,4^)?#WA>PGN$M(;_Q)KNE:
M!8S7<B22):17FKW=I;RW+QQ2R+;I*9Y(HI)%C*QNX]G'XJK''8BC2HX2,85%
M3ITZ>7X%I1C"FE_%P]6I)M*\FYN\FVE%6BO(PF"HO"4*E7$8N4G23J3J8EOF
MGSM.7PKEBVM(W:BO=N]SA_LW[6__`$?'X[_\,+^SQ_\`,71]F_:W_P"CX_'?
M_AA?V>/_`)BZ=<_&[X/6M_X7TE?BE\/;S5?&WB3_`(0_PA8:9XJTG6Y_$'BS
M^S+K61X<L3H=QJ*+JITC3]0U)(+M[;=:VEPT32$;:]0/4<YZ@=SG@$=`>,=,
M=O8USU<1C*,:<JM"G255-TG4R[+8QJJ$W";A_LCF^24)0ES1C:46KZ)G13P6
M"JJI[+$8JK.BHNJJ>(YHT5)0<?:OETYHRBXM73<EJKZ^6_9OVM_^CX_'?_AA
M?V>/_F+H^S?M;_\`1\?CO_PPO[/'_P`Q=>I$$$@@@@X.>QP#@^^"*"""%(PQ
M`(4\$@C.>?;D=O>L5F%1[?57;3_<<LW2C*W^Y;\JO;>S3V2*66T=+3Q;O:W[
M^6NUOLZWM\[ON>6_9OVM_P#H^/QW_P"&%_9X_P#F+H^S?M;_`/1\?CO_`,,+
M^SQ_\Q=>I`$\J"P'7;SCC.,CCD`D=L<YHP2,C.,;L].`>OTX.?QH685&KKZJ
MTFE=8'++7TTO]2W=GI_D']FTEO+%WM>WMYWTM?[-WMVZON>6_9OVM_\`H^/Q
MW_X87]GC_P"8NC[-^UO_`-'Q^.__``PO[/'_`,Q=>GR/'"H>>6.&/<BM)-(L
M,8+,%52\F%4NQ"H&RQ;&`>!7%Z?\2?`6J^/_`!'\*],\5Z)?_$7P=H&A^*?%
M?@R"[1]?T+P[XFDNH_#VMZC8X`M],UA[.[%C,TC22^1*6B4D$:TL5B*JG*%*
ME4ITH2J5ITLNRN?LJ5/V:G5FGA8KDC*=*,G>\?:0MHTR7@<)!P56OBZ?M)1A
M37MY.52<KN,8+D]Z4E3FUJD^2>NDD8GV;]K?_H^/QW_X87]GC_YBZ/LW[6__
M`$?'X[_\,+^SQ_\`,77J0!(R!D8W9'(QZ\=JRK'7-#U2[U.PTO7-%U6_T6X6
MRUJQTW5M/O[[1;UE+K9ZQ9VES/<Z7>.J.ZVU_%;W!2-V$>%<U$<;7<>;DPSB
ME&4I+`9:XI2:46Y?4=I--)[-II:QL.>74*<W"53%Q:<ERSQ%IW@DY)I)WE%:
MS5VXQ3;]V[."^S?M;_\`1\?CO_PPO[/'_P`Q='V;]K?_`*/C\=_^&%_9X_\`
MF+KU+:20"#G!(X[+D,0/08/^-)D9"Y&X@D+_`!$#@D#T'>E]>JW:2PW,E=KZ
MAEEU;EW2P5TM-W;\$']G4'M4Q3UMIB);Z:?#OIMYON>7&V_:Y/\`S?+X[QTQ
M_P`*%_9X/X_\B9C_`#TKR/XD>-/VRO!GC#X%^';#]M;Q==6WQ6^)6I^#-7N;
MGX$?`!9]+LM-^'GC+QDE[8+%X0$<MU/>^'K:QE2\1[<6<K/#&MU&DH^K:^:?
MCO\`\E1_8Y_[+UXE_P#5&_%"N[+L3.OB)0J0PTH+"XFHE]0RQ>_3I<U.7^Y-
M>[**=K:]SEQF!I0HQ]G*O"?MZ"<_KF8-N+J1C./*L9"*<XNS:BE'51BE9+T7
M[)^UNA*C]N/QW@$@?\6&_9WSCL,?\(7Q@''X=Z5;7]KIB%7]N/QX23M4#X"?
ML\$Y)P`!_P`(9SD]L<FO4G^\_P#O-_,U\:?\%$KJ[LOV$_VLKNRO9M.NK?X)
M>+9(;^VF>VN+5A%`-\,\;QS(<''[J:.0C.)E3)$9=.MC\9@\&Y8:G]:Q-##<
M_P#9N63Y/;-1Y^5X1<W)9-KFC?9R1>+PN'P^'KUTL145*EB*RISQN)@OW.'J
MUU%3HSIRM/V2IMS]JU?F7O+WO>VL_P!KI0K-^W)X^4$C!/P#_9Y`8C&0&/@S
M#$9Z#D'TXS&;;]K?*D_MR>.N2>?^%#_L[G<<DD?\B9S@*^>?EY/&*_"G0M+_
M`&F/V5_@W\3OVBOA5X0F_9C\$^.-%_8_\"?#_P"&7C7QO8?&*WUKX@Z[XQ\.
M:'\0/C-=:(NK^)-(\-Z9XYT;Q`;+[!;:M;:Y=)*UU<0:+J%I:3P_3'QO^./[
M17@#Q]\8OA+??M@^`_A7?_LS?LUZ'\9D\9>-_A-\.+6__::\6^(9?%M_+81Z
M#J]_'I>A>$?#@T.P\'3V?P\:Y\2W-Y?"YN+Q]0E\Q?IWPWCJE6+PV/RN6'J/
MEIU:V68134H8C#X"LJU/"Y;B734<QQ-/"PES2]I'FKZ1C.,?G8YO@8QASX/'
MTJKBW-?VBXT?=PU;&24:N/Q/OM8;"XN=H0@W*G"+NYPY?TOUF_\`VH/#ND:E
MX@\0?M_^*M!T+1[66_U76M:^"_[-NEZ1IEA"5%Q?:EJ-_P"$;:RL;&$NGG75
MS<16\6]6D.&4U;M_^&L+RVM[RS_;N\;7=E>6T-W97MK\"OV=KBSO+6XC66WN
MK2YC\&M%<VT\3)+#<1MY<T<B2Q^;$ZRO^%'[47[5/QF^-OP<_:2\/>*OBGX"
M_9Q\/>%_V(_@[X_U/X):]X3T&_\`$7QOU[X]^#IM4\56&GZIXHU.R\5:-8:+
M=20Z'X8B\("34+/69;9M=BU*W,_E>V>+/VT?&WP:^'?[7_A]?BCX6\&ZE\&/
MV-OV3?%_[.FBZU8>%(M23Q5XW^&FW6YM(M=8LWNO'/VS6X[.)=.NQJMKILBB
M.VM((O.#5_JMG$Z&&=*MEM3%5L3+#5,/]2R^U.];!X;#RC46`E[55L1C*<&E
M%*"O)2DTXQ=+-\KDZ\ZF%S"EA:6'IXB-=8O,)2EJYUXRI_7$H.CAJ=:M%R<E
M.4?9V7,I1_7'[)^UQP?^&X_'8!`8$_`;]G<9#?*"/^*,RPR/E8<DY`Z8I6L_
MVNT=D;]N/QZ&7!*'X!_L]*P#*&&X'P9D*RG<">N/I7Y]^$/C5\;/C)^T%\6O
M`\?[4?@_]G_2OA/+\(?!7A_X9:EX`^'?B#Q7\6M0^)WPHTKQ1>>/[:]\7ZA:
M:T]Q)XBUWR/"&E^$K670VN=+$.JVNHQSW4%STW_!)G5O&>M_LD:+J?C7XUZE
M\7]4G\7^.K8Z9K0T:77_`(;OI7CCQ1IEWX?UG5[.[O/$&K7&O26B^(8G\52+
M<Z=9WEKI.BH-$LK0KYN/RK&99@\1B\7B<$GAZF7Q>&ADD77=+,)25*I+GRI0
MA&*C=OG<5?WI124GTX7&8/&8FC0IX7'.G6PF+Q,<36S%4(TWA8TW[)PCB<.Y
MSJ.=OX=7EY4K7?*_MPVO[6Y!'_#<?COGC_D@W[/'_P`Q=>.ZWXP_;)L/CU\.
MOAC!^VMXN.D^+?AA\3_'-[J3_`CX`&_M;_P/XF^&ND6-E;0CP>+,VU]!XSOY
M;N:6-KE)+.U$+*GF$?6?Z?Y_&OFCQ1_R>)\$/^S>OVA/_4Z^`]>3@,5.M+'*
MK##3C2R[$5X+ZAEL;3P^%Q>+B_\`<MY/!Q@WT4V[/EY7ZF+P=*"PZA/$<U3,
M,#3<Y8K%1:IOZU*45&A6H1:ERV;DI;]E8]&^R_M<@G'[<WCH@GI_PH7]GCO_
M`-R8!]23VIZV7[7;@D?MR>/2-K,S#X!_L\LH51DD[?!AV@##'G`#$UZ:>`3D
MC`)R#@_GV^O:OY??C%?7WA+]I[]H[XSX\(Z>OPV_X*&_"NRO/&&A_&;7]$_:
M:/AW4+/P-97?P_\`A?\`"261/"/BOP=X@FU<OK[WBM<RVQUB!+&Y,.Y/5X>P
M%?/9X^"K86C+`4</75/^S,MJ2Q/MGB%[*"6$CRR7U5).5XR=1;.*4O.SFOA\
MHCA9?4\7BUB:WLG[/'YC'V*2C>K/_:I?NTM96LU%.R;21_0MHVN?M+>(SJH\
M/?\`!037M=.@:K<:%KQT;X-_LT:F-#UVU6-[G1-96Q\+7)TO6;1)HY+K3+ME
MO+998FN8+821L\E]K'[2^EZMH.AZK_P4#\1:5K7BFYO++PSI6I_!W]FJQU#Q
M'>V%HVH7]GH.FW?A*&[UBYL;%7O;ZWTQ+V>SM$:ZN8XX&,J_DSI'[0?Q&\/^
M+O&'PQ\'>-OAA^SS%\9O^"D7[1OPO\0?'+_A7'@:#3O!VB>!/`F@^+K""XT_
M46T[PIK7Q!\<7J)HR^)?'US/?70M[N.X-U)%;/;X&B_'GX@_$7XJ?L;>*O&^
MJZ-\7M:^"W[37[=G@#PI\1/!VCVV@Z3\;-$^&_P(OKK1_$6EZ5I#3:-!J&L7
M4[^';\Z!(VB7>J6C7%E:IDQO[4N&\<_;2C'`1HK#SJT9SP674ISE*,HT8-UL
M%##.M.O"=/ZO3KU<2DH25*2JPYO,_MS*Y1;AAL7.2J4*<[8_,>6GS3BJ[E)X
MG:C3<:B:BU/FY4XV;/V=-K^UOG:O[<_CPD@$8^`O[/.<'&<K_P`(8&R"-I&/
ME</'U6L?7]8_:8\*:-J/B+Q/_P`%`O$?AKP_I,/VC4M?\0?!G]FK1M$TR)G2
M))]2U74O"EK8V<!EEBC,EQ<Q&221(X?-EDCAD_)OX8?MJ_M!PP_L_P#Q#U#X
M^?"GXYQ_M'?!WXZ?$KQ;\%=*\'>&O#\7[.5_\.?A_J7C;P_)<Z[X8O;[QC_P
MC^CZU#;^!?%S^/XGO+J[9I--9+R(;?`C^T[^TQ\7OV3_`-K+XI^.?B)#\3?A
MCH'P$^$VJ6GAKXF?`3X3>'O#H^,?C3QOH6H^+M&L/#6-=U+Q;X&\!V$4%EX9
MUWQ$9K'7_P"T[>\N8I]5TCSJPAPOF].4)8FIE=.A%T(UYO"Y;",*M27LJU%S
MJ8"%.,Z->CB(J52=.%2%.,^:,9/DVEG652Y8T,+F-2M.-6K"$L7CZ<)X>GRU
M:=:%3Z[*ZJ86I0JVLG&51T[7AS/]]8H?VM9422/]NGQRR2QQSQO'\"OV=I(W
MBD198I$9/!A5XI(V21)%9E="A3*L&J<6G[73$J/VY/'O`.<_`3]GG=@':20/
M!F2`<*3QR?PKX9^"GQN^)GQ1_:9^*6BZM\?_``!\+/!WP4^*6@?!_0OV9;KP
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ME\=Y'!_XL'^SR3CW'_"&<`=\GWI#;_M;@\_MS^.QD;@#\!?V>`<$'!Y\&YQP
MPX_NX'!K\6OC?_P47^,WB'X7?LOZI\'_`!K>^`/$_P`6OV</&?CC48?"?PP\
M+?$SQ'K'[0_@O7M,\!3?#;Q3%XYN;'1O`?@5_%B^(!K/BI87U&QN8+<3);6:
M3>9>^/?[77[;W@?XLWWP=\$>(/#+^)?@E\#/@_XZ\47_`(I'[//A'P]\6/&'
MB_1'U+QEJWC6Y^)?C+P;)8>!K?4+6]T2QF^">R^L+B"ZO;F[AAET^"#:EPEG
M=2%)RJY52JU*6+JNE5P>7QDHX2-!3:<<N:ES3JIZ-M1:FTXM)95,YR6E.JN3
M'3IPK83#1J1QF/<9UL2ZCG!Q^O)Q5*%%W>O,_=M&US]E_LW[7/(/[<WCO/''
M_"A?V>,X)QDC_A#.0<@=?\:<;/\`:Z4!C^W'X]53NVL?@+^SRJ'!PVUO^$,P
MP!Y.!\N*_)7XR?M2?M<>'-6_;(^(WA?XJ^%?#'@_]D_XC_LZP6OPBO/AMX5\
M26_B_3_BCX4^'ESXQ\(:WX^>6#5;#1K&\U_5+K2-3T42Z[<7<A235$TU++34
MZ[X/_$[Q/\'/VGO^"GGQ!^*/[0NJ>(_`OP471/&\'PC\0V7ARTCN=#NOAS:>
M*-#U'PU$]V^M:#IWAJU:W\#11>'+.WT7Q9J.M6.M^)%.MS1-+FN&\R4*TEC,
MFJ5:<::HT(Y9AJL<3B95LLIU,.JRRM4(\E/-\!.-1U)>]5<?9\\%&6M+,\I=
M6C[3#8N-"=:O&K6GF>)BJ6%H4:DJF+5)9C[>;A.G)1I*FHRLI.HHNZ_17P_X
MK_:)\67GBG3?"_\`P4*\0>(-0\$>()?"GC*RTCX*_LY7T_A?Q1!9VNH3>']<
M6#P:RV&KPV-[97DMB[_:(;>\MGECC\P&L[XF:Y^V#X*^&OQ%\;V/[;GC.]U#
MP9X%\6^*K*TN_@/^S]';7EUH/A_4=4MK.Z>#PA%-';7%Q;1+<26[)/L#>3(K
M[F'#_L)?#?7?AU^S1X*N_&MJ;?XE?%B]U[X[_%%Y`/M3^.OC#J4OC._LKIN7
M:30--U'2O#J+*\K11:2D$<K11J%]F^/_`/R0'XZ_]D<^)G_J&:U7B5:L(9T\
M+1C2G@X8]X:#JY=EL:E>E3J*DZC_`-CER*MRNI&+<^2,XQYI/5^BL'?+%6J1
MKT<5+!QJSBL?F%18>K4A&7+=XR"FJ,FH*34.?EO[M^58?@V[_:^\0>#O"'B.
MZ_;?\;PW7B/PIX;UZYAA^`_[/)A@GU?1[/4Y88&?P67:*%[LP1F0^:T42F1F
MD=C72?9OVM_^CX_'?_AA?V>/_F+K;^&'_)+_`(8=_P#BW/@7@=?^15TBK^G^
M.O`FK:S)X;TSQUX*U3Q%#+<PS>'M.\6^';[7X9K-BMY#+HUKJ<VI1RV;*XNH
MI+17M6C<3+&R,1P/%8B5:JH4:<Z=*M44_99;EE25*FIM1;7U2*22MJVO=N^A
MVT,!AG3I.=7%1<J5-M1Q-23<N2+E+][*=1W=V[SG))V5TDCE?LW[6_\`T?'X
M[_\`#"_L\?\`S%T?9OVM_P#H^/QW_P"&%_9X_P#F+K>\)_$?P!X\U#QKI'@O
MQ;HWB?5OAOXHG\$^/=/TF[2XN/"7BRWLX-1F\/:V@"M::K#8W=O>/:A94%K,
MA$P9'`[/IUXZ>G\0RO?^(<CU%9U<7B:%2=*O3PU*K3DHU*<L#EEX-\KBI6P5
ME=6L]FW9:JPZ>"PM6*E1KXFM!ZQE#$2:DM-=8I]-;I==[GEWV;]K?_H^/QW_
M`.&%_9X_^8NC[-^UO_T?'X[_`/#"_L\?_,77J6"`20??CIR!S]=RD9_O48(S
MP?E.#QT.,\GZ<U"Q]5INV&T[8#+>BC)[8+2T;2?924G:*NK_`+.HJUZF+U2:
MO7DKIM);Q3LW%J_67,O3RW[-^UO_`-'Q^.__``PO[/'_`,Q='V;]K?\`Z/C\
M=_\`AAOV>/\`YBZ]2(P,_7G&`<8S@G_>7\Z3!../O?=]_IZT+'5I7C%89M63
M2P&6-I^[O%8*^MUT^U'R%_9]#3]YBM?^HB2>FCWCT<6GIOS'E;6G[7`)9OVY
M?';*JLVP_`7]G<KE8V*$_P#%&'(5QN49"%T&X8)KR3]G_P`<?ME?%;X*_#7X
MD:Q^VOXNTS5?&/AF+6;_`$_3?@1\`9+&UN'O+RV,5K)=^$);EHBMNCCSG:16
M=QDIM(^KV/#9.#LD'_D-L`\>E?,?[%W_`":C\!O^Q#M__3IJE=JQ,W@:];V>
M%]I#&8.$)+`Y:[4JV$KU'#_<M;3I*2G=-J5K*ROR?4J7URE2YJ[I_5L3*47C
M<>N>K1Q.'C&J^7%QC%N%9QY8Q459N-DTEZ7]F_:W_P"CX_'?_AA?V>/_`)BZ
M/LW[6_\`T?'X[_\`#"_L\?\`S%UU^N^,/!WA62SB\5>,/"?A:34!(UA%XF\2
MZ'X>DOUB*),]BFL7UFUV(GD1)6@$H1GC#D/(*Z(<J)%^:-E#K(N#&T;@,C*P
M+!D=64HP8JP9<%MRD\;QN(BDY0H13M9RR_+8I[/1_4K/1=/7HK=<<OP\GRPJ
M8J4EO%8F4FM5_=<MU;WG)ZZMMGEWV;]K?_H^/QW_`.&%_9X_^8NE^S_M<?\`
M1\GCS_PPW[/!_P#=,%>HXY`/<@#W)&<#&><<_P!*Y'Q1\0O`_@B_\':7XP\4
M:1X=U+X@^(U\'>!K+4[D6]SXI\6/8W6I)H&DJ599=0.GV%]>,&:.-;>UE+,S
MX%70Q.*Q-2%&A2HU:M1>Y"&795*]E&6K>$22:LTU=6UT2USJ8/!TH\U:M5C'
M5<U7&8FFDU:+UH3I:W:3YV[.22MS._.?9_VN?^CY?'G_`(83]GC_`.8ZD^S_
M`+77_1\OCO\`\,+^SS_\QM;OP\^(W@7XM>%-/\=_#3Q5HOC;P;JUQJ-MI?B7
MP_=&]TF]FTC4;K2M3A@N-D;/+8ZC97EE<J$"Q3VTL09MH-%Q\2?`=I\1-.^$
MEUXLTBV^)^L^%;[QSI7@62XSXAU#P=IFI0Z/J'B2UM$R&TNTU.XAM+B21H7B
MEFC5D/SR"Y5<="K7HO"J%7"475Q=*>692JN']FXJHIQ^J:J/-#EL[R3;LK>\
M2P>71IT:OMI^SKWC0G/&YE&%>HG&T*3^MRE)--\TFER^[92N[8GV;]KC_H^;
MQV?;_A0G[///M_R)M-^S?M;_`/1\?CO_`,,+^SQ_\Q=>H@]2.<'H<<>F<'`S
MZ%CS7)S>/O!EMX[T[X7W'B?1XOB)JWA?4?&NG>#I+B3^W;[PEH^IP:1J7B&W
MM%AV?V3::E<PV<MT\RMY\T!$31N7$TL3BZT:LZ5"E5A0H^WJRIY=EC4*2<8\
M[_V176J>B>EY;*ST>`PD$G.IBJ3=E&V)Q,XR;LDN:O.LT]%90Y4T]4[1MXC\
M9O%7[8OPX^#WQ9^(FE_ML>,=0U/P#\,_'?C73K"^^!'[/L=E?7_A;PMJNN6=
MG>26_@Y+A+6YN+&.&X>!TF6)W,3+)M(ZWPT_[7NL>'O#FMR_MP^-X)]9\/Z%
MJ]U%%\!?V>C''/J>D65]*B,W@T.RH\YC5FP6"+D;OF-/]JK_`)->_:4[_P#%
M@?C'[_\`-//$7/OCKG\:]1\!_P#(B>!?^Q*\(?\`J-:5]*WCBI_4Z514\-[2
M6/=&4OJ&6N]+ZJZG(U]2_G2DM>VFQR+!4_KDZ3GB9T_J]#EB\5BH\M6KB9P=
M6U"M0YFH0E&S3DW*_,K6?,&V_:X_Z/F\=GV_X4)^SSS_`.6;3?LW[6__`$?'
MX[_\,+^SQ_\`,77;ZYXF\,^%K:.]\4^)/#WA>RFE^SPWOB37=*T"SFN`C2?9
MX;O5KJS@FG*(\GDQR&38DC[`@)'/W?Q.^'=GXE\#>$)_&OAL>)/B98:]J?P\
MTB'4XKJX\::=X8L;?5/$.H>');/[59:E9Z/87=K=WL\=T$2WN8)8GD!)&5*M
MCJJE*GAH58PA*I)TLLRVT84XIRJ2D\)"/)!1;FTVTE?E9TO!X"FO?KXBFW.$
M(PCBJ]23E.RA?ZQ4K3C&3:U4E#=VO=O(^S?M;_\`1\?CO_PPO[/'_P`Q='V;
M]K?_`*/C\=_^&%_9X_\`F+KU'(]1V[COR*!R,CD`X)[`G'&?7E?T_#F_M&HK
M7^J_^$.6*]FD[7P:OJFM-GINDBGEU&+2=3%)M)V>(EKHGUBK[?B^YY=]F_:W
M_P"CX_'?_AA?V>/_`)BZ/LW[6_\`T?'X[_\`#"_L[_\`S%UZE@\Y!&,9SQC/
M3.>F?>J"ZII<FI3:-'J>FR:S;6<.HW.CI?VCZM:Z?<R/#;:A<:8)C?P6%Q,C
MPV]Y-`EO/*CQQ2.Z.*M8VN[VCAWRJ[ME^6NWPZNV"T7K;=:Z(7U##V7[[$J[
MLO\`:7JU;1>[J^OS9YZ+7]KCI_PW)X[Z8Y^`O[/'/KG'@O&/7.!7D?P[\8?M
MB^+_`!E\;]"N_P!M7Q?:0_#/XC:=X-TNZMO@3\`9+C4K&\^'W@SQ?)<WRS>#
MS%#.M[XCN+;RK14@:&VMI=B2-,9/JROFWX&_\E,_:W_[+MH?_JD?A9Z\5UT,
M5/ZICZDZ>&G.FL'.C+ZCEL?9^TKRHS5OJ3YN;E4NFW*ELURU\%2CBLNA">(4
M95L>JO-C,9%U(K!4W&+5#$4*<>5NZ:IW3U;;U/0?LW[7/?\`;E\=M_W07]GC
MCVY\&?Y]:/LW[6__`$?'X[_\,+^SQ_\`,77H.K:QH^@6$^JZ]J^DZ#I5LT:W
M.J:[J5EH^F6S32+%"+C4-1N+:S@,LKI#"LTZ-)+((D+RD"N.U;XM?##0]-\+
MZSJ/Q"\'1:3XW\6:=X"\':K%KMEJ6F>)_&^L&Y&E>%='O](>_M;O6;UK.["6
MPF0(UO+YA4^6M94:V-K2BJ6&IUG-N,52RS+I2DXQNU'_`&.,6XQBY-.2TC)]
M+&\\)@J=W4Q%:C&*CS-XNK)1YI1A%OVLJM3WI.,5>3C>5ERQ>F?]F_:W_P"C
MX_'?_AA?V>/_`)BZ/LW[6_\`T?'X[_\`#"_L\?\`S%UZG@G@*P.,E?O$$##`
MX[*!EB`.Q;V3!)V@'.`<<9P1G./0CY@>FT&L%CZM]L+Y+ZCEC>ZT=L$U?3IH
M]&FURFT\MH1?QXU+EC)<]=IN+49*5DG[LE9K79O:YY;]F_:W_P"CX_'?_AA?
MV>/_`)BZ/LW[6_\`T?'X[_\`#"_L\?\`S%UZB,DX')!].N.N!SG:2`WN<5GW
M.K:197EKIMYJVEV>IWUO>7=CIUWJ5E:ZA?6FG('U&[LK">=+JZM-.C=)+^XM
MX98;%&5[J2-&4AQQM>7P0P\MW[N`RUZ1<5)Z8%[6U[-I.UD0\OP\4G*KBDO=
MU>(DE=I-*[C9MKMO=V//C;?M;X/_`!G'X[Z?]$&_9W'Z_P#"%\?6O)O'WC#]
ML;PO\0/@1X4M/VU/%UU:?%'QGXR\-ZM>7'P)^`*76EVOAOX5^,?'MK<::D/@
M]89)[K4/#EM87"W:21K97$[PJ+B.&0?3NGZEINKV5KJ>CZCI^KZ9>Q":RU32
MKZVU+3KV')3SK._LI;BUNH3(CKYL$LB;T9-P*L5^>_C+_P`EI_8Z_P"RK_%3
M_P!9S^*7N/YCZUVX'$3JXB5*M3P[2H8B5G@,M34Z5&4U=?4KIWA9Q:33>JT2
M.?%8"FJ*G3K8I-5*%[XFLE*,ZU.FU>C.C/52OI.WD[Z>@&V_:X!P?VY/'9Z`
M`_`;]GCH/3/@O)]>?_KTOV;]KC_H^7QX!_V07]G@_P#NFBO1]1OK#2;*ZU/5
MM0L=+TRRA>XOM3U2\MM.TZR@C(#W%Y?WDL%K:VZ;@'GN9HHU)3)W/FN`UWXR
M?"+PUX5/CC6OB9X(M?!R:_HWAA_%%OXATW5M$C\1^(=3LM&T+0FOM%GU"(:M
MJVJZE86-K:,T;B:[AR%C):N?#U<?B71C1PU.M*NZ<::IY9ETDYU(1G&%W@N7
M?1:-O1*.NFU;"9?1G-5:M>-.G*<9_P"UXA\D*<G"4TH5HXB2<E=J5>22DVVU
M%-5_L_[7'_1\WCS_`,,)^SQ_\QU(;;]KC_H^/QV?<_`7]G@<?^$8?RS^->I,
MK`D'`9?E8#YE4AMG#`X(+`;2,<,(P-X<4;3UP<\$C!SANA(QP#C@GT]*P>/J
MK5QP\5M[V7Y8G=6TTP5K^5[];;-4LOPZ2D_K$+V5_K>+;6RY6L17K03T?V.9
M.Z35K/RW[-^UO_T?'X[_`/#"_L\?_,71]F_:W_Z/C\=_^&%_9X_^8NO4"RCJ
M0.O4CG'IZ_3UXZU3NM3TNQN=/L[[4].LKW5[B2TTBSO;ZUL[O5[N*%KB6TTJ
MUN)HY]2NHH%>XEMK*.:6*WC,K(8\O51QU:3M".'FTDVHY?EK:T3V6"TT3?IJ
MMAO+Z$?BJXI6M>^(DK7M:]XK>WSN[;GG?V;]K?\`Z/C\=_\`AA?V>/\`YBZY
M?QS??M@>'/`_C3Q':?MO^.);OP]X1\2Z_9Q2_`?]GE8IKO1=$O=2MXI2G@O>
M(I9;9(9F4;A&Q,3"3!KURU\4>%KXZ<MCXG\-WK:S<7UIHPL_$&D79UB[TG>-
M5M-(%O>2'5+K2C'(-3MK'[1)I[1R&[2W"DCGOBT#_P`*F^*8.1CX;>/3@\8_
MXI/6.F>OTKJP>+K?7,%2J4<')5<9A*4HULLRZ:Y)UXTZB47@X_%RSA=K>,E9
M\K2QKX/#1PN+G&=>I*&&K2C_`+7B(\M14DX23H5*,N:+<9\KDU)=-5)>>?\`
M#97QZ_Z&2P_\$6A__(E%?+%%?0?4\)_T#8?_`,)\/Y?].?)_?Y'C^UQ/_/VK
MT^U5\O\`IYY/[V?6'P!_Y!OQF_[.J_:C_P#5T>+*;^TYX`\!?$+X$_%.P^('
M@KPGXWL-$^'WCSQ'HMIXNT#2]?M='\1Z9X,UU]-UW2XM4M;J.PU>P#3"UU&V
MV7,`DE"2@-P[X`_\@[XS?]G5?M1_^KI\65[M)&DB21R1QR1RQO&\<J*Z.C@J
MZ.L@9'1D+(Z.I5U8AE()%?/5L7]2SV6*4IQ>'QU*JW2G&%3D@Z3FXMM)/EOH
M]&KKJCVJ=*&)RN.'DJ<U6PTZ7)42<7*I*48N2;M:,I1D[[6OTU_GG\._"+PE
M%^S]_P`$:;#X<+IOP5\4?%GXB>$KCQ=\1_AIX=\+:3XWU/59/@9XL-WK[W]Q
MI<MIJ/BD:;+J%I9:]K-CJTVFM=O>QV[RQ(#F^/\`]IO]I[PQ\&/A]X);XX:Q
M9Z)IW[8W[2_P+\:_M`^,/'NC_"G6F\(_"=[6X^&6@^./C5%\/O&VG>!]1UJY
MN]1CN?$DWA2.?Q)<:98:'-?6$-U-(_\`1"-/T\)9(NFZ<J:=M.F(MA9B+2S'
M'Y2/ID8@\NPD6',0DM4B<Q;D?*2DTQM(T=[>[LY='T>;3[V5Y[W3Y]*T^?3[
MVXDD$SW%W9S0-#<SM,%F>>8/<>8H?S0P6OHH<:89XFE5QF74<?3HXO&UX/&8
MK`2J7Q>,Q&)ISJ\U+V]2C0>(C46#J5O95*E)3<H\W+#PI</581Q/U3,OJ$JV
M&HT'1PZJ2@JF&P]*C&,:-)_!5J4DY..B4Y2VN?AY\,/B-^TM\3O'7['/@?QC
M^U%KTECXE^`W[2GQ$\9^(_V==:T/7+?XO0?!_P"(^D1^!FMM>U?P=I=AJ^KW
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MWS\&_#_[6GQ^T[2/BIK?[/\`^T+X\_:IN+3]A"+XP?$A/$GAK3-7M?@9^T"=
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M#/YT3R0-NCG8':MQ;EE:K76&R3`QH2Q5*]:M6RNCB<11I1E%<\8X2-*G6Y96
M@EAX))6T<IN6D,BQE.6%;SS$0C1P\Z4*.&HY@Z%&I5]C*5.,IXC$5,33]I!M
MU*E6;?,TM$D?SO\`[8GQE;]I;P/_`,%![_P)\;?&GB/X&_"S6/V+/%7@4^"]
M2$?@<Z=?ZD]G\1=4LWN=+N$O_"EI?X\17NLV,HTQ_$?A:UO5U.ZT_3;RVF[?
MXP_M`?$CX?\`B3]IN;X*?'3Q9XW\$>'?@#^PT=,^.*C1?'7B70OAS\0/'?B/
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MDCX8_%WX4?#3]EGXA_%_0_VD-?\`VF/A=\+;?XB>*'^+_C#6-)\0ZKJ-OX:L
M?[0G\+S^*-'T3P]IGB"VT_4#%I-AJ4=A_K;E])DE>73V$7Y)?L8ZW\2?@'^T
M'\./&7Q/^$OQ1^$R?MN?"_X@:?\`$?QG\0KKPC_8_P`0?VC[B]\2?&OX?ZOX
M4/AWQ-K6H6.[PCKM[X,L;/Q)IVAZHUM;Z8L%H5#"W_HC&F:6EB-+CTC28M)"
ME/['CTVS723&7\SRFTSR#8O!Y@R89+=DD;+LI?>XEFM+*Z-M]JL;*[^Q2)+:
M"ZLX+G[+(BLL3VIN(Y6@DB0F-)H62586>$NR.ROY^!XFPN#H8^E+`QQT,UQ,
M*F+JX[$8/#RJX6FU6I8:*ITZ>%G.GB95L1'V=*C3;K3Y80C'EEU8O)7BIY>X
MXJ.$I9?05+"T:,J\:3J5(JCBY\U>K6Q$5C,!&."G&M4JU(4Z<9SJ5:ET_P"=
M;4/C=^U1X2_8;_97^,7_``T7\1-5OOVE_']KIWQ;^(OC/QIH'@'P[\)/#&@0
M^+=/T#2="^(%E\-O&!^%]OXTU'3+&+Q!\0]6\/\`B*]O]0L((6DTXZC-G)^)
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M2-:-//:N'G4PV'C:G[>JY8N@J495O94GR\M3EF_;.7,Y345%.;OX'^R+X_\`
M$_Q5_99_9Y^)?C6_35/&'COX/^!_$WB?4X[2WT]=2UW4]%MY=2O_`+#:+':V
M;7=QNG>WMD2"*1V1$1`HJA\=_P#DJ/['/_9>O$O_`*HWXH5])0P06T,5O:V\
M-I;01K%;VMK#';VUO$@PD4,$2)%#&H^Y'&B*J@;5P2:^;?CO_P`E1_8Y_P"R
M]>)?_5&_%"OGL)6I5\SQ=:E!4:5:CF=6G1C9JC2E3J5(TUR+EM2I7OR+D48-
MQ?*FU[E?FA@L/3J5/:UH/"1JU'HZE2#IJI-QDW).<DY.+O+WK-'TRP)<@`DL
MY"@#.XDX``P=Q)(``!SG'>O"I?B]^S+\6/$OBK]GFY^)'P:^)/B^6RU+3O&'
MP8E\3^%O%.J75A9"(:SIFO>#Y+BZ-W#:K(IU.QN+2Y6`Y^U0(89&C]7\7V>L
M:AX4\7Z;X<O5TWQ'J7A7Q'IGAW4'+(FG^(+_`$B\MM%OI"J,8Q9:G+:76YE(
M00;Y`4!K\2?V=_BE\-?AI^QSI/P-'[/?Q4'[9OP<^&'Q1DU;P1IOP@\9>'/'
M<_Q3T_2/$Z^)_B!H'QJM_"ESI>FW/C6SO[F72O%]CK=]JM\=;T_3+"RFN;J,
M1]F0Y93QF#J8OVE:>*C7P.%IX;"3ITJ^#J8NFY1S#$U*LXRAA<+4355T8SJ*
MUG&^CRS7,7A)J@E0AAYT,36Q%7%0E5ABJ6&K<DL#A%2C-K%8BF^:'MO9TV[:
M\J1^UVO^`?"?B30;7PAXF\':#K?ABR;2;BT\,Z]H5AJ6BVQ\,W%O<:%-#I-]
M;S6B/H%Y8VL^FRK`1IUQ9PO%L:%6CP_&_P`'?A9\2M6\/:K\2?A=\/O'NM>&
M9A=^%M1\;>"=!\3ZKH5R\T=T9]%O-<L;VZLC)<QP73);,D<EPB715IV$A_F?
M\">*?V@IO@9^UIHWASQ9\:(=$N]1_8I\4^`+OPZG[2,=SX<\0>)_BA;Z/\2#
MX'UGXZR:K\2+VZTZSMTL/&%S;32>%+V\TJ:ZAL1HPA67ZI^,>A?&3X/6'[;7
MPK^'_BW]I34?@SX=^+?[(6OZYK-OX@\<>._B9HWPH\=VUY/^T9J'PY\5727_
M`(GNFN8[>WEUZW\,375QHD4^I/:168*VZ^W5X1JX:K&G3SUJHE4A!QI8Z,88
M>K_9:Q?LIT<525&<_K=FTY^U^KI))1DGY%/B+#5Z,ZTLF4X3I+GC*ME\I?6(
MK,?J;KQJT*TJ\8/!Z)J'LOK+>KG!O])OB3\2?V//$GC?Q?:?$[P1X4\=>/?A
M)XS\$_`K7KK6?@K=>/-<\-Z[\<-)N)O#?AFPU!O"^K32>&=?TJ>X&MWMA(GA
MW18I[A=8N=/DFF+=Y\;-%_9?\(ZA\+]1^,_PR^&U]J?C3Q!I/[//PSU'7?AA
MI?BZZ6Y\8V=]8Z=X"LK\Z/?OI/A>^L;>[LWBFEL]$MT9UEN%1_+?\4O!UMK>
M@ZS\==1^"C_M"P?#GQ+_`,%`OV!6\&>(/&]M\3;;QWXE^$ATZ[M]7EU*^\2V
M]OXSUOP$MO&;/[3XLC=W\-)IR:Z5=Z-1M?%'BCX\?"2Y^('_``TKJ_[2&@_\
M%+K&_P#BAHNLZ9\2;CX">%_@S8^--6M/A'JF@6MQ8R?#6P\/IX;&ECPKK'AJ
M:+5KD7'B-=<N7L90R^O/AF$ZL$LUQ<L'A<MJ2I4EBL54QG/'**F8*DGA\31I
MT8U:U*.&FI.<I<T$H\ZE%^9#/91PRY\IR_ZSBL93DZ\9X:.$DJF/EA:CJP]F
MYSE2HPC6IN5-+]Y)NT4T_P"@35?A'\*;GQ5H7Q-USX8^`9O&?@S2_L/A?X@:
MEX2T$>)?"FD6-M<1&#0_%-S8/J.CV5E8R2QQ/:WL#65L'$<T0RRN^''A;X6:
M5IU_XE^$?AKP!IVD?$C4'\9:GX@^&^EZ#:Z7X\U:Z$B'Q7=ZGX9B2Q\275P%
MD5M8:6Z:79*#<.5/E_ST_!N_^,?Q3_:P\0>%=;MOC;X8\,?%OPC^U[X*^+7P
MXU/Q%^TK=:AHVH:5IFJ2^`;#Q=XX\9RZ?\-+'Q%J5S8V.I^$S\$H/#UK9:1>
M1Z9?27!DMUEY'2+;QWX7_8J_8S\'>`-1^+GP_P#AQ;^*_'>A?M<'Q+IW[41M
M?"?QATKPUHT7AKPWK5A\-6L?BOHGP\6Z;;HD/PTG7X>'Q-)9R3PN[W,:\<^%
M93I1I5,_@HXRG@Z=.DWB:^#CE\Z-5Q6(7UFLZ=:GB,-5A3NE'V?)4;_>:=G^
MM%&FJV)PV1WHT7*47"O@(X^I7K8NE1Q'LE2H4/W?O*I+F<I5+*UE=G]0!!!*
MG@J2"#C<"IPRL.H9<8*\X!SP>GS/XH_Y/$^"/_9O7[0G_J=?`>LO]B%?'$?[
M+?PI7XA>/=4^)WB%=.UB*'QQKGASQAX5UC6_#T6O:C'X7?4-)^(%I8^-&>UT
M$6%G::IXELX-6UK3[:SUBZ#M>J[:?BK_`)/#^"/_`&;U^T'_`.IW\!J^+H8>
M6%Q&<T>>-94,MS.G[6BI.C4Y,KS>S@VKVDE?YZ+9'TE:K&O2RNNHSI*OCLNJ
M.G6455HN5/$MPJ)-QYHMV>JVUW1[;XW\?^"?A?X8U3QW\0_%>@^!_!V@+;R:
MWXJ\3ZC#I&AZ1%=74%C:37VHW.(+5);VZMK9)9G1'NKBV@B+22NB?/GPKT[]
MB/XX^,-1^,_P6TW]FKXJ_$'3-;^V:Q\3?`NF>`/%7C73_$-Q"L:7FH>(["WG
MU^TU6X@81VUW<RP231&5K.:66&01^7?\%0;*]U']AKXWVNG:9J6LW)7X=3?V
M9I.F7NLZC=VUC\5/!5]?I;:7IUO=WEXT=A'---%;6TSI`IE*[`7'Y_\`[0?B
M`?&'QA^T!^T/^R9X(^(GACPGX&_8(^*G@'QK\4-)^&GC7X3/\2/BEJ&M:'J?
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M_#)KP_#NVT[PKI%DG@!M4LI--U#_`(0^"UL4B\-R:EISR:?>#3(K;[9:/-#.
MLJ-(#^3.IW5]^RG\5OV/?%.KW?[1_B_X=>-/V<OC/8^,KXR_$_XR:GK7[0/C
M_2_`7B#0]/\`$&D60UBXT_6M6N+77+#PK:S:?I>A^'99[BTM%TJ%[UX?S'^*
M'Q)^*-Q\)?V;/ASX[\:?%WP_//\`LEZGKVH^(-6^)'Q=\#W/P9^(FM_'7Q3I
MTGQ@^)D7P]TCQ1XI\:G3_!NE/I4FB^/(=*T:TL+-)M*U:Z:6Z:",)POC,T>&
MIT\QI?5JJ<Z=*O1S2I'$QKX?$*I.AAGCN95,,\(E7=2,9.G5I))RT6,^)L-E
MMZL<LP^'Q52.'52E2K8!SBX5\+*ASNKA*BDJ<L9.I+DJI\U.45%6DW_27XL^
M`O[/?A_PC\9KQ_"/@;X,V_Q'\&^)M,^*WQ0\&:;X=^&?BD:'JEG>+K6LZGXZ
MLK&RN;.:U>XDU$:A?W9MH[]!+<"0DH?B+]B']C?]CBQ7QQXT^%?QC\(?M7Z1
MJ_@W3/@SX@M]/\/_``8B\"6?AS2M3M/$5OI7BKPO\+O#FEZ3XG\47&HV-C?R
M^)/&T6HZS/!;*UE*X+WU=5^WAX"U?Q;^Q3\-[+X4V&M?&7X>^"O&O[/7CGQE
MX?\`#]QJ7C#7?BY\"O!VI:5?>((;%KZZOM4\:?VIIT&F^([BWN+G4+S7K&">
MX::[D+M)X]^T1\</A1\4_"WP_P#$'P2T/XQ^$OV?Y/C7X$\/_MA^,_A'\&_B
M?\)O'*_"Q/#/B2\\':$+O1O"OA_Q]J&@:%XDGTNV\5W?@W3KZ[T73-6M;..[
M\O4E0:9;]?QF5U*>$SC'O^U<55HXRLXN.7X6E@%&G*EB:&(JRS)SQ4'R4:6'
MQ%.$G%\KC)RN8C$8+#9E&J\HP:EEV%H5,+'$QCA\2ZF-E.3G0KPI_P!GTZ5%
MQY\1/$X><H<T&XU+J,?U8F^#_P`,+OQWI_Q.O/AAX%O/B=H6GKH^D_$"X\&:
M%+XYT?2UBFL%TVP\3'3SKEE9?9[B6PCACO55+65K*-EMY9(WZ:T\(^']*\1:
M_P",]/\`#>D:7XH\20Z58^(_$]EI5K:Z[K-KH,5S'H=CK&L0PQW>H6VBQW5X
MFF6]U+*EG'-<""-$DE4_@QX8T;XI>,;#]G;P;9^+/VH-*_9U\:_\%"/&?ACX
M6Z[K?B/XB^&?BG??LM7_`,)-3C-MXF\3WPM_&]GX%U'Q2NM:;X5U3QE/!JJ6
M+0S6=U;7L>GW$;_@CX2^*O@7Q%^S3X[C\?\`[2.NZSIG_!0SXK_LVW&C^-?&
MGCOQ'X<A_9LTP^,H=(L-;\-:JK:??Z>);2RU"#Q[K4$VH7%U-;*-=EMHK"WB
MQEPO7KO#8=Y_*6)=-8+#N<,;[&CAZM/,ZWLN:I7K2C&^74HV<[1EB(1Y4Y13
MF'$$:=2%2>13I495:<\34DL'.K5J2J4XRQ,*-&G2]M"*>E2*4904IR=H-+[G
M_:+_`."97P?^/6O:/K]GJM[\)+;2_#WB?PKJ?ACPQ\-OA;XD\'ZC;^,]:;Q'
MXEUVP\.>./"FLZ9X.^(.L:G)/<7_`(_\+PZ?XEN_]&DENO/LHY6^GK3]EOX#
M1>$?A=X2\0?"?P7X]LO@]X;T/PE\.]<^)7A?0_'7B;0M+\/VUG;Z<MMXA\1:
M==W@NPUI9WDLT;1EKX1SQ(@95'X4_LH>,/'/B?QI^S)>?#3QE^U#XL^/L'[0
M'QWT[XNVWC#5/B5JGP$3]FW3-;\?VEG9O>:Y%_PK<Z;8^(4T&TT>XLKZ7Q-#
MXG@U6SOYH6MM'BA]'_9GOOBCK/Q2_9R;0M;_`&J;G]J&_P#$?Q?B_;TT3XFM
M\4(OA+HGAAM*\61Z19I8^*;:'X8Z4EOKR>&8_A;+\/F^U-$JM<R0R*\(].OD
MF;.E1P5?B2K3IY?1Q$*-*G2QLI4Y3PJI8K^T%AZM.KA:6+I8>E0P\JLO?M2^
M%5+'/0S?`5:LL73X:IQ6,ES8B4,3@*[G3P\E6HRP'-2G3Q-:<\4_K-*$%+#Q
MIU'*4IQG)?N7J/PD^&6J1>,[?6?AOX*U*W^(%SHU]\0+:_\`"ND30^-+SP_%
M:P:%>>+8I;-EURYT>*QTY-)FU$3'3%L;4V9B$,6/-?C;^RK\'_COIVNQ>,_"
MEIINK^)E\*Z/XK\;^&]*T+2_&_B3PGX1\1Z3XDM?A[K/BJXT:]U*Y\%ZIJ.A
MZ9!KNC>:OVZSMOLT,]J5B>'\@_@#\5OB5XDC_81^%\UK^T##XO\`A+X._;`\
M+_M"3^*?#?Q-T?2(/&H\!^*U\)Z-XD\3ZU;VMAXOU@S6=MJFBR0W>M1Z<)=.
M:"ZBOY(($K_`/0OV@OA_H/['OC7P/XM^/_B/XI?'?]C']I.;Q]I_Q)\4^,O%
M>A'XC>"/`]CJ'P8L3X?\1QS:1X+U71]9:WM-!B^R6=]JBB1+TZG<W%]/<<.&
MX:Q6%KT:E//*6%K4YXB>%BECL+3C]7E357VM2IC:U.I/%PRS!NFIQ;G*G1C3
M?/-..^+XBH5HN-7)JF*HTJ<U*2IX;VL*,J3A%1H*G2;O6:IU6DO9TG.O>4(I
M2_<75OBIX%T'XK>#/@GJ6I7%G\1/'WA+Q/XV\)Z"ND7XLKWPOX-ETZTU^[35
M4M_[,M7T^;4+&&*RN;B"ZN8=XM;?9;FLGX_\_`#XZ_\`9'/B7W_ZDW6CVSZ]
M!QZ]Z_$S]AJPL=1_:T_9.\3:-+^TSK^LQ?LP_&>R^/&M_'>P^)TFEZ/\>KI?
M"D_C;1M`O_B!9QVVG7DEZ3_:6E>%[@>%6MX-$FTJ-KE[YF_;+X__`/)`OCK_
M`-D;^)O_`*ANL5YF,RBCE6:9+1HU\1BIU<-A:N)G7C4A)XQXSD<UAZCE.@ZJ
M<7&#ES5(RC424:D8KU</CZN9X+-,;7C3I-XK&4</0P]6-6E#"TOJTJ5-U:*C
M3Q"4JT[M12ISINFVY4YVZSX49_X5O\*,''_%`>`-IP3@_P#",:-R`OS'![+R
M>@YK^:"^/[.%_P#!7X]:#X,M/!&H?\%"W_;W^*)^!\/@'3XY_P!H/3M6M_CM
M:3Z)JMUJ.BV_]OVG@"ST"/6WU2ZUNYB\+IH\-VA>9KBW2OZ5_A@2/A?\,"#@
MCX<^!2#Z$>%=(P>,G\@:Z:VT;1[*]DU&RT?2+/4IQ(MQJ-EI5A9ZC<>:%\XR
MWMO;QW4AN`@-R9)'^U9>2?=*Q<8Y7GJR=9FXX>=>M7Q<:N&C&O1P^%G/#PKT
MG1QT:FE>E5IUW/EE'EFTHII6:C'99_:,L#)XJCAZ<,.J52HZ=2MBZ/-326)P
M2I:PK4G9PJW3@F[)GX"?&3X^_%WPWIW[5$O_``T78?"^/PC^W7XE\/:K8GQS
MX=^#?C'QSX-\.?!;P?K.J?#KX4_%?5O!7BGPUX<\4Q:Q</KMII_B>P2X\:)M
MT6#5HD:1U]8\'?M(7GQ`^/OPUTKXM?M1?&C]F_P2?@3^S-XS_9_\'>(+3PWX
M2\2_M+^*?',C?\)_#\2M-;PE?Q^.M=DU*&Q\-:SX7\,?V;'IR:F^O64=G:SR
MS)^TD^CZ+<QRQ7.AZ%<I<77VZYBN-&TR:.XU`((EOKA);5EFO4C'E)=29F5%
M0"5E2$QVY[2QNKBUO+K3]/N[RQE$UC=WMC;7=S82!0N^PGN$DELW^6,E[1X6
M9HD\PMM`'H5N*,OQ=-TYY904I1K0I5(XW*5.BV\.I.IS824JZ3@XX=59+V%.
M<X*<T[G!2X?Q%*:<,U<%3AAK)1QC]K5A&:J3J4*-2E5@TI1?QM7<KQ=TU^!W
MPL_:,^,/C'XG?!EK7]IWXC:Q^T7\0_VH/B'\,/C_`/L>?9=&A\+?!WX*65_X
MPTJ[\0V7A5?#5MK?@R3P-H>G>'?$.C_$[4-<?_A)-2NXGC%T;R7[8SX9_M-_
MM9^(9_'7PRTSQ+XN\5_%#]@7X'?M.77QAN)+-KV7XU_%Y=;UKP_^SQ_PD=BM
MFD7B-X_!]M;_`!!?3[<)'JNI6L2/"Q0JW[X+8V"7EQ?QZ=IT&HW:I%=:E#86
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MOA+\/+;X9:1>Z9JVHZ-??"O7)]4ETF>`PV@FB>XGM_JO]ISXF_M&_L<7WAC1
M]&^+_P`7?C2O[5/P0U+X3?"[5O'-SIFJW?A#]K?5O%NC2^'_`!%HZ:+H^G6/
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MZ[J4VU=][JM]#<7MRVTCS9BH(XKPG]B[_DU+X#?]B';_`/ITU2OILCY6]DD'
M;('EM@9'!QW(XV\5\R?L7?\`)J/P&_[$.W_].FJ5\M.;E@,74G:+J8[+I.T%
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M+SX?:GXE\0V.M?91%:3:M<6S-7L-KXN\$^,+_P#X)]ZMX/\`VM/&?[5T\_[7
MGP[U7Q1KGC35=(UFZ\`^+]<^`7C34-7\(6%SI/AS0(]*CEO$-[+X-O#?7WA>
MY@BAD%LUR%F_>2UL-/T^ZNK^QT_3[&^OF1KV^L[*SL[Z^=#\KWEY:Q0W5U*`
M6VO/+*0Q:0$R,7,<&D:+:B-;71-%M$ANSJ$"6FDZ=:I;ZBRM')J44=M;1QQZ
MC)"/(EOE47+P.T;RR*Q!NIQ9A74K8G#91A\%*I[2-*A1QN68>A[*6#^I1I8V
M"P\Z\*=&+=7#O"5\/*3G4C534:3CRT>'*RH8>AB<U>)?)*-?%5,'F$W3G+'0
MQSJX6*Q$:3J5I+V=:.(P]>*C"$J3C+G4OY_O@!X\^.WQD@_8]^&4/[2'Q4^&
MFF_$#]G_`/;)\=>,]6^',OA72]>U_6_AK\:[NP\+7<,E[H%WI^EW>GQ)8V,^
MI:;IT5X^DI=Z4);>75GO$IZ5^UE^TY?>!_AE\2_#OB2]\9_%.[_X);?%CXB1
MP6^@:5J=QK_Q!\-_&VS\(+XX72K?3S-?:OI?AM;K69M-MIQIEY=1RR3Z;>+(
MUO/_`$(6^FZ7:&$VVEZ3;O;13V]LT6E:=$]M;W;F2[@MWCMT-O%=R$R7:0[%
MGF(DD`?84=;:?IMG+#+:Z7I=O);VSV5NUKIUG:/;V<K[Y+.W>V@A>VLWDVRF
MW@:*-I529P\R"0.?&.7RKUZKR;"5J4I8=T,)6Q^5MP2YEB^>K]6^L2>(M0DU
M7KXI)T5R\J=132X:K1A&#SA1Q,.93=*KBE27PK#J%.I6K1C[#]\DJ;BIJK+F
MNU!K\!OBY^TMI'A/X%?#"P^#O[<OQB^,X^(_Q`DAUWXR:U\7_!?PZ\-^`M>T
MSX4VOB#4/`7BOXS6_P`'_%=QH=OK%\T.I^&_AUI'A^\UR7Q`TOAR_P!0MXD2
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M%.&+HXG^TG*E1J8.<,+-8ZE1CB,%4YI2]GBJU9U=W&$H\B2G+5NS/#_VJ?\`
MDU[]I+_L@7QB_P#5>>(J]0\!_P#(B^!?^Q)\'_\`J-Z7^->7_M4C_C%W]I3V
M^`'QC/K_`,T\\1?Y/YUZCX$X\"^!#_U)'@__`-1S3*^?@_\`8*,MXPS9S=M5
M:&";E=KHDE=[+=VZ^_"HHYA-6YE[#!-I-7?^UU[\J;2>BM9NVJOH[K\T_P#@
MI[HMSXCUG]A+1+'X=>!?BYJ.H_M:6UOIOPT^)U]#IG@+QC=M\-_%K+HGB:_N
M-%\2PV>G7$8EEFN)-!U..-HXE%M/YQ$7RCH'[)GQ%^%?QA_8*^`^M?%>]^%?
MBSQ3JW[<_CV6\^!=W;2VWPK\/^+=+\/^)$^%?PNU;QCI=XMIHVA6KPZ7!KR:
M!%-$;C4;K2;&QDN+>Z'[^SVUI<-$]S9V=S-:S">TFGMK>::TN!N`GMI9$9K:
MX5'9!<6[1R['==[(_"26EK+-;W,EM:O=6HE6UNI+6![JU$P"R""X=#/;B55"
M3+%(JS1JJ3(P1`OT>7\85\KP.$P%&CRK"8+%T9U)+"SE5JXN5:49-XAUL/#!
M*G64:TO8?6$U43J*,4E\]C>'J>+Q57&U:LI2=;+VJ'//V5/#Y?&C^]J1PSH8
MB6)DZ3?LZ>(]FURI4YR<F_YE_B[^V?\`'>/]F']G7S?CM\0O"OQ1O?AE^T5X
MCF^),?Q*\,?";PQX\U#X2_$O7_`?AVPO+J/X9>.=5^)OQ5N;#1=/E;X:Z8WA
M33M?L;J\U6]U2&^NP\7T[8_M3_$V7]IO]DV;Q5\=]6\1:?\`%+P7^SBG_"B/
MA#XL\.Z'XIT3Q=\0?`-MKWBCQ!\6/@OJW@:\O_B'\-?%UW>S:C)XT\%>,[%O
MAY:I'"+./^SY2G[A#1]%^SVUJ^BZ*;>Q,TEA;G2--:WL);EG:X>S@DM7BM9;
MEII1=2Q!9;@R2&5GDD:1GII>E1W,=Y'I.DI>PVZ6-O?+IUBE[;6")L73K:[C
MA6Y@T]5VHEI#(D**H"A`9!)M/BS*)T%&6286:Y,8ZM.>+RB4*LL54G6E&E..
M$C.G2A4JMP4.27-S2]WFN\*?#^-IUHNIG>)Y9+!J%2GA,P;IT<-R4GI4K5GS
M5*4.22YDE&,6DVW?\#_V+OVE_P!J;XG_`+4'A*W^(/QV\)Q3>(?''QB\/_%C
M]G#Q#\3[*[\7^'=(\.1:^F@Z=X5^`FG_``DT?5OA7<>%;O1M-NG\6W7Q$UFQ
M\6V#R7MU=/<ZM%9-]\^#1&O_``5'^/:D(MRO[%7P/65=L:R@?\+3\885E3E4
M#AO+_A*JQ'!-??$>G:;!?SZI#IFFPZI<((KC4XM/LXM2FA1%2.&>^C@6\N(8
ME5%B2YFE";(=F-E2K;6L=Q)=I:VJWDT203WJV\0OIX8B6BAGN]@N9((BS&.W
M>9H(W9WCC5W9GX<9Q'1Q-3'U(9?1PD,;E,<!"C@JF'E"BU75?VE:5*2C.SBH
MR=^?DZ.T$>AE^4XC"T\/AYXN6,^JYA/'*M5A.E*5&5!T%#DK/F;7-.7NW3M9
M:)MS5\V_`W_DIG[6_P#V7;0__5(_"ROI(@XX]1_//Z@&OFWX&_\`)3?VMO\`
MLNVA_P#JDOA97AT%?`9C)?"J6`;?1?[=/JKK\3U*\H_7,NU5O;8]WNK6^I4M
M3YH_X*W0_:?V(?&5N;*PU/S_`(G?`6!=,U69;?3-4DF^,'A*.'2]0F>&Y2.Q
MU&=XK2[9[6Z58)I&:VG`,3_"?Q)_97^)?P=TKP;>ZVWP_P#V>-2_:(_X*-_L
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M`(F^#_A1J%GX+TKX;Z5X\T[2_C)\:)_AKXSCT>V>]U2\M]&_L7P0NH^)[];/
M05EMM+*60\SG_;(^-;?`/]CGXE^.OVFM?M[BX\.>-T\9^`/ASXV\-^!/V@_B
MCK>B_&W5_!'A?QKX<T[Q+\/-6T#XXVUIINA1Z1XC^&E@WA3Q#JY$^O7T4%SJ
M""OZ17TC1Y5GCGT;1KB"ZNEO[RWGTJQFM[N_0JT=_<Q20.L]XCHKI=2%KA2L
M:B54CC%)_8NBYM'71=%273YY;FPF72=.$UE<3R^=+<6,AMO]"N9)B)I+FV$4
MLLX>>:221Y2_9'BK*:>%4(911IU$ZDI>SQF3\LW/#RPT:5)+`KZO!<\51=/F
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MM+.::*XFL[2:Z@BFBM[J>T@EN;>&Z4)<PP3O&988;J,!+F&)TCG`7S4;8@3*
M?$^$CB<%B*>64L%"AE>+RZM"%?!0C6K8JG0;F\72C"E6Y/90<ZDZ=-SJRJWO
M4]Z6]'(\1'"X[#8O-WC7B,?3QE&M6]JI4HTJL)JF\/5;^K0E&/+2IPE-0IN,
M4U&*1\/?\$R?+_X8`_91$/EF+_A55N8_+V^64/B#7R&3;A<'(;Y<]3G'?U?X
MR_\`):?V.NW_`!=?XJ<^G_&.?Q2KZ+M[>"SMX;2TM[>TM+=!';6MI;PVEK;1
M!BPB@M[9(H8HP68JBHH!+8!"J3\Y?&;_`)+5^QY_V57XI_\`K.?Q4KQJ6-EC
MLVQ^/]G&G4Q-'/<P]C"K&NHS67X_&*C&I!<M2,JD8TE)*_O[.7NOV/9K#9=1
MH.<)^Q6"H\\6U&2AB,/!25]=4DWTO=*R21Y-_P`%/]O_``[Y_:R\S9Y;?#"0
M.7V^6%&O:(Q8^8K+L+#:WMSWK\I_C'^RS\0/A7^SM\7/B[XA\/\`PH_9^M/C
M=XS_`&"_#/@_X1?!:_E\2>%-`U3PI\3?"4+_`!;\02W7A_PSH%WXX\2W.J17
MDUC::%LC=+BTUF]OY9GDN/Z0;FVMKRWEM+VTMKZUF4)-:7MO#=VDR?W)[2X2
M6"=>>%FCD49X4/APR>UM+J`6]U:6ES`LT4Z07-G;7%N)H"'MY/L\T36XD@E'
MFP,L<9B95$94@&O4R;BFID>$P^"H4:G[G,GBL35IN$:U>&$>%^H.G.M4KT:,
MHUL'2Q/MJ5#VBM[.*4)N_F9UD-/-L9BZU?%4_93HXS!T,/*;BJ56I&O0K8CF
MH0HUN:*K1E&,J\J<]GS:./X5_%WX]?%GX#Z3^V)\)=9^/7QH\96O@']HW]G/
MP3X.^+>N^./`WP_\7^#-*^,?@AO%6OCXC?%L^`-:T/P+\-+;5+)XWUR'P;=7
M>C6U[9Z1I4,?VZ69?GAOVP?CI=_LC?#/QSXP_:GNM"_X1?XS_M(^'O$=EX8^
M*F@>!/C1\:O!_P`/K_P[%X+7X7_%/Q-\,;KPY\2M=\*2ZM(\?A74O#7A#6/B
MA87NB7`M;.2VDMXOZ59],TRZ-[]HTG2IUU,1#4EFTRQDBU`6^TV_V^.6!A>_
M9MJ-!]J$OEX'R[1BHVT;16CBBDT3198X+I[Z!)M&TR1(+^1E,E_"KVI$5Z[*
MI-S&1.H!VR*ZJ!UT.,,OA3HTIY/A(5(XRGB*DYULL_>166RP6(E*C6HNE2^L
MU%3KNC"FG2J\DHR:I0OPU<AQE>5::S>;A".(CA\/RXJAAZ5:OBJ-:/+4G*<:
MSHPC.,*LFY36MU=G\]'QW_:I_:JOOVE-4T?PS\;](^!FF>'-$_9^U;X.^#_C
M%\0+/X1CXA:-XT\-:%K?B'4M<^%!^$?C"Z^,^O>(]2NM1\/:SH^@^*=`N?!6
ML1+IUG8-'Y-W/^EG[680?M/_`/!-+[1Y:RK^TE\0CAF9@DP^"FO-<+`TS-(R
M1L2BN6WE`/,"DE3]Y7.GZ??7<%_>:?87E_92^;87U[8V5Y>Z=(6#L]C=W$,L
M]H\DJI+));R(Y=$;=\H%330VL[VTDUG932V3,]E<36MO-<6DA4HSVD\L3/:R
M-&6A=[<QM);,+60F+$;<#XGPL,3DV(P^58;"TL!@J^$K0698&.(J.M1IT(UZ
M]>$8QQLI1BZD*DHTW#F<%&U2;792R2O3PN.P]?-WBOKN84L51GBJ=?W:.&JN
MIRQJSYHV=3DA"$5=P:E'2-G_`#V?LI&T&I?\$M_+-OE/VEO^"B!B*&,D-O\`
M%XEV8Z,6202[/XE<,/DK]VOB^2?A5\5#R0?AMX]P>H_Y%/5NF..?_KG-=C'I
MFEP?9C;Z7I<'V-YI++R=,L(_L;W!4W#V92!?LKW1PUW);M$UTQ?[0\@GD#\;
M\6C_`,6G^*?7_DFOCW&26X_X136.Y))&>[$,<9/(%1C,UAG&<997IT:E.5/'
M82E*/-"I!QJ9SF.94Y0G"_/=9I.#:2A:C"2:YVEO@<N_LS`YA3^L4:W/0=7W
M-)<U'+<#@.5J22LXX*,[J3<93<4N6*O\*4445[O*OYOP]//S1R>VEV73J_+S
M\G][._\`AE^TO\$?`-U\;/#/BKQ?J.G:W9_M2_M-37=E!X#^).LI"MW\8O%,
M\)&HZ%X.U+2I`T3K)BVOKAE\SRYO+=64^F_\-E_LW=/^$[U;TS_PK#XO_G_R
M(']/PK[V_8A1G^&?Q,*EN/VIOVK>`S8S_P`+X\;\G#9)]-W(XP>]>E?'']H/
MPC\")O`5AK_AWXF>,=?^).LZWHWA+PO\+/`NK_$'Q)J5SX=\/WGB76)&TG2"
MLUO96.D6<UQ)=2.(PRQP@,\@%?,8ROAL1F->$,NQ\VG[]+#YE&A?V-"+J3]C
M+"5%&T82JU/WK2M-W5CT,-'&4<OP\I8S#8:*IQC:IAI55!SK*,(MJ2G)SDXQ
MWLG):6NS\P/^&R/V</\`H?-7_P##7_%__P"=^*/^&ROV<0#_`,5YJP^GPP^,
M(Q[G_B@:_5KP5\=_A'X[\"^"?B/I'CK0[7PG\1)8[/PA>^([U?"5YJFLF\N=
M-N/#(TOQ"^G:A'XJT_5;*^TC4?#CVZZM9ZI97=E+9^:A(S-#_:`^&M]JGQ=T
MS7-<M_!<7P6\?:5\./%NM>-]4T;PYH,WB'6O!?A?QYIATK5;W55MI[2[T/Q=
MI2*UW]AG.II?6<=O+]F$LO'[7"*_)EN:KEWJ/.(1Y5S*'O0^H2DDYODNY6<F
MK+9/HD\?&7*\=A&U9:85ZOE4WM.RM'WG%ZQ5[Z)GY;_\-D_LX#_F?-7;/.?^
M%7_&`G\SX!_H:/\`ALG]G#_H>]8_\-A\7O\`Y@*_8S5/'W@30VTM-7\<^$]%
MDUJ73+?1TU7Q3I&GMJTVMR2Q:+%IHNK^(W\FL2P7":5';>:^H/!,EHLS02;<
MCQ5\4?!GA6'Q'!-K^GZOXH\-^$M5\:S>`='UG1Y_'6H:)IEC=7JS:=X>O=2L
MKDI?R69LM/O+YK'2GNY(TN-1AC+2HO;T%:7U+,Y)V]U9U%-ZI/666M66J7?;
M=H*<L;.;C]?H::27U#W4VHM7J^W=FXM22]E%R4E;1IO\BO\`ALO]FX\?\)WJ
MW/\`U3'XO_T\`Y_*E_X;(_9O[>.]7_\`#8_&+_Y@:_7'1?BCX*O[3PJNK>)-
M$\-^(/%UEI=QI?A#7?$F@6GBK[9JFD0:TFB-I,.JW#W.LV]C<I/<V>FO?KY?
M[ZWFN+0I<2:0^)/PW;Q1_P`(*GQ"\'#QL@4OX+'B[1AXM4/:?;U+>&1J!UI=
MVGG[:`UEN-F!<$>4-X7M\/O+!9G%6OKG,'9*RD^:.76:5][6OU'?&J7+]?P^
M]ERX+VDG)\MDH^TIWOY2NM=&F?CW_P`-E?LX_P#0]ZL/?_A5_P`8./?_`)$+
MM1_PV1^SA_T/FK'O_P`DO^,`_EX!'7WXK]F=0\5^$]+U"QTC5?%&A:=JVHRV
MMOIVF:CKEC9:EJ,U_)<QV%O86-W<PW=Y->2V=W':0V\$LES):W$,22-!+MH6
MGQ#\`:A%>W&F^._"5Y:Z7K">'M4N+/Q3I-S!I?B!YHH(]"U*>"]DAL-9DN)[
M>"/2[QHM0EFEAA2%Y752*OA7\.!S'G5G*2SI.Z:B]GES^)<KM;5--/7693QL
M-'C\.ELG_9]WI+E=Z?MXJ/*TU)JI*SNGJF?CM_PV5^S?_P!#SJ__`(;#XO\`
M_P`P-'_#97[-_P#T/6KC_NF'Q?\`_F`-?K]8_$OX=:U_8<.A_$#P9K-WXHCU
M.3PM%IGBW1-0?Q,FB2"/6Y/#Z6NH2OK<6C.2NKOIBW0TUPR7GDR*<>.Z'^U9
M\(KW7_"_@[Q%XHT[X?>.?&6F^.];\/\`@?Q[K7A_1/$M[H7P]\6GPAKFMJMO
MKNI:2+*YO##?:)`^J)J.JZ/*VHQV:MINM6FG6JM";:65YM7BE>36>4HJ/+=M
MN/\`9O/RI1DY5'[J2;?8EU<7&,9/,,(HSDH1<\)R<TFTHP7[QI3;]WD4I/F=
MKO8_./\`X;(_9P_Z'S5__#7_`!?_`/G?BE_X;*_9P`Q_PG>K8/I\,/C"/S_X
MH'^7-?I'X*_:D^$GQ&3X>:O\/_$,'C;P1\1+'QI>VGQ!\.:AI$WA'PVO@C3;
M'4M2A\97-[K%CJ^@W%W!?(VG1'1[EE2":XU1=)LIK.YN?:8O'O@2>QUW5+;Q
MUX6GTOPO+<P^)=0M_%.ES:?X<FL[>.ZNX=?O(;U[;1I+6TEBNKE-0EMV@MW6
M>0+$Y83.MA82<?[,S2C*+2DWG=-NZDHN+2RY-.]]UOINU>X/&SBI1QV&<&E)
M2I8#VJDK1E=7K4U:S3NF]--.OXY?\-D?LW#_`)GO5_\`PV/QB/\`[H%?.WQI
M_:T^`>J?$G]E.]LO&FHS6GASXW>(=5UB0_#KXJ6\EOITOP9^)&G1RQ07?@BV
MFO9)+^]MX%M]/6YN$`>XEC%FKSK_`$/>&?&'@_QM8MJ?@OQCX?\`&&F)/+:O
MJ?A;Q'8>(+!+F)$DFM7O=(N[JV6XBCDCDDA,@E1'5F0!T-?*W[3@Q\:OV%(U
M>7:_[2/B;>=S%F'_``SK\:AC=R=H_P!GGZUTX/$X%5YTZV"QS4L'F5-JIF\9
M6>(RG&X.3Y7E\4G&&*G.-[^]&-U:]\L0L>Z,90QM&2=6@TWESA%Q]M!-QE&O
M5YK7[)=WH?"9_;*_9P/S?\)YJW/)*_"_XP;<8YX'@!@`!Q@$\]`34[?MJ?L[
MLJ1M\0-<,:%-B?\`"L_C"$4H-J[47P$$Z;@?,#L2[D%2XK]LUBD9%(>8@@8S
M+)R#^/\`^NEV')&]MV3G+2^GUY/O7+]<PK;DL)BWS>]9YNI)<W+HDL#%I:\K
MNWI\SMA'&7ESXJC/73GR_DMKK9JO._9Z1LK/R7XEO^VI^SRQ!/Q$U_(9SD?#
M7XPC+21F-P2O@$$B0<L&X9415VH2K1Q_MG?LZ1;/*^(&M1B,8C5?AG\8T1!D
MMM1%\!!%&\^:45$`DP1^[147]N3&V3^]FZG_`):RX[=L_EU_Q3RV_P">LW_?
MR:G'&X7[6`K5-M'FE[?#=I+";^NVG;3)4L73;<<72A=K_F6:22<>OUOWEO?N
MK;'XCC]M#]G3<'/Q`UUB=^2?AI\8QE9-V]3L\!`.'!RZN'#GF0%@_F./[:?[
M.Y38?B#KFT9"Y^&?QB^0$<B-?^$""1J6Q(5C6(AXP6)K]M=IS@32YQG'FS=.
M@/TS2[&Z^;+QP?WLO^-2\?EK5YX&O*SM%RSF4+.ZT]W!J]W;>]K)*S=S7EQ?
M6O0V3_Y%3V?+K_OG]?<?B3_PVE^SKY8A/C_7&A!4^6?AG\8MIVN)%W8\`C)#
MJD@<!6,@#L3(S4?\-I?LZ^:DW_"?ZZ)4&P/_`,*T^,B93G*LT?@19/+P74C>
M`$<H!L)K]MO+;_GK-_W\FH\MO^>LW_?R:J>.P2T>6U%=+?-'K>VO^Z*^EUK?
M\R?]J>V(P^RVRO;X5I?&;I^7X6M^(9_;+_9P)9F\>:TS.=SL_P`,?C`S,S'Y
MF+-X!+$L0Q)8Y)(`/>OGGQ)^UE\`KC]JWX0>(8O&FI/H^E_`CXYZ9?W+?#OX
MIQ307VK>-/@M<Z?!'82>"!?W2SP:3J+27%O:M;6C01PW%Q%+=V\<G](6QAR9
M)B!R09)<'V.>/SXKXU\8*6_;Z^`8#R#'[+G[2^6#$9;_`(63^S6`O).U@&4-
MMPYVIGY405T8#%9<I8RE++J_[W+<<[K-7>-L%B*6O^Q-)<F(J2N[>]"+NH^T
M.7%+'QCA;8RD_P#A1PDK2R]P>D:T7RI5JCD[33^**O9.W-S+X07]LW]G%&5H
M_'NM1LK!E>/X9?&%&)"L%R5\`+]U2Z(5P\:RR;&022`RM^VI^SNX!?X@ZX[8
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MS9TJ5^:*3J+_`&&4E.#LU)22BU%NS2:SGAL16AR5ZV'KJ/O+VF5<RBVHV=GB
MFG;5M/1VU5C\.=+_`&O/V8=$L+#2M(\87^FZ;I5C::;I5A8_"GXN6MGINGZ?
M!':V-C901?#U$MK6RMH(K:VAB14A@C2*-?E!72'[:G[/(F6X_P"%AZZ94$FP
MGX:?&-A&)3\ZQK+X#E$:D;B&0Y!>1F+N[$?MIY;?\]9O^_DU'EM_SUF_[^35
MG]?PGVL!6J+5R=7-8N4]4XN<HX*',X2E*49-7NWS-I66BACY7DL="\FN=K+&
MTY6@M$\9:*244HK1*.FA^(Q_;-_9T8NW_"P-<#R`AW'PT^,.YD."T;`^`""C
M84O&%5'VHC(RJHI5_;/_`&=48L/B'KQR(U?/PV^,;;DC=G2([_`;-Y0)SL#*
MK`DL"PW#]N/+;_GK-_W\FH\MO^>LW_?V6E''X-J,Z>75(M.,H5(9HW:47%II
M_5'>S2:L]U9WLV0X8S6-3&TI1DG&4)Y7I*,TE*+7UO:2;3]/2WX"_##X]_L;
M_!OP9;_#SX;>(=9\->#K36/$.OV^BIX!^.>I10ZOXKUF[\0Z_?QSZQX,U"[+
M7^L7U[>&-YFAMI+AEM8HE$:IZ++^VG^SM,L:2?$'6F2-51$_X5C\8`BH!@;5
M'@'!V]B<D#+@J78U^VWE/_SUE_[_`$G^-)Y;?\]9O^_DM7]?PTI5*L\OK5*M
M>7-7JO-'S57[MN:V$W7*O_`>FME&GBHJ%.EC*-.$(QA3I0RSW8Q25HJ^+Z:_
MCMI;\3?^&U?V=VP&^(.MMA`FUOAI\8@FU3N1%1?`2)%L9B8S'L9"[YW%S4$G
M[9O[.3F4GX@Z]FX_UV/AK\9#O.00SA_`;;L-AT63=$LBKB+Y>?VZ$4A&1)-_
MW]E_QI?)D_YZ3?\`?V7_`!J/KV"_Z%M3I_S-7_=[X7U^_7K;2-/')J^,I26F
MCRO1WY=[8OSOI;7RT/Q&/[:/[.K*4;X@ZZT9"`HWPR^,)0>7Q'M0^`0FV+)6
M*,H(X@2$BPI->4?'+]K[]GO5/@E\9M*T[QOJ<U_JOPG^(EA9P2?#?XL6JS7E
MWX2U:VM(OM-UX$@M(%EN)H4:>\N(+>),R3R(I+K_`$(>3)_STF_[^R_XUX'^
MU2IB_9F_:(8O*7'P*^+A4L[L!CP#KQ!`)(R&QU!'J#FM<%C,!3Q^"JO+:WN8
MW!5DHYKO+#XFA7C'_<V[2E247H]&[6EMCBECHT*\EC*45[*5E++N6*7(GK+Z
MQ-JRW]UWZ6V/R+^''[87[.UG\./AW877CK5$NK'P%X+L[N-/AI\6Y42ZMO#.
ME07*I-!X%F@F03(XCGA=HI$VO$[(R,_9_P##9'[-_;QWJ_\`X;'XQ?\`S`U^
ML_P,#-\%?A`QEERWPM^'9($D@&YO!^CDD!0!\S98^YSZUZIY;?\`/2;_`+^R
M_P"-83Q&"IR=..%Q\84W[.*6<QBE&G:"]W^SG9M1YGK;F;M9%0CCW"$OKU/X
M(*\<MYXZ1BM)_6XIJZLK);;'XA_\-D_LX_\`0]:M_P"&O^,'_P`P5+_PV3^S
MA_T/>J_^&O\`C#_\P-?MWY;?\]9O^_DU'EM_SUF_[^34OK>!MIA<<I.UY+/(
MW?PZ:Y?;73\-M;5R8_\`Z#8?^&K_`._/-?>?B+_PV3^S?_T/>K?^&P^,'_SO
MZ3_ALC]F_P#Z'S5__#7_`!?_`/G?5^W?EM_SUF_[^34>6W_/6;_OY-0L5E^E
M\%C6]+O^W%J[QUM_9_I^'F')C_\`H-A_X:D^J[XQ^7W^9^(G_#9'[.'_`$/F
MK_\`AK_B_P#_`#OQ_,?6D_X;)_9Q_P"AZU;_`,-?\8!^H\!''Y&OV\\MO^>L
MW_?R:@HW>68?]M9A_6E]:P/V,'CHO359VG?163OESTW_``ZW&H8]NWUV+>G_
M`#*O3HL7\]NI^(4G[97[-X1]OCS50WEO@M\+_C"`3Y;<G'@`E21G`[OB/!W#
M/SQ^R1^U?\`_#G[-'P6T+6O&6JVNJZ5X+AM+^UC^'?Q3OTM[A-3U)R@O=-\$
M75A<C9(I$MO/+&VXDLDNY!_1[<+NBD!>4@1.<!Y-Q<1M\QW$@K@G(?E6`)^?
M%?'W_!/@2#]BS]G+:SX'PZM`"7?.U=2U)1G:0.%"Y]#WZ5VQQN6_V?7<<)C(
MR>,R]N4<YBI24,-C8.\I9?*_-N_=5Y7\SDJK,7C:7^UTM,)7FW'+G4DW4KX9
M23BJ\>6WLXZ*3:NU:2UC\&?\-E?LW_\`0]:O_P"&P^,']/`-'_#9'[-W_0]Z
MO_X;'XQ?_,!7[=['/628>WFRX_#FCRV_YZS?]_)JXEB\&_\`F'S#I_S.X?W?
M^I<N[^]=#J4,?97QL;M+_F5>2_ZC//\`'T/Q$_X;(_9N_P"A[U?_`,-C\8O_
M`)@*/^&R/V;O^A[U?_PV/QB_^8"OV[\MO^>LW_?R:CRV_P">LW_?R:A8O!_]
M`^/Z?\SN.OP_]2_S_+S#DQ__`$&P_P##5_\`?GFOO/Q%_P"&R?V;_P#H>]6_
M\-A\8/\`YW])_P`-D?LW_P#0^:O_`.&P^,']/A_7[=^6W_/6;_OY-1Y;?\]9
MO^_DU/ZUE_\`T!8V[MK_`&Y'^[_U+U?5WU[KI<.3'_\`0='_`,-2\O\`J+]/
MO\S\1/\`ALC]F[_H>]7_`/#8_&+^O@"C_ALC]F__`*'S5_\`PV'Q?_\`G?5^
MW?EM_P`]9O\`OY-1Y;_\])C[&2;!]CSTH^MX&WOX3'2V:;SR-TO=O;_A.\]/
ME\CDQ_\`T&Q_\-2?9_\`06_+;OYG\[?[2?[6O[/VN_LY_M`:'I?C35+G4]9^
M"7Q6TK3;>3X<?%:S2YO]1\"Z]:6<#7=[X&M[*U66XFCC:YO)X+:!6,MQ-'$C
MNOH7@K]L3]G6V\&>#;6X\=:JD]OX0\+V\L:?#/XN2".:WT#3(9D:6/P$\<A6
M1'`>*21)%9&5VRIK]2?VU1*/V-?VM22Q'_#,OQY)S+)C`^%?BL_WL@^X((//
M&*]<^%8/_"LOAV-T@_XH7P@.6?<2?#FF$-G.>"6YR2#TS76\;EKR^@WA,7.4
M<;C+2GG,9N/M,%0C>+6`C9)QNFU+6U[*.O+168_7:C^N4FGA:3][+7!\U*O.
M44H^VFFGSN]YQNURJVY^0/\`PV1^S=_T/>K_`/AL?C%_\P%'_#9'[-W_`$/>
MK_\`AL?C%_\`,!7[=^6W_/6;_OY-1Y;?\]9O^_DU<?UO!O?#8][;YW&W1=<N
M^[MH=?L\>M\;'_PU?_?GFOO/Q%_X;)_9O_Z'O5O_``V'QA_^8"D_X;(_9N_Z
M'O5__#8_&+_Y@*_;ORV_YZS?]_)J/+;_`)ZS?]_)J?UO!*W+A<=%::+/(_W?
M^I?YW];?)<F/_P"@V+V_YE2\NV,]/O/Q$_X;(_9N_P"A[U?_`,-C\8OZ^`*/
M^&ROV</^AZU?_P`-A\7_`/Y@:_;ORV_YZS?]_):0I)_#)+D<\RRX^G)ZTOK>
M$_Y\9ATVSR']W_J7^>GR[,'''I-_78?^&J_;I]<UWVTW6MC\1/\`ALG]G`?\
MSWJQS_U3#XP<?]]>`"!^`/\`*O`_@]^UE^S]IGQ"_:>O+SQIJD-MKWQFT;5-
M*E3X=_%2Y%U9)\(?AQIDDLD5MX'DN+"9;ZPNH3:7T-O<`1><JO:S6DLO]&K!
MP,M(^,X#;I#@GIC)XSZG_P#5\C_LWEW^+_[;:&24"/\`:*\/A`'<8!_9_P#@
MYG!'/H<>GMLKLH8S+_JN8*6#Q<JCHX2U1YQ%SCR8V-E&?U%+7F=M'HGLCFJ_
MVC[?+_\`:Z-O;8U-_P!G.,ES8-)6A[:5]8I:U8WOO?W7^?\`_P`-D?LW?]#W
MJ_\`X;'XQ?\`S`4?\-D?LW?]#WJ__AL?C%_\P%?MWY;_`//6;_O[-1L;C,LW
M/'^MF'7T/]>W6N+ZY@;I2P^.:TO%YY"SOR[_`/"=YO[U<ZN3'O;&Q?\`W2O_
M`+\/Q%/[9/[-^#CQWJW_`(:_XP?_`#`4S_ALG]G'OX\U?'?_`(M?\7Q_+P#G
M\J_8KP9\0O`7Q$TR\UGP#XY\-^--*T[5]1T#4M0\+^(+36[73-=TB]DT[5=%
MU*73[FY73M5TZ^@EM+W3KSR+NWN(VBEB0@+79;3@'SI>1D8FD.1^>.?_`-=4
M\5@HSE2^JX^G-;TO[;BI)76\7ERDO62M?KT)C'&RBIK'TG%I-265IQ:=DFI+
M%\LD]7H_S1^(O_#9'[-W_0]ZO_X;'XQ?_,!1_P`-D?LW]O'>K_\`AL?C%_\`
M,#7[>+$[<B2;_O[)_0FE\F3_`)Z3?]_9?\:%BL%?7"X^2V:>=QM>Z_ZER=XN
M_7\KJO9X_P#Z#J?3_F5]^7_J+\_P/Q!_X;*_9Q_Z'K5O_#7_`!@_^8*O`OBM
M^UG^S[J'Q;_94U*U\::K+:>'_B7\2=0U>9OAY\5+=[6TO_@/\1M&M9(K>Y\#
M)=7[37]_;6QAT^*:>+S/M=S''9075Q#_`$=^3)_STF_[^R#]2<#\:^/_`-H"
M(C]HG]A`,)9#_P`+D^+_`"9)&/'[+OQI8#.[IE>`V<#S,=*Z<)C\%1K.;P6,
MG#V&(CR3SE3A[]"<-E@%*ZYKQ=VDTKK=/FQ5/,'2LL;2UG0>N6\JTK4IK7ZQ
M4L[I)+D?-JM/BC\!?\-E?LWD_P#(]ZOSC_FF'Q?Z'.#QX`/)Z'GKSUS1_P`-
MD?LW]O'>KY[?\6Q^,)_GX`Q^=?M[Y3G[IF0>@=U`/?@']>^/S/)D_P">DW_?
MV7_&N.&)P2C",<+CE",(0BHYU%)1BHQ5D\O=M%MLO1:=3CCYMR^NTDYRE)I9
M9=)SDG9/ZU&\5S:/ECHOF?B`/VR?V<<C_BO-7_\`#7_%_P#IX!S^5/\`^&RO
MV<>_CS5L=_\`BU_QA_KX!Q^=?MYY,G_/2;_O[+_C1Y,G_/2;_O[+_C5K%8-V
MYL+CY+3W7G<;=/\`J7_=Z:[.R]GC_P#H.IZV_P"97WY?^HOS_/OI^(/_``V7
M^S=_T/>K?^&Q^+__`,P-._X;)_9O_P"A[U;_`,-A\8?_`)@*_;SR9/\`GI-_
MW]E_QH\F3_GI-_W]E_QH^LX)OWL)CI1Z1>=QTVV?]GWT\_GU#V>/_P"@ZGK;
M_F5]^7_J+\_S[Z?B%_PV1^S</^9[U?\`\-C\8C_[H%</\3OVP?V<[[X9_$FR
MB\=ZN9[SX>^-[6W4_#+XM1K+<3^%]5BBC>:;P$L4*22.J&>1E2%B))6$*O7[
MZ^3)_P`])O\`O[+_`(UY;\;U9?@K\8.6)'PM^(6%;>V3_P`(AK/WLDYSZ'J!
MC@5MA<7@8XS!SE@\7-4\;@ZD8U,X4E>->F^56P$;-[*[?9J^AC7IXYT,0GCJ
M*O0JJ\LNY$N:F];O$3O:ZTTOO?0_`3SX_P#GL/\`Q_\`^)HHWO\`W1_WQ17V
M7/2_D73_`)B/\/\`T[\G_25_+4:NG[^GT[?W/\_S[Z?L9^PY_P`DR^)@]?VI
M?VKO_5\^-OKZ^E8O[7'[.OC+X_?$']F@^'O%7Q!^'V@>!O%?Q1U3Q;\0?A9X
MRL/!?CCPG#X@^%NN^'?#]SI-[=07MQ>PWVOW=I97UA::=>))!*7OUCL4ED&U
M^PW_`,DS^)?_`&=+^U=_ZOKQM7V5+D`8]&P/4XX_KTQ7Q&,Q%7"9ECJ]&2C4
MA6Q$4W!S]VK2]E4BH+63E3G**6OO--IK0]R%"GB,)3I54W!QIR:4G&[I3C5C
M[RU7O06JZ7/YZO'/["O[0NO>%/@AHWB?X7>)=:T+P1\#OB3^SYX@\#_![Q1^
MSO'=1^*+[XD7%VOQRBNOVB=(\=Z1:6/QL\,)!XG\5:YX6U73/BSX4\0N(KJW
MUAKETT[VSXB_LN_M%K:_$.QT+X=S>+?#?BK]H7P!XCU)DN/@)XL^*FI>`/#W
M[)_P]^%T'B'PO??';2M:^&%IK*_$?PU>Z;XZU/Q!X;3Q#>>%CJNI>%M(F?4(
M(;KV;XP_MG_'_P"'WQ!^.6F>#O@IX!\<>`/@/X[^`'@K7[W5?B3?>%/&7BN^
M_:$M?!EGHEGX7L#X8U71-/F\*Z[XUT^YU[5/$6HP6-YH6(M*M;G4X+P)V'@C
M]K7XIW7CCPW\+/B3\/\`P1H7CIOVF_$G[/'C&]\'^*-7UWPC!!9_LZ7W[0WA
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MKI\>>.6_9MLOA9X2\2_!W6/MD/QI\`ZYXK\1V>GZ9X\\*^+Y(_AK'HZZKK]F
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M+*$.>:<8M/F<_>32:BDEPE]^Q%XYN=)^*'B:[^%'A:;XN7%W_P`$_'^&'BZX
MN_"DOB;1;7X`V7PI7XC'0_$4UZ]SX6;0+C1/%\`>VN]/?Q)&9(;0ZE:7EO&?
MFG]EFV\-^)_VN[N]UB[T^W\:^+O''[9/ASX4^*?AYK'P9U+XJ?"O4/$WC7Q)
MJ_B7QG\2?"5YX*E^,&CQOI/A6STGP1??%VZU[2/#&JZAIN@?V#=:1K^D&S^N
M?$7[77Q/@^)O@&Q^+&F6?@O4_@5\9?CSX=^->@_"SQ'J>N^"/B'X4\-?L;^*
M/CQX5N-)?6=/T'5KN-+:YTRY?0O$-E!-IWBO1A=K*]E+82-ZO^QC^T_KOQ_\
M3>+;WQ-\"[;X;7NH^!?"7Q%TKQUI'@/XJ^';#5=,\17,T9\`^*/$_P`4_A5\
M-9O$_C?PU'#I&J7FI>#I/$/A#5M.OH[W3+J&*S*W.->MF%+#8A8FA"2J483?
M+&$)4:3HPI4E&=U"//34)+I4@W)74Y2C<:.7XK'8*&'Q,U.,]54C77M:JE[3
MFFKPORKF3LTU+D2E:G9Q:U^Q[XTUGXT^*?%&MZ[JWQ$U:U_8\UGX3_#']H+X
MEVGP_N_'7A;XK^(/'7C+65UJUL/!^@>%[+0M2\/Z=J/AZYL_$/AWPCI4PL[3
M[)'?G4#<K<?#/@C_`()]_$V/X0>)O!6N_"7Q]9>*-2M/V3/!/B[0/&7C+]FF
M+X;^/M#^%?QX\'^-?'FJ>%--^"OAGP?=:A8VWA_3_%%];>)_BP\?Q`U_3-8;
MPY+I;Z@]P9ONOQW^W/XJ^&?Q'^/.B^,O!7AC0?"'PA\">-/&7A'1-5U/Q5H_
MQ7^,^G^#?">D^)KGQ9\.GU?PI;_"OQ'X1N+G49O#^JV6B^-]1\6^"I[:/5?%
M&CVMA)]FDY#XI?'WX^?"WQA\`_'OQ\T_PEX0TC2M%_:<^(?BOPG\%/&'B3Q3
MHWBSP=\/?V>;OQY8Z5KX\2^'_#/VWQ!X:UFTO#IC007^CW-Y!!J=G+;;Y8%F
ME4S&FE3<:,&Z=.4'&$7SJAAJ?)&,M5-3A&,I6YGS7EM<Z*E+*)QG5<ZM:G2E
M6C.U25J<JV(E6FZD7K#EJ2E&\VFDDFV]3G)/V$I/#WC_`,?^-_`GP0\"^']6
MD_;T_9^^+_@'7=%M?"&D:CHOP8\*Z!\*[#XC7/AQ[2ZMY/#-K=7=G\33J7A?
M3QI=WXB?6M5F?2=4.JPM<L^$7[*'Q"\"_$C]FWQ7XV^`'A?QQ8:':_M<>!O&
MUV\GPSU/5_A];?%[]H>?XE_#GQQ.NOWD;ZUX<7PB-3M+[3_"UYJ?BO1;KQ$=
M/CT*X@O-;FC;X3_X*+?'?Q#X-U#4I?V<[5?$^I^+?V?M"\`2:G;?&?X<>`M5
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MB+08[!QXCM--TZVL;R[X_P#:?_9_F_9]^&EW>>&?`/@+X<>"O$_PI_84^%^H
MD3^!?#O@BY^+O@3XX^(]8\0W/CV36;;4/!/D:7H5[IL6I>,?B?I.I^#?$-I<
M/HFJ7FJ3O:0K]'_$;]LCXD:GX5_:#T3Q?H6F_#75?AQXU\!66B>"="\8>._!
M'QUA\+S_`+0OAKX?6WC;5;W5O`MEX<U?P)XRTZYMM9TSQ)\+]1\7^'+K3-0N
M?`^OW]MJE[<S6?TM\(OCYXC^+_QN^,?P.^)_@?P/X/TSPM<>)[?P]X&\07/B
M9/B7XL\,:!XDBT.W\?WWASQ)X2L/!7B[X<>,;2XM=5T_7/A]XD\4V7A^ZO;/
M0?$ZV^MW++9W'%X^G-5JM&E*G"52K4A*'/&\JOMI2<KWE&-2K=:N+C..][FD
M\/@,3"G##XB<*CC##TZG--;1A%4N2FTH3Y*=I1<>>,5)-<RNN)_X)F#P9!\!
M=<T_PAHMGI]UIWQ@^)G_``G.M:%>^`-6\#^,?'VM:C:>)?$GB7X<:U\+M.T?
MP+J'@B2?6X='TNVT'3+2WT"YTB^\-SI+>:1-=3^D_M._\EM_80_[.2\3?^LZ
M?&BOKW2M#TS1+*VTW1=-LM*TVR@^S6&G:;;06&GVEL6W>5:6-I'%:6T6]F?R
M[>&)`S'Y<$&OD']ISCXV_L'C_JY'Q,/_`#73XT9KRZ5=5\94JVDG4I8N;NFH
MZX:7PM].O7?RL>Q&C[#!TJ3=W3G1AN_>2KP?-J[[Z)M7M:]W=O[7B_U2?[HK
M\U_B]^T!^U?\//VC;/X:V5K^SI_PK35_AS\5/C/9Z[JND_%*Z\6Z;\/_`(1Z
MOX'M?$6D7]O8:Y;:3?\`C#4=/\7RSZ;+9+:Z3%-IXCN4<7`"_I1%_JD_W!_+
M\?Y&OESXI_LZ#XF_$RP^(EQXGO-+?3/@C\9O@G%I=KIMI<Q2Z=\9KOPK/?>(
MFN9KN%DO?#W_``B5LMI8;'BOX[N=KB>)D0/EA)T(U(?6:=&I1E0G!^UH2K.$
MI^RA&=-1VG#F<ES)Q=KR4H1E&5XR%:<$Z-2=.4*U.I+DMS5(0FG*D[W]VI%2
MC*WO:KE<7J?/R_\`!0#PI>VWA[XG#3O'/A#X-7_[/GQH^/9LO'/PGU+2O&_B
MOP1\,[;X7Z[;^/\`PE*?%:);>&SH?CA[:'1-;T&#6?$][<_;K"YTC3M()U4D
M_P""E7PIM;S4[34_AS^T'H(T"X\(7GBZYUWX+ZYI]CX*^'WQ!NET_P`#?&;Q
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M+EP]:I[R5W#]]3I0C=)M3:7-+E<5?]N;X.6GQBNOA!?7'B>"?3_$&N^`KSQ\
MOAR*;X;2?$SPWX?NO%>N_#VT\01ZH^M3>)M*T+3M2FN(SX8_L.?4+>71+;76
MUZ+^R9?)O$7_``43MH?AA\-/BM\._P!GSX^^.?#/Q,^+G@7X>:#GP7I6C7NO
M>&_'$%Q?Z7X]\'07'BF6SU[3]6M8UM?#^FWNIZ1J$NK,=/\`$T?ABXCV/K^'
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M[K>_M6^'C\8M%^`.I>'/BMX'\5>-_P"T-'\&^,M7\%:3;>#]4\21^%M0\6?V
M3H^JZAJM_<3ZOIN@:9JVIPWFH>%&\&:M=:'?V&FZYJ=PB6,WAMW\3?VTM&T0
MV-CH^L^*]8U_X8^&9+#6[OX:Z7%)X*^)2Q^)/%/BR?5K+24TRPOM,N/#NEKX
M4TG1VMYKJR\7R^'[>YFN6UB0RS:/_P`$[[73/VH;']I:;Q_9:AJFG?%76?BS
M%87/PJ\%'QG?:SXE^'][\/M7\,:K\8Y+N;QU<_#.PM;^YU7P?X"MULM,\,S&
MVLG?6+2QTY+#]*UL+8<B,CG.[S'))QM+9+<$J`"0<[>.M9U:F#H*,:,(XCGI
MP<I.-5<DV[-:ROHFFU:UFE:]TM</3Q==2GB95*/+5:HPC*GS2IQ<;.JHQTE+
M=;;Z+2XV*3SHB^"`0&Q@KM)`.#G:3M.Y>=QW#J0*^./%O_)_?P"_[-?_`&F/
M_5D?LSU]H>6D:2;01N!8C)(S@`8!S@#'0?4U\7^+?^3^_@%_V:_^TQ_ZLC]F
M>HP/\?%_]BK,O_5=CSIQ/Q83_L)A_P"ETS[6HHHKF.DCE;9&S8SC'&0,C/(R
M?4<?C7Y_^*_C[^TQXQ\>_&S2_P!F_P`"_![5O"?[/^JP>$O$$WQ8UWQ?I6L_
M$KQ_!X0T?QUKOA3P5/X7TVXTWP?IVEZ/XCT#25\7^)UUV&]\07]U&/#MMIFD
MO?ZC^@$L8DC:,[@&ZE6*L.<Y##!!]".0<$<\U\+^-?V3OB1-X]^*OB/X,_M$
M^(?@UX8^.]Q9:G\5?"]K\/O"?C*Z'B&W\+:;X*O_`!;\-?$FM7UG<>`O$VM^
M&=&TFTU*?4=-\9Z.NI:98:Y8:#9ZC)J<E_K0]ES5?;*%G&"IN2;C&]1>V<N7
MWM::M'E3UW3Z<>+^M7H/#Q<HJI)UN2I"G524?W?+[1\DH.;]^-N:RO%Z,Y_P
M;_P4"\"^-UT"#PU\-OCAXHU74?@[\.OCAK]EX/\`APWBBU\'^$?B=H.MZSX<
MT[7M4LM5M;9O$4M[X=U?PRFEV"7=[)J]LMZ]G!H`O-5T_/TO]N`?$/Q3\`M+
M^'6BZMHD?C;]I'Q!\#/BQX8^(_AV#3_&?A"72O@3XU^+UC#;?V!XDUOP\+K4
M[?2_"NIVNM66KZ_I%WH&J30*+?4]RV5S5/V!?"TO@'XR_#7PUXMU[PGX8^*_
MP3^"'P1L8;&VM;Z;P=X>^!MAXGL_#\RRW5_YGB>+7X]?6V\8:/J(M+/6]+AO
M-/FN)?[9O)(L#X+_`/!//3OA%KOA/Q!%XUTF6[\._M#7W[0\FD^"OA-X*^%O
M@G^U[_X$ZA\"9?">@^#_``G>G3O#.@QZ=?\`_"3)<1?VGJ]SJD=PFJWU_-?2
M7L?<XY+:I.FII6<:$'"IS.7L8->TNE%+VKE'H^6"UM),XHO-IJA"5)1J-.6(
MJ*K2A3BHSO&-*]DY2BOM7?O6=K'KGQW_`&V?A1^SUXNT[P=XTB\6ZAJ"^'(/
M&OC";PIX>M=:T_X;>`;K5+G1[;QUX]N9M9TN;3M`FOK#4ML>A6GB37FM=,U;
M4DT!]-TRZN4XKQE^WAH6DZ+^T?J/@7X8_%CXER?LX>'?'%_KFK>'O"MI'X!U
M[Q9X+LM/O=4\$Z?XKGUO[5;:EI46JV]]JUYJ6BV-G+HMMK&K>&9/$RZ6]M<1
M?M$?L'Z!\</C%IOQJMM1\#6'BAO!6D?#[Q-;_$3X#?#+XY6%_P"'_#^O:EX@
MTC4O!R?$`QOX`\7V5SK>LV@UFT?5=(O[.YLFU3PWJ%SIMI.D.I?L,3^)OBM\
M4OB9XK^(R&U^)?PJ^(WP?;0O!OPW\)^`];_X1;XBZ;IVD@?$3QEH][<O\6;G
MP'IVG):_#B?7O#^FW'A^*XN!=3ZK+*SOE3I9=[.A%IJT:?.I.:NN:'-!1AR\
MC4'4]Z3Y5=?:4D[G5S*-3$2A1<J;K6ITXU**=.C*#7M$ZD9^T<9.ZA%+EDFK
M.+N2P_MV:?>Q^&/#S?"WXS>&OB5XP^"UW\:/^$:U?X:IJ-G\._!S3:_I$7BS
MXCWVG>*A8Z9H-EKVC(?LD&J'6];T>]T^72K'[9-J4>D4[7_@H1\.M#\.^!YO
M%5IXX\3N_P`,_@]XZ^+OQ(\!?#+4W^&/PC@^+NB:3J/A35OB+)<^(+_4O!]C
MXB74&U9=&LY/%^J^$_#CVVK>*9+726AUF\[GP5^RIXIT9M3U#QI\4#XV\2ZG
M^S3;?LV7^M1^"].\*65[H^G:YXGU+3O%+Z+8Z[JL<&J16'B6/3+G3X;S[)=R
M6,VH)+:G4&L[7R6X_P"">%W;Z!>>`_#WQR\4Z)\+O'GPY^#7PY^/'@J/PCX?
MO-1^*%G\&O".C^`[/4_#OBVZU%+[X97/C3PCH>F^'O&45C:>(%FT^TCET&30
MM9:;59M5')I)7]I3C>BI1Y*TU-2:=?E44W%0BY2I<W,I3C&G-KF5I<LW2I05
M.,FJ-3VDI5**<I)..'3DN5<\WRNO:7NKF<%\*7U+^S9\6_$_Q<M_C7/XGMM(
MMC\//VB/BG\*-`&CVUS;I/X<\$7FF6^DW5^;B[N_M&K3QWDK7UU;FWLYRL;V
MUK`H8'Z6KP[X(?!R#X-P?$NUM-7N-6@^(OQ<\<?%N87-I#:?V3?>.)[*:XT*
MU\FXG-U8Z4+%([:]F\F>Z$C/+!&RC/N-<%5455G]735#F_=J2<9<ME\2DVU*
M][W;[[:'I8=U71INNN6LXKVD4TTI]5%K>-_AOK:U]0KY\_:NC>3]FC]H5(Q\
MS?`OXMJ/8OX$UT!O3@G/:OH.O`/VJG,?[,_[0L@&[9\#OBRY'(RJ^`]=;;D<
MY8IQCD=L=:>':6)PS=K*O2;OM;G2::34FFGJHM2_E=[7C&<WU7$<J;E[*=E%
M)RO9VY5+W;WVYE*/>+V/P/\`#_\`P<;?LB_"31-$^%>N_!S]HC4-9^&^@Z#X
M%U6^TG2OAU-I=[J/A?1;#2+VYTZ2[\?6MR]E-<6DKVKW%O!.\962:&%FV+KG
M_@YX_8O_`.B'_M-?^"3X8?\`SR/Y5Q_A_P#X-OOV8/B[HNC?%36?CS^T%I>L
M?$G1-`\=ZIINDO\`#5M*L-0\5:+8:S=V.F&\\$W%X;&UFNV@MFO)IKAX5C,L
MLCAI6V_^(7G]D[_HX?\`:1_[Z^%?_P`PE?K%.CX-\D76Q_%4:SUK*CAE*BJK
M:=54G.LI."FYJ/,N9I>\W?7\\@O$QI-PR?EO>,9QPLFH)KV;E)2A>7)RN5DE
M?FMHM=7_`(B>/V+_`/HA_P"TU_X)/AC_`//'H_XB>/V+_P#HA_[37_@D^&/_
M`,\>LK_B%Y_9._Z.'_:1_P"^OA7_`/,)1_Q"\_LG?]'#_M(_]]?"O_YA*OV/
M@O\`]##B[I_S"0_N_P#3_P!?N\W>E'Q)T_<Y'T_Y=X?^[_T^\E?T9J_\1/'[
M%_\`T0_]IK_P2?#'_P">/1_Q$\?L7_\`1#_VFO\`P2?#'_YX]97_`!"\_LG?
M]'#_`+2/_?7PK_\`F$H_XA>?V3O^CA_VD?\`OKX5_P#S"4>Q\%_^AAQ=T_YA
M(?W?^G_K]WF[BCXDZ?N<CZ?\N\/_`'?^GWDK^C-7_B)X_8O_`.B'_M-?^"3X
M8?U^(]'_`!$[_L8<_P#%D/VFAQ_T!OA=Q^/_``LC^M97_$+S^R=_T</^TC_W
MU\*__F$H_P"(7G]D_P#Z.'_:1_/X5_\`S"4>Q\%[?\C#B[I_S"4]_=_Z?^OW
M>>IR^)?V89+'3I3PW]WO5_K7L7Y_^#G3]C&1&0?`_P#:9;?D$?V-\,AP00<9
M^(Q&>H^7J>A'6O"OV7?^#B/]D[X(?L^_"CX3>)_@_P#M"ZGX@\">%;?0]6O]
M#TGX=2Z3<W<=U=7#O827_C^SO)+<K<*%>:U@?(8^6$`9O7;C_@U__90CB=HO
MVA_VD1(N6;>WPL(*KR54#P&H4M@`/EQ&2&VL!BO$/V9/^#=']F7XZ?`3X6_%
MO7?CM\?](UGQYX8AUW4=+T<_#8:79W$MW=0-#8"^\%W=U]G58$*_:+J>4_,W
MF9<JNE.'@W+"XB"Q7%L*-/%X:,ZC@ZLY551Q#I<M-^PI4X5*<JKDVZLU**C&
M;BI-\W)XD+&+W<EC5^KR2<*>&Y9P=6#E*3<VU+F44TGR=5'1,^C/^(GG]B__
M`*(=^TW]?[$^&'_SR,_I2_\`$3Q^Q?\`]$/_`&FO_!)\,?\`YX]97_$+S^R=
M_P!'#_M(_P#?7PK_`/F$H_XA>?V3O^CA_P!I'_OKX5__`#"5G['P7_Z&'%W3
M_F$A_=_Z?^OW>;OTJ/B3_P`^LD[ZT\-_=>MJJ7KZ,U?^(GC]B_\`Z(?^TU_X
M)/AC_P#/'H_XB>/V+_\`HA_[37_@D^&/_P`\>LK_`(A>?V3O^CA_VD?^^OA7
M_P#,)1_Q"\_LG?\`1P_[2/\`WU\*_P#YA*/8^"__`$,.+NG_`#"0_N_]/_7[
MO-W%'Q)T_<Y'T_Y=X?\`N_\`3[R5_1FK_P`1/'[%_P#T0_\`::_\$GPQ_P#G
MCT?\1/'[%_\`T0_]IK_P2?#'_P">/65_Q"\_LG?]'#_M(_\`?7PK_P#F$H_X
MA>?V3O\`HX?]I'_OKX5__,)1['P7_P"AAQ=T_P"82']W_I_Z_=YNXH^).G[G
M(^G_`"[P_P#=_P"GWDK^C-7_`(B>/V+_`/HA_P"TU_X)/AC_`//'H_XB>/V+
M_P#HA_[37_@D^&/_`,\>LK_B%Y_9._Z.'_:1_P"^OA7_`/,)1_Q"\_LG?]'#
M_M(_]]?"O_YA*/8^"_\`T,.+NG_,)#^[_P!/_7[O-W.7Q)_Y]9)T_P"7>'_N
M_P#3[R7W,\W_`&@O^#C;]D7XM_`/XX?"G0O@U^T5IVN?$WX0_$KX>Z+J&K:1
M\-X]+L=6\:>#-:\-Z=>:E):?$*YNH]/M;S4H9[Q[>UN;A+=)&AMYI`L;=MX,
M_P"#ES]CCPWX1\*^'KOX*_M*3W.A>'-!T>YGM]&^&YAFN=+TJSL+B6+S?B)$
MXA>:W=H?-C1VC(:2*(Y1/-?CY_P;>?LO_"+X%?&OXKZ3\>_V@M3U?X7_``D^
M(_Q$TO3-5/PU_LO4=1\%>#]9\2V5EJ1LO!%O=_8+NYTR*VO/LES;W'V>23R)
MXI=KKVG@O_@V6_95\2^$O#6OWO[0?[14%WKGA[0]8GBM&^&*V\4NK:19:A+#
M$LO@21VBBEN'2)G.\QA0Q9LO5U(^#<,+1B\5Q;4HSQ<XJHH.E.%5T(.5X)UH
M3C&"NKNF^;1S46<_LO$CZVI^QR-OZORO]WAN:$5--37[V[M*UTVXW6JZG??\
M1._[&'_1#_VF?_!+\+__`)Y%)_Q$\?L7_P#1#_VFO_!)\,?_`)X]9`_X->?V
M3^W[1/[2)&>I/PLS^O@0?R_"G?\`$+S^R=_T</\`M(_]]?"O_P"82H]CX+_]
M##B[I_S"0_N_]/\`U^[S=^A1\2M.:GDDGIJZ>&7\O:JO*_H^R-7_`(B>/V+_
M`/HA_P"TU_X)/AC_`//'H_XB>/V+_P#HA_[37_@D^&/_`,\>LK_B%Y_9._Z.
M'_:1_P"^OA7_`/,)1_Q"\_LG?]'#_M(_]]?"O_YA*/8^"_\`T,.+NG_,)#^[
M_P!/_7[O-W%'Q)T_<Y'T_P"7>'_N_P#3[R5_1FK_`,1/'[%__1#_`-IK_P`$
MGPQ_^>/1_P`1/'[%_P#T0_\`::_\$GPQ_P#GCUE?\0O/[)W_`$</^TC_`-]?
M"O\`^82C_B%Y_9._Z.'_`&D?^^OA7_\`,)1['P7_`.AAQ=_X2P_N_P#3_P!?
MN\W<4?$G3]SD?3_EWA_[O_3[R5_1FK_Q$[_L8!O^2'_M-#GG_B2_##KC&3CX
ME`D#(X]1ZX->%?";_@XG_9*\`^._VA?$^J?!_P#:'O++XN_%+2O'F@VUAI'P
M\>XTW2[+X9>`_!$EIK'VGQ]:PQ:DVI>%;ZZ2*PEU&V^P3VCO="X:6WB]=/\`
MP:]?LG*"6_:(_:1;CIN^%@^O"^!.?R]NXKQ#X5?\&YG[,?Q`\>?M`^%;WX\?
M'^ST_P"$'Q-TCP+HT]D?AN+O4K2^^&G@3QQ/=ZNUUX+FB:]BO_%=W81FRCM;
M9K*UM9#";EKAWNE#P92QE.&-XK:>'PTISG1G%Q_VR/P4XOV4I-+:=9WU;5TF
M<M6GXD/$864H9)%TYU72CR87]Y*=#DFFG4;?)"[]VSO>[:LCZ'/_``<\_L8#
M/_%C_P!IL8'7^Q?AA_,?$C/3Z4#_`(.>?V,MZ9^"'[307=RPT7X:,P'0G8OQ
M&&3@\#>/J#S65_Q"\_LG?]'#_M(_G\*__F#J-O\`@U[_`&3@5_XR(_:2P6`.
M#\+!C)QR3X#ZGH.#UZ$\'.5/P5C";>-XMG+V<^1/#**]HX6IWE"=644I\MW[
M.5TG>R;<=YKQ-4;PADMHN,N10PD5)1E"3BY.H[72:;WM?E:>I_*1HO[8_P`:
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M`!^=1N"8=0'P1^$VJ/;Z;"QR\=CXV^)?[J]O]J%$N;7P/8V*!C(EOXCN%/FR
M?I?'T/#.IE\:F?NE''1I8=9?++ZCEG]3#K!TI4&Z%.E1HRFVH2G+&5G%)2:B
MII4CX;A3_7>&,JPR>TJ,:\J>)ABI*GEU&7/*+7+*E5?(I72EATF]7S).4C^J
M+X2?&7X4?'7P=IWQ`^#?Q$\'?$SP9JD:/:>(_!6OZ?XATQI&17>UN)K":5K*
M]AW8GL+Y+:^MV^2YMX7!4^GUX[\$O@-\'_V=?!5G\.O@E\-/!GPM\&6+"6/0
M?!>B6FCVES=E%CEU'4YH0U]K6K7`15N=7UBXO=3N=N9[R8D;?8J_EBHZ+J3>
M'56-!SE[%5U!5_9\SY'55.4H*HXV<U&37,WML?T#0]JZ5-U_9>V<(^V]CSNE
M[112G[-U(QFX<R?*Y*]O*P5\>_M!?\G$_L(_]ED^+W_K+7QKK["KX]_:"_Y.
M)_81_P"RR?%[_P!9:^-=51_B?]N5?_34PK?P_P#M^E_Z=@?7Z=#]?Z"GTQ.A
M^O\`04^N6A_"AZ/\V:A1116H!1110`5Y+\<O^2+_`!B_[)?\0_\`U#]8KUJO
M)?CE_P`D7^,7_9+_`(A_^H?K%53_`(^&_P"PK#?^GH&6(_W;$_\`7BK_`.DL
M_`&BBBOMCY0_6S]B?Q/X;TWX<_$^TU'Q#H6GW47[4O[51>VO=6T^VG17^.WC
M212T4URCJKJRLA*@,C*Z?(RU]A/XU\&$<>+?#&1_U']*Z?\`@77YC?LQ?LD?
MLK_$OPI\6/&7Q)_9Z^#_`(W\4:E^U)^U&FH^(O$_@#P]K.L7L=C\;_&EK9_;
M+^\LI+B1;6TB2WMS*["""..)-BJ0?4/`_P"S'_P3%^)=QK]I\-_@Q^R!\0+K
MPI?-I?B>U\$^&_AIXJN/#NI)(\#V.MP:']OFTNZ6:*2(Q7B1-YD4D('FHZ#Y
MO'2P$L9C)RECHM5Y>T4,/0G"$VJ;:<IXJD[I3B[.,6E):;7]G#5<P]C02IX)
MN5*,K3JXBG+>S:A##5DHWO;WY>=D>_:W\+_V<?$5U\0KS6/^$7N[CXJ>)?AM
MXP\=RGQO/"=<\1?"*;P[/\/M1VV^OQIIYT"7PIH+"VTU;2UU`V`&IP7RW%V)
M^?\`&WP)_9<^(*>(_P#A(_[)^V^*/B5HWQAU'7-!^*7B'PEXEM?B3H/A+2_`
MFF>*_#_B?PMXMT?7_"U]'X.T>S\-W4/AS4-,L[_2I+^VO[6=-3U#[7AK^P5^
MPU(R[?V3?V?V9QE0/A5X5)(`!+$?V<2JC<<L0,#))&#2?\,%?L-`L#^R7\`=
MP=T(_P"%3^%@<IC/73LXPRD$<#=GUKGC4P4FIQQ6:M645^XPMM%"*M;&7TBD
MK-[)+X5I<EC%&SPV6J"U:=;%6W3DW_L.[E)MM/XG?J[.T#]F#]C7PQX=A\):
M+X9\%VGAFW^&WQ'^$*:)+X[U.]L/^%=?%KQ9_P`)OX_\-R)?>)[EYHM>\38U
M,ZC+(^KZ<P$&E:A9V_[E?+/C%^R!\!/''PXA\`^$O$NCZ;-=O\`/#OB'7O&?
MQ3\5^-=6UWX7?`WXR1?%:V\&:AKNN^,=1\27.HW*WWBG3-'\2R:HVM:=-K5N
M[ZB;+1].M8.BTC]E#_@G%X@U#7])T?\`9\_9BU#4_"_BN3P+X@L(/AUX/^V:
M9XRBT:S\12>&9H'L(Y)-830M0LM8>QMA-*FG7*717R&:02^%/V/_`/@G;XZT
MZ_U7P?\`LW?LX>(=.TOQ#XD\)ZA>:9\+?"T\%IXD\(ZO<Z#XFT69O[+4IJ.A
MZS9W>FZA;X)@NK>6(D[>=8UJ$*D:CQ6<-TY+DC/#89PBY132L\8G9WYM7:3O
MNM"%3JU/=EA<LDFKM4Z];F6G]_#0C9/5MR\DI;'=>%?V>/V3?!T&@1:19>'[
MJX\.^+O&GCNWU7Q+\2M;\9:[J_C#XA^#K[X?>+]>\8:]XK\5:SK/C:]U?P1J
M$WA<GQ=?ZS'::-%96-A':0:=8K;['P?^#'[-_P`"%O8?AQJYTZTN;'3])L].
MU_XS>,O'&D^'M!TDW!TOP[X/TKQMXV\06/@_0+`7,JV^C>&K?2M/2);:W$+6
M]I:PP\NG[!'[#>T./V3?V?\`'F"/<WPI\*9$A90J$#3\@\\9`'O4=]^PC^PI
M8Q7%Q>_LH?L_Q0VMK->7,K?"OPL4@M+=&DFGE9=..(XXXV=N,@*:S]KA)1E"
M6)S:K&7)&2GAL++F2Y8Q3MC5>[LDFGT44M+U[+$TYJM#"Y=#V*ERS=;$)PBH
MIRE*4,).,7&*=W&;25KLTM3_`&=_V4=;\<^)OB!XACTKQ3K/BO3O%>E:GIOB
MWXL>)O%/@FTL_'6C1>'?&R^'_AWX@\8ZAX&\*S>*]#A&DZ_<>&O#VD7%_8RW
MD$LFV]O!<4?"'[,O[(G@F+1(]+M=*U3_`(1YO$_]ER^-?BWXL^(4Z6?B_P`'
M+\/=<T:YF\=>,_$,U]X>F\$HOANR\/7KSZ+I.G`QZ786<CRR28OAC]BK_@G[
MXV\.^'O%_A+]F3]G/7_#'BK1M,\0^'-<TWX7^$;C3M9T35[2&_TK4["<:<%N
M+._LKB&YMID&V2%HV7Y=E9WC/]D'_@G7\.O">N>._''[-W[-_A?P?X8TBYUW
MQ#XDUGX8>%+32])TNS_X^+J[G;3"$$;,(EA"/-<7#+!;Q2SNBFG5PO-"'UC-
ME+^%&*PN&;>J3C9XQM/O&ZWNTR5AZG)*K#"9=%U4JU2:KUO9S4N63G>.'E.4
M6[2BY0BFFE=:'6>#OV:/V3_!&EV6AZ/<O=Z/I/B3X?>*=`T_Q5\<_B!XVM_"
M^H_"K5SKOP\M/"L?C#Q]K@\,Z!X8U3$]EX<T/[#H<RA;6_T^[MHDB30\5?L[
M_LE^-/BA_P`+?\1V.@7_`(SFU7PIX@U2.+XG>(+#P=XF\1>!#"?!/B7QC\-]
M.\6VOP]\8^)?"?V:R/A_7O$WAC5=5TT:;I0M[M5TK3Q;<CX;_8P_X)^>+_#V
MC>*O#7[+?[/FK>'O$6FV>KZ+JD'PD\-PPW^FZA!'<6=U''=:3!<0B>":)ECN
M(89075'17RJ[4?[!_P"PPQ'E_LF?`,G>8U_XM/X7!9P,D+_Q+L#@G!.T,,LF
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M_P`$\/&\6JW/A/\`9M_9R\00:'XCU_P=K$FE_"WPI<QZ;XH\*WSZ;XCT*[8:
M8!%J.C7\;V>H1-A8IUV!R5Q2]IA'%MXC-73=T[X;#\K]Z,7%WQSZI1MUM;H:
M4J>)3Y8X3+UROFM2JUN93M?G?M,-3L^2_5RL]K)M?:(\:^#`N/\`A+O#'3OK
MVE8Y_P"WKI]>:^+OVG/%GA27XU?L+S0^)O#LT=M^T?XHFN737-+<6\!_9V^,
M\7G38NSY<1D>)/,8$;Y(T8?.E=./V"_V&#LV?LF_`!]Q*KCX4^%<LP)SC.FK
MV4D$C:5&Y3M!(^5OVA?V)_V/M$^+G[%VFZ-^S'\$=-T[Q9^T!XATGQ%9V?PX
M\,VUMKFE6_P%^+VKV^GZI;I8HEY8Q:KI^GZE':W"M#]MLK:Y*&:)36F%67>W
M2]IF"?U;%VOA<,DW]7FUOC=NKUNEW9&(GF2A_!P+7M:*UQ&*O;VL-7RX-I/R
M3:Z7/U2C\:^#EC0-XM\,`A0"/[>TK@_^!?Y4_P#X3;P9_P!#=X8_\'^E?_)=
M?+J?\$_?V'RH`_9+_9].5!/_`!:[PH3CH.NGACQT].P.*<?^"?W[$`X_X9+_
M`&?>,?\`-+/"?]=/&*YHO+5&-ZF8?"O^8;"ZZ+5?[;Y]OP-G/,F_X.`W_P"?
M^+?6.UL%I_FDSZ@_X3;P9_T-WAC_`,'^E?\`R71_PFW@S_H;O#'_`(/]*_\`
MDNOE_P#X=_\`[$!_YM*_9^_\-9X2_P#E?2G_`()^?L0GK^R3^S\?^Z6^$?\`
MY`IJ662;2J9@[=L-A?+_`*CO/\&+GS)?\N<!T_Y?8S^[_P!0/W?(^G_^$V\&
M?]#=X8_\'^E?_)='_";>#/\`H;O#'_@_TK_Y+KY@_P"'??[$'_1I'[/O_AK/
M"/\`\KZ/^'??[$'_`$:1^S[_`.&L\(__`"OJO^$W^?,?_"7"_P#S;Y_GV8N?
M,?\`GS@.G_+[&>7_`%`^3MZ(^G_^$V\&?]#=X8_\'^E?_)='_";>#/\`H;O#
M'_@_TK_Y+KY@_P"'?G[$`_YM)_9]'_=+/"/]-/IO_#O[]A\_\VE_L_G_`+I=
MX3_K84F\M7V\Q_\`"7"^7_4;Y_IOH-3S+_GS@-+7_?8S^[_U`_=\NQ]0-XV\
M&%2!XN\,$D$`?V_I7)/0?\??<\>E?&'B[Q;X4'[>_P`!9?\`A)_#QAB_9A_:
M366?^VM,$,;S?$G]FPP1O+]IVB25+>=XXRV]EB=@/+C-=C_P[]_8@7G_`(9)
M_9^&/FR/A9X1XQWR-/ZCVYKY/\5?L3?L?Q?MM?!+PG#^S'\#H_#>J_LX_M#:
MUJ6AQ_#CPS'I-_K>C?$#]GRSTG4[K3UL1;7%_IEEK6K6MC=2QM);6^K7\<+H
MMW*#T8/^SU6Q+A4Q_,\NQT9IX;#74'A:T)226-5N6E4K5+MM)P4FFE)'-B9Y
MB_JUZ.!;6+HI+V^*NHOXVD\%JTU%)62LVF[M)_J?_P`)MX,_Z&[PQ_X/]*_^
M2Z/^$V\&?]#=X8_\'^E?_)=?,'_#OO\`8@_Z-(_9]_\`#6>$?_E?1_P[[_8@
M_P"C2/V??_#6>$?_`)7UA_PF_P`^8_\`A+A?_FWS_/LSHY\Q_P"?.`Z?\OL9
MY?\`4#Y.WHCZ?_X3;P9_T-WAC_P?Z5_\ET?\)MX,_P"AN\,?^#_2O_DNOF#_
M`(=]_L0?]&D_L^C_`+I9X1_^5](/^"?O[#X)4?LE_L^_3_A5OA(Y_P#*?[=^
M.#1_PF_SYC_X2X7_`.;?/\^S#GS'_GS@.G_+[&>7_4#Y.WHCZ@_X3;P9_P!#
M=X8_\'^E?_)='_";>#/^AN\,?^#_`$K_`.2Z^8/^'??[$'_1I'[/O_AK/"/_
M`,KZ/^'??[$'_1I'[/O_`(:SPC_\KZ/^$W^?,?\`PEPO_P`V^?Y]F'/F/_/G
M`=/^7V,\O^H'R=O1'T__`,)MX,_Z&[PQ_P"#_2O_`)+H_P"$V\&?]#=X8_\`
M!_I7_P`EU\P?\.^_V(/^C2/V??\`PUGA'_Y7T?\`#OO]B#_HTG]GT?\`=+/"
M/_ROH_X3?Y\Q_P#"7"__`#;Y_GV8<^8_\^<!T_Y?8SR_Z@?)V]$?3_\`PFW@
MS_H;O#'_`(/]*_\`DNC_`(3;P9_T-WAC_P`'^E?_`"77S`?^"?G[$`Y/[)7[
M/W/!_P"+6^$__E?0/^"?O[$##`_9*_9^P,=?A;X2[=!_R#_;_&IYLLYN7VN8
M<VGN_5L+?6W_`%'>8^?,?^?.`Z?\OL9_=V_V'U^Y=F?3_P#PFW@S_H;O#'_@
M_P!*_P#DNC_A-O!G_0W>&/\`P?Z5_P#)=?,'_#OO]B#_`*-(_9]_\-9X1_\`
ME?1_P[[_`&(/^C2/V??_``UGA'_Y7U7_``F_SYC_`.$N%_\`FWS_`#[,7/F/
M_/G`=/\`E]C/+_J!\G;T1]/_`/";>#/^AN\,?^#_`$K_`.2Z\"_:I\8>$IOV
M9_VAHH/%7AN:63X&_%F..--=TDR2R/X#UU4BC5;L,\DC,%C102SD``D@5SO_
M``[[_8@_Z-)_9]'_`'2SPC_2PS^5>)_M)?L*?L9>'OV>?COK>C_LL_`G3-7T
MCX-?%#4])U*P^&OA:VO=.U&P\$:[<V-]:7$>GB2WNK2XCCGMYHV#Q2QI(I#`
M5=%9:\1AE[3,$OK%*[>&PJLN=7WQN_9::_,SK5,Q5&J_8X!?NY;U\6E\*6O^
MQ)_YKTL?6?P*\7^$8?@M\(HYO%/AN*2+X7?#R-XY-=TH.DD?@_1ED5@;OY65
MR5<$9W#Z&O6/^$V\&?\`0W>&/_!_I7_R77PK\&OV#OV+=6^$7PJU/4OV5/@'
M?:AJ/PU\!7M]>77PP\+37-W=W7A/2)KBZN9I+`M-<7$KL\TKDR22,SR%F=V'
MI?\`P[[_`&(/^C2/V??_``UGA'_Y7U#_`+-YJB]IF#M5JZK"X6W\66W^V_UV
M732-3,G&#='`/W8_\O\`%O91V_V)^>_6W:Y]/_\`";>#/^AN\,?^#_2O_DNC
M_A-O!G_0W>&/_!_I7_R77S!_P[[_`&(/^C2/V??_``UGA'_Y7T?\.^_V(/\`
MHTC]GW_PUGA'_P"5]'_";_/F/_A+A?\`YM\_S[,.?,?^?.`Z?\OL9Y?]0/D[
M>B/I_P#X3;P9_P!#=X8_\'^E?_)='_";>#/^AN\,?^#_`$K_`.2Z^8/^'??[
M$'_1I'[/O_AK/"/_`,KZ/^'??[$'_1I'[/O_`(:SPC_\KZ/^$W^?,?\`PEPO
M_P`V^?Y]F'/F/_/G`=/^7V,\O^H'R=O1'T__`,)MX,_Z&[PQ_P"#_2O_`)+H
M_P"$V\&?]#=X8_\`!_I7_P`EU\P?\.^_V(/^C2/V??\`PUGA'_Y7T?\`#OS]
MB`?\VD_L^C_NEGA'_P"5]'_";_/F/_A+A?\`YM\_S[,.?,?^?.`Z?\OL9Y?]
M0/D[>B/I.Y\9>#C%-_Q5GAG#1R<G7]*`Y''/VO`R!ZC'4XKY$_X)]^+?"MI^
MQC^SO!=>*/#UO-'\/K59(I]:TV&9&_M+4>'C>Z#H>H96`(8$%48,#T4_[`/[
M$0AD5OV3/V?2GEL2J_"WPF#E<,,'^SNH8`@@CGD$=1\K?L,_L0_L?^,/V1_@
M-XD\4?LQ_`[Q#X@UCP+;7>JZUK'PX\-:AJ>HW+:CJ"M<WEY<V,D]S.ZJFZ66
M1V(`!;"`5TTOJ']GXCFJ8_7&8!M+#X9VDL-CE9WQVCL[]4TF]$CGE+,5C:5J
M6!NL'-?[QBMO;T[NRP3TZ+6_=+4_4[_A-O!G_0W>&/\`P?Z5_P#)='_";>#/
M^AN\,?\`@_TK_P"2Z^8/^'??[$'_`$:1^S[_`.&L\(__`"OH_P"'??[$'_1I
M'[/O_AK/"/\`\KZYO^$W^?,?_"7"_P#S;Y_GV9T<^8_\^<!T_P"7V,\O^H'R
M=O1'T_\`\)MX,_Z&[PQ_X/\`2O\`Y+H_X3;P9_T-WAC_`,'^E?\`R77S!_P[
M[_8@_P"C2/V??_#6>$?_`)7T?\.^_P!B#_HTC]GW_P`-9X1_^5]'_";_`#YC
M_P"$N%_^;?/\^S#GS'_GS@.G_+[&>7_4#Y.WHCZ?_P"$V\&?]#=X8_\`!_I7
M_P`ET?\`";>#/^AN\,?^#_2O_DNOF#_AWW^Q!_T:1^S[_P"&L\(__*^C_AWW
M^Q!_T:1^S[_X:SPC_P#*^C_A-_GS'_PEPO\`\V^?Y]F'/F/_`#YP'3_E]C/+
M_J!\G;T1]/\`_";>#/\`H;O#'_@_TK_Y+H_X3;P9_P!#=X8_\'^E?_)=?,'_
M``[[_8@_Z-(_9]_\-9X1_P#E?1_P[\_8@'_-I/[/H_[I9X1_^5]'_";_`#YC
M_P"$N%_^;?/\^S#GS+_GS@.G_+[&+M_U`^3^Y$O[:GB_PE<_L<_M:06_BCPY
M/-/^S+\>(888=<TR6::63X6^*DCBBC2[+O)(S!$1069V"J"2!7JWPJ\9>$%^
M&OP\#>*_#2G_`(07P<"K:_I08!/#NF*^0;H,"K`J>`0>#WKX<_:\_87_`&-O
M#7[)W[4'B/0/V7/@5HVO:!^SK\:];T36--^&OA6TU'2M7TOX;>)K[3=2L;R*
MQ66VO;&]@@NK2XB=)(9XHY$=64$>H_#C]@S]BO4?A[X#OKS]E/X!W5W=^"_"
MES<W,_PP\+/+<33^'].EGEE9].#//-(SO)*26=FWR%G+D[5HY=++\,G5QZC]
M?Q%_]EPJ=_J=.UKX[K=K;33=Z&,9YG];J+V.`_W:G_R_Q>JE6FIMIX-;<L&G
MJEN]+7^U1XU\%CIXN\,?^#_2O_DNE_X3;P9_T-WAC_P?Z5_\EU\PC_@G[^Q`
M1Q^R7^SZ?8_"WPEG_P!-_>D_X=]_L0?]&D?L^_\`AK/"/_ROK'_A-_GS'_PE
MPO\`\V^?Y]F;<^8_\^<!T_Y?8SR_Z@?)V]$?3_\`PFW@S_H;O#'_`(/]*_\`
MDNC_`(3;P9_T-WAC_P`'^E?_`"77S!_P[[_8@_Z-(_9]_P##6>$?_E?1_P`.
M^_V(/^C2/V??_#6>$?\`Y7T?\)O\^8_^$N%_^;?/\^S#GS'_`)\X#I_R^QGE
M_P!0/D[>B/I__A-O!G_0W>&/_!_I7_R71_PFW@S_`*&[PQ_X/]*_^2Z^8/\`
MAWW^Q!_T:1^S[_X:SPC_`/*^C_AWW^Q!_P!&D_L^_P#AK/"/_P`KS1_PF_SY
MC_X2X7_YM\_S[,:GF/\`SYP'3_E]C/+_`*@?)_<CZ;?QIX-*$+XM\,$\\?V]
MI1R.?^GKW]\9R<\U\B?LW>+/"MO\8/VV&F\3^'HDN/VAO#\\#R:WIBI/"?@%
M\'X_-A9[K#QB6*6%F7CS8IEZHU;[?\$_?V(5&?\`ADO]GT8Y!_X5;X3P#W)_
MXE^3P.O)^E?+?P`_8A_8]USXI_M@:;JW[,7P/U*P\+_'G0M'\/6=]\./#-S;
MZ-I4WP/^$NJ3:=ID,UB\=C9/JFH7^H-;6ZQ0M>7UU.%WRL:VH1RYTL<W5QZ2
MHX6R^JX:[_VN%]\;9>2OKY;G+7GF'UG`MTL%?VV)2_VC$[_579_[G=^>UEM=
MW2_43_A-O!G_`$-WAC_P?Z5_\EU$_C/P8<;?%OA?.<_\A_2L9_\``OZ]*^9?
M^'??[$/;]DG]GT'L?^%6>$>/_*?3'_X)^_L/JO/[)?[/R^X^%?A(^W_0.;KG
M`ZD5S3662A).KF44XM.2PN%3BFM6F\8TFEK=K1[['7&>8-I2HX%IM*RKXI-O
M1)+GPE.+=]$G)77I9^J^`_#'P"^%^GZCI/PWL/A?X&T[5]:U/Q)K=OX7F\.:
M.-;\0:UJ%UJFK:UKDMG/'<:SJNH:A>7-U=ZAJ4MU<S332@RF-BE>E)XT\&J#
M_P`5;X8``4<:]I.`!QC`N\`=J^68OV!OV&I&=(_V3O@`QC8JP;X5>%%'R':V
M&.G`'YO3'IT/%D?\$_?V'V/'[)7[/WR@]?A9X3`YXQ_R#\'/Y4VLOE4E4G6S
M2=3F]^53#T)-M)12?/CGR\ND=%%*UDK(2ECTKTZ."Y'9I^VKK>W_`#YP4H.]
MVU[\GM>S;M]0?\)MX,_Z&[PQ_P"#_2O_`)+H_P"$V\&?]#=X8_\`!_I7_P`E
MU\P?\.^_V(/^C2/V??\`PUGA'_Y7T?\`#OO]B#_HTC]GW_PUGA'_`.5]5_PF
M_P`^8_\`A+A?_FWS_/LQ<^8_\^<!T_Y?8SR_Z@?)V]$?3_\`PFW@S_H;O#'_
M`(/]*_\`DNOD'X_^+_"<O[0_["\L7BCP])%;_&+XN/<2)K>FO'#&_P"R]\:H
MD>9UNBL:/+(D2L_RM*\<8.\C&_\`\.^_V(/^C2?V??\`PUGA'_Y`KY8^-_[#
M_P"QWI/QX_8OTC3?V8?@?8:7XF^+/Q3L/$5A9?#GPS;VFMV-A^S=\7=;LK+5
M+:.Q6*^M;76-,T_4X(;E)$BO+*VN(E66(&KH_P!F^T_B9@OW=6S>%PW_`#[>
MG^^WUOK:[^9G5GF?)I1P'Q0O>OBTE:</^H+OHO+T9^HB^-/!RY#>+?#(.<X.
MO:5TP.?^/NG?\)MX,_Z&[PQ_X/\`2O\`Y+KY@;_@G_\`L0LWS?LE_L_,<<'_
M`(59X3Z>F3IP`^@/-'_#OO\`8@_Z-(_9]_\`#6>$?_E?648Y=%*/M,P=NV&P
MS_%XU=7V7X&KGF5_X.!Z?\OL7?[+Z8)KOKU:7F?3_P#PFW@S_H;O#'_@_P!*
M_P#DNC_A-O!G_0W>&/\`P?Z5_P#)=?,'_#OO]B#_`*-(_9]_\-9X1_\`E?1_
MP[[_`&(/^C2/V??_``UGA'_Y7U7_``F_SYC_`.$N%_\`FWS_`#[,7/F/_/G`
M=/\`E]C/+_J!\G;T1]/_`/";>#/^AN\,?^#_`$K_`.2Z/^$V\&?]#=X8_P#!
M_I7_`,EU\P?\.^_V(/\`HTC]GW_PUGA'_P"5]'_#OO\`8@_Z-(_9]_\`#6>$
M?_E?1_PF_P`^8_\`A+A?_FWS_/LPY\Q_Y\X#I_R^QGE_U`^3MZ(^G_\`A-O!
MG_0W>&/_``?Z5_\`)=>4_&WQAX1E^#/Q>CB\5>&W>3X8_$!8T37=*9G9O".K
MJJJJW?)9B``.IKS;_AWW^Q!_T:3^S[_X:SPC_P#*^O-_C%^P9^Q3I?PC^*NH
MZ?\`LI_`2TOM/^&WCNZM;J#X8>$XKBUNK?PKJLD-Q;S+I^^&6.159)(V#`J"
MI!`JJ2RUU\->IF"MBL,]<-A5_P`OH/3_`&W5^7R9E7GF?U?$)4<!K0J7?M\8
MDO<Z_P"PZ>6^EC\M</\`\\Y/^^#146T_W1^9_P#BJ*^PY:'\U;ITH_W?^G_K
M^OVCQN6I_P!.>G_+VIY?].O3[_2WWWX;\-^.O&7["?[8OA+X9+=2?$/Q+\3O
MVY=$\(065Z=-O;W6M0^+/Q$MX--L-2$UN+#4-3C:73]/NS/"(+VYBF,T>S>.
M'\??%#X6^)/@/H,'[,G@3XJ?"^S\%3?!?P7\=M:\!_`?QY\/OB?\+?V>QXKT
MNT^)?P^\/ZJ?"&E>(/\`A*?"]C;/-K^F^`#KNN^'M#@UWQ%X?,>HII]Z_P!A
M?L1HDGPP^)*NJLI_:F_:N;!`(#+\>?&^&.X$$J0<,,[>#GC-4OC7^U-H/P"^
M)?BS_A/-0UG4/!'@?X":9\3[[PIX4\`SZ_XKFN]9^+NF?#>RU;1=:B\10W&J
M3-/J]CIQ\#6GAXWER0VI6.K7,[0:++\U5E4ECL70H4)5JD,;4KQC'E3FZD</
M0LVXRYXJ48*$6DU.6\E)H]:I3P\*5"M6JQI*I1=!N=*4K\JE6YE-5(I1C&#Y
MFXMII6:LK_E'\3OB!\8+3P]H?@KX<:]^TQXU^#GC+XX?%Z7X+07_`(@_:4TK
MXH^)/A=X;^"W@2<ZG<>*_A[X5\4_M/:CX,\#_&?6_$VI^$;K7]"N-.\0V]A'
MX?\`$_B&#2YO"DM]VNJZ9\0-?^'OC+Q7\./CY^T3XWTOX*_\$^_@CX[^#_C#
MPIXS^)UGHWQ(^.FC>*?C+)XA\6:YHNIRSZMX\\3W]YX7LM'\4?#OQE+J3+I-
MXND^)?#DUS'H<UC^CEK9_`7]NF#5$\;?"SXD^$O&WP/\67GAG5M`\9ZMXE^$
MWQ4\&77B[PUX<\01&/7_`(2>.XKNX\+^/?"=YX?U&2RMO%]U8:A;PVMIKFFV
MVJZ3+:67E7@']OO]G_P]I/@CX=_"G]GK]HD>';N#QUX0^"VA^#?A)I4.B>.M
M6^#.JW.A>/\`PAX&,WC"SM+2?PM'8WFL7GB'Q=)X9\(:Q917<NF>+-8U=)[*
MM'5JRIJ-'`<^(PRITL7S*FX7E5GBH3<UHYU,/3=YVY94H5&HV?,N.-&E"LZE
M?'J&$KJ^#5)SO).$:34HROR*-9^ZG*3;<->:5CYD^*WAE?%'Q5L?''Q4N?C9
M9^#?AS_P4<O+>#4/".M_&#2K;PM\/O%'[*>@6&BZC:V?P\NH;]?"=U\4[N#1
MEUFSM+G2]+O/$.N:7=7UGINOZ^D[/%OC?]ICX>:!-XM\+'XM^(M2^*OQC_;3
M_96T[1%M?$NHV7@KQ1X\^.>NR_LY_%^?2-DO]E>&O!-A8ZSILGC1ECTN'PC>
MZ(IOXK`6LI_173OVUO@GKG@_6O'NF6OC*[T/P]^S39_M2W$[>'(+>^/PWO)_
M%%F=*BM+K4H)AXSLKWP=K-KJ'A^Y6"&VN$A2343YK&/YF\1?MV_$?P5\1_%V
MB6OP<\5?%[0)_P!J#X9_!#PC9?#ZS\-V/B3P_P"$/'/[-WA7XQO=ZN_B3QAH
M5GK'B>?5]8OXM*A%S#IATNPN+6]N;2ZM+:XUBZ<\;7E5B\%!TL/2ESQJU*<(
MPIJBG)0<E!QJ0G4]LVW*::BXJZDC*6%PE"3;Q]15L8W)5:-"O>3@XJ[LY)\L
M*+AHHI)/RMXAX13]H?3/VVK?P?XF^,?BWPXO@_XN>&_#W@?P[KVF?M'^(XOB
M7^SCH?P\T2U=?^)/;W'[.6HOXIO3K6K^(_B/XKE7X@^&_'%C>QWVL6D/]DZ1
M<_1O[=6I:Q;?$_X8:9XMU[X]^'/@GJ7PM^+JVMY\`U^(/]L:I^T(+KPI:_#'
M0O$TOPST_4=>FBG\/77C.X\(Z%XB1?A[XA\013VWBFWOI+73+:NLTW]MW1/#
MU[J7AK7O#/Q/^,'CC7?C1\?_``-\.O!?PK^&6G6^NK9?`Z?PW)K>A7O]M>/8
MM"FN]!L/$4,@\;:KKGAW3?$$T5S;16&EZ@=.T_4.?7_@H+X"A\4>+/'MWJT]
MS\`8?V>?@3\1O!%G;:$MA\0?$'CCXP_$SXF>`U\)36VNZGI5M;ZQ)J'@_3-"
M71]7N-(M=!U:/7KK6M6M=/MIKJUS]GC98A5OJ?+["$8NE348^TG3G"G'V<N6
M2YW5BT[Q=VJD5\$FNB,<'["K0^M\M2K*2]K::E!2I.4O;0G)/E5&]TN6R4;<
MO7Y#^'-]\:O"6E_L=?L[Z?JOQ/T[3_VK_@/^RW=FZ676=.N_@O-^S?X9T;4/
MVD](MKD^7_PA5QX]\!KX2T::U46$C^*=7UJ9?-N[F7S?.?$VA^*/B?\`"S]J
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M)/BOX$1ZC\=+KQ-=_MO_`++NO>!G_L_XH^+=,E_9?O--^"6B^([^\^)L\.IZ
M0W@>YUS2/'6C^-X]6\32W]WXCOM5D\164QUNYOY_.O#=C^TAX3TOPA\3?`GB
M[X\^)?BM\4;_`/;[\*W/AGQOKWB3Q%X'LU\()\6M9_9XL]/\#Z]`_ACPI'I?
MB3PUX3LO!NNM;:??>(-/UF33-3U?7]+N]-AMOJ.Z_;JT_P`&_$+XKW_Q,\/^
M)O!/P]\)_#/]G#5?"'PXUKP_H6D?%V7XG?&OQ9\7/"TW@?48Y_%?_"*/J=\W
M@K2QIC2>)+3PSIEC)K&O7WBDZ'(+VQ[OP]^W[\&_&$GPRTOP;X$^+WC/Q1\4
M==^(OAR#P;X<\->%]5U;P;K?P?USPII'Q&B\?:G%XU/@[2;/PDGC#1=;DUO3
MO%.LZ'JND2*WAK4=8OKW2-/U`]GBZ<)/ZBJB:A4E4YXN,E]7E4J-I*RBHMUG
M*+<8<OQ-71T7PM;$3FLRG2Y+T*6&Y'&UZU.--RC)N3FWRTDG9MSMRI.S_._Q
M%X7^$'BWP3^S/X_;Q/\`MKZ]X?\``W[1/PXOOC?XC\;>)/VJ+;6_#GBKQ)\*
MO&V@^(+R"QC?3/$EA?V7C2Y\.Z9XL_X0C2YO!'A&YUAM/TA=+T[4]81^EUOQ
M1XSM_$@LOCYXS_:3\&?L_7?QP_;8@GUWX4S?%K3?$4_CG2OB'X?MO@5X>UK6
M/AGIMQX]TWP*/`TWC/5/`-GI<D?A'Q#K]G:VVM2WEM';:?<?=^G?\%"O@7=W
M%]J&H>&OBSX<\$S>%/B;XP\`?%77/!,<?@/XP>'_`(/Z;>ZSXZN/AE=Z;K6I
M>([]['1=.OM:T:#Q)X<\+R>+-&M+C5O"PU?3XS.<Y_VS=#U4?`WQU/IGC?X7
M>`O'TGQ?OM6T#QQX$T/7]?\`$W@[X=_"#4_B5#KVA^)/A]\0_$VB:7H1L;+^
MU=.O-*G\5W/B"6*;PO<:5HFI&XGAI5,9R^RJ8%N/)+D4G&4XVG5G[CC3OS1G
M&HI7C))TN5KF3OG&A@:DG-8Z/.^6I4Y5./->,*;;7M$G&46FHI[M2NXM)_GW
MJFD?M4:W\,?'7C?X@>//VD_#OQ:^$7["7P0^)'A?0_#6N>(?#-OJOQRB\5_&
M>^;5_%WA/PQ$FB>,?'MYX;T3P;IOQ!\`W$5]H5R=6O8=8\/G49M&NM._2O\`
M:.=Y?B]^P%+)@22_M$Z]*^T;5W/^S=\:&<`$*0`QP`54]!@]3[-^S[\;]"_:
M!\!:=\0/#_@?Q[X+T34FAN_#Z>/=.\,VEQX@T:^T^RU+2_%.A7/A#Q1XNT*]
MT35K.]C$+1:LNH65Y;WFFZQIVFZA;/;5Y'^TXH7XV?L'!1@#]I+Q/@#IQ^SK
M\:<_U)].<]#7)/$.MBW3E1A1G"GC)2C!-<M\-+W$KVY$U==FY+2]EWT<-3H4
M5*E/G3>'CSWDW-0J05WS2>KW?G\C[7B'[I.Q*CG\/Z5\*?$#]L+Q#X$^-"?!
MJ^_9N^,E_<:AHOBWQ?I/C?3?%/P(M/!M[\/O`^I>';#Q;X[:XUWXKZ9K.EZ7
MH`\4:9<W.GZUH]CKUS;)>266D71M75_NR+_5)CKM&*^+_C9^S[XU^(/QETCX
M@^')_#L&D6/[,/[1WP>E&H7MW:ZD/%OQ8O?AY<^%KF**#3KF/^QX%\+ZF=6O
M!<QW5JSV?V>QO!*[0<6#AAJE2$,7&/LI4)J-5M_NJW[OV;<?M1^)R7]U)-7N
M=.,590A*@Y-PKQ]I&*NYT.6I[2,;Z*;DH*#Z7:L[Z:MA^V)\&M<\06$?A7XB
M_#GQ5X`B\%_$;Q=XH^)>D?$OP:^B>&!\-6\%RZU:7^EB[&IWMI#IWC?3]3UC
MQ!IXET3PQ;Q6J:_/92ZSIBR[=I^VS^R-?W%A:V7[2'P9NKG5/&I^'6FPV_Q!
M\-RO?^.,PHGABUVZB1/JDLEQ;Q6Z+F.XEGACMY)'EC5_C?XB_L*_$C7_`(.?
M#3X<>%8_AYI4_@[_`()U_&O]E34+1;V\TW1?^%E?$7PA\(]%TBYLH[/P^5?P
ME_:/@?7)]4U)[6&]ACGLYXM(GEN)TBZOXI_L2>(O%,/[39\,:)\,=/O/BU^S
MC^SQ\(_`MR\2V$NEZ]\(M9\<ZEJ?VZ>U\/RRZ7HMNNL>&VT&73VNI3<:9$[6
M=FVG6<A[_JV6JG"7UI)RE).%."4HJ-6$(RFETE3E*HMM(M:-W7+]8S%2?^S4
M%"$(R;DZ[E4YHMN-/V<)\DH.+C/G5GS+ELURO[;'[0GP0;XGW'P57XJ>!C\7
MK;2FURX^&H\2Z5_PFL.E1VZWKWLGA\7/]H1Q)8NM^P>%91ISI?F,6;K<-XCX
MN_X*'?L9^"_#6C^,=3_:`^'5[X7UCXF6/PC37=#\3:1K&FZ?XUO83=366KWE
MG>O%IUGI5D%U#5K^1C;VE@Z7>9(FROREIO["/Q$L?VCO&OC+7--C\>>`];^-
MOQ`^/7A;6M4_:1^).@>'=(U;QMX4U'2$\+:Y^SY8>"=1\-:E?V;:E>>$;CQ)
M!XRCL=2\$W<=S=:.=5M'LKNGX5_9,_:H\/?"R#1;/2?AS:P?#'XX_`?XD?`W
MX+:_\8=<\<VV@>$/A3-,GBCP0_QPU#X2Z;XEAT+5(KMS\-M%\1>&_&A\$6FG
MQZ;/KDUA?I9Z2XX7`/DMBV[JCS\TJ5-+GY^;E?-.5E:-W**Y?><G\/,GB<P4
M;3PU.FW[=J:AB,1R*G*E[).E1B[NHI3WG'X5R]6OT(N/VB_A#KOCF\^#_@GX
MN?#74_C7:Z.VKP_#1_%FFR>(3:265IJ45W?Z-9/=ZW#:)I]]9:C<M;6<MY9Z
M;=QZA):21&,U\IS_`+<7BO0]"^U^(?AYHKZ]J_PV\+^./!FGZ/XSNIM/\1ZY
MK<NNZQJWA![N^\,VL^F2>'/`&@:AXPNM3%M?175KI?B"..U7^RENKO@X/V3?
MVHM<_;#\"?&7QKK>@W_P\\"?&KQ#\1M*%K\7O%,6E:?X(U_X0^)?`VD^#="^
M!UC\/]+\(6GC#PYK.NLGB/XF:KXKU37/&>F23W"IIZ2QZ38_JB?#VA%0AT31
MC&BF)$;3;,HL?DS6^P*8"%06]Q/`$7*K!/-#@1.Z-A6C0PKA%<N+=6G"I)TJ
ML5&A)N7N.24E-VY923Y90>C2=[;4WB*[<I*6'C"K.,+TWS5J2<>5RBW>EHI*
MWO1E?F3MO>MY&EMR[G=D<-AER"JNIV$DQ_>PR%G*ME2S!:^-_%O_`"?W\`O^
MS7_VF/\`U9'[,]?9ZQI%&ZHH48/"@`9V@9(&!P,#@#(`XP*^,/%O_)_?P"_[
M-?\`VF/_`%9'[,]98'^/B_\`L59E_P"J['FV)^+"?]A,/_2Z9]K4445S'2-=
M@B[CTRHXY.68*.._)%?%_P`1/VO;/PGXS\?^%_!7P;^-'QI@^$L.GR?&#7_A
MAI?@Z;2/AY)?Z#:^*ET..'Q9XO\`#&J^.O%\/A6ZM/$-[X3^'^G>)=;T^PU/
M1X9X8[_6;2R;[+N(_-A=-H8L-I4N4X)!(WKR"!R#V-?GEK7PG_:G^&7C[]H&
M;X&>'_@SXU\)?M!>+H?B)I.M?$3QWXK\'ZM\)/'>H_#WPW\.O$TFM>'='\$>
M)X/B-X1>'PMH_BK1=/TS6_"FL)>RZSH-Y<);/IFJ6N^'C"<I<ZC*2Y.6-2LL
M-!KGAS_O7">O)S67NZI;[/EQ4Z\(Q]DFDU4YI0IRK24E#W%[.+BU'GM>5[.]
MG8]WC_;'_9<2R\+7E]\=OAOIA\8^#-/^(GA^UUOQ/IFBZG?>"=9\.W?B[3?$
M<FF:G<6MY9Z9<>'+*[U#[3>00(BVDT#E;A/).#-^U]\+?$&I_`@?"SQ%HOQ5
M\-?';XI^(/A1I7C#P/XDT;5=%\/:UX=^'?C'X@:C/JS0"Y>62VA\%W6DRZ4C
M0:C!>:I:W,T?V)&#?+&C?L+?%/X9^!/C?H'PH\2^#;;QCJ_[,'[,?P,^$_Q`
MUE$BUY]1^"EOXWC\8S:O<3>'/$$?A2#Q.^OVLOA_4;&S\31>'M7N8];&BS2:
M%9V\^#\!OV)OCIX-\9>"/&OC.ZT.*73_`-L#4?V@-9L=6^,'C/XQ>)[7P9>?
MLI:I\$;73K[XA>*O"7AW4/%OBR+Q3<6MQ<K<:;IVE6^B-Y>FW*K91VT_H?5L
ML_VBI];;I4U4C132C6G)T8RHR=.S;2K2Y7RWNH3YG!N)YWUO-E/"P>"@XU(-
MUZJ<K4WSM*\+WBW%*3@Y7][1V3M^C?C?X]_!CX5:SX2\,?$WXI>"/`GB/QS>
MMI7@S2O&/B31_#^H^*]066"W,&AVFH7<$U\PN;JVLP\:>4UW<0VBR&XD2(\-
M\0?VR_V9?ADOQ7M_%GQC\#V^O?!#PA>^.?B9X1M/$&EWWB[PQX?M%M%6>]T"
M"[-Y'<7=SJ>DZ?9V<@2:74-7TJU<1/>PE_C+]K_]AWXD?&SXYZK\1-#2X\9>
M"/B#\'_#OP9\7^#X_P!H?Q_\`QHEIH?BS7/$,NIWX\&^"O&-O\0/"^LVWB*6
M/5?#=VFC:I:WFAV-SI^H2M>DV&A??LA?&[4/'_[26F>'(O!WPV^#OQD^'/QO
MT34-.D^)>O\`Q!T_QU\3/B1H6FZ'X3^)UCX*U3X>Z7?_``7UBTCM;NZ^)]OX
M7\=Z[HWC.\>TN8M%DU&-M73"&'P3CA92Q4IRE3H3Q,+4Z5G*5+VM.$JDGRSA
M%U'[RU<$TN5W5U<5F;EC(TL#3I*G4J0PM6I.=6,XQI2E2JSA"*E+GJ*,>2&J
M<N5OFO;ZB/[:G[-NN>#_``KXG\'_`!E^'>LS^/\`PW/XF^'&@OXPT/2-5\?P
M1V^N+!9:(NHW*_.VJZ!JVD7EZ\;V.E7^F7T>I2Q+;/G;TG]K3X'I!\([#QS\
M2OAY\/O'7QF\)^&/$W@_P%K7Q`\+76L:P/$MK;O!!H%Y9WHLO$]@U_.VEZ7X
M@T??I/B"[A?^QY;D'8/GCP?^S7\6M9U_4?'WQ#\+_#/POXJO_P!B&U_9L@TO
M0/$EQXNAT?QE:>)/%=S=WNF^(KOP=X;NXO"^OZ;<^'K^\\G3K.XBN4_LZZLK
M_P#LBUU"?YTG_80_:*LO`GC#X1Z;:_!G6_#WQY^"W[-7PZ\??$'7O$VO6_B;
MX+ZK\%/A_H/@?Q"/!VAP^"+_`/X3[1I&T63Q5\-4&O\`@-O#_C34=0U#4HA'
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M/Q=<``C=CP#K_&>#N)&`O`/'-?05>`?M4-Y?[-7[0LIQA/@3\7#UR<CP%KIZ
M'J.!]>]&'498G#J3Y8^WI7?;]Y%7^2;?R(Q>F'K/>U*H[;<UH-I7W5Y**OJD
MWJGL?!GPW_X*V_\`!-_P%\//A_X+\7_M;_##0O%7A+P/X/\`#?B31;T^)!>:
M1KFA^'M.TS5=-N?+T"2(W%C?VMQ;3"*211)$VUFP2>X_X?.?\$N_^CS?A/\`
MGXG_`/F>K^;F\_X-O/VJ?BY=S?%;0_CU^SUINC?$L6WCK2=,U6/XDC4=,TSQ
M196VM6-GJ!M/"TUHU[;P7BP71MY'A::-I(Y9-V:K_P#$+S^U]_T<-^S0?=D^
M*6?_`%$.GI^G%?KD.&?">/,JO&N,G/VE3F5-5Z7O.I)NT7P]7I):V2CB:OK>
M\5^;QS_Q#<8N'"=.,>2G9-86I;W()^_4XAPLY?:MS8>DU9+E=N:7])W_``^<
M_P""7?\`T>;\)_S\3_\`S/4?\/G/^"7?_1YOPG_/Q/\`_,]7\V/_`!"\?M??
M]'"_LS_]\?%+_P"9"C_B%X_:^_Z.%_9G_P"^/BE_\R%7_J[X1?\`18YET^W+
MR_ZIOS_'R8_[>\1O^B4I=/\`EW@O*_\`S5/K]WW_`-)W_#YS_@EW_P!'F_"?
M\_$__P`SU'_#YS_@EW_T>;\)_P`_$_\`\SU?S8_\0O'[7W_1PO[,_P#WQ\4O
M_F0H_P"(7C]K[_HX7]F?_OCXI?\`S(4?ZN^$7_18YET^W+R_ZIOS_'R8?V]X
MC?\`1*4NG_+O!>5_^:I]?N^_^D[_`(?.?\$N_P#H\WX3_GXG_P#F>H_X?.?\
M$N_^CS?A.?Q\3_\`S/5_-C_Q"\?M??\`1PO[,_\`WQ\4O_F0H_XA>?VOO^CA
M/V9_^^/BE_\`,A2_U=\(O^BQS'_P.7E_U3?G^/DP_M[Q&_Z)2ET_Y=X+RO\`
M\U3Z_=]_](D__!9;_@E])'*%_;+^%+%HV4`#Q4Q!88'RIX<)P#\H(/+$+Z5\
MT?L7?\%8?^"='PT_99^"'@7QS^UG\,O#GBWPSX*MM-U[0K\^(OMFF7Z7U]*]
MK="'0)(UEC66,G9(Z9;Y6;@G\3Y?^#7O]KP*2?VBOV;(T7,C>7;_`!0W_*I9
M0&/A(\%@@8E&.S=MVR[91YG\%_\`@W2_:F^.?PK\#_%OP]\=OV?=*T3QYH<.
MN:=INMQ_$C^U;."66:W\B^-GX7N+5IT>W8,UO,\;J0550`M;PX=\*%@ZR7&6
M.E1EB</*HU[>$Z=2%+$1H0DI\,J-I4W6O*,I<W(I+E2,I9YX@_68M\+TO:J@
MTH>SP4E[)U(2E+F7%"2:GRKE:NGI=V=OZG?^'SG_``2[_P"CS?A/^?B?_P"9
MZC_A\Y_P2[_Z/-^$_P"?B?\`^9ZOYL?^(7C]K[_HX7]F?_OCXI?_`#(4?\0O
M'[7W_1PO[,__`'Q\4O\`YD*Q_P!7?"+_`*+',NGVY>7_`%3?G^/DS7^WO$;_
M`*)2ET_Y=X+RO_S5/K]WW_TG?\/G/^"7?_1YOPG_`#\3_P#S/4?\/G/^"7?_
M`$>;\)_S\3__`#/5_-C_`,0O'[7W_1PO[,__`'Q\4O\`YD*/^(7C]K[_`*.%
M_9G_`.^/BE_\R%'^KOA%_P!%CF73[<O+_JF_/\?)A_;WB-_T2E+I_P`N\%Y7
M_P":I]?N^_\`I._X?.?\$N_^CS?A/^?B?_YGJ/\`A\Y_P2[_`.CS?A/^?B?_
M`.9ZOYL?^(7C]K[_`*.%_9G_`.^/BE_\R%'_`!"\?M??]'"_LS_]\?%+_P"9
M"C_5WPB_Z+',NGVY>7_5-^?X^3#^WO$;_HE*73_EW@O*_P#S5/K]WW_TG?\`
M#YS_`()=_P#1YOPG_/Q/_P#,]1_P^<_X)=_]'F_"?\_$_P#\SU?S8_\`$+Q^
MU]_T<+^S/_WQ\4O_`)D*/^(7G]KX?\W"_LS_`/?'Q2_^9"C_`%=\(O\`HL<R
MZ?;EY?\`5-^?X^3#^WO$;_HE*7_@O!>7_54^OW??^Z7[5?\`P5O_`.";OCS]
ME_\`:1\$>$?VN/AAKOBSQE\`OC#X4\,:'9GQ']LUCQ%XA^'OB+2-%TJU\[08
MHOM.H:E>6UI!YLD<8EF3>Z+EAZ/\/O\`@L+_`,$R]%\"^"M)U/\`;$^%=IJ.
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MBE!3OS<[XH<4^;1)K7NK<Q_3(O\`P6:_X)>*"#^V;\)\Y]?$_M_U+M._X?.?
M\$N_^CS?A/\`GXG_`/F>K^;'_B%X_:^_Z.%_9G_[X^*7_P`R%'_$+Q^U]_T<
M+^S/_P!\?%+_`.9"L_\`5WPB_P"BQS+I]N7E_P!4WY_CY,O^WO$;_HE*73_E
MW@O*_P#S5/K]WW_TG?\`#YS_`()=_P#1YOPG_/Q/_P#,]1_P^<_X)=_]'F_"
M?\_$_P#\SU?S8_\`$+Q^U]_T<+^S/_WQ\4O_`)D*/^(7C]K[_HX7]F?_`+X^
M*7_S(4?ZN^$7_18YET^W+R_ZIOS_`!\F']O>(W_1*4NG_+O!>5_^:I]?N^_^
MD[_A\Y_P2[_Z/-^$_P"?B?\`^9ZC_A\Y_P`$N_\`H\WX3_GXG_\`F>K^;'_B
M%X_:^_Z.%_9G_P"^/BE_\R%'_$+Q^U]_T<+^S/\`]\?%+_YD*7^KGA%_T6.8
M_P#@<O+_`*IOS_'R8?V]XC?]$I2Z?\N\%Y7_`.:I]?N^_P#I+D_X+-?\$O67
M"_MF_"?\_$^!P1_T+O(R1P,'^5?,_P`"?^"L?_!.7PK\3OVK]:U_]K7X9:=I
M7CWXV:+XG\(7TX\3>1KN@V_P8^%WAZ?4K-U\/D-!%KFB:MIDGFA)/M.G3A$,
M7E2R_B9_Q"]?M?+S_P`-#?LT+_NI\4N?;CPAGUZ<UYIX&_X-S?VI/B!XF^*_
MA72_CO\`L]6=Y\(O'%GX$\03WZ?$G[-J>J7O@SPOXWAO=*:W\+._V!--\6V-
ME(EW%;W/]I6M^VU[9[>:6X<.>$W+7Y>,L=R2ITU53E7<U&-6,H--<,N"YIN*
MM*6OD[&-3//$!U<.Y\+TE5C.JZ,>3!>]*5'EGI_K0V^6FF[:/SMO_4S_`,/G
M/^"7?_1YOPG_`#\3_P#S/4QO^"S/_!+PE3_PV;\)^HR"?$_([=?#V`,XZD#U
M.,U_-I_Q"\_M??\`1PG[,_\`WQ\4O_F0I1_P:]_M?*1C]H;]F@;L#B+XIG/Y
M>$E(_'`]_3&IPWX22IR4>-<QI-V7M'"5=13:;O2_L/"\]UI;V]/EOS7DX^SG
MNL_\0TTY\)TY133:MA:=WI;WZ?$.+DK2U=J%2Z7+:*;G'Y"^%_\`P6>_:Y_9
M6^/_`,8+CX7_`!/M/C+\`M9^-?Q,U_0_AO\`$I]2\1>%+GPIK/C?6-6L+KP-
MX@FE3Q9X-AN[&YADTZVL;DZ1:QSJLNARE-H_J0_8F_X+J_L8?M9-I/A/Q5XC
MD_9Z^,.IM!9I\/\`XI:A8P:'JVI2/Y20>#?B)$EKX9UO[6RA[6SU)M#UB421
M^7IK9`K^`/QOX$U3P+\4/&/PJE8:[XD\(^._$?P]=M"MKRZ77M;\-:]?>'YS
MH=@(/[2N4OKVQE?3K86YOKB!X5:`3$Q+^T7[$O\`P0(_:W_:C&E>+/C#"O[,
M/PEN9+>[EN/'&E-??%37M.E4OYWAOX=-)"^D^<L@:+4/&MUHP42":/2=1`"-
M^@\:<'<`1P-/%YAC*?#]>6$H.EC,)R3JXODI4^6M/+;MXFM5II/V<)49N4[R
MG=7/D.%^(N+HUUAL%0K9Q0A6J?[+B).-.GSRG-T_KJ25*$)RM.I)5.6,6N32
MQ_H"6]S%=`/"2Z$1ND@!\N6.1`ZR12#*RH5.`ZLRY)`)P";5?*?['?[*'@_]
MC3X.:1\%O`_B_P")OC;0M(D$\6M?%/QUJOC;66FDB1)8--2^9--\,:/&R;K/
MPYX>L[/2K0.3'$\C/*?JROY@J1IQJ5(T:DJU*,Y1I5I4W2E6IIVA5E2<INE*
MI%*;IN<G3;<')N-S]YH.K*E3E6@J=:4(NI3C+FC3FTN:G&>BG&$KQC42BJB2
MGRQYK!7QY^T%@?M$_L)`8&?C)\7L<?\`5K7QKYK[#KX]_:"_Y.)_81_[+)\7
MO_66OC73I?'_`-NU/_3<@K?P_P#M^E_Z=@?7Z`8['GK_`/K&:?3$Z?CS_GZ8
MI]8P<G%.2L];JUNKMIZ&O]?<%%%%4`4444`%>2_'+_DB_P`8O^R7_$/_`-0_
M6*]:KR7XY?\`)%_C%_V2_P"(?_J'ZQ54_P"/AO\`L*PW_IZ!EB/]VQ/_`%XJ
M_P#I+/P!HHHK[8^4/V"_8@)'PP^)8[?\-3?M7+WZ_P#"^?'!&.3Z\_UJ7XY?
MLBZ1\<O%OB#Q9JWC75]!F\0_"WPO\+;BRT[3]/NHK>P\,?&+0/C%!J\<MYN>
M:]NM2T"+0I;60"V33;F6YB_TI5KY<_9D_9A?XC^'/BUXH7]HK]J3P*M]^U'^
MU"@\.?#OXM+X9\+6*VGQO\9VX_L[2#X=OOLK3E&GNV^TO]INFDNMJ>9L7Z2_
MX8DD_P"CN_VWO_#]K_\`,C7S&+BJ.88V4,7"G4G6M-NAB)N+2IZ1E!I+92TZ
MJ^NJ7L4I8BMA*$*N!<DHQG[N(H)*6L6DIQ<DG%M23;4D[/3;W7P'\);/P+\1
MOC5\1K?5KB_OOC1K?@C7-3TR2WMH;/0Y_!7@C2?`]O!I\T7^DW,5]::1'J$[
MW;/+#<W#Q18@1,>+_#K]D+1_AS_PH?['XSU35_\`A0VJ_'G5=,-_INFP#Q1-
M\>M4UK4]9BU<0`BRB\.?VU/;Z.MGY@NK>*W6^`((JE_PQ))_T=W^V]_X?M?_
M`)D:/^&))/\`H[O]M[_P_:__`#(US*<TII8^FO:>SY[87%+F=.C*A"^NMJ56
MI%ZZIMO576D85(J*_L^;4)<T5+$X9J+]JJUDN31*HKV71);7/&]?_P""<)O?
M`NC?#_PA^T/X\\`Z9)\`-<_9L^(=]I'A7P9J5]\0/ASJ7B'Q!XHT\K_;-C=I
MX1UO1]2\5>(K4:AI`N#J&CZI<V,T<%TMIJ-GZ!KW[$$EY<>(]8\,_%_7O"'B
MO5?CA\+OCSHGB&W\->'=:A\.>)OA=\(_#WP9M-)?0M762RUO0]=\+Z->W.J1
M7D\5S:ZEJYFTV>%+&W5NB;]B9USG]KO]M_@9_P"2]K_\R5)_PQ,_7_AKO]N#
M'_9>EQ_ZB/>M'B:W)*DLRBE*$XR2PF)=XU8^SE=RBU*ZU=TY)QCI:.F4\(JE
M7VT\LFZKU]HL?3A*.BB^6,)14$TW?DC&^[W/G_QO^QI\4M)^-OPCU_X0?%K7
M?!NWQY^UM\5/%WQ,B\.>!?$%QX6UKX\6OP^CTOPLW@GQ%YMIXCT*^OM`U0VU
MU:VT=[87VFV5]>7=JBB"\ZG4_P#@F?\`#34/!$_@B'QEK,=K%\,_@QX&T.^U
MG0?"7BUK#Q)\%?B)XY^*6F?$+6M)\3:/J'ASQ?>>+/%GCW5Y/&'A?6=#_P"$
M<U'3Y[JQMX+2*[`MO4Y/V*3&CR']KK]N$A$9B!\>UR0!G`SX3`R<<$D#U/&1
MG_\`#'<6\1?\-<?MR>80I4#X^0XD+9RJ%O"PW,N`2IVG;EU#1@YT>85^;]WF
M<85$N:K['!8J+GSUI54ZG)!*7OU)<JC91BDE%.[<O"0Y6IY6Y1OS?O,90G:3
MI^QYDY*_,J;LI-MW=[W2Y?<?@/\`!>?X*?"^X^'YU_P[JVH7.IZ[JLFM>$?A
MAX"^$.CPSZKY<=J+'P7X"TRUT&V?3K:WM8_M]ZNJ:G?S0^=?WDZ"&VM_DK2?
M^">-YI$OBCQ+;_'C6;'XJ:Q\2/`7Q5T#Q_X6^&WP\\#Z)X;\9_#_`$_Q3H]O
MKVH?"OP[8V_@OQ9K?C31?&GB+1OB;KNH1V&I^+].GLK:.;1VTK3Y8_1&_8\M
MA+Y8_:]_;?=L'YU^/D.P8P"`Q\*<_P`9)7>%*;79"Z"2T/V,`8Y)O^&NOVX@
MD6[>3\>HQC8,OD?\(F0``<@L1GUP4+84ZLX3J.GCX1>(4E-?4<1^]2E#G3A.
M+BXN2BY-)7O9.UT:RHSK0HJIE\JD<,TZ4ECJ"=.44EI*'*[I)+5MNRNWN<'\
M0/\`@GEI7Q2MO%M_\0?B]X@\7^._$^A_`Z-?&7B#P3\/=5MM/\9_`?Q-\0_%
M/AWQ=-X%OM#N/!&N:9K,_P`2-:T+5_`NJZ/+H0\,1P:=#<?;D_M-_3?A1^R)
M;_#'Q%\,/%4GC#1M5U7X<^$_C!X7:S\,_"[P#\)_"NLI\7M:\":M?7:^$/A[
MIVF:3I?]@P?#_3--LBB7NH:H+^]NM:U.\,-K%#0A_8O6==\?[7?[<++NVC'Q
M]A8<`,>1X4*G:#@G[P8CTJRO[$KL,_\`#7?[;_4CGX]IGCCMX2_S],4YUZE3
M]U/,(6A3E1M]4Q4>2$J:I2IQLERQ4-$EHK1:Y6E;.GAE"<JE/+9QE.I&M.4<
M71_>58U(U?:3;C[\W-<SD[N2;5^63.*\'?L)ZEX-NO#-O:_'SQ??^%/A)H7Q
M%T3]G#PO>>%/!,B?!B3XC:9=Z'<:M>ZI+I=Q)\5+KPIH-]>>'O!]KXQM(].M
M-"N9[;6K37;R1-2MZ'PW_P""?T'PYG\,:KIGQ;U&#Q'X;\?_`!5^)4%WX<\!
M>!O!GA.Q\1_%/X4M\)YE\(_#32K"Y\(>#],\/6,<7B[^SK2"^MO%/BZ74]0\
M1K<PZG-`GHW_``Q))_T=W^V]_P"'[7_YD:/^&))/^CN_VWO_``_:_P#S(UI'
M%8B-^7,H1YHN,K83$ZQE*<I)W6S=:HY:I2;ES)W:&L*DTWEDIM<O*YXG#RY'
M%)*4?=TDDK)]$DHV6BZO]EW]F>+]FRP\>Q?\)@OB_4?B/XO_`.$TU^73/"7A
MKX;^$=/U0:+I>A%?"GPU\'0Q^%_#']IQZ4NK^)+RP9KOQ'X@O+W5=182/!#'
MS/[3C9^-O["&`3_QDEXH(8[<9'[.GQH)[]@?0>E1?\,22#_F[O\`;>/M_P`+
M['/_`):-?)_[0/[)3:)\7OV-M./[3O[8&J_\))\?/$6E&]U;XVO?:AH?V?X#
M_%S4EU'P_<#PU`FEZG.++^S;FZ$<YET>]U"S,)^VO-$\+&E5QDJE;&TE*6%Q
M5VL'B4FXX22AI%Q2V4=%9;VMHM*L\5"BHPP-1KVU!\KQ>&6]:%W=PN[7;MUL
MM4V?L5%(JQJI_A`&,CT!]?>G^<OH?S7_`.*KX?7]B5V52/VNOVWERJM@?'S<
M!P.-S>$BS>S,>>".G#_^&))/^CN_VWO_``_:_P#S(UQ0IPY8_P"UTK67_,)B
MMO=_O/I?K_P.AUL5?_<JC],3A>ZV]Q_+;9'V[YJ^A_-/_BJ3S(_[O_H'_P`5
M7Q'_`,,22?\`1W?[;W_A^U_^9&C_`(8DD_Z.[_;>_P##]K_\R-4J<-/]KH]/
M^83%?W;]?-_CV%[7%?\`0%5Z?\Q.%\O^G?D[>B/MOS8_[I_)?\:/-C_NG\E_
MQKXD_P"&))/^CN_VWO\`P_:__,C1_P`,22?]'=_MO?\`A^U_^9&A4X:?[71Z
M?\PF*_NWZ^;_`![![7%?]`57I_S$X7R_Z=^3MZ(^W?-0=`1^*?\`Q5'G+Z'\
MU_\`BJ^(O^&))/\`H[O]M[_P_:__`#(T?\,22?\`1W?[;W_A^U_^9&E[.'_0
M71Z?\PF*_N_WEW?X]@]KBO\`H"J]/^8G"^7_`$[\G;T1]MO(K*P`.2#CE>O_
M`'U7Q;XO=5_;\^``/(;]EW]IEU(Z$#XE?LTC'8YRO'&WIEN]53^Q+(H+?\-=
M_MO<#/\`R7M>WU\(D?GD5\F^*?V1Y8OVUO@KX;7]J']L*8:K^SG^T#J;ZY<?
M'!V\1Z:=(^(?[/D']FZ5J2>%U2WTC5/[46XUFS:U9K^YTK1F:6-;(A^K`TZ?
MM<4UC*//_9N.4U]5Q3_=O"5HR=F]U2E7>ZM9R6L5%\V)JXK_`&6V"G?ZW12O
MB\,GRN_.TO9V:5HJV[326[:_9#SE]#^:_P#Q5'G+Z'\U_P#BJ^(O^&))/^CN
M_P!M[_P_:_\`S(T?\,22?]'=_MO?^'[7_P"9&N94X:?[71Z?\PF*_NWZ^;_'
ML=/M<5_T!5>G_,3A?+_IWY.WHC[=\Y?0_FO_`,52>8AZC\]G_P`57Q'_`,,2
M2?\`1W?[;W_A^U_^9&C_`(8DD_Z.[_;>_P##]K_\R-"IPT_VNCT_YA,5_=OU
M\W^/8/:XK_H"J]/^8G"^7_3OR=O1'VYYB?W?_0/_`(JCS$_N_P#H'_Q5?$?_
M``Q))_T=W^V]_P"'[7_YD:/^&))/^CN_VWO_``_:_P#S(T*G#3_:Z/3_`)A,
M5_=OU\W^/8/:XK_H"J]/^8G"^7_3OR=O1'V[YJ^A_-/_`(JD\R/^[_Z!_P#%
M5\1_\,22?]'=_MO?^'[7_P"9&C_AB23_`*.[_;>_\/VO_P`R-"IPT_VNCT_Y
MA,5_=OU\W^/8/:XK_H"J]/\`F)POE_T[\G;T1]M^;'_=/Y+_`(T>;'_=/Y+_
M`(U\2?\`#$DG_1W?[;W_`(?M?_F1H_X8DD_Z.[_;>_\`#]K_`/,C0J<-/]KH
M]/\`F$Q7]V_7S?X]@]KBO^@*KT_YB<+Y?]._)V]$?;OG+Z'\U_\`BJ/.7T/Y
MK_\`%5\1?\,22?\`1W?[;W_A^U_^9&C_`(8DD_Z.[_;>_P##]K_\R-"IPT_V
MNCT_YA,5_=OU\W^/8/:XK_H"J]/^8G"^7_3OR=O1'V[YR^A_-?Z-7S[^U;*#
M^S)^T00&^7X%_%O(XZ'P%KXSU_SSUKR3_AB.3_H[O]M[_P`/V/\`YD:\4_:/
M_8Y;0OV>_CIK#?M5?MF:N-*^#GQ-U+^R]9^.?VS2+_[%X*UNX^P:G8IX6@6]
MT^\V>1>VK31B:V:6-71G##7#TJ3Q.&4\92C%UZ-VL)BOYHW^UI;5^;TN95ZF
M)E0K1>"J6=*6^*PRUY4E_P`N^_KI;30^\/@3(H^"?P?RN?\`BUGP[!Z=O!^C
M>O/T_#U%>K>;'_=/Y+_C7YN?![]C5M6^$OPNU%?VKOVTM-6]^'/@6[%EIWQW
M\BPM1=>%=)N!;VELWA6;[/;0^9Y4$(E?9&$'F-TKTC_AB23_`*.[_;>_\/VO
M_P`R-9RITO:5.7&4G'VM2S^J8O;VCNM^GO*]]=]-#2%7%*,$\%4TA3VQ6%=O
M=C?7V?X]79GVWYL?]T_DO^-'FQ_W3^2_XU\2?\,22?\`1W?[;W_A^U_^9&C_
M`(8DD_Z.[_;>_P##]K_\R-)4X:?[71Z?\PF*_NWZ^;_'L/VN*_Z`JO3_`)B<
M+Y?]._)V]$?;?FQ_W3^2_P"-'FQ_W3^2_P"-?$G_``Q))_T=W^V]_P"'[7_Y
MD:/^&))/^CN_VWO_``_:_P#S(T*G#3_:Z/3_`)A,5_=OU\W^/8/:XK_H"J]/
M^8G"^7_3OR=O1'VWYL?]T_DO^-'FQG^$_DO^-?$G_#$DG_1W?[;W_A^U_P#F
M1H_X8DD_Z.[_`&WC_P!U[7_YD:%3AI_M='I_S"8K^[?KYO\`'L'M<5_T!5/_
M``IPOE_T[\G]R/M*X<-'*!U,4AVCV'Y?CG%?'W_!/9U7]BS]G0L.GP\M1C*G
M&=3U'H,^HQ6)<?L4RI#*!^UU^VZ?W;@D_'I1T!SPOA#=DXQU!V?=(.#7RW^P
MY^R')XH_9*^`^O-^U%^V%X>?4_`MM<-H_ACXV_V9H%AF_OT$&F:>WA>Y-G:@
M*"D!GE\L';YK8#GKITZ;RW$M8NG=XW`\W^R8FRD\-C;?:NM%M9_S.6EGSRK8
MGZ[3M@I_[E-NV+P[T]O2T2<+WW=[VT]3]B?-C_NG\E_QH\V/^Z?R7_&OB3_A
MB23_`*.[_;>_\/VO_P`R-'_#$C]_VN_VWO\`P_:__,C7'[.'_072Z?\`,)B_
M[M^OF_Z1T>UQ7_0%5Z?\Q.%\O^G?D[>B/MOS8_[I_)?\:/-C_NG\E_QKX?\`
M^&*&PQ_X:Z_;?XW#_DO<><`GO_PB6,>Q_&I!^Q(Y`/\`PUY^V\,X_P":]K^1
M_P"*1/TX[]Z453E9?6Z>R>N"QL5K9--NUGOH];-/:P_:XI;X*HMO^8K"_P!W
M1?N_N^78^W/-C_NG\E_QH\V/^Z?R7_&OB3_AB23_`*.[_;>_\/VO_P`R-'_#
M$DG_`$=W^V]_X?M?_F1JE3AI_M='I_S"8K^[?KYO\>PO:XK_`*`JO3_F)POE
M_P!._)V]$?;?FQ_W3^2_XT>;'_=/Y+_C7Q)_PQ))_P!'=_MO?^'[7_YD:/\`
MAB23_H[O]M[_`,/VO_S(T*G#3_:Z/3_F$Q7]V_7S?X]@]KBO^@*I_P"%.%\O
M^G?D_N1Z!^VNZG]C7]K?`Z_LQ?'H8^7_`*)9XKYX)^OZ5ZS\*G"_#/X=9'`\
M"^#@3URW_"-Z5QSSS^1[]#C\X/VN/V.VT#]E+]IW7#^U1^V1K?\`8G[//QIU
M<Z-K_P`;QJ6@ZO\`V;\-_$MY_9>MZ>/"T!OM(O\`R?LFI60FA-S9330"6/?N
M'IWPW_8REO\`X?\`@2[;]K/]M6V:Y\%^%)S!:?'=8[6(W'A_392EO&WA-VBA
M0NRQQ98J@'[PYR>N<*7]G4%/&TDGC\1HL)B=9?4Z-E?FNGJ]+6TW2>F,*N,^
MNS_V*7+]5I6_VO#)N]:7/M':*2OI=WM'9GZ)^;'_`'3^2_XT>;'_`'3^2_XU
M\2?\,22?]'=_MO?^'[7_`.9&C_AB23_H[O\`;>_\/VO_`,R-<BIPT_VNCT_Y
MA,5_=OU\W^/8V]KBO^@*KT_YB<+Y?]._)V]$?;?FQ_W3^2_XT>;'_=/Y+_C7
MQ)_PQ))_T=W^V]_X?M?_`)D:/^&))/\`H[O]M[_P_:__`#(T*G#3_:Z/3_F$
MQ7]V_7S?X]@]KBO^@*KT_P"8G"^7_3OR=O1'VWYL?]T_DO\`C1YL?]T_DO\`
MC7Q)_P`,22?]'=_MO?\`A^U_^9&C_AB23_H[O]M[_P`/VO\`\R-"IPT_VNCT
M_P"83%?W;]?-_CV#VN*_Z`JO3_F)POE_T[\G;T1]L22)M..,9.3MP.HQ\I)[
MX[X]#CCY!_9K94^,'[;Q89S^T7X>('7@_L__``;/?IZXK#;]B:1!O_X:Z_;>
M;'\)^/:XSS@G/A`]#U]/3-?+_P``OV1FUKXH_M=:>/VHOVP],_X1SXZZ'I7V
MW2OC>;:_UO?\$/A1J+:AK\Y\+R)J&I*U\+"*Z6.#RM*L=-LEC*VI9^G#TJ+H
M8YO&4E)4<-9+"8JW^]TU9JZM=7UV5K):W.2O6Q7UK`7P4_XN)_YB\,FK87M[
M/5NVW1Z[61^OOFQ_W3^2_P"-,DDSPF%.<@G';''!Y&>ISW/I7Q/_`,,1R?\`
M1W?[;W_A^Q_\R-,;]B9DV@_M>?MOY)(`'Q[4DD#..?"623^?3UKD=.%M<52:
M:LTL)B[ZJ*Z-[-N[V2NVTDSK]MB[JV"J:.+_`-ZPN\7%Z^XM-+?X>SL9/[.O
M_!.']DS]F3QWXT^*G@'X6Z)J?Q8\=^+O$WC+7/BIXT6/Q1XXCU/Q7KFHZ_J-
MMX?O]0@^R^$M,AN]1E@M++PO:Z7OM%C2^GNY5>1_N^,11EF"*&<@L45%+,.K
M,0<DXXSW''%?$R_L3LQ*C]KO]M\$`'!^/:YP?;_A$B13_P#AB23_`*.[_;>_
M\/VO_P`R-;XBK5QE:5?$YE*O5:A#FKT,=)J-.,*<8QYY?"HQM'EO'E2</=L8
M8>B\'!4L+E:PM-7_`'=&MA(0O)J4I-*FKRE)N4F]7)W;OM]N^<OH?S7_`.*H
M\Y?0_FO_`,57Q%_PQ))_T=W^V]_X?M?_`)D:/^&))/\`H[O]M[_P_:__`#(U
MDJ<-/]KH]/\`F$Q7]V_7S?X]C?VN*_Z`JO3_`)B<+Y?]._)V]$?;OG+Z'\U_
M^*KX^_:`D!_:*_81P#S\9?B^.J]1^RS\:R>_3GC';%89_8DDP?\`C+O]MX\?
M]%['_P`R-?+GQL_9$DTKXZ?L::2/VH/VOM2'B/XK_%*S.I:K\:S=:MH1LOV<
M/BWJRWGAR\7PU$FF7]T+%M,O+DQ7/VC2;Z_L/+`NC-#K0I4I5/?QE-)4ZDM,
M+BE=JDVE=M]4[NVGGL9UJV+Y%;`U'[]*]\7A5_R\AUY$M/FW9)'Z_+*`,'W[
MK^6,_P#UJ=YR^A_-?_BJ^(1^Q*[?\W=_MO9&,G_A?:<_EX07Z=/QXI?^&))/
M^CN_VWO_``_:_P#S(UBH4WJL91:;T?U7%;7BNC7][HC7VV*OK@JG3;$X7M%_
MR;_JDS[=\Y?0_FO_`,51YR^A_-?_`(JOB+_AB23_`*.[_;>_\/VO_P`R-'_#
M$DG_`$=W^V]_X?M?_F1IJG#3_:Z/3_F$Q7]V_7S?X]A>UQ7_`$!5>G_,3A?+
M_IWY.WHC[=\Y?0_FO_Q5'G+Z'\U_^*KXB_X8DD_Z.[_;>_\`#]K_`/,C1_PQ
M))_T=W^V]_X?M?\`YD:%3AI_M='I_P`PF*_NWZ^;_'L'M<5_T!5>G_,3A?+_
M`*=^3MZ(^W?.7T/YK_\`%5Y1\<,GX+_&#'\7PN^(..1DY\(ZPO/)SSZ#U[U\
M\_\`#$DG_1W?[;Q_[KVO_P`R->;_`!@_8T.G?"3XIWC_`+5_[:>H+9?#KQQ=
M&SU#X[^;9W?V;PQJ<_V>[BC\*PR36TQ013Q"9!)$[J2`<C2A2I.OAE/&THKZ
MSAM?JF+W=6GT]?\`@K8RKUL6J%?_`&*=O8U+WQ6&7V=KJGI]ST73K^:-%-S%
M_P!-O^_R_P#R-17VJC1T_?+I_P`NY_W?[_\`5WY7\9<^G[BIT_YB(=>7^YY_
MGY6_8O\`8;_Y)G\2_P#LZ7]J[_U?7C:OL^OBO]A]L?#'XE'J3^U+^U:<<?\`
M1>O&WK]>YQQU%=GKW[57PW\"^+?BIH?Q/\0^"_AUX>^&U_\`#[28O%6O^/=%
M4:IJGQ!\.ZOXAL=/UC13#%>^$;LPZ-=1Z);ZI-<3>*(E>YTM1L$#_'XV$ZF8
MX^-.+G*->4G%-<UFX17*G\3<G9)7?6UKM?0T:M.GAL/*<U&-1*,)2NDY6D[-
MVM'2+UE9:;GU#17Y\_$?_@HA\%_#GB+]FCPO\.]:\&?$V_\`VG/$UWI_@S4A
MX^M_"_ARV\*Z-)-:>(/$QUF30==:_P!2MM8A/AS2?"C65A=:EXA,NGW^H:$D
M+W->V:%^V-^S%XF\+>/?&^@_&_X;ZEX.^%[0+\0/$</B>Q72O"OVJ66"QDU.
MY<HBVNISP3V^D7EJ;NTUJYB>UTJ>]F5D7"6&Q,5!NA5M4UBU"4E_$=+7E3Y;
MU(RC'G4;N+:TLREC,*W5BL11O0DH54ZD5RR=&&(2U:O^YJ1G>-U9M;II4OVT
MOBGXE^"7[,7QI^*_@TQ)XH\%>`=4U30KN[B-SIFD:E/-:Z9;>)=8M<[;G1/"
MK:@?$>M12@0OINEW*SNL18UP/P(^%7P.^$E_INOZ%\7M4\?_`!*U_1M)T+Q5
MX\\6?';Q'XPO_B9J_B$+J-KK6H>&-2\97G@^+7/$,NC:E=>%;;PSX:TNWTS3
MQJ.F^%+6+1K>:"+.N/\`@H1^RGXG\5VWPL\+^/O#'CGQ7XN^$_B?XD^%=.2Y
MC3PIXMT;1?[9L[SP]-KE]:FSLM1O&T35FO;'5+6."RTK3M3N=1>.2U-C+RGP
M]\?_`+"_P]T_X':"=(_9E^!WC#XG6G@?XL^`?AMH,/P]A,?BOQAH)T_1M=\.
M:IH.CV&E7=W=OJVJ>%?"WC.(::?$,;75MH5R]MJ+V0U=*O"A3A4PU6/-452$
MU!MSI5*5&<)337/&#4U*FXW4G-W=X2MR^TYL9.M1Q%"=-4'0JTW4:G3J8>M[
M\J<5^[E9U*<*BUFE&\79D'[9W[2_B_X9>-9/!'A3XE^`_@KI7@3X">-?VD/B
M)\1?'WAV'Q?)?:+X=URV\-^%/`?A#PO<Z[X?M[^Z\1:XNHGQ1J"7-QJ>G6$6
MAZ5H=LFK>)+2\MOS<N])^)M_\&[3X4:#XGB^'OQ2N_A'^QG^S[JWQ!M?#DFH
M>,;[Q[^V?\0-;^+7Q[\,VU]=Z\D6E6%GX;UG3M=E6VMUU>QDM)(K;4(K34(_
MLWZX>(_B1^Q;\:_C!H7PI\4ZI\"?B%\;/#,GC#1](\&^)M/\,^*?&GANXMK4
M6_CK1=,@U;3[JXT^]&GQ$Z[H]M);W=[I</VN:SN=-C-S'QG[2_AOX(>`?%WP
M_P#B1\2OCGH'P'T30;S5_&OA[0YM%\%:5I7BCXM:!X,O?!OA[XDZUJ-UI4WB
M3QGK'PS\%ZO):^&_!4U]+H<WV;2[J[TV^&CV<4?;A\32H/#4/J[A55.I4E*I
M0IU(R<&FN6\93?/*T$FG&*E=)*,I/AK89XAXG$_75:I*C34(U>2-.G&<4U):
M0IS<4Y.ZC.=DKRO#E_-'2O@Q8>%/B5XDUK6;_P`!_$;PKHG[4'PS_9%^%/A-
M?A!X;\+V'@7P-\&]`L/CI\<]1\`Z?X:U>U.@2WFH:/\`$2VO;+2L0ZUXJLM(
MU;7EO8M-ATY?IFZ^*OQ0^,?P1^%/BOQI\2/A/XY\._M=?$#]G71-%^`OA[P=
M!+9_#3PC\1?'VG^,IVU7Q?9^,$\2>,+NW^%'ACQ0VNW.J:?I5DGB[3KN\TVW
MBTO2+K1I_I#X3:Q^RI\)-$^#W@"X^-G@;XB^//'/B#7?BY\._&/B:_\`#6I>
M./B;XK^,NJ>);_Q/\3?"R:-91V6GP^*K[5?$NEI+X7LM/T72=%E_X1>(VNGO
M''<:?PO\=_L"WUS*?@Y>?LVVLC_%S3-)O)O`VB^#],:7XR^*[/7-&T!L:5IM
MH9O%'B>TE\3:-HWB.,W$6KP2ZUIFEZO<_:KY&*^.]M*566!K<U&5"-XT%)QA
M&C=)-14(QJ.<*DG%JTE;F6J"A0HTO:4EBX1A5BG2A'$M<T_:2A*>LWS27)*&
MJ>]W%M-K\W-`_:7_`&D8I+WPI^S5I^F6GB3XHM\2?VL_$OC'Q5<?#>31Q;_&
M'XU^//!OP)\,:S'\3/B-X(FTGX>MX2^'-JWC'Q1X(TKQQXELH;S3++1-$LM2
MNK?^T?Z!/"[:HV@Z4=<^RC6C96_]KI8O<26$>J")/[1BL'NUCO'L(KOSHK%[
MM$NGM$@>Z5;EY5'Q#X\\9_L#>$I?!FI_%&Y_9MTV;X6^+;KX9?#_`%#Q5X>\
M&&^^&_C#PVFCZAJWA/PE+<Z5<7'A27PRMUH6H:Q'I4=EIGA^6ZTRXU"YT^>2
MW:?VR^_:L_9]T#XE6'P:UGXN?#[3_B?JE_IVGZ=X)N/$EI#XCO;[6](@U[1;
M1=/(8K-K>EWEG=:+Y]PHULW,4.G/=W?F0+SXFK];49X?`U,/3?--IPDY25XQ
MO*2NGRN7*DK)-VU5I'9A(_475CB\RCB'..'C!5*B2@J=+EY5'2,9+:3?O3>K
MOT^D:*^&O!_[??P/^*EW;V/P@US1O&UU9?'NU^`_BVUU#Q'9^$[K0=4N&\5P
MIK6F0:I;S_\`"4#4+CPCJ+>'-!L)+?5M=M(KN\C6S^PRPOZ9I/[87[->O:A\
M1=*T7XS_``ZU75/A)I>L:W\2+#3_`!3875SX2T;P[)-;^(M8U!8=\=QI/A^[
M@EL=:O\`39-0M]*U!38WSV]UB(\DJ%>$N65&I&79PE=+3?2U[M:7]+['?'$4
M)QYH5:<HZZJ2>RNVTG=*W5JU[+=I'TS7Q+^U!_R6_P#80_[.4\4?^LZ?&JO<
M_A/^T!\'?CG!KT_PB^(O@WXC1>%M271_$DO@_P`066N1Z+JDMO\`:X+:_DM#
ML2.\M3Y^GW:E[/4H%DEL)[F.*1E\,_:=)/QN_80.,$_M)>)^,YZ_LZ_&CO58
M=..)49)QE]7Q>CT_YAY?Y]1591G1C.$HRA*=%Q<6I:>UIM72=U=6W2:OJ?:T
M7^J3_=%>)?&#]HSX.?`:WT:X^*_C?3/"0\17-];:):SPZIJ6IZH-*C275KFS
MT?0M/U759=.T=)8)-;U?[''I&BPW-K+JM_:)/&&]MBSY28Z[!CZXK\TOVYM-
MU*+6/!'C3X=:-^T59_M">$O#_P`0(/@_\0/@9X#LO'_AV.\UYM"%_P##3XQ:
M-JGG>'#X`\;:AI'A^;4)_$\6CV>GC09-9L/&?A_4K!G,82G&M.G2E+D4Z;49
M6;49VBHN6CM&[]YZNVR;T#%U:E"E.K3A"HX3@Y1E)J]-R]_EMJVH_P##JY]>
M#]H_X-'3]0U0>.-&^PZ5\1M&^$.HRQRW$CVOQ.\1W>B6/A[P3]ECMVNYM<UN
M7Q'H4NE16UO-;7NGZK9:M#</ILGVI:/AO]J3X!^,/#6G>,/"_P`3?#.O>&=8
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MXB5>G.3::]G[*#A4@FI.?+9-Q;\FOF>,I3I-82,Z3=JKIJM*JO\`:<#2A.$>
M6UIQQ-6\96<>127-9H_<+XN?'7X6?`G0M.\1_%;Q=IWA#2]9U)=&T@W4.H:E
MJ.KZL;2YU!].T;0M"LM5U[6;BWTVSO=3O$TS3;L:?IEG=ZA>F"SMWE'F/BC]
MMK]E[P7I'@OQ!XH^,G@S3=!^(FC#Q-X+UF'49-7TS6O"OF6<$GBZ2^T2WU*W
MT?P?;7%];6U]XLU^32O#UA<R?9K[4;:Y5HD^8_B-X;^/OPD^.G[/GQU^*<^M
M?M,>&?!UA\??!MY;_`?X'W>C^)?`B?$S3OA[=^$=3D\`6GCSQQK/B>%9?!.M
M^'-6\4Z/+;2:8/$5B+VPM]+GU"['R3\.OA_\7/@!X<^*2>+OV<_B?XUG_:4_
M9H\3>#?`_A;P)X9L/%Z_#KQ9X@^+W[0OC*'X.?$*>RU";2_!5@VA_&[P@-3\
M174Z>`;67P]K\%UJ1N-,M8KQ8?!X:=*$ZE=.IRT^90G&$)2G.I&HH>UBIQ]C
M&G&I)M-2C44;77,]*V/Q-/$.C3I*$5S0<ZN'K5I<\(TW&I)T:T:<56<W&"N^
M7V;<DG='[2>+_CC\+O`/B'X;^$_&7C'1M!\2_&'6KGP]\+]$N;KS=0\<ZS9:
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M5=2C:3<%3YG?F<;_`$:^=C?0]O7MU_6OBSQ;_P`G]_`+_LU_]IC_`-61^S/7
MVG)]QOI7Q9XM_P"3^_@%_P!FO_M,?^K(_9GKGP/\?%_]BG,O_5=C_P`CJQ/Q
M83_L)A_Z73/M:D8X!/H.W7Z4M(PR,?J>U<QT_*_EW\CB_'/Q!\(?#7PKK?C?
MQWX@TCPGX3\-V?V[6]?U[4;73-*TZU,L4"27-U<NB*99YH+:VB7=-=7<\-G;
M1RW4L<+>=?!W]I?X,?'J35[?X6>-;#Q-?>'7M4\0:1]GU31?$.AKJ$#W&F3Z
MOX9\16&C^(K&SU2&&Y?2[^ZTJ*QU$6US]AN;@VUR(O)OVU/"'B[Q!X$^'GB#
MPKX2U#XC)\*/CY\'?B]XE^'&B065YXA\;^$O`_B&6[UVPT#3M2O+*QU?7=#2
MZMO&>A:+<W5LVL:MX7MM/LW^VSVBR?"O[0?AWXF_M/ZA\7_BE\/?A)\:_AWI
M+?`CX>?`^SG\0:'JWPQ^+_CO7-4_:3\#>._$%UX9\/I<Q^,])T;X:^#M.U.6
MV\2ZA'IDDMWXEUI-&BN+33I[^;IPV&I5*=&-:ORRFK3KI14*$HU:%O:0TE44
MZ<JM_9*T5%26JNO+Q6+Q-&I/DI3:I0]HL/'#SJSQ$9<R7)B(UHTZ37([J<')
M-WM).$7^V\LOEIO$;N0<!0/FYX&,\=<#^E<'\-/B?X/^+O@[2O'W@2_FU7PQ
MK-QK5I87TUE=Z=))<>'M>U7PSK$;V=_#;W<1L]:T>_LRTD2I,8A/"9+=XI6_
M$WQW\$/B1X6_;5^%`^$7P:\6^"/`?PG^+_P7TGP]XH\'>#_B-XKTG7O@??VM
MO)\2M1U[XSZM\7&\+>$M(LM3U+5]`UWX51?#G5=5U>.%_%U_/)_:7_"0V/U-
MX:^&_P`?]*_X)F^,OAYX!T_7O!?Q[GT+XY?\(GILJII/B:WO]<^+OCS7-.33
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MFW.SA':;CNOZ`#)CC:Q..@&<>F>YS0)#G_5N/<C@>YK\)?&_@;XQZ_\`$G]J
MG]G?0K3QAJ?@_P"`'PX_:)_:!^&EWH>KW,USXJ\>?M:?#CQ-8_";X;Z=':7Q
MU#^T/A_XDU#XZ+I&DW:I%!;7_@"]M4W)92Q\WXW_`&+;_1?#_P`99?`W@WXT
M2:Y9_L9?"[XE?#*&/X@_$^^FN/VU-+D\<P:KXRT^"[\4W":A\:8+33?`T6IR
MRF4/9W$-I-;>7J%^]PYX!4E'VN+I<\H4ZD:<*:G^[JN#@W-5DU)TIJI*'LN:
M.L6KILI9C7J5$J6"<J;JUJ/-.O*-3VN'C)U8QHQP\FU&<)0C)U>6H[2BW%G[
M^^9_TS;;@X88Q^&#D9Z>N?6I%;=VQT//OS^E?A'9?"'X]7'[=\_Q"\;ZI\7M
M+E@^,GA[Q#X"\4>'/@OXC\1>&=0^!</@+2H;GX>:[\:;/XOZ5X%\$^$;S5F\
M36'C#P+JWPQF\2#Q-+::[I4&M7%UIFJ0?NM`VY%/3<B,.G<;B,CY3@$`D<=<
M=..?$4%AY1BJT:[E%2DXIQY.9<RCJE>UTKKJG?5,WP&,EC8U93P]7#2I2Y'3
MJV4Y-2_B+E;2B[6C&]VFFT6*^?OVK03^S+^T2`,D_`KXM@#U)\!:_@5]`UX%
M^U.RK^S7^T&6P%'P/^*VYFR0J_\`""Z[EB!R0!U&"3C&,5-!)XG"INREBJ$;
M]KU(J[>R2O=MZ):LZ<3)0P^(DW9*C-MV;M97V6KO:UEJ[C_@9XGT&W^#'PCA
MFUG1XIHOA?\`#V.6&;6-+BEB=/"&CHR21-=!T=2K*RL`5964CY0*]6_X2WP[
M_P!!S0__``=Z7_\`)5?YU7C7_@D;_P`%*O&_C'Q+XT\'_LM>.=>\)>+]7G\3
M>&-:L_&/PWM[75M!UJ.&_P!+U&WM[SQY9WD$-Y93P3+%<VUO/&&V30(R,IYK
M_AS+_P`%3/\`HT+X@?\`A;_"[_YXM?K"\-,B>K\1>&HN;<Y1=3#<T)3DI.$K
MX^#O!R<'>"=XVL]'+\Y_UYS>+<?]3L\ERMP4HT\0XR46HQG'ERZJDIQM-+VD
MFD];--'^CU_PEOAW_H.:'_X.]+_^2J/^$M\._P#0<T/_`,'>E_\`R57^<+_P
MYE_X*F?]&A?$#_PM_A=_\\6C_AS+_P`%3/\`HT+X@?\`A;_"[_YXM/\`XAID
M7_1QN&NG_+S"_P!W_J9>;_#OJO\`7K-_^B-S[I_RZQ7E_P!2KS?X]M?]'K_A
M+?#O_0<T/_P=Z7_\E4?\);X=_P"@YH?_`(.]+_\`DJO\X7_AS+_P5,_Z-"^(
M'_A;_"[_`.>+1_PYE_X*F?\`1H7Q`_\`"W^%W_SQ:/\`B&F1?]'&X:Z?\O,+
M_=_ZF7F_P[ZG^O6;_P#1&Y]T_P"76*\O^I5YO\>VO^CU_P`);X=_Z#FA_P#@
M[TO_`.2J/^$M\.?]!S0__!WI?_R57^<+_P`.9?\`@J9_T:%\0/\`PM_A=_\`
M/%H_X<R_\%3/^C0_B`/?_A-_A=Q[_P#)13_(T?\`$-,BM_R<;AK_`,&86WV?
M^IEYO\.^I_KWF_\`T1F??^"L3Y?]2OS?]+7_`$;;OQ9X>\F=AKFAD^5*57^W
M=)&[$9(7<;K"[RH5<\`GDXKY$_X)]^)-"M?V,?V=HIM7T>*5/A[:K)%+JVFQ
M2Q.-3U'<LB/<JRNI!W`JI5@594965?X3?^',G_!4X#G]D;Q\%.,_\5S\+00.
M[$#XB9R`,@`9)&!FN5\$?\$G/^"D'Q(\):!XZ\!_LO>.?$7@[Q/I\6J>'];L
M_%_PXM;34]/E=ECN8;:_\>V=Y#&[I(%6YM89/E!"["I;HCX;9%'"UJ4?$CAB
M:J8C"5I.-7"6I\M#$4Z=-WS1MSE&525_L\MI<K:3R_UUSKVT*[X,SR$84)4'
M%QK2<Y2J0J1FDLM;248N-O=3<]8W29_I2?\`"6^'?^@YH?\`X.]+_P#DJC_A
M+?#O_0<T/_P=Z7_\E5_G"_\`#F7_`(*F?]&A?$#_`,+?X7?_`#Q:/^',O_!4
MS_HT/X@#_N=_A=_\\4US_P#$-,B_Z.-PU_X,PO\`=_ZF7F_P[ZZ_Z]9O_P!$
M;GO_`(*Q7E_U*_-_CVU_?S_@HA_P65^.W[!__!0S5/AWHND^$_C'^SU-\.?A
MMXBO_`=[/#I.M:5J.JKJG]O:AX5\=Z,LTEM=79MH?^)9XALM9TII8MT-M;"2
M:<?JU^Q=_P`%>OV-/VV8M-T3P%XY/@7XHW,5LEU\(/BA)8^%?&'VN10LL7AR
M::\?0_&D$4PDC1O#.I7U\\:)-/IMKYB(/\\WX]?L_?&G]F7XA2_"OX^>!-5^
M'7Q!@T73-?D\,ZOJ6C:M>IHFM&X;3+W[5H.JZSIIAO#:W(6-;]IHW@=9HH6(
M!B^!GP`^-_[2'CBR\!_`'X8^-?B9XU2>.:&U\(:9<2Q:'ME95U36_$!>VTCP
MQ;6TB+NU'5-3L8()`,7`F4!_T''^%?"-?A[+ZRS3`8"MAL!2=;B+"5Z3P&.?
M)"K+%U<&ZO+BZE2%2#YJ6)HUTDE5E5]U1^3P?'?$6'S>O3E@\5B:6+QV)J1R
MROAZSKX;DE"E/#TYQH>UBZ<XM>^E!W4H1<4V?ZK<OBC1+:1[>\U+3;&XCP9;
M6\U/3[6Y3)^5F@FN8Y$#'[K-P1C&,5H2ZM:0Q/<2S11V\<8FEN)9H8H(XL;B
M[32.D814!?>7",GS!BK*:_SN_C#_`,$<?^"N6H^-KZY\7?!WQC\;=>_L+PQ:
MS^/]+^*/@[Q%;7MM::!8P:?H`U_Q5XRTC7-4D\(6JQ^')KF[LFA$MB\>GWVH
M6%O;WDW]HW[8GPP^)'C_`/X)Q?&;X,>"?"U]KWQ2\3?LV+X(T+PG97>G6^HW
M_BE_"VG:8VE0WUW>6FFPW"7L;PF>?4(+;=$6%QC##\1SSAK*LIGDT<'Q5E.=
MT\VK2HU,1@)0C1P'+*@E4K)XFK5Y9QJU)+VL*"M0GRN6O+^GY7Q!F..HYM6Q
MF08W+5EU"-:A3K+$2GC)6JN=.FJF$H2YH\E-/E4V_:+9KWOO2V\2Z+?OY.GZ
MGIU_-MW&*RU&RNY53H&,=O/(XRY"+\N"Q'/:BZ\1Z18,$U#4=.T]SE@E]J-C
M:R-&#@R+'-/&63G&Y-Z<=CP/Y*/^"$?[`?[9_P"RC^UKX\\??M%_`KQ3\,?!
M>L_`O7/"FFZ]K7B/P?K%G<^(KSQ;X1U*UT\6_AWQ1KMU'+)8Z=J$BS26T4(6
M*1&G0R8?L?\`@OI^PA^V+^UC^T#\$/%_[./P1\3?%'PSX5^#>J>'/$.IZ%XA
M\(Z1!IVNS^,M1U.+3)X/$?B;0KB6>33YH+@2VT%U;B)TB,R2J$JGPKE:XM_U
M<7&&3?4I8-XF.=J,'@U.6'E4I47*..E"+G4BJ7-S.,9-N4?=:>:XDQBR'^UW
MD>.>*5>I1>5J$EBE&E.,7-0Y.9Q:?,K*2:^%G]#'[95_:ZE^QA^UO<6LD<UN
MW[,?QY$=Q%)%/!*K?"OQ4?,AE@DD25.3ED//0UZ1\)?$>BR_#[X;6<.IZ;<7
M4O@7P8%@M]4TVXG:0>'=.&Q88;IYY2BJ7=HXV15!8OA2*_,GX(_"KXB_`_\`
MX(@:W\)?B_X=O/!GQ%\"_L4_'K2/%WAO4[NPU&]T:_;PE\1+Y8;R\TJ]U+3Y
MI/L-Y;2$VM_<H(V13*3\B?SN_P#!*/\`X)G?M\_!_P#;D_99^-/Q._9T\8>%
M/A7X<UJ]UO7?&&H>*/`UY86.E:QX$\16.GW$MEIOB_4-4E2YGOK$K'%I\LB+
M<1>8D:B4JL%PY@,PRC/:M;B/+<%+(\9CG@Z5?D<\WE1PZ@OJ;^M4OXK@N1<E
M35JR;LG6+SK%X7,\HI0RK%8B.:87#.M4BW2C@(SJ.I5]O&6'G*T(N"DI2I-M
M6C9W:_NDU#7--TMT74;RUL(Y`!'->W=K9PR.=P$<<ES-'OD^7.U>1G)XYHM]
M:T^]C::RN;6]@3(>:SN[>ZBC=2,AIH'>-6"G)3=Y@Z[,<U^!G_!P%^R?^T?^
MUI\%_@!X:_9N^%^N?%+7?"'Q9UOQ!XFTS0=8\.Z//I>CWGA*\TRVO;B7Q%KF
MA6TT+7T@C5+::YF1CN,2*#*OI?\`P0J_9O\`CU^RM^QYXK^'7[1'P[U?X:^-
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M\%'OB?\`&[PI^S9XUU7X4ZU^UI;_`!#TCQ;!XL\`V]E>^"T^(&CZP=;BT^Y\
M96NK);#3+>6?[.^FQW7EJ\8MF8")_P"F;_@L3\%/BY^T?^P-\7/A1\#?!6H>
M/OB+XAUKX<W&B>&=*U'2M,OM0@T;QQHFJ:K)#>:YJ&D:?"+/3K6XN)5N+V$R
M(K+"LK,$;T\9PWEN#S#A[`QXFRK%4L[CAOK.-HRIJAD[KRH^U6,2Q-1)X:%7
MVE12J4GRP=U%>\>?@N(,PQF$SG$3R3%82KED:LL/AJ]12EF,8.I&G*C.%%-*
MK.DU%1I5))23L]$_T[L]>TK491%I]]9W[#/F&PO;6\6'"[P)C;2R!"P^X&Y8
M9*\@U7O_`!3H>FW)M+_4]-L[@$9@N]3T^TFVLK%&\FYN8I"CC;M8*5.[@DBO
MYJO^#?/]BG]JW]DGQ1^T_>_M*?![Q#\++;QSI/PTM?"$NNZ]X6U==8N-#N?%
M<FKI;)X<\0Z\T'V6/4+'S6NUM`PD18VF='V?&?\`P6W_`."<W[<W[37[=?BW
MXG_`3]G[Q=\1_A_J'PQ^'/A^R\2:/XD\%Z99/J^CZ+J,&J6IM=>\6:1?*]K-
M.JO(;-(6W@1S./,,=X;A/`8CBK'<.2XLRFCA<)0K5J6?3G2C@,3*A2A65&G)
M8BM"52MSQA&U2[;7NJZ03X@S*.08/.(Y!BZN,Q-6G">54INI7HPJ3<)U:DI4
MJ,HJE&/M)PG",K-)7NC^RVXU.V2Q2^WJUK*%=9Q)%Y0AD5F69I6=8EAVX8R%
M]@0[MV!NKXW_`&8]>TBX^,?[:\=KJ6G7;W'[0>A7$2VE_:7+M#%\`O@ZCNL<
M,K,R(Z[7D1=BD_,XQFN>UKX8_$6Y_P""9T_P9M?#%W-\5Y?V+X?AG#X2^VV"
M:@_CW_A3<?AO^PEU"2[73!?#7`;07;:@MEYW[T7@C*SU_-%_P0D_89_:\^!'
M[>&L>-/C!\$_$?@?PI\//A[X^^&WC75=4U_PG>VV@^./$'AWP;XDT+P_<0Z1
MXBU.XN[O4M"U.QU&*YL8;NPA@NHDEO8I]\*<F49-@,9D?$N95L^R_"U\L]C'
M#Y;6E2CBLSIQJ\ZEAG+$TV^5Q;:A1FY<RLC7'YGBJ&<Y#A(Y;B\11QLI.IC*
M-"K.C@I5*:IR^L.,)1I\RDO>J.*A9I\K=W_:!=^(=(L3&NH:A86!F#&$7M_9
M6C2!=NXH+B>-F*;E)*@J-P)(QFOD#]OSXO>*_A3^Q'^TW\7_`(4^(8M&\;?#
MOX0>+?%WA'Q):Q:9J\-AK.BVOG6MPMM=)>Z=>+YT<D4T-S%/`R&1)8VR4/XG
M?\'`/[%/[6?[7?CW]FC4?V:_@UXC^*&G>!?!WQ$L/%EUH>O>%=&ATB]UK6/#
M,^F6]P/$OB/0&GEN(M.O'1K1;M45)%9HP<2>C>%?@W\5/V?O^#>?XS_"#XU^
M#M2\!?$KPM\`?V@&\0>%]6O=-U*]TY=8\6^(]8TTRWFCW^J:;,L^F7UI.@@U
M"X"+(L;[-OE+T87(<N6"X8S9YWEF*JYKGF"P&)R%RI/%4:%?$J"E7;Q,9*G7
MBHK6BHM5>5M[OFQV>XQU>(L!'`8O"T\NR?,,5A\T<9QHUJM##2]VE)QMSPF^
M9J[NHM)-7/F[]B?_`(.5?"NH?V9X/_;F\#3>$]3G$%BGQD^%6F7FI>$KAMH_
MTSQAX$>YO->T"0A#)<W_`(7EUBQ=GF/]C6"[:_J!^$GQM^%/QX\)67CSX-^/
MO"GQ)\%ZC'')9>)/!NN6&NZ6[.H9K6XFLI7DT_4(#E+G2]1BM=0MG5TGMXV4
MJ/\`)SW+&(R2H)"HFYE&]F4!50D@9;&XDD;4SO<'"2?N]_P2V_X)Y_\`!4W6
M_%^A?&+X!>)?%W['7@+5)+:2Z^)OC>6]TC3O&>C&4OBP^$%R!>_$JSN$3-M_
M;^CZ;H4XECGMM=C#I(WZQQ]X9\*X"CB<TRW.,#P^N9NAE^*Q/UG"XJ3<?W>&
MA3YL7@HQ@VX1Y,73E)*,%2A)>S^#X5X]SNO5C@<3EN*SJC"4*4<7@J3G6A&R
MM*I/W,/)4W93E5G&:C&3NZEHG^@)GK[=:*XKP#I'BK0_"VBZ;XV\6)XW\4VN
MFV$&N>*8=`M?"T&M:E%`BWNHQ:!8WE]9Z2MY/OE%C!=3Q09\M)'`#'M:_G=6
MUM)22E**DE9249./,KZ\LK7C=)V:;2>A^UQ;E&,FN5RC&3BVFX\R3Y6TVKJ]
MG9M732;W"OCW]H+_`).)_81_[+)\7O\`UEKXUU]A5\>_M!?\G$_L(_\`99/B
M]_ZRU\:ZVH_Q/^W*O_IJ9G6_A_\`;]+_`-.P/K].A^O]!3Z8G0_7^@I]<M#^
M%#T?YLU"BBBM0"BBB@`KR7XY?\D7^,7_`&2_XA_^H?K%>M5Y+\<O^2+_`!B_
M[)?\0_\`U#]8JJ?\?#?]A6&_]/0,L1_NV)_Z\5?_`$EGX`T445]L?*'["?L/
M\_#'XF#C!_:G_:M).<?\UX\;<]#]?Q]:\=^(/[*OC?Q;^T7XI^)_G>%+CPOK
M?Q__`&5/BW::;J,NH2ZE'HOP`\$>,/#/B:&>R_L2YLAKEQK'B#2]1\)K'>-%
M*MI+?3WVF7-I;)-R?[+/A+]JC4O#'Q9N_AS\9O@WX4\(R?M0_M1'3]!\5_`;
MQ-XTUNRD7XX>,ENC<>(=,^-7A&SO$N)Q+<111:%;-:QR);.\SQ[A].-X!_;<
M.,_M$_L^?^(O>-N/3`'[1V1C_P"M7SN)A6H9CC*M+'X",ZLW"HYK&QE32=.3
M5J>`K05YP7O1J-V>C6J/8PR6*R["QJX2K-*/,H*>'<;WG"_O54W>,I*TE;5>
M[T/F74/V*_'7BC4[JRO/$.@:)X:U[XE_MW^)M0O=+N-3;5M*\-?M8>%-3T+P
MO/H]G)IMI"_B30[O4[C4/$=LUY;6UO,T@L-2OFN/E\?\$_L!_&#PWX0M=2ET
MKX?P?%WX;WO[/5QX1U7Q)^T7\?OC-X2^)5I^S]XPN/%%KX6U6Q^(?A5V^"_@
MK55N+RZ\.:/X5L?&]SX0UZZ@O!<:M9Z8D-Y]\CP%^V\H^7]HK]GL#/(;]ESQ
MLV?P/[1V1]1WH_X0+]M\`C_AHK]GOU)'[+OC53^!'[1V">_7K^CHXW&4HN']
MH8%\LE4BTL<E*47*?+*?U/WTY2EI.BTI6>ZYUC4R[#592E4RW&.4DE)PJX!1
ME[D*5]:][^R@H\S7-965HZ+QGQ%\)/VC_%/Q&L?B)KFE?!JQOO&W[-GQB^!G
MQ*\/:)XM\8+9>"KCQAXDD\3^`]>\):G>>!';XBR0&./0_&KZM9>`C+>2W7B'
M2[4QI%HL_P`]VW[$?Q^TOX?>,/@SIL_P:U3P;\=/A-^S'X)^*GC+7]6\3CQC
M\,=0^!W@#PKX#\2K\/M`MO"%_I/Q$TR]M_"[Z]\.7UCQ)X%G\'>,=2U'6+VT
MOH+AHA]SGP'^V^`%_P"&BOV>3U/S_LO>-,CZ!OVCAG'<]^^*/^$#_;@QQ^T7
M^SIQZ?LO>,^,YZ'_`(:/Z]./7K5PQN+A2=+^T,O=-TZ5/EYL?/E5!T:E%6>`
MI./LYTJ<N95$VX^\YQE)2J6$P\IJH\!F4:D9UY\T)X!+FQ*BJ[3A5BI1J)?"
M_=BU[BCI;R'2_P!E[QE9ZIHNJHWA..[MO^"@/B7]JJ^NX9;M+RZ\`Z[X6\4^
M&;733,FD_/XS2SUS3K:^MII%TXZ?;W,$>LR!8D>]^V)8_$]_CW^Q3KWPH\$^
M$_&_B;PEXN^-^KI8^.;S7M!\*);S?!S5],S=^,=`\,^+;CP;JD\MW';Z-J]S
MH&H07%R[Z8EK)+="6#U#_A!?VW\9/[17[.G4]?V7_&O3ZC]I#'YT]/`O[;Q!
M_P",BOV>1DX(3]E_QD1D<@'/[1K'/?T_6N:E.I+$4\16QV6573I5J2BYX]VA
M7BHSARPP$[)WO=5;Q^S.+-OJ\)8;V%/"8S#J4J<Y3Y,$ZCY)J2<W4E.E.5TK
M2DI2MJG<^:/@W^Q!XG\%:9JNG>*]?\+J_BO]D?QK\#=7USP?:7MO?>'/&?Q7
M^+/Q$^)WC!O!5E>V-N]IX&T9_'=K8^&4DOK.[ND\/V+7VG6;11[/'?AK^P!\
M2=%^%'CSP]K]CX6T3XJZ5\*_A?X*^$_Q1/[0OQW^-%O+XQ^#'BNS\>^`->B\
M,?$O0K"/X2>!;7QSHFDZN_A+PI=^*+_3;34/$&F6NHRZ<+:*Z^^!X!_;?!X_
M:*_9[QD\M^R[XS8_I^T<N!^>.X'9&\!_MNKP?VB?V>@`"<C]E[QJH`YR3_QD
M<>G7V]*Z)8W&-M_VE@'S5(S:A+,8INE%0IN48Y9&+BXI+V;3@G'6&Y@L'AHJ
M,I9;C8OV<J;4IY7+E4YNI+E:K.,9.I)S4X^^MHM1]U?`WC+]@#XKZCI/PF\0
M23Z'X]\=0_#+XN^&/C]X>L?CU\:OV>?#?BGQG\<O'5O\2_'WBW0/&'PMT#6-
M;\3>'I/$<^L>&;WP=XLT"W&M^#(?#;6]]IT^B)92^SZA^QMXF&@?%;1M!A\$
M6/\`PF?Q+_8D\7>$]^H:_=-I7AK]EVU^#4.M:/J&JW^EW>N2W:1>`-=A\&F[
MN]3EOCJ%G-JNH:=<ZEJ;P_2:^`OVW\L1^T3^SS@\8/[+OC1L>F"/VCQTR3T^
ME'_"`_MND#_C(G]GHG)Z_LN>-,G![Y_:-/3M^76I>*Q,G)O,,O\`>;;2EF$8
MI2JQK.*C'*THI5%&245%)1Y5HK#C@,+R*+R_,)1E9V=7+I33C!4[N<\1[1\\
M6YN\F^9-NS;1\]2?LV_&34-5_L74)/`,'@O1?VY;[]J+POXDT[Q+XB;Q5J7@
MGQC#XVF\2>'-8\.3^$$T[0O%?AO6/%EG!H4UEXEUC3=?M+=M4NYO#EQ;?9+G
MQFW_`&'OV@=>^%7ACX1>*9?@=HVC_`S]F;]H3]GKX6>(O!VI^*;G5OBGJ?QF
M\%Q^`M,\2>/]%O\`P1IEO\.=!LM)M+;7/%N@Z+JGCU_$7C.4:NEQ#;Z;%;7?
MW7_P@/[;XZ?M$_L\\GC/[+?C7.._3]HT8Z<9ZTX^`OVW\'_C(G]GD^W_``RY
MXUY_\V/I?6,19+Z_E]E/VBO+,+J;C*+E?^S+[5)Z?"DY65TF7/!4)IIX',5S
M0C!N-7+J;<(N$HJ\*\;V<(N^[22ES1NB[\)?@QJ?@?XW^,/B)Y>@6?AGQ#\`
MO@-\)].TS2UGM[NTU?X1ZC\3+C4VFM5L+6Q3138>-M*M-`DBGEN%CLKRW>TL
MK=+<3\W^TZ3_`,+N_80&!G_AI+Q,1AN#_P`8Z_&GIQ[?G]`:UAX"_;?`_P"3
MB/V>/I_PRWXV('Y?M(#\>1]>]?(_[1'@W]KZW^+W[&$6K?'GX&WNHW7[07B&
M/PU/8?LZ^+-,M-)U1?@-\6Y;F_U:TF^/6H/K=HVE1ZA8Q:=#<Z1,MY>6>HF_
M=+&2TN8PU%UL4Y5<?@/]VQ2CRO'WTPTDE_R+%KM=N]VGS/>:UKMT,/"-+"8B
M%ZU#F2E@[MNK%MM^U>M[MV;N[V>I^N:2!0O&3M`(Y&.!W(_S^%+N3);:`3GM
MDCGL<?B.G-?(*^`_VX"`5_:,_9]P>1C]E[QJ0`<D<C]H\>IX'/M3O^$$_;A_
MZ.._9^_\1=\;_P#T1]<$<)%12^OX>UE9J>*NOAU3_LQ->G2S]3M>(G_T`UWZ
MU,*T]M6G7]7_`,%(^N]R#H`,?=XX&>N/3WZ9]ZBVC.>AZ'@XX38,?@?<9Z^W
MR3_P@G[</_1QW[/W_B+OC?\`^B/H_P"$$_;A_P"CCOV?O_$7?&__`-$?26"I
MZ_[;AG=:MRQ3>KB^N6NUKO[NEM%[>;_Y@,0OAO:MA5?EE":O;$+:44[;:6VW
M^O=Z^O\`/_"F%E*D$#!ZC!/7G)&WDYQZ\_2OD7_A!/VX?^CCOV?O_$7?&_\`
M]$?1_P`()^W#_P!''?L_?^(N^-__`*(^G]3@U%/&X5J-K<SQ3M\%]\M]5WTW
M#ZQ4_P"@'$+;55<(F[-;M8B[_P"'MTO]=J4`X`&3D@*5!/3/3T[XZY]ZE$RC
M`QV]3_\`$\_I7Q__`,()^W#_`-''?L_?^(N^-_\`Z(^C_A!/VX?^CCOV?O\`
MQ%WQO_\`1'T1PD(Z1QN%BG;9XGM!?]"WM?\`'L"Q%3_H!Q+\W6PK?3=O$-[7
M_'RO]@&56!`&21QR1S^5?%_B["_M]_`/G*C]ES]IB0-C@Y^)7[-`"X'?(Z]<
M]O70_P"$$_;A[_M&_L_'V_X9=\;C/MG_`(:/XKY*\6>#/VOA^W#\$;:?X[?`
MU_$\G[-?[0L^EZO%^SIXMBT>RT>'XA_L]QZI8W.A-\>YKJ\U*^NI]+FL-3BU
M>Q@T^VL=0MWL;Y]3@DL^S`86*KXA_7<-KEN/C+3$RYE+#SI\KD\%3Y6X5JD;
M\LK)N2;E&*./&5ZM\*UA,1%K&X9*U3"NZES.5OWKWY4GJFG:W+N_UV\Y?\Y_
MPH\Y?3^?^%?'W_""?MP_]''?L_?^(N^-_P#Z(^C_`(03]N'_`*.._9^_\1=\
M;_\`T1]<OU:/_0=AO_`L5_=_ZEGF_P`?EV?6*G_0!B>G_+W">7_3_P!?Q[*_
MU^95(Y`)XZ\]#GN!DYY'3GK4.V(E6VX*Y`P`",]>G8]\'\*^1&\"_MPJ"3^T
M=^SXHXR6_9>\;`9/`Z_M'\^_3C]&_P#""_MP\C_AI#]GC@<Y_9A\:@#/N?VC
M\')I*A#F:_M'")QBI->TQ*M%]6GEB:3L]7U36A7UFK%<RP&*LW;2IAI=.J5;
M\5W:UT/K[]V,D8S@]CSP!S@9/3O[T;E!'`]>$].G.2/S]O7CY"7P-^W"2%_X
M:._9Z/'5?V8?&K9QUQ_QD?SCOS^?>3_A`OVXO^CCOV??_$7O&W_T1]/ZM9W_
M`+0PS32:_>8NWV6G_P`BWYWUNM^I*Q-623>!Q2\G5P\;[='77,M'9ZK6ZU/K
MDE!@*%&"2,)@'<06'`X+'G./Y&C<N[)QZ=.2.F=V.">P_P#UU\BMX#_;A'7]
MH[]GO_@7[+_C8#_UI#^M1_\`"$?MP;RH_:/_`&>#C.1_PS#XV&".#_S<AG`/
M7KU[\4EAHN\5F.%;24FN?%)V]UWTRV]G9].EV)XJ44E+`5E%M*SJ86W3_I_9
M6>S>SU5]W]+Z/X0\-:%KWB3Q/I6BZ7I^O>,KBQNO%FKV.GQ6M_XDN=)T^WTC
M1[K6[F-?-U&XTK2+2#2M/EN69[/3T6UAVP86NG8J>RGO@CZY[=^GXYKY"'@7
M]M]SQ^T;^STW`R1^R_XV/&<9Y_:/Y]/Y"G-X$_;B7_FX_P#9['^]^S!XV'_O
MQ]"PT4W)8_"7;NYN6)=OANDWECLK:12=K*UK)6%B9M7C@,1O]BIA5);-N-J^
MC>[:=W=MNY]>%E)'RKP"`<<X_+C)Y/7Z5-YR_P"<_P"!KX]7P'^W">G[1O[/
M?U7]F#QL?IG_`(R/[#Z4X^`_VXA_S<=^S[_XB[XV/\OVCZ%A4G;Z_AK;W<\5
M+=IZ/^S/739>5A_6)Z?[!B-EK[7"7Z7N_;Z_C;IY_8'G+_DG_"OG[]JHY_9C
M_:(P?^:&?%L'KW\!:^",8Z$'`)X->?\`_""?MP_]'&_L_?C^R[XW`_$_\-'\
M5XA^TIX(_;,M_P!GGX[W&N_M!?`:^T>#X,?%&75;*Q_9K\8Z;J-YI<?@G6WO
M[*QU*;]H34$T^YN[<-%#?-97JVDYCG:TN/+,+[X7"QEBL,GC\*HNM24KO%VL
MY1O?ERR_7I=WZ-71ABJTY8:M%X+$QO3?O*KA;K1/2U=ZW\G9O3:Y]I_`O'_"
MD_@[N!_Y)5\.ONDJ#_Q1VB\X'?\`'CUQ7JO[OT;_`+Z;_P"*K\^_@SX)_;4F
M^$7PKDTW]H3X!6=@WPU\"/:6EQ^S3XQO[FUM9/"VD/;6]Q>P_M#64=W<0P,B
M3726=M'<,IFCMX`WDQ^E_P#""?MP_P#1QW[/W_B+OC?_`.B/K*I@X>TJ)8_"
M-*I-)Q>*Y;*I9-)Y9HFM;>OF7"HW"#>`Q%1N$&Y2JX6[]V._[];6_!=E?ZY_
M=^C?]]-_\51^[]&_[Z;_`.*KY&_X03]N'_HX[]G[_P`1=\;_`/T1]'_""?MP
M_P#1QW[/W_B+OC?_`.B/J%@XZ?[=A>G7$_W?^I;Z_<_.[]I_U+:_3_E[A?+_
M`*B/ZMY*_P!<_N_1O^^F_P#BJ/W?HW_?3?\`Q5?(W_""?MP_]''?L_?^(N^-
M_P#Z(^C_`(03]N'_`*.._9^_\1=\;_\`T1]"P<=/]NPO3KB?[O\`U+?7[GYW
M/:?]2VOT_P"7N%\O^HC^K>2O]<_N_1O^^F_^*H_=^C?]]'_XJOD;_A!/VX?^
MCCOV?O\`Q%WQO_\`1'T?\()^W#_T<;^S\?;_`(9=\;\^W_)Q]+ZI'_H.PO3K
MB?[O_4LOW^Y^=SVG_4MK_P#@W"^7_41_5EV5_K&8'RY54DYBE8`Y)`9&`*L>
M59>Z]P..3BOD#_@GP`?V+/V<QC_FGEIQ\^>-2U'G('KGIQST-6+GP)^VZ+>3
M?^T9^SW@*Q<C]E_QIN("G<`6_:-)!(X!VR<G/E-]T_*?["O@G]L"Y_9"^`4_
MA7X]?`_1O#S^`[0Z3I>K_LY^+=<U*RM5U#4`D-YJUI\>]&AOYU(=FN$TJQ\S
M?\\.Y3(_;2PE-9=B(K'81<N,P2>N*;YGA\=*S<LMUW=VDTK;7UCQSJ2^OT;8
M+$2BL#4M%5,(DKXBE)Z.M%-WMJV[*]G=GZU_*.",]NK9_P#01^9Q]:,1^C?]
M]-_\4?Y'Z5\C?\()^W#_`-''?L_?^(N^-_\`Z(^C_A!/VX?^CC?V?O\`Q%WQ
MO_\`1'5QK"1T_P!NPW3KB?[O_4L]?N?F=GM/^I;7V7_+W"?W>V(\OP\E?X*_
M:<_X(Q?!O]M#]L_5/VG_`-H+Q]XIO_!<?@SP3X4TGX.^$`_AY=5N/",>H1W>
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M[/W_`(B[XW_^B/H_X03]N'_HX[]G[_Q%WQO_`/1'UY,L%2G'EEC,(XNSM_M*
ML_=U366*SU=VM=-+'=&M.+NL!B5Z5\*KZI^]_M%G]W=KH?7`P,`<#D\9Z]>_
M3T'''\EP.,8SQU+YZ_[.!^GYU\C?\()^W#_T<=^S]_XB[XW_`/HCZ#X#_;AP
M?^,C?V?O_$7?&_\`]$?3CA(Q22Q^'LDE;GQ>VFC_`.$W97VTV?316\55?_,%
MB;Z:JMA$[Z:W5>]WKN^GDK]#^VI\O[&G[7'"J#^S'\>CP&!X^%GBKD9'4#G'
M3/%>M?"KCX:_#HL.?^$$\'C:"QR!X<TH[C@'G`SCO[\5^?O[77@C]LJW_9/_
M`&G[CQ!^T!\"]2T"']GCXU3:[IFE_LW^+]&U/4='B^&WB5]3L=.U>Y^/^JP:
M5?W=DL]O9ZE/I>HQ6-Q)'=26%XD;6\GIGPT\$?MK?\*\\!?8?VA/@%;6<O@K
MPG)9VUS^S/XTN[FUMG\/Z7Y-O/=1_M$6RW,\*$"6<6UJ)V!86T2':.V6$@LN
MP[^OX:*6.Q*M%XQ*RP5-ZQCEJBTWK=[-)VNE?@AB*JQLD\)BE_LL%:=7"S;<
MZ\HQ7-[:3]YIQNVDNMM&?>AP3G@^APP.#Q]1@=>G>@$#GCCI@M_4$Y]<G'/U
MKY&_X03]N'_HX[]G[_Q%WQO_`/1'T?\`""?MP_\`1QW[/W_B+OC?_P"B/KC^
MJQZ8[#1N[M1>*2;?+=M++=7OJ[NZ=[G:L157_,%B;=G6PTDMMD\2_P"KVZ'U
MP=I(&U2!UR&/7MDXX[\`TXLN"!C!Q@;2.G//`Q[=*^1?^$$_;A_Z.._9^_\`
M$7?&_P#]$?1_P@G[</\`T<=^S]_XB[XW_P#HCZA8&ES<[QF%<M/>;Q,FOA_F
MRQZZV;5M(I/1*Q]8J?\`0#B5KO[;"76UK-5]+:[=;NUW=_78=%.0,'&"0&X_
M3''4$>Y^K&VLP.U3R.64Y&#U'((Z9'&?:OD?_A!/VX?^CCOV?O\`Q%WQO_\`
M1'T?\()^W#_T<;^S]_XB[XW_`/HCZ;P5.3O+&X9NUKREBI-7Y;V;RW1;W6VF
ME@6(J*]L#B8_X*^&AVWY<2K^?7?7:_UQ)M=-N!C.3G<!CDGA<]_7..W>OD']
MFWY?B_\`MNKC*C]HCPXH+$ODC]GWX-@'@9;Y<GVZ]<5-_P`()^W`,$_M&?L^
MGD9#?LO>-B.A]/VCLC/;//Y&OE?X`>#/VPIOBO\`M@Q:1\>O@=97]M\=]$B\
M0W5[^SEXLU&WU35&^"7PGFAO=*MH/CY82Z191Z:]I9MIUS<ZG(]U;7%\EZT5
MU%!#U4,'#ZOC$L;A;0HX=QBYXNT>;$PA.T?[-Y=FD]/M:<KOS\5>M-8O!26#
MKQE4GB:<WSX5SE".&<X1=3VKDFI)6:DF[:MK0_6+Y>,`<8Z;AW]1S@>_3!XQ
M7S7^U_\`!2]_:1_9D^-OP$TS7[7POJ'Q>\`:[X$M_$E_8W&HV>B-K<*12:G<
MZ?:S6L][%:0QR2-:1W-L;G:81/`7W5S/_""?MP_]''?L_?\`B+OC?_Z(^C_A
M`_VX3P?VC?V?O_$7?&W]?VCB*RPE*6!Q%'%87'X:E7H5Z6)HRB\2E"M1G"I2
MFH/+'"\*B32MRVCRM.-T=->4L3AZV&JX#$SI5Z,Z%6#K8;FG2JQ]G4CS?65)
M.49.+:DGJVNC/CO]B_\`X(I?L7_L=Q:3XCM_##?&OXM6D<,S_%+XM6%GK4UA
M?(PF-WX,\&",^%?!N)/+%O<VMEJ&N0QI$DNM3N)&D_7H*@*\;MJJOS;B?E4*
M,'.`<=3CH#DY(6ODG_A`_P!N$8`_:-_9]]_^,7O&W_LO[1V/Y4?\()^W#_T<
M=^S]_P"(N^-__HCZZ<QK8S.,5/'9IG"QV)JVYZF*Q&-KNR<;)1GETH04;+E4
M4E%*T5%'/@:%#+Z*H8+*:N%I7NX49X.G=W3O)T\1[S?VFVW+7F;;N?7RR@9R
M/3G)_P`,_I3_`#E_SG_"OC[_`(03]N'_`*.._9^_\1=\;_\`T1]'_""?MP_]
M''?L_?\`B+OC?_Z(^N..%BDE]>PW3[6*_N_]2W1:O[G\NSZQ4_Z`,1T_Y>X3
MRO\`\O\`UV\]]+_8/G+Z?S_PKX\^/S_\9$_L)8`/_%X_B]@9P<_\,M?&O(QM
MR<#/3\J=_P`()^W#_P!'&_L_?^(N^-_Z_M'U\J?'/P5^V%'\>?V+X]5^/?P-
MO-6E^*_Q37PY>6O[.?BZRL=)OD_9Q^+4U_=:Q83?'V^FUNTNM'CU'3[6SM[W
M1WM-0N[75&NKF*S.GS[4,+%S?^W872E5D[O%M65)MJT<M72_K9I6OICB,14]
MEI@L3%\]+WE5PCM^\A=->W>[O^6V_P"M`?!&X8[]2?3C[HY_SZU)YR_YS_A7
MQXG@7]N%ES_PT9^SXIST3]EWQJ`<A3DC_AHW.<=>>F<<T[_A!/VX?^CCOV?O
M_$7?&_\`]$?6$,+#ECRX[#<KC&2][%_:Y7JGEMU=.^NNKV-OK%32^"Q,G97?
MM<(KVLME7\GM^=D?8/G+_G/^%'G+_G/^%?'W_""?MP_]''?L_?\`B+OC?_Z(
M^C_A!/VX?^CCOV?O_$7?&_\`]$?5?5H_]!V&Z?:Q/]W_`*EGF_N?R/K%3_H`
MQ/3_`)>X3R_Z?^OX]E?[!\Y?\Y_PH\Y?\Y_PKX^_X03]N'_HX[]G[_Q%WQO_
M`/1'T?\`""?MP_\`1QW[/W_B+OC?_P"B/H^K1_Z#L-T^UB?[O_4L\W]S^1]8
MJ?\`0!B>G_+W">7_`$_]?Q[*_P!@^<O^<_X5Y1\<74_!;XPG&,_"WXAGOG`\
M(:P<#CIQC&>F<=J\5_X0/]N$_P#-QW[/W7_HUWQM_7]HX@?6O-_C)X(_;4B^
M$/Q4DU+]H;X`W5C%\-O'<EW!!^S+XSMKB>W3PMJSSQ07$O[0UU'#))"'1)7M
M+I(V8.UM,J^6VM##0^L852QN%E?%89*\L6K/VL'S>[EJ;2>ZZVMI<SKUJDJ%
M9?4\3']S4O>IA'S>YMI7;6M]=/4_+#=_O?\`?7_UJ*?O/_/:+_P'EHK[?V2_
MDAT_Y>U/+_IQZ_CM]GQ%';]W+I_R\I?W?/S7]+7]BOV&5Q\,?B8.F/VIOVK#
MP?\`JO'C?M[$?3\*^T,'U/Z?X5\8_L-_\DS^)?\`V=+^U=_ZOKQM7V6[;2%&
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M4DH7E)0C[VSYI-*/=M;7/7IE48!&_@@`D@X.01D<\],CD?E7X`>#/VEOC[\/
M[;Q?^T/J,W[3OQ"^&OP[\0?M77GQKT[XC67A*'X*:MH/A#XA^,/"WP5\/?`&
M[LM"'BZ3Q&?$EIX8T*\N].CU33K#P_:>+9->M[N\31EE_>"Y\5^%X=)MM?N?
M$WA^UT.Z%LUIK<VLZ=#I-P+PYM&M]2EN!8S_`&H\6QCG=9VYB$N./+(?A3\%
MO#7P_P!1^#5[9^'4\`_$&]\;0WG@OQ'J<=Y9^)Y_B+JNJ:_XRTZ"'6KR6[U)
M=;U3Q!JM[)9022FU%\([.."".U2+JP5:&&E-2PT:].I6H\RLG*-",*L:R3LY
M*3DZ;C)-R4DI*RCKQ8[#SQ48NGBYT)TH3=)0GRIU'RNFY+:R<;M235N9;RT^
M#?#W[=/[0VO:%I&C+\`M$LOB-XI^.O@/X/\`AC6/%>G?'3X4_"_6K#Q]X$\9
M>++KQ#8GXL?"?PA\1+J[^'5WX0NM,\56&F^%[RQU1;BQGT;5X9KY8;+1\,?M
M0?M.>"=:_:"O/BOI7P?\2>%?!_[4_P`%?@5X2L_"FH^+++4]%_X6K>_!+1K_
M`,VXU/0+>"_TG2[?X@:CK=E<7=Q-J\_B&5M*E\C04TZ=/ISP5^S'^SC\/9?"
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M_$[P3)\25\*_##PP^A?#7]H2[^$?BKXE^*KGX@7_`(!\">$+'X0>"?B9%XU\
M?V_PY\'>+O%NC6^MZUXMD\(1:M#HK^%/#+6\.M^*-9M+-W04/'W[8/CL^-/B
M_P##_5?"WA/PGX'MO@5XU\8_#GQ'#XK\>Z?XL^,D5C\'#X_N/%WP2\<:?X(?
MX;:OHVE7,]_HT]I9>*T^(VA?V3)XT?PX-'DLDG]-U']C#]CS2/#3_"S41>Z!
MIWB;Q3JOC74=*_X7G\1?#WBCQQX@\3:#I7@SQ%>>)M:@\?:?XJ\;67BO2M%T
MZQ\2Z9KNH:MIOB2\CGN=5M[V_OKN2;L]?_9-_9BT[7M2^(?B;3?L#77AB_\`
M!"1:]\1/%5E\//#ND:]X17X=7R>$O`U[XHA^'W@K5]4\'%O"\FM^&="TC7)-
M-GN+1+[_`$NY\['V^5QE&4,%BHQY9)ITOWOPP2<DZZ@W[1-ODFTE))*_,V^3
M,9*3Y\-/W'RS>)FJ?M72J)6A#"/DE[25/3GFE9N]O=/$_@A^U1\0;[XK?!OX
M/^(_"&B>#_A_XO\`A!\,=9\'^,/B#K_Q`U'Q?\6M7UWX16/C/63X"\7OX,/P
M]\4:GX6U!+C0_$WAK7_%.D_$+4TL-6\:PZ2-+,4$GZ7+D@,203VXZ9X[?CGW
MKY'\/?LP?LW>%OB=X&\9:?%/-XW\'>'=,B\`:!JOQ.\7:OH&D:?X?\*+X&T_
MQ7X?^&>H^*KGPC'XDM/!\)\/2>.[/PW_`&\^F/>1S:IYMW>2R_4<.MZ5/]E%
MOJNF3_;7N([+RKZVE^UO:-(MVEJ(I&^T26K12+<I$':!HY!(`R.*Y,2\/4G&
M=&A4I1Y(IQ:FI3GH^>2]I47-)J\HJ3C?2-H)([,*JM.G-8FO"I-S<E:4>6G"
MR]R+Y*<I1BVTG*//9+FN[LU\'U/Z?X48/J?T_P`*\-^('[0?PR^'^B6FMWGB
M/3M<@O/'7P_^'0@\+7^FZ_=V/B+XE>,=-\">'&U>WM-1#:=I?_"0:I;Q:E?3
M'-G!%=S"&9[=HC)XD^.'AOPUK/PFLIC'JNA_&#QA?>`]`\6Z+>:?J'AVQ\2Q
M^'->\2:/:ZA>1WVZ:+Q%'X:U?1]-ET^.Z5-<ABLKOR#<*1E&C*2BUAZR4FE%
MN$TFU:Z3>[BDFUNE9NR9K[>CS.'M:;FDI."G%R47HI.*=U%O3FV[L]NP?4_I
M_A7Q-^T_Q\;OV$C_`-7)>)_T_9U^-)K[5@D\Z))<%=ZAMI&"N?X2,G!!R#[B
MOBK]J#_DM_["'_9RGBC_`-9T^-5:X%Q=:$Z=TIX7%25[IVEAFU=2V=FM'JGY
MDXA*5)=5[2@UY_OJ?^9]J1C,2<G[HQ@\<C'Y?XGUKE]<\<^#/#&IZ#HWB3QA
MX7\/:OXKO3IWA?2M=\0Z1I&I^)-11H8VL-`L=0N[>ZUB\5YX4-KIT5Q.LD\(
M\K=(,]5%_JD_W17XV?MI:CX'\`?M.>$?BGH%U\/?B1\;(_#OP[\$?\,O?$?X
M97?B_7/B5X3F^)E[J>E^(OV?_%$&FS7_`(!^(^@:EJ&K:EJ>K6$>O>%+F+1M
M-F\<6&@G2M/\16TX;#0KM1<N1^R<XOWO>FE&T'9Z*763M&-KR<5=HQ-?ZM",
M^1S3JPIRMO&$G:4TMVXK:*NW?1.UC];!XV\(&PT[5_\`A*_#7]E:O+/!I.J#
M7M+_`+.U:>V@O;FYATZ]^U&TO9K:WTW49YXK:21X8=/OYI`J6MPT<EEXO\+Z
ME%H,^F^)O#^H0>*K>2[\+S66M:==0^);6&U^W3W.@26]S(NLV\-B!>2SZ<;I
M(K3_`$EW2`^8?QOU'X$-H?QF_;8T`WMS>_"OX)?!3XA?%[X"^!UTRX%CX/\`
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MM';Q/XCT?05U;6;@C[-I.FOJUY:"_P!3GRIAL;7?=2`J8H2#BC4O'7@S1O$6
MB>$=9\7^%=)\5^)4F?PWX:U/Q#I5AX@\0+;;FNGT/1;J[BU/5EMMKF9K"UG6
M+:1*5PQK\;/CYJ6AZ=\8_$7B']O3X=?#58?%_P"Q[X@\#?"#3M'T[Q9\5_`-
MQX_C\>>+Y?&/@[P!JOB3P'H6HP_%7QKH6H?#.6PTF#0-)\1ZU#I*P^'+V^MM
M(O#%\JGPDVA?##XL?"+XV^%[J_\`V\/%UC^QK%^S]-JWAN_U[XAZE-X:^&'P
M7L]'NOA]XQETNXEL]'^&WQ0T/XB:C\2M3TK68+;PU.FNZIXKN1'JB2W<T\KI
M2A3E.O&"JSA1BU).,G4Y;U8SORN-%+]Y)/EAS1O;F5BOF=2$OW>'G)/VM2,6
ME&IRT^1TJ4X2NX2KJ4G3C)<\N5\M[,_HA?XR?"@^(=4\'1?$[X?W/C/1;?4[
MG5/!MKXR\.W/BVP31K-[_5/M?ANWU%]:A;3[.-[F\22R1K:%3+*$0;JY:?\`
M:$^'%GJ_@+0KS6;@:I\2[>TN_!<%AX:\9:O!XAM;^WCO;6[L=3TWPW<:0+<:
M?)'J%U+>7]JNFV,J7VI&TLU:=OR^T;3/!N@?M?ZEX4^"/Q!\.?%75/C)\5/C
M@OQX\#77P+\.1>/_`-GW2_&'@_Q/J^L^-E^+VE^'-$\7Z7IL'C&WT+PQINB>
M/]0U#3_&NC^*(+;PW*MO:V]\_P"@W@3X4^+;#6_AG/X@U6Q;1_@K+>:!X(@L
M=.N4N]<\)W/PL\->"!?>);B:Z,5MK$VO6NO:V+2QAG@L],GTS3I;F:XAEN9L
MGA,''D_>U)7C.7N2Y8N3H/DC)5$G>-?D7N)JUY<TK6-H8O$5-(THQE&M.E5C
M.,I<BA4C:<)4Y<KYJ=W9R;C)J,K.Z/JYN%)).`.G;U]![=@<Y!..GQ;XN/\`
MQGY\`V]?V7?VEU(Z]?B5^S0<^G&>M?:<GW&^GM_^O\_PKXL\6_\`)_?P"_[-
M?_:8_P#5D?LSU.7I1KXN*VCE>8R2;;L_[/QDEN[NTJ4):NUXJZM>_1BHJ4L*
MGL\52?SC)*+^7/(^U<'U/Z?X48/J?T_PI:*Y?9P[?B_+S\D=1P7Q0OKW2OAK
MX_U;3;J2RU+2?!?BC5-/NXO+:2TO]-T6^O;.YC\Q'BWV]S#%*OF1O'E`'1AD
M5^'?P[_:K^.][^QO!\"M5^*^LWO[7?BC2/"EYX1^*]]%H<?C>7X/_$3X3CX^
MW/QP?38-*329+GP)X-L?'?P_BO6TEM/F\:^%=%BO+>6;6(8+O]Z]>T6P\2:+
MJWA_5$>73-;TZ]TG488Y9('FL-1MI;2\A6:%DFA,UO-)'YL,D<L>[?&Z.`P^
M>K/]D;]G_2-<\/\`BJS\#6EKX@\*?`]_V;=!UIM0U*2_TWX*SBT#^"4NI[N1
MY;=GLX&75KHSZXA\Z--25+NZ67TL%BL)A*<XU\+'$/VU+$4[PA+EJ8=.5.-6
M4OWE3#SDW"K0A*TTU[MTF>?C,+B:TZ<\-B?8IQJ4,13;J6G1JI+VE/D:4:U*
M[E3EM?XDUH?">@_MO?&_1_A!9>+=#\!>#OB#X?\`V?OV:?V>_BO^T?XI\=>.
M+_PWX_\`&EY\3OAK9>.]9C^'.DZ-X7O_``\-8T[P]!=Z[>:CXHOM&T76]>U!
M?#VEV^G)9W5[%ZC8?MJ_%IOBI/:ZG\*?`MK\#+7]J,?LM/XFMO&NNS_$JXU[
M5O!UCXHT#QDGA.3PQ#H=IH5K>WL6A:WI,VOOK,C7`U+30]O:B*\]1O\`]C[]
MD#Q?<>&=7;1](O;?X<:!X+^&I@T;XB^(K7PYJ?AWX<O#%X"\&_%/0]'\4P>'
M?B3:>$;A@=!TWXG6'B62RNKIO+0F<1F_XOT/]ECP</"=WXC\0>%;%/B/^T;I
M_P`2_"5[>>+KDZ?XB_:`M=&O-NNZ=<6]_-8?;(]*\.W,=UIKM;^%+::T*75G
M!<W%NLFL9X"IK_9TW*49.2<JOM81E&%THPJ<G/&7/)2^"--QCRN4682HXZ7+
MRYA"C&DDHN4J-2%9IZ>TDX\R36DHJ46[2=U=6^:!_P`%$_B1X8\'>'/C'\0?
M@OX23X1?%SX4_%CXK?!>U\'^/M0O_B''9_#+PP?&^G:'\2K75O#EAX8TVX\<
M^$L7T.K>&]5U6R\(ZIOT?5X=0"K?RM^*7Q_^/_PI\:_`KQM\>=-\(>'],T?P
MO^U+\0/$W@WX)>+O%6NZ%XS\,>!_@1!XPTS2]=M_%OA_PY<7&O:)KEI?QZ;.
MUE<:)*TEKJT$UFS7-M'T_@SX?_L3^"/B/?>'6^&6N>$=1^)T/[0_P_M[/XA:
MAXAO?AIIGA;PS?>')OBY;^$?#_C#Q?J_@OX>>"/B!=^)=&O+&'P;I&@6/BN/
M<MW8VIM%CKWCPO\`LB_LK?#)O"EA'I4=S+&_BO3O"\/Q$^(_BKQS>ZO%XU\(
MVW@7Q#H$<GQ"\4Z]?>)-'N/!L=EX<L?#<TM_I.D:,D5MI&GV:3,99E]3P[BU
M@:M.<J4N=RCS3DI.<8JDW4Y%*"]QSG+EYHN<4G9+GC#,*\4_[0P]173A*'L^
M52CRN7M5.*E)2=Y<D.645))Z;_-?BW]NCX_?"K0?$MO\2/@K\++KQ_>?"WX<
M?%_X8Z'X'^)GB&[\.:AHWC?XR^!?A!J'@SQOXAU_P?IUQI/B+0+_`,?Z)?6O
MB/1]-U/0/$$9O6LK6+^SY$N-77_VWOB[X6\-_$3PSXI\&?"'0/CMX`^->D_"
M2WT:SU'XS_$'PMXX7Q'\+]'^+VCWO@#PQ\.?A;XB^+/B/6K;PYK"V/B'1U\+
M6EEI`TW4/$]QK*:2UK9OT_B?]GK]B_\`9W\.1^#;KP_JLZ?%/QK\$_AV-)N_
M'GC'QKXLM%'Q&TJ;X1:-87OBCQ?J/B3PA\*O"7CF'3[^WT#P_=6/A/3E@G;^
MR+O,L$GMOCG]E/\`9V^*%[J6J^+=.FNM9\>>--&^*$NN:!\0/%/A3Q%=^,?#
MW@6P^'EKKGA;Q%X1\2Z/KFD0R>`K:U\,ZS9>&M1M=)UO19IH-<MKY+VX>:N?
M+N>#J9?4C3J-U(UG!J<G34*:IQI?672<>>\Y)U)7^*ZTB)T\T:G&CCJ4JE/D
MIRA%PC!*HN?VLI1I5:L9<O+"+46FOBCO)?.W[)W[1WB7]H7XX^%?&\HU;PSX
M6\??L4>$?B'<?#B35-0N]$T3QH/CAX\\):IJ<%KJ-EI-V+^:UT:.S6YU'1]*
MU8:9'9VNI6-K?P7-M#^HF.,#C_/OFO`_A1^S9\&?@O=:->?#3P@GAR;P[\/K
M3X6:*8]6UF_BL/`5GXHU?QC;:##%J-_=QM%'XAUO4[];V42Z@WVD6[7;VL,4
M4?OE<.*J4:]6<Z,9QHOEC",XQIS48Q4?>4)3C?3=3E?=MN[/5P-&MA\+3I8B
M495H\SFXU*E6+<Y.?NSJQC-KWK).*MLDE83!]3^G^%?/7[6#$?LR_M$`\@_`
MGXN,3CL/`>N\''/?V]N]?0QZ'_/\Z\`_:HB67]FK]H1)#A6^!OQ90X[[_`FN
MC&,'@YP<@DX/!S@SA81CBL,XJS^L44G=NUYQ6VKE:R]U*[MIJ5C';"UWT5*;
M>J3V[O1>KT7735;WP(<I\%/@\I*AO^%5_#K(+`'/_"'Z-Q@\X.!CV]J]8,QX
MR!^#?X'^=?YT_B__`(+,_P#!2?X?^+/$G@7PA^TQJ>B^%?!FJR>%_#>D+\/?
MA9>)IFA:'##INE6"7.H>"+J[N!;6=O%$9KN>>XF9!-/+)*21SI_X+C_\%23_
M`,W5ZG_X;/X.G_WG_P#B/:OU*/@QQ9B(K$0JY*J=?]]!2S*5*7)4ES0YJ;IM
MTY<DH\T96:E>Z3NCX"GXE9/RQBL#G-H-TW4CA</4BW3ER2Y9>VCS1<HNSY=5
MJKIZ_P"CWYG^=W_V='F?YW?_`&=?YP?_``_&_P""I/\`T=7JG_ALO@W_`/.]
MH_X?C?\`!4G_`*.KU3_PV7P;_P#G>T_^()<7?\_LC_\`#O+R_P"G?E^/K>UX
MDY1I_LF=]/\`F"H?W?\`I_Y:?+NS_1\\S_.[_P"SH\S_`#N_^SK_`#@_^'XW
M_!4G_HZO5/\`PV7P;_\`G>T?\/QO^"I/_1U>J?\`ALO@W_\`.]H_X@EQ=_S^
MR/\`\.\O+_IWY?CZW%XDY1I_LF=]/^8*A_=_Z?\`EI\N[/\`1\\S_.[_`.SI
M!*PR,`^Y89_G7^<)_P`/QO\`@J3_`-'5ZI_X;+X.?_.]I1_P7&_X*DY'_&56
MI_A\,_@[G\/^+?4?\02XN7_+W(__``[2?9?\^G_6O1W/^(DY0M?J.=U-E;ZG
M05K)?]/UY_A?2]_]&ZZD*Q3,06'EN`JG+$E>@SQR?3J>F:^0?^">SX_8L_9T
MZ''P]LSDG'/]I:CQSU.<Y_\`U5_":_\`P7$_X*CLIW?M5ZJ%P2S#X:_"!<>Y
M/_"`!!CZ;OKP*Y'X?_\`!8C_`(*._"SP9X<^'G@3]I34M!\(>$M.32/#^CI\
M/?A7?+86$+R.(#>:CX'N[ZX(EDE)>[N9I>0A8*J!>B'@YQ5+!UL.L7P_.J\3
MA:DHPS6;Y/94<33DJDOJZA&<95*:Y>9N7-=.7+<YO^(CY0\7"M]2SEJ.&G1=
M!8&A%Q;JTY*7,\3=JT7LW%WOJU8_TJ_.;T7_`+Z'^-)YK=\8[_,O_P!:O\X7
M_A^-_P`%2/\`HZK4_P#PV?P=_P#G?4?\/QO^"I/;]JK4_P#PV?P=_P#G?5S_
M`/$$^+E_R]R/9?\`,VEV7_3J_P#5];._3_Q$K*%?_A/SN6W_`#!T%;9VUQ&O
MZ^1_7?\`M(_\%GO@'^R!^V-J7[*W[0GA?Q1X4T(^#O!?BK1_C1HD4WBCP[:R
M^+(KYY=/\6^&=/LT\1:3::>]D"-8T:+Q&LD4NZYT^R6(M)^HOPP^,'PV^-/@
MW2_B!\)?'GA/XB^#-7ACELO$GA#7;'7-*E+HCF`SV4LIMKN(N%N+&]6WO;9B
M([JW@E'EU_EM_M!?M(?&C]JKXC3_`!:^/?C>;X@_$.;0])\.S^(I](T'0Y6T
M;11,=+L_[.\.:7I&E1):BYF9)HK)+F<39GGG&Q4L_L]_M0_'_P#92\6KXT_9
M^^+/BWX9ZS--$=2M-$O_`#-`\2\;8[/Q+X4O5N?#OB2"1<HL6I:9<RCG[/)!
M(0X^NQW@93KY7@ZF#QU++<WI8'#QQL,1B76RO&XR%*'MZU/$NE3K8/"UJKE&
MDHTL0I.,Y25*G[/VGS6$\4*M+,,1#&4)8O+*N+Q,L-.C1ITL9AZ'MG['#M4Z
MU6%9TZ+@Y<T(U4_CG)OW?]6<#=\V>3W';V[C'\Z=@^I_3_"OQ_\`^"6G[9G[
M;'[4_P`-AKG[4?[)EY\*;*UTVTET'XQQSMX1T3XF;O*03:?\*/$;-XUTAY8F
M:X.LVYN/#%ZP9=.-NK16]?L`#D`\@D`D'J/8@C/MT%?@6/RVIEN,KX'$JE[?
M#5'2JNAB*>)I<\>6ZC5HU)PE;39]+61^P8/%T<=AJ.*H>T5*O!5(*K3G2J<L
MMG*G-*<6UK9KJ&#ZG]/\*,'U/Z?X4M%<GLX=OQ?EY^2.H^7_`-MA<?L:_M;C
M/3]F+X]'_P`Q9XK/^<YKUCX4C=\-?AV1T'@7P;_ZCFE$X[<[?Y5Y3^VS_P`F
M;?M<?]FP_'O_`-59XKKU?X3_`/),_AU_V(G@S_U'--KHK)1R[#QC=*688BZO
M?_F$I][G/&,7C)2:U^JK7_!6<H_<VWY]3T;!]3^G^%&#ZG]/\*6BN?V<.WXO
MR\_)'0)@^I_3_"C!]3^G^%+11[.';\7Y>?D@$P?4_I_A1C/<_I_A2T4>SAV_
M%^7GY("*7A#ENYZX]&X[?7\,5\??LT#/QA_;?_[.+\/G\?\`AG_X-U]A2_</
MX_R-?'W[-'_)8OVX/^SB_#__`*S_`/!JNBBK4L=!?"Z&&T_[FX=;WZ6W.*O_
M`+U@/^ON)_\`44^Q,'U/Z?X48/J?T_PI:*Y_9P[?B_+S\D=HF#ZG]/\`"C!]
M3^G^%+11[.';\7Y>?D@$P?4_I_A1@^I_3_"EHH]G#M^+\O/R0"8]S^G^%?'/
M[0B$_M&?L(G/3XQ_%\\^_P"RS\;!CZ>OMFOL>OCW]H+_`).)_81_[+)\7O\`
MUEKXUUMAXJ-2\5;]W6CN]G1G%[NWPW6U_,RKI.G9ZKGIZ?\`<6%M?+\3Z^1<
M`C)Z^W4`#T]J?@^I_3_"FIT/U_H*?7+2C&5.$FM;);O11T2T=M%%+;6VIKL)
M@^I_3_"C!]3^G^%+16GLX=OQ?EY^2`3!]3^G^%&#ZG]/\*6BCV<.WXOR\_)`
M)CU)_3_"O)_CB<_!;XQ#O_PJWXA<>F?".L&O6:\E^.7_`"1?XQ?]DO\`B'_Z
MA^L5I1BHU\,XJS^M8;7?:M!=;]+KYLRK_P"[XAK=4:C3[/E_K\.Q^`-%%%?=
M^UG_`#/[E_EY?GW9\S[:7G]__`\OS[L_8G]AO_DF?Q+_`.SI?VKO_5]>-J^Q
M;I6=,+@-AL-U"GC!QU.._P"-?E/^RWXP_:FTKPM\6;+X<?`[X5>,/"L7[4?[
M436.N^(_CCJW@_5;N23XW^,VNDGT&#X4^(X[3[/<F:"-UU>Y%S"L<N(=VT_2
MY^(G[<9Z_LR_`W_Q)G7/_G'>_P#GBOE,QPTGF&+:J8=/ZTJBC.O2BWRRIS2M
M*::O:UVM'K;0]O#58UL%3Y8UE&I0<5)4Y*24DX-V=FFKMKK:SNNGYN^%_@1\
M2/B'^S-^S/IWPV\/KJ'BGPW??'_]BS]I:RCU6QTK5-$^%/CGXAZUX<^*>O7;
MW\\$ES<^'==\&Z7XHM=/@>;5;NR\02S:9:S-?I/'L:1^Q;\5O&7A[PEI_P`7
M_A@GB"/PE^TG^SA\,+;2]6U'P]JUKJW[)/[,4?C2W\->,]1@>^Q_9OBG4O%^
MI:YJWA2=Y=:OX#;6^K:$7>ZMV^\],\4?MH:.]\^G?LM_`>T.IW<E_?"W_:1U
M2V^U7\_-S?W/D?`>)KF^NB%:ZO+EI+BX95,DC[01J_\`"POVXO\`HV;X'?\`
MB3.M_P#SC:ZY8[$M2C"K@(QE4G54E4H*M&52M[:2552YE%3DXI:KDM'R?'2R
MR@O9NJL74E3IPI.,I2=*:I4HT83=-KE3<8J3TNIWDFFKGP%+^ROXX\$:UHMS
MKW[*B_';X#^#/C'^V0/#7[/.GR?"^[TSP_I/Q:\5>%]8^$7Q"\,>!O'?B#1?
MA]_PC5IHUCXV\*1Z6]S9:W\/]-\9W%SHGAY4N+Z`><:Q^Q9\:],\!R>!O'W[
M/-O^T-XL\5?LF>#/@O\`"3QI_P`)CX3U*Q_93^(FDZKXUNKB*37O'6L:5XHT
MCP]X;;Q1X)UBP^)WPXL]>\7:Q+\-4L#IT!CT<7'ZB?\`"P?VXL9_X9H^!@ZY
MS^TQKAQ[\?`X=.O6FCXA_MO2JP7]FGX%2@@JVW]IK6SP02`V/@<>2">#V]LU
ME]:Q/*XN6`D[1M)UZ,9/EDY)\RDTG>;N[7<;*3=[ERR[#3DIIXV.JNKN4;.,
M8-6Y=5RI6Y7:]]UH?F9X<^"GB3Q[^T=\;;#0O@<OB?X@^$_VX?V?M=N?VN1?
M^#K:3X>Z'\+O@_\``'Q+\1-+DCO=3B^(5A>^*M+AU;3K'P_X7TB^\/\`C63X
M@W(\3WMI:Z5=+/U'A_\`85\4>*]%LK/XM?`[2/$7]B?LN?MC^#/"]IXD'AK6
MK;0OBC\3OVC/%'C;P$=/@>^O+2QUK4O">I6NJZ1XF$.?#HF9!JNC:I]HAF^^
MM.\4?MEZ1+J,^F?LI_`"PGU>\74=6GM/VCM4MIM3OQ;PV@OM0E@^!$3WUW]E
MMK>V^UW;2W/V:WMX3)Y4,2IIGX@_MPD$G]F7X&\@@_\`&3.N9Q_X8[']:=3%
M5Y.7LYX.*DH+^/1DXVIQISE%\R:E+WK*]DY,BAET(1@JU3%U.1RERN+Y)7GS
M0C)7?-&.B:WDEKI:WXG6FDZ/!^V-X0U'XW>'=%\0Q?#[XI?L>^%-9M`?@AXC
M^+D'QLTSX+?#GPYID5NOC#5?^%TW/@NP\9^*WU;QKIWPTTC5?"6IC3]2\4V&
MMS?9?%ELGZX_M@_"_7O%WC#X#^+I/@1)^TY\.OA]J'Q-M?&GP79_!-TUWKOC
M;PWIVD>!?B#%X?\`B7JFB^!?$,7@^:TUK2+F/4M2BU'0;'QG+XBT>"[N-/GM
M*OR-^U)+XLL_',_[''[,$OCFRM?L%AXON?CPTWBVSL'6X0Z?8^(7^`)UBVLG
M6>Y3[);WD5NT<UPH0>;(K=G_`,+!_;B&!_PS-\#6P.O_``TUKO!_'X'$XS[=
MZ,37G7J4ZL7@Z7LZ4:<8+$46DHPA"[=TY2=G+FOIS63LE?7!X586A4H3GB*S
MG7=;G]G)6?,Y*,8I^[&TK6OT;;U;7P%<?LJ_%&7XDZI;I^S+86'CK7OVC/@I
M\8OAU^T]9>(?`UWIOP)^#7@BU\!OJ7PAL]1EU*Q^)%E>>"M&\->+OAIHW@?P
MMX4N/`?C/3_%BZS?7]O9:AJT-OR?CWX?_'OX>>`++3_$?P6UGPSX*_9ITC_@
MH=XKUOXP+XP\/+H7B#3/B_X,^+NL?#O5/!^F^$]4U+X@K%=P>*["Q\037.B:
M)J_A?7K?9:66I6R1ZO#^E'_"P?VXST_9E^!V!W'[3.N8_7X'5%/X[_;=N8);
M>?\`9A^!<L,R-'+&_P"TOK3I)&X(9'1O@:R,C+E65E*LI(8$$TH8FHN13^H3
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MX3D_:L\!V<FF^"/V./V:/!VFS74M_/IOA3X\R>'-/N+^X4+/?3V6C?`&RMY;
MR551'N7B:5U1`SD`&M63Q%^V5/J,&KS_`+*WP#GU2T:9K+4)_P!I'59KJP^T
M0+;72V%R_P`"3/9)>6ZK!="V>(7,6(K@2QDK6M3'5W-SC4PO*US*#Q-)1C-1
MAR246W%)>SA!*UE!N/4FAET*,(1M5E*,DI34)7E2LURR<KSE)MWE+FLY+F44
MS[<MLB")?10`<8RH/!QCCY>O`&3@$5\7?M/_`/);_P!A+V_:3\3?K^SK\:O\
M*NK\0?VY(U51^S/\#B``,_\`#3&N9)QR>?@;CGJ,?C7R7^T/XZ_:\N/B_P#L
M82:U^S[\']/U*U^/_B&;P[:67[0.L:C:ZMJS?`;XNQ3V6IWLGP@L9-'M(M)D
MU*_2]AM-6>>\L;;3OLD(OA=P\."PM25:/[S"J:PN+<HQQ%&T;8:;DE:;T3NE
MHD_))L[,765.A!*%9)5</%-TY7:56&^^Z76_ZGZ^18\M!G^`?4<?TJF]BCN'
M,TX(9F4*^Q0LA&Y610$8-_MJ6([Y+$_(8^(7[<(`*?LR_`W;V/\`PTUKAXZC
MK\#O3GGIQ3O^%B_MR?\`1LWP-_\`$F=;_P#G'5A##22@U6PUU%*_UBDFKJ*:
MUDNZN=;J1DK.G4:NG9TWNG=/7L_^#LSZX7385&T23[2!\H90H(QAPH0!6&`#
MMV@A4#`E$JRUL&V_O)!M(SR"'`"@[U92&)"XR<X]#7Q]_P`+%_;D_P"C9O@;
M_P"),ZW_`/..H_X6+^W)_P!&S?`W_P`29UO_`.<=0L(_^?V&WO\`[U2W;3_G
M[R_1:)#51+:G45U;X.FG_`^[R9]@2VRR;1YDJ;5(^5PN<@<D8*EAM^5BN5^8
MCK4)L(RCQO+.P<'=\X!^\2,!4X`W84D%@%4@DC(^1?\`A8O[<G_1LWP-_P#$
MF=;_`/G'4?\`"Q?VY/\`HV;X&_\`B3.M_P#SCJ%A7TK897LDEB:226G3GLOB
MW27^:YXW4O95.92C)/V>O-%6B_DI/3;5Z;GUTMBJF,^?./*4HHWC;MPH&Y=N
M#M`PI.2%8@]:N[`#G)/.<<8YQVP!V^M?''_"Q?VY/^C9O@;_`.),ZW_\XZC_
M`(6+^W)_T;-\#?\`Q)G6_P#YQU#PG-9RJX5V2LWBJ6B]VWV_-?B"J*/-:G47
M-)RE^[=W)VN_7;\?,^QY/N-]*^+/%O\`R?W\`O\`LU_]IC_U9'[,]7?^%A_M
MQ'[W[-'P-`(PW_&3&N'@]?\`FAP`('?FODWQ9XV_:^_X;<^"=W+^S_\`!V/Q
M)'^SA^T)#I>AK^T%K3Z==Z3-\0/V?9-6U.YUMO@XDEK<V%W;:/;6FF)I5PM]
M%J-W<O?VAL$@N^K`X>7ML4_:X=J669A!6Q%)ZRP6)I*]I?SUH:*[Y>:5K1E;
MEQ6(C&6$O"K_`+Y1A;V;6M22Y6WLH^XTWT=EJ?KW17QK_P`+$_;D'_-L_P`#
M#]/VF-<'\_@=1_PL7]N3_HV;X&_^),ZW_P#..KF6'D_^7N&^>)H]6O[WFCK]
MK_T[J_\`@#/LJN6\;6^IW7A+Q';Z):65_K,VC:DFDV.J/+'I5YJCVDJZ?:ZL
M\"M.NE7%X88]3>`&X6R:X:#,@45\O?\`"Q?VY/\`HV;X&_\`B3.M_P#SCJ/^
M%B?MQG@_LS?`W!X/_&3.M]/_``QPIJ@XM/VV%T:=GB:7D^D[]>G9@ZFCM"JG
M;1J#NO->:O\`U9GY%^`/V*?V@M8\(_'?2/%GP*U#0-.^)O@;]E'1/$7@Y]"_
M9Y^''AG7_%WP]_:'B\5_%J+POX:^!EW:64GA#2?!5Y>1>&O$OCG5=2^(?BGP
M]:QV^H:JU]%;Z:?H_P"(7[&M_HWB#Q+J7AS]F'PQX[^%/@O]MCX;_&KP7\']
M)\/_``P2WN_AMJ7[/^@^!_BA-\/?#'BN]T;PII#7'Q#DDUSQ#X9OKKPRNOW6
MC76MQQ7>H26\EY]Q_P#"POVXO^C9?@:/^[FM;_K\#C2?\+!_;B_Z-F^!W_B3
M.M__`#C:])X[&^T<XU,ODI7YHRK4HWYH4J;2Y)JUH02BTE9N33U9X]+*<)2P
M\*">,E*'_+UW4F_:2JW:?-%MRF[W5G977;\_?&'[+WCZT\;:#XT\:?LGS?M#
M>"/#O[1G[<?Q!O?ANFH_#O4)KS1OB]<^$(OA;XDL]!\<>(]+\-ZZ-0BL+]7T
M?5K^WN=&M9KO5)H%U+3K&UNO/+S]C3XW:5\,[;P5X\_9UA_:$\7^)/V2O`?P
M8^%/BT>+/"$]I^RS\3-%U3Q_>:E#<:_XZU;3?%6@:1H<GBOP3J=A\4?AGI^M
M>)]4;X;6MF=/C:WTAY_U''Q!_;B(_P"39O@:/0G]IG7>?;CX&]^F./ZTP_$7
M]M\'#?LU?`D<XP?VFM<!SC(7GX'^G_ZNQS^N8ITZ4)2P#=&"@I?687:56=9-
MOVCUYJLDW9-Q48N]KC>681SG./UV'M)\[BK\D6XTX-*,::3BU%->]H^9Z]/S
M]UO]E/XMO\8]-FU_]G>V^)/C2V_;$^!7QL'[7-[K'@E)H/@OX4A\"Z=J_A/;
MJ.K1_$H:KX=;1->M;OX?1:(O@V^TN\E\56FIWNN7`TZ3UW]B+X8ZNGQ^^,6A
MZO!'<?#C]C"\\7?L]?`/44OH;^*6R^+VM:?\:_%L$:J6.F:C\/O">K_#GX/R
M6KKYJ6?AVX4M"T\MM!]2GX@?MPL,']F?X&$'H1^TSKH//.<_\*./'8=>#6?8
M>*?VSM*>]DTW]E?X!6#ZA>3W]_\`9/VC]5MOME_=2>9=7UUY'P*C-S>W+*IN
M+J<O<3%5$LDF-RT\35J8>K2J2P?-*$8P?UBC)TK5(2<H-R7*YQ3@U%6Y9-I)
MV"EE].EB*%:#Q-H5*M2K%PE%5;T:=.BII-*:IR4IKF3L[7NUI]MI&$^Z3R`.
MW8`#MZ#'/X8I]?&:?$?]N"3/E_LT_`J0@\A/VF=;.!TY'_"CS@YI_P#PL3]N
M7_HV7X'?^),:W_\`..KSEAFM%5PR7_812ZM?WN\OZTOZ_M;_`/+NKTWIM>2W
M/LFOG_\`:NS_`,,R?M$,"04^!GQ:8$8R"/`6O8(R0,Y''(YZD5YK_P`+%_;D
M_P"C9?@;_P"),ZV/_>'&O$_VE/'O[9MS^SO\>(==_9T^#&F:1-\&_B=#JM_8
M_M%:UJE[9:9)X(UP7U[::<_P8T^.^N+6W9YX+1[^T6YE1(6N8`YE76AAIO$8
M=1K8:[KT4O\`::*WG'KS]+W;Z>MC#%5H+#5G.G4<53DY+V;>ENJZ^GR/JWX&
M^!O!5U\'/A+<7/A'PQ<37'PP^'<LTMQX?TB>:263PAH[222RS6+332R,VZ62
M9FD=@'8Y:O6/^%>>`_\`H2O"7_A,Z'_\@5\/?!WQ[^VC!\(_A3%I/[-_P5O=
M/C^&O@1;*ZNOVD=:M+F>T3PMI2VLUQ:)\$[A+>>6W$<DT"3SQ02L\:3W"(LS
M>D?\+%_;D_Z-F^!O_B3.M_\`SCJ'3K\]1/%4KJI45WBX7_B.V\[]4TMK6:TL
M.FZ$H0:PUDX0M_L\5]F/1Q79/MOYGTS_`,*\\!_]"5X2_P#"9T/_`.0*/^%>
M>`_^A*\)?^$SH?\`\@5\S?\`"Q?VY/\`HV;X&_\`B3.M_P#SCJ/^%B_MR?\`
M1LWP-_\`$F=;_P#G'4O9UO\`H*H]/^8RG_=_O^:^[R15J/\`T#+I_P`N(^7E
MY+[GYGTS_P`*\\!_]"5X2_\`"9T/_P"0*/\`A7G@/_H2O"7_`(3.A_\`R!7S
M-_PL7]N3_HV;X&_^),ZW_P#..H_X6+^W)_T;-\#?_$F=;_\`G'4>SK?]!5'I
M_P`QE/\`N_W_`#7W>2"U'_H&73_EQ'R\O)?<_,^F?^%>>`_^A*\)?^$SH?\`
M\@4?\*\\!_\`0E>$O_"9T/\`^0*^9O\`A8O[<G_1LWP-_P#$F=;_`/G'4?\`
M"Q?VY/\`HV;X&_\`B3.M_P#SCJ/9UK?[U1_\+*?]W^_YK[O(+4?^@9?^"(^7
MEY+[GYGT9=_#[P*T$BGP;X4*H"Z?\4YH?RLH)5D/V#:C#/RMP5(!'3-?(_\`
MP3^\$>#;[]C/]GBYO/"?ABZN9?A]:M+-/X?T>660_P!HZBNYY)+%Y)#M`!+M
MEL;F&XG'3W'Q"_;<\B5C^S3\#@WE/N`_:7UP]<CK_P`*.Z`]1U/(%?*W[#/C
MG]L.R_9&^`EMX6_9\^#FNZ!#X$MX]+U;5/V@]:T/4+ZV&HZCMGNM)C^#FJ1V
M$K$<P)J-XJ##>8@)C7HI4:JR[%2^L4TI8[`M.6,36N&QJERJ55J*ERI\JM:V
MJU?-Q-T)8^*>&U^I3D_]FBD_WU-+7EN[+;LM.B/U'_X5YX#_`.A*\)?^$SH?
M_P`@4A^'O@0#CP5X2]Q_PC6A\C_P`_Q^E?,__"Q?VY/^C9O@;_XDSK?_`,XZ
MC_A8O[<G_1LWP-_\29UO_P"<=7/[.L_^8JCT_P"8NG_=_O\`FON\D=MJ/_0,
MO_!$/+R\E]S\S\!/^"CG_!'/]HS]N;_@HGJWB[X?VG@_X1_L^VWPW^&FA:G\
M3]9A@EBEU33;?5SK5AX1\"Z(UOJ>O:C9K-;F:6[DT/15N'$<FK.RF./]4?V*
M?^",/[%W['!TGQ/I_@R7XO?%_3TMYV^+/Q7MK#6]7L+^-2#/X1\-_9V\-^#E
M#._DR:?9W6L1!$WZ[<,-R_5'_"POVXO^C9?@;_XDSK?_`,XZE'Q$_;C'3]F7
MX&_^),ZW_P#..KZ#&<4<18[+,%DU3,Z-#+<!AHX:CA\/BXP=6$6KSQ%;VGM*
MCF[-0<U3A9\L=;+PL)PWDV$QF,QT<%*MB<9B)XF<ZU*,E3E-13C2@HJ$$K;\
MMWN]4SZ_2TC7/SNV0@&X@D;>!VR=W&=V6.T9(P!5L`#I7QM_PL7]N3_HV;X&
M_P#B3.M__..H_P"%B_MR?]&S?`W_`,29UO\`^<=7S4<(HW<:F$BYOFDU7H1<
MI/E]Z5I*[U6K/H?:*]_9U%HHZ0LE&.R2V27,]$N_9GV517QK_P`+%_;D_P"C
M9O@;_P"),ZW_`/..H_X6+^W)_P!&R_`W_P`29UO_`.<=3^K.U_;8;_PIH^7]
M[S0>U_Z=U?\`P!_UU_JS.L_;9_Y,V_:X_P"S8?CW_P"JL\5UZO\`"?\`Y)G\
M.O\`L1/!O_J.:;7Y[?M=>//VRKO]E#]I^W\1?L[_``8T?0+G]G?XUV^N:MI_
M[1.M:M?Z9H\OPV\2QZEJ-CI3_!BP34KNRLVGN;;3WO[%;V>-+9KNV$IG3U+X
M;>/?VTX_AWX$6P_9O^"=S:KX*\)K:W$W[2&N6LMS"GA[31'-+;#X*7/V5Y%P
M3!YTOE,2AEE4"9MZV%G++\,XU<.TLPQ%W]8I67^R4MWS65[Z=79V.98B*QKC
M[.M=X1O^%*UO:I;_`*=>E[.WW]D'H<T5\:#XB?MQCI^S+\#?_$F=;_\`G'4O
M_"Q?VY/^C9O@;_XDSK?_`,XZL?JTO^?V%Z?\Q-'K;^]_>7XG3[7_`*=U?_`'
M_77\^S/LJBOC7_A8O[<G_1LWP-_\29UO_P"<=1_PL7]N3_HV;X&_^),ZW_\`
M..H^K2_Y_87I_P`Q-'K;^]_>7XA[7_IW5_\``'_77\^S/LJBOC7_`(6+^W)_
MT;-\#?\`Q)G6_P#YQU'_``L7]N3_`*-E^!O_`(DSK?\`\XZE]6E_S^PW_A31
M\O[WF@]K_P!.ZO\`X`_ZZ_GV9]C2_</X_P`C7Q]^S1_R6+]N#_LXOP__`.L_
M_!JHU^(7[<#,!)^S/\#U4@\K^TQKG7&1_P`T-..O7U.><\_+'P`\<_MB6WQ4
M_;!ET?\`9Y^#M_?77QZT.;7[>\_:&U:Q@TS45^!_PHACL["YC^#MX^JVTFG0
MZ?>&]FM]+ECN;JXLVLF2UCNKC>AA)NECI*KAK*AA;_[12MKC(+1\W=V>R6[>
MJ.'$5DL7EZ]G5NZN*^P^F$;_`$T/UPHKXU_X6+^W)_T;-\#?_$F=;_\`G'4?
M\+%_;D_Z-F^!O_B3.M__`#CJQ^K2_P"?V%Z?\Q-'K;^]_>7XG=[7_IW5_P#`
M'_77\^S/LJBOC7_A8O[<G_1LWP-_\29UO_YQU'_"Q?VY/^C9O@;_`.),ZW_\
MXZCZM+_G]A>G_,31ZV_O?WE^(>U_Z=U?_`'_`%U_/LS[*HKXU_X6+^W)_P!&
MS?`W_P`29UO_`.<=1_PL7]N3_HV;X&_^),ZW_P#..H^K2_Y_87I_S$T>MO[W
M]Y?B'M?^G=7_`,`?]=?S[,^RJ^/?V@O^3B?V$?\`LLGQ>_\`66OC7_DU7_X6
M)^W&>#^S-\#0#P?^,F=;_P#G'5\L_&_QU^V'+\=_V,)M5_9]^#EAJEK\6?BC
M+X=L+7]H#6[^TUB^D_9P^+5O>VNHZ@?@[:MHT%MHLVIZC!=I::F;J]LK;3S;
MV\=VU[#I2PTW-\M7#-JG4E_O-'5>SDVOCU=GM^FIAB,1&%.\J=:W/2U5*3M>
MK"VW?;5K6R]/UM0C&.,Y_/I3Z^-6^(7[;X(V?LS_``.(P.O[2^NCG/\`V0W&
M/KC\:/\`A8O[<G_1LWP-_P#$F=;_`/G'5C'"M*RJX56Z?6:6EVO[W=FRK*23
M4*MFEO3:WMWLUO?7I]Y]E45\:_\`"Q?VY/\`HV;X&_\`B3.M_P#SCJ/^%B_M
MR?\`1LWP-_\`$F=;_P#G'57U:7_/["]/^8FCUM_>_O+\1^U_Z=U?_`'_`%U_
M/LS[*HKXU_X6+^W)_P!&S?`W_P`29UO_`.<=1_PL7]N3_HV7X&_^),ZW_P#.
M.I?5I?\`/[#?^%-'K;^__>0>U_Z=U?\`P!_UU_JS/LJO)?CE_P`D7^,7_9+_
M`(A_^H?K%>'GXB?MR<@_LS?`T?7]IC7#^G_"C>?IWKS7XQ_$#]M-_A#\5DU'
M]F[X*VUC)\./',=[<VW[2.MW5S;VC>%]46YN(+5O@E"MS-!`7ECA:>V6>15B
M:6`-YJW2PLY5\,E5PS_VK#?\Q%*UO;0[2?1_YV5V<^*Q$(8:OS0K:T:J5J4I
M._(WLE?I;U^\_+NBC_ME_P"3'_V-%?9>QJ?]._\`P8O\O-?>?.6?9_U_PZ^\
M_8C]AQ<_#+XEY[_M2_M7'CU_X7SXV''Y=Z^S=@]3^G^%?&?[#?\`R3/XE_\`
M9TO[5W_J^O&U?9]?&YCKF&-TVQ$TO*RC^NI]3A4EAZ*2LE3BDELO^'=W\R,J
MHZD_Y_`XK\YOV^/VP]8_9U\-:;X;^%VO?#6U^+NJ^&/%_P`5)+?XC:I96VEZ
M7\*?A3#;ZMXTO8],GUC1;C5/$/BRXDL/A_X)L(KH,^N:[=ZX(+ZS\+ZC:/\`
MHVR*_!]"/P/_`.JOD_7OV0/@SXW\1_&#Q=\1O"-K\0O$'Q>TNP\.7FH^.-*\
M,^(KCP7X4T?PY<^'M*\+?#DWVD3CPEI%K)JNN>),P&XO+KQ/K>IZKJ%]*/LM
MM;YX.5"EBHUL5!U:-)*<:"^&K/F2<*MVDJ:@W.^MY1Y>5<W,LL=#%U:#I8.M
M3P]2I92KSCS2I14DVZ<?M2DKPU:Y>;F5W%)T]8_:@N[[XD:1\.?A/\*/%/Q=
M>#0O`WBKXD^(M%USP?X:T'X:^&/B4[2>$KFZN?%FLZ7+XHU^]T>VU3Q+)X4\
M-Q75];>'=.:\GNH;G4-'L=3^2=/_`."A=WX(\'7>L#X;_%'XV+-\//BK^TYJ
MNM6$'PV\&V7@GX#Z)\6_%GA/P_#J-U-K&FZ/<WDOASP]<W_@2TA?4/%7CO3[
M!IM02VU7^U+FS^E?"W[&>A>`?$L?B7P?\5_C5H$=[\//`'@#QGX<M?$'A.YT
M/XAGX8^"9_AYX+\6>)9-0\'7>MV_BO3?#;6RWY\,ZSX;T+7K[3].GUS2;Y(I
MH9.&\'?LI_L_>)_`/Q-^&7A;Q-XQU?0HO"'PE_9?\;B"Y2SU/2=%_9ZB.HV?
MA*VGN=`LTEFUP^*);OQKJ=I#?Z7K;>(KY--GL22L/7&>61?-RU*E.,*$90DI
M1FJCITUB&YQ3NH5I5'2M\=.$'4M)R2Y:W]J>]R2I4E4JUE"34*BY:<G*E[.$
ME%)5*2@JMY<T9RGR<ZA%RK:Y_P`%&OAO#^T)I?[/'A#PQJ_CCQ/)XQ\*_#WQ
M-/I&N^#H-9\+>+O&.C6.OV,;?#JXUK_A8&N^&/#>F:GI\WQ&\;:;HL?ACP,\
MLD-Y?WUQ9ZA;6O+?"C]O+XJ^,O!NF:MX@_9QOYO&WQ.^*?Q3\+?L^^`O!GCO
MP/?R_$7P+\-M>\0Z;KGC#7?$NH:^FA>#M,\(6NB0KXC\0:G,EEK^J:SHT'A/
M2KE-4M5;T?3?`/PC^!_[2+&P^,?Q0T7Q)^T%XE\8_$/3_@);Q6FM^`M6\3W.
ME:=HOC+QI<W^D?#^_P#&7A31)9O[.F>#Q+\0M&\`?\);<6[:?8R:K(EK5/2_
MV#?"VA^$?A7X8\*?&GX]^#]4^"">/M+^'/C[0]<\#OXQT3P'\2_[//B;X9RR
M:A\/K_1];\-HNE:++I&M:MHMYXZM+W3;75QXMDU`S37+<LM472^KJ\E0G&M4
M^MPG*%IMJ*IUHQUJ<E.7(E>*?+R2O)8?\*E1N<<2U*FI4YT<.L%.E3J-PY75
ME5H.I%\G--:37O)M-61XUXB_;_\`%VN>(O@]XC^%GPG\>>)-(/P@_:1^)_QA
M^%Z_\(-IFN:%_P`*8\;Z7\-+BQUOQGKVLIX:TFVT+Q9IOCQ=*O='U6X;QQ/I
MUA#IT2V<UQ)9^E^(O^"A5A!;#Q!\/O@U\0OBEX$L_P#A26G^)?&>CWG@SPW#
MX9\7_M!Q^#+KX<>`SH?BCQ!8:OX@\1MIOC[PGJ?BY-#AN8?"EIKVEJ6U2]DN
M;.SY?XC_`+(?[,GA/1=?O[SXO_$WX6_#GP)\%?#WPJ^+7@GP7XTM+NWU?X+/
MKGBOQ)/HWCR,>&?$_P`24D^)&N^(/$FH>)/%6@ZCI/C'Q8\NIQ6NL16\NJ^9
MZEJ7[#GPLO?B%:?$"Q\9_%33/#%C\8/`'QVB^%&C:_I%A\*$^)_PUT+1/"NB
MZ]-I:>&_[?O+==$\+>'[27P[>^(9=`M[K2[75-+TRSU9I;LE6630Y9UX5(JG
M3;BE+%*G)3G"3A45.HIU)P34:,W*2M[\Y-WBKY,W?.J5>,N>HN:K_LTW!0M%
M0IPE1=)*H[SJJ*333C#E3;.5^)G[='C?0_AC\;OBM\,_V>_$7C#X<?"[0?B1
M#X=^*>K^,?`N@^%?&WCGX?:J_A>^T[2?#-WK\/C*Z\*'Q5%?Z;IWB5;2!/$T
MV@WUMHMLJ:GHE]>\MXI_X*46GPMUSP3\+/B;\+KI_CW+X<\`ZO\`%;X7>$?'
M'P]U#7_!\_CW6#X?T>'P3H<WB8ZY\6=5U"56\3?\(MX'M=4N/#GA"2&^\2ZY
M:77E+=>H6_["W@VW^&'Q+^#$'Q7^.'_"LO'37[^%?!\NO>$9M/\`A)/>^//^
M%G32^`Y3X'6^NGB\8*EW;6_Q"O/'%I;:5N\/_9_[&NI[&7N]&_9;32/BY-\8
M])^+'Q?TS6]<MO`Q^(^A)?>!3X:^+.M_#[P_'X9T+Q+XL"^"WU_2-1N-(@M+
M7Q#IW@+6_!OA[Q'#86\%_I1MI[B(U"64^QJQE']Y"=66'E%XB,ZJO@XTHUY5
MJM2"A[-8NHW"GS>V]FO>A*7*FLYC5I3IS=2E*-&GB.=86:IM+%2JSH0I4J4G
M-S>%2YJB7L55NE.,6^A^#?[1.H_&KQ[\2=!\/_"_Q/IGP^^&OC?QI\.+GXK:
MWJ?AZWT3Q5XV\#:A8Z9K.F>#]"MKV;Q%J6EV]W<7\%UXCNK*STJVU31K_1HY
M+F[4F'ZB"`@$YR?\C_'^=>5?!KX3Z!\'/`EAX(T&XU6]MK?6O&7B.[U'6[F"
MZU?4];\=^,=<\;^(M0U&XM+:R@GGN];U^]D1OLZM';F&%B[(9']9``X%>74Y
M77JRI7C0;2I0;YG:*2<W*[MSVORK1;Z7LO5H*JJ,/;_Q6DZEK64FDVE9:).Z
MMTV]6;!ZG]/\*^*/VGE`^-_[".!_S<GXGZ>W[.OQI'3\:^VJ^)?VH/\`DM_[
M"'_9RGBC_P!9T^-5:89+ZPO+#XO_`-1YK\M!8A)TU=)_O*.__7ZF?:D:@QH3
M_='\L#_/K4<CI']YU7)(7.><`GCZ`9//3\ZFB_U2?[HKYJ_:S\'?$WQY\#O%
M7A?X.^*8/"?Q#U&ZT!M$NIO$^J>"6URWM-?TZ^\0>"[7QSH5M>:]X(O?''AZ
MVU7PM:^+="L[O5]`FU1-4L(3+;B6/"G!35.+FX*T=8V6EEO?2W]>9I6E.$*D
MZ<5*<;N,9:1;OLWK^3/HA+RV<,R31LJEE++RNY20R;AD,R[<;1\V588^2I3-
M$`"9$`+!`6.T%CC@;@"3STQG\Z_"OQ%\2?B1H?PN^%OCW]G:7XH^$=<NOB;X
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M6VOWL\Z$D#S4!/(!.,@=3R,$>I!_&HOM=OU\Z,*<`9R.>XR00W?I[#WK\COB
MM^T-\0M$_9$\':3INC_&7P?JNK?#/]E6V\1_M+3V^AP>"[72_BEKGPA\,^/M
M<T/QW=^)KK78_&MGH/B[7;C^VM1\+6Z:=J]M>ZJE^9;.&>3RGQ(^O^%?VH%_
M8\TOXN?&-OV>/$GQV^"6F:QK-Y\7O&VI^._"UWXG^`'QP^(&J?![2_C1J^OW
M7Q*TFT\9^*?AWX`UV?2[;Q:NOPV7BBYT;0;ZQTO7!9#.GEM>I!SYH1A#VDZM
MHQG-T:#HQK<FL4JEZ]+V<92CSIR=URN^KS1.2@J,ISO0Y%!R@N>NJGLU4O!?
MNK4I.K*TG#W4HR;N?N/]MM"<?:(AZ9.,;0&.21C&UE)/&=V*FBFAE9E26-VC
M8+(JM\RD@,`P'()4C&<9[<8K\,?&]U\3!^RO\6;OP]\=_BS:Z1^SS^V9J'P^
M\'>(+#Q1]O\`%'Q%^'^G_&GX8:-I/AGQM\1=0BO?%NO:'X0O?$GBWP7J4MGJ
MJ:OXKAT!-/\`%>KZB+74+.]_6KP5X,US2?C%\9O&=V;8:!XTM_AC::$L5V9;
ME9_"&D^(;#6C=6FW99HT]]9BV*.YN(R[NL94`\^(PLL+3C4J5H5(SQ%>C'DB
MXN/LEAY1YDTM9QQ$&]7:2FE=JQKAL?\`6:CITH07+1P]63=:E6UK.O&23I2J
M6498>27-;F4E):*27MC*JJ3SP#^?;MZ__7S7Q9XM.[]OOX!$GI^R[^TS'^'_
M``LK]F<C\>GZ?C]J2?<;Z5\6>+?^3^_@%_V:_P#M,?\`JR/V9ZG!*,J^+4DI
M*.5YA.-]HR6!QDXR2[QG2A)/^:*?0WQ*3EA4_P#H*IO7:\91MIY<SMY-KKI]
MI[!ZG]/\*-@]3^G^%/HKFLNR_K_AE]QU'(>/M8N_#?@;QGXBTY86O]`\*>(M
M:LEN%,ENUWI6D7E];+/&&4O"9H$$J!T+)N4,"01^17@#]O/XYZ]^Q==:]K,'
M@)OVP;C4/#7@WP[9VGAS4K7P/JFH?$/X>VOQM\*?$[_A%)=<GU,^#-&^#%[J
M?B?6[6+7O])U7P/XCTZ*[M@ZI!^PGBO1(/$WACQ#X;N7GCM?$&BZGHEU):-$
MES'::K936%R]N\L<T23+!<2-$SQ2JKA2T;@%3\7Z3^PE\&_#OBWP7X_MT\5R
M>(_`?[-=M^S!HUU/K=H;63P=:Z3)X>L/%%[8Q6,5E>?$BU\/WFI^';3Q4$A2
M'1]8U#3WL%LWB2W]/`8C!TERXJC2GRXO#8J,YP4Y.-"-:$L+)<T+X7$*LYUX
M*5Y3HT7IRW/.QF'QM6K&>&KNG'ZO6H2@IJ+YZU7#_OX*4)P]K0I0JNDYIQYY
M<K7+*37E&E_\%!M6TSX>^&O$^I_"'Q?\0K7PA\!?@C\7OVE?&G@IO#&D:#\+
MXOBQX-M/%(FTC0-?\00ZYXWN;+21J/B[5_#OA>.ZN=!\+"Q9+O4]3OH+`^@V
M/[=4-S\49/!%W\&/'NG>!;?X[3_LX7'QJGU7P9+X//Q/E\*VWBS0H;3P]%KK
M>,KKP[JUI.+"[\0?V3%:Z-J\D%E=1RAKB:TSM4_X)_\`PMNK*RT6V\;_`!BT
M'PG=_#+X8?"7XG^"-!\3Z-#X:^./@KX-Z2NA^#+?XAB_\,WNLV=_!HJR:/KF
MK>`-3\$WWB70YO[(U26[LHK=;;T[4OV=_A1I\L":GXAU?2WU[]J32_VA]+M+
M[6-$L3J?Q1MM%2UL?"FDV]W812ZAH-QI.BRW$6@6JR:U<06UY<Q7T=K`\<=S
MEDSF^6.)E3FDGRQE&K"]*CS<L5*RJ*JJKBOA=)P<WS72YY?VM#EY*U*4?9KD
M]K]7DZK5TG*4(4HVD^5.T>9.+:>MEX]IW_!1GPR+"+QAXP^$OQ!\`_";Q5X"
M^(_Q)^#_`,2M5N/"FM)\4?#/PPTD>(-:2'P=H6MW/B?P=K&O^&L^(_`VE>*8
M+=_$NDX:2YTO4"VGKE>+_P!K?XG^$_'?P0UKXK?#O7OV?OA_J&E?M%>*OB/X
M;U_6/`/CS4?$/@OX9?!NU^(&F:U8:IX(O]7.EW.CW[7D&HZ(+FRU,ZA9_8W3
M4]/FBO6YWP;^S1^R5>ZU;_"R?XL?$OXE:%<:'^T)\$_A;\'_`!CKT\6@?##2
M+:WM=&^-WASX;76G>$/#GB">]\.Z7J^E:!I?BCQ9XD\4WN@>')H=*\#ZTE@U
MRP]NM_V*O">IP^'3\3/B7\8?C6?#^E_$?0TE^)GB/P]<I=^$?BEX!7X:Z]X=
MOHO#/ACPK:6-E!X9B9K6_P!'M=,US4-:N;K7_$&L:SJ$R^6Z<LKA%5)TI/VD
M*KY6J\I*,Z4Z=&=&7M%2O&KRN;E!I25X1;30E+-I+D]I2E5NXRE3]A[*E4C&
M$IPJP=)54VI7BH5+VY?>U;?`ZM_P4-G\(^'/$^K_`!#_`&<OBSX'UW2O!7@/
MXG^#_`DNI?#_`,1^(_B1\/OB#\2/#7PKL;C2[G0O$TVC^'/&&@^(_&'AX^)?
M!7B.^M+JT74;6&VU.ZCEN;BUZ'6/VZ+OPYX!^(WBCQ/\'[OP9XR^$WQ+TSX7
M^/O`/Q`^+?P8\#Z7H6J>(_"6D>._"^KR?%37/%]OX"O=*USPUX@T;[!;Z3=:
MCK1UV\DT6;28?L-WJ"\UK_[(_P`$?!/AP6WQ9^,GQ=\8W?C2]^"?P4\)^-?B
M'X@T74_$&@V'A_XJ^'/&WPT^%'A2;P[X+TS3)(_$'CO1=!B\0^(O$.EZKXH\
M20VMDOB#Q9FSMKNQ]0^('[&G@CX@>+/$'CL>+_B/X*\=ZS\6=!^,MIXK\*77
MA5[OPMXMT;X2VGP.EMM$T_Q3X5\1Z"VDZ[X"MIK"^75]+U?4;;4[N76]#U/2
M+B.W%MBI95>E[2G5IP;A4E/FJJZINC3G"FG)7IS_`'G.FV^;EG'E7NRTY<Y5
M.IR5</4JJ$U&/)!J,I1G&$I-6U4O9S32Y6N9=VN6_9T_:NN?VB/C3X:O_"%Q
M/:?!_P`<?LA>#_C7H/A_4]/T?^VK+Q3J_P`5_&'@[4Y+W6=,DNTNT@M-!&G)
M'8:GJ&AW1MAJNGR,EVDTWZ&;%]_SZ?Y]\U\F_`;]D?X??`+4_#FJ>$=3\97T
MWA3X.V'P3TX>)M6LM4-SX5L?'OB7XA17^HSPZ=9SWGB*36O%&H)=:ENBM[BQ
M6WC-BEPDD\GUI7-B)X>I4OA4U0C"G3IN2]^7LX1BYSZ\\Y1<YWU<VV=V&C6A
M2MB)\]1U*DF[)6C.;E"*2NDHQ:BDFTDK)C-@]_\`/X5\_P#[5J@?LR_M$`#C
M_A1?Q;R/^Y!\0#_/-?0=>`_M3()/V;?VA(WP8V^!7Q;W8)!R/`FNCKG@<CD'
M(YJ:$7+$8>,4KNO1LN[YXI?HA8MI8:M=V7LYZVNDE%MMVU226K2=M-#HO@0%
M_P"%)_!_/'_%K/AT/3C_`(0[1NGT./;%>L;4_O?J*_S[?$G_``7N_P""BGPP
M\0ZS\-O"WQ&^$UAX6\`7G_"&^&K2_P#A-X:O;ZWT+PY;V^F:9;W=Y/>I+>74
M-I;0I<7#A6EE!9U#'RUQO^(BC_@IA_T5'X.?^&<\*?\`R?7ZQ_Q!3C"3<HU,
MGG&4YN,H8G&5(N]1W2G#+Y1;3=GRR:33UNFE^?P\4.&E""]GFSM&"NL!=.\8
MM-/VVJ:=T^Q_H1SL8U8Q\D*2!@$LP5B%!/RC)P.>,GGBORF7_@L1^R#X>_:M
M^*/[(OQ?\4W'P3^('PX\6V?A;3_$GCV**W^'7C.74=+T;5+.>Q\96TCZ?X;N
M&&KI;36'BQ-*A$T):VU*?)A7^3,_\'%'_!3#!)^*'P;P!DG_`(4YX5)`&3P/
MMQR<9./K7Y1_'?XW^.OVF/BOXY^-_P`4K[2-8\>?$C5(]6\57VBZ3;:-I%Y>
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M=<7$>H>%KJ\V^6;_`,(W^D7;2.#(MP`8F_O0_P"">7[:'Q._;0^$MI\0/B-^
MR]\3OV<+]!9F.7QI%:GP?XZM[E)"=8^'=Q?2:9XPN=)8J&+Z_P"%M-M8TG@_
MLW5==1I9D^$XR\.\ZX,=.OB9T,7E^(ERX;$4Y0P^)LDUS5<%7G#$NE/EO2Q-
M&%?#SC9NLG*$7]=PYQCE^?JI35.I@\92]ESX>ISU(3]K!-NA64>648/W9*2@
MXRDEK>Y^B6P>I_3_``HV#W_S^%*I!&[W(_7'ZX%.KX)6:36S2:TZ.S7Z?<?7
ME"Z`\J<?],Y`?R'],?\`ZZ^/_P#@GF`?V+/V=!U'_"O+;!_[B>I5]@W7^JF_
MZYR_TKX__P"">7_)EG[.?_9.[3_TY:C792@EE^*:Z8W`)>DL-CV]-OLQ^XXK
MOZ]3_P"P*I^%:B?9>P>I_3_"C8/4_I_A3Z*X[+LOZ_X9?<=HS8/4_I_A1L'J
M?T_PI]%%EV7]?\,ON`9L'J?T_P`*-@]3^G^%/HHLNR_K_AE]P#-@]3^G^%'E
MK[_I_A3Z*++LOZ_X9?<!\P?ML`#]C7]K@#_HV'X]_P#JJ_%=>L?"@8^&?P[7
MU\"^#O\`U'-,'\AG\Z\H_;9_Y,V_:X_[-A^/?_JK/%=>K_"?_DF?PZ_[$3P9
M_P"HYIM;UTE@,-9)-YA75_)82G9>FIA%)XN6FOU5Z^E6YZ)L'J?T_P`*-@]3
M^G^%/HK"R[+^O^&7W&XS8/4_I_A1L'J?T_PI]%%EV7]?\,ON`9L'J?T_PHV#
MW_S^%/HHLNR_K_AE]P$$H"KQW_Q'^-?('[-(W?&']M\'H/VB_#__`*S_`/!O
M_&OL*7[A_'^1KX^_9H_Y+%^W!_V<7X?_`/6?_@U6U'X,;_UXPW_J7$XJ_P#O
M6`_Z^XG_`-13["V#U/Z?X4;!ZG]/\*?16-EV7]?\,ON.T9L'J?T_PHV#U/Z?
MX4^BBR[+^O\`AE]P#-@]3^G^%&P>I_3_``I]%%EV7]?\,ON`9L'J?T_PKX^_
M:!`'[17["0'_`$63XO'\_P!EKXU_X5]B5\>_M!?\G$_L(_\`99/B]_ZRU\:Z
MUI*\[+3W:C[;4Y=K=%;_`(!E6UIZ_P`]+_T[`^O54$9YZX_SQ3M@]3^G^%"=
M#]?Z"GUC%QE%-+3I=:K7_-&HS8/4_I_A1L'J?T_PI]%.R[+^O^&7W`,V#U/Z
M?X4;!ZG]/\*?119=E_7_``R^X!FP>I_3_"O*/CE@?!?XP>J_"[XA#W_Y%'6"
M/S_SBO6J\E^.7_)%_C%_V2_XA_\`J'ZQ54U^^PW3_:L-M=;5H=FNFACB$GA\
M1?6U"JUY/E9^`-%%%?;67;^M/\D?+<TN[_K_`(;\^[/V(_8<./AG\2_?]J;]
MJX?G\>O&U?:%?F)\!_B5\3?@=I'Q(\%>(/V4?VE?$-Q/^T!\?_%VFZYX.T/X
M8:AX<UGP_P"-OBMXE\4>'=4TVZU7XJZ3J+1WFDZE;SM'=:;:.DKS;XD(15]T
M_P"&K?&/_1F_[7?_`(2WP@_^?+7RV,I5:V,Q56E!2IU:TIQE[;#+1\JLTZR=
MU]STL]3Z+#5Z:P])3YZ<N17C.G/F6V_)&2ZJUF[GV/17QO\`\-6>,O\`HSC]
MKK_PE?A#_P#/FH_X:L\9?]&<?M='_N5/A!_\^>N?ZOB?^?4>G_,1A?+_`*?>
M?]71O[>C_.__``75_P#E?FOO/L.4I@AN@!8YZ;<$-GVP>:_%YOA;X^^*GQRM
M_!WQ$E^-MI\*M5_;(_:JN?$`T3QC\2?`FG:C\,$^!?@L_#^QN_$GAC4]%U"U
M^'6H>*X[H:##IFL:;I=[KUK-;V%P\@U&UN/MMOVJ?%[<M^QO^UY]TJ?^*6^$
M73.3T^,^>>G!SZ'M50_M->(VWAOV,?VNV#*J'_BF?A)C8"S*@(^-'`!=F^3'
M)YYKHPZQ-#G_`'$9<\91C_M&%5G*#BII^U=I1<E*-D[2BFGKKSXB&&Q2I^TD
MVZ-1S25.HXRC)13NU#6_9=-.I^1U[\%?VA=?\(^'_BSX;T7XW?\`#2^@?L"^
M*O#.D^+[K4_B1!K9\1Z%\<+7PP--N?#R>(M`T/6?B1??!H:Q?Z-I5['9ZQK^
MMMIWB>&Z'B6WT?Q!9=AX+\)>-=)^&NB0>.?$?[0/CS]EC5/V@8+KXD^%?AG\
M+?VROAIXI\+^&C\'M6M],L+*V^(?BSQA^U'XG^'UY\6$T#6/'!\+ZZFFV/B6
M<+:PR>'CJ\$7ZB)^T_XFBSM_8S_:[#9W$GPQ\)6YXR?F^-'`P`#MZ=_6E;]J
M#Q0Q!;]C3]KQMI#J6\,_"5B&1@ZDD_&GD*P!`/3''2NJ6-S"K&,*F%H.,=8V
MQ.&YX1NG"$*CJ*<8T]X)/1R;=^9I^?'+,#&I*K"M4IRDES<E&;C)I)/GCRI3
MYU\3ES7MI;1O\P?'/PHL_"&N_MC^+OAA\._VEO#?Q!^)'['WP>U'X%ZO?7WQ
MVUK7)8-(T77M$\9Z%J^IG6]?\.:9\4=!$/A1!H7B2]7QQ:/=7%]X=CW7FOS2
M^HWVF?$FZ_:2ENCIO[2,?[0<7[8/AF70]<M)?B='^SLG[%,<NC+K-M+,)A\!
MW\/WGP_36;'6+&^B/Q9D^+\_GVP1'L;B+[I/[3?B0RM+_P`,9?M=K*[I(Q3P
MQ\)4#NB[5=E7XTA2R@+A@-WR]0:1/VFO$:%MO[&7[78#,K,/^$:^$Q#E<;22
M?C4<].HZ]/>KGC<7.+3PE.;DJ2DYXG#2DG3ITZ<4I^U;]G-03JQLE.7O6T0H
MY?2B[PQ3I)RNZ=/"<E.7M).52<HQBE[2#Y8T96;BG*S6KE\??LA_#+XA>`/'
M?[*WC6^N/CC/K/Q2\._M/Z;\?4^(?BOXB>(M'M!HOBVRU;X/6.K>'?$U_=^'
M?!-WI%N;O3_!4NFZ7H=[J>BW-];RW&K1/&U?LDJ+@9)]!R1W)Z#C.>/I[U\9
M+^T]XEC977]C']KE"AW+CPO\(SM.`,C/QG/8?Y'%6Q^U9XP`P/V./VN_Q\*_
M"'_Y\O\`+],UP8E8K%UI5)X>G%2<I<BKX5Q@YSE-0A^]5X04^1.R?*HKHD_2
MPT</A:/LHU)S3<92E.G5YI3Y(QDVN67Q-<SUTDY65C[(``X%%?&__#5GC+_H
MSC]KK_PE?A#_`//FH_X:L\9?]&<?M=?^$K\(?_GS5@L-B$DE2BEHO]XPOE_T
M^\_P7=&_MZ/\_P#Y3J^7_3OS7WH^R*^)?VH/^2W_`+"'_9RGBC_UG3XU5I?\
M-6>,>_[''[76._\`Q2GPAZ?^'GKYQ^-'Q;^*GCWXD_LP^*M$_8Y_:K&E_"3X
MQZUXV\5_;?#GPFBN3H>H_"/XC>"X6TF*+XQNEY=C6?%.E%X96@5+/[3/N9X@
MDG1A<-7]OS2A"$5A\4G*6(PUKRH248I^V^*3=HKJ[=T88G$TE23C[2HW5H+E
MITJLI*]:G>33@O=BM9/HM3]48B#&B]]@R/;_`":XGXC_``Q^'_Q>\)ZAX$^)
MOA+1?&_@_59+2;4/#^OVB7VGSW%A<QWEC<F)\-%=65U%%=6EU"\=Q;SQI+#(
MDBJP^;H_VJO&*JH_X8X_:[)"@9/A3X0^@ZY^,^0<5)_PU9XR_P"C./VNO_"5
M^$/_`,^:N>&&Q45']TDTHJ_UC#)IVC_T^O?7\/-&\JU!WC*5T]+.G4::TZ<C
M3W7S/:]+^`_P;T3PAX7\`:/\./">E^"?!.MZ+XF\(^%['2;>WT7P[XD\.ZHV
MN:+XBTNRC18;;7;'6RVL)J^UK^74W>^FN);F221K>O?!;X4^*++XB:;XC\`^
M&]<T_P"+NF0:-\4+#5M-AOK7Q[I-II4NA6FG>*X+D2QZQ9VNCS/IUM#=K(D-
MJ?+C"X45X3_PU9XR_P"C./VNO_"5^$/_`,^:C_AJSQE_T9Q^UU_X2OPA_P#G
MS52HXQ.\8N+<HR;6*P]W)5(U>:ZK[^T?.GOSI26MF2ZF&>[B_=Y=:-1JW(J=
MOX;TY+0L[I0?*M&T_I'4/AQX$U;P?)\/=5\)Z#J?@.30(O"LO@W4-,M;WPQ/
MX:M[`:9!H,VBW4<NGRZ5%8JEJED\+0K#'&@`"$5Y3:_LC_LS6/PSO?@U:?!'
MX=P_"[4=4&N7W@C_`(1ZU;0[O7XY8)H/$$\+J\TFO6DEK;?8M;,PU6R2VMH;
M.[@AAB1>$_X:L\9?]&<?M=?^$K\(?_GS4?\`#5GC+_HSC]KK_P`)7X0__/FI
MQHXR"M&+BF^9I8K#I.3M=V5=*^N_^:$YX64U-\KFHJ$9NC4<E'2T8R]G=+:R
M32U\]>Q\6?L<_LM^.O`OA'X8^+?@5\.M=^'G@.22;P;X*O?#]M_PC7AR:8[I
MYM,TJ+R[."XGE'VB><QM+->?Z;*SW9,Q]U\+^%?#O@OP_HWA3PII-KH?AWP_
MIUEI&B:/8HT5GIFF:=`EO965K&6;R[>V@C6*-,G:%QGT^6?^&K/&7_1G'[77
M_A*_"'_Y\U'_``U9XR_Z,X_:Z_\`"4^$/_SYZ4J.+FK3@Y*_-9XG#M<SY$Y6
M]O9R:C%-VNU&*OL*,\)3?-!0A)1C&\*$XOEC=QC>-).T7)N*V3DVM6?8LGW&
M^E?%?BP@?M]_`$'J?V7_`-IHCZ?\+)_9F/\`(C_(K0/[5?C`@@_L<_M>8(P<
M>$_A!G!ZX_XO.>?P-?-_B/XN?%/4OVJ?A1\8+']CG]JQO"7@_P""?QD\!ZP)
MO#?PFCU4:]X\\9_!W7-&>UM_^%P-!/8FP\":R+V5IXI+:;["L,4RW4[0;X*A
M6C6Q+G"$%/+\;1BY8C#)<];!XFC!/]]_/6CYM)\J<K1>%?%4I+#SC[27)B:;
ME%4JCE9SIW:7+LEJV[+LS]5Z*^-_^&K/&7_1G'[77_A*_"'_`.?-1_PU9XR_
MZ,X_:Z_\)7X0_P#SYJY_J^)_Y]1Z?\Q&%\O^GWG_`%='9[>BOMO_`,%U?_E?
MF?9%<IXWDNK;PAXEN;#3KK6-0M=$U.YL-'L;W^S;_5[Z"SFEM-*L=29XUTV^
MU*Y6.SL]09PMG<3I<'_5DU\Q?\-6>,>_[''[76.__%*_"$?K_P`+FXIDG[5'
MBV5=LG[&O[73KE25;PM\(B"58,IP/C,<8(!X!Z=J2PU=2C)T(-Q:EK7PNMK.
MW-[5M;[I::/J2Z])II5+-JR?LJKM?K;DUW6GH?C?\+M(_:-UWP5^T7I-GIOQ
M_P#`^A>//#O[)VMV&DZ-IW[4N@ZWX,^(%_\`M(VUO\9M-\/>+_CSXK\7>,->
M\;>$O`DZVOC_`,8^`H/"W@#6+*PBUJQ\.16B2WK>W?%W]GS3=-U(Z'XH\'_'
MSQ=\#_@;^WM\-M?\'_8/$GQ^\:^(]`^%/CWX`:4_C34]`U/P_KM_\2O%WA/2
M_B]K)3[39WGB*;P?<S:S9Z;)INAIJ5O'^C#?M.>)69G?]C+]KMF?&\MX:^$Q
MSA`F<_\`"Z<`[01G`R..!2-^TWXD(0']C/\`:]PA&P#PW\)TVG#`D;?C4,D[
MFXQ^O(]2.+Q<*SG'"0C3DVVOK>'<O>ITX2DI.JFI6@[;I<ST:DT>)'*L-["&
M&JXAU:<%RQY\(I-P5252*ES)K2<]8]HQU5KK\U_B'X1OM2\>>$-?^._A/]I[
M6_A1H?[1/[?*:G<?#.Q^,DWB.T\"^()?`$/PLA:X^&3V_P`1;?X?ZS)IX_X1
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M@^D/V/M/^)WB#XZ>-?AGXXUKQOJ'AS]AG3?$_P`'M(UK6=7U"2+XH:_\5O$4
M/COP-XNU.Z>XD7Q1J'@K]GZ/P!H4MYK!N[S3O$?B7Q%(NV=C<S?23?M->)&1
M4/[&7[7NU"=H'AKX3`C<4W`;?C4,@[%#`@Y"^AK!\+?'`^";CQ3=>%/V&/VK
M-#NO&WBB_P#&GBRXL_"?PD$WB#Q5J=II]C?:YJ4DGQJD:>^GL=*TRS+;A'#;
M6-O;P1Q1Q*M*KB,15I5*;P5)7AR47]:H-47.M3J3G2C[:T+Q4Z:BG;EJ2UNH
MFE'"QHSH3^M-\M2=3$_[/.,JZ]A3I4J<I*#;A"I&=9N6O,HM):'WDB*BJH)X
M"CD\D@<9&<`GK@`<Y(J2OC?_`(:L\9?]&<?M=?\`A*_"'_Y\U'_#5GC+_HSC
M]KK_`,)7X0__`#YJ\SZOB7O273_F(PS[?]/O/\%W1Z<:U"*LIV71*E57;M3]
M/O1]D'&#GICGZ5\_?M6\?LR_M%$<G_A1'Q<`_'P#KX(XY_J">#7G'_#5GC+_
M`*,X_:Z_\)7X0_\`SYJ\J^.7Q[^(OQ#^#/Q;\!Z!^QQ^UB-=\;?#+Q[X2T=K
M_P`,_"**P&J^(O"^IZ1IOVR>/XR.\%LUW>P_:)4C=H[=9'"LXC!TH8;$^WH-
MPA!*M3<I/$89*,>:+;;5;;77IL]C+$UZ/U>M92JVI3?)&E4<I^[\*3@DW)/1
M:WZJS/1_@W^RQ^R]KGPE^%VL:U^S?\!=8U?5?AQX$U'4]6U/X0?#Z_U+4M0O
M?"FDW-Y?7]]=>'9;F\N[JXDDGN+FXE>:660O*^Y\UZ7_`,,@?LF?]&N_L\#W
M_P"%*_#7CW_Y%NO!_AC^T5X^\)?#GP!X7U/]CC]K4ZEX<\#^#]`U`6_A?X22
M6ZW^B^'M/TV]%O+)\94:6`7-M(L3LBNX'F,-K)7=_P##5OC'O^QQ^UUCO_Q2
MOPAZ?^'FK5SS.,II5J[3JU7=8ZE9WJ/5?[3K=._GZLB%/`*G3_<48_NZ=HO#
M:Q2A!*-E2=N72-NC5EHD=M-^R'^R<H./V8/V=PN`<_\`"E/AJ<C#;N?^$9S^
MN>F.U?R/_M!_\$1_VEOVL/\`@H=^TKJ'PQ\$>$/V>OV:Q\1=/CT/Q_KFE66A
M>%9])C\'^'8KX_#/X?>'4L[S7T34(KM))[:WT;P\;]IO,U<3&3=_5.W[57BU
MP0?V-_VN\L",CPQ\(E(!&TE2OQF&#CH>Q'&*C7]J3Q4OW?V-?VNP>"I/ACX2
MG;P%^4'XT%<``!03D9SUS7M</<2<1<-UL=B,!*#KX_"_595*^+C4=&V(52-:
ME&.+C%UE&,81=3VM))M2I3LF>5F^19-G5/"4\5%PAA<1[=1H4I0=6\;.E4E&
MG=4VI;);KJ?(_P"Q+_P15_8P_8^_L?Q5_P`(;+\;?B]IY64_%#XLQ6.M/IE\
M%/F7/@[P8D9\+^%(P69;2Y2RU+Q%;H$W^()#O)_7R.S@CVE%88;=\SNQS@+C
MYF.0%`51_"``I`4"OD!?VJO%Z<+^QO\`M=_CX6^$)/YGXS=*=_PU9XR_Z,X_
M:Z_\)7X0_P#SYJ\G,<5G.<8B6,S7$5\?BJC;E5Q.+PM22YFGRP2JQITZ>MXT
MJ,*=**?+&$8V2]3!X?+<NHK#X&A2PE&*24*5&<7*R23J2C23J3V4IS;DWJW<
M^QP`.!2U\;_\-6>,O^C./VNO_"5^$/\`\^:C_AJSQE_T9Q^UU_X2OPA'_O9C
M7"L-B/\`GU'I_P`Q&%\O^GWG^"[HZO;T?YW_`."ZO_ROS7WGUU=?ZJ;_`*YR
M_P!*^/\`_@GE_P`F6?LY_P#9.[3_`-.6HTRY_:J\8R0NJ?L;_M=%RK(<>%OA
M%EMRE<<_&8X(!5^,[L8`->`?LF_%WXJ_!C]G#X0?"[QC^QS^U4WBKP3X2@T7
M7&TC0/A+>Z6;Z.^O9F-E=3?&"UEN(#'/&R2/;QDY9-@923V0HUU@<3!PASSQ
MF"E&*Q&&<G&GAL7&<TO:WY4ZT4WT>CLW&_)[6'UVG+W^3ZG4CS^SJ<O,Z])*
M-^5^]97MO8_5"BOC?_AJSQE_T9Q^UU_X2OPA_P#GS4?\-6>,O^C./VNO_"5^
M$/\`\^:N3ZOB?^?4>G_,1A?+_I]Y_P!71U^WH_SO_P`%U?\`Y7YK[S[(HKXW
M_P"&K/&7_1G'[77_`(2OPA_^?-1_PU9XR_Z,X_:Z_P#"5^$/_P`^:CZOB?\`
MGU'I_P`Q&%\O^GWG_5T'MZ/\[_\`!=7_`.5^:^\^R**^-_\`AJSQE_T9Q^UU
M_P"$K\(?_GS4?\-6>,O^C./VNO\`PE?A#_\`/FH^KXG_`)]1Z?\`,1A?+_I]
MY_U=![>C_.__``75_P#E?FOO/LBBOC?_`(:L\9?]&<?M=?\`A*_"'_Y\U'_#
M5GC'O^QQ^UU_X2GPA_\`GST?5\3_`,^H]/\`F(POE_T^\_ZN@^L4?YW_`."Z
MO_ROS7WG5?ML_P#)FW[7'_9L/Q[_`/56>*Z]7^%'_),_AU_V(G@W_P!1S3:^
M%OVD/CE\2_BE^SQ\>OAEX9_8W_:O/B7XB_!;XH^`O#_]H^&_A+:Z?_;GB[P/
MKOA_2OM]U'\8YGM[/[?J%O\`:;A(I7A@+RK$Y4*W=^!_VDO''AWP7X0T&_\`
MV./VMWU#1_#'AW2+UH?"OPB,)N],T>SLKAH7/QG0M&9H)"C;`"@&4!8BMJN'
MKSP6'A&$.>..JS<'B,,I*$\+"*E;VS]WF5F^[5KO0Y88NB\5)KVG+]6MSNE4
M4>9U=(W<=^MNQ]Z`@\BEKXW'[5GC`#`_8W_:[_\`"6^$'7_P\M'_``U9XR_Z
M,X_:Z_\`"5^$/_SYJQ^KXG_GU'I_S$87R_Z?>?\`5T=7MZ/\[_\`!=7_`.5^
M:^\^R**^-_\`AJSQE_T9Q^UU_P"$K\(?_GS4?\-6>,O^C./VNO\`PE?A#_\`
M/FH^KXG_`)]1Z?\`,1A?+_I]Y_U=![>C_.__``75_P#E?FOO/LBBOC?_`(:L
M\9?]&<?M=?\`A*_"'_Y\U'_#5OC'O^QQ^UU_X2OPA_\`GS4?5\3_`,^H]/\`
MF(POE_T^\_ZN@]O1_G?_`(+J_P#ROS7WGV)+]P_C_(U\??LT?\EB_;@_[.+\
M/_\`K/\`\&JC;]JSQ?@[OV-_VNR#P!_PBWPB'7_=^,V?R]^YKY^^#GQB^*/@
M;XA?M*^)=8_8Z_:L.F_%7XN:1XU\+BT\._">>X_L:S^%/P\\'SG44E^+T*6M
MR=8\,ZF$MXI+E1:"UE$X:9H8MJ.&K^SQ5X03G1HI1>(PU[PQ$*C_`.7VMX[6
MOKO9.YR5ZL'B<)).3C3J57)JG5?\2@X+:GT:UO;=;GZE45\;_P##5GC+_HSC
M]KK_`,)7X0__`#YJ/^&K/&7_`$9Q^UU_X2OPA_\`GS5C]7Q/_/J/3_F(POE_
MT^\_ZNCK]O1_G?\`X+J__*_-?>?9%%?&_P#PU9XR_P"C./VNO_"5^$/_`,^:
MC_AJSQE_T9Q^UU_X2OPA_P#GS4?5\3_SZCT_YB,+Y?\`3[S_`*N@]O1_G?\`
MX+J__*_-?>?9%%?&_P#PU9XR_P"C./VNO_"5^$/_`,^:C_AJSQE_T9Q^UU_X
M2OPA_P#GS4?5\3_SZCT_YB,+Y?\`3[S_`*N@]O1_G?\`X+J__*_-?>?9%?'G
M[0)!_:)_82Q_T63XO#_S5KXU_P">:A_X:M\7@'/['/[76#G_`)E3X1'\B/C0
M/R_^O7SW\5_C#\5/&/Q<_9>\::-^QW^U6-%^$GQ"\?>)_%@N_#WPFAO/[,\2
M_!3XB_#_`$W^RX%^,$J7UPVN^*=-%Q#++;B&P-U=AVD@$,NE+#XCG_AQ2Y9J
M[KX:RO!I;5G_`#?.UD<]?%T4N1>TE+GIZ1I5'M4@[_"NFI^I*$`8SR3_`(5)
M7QK_`,-6>,,_\F;?M=#&`,>%OA$0/0_-\9LGGL.!TIW_``U9XR_Z,X_:Z_\`
M"5^$/_SYJS^JUXZ1I0:\J^&MJUM^^\[_`(=4='UBB[/FDKI:.G4OLNT&MW8^
MR**^-_\`AJSQE_T9Q^UU_P"$K\(?_GS4?\-6>,O^C./VNO\`PE?A#_\`/FH^
MKXG_`)]1Z?\`,1A?+_I]Y_U=![>C_.__``75_P#E?FOO/LBBOC?_`(:L\9?]
M&<?M=?\`A*_"'_Y\U'_#5GC+_HSC]KK_`,)7X0__`#YJ/J^)_P"?4>G_`#$8
M7R_Z?>?]70>WH_SO_P`%U?\`Y7YK[S[(KR7XY?\`)%_C%_V2_P"(?_J'ZQ7B
M/_#5GC+_`*,X_:Z_\)7X0_\`SYZX3XG_`+1_CSQ3\-OB%X:TK]C7]K1]5\1^
M"/%F@Z>DWAGX21P/J&L:!?Z=9K/(OQED:*%KBYC$LJ(YC0LX5F4`U3P]=5L,
MY0C%+$X=MNO0:455@Y2;C5E915VV[*R\S'$XFBL/62E*3G1J1BHTJK;?(W_(
MNG]6/RJHKWC_`(9<^/\`_P!$PU[_`,&&A?\`RZHKZSV]#_G_`$.G_+V'6WG_
M`'E^)X'L9=JG3_EU4ZV_N_WE^)^W^OZYH'A?3I]9U_4]/T32K4&2ZU+4KR"Q
MLK:/*`R7%W<RQ00HS>6-SR`EFC`Z9%ZTNK6\WF%Q)MSQO!QM;:_0\;'4Q-C[
MKJ48*P.?`/VJ/V;?"'[5?PGO?A/XVOM9TW1[W4K35DOM!NH[+4;:^L8+R&VE
MCN3&;J-`EY.KI8W=A<2JWDR79LWNK>XL7OA7XD?";X6>'/"?[/\`X7\&>+]7
M\+6FB>&],TGXH^/-6\%Z3+X=TZW:T>^N_$GA7X?^+KN?6(88;;;;IX7@M]1?
MS9+F^M759)?BO9X?EOI.O*3]K%I2Y4DN65WK>77W5?>^Y])&I456K"5)1HTX
MTW1J1G).4I<O/'DTA:+T6OGN>S^(?$GAKPI9)J7B;7]%\.:<\\5F-0U_5K+1
MK!KNX<);6HOM1N+:V%U<2';;P>:)IW#"%'*N*U8WCD!9"64X*L&RI4KN5E(.
M&4J2<@D<G:Q4`U^8W_!1NQ\(R>%?@_XP\4WT,7Q'\#W_`(TUCX>^!=<^!?C'
M]HOX3?$_Q+?^$#I6L?#7Q=X7\->'+R6ROM=6>*#P5XPDET'6=$NDO-0TV*ZA
M;5M-?S6R_:+^+]I\1O#GPKUC2/BQX&\9^)/VH?V;=>M/`5EX,\1:IX4\&_L^
M>)?@QX%D\;^&V\>6?AO_`(0J+P;HWQ)MO%_A35$EUR'58O$-K)";.TMIHFCZ
MHY?&K1A6I.FVE+VU.4:4.5<UH\G-:=1*/+.4HJT?>4K))ODGF$*5=TZ\)QBW
M%4*D%5FI-PBY<Z@I0A[[E&*;UTDF[W7ZXZ5K^@ZU;1WFD:G9:M8SC-O>Z;<P
MWUE<INP9;>[LY9K>XB#93S8I"A=&C7YU*UM+&A!)'<@Y)'U.#@C\?K7\YNB1
M?'+P?K/@SXM^&-6^-$7QNU[_`()_^/K3X4^"3HNN0_#+Q)\5_!_C[Q[>7GAG
M6_!VC^$H]"LM9L/#^HV'C#1M%U6ZT.?Q#XCM].ETQ-6N99+"3[O_`&%_%?QI
MU3X$_&O6;KXPZG\?]9TZ]U2;X62>*/!OQ3\+:AIWB*'P:+N?PGJVN_%GPGX$
MUKQ);7?BH6TQ^Q:>=*\*I?2^'HM39K218;JY;2I4W/VV%FU4IT^2$9-WJ>TU
MYO9J+2]F]>;7IMJJ>9JI45)X:O2;IU*G/5Y(TTH.DK.7-I)JJG:SY6K2MN?I
M-XE\1:#X2T35?$GB;6M,\/>'M#L+K5-:US6]0MM+T?1]-L87N+W4M4U._F@L
MM/L;2&-Y+F[NIXX(4`,K)M)IGA;Q-X:\:^'M(\5^$]:TSQ)X8\06%MJN@^(-
M$O8=3T76])OH4GLM2TG4[.6:SU'3[N!DEMKRUGFAFC9723!VU_/=XK?XG?'3
MX#_%_P`%VOQ2_:S^(7AO6OA-\*=;^,J>/O"FJ^"=<\&?M&S?&#P9:^)?AI\/
M4O\`X<:#+_PC!\/WGBFX\5>#?#UEXK\+:-I_A_PO=6>OR+J=VVH_H]^UKJ6N
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M;?&7XFWWP=N/'5YX[\::%X+_`&X8+GP1X@\3S^.O%]]9>!-7_8_^(E_J<EQX
MY\=?!_X)^)->T33?'.MZGI%OKFK^`-*TW2]4N9?#=CK&J16VGRR-Y734:DO:
MX5RI1C.4+<LK/=>]%6DM+QW5WV=E+,U[:&'^KXJ$IV:J>S?(E>-TVM=WHTFM
M$[]OWD"1X&X<^F6Q_GI^5+LA]/U;_&OQN\=?$3]ID?\`!00>&9_BSJ_P]\`:
M9XG\#P?#SX<CX>_%/Q!X>^*OPJNO!%CJ?C_4#K'AWP=JGPO@UL^*I?%6EW'B
M3Q?XOT?4_`;:!IEP;:/39((=6\ET+Q]\=?AQ\*&\7?%KXN?M6>-M-^(7[&UY
M\5/%UIH]E]@\7^%?B[I'Q5\%>'?!VA?#F[\.?#^74O`+ZOI'BB72O%EE<:7K
MMQ-H.G77BV\M9KZRU.]N*CE$7_R\PTI2AAYPA3A*K.?MZ:J.*C&%[THWC4=G
M%32BFV]''-(VFG0JP5)UX.=9QI0?U:HJ,FI3>\Y-2A%I2=.\[:6/WM*1D;B.
M/7+?3UINV+T_5O\`&OQ.\.?$7XY^&[3]F+X=>&/C=\2OB]#^U;X)\->`[#XF
M:MIFKZ;J7@WQS\+/B)>>,_CIXQCC\6>%O#GB#2K75/@MJWBC0_#>H>(]!L[S
M4+WX?^'+N:*.]U023<S8:-^U'XHF\(W6H_M+?M1Z#!\4?`W[9OB7Q'I^DQ>'
MM/A\+:Q\&?B8(?@/HGA=[OX=W%[X7BO=#U.1KKS[N^U/XF:9IMO;W4MU90SJ
M[>4THTYU)XC!P2G&-"+C+GQ"D\3'FC#V=Z:C+#3A)55!QG*$7NW%0S:-5QC3
MPF)G+FG&I94U&ER+#R4G)S4:D9PQ,)P=-SO!2E:Q^[(BC[#J/5NGYTABB')4
M`],\Y_,<G\:_"CPO\6_VO/%'[4OP7/C7XJ^(/AUI>I:!^SWK.D?#N;X8?%*\
M\.?%/PKXF^%/AS5_C0\S>%_!U[\.]-UA?'5]XMTVZU'QOXFT'5/AS-I6ER6U
MK%I[0)JOU?\`M+>-_$>G?M&?"'0?%WQ.^.?PL^"][X-74O"NJ_!;PQKVKIX\
M^.G_``GMC8GP1\0M2\/>!?&UQ9Z'#X1-G>:3HFJP^'_#_B#^UM<N+[5@='M8
MTPK9;3IU*5.4\+/GH.M-P7.J4EROV3Y8-SG9IMPYH)J2<KQ-:69*K"I4IX?$
M+DKPH*,XJE.:E92JJ,I)JG!M\S=F[)Q34HM_I/LA]/U;_&E"1G@`GCIE^@]L
MU_//JW[07[55_P#$;]L:'P7K/QYT"PM/@W^TC<Z3I?BD>(_%>J_#WXD^!?&_
MA#0OAI-X9T$?`OP=\/\`PC=ZIHFIZUK?A+PUX(\?_%QO%WA6[TS4/$EU'K-E
M-/<>Y>-=?^,WPOG\3_#KQC\;_P!I@?!'1_CQ\+U\9?&?2=&E\7?&+P]X0\;?
M`K4/%MUINC:SX2\`:I?#P;=_&^W\/:'J5_HWA/5)?"MGK4OAEI+31+@O8Z3R
MJ%-1<ZV$7-#GM&TVDN5.+4(OWTY:1WE9VUT40S2%2<X1PN*7(TN:4(QC*[:3
MBW/6.B;ET4E?<_7K0_&?A#Q*RIX>\3Z!K;RQ:C<11Z3K%AJ$LMOI&JSZ%J=Q
M##:7,LDL.FZW;3Z/?31H\5MJMO+IT[QWB/&EG1O$WASQ%<Z[8Z'K>FZI>^&M
M3_L7Q%:V%Y!=7.AZN;.UU`:7JT44C2Z?J)TZ_L=0%I=+'<?8;ZRN]GV:[MWE
M_!#P'K7QY\"_"73)_"7_``N#3_*_9M\<7^N>*V^&"VGQ4TG2-<_;TOE\?^-K
M719O"K7%O\3K#X-:QXB\:6'A*WTV017R0ZQ8>$[N2*UMCPOBCXB?$/P%\)_C
M%<_"OQ5^U5J-M\0_VH?$=_X/^,&J1>/?AYXGUK3]*_9L^%2^"9_&E]I'[.7Q
M&^(GB*WU_7M.G\/^`K8_#70-.\<:AH[P>-O$EJ@\R]TCDM)WM6HR7ME3;C!U
MK)/WJC4(/ECU@FTY).R]UF,\U=&$*DX5FHX;ZQ*,:4FY\Z7LZ4+I7G>+7\NC
M][M_1]%/#.[QQ2J[QA6D7/(5R=A]<,%S]"G>KH6/OG/&>7Y(_&OYT;_6?VCO
M#>M?'7XN:!XQ^.MC\??BU^R3^QQXZT[0D\.>*]2\!IITT=KH7[17B;0O".E>
M![_3[?Q5\*+34]2U?2?!=I<'QII4VKZD^B>'=8:>-+3K8_BY\=/#GPS_`&?-
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M-G0JWC1J5::I<W[N'.JLW.,5"#5[-+WKSY%RZWV3_;MQ$D<DAPJJK%F9BH``
M).2Q`''.:KP-!<(LL;"2-L,'5B<C`8$D,>JD-CMG//%?A3\=#\5O$/B_]K;X
M":'\3_VE?B78ZE^RI\2=`\-0:'<>+O#\/@"^\*_"[2;G1++Q5_:?PITWPSXW
MU_XH:_;RIIGQ+\!?$K5M>\2W'B/7/!VM>#-.L[;^T[>Q^TU\9O$'@#]F#]C[
M0_A)\8_C9_8WQ&LO%"WWC*\U[Q!X/^,^MKX;\`7MWI-WK>M7?PB\8^.;33?#
M/BR[LI=<T]?A5!_;&D:;9:3>ZI96S6-IXBIY12J*A"%7#3G6J6Y5!ITXPHJO
MSS4HJR=I4XVU<DW\.JYZF;PI4<17EAJ\:="'-S7IJ-1NM['D@^?XD[3ES)*,
M-=9+E/W7"19&!SVY;_&E*1`\CGZL?ZU^"'A3XE_M)W7[1'[/GAZT_:=U:_\`
MAQ'X5_9Z?X?^)8O"'Q5\?^&/VG?#NKZ!87?QK\5W&O\`A/P/>>!;S4-4UO\`
MX2/24U'QYK'A&^^'6F0:#XC%G91?:CJ,MMXL_;=\'?"^7QIX/^(WQG^(WQ*^
M*?[-WQZ\8S>&_'.@V>K:)X'\5>!?C1X$T;P/+X'\.Z7X0TW4-+\06'PL\2^+
M9[?19)-7O_B%/HUEJ2P7]_;PO/I_8])RI06*P+G5]DDFIQ4956[QE)TDE[*.
MM1W]UNSZM$\VC!8B3PF*<<-*M&HXQIR3]C&+4J=JCYXU9/DIO2[6MDT?O7LC
M^]CIWRW;\?6H)Y+>"-I9&"("B[BQ'S2.$51N8`L[$*H[FOP[^"]]^T3X^M/V
M>?!NH?M,_%OQ+X!\7?'KXJ0:SX\\$^&?B/X+\4KX*\,?`^Z\6Z;X+\0>-/C)
M\.]&\1ZEI5W\2M.=;?Q*NBV,L$5_/X%T[7Y[FR$D7RSXF\?_`+0OQT\!_ME>
M%M9U;]IJR\"P?#?0/B0-(U+4_&&H>//"7C/P3\=;1?$?A2SFD^`OPXT?0=4M
MO`=O/JFJ_#;X6ZA\4-!GM;/2+[3/$$]VZF_5/)X59J'M\)"'/3C5JNZC1C4K
M2HJ4FX*3MR2G*,8RDH\NC<M'5S>-&GS_`%7%<S]HJ<?9W<YTZ-.MRI1E+22F
MHQELY)I=+_TM66L:1J%W>V%GJ%K=WFFM!'J5I!<1RW&G27=LE[:1ZA;QLTUE
M)=V;I=6R7:PO<6TD=Q$CQ2I(VL$C/`!/MEO\:_$?Q?X[\5:/=^,38?$3]H'0
M/V>=4^*'P"T[QA\=_"'@W6[WXT1?"V]_97@UG3-??4;?X>WWC19O$_Q2C\-:
M/X^\31>#KGQ%X;>_O-(FM_#\4]TUAQNK>(_VNO$W@^^U\?&#]HOPS-\,OV4/
MB9\6O`$%AX>TW0-<^)GB/PK\;?&-I\#M1^+.B7W@NZEO/$7BSX2:7X:N/%OP
M\BM-`U'7AJTMSK.F6&H@0V40RF"I*I*=*$96:]I!S23C=<TX1E&+TO*#?-33
MBY*SNJJ9DJ<I0]G[:4;:4YQA.>D;J%.HXS>K:3LHR<9*+?+K^]?E1C^']6_Q
MINR'T_5O\:^!_P!L[QMXP\.?#CX4:A)XP^)7PX^&FN?$#1X/CY\0O@_I&IZI
M\0/!?@F7P?XBO=-DTA-'\.^+=?T31]7^(=KX8T+Q)XAT?P_J.H:-H]]-AK:V
MN9KR'XP\0_'+XRV?[7?[.OA;X>^+/V@-4\!G4/@EH>K7WCY/%\6D_$?X8>,_
M"-]<:YXTU/P)8_L_6?A&WNH+ZXTZU\5^-_&WQ5\$^,M"\;PG3]/\$QZ<T5G?
M31RSV\.>G&FURUIW]DU!*BX*SJ.*@I2YFTG*R4=7>44]*^84\/S\U*O*4*E*
MFXTZ4IM^TBI.2Y;WC3ORS?2=UTN?N/LB[#)[?>_Q%<=!XZ\%7.L7_A^W\4Z'
M/KFFZM%H.H:1'JMB=2M-<N=*.OVNCS6/GBZ35;K0O^)U;V!B^U3:/C4HHGL&
M2=OQ1T3Q=^V)X.^&%MXML/B7\?/'GBCXI?LO?$7QUXIT[7_#>EZY=_#;Q/X2
M^-7PZT"TO/AGX?A\%V+:3XOT;X0>+?'-U8>&-375KKQIJWAO2=6N]+U#4;28
M3U/A+J/B^R\=^(?$'PJU?XO_`!1TG7?VLM#OO"?C+XT^"];T_P`2>--$TS]@
M+Q,NA2ZQJ_B;P7X1UB/PU#\0-%TK0(/&%[I&CWE[<0QZ5<:G<AVBO-GDT'&J
MU7PDHQ<J?/!\JY[135Y0BT^:5E_-%2E"Z3MR5,XFHTG3P^(BW5HJI3G2<ING
M4E'EY.522ERM74FE&]I-2]T_<JW\2^')_$$WA2/6=/?Q-;Z1;Z_+X?\`M<0U
MB/0[B\>PBU=M/+B[&G27T<ED+SR1`+R.2V\P2JR5L7$MO`8E>14,K%50M\S[
M4+D!2=S!0,DKPO?')K^=+P_\2?'>E6/Q<^*6E^,OVM/B'XFE_9-^%^@>-_$?
MBGPQXD^'_B/X=_%O7/C>T7Q4\.^#-=/P5U+4=*\(>`)+^XU#Q5I_@OP1\2M4
M\#^&;>Y/@I+V]EA:"_\`#37OCAXOU?\`9%^+'Q!\9_'J3Q7X8OOVT?A=X#C$
MGCM_#?CC7K'Q-X9O_P!G[P]\2Y=1^%O@[7]9T;XB:+HUU9WWCOQOX1^'T7BW
M0]!TV?4Y-)U%S_:!')H04N:OA%&C3GK-W<Y4L(Z[27*Y-SY/9QDTDZDHW=M4
MUGD555-X?%.<JD(1?L9.,54QD,-&,_.%.7UBHE>U.,G\5HO^B!54`DG([X)P
M0.>Q'/7OCGKWKS75/C'\)=%32)-<^(W@G1HM?\;_`/"M-!DU7Q/HU@NL?$3[
M7<Z<?`VEFYO8Q?\`BV.^LKRTD\/6OFZI'<6T\4EH)(I`OYO_`/!-;QS^T'XV
MB^(FH?%[XP:OX_U*3P]X/NO$'@?Q+\//BSX7U+X9?%RZ.J3>,]#76?B-X1\*
M:-!9B39I1\$^"9M?T'1&T6+5=.O(K'5(Y+WYOT?X;^//$/PW_8*^)'PYG^)-
MS\2O`'P3_:[\;6>AZ/.(_#.J?'G3K!-1%IXZL;O2;FWFU/Q?\0[S7?#6K0:A
MJ&EW^LV[7^FPW,4R7$QSCE5&->IAJM:BXT^:#JJE-J4U1G5Y;>S4UK"5)RE&
MR:OK%-H>:UZE'"UZ.'K)U:4JZI<L54=.-?#T6VN=K55HU;7TIIWUT7[_`"(@
MR#GKA>6X`/`')QSDXS@Y!%/*1`\CGZL?ZU^$WA3X@_&OQ+X/UG1?A1\<?VK/
M$W@WQ+XC_92T7Q%\4/B1X&O?#_Q%\#?%7QM\:+70OCAX3\#1>*OAIX<:WT*P
M^'TMO=>(]-;PSK?A;X<ZA-"=/UIH[JYM+;M/'F@_M(P?$_Q;;:'^T7^TEH?A
MCP?^T9^S5\"]`T^Q/A_5K.[^%7COX8^!;'XJ^,=4O=3\!ZD?$7B>74-4U34C
MXZFN$M/!?B2SN-6L[.WN9+RVE2RFE3=2E/$8:$J-%5I*K&7M.2=2G2I)I0;Y
MYSJKW/CIPA*4XI<O-LLT<U%QPF*DY3G#2$>7F@FY-3YN1II67O7;TUW/VDVQ
M#M^K?XUSWB/Q)X?\*V7]I>(=6L=#TW[5IUC_`&AJEU%96/V[5M0M=(TJR-U<
MO'`+O5-4OK'3=.MVD$EY?W5O96ZO<W"1-^"'Q?\`'_[8OAS1_AIX.A^.OQ)\
M`^$_#_B#]HKPMH'Q@\1>!/B5XT\4>,O''@+XXWWAOX1:5X^3X1^`-:O/$MQ=
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MQS\9_%'[0/Q$^$WC+Q'XDU#P]^RY/XV\/^(];U`PI#\4-1^+_C"V\9_`Z[O[
MG[-$-1N?`7P5C6UU<V3P1)K^L027(GEAAC7X@\":S^TCX?\`A[\2/`$?B3XL
M_"W6M5^),EM\"I_`OA>670HOAEXM_;=GT[XK^.M2BU3P]J@;XOV0\0WGG6OB
M6$>'K'X7:IX?\0^'-.U:"X\4WT*H9.Y>UA4E0A4I2H.R2J/ZOB82J0J\D(RJ
M3Y81IRJ**<ESJR=F-YK>5-TJ5:M3J4ZJ2A3:E+$4YPBZ:G)J$5*\K<\DFXW;
MM9O^@4)%D8'/;EO\:?Y:>A_[Z;_&OPT\5^._BSX*#?#7XJ?&[]J/0/@5X,^/
M/QW\'3?&OP+H&J>)?C/JJZ/X5^&/B/X'^&?$7B+PK\._$.L7WA_5]2\5?$BV
MM=?M/"9MO$FH^%/#WA?5]9,3O!?T];^,/[<OABR\`6^MW_Q&;Q1KGPK^$_[3
M_C.(^"E:"PT7X#:=K$'Q\^#,UMHNG76G^'O%_P`8;=?AGJ(\(VLYU%=?\0^,
M[3P_!);Z>;>&ED\922A7P3C)KDG)^S4H2<N65I1NGRQYIP?O4U*',KR2*GFM
M.G&;J8?$QG3NJE-4^9QG&RE'FC[K2D^533Y)--Q;2;/W6,49QE2<$$<GMT')
MZ4>7&!C;@`],MU/T-?ASXRUG]JWQ7X5NO&L'Q=^/?@B_T[]DSXH_M0Z!X6\+
M6&EV7VGXB:U\6=<\6?"CX=^*K'4_"&JW5Q%X1^'\NA^#]3^'"36>H:Q;I>6V
MK*+BU$J^[_\`!1'XL_$[P9\(/AE_PAMS\5]&UOQ=J.I&_P#$/PRUKQ/X6LM(
MU>R\$S:QH^F>)-2\#?!KXZ>.WDU_6V%AX0\.:7X.L=*\1ZU;C3?%'B&PL"B7
MN;RN'M:5*-3"SG.<Z<N7X:3AOS3<5%QDDY1E%N,DEKJ-YI!4*^(E0Q"IT%1E
M%<B<ZRK*+7LH)MWBY<LXNTE).Z/U.VQG@`G`Z;FZ#ZG%<=/XW\%6OB6#P9/X
MQ\,0^+[J&2XM?"DOB'28_$UU`$DE\ZUT!KQ=6N(5BBDF\R*S=!%'*XW*"1^4
MOP8^-7QDUC]IGX#0>.?&7Q8\47GC;X`?#6_\:_#W2?#_`(D\$^"_A=XAU+X1
M0^)?%7BCQ_H^H_#,>`_%&D>)/&,QM[/7/#_Q-TOQSX)\67-EX)_X0S4="BOY
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M?%4E\=,B\-131SF-O$$FI*VFIHP(U!KX?91;B<;!^3UI\=OAE\'_`(Z_M]WW
MPA\(Z]?>/'^&/@36M!\/:/\`##XC:?:_$7XQ>#[WXIZ?XDLAXKU'PE;Z)KNH
MKXO\7^$;&\OAK-Y'+I6I6]QI<UQIFG3&U^=-&\+?$_X`?`S]ICX%^/OA1>_#
MBX\0^#/@]\>/A3?6'C&S^(VFZM\>K+QKX*\'?$'6W\9Z7HNDV.G^-?&OQ<M?
M`GCP:),AU?4-4\2>(=6AGN8OM)MNB&3PFN6%6G&K.I@O91G3P_O4J].G4KS:
M<HS2I1K4KN,9*W.VXN"C/G69RC*$72E4H0EB54K059)5:%9TJ4(S4+2]I.%6
M+YVKI1?O7;C_`$'W>J:38W.G6=Y?6EM>ZLUPFF6<US%%=ZE):6[WMY'86KR+
M<7DMM9QRW=PEJDCP6T4DTBK$I-&I:GI.BV=QJ.K7]GING6D+W%WJ%_=Q6=E:
M6\:AI)[J\N)(K:V@1<N\TTL<*@,690I8?&'[7.J^,M*\8_`F?PKJNL>'[=8?
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ML@Y(;(.<J2#W/`-<;J?CSP3HVN:9X9U?Q;X;TKQ-K6#HWAS4M?TJQ\0:RI,B
MAM)T6YO(M3U1<Q2KNL;6?>R2HO,3JOYFZ/>_M`6W[0Q\>R?%'XQ77AB;]M:\
M^"<'PKO+33%^%=E\$KSX&C7KC4UTF/PTFI236OCFSBN].\<'Q`]OI]\S>'[=
MEM[J\MGH?M)?LT^*_P!HO]K/QIHNEZ1\--%\)S?`#X#6FK?$SQMX$U?Q!X_\
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M-I#\S^#_`-H+]HK4?@1\9M2UCXO_`!J\,^'-*^*/P2U?PA>ZK+\8_$GC7Q'I
MWB7P7XKU+QM\*]'^+UM^RKX>\8^$KBX\6:#IMC-K%O\`!OQ-X+\,>+;6?P$F
MNW6B>)&DL=(9-&;FZ$Z56DI4::G&G.?*ZDG%QF^3F]V4;Z)IQ:DG9W,8YQ&"
MC"M0KJLZ=2=10A>GRTM9235HI*SM%OGO'X$VD?TE,D8!XP<''+'M@=_TK`O?
M$/A_3+IK/4=:TJQN8UT]Y+6[O[:WN`FJ7;V&EL899DE`U/4(Y+#3CL`OKY6L
MK0SW*R1+^+WA#XJ?M3^+?VT/AS:>)?B7XY^$_A:4_"V3PQ\%?&GPX^)&J7/C
MWX9:W\,-#UKQT_BN^\'>"KGX2V?Q`LO%UWXITCQ#XDUOQ;HDO@G6/#T=K!I4
M5I=:=;7'JW[7'AK6]0^//C6]LO#FMZE#/I'_``376&]L-&O[R"=?#G[<WC/6
MM?CBNH+>2&0Z!I,\>LZPB2;M'TZ>+4K\6MI.EQ)A4R^%.I3IN>'FYT(5W[--
MN$IZJG-\B3=K<UFXW;2;:=]8YC4E"5:GAJT8+$2PW[Z,8JI",HJ5>$>9R2?O
M<JJ*,FHWY4FF?K2@CD^9#E<L&Y8?,"0P[9((Q^'IBI/+7T/_`'TW^-5[=E*@
M)D`/)P1C'S-VY'0*`#@@9JW7$H4VY+V</=DXOW8[JWEYGIIW2?=7Z?I=?B,\
MM?0_]]-_C1Y:^A_[Z;_&GT4_9T_^?</_``&/^0R,Q1GJN>_5NWXTBPQ*/E3'
M)/5AR3DGKW(S^1J6BCV5.[?LX7>C?)&[79Z#N[6N[=NGW#/+7T/_`'TW^-'E
MKZ'_`+Z;_&GT4>SI_P#/N'_@,?\`(0SRU]#_`-]-_C1Y:^A_[Z;_`!I]%'LZ
M?_/N'_@,?\@&>6OH?^^F_P`:/+7T/_?3?XT^BCV=/_GW#_P&/^0#/+7T)^K-
MS]>?Z?A2>6A'*@?3/\^*DHH]E3_Y]P_\`C_D!'Y4?]W]6_QI?+7T/_?3?XT^
MBCV=/_GW#_P"/^0#/+7T/_?3?XT>6OH?^^F_QI]%'LZ?_/N'_@,?\@&>6OH?
M^^F_QH\M?0_]]-_C3Z*/9T_^?</_``&/^0#/+3T/_?3?XTAB3T(^;)PQ&2>Y
MP>OI4E%-0@G=1BGW44G^0?U]^_WB8'H/R%%+15`<5XN\>^%/!5YX,T_Q)J7]
MGWGQ`\6Q>!O",/V>YF;5_%,^AZYXCBTM'MXI8[:1M$\.:W?>?>-!:".PEC,P
MN)+>*7L59'4,`",`Y8#G<.YY&>Q_KFOFW]H#P-XE\8^*/V8]1\/Z<+^R^'_[
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M/"4>BIXJUS2="@\3^)],\%:"=5G2W@UKQ;KIDBTGP[IS$^7-JVI,LT5O`I0R
ME)5WY5P/C+]L_P""OQ/^*/\`8\?@;3'UNYA_9>_;!^'%SJT>IZ9X?G'C7XI>
M#OA]I/@R"`W&HV$EB^N:KH.I,=0M)4M-#DMXIKN^LE:VEE^2/B+^P:=/MM2T
MGPK^SIH?CSX8^%?C)^R+\8=%^%9UGPK<#Q3=>$]`UCPW^T!=Z*/'6OVFA6WB
MS7+.3P[/XAF\2ZUI</CIM+>YGU"\U:62XF[Z6$P=2-"I5QKA4<:KE1@Z;DK5
M/9VM.47>49QFD[+EC4E=I67+/%8NG4G&E@Z?)[2--5)RDE*]#VUW&,?A4DZ5
MU=N5K;'[2FZTFX$L+QQ2"%5N9(R05`5<&4JQVR+$!@/\R*X8*2T;&IFU'38G
M8.RJS*7D?>#A$B\Q6ED+'8AB`:,R$<?=&=]?BS\3OV)?'.M?"OXV7>@>!M1M
M?&7Q`_;'\0?$+QY9>&]<^'A\<?$W]FFQ\2ZI?>&_A]HM]\2O^$A^&<5A:&]T
MOQ':?#WQ=;67A2]NM(U&UU.+3M1UA]2;*@_9$^,&FQ?LTR>#_`?Q'M_"OPET
MBRN?BIX3^)'Q"^'%SXR^+_@[5/C9)XS\(_"75;?P!+IGP[T^/X"ZA%%\6M+T
M^V%AX7NK&TL_@EIE]JVA:GKCHZ6!P;2C_:#@N><8N<82Y7"G[2-VKWYG[D'T
MYKRY4FUSU,RQ=.3C]1E4J*,)25.-;EY:DXJ3B[-62BISTNW%VNTF_P!N9=2T
MN%M\CJKQ`?,#O\O?&T@02AF"%T.41&!</A!M)JQ;W-C<PO?1!3'"94+X7<OE
M%@ZY1FQDXRN01U(['\#X_P!C;XY7GPZ\8>&-/^"<GPX\;W7P`\?_``V^,_CM
M/BCX:O[K]KGXH^*_'G@G6=&^(EA?:3XGFU^TBTZVTCQ?XIM?%OQ#7PAXL\/O
MXJ_X0G2-/%A;FY7](/@=\!M0^#MO^U5X-^'&CVGPU^'OBSQ59:I\#[33+T7&
MBZ/=:G\%_">B^(M>L-)-[>W&C/+\1K'5]7U2.YAM)=5U-+O7&AGEU'[7<Q4P
M>'4(R^N1G)U(\U*4J<91_>TJ?-+E5^;]YSQ4>9N,97<9)QCM3Q6(FVY8-1IM
M5%[5QDW:,8MMTY^\[OW7&5Y73WC9O[`:_P!(22;=$2ZR1M+L0$%V4".1Y`VS
M*8".TA#KG+#:#7D?Q+_:,^$_PEU'4M'\:ZCJ5I=Z/X#?XE7J6>B:AJ<47A(>
M--$\"2WBR6D<J33IXF\1Z3;/IT8>Y\F:2\2)K:VE9/RS\/\`[-/BZQ^#WPV\
M,W7[$US"/`WCKX:ZI^T[\-T^(_POO9_VQ;CP_P"!_&VB:CXXMM0E\=C1/&0T
MGXBZYH7Q):T^,>I^#=1\>P*MIKMK!<Z%I]HZS_LI_'8?#34?#L?@-+.>Y_9_
M\?\`@SP]X/'C/1/$(\`?\)7^UGX>^*_@;X2+KU]JJQZE'X"^&%G]@&IV\UQX
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M;E;FE_LJ_$FW\,:M=Z3^RS-X9^$L6O?LZ#XE?LN1_%+P7JC?M`7/PUTKQ[:_
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MR@\`_LD>,Y-6^&&J^*?@_H0T'P#X*_:V\0?"?X6>+O'"ZEX:^#WBWQ]\0?`/
MB7X!?#K5)]$U>Z2>7PQHVB>(FMM8\-1:_HOPU:[GTSPAK"IIVC7<ORWX,_8K
M^,5YX"^((^)W[+NC:_8)\7_V2?BYHWP1&G_`[P[IVOWOPVU?Q!;?'FW\*>']
M%^)/B;P+8WFL>&M2M+:T\2>,?%]EKOQ&T"WLQXHN+?4TFAMB&#PKE:IC91]C
M"RC>DE+FJ<GLZ;;4+1<Y57M"R<U=W;)XW$0C&3P,5[6<6Y1C4YH-1A+GJ)+F
M5XQ]FKM2O97LK']!FD>*O#VM0ZRUI'>QQ:-X@O?#VHG4=*U'2(Y=5TOR3</8
M+J=K:_VIIZLZ"SUBP%SIE^R2#3[NZ:.3;J?;-,69+9$96ECN(D1!M618@QDB
MX8,I"EG*E1\F6Z5^/7CC]F_Q]?:Q=:CXP_9ND_:&^$LWQP_:,\3P?`=?'/@;
M1V'_``L/0OAKI_P@^)$=KXH\5:)X,N;+P9::#XT\+2:1=:RNN>#CXG'BGPWH
MU_J-A#'6;#^Q;\35M[3Q7XUT%?&OQK\">#?V$M$^'7Q"/CB6\O=#UOX7>-YK
MOXV7/AO4M2U>TEBNX/##G0]9\2ZG9V6K?$/14N-,G;4$NKC3VSEE^%C&;ECU
M%0Y.5P5-RJ:15VU9J--M^V4G9I6I^TUM2QN)G-2C@Y1<HR;G*,TE'GY7"\KI
MNI!<\%%Z))347=+]LH8;=HXV2)0C!9%R"""1E6')Y'4=U.".:I7<MI8Q+,\.
MU(V9%,:C,8;.=K;E"[\E`B_/(2(@CE@#\]?$'X*_$KQQXBFU_P`+_M4_&WX3
MZ1/96EK;>$O`VB?`V]\/V<MJLR27T,GQ`^#OC3Q";F]\Q);F*YUN>Q4Q0I96
M5HGF)+X=^V%\'_%/C=/V?VO?A=??M.^!O!>M>)[7Q[\-+OQ/X7\+7NO>(-;\
M%QZ#X*^*.I'6K_PEX2NV\%ZVFHW-Y#:O:WVBS>)3XF\(:->ZQH5AI[<^'A0J
MU,/^^C)54W*2C*$XJ.BNZBA33E9VYIQ6JM))MKKQ%:M3H5)JE+VD%%TTK5VV
MVDVJ<.:;Y5:]H]UT/KOP#\2?!OQ-\%^%/B!X4EO+KPQXST:T\0^&[R]LY["Y
MOM/N4WP2&QNPMY:7`7;^YN8XYH@T0(3Y,[.M^+/#^AQ65SJB:D5OM<T?PS;F
MQTC5]8G&I:]>06FG)=Q:19W]S86'VN:)K[5[^.#2M(@#W^JWME8QO<U^$?A7
M]B'XYP>+/V9;WQSX6^*\]O\`#3X2_LW^%?#+?"_X@_`:.P^!WC#X9:]?:C\1
M]/\`%?B+XC:;?_$271-;%UIMU=>(/@C?W&J?$31X=2\)^)K-81ILR>K>`/V>
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M-\'/$&I>'O#=S96G@U=4T"YBL_VO^"7AV_\`V;?'GBOX2^$?A7J-E\,_BM\=
M?$GB3X?VGA:^M8O"GPY^'-A\%O`M[XB\57=G+-=KHFEZS\5K/5M#3PVTFFZI
MJ7B+Q'=:Y8:=+;M=SM&-RVG@76I/%QJXBE4G'V=.,:<>6FJ2A4C*G5FIQJ7F
MH*R<%1:W:2>"S6MBZE"7U6=/"U*,)SJ^RJMJ=6]Z3;C=>R<8^T:=FJD;1;1]
MS:78^'?#MG_9VAZ18:)8K)>:B-.TJQMM/MS->7D^HZC>BTM$@C,]YJ%Y<:A?
MS!#-/=W<UU=,9IY96LQZGI\IDB6&7,;;=I09?S6(WIAR2DO+!SM\V(B1=ZDL
M/R6^)O[*OQ*\2_MYZ=\;==T_XM^(/!]GXJ^#FO?#7Q9X$\5?`_2O"WPW\.^!
M]-BB\<^$O'`\;Z3=?&BSTGQ#KMMK>JZMHWPIN[G1OB#H_B-=#U^+3)K:>\?Y
M:^*W[,_B3]GK]F7Q/XYLO!^H>$=>U3]EWXG>$_C_`*YI&O\`]LZIXA\<>*/C
MW\*[[P3%XG,?BR`:]9Z3X/NO'MNE\^K:3X7\,>#KS5O#VH^)O"&A72M:E+*Z
M%>I0C3S)N>*CAHSM&$8JO4A>HG>Z7(XI2N]9247;6SAF.)A[=3P4Z,*'M'#D
M3G&M"E*$5."7PQG>\>;[-WT/W\O?$OAW2]1T/1+A;LW7B6;55TS[!I6HZAIR
MRZ983:M?MJFIV%K/I7A]7M5>2WFUR[TV/4+EUL[)[C4)HX6X/XH?!GX)_''3
M],M?BS\.O#'CRS\/WUY?Z.?$6G+=3Z1=W%LEKJ$]E>1NES:I=V@CCO8X[A8K
MR*&%;F.06L&S\4/V9?A7=?$'X,6VI_`OP3]@`\>?M@WWQ"?POI/@CX??#O\`
MX2WXG?LY7_@[P-;_``K@\*_$WXC>'-7\$66I:CX=\.VTVE^/_%,GA?Q`-9@U
MB[TPZ;<K9]]XU_86^)7A_P"&VI^!/A/X-UCPWX/U_P`#?L;:O\4_!W@_Q=X*
M;5OBKXP^'NK?$"'X\Z2#\3;GQ%X*UOQQK>C7_@*YU.^^(%E+X3^(MOH%EHVL
MZNZ*+NUT_L^G&LJ#S"6'J0J<LJR4$W3A\4YN-W%3TC%15FFV[1DD*IBJU6C+
M_A/CB*<J:E[.K!^^Y2BG!0DN63BGS2<E96TON?MGI&F^&?#&D:;X>\/Z-INA
M:#H]I::/H^AZ196^FZ1IVG6T$5O96.FZ?:)!806=M:1(EO;VL92&TCVPH(BN
M:NN^+O#_`(>M[.[U6'4GCO=7TC1H!INC:IKMPE_JU^FE6$MS:Z)9ZC>6NGQW
M,B_;]:NH(]*TBV$EYJU]9V<,LR?@IXR_8-^+&J:5\$=,/AG]I+5?AOX3\`:W
MH6@>%;+X@_LFQ?$WX._$'5_BYJ/C&#Q!K5]K>@-X'\+:4_AF^T32_#^L_`"6
M?Q)\.[+PY!X4TNVU?3;B$Q_8-A^R[XAL3\4/&<'@>./XI>//V[/AO\1)O%4F
MLVDFMZE\`O!/QC^&WBTI_:%QJX_LK0K31M#\0ZS)X+M4M)+[4?M9ET&>^U53
M.JN%PD.23S%U7*?*FH1O%R:BF^;5<T7S-)M[):-VNGB<3-3C+`0I1C3<DI.5
MI2BG)4UT;;2LW:-W=V:/U#34-.O$9@&FW.D;H<L_($D1906)1@-\;C<C;/,4
M84L(OM>D2S*H"2RV[B-0A$SPLC_*@\MF"88?NURO;RAC;7X*_$G]F?Q?\`O@
M-\0/BMIW@W5/#/CG5?A%^W%:_&OQ1X<\1W6I>*]8;XF_$BPU_P""-OJ$^G:Y
M<76KVFG:$]]-HD6FS6NG>!+$ZC;7FH^$;2XU.[/IO[!.C:-J/[*O[5-E\$OA
M[X7E^)WBO7?%0ETQ?#GA?P!\$/$7C*Z^&.EZ'X4\-^#=1^&/Q4^*.EOX0@M;
M"WA\4O8?$R^UW2O$VL^(/M-QX?DOH;:V<LMI+#2Q$,3[2G&M&E%+V:O.4XQG
M.:7PP2<)*I9.\HVDG%L*&95JF(CAIX54*OL9UDY1K2BJ<(INTXK6;::]FO>O
M%:>]%'[.2ZEI"H)I0`2TBKP"VX%GGRZ/M4JRN92[@[PP?YJYKQO\0O!WPW\"
M^+/B+XEFEM?"W@G0]7\6>(KFSM)-0N[73-#TZ;5-2N8-/M?,N[ZYAL()Y8X;
M..::XV!(%E9@6_$OX'?L4?%74].TGP?\8/@\FD?"J\_:N^&_Q3UCX;74/PS\
M%^'(?`ND_L[^*_"7BU;GP!\)?'WB_P`(Q6&H_%"31(M9\,6&N:U)XQ_T?Q!X
MBM[]KS5E@R?B7^QW\8]7^%<?@35?V>Y/C(]I^SQ\3_A#\'HV^*/AO2K;]GCQ
MDOQ>^(^L^&O$LEWK_BJUD73];^%NJ?#?0=,U7PK_`,)%X@MK7P6O@+7X-/\`
M#FJ:C<VY#+L&IJ,L9!_PY3Y>647[1_#S-I\T'&+GS/1--7T3Q>98ET8U%@*L
M8U/:*$HTZLI)TTFI.*3:A+7EF[];V5VOWW34M.&G6^IQ!A:30P2PLH";5G4-
M%D;P%9E(^4D?>"Y!(%1R:G8(B@+(P=L[<9+2,DCD;#(K/*XCDZ!WE*ML.X,*
M^"OVM/A=X@\?6'P"OKOX-/\`M(_"_P`%ZGXDE^)OP&CUWPGHLGB34]7\'QZ1
MX'\5&P\<:YX:\$>)D\":W'?S2:/K>N6WV6/6CXFT>&]UC0["W?\`./5?V;_B
MSJ?B*/X.ZO\`".]^)7Q>T+]E3]GC2O!_Q2;XKQ6VG?LU>-)?B[\9]7T3Q.NL
M^)-6TO7/$,_@7PU;:5HC^-?"=AKOCK6F\*6OA]M-BT+Q7=WJYT<%1KTW.6(4
M(I2<H6I3<(QKRHVE"4XMRBH*I)<R]V<7'G:DEK6S*K0K<D<,YS<HQA4<*L8S
MG*A2K1E?EY5&?.Z<7=R4X-R<4TS]V+;XO?#G47\K3-<37'C\?7GPVO4T+3=2
MUI=(\>:7;SWFIZ+K\NFVES#X>DTI;9EO]1UM[#2[.YELK>6_2ZOK2&?MH]5T
MF[C9U/FJJ+$X=6+XFD\M(720[F,Y^>-7!\Z,F2,R)O8?E#X!_9:\1^`/B;XA
MF\,?`_2_"-O-^WR_QZUCXC:%J7@>QL/'GPDU[X;_`!(M[!Y+2QUR+Q.UQX)\
M2>(X+#4_#VNZ+8G[5K)U'PTFM6`OKN#P"W_X)P7R_#5K6+X0P)X]'[$?B72I
M;@>.1]NE_;$A\03WW@WQ9>WS>*A;7WCWPU:WNIQ>%?B#=O/;^%M/E.DZ-K&E
MZ>D.GJ+`X.*YHXQRB^3EBXTX<ZES7DZ:J2:C%1O=2DW[K<8VL5''8Z32EA(Q
MDH^\E*2IQFG'F@I6;<DY6;CH[:-H_<O3O$WAW4;S78;3[3#=>&M9&@:D]]IF
MJ:5&=1_LNPU/&EW>IVMG!KE@EAJ=KNU31Y;_`$Q+C[1I[7@U#3=0M;1=7\2^
M&]`T[4]<UFXAT[3-,TZ[U'5M5ND,<-CI%A!)?7EY>3,08;&"W@GGD>7;"$@E
M*[MG'Y$?'W]G7XD^/;'QCX;\2?LVW_QQ\+_$3]JS1/'^M7^DZ[\*SXT\+_"S
M2?V?_@OH.KZAX$F^('CCPI:>'O$7COQYX0U7P7=:I8ZM;:_H/A\>(-=L;1KF
M]T6[?A_%'[*7QS^(?[5_Q!\0>(_@UX0\/?#SQGH_[0GA&^UBUL_AY'H?C?P1
MXZ^$C:%\,;7Q?KD?CG7_`(G^.KFV\26^EMXB\*Z[X-T;P9X#UG2K34/!,&HZ
M>PU05#+\/4G!RQ<8)P=2:4:/.XQ?)*,9NKSJI4C&2BI06Z7PR4E%7,,33C)P
MP//552-.$5"K*TY0C-592::<(*2E/>5E)=#]DO#OQ/\``_BR?38O#=[=ZQ;:
MQX1T[QWHNL66DZM+X<U7PIJLQAT[5-.\2M:#0+A[L$SPZ1%J(U==/:/4WTV/
M398KA]#1-+\$^#[";3_#6AZ=HFG:AJFK^(;O3M(M(;:SDU;Q)JEUK>NZI/#"
MP@6;5=6N[S5;^90%N+V[GN9=UQ=,7_%W2/V5/C-:?"7PEX;\,_`@?#W2-!_9
M1^"_PU\;_""W\:>!M#C^(?B'X?\`[0%KXN^-_@FUUKPEXGU'1+#_`(7;X&T_
M5S8^*KN]L8-37Q/%IWBV[T6ZGU6VL>S\*_L9W?C+6O!MOX\^`5MX*_9[D^,7
MQF^(.G?LZ:MXK\.ZMI/PS\+Z_P#!'P[X-\-Z5K>A^$_$VH^$Y%\5_$O2=>\9
MQ^!?"VK^)_"GA?4M6AU*9DO_`#I["7@\)+VD*F,J>QO5:=J4VU%.5.SC+EG4
MD[1C:7+&5WSZV!8[$<T%#!KVSC2A*2I5(J$9*FZRBYQ2C37*I.+2=E&ZT4C]
MCKN?3HQ-<W<)`M8\23,-WDQG)<*P8JL15&\U58($V[@!7F/BWXV>`_!_CSX<
M?#"^M/$NK>*_BDNN3>'M.\-^%M7\06NGZ#H`TW^W?$WBN_TZWELO"OA6PN=7
MTBUGUO69K6SDN]2M88&FD$WD?"OBSX(?%.__`&0?V2O!7C;X;WGQCN?A1-\-
M;S]H7X(77B_PX=0^)^B>'/`FO^'KKP])K'BGQ%8>$/&-SH'C"[\,>+9-&\6^
M*+;0/%47AXPW>IO<I96]QG_L[?LG7OAKXI?L_?$GQ]\(?#VF2_#[P'^T?;^&
M[:\U31?%VM_!.Q\?_&/0/%?P<^%^G:\+RYGU"7P/X!O_`!+H*7WA][WP]H:3
M:CX>TK49=-?3VNN>GA,-&E4E6Q5256-.M[*-*---U7%JDY)I.TG&$JC2:DG%
M;_#T2Q&*5>E0H4U*DIT)3=2%105.K*U5J:5K]*;5_>UE9+7]%]&^*'@S7O&7
MCSP1IKWC^)/AM'X27QC')87$%KI\?C72+C7/#ODWTNVWU".XTZWE:X-F\_V*
M3$-V$9@A[+^T=+,D=F``9%VP1[-B.H^9EB#;<J@*[B@Q'D@D"OR%_:W_`&9/
MC#\4/&?QBU#0/#WB35O`'B[XF_LZ^*-8\*>$-6^%">)?B?X&\`?"OQSX9\1:
M1I>F_&"#5/AK<S^&?&^O>%?$<WA[XBV5II'B*UT6Y-C>B^M+25?"/&7[)O[2
M2:M^S'I7A#X4ZS?:+\*=+^$%UI/CKQCKOP=\4?&SP5%X>^.%QXK\=>%/&'Q"
MB\8^&;?PE9Z7\/);2Q\.6?P$\&:WI7B33KJ_\%>)-;FTC2=&67LHX'"U(TG]
M>ITY32=Y2C&<6E#GBW*T>;GFWRPO+24M.63,*V/Q<*E6D\#5J*#V]G-TI1E)
M\CA+5M<J5[V:NM'>Y^TJ:Q\)OA[X_P!(\(6.CVFB^,OCIX@\1:PS:9HKN/$W
MB3PIX-T^\U;4?$.HV\;1V]];>#])TRUL7U*2%I+*RMK"Q79$D8]2FNK2SF,1
M`25D!"(?WDL28!=8U</)$C28<[2%/.3NK\@_@G^SM\1/#/[6'PZ\>:Y\#AHV
MM^&O'O[4^K?$;]HJ7Q_X<U-?C!HOQ1EU:X^%4ECX<AUZ\\6S1:-H,^E>'9;+
MQ)H6CGP%-H\GA_PS'>>&KC^T']-\7?!GQ[!^TG\</'5S^SIIWQ5\6^,-*6[^
M`?Q^UOQOH-IX;^%VCV7P5;PFGPFU_3Y/$>G_`!%\/Z=JOQ!37KR^B\"Z#J6E
M^(+3Q]+KFI:MI^JZ3FWQKX/#NHXQQ,)R^K1J.4XTY3JSAB)4(PY9RBHI13JJ
M[;C3NU&_NJJ6,K*C%SPLH<V(E!1]E54*,73<U*:45*[G%4W)77-*[>FOZ4G5
M=-BC\]F*A2T8(P"2N6D0`/E#&=V]7V%'+JP5L*>=\4>-O"W@;P?XI\<ZW*]I
MX9\'Z)K'BS7I[:W:[G@TKP_I%QK6HW-I96Q>XOIHM-M+B:."TCEN;IXA'#&\
MK(K?A;\%?V*?C5?:/>>&/BQ\'(/"WP^\2?M$_LR>/]>^',+?#7P9X9'A[P5X
M.\=Z3\6YSX4^%?Q"\7Z'+I][KTWAJSU"*?7[[Q%\2=*CT[4/$UG>R2:G:6^S
M\4?V._BE<_#E/A_-^SP?C1X8T[X4_M8?"_X,>$(?B9X<T&Q^`_B+Q?\`%_Q=
MK7PE\=1W.N^*[%-/T63X67OAGPOI6H^&FUKQAX.M-&C\)_V-::)JVL&SV_L[
M"J:B\?3<%R2YH.C#VD7!.HH<TERRIR:IS7/I)Z2>B>$,SQ3@G++W";A)QNJL
ME3J7BHJK3IJ4N6K3;G%\KL[)I6NOVV\+^//"WBZ.\FT(:A)#93:,;FZOM"U?
M2K:237]"TOQ%ILME>:G9VMCJ\;:;K%B+B\TJYOK2TOGGTJXN(]2M;FSCSOAM
M\4/`GQ5\':%X]\#7-Q>^'?$PU0:5<75A=:5=7']CZQJ.A:BKV5\D%S`8K_2[
MS$<B*TT*)<Q*R21D_E9XK_9W^*]_K5UJ'BGX/3_&?X:R_'3X=^+=>^"X\8>%
M=,_X3WPWHO[('@+X4V7B*.#7/$FE^&)+;X;?%_2;O6&\-Z[J-@;Q;4^*]$@U
M&_L=)CN_FS5_V0?VJK7PM^RSX8TCX(:'INI?"31/`$J>*M)UWX?>)/%?@;6M
M%_:*UOQQXQ\.7WQ(\6>/-(USPUI5G\.;BS.CZY\+?#OB36_B-+?:WHGCV^TZ
MVCTJRJZ>78.4:W^W0<G6I*ESU:2A*C*A)S;<9J4ITZD84W)QM%.RD[KE)YCB
M82P]LO?*Z/-4C&E6<XUOK%*$'%\O(H>Q<JK][FO>ZB[.7[\^&_'?@3QI;ZU+
MX6UG3?$%IH/B'7?"/B";39A<6^F^)?#5^^F^(-$OVW!4OM*U)9;.\C(/EW2/
M$7(.#U:7NGPR"$`0S;'*Q-&8G*J^)#'N"AU5POFF,NBL09&4\C\"?'G[#7CE
MM$\>^&_"?P%U/2/!=Y^V3\3_`(O>-=.^%MY^SO:ZM\>_A1XZT[QK<_#,Z+I'
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MVG3;6:TO(8[F+9/&LB]!$"(X@QR0B`D'.3@?-GT)'?J>W`J:O,6C4EHTK*2>
MJ6FS6MG97[I*][(]FRMR[I.]K6C>]^9+:]];VNFWUN1-!"P4-&I$9RG&-A`&
M"N,8*X&T]5(!!&!AK6T#/YK1(91MQ(PW.-IRI#')&T@$<]14]%%DE9)6[=!E
M<6UOM""&/8J[`NP8"[MVW.,D;N<9P#D]:4V\+$EHT).<Y&2=P`)/;)"KSC.!
MCH*GHIK166B;NTMF^_J)12MHM+6=E=6T16%I;89?(BP46,C8,;%((7_=!`(&
M3@C-(;.V8$&)6!,AYW9_>/ODPV<@.Y+L`<,QW>E6J*7+%[Q3LTUHM&M4_5/5
M/H'+&UK*U[VLK7>[MM=]RK':6L0"QPHBJQD`50H\QL@OM`YD[;B,G/4D5(\,
M3D[D0Y!!RN<@J%(XQP5`4]L!1VJ:BA))MK1NUVM&[*RO;RT!I/1ZJ[>NNKU;
MUZC555``"@#I@8'/I]?UIU%%.R6RWU?F^X]M@HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`/E[]J/]H74_V</A[=?$J+X.^+
M_BMX;T(7-UXN_P"$3\0^`]$O?#6G17%E96NHR6WC/Q'H)U9;V]O5MTMM'-U=
MVQ1Y;F&.)E>O8?ASXHU_Q9X7TS5_%G@/5_AKXDNHKAM2\$:WK/AGQ%J>A-#=
MS00Q7.L>$-5UOPW>/=6R07T;:7JEW#'#<I#-(MQ%)$G"_M,?"6_^.7P.^(?P
MHT?5[#P_J7C?2;73;36=0M9[NRLI(-9TW5&FN;:U>*YF5H[%X\12!@\BLW`K
MJ?B=\,M#^*_A[_A&-<UGQUH-B=0M]1:]^'?Q!\:_#'Q&T]KO$41\3^`M;T#7
MFL',CFZTUM0-A=@1?:K6<P1E+M1Y(M<D:BE+VTWSM\EH>S37-RJ\G)+W=E?5
M[\S>(C.LXQG5IQ5+V=)<L(J4GRSUY7)V5I;N[T225CQ/]HK]I/Q)\#KKP8=)
M_9[\<?%K1?&/B+POX,LM>\,^+_A?X>MK3QMXV\1IX8\-^';FQ\<>+O#^J.=0
MNIH)I]7M[231K&TG+W=VDD,B)@?"S]L7X9^+/B=XK^"'C6XT?X9?&#1/$NF^
M&M,^%OB/Q;H&K^*M;O+OX<^%_B->+9_V++-H[75G;^([W3(K*RU&^34V\-:K
MJ.DW-[9QSBU]A^,OPBNOB7H/PUT72=7M]+_X0+XR?!WXEW%SJJ7FHS:EIOPR
M\7:;XBO=+6X,IN6U/5K2Q>VAO[R64"XF,]UYP:0MX=XD_9%U'7?%'B[Q`OB/
MP];CQ1^UW\-/VCF9='N%U*/PYX&^%_A3X>7?A:6]1PTVMW)T/5+S2]2)-E90
M:GY+PEO.+W36!<;5W[&LU[TZ4K5&^=*#GS737LV](\MTDK]5E5ACE7<Z=12H
M*-UAYP7)S>SC=7BN9MS::;;:;:2:;1[[\/OCQ\&OBIJ_BKPU\/?'7A3Q9K_@
MVY%IXKT?0M4LKZZTF5KF:Q9IE7:EW9_:[>6S?4;$W6F&ZA^Q_:S=?Z.?-_$'
M[4_@GP_\/_CC\1[OPOXDN-*^`_Q:B^$/B&R@72?M^L:T]]X`L%U311)J"V_]
MD^;\0-.D_P!.FM;[R[*_Q:L_V<7'@7[%/[!]Q^ROK.I3W_\`PK+51I7@:U^&
MOA7QOX:D^++_`!!\2>&[?7(=8%SXV@\<>//$WA#PY-,;.SN[[1?`&D:?I=_K
MLMUJT4^G6IM]*BT/''[(/Q@\1>(_BEX+T;XC_#JT_9Y^.?QC\-?&OXB6.I>%
M?$=Q\6]%U+2+OP#>^(/!W@W5K7Q!!X4DTCQ5=_#G2WA\0:QIBZKX8@UC5H;7
M3]3:.RE2Y4<)[3V:JSG1C4BU.:Y9RBG"[]UWNXMV3UMHU9.\^UQD:6&G+#*-
M24ZJJTH2NJ5J;]DY-\KE"53EOR_`Y:745(^BT_:G_9ZU#QKXL^&NB?$SP+KO
MQ2\&6'BB_P!:^'MKKFF1>);>7P9!+-X@LKA+N2*UL[[2EV2:E;W5RD^F65S;
MZK?1P:5/%>2:WA/]HKX2^)_#&G>)AXH\/:;#=W7P^T;4+1]<TC4!I7BWXG:!
MX?\`$?@WPK-?:7=76GWVI:]IGBK0[K1[G3YY]/U6TU2UU"PN9;*Y6:O"&_8^
MU<WUM?1>)_#,;Q_'_P#:;^,MRZ:+<I-<V?QX^''Q#\"Z5I4D\;K(^IZ`_C#2
MYM4OY&>*^L-':TM5B/V98?-['_@GUJT7B_X3WMW\0]+A\#>'?V?_``7X!^)_
MAG2]&O8+_P`6_&7X8?"OQ%\'OAU\5=`OIKPV^D0:)X2\>^+C<Z=>6ES=7&H:
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M7HE]KJZ=OT_PQX2M;3P[H>MWE_?&^U"U>&SM_1?BQ^QC\7_B1XW_`&BKO2OB
M%X"\!^`?C5\)_B7X)NM%T"V^($TWC?Q9XX^'NF^!_#WB[XG^&=3\27G@BUUW
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MF#Q/%\`OV?\`P3\-O$WA:R^(W[/?B;P3\0]#U'QSI6HZYX)\9>-M$T;Q#I?B
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MDWA/XK^!-=BO_%R^`;&6SU6U/VWQ<^C:CXAM-"@^T>4S76HZ#H^K:QI$S!;/
M6-/TV[GTBYU`12!2S_:N_9OO?%'@OP78?%CP1<^*_B-I.G:WX%T6#4[=;OQ9
MINLQ7L^C7.CNRK;3'6K>RO+G0[>:XAN-:@C:;28KR*17?\^=%_X)?ZQJ7P9\
M6?!;Q;J7PB\&Z7\1M3^&VE?$3Q9\)[7XM7OC'7?!/PHL=8U#PS=Z3JOQ5\>>
M-&\+>*[CQA-I-S:V^BF'1_"'AN7Q3INFW&LW^L6U_IW=>)_V(OVC_&WQ0^!W
MB[Q1\;O!TG@_X8ZI^SYXFU;P?H2?$[PSX7M];^#%W')KMKX1^&?A_P`5:9\-
M;RU\;S6MKK5CK?C[0?%&N^!)XXO#GAMX='LM/NH!8?+'*7+BI)/GUJ1336CB
ME&"E;GE[J7,^5*^LFHF2QF;*-IX&FVI4X\L*C5E)J,WSS6L::U:Y8N6FBW?W
M=X#_`&@O@W\3CXL_X5[X^\.^+8?`E_/I/C"?1-3@NK3P]?PQW$LL-_=XBMU@
M6*UO'CU*"2;2IA97AAOI3:77E>&^+/\`@H;^R#X8\$P?$"3XN^'?$?A0_$CP
MK\*M0O\`PT6UI]&\5^+[DQ:=_:UDHBN8=*CLEN=:GU*&*>&XT6SO+W21JBPF
M,YG[.?[,OQ;^$FB?&+1-=^(/@_1='\9V?]F_#'P1\.K#QCJO@7X478M_$/VW
MQ7X<TWXEZ_XBU#2QK^IZU:ZI<?#/2[Y/AYX?GTAO[#MR^MZM++\V>!?^"?O[
M0?AOPS\1-2\0?&;P7XH^*VO>)/V6O%_AG5O$%_\`&#QCH5UK_P"S1XMU;Q*[
M^+M3\:^+M;\36&D>/'U2X=M`\$OHFB^")KB2T\.:<]I%YL[IPRR,G*MB7&,)
MQ5-+W7.#<%*5K.,>17]WWG=-)R34EI.MF*E05'#TI>TC*6*J5'?V-31*,8QF
MKJ22N[K?O>_WS^T+^T'X-_9[^#\WQ@U+PUKWCRQFGT2S\.^%_`UE87GB?Q;>
M:Z5GM;;0K;4[G3;25H-'BOM=NVN;JW\C2-+O9_FDACA;H&^/7P8CT6?Q#<>-
M?#=KI-K\-]`^+VH75Y<V\":?\-/%)NAH/C*]+@B/1]2DL;V&&XR=TMI.C+NC
MRWF'QU_9O\3_`!Z\4_!B\U3XJ^+/AWX:^%MOXN\0WZ?"K56\.>*M8^(^O:#:
M>$=,O8=6U;3O$%@GA+3/"^K^/[*?3+K3YM2N[C7["9;Z%;*7SOB_4?\`@GK^
MT#I7@&^^%W@?XX?#JY\,:Q\$M3_9POM4^(7A'Q-KGBNP^%.@?$_Q=XW^%USI
M]YHNKZ+I]YXPT_PIXLF\`^(KN]L8],B?2].\3:/:-(L^AS*E1P%2E3]KB(4J
MSK0C4515915&;=Y^Y":O14>:4;)S]HK-N#3JOBL=3KR5/#5L10<8J#H^Q;4T
MKSYO;5J-E-\JA9U-I.7+'E;^Q?BS^W+^RY\%M&^*.K>,/B+H<][\((M%G^(G
MACP^]OK'B?1[C7=3T_1M.M6LHWBM[W48[[5+2&_@@OI'TEI4BU$VT\UO%/IS
M?MB?L\Z7:>(M?\3>/?!WACP5HUUX*M](\8ZMXBTE=/\`$4_CWP8_CCP_;66G
M0RR:WIFIZGH5O>7.CZ+JVG6NK^(+:T>YT:RO()K<O\S^/?V'?C%XYU/]I>VM
M_B9\/O`7@/XQ>&_$D/A_P?X5TKQ]?:+JWQ#U7Q7X=\5Z5\3O'V@:_P"*[S1?
M#WB2T'AG^P_%#_"J+PW#X]77]0\0^((_[7TK1X8O2K/]D[Q_K'Q9M_B_XY\5
M^!)]8O\`XT?`WXS>(-#T+1M:DT6VU+X7_`+Q;\)]:T[P_)K$\UY&=0\1^)(?
M$&@WU^7N+'3;!(;@G46680Z&7*C!^TJUJ\I5I5>:;]R+=!THQO%-72K)I.44
ME#2[8X5,Q]M4A.AAX4.>E'#M0EM)575FTJGO-.-.ZLF^9[6/M#P3XS\)?$GP
MQHOCCP-K>D^*/"OB.P@U/0/$FBW<&HZ9J^F70_=7=C>V[.LL1:-XW!VO'-')
M#.L4T;PKJ:[JV@^&=(U/7?$%QIVE:-I&GWVJ:OJ^IR6MGINF:786\EU?WVH7
MMTT=M:65K;1/-<SS/';PQ)^]=`%6OE_P=^R=X6C^`%K\!_BDT/C#08O'/Q"\
M97/]@:OXM\%QR/XK^*WC/XB:/!%>^&-;T37(7TFW\4Q6%Y&FIK9WEU;2R&!H
M'C5=*V_9:\(_#WX3_%GP#^SS?7WPA\2?$OPYJMA8^,KW7/%OQ&G\/>)9M%O-
M*T/Q'!8^/?$NO$G2)+L3?8K.XT^"9E9W5IDCD&,84%*--590BY)0:I/V<*;:
M4I3J)\T9*_,DJ<Y-)VVUZ5/%1IKGITY25&,I3E5]FG6E'F]BH<LE:$DH-\ZN
M]EV8/VTOV48O`D'Q(/QL^'%OX!D\1/X*B\0OJT=K8+XLBT^XU=O"?V:6"._B
M\0OI-K/JMGHKV(OM0TY8K[3H+J*XMC+RNN_MY_LSZ=XSB^'>F^-=)\1^*]5^
M!.I_M!>%6T[4-+C\*^*/`6GV^I7D;V/C.[NHM#LKBZT_2[_5_M&I36^E66D0
M3WNH:C!)$]O7@_P&_81^)W@#Q!X;\6?$KXC>&O%VN:?^TAX>^.^HQMJ/Q1\?
M3?9M`_9U\2_!&#1K?QC\7?$_BKQAJ6JC5-9MO$UGJFI:A%::9912:5IEA9I#
M;,9X?V%/B;HVD1Z'X?\`B#X`.G:[^S1^T/\`L[^,DU+P_KJ/90_%7QOXO\?>
M#/$O@_[!=Q1H^D:EXFATOQ1I>K(]O<Z;8K<:.\%UL0]-2AED*UJ>)J8GX>>:
MFURW=W%N5.#;AHWRN2;E=2L<*Q&:RIQG.AAX349R]BHRJ337*U&,O;0BY3CS
M)/W4VE=^]>/OWA+]L;X.^(/BWXB^"OB+Q-X6\'^.[77O!NC^#/#FK>*M,EU3
MQ^/%OPQ\*_$NTGT2UC5;90(?$4NBV$`N[G_A(KW1KN?19;L$P#T#1?VI?V;_
M`!!J/Q!T70_C!\.=1U3X56>J:I\1;"W\3:2K>$M-T:XFM->U35)I9XK4Z7H=
MU%/;:]J-I-<66B7B-9ZG-;79CMY/D^[_`&*?BY??$#5(9?B)\+X_@]XP^)/[
M.'Q.\801^"M=/Q5M-5_9P\&_#O2=(TGPOXB.L)H4-GXJ\1_#ZSN9]2U#33?^
M&=%O-4MM-6^O=7:2RX!_^"='Q5\1>!]/^&/C+XL_#>+PE\(_A;\0?A?\"-5\
M,^`-7_X2;58?&7B/PMKUEK?QJBUC7KK2=6@LH_!.A6'B/PUX5BL].\87=[KF
MO7=W87,ME96KE2RYM1^MU8Q:CS<R4K/E7-)?NT]9OEC%M-:2YG\*5+$YG*+E
M+`J+NTU4BJ3;BX.DH^RQ%96@_>E-RO+6')'XSZO^#O[9?P3^-WQ`\6^%O`_B
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MG:/X=^`/Q,^%/BVTM=3LY+PZCH/PJT[4]*M=,A6/:(=6N'FM+R"^N4=8+N![
MECY[0R":]#!OV=:EB:[I3?)4I1J)SA.G2I2DVO9_#4G-PIU'%*\)MQ:T-,-5
MS"[IU</0C5IQC.%1PG&$XU*TU+E?._?IQCS2IQE=QE%.4;W.KMOVE/@%>>,)
M/`<7Q0\$?\)K!X<?Q9+X?N-6MK._M]`&D)X@GOIY;P0VENT'A^5->OK"6X34
M[+1)/[5O+*&R;SQS#_MC?LMIX%T_XFR_&'P)'\/M8UV[\,:?XI-^387GB+3X
MUN+_`$N*!+<ZB9=/M9/M]]<M9+96FGRQ:A<3QV5S#,WR&/\`@G7?V?Q_^*7Q
M00?!OQ=H?CSQ=\3OB=H]_P#$2R^+VN>+/#WBSXE>!=0\(7WA:;PO8?$?3?A9
M?^%$;4[VTNO$*>&[7Q1<^![^^\(BW6[>+Q''Y_X@_P"";7Q<\6>%_A[+XO\`
M'7PS\9Z[\/M6^)&GZ#\-?%.M?'ZX^%OASX:?$3P]X)T,>#-#\=:9\0],^,NH
MGPW=>"AJ6E-XJUO6]/.D:_J/@>"ST[0K#1Y;1QHY:G98F:7LU-N4$Y.K9MTH
MI25W=12E-Q:NY-62O,L7FD;+ZG3;=54W&-3EA&BY12JS34FT[R?)#F3VW9^D
MB_M(?`&3XBV/PBB^)7@F;XE:MID&LZ7X+@U:SGUG5--N=);Q!97.GQ1,\%V]
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MM3L]>T/Q#8ZEX:TO4-,O-US_`&A:76N:3JD@74WO(I=++N6%18JM*4J-2K45
M)\BIRA>4(2?+/F]M[OOQ]V'-)OG42W5S!NM%X.A%TJE.$')N:G"7*Y55[R<?
M9):P;;DVN5KK[1\/OVO?@QXU^,/C7X,7'BOPEH_Q%T/QG?>%_"GA2?Q)I]YK
MOCO2K7P5X4\>+XHTFSCC1+>SO--\2W`LK"2>>ZOK70;W4]/:XM%N!:?7L21$
M$*B!'56QM7#<#;D8P?E4?45\.6_[)VLCQ%'XDF\1^%#>2_M>^&?VEKV:ST"Z
MM9+G2]"^#-C\+I?#4;&XEFCU$WT%S?Z?<RW%Q:V6D7)T\F60O-+]SQ+C\%"_
MET_K6&,C@U5H_5)2E*T8U.9IR25*-]HPM%-J*7*]-;W=ET826+ES_6HTXQLG
M3]E%QBW=<UTY2;>MW?OHK#A%$.!''ZG"*.N1TQWR>OJ::;>!L`PQ'9C:#&IV
M]_3U&1TJ:BLK+MY?+L=B;6SMUT[]R$P0'(,,1R/FRB'/&!D;?3C^5*8(6&&A
MB(YX,:$<]<<<9[U+12LK6LK=K:?=L!$8(2"IBC*D`$%%P1D8!&,'D#KFCR(,
M$>3%@YR/+3!W'+9&,?,>6XY.,]!4M%%E>]E?OU`A-M;L<M!"QP1DQ(>",$<J
M>"./IQTI!;6^=WD0Y^09,29Q'N\OG:<[-S;.FT,>]3T463M=)V=UY/NO/S'=
M]W]Y"+>W4JRP1*5)*D1H"I(P2I`XR.#BG>5'DGRTR<<E%)X.1DXR<'D<\=L5
M)119=D(A>")MN^*-]IR,QHV..2-RD\]\')^HI1#$.D48[<1J.A/MZEC^/YRT
M4G&+M[L=-M%IK?3L&U[==_/U[D(MX!G$,0W$%L1J-VW.W/'.W/'O]:7R8<!?
M*CVCH-BD>O0CUJ6BGRI6LEIY+KOTZ]0(?L\`!`ABP<9`C3!QC`(VXXPI'N!T
MQ2"WA3&R"(<CHB#&`1V7LO`QV)Z]YZ*2C%7M&*O>]DE>^]^]^O</F^FSMML`
M`'`&!Z"BBBJ2LK=M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
B****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tsig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tsig.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@#0`P$1``(1`0,1`?_$`(,```$#!0$!````````
M```````("0H"`P4&!P0!`0$`````````````````````$```!@$#`@,$!0D$
M"P`````!`@,$!08'`!$($@DA,1-!,C,4(A4U%C9A<9'!8B-C-`I10E)#\*(D
M1%1D565F%SD1`0````````````````````#_V@`,`P$``A$#$0`_`)S^8LLT
M3`^,\@YJRI96]4QOB^IRMRN,\]*<6$37X-!1\[?[%*)UG944O3(F7?K.(%\Q
M#01>4^Y_WG\Y<E\$SW&WC5AJG\<,W53+>:,.8*S,#AAFO,W'K%9*J@MD">L[
M511'&#ZZO;BQ/`,SIG5<E?(^H7I-N`2"N$/,.B<W,),<K4R*EZ78H.P3V.<N
MXKLAVX77#67J@^=1ESH-O11.9O\`/P,BF((G2$R3INL14@B0P#H%H($Z$4R=
M(%Z2@'241$`_,([CH+N@-`:`T!H#0&@-`:`T!H#0&@-`:`T!H#0&@-`:`T#4
M_=@XOYQYD<>ZGQUQ(ZC&U2OV?L0%Y"A,3PP<@ZX_0-D1F[Y%PZOU'8VKQ.4;
MMDTED%FY%5$=P#U!'IT&K5AN_>]YUY!U\T:RQMQQ[:;"C1E2B&ORZ%5=YSSG
M3I&&_=-XQL$>U>0^"/0;H%5=))(,!.8&WT06#5.V^SCI/G-WB\BT1E')X=MW
M)C$$169N#;H-:Q8\ATCCKCJ(R](1K=@FC&R+]I=3J)R,@F4ZKU\"@**'.F(@
M#U*10(F0H`(`!0``$1$?TB)A_2.@KT!H#0&@-`:!$/,;G9ASA=-\:ZYE1.Z.
MI?E1FV'P-C9K3*_]?J(6J5:JR!YB;2*=-5I`1;5+J<JI%<N`*8/2;+"`](+3
M:B.ZY!,4X)J[`8I^L0ZB%,8BNX]15BB;<0V``*(;!H+$@90!;I%7%$JYCI?N
MP`JYE1`IB>BJ<#I@/04X"02&$2B)@$O0(Z!N/#O=FX"<B>1"G%K"O(2$O66"
M*VY!%BS@+FSK4_(4%^HRNL+3[W)PT74[A*P9TMU0B73Q$I0'901'8`<F1`X;
M`<XFW*)OI@`'.)A`>K8!$"`0H@7;0>C0&@-`:`T!H#0&@-`:`T%`)D*(F`A0
M$PB)A``W$1\1W'V[Z"!#EGB3R^[K'>^[D.,L2<]+IQQQ9A&W89C[U'8_)9B.
M)NE4BJUUI$Q3-_6I)A!?>^+<Y&LY(H[_`-<0.9T50O04Q=`KO%G-G,_;`[1W
M<APA%U5R]Y`]KS-,OBFOY,85N#=1M[K6<;E%W'%F?+M'S2/U7*3TDVOI#S::
MC4XJJG1/U',YZR@I+M+<K.]/D^?-8.=K^N0.&_NVVR'+OLN<2Y#"LR./6<$I
M)3KK&5PH-\8PCR60.)3@69A5TOEB&6*8`.4@!Q3&W>[RAS8[D6&EN&.7:[(\
M7$L_5+C*YXR25=1=9;S=3IV&FY7-O*=4S5=PK1<?X;&)8JQCEPH"SI`ZYC`)
M5?2`'3,Z=\;C-QKY@9EXQYGJ>1ZQCW`-1H$AEGE0Q9-IG$F/LBY1K5FO-!Q5
M>V;7:;K,K=J?4G*D2_$JS1V_41:;)*+)F$.\2/=%XZ3';5NG<TQI9W$_@Z`Q
M5<\@Q#F>C',1)2<Q7_G8./J$K$I.5G43*OKP5"/5134]1$3F`!`0WT"-^S=W
M8<L<Z[%R%Q/R4:8*KV8<.P.-,I1"F!;%)6&D2&(LH0B<TDM+RDO*22:<_4))
MP2-?%*"9DS%,*@@;0.+\N>=&/.*O#'+/-./9'Y`4?%\"WG@AL.V*!F5+'\S/
MQ,(5"-L1'KJ#;,V2DL1=XNH=3Y5L50XE,!.D05Y2K&O;:I6K.YC7L$>Q5Z'G
M30\B*8OHOZWCT'JD<]50'T%7C$QQ()DP`I@#?;QT#!'+ZDUW.7]0#VVZ9<+1
M!NZ_@;BWG7D?`X_?3`%=N\J1MK:5^F3\7$;B#V6BFJXNC;[&*W;F$`$!W`)#
M;/Z)#)]1C"02@83%(4P&$A=RF`GAU[>(A[-]@\M`B;N4V&ZUC@OR<?XXEDJ]
M?)/$]AIE4L2IG6]?EL@J,:.G-MBLE4'8/XA&P'=-SI'*HFLB40'0(:I7`JIX
M;R#V]I@S;'6,^)/;NP1:)ZMY(FKHT@K1:<QY,KL52'`7`SE&/02J#"-%636?
M/WICR,F]Z5`'H*(@[I(9-HD+4G&0Y'(-/CJ"QB%+4]MZE@A!K:%4;*`FXGQG
M"/5(H\(50P`LY`XHI=8=(@;0;S&22$M&MI%E(,I)E()(NF+V.>HNFKEH[2*Y
M(=J^9F%H\3*W5$4E4AZ5"E*;?QT%3F58L56C9](-VKB26]&,;NG2#-9^J!3K
M?)L"*J%6>ODD$A4.1,#&Z/'RT&/LEEAZ5`S5NMDY'P-9K\2[FYVP2[Q-E#0\
M='HJ+/'[]98Q$F<<T:E%194Q@`H%W'0>"B7NIY-J,#>\>VB%NM(L\>:1@[77
M)$DI$S+0ZZB0.8EZU.9!=L!TU"E.!A\2`&@S,1+,I4R@Q\LQDD63MZQ?"S>M
M7RB$JU<'0>,'?RBBI6;EBLD<JB!]CI'W((`)=!L.@M+&,5%4Q`$3%3,)0`!,
M(B`"(``%$IA'?V`(:!">3>X1QJQ!RYPIPNR!;+%`YHSO75;5CY!2`=+5!1J5
M>7CV$;9+6DN6/KTO8'L"];1S9V39ZX;&!(XJ"`""\##L4P[".P".Q?$P[!Y%
M_*/LT"<<<\IL`9DN^5,78GS'3K_D;!L\G7,P5*MS#1Y.X\F%4Q4*TLS,$=VI
MT@#I$$P4(*H>F8W4(AH%'Z#&O2*N&SML1VJS47;.$T7#<"?-M_62.D5TD"B:
MA/6;*F`Y-RF#</$!#PT$9C#?:A[CW;[SGR;R/P&Y1<=LGPW-2Q%O>9K)S)J5
MQ+<J1DB,F;N^AIVKIXR;/HJRP2+*UJ-3M'*[,ZJZ:8B!"E^B"_L.]J;%\7Q*
MY$<=>4UUL')VX\UK/,9(Y=94FQ)7W=XO,VU@"-VU*1*F]?U2ET!I58Q&N,/5
M=$8!'D4Z2`<R0!N_%KMDTGCQ"WUI><]Y[Y1VN[XS_P#1S&^YSM#:9FZ1@\L8
M\C&>-J:UB&L?$1L8DB^4,I(*HJR#AQL*JQB@!-!I/'#LM<!>+$IQRLV!,7OZ
M+>>,[R>&GY.A9YJCD2[,;+'S<=9*YF:P(LD"Y`@7B<P)A;F12.F9LCT'*!!`
MP=7KG:\XKMK+S5LN1JJOFU'GG=:;<,XP.5CM;)%.V^/(&,AZ?4XP4&[)9O"5
M9RS56CB@8%FWJ=`',!`-H$/Y5[%6/Y+B%?N$>(,VW6E8)S!R_CN1.2J-+@UD
M(J'QBZFU9VU8-Q8UCDXUM2:[89!,A_44*X#YE550=A$-@3WR!_IO\;Q,RUF>
MV=E:2[>R\YAQ]B7*:V/7MIE7V1TEY^/FXY[.KO)"1(K\P5HHTD3)J))G1.`E
M3`P;Z!/_`"<[)O)'BUQZ7XF=MV2?73C9S)B<+X8Y=X]O=G*+#"3BGRL&^N/)
MK$+F?E#)Q`Y$BVDJWL<2BT4ZG;QNZ2/^Z],H2XH5F$3`Q4:<!.G#,8V/3!/8
M3%)'-4F?J";P*J42)"8VP>Z/E[=!$;[KN'<QV/-W(JR16'.<3OES]Z*7,]O;
MDOQ(Q2E;X*I5EGCU>!?XML5S1.C'U:M6:0=+'LOUHJB1)<Q'28]).DP2+NWM
M3N2F.N$O&VC<N[:>]\EZ[C6%99@LY72#ET\LAG*SLK-Y)I-TFLO(5^#<MH]T
M[(`E>.6BBA3&ZNH0W7D#AT.56#>0/'F]HRE3J&3*Q,T*%ML,\!6PD96*LL'+
M*\19$3M5(B6J5H<*_+ME3IB<S$AC*$*IOH(O/<]JW<=Y$X'XU<-+EP_SKF)S
M@7(T3-<DXK$SE.-P/S#P[781S"8[?(Y*92`(15A6D6#>4E*TY4!5BY,8#`L4
M$E!#HN&NPIE?,G`/@1@ODIE&S806Q=9;ZZSKAFIV>PV*/N'&_(MX;9(9<:Y-
M5G,LVZJM;E(.,ZEC%41:;'+T&Z3IB"MNW3Q4[IG!_FI;,#Y(RJSSQVP'V*;?
M&<<#2<DV<V?!;>HV^NFQS4Y^35C(^:<V)Q4;4]CW*IQ=I2AHTJZ0H%1$A@1+
MG;E5F/F?_4A\8.+N);"L;"7`>S*9#NU>C7+F*^L7ZF-9)+*UINOS#EJLNE6Y
MBU1,+&M!242672<F`/`1$.V=]^>YG<TI28[:7!7&]AFI>@T:+Y%<IIFVS!<>
MXGR)B^0:2#>KX+C+TI(1Q)&<L$T0KIZR!R@@=N@!%E`(8V@;T>9`[@-5X(=C
M_AAP:M%@QMG4F,>0&=,B(LXH9.IS(\/OO'8FF*,A/(#Y\ZL?DBY($BVK,ID$
M)!V<A%'*)3>(=T[*_=P^[V'\LY=S]AFW8CX[9O[@N9W,CR$N[Q]!4#&4KF7Z
MVOM693;^Q*'CVM0BIEB]AWSI)ZHWC72S0I]S*GZ0?GX<]TW"W.SDQGW"?'#Y
MB_X[P+0Z'9Y'.\2L1:DS]LO3M^DI0(U,Z:2Z\A7V3('*BY1%-0APZ=_,0<Y*
MZ7Z!W],>H#BF(^J<#"!DP.0X`D`](',8.H-P`@;^/CH(G#;BID7NL=YC,/+!
M+)475N%G"/*6'<#,(6#0>KV;.&4^+C]WE)Q%1\XFB2!B:Y2,O7N22D#@X747
M%K\N"8"90R0.>]PONHU?!^!,^1/%I.0Y"<LZWD*/XKU/#V-61YZT5GD5DB'>
M&I[NP-B)'6;0=:Z3.G:@(*E]1$"=(@)M@C,]O3D&MPV[@?;S@\@<9>6F(^1V
M4J3E+BGSD/><2.V@\A,T72=D,D4#+4;;&D@>(MV]M.<RJH%]1G"%.<PE(D4-
M!/U$ZI502%4P&-N<PB4QBDV$@)@!BI@0I5$TC&$HCOU#L`[>0>OT$]Q$0$1$
M3CN)CB(=?O`4>K<I1V\@\`T`*"8]7@.YBB03`8X'Z1,)@#K`P&`2B/T1\R^S
M07.@H;_1#<?,=O$?$1\1\_,1_3H+0-D`*)/2*)3;]0&#J$VYNL1,([B81/XC
MO[=!5Z*7TMR]0FW`PF$3"("(#TB(B(]&X>7EH+@``>0;>7E^3RT%D&R(&,<"
M;&,`E$0$?`H[;@4-]BAN&_A[?'ST`5L@4H$!,O0'6`$'<2E!0-C@4!$0`#;C
MO^?05%02+MT%$@%(<@%(8Q"`4XE$WT"B!-]R^`[;AN.WF.@I%L@.X^D0!'QZ
MBATG`>@$^HIR[&*<"!MN`[[:#XDU00Z_13!+U3"HKT")?54-MU*J;"'6J;I#
M<P_2$/,=!7Z"(=0`F0`.8IS`!0`!.4``IQ`/#K#I#Q\_`/[-!0#1L`"'HD'J
M$1.(AU"H)B`F8R@CN*AC$``$1W$0#QT%P4B;;``E#80`"F,4`W]H=(AL8/8/
MF&@^`BF`@;IZC`7H`QQ$Y^D>G<O4<1-L(E`1\?$?'0:=D!S9HJBVMU0(:`GK
MVUKDTO1*[:)9Q7ZO.W-O&.5ZK"V&>:1LPY@X61FT6Z"[M-JY5;(F$Z:2ABE3
M,#9G:U[=,%PTQFO;\KTW#\SS0R[/Y!R/R#S53*ZDYG).Q92N#Z[R^-X?(4TW
M2NT_1J(Y?$CV1G0ID=MVZ:XHI&.)0!U_Y%J)%4S(E.1=,R*Y5-U/62.`@9-;
MK$14)TCT[#N`%';RT&L4O'],QU7V=5I-=C:W7HYS+.V$3&(`BT9+SLN_G946
MI-Q%`CR4DEE#$*(%#KZ0`"@``%F4QS096HOZ)(TFHR%,E"^C(5*1KD8^K#\B
MKPKPZ;V!4;#'N2*/?WH@=,0]7Z8^/CH&<NS'!0-EB>;7)RM1,158?D-S2R3"
MUZHUULR;U.LT7C\<V&Z>VK4C'(LHZ582+"'4<$<-&Z*!SF$I2B`&$07SB?"F
M9:MR-Y9Y$O&7WMVPQFM/$ZF(L>/!E05Q"[J]<LU?OK*#,^?N6K9E;W,BT<*%
M011+ZJ74``.XB&^\7N+N&.'N&ZE@3`E.^YV-J=]9O(V'4E96<<J2]AF'LY-R
MTC-3[V2F926?2<BNJJX<+J*F*8"B;8I0`.P0E$H]6=3\E7JE6X-]9YM2T69]
M%P\>P=SUB.B5%2?F'*"":LA,'1(!1<K&,L(!XFT"2.7?$E3DY:N)=QB[V&/Y
M'BSR;H_(-%=O`-9:0ML=6VKUG.4)K)_.-WT$PMT0_5:OE$#?[2W.9)0ITSF*
M(;!"<8K!#<QK_P`KW.?<LS=>NN(ZUBJ/XZOY--/#51-79I266O<3!)$Z%K:_
M.X4*=RH4RHIG$@&Z/``6+H#0&@-`:`T!H#0&@-`:`T!H#0&@L.?A?Y?Q4/B>
M[\=/_7_P_M;:#%1/PF'P?L]+W?S!\+]?Y-M!G-`:#5KQ^"[=]J?AB>^P_MO[
M+=?8_P#W3_A_XW3H&KNQI_\`+/B-]B_A6Q_9OQ_QM9OQ+_YI_P!1_P"<Z]`[
M67^;7][^7;^]Y^:GN_Q/UZ#T?WB^]\53\_D;S_9_5H+I_<-[ONF]_P!SR'WO
KV?[?R:#'G_R/A_&2\_/R_N_QO\/[&@^C\0?C?S(>]Y?R/^[_`.GGOH/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQJBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="nump">2,539,091<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.78<span></span></td>
        <td class="nump">$ 1.34<span></span></td>
        <td class="nump">$ 1.32<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">6 years 5 months 5 days<span></span></td>
        <td class="text">6 years 0 months 4 days<span></span></td>
        <td class="text">6 years 11 months 19 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="nump">2,891,877<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">5 years 8 months 16 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-2.00 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="nump">2,162,362<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">5 years 9 months 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="nump">1,801,187<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">5 years 6 months 7 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-2.00 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-2.00 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 2.01-3.00 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="nump">2,212,227<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 2.26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">7 years 1 month 24 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="nump">1,011,533<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 2.17<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">6 years 1 month 20 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 2.01-3.00 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 3.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 2.01-3.00 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 2.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 3.01- 6.00 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="nump">79,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 4.87<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 5 months 26 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="nump">79,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 4.87<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 5 months 26 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 3.01- 6.00 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 3.01- 6.00 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 3.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-6.00 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.78<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">6 years 5 months 5 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="nump">2,891,877<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">5 years 8 months 16 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-6.00 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 6.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-6.00 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-4.57 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,889,011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years 1 month 10 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,364,608<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years 8 months 19 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-4.57 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-4.57 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 4.58-9.05 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89,999<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.93<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 9 months 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89,999<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.93<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 9 months 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 4.58-9.05 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.05<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 4.58-9.05 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4.58<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-9.05 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.34<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years 0 months 4 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,454,607<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.46<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years 7 months 13 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-9.05 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 9.05<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range Of Exercise Price 0.09-9.05 [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsExercisePrice', window );">Range of Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_OptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_OptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Aug. 31, 2012

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2011

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Intrexon [Member]

</div>
          <div>Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Mr Kanzer [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Mr Kanzer [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EmploymentAgreementDescrption', window );">Employment Agreement Descrption</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Mr. Kanzer entered into a two year agreement with us on a part time basis (2.5 days per week).<span></span></td>
        <td class="text">Mr. Kanzer entered into a six month employment agreement with us on a full time basis (the "Kanzer Employment Agreement"), which may be extended for an additional three (3) months upon consent of the parties.<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Noninterest Expense Directors Fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 150,000<span></span></td>
        <td class="nump">$ 90,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
        <td class="nump">44,444,230<span></span></td>
        <td class="nump">31,374,002<span></span></td>
        <td class="nump">3,552,210<span></span></td>
        <td class="nump">3,123,558<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 44,444,230 issued and 44,362,748 outstanding and 31,374,002 issued and 31,292,520 outstanding</a></td>
        <td class="nump">44,000<span></span></td>
        <td class="nump">31,000<span></span></td>
        <td class="nump">7,800,000<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 2.2<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Costs and Expenses, Related Party</a></td>
        <td class="nump">$ 2,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EmploymentAgreementDescrption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The description explains about the employment agreement between the company and related party during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EmploymentAgreementDescrption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoninterestExpenseDirectorsFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">2013</a></td>
        <td class="nump">$ 287<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">2014</a></td>
        <td class="nump">60<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">2015</a></td>
        <td class="nump">35<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">2016</a></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFifthYear', window );">2017</a></td>
        <td class="nump">10<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthAndFifthYear', window );">Total</a></td>
        <td class="nump">$ 402<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFifthYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the fifth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInFifthYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthAndFifthYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the fourth and fifth fiscal years following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInFourthAndFifthYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the fourth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInFourthYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the next fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInNextTwelveMonths</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the second fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInSecondYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the third fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInThirdYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EE4EM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="3">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="7">0 Months Ended</th>
        <th class="th" colspan="6">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 06, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 28, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2001

</div>
          <div>2001 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2001 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 25, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 15, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 02, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 28, 2011

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrant [Member]

</div>
          <div>General And Administrative Expenses And Research And Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Epitope [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Common Stock Purchase Agreement With Single Investors [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 28, 2011

</div>
          <div>Common Stock Purchase Agreement With Single Investors [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 02, 2010

</div>
          <div>Common Stock Purchase Agreement With Single Investors [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Stock Purchase Agreement With Three Institutional Investors [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 28, 2011

</div>
          <div>Stock Purchase Agreement With Three Institutional Investors [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Common Stock Purchase Agreement With Institutional Investors [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Consulting Agreement For Financial Advisory Services [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Employees and Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Employees and Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Employee [Member]

</div>
          <div>General And Administrative Expenses And Research And Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Employee [Member]

</div>
          <div>General And Administrative Expenses And Research And Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Consultant [Member]

</div>
          <div>General And Administrative Expenses And Research And Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Consultant [Member]

</div>
          <div>General And Administrative Expenses And Research And Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2007 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 20, 2007

</div>
          <div>2007 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>2010 Stock Plan [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 02, 2010

</div>
          <div>2010 Stock Plan [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="nump">2,539,091<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,066,007<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">872,739<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="nump">2,515,000<span></span></td>
        <td class="nump">3,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,075,000<span></span></td>
        <td class="nump">557,002<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,500,000<span></span></td>
        <td class="nump">$ 609,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock', window );">Issuance Of Warrants To Purchase Of Common Stock</a></td>
        <td class="nump">844,391<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">635,855<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,428,572<span></span></td>
        <td class="nump">844,391<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePricePerShare', window );">Warrants Exercise Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.40<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LifeOfWarrants', window );">Life Of Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExpirationDate', window );">Warrants Expiration Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,
         2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsFloorPricePerShare', window );">Warrants Floor Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.40<span></span></td>
        <td class="nump">$ 1.40<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">716,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,492,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">776,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">242,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">6 years 5 months 5 days<span></span></td>
        <td class="text">6 years 0 months 4 days<span></span></td>
        <td class="text">6 years 11 months 19 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years 5 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Balance exercisable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,891,877<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years 9 months 18 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">15 months<span></span></td>
        <td class="text">15 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExpirationDate', window );">Investment Warrants Expiration Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Oct. 25,
         2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.34<span></span></td>
        <td class="nump">$ 0.57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssuanceOfWarrantsExpensesRecognized', window );">Issunance Of Warrants Expenses Recognized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">63,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod', window );">Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable In Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisablePricePerShare', window );">Warrants Exercisable Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsFairValue1', window );">Warrants Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative Liability, Fair Value, Gross Liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">253,000<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseInFairValueOfWarrantLiability', window );">Increase In Fair Value Of Warrant Liability</a></td>
        <td class="nump">765,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice', window );">Share Based Compensation Arrangement By Share Based Payment Award, Warrant Exercisable Price</a></td>
        <td class="nump">$ 2.0725<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod', window );">Share Based Compensation Arrangement By Share Based Payment Award, Warrant Exercisable Period</a></td>
        <td class="text">13 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AntiDilutionPriceProtectionWarrantsPricePerShare', window );">Anti Dilution Price Protection Warrants Price Per Share</a></td>
        <td class="nump">$ 2.0725<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DecreaseInFairValueOfWarrantLiability', window );">Decrease In Fair Value Of Warrant Liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">523,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-Based Compensation Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">271,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,400,000<span></span></td>
        <td class="nump">268,000<span></span></td>
        <td class="nump">216,000<span></span></td>
        <td class="nump">705,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions', window );">Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 127,000<span></span></td>
        <td class="nump">$ 15,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of warrants held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AntiDilutionPriceProtectionWarrantsPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share value of anti dilution price protection for warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AntiDilutionPriceProtectionWarrantsPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DecreaseInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The decrease during the period in the fair value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DecreaseInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase during the period in the fair value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssuanceOfWarrantsExpensesRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses recognized from issuance of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IssuanceOfWarrantsExpensesRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssuanceOfWarrantsToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IssuanceOfWarrantsToPurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LifeOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Life of the warrant issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_LifeOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercisable period of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercisable perice of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisablePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercisable term of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of exercisable share warrants that may be converted as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of Warrants into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisablePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants exercisable price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExercisablePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>per share amount of the warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExercisePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of the warrant issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsFloorPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Floor price per share amount of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsFloorPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative liability, presented on a gross basis even when the derivative instrument is subject to master netting arrangements and qualifies for net presentation in the statement of financial position.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 205G<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44C<br><br> -Subparagraph a<br><br> -Clause 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7476318&amp;loc=SL5624163-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeFairValueOfDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate proceeds received by the entity during the annual period from exercises of stock or unit options and conversion of similar instruments granted under equity-based payment arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate unrecognized cost of option awards made to employees under a stock option plan or plans, that have yet to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
        <td class="nump">$ 682<span></span></td>
        <td class="nump">$ 692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Bad debt allowance - customer</a></td>
        <td class="num">(682)<span></span></td>
        <td class="num">(287)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 405<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 3<br><br> -Subparagraph a, b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableGrossCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3-4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a(1)<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7512638&amp;loc=d3e5074-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2012 (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 3.96% for Michigan State Corporate taxes, the blended rate used was 37.96%) and December 31, 2011, (computed by applying the Federal Corporate tax rate of 32.13% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows <i>(in thousands):</i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;"><b>2012</b></font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;"><b>2011</b></font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 66%;"><font style="font: 10pt times new roman, times, serif;">Computed &#8220;expected&#8221; tax benefit - Federal</font></td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="text-align: right; width: 14%;">(5,803</td>
<td style="width: 1%;">)</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="text-align: right; width: 14%;"><font style="font: 10pt times new roman, times, serif;">(2,618</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Computed &#8220;expected&#8221; tax benefit - State</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">(676</td>
<td>)</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">(448</font></td>
<td><font style="font: 10pt times new roman, times, serif;">)</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Meals, entertainment and other</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">5</td>
<td></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">5</font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Non-deductible stock-based compensation</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">518</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">366</font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Warrant expense</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">-</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">562</font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Change in fair value of warrant expense</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">-</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">91</font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Realized loss on debt securities</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">-</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">7</font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Change in valuation allowance</font></td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5,956</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">2,035</font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">-</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">-</font></td>
<td>&#160;</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The effects of temporary differences that gave rise to significant portions of deferred tax assets at December 31, 2012 and 2011 are as follows <i>(in thousands):</i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;"><b>Deferred&#160;tax&#160;assets:</b></font></td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;"><b>2012</b></font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;"><b>2011</b></font></td>
<td>&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 66%;"><font style="font: 10pt times new roman, times, serif;">Stock issued for services</font></td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="text-align: right; width: 14%;">318</td>
<td style="width: 1%;"></td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="text-align: right; width: 14%;"><font style="font: 10pt times new roman, times, serif;">321</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;"></font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Bad debt &#8211; change in allowance</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">1,099</td>
<td></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">205</font></td>
<td><font style="font: 10pt times new roman, times, serif;"></font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Stock issued for acquisition of program</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">527</td>
<td></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">-</td>
<td>&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Net operating loss carry-forward</font></td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">14,964</td>
<td></td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">10,425</font></td>
<td></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Total gross deferred tax assets</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">16,908</td>
<td></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">10,951</font></td>
<td><font style="font: 10pt times new roman, times, serif;"></font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Less valuation allowance</font></td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(16,908</td>
<td>)</td>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">(10,951</font></td>
<td>)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;">Net deferred tax assets</font></td>
<td>&#160;</td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">&#160;&#160;&#160;-</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">-</font></td>
<td>&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Repurchase Program (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare', window );">Subsidiary or Equity Method Investee, Price-Per-Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</a></td>
        <td class="nump">81,482<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount', window );">Stock Repurchase Program, Remaining Authorized Repurchase Amount</a></td>
        <td class="nump">$ 50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred Stock, Redemption Price Per Share</a></td>
        <td class="nump">$ 0.61<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 20<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRepurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 7<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockRedemptionPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The remaining repurchase amount authorized by an entity's Board of Directors under a stock repurchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price-per-share of common or preferred stock issued or sold by the subsidiary or equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section H<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsidiaryOrEquityMethodInvesteePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6LAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 5) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Warrant [Member]

</div>
          <div>Commitment Date [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 28, 2011

</div>
          <div>Warrant [Member]

</div>
          <div>Commitment Date [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 06, 2011

</div>
          <div>Warrant [Member]

</div>
          <div>Remeasurement Date [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 28, 2011

</div>
          <div>Warrant [Member]

</div>
          <div>Remeasurement Date [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice', window );">Closing stock price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.39<span></span></td>
        <td class="nump">$ 2.08<span></span></td>
        <td class="nump">$ 2.08<span></span></td>
        <td class="nump">$ 0.84<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
        <td class="nump">110.00%<span></span></td>
        <td class="nump">174.00%<span></span></td>
        <td class="nump">117.10%<span></span></td>
        <td class="nump">112.10%<span></span></td>
        <td class="nump">104.60%<span></span></td>
        <td class="nump">105.60%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.26%<span></span></td>
        <td class="nump">0.71%<span></span></td>
        <td class="nump">0.28%<span></span></td>
        <td class="nump">0.29%<span></span></td>
        <td class="nump">0.29%<span></span></td>
        <td class="nump">0.21%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">1 year 29 days<span></span></td>
        <td class="text">1 year 29 days<span></span></td>
        <td class="text">10 months 6 days<span></span></td>
        <td class="text">1 year 15 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Closing stock price of share-based payment award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsClosingStockPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">110.00%<span></span></td>
        <td class="nump">174.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk fee interest rate</a></td>
        <td class="nump">0.26%<span></span></td>
        <td class="nump">0.71%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod', window );">Expected forfeitures</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne', window );">Exercise price</a></td>
        <td class="nump"> 1.69<span></span></td>
        <td class="nump"> 0.49<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">108.00%<span></span></td>
        <td class="nump">175.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk fee interest rate</a></td>
        <td class="nump">0.37%<span></span></td>
        <td class="nump">1.30%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne', window );">Exercise price</a></td>
        <td class="nump"> 2.47<span></span></td>
        <td class="nump"> 2.22<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">174.00%<span></span></td>
        <td class="nump">188.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk fee interest rate</a></td>
        <td class="nump">1.98%<span></span></td>
        <td class="nump">3.58%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">7 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were expected to be cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsStocksIssuedForServices', window );">Stock issued for services</a></td>
        <td class="nump">$ 318<span></span></td>
        <td class="nump">$ 321<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsBadDebts', window );">Bad debt - change in allowance</a></td>
        <td class="nump">1,099<span></span></td>
        <td class="nump">205<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram', window );">Stock issued for acquisition of program</a></td>
        <td class="nump">527<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forward</a></td>
        <td class="nump">14,964<span></span></td>
        <td class="nump">10,425<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
        <td class="nump">16,908<span></span></td>
        <td class="nump">10,951<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAmount', window );">Less valuation allowance</a></td>
        <td class="num">(16,908)<span></span></td>
        <td class="num">(10,951)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsBadDebts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from bad debts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DeferredTaxAssetsBadDebts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Stock issued for acquisition of program.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsStocksIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stocks issued for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DeferredTaxAssetsStocksIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComponentsOfDeferredTaxAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsLiabilitiesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6969291&amp;loc=d3e28680-109314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the valuation allowance recorded as of the balance sheet date pertaining to the specified deferred tax asset for which an assessment was made that it is more likely than not that all or a portion of such deferred tax asset will not be realized through related deductions on future tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Valuation Allowance<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528051<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowanceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENECI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 06, 2011</div>
        </th>
        <th class="th">
          <div>Jan. 28, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Prev Abr Llc [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2012

</div>
          <div>Private Placement [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
        <td class="nump">1,688,782<span></span></td>
        <td class="nump">2,857,144<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,750,000<span></span></td>
        <td class="nump">6,750,000<span></span></td>
        <td class="nump">4,545,926<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_CommonStockClosingPricePerShare', window );">Common Stock Closing Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuanceCost', window );">Stock Issuance Cost</a></td>
        <td class="nump">$ 243,000<span></span></td>
        <td class="nump">$ 296,000<span></span></td>
        <td class="nump">$ 680,000<span></span></td>
        <td class="nump">$ 539,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for options exercised (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">374,851<span></span></td>
        <td class="nump">23,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">127,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesConsultingFees', window );">Issuance of common stock for consulting fees (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">171,796<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees', window );">Fair Value Of Stock Issued During Period Value Consulting Fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">165,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SaleOfStockForConsultingFeesPricePerShare', window );">Sale Of Stock For Consulting Fees Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.96<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants', window );">Stock Issued During Period Shares For Exercise Of Stock Options And Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">28,333<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement', window );">Stock Issued During Period Fair Value For Exclusive Channel Collaboration Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for employee compensation (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73,585<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for employee compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">94,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SaleOfStockForEmploymentServicePricePerShare', window );">Sale Of Stock For Employment Service Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.29<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised', window );">Stock Issued During Period Shares Stock Cashless Warrants Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,615<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,552,210<span></span></td>
        <td class="nump">3,123,558<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Equity Issued in Business Combination, Fair Value Disclosure</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,800,000<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SaleOfStockForChannelAgreementPricePerShare', window );">Sale Of Stock For Channel Agreement Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.20<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 1.87<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Stock Issued During Period Shares Stock Warrants Exercised</a></td>
        <td class="nump">844,391<span></span></td>
        <td class="nump">1,428,572<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod', window );">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,768,167<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement', window );">Proceeds From Issuance Of Common Stock For Exclusive Channel Collaboration Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,552,210<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">625,000<span></span></td>
        <td class="nump">3,125,000<span></span></td>
        <td class="nump">625,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Noninterest Expense Offering Cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 680,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_CommonStockClosingPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock closing price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_CommonStockClosingPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock issued during the period as a result of consulting fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_FairValueOfStockIssuedDuringPeriodValueConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution for exclusive channel collaboration agreement to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_SaleOfStockForChannelAgreementPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold for Channel Agreement with Intrexon.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_SaleOfStockForChannelAgreementPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_SaleOfStockForConsultingFeesPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold for consulting service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_SaleOfStockForConsultingFeesPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_SaleOfStockForEmploymentServicePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold for Employment service.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_SaleOfStockForEmploymentServicePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share warrants exercised during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuanceCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issuance Cost during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuanceCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value of stock issued during the period For Exclusive Channel Collaboration Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodFairValueForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of consulting fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period For Exclusive Channel Collaboration Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period in connection with the exercise of stock options and warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesForExerciseOfStockOptionsAndWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of cashless stock warrants exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesStockCashlessWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesStockWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of stock warrants exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesStockWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity issued in a business combination, valued at fair value by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7578670&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoninterestExpenseOfferingCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
        <td class="text"><table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0in;">&#160;</td>
<td style="width: 0.5in;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><b>1.</b></font></td>
<td><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><b>Organization and Nature of Operations and Basis of Presentation</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px 0pt 0.5in; text-indent: -0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"><b><i>Description of Business</i></b></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a<font style="color: black;"> biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of<i> C. difficile</i> infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and <i>Acinetobacter</i> infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis, and has partnered the development of a treatment for fibromyalgia.</font></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0">
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="width: 27%; text-align: center; font-family: times new roman, times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><b>Therapeutic Area</b></font></td>
<td style="width: 2%; text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="width: 27%; text-align: center; font-family: times new roman, times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><b>Product Candidate</b></font></td>
<td style="width: 2%; text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="width: 42%; text-align: center; font-family: times new roman, times, serif; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><b>Status</b></font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Relapsing-remitting MS</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="font-family: times new roman, times, serif;">
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: times new roman, times, serif;">Trimesta</font></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: times new roman, times, serif;">(oral estriol)</font></p>
</td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Patients fully enrolled in Phase II clinical trial;</font><font style="font-family: times new roman, times, serif;"><br  /> <font style="font-size: 10pt;">dosing and monitoring underway</font></font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Cognitive dysfunction in MS</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="font-family: times new roman, times, serif;">
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: times new roman, times, serif;">Trimesta</font></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: times new roman, times, serif;">(oral estriol)</font></p>
</td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Patient enrollment underway in Phase II</font><font style="font-family: times new roman, times, serif;"><br  /> <font style="font-size: 10pt;">clinical trial</font></font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><i>C. difficile</i> infection prevention</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">SYN-004</font><font style="font-family: times new roman, times, serif;"><br  /> <font style="font-size: 10pt;">(monoclonal antibody)</font></font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="font-family: times new roman, times, serif;">
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: times new roman, times, serif;">Series of oral enzyme candidates; first generation candidate (formerly known as P1A) is in Phase II;</font></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: times new roman, times, serif;">next generation candidate, SYN-004, (formerly known as P3A) is in preclinical</font></p>
</td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Pertussis</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">SYN-005</font><font style="font-family: times new roman, times, serif;"><br  /> <font style="font-size: 10pt;">(monoclonal antibody)</font></font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Preclinical; Collaborations with Intrexon and The University of Texas at Austin</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;"><i>Acinetobacter </i>infection</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">SYN-001</font><font style="font-family: times new roman, times, serif;"><br  /> <font style="font-size: 10pt;">(monoclonal antibody)</font></font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Discovery; Collaboration with Intrexon</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
</tr>
<tr style="font-family: times new roman, times, serif; vertical-align: top;">
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Fibromyalgia</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Effirma</font><font style="font-family: times new roman, times, serif;"><br  /> <font style="font-size: 10pt;">(oral flupirtine)</font></font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font-family: times new roman, times, serif;">&#160;</font></td>
<td style="text-align: center; font-family: times new roman, times, serif;"><font style="font: 10pt/normal times new roman, times, serif; font-size-adjust: none; font-stretch: normal;">Partnered with Meda AB</font></td>
</tr>
</table>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">To prioritize the Company&#8217;s focus on the<font style="color: black;"> development of product candidates for the prevention and treatment of serious infectious diseases, it does not intend to pursue</font> further development of the previously announced program for pulmonary arterial hypertension. However, the Company is currently in discussions with Intrexon to substitute this program with an alternate program better suited to its current objectives and focus.</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">In order to further prioritize the Company&#8217;s focus, it has elected to discontinue further development of AEN-100 for the treatment of amyotrophic lateral sclerosis. However, the Company is currently seeking development partners for its zinc-based intellectual property and assets including, AEN-100.</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"><b><i>Basis of Presentation and Corporate Structure</i></b></p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">As of December 31, 2012, the Company had seven subsidiaries, Pipex Therapeutics, Inc. (&#8220;Pipex Therapeutics&#8221;), Effective Pharmaceuticals, Inc. (&#8220;EPI&#8221;), Solovax, Inc. (&#8220;Solovax&#8221;), CD4 Biosciences, Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals, Inc. (&#8220;Epitope&#8221;), Healthmine, Inc. (&#8220;Healthmine&#8221;) and Putney Drug Corp. (&#8220;Putney&#8221;). As of December 31, 2012, Pipex Therapeutics, EPI, Healthmine and Putney are wholly owned and Solovax, CD4 and Epitope are majority-owned.</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics, Inc. All statements of operations, stockholders&#8217; equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January 8, 2001, except for EPI, which was incorporated in Delaware on December 12, 2000, Epitope which was incorporated in Delaware in January of 2002, Putney which was incorporated in Delaware in November of 2006 and Healthmine which was formed in Delaware in December of 2007.</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p>
<p style="font: 10pt/normal times new roman, times, serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner, in consideration for (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note secured by all the assets of the Lab. Accordingly, this business has been presented in the consolidated financial statements as discontinued operations. This transaction is described in more detail in Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS140-4/FIN46(R)-8<br><br> -Paragraph 8, C1, C7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4, 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7880789&amp;loc=SL6228881-111685<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]B9#5E.#(T9E]C-S$T7S1F9C-?.#0Q-U\W.6,U
M9CDQ9F1B.3$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0VAA/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0VAA,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;G-O
M;&ED871E9%]3=&%T96UE;G1S7V]F7T-A<S$\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#@N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A;FEZ871I;VY?86YD7TYA='5R95]O
M9E]/<&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$:7-C;VYT:6YU961?3W!E<F%T:6]N
M<U]O9E]!9&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y396QE8W1E9%]"86QA;F-E7U-H965T7TEN9F]R;6$\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A
M=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T
M;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y,:6-E;G-E7T-O;&QA8F]R871I=F5?86YD7T5M<&P\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]297!U
M<F-H87-E7U!R;V=R86T\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y7U1R86YS86-T:6]N<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?
M4VEG;FEF:6-A;G1?06-C;W5N=#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0R
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&ES8V]N
M=&EN=65D7T]P97)A=&EO;G-?;V9?061E,3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-E;&5C=&5D7T)A;&%N8V5?4VAE971?26YF
M;W)M83$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]486)L97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C,N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,:6-E;G-E7T-O;&QA8F]R871I=F5?
M86YD7T5M<&PQ/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^26YC;VUE7U1A>&5S7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?3F%T=7)E7V]F7T]P
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM
M87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!
M8V-O=6YT-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#4\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$:7-C;VYT:6YU961?3W!E<F%T
M:6]N<U]O9E]!9&4R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^1&ES8V]N=&EN=65D7T]P97)A=&EO;G-?;V9?061E,SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1I<V-O;G1I;G5E9%]/
M<&5R871I;VYS7V]F7T%D930\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y396QE8W1E9%]"86QA;F-E7U-H965T7TEN9F]R;6$R/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5L96-T961?
M0F%L86YC95]3:&5E=%]);F9O<FUA,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-E;&5C=&5D7T)A;&%N8V5?4VAE971?26YF;W)M
M830\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,S4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y396QE
M8W1E9%]"86QA;F-E7U-H965T7TEN9F]R;6$U/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?
M1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#,W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W1O8VM"87-E9%]#;VUP96YS871I;VY?1&5T86EL,3PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T
M:6]N7T1E=&%I;#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]$971A:6PS/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#0P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP
M96YS871I;VY?1&5T86EL-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T;V-K0F%S961?0V]M<&5N<V%T:6]N7T1E=&%I;#4\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D
M7T-O;7!E;G-A=&EO;E]$971A:6PV/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0S+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?1&5T86EL
M-SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970T-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M0F%S961?0V]M<&5N<V%T:6]N7T1E=&%I;#@\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#4N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]$
M971A:6PY/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W1O8VMH;VQD97)S7T5Q=6ET>5]$971A:6QS7U1E/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0W
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&EC96YS95]#;VQL86)O<F%T:79E
M7V%N9%]%;7!L,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970T."YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/DQI8V5N<V5?0V]L;&%B;W)A=&EV95]A;F1?16UP;#,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:U]297!U<F-H87-E
M7U!R;V=R86U?1&5T86D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]$971A:6QS7S$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?
M5&%X97-?1&5T86EL<U]497AT=6%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4S+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G-?1&5T
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#4T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(
M4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53
M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E
M/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD
M;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB
M;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*
M("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O
M9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?
M-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D
M-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S
M+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$584D%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#(W+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/E-Y;G1H971I8R!":6]L;V=I8W,L($EN8RX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L
M($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P
M,#@Y-#$U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R
M($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3;6%L
M;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^<WEN/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T
M;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0T+#8U-"PT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C$P+4L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y$96,@,S$L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D99/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%=E;&PM2VYO=VX@4V5A<V]N960@27-S=65R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%9O
M;'5N=&%R>2!&:6QE<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/DYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;G1I='D@0W5R<F5N="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#Y997,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!0=6)L:6,@1FQO
M870\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#0L.38Y+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U
M93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y
M8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$50
M64%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA
M;F-E(%-H965T<R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T
M:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^07-S971S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.2PY-30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-C<X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT
M<R!R96-E:79A8FQE("T@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!C=7)R96YT
M(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU,#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^07-S971S(&]F(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-#8S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPQ
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@;F]T92!R96-E
M:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M97!O<VET<R!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@07-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPT,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#0W-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI
M=&EE<R!A;F0@4W1O8VMH;VQD97)S)R!%<75I='D\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!#=7)R96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E-T;V-K:&]L9&5R<R<@17%U:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("0P+C`P,2!P
M87(@=F%L=64[(#$P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L(&YO;F4@
M:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N,#`Q('!A<B!V86QU93L@
M,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L(#0T+#0T-"PR,S`@:7-S
M=65D(&%N9"`T-"PS-C(L-S0X(&]U='-T86YD:6YG(&%N9"`S,2PS-S0L,#`R
M(&ES<W5E9"!A;F0@,S$L,CDR+#4R,"!O=71S=&%N9&EN9SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN
M(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+#DR
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4X+#DP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-C@L.30Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q+#@W,RD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!3=&]C:VAO
M;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,L,#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPP-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!,:6%B:6QI=&EE<R!A;F0@4W1O8VMH;VQD
M97)S)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3,L-#(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`W+#0W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?
M-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,#,N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5#34%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O
M;&ED871E9"!"86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E("AI;B!D;VQL87)S
M('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@9&]L
M;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R
M:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,L(&ES<W5E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-#0T+#(S,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#,W
M-"PP,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PS-C(L-S0X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,CDR+#4R
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U
M93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y
M8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$
M6$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T
M96UE;G1S(&]F($]P97)A=&EO;G,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L
M(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^3W!E<F%T:6YG($-O<W1S(&%N9"!%>'!E;G-E<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M
M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-2PP,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L-3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#(X-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S0P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M3W!E<F%T:6YG($5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-RPR.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#DR.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@9G)O;2!/<&5R871I;VYS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPR.3DI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2PY,C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D]T:&5R($EN8V]M92`H17AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#DR*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E(&EN
M(&9A:7(@=F%L=64@;V8@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&EN8V]M
M92`H97AP96YS92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$X
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@3W1H97(@26YC;VUE("A%>'!E;G-E*2P@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-CDX*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M
M($-O;G1I;G5I;F<@3W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3<L,C@T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<L-C(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE("A,;W-S*2!F<F]M($1I
M<V-O;G1I;G5E9"!/<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@U,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@86YD($-O;7!R96AE;G-I=F4@
M3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q-RPP-C@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@X+#$T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^3F5T($EN8V]M92`H3&]S<RD@4&5R(%-H87)E
M("T@0F%S:6,@86YD($1I;'5T:79E.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT:6YU:6YG(&]P97)A=&EO;G,@*&EN
M(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C(W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&ES8V]N=&EN=65D(&]P97)A=&EO;G,@
M*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@P+C`R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!);F-O;64@*$QO<W,I(%!E
M<B!3:&%R92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C(Y*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E
M<F%G92!N=6UB97(@;V8@<VAA<F5S(&]U='-T86YD:6YG(&1U<FEN9R!T:&4@
M<&5R:6]D("T@0F%S:6,@86YD($1I;'5T:79E("AI;B!S:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"PX.38L-3DR/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L-S$P+#0R
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U
M93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y
M8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$50
M,D%)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T
M96UE;G1S(&]F($-H86YG97,@:6X@4W1O8VMH;VQD97)S)R!%<75I='D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%D
M9&ET:6]N86P@4&%I9"U);B!#87!I=&%L(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E)E=&%I;F5D($5A<FYI;F=S(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1O=&%L/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T
M($1E8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0W+#(X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H-#,L-S(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU-SD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('-H
M87)E<RD@870@1&5C+B`S,2P@,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C,L,S,X+#<P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3<S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDW,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E;7!L;WEE92!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E;7!L;WEE92!C;VUP96YS871I
M;VX@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<S+#4X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E>&-L=7-I
M=F4@8VAA;FYE;"!C;VQL86)O<F%T:6]N(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C@T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@9F]R(&5X8VQU<VEV92!C:&%N;F5L(&-O;&QA8F]R
M871I;VX@86=R965M96YT("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$R,RPU-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!F;W(@8V]N<W5L=&EN9R!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M(&9O<B!C;VYS=6QT:6YG(&9E97,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$W,2PW.38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:R!F;W(@<W1O8VL@;W!T:6]N<R!A;F0@=V%R<F%N=',@97AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<W1O8VL@;W!T:6]N<R!A;F0@
M=V%R<F%N=',@97AE<F-I<V5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS."PY-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPY-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY-C$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S("AI;B!S:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#4T-2PY,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A
M;G0@;&EA8FEL:71Y(')E8VQA<W-I9FEE9"!T;R!S=&]C:VAO;&1E<G,G(&5Q
M=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S,T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-S,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X+#$T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@X+#$T.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU."PY,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,2PX-S,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP
M-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@,C`Q,3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$L,CDR+#4R,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PX-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PX-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F
M;W(@97AC;'5S:79E(&-H86YN96P@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@Q,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#@Q-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E>&-L=7-I=F4@8VAA;FYE
M;"!C;VQL86)O<F%T:6]N(&%G<F5E;65N="`H:6X@<VAA<F5S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU-3(L,C$P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@9F]R(&%C<75I<VET:6]N(&]F('!R;V=R86T@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@86-Q=6ES:71I;VX@
M;V8@<')O9W)A;2!A<W-E=',@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!F;W(@<W1O8VL@;W!T:6]N<R!A;F0@=V%R<F%N=',@97AE<F-I<V5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP.#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP.#(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<W1O8VL@;W!T:6]N<R!A
M;F0@=V%R<F%N=',@97AE<F-I<V5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#$T,RPP,3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O
M;6UO;B!S=&]C:RP@;F5T(&]F(&ES<W5A;F-E(&-O<W1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3$S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#$R,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K+"!N970@;V8@:7-S=6%N8V4@8V]S=',@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-S4P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3<L,#8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$W+#`V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#$L.3(U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V."PY
M-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,RPP,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@
M,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L,S8R+#<T
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U
M93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y
M8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)
M0D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T
M96UE;G1S(&]F($-H86YG97,@:6X@4W1O8VMH;VQD97)S)R!%<75I='D@*%!A
M<F5N=&AE=&EC86PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%P<BX@,#8L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2F%N+B`R."P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5A;F-E($-O
M<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C0S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R.38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-3,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]B9#5E.#(T9E]C-S$T7S1F9C-?.#0Q-U\W.6,U9CDQ9F1B.3$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8F0U93@R-&9?8S<Q-%\T9F8S
M7S@T,3=?-SEC-68Y,69D8CDQ+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P135'0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A
M=&5D(%-T871E;65N=',@;V8@0V%S:"!&;&]W<R`H55-$("0I/&)R/DEN(%1H
M;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@1FQO
M=W,@1G)O;2!/<&5R871I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<L,#8X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H."PQ-#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@
M8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C
M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M.#4Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:R!I<W-U960@87,@8V]M<&5N<V%T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!F;W(@
M8V]N<W5L=&EN9R!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:R!I<W-U960@9F]R(&5X8VQU<VEV92!C:&%N;F5L(&-O
M;&QA8F]R871I;VX@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#@Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@9F]R(&%C<75I<VET
M:6]N(&]F('!R;V=R86T@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#$V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU
M92!O9B!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N(&9O<B!U;F-O;&QE8W1I
M8FQE(&%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!S86QE(&]F(&1I<V-O;G1I;G5E
M9"!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06UO<G1I>F%T:6]N(&]F('!R96UI=6T@;VX@:6YV97-T;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!S
M86QE(&]F('-H;W)T+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O;B!S86QE(&]F(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE
M;G0@;VX@;&]S<R!O9B!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1V%I;B!O;B!T:&4@<V5T=&QE;65N="!O9B!A8V-O
M=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@
M;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-#@P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L-30T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5P;W-I=',@86YD(&]T:&5R(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S(&]F
M(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B
M:6QI=&EE<R!O9B!D:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H(%5S960@26X@
M3W!E<F%T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#@L.3$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(L.#<U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S($9R;VT@
M26YV97-T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F('-H;W)T+71E<FT@:6YV
M97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#,W
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;V-E961S(&9R;VT@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,CDS/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O
M9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!S86QE(&]F(&5Q
M=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@0V%S:"!5<V5D($EN($EN=F5S=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!&
M;&]W<R!&<F]M($9I;F%N8VEN9R!!8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<W1O8VL@;W!T:6]N(&%N9"!W
M87)R86YT(&5X97)C:7-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPP.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@9F]R(&5X8VQU<VEV92!C:&%N;F5L(&-O;&QA8F]R871I;VX@86=R
M965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!T:&4@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K+"!N970@
M;V8@:7-S=6%N8V4@8V]S=',@;V8@)#8X,"!A;F0@)#4S.2P@<F5S<&5C=&EV
M96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PQ,C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DV
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!#87-H(%!R;W9I9&5D($)Y($9I;F%N8VEN9R!!8W1I=FET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPR,#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DW.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!I;F-R96%S92!I;B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#(W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L,#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&)E9VEN;FEN9R!O9B!Y96%R
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#8W.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C0Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&%T(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY+#DU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L-C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S
M=7)E<R!O9B!C87-H(&9L;W<@:6YF;W)M871I;VXZ/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@:6YT
M97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M('!A:60@9F]R('1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@9&ES8VQO<W5R97,@;V8@;F]N
M+6-A<V@@:6YV97-T:6YG(&%N9"!F:6YA;F-I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;&%S
M<VEF:6-A=&EO;B!O9B!W87)R86YT(&QI86)I;&ET>2!T;R!A9&1I=&EO;F%L
M('!A:60M:6XM8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+#<S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?
M-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,#@N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5)1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI
M9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A087)E;G1H971I8V%L
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y087EM96YT<R!O9B!3=&]C:R!)<W-U86YC92!#;W-T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4S.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S
M7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K
M<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX@86YD($YA='5R92!O9B!/<&5R871I
M;VYS(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N
M+"!#;VYS;VQI9&%T:6]N(&%N9"!0<F5S96YT871I;VX@3V8@1FEN86YC:6%L
M(%-T871E;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ871I;VXL($-O;G-O;&ED871I
M;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA;F-I86P@4W1A=&5M96YT<R!$
M:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,&EN.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SX\8CXQ+CPO8CX\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
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M="`P<'@@,'!T(#`N-6EN.R!T97AT+6EN9&5N=#H@+3`N-6EN.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^/&(^/&D^1&5S8W)I<'1I;VX@;V8@0G5S:6YE
M<W,\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/"]P/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!T(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/E-Y;G1H971I8R!":6]L;V=I8W,L($EN
M8RX@*'1H92`F(S@R,C`[0V]M<&%N>28C.#(R,3L@;W(@)B,X,C(P.U-Y;G1H
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M=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL
M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T
M:#H@,C<E.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#%P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CY4
M:&5R87!E=71I8R!!<F5A/"]B/CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`R)3L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
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M='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#0R)3L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
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M.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
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M;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^4F5L
M87!S:6YG+7)E;6ET=&EN9R!-4SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ92UA
M9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^5')I;65S=&$\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
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M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M<RP@<V5R:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^5')I;65S=&$\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
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M<RP@<V5R:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS
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M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
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M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[)SY364XM,#`T/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQB<B`@+SX@/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^*&UO
M;F]C;&]N86P@86YT:6)O9'DI/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^4V5R:65S(&]F(&]R86P@96YZ>6UE(&-A;F1I9&%T97,[
M(&9I<G-T(&=E;F5R871I;VX@8V%N9&ED871E("AF;W)M97)L>2!K;F]W;B!A
M<R!0,4$I(&ES(&EN(%!H87-E($E).SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^;F5X="!G96YE<F%T:6]N(&-A;F1I9&%T92P@4UE.
M+3`P-"P@*&9O<FUE<FQY(&MN;W=N(&%S(%`S02D@:7,@:6X@<')E8VQI;FEC
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M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M;6%N+"!T:6UE<RP@<V5R:68[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT
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M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[)SY364XM,#`U/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQB<B`@+SX@/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^*&UO
M;F]C;&]N86P@86YT:6)O9'DI/"]F;VYT/CPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N
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M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
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M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I
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M4UE.+3`P,3PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM
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M;'DZ('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M=&EM97,L('-E<FEF.R<^/&)R("`O/B`\9F]N="!S='EL93TS1"=F;VYT+7-I
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M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P="`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^5&\@<')I;W)I=&EZ
M92!T:&4@0V]M<&%N>28C.#(Q-SMS(&9O8W5S(&]N('1H93QF;VYT('-T>6QE
M/3-$)V-O;&]R.B!B;&%C:SLG/B!D979E;&]P;65N="!O9B!P<F]D=6-T(&-A
M;F1I9&%T97,@9F]R('1H92!P<F5V96YT:6]N(&%N9"!T<F5A=&UE;G0@;V8@
M<V5R:6]U<R!I;F9E8W1I;W5S(&1I<V5A<V5S+"!I="!D;V5S(&YO="!I;G1E
M;F0@=&\@<'5R<W5E/"]F;VYT/B!F=7)T:&5R(&1E=F5L;W!M96YT(&]F('1H
M92!P<F5V:6]U<VQY(&%N;F]U;F-E9"!P<F]G<F%M(&9O<B!P=6QM;VYA<GD@
M87)T97)I86P@:'EP97)T96YS:6]N+B!(;W=E=F5R+"!T:&4@0V]M<&%N>2!I
M<R!C=7)R96YT;'D@:6X@9&ES8W5S<VEO;G,@=VET:"!);G1R97AO;B!T;R!S
M=6)S=&ET=71E('1H:7,@<')O9W)A;2!W:71H(&%N(&%L=&5R;F%T92!P<F]G
M<F%M(&)E='1E<B!S=6ET960@=&\@:71S(&-U<G)E;G0@;V)J96-T:79E<R!A
M;F0@9F]C=7,N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/DEN(&]R9&5R('1O(&9U<G1H97(@<')I;W)I=&EZ92!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&9O8W5S+"!I="!H87,@96QE8W1E9"!T;R!D:7-C;VYT:6YU
M92!F=7)T:&5R(&1E=F5L;W!M96YT(&]F($%%3BTQ,#`@9F]R('1H92!T<F5A
M=&UE;G0@;V8@86UY;W1R;W!H:6,@;&%T97)A;"!S8VQE<F]S:7,N($AO=V5V
M97(L('1H92!#;VUP86YY(&ES(&-U<G)E;G1L>2!S965K:6YG(&1E=F5L;W!M
M96YT('!A<G1N97)S(&9O<B!I=',@>FEN8RUB87-E9"!I;G1E;&QE8W1U86P@
M<')O<&5R='D@86YD(&%S<V5T<R!I;F-L=61I;F<L($%%3BTQ,#`N/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!T(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'0@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4M861J=7-T.B!N
M;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P="`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^/&(^/&D^0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!#;W)P;W)A
M=&4@4W1R=6-T=7)E/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^07,@;V8@1&5C96UB97(@,S$L(#(P,3(L('1H92!#
M;VUP86YY(&AA9"!S979E;B!S=6)S:61I87)I97,L(%!I<&5X(%1H97)A<&5U
M=&EC<RP@26YC+B`H)B,X,C(P.U!I<&5X(%1H97)A<&5U=&EC<R8C.#(R,3LI
M+"!%9F9E8W1I=F4@4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[15!)
M)B,X,C(Q.RDL(%-O;&]V87@L($EN8RX@*"8C.#(R,#M3;VQO=F%X)B,X,C(Q
M.RDL($-$-"!":6]S8VEE;F-E<RP@26YC+B`H)B,X,C(P.T-$-"8C.#(R,3LI
M+"!%<&ET;W!E(%!H87)M86-E=71I8V%L<RP@26YC+B`H)B,X,C(P.T5P:71O
M<&4F(S@R,C$[*2P@2&5A;'1H;6EN92P@26YC+B`H)B,X,C(P.TAE86QT:&UI
M;F4F(S@R,C$[*2!A;F0@4'5T;F5Y($1R=6<@0V]R<"X@*"8C.#(R,#M0=71N
M97DF(S@R,C$[*2X@07,@;V8@1&5C96UB97(@,S$L(#(P,3(L(%!I<&5X(%1H
M97)A<&5U=&EC<RP@15!)+"!(96%L=&AM:6YE(&%N9"!0=71N97D@87)E('=H
M;VQL>2!O=VYE9"!A;F0@4V]L;W9A>"P@0T0T(&%N9"!%<&ET;W!E(&%R92!M
M86IO<FET>2UO=VYE9"X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'0@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P="`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R<^1F]R(&9I;F%N8VEA;"!R97!O<G1I;F<@<'5R<&]S97,L('1H
M92!O=71S=&%N9&EN9R!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@:7,@
M=&AA="!O9B!3>6YT:&5T:6,@0FEO;&]G:6-S+"!);F,N($%L;"!S=&%T96UE
M;G1S(&]F(&]P97)A=&EO;G,L('-T;V-K:&]L9&5R<R8C.#(Q-SL@97%U:71Y
M(&%N9"!C87-H(&9L;W=S(&9O<B!E86-H(&]F('1H92!E;G1I=&EE<R!A<F4@
M<')E<V5N=&5D(&%S(&-O;G-O;&ED871E9"X@06QL('-U8G-I9&EA<FEE<R!W
M97)E(&9O<FUE9"!U;F1E<B!T:&4@;&%W<R!O9B!T:&4@4W1A=&4@;V8@1&5L
M87=A<F4@;VX@2F%N=6%R>2`X+"`R,#`Q+"!E>&-E<'0@9F]R($5022P@=VAI
M8V@@=V%S(&EN8V]R<&]R871E9"!I;B!$96QA=V%R92!O;B!$96-E;6)E<B`Q
M,BP@,C`P,"P@17!I=&]P92!W:&EC:"!W87,@:6YC;W)P;W)A=&5D(&EN($1E
M;&%W87)E(&EN($IA;G5A<GD@;V8@,C`P,BP@4'5T;F5Y('=H:6-H('=A<R!I
M;F-O<G!O<F%T960@:6X@1&5L87=A<F4@:6X@3F]V96UB97(@;V8@,C`P-B!A
M;F0@2&5A;'1H;6EN92!W:&EC:"!W87,@9F]R;65D(&EN($1E;&%W87)E(&EN
M($1E8V5M8F5R(&]F(#(P,#<N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86P[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'0@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4M
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M*&EI*2`D-S`P+#`P,"!P87EA8FQE('!U<G-U86YT('1O('1H92!T97)M<R!O
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M:6X@;6]R92!D971A:6P@:6X@3F]T92`S("8C.#(Q,3L@1&ES8V]N=&EN=65D
M($]P97)A=&EO;G,@;V8@061E;VYA($-L:6YI8V%L($QA8F]R871O<GDN/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U
M93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y
M8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E;G1A=&EO;B!A;F0@4VEG;FEF:6-A
M;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;5&5X="!";&]C:UT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL93TS1"=W:61T:#H@
M,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P:6X[)SX\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O
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M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E
M;G0Z("TP+C5I;CL@;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^/&(^
M/&D^4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T:6]N/"]I/CPO8CX\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^/&(^/&D^16UE<F=I;F<@9G)O
M;2!T:&4@1&5V96QO<&UE;G0@4W1A9V4\+VD^/"]B/CPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/D1U<FEN9R!T:&4@<V5C;VYD('%U87)T97(@;V8@,C`Q,"P@=&AE
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M979E;G5E+B8C,38P.T]N($UA>2`V+"`R,#$P+"!T:&4@0V]M<&%N>2!E;G1E
M<F5D(&EN=&\@82!3=6)L:6-E;G-E($%G<F5E;65N="`H=&AE("8C.#(R,#M-
M961A($%G<F5E;65N="8C.#(R,3LI('=I=&@@365D828C,38P.T%"(&]F(%-W
M961E;B`H)B,X,C(P.TUE9&$F(S@R,C$[*2!A;F0@<F5C96EV960@86X@=7`M
M9G)O;G0@<&%Y;65N="!O9B`D,BXU(&UI;&QI;VXN(%1H92!E>&5C=71I;VX@
M;V8@=&AE($UE9&$@06=R965M96YT(&-O;6)I;F5D('=I=&@@<F5V96YU97,@
M9G)O;2!!9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>2!W97)E(&%N(&EN9&EC
M871I;VX@;V8@=&AE(&-O;6UE;F-E;65N="!O9B!P<FEN8VEP86P@;W!E<F%T
M:6]N<RP@86YD('1H97)E9F]R92!D979E;&]P;65N="US=&%G92!R97!O<G1I
M;F<@=V%S(&YO(&QO;F=E<B!R97%U:7)E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SX\8CX\:3Y5<V4@;V8@17-T:6UA=&5S/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
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M871I;F<@;&]S<V5S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
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M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SX\8CX\:3Y!8V-O=6YT<R!296-E:79A8FQE(&%N9"!!;&QO=V%N
M8V4@9F]R($1O=6)T9G5L($%C8V]U;G1S/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
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M9G5L(&%C8V]U;G1S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CQB/CQI/E)E=F5N
M=64@4F5C;V=N:71I;VX\+VD^/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
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M96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2P@=&AE($-O;7!A;GDF(S@R,3<[
M<R!O;FQY('-T<F5A;2!O9B!R979E;G5E('=A<R!L86)O<F%T;W)Y(')E=F5N
M=64N)B,Q-C`[)B,Q-C`[3&%B;W)A=&]R>2!R979E;G5E<R!A<F4@82!C;VUP
M;VYE;G0@;V8@9&ES8V]N=&EN=65D(&]P97)A=&EO;G,@9F]R('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2X@4V5E($YO=&4@
M,R`F(S@R,3$[($1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N82!#
M;&EN:6-A;"!,86)O<F%T;W)Y+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
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M<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M96QA=&5D(&9E97,@8F5C;VUE(&1U92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^26X@,C`Q,"P@=&AE($-O
M;7!A;GD@96YT97)E9"!I;G1O('1H92!-961A($%G<F5E;65N="!F;W(@=&AE
M(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!%9F9I<FUA
M("AO<F%L(&9L=7!I<G1I;F4I(&9O<B!F:6)R;VUY86QG:6$N)B,Q-C`[($%S
M(&-O;G-I9&5R871I;VX@9F]R('1H92!S=6)L:6-E;G-E+"!T:&4@0V]M<&%N
M>2!R96-E:79E9"!A;B!U<"UF<F]N="!P87EM96YT(&]F("0R+C4@;6EL;&EO
M;B!U<&]N(&5X96-U=&EO;B!O9B!T:&4@365D82!!9W)E96UE;G0N(%1H:7,@
M<&%Y;65N="!W87,@<F5C;W)D960@87,@;&EC96YS92!R979E;G5E(&EN(#(P
M,3`N(%!U<G-U86YT('1O('1H92!#;VUP86YY)B,X,C$W.W,@;&EC96YS92!A
M9W)E96UE;G0@=VET:"!-8TQE86X@2&]S<&ET86PL('1H92!#;VUP86YY('!A
M:60@,34E(&]F('1H92`D,BXU(&UI;&QI;VX@<&%Y;65N="`H)#,W-2PP,#`I
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M;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SX\:3Y,86)O<F%T;W)Y(%)E=F5N=65S/"]I/CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M96EP=',@9G)O;2!S=6-H('!A>65R<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
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M(&)Y(&EN<W5R86YC92!C87)R:65R<R!O=F5R('1H92!P<FEO<B`Q,B!M;VYT
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M92`S("T@1&ES8V]N=&EN=65D($]P97)A=&EO;G,@;V8@061E;VYA($-L:6YI
M8V%L($QA8F]R871O<GDN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!H96QD(&EN=F5S=&UE;G1S(&EN(&UA<FME
M=&%B;&4@<V5C=7)I=&EE<R!T:&%T('=E<F4@8VQA<W-I9FEE9"!A<R!H96QD
M('1O(&UA='5R:71Y(&%N9"!C;VYS:7-T960@;V8@8V]R<&]R871E(&)O;F1S
M(&%N9"!C97)T:69I8V%T97,@;V8@9&5P;W-I=',@87,@9F]L;&]W<R`\:3XH
M:6X@=&AO=7-A;F1S*3PO:3X@.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@-S`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=VED=&@Z(#<R)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^4'5R8VAA<V4@
M;V8@<VAO<G0M=&5R;2!I;G9E<W1M96YT<SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`R-24[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B@T+#,W,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/C0L,CDS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/CQB/CQI/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+VD^/"]B/CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
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M;&4N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]P/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`W
M,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[)SX-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#0Y)3LG(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([('=I9'1H.B`T-R4[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[
M(&9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^
M/&(^17-T:6UA=&5D)B,Q-C`[57-E9G5L)B,Q-C`[3&EF93PO8CX\+V9O;G0^
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O
M<#LG/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G('-I>F4],T0R/D]F9FEC92!E<75I<&UE;G0@86YD(&9U
M<FYI='5R93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[
M(&9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^
M,RTU)B,Q-C`[)B,Q-C`[>65A<G,\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
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M97([)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)R!S:7IE/3-$,CXW+3$P('EE87)S/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)R!S:7IE/3-$,CY-86YU9F%C='5R:6YG(&5Q=6EP;65N=#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^,3`@>65A<G,\+V9O;G0^/"]T
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M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^1&5P<F5C:6%T:6]N(&5X<&5N<V4@=V%S(&%P
M<')O>&EM871E;'D@)#8S+#`P,"!A;F0@)#$T-"PP,#`@9F]R('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2P@<F5S<&5C=&EV
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E
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M96QY("0T-RPP,#`N($9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,2P@=&AE<F4@=V5R92!N;R!S:6=N:69I8V%N="!E=F5N=',@;W(@8VAA
M;F=E<R!I;B!C:7)C=6US=&%N8V5S(&ED96YT:69I960@8GD@=&AE($-O;7!A
M;GD@=&AA="!W;W5L9"!I;F1I8V%T92!T:&%T('1H92!C87)R>6EN9R!V86QU
M92!O9B!A;B!A<W-E="!W87,@;F]T(')E8V]V97)A8FQE+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M=',\+VD^/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M<R!F86ER('9A;'5E+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CQB/CQI/D=O;V1W
M:6QL/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M9'=I;&P@=V%S(&%S<VEG;F5D+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D%30R!.
M;RX@,S4P+"`F(S@R,C`[26YT86YG:6)L97,@)B,X,C$Q.R!';V]D=VEL;"!A
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP
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M;7!A:7)E9"X@4V5E($YO=&4@,R`F(S@R,3$[($1I<V-O;G1I;G5E9"!/<&5R
M871I;VYS(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y+CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/CQB/CQI/D1E<FEV871I=F4@3&EA8FEL:71I97,\+VD^
M/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
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M-C`[861D:71I;VXL('1H92!F86ER('9A;'5E(&]F(&9R965S=&%N9&EN9R!D
M97)I=F%T:79E(&EN<W1R=6UE;G1S('-U8V@@87,@=V%R<F%N=',L(&%R92!A
M;'-O('9A;'5E9"!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I
M8VEN9R!M;V1E;"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\8CX\:3Y.970@26YC
M;VUE("A,;W-S*2!P97(@4VAA<F4\+VD^/"]B/CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M;'5T:79E+"!A="!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L
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M87(@96YD960@1&5C96UB97(@,S$L(#(P,3(@=V5R92`T+#0U,RPW-#8@86YD
M(#$L-C,R+#4P,2P@<F5S<&5C=&EV96QY+"!A;F0@9F]R('1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R(#,Q+"`R,#$Q('=E<F4@,BPY-SDL,#$P(&%N9"`S+#(U
M.2PQ.#8L(')E<W!E8W1I=F5L>2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\8CX\
M:3Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@0V]S=',\+VD^/"]B/CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
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M-SMS('!R;V1U8W0@8V%N9&ED871E<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M87,@9F]L;&]W<SH\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y
M;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@
M,R4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`S)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M<WEM8F]L.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S
M:7IE/3-$,CXF(S$X,SL\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!W:61T:#H@.30E.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^3&5V
M96P@,2!I;G!U=',Z(%%U;W1E9"!P<FEC97,@*'5N861J=7-T960I)B,Q-C`[
M9F]R(&ED96YT:6-A;"!A<W-E=',@;W(@;&EA8FEL:71I97,@:6X@86-T:79E
M(&UA<FME=',[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`M,"XR
M-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
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M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('-Y;6)O;#L[(&9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^)B,Q.#,[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=VED=&@Z(#DT)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G('-I>F4],T0R/DQE=F5L(#(@:6YP=71S.B!);G!U
M=',L(&]T:&5R('1H86X@<75O=&5D('!R:6-E<R!I;F-L=61E9"!I;B!,979E
M;"`Q('1H870@87)E(&]B<V5R=F%B;&4@96ET:&5R(&1I<F5C=&QY(&]R(&EN
M9&ER96-T;'D[(&%N9#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M+3`N,C5I;CL@;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@
M,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)3LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#,E.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!S>6UB;VP[.R!F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R/B8C,3@S
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[('=I9'1H.B`Y-"4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CY,979E;"`S(&EN<'5T<SH@
M56YO8G-E<G9A8FQE(&EN<'5T<R!F;W(@=VAI8V@@=&AE<F4@:7,@;&ET=&QE
M(&]R(&YO(&UA<FME="!D871A+"!W:&EC:"!R97%U:7)E('1H92!R97!O<G1I
M;F<@96YT:71Y('1O(&1E=F5L;W`@:71S(&]W;B!A<W-U;7!T:6]N<RX\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY);B!M86YY(&-A
M<V5S+"!A('9A;'5A=&EO;B!T96-H;FEQ=64@=7-E9"!T;R!M96%S=7)E(&9A
M:7(@=F%L=64@:6YC;'5D97,@:6YP=71S(&9R;VT@;75L=&EP;&4@;&5V96QS
M(&]F('1H92!F86ER('9A;'5E(&AI97)A<F-H>2!D97-C<FEB960@86)O=F4N
M(%1H92!L;W=E<W0@;&5V96P@;V8@<VEG;FEF:6-A;G0@:6YP=70@9&5T97)M
M:6YE<R!T:&4@<&QA8V5M96YT(&]F('1H92!E;G1I<F4@9F%I<B!V86QU92!M
M96%S=7)E;65N="!I;B!T:&4@:&EE<F%R8VAY+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M:71Y(&9O<B!T:&5S92!I;G-T<G5M96YT<RX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S(&EN8VQU9&4@;6]N97D@;6%R
M:V5T(&%C8V]U;G1S(&%N9"!M=71U86P@9G5N9',@;V8@)#@N-B!M:6QL:6]N
M(&%N9"`D-2XP(&UI;&QI;VX@87,@;V8@1&5C96UB97(@,S$L(#(P,3(@86YD
M($1E8V5M8F5R(#,Q+"`R,#$Q+"!R97-P96-T:79E;'DL('1H870@87)E(&UE
M87-U<F5D('5S:6YG($QE=F5L(#$@:6YP=71S+B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/CQB/CQI/E-T;V-K+4)A<V5D(%!A>6UE;G0@
M07)R86YG96UE;G1S/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
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M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^/&(^/&D^26YC;VUE(%1A>&5S/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SY4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@:6YC;VUE('1A>&5S
M(&EN(&%C8V]R9&%N8V4@=VET:"!A8V-O=6YT:6YG(&=U:61A;F-E(&YO=R!C
M;V1I9FEE9"!A<R!&05-"($%30R!4;W!I8R`W-#`L("8C.#(R,#L\:3Y);F-O
M;64@5&%X97,\+VD^+"8C.#(R,3L@=VAI8V@@<F5Q=6ER97,@=&AA="!T:&4@
M0V]M<&%N>2!R96-O9VYI>F4@9&5F97)R960@=&%X(&QI86)I;&ET:65S(&%N
M9"!A<W-E=',@8F%S960@;VX@=&AE(&1I9F9E<F5N8V5S(&)E='=E96X@=&AE
M(&9I;F%N8VEA;"!S=&%T96UE;G0@8V%R<GEI;F<@86UO=6YT<R!A;F0@=&AE
M('1A>"!B87-E<R!O9B!A<W-E=',@86YD(&QI86)I;&ET:65S+"!U<VEN9R!E
M;F%C=&5D('1A>"!R871E<R!I;B!E9F9E8W0@:6X@=&AE('EE87)S('1H92!D
M:69F97)E;F-E<R!A<F4@97AP96-T960@=&\@<F5V97)S92X@1&5F97)R960@
M:6YC;VUE('1A>"!B96YE9FET("AE>'!E;G-E*2!R97-U;'1S(&9R;VT@=&AE
M(&-H86YG92!I;B!N970@9&5F97)R960@=&%X(&%S<V5T<R!O<B!D969E<G)E
M9"!T87@@;&EA8FEL:71I97,N($$@=F%L=6%T:6]N(&%L;&]W86YC92!I<R!R
M96-O<F1E9"!W:&5N(&ET(&ES(&UO<F4@;&EK96QY('1H86X@;F]T('1H870@
M<V]M92!O<B!A;&P@9&5F97)R960@=&%X(&%S<V5T<R!W:6QL(&YO="!B92!R
M96%L:7IE9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY);B!A9&1I
M=&EO;BP@86-C;W5N=&EN9R!G=6ED86YC92!N;W<@8V]D:69I960@87,@1D%3
M0B!!4T,@5&]P:6,@-S0P+3(P+"`\:3XF(S@R,C`[26YC;VUE(%1A>&5S("8C
M.#(Q,3L@26YT<F%P97)I;V0@5&%X($%L;&]C871I;VXF(S@R,C$[(#PO:3YR
M97%U:7)E<SQI/B`\+VD^;6%N86=E;65N="!T;R!A<W-E<W,@=&AE(&YE960@
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M(&EN('1H92!T87@@<')O=FES:6]N+B!!="!$96-E;6)E<B`S,2P@,C`Q,B!A
M;F0@,C`Q,2P@<F5S<&5C=&EV96QY+"!T:&4@0V]M<&%N>2!D:60@;F]T(')E
M8V]R9"!A;GD@;&EA8FEL:71I97,@9F]R('5N8V5R=&%I;B!T87@@<&]S:71I
M;VYS+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CQB/CQI/E)E8V5N="!!8V-O=6YT
M:6YG(%!R;VYO=6YC96UE;G1S/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
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M+"!O<B!C87-H(&9L;W=S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N82!#;&EN
M:6-A;"!,86)O<F%T;W)Y(&%N9"!.;W1E(%)E8V5I=F%B;&4\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&ES8V]N
M=&EN=65D($]P97)A=&EO;G,@86YD($1I<W!O<V%L($=R;W5P<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1I<W!O<V%L($=R;W5P<RP@26YC;'5D:6YG($1I<V-O;G1I;G5E9"!/<&5R
M871I;VYS+"!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R<^/&9O;G0@<W1Y
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M"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TP
M+C5I;CL@;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^3VX@36%R8V@@
M."P@,C`Q,BP@=&AE($-O;7!A;GD@<V]L9"!A;&P@;V8@:71S(&EN=&5R97-T
M(&EN($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y+"!,3$,@*'1H92`F(S@R
M,C`[3&%B)B,X,C(Q.RD@=&\@2&%R=&QA8BP@3$Q#+"!A;B!E;G1I='D@8V]N
M=')O;&QE9"!B>2!T:&4@3&%B)B,X,C$W.W,@9F]R;65R(&]W;F5R+B!);B!C
M;VYN96-T:6]N('=I=&@@=&AE('-A;&4@;V8@=&AE($QA8BP@=&AE(&-O;G-I
M9&5R871I;VX@<F5C96EV960@=V%S("AI*2!T:&4@:6UM961I871E(&%S<VEG
M;FUE;G0@;V8@=&AE($QA8B8C.#(Q-SMS(&]U='-T86YD:6YG(&%C8V]U;G1S
M(')E8V5I=F%B;&4@=7`@=&AR;W5G:"!T:&4@9&%T92!O9B!C;&]S:6YG+"!P
M;'5S("AI:2D@)#<P,"PP,#`@<&%Y86)L92!P=7)S=6%N="!T;R!T:&4@=&5R
M;7,@;V8@82!T=V\M>65A<B!P<F]M:7-S;W)Y(&YO=&4@8F5A<FEN9R!I;G1E
M<F5S="!A="`U+C<E('!E<B!A;FYU;2!S96-U<F5D(&)Y(&%L;"!O9B!T:&4@
M87-S971S(&]F('1H92!,86(N(%1H92!N;W1E(&%N9"!A;&P@=6YP86ED(&EN
M=&5R97-T(&%R92!D=64@;VX@36%R8V@@,2P@,C`Q-"X\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY);B!A8V-O<F1A;F-E
M('=I=&@@05-#(%1O<&EC(#(P-2TR,"`F(S@R,C`[/&D^4')E<V5N=&%T:6]N
M(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S)B,X,C$R.T1I<V-O;G1I;G5E9"!/
M<&5R871I;VYS/"]I/B8C.#(R,3L@*$%30R`R,#4M,C`I+"!T:&4@0V]M<&%N
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M971S(&%T($1E8V5M8F5R(#,Q+"`R,#$R+"!A;F0@1&5C96UB97(@,S$L(#(P
M,3$L(&%N9"!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<@/&D^*&EN('1H;W5S
M86YD<RDZ/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N
M=#H@+3`N-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$-CX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D1E
M8V5M8F5R(#,Q+#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,C`Q,CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q)3LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
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M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E1O
M=&%L(&%S<V5T<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXR,SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^5&AE('-U;6UA<FEZ960@<W1A=&5M96YT(&]F(&]P
M97)A=&EO;G,@9&%T82!F;W(@061E;VYA($-L:6YI8V%L($QA8F]R871O<GD@
M9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@1&5C
M96UB97(@,S$L(#(P,3$@87)E(&%S(&9O;&QO=W,@/&D^*&EN('1H;W5S86YD
M<RDZ/"]I/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@
M,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@.3,E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,"XU:6X[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z
M(&)O;&0[)R!C;VQS<&%N/3-$-CX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D1E8V5M8F5R(#,Q
M+#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,C`Q,CPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
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M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3`E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ,34\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE/3-$,B!S
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^3W!E<F%T:6YG($-O
M<W1S(&%N9"!%>'!E;G-E<SH\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#EP=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+V9O;G0^
M/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXT-C8\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXU,SD\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M;&5F=#H@.7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY#;W-T(&]F)B,Q-C`[(&QA
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M)SXQ,3`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXM
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M
M;&5F=#H@.7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY4;W1A;"!O<&5R871I;F<@8V]S
M=',@86YD(&5X<&5N<V5S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ
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M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z
M(#`N,3(U:6X[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D=A:6X@;VX@<V%L92!O9B!!9&5O
M;F$@0VQI;FEC86P@3&%B;W)A=&]R>3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^-C<W/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXM/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B0\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4V5L96-T960@0F%L86YC92!3:&5E="!);F9O<FUA=&EO
M;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY/<F=A;FEZ871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A
M=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U<'!L96UE
M;G1A;"!"86QA;F-E(%-H965T($1I<V-L;W-U<F5S(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN
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M93TS1"=T97AT+6EN9&5N=#H@+3`N-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T
M(#`N-6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^06-C;W5N=',@<F5C96EV86)L92`H
M:6X@=&AO=7-A;F1S*3PO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#DS)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN+6QE9G0Z(#`N-6EN.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P/D1E8V5M
M8F5R(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!W:61T
M:#H@-S0E.R<^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/C8X,CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T
M:#H@,3`E.R<^-CDR/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SY"860@9&5B="!A;&QO=V%N8V4@+2!C=7-T
M;VUE<CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R<^*#8X,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/BD\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/B@R.#<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E1O=&%L/"]T
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M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C0P-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^)B,Q-C`[/"]I/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQI/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S
M("AI;B!T:&]U<V%N9',I/"]I/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T
M:#H@.3,E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@
M,"XU:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0V(&YO=W)A
M<#TS1&YO=W)A<#Y$96-E;6)E<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=VED=&@Z(#<T)3LG/DEN=')E>&]N('!R97!A:60@<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S("T@4V5E($YO=&4@,3`\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,"4[)SXR+#0Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^+3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
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M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG/E!R97!A:60@97AP96YS97,\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C@P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
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M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C(L-3`Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
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M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\:3XF(S$V,#L\+VD^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^/"]I/CPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/E1H92!);G1R97AO;B!P<F5P86ED(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E<R!A<F4@8VQA<W-I9FEE9"!A<R!A(&-U<G)E;G0@87-S
M970N(%1H92!#;VUP86YY(&UA>2!T97)M:6YA=&4@=&AE(&%R<F%N9V5M96YT
M(&%T(&%N>2!T:6UE(&%N9"!R96-E:79E(&$@8V%S:"!R969U;F0@;V8@=&AE
M(')E;6%I;FEN9R!B86QA;F-E(&UI;G5S(&%N>2!A;6]U;G1S(&]W960@=&\@
M26YT<F5X;VXN(%1H92!#;VUP86YY(&%N=&EC:7!A=&5S('1H870@=&AE(&UA
M:F]R:71Y(&]F('1H92!P<F5P86ED('=I;&P@8F4@87!P;&EE9"!T;R!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@9V]O9',@86YD('-E<G9I8V5S(&1U<FEN
M9R`R,#$S+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
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M/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Y,R4[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;BUL969T.B`P+C5I;CLG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0V(&YO=W)A<#TS
M1&YO=W)A<#Y$96-E;6)E<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=VED=&@Z(#<T)3LG/DUA;G5F86-T=7)I;F<@97%U:7!M96YT
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,3`E.R<^,CDW/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXT,#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^
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M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/DQA8F]R871O<GD@
M97%U:7!M96YT/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ,S,\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0V
M-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/B@R-#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C(R,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT
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M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/CQI/B8C,38P.SPO:3X\+W`^#0H\<"!S='EL
M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\:3Y!8V-R=65D(&QI86)I;&ET:65S("AI
M;B!T:&]U<V%N9',I)B,Q-C`[/"]I/CPO<#X-"CQT86)L92!S='EL93TS1"=W
M:61T:#H@.3,E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F
M=#H@,"XU:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT
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M:6=N.B!J=7-T:69Y.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#(^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
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M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXM/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,"4[)SXQ/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY#;VUP
M96YS871I;VX\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C(X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
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M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
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M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E
M($]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S+"!3:&%R92U"87-E9"!0
M87EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E
M;&%T960@0V]S=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M497AT($)L;V-K
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#!I
M;CLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#`N-6EN.R<^/&9O;G0@
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M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3`N
M-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^1'5R:6YG(#(P,#$L('1H92!#;VUP86YY)B,X,C$W.W,@0F]A<F0@;V8@
M1&ER96-T;W)S(&%N9"!S=&]C:VAO;&1E<G,@861O<'1E9"!T:&4@,C`P,2!3
M=&]C:R!);F-E;G1I=F4@4&QA;B`H=&AE("8C.#(R,#LR,#`Q(%-T;V-K(%!L
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M8VL@4&QA;B!S:&%L;"!N;W0@97AC965D(#(U,"PP,#`N($%L;"!A=V%R9',@
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M87)D<R`H=&AE("8C.#(R,#M!=V%R9',F(S@R,C$[*2X@5&AE(#(P,#$@4W1O
M8VL@4&QA;B!C;VYT86EN<R!C97)T86EN(&%N=&DM9&EL=71I;VX@<')O=FES
M:6]N<R!I;B!T:&4@979E;G0@;V8@82!S=&]C:R!S<&QI="P@<W1O8VL@9&EV
M:61E;F0@;W(@;W1H97(@8V%P:71A;"!A9&IU<W1M96YT+"!A<R!D969I;F5D
M(&EN('1H92!P;&%N+B!4:&4@,C`P,2!3=&]C:R!0;&%N('!R;W9I9&5S(&9O
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M(&]F($1E8V5M8F5R(#,Q+"`R,#$R+"!T:&5R92!W97)E(#$L,#8V+#`P-R!O
M<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD97(@=&AE(#(P,#$@
M4W1O8VL@4&QA;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY/;B!-
M87)C:"`R,"P@,C`P-RP@=&AE($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O9B!$
M:7)E8W1O<G,@87!P<F]V960@=&AE(#(P,#<@4W1O8VL@26YC96YT:79E(%!L
M86X@*'1H92`F(S@R,C`[,C`P-R!3=&]C:R!0;&%N)B,X,C(Q.RD@9F]R('1H
M92!I<W-U86YC92!O9B!U<"!T;R`R+#4P,"PP,#`@<VAA<F5S(&]F(&-O;6UO
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M92`R,#`W(%-T;V-K(%!L86X@:7,@9&5T97)M:6YE9"!B>2!T:&4@8V]M<&5N
M<V%T:6]N(&-O;6UI='1E92!O9B!T:&4@0F]A<F0@;V8@1&ER96-T;W)S+"!A
M;F0@;6%Y(&)E(&5Q=6%L('1O(&]R(&=R96%T97(@=&AA;B!T:&4@9F%I<B!M
M87)K970@=F%L=64@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O
M8VL@;VX@=&AE(&1A=&4@=&AE(&]P=&EO;B!I<R!G<F%N=&5D+B!4:&4@=&]T
M86P@;G5M8F5R(&]F('-H87)E<R!O9B!S=&]C:R!W:71H(')E<W!E8W0@=&\@
M=VAI8V@@<W1O8VL@;W!T:6]N<R!A;F0@<W1O8VL@87!P<F5C:6%T:6]N(')I
M9VAT<R!M87D@8F4@9W)A;G1E9"!T;R!A;GD@;VYE(&5M<&QO>65E(&]F('1H
M92!#;VUP86YY(&]R(&$@<W5B<VED:6%R>2!D=7)I;F<@86YY(&]N92UY96%R
M('!E<FEO9"!U;F1E<B!T:&4@,C`P-R!P;&%N('-H86QL(&YO="!E>&-E960@
M,C4P+#`P,"X@3W!T:6]N<R!B96-O;64@97AE<F-I<V%B;&4@;W9E<B!V87)I
M;W5S('!E<FEO9',@9G)O;2!T:&4@9&%T92!O9B!G<F%N="P@86YD(&=E;F5R
M86QL>2!E>'!I<F4@=&5N('EE87)S(&%F=&5R('1H92!G<F%N="!D871E+B!!
M<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@=&AE<F4@87)E(#@W,BPW,SD@;W!T
M:6]N<R!I<W-U960@86YD(&]U='-T86YD:6YG('5N9&5R('1H92`R,#`W(%-T
M;V-K(%!L86XN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^3VX@3F]V96UB97(@,BP@
M,C`Q,"P@=&AE($)O87)D(&]F($1I<F5C=&]R<R!A;F0@<W1O8VMH;VQD97)S
M(&%D;W!T960@=&AE(#(P,3`@4W1O8VL@26YC96YT:79E(%!L86X@*"8C.#(R
M,#LR,#$P(%-T;V-K(%!L86XF(S@R,C$[*2!F;W(@=&AE(&ES<W5A;F-E(&]F
M('5P('1O(#,L,#`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1O(&)E
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M(&]P=&EO;G,@=6YD97(@=&AE(#(P,3`@4W1O8VL@4&QA;B!I<R!D971E<FUI
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M<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@=&AE<F4@87)E(#(L-3$U+#`P,"!O
M<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD97(@=&AE(#(P,3`@
M4W1O8VL@4&QA;BX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M97-T:6YG('!E<FEO9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q(&%R92!A<R!F;VQL;W=S.CPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=W:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#,^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY996%R
M)B,Q-C`[96YD960F(S$V,#M$96-E;6)E<B8C,38P.S,Q+#PO9F]N=#X\+W1D
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,C`Q,3PO9F]N=#X\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SY%>&5R8VES92!P<FEC93PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXD,2XV.2`M("0R+C0W/"]F
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,3`X)2`M(#$W-"4\+V9O
M;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^,3<U)2`M(#$X."4\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXP+C,W)2`M(#$N.3@E/"]F;VYT/CPO=&0^#0H\
M=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXQ+C,P)2`M(#,N-3@E/"]F;VYT/CPO=&0^#0H\+W1R/@T*
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXU("T@,3`@>65A<G,\+V9O;G0^/"]T9#X-"CQT9#X\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^-2`M(#<@>65A<G,\
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXP)3PO9F]N=#X\+W1D/@T*/'1D
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXP)3PO9F]N
M=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
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M<R!T97)M<R!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I
M;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Y)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,E.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!S>6UB;VP[.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G('-I>F4],T0R/B8C,3@S.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`X."4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CYI;6UE9&EA=&4@=F5S=&EN
M9RP\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#LG/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('-Y
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M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@<WEM8F]L.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/"]T9#X-"CQT
M9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
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M"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('-Y;6)O;#L[(&9O;G0M
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M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@<WEM
M8F]L.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE
M/3-$,CXF(S$X,SL\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CYO;F4@
M:&%L9B!I;6UE9&EA=&4@=F5S=&EN9R!W:71H(')E;6%I;FEN9R!V97-T:6YG
M(&]V97(@;FEN92!M;VYT:',L/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@<WEM8F]L.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)R!S:7IE/3-$,CXF(S$X,SL\+V9O;G0^/"]T9#X-"CQT9#X\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M='EL93TS1"=F;VYT.B`Q,'!T('-Y;6)O;#L[(&9O;G0M9F%M:6QY.G1I;65S
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M:')E92!Y96%R<RX\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TP+C(U:6X[(&UA<F=I;CH@,'!T(#!P
M>"`P<'0@,6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SY$=7)I;F<@,C`Q,BP@=&AE($-O;7!A;GD@9W)A;G1E
M9"`R+#`W-2PP,#`@;W!T:6]N<R!T;R!E;7!L;WEE97,@86YD(&-O;G-U;'1A
M;G1S(&AA=FEN9R!A;B!A<'!R;WAI;6%T92!F86ER('9A;'5E(&]F("0T+C4@
M;6EL;&EO;B!B87-E9"!U<&]N('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P
M<FEC:6YG(&UO9&5L+B8C,38P.R!$=7)I;F<@,C`Q,2P@=&AE($-O;7!A;GD@
M9W)A;G1E9"`U-3<L,#`R(&]P=&EO;G,@=&\@96UP;&]Y965S(&%N9"!C;VYS
M=6QT86YT<R!H879I;F<@86X@87!P<F]X:6UA=&4@9F%I<B!V86QU92!O9B`D
M-C`Y+#`P,"!B87-E9"!U<&]N('1H92!";&%C:RU38VAO;&5S(&]P=&EO;B!P
M<FEC:6YG(&UO9&5L+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE
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M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2!W97)E("0Q
M+C0@;6EL;&EO;B!A;F0@)#(V."PP,#`L(')E<W!E8W1I=F5L>2X@4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@:6YC;'5D960@:6X@9V5N97)A
M;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,@86YD(')E<V5A<F-H(&%N
M9"!D979E;&]P;65N="!E>'!E;G-E<R!R96QA=&EN9R!T;R!S=&]C:R!O<'1I
M;VYS(&ES<W5E9"!T;R!C;VYS=6QT86YT<R!F;W(@=&AE('EE87)S(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q('=E<F4@)#(Q-BPP,#`@86YD
M("0W,#4L,#`P+"!R97-P96-T:79E;'DN/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#LF(S$V,#L\+V9O
M;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[
M)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
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M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY7
M96EG:'1E9#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT
M.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[
M)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
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M,T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
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M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SY#;VYT<F%C='5A;#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
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M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^3W!T:6]N<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW
M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SY0<FEC93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z
M(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SY,:69E/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
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M(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=VED=&@Z(#0X)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^0F%L86YC92`F(S@R
M,3$[($1E8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!W:61T:#H@,24[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C(L-3,Y+#`Y,3PO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=VED=&@Z(#$E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/C$N,S(\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL[(&9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS
M1#(^-BXY-R!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=VED=&@Z(#$E
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXQ+#`R."PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q
M)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^-34W+#`P,CPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M86XL=&EM97,G/C`N-3<\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B@Y,RPW-3`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXI/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D)A;&%N
M8V4@)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`Q,3PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/C(L.3<Y+#`Q,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<@<VEZ93TS1#(^-BXP,2!Y96%R<SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
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M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXR+#`W-2PP,#`\+V9O;G0^
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/D9O<F9E:71E9#PO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^0F%L86YC92`F(S@R,3$[($1E8V5M8F5R(#,Q+"`R,#$R("8C.#(Q,3L@
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
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M;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@
M<VEZ93TS1#(^-BXT,R!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXQ+#,P."PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^0F%L86YC92`F(S@R,3$[($1E8V5M8F5R
M(#,Q+"`R,#$R("8C.#(Q,3L@97AE<F-I<V%B;&4\+V9O;G0^/"]T9#X-"CQT
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M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,BPX.3$L.#<W/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C$N-C`\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^-2XW,2!Y96%R<SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ+#$V,"PP,#`\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
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M=&4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@)B,X,C$Q.R`R,#$R
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY796EG:'1E9"!A=F5R86=E
M(&=R86YT(&1A=&4@9F%I<B!V86QU92`F(S@R,3$[(#(P,3(\+V9O;G0^/"]T
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M;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^1W)A;G0@9&%T92!F86ER
M('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"`F(S@R,3$[(#(P,3$\+V9O;G0^
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^-C`Y+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SY796EG:'1E9"!A=F5R86=E(&=R86YT(&1A
M=&4@9F%I<B!V86QU92`F(S@R,3$[(#(P,3$\+V9O;G0^/"]T9#X-"CQT9"!S
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M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[)B,Q-C`[/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^5&AE(&]P=&EO;G,@;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE(&%T
M($1E8V5M8F5R(#,Q+"`R,#$R(&%R92!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S
M='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0Q,2!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SY/<'1I;VYS)B,Q-C`[3W5T<W1A;F1I
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^5V5I9VAT960\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY7
M96EG:'1E9"8C,38P.T%V97)A9V4\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@
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M:6UE<R!N97<@<F]M86XL=&EM97,G/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO
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M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SY296UA:6YI;F<\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY!
M=F5R86=E/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^4F5M86EN:6YG/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D5X
M97)C:7-E)B,Q-C`[4')I8V4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY/
M<'1I;VYS/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D5X97)C:7-E)B,Q-C`[4')I
M8V4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^0V]N=')A8W1U86PF(S$V,#M,:69E/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^3W!T:6]N<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
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M;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D-O;G1R86-T=6%L)B,Q-C`[
M3&EF93PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@,30E
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXD,"XP.2`M("0R+C`P/"]F;VYT/CPO=&0^#0H\
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M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,B4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C$N-S@\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`Q,R4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/C4N-S8@>65A<G,\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/C$L.#`Q+#$X-SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
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M.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)#(N,#$@+2`D,RXP
M,#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/C(N,C8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXW+C$U('EE87)S
M/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,2PP,3$L-3,S/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M,BXQ-SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)#,N,#$@+2`D-BXP,#PO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^-SDL,34W/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXT+C@W/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M-"XT.2!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXT+C@W/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
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M+'1I;65S)SXD,"XP.2`M("0V+C`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/C0L-#4S+#<T-CPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
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M<R!N97<@<F]M86XL=&EM97,G/C$N-C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^-2XW,2!Y96%R<SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/E1H92!O<'1I;VYS(&]U='-T86YD:6YG(&%N9"!E
M>&5R8VES86)L92!A="!$96-E;6)E<B`S,2P@,C`Q,2!A<F4@87,@9F]L;&]W
M<SH\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$,3$@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^3W!T:6]N<R8C
M,38P.T]U='-T86YD:6YG/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$.2!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY/<'1I;VYS)B,Q
M-C`[17AE<F-I<V%B;&4\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^5V5I9VAT960F(S$V,#M!=F5R86=E/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^5V5I9VAT960\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
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M/E)A;F=E)B,Q-C`[;V8\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R
M87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SY!=F5R86=E/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^4F5M86EN:6YG/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
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M;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY%>&5R
M8VES928C,38P.U!R:6-E/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A
M<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D-O;G1R86-T=6%L)B,Q-C`[3&EF
M93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)#`N,#D@+2`D-"XU-SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M=VED=&@Z(#$R)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,BPX.#DL,#$Q/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
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M>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/C$N,CD\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q,R4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C4N-S(@>65A
M<G,\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B0T+C4X("T@)#DN,#4\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
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M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^-2XY,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
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M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
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M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^-2XY,SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\
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M;6%N+'1I;65S)SXD,"XP.2`M("0Y+C`U/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/C(L.3<Y+#`Q,#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^,BPT-30L-C`W/"]F;VYT/CPO=&0^#0H\
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^-2XV,B!Y96%R<SPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@;F]N+79E<W1E9"!S=&]C:R!O<'1I
M;VYS(&%T($1E8V5M8F5R(#,Q+"`R,#$R.CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=W
M:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
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M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E5N
M=F5S=&5D/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SY'<F%N=#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^
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M)B,Q-C`[3W!T:6]N<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O
M;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SY$871E)B,Q-C`[1F%I<B8C,38P.U9A;'5E/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`W-"4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/DYO;BUV97-T960F
M(S$V,#LF(S@R,3$[)B,Q-C`[1&5C96UB97(F(S$V,#LS,2PF(S$V,#LR,#$Q
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M.R!W:61T:#H@,3`E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXU,C0L-#`S/"]F;VYT/CPO
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M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^/&9O;G0@<VEZ93TS
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M+#`W-2PP,#`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ
M+C<Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/DYO;BUV97-T960@)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`Q,CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
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M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY7
M96EG:'1E9"!A=F5R86=E(')E;6%I;FEN9R!P97)I;V0@9F]R('9E<W1I;F<\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CQB/B8C,38P.SPO8CX\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY!<R!O9B!$96-E;6)E<B`S
M,2P@,C`Q,BP@=&]T86P@=6YR96-O9VYI>F5D('-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@<W1O8VL@;W!T:6]N<R!W87,@
M)#,N,B!M:6QL:6]N+"!W:&EC:"!I<R!E>'!E8W1E9"!T;R!B92!E>'!E;G-E
M9"!T:')O=6=H(%-E<'1E;6)E<B`R,#$U+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
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M<R!I;B`R,#$R(&]R(#(P,3$N)B,Q-C`[($-A<V@@<F5C96EV960@9G)O;2!O
M<'1I;VX@97AE<F-I<V5S('5N9&5R('1H92!#;VUP86YY)B,X,C$W.W,@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N('!L86YS(&9O<B!T:&4@>65A<G,@96YD
M960@1&5C96UB97(@,S$L(#(P,3(@86YD(#(P,3$@=V%S("0Q,C<L,#`P(&%N
M9"`D,34L,#`P+"!R97-P96-T:79E;'DN/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M/&(^/&D^4W1O8VL@5V%R<F%N=',@86YD($1E<FEV871I=F4@3&EA8FEL:71I
M97,\+VD^/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M97AE<F-I<V4@<')I8V4@;V8@)#$N-C`@86YD(&$@;&EF92!O9B!F:79E('EE
M87)S+B!4:&4@=V%R<F%N=',@=F5S=&5D(&EM;65D:6%T96QY(&%N9"!E>'!I
M<F4@3V-T;V)E<B`R-2P@,C`Q-RX@4VEN8V4@=&AE<V4@=V%R<F%N=',@=V5R
M92!G<F%N=&5D(&%S('!A<G0@;V8@86X@97%U:71Y(')A:7-E+"!T:&4@0V]M
M<&%N>2!H87,@=')E871E9"!T:&5M(&%S(&$@9&ER96-T(&]F9F5R:6YG(&-O
M<W0N(%1H92!R97-U;'0@;V8@=&AE('1R86YS86-T:6]N(&AA<R!N;R!A9F9E
M8W0@=&\@97%U:71Y+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@86QL('1H
M92!W87)R86YT<R!W97)E(&]U='-T86YD:6YG+CPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D]N($UA<F-H(#$U+"`R,#$R
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VYS=6QT:6YG(&%G<F5E
M;65N="!F;W(@82!F:6YA;F-I86P@8V]M;75N:6-A=&EO;G,@<')O9W)A;2P@
M9F]R(&$@<&5R:6]D(&]F('1W96QV92!M;VYT:',@=&AA="!B96=A;B!O;B!&
M96)R=6%R>2`R,"P@,C`Q,BX@07,@8V]M<&5N<V%T:6]N(&9O<B!S=6-H('!R
M;V=R86TL('1H92!C;VYS=6QT86YT(&ES('!A:60@82!M;VYT:&QY(&9E92!A
M;F0@=VEL;"!B92!I<W-U960@82!P97)F;W)M86YC92!W87)R86YT(&5X97)C
M:7-A8FQE(&9O<B`R-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;6UO;B!S=&]C:R!B87-E9"!O;B!A8VAI979E;65N="!O9B!C97)T
M86EN('-T;V-K('!R:6-E(&UI;&5S=&]N97,N(%5P;VX@:6YI=&EA=&EO;B!O
M9B!T:&4@<')O9W)A;2P@-3`L,#`P(&]F('1H92!P97)F;W)M86YC92!W87)R
M86YT<R!V97-T960N(%1H92!P97)F;W)M86YC92!W87)R86YT(&ES(&5X97)C
M:7-A8FQE(&9O<B!A('!E<FEO9"!O9B!T=V\@>65A<G,@9G)O;2!T:&4@9&%T
M92!O9B!I<W-U86YC92!F;W(@86X@97AE<F-I<V4@<')I8V4@97%U86P@=&\@
M=&AE('!R:6-E("@D,BXR,"!P97(@<VAA<F4I(&]F('1H92!#;VUP86YY)B,X
M,C$W.W,@8V]M;6]N('-T;V-K(&]N('1H92!D871E(&]F(&5X96-U=&EO;B`H
M36%R8V@@,34L(#(P,3(I+B!4:&4@97AP96YS92!R96-O<F1E9"!F;W(@=&AE
M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3(@87!P<F]X:6UA=&5D("0V
M,RPP,#`@86YD('=A<R!E<W1I;6%T960@=7-I;F<@=&AE($UO;G1E($-A<FQO
M('9A;'5A=&EO;B!M;V1E;"X@5&AE(&%S<W5M<'1I;VYS('5S960@8GD@=&AE
M($-O;7!A;GD@87)E('-U;6UA<FEZ960@:6X@=&AE(&9O;&QO=VEN9R!T86)L
M93H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#@P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`X-R4[(&-O;&]R.B!B;&%C:SLG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^17AE<F-I<V4@<')I8V4\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C`\+V9O;G0^/"]T9#X-"CQT9"!S
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ,3`\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@
M8FQA8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B4\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!C;VQO<CH@8FQA8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E)I<VL@9G)E92!I
M;G1E<F5S="!R871E/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z
M(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@8FQA8VL[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!C;VQO<CH@8FQA8VL[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/C`N,C8\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
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M8FQA8VL[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D]N($1E8V5M8F5R(#(P+"`R,#$Q
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M87)R86YT(&5X97)C:7-A8FQE(&9O<B`Q,#`L,#`P('-H87)E<R!O9B!T:&4@
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M:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@87!P<F]X:6UA=&5D("0R,#`L,#`P
M(&%N9"!W87,@;65A<W5R960@=7-I;F<@=&AE($)L86-K+5-C:&]L97,@=F%L
M=6%T:6]N(&UO9&5L+B!!;&P@;V8@=&AI<R!E>'!E;G-E('=A<R!R96-O<F1E
M9"!I;B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BX@5&AE(&%S
M<W5M<'1I;VYS('5S960@8GD@=&AE($-O;7!A;GD@87)E('-U;6UA<FEZ960@
M:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^
M#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`X-R4[
M(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^17AE<F-I<V4@<')I8V4\
M+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&-O;&]R.B!B
M;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M/C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!C;VQO<CH@8FQA8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B4\+V9O;G0^/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C
M8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M17AP96-T960@=F]L871I;&ET>3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C`N-S$\+V9O;G0^/"]T9#X-"CQT
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M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!C;VQO
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M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
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M<G)A;G0@=V%S(&5X97)C:7-A8FQE)B,Q-C`[9F]R('1H:7)T965N(&UO;G1H
M<R8C,38P.V%T("0R+C`P('!E<B!S:&%R92!A;F0@<W5B<V5Q=65N=&QY(&5X
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M<F4@=&AA="!I<R!L97-S('1H86X@)#(N,#`@<&5R('-H87)E+"!T:&4@=V%R
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^3VX@07!R:6P@-BP@,C`Q,2P@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&%N;W1H97(@0V]M;6]N(%-T;V-K(%!U<F-H87-E($%G
M<F5E;65N="!T:&%T('1R:6=G97)E9"!T:&4@<F%T8VAE="!P<F]V:7-I;VX@
M86YD(')E+7-E="!T:&4@<')I8V4@;V8@=&AE<V4@=V%R<F%N=',@=&\@)#$N
M-#`@<&5R('-H87)E+B!$=64@=&\@=&AE(')E+7-E="!T;R!T:&4@9FQO;W(@
M<')I8V4L('1H92!W87)R86YT(&QI86)I;&ET>2!W87,@;6%R:V5D+71O+6UA
M<FME="!A;F0@<F5C;&%S<VEF:65D('1O(&%D9&ET:6]N86P@<&%I9"UI;B!C
M87!I=&%L('-I;F-E(&ET(&-E87-E9"!T;R!C;VYT86EN('1H92!P<F]V:7-I
M;VYS(&]F(&$@9&5R:79A=&EV92!L:6%B:6QI='DN($%S(&]F($1E8V5M8F5R
M(#,Q+"`R,#$R+"!A;&P@;V8@=&AE<V4@=V%R<F%N=',@:&%V92!B965N(&5X
M97)C:7-E9"X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/E1H92!W87)R86YT<R!W97)E(&EN:71I86QL>2!R96-O<F1E9"!A<R!L
M:6%B:6QI=&EE<R!A="!T:&5I<B!E<W1I;6%T960@9F%I<B!V86QU92!O;B!T
M:&4@8V]M;6ET;65N="!D871E+"!W:&EC:"!W87,@)#<Q-BPP,#`@=VET:"!S
M=6)S97%U96YT(&-H86YG97,@:6X@97-T:6UA=&5D(&9A:7(@=F%L=64@<F5C
M;W)D960@87,@82!W87)R86YT(&5X<&5N<V4F(S$V,#MI;B!T:&4@0V]M<&%N
M>28C.#(Q-SMS('-T871E;65N="!O9B!O<&5R871I;VYS(&%T(&5A8V@@<W5B
M<V5Q=65N="!R97!O<G1I;F<@<&5R:6]D+B!/;B!!<')I;"`V+"`R,#$Q+"!T
M:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R<F%N="!L:6%B:6QI='D@=V%S("0Q
M+C4@;6EL;&EO;BP@=VAI8V@@<F5P<F5S96YT960@86X@:6YC<F5A<V4@:6X@
M9F%I<B!V86QU92!O9B`D-S8U+#`P,"X@5&AE(&9A:7(@=F%L=64@=V%S(&UE
M87-U<F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E
M;"X@5&AE(&%S<W5M<'1I;VYS('5S960@8GD@=&AE($-O;7!A;GD@87)E('-U
M;6UA<FEZ960@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#DU)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!C;VQO<CH@8FQA8VL[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY#;VUM:71M
M96YT/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<@;F]W<F%P/3-$;F]W
M<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!C;VQO<CH@8FQA8VL[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY$871E/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!C
M;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@8V]L;W(Z
M(&)L86-K.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^1&%T93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&-O;&]R.B!B;&%C:SLG(&YO=W)A<#TS1&YO=W)A<#X\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&-O;&]R.B!B;&%C:SLG(&YO=W)A<#TS
M1&YO=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!C;VQO<CH@8FQA8VL[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY!<')I;"8C,38P.S8L)B,Q
M-C`[,C`Q,3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&-O;&]R.B!B;&%C:SLG(&YO=W)A<#TS1&YO=W)A<#X\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L
M86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[(&-O;&]R.B!B;&%C
M:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^,2XS.3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M+C`X/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M=&EM97,G/C`\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXP+C(Y/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXE/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@8FQA8VL[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/D5X<&5C=&5D(&QI9F4@*'EE87)S*3PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z
M(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ+C`X/"]F;VYT/CPO=&0^#0H\=&0@
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)W1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY/;B!!
M=6=U<W0@,3`L(#(P,3$L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!A
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M-C`[97AT96YD960@8GD@='=O(&UO;G1H<RX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
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M,38P.V9O<B!T:&ER=&5E;B!M;VYT:',F(S$V,#MA="`D,BXP-S(U('!E<B!S
M:&%R92X@5&AE('=A<G)A;G0@:&%D(&%N(&%N=&DM9&EL=71I;VX@<')I8V4@
M<')O=&5C=&EO;B!F96%T=7)E.R!T:&%T('!R;W9I9&5D(&EF('1H92!#;VUP
M86YY(&ES<W5E<R!S96-U<FET:65S(&%T(&$@<')I8V4@<&5R('-H87)E('1H
M870@:7,@;&5S<R!T:&%N("0R+C`W,C4@<&5R('-H87)E+"8C,38P.W1H928C
M,38P.V5X97)C:7-E('!R:6-E(&]F('1H92!W87)R86YT)B,Q-C`[=VEL;"!B
M92!R871C:&5T960@9&]W;B!T;R!T:&4@;&]W97(@;V9F97)I;F<@<')I8V4N
M)B,Q-C`[3VX@2G5L>2`R."P@,C`Q,2P@=&AE('=A<G)A;G0@=V%S(&5X8VAA
M;F=E9"!F;W(@82!N97<@=V%R<F%N="!W:71H('-U8G-T86YT:6%L;'D@<VEM
M:6QA<B!T97)M<R!E>&-E<'0@=&AA="!I;B!T:&4@;F5W('=A<G)A;G0@*&DI
M('1H92!A;G1I+61I;'5T:6]N('!R:6-E('!R;W1E8W1I;VX@=V%S(&5L:6UI
M;F%T960L("AI:2D@=&AE(&5X97)C:7-E('!R:6-E('=A<R!L;W=E<F5D('1O
M("0Q+C`P+"`H:6EI*2!T:&4@97AP:7)A=&EO;B!D871E('=A<R!E>'1E;F1E
M9"!F;W(@86X@861D:71I;VYA;"8C,38P.W1H<F5E(&UO;G1H<R!T;R!!=6=U
M<W0@,3(L(#(P,3(L)B,Q-C`[86YD("AI=BD@=&AE('=A<G)A;G0F(S@R,3<[
M<R!I;FET:6%L(&5X97)C:7-E(&1A=&4@=V%S(&-H86YG960@=&\@2F%N=6%R
M>2`R,#$R+B!$=64@=&\@=&AI<R!W87)R86YT(&5X8VAA;F=E+"!T:&4@=V%R
M<F%N="!L:6%B:6QI='D@=V%S(&UA<FME9"UT;RUM87)K970@86YD(')E8VQA
M<W-I9FEE9"!T;R!A9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;"!S:6YC92!I
M="!C96%S960@=&\@8V]N=&%I;B!T:&4@<')O=FES:6]N<R!O9B!A(&1E<FEV
M871I=F4@;&EA8FEL:71Y+B!!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@86QL
M(&]F('1H97-E('=A<G)A;G1S(&AA=F4@8F5E;B!E>&5R8VES960N/"]F;VYT
M/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY4:&4@=V%R<F%N
M="!I<R8C,38P.VEN:71I86QL>2!R96-O<F1E9"!A<R!A(&QI86)I;&ET>2!A
M="8C,38P.VET<R!E<W1I;6%T960@9F%I<B!V86QU92!O;B!T:&4@8V]M;6ET
M;65N="!D871E+"!W:&EC:"!W87,@)#<W-BPP,#`@=VET:"!S=6)S97%U96YT
M(&-H86YG97,@:6X@97-T:6UA=&5D(&9A:7(@=F%L=64@<F5C;W)D960@87,@
M82!W87)R86YT(&5X<&5N<V4F(S$V,#MI;B!T:&4@0V]M<&%N>28C.#(Q-SMS
M('-T871E;65N="!O9B!O<&5R871I;VYS(&%T(&5A8V@@<W5B<V5Q=65N="!P
M97)I;V0N($]N($IU;'D@,C@L(#(P,3$L('1H92!F86ER('9A;'5E(&]F('1H
M92!W87)R86YT(&QI86)I;&ET>2!W87,@)#(U,RPP,#`L('=H:6-H(')E<')E
M<V5N=&5D(&$@9&5C<F5A<V4@:6X@9F%I<B!V86QU92!O9B`D-3(S+#`P,"X@
M5&AE(&9A:7(@=F%L=64@:7,@;65A<W5R960@=7-I;F<@=&AE($)L86-K+5-C
M:&]L97,@=F%L=6%T:6]N(&UO9&5L+B!4:&4@87-S=6UP=&EO;G,@=7-E9"!B
M>2!T:&4@0V]M<&%N>2!A<F4@<W5M;6%R:7IE9"!I;B!T:&4@9F]L;&]W:6YG
M('1A8FQE.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS
M1"=W:61T:#H@.34E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<@;F]W<F%P
M/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!C;VQO<CH@8FQA8VL[
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY2
M96UE87-U<F5M96YT/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8V]L;W(Z
M(&)L86-K.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@
M8FQA8VL[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M93TS1"=C;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@
M8FQA8VL[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
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M9&1I;F<M8F]T=&]M.B`Q<'0[(&-O;&]R.B!B;&%C:SLG(&YO=W)A<#TS1&YO
M=W)A<#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!C;VQO<CH@8FQA8VL[)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY$871E/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@8V]L;W(Z(&)L86-K
M.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@8V]L
M;W(Z(&)L86-K.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6EN9&5N=#H@+3$S+C)P=#L@<&%D9&EN9RUL969T.B`Q,RXR<'0[
M('=I9'1H.B`W-"4[(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^0VQO
M<VEN9R!S=&]C:R!P<FEC93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M:#H@,3`E.R!C;VQO<CH@8FQA8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C(N,#@\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!C;VQO<CH@8FQA
M8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L
M86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[(&-O;&]R.B!B;&%C
M:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^,"XX-#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@+3$S+C)P=#L@<&%D9&EN9RUL969T.B`Q,RXR
M<'0[(&-O;&]R.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^17AP96-T960@9&EV
M:61E;F0@<F%T93PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B
M;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXP/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXE/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!C;VQO<CH@8FQA8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!C;VQO
M<CH@8FQA8VL[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C`\+V9O;G0^/"]T9#X-"CQT9"!S
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M:6YD96YT.B`M,3,N,G!T.R!P861D:6YG+6QE9G0Z(#$S+C)P=#L@8V]L;W(Z
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M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C`N
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ+C`X/"]F
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&-O;&]R
M.B!B;&%C:SLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,2XP-#PO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P
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M=&EE<R!A="!$96-E;6)E<B`S,2P@,C`Q,3QI/BAI;B!T:&]U<V%N9',I.CPO
M:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,#PO9F]N=#X\+W1D
M/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A9&1I
M;F<M;&5F=#H@,"XR-6EN.R!W:61T:#H@.#<E.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY7
M87)R86YT(&QI86)I;&ET>3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A
M9&1I;F<M;&5F=#H@,"XR-6EN.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY#:&%N9V4@:6X@
M9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>3PO9F]N=#X\+W1D/@T*
M/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E
M>'0M:6YD96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^4F5C;&%S<VEF:6-A=&EO;B!T;R!A9&1I=&EO;F%L('!A
M:60M:6X@8V%P:71A;#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6EN9&5N
M=#H@+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P+C(U:6X[)SX\9F]N="!S:7IE
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M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/D$@<W5M;6%R>2!O9B!W87)R86YT(&%C=&EV
M:71Y(&9O<B!T:&4@0V]M<&%N>2!F;W(@=&AE('EE87(@96YD960@1&5C96UB
M97(@,S$L(#(P,3$@86YD(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S
M,2P@,C`Q,B!I<R!A<R!F;VQL;W=S.CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T
M:#H@.34E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^3G5M8F5R)B,Q-C`[;V8F(S$V,#M787)R86YT<SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SY%>&5R8VES928C,38P.U!R:6-E/"]F;VYT
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`W-"4[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3`\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/C$L,3,Q+#`W.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
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M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M,2XR-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^,BXP.#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY"86QA;F-E(&%S($1E8V5M
M8F5R(#,Q+"`R,#$Q/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^,2XY-3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^1W)A;G1E9#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D9O<F9E:71E
M9#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXS+C,R/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^,2PV,S(L-3`Q/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
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M96UB97(@,S$L(#(P,3(@=V%S("0R-S$L,#`P+B!4:&5R92!W87,@;F\@<W1O
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M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/D$@<W5M;6%R>2!O9B!A;&P@;W5T<W1A;F1I;F<@
M86YD(&5X97)C:7-A8FQE('=A<G)A;G1S(&%S(&]F($1E8V5M8F5R(#,Q+"`R
M,#$R(&ES(&%S(&9O;&QO=W,Z/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)W=I9'1H.B`X,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CY%
M>&5R8VES93PO9F]N=#X\8G(@("\^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^4')I8V4\+V9O;G0^
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CY787)R
M86YT<SPO9F]N=#X\8G(@("\^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^3W5T<W1A;F1I;F<\+V9O
M;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CY7
M87)R86YT<SPO9F]N=#X\8G(@("\^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^17AE<F-I<V%B;&4\
M+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$
M,CY796EG:'1E9"8C,38P.T%V97)A9V4\+V9O;G0^/&)R("`O/CQF;VYT('-T
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F
M8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-R4[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q-R4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXQ,#`L,#`P/"]F;VYT
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M/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M-R4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)R!S:7IE/3-$,CXQ,#`L,#`P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`R,"4[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$
M,CXT+C`Y('EE87)S/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
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M.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
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M/C8R+#`P,#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXQ
M."PQ.#(\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M,#`@>65A<G,\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M<F]M86XL=&EM97,G('-I>F4],T0R/C@L,#`P/"]F;VYT/CPO=&0^#0H\=&0^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4]
M,T0R/C$N-C`\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P
M.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G('-I>F4],T0R/C$P,BPP,#`\+V9O;G0^/"]T9#X-
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M>F4],T0R/C(N,C`\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M,T0R/C(U,"PP,#`\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M,T0R/C4P+#`P,#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y
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M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
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M93TS1#(^-C$L,C`W/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE
M/3-$,CXV,2PR,#<\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M,T0R/C,N,S`@>65A<G,\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
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M9#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G('-I>F4],T0R/C4P+#`P,#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXU
M,"PP,#`\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^,RXQ,R!Y96%R<SPO9F]N=#X\
M+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
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M86-K(#(N,C5P="!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXQ+CDY/"]F
M;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL[(&9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^,2PV,S(L-3`Q/"]F;VYT/CPO
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M;VUA;BQT:6UE<R<@<VEZ93TS1#(^,2PT,S(L-3`Q/"]F;VYT/CPO=&0^#0H\
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
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M;VUA;BQT:6UE<R<@<VEZ93TS1#(^,3<R+#`P,#PO9F]N=#X\+W1D/@T*/'1D
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T
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M/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D%S(&]F($1E8V5M8F5R(#,Q
M+"`R,#$R+"!%<&ET;W!E+"!A(&UA:F]R:71Y+6]W;F5D('-U8G-I9&EA<GD@
M;V8@4WEN=&AE=&EC($)I;VQO9VEC<RP@:&%S(#4P+#`P,"!S=&]C:R!O<'1I
M;VYS(&]U='-T86YD:6YG(&%N9"`T,"PP,#`@<W1O8VL@;W!T:6]N<R!E>&5R
M8VES86)L92X@5&AE<V4@<W1O8VL@;W!T:6]N<R!H879E(&%N(&5X97)C:7-E
M('!R:6-E(&]F("0P+C`P,2!A;F0@82!R96UA:6YI;F<@8V]N=')A8W1U86P@
M;&EF92!O9B`U+C4P('EE87)S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R
M<R<@17%U:71Y($YO=&4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>2!.
M;W1E($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M
M87)G:6XM8F]T=&]M.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/@T*/'1R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('9E
M<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,"XU:6X[)SX\8CXV+CPO8CX\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CY3=&]C:VAO;&1E<G,F
M(S@R,3<[($5Q=6ET>3PO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S
M='EL93TS1"=T97AT+6EN9&5N=#H@+3`N-6EN.R!M87)G:6XZ(#!P="`P<'@@
M,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^665A<B!%;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,3PO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/D1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S
M,2P@,C`Q,2P@=&AE($-O;7!A;GD@:7-S=65D(#(X+#,S,R!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE<F-I<V4@
M;V8@<W1O8VL@;W!T:6]N<R!A;F0@=V%R<F%N=',@9F]R('!R;V-E961S(&]F
M("0Q-2PP,#`@86YD(#$P+#8Q-2!S:&%R97,@;V8@8V]M;6]N('-T;V-K(')E
M;&%T960@=&\@82!C87-H;&5S<R!E>&5R8VES92!O9B!W87)R86YT<RX@5&AE
M($-O;7!A;GD@:7-S=65D(#<S+#4X-2!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&9O<B!E;7!L;WEM96YT('-E<G9I8V4L(&AA=FEN9R!A(&9A:7(@=F%L=64@
M;V8@)#DT+#`P,"`H)#$N,CD@879E<F%G92!P97(@<VAA<F4I(&%N9"`Q-S$L
M-SDV('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@9F]R(&-O;G-U;'1I;F<@<V5R
M=FEC97,L(&AA=FEN9R!A(&9A:7(@=F%L=64@;V8@)#$V-2PP,#`@*"0P+CDV
M(&%V97)A9V4@<&5R('-H87)E*2P@8F%S960@;VX@=&AE('%U;W1E9"!C;&]S
M:6YG('1R861I;F<@<')I8V5S+B!4:&4@0V]M<&%N>2!A;'-O(&ES<W5E9"`S
M+#$R,RPU-3@@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A<R!C;VYS:61E<F%T
M:6]N(&9O<B!T:&4@17AC;'5S:79E($-H86YN96P@0V]L;&%B;W)A=&EO;B!!
M9W)E96UE;G0@=VET:"!);G1R97AO;BP@:&%V:6YG(&$@9F%I<B!V86QU92!O
M9B`D,2XW(&UI;&QI;VX@*"0P+C4T('!E<B!S:&%R92DL(&)A<V5D(&]N('1H
M92!Q=6]T960@8VQO<VEN9R!T<F%D:6YG('!R:6-E+CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@2F%N=6%R>2`R."P@
M,C`Q,2P@=&AE($-O;7!A;GD@<V]L9"`R+#@U-RPQ-#0@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@97AE<F-I<V%B;&4@9F]R)B,Q-C`[
M,2PT,C@L-3<R('-H87)E<R!O9B!C;VUM;VX@<W1O8VLF(S$V,#MF;W(@)#0@
M;6EL;&EO;BX@1&ER96-T(&]F9F5R:6YG(&-O<W1S('=E<F4@87!P<F]X:6UA
M=&5L>2`D,CDV+#`P,"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
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M('-T;V-K)B,Q-C`[9F]R("0S+C4@;6EL;&EO;BX@1&ER96-T(&]F9F5R:6YG
M(&-O<W1S('=E<F4@87!P<F]X:6UA=&5L>2`D,C0S+#`P,"X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,'!X.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\:3Y996%R($5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$R/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
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M96YT(&9I;F%N8VEN9R!O9B`\+V9O;G0^-BPW-3`L,#`P('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A(&-L;W-I;F<@
M<')I8V4@;V8@)#$N-C`@9F]R(&=R;W-S('!R;V-E961S(&]F("0Q,"XX(&UI
M;&QI;VXN)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@<&%I9"!D:7)E8W0@;V9F
M97)I;F<@8V]S=',@;V8@)#8X,"PP,#`N)B,Q-C`[)B,Q-C`[4V5E($YO=&4@
M-2!R96=A<F1I;F<@=V%R<F%N=',@9W)A;G1E9"!W:71H('1H:7,@;V9F97)I
M;F<N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G8V]L
M;W(Z(&)L86-K.R<^1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@,S<T+#@U,2!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K+"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&5X97)C:7-E
M(&]F('-T;V-K(&]P=&EO;G,L(&9O<B!P<F]C965D<R!O9B!A<'!R;WAI;6%T
M96QY("0Q,C<L,#`P+B!4:&4@0V]M<&%N>2!A;'-O(&ES<W5E9"`Q+#<V."PQ
M-C<@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@
M=&AE(&5X97)C:7-E(&]F('=A<G)A;G1S+"!F;W(@<')O8V5E9',@;V8@87!P
M<F]X:6UA=&5L>2`D,BXP(&UI;&QI;VXN/"]F;VYT/B!4:&4@0V]M<&%N>2!A
M;'-O(&ES<W5E9"`S+#4U,BPR,3`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A
M<R!C;VYS:61E<F%T:6]N(&9O<B!A('-E8V]N9"!%>&-L=7-I=F4@0VAA;FYE
M;"!#;VQL86)O<F%T:6]N($%G<F5E;65N="!W:71H($EN=')E>&]N+"!H879I
M;F<@82!F86ER('9A;'5E(&]F("0W+C@@;6EL;&EO;B`H)#(N,C`@<&5R('-H
M87)E*2P@8F%S960@;VX@=&AE('%U;W1E9"!C;&]S:6YG('1R861I;F<@<')I
M8V4N(%1H97-E('-H87)E<R!A<F4@<W5B:F5C="!T;R!T:&4@<F5G:7-T<F%T
M:6]N(')I9VAT<R!A9W)E96UE;G0@87,@9&5S8W)I8F5D(&EN($YO=&4@-RX@
M26X@8V]N;F5C=&EO;B!W:71H('1H92!P<FEV871E('!L86-E;65N="!T:&%T
M('=A<R!C;VUP;&5T960@;VX@3V-T;V)E<B`S,2P@,C`Q,BP@=&AE($-O;7!A
M;GD@86QS;R!E;G1E<F5D(&EN=&\@86X@86=R965M96YT('=I=&@@3E)-(%9)
M22!(;VQD:6YG<R!)+"!,3$,L(&%N(&%F9FEL:6%T92!O9B!);G1R97AO;B!T
M:&%T(&%C<75I<F5D(#,L,3(U+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF
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M+"!T:&4@0V]M<&%N>2!I<W-U960@-C(U+#`P,"!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K(&%S(&-O;G-I9&5R871I;VX@9F]R('1H92!A8W%U:7-I=&EO;B!O
M9B!T:&4@/&D^0RX@9&EF9CPO:3X@<')O9W)A;2!A<W-E=',@;V8@4')E=B!!
M0E(@3$Q#+"!H879I;F<@82!F86ER('9A;'5E(&]F("0Q+C(@;6EL;&EO;B`H
M)#$N.#<@<&5R('-H87)E*2P@8F%S960@;VX@=&AE('%U;W1E9"!C;&]S:6YG
M('1R861I;F<@<')I8V4N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y
M,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F
M7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T
M,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,
M:6-E;G-E+"!#;VQL86)O<F%T:79E(&%N9"!%;7!L;WEM96YT($%G<F5E;65N
M=',@86YD($-O;6UI=&UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@3V8@3&EC96YS92!#
M;VQL86)O<F%T:79E(&%N9"!%;7!L;WEM96YT($%G<F5E;65N=',@86YD($-O
M;6UI=&UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!#;VQL86)O<F%T:79E(&%N9"!%
M;7!L;WEM96YT($%G<F5E;65N=',@86YD($-O;6UI=&UE;G1S(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#`N-6EN.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SX\8CXW+CPO8CX\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\8CY,
M:6-E;G-E+"!#;VQL86)O<F%T:79E(&%N9"!%;7!L;WEM96YT($%G<F5E;65N
M=',@86YD($-O;6UI=&UE;G1S/"]B/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3`N-6EN.R!M87)G
M:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\:3Y,:6-E;G-E(&%N9"!#;VQL
M86)O<F%T:79E($%G<F5E;65N=',\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M;VYT86EN(&UI;&5S=&]N97,N)B,Q-C`[(%1H92!S<&5C:69I8R!T:6UI;F<@
M;V8@<W5C:"!M:6QE<W1O;F5S(&-A;FYO="!B92!P<F5D:6-T960@86YD(&%R
M92!D97!E;F1E;G0@;VX@9G5T=7)E(&1E=F5L;W!M96YT<R!A<R!W96QL(&%S
M(')E9W5L871O<GD@86-T:6]N<R!W:&EC:"!C86YN;W0@8F4@<')E9&EC=&5D
M('=I=&@@8V5R=&%I;G1Y("AI;F-L=61I;F<@86-T:6]N<R!W:&EC:"!M87D@
M;F5V97(@;V-C=7(I+B8C,38P.R!&=7)T:&5R+"!U;F1E<B!T:&4@=&5R;7,@
M;V8@8V5R=&%I;B!L:6-E;G-I;F<@86=R965M96YT<RP@=&AE($-O;7!A;GD@
M;6%Y(&AA=F4@=&AE(&]B;&EG871I;VX@=&\@<&%Y(&-E<G1A:6X@;6EL97-T
M;VYE<R!C;VYT:6YG96YT('5P;VX@=&AE(&%C:&EE=F5M96YT(&]F('-P96-I
M9FEC(&QE=F5L<R!O9B!S86QE<RXF(S$V,#L@1'5E('1O('1H92!L;VYG+7)A
M;F=E(&YA='5R92!O9B!S=6-H(&-O;6UE<F-I86P@;6EL97-T;VYE(&%M;W5N
M=',L('1H97D@87)E(&YE:71H97(@<')O8F%B;&4@870@=&AI<R!T:6UE(&YO
M<B!P<F5D:6-T86)L92!A;F0@8V]N<V5Q=65N=&QY(&%R92!N;W0@:6YC;'5D
M960@:6X@=&AI<R!D:7-C;&]S=7)E+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D]N
M($1E8V5M8F5R(#$Y+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M82!,:6-E;G-E($%G<F5E;65N="!W:71H(%1H92!5;FEV97)S:71Y(&]F(%1E
M>&%S(&%T($%U<W1I;B`H=&AE("8C.#(R,#M5;FEV97)S:71Y)B,X,C(Q.RD@
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M;G0@;V8@)#4P+#`P,"!P97(@>65A<B!C;VUM96YC:6YG(&]N('1H92!E9F9E
M8W1I=F4@9&%T92!T:')O=6=H($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"!A("0R
M-2PP,#`@<&%Y;65N="!O;B!$96-E;6)E<B`S,2P@,C`Q-2!A;F0@;6EL97-T
M;VYE('!A>6UE;G1S(&]F("0U,"PP,#`@=7!O;B!C;VUM96YC96UE;G0@;V8@
M4&AA<V4@22!C;&EN:6-A;"!T<FEA;',L("0Q,#`L,#`P('5P;VX@8V]M;65N
M8V5M96YT(&]F(%!H87-E($E)22!C;&EN:6-A;"!T<FEA;',L("0R-3`L,#`P
M('5P;VX@3D1!('-U8FUI<W-I;VX@:6X@=&AE(%4N4RXL("0Q,#`L,#`P('5P
M;VX@175R;W!E86X@365D:6-I;F5S($%G96YC>2!A<'!R;W9A;"!A;F0@)#$P
M,"PP,#`@=7!O;B!R96=U;&%T;W)Y(&%P<')O=F%L(&EN(&%N($%S:6%N(&-O
M=6YT<GDN($EN(&%D9&ET:6]N+"!T:&4@56YI=F5R<VET>2!I<R!E;G1I=&QE
M9"!T;R!A(')U;FYI;F<@<F]Y86QT>2!U<&]N(&YE="!S86QE<R`H87,@9&5F
M:6YE9"!I;B!T:&4@3&EC96YS92!!9W)E96UE;G0I+B!4:&4@3&EC96YS92!!
M9W)E96UE;G0@=&5R;6EN871E<R!U<&]N('1H92!E>'!I<F%T:6]N(&]F('1H
M92!P871E;G0@<FEG:'1S("AA<R!D969I;F5D(&EN('1H92!,:6-E;G-E($%G
M<F5E;65N="D[('!R;W9I9&5D+"!H;W=E=F5R('1H870@=&AE($QI8V5N<V4@
M06=R965M96YT(&ES('-U8FIE8W0@=&\@96%R;'D@=&5R;6EN871I;VX@8GD@
M=&AE($-O;7!A;GD@:6X@:71S(&1I<V-R971I;VX@86YD(&)Y('1H92!5;FEV
M97)S:71Y(&9O<B!A(&)R96%C:"!O9B!T:&4@3&EC96YS92!!9W)E96UE;G0@
M8GD@=&AE($-O;7!A;GDN/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
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M(&$@9FEX960@9F5E(&]F("0S,38L-#,X(&%N9"`D,S(X+#<U."!R97-P96-T
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M8F5R(#,Q+"`R,#$U.R!P<F]V:61E9"P@:&]W979E<BP@=&AE(%-P;VYS;W)E
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M;F%T:6]N('!R:6]R('1O($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@0V]M<&%N
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M87)I97,@86YD($1E8V5M8F5R(#,Q+"`R,#$T+B!5<&]N(&$@=&5R;6EN871I
M;VX@869T97(@1&5C96UB97(@,S$L(#(P,30@;W(@9'5E('1O(&$@8G)E86-H
M(&)Y('1H92!5;FEV97)S:71Y+"!T:&4@0V]M<&%N>2!S:&%L;"!O;FQY(&)E
M(')E<W!O;G-I8FQE(&9O<B!A;&P@<F5A<V]N86)L92!E>'!E;G-E<R!T:&%T
M(&1O(&YO="!E>&-E960@=&AE(&9I>&5D(&%N;G5A;"!A;6]U;G0@86YD('1H
M870@87)E(&EN8W5R<F5D(&)Y('1H92!5;FEV97)S:71Y('!R:6]R('1O('1H
M92!T97)M:6YA=&EO;B!D871E(&9O<B!S97)V:6-E<R!P97)F;W)M960@<')I
M;W(@=&\@=&AE('1E<FUI;F%T:6]N(&1A=&4N/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E
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M0E(@3$Q#("@F(S@R,C`[4')E=B8C.#(R,3LI+"!P=7)S=6%N="!T;R!W:&EC
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M="!O9B`D,3`P+#`P,"!U<&]N(&5X96-U=&EO;B!O9B!T:&4@4')E=B!!9W)E
M96UE;G0@86YD(&%T(&-L;W-I;F<@<&%I9"!A;B!A9&1I=&EO;F%L(&-A<V@@
M<&%Y;65N="!O9B`D,3,U+#`P,"!A;F0@:7-S=65D(#8R-2PP,#`@=6YR96=I
M<W1E<F5D('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K('1O(%!R978N(%-E
M92!.;W1E(#8N($EN(&%D9&ET:6]N+"!U<&]N('1H92!A8VAI979E;65N="!O
M9B!T:&4@;6EL97-T;VYE<R!S970@9F]R=&@@8F5L;W<L(%!R978@;6%Y(&)E
M(&5N=&ET;&5D('1O(')E8V5I=F4@861D:71I;VYA;"!C;VYS:61E<F%T:6]N
M('!A>6%B;&4@-3`E(&EN(&-A<V@@86YD(#4P)2!I;B!O=7(@<W1O8VLL('-U
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M:6YI8V%L('1R:6%L.R`H:6EI*2!U<&]N(&-O;6UE;F-E;65N="!O9B!A(%!H
M87-E($E)(&-L:6YI8V%L('1R:6%L.R`H:78I('5P;VX@8V]M;65N8V5M96YT
M(&]F(&$@4&AA<V4@24E)(&-L:6YI8V%L('1R:6%L.R`H=BD@=7!O;B!":6]L
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M<W1U9&EE<R!I;B!N;VXM<F]D96YT(&UO9&5L<R!O<B`H:6DI('1H:7)T>2!S
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M('1H:7)T>2`H,S`I(&%N9"!T:&ER='D@<VEX("@S-BD@;6]N=&@@<&5R:6]D
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M;VUP86YY(&5X<&%N9&5D(&ET<R!R96QA=&EO;G-H:7`@=VET:"!);G1R97AO
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M;VUP86YY(&ES<W5E9"`S+#4U,BPR,3`@<VAA<F5S(&]F(&ET<R!C;VUM;VX@
M<W1O8VLL("0P+C`P,2!P87(@=F%L=64L('=H:6-H(&ES<W5A;F-E(&ES(&%L
M<V\@9&5E;65D('!A:60@:6X@8V]N<VED97)A=&EO;B!F;W(@=&AE(&5X96-U
M=&EO;B!A;F0@9&5L:79E<GD@;V8@=&AE(%-E8V]N9"!#:&%N;F5L($%G<F5E
M;65N="P@9&%T960@075G=7-T(#8L(#(P,3(L(&)E='=E96X@=&AE($-O;7!A
M;GD@86YD($EN=')E>&]N+B!4:&4@9F%I<B!V86QU92!O9B!T:&ES('1R86YS
M86-T:6]N('=A<R`D-RXX(&UI;&QI;VX@86YD('=A<R!C:&%R9V5D('1O(')E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!E>'!E;G-E(&9O<B!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,BP@:6X@86-C;W)D86YC92!W:71H('1H
M92!#;VUP86YY)B,X,C$W.W,@86-C;W5N=&EN9R!P;VQI8WDN($EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@=')A;G-A8W1I;VYS(&-O;G1E;7!L871E9"!B>2!T
M:&4@4V5C;VYD(%-T;V-K($ES<W5A;F-E($%G<F5E;65N="P@86YD('!U<G-U
M86YT('1O('1H92!&:7)S="!!;65N9&UE;G0@=&\@4F5G:7-T<F%T:6]N(%)I
M9VAT<R!!9W)E96UE;G0@*'1H92`F(S@R,C`[1FER<W0@06UE;F1M96YT('1O
M(%)E9VES=')A=&EO;B!2:6=H=',@06=R965M96YT)B,X,C(Q.RD@97AE8W5T
M960@86YD(&1E;&EV97)E9"!B>2!T:&4@<&%R=&EE<R!A="!T:&4@8VQO<VEN
M9RP@=&AE($-O;7!A;GD@86=R965D('1O(&9I;&4@82`F(S@R,C`[<F5S86QE
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M=6YT:6P@07!R:6P@,S`L(#(P,3,N(%5N9&5R('1H870@86=R965M96YT+"!T
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M<W5A;G0@=&\@4G5L92`Q-#0L('=I=&AO=70@86YY(')E<W1R:6-T:6]N<RX\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M:6YG(&%R<F%N9V5M96YT+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
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M(&UI;&QI;VX@9&]L;&%R<R`H)#)-*2!W:&5R92!S=6-H(&9A:7(@;6%R:V5T
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M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M<R`H)#--*2!I;B!C87-H+"!O<B`H:6DI('1H870@;G5M8F5R(&]F('-H87)E
M<R!O9B!#;VUM;VX@4W1O8VL@*'1H92`F(S@R,C`[07!P<F]V86P@36EL97-T
M;VYE(%-H87)E<R8C.#(R,3LI(&AA=FEN9R!A(&9A:7(@;6%R:V5T('9A;'5E
M(&5Q=6%L:6YG('1H<F5E(&UI;&QI;VX@9&]L;&%R<R`H)#--*2!W:&5R92!S
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M<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M;V8@=&AE(&YU;6)E<B!O9B!T87)G971S(&EN(&5X8V5S<R!O9B!T:')E92`H
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M87)K970@=F%L=64@97%U86QI;F<@='=O(&UI;&QI;VX@9&]L;&%R<R`H)#)-
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M=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/D]N($YO=F5M8F5R(#$X+"`R,#$Q+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@=&AE($EN:71I86P@0VAA;FYE;"!!9W)E96UE
M;G0@=VET:"!);G1R97AO;B!T:&%T(&=O=F5R;G,@86X@)B,X,C(P.V5X8VQU
M<VEV92!C:&%N;F5L(&-O;&QA8F]R871I;VXF(S@R,C$[(&%R<F%N9V5M96YT
M(&EN('=H:6-H('1H92!#;VUP86YY(&EN:71I86QL>2!I;G1E;F1E9"!T;R!U
M<V4@26YT<F5X;VXF(S@R,3<[<R!T96-H;F]L;V=Y(&1I<F5C=&5D('1O=V%R
M9',@=&AE('!R;V1U8W1I;VX@;V8@4$=)4RX@07,@8V]N<VED97)A=&EO;B!F
M;W(@97AE8W5T:6]N(&]F('1H92!);FET:6%L($-H86YN96P@06=R965M96YT
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@=&AE($EN:71I86P@4W1O8VL@
M4'5R8VAA<V4@06=R965M96YT('=I=&@@26YT<F5X;VX@<'5R<W5A;G0@=&\@
M=VAI8V@@=&AE($-O;7!A;GD@:7-S=65D('1O($EN=')E>&]N(&$@;G5M8F5R
M(&]F('-H87)E<R!O9B!O=7(@8V]M;6]N('-T;V-K(&5Q=6%L('1O(#DN.3DU
M)2!O9B!T:&4@;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&-O;6UO;B!S=&]C:R!I<W-U960@86YD(&]U='-T86YD:6YG(&9O;&QO
M=VEN9R!A;F0@9VEV:6YG(&5F9F5C="!T;R!S=6-H(&ES<W5A;F-E(&%T(&$@
M<'5R8VAA<V4@<')I8V4@97%U86P@=&\@=&AE("0P+C`P,2!P87(@=F%L=64@
M;V8@<W5C:"!S:&%R97,L('=H:6-H(&ES<W5A;F-E('=A<R!D965M960@<&%I
M9"!I;B!C;VYS:61E<F%T:6]N(&9O<B!T:&4@97AE8W5T:6]N(&%N9"!D96QI
M=F5R>2!O9B!T:&4@26YI=&EA;"!#:&%N;F5L($%G<F5E;65N="X@5&AE($-O
M;7!A;GD@86QS;R!A9W)E960@=&\@:7-S=64@861D:71I;VYA;"!S:&%R97,@
M;V8@:71S(&-O;6UO;B!S=&]C:R!T;R!);G1R97AO;B!U<&]N(&1O<VEN9R!O
M9B!T:&4@9FER<W0@<&%T:65N="!I;B!A(%!H87-E($E)(&-L:6YI8V%L('1R
M:6%L('-P;VYS;W)E9"!B>2!T:&4@0V]M<&%N>2!I;B!T:&4@52Y3+BP@;W(@
M<VEM:6QA<B!S='5D>2!A<R!T:&4@<&%R=&EE<R!M87D@86=R964@:6X@82!C
M;W5N=')Y(&]T:&5R('1H86X@=&AE(%4N4RX@5&AE('!R;V=R86T@=6YD97(@
M=&AI<R!);FET:6%L($-H86YN96P@06=R965M96YT(&ES(&EN('1H92!D:7-C
M;W9E<GD@<W1A9V4N($EN(&-O;FYE8W1I;VX@=VET:"!T:&4@=')A;G-A8W1I
M;VYS(&-O;G1E;7!L871E9"!B>2!T:&4@4W1O8VL@4'5R8VAA<V4@06=R965M
M96YT+"!A;F0@<'5R<W5A;G0@=&\@=&AE(%)E9VES=')A=&EO;B!2:6=H=',@
M06=R965M96YT(&5X96-U=&5D(&%N9"!D96QI=F5R960@8GD@=&AE($-O;7!A
M;GD@=&\@26YT<F5X;VXL('1H92!#;VUP86YY(&%G<F5E9"!T;R!F:6QE(&$@
M)B,X,C(P.W)E<V%L928C.#(R,3L@<F5G:7-T<F%T:6]N('-T871E;65N="!R
M96=I<W1E<FEN9R!T:&4@<F5S86QE(&]F('1H92!&:7)S="!4<F%N8VAE(%-H
M87)E<R!W:71H:6X@,3(P(&1A>7,@;V8@=&AE(&-L;W-I;F<@9&%T92!O9B!S
M=6-H(&ES<W5A;F-E+B!4:&4@<F5G:7-T<F%T:6]N('-T871E;65N="!R96=I
M<W1E<FEN9R!S=6-H('-H87)E<R!W87,@9&5C;&%R960@969F96-T:79E(&]N
M($%P<FEL(#$S+"`R,#$R+"!B=70@:7,@;F]T(&-U<G)E;G1L>2!V86QI9"!D
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M=6-H('-H87)E<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#LF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SY);B!397!T96UB97(F(S$V,#MO9B`R,#`U+"!T
M:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!T:')E92UY96%R(')E<V5A<F-H
M(&%G<F5E;65N="!W:71H('1H92!5;FEV97)S:71Y(&]F($UI8VAI9V%N+B!0
M=7)S=6%N="!T;R!T:&%T(&%G<F5E;65N="P@=&AE($-O;7!A;GD@<W!O;G-O
M<F5D(')E<V5A<F-H(&]F(&%P<')O>&EM871E;'D@)#0V,"PP,#`@<&5R('EE
M87(N)B,Q-C`[)B,Q-C`[3VX@36%R8V@@,C`L(#(P,#@L('1H92!#;VUP86YY
M('1E<FUI;F%T960@=&AE(&%G<F5E;65N="XF(S$V,#LF(S$V,#M/;B!-87)C
M:"`R-"P@,C`P.2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@<&%Y;65N
M="!P;&%N('=I=&@@=&AE(%5N:79E<G-I='D@;V8@36EC:&EG86X@=&\@<&%Y
M('1H92!O=71S=&%N9&EN9R!B86QA;F-E(&]F("0Q.3<L,#`P+B8C,38P.R8C
M,38P.U1H92!#;VUP86YY(&%G<F5E9"!T;R!P87D@)#4L,#`P('!E<B!M;VYT
M:"P@=&AE(&)A;&%N8V4@=V%S('!A:60@:6X@9G5L;"!*=6QY(#(P,3(N/"]F
M;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\:3Y%;7!L
M;WEM96YT($%G<F5E;65N=',\+VD^/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SY%9F9E8W1I=F4@1F5B<G5A<GD@,RP@,C`Q,BP@
M1'(N($MU;R!R97-I9VYE9"!F<F]M(&AI<R!P;W-I=&EO;G,@87,@4')E<VED
M96YT(&%N9"!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<BX@26X@8V]N;F5C=&EO
M;B!W:71H(&AI<R!R97-I9VYA=&EO;BP@1'(N($MU;R!E;G1E<F5D(&EN=&\@
M82!N:6YE+6UO;G1H(&-O;G-U;'1I;F<@86=R965M96YT('=I=&@@=&AE($-O
M;7!A;GD@*'1H92`F(S@R,C`[0V]N<W5L=&EN9R!!9W)E96UE;G0F(S@R,C$[
M*2X@4'5R<W5A;G0@=&\@=&AE($-O;G-U;'1I;F<@06=R965M96YT+"!$<BX@
M2W5O('=I;&P@8F4@96YT:71L960@=&\@82!C;VYS=6QT:6YG(&9E92!O9B`D
M,3<L,#`P('!E<B!M;VYT:"!A;F0@<F5T86EN('1H92!R:6=H="!T;R!E>&5R
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M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D5F9F5C=&EV92!&
M96)R=6%R>2`S+"`R,#$R+"!*969F<F5Y(%)I;&5Y('=A<R!A<'!O:6YT960@
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M<V4@<V%L87)Y(&]F("0S-#@L,#`P(&%N9"!W:6QL(&)E(&5L:6=I8FQE(&9O
M<B!D:7-C<F5T:6]N87)Y('!E<F9O<FUA;F-E(&%N9"!T<F%N<V%C=&EO;F%L
M(&)O;G5S('!A>6UE;G1S+B!!9&1I=&EO;F%L;'DL($UR+B!2:6QE>2!W87,@
M9W)A;G1E9"!O<'1I;VYS('1O('!U<F-H87-E(#<U,"PP,#`@<VAA<F5S(&]F
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M;G0@=VET:"!T:&4@0V]M<&%N>2`H=&AE("8C.#(R,#M"86QL86YT>6YE($5M
M<&QO>6UE;G0@06=R965M96YT)B,X,C(Q.RDN(%!U<G-U86YT('1O('1H92!"
M86QL86YT>6YE($5M<&QO>6UE;G0@06=R965M96YT+"!-<BX@0F%L;&%N='EN
M92!W:6QL(&)E(&5N=&ET;&5D('1O(&%N(&%N;G5A;"!B87-E('-A;&%R>2!O
M9B`D,CDX+#`P,"!A;F0@=VEL;"!B92!E;&EG:6)L92!F;W(@9&ES8W)E=&EO
M;F%R>2!P97)F;W)M86YC92!A;F0@=')A;G-A8W1I;VYA;"!B;VYU<R!P87EM
M96YT<RX@061D:71I;VYA;&QY+"!-<BX@0F%L;&%N='EN92!W87,@9W)A;G1E
M9"!O<'1I;VYS('1O('!U<F-H87-E(#0R-2PP,#`@<VAA<F5S(&]F(&]U<B!C
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M;G,@870@87!P<F]X:6UA=&5L>2`D,2!M:6QL:6]N('5S:6YG(&$@0FQA8VLM
M4V-H;VQE<R!V86QU871I;VX@;6]D96PN/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SX\:3Y/=&AE<B!#;VUM:71M96YT<SPO:3X\
M+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D%S(&]F
M($1E8V5M8F5R(#,Q+"`R,#$R+"!A;6]U;G1S(&1U92!F;W(@;&EC96YS92!A
M;F0@<W!O;G-O<F5D(')E<V5A<F-H(&%G<F5E;65N=',@87)E(&%S(&9O;&QO
M=W,@/&D^*&EN('1H;W5S86YD<RD\+VD^.CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@-3`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UW96EG:'0Z(&)O;&0[)SX\
M9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XL=&EM97,G/EEE87(F(S$V,#M%;F1I;F<F(S$V,#M$96-E;6)E<B8C
M,38P.S,Q+#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^-C`\+V9O;G0^/"]T
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,C`Q-3PO9F]N=#X\+W1D
M/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/C,U/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#$W+C-P
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^,C`Q-CPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL
M=&EM97,G/C$P/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL969T
M.B`Q-RXS<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C(P,3<\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
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M=R!R;VUA;BQT:6UE<R<^-#`R/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CQI/D]P
M97)A=&EN9R!,96%S93PO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D1U<FEN9R`R
M,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!O;F4@>65A<B!O<&5R
M871I;F<@;&5A<V4@9F]R(&]F9FEC92!S<&%C92!I;B!!;FX@07)B;W(L($UI
M8VAI9V%N+B8C,38P.R!);B!-87)C:"`R,#$S+"!T:&ES(&QE87-E('=A<R!A
M;65N9&5D('1O(&5X=&5N9"!T:&4@=&5R;2!O9B!T:&4@;&5A<V4@=&\@1&5C
M96UB97(@,S$L(#(P,30L(&9O<B!A;FYU86P@;&5A<V4@<&%Y;65N=',@;V8@
M)#,S+#`P,"X@26X@36%R8V@@,C`Q,BP@=&AE($-O;7!A;GD@86QS;R!E;G1E
M<F5D(&EN=&\@82!O;F4@>65A<B!O<&5R871I;F<@;&5A<V4@=&AA="!M87D@
M8F4@<F5N97=E9"!F;W(@='=O(&%D9&ET:6]N86P@=&5R;7,@;V8@;VYE('EE
M87(L(&9O<B!O9F9I8V4@<W!A8V4@:6X@4F]C:W9I;&QE+"!-87)Y;&%N9"P@
M9F]R(&%N;G5A;"!L96%S92!P87EM96YT<R!O9B`D,S4L,#`P+B!4:&4@36%R
M>6QA;F0@;V9F:6-E(&QE87-E(&UA>2!B92!T97)M:6YA=&5D('=I=&@@-C`@
M9&%Y<R!W<FET=&5N(&YO=&EC92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/D1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB
M97(@,S$L(#(P,3(@86YD(#(P,3$L('1H92!#;VUP86YY(')E8V]G;FEZ960@
M<F5N="!E>'!E;G-E(&]F("0Q,C,L,#`P(&%N9"`D-C0L,#`P+"!R97-P96-T
M:79E;'DN/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VL@4F5P=7)C:&%S92!0<F]G<F%M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K(%)E<'5R8VAA<V4@4')O
M9W)A;2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K(%)E<'5R8VAA<V4@4')O9W)A;2!;5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQT86)L92!S
M='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`P+C5I;CLG
M/CQB/C@N/"]B/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3LG/CQB/E-T;V-K(%)E<'5R8VAA<V4@4')O9W)A;3PO8CX\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3`N
M-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M3VX@07!R:6P@,RP@,C`P.2P@=&AE($-O;7!A;GDF(S@R,3<[<R!";V%R9"!O
M9B!$:7)E8W1O<G,@87!P<F]V960@82!3=&]C:R!297!U<F-H87-E(%!R;V=R
M86T@875T:&]R:7II;F<@=&AE($-O;7!A;GD@=&\@<F5P=7)C:&%S92P@9G)O
M;2!T:6UE+71O+71I;64@86YD('1H<F]U9V@@1&5C96UB97(@,S$L(#(P,#DL
M('5P('1O("0Q(&UI;&QI;VX@;V8@:71S(&-O;6UO;B!S=&]C:RP@=7`@=&\@
M82!M87AI;75M(&]F(&9O=7(@;6EL;&EO;B!S:&%R97,@870@<')I8V5S(&]F
M('5P('1O("0U('!E<B!S:&%R92X@07,@;V8@1&5C96UB97(@,S$L(#(P,3(L
M('1H92!#;VUP86YY(&AA9"!R97!U<F-H87-E9"`X,2PT.#(@<VAA<F5S(&9O
M<B!A<'!R;WAI;6%T96QY("0U,"PP,#`@*"0P+C8Q('!E<B!S:&%R92DL(&)A
M<V5D('5P;VX@=&AE('%U;W1E9"!C;&]S:6YG('1R861I;F<@<')I8V4N)B,Q
M-C`[)B,Q-C`[5&AE<V4@=')E87-U<GD@<VAA<F5S(&%R92!N;W0@:6YC;'5D
M960@:6X@=&AE(&-O;7!U=&%T:6]N(&]F(&5A<FYI;F=S("AL;W-S*2!P97(@
M<VAA<F4@86YD(&%R92!D965M960@=&\@8F4@8V%N8V5L960@86YD(')E=&ER
M960N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X
M-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE(%1A>"!$
M:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!V97)T:6-A
M;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#!I;CLG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#`N
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M86)L93X-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`M,"XU:6X[(&UA<F=I
M;CH@,'!T(#!P>"`P<'0@,"XU:6X[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CPO9F]N=#XF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E1H97)E('=A<R!N;R!I;F-O;64@
M=&%X(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,B!A;F0@,C`Q,2!D=64@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!N970@
M;&]S<V5S+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E
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M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B`H8V]M<'5T960@
M8GD@87!P;'EI;F<@=&AE($9E9&5R86P@0V]R<&]R871E('1A>"!R871E(&]F
M(#,T)2!T;R!L;W-S(&)E9F]R92!T87AE<R!A;F0@,RXY-B4@9F]R($UI8VAI
M9V%N(%-T871E($-O<G!O<F%T92!T87AE<RP@=&AE(&)L96YD960@<F%T92!U
M<V5D('=A<R`S-RXY-B4I(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2P@*&-O;7!U
M=&5D(&)Y(&%P<&QY:6YG('1H92!&961E<F%L($-O<G!O<F%T92!T87@@<F%T
M92!O9B`S,BXQ,R4@=&\@;&]S<R!B969O<F4@=&%X97,@86YD(#4N-24@9F]R
M($UI8VAI9V%N(%-T871E($-O<G!O<F%T92!T87AE<RP@=&AE(&)L96YD960@
M<F%T92!U<V5D('=A<R`S-RXV,R4I+"!A<R!F;VQL;W=S(#QI/BAI;B!T:&]U
M<V%N9',I.CPO:3X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\=&%B;&4@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G=VED=&@Z(#@U)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<@<VEZ93TS1#(^/&(^,C`Q
M,3PO8CX\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
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M,24[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-"4[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B@U+#@P,SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^*3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M-#@\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXI/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F
M8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C4\+V9O;G0^/"]T
M9#X-"CQT9#X\+W1D/@T*/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXS
M-C8\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N
M=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^/&9O
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ
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M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
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M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/C4L.34V/"]F;VYT/CPO
M=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R<^
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF
M(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SY4:&4@969F96-T<R!O9B!T96UP;W)A<GD@9&EF9F5R96YC97,@=&AA
M="!G879E(')I<V4@=&\@<VEG;FEF:6-A;G0@<&]R=&EO;G,@;V8@9&5F97)R
M960@=&%X(&%S<V5T<R!A="!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2!A
M<F4@87,@9F]L;&]W<R`\:3XH:6X@=&AO=7-A;F1S*3H\+VD^/"]F;VYT/CPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$
M)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CX\8CY$969E
M<G)E9"8C,38P.W1A>"8C,38P.V%S<V5T<SH\+V(^/"]F;VYT/CPO=&0^#0H\
M=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
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M1#(^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/B8C,38P.SPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
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M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$
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M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
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M/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4]
M,T0R/C(P-3PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R/CPO9F]N=#X\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M.R!F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R
M/C$P+#0R-3PO9F]N=#X\+W1D/@T*/'1D/CPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
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M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V
M,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXH,38L.3`X/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXI
M/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CXH,3`L.34Q/"]F;VYT/CPO
M=&0^#0H\=&0^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXI/"]F;VYT/CPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.SL@9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)R!S:7IE/3-$,CY.970@9&5F
M97)R960@=&%X(&%S<V5T<SPO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
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M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[.R!F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G('-I>F4],T0R/BT\
M+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N
M=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M;R!P;W1E;G1I86P@;W=N97)S:&EP(&-H86YG97,@=6YD97(@4V5C=&EO;B`S
M.#(@;V8@=&AE($EN=&5R;F%L(%)E=F5N=64@0V]D92X\+V9O;G0^/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E1H92!V86QU871I;VX@86QL
M;W=A;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$Q('=A<R!A<'!R;WAI;6%T96QY
M("0Q,2XP(&UI;&QI;VXN(%1H92!N970@8VAA;F=E(&EN('9A;'5A=&EO;B!A
M;&QO=V%N8V4@9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$R('=A<R!A;B!I;F-R96%S92!O9B!A<'!R;WAI;6%T96QY("0V+C`@;6EL
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^05-#(#<T,"TQ,"`F(S@R,C`[/&D^06-C;W5N=&EN9R!F
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M9GD[('1E>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY!
M<R!O9B!$96-E;6)E<B8C,38P.S,Q+"`R,#$R(&%N9"`R,#$Q+"!T:&4@0V]M
M<&%N>2!H860@;F\@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R!A;F0@;F\@
M861J=7-T;65N=',@=&\@;&EA8FEL:71I97,@;W(@;W!E<F%T:6]N<R!W97)E
M(')E<75I<F5D('5N9&5R($%30R`W-#`M,3`N(%1H92!#;VUP86YY)B,X,C$W
M.W,@<')A8W1I8V4@=V%S(&%N9"!C;VYT:6YU97,@=&\@8F4@=&\@<F5C;V=N
M:7IE(&EN=&5R97-T(&%N9"!P96YA;'1Y(&5X<&5N<V5S(')E;&%T960@=&\@
M=6YC97)T86EN('1A>"!P;W-I=&EO;G,@:6X@:6YC;VUE('1A>"!E>'!E;G-E
M+"!W:&EC:"!W87,@>F5R;R!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,3(@86YD(#(P,3$N(%1H92!#;VUP86YY(&9I;&5S(%5N
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M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
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M('EE87)S(#(P,#`@=&AR;W5G:"`R,#$R(')E;6%I;B!S=6)J96-T('1O(&5X
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M87)D<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X(#!P="`R-"XT-7!T.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@
M,'!X.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SY4:&4@0V]M<&%N>2!D;V5S(&YO="!A;G1I
M8VEP871E('1H870@:70@:7,@<F5A<V]N86)L>2!P;W-S:6)L92!T:&%T('5N
M<F5C;V=N:7IE9"!T87@@8F5N969I=',@87,@;V8@1&5C96UB97(F(S$V,#LS
M,2P@,C`Q,B!W:6QL('-I9VYI9FEC86YT;'D@8VAA;F=E('=I=&AI;B!T:&4@
M;F5X="`Q,B!M;VYT:',N/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!0
M87)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(%!A<G1Y(%1R86YS
M86-T:6]N<R!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^,3`N(%)E;&%T960@4&%R='D@5')A
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M9B!T:&4@0V]M<&%N>2X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY&<F]M($IA
M;G5A<GD@,BP@,C`Q,B!T:')O=6=H(%-E<'1E;6)E<B`S,"P@,C`Q,BP@4W1E
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M=VEL;"!B92!E;G1I=&QE9"!T;R!A(&)A<V4@<V%L87)Y(&]F("0Y,"PP,#`@
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M96UE;G0@=V%S(&%M96YD960@*'1H92`F(S@R,C`[06UE;F1E9"!+86YZ97(@
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M86QA<GD@;V8@)#$U,"PP,#`@9F]R('1H92!T97)M(&%N9"!H96%L=&AC87)E
M(&-O=F5R86=E('!U<G-U86YT('1O('1H92!#;VUP86YY)B,X,C$W.W,@:&5A
M;'1H8V%R92!I;G-U<F%N8V4@<&QA;G,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
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M<B`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@17AC;'5S:79E
M($-H86YN96P@06=R965M96YT('=I=&@@26YT<F5X;VX@86YD(&ES<W5E9"`S
M+#$R,RPU-3@@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A<R!C;VYS:61E<F%T
M:6]N+"!H879I;F<@82!F86ER('9A;'5E(&]F("0Q+C<@;6EL;&EO;B`H)#`N
M-30@<&5R('-H87)E*2P@8F%S960@;VX@=&AE('%U;W1E9"!C;&]S:6YG('1R
M861I;F<@<')I8V4\9F]N="!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SXN($EN
M(&-O;FYE8W1I;VX@=VET:"!T:&4@3F]V96UB97(@,C`Q,2!A;F0@075G=7-T
M(#(P,3(@/"]F;VYT/D5X8VQU<VEV92!#:&%N;F5L($%G<F5E;65N=',L('1H
M92!#;VUP86YY('!A:60@26YT<F5X;VX@87!P<F]X:6UA=&5L>2`D,BXY(&UI
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M=&4@-"X@26X@3V-T;V)E<B`R,#$R+"!T:&4@0V]M<&%N>2!C;VYS=6UM871E
M9"!T:&4@0V]M<&%N>28C.#(Q-SMS($]C=&]B97(@,C`Q,B!0<FEV871E(%!L
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M=&5R97-T('1H97)E:6XN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y
M,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F
M7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T
M,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5.1D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H
M4&]L:6-I97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS
M;VQI9&%T:6]N+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^4')I;F-I<&QE<R!O
M9B!#;VYS;VQI9&%T:6]N/"]I/CPO8CX\+W`^/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D%L
M;"!I;G1E<BUC;VUP86YY('1R86YS86-T:6]N<R!A;F0@86-C;W5N=',@:&%V
M92!B965N(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;65R
M9VEN9R!&<F]M($1E=F5L;W!M96YT(%-T86=E(%M0;VQI8WD@5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/D5M
M97)G:6YG(&9R;VT@=&AE($1E=F5L;W!M96YT(%-T86=E/"]I/CPO8CX\+W`^
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/D1U<FEN9R!T:&4@<V5C;VYD('%U87)T97(@;V8@
M,C`Q,"P@=&AE($-O;7!A;GD@96UE<F=E9"!F<F]M('1H92!D979E;&]P;65N
M="!S=&%G92XF(S$V,#LF(S$V,#LF(S$V,#M!(&1E=F5L;W!M96YT+7-T86=E
M(&5N=&5R<')I<V4@:7,@;VYE(&EN('=H:6-H('!L86YN960@<')I;F-I<&QE
M(&]P97)A=&EO;G,@:&%V92!N;W0@8V]M;65N8V5D(&]R(&EF(&ET<R!O<&5R
M871I;VYS(&AA=F4@8V]M;65N8V5D+"!T:&5R92!H87,@8F5E;B!N;R!S:6=N
M:69I8V%N="!R979E;G5E+B8C,38P.T]N($UA>2`V+"`R,#$P+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@82!3=6)L:6-E;G-E($%G<F5E;65N="`H=&AE
M("8C.#(R,#M-961A($%G<F5E;65N="8C.#(R,3LI('=I=&@@365D828C,38P
M.T%"(&]F(%-W961E;B`H)B,X,C(P.TUE9&$F(S@R,C$[*2!A;F0@<F5C96EV
M960@86X@=7`M9G)O;G0@<&%Y;65N="!O9B`D,BXU(&UI;&QI;VXN(%1H92!E
M>&5C=71I;VX@;V8@=&AE($UE9&$@06=R965M96YT(&-O;6)I;F5D('=I=&@@
M<F5V96YU97,@9G)O;2!!9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>2!W97)E
M(&%N(&EN9&EC871I;VX@;V8@=&AE(&-O;6UE;F-E;65N="!O9B!P<FEN8VEP
M86P@;W!E<F%T:6]N<RP@86YD('1H97)E9F]R92!D979E;&]P;65N="US=&%G
M92!R97!O<G1I;F<@=V%S(&YO(&QO;F=E<B!R97%U:7)E9"X\+W`^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@
M;V8@17-T:6UA=&5S+"!0;VQI8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^57-E(&]F($5S
M=&EM871E<SPO:3X\+V(^/"]P/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
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M<V4@97-T:6UA=&5S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R96UI=6US(%)E8V5I=F%B;&4L($%L;&]W
M86YC92!F;W(@1&]U8G1F=6P@06-C;W5N=',L($5S=&EM871I;VX@365T:&]D
M;VQO9WDL(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y!8V-O=6YT<R!296-E:79A
M8FQE(&%N9"!!;&QO=V%N8V4@9F]R($1O=6)T9G5L($%C8V]U;G1S/"]I/CPO
M8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
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M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@
M4F5C;V=N:71I;VXL(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y2979E;G5E(%)E
M8V]G;FET:6]N/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@
M0V]M<&%N>2!R96-O<F1S(')E=F5N=64@=VAE;B!A;&P@;V8@=&AE(&9O;&QO
M=VEN9R!H879E(&]C8W5R<F5D.B`H,2D@<&5R<W5A<VEV92!E=FED96YC92!O
M9B!A;B!A<G)A;F=E;65N="!E>&ES=',L("@R*2!T:&4@<V5R=FEC92!I<R!C
M;VUP;&5T960@=VET:&]U="!F=7)T:&5R(&]B;&EG871I;VXL("@S*2!T:&4@
M<V%L97,@<')I8V4@=&\@=&AE(&-U<W1O;65R(&ES(&9I>&5D(&]R(&1E=&5R
M;6EN86)L92P@86YD("@T*2!C;VQL96-T86)I;&ET>2!I<R!R96%S;VYA8FQY
M(&%S<W5R960N)B,Q-C`[)B,Q-C`[5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!M
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M;FEC86P@3&%B;W)A=&]R>2X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
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M;&4@=7`M9G)O;G0@9F5E<RP@<&%Y;65N=',@<F5L871E9"!T;R!T:&4@86-H
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M:&4@<F5L871E9"!F965S(&)E8V]M92!D=64N/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!T:&4@365D82!!9W)E96UE
M;G0@9F]R('1H92!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@
M;V8@169F:7)M82`H;W)A;"!F;'5P:7)T:6YE*2!F;W(@9FEB<F]M>6%L9VEA
M+B8C,38P.R!!<R!C;VYS:61E<F%T:6]N(&9O<B!T:&4@<W5B;&EC96YS92P@
M=&AE($-O;7!A;GD@<F5C96EV960@86X@=7`M9G)O;G0@<&%Y;65N="!O9B`D
M,BXU(&UI;&QI;VX@=7!O;B!E>&5C=71I;VX@;V8@=&AE($UE9&$@06=R965M
M96YT+B!4:&ES('!A>6UE;G0@=V%S(')E8V]R9&5D(&%S(&QI8V5N<V4@<F5V
M96YU92!I;B`R,#$P+B!0=7)S=6%N="!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&QI8V5N<V4@86=R965M96YT('=I=&@@36-,96%N($AO<W!I=&%L+"!T:&4@
M0V]M<&%N>2!P86ED(#$U)2!O9B!T:&4@)#(N-2!M:6QL:6]N('!A>6UE;G0@
M*"0S-S4L,#`P*2P@=&AA="!W87,@;F5T=&5D(&%G86EN<W0@=&AE(')E=F5N
M=65S(')E8V5I=F5D(&9R;VT@365D82!!0BX@5&AE($-O;7!A;GD@:7,@86QS
M;R!E;G1I=&QE9"!T;R!A9&1I=&EO;F%L(&UI;&5S=&]N92!P87EM96YT<R!O
M9B`D-2!M:6QL:6]N('5P;VX@9FEL:6YG(&]F(&%N($Y$02!W:71H('1H92!5
M+E,N($9$02!F;W(@;W)A;"!F;'5P:7)T:6YE(&9O<B!F:6)R;VUY86QG:6$@
M86YD("0Q,"!M:6QL:6]N('5P;VX@;6%R:V5T:6YG(&%P<')O=F%L+B!4:&4@
M365D82!!9W)E96UE;G0@86QS;R!P<F]V:61E<R!T:&%T('1H92!#;VUP86YY
M(&ES(&5N=&ET;&5D('1O(')E8V5I=F4@;F5T(')O>6%L=&EE<R!O9B`W)2!O
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M92!R;WEA;'1I97,@=&AE($-O;7!A;GD@<F5C96EV97,N)B,Q-C`[)B,Q-C`[
M1G5T=7)E(&UI;&5S=&]N92!P87EM96YT<R!W:6QL(&)E(')E8V]R9&5D(&%S
M(')E=F5N=64@=VAE;B!P87EM96YT(&ES(')E8V5I=F5D(&%S('1H97)E(&%R
M92!N;R!F=71U<F4@9&5L:79E<F%B;&5S+"!A;F0@:70@:7,@;F]N+7)E9G5N
M9&%B;&4N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^3&%B;W)A=&]R>2!2
M979E;G5E<SPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M86-H('!E<FEO9"X@4V5E($YO=&4@,R`M($1I<V-O;G1I;G5E9"!/<&5R871I
M;VYS(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y+CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VMS
M(&%N9"!5;F-E<G1A:6YT:65S(%M0;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/E)I<VMS(&%N9"!5
M;F-E<G1A:6YT:65S/"]I/CPO8CX\+W`^/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/CQP('-T>6QE
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M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',L(%!O;&EC>2!;4&]L:6-Y
M(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SX\8CX\:3Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]I/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M(&EN8VQU9&4@8V%S:"!A;F0@:&EG:&QY(&QI<75I9"!S:&]R="UT97)M(&EN
M=F5S=&UE;G1S('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O9B!T:')E92!M
M;VYT:',@;W(@;&5S<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-87)K971A8FQE(%-E8W5R:71I97,@2&5L
M9"!4;R!-871U<FET>2!4<F%D:6YG($%V86EL86)L92!&;W(@4V%L92!396-U
M<FET:65S(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
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M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY4:&4@0V]M<&%N>2!D971E<FUI;F5S('1H92!A<'!R
M;W!R:6%T92!C;&%S<VEF:6-A=&EO;B!O9B!I=',@:6YV97-T;65N=',@:6X@
M9&5B="!A;F0@97%U:71Y('-E8W5R:71I97,@870@=&AE('1I;64@;V8@<'5R
M8VAA<V4@86YD(')E979A;'5A=&5S('-U8V@@9&5T97)M:6YA=&EO;G,@870@
M96%C:"!B86QA;F-E('-H965T(&1A=&4N($1E8G0@<V5C=7)I=&EE<R!A<F4@
M8VQA<W-I9FEE9"!A<R!H96QD('1O(&UA='5R:71Y('=H96X@=&AE($-O;7!A
M;GD@:&%S('1H92!P;W-I=&EV92!I;G1E;G0@86YD(&%B:6QI='D@=&\@:&]L
M9"!T:&4@<V5C=7)I=&EE<R!T;R!M871U<FET>2X@1&5B="!S96-U<FET:65S
M(&9O<B!W:&EC:"!T:&4@0V]M<&%N>2!D;V5S(&YO="!H879E('1H92!I;G1E
M;G0@;W(@86)I;&ET>2!T;R!H;VQD('1O(&UA='5R:71Y(&%R92!C;&%S<VEF
M:65D(&%S(&%V86EL86)L92!F;W(@<V%L92X@2&5L9"!T;R!M871U<FET>2!S
M96-U<FET:65S(&%R92!R96-O<F1E9"!A<R!E:71H97(@<VAO<G0M=&5R;2!O
M<B!L;VYG+71E<FT@;VX@=&AE(&)A;&%N8V4@<VAE970L(&)A<V5D(&]N(&-O
M;G1R86-T=6%L(&UA='5R:71Y(&1A=&4@86YD(&%R92!S=&%T960@870@86UO
M<G1I>F5D(&-O<W0N($UA<FME=&%B;&4@<V5C=7)I=&EE<R!T:&%T(&%R92!B
M;W5G:'0@86YD(&AE;&0@<')I;F-I<&%L;'D@9F]R('1H92!P=7)P;W-E(&]F
M('-E;&QI;F<@=&AE;2!I;B!T:&4@;F5A<B!T97)M(&%R92!C;&%S<VEF:65D
M(&%S('1R861I;F<@<V5C=7)I=&EE<R!A;F0@87)E(')E<&]R=&5D(&%T(&9A
M:7(@=F%L=64L('=I=&@@=6YR96%L:7IE9"!G86EN<R!A;F0@;&]S<V5S(')E
M8V]G;FEZ960@:6X@96%R;FEN9W,N($1E8G0@86YD(&UA<FME=&%B;&4@97%U
M:71Y('-E8W5R:71I97,@;F]T(&-L87-S:69I960@87,@:&5L9"!T;R!M871U
M<FET>2!O<B!A<R!T<F%D:6YG+"!A<F4@8VQA<W-I9FEE9"!A<R!A=F%I;&%B
M;&4@9F]R('-A;&4L(&%N9"!A<F4@8V%R<FEE9"!A="!F86ER(&UA<FME="!V
M86QU92P@=VET:"!T:&4@=6YR96%L:7IE9"!G86EN<R!A;F0@;&]S<V5S+"!N
M970@;V8@=&%X+"!I;F-L=61E9"!I;B!T:&4@9&5T97)M:6YA=&EO;B!O9B!C
M;VUP<F5H96YS:79E(&EN8V]M92!A;F0@<F5P;W)T960@:6X@<VAA<F5H;VQD
M97)S)B,X,C$W.R!E<75I='DN($%T($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R
M,#$Q+"!R97-P96-T:79E;'DL('1H92!#;VUP86YY(&AA9"!N;R!D96)T(&%N
M9"!M87)K971A8FQE(&5Q=6ET>2!S96-U<FET:65S+CPO<#X\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!T:&4@0V]M<&%N>2!H96QD(&EN=F5S=&UE;G1S(&EN(&UA<FME=&%B;&4@
M<V5C=7)I=&EE<R!T:&%T('=E<F4@8VQA<W-I9FEE9"!A<R!H96QD('1O(&UA
M='5R:71Y(&%N9"!C;VYS:7-T960@;V8@8V]R<&]R871E(&)O;F1S(&%N9"!C
M97)T:69I8V%T97,@;V8@9&5P;W-I=',@87,@9F]L;&]W<R`\:3XH:6X@=&AO
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M;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^1&5C96UB97(@,S$L(#(P,3$\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CPO='(^/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=VED=&@Z(#<R)3LG/E!U<F-H87-E(&]F('-H;W)T+71E<FT@:6YV
M97-T;65N=',\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H
M.B`R-24[)SXH-"PS-S`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[)SXI/"]T9#X\+W1R/CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<^06UO<G1I>F%T
M:6]N(&]F('!R96UI=6T@;VX@:6YV97-T;65N=',\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^1F%I<B!V86QU93PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L(%!O;&EC>2!;4&]L
M:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\8CX\:3Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]I/CPO8CX\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
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M:6YG('1A8FQE+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`W,"4[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@=VED=&@Z(#0Y)3LG(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^/&(^07-S970F(S$V,#M$97-C<FEP=&EO;CPO8CX\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`T
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M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q
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M;W`[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
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M=&5R.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^3&5S<V5R(&]F(&5S=&EM871E9"!U<V5F
M=6P@;W(@;&EF92!O9B!L96%S93PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SY$97!R96-I871I;VX@97AP96YS92!W87,@87!P<F]X:6UA=&5L>2`D-C,L
M,#`P(&%N9"`D,30T+#`P,"!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R
M(#,Q+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN(%=H96X@87-S971S
M(&%R92!D:7-P;W-E9"!O9BP@=&AE(&-O<W0@86YD(&%C8W5M=6QA=&5D(&1E
M<')E8VEA=&EO;B!A<F4@<F5M;W9E9"!F<F]M('1H92!A8V-O=6YT<RX@4F5P
M86ER<R!A;F0@;6%I;G1E;F%N8V4@87)E(&-H87)G960@=&\@97AP96YS92!A
M<R!I;F-U<G)E9"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY$=7)I;F<@,C`Q
M,BP@=&AE($-O;7!A;GD@<F5V:65W960@<')O<&5R='D@86YD(&5Q=6EP;65N
M="!F;W(@:6UP86ER;65N="!A;F0@9&5T97)M:6YE9"!T:&%T(&-E<G1A:6X@
M:71E;7,@=V5R92!I;7!A:7)E9"!D=64@=&\@;V)S;VQE<V-E;F-E+B!!<R!A
M(')E<W5L="!O9B!T:&ES(')E=FEE=RP@=&AE($-O;7!A;GD@<F5C;W)D960@
M86X@:6UP86ER;65N="!L;W-S(&]F(&%P<')O>&EM871E;'D@)#0W+#`P,"X@
M1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&5R92!W
M97)E(&YO('-I9VYI9FEC86YT(&5V96YT<R!O<B!C:&%N9V5S(&EN(&-I<F-U
M;7-T86YC97,@:61E;G1I9FEE9"!B>2!T:&4@0V]M<&%N>2!T:&%T('=O=6QD
M(&EN9&EC871E('1H870@=&AE(&-A<G)Y:6YG('9A;'5E(&]F(&%N(&%S<V5T
M('=A<R!N;W0@<F5C;W9E<F%B;&4N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N="!O<B!$:7-P
M;W-A;"!O9B!,;VYG+4QI=F5D($%S<V5T<RP@4&]L:6-Y(%M0;VQI8WD@5&5X
M="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB
M/CQI/DQO;F<M3&EV960@07-S971S/"]I/CPO8CX\+W`^/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
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M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W:6QL
M(&%N9"!);G1A;F=I8FQE($%S<V5T<RP@1V]O9'=I;&PL(%!O;&EC>2!;4&]L
M:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\8CX\:3Y';V]D=VEL;#PO:3X\+V(^/"]P/CQP('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
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M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^05-#($YO+B`S-3`L("8C.#(R,#M);G1A;F=I8FQE<R`F(S@R
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M;7!T:6]N<RX\+W`^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D%T($1E8V5M8F5R(#,Q+"`R
M,#$Q+"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($-O;7!A;GD@8VQA<W-I9GEI
M;F<@061E;VYA($-L:6YI8V%L($QA8F]R871O<GD@87,@9&ES8V]N=&EN=65D
M(&]P97)A=&EO;G,L('!R979I;W5S;'D@<F5C;W)D960@9V]O9'=I;&P@=V%S
M(&-O;G-I9&5R960@:6UP86ER960N(%-E92!.;W1E(#,@)B,X,C$Q.R!$:7-C
M;VYT:6YU960@3W!E<F%T:6]N<R!O9B!!9&5O;F$@0VQI;FEC86P@3&%B;W)A
M=&]R>2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$97)I=F%T:79E<RP@4F5P;W)T:6YG(&]F($1E<FEV871I
M=F4@06-T:79I='D@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\8CX\:3Y$97)I
M=F%T:79E($QI86)I;&ET:65S/"]I/CPO8CX\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
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M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5A<FYI;F=S(%!E<B!3:&%R92P@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C
M:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/CQI/DYE
M="!);F-O;64@*$QO<W,I('!E<B!3:&%R93PO:3X\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^3F5T(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&ES(&-O
M;7!U=&5D(&)Y(&1I=FED:6YG(&YE="!I;F-O;64@*&QO<W,I(&)Y('1H92!W
M96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T
M86YD:6YG+B!$:6QU=&5D(&EN8V]M92`H;&]S<RD@<&5R('-H87)E(&ES(&-O
M;7!U=&5D(&)Y(&1I=FED:6YG(&YE="!I;F-O;64@*&QO<W,I(&)Y('1H92!W
M96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T
M86YD:6YG(&EN8VQU9&EN9R!T:&4@969F96-T(&]F(&-O;6UO;B!S:&%R92!E
M<75I=F%L96YT<RX@06QL(&-O;6UO;B!E<75I=F%L96YT('-H87)E<R!W97)E
M(&%N=&DM9&EL=71I=F4L(&%T($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"!$96-E
M;6)E<B`S,2P@,C`Q,2P@87,@<W5C:"!T:&5R92!I<R!N;R!S97!A<F%T92!C
M;VUP=71A=&EO;B!F;W(@9&EL=71E9"!L;W-S('!E<B!S:&%R92X@5&AE(&YU
M;6)E<B!O9B!O<'1I;VYS(&%N9"!W87)R86YT<R!F;W(@=&AE('!U<F-H87-E
M(&]F(&-O;6UO;B!S=&]C:RP@=&AA="!W97)E(&5X8VQU9&5D(&9R;VT@=&AE
M(&-O;7!U=&%T:6]N<R!O9B!N970@;&]S<R!P97(@8V]M;6]N('-H87)E(&9O
M<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!W97)E(#0L-#4S
M+#<T-B!A;F0@,2PV,S(L-3`Q+"!R97-P96-T:79E;'DL(&%N9"!F;W(@=&AE
M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3$@=V5R92`R+#DW.2PP,3`@
M86YD(#,L,C4Y+#$X-BP@<F5S<&5C=&EV96QY+CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N
M9"!$979E;&]P;65N="!%>'!E;G-E+"!0;VQI8WD@6U!O;&EC>2!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^
M4F5S96%R8V@@86YD($1E=F5L;W!M96YT($-O<W1S/"]I/CPO8CX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O9B!&
M:6YA;F-I86P@26YS=')U;65N=',L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y&
M86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO:3X\+V(^/"]P
M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`S)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
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M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N,C5I;CL@
M;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S
M='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`S)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#,E.R<^
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M;"`Q('1H870@87)E(&]B<V5R=F%B;&4@96ET:&5R(&1I<F5C=&QY(&]R(&EN
M9&ER96-T;'D[(&%N9#PO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M+3`N,C5I;CL@;6%R9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`S)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED
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M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
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M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SY#87-H(&%N9"!C87-H(&5Q=6EV86QE
M;G1S(&EN8VQU9&4@;6]N97D@;6%R:V5T(&%C8V]U;G1S(&%N9"!M=71U86P@
M9G5N9',@;V8@)#@N-B!M:6QL:6]N(&%N9"`D-2XP(&UI;&QI;VX@87,@;V8@
M1&5C96UB97(@,S$L(#(P,3(@86YD($1E8V5M8F5R(#,Q+"`R,#$Q+"!R97-P
M96-T:79E;'DL('1H870@87)E(&UE87-U<F5D('5S:6YG($QE=F5L(#$@:6YP
M=71S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K($)A<V5D(%!A>6UE;G0@07)R86YG96UE;G1S(%M0
M;VQI8WD@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQB/CQI/E-T;V-K+4)A<V5D(%!A>6UE;G0@07)R86YG96UE;G1S
M/"]I/CPO8CX\+W`^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)W1E>'0M86QI
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M9&5D+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN8V]M92!487@L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
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M(&=U:61A;F-E(&YO=R!C;V1I9FEE9"!A<R!&05-"($%30R!4;W!I8R`W-#`M
M,C`L(#QI/B8C.#(R,#M);F-O;64@5&%X97,@)B,X,C$Q.R!);G1R87!E<FEO
M9"!487@@06QL;V-A=&EO;B8C.#(R,3L@/"]I/G)E<75I<F5S/&D^(#PO:3YM
M86YA9V5M96YT('1O(&%S<V5S<R!T:&4@;F5E9"!T;R!A8V-R=64@;W(@9&ES
M8VQO<V4@=6YC97)T86EN('1A>"!P;W-I=&EO;G,@9F]R('!R;W!O<V5D('!O
M=&5N=&EA;"!A9&IU<W1M96YT<R!F<F]M('9A<FEO=7,@9F5D97)A;"!A;F0@
M<W1A=&4@875T:&]R:71I97,@=VAO(')E9W5L87)L>2!A=61I="!T:&4@0V]M
M<&%N>2!I;B!T:&4@;F]R;6%L(&-O=7)S92!O9B!B=7-I;F5S<RX@26X@;6%K
M:6YG('1H97-E(&%S<V5S<VUE;G1S+"!M86YA9V5M96YT(&UU<W0@;V9T96X@
M86YA;'EZ92!C;VUP;&5X('1A>"!L87=S(&]F(&UU;'1I<&QE(&IU<FES9&EC
M=&EO;G,N(%1H92!A8V-O=6YT:6YG(&=U:61A;F-E('!R97-C<FEB97,@82!R
M96-O9VYI=&EO;B!T:')E<VAO;&0@86YD(&UE87-U<F5M96YT(&%T=')I8G5T
M92!F;W(@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G0@<F5C;V=N:71I;VX@86YD
M(&UE87-U<F5M96YT(&]F(&$@=&%X('!O<VET:6]N('1A:V5N(&]R(&5X<&5C
M=&5D('1O(&)E('1A:V5N(&EN(&$@=&%X(')E='5R;BX@5&AE($-O;7!A;GD@
M<F5C;W)D<R!T:&4@<F5L871E9"!I;G1E<F5S="!E>'!E;G-E(&%N9"!P96YA
M;'1I97,L(&EF(&%N>2P@87,@=&%X(&5X<&5N<V4@:6X@=&AE('1A>"!P<F]V
M:7-I;VXN($%T($1E8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T
M:79E;'DL('1H92!#;VUP86YY(&1I9"!N;W0@<F5C;W)D(&%N>2!L:6%B:6QI
M=&EE<R!F;W(@=6YC97)T86EN('1A>"!P;W-I=&EO;G,N/"]P/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5W($%C
M8V]U;G1I;F<@4')O;F]U;F-E;65N=',L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
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M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
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M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D8^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT
M:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y(96QD+71O+6UA='5R:71Y(%-E8W5R:71I97,@6U1A8FQE(%1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!I;B`P:6X@
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M;W=S(#QI/BAI;B!T:&]U<V%N9',I/"]I/B`Z/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@-S`E.R!B;W)D
M97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!M<V\M>69T:2UT8FQL;V]K.B`Q,3@T
M.R!M<V\M<&%D9&EN9RUA;'0Z(#!I;B`P:6X@,&EN(#!I;CLG(&-L87-S/3-$
M;7-O;F]R;6%L=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)VUS;RUY9G1I+6ER;W<Z(#`[
M(&US;RUY9G1I+69I<G-T<F]W.B!Y97,[)SX-"CQT9"!S='EL93TS1"=P861D
M:6YG.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG(&-L87-S/3-$;7-O
M;F]R;6%L/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@<&%D9&EN9RUL
M969T.B`P:6X[('!A9&1I;F<M<FEG:'0Z(#!I;CL@<&%D9&EN9RUT;W`Z(#!I
M;CLG('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^#0H\<"!C;&%S
M<STS1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/CQB/B8C,38P.SPO8CX\+V9O
M;G0^/"]P/@T*/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B!M961I=6T@;F]N93L@8F]R
M9&5R+71O<#H@;65D:75M(&YO;F4[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO
M;F4[('!A9&1I;F<Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^#0H\<"!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;&%S<STS1&US;VYO<FUA;#X\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/CQB/D1E8V5M8F5R(#,Q+"`R,#$Q/"]B/CPO9F]N=#X\+W`^
M#0H\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A
M9&1I;F<M;&5F=#H@,&EN.R!P861D:6YG+7)I9VAT.B`P:6X[('!A9&1I;F<M
M=&]P.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/@T*
M/'`@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SX\8CXF(S$V,#L\
M+V(^/"]F;VYT/CPO<#X-"CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)VUS
M;RUY9G1I+6ER;W<Z(#$[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@-S(E.R!B
M86-K9W)O=6YD.B`C8V-F9F-C.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0W,B4^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R<@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY0=7)C
M:&%S92!O9B!S:&]R="UT97)M(&EN=F5S=&UE;G1S/"]F;VYT/CPO<#X-"CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B86-K9W)O=6YD.B`C8V-F
M9F-C.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"CQP(&-L87-S/3-$;7-O;F]R;6%L/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B
M86-K9W)O=6YD.B`C8V-F9F-C.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)3X-"CQP(&-L87-S/3-$;7-O;F]R;6%L/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^)#PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`R-24[(&)A8VMG<F]U;F0Z("-C8V9F8V,[('!A9&1I;F<Z(#!I;CLG
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(U)3X-"CQP(&%L:6=N/3-$<FEG
M:'0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)R!C;&%S<STS1&US;VYO
M<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/B@T+#,W,#PO9F]N=#X\+W`^#0H\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F%C:V=R;W5N9#H@(V-C9F9C8SL@
M<&%D9&EN9SH@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H\
M<"!C;&%S<STS1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/BD\+V9O;G0^/"]P
M/@T*/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G;7-O+7EF=&DM:7)O=SH@
M,CLG/@T*/'1D('-T>6QE/3-$)V)A8VMG<F]U;F0Z('=H:71E.R!P861D:6YG
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R<@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SY!;6]R=&EZ871I;VX@;V8@<')E;6EU;2!O;B!I;G9E<W1M96YT<SPO9F]N
M=#X\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)V)A8VMG<F]U;F0Z('=H:71E
M.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^#0H\<"!C;&%S<STS
M1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\
M+W1D/@T*/'1D('-T>6QE/3-$)V)A8VMG<F]U;F0Z('=H:71E.R!P861D:6YG
M.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^#0H\<"!C;&%S<STS1&US;VYO<FUA
M;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)V)A8VMG<F]U;F0Z('=H:71E.R!P861D:6YG.B`P:6X[)R!V
M86QI9VX],T1B;W1T;VT^#0H\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXU-SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)V)A8VMG
M<F]U;F0Z('=H:71E.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^
M#0H\<"!C;&%S<STS1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO
M9F]N=#X\+W`^#0H\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=M<V\M>69T
M:2UI<F]W.B`S.R<^#0H\=&0@<W1Y;&4],T0G8F%C:V=R;W5N9#H@(V-C9F9C
M8SL@<&%D9&EN9SH@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4]
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M/'`@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O
M;G0^/"]P/@T*/"]T9#X-"CQT9"!S='EL93TS1"=B86-K9W)O=6YD.B`C8V-F
M9F-C.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^#0H\<"!C;&%S
M<STS1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^
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M.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@8VQA<W,],T1M<V]N;W)M86P^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G;7-O+7EF=&DM:7)O=SH@-#LG/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@,&EN.R!P861D
M:6YG+7)I9VAT.B`P:6X[(&)A8VMG<F]U;F0Z('=H:71E.R!P861D:6YG+71O
M<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G=&5X="UA
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M86-K9W)O=6YD.B!W:&ET93L@<&%D9&EN9RUT;W`Z(#!I;CLG('9A;&EG;CTS
M1&)O='1O;3X-"CQP(&-L87-S/3-$;7-O;F]R;6%L/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M
M(&YO;F4[(&)A8VMG<F]U;F0Z('=H:71E.R!B;W)D97(M=&]P.B!M961I=6T@
M;F]N93L@8F]R9&5R+7)I9VAT.B!M961I=6T@;F]N93L@<&%D9&EN9SH@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@8VQA<W,],T1M<V]N;W)M86P^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&)O<F1E<BUL
M969T.B!M961I=6T@;F]N93L@8F%C:V=R;W5N9#H@=VAI=&4[(&)O<F1E<BUT
M;W`Z(&UE9&EU;2!N;VYE.R!B;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R!P
M861D:6YG.B`P:6X[)R!V86QI9VX],T1B;W1T;VT^#0H\<"!A;&EG;CTS1')I
M9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@8VQA<W,],T1M<V]N
M;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXR,#PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@
M,&EN.R!P861D:6YG+7)I9VAT.B`P:6X[(&)A8VMG<F]U;F0Z('=H:71E.R!P
M861D:6YG+71O<#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@8VQA<W,]
M,T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G;7-O+7EF=&DM:7)O=SH@-3L@
M;7-O+7EF=&DM;&%S=')O=SH@>65S.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!P861D:6YG+6QE9G0Z(#!I;CL@<&%D9&EN9RUR
M:6=H=#H@,&EN.R!B86-K9W)O=6YD.B`C8V-F9F-C.R!P861D:6YG+71O<#H@
M,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3LG(&-L87-S/3-$;7-O;F]R;6%L/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M1F%I<B!V86QU93PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`P:6X[('!A9&1I
M;F<M<FEG:'0Z(#!I;CL@8F%C:V=R;W5N9#H@(V-C9F9C8SL@<&%D9&EN9RUT
M;W`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;3X-"CQP(&-L87-S/3-$;7-O;F]R
M;6%L/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.R!B86-K9W)O=6YD.B`C8V-F
M9F-C.R!B;W)D97(M=&]P.B!M961I=6T@;F]N93L@8F]R9&5R+7)I9VAT.B!M
M961I=6T@;F]N93L@<&%D9&EN9SH@,&EN.R<@=F%L:6=N/3-$8F]T=&]M/@T*
M/'`@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO
M<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@8F]R9&5R+6QE9G0Z(&UE9&EU;2!N;VYE.PT*(&)A
M8VMG<F]U;F0Z("-C8V9F8V,[(&)O<F1E<BUT;W`Z(&UE9&EU;2!N;VYE.R!B
M;W)D97(M<FEG:'0Z(&UE9&EU;2!N;VYE.R!P861D:6YG.B`P:6X[)R!V86QI
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M=#H@,&EN.R!B86-K9W)O=6YD.B`C8V-F9F-C.R!P861D:6YG+71O<#H@,&EN
M.R<@=F%L:6=N/3-$8F]T=&]M/@T*/'`@8VQA<W,],T1M<V]N;W)M86P^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17-T:6UA=&5D(%5S969U;"!,:69E($]F($%S<V5T<R!;5&%B
M;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,&EN
M(#!I;B`P<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
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M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P:6X@,&EN(#!P=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQD:78@86QI9VX],T1C96YT97(^
M#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#<P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@;7-O+7EF=&DM=&)L;&]O:SH@,3$X-#L@;7-O+7!A9&1I
M;F<M86QT.B`P:6X@,&EN(#!I;B`P:6X[)R!C;&%S<STS1&US;VYO<FUA;'1A
M8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<B!S='EL93TS1"=M<V\M>69T:2UI<F]W.B`P.R!M<V\M>69T:2UF
M:7)S=')O=SH@>65S.R<^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@;65D:75M(&YO;F4[('=I
M9'1H.B`T.24[(&)O<F1E<BUT;W`Z(&UE9&EU;2!N;VYE.R!B;W)D97(M<FEG
M:'0Z(&UE9&EU;2!N;VYE.R!P861D:6YG.B`P:6X[)R!V86QI9VX],T1T;W`@
M=VED=&@],T0T.24@;F]W<F%P/3-$;F]W<F%P/@T*/'`@86QI9VX],T1C96YT
M97(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8VQA<W,],T1M<V]N
M;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SX\8CY!<W-E="8C,38P.T1E<V-R:7!T:6]N
M/"]B/CPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`T
M)3L@<&%D9&EN9SH@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@;F]W
M<F%P/3-$;F]W<F%P/@T*/'`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[(&)O<F1E<BUL969T.B!M
M961I=6T@;F]N93L@=VED=&@Z(#0W)3L@8F]R9&5R+71O<#H@;65D:75M(&YO
M;F4[(&)O<F1E<BUR:6=H=#H@;65D:75M(&YO;F4[('!A9&1I;F<Z(#!I;CLG
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#0W)2!N;W=R87`],T1N;W=R87`^#0H\
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M9"!S='EL93TS1"=P861D:6YG.B`P:6X[)R!V86QI9VX],T1T;W`^#0H\<"!C
M;&%S<STS1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D]F9FEC92!E<75I<&UE
M;G0@86YD(&9U<FYI='5R93PO9F]N=#X\+W`^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!I;CLG('9A;&EG;CTS1'1O<#X-"CQP(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-L87-S/3-$
M;7-O;F]R;6%L/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,&EN.R<@=F%L:6=N/3-$=&]P
M/@T*/'`@86QI9VX],T1C96YT97(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8VQA<W,],T1M<V]N;W)M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXS+34F(S$V
M,#LF(S$V,#MY96%R<SPO9F]N=#X\+W`^#0H\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=M<V\M>69T:2UI<F]W.B`R.R<^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9SH@,&EN.R<@=F%L:6=N/3-$=&]P/@T*/'`@8VQA<W,],T1M<V]N;W)M
M86P^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SY,86)O<F%T;W)Y(&5Q=6EP;65N=#PO9F]N=#X\
M+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!I;CLG('9A;&EG
M;CTS1'1O<#X-"CQP(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&-L87-S/3-$;7-O;F]R;6%L/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,&EN.R<@=F%L:6=N/3-$=&]P/@T*/'`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8VQA<W,],T1M<V]N;W)M86P^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXW+3$P('EE87)S/"]F;VYT/CPO<#X-"CPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)VUS;RUY9G1I+6ER;W<Z(#,[)SX-"CQT9"!S
M='EL93TS1"=P861D:6YG.B`P:6X[)R!V86QI9VX],T1T;W`^#0H\<"!C;&%S
M<STS1&US;VYO<FUA;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/DUA;G5F86-T=7)I;F<@97%U
M:7!M96YT/"]F;VYT/CPO<#X-"CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,&EN.R<@=F%L:6=N/3-$=&]P/@T*/'`@86QI9VX],T1C96YT97(@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8VQA<W,],T1M<V]N;W)M86P^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG.B`P:6X[)R!V86QI9VX],T1T;W`^#0H\<"!A;&EG
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M:6YG.B`P:6X[)R!V86QI9VX],T1T;W`^#0H\<"!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;&%S<STS1&US;VYO<FUA
M;#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W`^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!I;CLG('9A;&EG;CTS1'1O<#X-"CQP(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-L
M87-S/3-$;7-O;F]R;6%L/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^3&5S<V5R(&]F(&5S=&EM
M871E9"!U<V5F=6P@;W(@;&EF92!O9B!L96%S93PO9F]N=#X\+W`^#0H\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^1&ES8V]N=&EN=65D($]P97)A=&EO;G,@;V8@061E;VYA($-L:6YI
M8V%L($QA8F]R871O<GD@86YD($YO=&4@4F5C96EV86)L92`H5&%B;&5S*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$:7-C;VYT:6YU960@3W!E<F%T:6]N<R!A;F0@1&ES<&]S86P@1W)O=7!S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V-H961U;&4@;V8@1&ES<&]S86P@1W)O=7!S($EN8VQU9&EN
M9R!$:7-C;VYT:6YU960@3W!E<F%T:6]N<R!"86QA;F-E(%-H965T(&%N9"!!
M9&1I=&EO;F%L($1I<V-L;W-U<F5S(%M486)L92!497AT($)L;V-K73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G
M/E1H92!A<W-E=',@;V8@=&AE(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS(&%R
M92!P<F5S96YT960@<V5P87)A=&5L>2!U;F1E<B!T:&4@8V%P=&EO;B`F(S@R
M,C`[07-S971S(&]F(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS)B,X,C(Q.R!I
M;B!T:&4@86-C;VUP86YY:6YG($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T
M<R!A="!$96-E;6)E<B`S,2P@,C`Q,BP@86YD($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!A;F0@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG(#QI/BAI;B!T:&]U<V%N
M9',I.CPO:3X\+V9O;G0^/"]D:78^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N
M=#H@+3`N-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&9O;G0@<VEZ
M93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I
M;65S)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'1A8FQE(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S:7IE
M/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM
M97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$-CX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/D1E
M8V5M8F5R(#,Q+#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^,C`Q,CPO9F]N
M=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
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M;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<VEZ93TS
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@
M.7!T.R!W:61T:#H@-S0E.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SY0<F]P97)T>2!A;F0@
M97%U:7!M96YT+"!N970\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$P)3LG/CQF;VYT
M('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;BQT:6UE<R<^+3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('=I9'1H.B`Q)3LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R<^/&9O;G0@<VEZ93TS
M1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S
M)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
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M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/E1O
M=&%L(&%S<V5T<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
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M9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXR,SPO
M9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($1I<W!O
M<V%L($=R;W5P<R!);F-L=61I;F<@1&ES8V]N=&EN=65D($]P97)A=&EO;G,@
M26YC;VUE(%-T871E;65N="!A;F0@061D:71I;VYA;"!$:7-C;&]S=7)E<R!;
M5&%B;&4@5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
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M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$@
M87)E(&%S(&9O;&QO=W,@/&D^*&EN('1H;W5S86YD<RDZ/"]I/CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQT86)L
M92!S='EL93TS1"=W:61T:#H@.3,E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XM;&5F=#H@,"XU:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9#X\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$-CX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/D1E8V5M8F5R(#,Q+#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
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M;VUA;BQT:6UE<R<^,C`Q,CPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
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M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
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M9G0[('=I9'1H.B`Q)3LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)#PO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^
M/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N+'1I;65S)SXQ,34\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SX\9F]N="!S:7IE/3-$,B!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C
M,38P.SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/CQF
M;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^/&9O;G0@<VEZ93TS1#(@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXD
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Q,"4[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
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M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4]
M,T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE
M<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
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M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
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M(')O;6%N+'1I;65S)SY#;W-T(&]F)B,Q-C`[(&QA8F]R871O<GD@<V5R=FEC
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M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXQ,3`\+V9O;G0^/"]T
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M;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L
M969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXM/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXQ-S@\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@.7!T.R<^/&9O
M;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N+'1I;65S)SY4;W1A;"!O<&5R871I;F<@8V]S=',@86YD(&5X<&5N<V5S
M/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
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M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
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M;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R
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M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
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M(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[
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M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I
M>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT
M:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R!P861D:6YG+6QE9G0Z(#`N,3(U:6X[)SX\9F]N
M="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XL=&EM97,G/D=A:6X@;VX@<V%L92!O9B!!9&5O;F$@0VQI;FEC86P@3&%B
M;W)A=&]R>3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B8C,38P.SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT
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M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N+'1I;65S)SXM/"]F;VYT/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F;VYT/CPO=&0^#0H\
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/CQF;VYT('-I>F4],T0R('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;BQT:6UE<R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N+'1I;65S)SXF(S$V,#L\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XL=&EM97,G/B0\+V9O;G0^/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
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M#0H\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F
M9&(Y,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B9#5E.#(T9E]C
M-S$T7S1F9C-?.#0Q-U\W.6,U9CDQ9F1B.3$O5V]R:W-H965T<R]3:&5E=#(R
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,4%!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M96QE8W1E9"!"86QA;F-E(%-H965T($EN9F]R;6%T:6]N("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO;B!A;F0@4')E<V5N=&%T:6]N
M($]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@
M06-C;W5N=',L($YO=&5S+"!,;V%N<R!A;F0@1FEN86YC:6YG(%)E8V5I=F%B
M;&4@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\:3Y!8V-O=6YT<R!R96-E:79A8FQE("AI;B!T:&]U<V%N
M9',I/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W
M:61T:#H@-S4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F
M=#H@,"XU:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<#Y$96-E
M;6)E<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
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M86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=VED
M=&@Z(#<T)3LG/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXV.#(\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#$P)3LG/C8Y,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R<^0F%D(&1E8G0@86QL;W=A;F-E("T@8W5S
M=&]M97(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/B@V.#(\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($]T:&5R($-U<G)E
M;G0@07-S971S(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^/&D^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!A<W-E=',@*&EN('1H;W5S86YD<RD\+VD^/"]P/@T*/'1A
M8FQE('-T>6QE/3-$)W=I9'1H.B`W-24[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;BUL969T.B`P+C5I;CLG(&)O<F1E<CTS1#`@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG
M:'0Z(&)O;&0[)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^1&5C96UB
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M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$
M;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/C(P
M,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('=I9'1H
M.B`W-"4[)SY);G1R97AO;B!P<F5P86ED(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#$P)3LG/C(L-#$R/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXM/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/=&AE<B!R96-E:79A8FQE
M<SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/C$W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SY0<F5P86ED(&5X<&5N
M<V5S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
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M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R<^,38\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/E1O=&%L
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
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M-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N
M9"!%<75I<&UE;G0@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\:3Y0<F]P97)T>2!A;F0@97%U:7!M96YT
M("AI;B!T:&]U<V%N9',I)B,Q-C`[/"]I/CPO<#X-"CQT86)L92!S='EL93TS
M1"=W:61T:#H@-S4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM
M;&5F=#H@,"XU:6X[)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS
M1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0V(&YO=W)A<#TS1&YO=W)A<#Y$
M96-E;6)E<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P
M86X],T0R(&YO=W)A<#TS1&YO=W)A<#XR,#$Q/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=VED=&@Z(#<T)3LG/DUA;G5F86-T=7)I;F<@97%U:7!M96YT/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,CDW
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[('=I9'1H.B`Q,"4[)SXT,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
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M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/DQA8F]R871O<GD@97%U:7!M96YT
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ,S,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
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M;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0V-3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/B@R-#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
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M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C(R,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T
M86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@17AP96YS97,@6U1A8FQE(%1E>'0@0FQO8VM=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SX\:3Y!8V-R=65D(&QI86)I;&ET:65S("AI;B!T:&]U<V%N
M9',I)B,Q-C`[/"]I/CPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@-S4E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM;&5F=#H@,"XU:6X[
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$-CY$96-E;6)E<B`S,2P\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('=I9'1H.B`W
M-"4[)SY!8V-R=65D('9E;F1O<B!P87EM96YT<SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3LG/BT\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#$P)3LG/C$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/D-O
M;7!E;G-A=&EO;CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,C@\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^5&]T86P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,CD\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%14E!0SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*%1A8FQE<RD\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&ES8VQO<W5R92!/9B!#;VUP96YS871I;VX@4F5L871E9"!#;W-T<RP@
M4VAA<F4M0F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP
M96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!
M=V%R9"!/<'1I;VYS(&%N9"!787)R86YT<R!697-T960@86YD($5X<&5C=&5D
M('1O(%9E<W0@3W5T<W1A;F1I;F<@86YD($5X97)C:7-A8FQE(%M486)L92!4
M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!A;F0@,C`Q,2!A<F4@87,@
M9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T:#H@.#4E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@
M8V]L<W!A;CTS1#,^665A<B8C,38P.V5N9&5D)B,Q-C`[1&5C96UB97(F(S$V
M,#LS,2P\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C(P,3$\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^17AE<F-I<V4@<')I8V4\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<^)#$N-CD@+2`D,BXT-SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXD,"XT.2`M
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M=VED=&@Z(#$R)3LG/C`E/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@=VED=&@Z(#$R)3LG/C`E/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY%>'!E
M8W1E9"!V;VQA=&EL:71Y/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG/C$P."4@+2`Q-S0E/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CLG/C$W-24@+2`Q.#@E/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^4FES:R!F
M964@:6YT97)E<W0@<F%T93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^
M,"XS-R4@+2`Q+CDX)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^,2XS
M,"4@+2`S+C4X)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^17AP96-T960@;&EF
M92!O9B!O<'1I;VX\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^-2`M(#$P('EE87)S/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CLG/C4@+2`W('EE87)S/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^17AP96-T960@
M9F]R9F5I='5R97,\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^,"4\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^,"4\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!3:&%R92UB87-E9"!#
M;VUP96YS871I;VXL(%-T;V-K($]P=&EO;G,L($%C=&EV:71Y(%M486)L92!4
M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M1'5R:6YG(#(P,3(L('1H92!#;VUP86YY(&=R86YT960@,BPP-S4L,#`P(&]P
M=&EO;G,@=&\@96UP;&]Y965S(&%N9"!C;VYS=6QT86YT<R!H879I;F<@86X@
M87!P<F]X:6UA=&4@9F%I<B!V86QU92!O9B`D-"XU(&UI;&QI;VX@8F%S960@
M=7!O;B!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"XF
M(S$V,#L@1'5R:6YG(#(P,3$L('1H92!#;VUP86YY(&=R86YT960@-34W+#`P
M,B!O<'1I;VYS('1O(&5M<&QO>65E<R!A;F0@8V]N<W5L=&%N=',@:&%V:6YG
M(&%N(&%P<')O>&EM871E(&9A:7(@=F%L=64@;V8@)#8P.2PP,#`@8F%S960@
M=7!O;B!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"X\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T
M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD
M.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A
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M"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO
M=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L
M<W!A;CTS1#(^079E<F%G93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
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M(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT
M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^
M4F5M86EN:6YG/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,CY!9V=R
M96=A=&4\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R
M87`],T1N;W=R87`@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT
M97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^079E<F%G928C,38P
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M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N
M.B!C96YT97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^26YT<FEN
M<VEC/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O
M;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([)R!N;W=R87`],T1N;W=R87`@8V]L<W!A;CTS1#(^3W!T:6]N<SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#L@<&%D9&EN9RUB;W1T;VTZ(#%P
M=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<"!C
M;VQS<&%N/3-$,CY0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L
M9#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
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M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!W:61T:#H@-#@E.R<^
M0F%L86YC92`F(S@R,3$[($1E8V5M8F5R(#,Q+"`R,#$P/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(L-3,Y+#`Y,3PO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!W:61T:#H@,24[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/C$N,S(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"4[
M(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^-BXY-R!Y96%R<SPO9F]N=#X\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3`E.R!B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2PP,C@L
M,#`P/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0^1W)A;G1E9#PO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C4U-RPP,#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^,2XR-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C4W/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^1F]R9F5I=&5D/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE
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M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C`N-3D\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR+#DW.2PP,3`\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ+C,T/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/C8N,#$@>65A<G,\+V9O
M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/BT\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E.R<^#0H\=&0^1W)A;G1E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(L,#<U+#`P
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXR+C(Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D/D5X
M97)C:7-E9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/B@S-S0L.#4Q/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXP+C,T/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R<^1F]R9F5I=&5D/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,C(U+#0Q,SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXR+C,W/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXT+#0U,RPW-#8\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XW.#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#,P."PP,#`\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^0F%L86YC92`F
M(S@R,3$[($1E8V5M8F5R(#,Q+"`R,#$R("8C.#(Q,3L@97AE<F-I<V%B;&4\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPX.3$L.#<W/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N-C`\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^-2XW,2!Y96%R<SPO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,2PQ-C`L,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY'<F%N="!D871E
M(&9A:7(@=F%L=64@;V8@;W!T:6]N<R!G<F%N=&5D("8C.#(Q,3L@,C`Q,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^5V5I9VAT960@879E<F%G
M92!G<F%N="!D871E(&9A:7(@=F%L=64@)B,X,C$Q.R`R,#$R/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(N,34\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/D=R86YT(&1A=&4@
M9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@)B,X,C$Q.R`R,#$Q/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C8P.2PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^5V5I9VAT960@879E<F%G92!G
M<F%N="!D871E(&9A:7(@=F%L=64@)B,X,C$Q.R`R,#$Q/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#D\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,BXU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE
M;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@5F5S
M=&5D(&%N9"!%>'!E8W1E9"!T;R!697-T+"!/=71S=&%N9&EN9R!A;F0@17AE
M<F-I<V%B;&4@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@
M;W!T:6]N<R!O=71S=&%N9&EN9R!A;F0@97AE<F-I<V%B;&4@870@1&5C96UB
M97(@,S$L(#(P,3(@87)E(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^
M#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,3$@;F]W<F%P/3-$;F]W<F%P/D]P=&EO;G,F(S$V,#M/=71S=&%N9&EN9SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N
M/3-$.2!N;W=R87`],T1N;W=R87`^3W!T:6]N<R8C,38P.T5X97)C:7-A8FQE
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M-C`[079E<F%G93PO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO
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M9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!N;W=R87`],T1N;W=R87`^5V5I9VAT960F(S$V,#M!=F5R86=E
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO
M=W)A<#TS1&YO=W)A<#Y286YG928C,38P.V]F/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
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M.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^17AE<F-I<V4F(S$V,#M0<FEC
M93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO
M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D]P=&EO;G,\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^17AE
M<F-I<V4F(S$V,#M0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS
M1&YO=W)A<#Y#;VYT<F%C='5A;"8C,38P.TQI9F4\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
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M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D5X97)C:7-E)B,Q-C`[4')I8V4\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^0V]N=')A8W1U
M86PF(S$V,#M,:69E/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$T
M)3LG/B0P+C`Y("T@)#(N,#`\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$R)3LG/C(L,38R+#,V,CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T
M:#H@,3(E.R<^,2XW.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3,E.R<^-2XW-B!Y96%R<SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3$E.R<^
M,2PX,#$L,3@W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#$E.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('=I9'1H.B`Q,24[)SXQ+C$T/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,R4[)SXU+C4R
M('EE87)S/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXD,BXP,2`M("0S+C`P/"]T
M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^,BPR,3(L,C(W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,BXR-CPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C<N,34@>65A<G,\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#`Q,2PU,S,\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR
M+C$W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^-BXQ-"!Y96%R<SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXD,RXP,2`M("0V+C`P/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[)SXW.2PQ-3<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C0N.#<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXT+C0Y('EE87)S/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXW.2PQ-3<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0-"B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R<^-"XX-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C0N-#D@>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)#`N,#D@+2`D-BXP,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXT+#0U,RPW-#8\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XW.#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
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M;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
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M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C4N-S$@>65A<G,\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@;W!T:6]N<R!O=71S=&%N9&EN9R!A
M;F0@97AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,3$@87)E(&%S(&9O
M;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UW
M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,3$@;F]W<F%P/3-$;F]W<F%P/D]P
M=&EO;G,F(S$V,#M/=71S=&%N9&EN9SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$.2!N;W=R87`],T1N;W=R87`^
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M<F%P/3-$;F]W<F%P/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0@
M;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P
M/B8C,38P.SPO=&0^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/E=E:6=H=&5D/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R
M87`^5V5I9VAT960F(S$V,#M!=F5R86=E/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y286YG928C
M,38P.V]F/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,B!N;W=R87`],T1N;W=R87`^079E<F%G93PO=&0^#0H\=&0@;F]W
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M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N
M;W=R87`^17AE<F-I<V4F(S$V,#M0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/D]P=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P/3-$;F]W
M<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,B!N;W=R87`],T1N;W=R87`^17AE<F-I<V4F(S$V,#M0<FEC93PO=&0^
M#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS
M1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CLG(&YO=W)A<#TS1&YO=W)A<#Y#;VYT<F%C='5A;"8C
M,38P.TQI9F4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y/<'1I;VYS
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W
M<F%P/D5X97)C:7-E)B,Q-C`[4')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<@;F]W<F%P
M/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!N
M;W=R87`],T1N;W=R87`^0V]N=')A8W1U86PF(S$V,#M,:69E/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$T)3LG/B0P+C`Y("T@)#0N-3<\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#$R)3LG/C(L.#@Y+#`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,2XR,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3,E
M.R<^-BXQ,2!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3$E.R<^,BPS-C0L-C`X/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M,24[)SXQ+C(Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,R4[)SXU+C<R('EE87)S/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXD-"XU."`M("0Y+C`U/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H-"B`Q<'0[)SXF(S$V
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M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/@T*
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R<^-2XY,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C(N-S8@>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXD,"XP.2`M("0Y+C`U/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(L.3<Y+#`Q,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
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M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C8N,#$@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,BPT-30L-C`W
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N
M-#8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R<^-2XV,B!Y96%R<SPO=&0^#0H\+W1R/@T*/"]T86)L
M93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3
M:&%R92!"87-E9"!087EM96YT($%W87)D($]P=&EO;G,@3F]N(%9E<W1E9"!A
M;F0@17AP96-T960@5&\@5F5S="!%>&5R8VES86)L92!;5&%B;&4@5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE
M/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/E1H92!F;VQL;W=I;F<@:7,@82!S=6UM87)Y
M(&]F('1H92!#;VUP86YY)B,X,C$W.W,@;F]N+79E<W1E9"!S=&]C:R!O<'1I
M;VYS(&%T($1E8V5M8F5R(#,Q+"`R,#$R.CPO<#X-"CQP('-T>6QE/3-$)W1E
M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`X-24[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^/"]T9#X-"CQT9"!N;W=R87`]
M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R
M87`^5V5I9VAT960F(S$V,#M!=F5R86=E/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
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M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D(&YO=W)A<#TS1&YO=W)A
M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD
M.R<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E-T;V-K)B,Q-C`[3W!T
M:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y$871E)B,Q-C`[1F%I<B8C,38P.U9A;'5E
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=VED
M=&@Z(#<T)3LG/DYO;BUV97-T960F(S$V,#LF(S@R,3$[)B,Q-C`[1&5C96UB
M97(F(S$V,#LS,2PF(S$V,#LR,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXU,C0L-#`S/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I
M9'1H.B`Q,"4[)SXP+C@R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/@T*/'1D/D=R86YT960\+W1D/@T*/'1D/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR+#`W-2PP
M,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXR+C(Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
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M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#$T-BPR,#(\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C<Y/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/DYO;BUV97-T960@
M)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXQ+#4V,2PX-CD\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R<^,BXQ,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,BXU<'0[)SY796EG:'1E9"!A=F5R86=E(')E;6%I;FEN
M9R!P97)I;V0@9F]R('9E<W1I;F<\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/C(N,#D@>65A<G,\+V9O;G0^/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V-H961U;&4@;V8@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9"P@4W1O8VL@3W!T:6]N<RP@5F%L=6%T:6]N($%S<W5M<'1I;VYS(%M486)L
M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^5&AE(&%S<W5M<'1I;VYS('5S960@8GD@=&AE($-O;7!A;GD@87)E('-U
M;6UA<FEZ960@:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+W`^/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H
M.B`X,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T
M>6QE/3-$)W=I9'1H.B`X-R4[(&-O;&]R.B!B;&%C:SLG/D5X97)C:7-E('!R
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M.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO
M<CH@8FQA8VL[)SY%>'!E8W1E9"!D:79I9&5N9',\+W1D/CQT9"!S='EL93TS
M1"=C;VQO<CH@8FQA8VL[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!C;VQO<CH@8FQA8VL[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R<^,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C
M:SLG/B4\+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^17AP96-T960@
M=F]L871I;&ET>3PO=&0^/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R
M.B!B;&%C:SLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!C;VQO<CH@8FQA8VL[)SXQ,3`\+W1D/CQT9"!S='EL93TS1"=T
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M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE(&%S
M<W5M<'1I;VYS('5S960@8GD@=&AE($-O;7!A;GD@87)E('-U;6UA<FEZ960@
M:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+W`^/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`X,"4[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F
M9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)W=I
M9'1H.B`X-R4[(&-O;&]R.B!B;&%C:SLG/D5X97)C:7-E('!R:6-E/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!C;VQO<CH@8FQA8VL[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[
M(&-O;&]R.B!B;&%C:SLG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@=VED=&@Z(#$P)3L@8V]L;W(Z(&)L86-K.R<^,2XQ-#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L
M;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=B86-K
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M/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE($]F(%-H87)E($)A<V5D(%!A>6UE
M;G0@07=A<F0@5V%R<F%N=',@5F%L=6%T:6]N($%S<W5M<'1I;VYS(%M486)L
M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX\9F]N="!S:7IE/3-$,B!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XL=&EM97,G/D]N($%P<FEL(#8L(#(P,3$L('1H92!F86ER
M('9A;'5E(&]F('1H92!W87)R86YT(&QI86)I;&ET>2!W87,@)#$N-2!M:6QL
M:6]N+"!W:&EC:"!R97!R97-E;G1E9"!A;B!I;F-R96%S92!I;B!F86ER('9A
M;'5E(&]F("0W-C4L,#`P+B!4:&4@9F%I<B!V86QU92!W87,@;65A<W5R960@
M=7-I;F<@=&AE($)L86-K+5-C:&]L97,@=F%L=6%T:6]N(&UO9&5L+B!4:&4@
M87-S=6UP=&EO;G,@=7-E9"!B>2!T:&4@0V]M<&%N>2!A<F4@<W5M;6%R:7IE
M9"!I;B!T:&4@9F]L;&]W:6YG('1A8FQE.CPO9F]N=#X\+V1I=CX-"CQP('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`Y-24[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=C
M;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&-O;&]R.B!B;&%C:SLG
M(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y296UE87-U<F5M96YT/"]T
M9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R
M87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
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M,7!T.R!C;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!C;VQO<CH@
M8FQA8VL[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@8V]L;W(Z(&)L86-K.R<@8V]L<W!A;CTS1#(@;F]W<F%P
M/3-$;F]W<F%P/D%P<FEL)B,Q-C`[-BPF(S$V,#LR,#$Q/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!C;VQO<CH@8FQA8VL[)R!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`W-"4[(&-O;&]R.B!B
M;&%C:SLG/D-L;W-I;F<@<W1O8VL@<')I8V4\+W1D/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&-O;&]R.B!B
M;&%C:SLG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!W:61T:#H@,3`E.R!C;VQO<CH@8FQA8VL[)SXQ+C,Y/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&-O;&]R.B!B
M;&%C:SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!C
M;VQO<CH@8FQA8VL[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[
M(&-O;&]R.B!B;&%C:SLG/C(N,#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)B,Q-C`[
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M="UA;&EG;CH@<FEG:'0[(&-O;&]R.B!B;&%C:SLG/C`\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SLG/B4\+W1D
M/@T*/'1D('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
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M=&0@<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&-O;&]R.B!B;&%C:SLG/C`N
M,CD\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R
M.B!B;&%C:SLG/B4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K
M.R<^17AP96-T960@;&EF92`H>65A<G,I/"]T9#X-"CQT9"!S='EL93TS1"=C
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M86-K.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
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M87)R86YT(&QI86)I;&ET>2!W87,@)#(U,RPP,#`L('=H:6-H(')E<')E<V5N
M=&5D(&$@9&5C<F5A<V4@:6X@9F%I<B!V86QU92!O9B`D-3(S+#`P,"X@5&AE
M(&9A:7(@=F%L=64@:7,@;65A<W5R960@=7-I;F<@=&AE($)L86-K+5-C:&]L
M97,@=F%L=6%T:6]N(&UO9&5L+B!4:&4@87-S=6UP=&EO;G,@=7-E9"!B>2!T
M:&4@0V]M<&%N>2!A<F4@<W5M;6%R:7IE9"!I;B!T:&4@9F]L;&]W:6YG('1A
M8FQE.CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)W=I9'1H.B`Y-24[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N
M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=C;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&-O;&]R.B!B;&%C:SLG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y2
M96UE87-U<F5M96YT/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@8FQA8VL[
M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M861D:6YG+6)O='1O;3H@,7!T.R!C;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!C;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@8V]L;W(Z(&)L86-K.R<@8V]L
M<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/DIU;'DF(S$V,#LR."PF(S$V,#LR
M,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!C
M;VQO<CH@8FQA8VL[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M:6YD96YT.B`M,3,N,G!T.R!P861D:6YG+6QE9G0Z(#$S+C)P=#L@=VED=&@Z
M(#<T)3L@8V]L;W(Z(&)L86-K.R<^0VQO<VEN9R!S=&]C:R!P<FEC93PO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!C;VQO<CH@8FQA8VL[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[(&-O;&]R.B!B;&%C:SLG/C(N
M,#@\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H
M.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M.B`M,3,N,G!T.R!P861D:6YG+6QE9G0Z(#$S+C)P=#L@8V]L;W(Z(&)L86-K
M.R<^17AP96-T960@9&EV:61E;F0@<F%T93PO=&0^#0H\=&0@<W1Y;&4],T0G
M8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M;&EG;CH@<FEG:'0[(&-O;&]R.B!B;&%C:SLG/C`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SLG/B4\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,RXR<'0[('!A9&1I;F<M
M;&5F=#H@,3,N,G!T.R!C;VQO<CH@8FQA8VL[)SY%>'!E8W1E9"!S=&]C:R!P
M<FEC92!V;VQA=&EL:71Y/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@8FQA
M8VL[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&-O;&]R.B!B;&%C:SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&-O;&]R.B!B;&%C:SLG/C$Q,BXQ/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@8FQA8VL[
M)SXE/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B
M;&%C:SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&-O;&]R.B!B;&%C:SLG/C$P-2XV/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@8FQA8VL[)SXE/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$S+C)P=#L@<&%D9&EN9RUL969T
M.B`Q,RXR<'0[(&-O;&]R.B!B;&%C:SLG/E)I<VL@9G)E92!I;G1E<F5S="!R
M871E/"]T9#X-"CQT9"!S='EL93TS1"=C;VQO<CH@8FQA8VL[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B
M;&%C:SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&-O;&]R.B!B;&%C:SLG/C`N,CD\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B!B;&%C:SLG/B4\+W1D/@T*/'1D
M('-T>6QE/3-$)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^)B,Q-C`[
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M97AT+6EN9&5N=#H@+3$S+C)P=#L@<&%D9&EN9RUL969T.B`Q,RXR<'0[(&-O
M;&]R.B!B;&%C:SLG/D5X<&5C=&5D(&QI9F4@*'EE87)S*3PO=&0^#0H\=&0@
M<W1Y;&4],T0G8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!C;VQO<CH@8FQA8VL[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!C;VQO<CH@
M8FQA8VL[)SXQ+C`X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!C;VQO<CH@8FQA8VL[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V-O;&]R.B!B;&%C:SLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@8V]L;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8V]L;W(Z(&)L86-K.R<^
M,2XP-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8V]L
M;W(Z(&)L86-K.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@
M;V8@1&5R:79A=&EV92!,:6%B:6QI=&EE<R!A="!&86ER(%9A;'5E(%M486)L
M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE(&9O;&QO=VEN9R!T86)L
M92!S=6UM87)I>F5S('1H92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4@
M=V%R<F%N="!L:6%B:6QI=&EE<R!A="!$96-E;6)E<B`S,2P@,C`Q,3QI/BAI
M;B!T:&]U<V%N9',I.CPO:3X\+W`^/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z
M(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE
M/3-$)W=I9'1H.B`X-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;BUL969T.B`P+C<U:6X[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG/D)A;&%N8V4@
M870@1&5C96UB97(@,S$L(#(P,3`\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CL@=VED=&@Z(#@W)3LG
M/E=A<G)A;G0@;&EA8FEL:71Y/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXQ+#0Y,CPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@+3`N,C5I;CL@<&%D9&EN9RUL969T.B`P
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M('1E>'0M:6YD96YT.B`M,"XR-6EN.R!P861D:6YG+6QE9G0Z(#`N,C5I;CLG
M/E)E8VQA<W-I9FEC871I;VX@=&\@861D:71I;VYA;"!P86ED+6EN(&-A<&ET
M86P\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/B@Q+#<S-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@=&5X="UI;F1E;G0Z("TP+C(U:6X[('!A9&1I;F<M;&5F=#H@
M,"XR-6EN.R<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q,3PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V-H961U;&4@3V8@5V%R<F%N="!!8W1I=FET>2!;5&%B;&4@5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/D$@<W5M
M;6%R>2!O9B!W87)R86YT(&%C=&EV:71Y(&9O<B!T:&4@0V]M<&%N>2!F;W(@
M=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3$@86YD(&9O<B!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!I<R!A<R!F;VQL;W=S.CPO
M<#X\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@U)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN+6QE9G0Z(#`N-S5I;CLG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N
M;W=R87`],T1N;W=R87`^5V5I9VAT960F(S$V,#M!=F5R86=E/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N;W=R87`^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^3G5M8F5R)B,Q-C`[;V8F(S$V,#M787)R86YT<SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A
M<#Y%>&5R8VES928C,38P.U!R:6-E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!N;W=R87`],T1N
M;W=R87`^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
M('-T>6QE/3-$)W=I9'1H.B`W-"4[)SY"86QA;F-E(&%T($1E8V5M8F5R(#,Q
M+"`R,#$P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I
M9'1H.B`Q,"4[)SXQ+#$S,2PP-S@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,"4[)SXS+C0Y/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9#Y'<F%N=&5D/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
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M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXI/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXR+C`X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQT9#Y"86QA;F-E(&%S($1E8V5M8F5R(#,Q+"`R,#$Q
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQT9#Y'<F%N=&5D/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^.3@U+#@U-3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C<Q/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQT9#Y%>&5R8VES960\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH,2PW-C@L
M,38W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXQ+C$Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/D9O<F9E:71E9#PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#@T
M-"PS-S,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^,RXS,CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^0F%L86YC92!A<R!$96-E
M;6)E<B`S,2P@,C`Q,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
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M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
M)SXD/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N.3D\+W1D/CPO='(^
M/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE($]F(%=A<G)A;G0@3W5T<W1A;F1I;F<@86YD
M($5X97)C:7-A8FQE(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M02!S=6UM87)Y(&]F(&%L;"!O=71S=&%N9&EN9R!A;F0@97AE<F-I<V%B;&4@
M=V%R<F%N=',@87,@;V8@1&5C96UB97(@,S$L(#(P,3(@:7,@87,@9F]L;&]W
M<SH\+W`^/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]P/CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W:61T
M:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^17AE<F-I<V4\+V9O;G0^
M/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/E!R:6-E/"]F;VYT/CPO=&0^/'1D(&YO=W)A
M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/CQT9"!N;W=R87`],T1N;W=R87`^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/E=A<G)A;G1S/"]F;VYT/CQB<B`O
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SY/=71S=&%N9&EN9SPO9F]N=#X\+W1D/CQT9"!N;W=R
M87`],T1N;W=R87`^)B,Q-C`[/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(@;F]W
M<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY787)R86YT<SPO9F]N=#X\8G(@
M+SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^17AE<F-I<V%B;&4\+V9O;G0^/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5V5I9VAT960F(S$V,#M!=F5R
M86=E/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY296UA:6YI;F<\+V9O;G0^
M/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/D-O;G1R86-T=6%L)B,Q-C`[3&EF93PO9F]N
M=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X\=&0@;F]W
M<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY!9V=R
M96=A=&4@/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY);G1R:6YS:6,@5F%L
M=64\+V9O;G0^/"]T9#X\=&0@;F]W<F%P/3-$;F]W<F%P/B8C,38P.SPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$W)3LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXQ
M+C$T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3<E.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/C$P,"PP,#`\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-R4[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^,3`P+#`P,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,24[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#(P)3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXT+C`Y('EE87)S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/C8R+#`P,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
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M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^,3@L
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M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXS+C`P('EE87)S
M/"]F;VYT/CPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)#PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXX+#`P,#PO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B0\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
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M/C8S-2PX-34\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^,3`R
M+#`P,#PO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/C(N,C`\
M+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^,C4P+#`P,#PO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXU,"PP,#`\+V9O;G0^
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
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M-RPR-3<\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^,RXS,#PO9F]N=#X\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXV,2PR,#<\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^-C$L,C`W/"]F;VYT/CPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/C,N
M,S`@>65A<G,\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C
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M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^,RXW
M-3PO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/C4P
M+#`P,#PO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/C4P+#`P,#PO9F]N=#X\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/C,N,3,@>65A<G,\+V9O;G0^/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
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M=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R
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M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^,2PT,S(L-3`Q/"]F;VYT/CPO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXS+C@P('EE87)S/"]F;VYT/CPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXQ-S(L,#`P/"]F;VYT/CPO=&0^/"]T
M<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F
M,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,C0N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,:6-E;G-E+"!#
M;VQL86)O<F%T:79E(&%N9"!%;7!L;WEM96YT($%G<F5E;65N=',@86YD($-O
M;6UI=&UE;G1S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L;W-U<F4@3V8@3&EC96YS92!#
M;VQL86)O<F%T:79E(&%N9"!%;7!L;WEM96YT($%G<F5E;65N=',@86YD($-O
M;6UI=&UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1'5E($9O<B!,:6-E;G-E($%G<F5E;65N=',@
M6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,BP@86UO=6YT<R!D=64@
M9F]R(&QI8V5N<V4@86YD('-P;VYS;W)E9"!R97-E87)C:"!A9W)E96UE;G1S
M(&%R92!A<R!F;VQL;W=S(#QI/BAI;B!T:&]U<V%N9',I/"]I/CH\+W`^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[('1E>'0M:6YD96YT.B`P+C5I;CL@
M=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO<#X-"CQT86)L92!A;&EG
M;CTS1&-E;G1E<B!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!W:61T:#H@-3`E.R!B;W)D97(M8V]L;&%P<V4Z
M(&-O;&QA<'-E.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R<^#0H\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&)O;&0[('1E>'0M86QI9VXZ(&QE9G0[)SY996%R)B,Q-C`[16YD:6YG
M)B,Q-C`[1&5C96UB97(F(S$V,#LS,2P\+W1D/@T*/'1D/B8C,38P.SPO=&0^
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M969T.R<^,C`Q,SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,3(E.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C(X-SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C9F9C8SLG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F
M=#H@,3<N,W!T.R!T97AT+6%L:6=N.B!L969T.R<^,C`Q-#PO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C8P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$W+C-P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/C(P,34\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXS-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$W+C-P=#L@
M=&5X="UA;&EG;CH@;&5F=#LG/C(P,38\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Q-RXS<'0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('1E>'0M86QI
M9VXZ(&QE9G0[)SXR,#$W/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXF
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C0P,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D
M8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W
M,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,C4N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O
M;64@5&%X97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C;&]S=7)E(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V-H961U;&4@;V8@0V]M<&]N96YT<R!O9B!);F-O;64@5&%X($5X
M<&5N<V4@*$)E;F5F:70I(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE($-O;7!A;GDF(S@R,3<[<R!T
M87@@97AP96YS92!D:69F97)S(&9R;VT@=&AE("8C.#(R,#ME>'!E8W1E9"8C
M.#(R,3L@=&%X(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q,B`H8V]M<'5T960@8GD@87!P;'EI;F<@=&AE($9E9&5R86P@
M0V]R<&]R871E('1A>"!R871E(&]F(#,T)2!T;R!L;W-S(&)E9F]R92!T87AE
M<R!A;F0@,RXY-B4@9F]R($UI8VAI9V%N(%-T871E($-O<G!O<F%T92!T87AE
M<RP@=&AE(&)L96YD960@<F%T92!U<V5D('=A<R`S-RXY-B4I(&%N9"!$96-E
M;6)E<B`S,2P@,C`Q,2P@*&-O;7!U=&5D(&)Y(&%P<&QY:6YG('1H92!&961E
M<F%L($-O<G!O<F%T92!T87@@<F%T92!O9B`S,BXQ,R4@=&\@;&]S<R!B969O
M<F4@=&%X97,@86YD(#4N-24@9F]R($UI8VAI9V%N(%-T871E($-O<G!O<F%T
M92!T87AE<RP@=&AE(&)L96YD960@<F%T92!U<V5D('=A<R`S-RXV,R4I+"!A
M<R!F;VQL;W=S(#QI/BAI;B!T:&]U<V%N9',I.CPO:3X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!A;&EG;CTS1&-E
M;G1E<B!S='EL93TS1"=W:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/C(P,3(\+V(^/"]F;VYT/CPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/C(P
M,3$\+V(^/"]F;VYT/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V-B4[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^0V]M<'5T960@)B,X,C(P.V5X<&5C=&5D)B,X,C(Q
M.R!T87@@8F5N969I="`M($9E9&5R86P\+V9O;G0^/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-"4[)SXH-2PX,#,\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/BD\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
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M:#H@,24[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY#;VUP=71E9"`F
M(S@R,C`[97AP96-T960F(S@R,C$[('1A>"!B96YE9FET("T@4W1A=&4\+V9O
M;G0^/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXH-C<V/"]T9#X-"CQT
M9#XI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M*#0T.#PO9F]N=#X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXI/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C
M8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^365A;',L(&5N=&5R=&%I;FUE;G0@86YD(&]T:&5R/"]F;VYT/CPO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-3PO=&0^#0H\=&0^/"]T9#X-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
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M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C4Q.#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^,S8V/"]F;VYT/CPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
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M/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXY,3PO9F]N=#X\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^4F5A;&EZ960@;&]S<R!O;B!D96)T('-E8W5R:71I97,\
M+V9O;G0^/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXW/"]F;VYT/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q
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M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/C(L
M,#,U/"]F;VYT/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG/B0\+V9O;G0^/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXM/"]F;VYT/CPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^)#PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!$969E<G)E9"!487@@
M07-S971S(&%N9"!,:6%B:6QI=&EE<R!;5&%B;&4@5&5X="!";&]C:UT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1H92!E9F9E8W1S(&]F
M('1E;7!O<F%R>2!D:69F97)E;F-E<R!T:&%T(&=A=F4@<FES92!T;R!S:6=N
M:69I8V%N="!P;W)T:6]N<R!O9B!D969E<G)E9"!T87@@87-S971S(&%T($1E
M8V5M8F5R(#,Q+"`R,#$R(&%N9"`R,#$Q(&%R92!A<R!F;VQL;W=S(#QI/BAI
M;B!T:&]U<V%N9',I.CPO:3X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQT86)L92!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=W
M:61T:#H@.#4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/D1E9F5R
M<F5D)B,Q-C`[=&%X)B,Q-C`[87-S971S.CPO8CX\+V9O;G0^/"]T9#X-"CQT
M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/C(P,3$\+V(^/"]F
M;VYT/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V-B4[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<^4W1O8VL@:7-S=65D(&9O<B!S97)V:6-E<SPO9F]N=#X\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
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M/3-$)W=I9'1H.B`Q)3LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-"4[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
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M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY"860@9&5B="`F
M(S@R,3$[(&-H86YG92!I;B!A;&QO=V%N8V4\+V9O;G0^/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+#`Y.3PO=&0^#0H\=&0^/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^,C`U/"]F;VYT/CPO=&0^
M#0H\=&0^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CLG/CPO9F]N=#X\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0^4W1O8VL@:7-S=65D(&9O<B!A8W%U:7-I
M=&EO;B!O9B!P<F]G<F%M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU
M,C<\+W1D/@T*/'1D/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX-"CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R
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M;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/E1O=&%L(&=R;W-S(&1E9F5R<F5D('1A>"!A<W-E=',\
M+V9O;G0^/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ-BPY,#@\+W1D
M/@T*/'1D/CPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D
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M="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^3&5S<R!V86QU871I;VX@86QL;W=A;F-E/"]F;VYT/CPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0[)SXH,38L.3`X/"]T9#X-"CQT9#XI/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S
M;VQI9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXH,3`L.34Q/"]F;VYT/CPO=&0^#0H\=&0^*3PO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9#X\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3F5T
M(&1E9F5R<F5D('1A>"!A<W-E=',\+V9O;G0^/"]T9#X-"CQT9#XF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE
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M=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D
M/@T*/'1D/B8C,38P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T0^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0Q/CQS=')O;F<^3W)G86YI>F%T:6]N(&%N9"!.871U<F4@;V8@3W!E
M<F%T:6]N<R!A;F0@0F%S:7,@;V8@4')E<V5N=&%T:6]N("A$971A:6QS(%1E
M>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F]T97,@4&%Y86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`W,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M&04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!S:&]R="UT97)M(&EN=F5S
M=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L
M,S<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06UO<G1I>F%T:6]N(&]F('!R96UI=6T@;VX@:6YV97-T;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!S:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PR.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@<V%L92!O9B!S:&]R="UT
M97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X
M-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5(1$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@
M4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T86EL<R`Q*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H
M;VQD(&EM<')O=F5M96YT<R!A;F0@9FEX='5R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DQE<W-E<B!O9B!E<W1I;6%T960@=7-E9G5L(&]R
M(&QI9F4@;V8@;&5A<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]F9FEC92!%<75I<&UE;G0@86YD($9U<FYI='5R
M92!;365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D(%5S969U;"!,:69E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9I8V4@17%U
M:7!M96YT(&%N9"!&=7)N:71U<F4@6TUE;6)E<ET@?"!-:6YI;75M(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E
M9"!5<V5F=6P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&%B;W)A=&]R>2!%<75I<&UE;G0@6TUE;6)E<ET@?"!-87AI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5S=&EM871E9"!5<V5F=6P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQA8F]R871O<GD@17%U:7!M96YT(%M-96UB
M97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%<W1I;6%T960@57-E9G5L($QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA;G5F86-T=7)I;F<@17%U
M:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5S=&EM871E9"!5<V5F=6P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%5D=!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@
M*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@36EL97-T;VYE
M(%!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^36%R:V5T:6YG($5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@4F5V96YU92!097)C
M96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);7!A:7)M96YT(&QO<W,@;VX@9V]O9'=I;&P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36]N97D@36%R
M:V5T($%C8V]U;G1S(&%N9"!-=71U86P@1G5N9',@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I
M=F%L96YT<RP@870@0V%R<GEI;F<@5F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I9&EL
M=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T:6]N(&]F
M($5A<FYI;F=S(%!E<B!3:&%R92P@06UO=6YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#8S,BPU,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(U.2PQ.#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@2&5L
M9"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T
M:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92P@06UO=6YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#0U,RPW-#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DW.2PP,3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUC;&5A
M;B!(;W-P:71A;"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,:6-E;G-E(')E=F5N=64L(&YE=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,S<U+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@4F5V96YU92!097)C
M96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUE9&$@06=R965M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQI8V5N<V4@<F5V96YU92P@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S
M7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K
M<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!0D%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N
M82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N9"!.;W1E(%)E8V5I=F%B;&4@*$1E
M=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E=',@;V8@9&ES8V]N=&EN=65D
M(&]P97)A=&EO;G,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?
M8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F
M9&(Y,2]7;W)K<VAE971S+U-H965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(3D%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R871I;VYS
M(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N9"!.;W1E(%)E8V5I
M=F%B;&4@*$1E=&%I;',@,2D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N
M;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@0V]S=',@86YD
M($5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#`Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPU.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3W1H97(@26YC;VUE.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YC;VUE("AL;W-S*2!F<F]M(&1I<V-O;G1I;G5E9"!O
M<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U
M,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9&5O;F$@0VQI;FEC86P@3&%B;W)A=&]R>2!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86)O<F%T;W)Y(&9E97,L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-CD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W!E<F%T:6YG($-O<W1S(&%N9"!%>'!E;G-E<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A
M;F0@861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]S="!O9B!L86)O<F%T;W)Y('-E<G9I8V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE;G0@
M;&]S<R!O;B!G;V]D=VEL;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!C;W-T<R!A;F0@97AP96YS97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4W-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-CDR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S
M(&9R;VT@9&ES8V]N=&EN=65D(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@U,C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($EN8V]M
M93H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1V%I;B!O;B!S86QE(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE("AL
M;W-S*2!F<F]M(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-3(S*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S
M7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K
M<VAE971S+U-H965T,S(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1$%#/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D1I<V-O;G1I;G5E9"!/<&5R871I;VYS(&]F($%D96]N
M82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N9"!.;W1E(%)E8V5I=F%B;&4@*$1E
M=&%I;',@5&5X='5A;"D@*%!R;VUI<W-O<GD@3F]T92!;365M8F5R72P@061E
M;VYA($-L:6YI8V%L($QA8F]R871O<GDL($QL8R!;365M8F5R72P@55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,#@L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;VUI<W-O<GD@3F]T92!;365M8F5R72!\($%D96]N82!#;&EN:6-A
M;"!,86)O<F%T;W)Y+"!,;&,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F]T97,@4F5C96EV86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`W,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@1&5B="P@
M4&5R8V5N=&%G92!"96%R:6YG(%9A<FEA8FQE($EN=&5R97-T+"!097)C96YT
M86=E(%)A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N-S`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14-"
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4V5L96-T960@0F%L86YC92!3
M:&5E="!);F9O<FUA=&EO;B`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R
M96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8X
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-CDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"860@9&5B="!A;&QO=V%N8V4@+2!C=7-T;VUE<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C@R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(X-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0T1!0SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#$^/'-T<F]N9SY396QE8W1E9"!"86QA;F-E(%-H965T($EN9F]R
M;6%T:6]N("A$971A:6QS(#$I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT<F5X;VX@<')E<&%I9"!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,BPT,3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(')E8V5I=F%B
M;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A
M:60@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+#4P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%3$=!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY396QE8W1E9"!"
M86QA;F-E(%-H965T($EN9F]R;6%T:6]N("A$971A:6QS(#(I("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0V-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CDU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S(&%C8W5M
M=6QA=&5D(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,W,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-86YU9F%C
M='5R:6YG(&5Q=6EP;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="P@
M1W)O<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M<'5T97(@86YD($]F9FEC92!%<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT(&%N
M9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3&%B;W)A=&]R>2!%<75I<&UE;G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='DL(%!L86YT
M(&%N9"!%<75I<&UE;G0L($=R;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14-"04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^
M4V5L96-T960@0F%L86YC92!3:&5E="!);F9O<FUA=&EO;B`H1&5T86EL<R`S
M*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@=F5N9&]R('!A>6UE;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2%-!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E=&%I
M;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AP96-T960@9&EV:61E;F1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<T+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4FES:R!F964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XR-B4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C<Q)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF92!O9B!O<'1I
M;VX@*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&9O<F9E:71U<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6YI;75M(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,2XV
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B`P+C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,#@N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<U+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F964@:6YT97)E
M<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XS-R4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+C,P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@;&EF92!O9B!O<'1I;VX@*&EN('EE87)S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA
M>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B`R+C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^(#(N,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#@N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9E
M92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+CDX)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,N-3@E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E(&]F(&]P=&EO;B`H:6X@>65A
M<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C<@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%2S9!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX@*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3`\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I
M;VYS($]U='-T86YD:6YG+$)E9VEN:6YG($)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L.3<Y+#`Q,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3,Y+#`Y,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F($]P=&EO;G,L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L,#<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4U-RPP,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS+"!%
M>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,W-"PX
M-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,C,L,S,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,L($9O<F9E:71E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(U+#0Q,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Y,RPW-3`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@3W!T:6]N<R!/=71S=&%N9&EN9RQ%;F1I;F<@0F%L86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT-3,L-S0V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-SDL
M,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU,SDL,#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@3W!T:6]N<RP@0F%L86YC92!E>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX.3$L
M.#<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E('!E<B!3:&%R
M92P@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E('!E
M<B!3:&%R92P@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R
M:6-E('!E<B!3:&%R92P@17AC97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X
M97)C:7-E(%!R:6-E('!E<B!3:&%R92P@1F]R9F5I=&5D(&]R(&5X<&ER960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXS-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92!P97(@4VAA<F4L($)A
M;&%N8V4@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XW.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XS-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XS,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@
M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L
M(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,@-2!M;VYT
M:',@-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^-B!Y96%R<R`P(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#$Q(&UO
M;G1H<R`Q.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!796EG:'1E9"!!
M=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#@@;6]N=&AS(#$V(&1A>7,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64@3W5T<W1A;F1I;F<L0F5G:6YI
M;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#`R."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64@3W5T<W1A
M;F1I;F<L16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S`X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`R."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS
M:6,@5F%L=64@17AC:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$V,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!O<'1I
M;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-"PT-C<L.3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V,#DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&=R86YT(&1A
M=&4@9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15%*0DL^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM
M0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS(#(I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M($]U='-T86YD:6YG+"!/<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#0U,RPW-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#DW.2PP,3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4S.2PP.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XW.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XS-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2XS,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!2
M96UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^-B!Y96%R<R`U(&UO;G1H<R`U(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#`@
M;6]N=&AS(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C8@>65A<G,@,3$@;6]N=&AS(#$Y(&1A>7,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@17AE<F-I<V%B;&4L(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L.#DQ+#@W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L(%=E
M:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,@."!M;VYT:',@
M,38@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F%N9V4@3V8@17AE<F-I<V4@4')I8V4@,"XP.2TR+C`P(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO
M;G,@3W5T<W1A;F1I;F<L($]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,38R+#,V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!7
M96EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#D@;6]N=&AS
M(#0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@;W!T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,#$L,3@W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X
M97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R
M86-T=6%L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@
M>65A<G,@-B!M;VYT:',@-R!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!/9B!%>&5R8VES92!0<FEC
M92`P+C`Y+3(N,#`@6TUE;6)E<ET@?"!-87AI;75M(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E
M(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A
M;F=E($]F($5X97)C:7-E(%!R:6-E(#`N,#DM,BXP,"!;365M8F5R72!\($UI
M;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,"XP.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@3V8@17AE<F-I<V4@4')I8V4@
M,BXP,2TS+C`P(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L($]P=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,C$R+#(R-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S
M=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U
M='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C
M='5A;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XW('EE
M87)S(#$@;6]N=&@@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@;W!T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,3$L-3,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N
M,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@4F5M
M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C8@>65A<G,@,2!M;VYT:"`R,"!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!/9B!%
M>&5R8VES92!0<FEC92`R+C`Q+3,N,#`@6TUE;6)E<ET@?"!-87AI;75M(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E
M(&]F($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)A;F=E($]F($5X97)C:7-E(%!R:6-E(#(N,#$M,RXP,"!;
M365M8F5R72!\($UI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXP,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@3V8@17AE
M<F-I<V4@4')I8V4@,RXP,2T@-BXP,"!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!/<'1I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW.2PQ-3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@
M4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XX-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W!T:6]N<R!/=71S=&%N9&EN9RP@5V5I9VAT960@079E<F%G92!296UA:6YI
M;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^-"!Y96%R<R`U(&UO;G1H<R`R-B!D87ES/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C
M:7-A8FQE+"!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW.2PQ-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-"XX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@5V5I9VAT960@079E
M<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<R`U(&UO;G1H<R`R-B!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M86YG92!/9B!%>&5R8VES92!0<FEC92`S+C`Q+2`V+C`P(%M-96UB97)=('P@
M36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y286YG92!O9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!/9B!%>&5R8VES92!0<FEC92`S
M+C`Q+2`V+C`P(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M86YG92!/9B!%>&5R8VES92!0<FEC92`P+C`Y+38N,#`@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N
M9&EN9RP@3W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PT-3,L-S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R
M86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$N-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,@-2!M;VYT:',@-2!D87ES/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M<'1I;VYS($5X97)C:7-A8FQE+"!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#@Y,2PX-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L
M(%=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2XV/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE
M+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S(#@@;6]N
M=&AS(#$V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)A;F=E($]F($5X97)C:7-E(%!R:6-E(#`N,#DM-BXP
M,"!;365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@3V8@17AE
M<F-I<V4@4')I8V4@,"XP.2TV+C`P(%M-96UB97)=('P@36EN:6UU;2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!O
M9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y286YG92!/9B!%>&5R8VES92!0<FEC92`P+C`Y+30N-3<@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T
M:6]N<R!/=71S=&%N9&EN9RP@3W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPX.#DL,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U='-T86YD:6YG+"!7
M96EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$N,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@
M5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-B!Y96%R<R`Q(&UO;G1H
M(#$P(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L(&]P=&EO;G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S8T+#8P.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%
M>&5R8VES86)L92P@5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS
M($5X97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT
M<F%C='5A;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU
M('EE87)S(#@@;6]N=&AS(#$Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E($]F($5X97)C:7-E(%!R
M:6-E(#`N,#DM-"XU-R!;365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I
M<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"XU
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F%N9V4@3V8@17AE<F-I<V4@4')I8V4@,"XP.2TT+C4W(%M-96UB97)=
M('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!/9B!%>&5R8VES92!0
M<FEC92`T+C4X+3DN,#4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@3W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#DL.3DY/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($]U
M='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N.3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@
M3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R
M86-T=6%L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@
M>65A<G,@.2!M;VYT:',@-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X97)C:7-A8FQE+"!O
M<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.2PY.3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P=&EO;G,@17AE<F-I<V%B;&4L(%=E:6=H=&5D($%V97)A9V4@17AE<F-I
M<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XY
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!%>&5R8VES86)L92P@5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,B!Y96%R<R`Y(&UO;G1H<R`T(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E($]F($5X
M97)C:7-E(%!R:6-E(#0N-3@M.2XP-2!;365M8F5R72!\($UA>&EM=6T@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@
M;V8@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.2XP-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F%N9V4@3V8@17AE<F-I<V4@4')I8V4@-"XU."TY+C`U
M(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0<FEC93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C4X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!/9B!%
M>&5R8VES92!0<FEC92`P+C`Y+3DN,#4@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!/=71S=&%N9&EN9RP@3W!T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-SDL,#$P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<'1I;VYS($]U='-T86YD:6YG+"!796EG:'1E9"!!=F5R86=E($5X97)C
M:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N
M,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]P=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M
M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C8@>65A<G,@,"!M;VYT:',@-"!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X
M97)C:7-A8FQE+"!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#0U-"PV,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@17AE<F-I<V%B;&4L(%=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,2XT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!%>&5R8VES86)L92P@5V5I9VAT
M960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`W(&UO;G1H<R`Q,R!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y286YG92!/9B!%>&5R8VES92!0<FEC92`P+C`Y+3DN,#4@6TUE;6)E
M<ET@?"!-87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#DN,#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E($]F($5X97)C:7-E
M(%!R:6-E(#`N,#DM.2XP-2!;365M8F5R72!\($UI;FEM=6T@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE
M<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W
M7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H965T-#`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$522T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;B`H1&5T86EL<R`S*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS+"!.;VXM
M=F5S=&5D("T@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R-"PT,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,L($=R86YT960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#<U+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VL@3W!T:6]N<RP@5F5S=&5D+T5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.#DQ+#,S,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,L($9O<F9E
M:71E9"]#86YC96QL960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$T-BPR,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!/<'1I;VYS+"!.;VXM=F5S=&5D("T@1&5C96UB
M97(@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-38Q+#@V.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!'<F%N="!$871E($9A:7(@5F%L
M=64L($YO;BUV97-T960@+2!$96-E;6)E<B`S,2P@,C`Q,3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M($=R86YT($1A=&4@1F%I<B!686QU92P@1W)A;G1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($=R
M86YT($1A=&4@1F%I<B!686QU92P@5F5S=&5D+T5X97)C:7-E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R
M86=E($=R86YT($1A=&4@1F%I<B!686QU92P@1F]R9F5I=&5D+T-A;F-E;&QE
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG
M:'1E9"!!=F5R86=E($=R86YT($1A=&4@1F%I<B!686QU92P@3F]N+79E<W1E
M9"`M($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(N,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,L(%=E:6=H=&5D(&%V97)A
M9V4@<F5M86EN:6YG('!E<FEO9"!F;W(@=F5S=&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<R`Q(&UO;G1H(#(@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?
M8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F
M9&(Y,2]7;W)K<VAE971S+U-H965T-#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+1T%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;B`H1&5T86EL<R`T*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XQ-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV
M:61E;F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<T+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN=&5R97-T
M(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,C8E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XW
M,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X<&5C=&5D(&QI9F4@;V8@=V%R<F%N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-DQ!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',@
M-2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^07!R+B`P-BP@,C`Q,3QB<CY787)R86YT(%M-96UB97)=/&)R/D-O;6UI
M=&UE;G0@1&%T92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6PN(#(X+"`R,#$Q/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^
M0V]M;6ET;65N="!$871E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%P<BX@,#8L(#(P,3$\8G(^5V%R<F%N="!;365M8F5R
M73QB<CY296UE87-U<F5M96YT($1A=&4@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`R."P@,C`Q,3QB<CY787)R86YT
M(%M-96UB97)=/&)R/E)E;65A<W5R96UE;G0@1&%T92!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQO<VEN9R!S=&]C
M:R!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C,Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R+C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R+C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('-T;V-K('!R:6-E('9O;&%T:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S0N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$W+C$P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q,BXQ,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#0N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`U+C8P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E(&EN
M=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,C8E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XW,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XP+C(X)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N,CDE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XR.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C(Q)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF92`H
M>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M-2!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C$@>65A<B`R.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,2!Y96%R(#(Y(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"!M;VYT:',@
M-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,2!Y96%R(#$U(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3DI!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E=&%I;',@-BD@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R
M+B`P-BP@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3`\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Y,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N="!L:6%B:6QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC
M871I;VX@;V8@=V%R<F%N="!L:6%B:6QI='D@=&\@861D:71I;VYA;"!P86ED
M+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#<S-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T
M,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE
M971S+U-H965T-#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5524%%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H1&5T86EL<R`W
M*2`H5V%R<F%N="!;365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%=A<G)A
M;G1S+"!"96=I;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPR-3DL,3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PQ,S$L,#<X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@5V%R<F%N
M=',L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX
M-2PX-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#(W,BPY-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!787)R86YT<RP@17AE<F-I<V5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#<V."PQ-C<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34L
M-C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F(%=A<G)A;G1S+"!&;W)F96ET960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#@T-"PS-S,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(Y+#(T,"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!787)R86YT<RP@16YD:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C,R+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4Y+#$X-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M079E<F%G92!%>&5R8VES92!0<FEC92P@0F5G:6YN:6YG($)A;&%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XY-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXT.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92P@1W)A;G1E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C<Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E
M9"!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!%>&5R8VES960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XQ,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XP,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M079E<F%G92!%>&5R8VES92!0<FEC92P@1F]R9F5I=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V
M97)A9V4@17AE<F-I<V4@4')I8V4L($5N9&EN9R!"86QA;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N.3D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N.34\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5TU"1SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX@*$1E
M=&%I;',@."D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2XY.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C,R+#4P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#,R+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A
M8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y
M96%R<R`Y(&UO;G1H<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$W,BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G0@6TUE;6)E<ET@?"!%>&5R8VES92!0<FEC92`Q+C$T(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E
M(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E
M<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R<R`Q(&UO;G1H(#(@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E($EN=')I;G-I8R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET@?"!%>&5R8VES
M92!0<FEC92`Q+C,R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$N,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PQ.#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X
M97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PQ
M.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI
M9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G
M9W)E9V%T92!);G1R:6YS:6,@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET@?"!%>&5R8VES
M92!0<FEC92`Q+C8P(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S-2PX-34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X
M97)C:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S4L
M.#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,
M:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S(#D@
M;6]N=&AS(#(Y(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!);G1R:6YS:6,@=F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`R+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M="!;365M8F5R72!\($5X97)C:7-E(%!R:6-E(#(N,C`@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXR/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V%R<F%N=',@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,2!Y96%R(#(@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE
M;6)E<ET@?"!%>&5R8VES92!0<FEC92`R+C(R(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U
M='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3<L
M,C4W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3$W+#(U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI
M;F<@0V]N=')A8W1U86P@3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,R!Y96%R<R`Q,"!M;VYT:',@,C@@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN
M=')I;G-I8R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT(%M-96UB97)=('P@17AE<F-I<V4@4')I8V4@,RXS,"!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R
M8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV,2PR,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,2PR,#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V
M97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L($QI9F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,@,R!M;VYT:',@,3@@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06=G<F5G871E($EN=')I;G-I8R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=('P@17AE<F-I<V4@
M4')I8V4@,RXW-2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S(#$@;6]N
M=&@@,3<@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!V86QU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P144T14T^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("A$971A:6QS(%1E
M>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0S/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#<^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$-CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`P-BP@,C`Q,3QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#(X+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,#$\8G(^,C`P,2!3=&]C:R!0;&%N(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^,C`P
M,2!3=&]C:R!0;&%N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^4W5B<V5Q=65N="!%=F5N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N
M(#(U+"`R,#$R/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`Q-2P@,C`Q,CQB<CY787)R86YT(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@
M,#(L(#(P,3(\8G(^5V%R<F%N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E=A<G)A;G0@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`R
M."P@,C`Q,3QB<CY787)R86YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%P<BX@,#8L(#(P,3$\8G(^5V%R<F%N="!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/E=A<G)A;G0@6TUE;6)E<ET\8G(^1V5N97)A;"!!;F0@061M
M:6YI<W1R871I=F4@17AP96YS97,@06YD(%)E<V5A<F-H($%N9"!$979E;&]P
M;65N="!%>'!E;G-E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^17!I=&]P92!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#`V+"`R,#$Q
M/&)R/D-O;6UO;B!3=&]C:R!0=7)C:&%S92!!9W)E96UE;G0@5VET:"!3:6YG
M;&4@26YV97-T;W)S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIA;BX@,C@L(#(P,3$\8G(^0V]M;6]N(%-T;V-K(%!U<F-H
M87-E($%G<F5E;65N="!7:71H(%-I;F=L92!);G9E<W1O<G,@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`P,BP@,C`Q
M,#QB<CY#;VUM;VX@4W1O8VL@4'5R8VAA<V4@06=R965M96YT(%=I=&@@4VEN
M9VQE($EN=F5S=&]R<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#`V+"`R,#$Q/&)R/E-T;V-K(%!U<F-H87-E($%G
M<F5E;65N="!7:71H(%1H<F5E($EN<W1I='5T:6]N86P@26YV97-T;W)S(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@
M,C@L(#(P,3$\8G(^4W1O8VL@4'5R8VAA<V4@06=R965M96YT(%=I=&@@5&AR
M964@26YS=&ET=71I;VYA;"!);G9E<W1O<G,@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`P-BP@,C`Q,3QB<CY#;VUM
M;VX@4W1O8VL@4'5R8VAA<V4@06=R965M96YT(%=I=&@@26YS=&ET=71I;VYA
M;"!);G9E<W1O<G,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^07!R+B`P-BP@,C`Q,3QB<CY#;VYS=6QT:6YG($%G<F5E;65N
M="!&;W(@1FEN86YC:6%L($%D=FES;W)Y(%-E<G9I8V5S(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^16UP;&]Y965S(&%N9"!#;VYS=6QT86YT<R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/D5M
M<&QO>65E<R!A;F0@0V]N<W5L=&%N=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY%;7!L;WEE
M92!;365M8F5R73QB<CY'96YE<F%L($%N9"!!9&UI;FES=')A=&EV92!%>'!E
M;G-E<R!!;F0@4F5S96%R8V@@06YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CY%;7!L;WEE92!;365M8F5R73QB<CY'96YE<F%L($%N9"!!
M9&UI;FES=')A=&EV92!%>'!E;G-E<R!!;F0@4F5S96%R8V@@06YD($1E=F5L
M;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY#;VYS=6QT86YT(%M-96UB
M97)=/&)R/D=E;F5R86P@06YD($%D;6EN:7-T<F%T:79E($5X<&5N<V5S($%N
M9"!297-E87)C:"!!;F0@1&5V96QO<&UE;G0@17AP96YS92!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/D-O;G-U;'1A;G0@6TUE;6)E<ET\8G(^1V5N97)A;"!!;F0@061M:6YI
M<W1R871I=F4@17AP96YS97,@06YD(%)E<V5A<F-H($%N9"!$979E;&]P;65N
M="!%>'!E;G-E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^,C`P-R!3=&]C:R!0;&%N(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,C`L
M(#(P,#<\8G(^,C`P-R!3=&]C:R!0;&%N(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^,C`Q,"!3
M=&]C:R!0;&%N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DYO=BX@,#(L(#(P,3`\8G(^,C`Q,"!3=&]C:R!0;&%N(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S
M960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@3W5T<W1A;F1I;F<L($YU;6)E
M<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT-3,L-S0V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY
M-SDL,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPU,SDL,#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP-C8L,#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#<R+#<S.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L-3$U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($]P
M=&EO;G,L($=R86YT<R!I;B!097)I;V0L($=R;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-S4L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-34W+#`P,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A
M<V5D(%!A>6UE;G0@07=A<F0@3W!T:6]N<R!'<F%N=',@26X@4&5R:6]D($9A
M:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PU
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V,#DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!/9B!787)R86YT<R!4;R!0=7)C
M:&%S92!/9B!#;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@T-"PS.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,S4L.#4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,C@L-3<R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0T+#,Y,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$N-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XT/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:69E($]F(%=A<G)A
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!%>'!I<F%T:6]N($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@1FQO;W(@4')I
M8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$N-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y787)R86YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<Q-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT.3(L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<V+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA
M;F=E(&EN(&9A:7(@=F%L=64@;V8@=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#(L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($5X
M97)C:7-A8FQE+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@3W5T<W1A;F1I;F<L(%=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG
M($-O;G1R86-T=6%L($QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C8@>65A<G,@-2!M;VYT:',@-2!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-B!Y96%R<R`P(&UO;G1H<R`T
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XV('EE87)S(#$Q(&UO;G1H<R`Q.2!D87ES/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`U(&UO;G1H
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F($]P=&EO;G,L($)A;&%N8V4@97AE<F-I<V%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#DQ+#@W-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E
M+6)A<V5D(%!A>6UE;G0@07=A<F0L($5Q=6ET>2!);G-T<G5M96YT<R!/=&AE
M<B!T:&%N($]P=&EO;G,L($YO;G9E<W1E9"P@5V5I9VAT960@079E<F%G92!'
M<F%N="!$871E($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R92!"87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R9"!%<75I='D@26YS
M=')U;65N=',@3W1H97(@5&AA;B!/<'1I;VYS($]U='-T86YD:6YG(%=E:6=H
M=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FUS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S(#D@;6]N=&AS(#$X
M(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,34@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,34@;6]N=&AS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E<W1M96YT(%=A
M<G)A;G1S($5X<&ER871I;VX@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^3V-T(#(U+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!"87-E9"!#;VUP96YS
M871I;VX@07)R86YG96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N="!!=V%R
M9"!787)R86YT<R!%>&5R8VES86)L92!.=6UB97(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!"87-E9"!#
M;VUP96YS871I;VX@07)R86YG96UE;G0@0GD@4VAA<F4@0F%S960@4&%Y;65N
M="!!=V%R9"!787)R86YT<R!697-T960@86YD($5X<&5C=&5D(%1O(%9E<W0@
M3W5T<W1A;F1I;F<@3G5M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E
M;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!%
M>&5R8VES97,@:6X@4&5R:6]D+"!796EG:'1E9"!!=F5R86=E($5X97)C:7-E
M(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,S0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5N86YC92!/9B!787)R86YT<R!%>'!E;G-E<R!296-O9VYI
M>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E($)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"
M87-E9"!087EM96YT($%W87)D(%=A<G)A;G1S($5X97)C:7-A8FQE($EN(%!E
M<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C4@
M>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE(%!R:6-E(%!E<B!3:&%R93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M($9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;BP@3F]N=F5S=&5D($%W87)D<RP@5&]T86P@0V]M<&5N<V%T:6]N($-O
M<W0@3F]T('EE="!296-O9VYI>F5D+"!3=&]C:R!/<'1I;VYS/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@
M3&EA8FEL:71Y+"!&86ER(%9A;'5E+"!'<F]S<R!,:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,RPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M8W)E87-E($EN($9A:7(@5F%L=64@3V8@5V%R<F%N="!,:6%B:6QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E($)A
M<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!">2!3:&%R92!"87-E9"!0
M87EM96YT($%W87)D+"!787)R86YT($5X97)C:7-A8FQE(%!R:6-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,#<R-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@0F%S
M960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT($)Y(%-H87)E($)A<V5D(%!A
M>6UE;G0@07=A<F0L(%=A<G)A;G0@17AE<F-I<V%B;&4@4&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,R!M;VYT:',\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&D@1&EL
M=71I;VX@4')I8V4@4')O=&5C=&EO;B!787)R86YT<R!0<FEC92!097(@4VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BXP-S(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M96-R96%S92!);B!&86ER(%9A;'5E($]F(%=A<G)A;G0@3&EA8FEL:71Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,C,L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;&QO8V%T
M960@4VAA<F4M0F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C@L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<P-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@
M0V]M<&5N<V%T:6]N+"!#87-H(%)E8V5I=F5D(&9R;VT@17AE<F-I<V4@;V8@
M4W1O8VL@3W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F
M9&(Y,0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]B9#5E.#(T9E]C
M-S$T7S1F9C-?.#0Q-U\W.6,U9CDQ9F1B.3$O5V]R:W-H965T<R]3:&5E=#0W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%3D5#23X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL<R!497AT=6%L*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#,^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`P-BP@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#(X+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/DEN=')E>&]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^26YT<F5X;VX@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CY0<F5V($%B<B!,;&,@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,CQB<CY0<FEV
M871E(%!L86-E;65N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D-O;6UO;B!3=&]C:R!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$Q/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E=A<G)A;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RP@;F5T(&]F(&ES<W5A;F-E(&-O
M<W1S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#8X."PW.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#@U-RPQ-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#<U,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#4T-2PY
M,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!3=&]C:R!#;&]S:6YG(%!R:6-E(%!E<B!3:&%R93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5A
M;F-E($-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C0S
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,CDV+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-C@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3,Y+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K(&9O<B!O<'1I;VYS(&5X97)C:7-E9"`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<T+#@U,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#,S
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')O8V5E9',@9G)O;2!3=&]C:R!/<'1I;VYS($5X97)C:7-E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(W+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K(&9O<B!C;VYS=6QT:6YG(&9E97,@*&EN('-H87)E
M<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W,2PW.38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A
M:7(@5F%L=64@3V8@4W1O8VL@27-S=65D($1U<FEN9R!097)I;V0@5F%L=64@
M0V]N<W5L=&EN9R!&965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y386QE($]F(%-T;V-K($9O<B!#;VYS=6QT:6YG($9E97,@
M4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R:6]D(%-H87)E<R!&
M;W(@17AE<F-I<V4@3V8@4W1O8VL@3W!T:6]N<R!!;F0@5V%R<F%N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#,S,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S
M=65D($1U<FEN9R!097)I;V0@1F%I<B!686QU92!&;W(@17AC;'5S:79E($-H
M86YN96P@0V]L;&%B;W)A=&EO;B!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K(&9O<B!E;7!L;WEE92!C;VUP96YS871I;VX@*&EN('-H87)E<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S+#4X-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E;7!L;WEE92!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@
M3V8@4W1O8VL@1F]R($5M<&QO>6UE;G0@4V5R=FEC92!0<FEC92!097(@4VAA
M<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XR.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R('=A<G)A
M;G0@97AE<F-I<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@
M4&5R:6]D(%-H87)E<R!3=&]C:R!#87-H;&5S<R!787)R86YT<R!%>&5R8VES
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#8Q-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!E>&-L=7-I=F4@8VAA;FYE;"!C
M;VQL86)O<F%T:6]N(&%G<F5E;65N="`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU-3(L,C$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,C,L-34X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<75I
M='D@27-S=65D(&EN($)U<VEN97-S($-O;6)I;F%T:6]N+"!&86ER(%9A;'5E
M($1I<V-L;W-U<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M.#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!/9B!3=&]C:R!&;W(@
M0VAA;FYE;"!!9W)E96UE;G0@4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(N,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XX-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M27-S=65D($1U<FEN9R!097)I;V0@4VAA<F5S(%-T;V-K(%=A<G)A;G1S($5X
M97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0T+#,Y
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#(X+#4W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4@0F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT($)Y(%-H87)E($)A<V5D(%!A>6UE;G0@07=A<F0@3W1H97(@5&AA;B!/
M<'1I;VYS($5X97)C:7-E<R!);B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-S8X+#$V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@1G)O;2!)<W-U86YC
M92!/9B!#;VUM;VX@4W1O8VL@1F]R($5X8VQU<VEV92!#:&%N;F5L($-O;&QA
M8F]R871I;VX@06=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R
M:6]D+"!3:&%R97,L($%C<75I<VET:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPU-3(L,C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3(U+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@27-S=6%N8V4@;V8@4')I=F%T92!0;&%C96UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#@P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO
M;FEN=&5R97-T($5X<&5N<V4@3V9F97)I;F<@0V]S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`V.#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-#04,^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^3&EC96YS92P@0V]L;&%B;W)A=&EV92!A;F0@16UP;&]Y;65N
M="!!9W)E96UE;G1S(&%N9"!#;VUM:71M96YT<R`H1&5T86EL<RD@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M,C`Q,SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R.#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$U/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15E91TL^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^3&EC96YS92P@0V]L;&%B;W)A=&EV92!A;F0@16UP;&]Y;65N="!!9W)E
M96UE;G1S(&%N9"!#;VUM:71M96YT<R`H1&5T86EL<R!497AT=6%L*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0S/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0X/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0T/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C(T
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0T/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#`Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^1FER<W0@665A<B!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E-E
M8V]N9"!996%R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^5&AI<F0@665A<B!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/DEN9"!-:6QE<W1O;F4@179E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY!<'!R;W9A
M;"!-:6QE<W1O;F4@179E;G0@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY&:65L9"!%>'!A;G-I
M;VX@1F5E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^4&AA<V4@22!#;&EN:6-A;"!4<FEA;',@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CY0:&%S92!):6D@0VQI;FEC86P@5')I86QS(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^3F1A(%-U8FUI<W-I;VX@26X@57,@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY%
M=7)O<&5A;B!-961I8VEN97,@06=E;F-Y($%P<')O=F%L(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\
M8G(^4F5G=6QA=&]R>2!!<'!R;W9A;"!);B!!<VEA;B!#;W5N=')Y(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^1&5C96UB97(@,S$L(#(P,30@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY$96-E
M;6)E<B`S,2P@,C`Q-2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D]F9FEC92!3<&%C92!);B!!
M;FX@07)B;W(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY/9F9I8V4@4W!A8V4@26X@4F]C:W9I
M;&QE(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3(\8G(^26YT<F5X;VX@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CY);G1R
M97AO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/DEN=')E>&]N(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,3(\8G(^26YT
M<F5X;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CY0<F5V($%B<B!,;&,@6TUE;6)E<ET\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`P-3QB
M<CY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@07)R86YG96UE;G0@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R.2P@
M,C`Q,CQB<CY$<BY+=6\@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1F5B+B`R.2P@,C`Q,CQB<CY*969F<F5Y(%)I;&5Y(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E8BX@
M,CDL(#(P,3(\8G(^0RX@179A;B!"86QL86YT>6YE(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^
M06YN($%R8F]R+"!-:6-H:6=A;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+#(X-RPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,L,S0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-RPX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T-C`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6YE(&]F($-R961I
M="!&86-I;&ET>2P@4&5R:6]D:6,@4&%Y;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3DW+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EN92!O9B!#<F5D:70@1F%C:6QI
M='DL(%!E<FEO9&EC(%!A>6UE;G0L($EN=&5R97-T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L
M($5Q=6ET>2!);G-T<G5M96YT<R!/=&AE<B!T:&%N($]P=&EO;G,L(%9E<W1E
M9"!I;B!097)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,R
M-"PY.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@
M8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"P@3W!T:6]N<RP@5F5S=&5D
M(&EN(%!E<FEO9"P@1F%I<B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS=6QT:6YG($9E97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F:6-E
M<G,G($-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S0X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Y."PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D+"!/<'1I
M;VYS+"!'<F%N=',@:6X@4&5R:6]D+"!'<F]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0R-2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!,96%S
M97,L(%)E;G0@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&5A<V4@17AP:7)A=&EO;B!$871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-87D@,S$L#0H)"3(P,3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M97)A=&EN9R!,96%S97,L($9U='5R92!-:6YI;75M(%!A>6UE;G1S+"!$=64@
M:6X@5'=O(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]P97)A=&EN9R!,96%S92!,96%S:6YG(%1E<FT\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/F5X=&5N9"!T:&4@=&5R;2!O9B!T:&4@
M;&5A<V4@=&\@1&5C96UB97(@,S$L(#(P,30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YO;F4@>65A<B!O<&5R871I;F<@
M;&5A<V4@=&AA="!M87D@8F4@<F5N97=E9"!F;W(@='=O(&%D9&ET:6]N86P@
M=&5R;7,@;V8@;VYE('EE87(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!,96%S97,L($9U='5R92!-
M:6YI;75M(%!A>6UE;G1S($1U92P@3F5X="!4=V5L=F4@36]N=&AS/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUI;&5S=&]N92!087EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E
M87)C:"!!9W)E96UE;G0@1FEX960@1F5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,#,L,C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$V+#0S.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R."PW-3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@4&%Y;65N
M="!&;W(@3&EC96YS92!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@0V%S:"!087EM96YT($9O
M<B!,:6-E;G-E($%G<F5E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^56YR96=I<W1E<F5D(%-H87)E<R!)<W-U960@5&\@
M3&EC96YS92!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@0V]N<VED97)A=&EO;B!087EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU,"4@:6X@8V%S:"!A
M;F0@-3`E(&EN(&]U<B!S=&]C:SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M(&9O<B!A8W%U:7-I=&EO;B!O9B!P<F]G<F%M(&%S<V5T<R`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU-3(L,C$P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C(U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17%U:71Y($ES<W5A;F-E+"!097(@4VAA<F4@06UO=6YT/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087)T:6%L($-O
M;G-I9&5R871I;VX@1F]R($5X96-U=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^26YT<F5X;VX@82!N=6UB97(@;V8@<VAA<F5S(&]F(&]U
M<B!C;VUM;VX@<W1O8VL@97%U86P@=&\@.2XY.34E(&]F('1H92!N=6UB97(@
M;V8@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@:7-S=65D/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!#
M;VUM:71M96YT+"!$=64@26X@4V5C;VYD(%EE87(\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,S+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5G:7-T<F%T:6]N(%!A
M>6UE;G0@07)R86YG96UE;G0L(%-E='1L96UE;G0@06QT97)N871I=F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y4:&4@0V]M<&%N>2!A;'-O
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M871O<GD@86=E;F-Y("AB;W1H(&%S(&%P<&QI8V%B;&4L('1H92`B24Y$($UI
M;&5S=&]N92!%=F5N="(I+"!T;R!P87D@26YT<F5X;VX@96ET:&5R("AI*2!T
M=V\@;6EL;&EO;B!D;VQL87)S("@D,DTI(&EN(&-A<V@L(&]R("AI:2D@=&AA
M="!N=6UB97(@;V8@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R`H=&AE("))3D0@
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M=&]N92!%=F5N="X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y5<&]N('1H92!F:7)S="!T;R!O8V-U<B!O9B!E:71H97(@
M9FER<W0@8V]M;65R8VEA;"!S86QE(&]F(&$@4WEN=&AE=&EC(%!R;V1U8W0@
M:6X@82!C;W5N=')Y(&]R('1H92!G<F%N=&EN9R!O9B!T:&4@<F5G=6QA=&]R
M>2!A<'!R;W9A;"!O9B!T:&%T(%-Y;G1H971I8R!0<F]D=6-T("AB;W1H(&%S
M(&%P<&QI8V%B;&4L('1H92`B07!P<F]V86P@36EL97-T;VYE($5V96YT(BDL
M('1H92!#;VUP86YY(&%G<F5E9"!T;R!P87D@=&\@26YT<F5X;VX@96ET:&5R
M("AI*2!T:')E92!M:6QL:6]N(&1O;&QA<G,@*"0S32D@:6X@8V%S:"P@;W(@
M*&EI*2!T:&%T(&YU;6)E<B!O9B!S:&%R97,@;V8@0V]M;6]N(%-T;V-K("AT
M:&4@(D%P<')O=F%L($UI;&5S=&]N92!3:&%R97,B*2!H879I;F<@82!F86ER
M(&UA<FME="!V86QU92!E<75A;&EN9R!T:')E92!M:6QL:6]N(&1O;&QA<G,@
M*"0S32D@=VAE<F4@<W5C:"!F86ER(&UA<FME="!V86QU92!I<R!D971E<FUI
M;F5D('5S:6YG('!U8FQI<VAE9"!M87)K970@9&%T82!O9B!T:&4@<VAA<F4@
M<')I8V4@9F]R($-O;6UO;B!3=&]C:R!A="!T:&4@8VQO<V4@;V8@;6%R:V5T
M(&]N('1H92!B=7-I;F5S<R!D87D@:6UM961I871E;'D@<')E8V5D:6YG('1H
M92!D871E(&]F('!U8FQI8R!A;FYO=6YC96UE;G0@;V8@871T86EN;65N="!O
M9B!T:&4@07!P<F]V86P@36EL97-T;VYE($5V96YT+CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E1H92!&:65L9"!%>'!A
M;G-I;VX@1F5E(&UU<W0@8F4@<&%I9"!C;VUP;&5T96QY(&EN(&5I=&AE<B!#
M;VUM;VX@4W1O8VL@;W(@8V%S:"P@86YD('=I;&P@8V]M<')I<V4@96ET:&5R
M("AI*2!T=V\@;6EL;&EO;B!D;VQL87)S("@D,DTI(&EN(&-A<V@@9F]R(&5A
M8V@@=&%R9V5T(&EN(&5X8V5S<R!O9B!T:')E92`H,RD@=&]T86P@=&AA="!T
M:&4@0V]M<&%N>2!E;&5C=',L(&]R("AI:2D@=&AA="!N=6UB97(@;V8@<VAA
M<F5S(&]F($-O;6UO;B!3=&]C:R`H=&AE(")&:65L9"!%>'!A;G-I;VX@1F5E
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M<&%N<VEO;B!&964@0VQO<VEN9RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E9VES=')A=&EO;B!087EM96YT($%R
M<F%N9V5M96YT+"!497)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y);B!C;VYN96-T:6]N('=I=&@@=&AE('1R86YS86-T:6]N<R!C;VYT96UP
M;&%T960@8GD@=&AE(%-T;V-K(%!U<F-H87-E($%G<F5E;65N="P@86YD('!U
M<G-U86YT('1O('1H92!296=I<W1R871I;VX@4FEG:'1S($%G<F5E;65N="!E
M>&5C=71E9"!A;F0@9&5L:79E<F5D(&)Y('1H92!#;VUP86YY('1O($EN=')E
M>&]N+"!T:&4@0V]M<&%N>2!A9W)E960@=&\@9FEL92!A(")R97-A;&4B(')E
M9VES=')A=&EO;B!S=&%T96UE;G0@<F5G:7-T97)I;F<@=&AE(')E<V%L92!O
M9B!T:&4@1FER<W0@5')A;F-H92!3:&%R97,@=VET:&EN(#$R,"!D87ES(&]F
M('1H92!C;&]S:6YG(&1A=&4@;V8@<W5C:"!I<W-U86YC92X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@
M17AP96YS92!A;F0@3W1H97(@07-S971S+"!#=7)R96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`Y+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,38L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#4P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%54=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!297!U<F-H
M87-E(%!R;V=R86T@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT<R!F
M;W(@4F5P=7)C:&%S92!O9B!#;VUM;VX@4W1O8VL\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S:61I87)Y(&]R($5Q
M=6ET>2!-971H;V0@26YV97-T964L(%!R:6-E+5!E<BU3:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!297!U<F-H87-E
M(%!R;V=R86TL(%)E;6%I;FEN9R!.=6UB97(@;V8@4VAA<F5S($%U=&AO<FEZ
M960@=&\@8F4@4F5P=7)C:&%S960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@Q+#0X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@4F5P=7)C:&%S92!0<F]G<F%M+"!296UA
M:6YI;F<@075T:&]R:7IE9"!297!U<F-H87-E($%M;W5N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C
M:RP@4F5D96UP=&EO;B!0<FEC92!097(@4VAA<F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XV,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R-&9?8S<Q-%\T9F8S7S@T,3=?-SEC
M-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V)D-64X
M,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,2]7;W)K<VAE971S+U-H
M965T-3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5+3D%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DEN8V]M92!487AE<R`H1&5T86EL<RD@*%531"`D*3QB<CY);B!4:&]U
M<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T960@)R=E>'!E8W1E
M9"(@=&%X(&)E;F5F:70@+2!&961E<F%L/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#4L.#`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,BPV,3@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP=71E9"`B97AP96-T
M960B('1A>"!B96YE9FET("T@4W1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-96%L<RP@96YT97)T86EN;65N="!A;F0@
M;W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM
M9&5D=6-T:6)L92!S=&]C:RUB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!E>'!E;G-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@
M:6X@9F%I<B!V86QU92!O9B!W87)R86YT(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5A;&EZ960@;&]S<R!O;B!D96)T
M('-E8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#:&%N9V4@:6X@=F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-2PY-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`S-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1A>"!E
M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V)D-64X
M,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F.3%F9&(Y,0T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B]B9#5E.#(T9E]C-S$T7S1F9C-?.#0Q-U\W.6,U
M9CDQ9F1B.3$O5V]R:W-H965T<R]3:&5E=#4R+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04Q!
M0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY);F-O;64@5&%X97,@*$1E=&%I
M;',@,2D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I
M<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D('1A>"!A<W-E=',Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(&ES<W5E9"!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)A9"!D96)T("T@8VAA;F=E(&EN(&%L;&]W
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP.3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K(&ES<W5E9"!F;W(@86-Q=6ES:71I;VX@;V8@<')O9W)A;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN
M9R!L;W-S(&-A<G)Y+69O<G=A<F0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$T+#DV-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#0R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&=R;W-S(&1E9F5R<F5D('1A
M>"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#DP
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P+#DU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5S<R!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-BPY,#@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L.34Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!D969E
M<G)E9"!T87@@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%4DA!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X
M97,@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W1I=F4@26YC;VUE(%1A
M>"!2871E(%)E8V]N8VEL:6%T:6]N+"!!="!&961E<F%L(%-T871U=&]R>2!)
M;F-O;64@5&%X(%)A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,T+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,R+C$S)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^169F96-T:79E($EN8V]M92!487@@4F%T92!296-O
M;F-I;&EA=&EO;BP@4W1A=&4@86YD($QO8V%L($EN8V]M92!487AE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXY-B4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C4P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T
M:79E($EN8V]M92!487@@4F%T92!296-O;F-I;&EA=&EO;BP@0VAA;F=E($EN
M($5N86-T960@5&%X(%)A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,W+CDV)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,W+C8S)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N($%L;&]W86YC92P@06UO=6YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#DP."PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$P+#DU,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E9A;'5A=&EO;B!!;&QO=V%N8V4L($1E9F5R<F5D(%1A
M>"!!<W-E="P@0VAA;F=E($EN($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PY-38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,S4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@
M5&%X($)E;F5F:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YC<F5A<V4@*$1E8W)E87-E*2!I;B!$969E<G)E9"!,:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E
M("A$96-R96%S92D@:6X@1&5F97)R960@4F5V96YU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!F;W(@56YC97)T86EN
M(%1A>"!0;W-I=&EO;G,L($-U<G)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y487AA8FQE($EN8V]M92!%>'!I<FEN9R!4:')O=6=H
M(#(P,S(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!E<F%T:6YG($QO<W,@0V%R<GEF;W)W87)D<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S.2PW,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15)5044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@*$1E=&%I
M;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#,Q
M+"`R,#$R/&)R/DEN=')E>&]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DYO=BX@,S`L(#(P,3$\8G(^26YT<F5X;VX@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CY);G1R97AO;B!;365M8F5R73QB<CY297-E87)C:"!A;F0@
M1&5V96QO<&UE;G0@17AP96YS92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y/8W0N(#,Q+"`R,#$R/&)R/DUR($MA;GIE<B!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/DUR($MA;GIE<B!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y;65N="!!9W)E96UE;G0@
M1&5S8W)P=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^37(N
M($MA;GIE<B!E;G1E<F5D(&EN=&\@82!T=V\@>65A<B!A9W)E96UE;G0@=VET
M:"!U<R!O;B!A('!A<G0@=&EM92!B87-I<R`H,BXU(&1A>7,@<&5R('=E96LI
M+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/DUR+B!+86YZ97(@96YT97)E9"!I;G1O(&$@<VEX(&UO;G1H(&5M<&QO>6UE
M;G0@86=R965M96YT('=I=&@@=7,@;VX@82!F=6QL('1I;64@8F%S:7,@*'1H
M92`B2V%N>F5R($5M<&QO>6UE;G0@06=R965M96YT(BDL('=H:6-H(&UA>2!B
M92!E>'1E;F1E9"!F;W(@86X@861D:71I;VYA;"!T:')E92`H,RD@;6]N=&AS
M('5P;VX@8V]N<V5N="!O9B!T:&4@<&%R=&EE<RX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;FEN=&5R97-T($5X
M<&5N<V4@1&ER96-T;W)S($9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,34P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E
M<RP@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PT
M-#0L,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S$L,S<T+#`P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L-34R+#(Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3(S+#4U.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"`D,"XP,#$@<&%R('9A;'5E.R`Q,#`L,#`P+#`P,"!S:&%R97,@875T
M:&]R:7IE9"P@-#0L-#0T+#(S,"!I<W-U960@86YD(#0T+#,V,BPW-#@@;W5T
M<W1A;F1I;F<@86YD(#,Q+#,W-"PP,#(@:7-S=65D(&%N9"`S,2PR.3(L-3(P
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M<&%R('9A;'5E("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N-30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O<W1S(&%N9"!%>'!E;G-E<RP@4F5L871E9"!087)T>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#DP,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8F0U93@R
M-&9?8S<Q-%\T9F8S7S@T,3=?-SEC-68Y,69D8CDQ#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V)D-64X,C1F7V,W,31?-&9F,U\X-#$W7S<Y8S5F
M.3%F9&(Y,2]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS
M.F\],T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E
M(CX-"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#4Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970U,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4T+FAT;6PB+SX-"CPO>&UL/@T*
M+2TM+2TM/5].97AT4&%R=%]B9#5E.#(T9E]C-S$T7S1F9C-?.#0Q-U\W.6,U
,9CDQ9F1B.3$M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 6) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 06, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsFairValue', window );">Balance at December 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant liability</a></td>
        <td class="nump">716<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,492<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">242<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,734)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsFairValue', window );">Balance at December 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalMilestonePayments', window );">Additional Milestone Payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_RoyaltyRevenuePercentage', window );">Royalty Revenue Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">63,000<span></span></td>
        <td class="nump">144,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss on goodwill</a></td>
        <td class="nump">47,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Money Market Accounts and Mutual Funds [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">3,259,186<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Options Held [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Mclean Hospital [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(375,000)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseRevenuePercentage', window );">License Revenue Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">15.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Meda Agreement [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalMilestonePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of additional milestone payment for revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AdditionalMilestonePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LicenseRevenuePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of license revenue</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_LicenseRevenuePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_RoyaltyRevenuePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net royalty revenue percentage from sales.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_RoyaltyRevenuePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Loss recognized during the period that results from the write-down of goodwill after comparing the implied fair value of reporting unit goodwill with the carrying amount of that goodwill. Goodwill is assessed at least annually for impairment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141R<br><br> -Paragraph 72<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph e<br><br> -Clause 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 47<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=14024403&amp;loc=d3e13854-109267<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MarketingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHDAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements and fixtures</a></td>
        <td class="text">Lesser of estimated useful or life of lease<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office Equipment and Furniture [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office Equipment and Furniture [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Manufacturing Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 7) (Warrant [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
        <td class="nump">3,259,186<span></span></td>
        <td class="nump">1,131,078<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
        <td class="nump">985,855<span></span></td>
        <td class="nump">2,272,963<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod', window );">Number of Warrants, Exercised</a></td>
        <td class="num">(1,768,167)<span></span></td>
        <td class="num">(15,615)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited</a></td>
        <td class="num">(844,373)<span></span></td>
        <td class="num">(129,240)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending Balance</a></td>
        <td class="nump">1,632,501<span></span></td>
        <td class="nump">3,259,186<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
        <td class="nump">$ 1.95<span></span></td>
        <td class="nump">$ 3.49<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
        <td class="nump">$ 1.71<span></span></td>
        <td class="nump">$ 1.25<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Exercised</a></td>
        <td class="nump">$ 1.11<span></span></td>
        <td class="nump">$ 1.03<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
        <td class="nump">$ 3.32<span></span></td>
        <td class="nump">$ 2.08<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending Balance</a></td>
        <td class="nump">$ 1.99<span></span></td>
        <td class="nump">$ 1.95<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share warrants exercised during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(e)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EABAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets of discontinued operations:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 23<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total assets</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 23<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value (measured at the lower of net carrying value or fair value less cost of disposal) for current assets (assets with expected useful life shorter than one year or one operating cycle, whichever is longer) of a disposal group, including a component of the entity (discontinued operation), to be sold or that has subsequently been disposed of through sale, as of the financial statement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For the disposal group, including a component of the entity (discontinued operation), carrying value (net of accumulated depreciation and any write-downs) of tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 47<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EHNAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">$ 5,012<span></span></td>
        <td class="nump">$ 2,588<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract', window );"><strong>Other Income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
        <td class="nump">216<span></span></td>
        <td class="num">(523)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Adeona Clinical Laboratory [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LaboratoryFeesNet', window );">Laboratory fees, net</a></td>
        <td class="nump">115<span></span></td>
        <td class="nump">1,169<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">466<span></span></td>
        <td class="nump">539<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts', window );">Cost of laboratory services</a></td>
        <td class="nump">110<span></span></td>
        <td class="nump">975<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill', window );">Impairment loss on goodwill</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">178<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating costs and expenses</a></td>
        <td class="nump">576<span></span></td>
        <td class="nump">1,692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from discontinued operations</a></td>
        <td class="num">(461)<span></span></td>
        <td class="num">(523)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract', window );"><strong>Other Income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on sale of Adeona Clinical Laboratory</a></td>
        <td class="nump">677<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations</a></td>
        <td class="nump">$ 216<span></span></td>
        <td class="num">$ (523)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DiscontinuedOperationIncomeLossOfDiscountinuedOperationsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount impairment loss on goodwill provided by the entity during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DisposalGroupIncludingDiscontinuedOperationImpairmentLossOnGoodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to laboratory services rendered by an entity during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DisposalGroupIncludingDiscontinuedOperationLaboratoryServicesCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LaboratoryFeesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for laboratory costs incurred on or before the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_LaboratoryFeesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss), after tax expense or benefit and not previously recognized, resulting from the sale of a business component.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 47<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating expenses attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating income or loss attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="nump">$ 680<span></span></td>
        <td class="nump">$ 539<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual) (Promissory Note [Member], Adeona Clinical Laboratory, Llc [Member], USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 08, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Promissory Note [Member] | Adeona Clinical Laboratory, Llc [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Notes Receivable</a></td>
        <td class="nump">$ 700,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</a></td>
        <td class="nump">5.70%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtPercentageBearingVariableInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesReceivableNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber', window );">Stock Options, Non-vested - December 31, 2011</a></td>
        <td class="nump">524,403<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod', window );">Stock Options, Granted</a></td>
        <td class="nump">2,075,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod', window );">Stock Options, Vested/Exercised</a></td>
        <td class="num">(891,332)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod', window );">Stock Options, Forfeited/Cancelled</a></td>
        <td class="num">(146,202)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber', window );">Stock Options, Non-vested - December 31, 2012</a></td>
        <td class="nump">1,561,869<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested - December 31, 2011</a></td>
        <td class="nump">$ 0.82<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
        <td class="nump">$ 2.21<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested/Exercised</a></td>
        <td class="nump">$ 0.81<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited/Cancelled</a></td>
        <td class="nump">$ 1.79<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Non-vested - December 31, 2012</a></td>
        <td class="nump">$ 2.11<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock Options, Weighted average remaining period for vesting</a></td>
        <td class="text">2 years 1 month 2 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, including stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeitedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans including stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsForfeituresWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period including stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period including stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, including stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans including option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonVestedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, including stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan including stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionVestedInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ERHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, At Federal Statutory Income Tax Rate</a></td>
        <td class="nump">34.00%<span></span></td>
        <td class="nump">32.13%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective Income Tax Rate Reconciliation, State and Local Income Taxes</a></td>
        <td class="nump">3.96%<span></span></td>
        <td class="nump">5.50%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change In Enacted Tax Rate</a></td>
        <td class="nump">37.96%<span></span></td>
        <td class="nump">37.63%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAmount', window );">Valuation Allowance, Amount</a></td>
        <td class="nump">$ 16,908,000<span></span></td>
        <td class="nump">$ 10,951,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Change In Amount</a></td>
        <td class="nump">5,956,000<span></span></td>
        <td class="nump">2,035,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Increase (Decrease) in Deferred Liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (Decrease) in Deferred Revenue</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liability for Uncertain Tax Positions, Current</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Taxable Income Expiring Through 2032 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
        <td class="nump">$ 39,700,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The domestic federal statutory tax rate applicable under enacted tax laws to the Company's pretax income from continuing operations for the period. The "statutory" tax rate is the regular tax rate if there are alternative tax systems.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 47<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement and the expected income tax expense or benefit that is attributable to changes in the income tax laws or rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate that can be explained by the state and local income tax expense or benefit, net of the federal tax benefit (expense) thereon, recorded during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of the amount recognized for uncertain tax positions as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 48<br><br> -Paragraph 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilityForUncertainTaxPositionsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of domestic, foreign and state and local operating loss carryforwards, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 48<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Unrecognized Tax Benefit<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=SL6600010-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 48<br><br> -Paragraph 21<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UnrecognizedTaxBenefits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the valuation allowance recorded as of the balance sheet date pertaining to the specified deferred tax asset for which an assessment was made that it is more likely than not that all or a portion of such deferred tax asset will not be realized through related deductions on future tax returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Valuation Allowance<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528051<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowanceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the change in the period in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32123-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 9,954<span></span></td>
        <td class="nump">$ 6,678<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - net</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">405<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">2,509<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">23<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">12,463<span></span></td>
        <td class="nump">7,122<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">223<span></span></td>
        <td class="nump">323<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Long-term note receivable</a></td>
        <td class="nump">700<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump">37<span></span></td>
        <td class="nump">31<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">13,423<span></span></td>
        <td class="nump">7,476<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">395<span></span></td>
        <td class="nump">388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">29<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">395<span></span></td>
        <td class="nump">417<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">395<span></span></td>
        <td class="nump">417<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 44,444,230 issued and 44,362,748 outstanding and 31,374,002 issued and 31,292,520 outstanding</a></td>
        <td class="nump">44<span></span></td>
        <td class="nump">31<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">81,925<span></span></td>
        <td class="nump">58,901<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(68,941)<span></span></td>
        <td class="num">(51,873)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">13,028<span></span></td>
        <td class="nump">7,059<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 13,423<span></span></td>
        <td class="nump">$ 7,476<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DepositsAndOtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value (measured at the lower of net carrying value or fair value less cost of disposal) for current assets (assets with expected useful life shorter than one year or one operating cycle, whichever is longer) of a disposal group, including a component of the entity (discontinued operation), to be sold or that has subsequently been disposed of through sale, as of the financial statement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 144<br><br><br><br> -Paragraph 46<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesAndLoansReceivableNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWMBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 8) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.99<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">1,632,501<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">1,432,501<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 172,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 1.14 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.14<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 1 month 2 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 62,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 1.32 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.32<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">18,182<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">18,182<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 8,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 1.60 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 1.60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">635,855<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">635,855<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">4 years 9 months 29 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 102,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 2.20 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 2.20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">250,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">1 year 2 months 12 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 2.22 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 2.22<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">517,257<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">517,257<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 10 months 28 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 3.30 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 3.30<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">61,207<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">61,207<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 3 months 18 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member] | Exercise Price 3.75 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Exercise Price</a></td>
        <td class="nump">$ 3.75<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life</a></td>
        <td class="text">3 years 1 month 17 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate Intrinsic value</a></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The intrinsic value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units, as calculated by applying the disclosed pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares reserved for issuance under non-option equity instrument agreements awarded that validly exist and are outstanding, including vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EIBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 06, 2011</div>
        </th>
        <th class="th">
          <div>Jan. 28, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuanceCost', window );">Stock Issuance Cost</a></td>
        <td class="nump">$ 243<span></span></td>
        <td class="nump">$ 296<span></span></td>
        <td class="nump">$ 680<span></span></td>
        <td class="nump">$ 539<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuanceCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issuance Cost during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuanceCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details 2) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">$ 465<span></span></td>
        <td class="nump">$ 695<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
        <td class="num">(242)<span></span></td>
        <td class="num">(372)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">223<span></span></td>
        <td class="nump">323<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Manufacturing equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">297<span></span></td>
        <td class="nump">400<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer and Office Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">35<span></span></td>
        <td class="nump">159<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
        <td class="nump">$ 133<span></span></td>
        <td class="nump">$ 136<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph b, c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Accounts receivable (in thousands)</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Accounts receivable</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">682</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">692</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Bad debt allowance - customer</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(682</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(287</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">405</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Prepaid expenses and other current assets (in thousands)</i></p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Intrexon prepaid research and development expenses</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">2,412</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Other receivables</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">17</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Prepaid expenses</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">80</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">16</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,509</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">16</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Property and equipment (in thousands)&#160;</i></p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Manufacturing equipment</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">297</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">400</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Computer and office equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">35</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">159</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt;">Laboratory equipment</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">133</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">136</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">465</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">695</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Less accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(242</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(372</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">223</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">323</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedExpensesTableTextBlock', window );">Accrued Expenses [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Accrued liabilities (in thousands)&#160;</i></p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" border="0" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Accrued vendor payments</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">1</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Compensation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">28</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">29</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedExpensesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AccruedExpensesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3,4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amounts of other current assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details 3) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedVendorPayments', window );">Accrued vendor payments</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedCompensation', window );">Compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">28<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 29<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AccruedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedVendorPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AccruedVendorPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract', window );"><strong>Disclosure Of License Collaborative and Employment Agreements and Commitments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DueForLicenseAgreementsTableTextBlock', window );">Due For License Agreements [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif; text-align: justify;">As of December 31, 2012, amounts due for license and sponsored research agreements are as follows <i>(in thousands)</i>:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif; text-indent: 0.5in; text-align: justify;">&#160;</p>
<table align="center" style="font: 10pt times new roman, times, serif; width: 50%; border-collapse: collapse;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="font-weight: bold; text-align: left;">Year&#160;Ending&#160;December&#160;31,</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 17.3pt; width: 85%; text-align: left;">2013</td>
<td style="width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">287</td>
<td style="width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-left: 17.3pt; text-align: left;">2014</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">60</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 17.3pt; text-align: left;">2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">35</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-left: 17.3pt; text-align: left;">2016</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">10</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 17.3pt; padding-bottom: 1pt; text-align: left;">2017</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">10</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-left: 8.65pt; padding-bottom: 2.5pt; text-align: left;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">402</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DueForLicenseAgreementsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of license agreements due.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DueForLicenseAgreementsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E5GBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (17,068)<span></span></td>
        <td class="num">$ (8,149)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">1,851<span></span></td>
        <td class="nump">973<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedAsCompensation', window );">Stock issued as compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForConsultingFees', window );">Stock issued for consulting fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">165<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfStockForExclusiveChannelCollaborationAgreement', window );">Stock issued for exclusive channel collaboration agreement</a></td>
        <td class="nump">7,815<span></span></td>
        <td class="nump">1,684<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForAcquisitionsOfProgramAssets', window );">Stock issued for acquisition of program assets</a></td>
        <td class="nump">1,169<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,492<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">242<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">63<span></span></td>
        <td class="nump">144<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for uncollectible accounts receivable</a></td>
        <td class="nump">442<span></span></td>
        <td class="nump">414<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_GainLossOnSaleOfDiscontinuedOperations', window );">Gain on sale of discontinued operations</a></td>
        <td class="num">(677)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of premium on investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">57<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Loss on sale of short-term investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfProperty', window );">Loss on sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">6<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EquipmentImpairmentLoss', window );">Impairment on loss of equipment</a></td>
        <td class="nump">47<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfAccountsReceivable', window );">Gain on the settlement of accounts payable</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(63)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="nump">14<span></span></td>
        <td class="num">(480)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num">(2,544)<span></span></td>
        <td class="nump">327<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
        <td class="num">(6)<span></span></td>
        <td class="nump">60<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">191<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">7<span></span></td>
        <td class="nump">153<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="num">(29)<span></span></td>
        <td class="num">(181)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(24)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(8,916)<span></span></td>
        <td class="num">(2,875)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of short-term investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(4,370)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from short-term investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,293<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(10)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
        <td class="num">(10)<span></span></td>
        <td class="num">(75)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises', window );">Proceeds from issuance of common stock for stock option and warrant exercises</a></td>
        <td class="nump">2,082<span></span></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement', window );">Proceeds from issuance of common stock for exclusive channel collaboration agreement</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of issuance costs of $680 and $539, respectively</a></td>
        <td class="nump">10,120<span></span></td>
        <td class="nump">6,961<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">12,202<span></span></td>
        <td class="nump">6,979<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net increase in cash</a></td>
        <td class="nump">3,276<span></span></td>
        <td class="nump">4,029<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of year</a></td>
        <td class="nump">6,678<span></span></td>
        <td class="nump">2,649<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of year</a></td>
        <td class="nump">9,954<span></span></td>
        <td class="nump">6,678<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in-capital</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1,734<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EquipmentImpairmentLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impairment loss on equipment during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EquipmentImpairmentLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_GainLossOnSaleOfDiscontinuedOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain loss on sale of discontinued operations during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_GainLossOnSaleOfDiscontinuedOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in assets of discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInDepositsAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInDepositsAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in liabilities of discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssueOfStockForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued for exclusive channel collaboration agreement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IssueOfStockForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution for exclusive channel collaboration agreement to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for stock option exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForStockOptionsExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>No authoritative reference available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedAsCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that accounts for the value of stock options distributed as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedAsCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForAcquisitionsOfProgramAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of stock granted for acquisition of program assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedForAcquisitionsOfProgramAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedForConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentForAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfProperty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gains (losses) included in results of operations resulting from the sale or disposal of property, plant and equipment, which do not qualify for treatment as discontinued operations. This item does not include any gain (loss) recognized on the sale of oil and gas property or timber property.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 37, 41, 42, 43, 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDispositionOfProperty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the net positive or negative amount derived from subtracting from net proceeds of sale, the carrying amounts, net of allocated reserves, of accounts receivable transferred to a third party in a transaction that qualifies for sales treatment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=13989330&amp;loc=d3e107425-111719<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gain (loss) realized on the sale of held-to-maturity securities disposed of during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 5<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
        <td class="nump">44,444,230<span></span></td>
        <td class="nump">31,374,002<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">44,362,748<span></span></td>
        <td class="nump">31,292,520<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="width: 0in;"></td>
<td style="text-align: left; width: 0.5in;"><font size="2" style="font-family:times new roman,times"><b>9.</b></font></td>
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times"><b>Income Taxes</b></font></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"></font>&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">There was no income tax expense for the years ended December 31, 2012 and 2011 due to the Company&#8217;s net losses.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2012 (computed by applying the Federal Corporate tax rate of 34% to loss before taxes and 3.96% for Michigan State Corporate taxes, the blended rate used was 37.96%) and December 31, 2011, (computed by applying the Federal Corporate tax rate of 32.13% to loss before taxes and 5.5% for Michigan State Corporate taxes, the blended rate used was 37.63%), as follows <i>(in thousands):</i></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>2012</b></font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>2011</b></font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 66%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Computed &#8220;expected&#8221; tax benefit - Federal</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right; width: 14%;"><font size="2" style="font-family:times new roman,times">(5,803</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right; width: 14%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">(2,618</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Computed &#8220;expected&#8221; tax benefit - State</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(676</font></td>
<td><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">(448</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">)</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Meals, entertainment and other</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">5</font></td>
<td></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">5</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Non-deductible stock-based compensation</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">518</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">366</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Warrant expense</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">562</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Change in fair value of warrant expense</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">91</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Realized loss on debt securities</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">7</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Change in valuation allowance</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">5,956</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">2,035</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The effects of temporary differences that gave rise to significant portions of deferred tax assets at December 31, 2012 and 2011 are as follows <i>(in thousands):</i></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>Deferred&#160;tax&#160;assets:</b></font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>2012</b></font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>2011</b></font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 66%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Stock issued for services</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right; width: 14%;"><font size="2" style="font-family:times new roman,times">318</font></td>
<td style="width: 1%;"></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right; width: 14%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">321</font></td>
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"></font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Bad debt &#8211; change in allowance</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1,099</font></td>
<td></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">205</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"></font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Stock issued for acquisition of program </font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">527</font></td>
<td></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Net operating loss carry-forward</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">14,964</font></td>
<td></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">10,425</font></td>
<td></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Total gross deferred tax assets</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">16,908</font></td>
<td></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">10,951</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"></font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Less valuation allowance</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(16,908</font></td>
<td><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">(10,951</font></td>
<td><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Net deferred tax assets</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">&#160;&#160;&#160;-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">At December 31, 2012, the Company has a net operating loss carry-forward of approximately $39.7 million available to offset future taxable income expiring through 2032. However, utilization of these net operating losses may be limited due to potential ownership changes under Section 382 of the Internal Revenue Code.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The valuation allowance at December 31, 2011 was approximately $11.0 million. The net change in valuation allowance during the year ended December 31, 2012 was an increase of approximately $6.0 million. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2012.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">ASC 740-10 &#8220;<i>Accounting for Uncertain Tax Positions</i>&#8221; prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return and also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">As of December&#160;31, 2012 and 2011, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740-10. The Company&#8217;s practice was and continues to be to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the years ended December&#160;31, 2012 and 2011. The Company files United States federal and various state income tax returns.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company is routinely subject to examinations by taxing authorities in these various jurisdictions. The Company&#8217;s U.S. tax matters for the years 2000 through 2012 remain subject to examination by the Internal Revenue Service due to the Company&#8217;s NOL carryforwards. The Company&#8217;s U. S. tax matters remain subject to examination by various state and local tax jurisdictions due to our NOL carryforwards.</font></p>
<p style="text-align: justify; margin: 0pt 0px 0pt 24.45pt; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="margin: 0pt 0px;"><font size="2" style="font-family:times new roman,times">The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December&#160;31, 2012 will significantly change within the next 12 months.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Synthetic Biologics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000894158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">syn<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">44,654,414<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 44,969,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>10. Related Party Transactions</b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In February 2012, the Company entered into a consulting agreement with Dr. James Kuo, a director of the Company.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">From January 2, 2012 through September 30, 2012, Steve H. Kanzer was engaged as the Company&#8217;s Interim Director of its Biologics Division. In connection with his appointment, Mr. Kanzer entered into a six month employment agreement with us on a full time basis (the &#8220;Kanzer Employment Agreement&#8221;), which may be extended for an additional three (3) months upon consent of the parties. Pursuant to the Kanzer Employment Agreement, Mr. Kanzer will be entitled to a base salary of $90,000 for the term, healthcare coverage pursuant to the Company&#8217;s healthcare insurance plan, reimbursement for certain relocation expenses and rent expense. The Kanzer Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Kanzer.&#160; Mr. Kanzer is not entitled to severance pay upon termination of his employment. On October 1, 2012, the Kanzer Employment Agreement was amended (the &#8220;Amended Kanzer Employment Agreement&#8221;) and Mr. Kanzer is engaged as the Company Licensing Associate. In connection with this appointment, Mr. Kanzer entered into a two year agreement with us on a part time basis (2.5 days per week). Pursuant to the Amended Kanzer Employment Agreement, Mr. Kanzer will be entitled to a base salary of $150,000 for the term and healthcare coverage pursuant to the Company&#8217;s healthcare insurance plans.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In August 2012, the Company entered into an Exclusive Channel Agreement with Intrexon and issued 3,552,210 shares of common stock as consideration, having a fair value of $7.8 million ($2.20 per share), based on the quoted closing trading price on October 5, 2012<font style="color: black;">. </font>In November 2011, the Company entered into an Exclusive Channel Agreement with Intrexon and issued 3,123,558 shares of common stock as consideration, having a fair value of $1.7 million ($0.54 per share), based on the quoted closing trading price<font style="color: black;">. In connection with the November 2011 and August 2012 </font>Exclusive Channel Agreements, the Company paid Intrexon approximately $2.9 million during 2012, including a prepayment of research and development expenses of $2.5 million for research and development goods and services to be provided in the future which has been recorded on the Company&#8217;s balance sheet in prepaid expense as described in Note 4. In October 2012, the Company consummated the Company&#8217;s October 2012 Private Placement and entered into a stock purchase agreement with several investors, including NRM VII Holdings I, LLC, an entity affiliated with Intrexon. Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital of Intrexon Corporation, and controls NRM VII Holdings I, LLC. Mr. Kirk disclaims beneficial ownership of the shares held by Intrexon Corporation and NRM VII Holdings I, LLC, except to the extent of any pecuniary interest therein.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EDXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">$ 5,012<span></span></td>
        <td class="nump">$ 2,588<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">12,287<span></span></td>
        <td class="nump">3,340<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
        <td class="nump">17,299<span></span></td>
        <td class="nump">5,928<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from Operations</a></td>
        <td class="num">(17,299)<span></span></td>
        <td class="num">(5,928)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,492)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(242)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">33<span></span></td>
        <td class="nump">14<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
        <td class="num">(18)<span></span></td>
        <td class="nump">22<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), net</a></td>
        <td class="nump">15<span></span></td>
        <td class="num">(1,698)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from Continuing Operations</a></td>
        <td class="num">(17,284)<span></span></td>
        <td class="num">(7,626)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (Loss) from Discontinued Operations</a></td>
        <td class="nump">216<span></span></td>
        <td class="num">(523)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss and Comprehensive Loss</a></td>
        <td class="num">$ (17,068)<span></span></td>
        <td class="num">$ (8,149)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Income (Loss) Per Share - Basic and Dilutive:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
        <td class="num">$ (0.50)<span></span></td>
        <td class="num">$ (0.27)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="num">$ (0.02)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Income (Loss) Per Share (in dollars per share)</a></td>
        <td class="num">$ (0.49)<span></span></td>
        <td class="num">$ (0.29)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</a></td>
        <td class="nump">34,896,592<span></span></td>
        <td class="nump">27,710,428<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4613673-111683<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 28<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 29<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph b(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph b(2)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656940&amp;loc=SL4569616-111683<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 29<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 28<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income (loss) derived from discontinued operations during the period, net of related tax effect, per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 14<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 10, 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 87-21<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 28, 29, 30<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A7<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141<br><br><br><br> -Paragraph 51<br><br><br><br> -Subparagraph g<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 86<br><br><br><br> -Paragraph 11, 12<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 2<br><br><br><br> -Paragraph 12, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
        <td class="text"><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"><font style="font: 10pt times new roman, times, serif;"><b>4.</b></font></td>
<td><font style="font: 10pt times new roman, times, serif;"><b>Selected Balance Sheet Information</b></font></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Accounts receivable (in thousands)</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Accounts receivable</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">682</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">692</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Bad debt allowance - customer</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(682</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(287</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">405</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Prepaid expenses and other current assets (in thousands)</i></p>
<table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Intrexon prepaid research and development expenses - See Note 10</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">2,412</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Other receivables</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">17</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Prepaid expenses</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">80</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">16</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,509</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">16</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i></i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Intrexon prepaid research and development expenses are classified as a current asset. The Company may terminate the arrangement at any time and receive a cash refund of the remaining balance minus any amounts owed to Intrexon. The Company anticipates that the majority of the prepaid will be applied to research and development goods and services during 2013.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Property and equipment (in thousands)&#160;</i></p>
<table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Manufacturing equipment</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">297</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">400</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Computer and office equipment</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">35</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">159</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt;">Laboratory equipment</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">133</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">136</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">465</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">695</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt;">Less accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(242</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(372</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">223</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">323</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Accrued liabilities (in thousands)&#160;</i></p>
<table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 74%;">Accrued vendor payments</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">-</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">1</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Compensation</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">28</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">29</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</a></td>
        <td class="text"><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>3.</b></font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</b></font></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In accordance with ASC Topic 205-20 &#8220;<i>Presentation of Financial Statements&#8212;Discontinued Operations</i>&#8221; (ASC 205-20), the Company determined that all the criteria for reporting a discontinued operation had been met. Accordingly, the Lab has been classified as a discontinued operation and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption &#8220;Assets of discontinued operations&#8221; in the accompanying Consolidated Balance Sheets at December 31, 2012, and December 31, 2011, and consist of the following <i>(in thousands):</i></font></p>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font size="2" style="font-family:times new roman,times">December 31,</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2012</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2011</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Assets of discontinued operations:</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 74%;"><font size="2" style="font-family:times new roman,times">Property and equipment, net</font></td>
<td style="padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt; width: 10%;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">23</font></td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Total assets</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">23</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The summarized statement of operations data for Adeona Clinical Laboratory for the years ended December 31, 2012 and December 31, 2011 are as follows <i>(in thousands):</i></font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font size="2" style="font-family:times new roman,times">December 31,</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2012</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2011</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;"><font size="2" style="font-family:times new roman,times">Laboratory fees, net</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">115</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">1,169</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Operating Costs and Expenses:</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">General and administrative</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">466</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">539</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Cost of&#160; laboratory services</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">110</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">975</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Impairment loss on goodwill</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">178</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Total operating costs and expenses</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">576</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">1,692</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Loss from discontinued operations</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(461</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(523</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Other Income:</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in;"><font size="2" style="font-family:times new roman,times">Gain on sale of Adeona Clinical Laboratory</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">677</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Income (loss) from discontinued operations</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">216</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">(523</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 43-48<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EEIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2012 and 2011 are as follows:</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="3">Year&#160;ended&#160;December&#160;31,</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;">2012</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;">2011</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Exercise price</td>
<td>&#160;</td>
<td style="text-align: center;">$1.69 - $2.47</td>
<td>&#160;</td>
<td style="text-align: center;">$0.49 - $2.22</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; width: 74%;">Expected dividends</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: center; width: 12%;">0%</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: center; width: 12%;">0%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: center;">108% - 174%</td>
<td>&#160;</td>
<td style="text-align: center;">175% - 188%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Risk fee interest rate</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">0.37% - 1.98%</td>
<td>&#160;</td>
<td style="text-align: center;" nowrap="nowrap">1.30% - 3.58%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;">Expected life of option</td>
<td>&#160;</td>
<td style="text-align: center;">5 - 10 years</td>
<td>&#160;</td>
<td style="text-align: center;">5 - 7 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Expected forfeitures</td>
<td>&#160;</td>
<td style="text-align: center;">0%</td>
<td>&#160;</td>
<td style="text-align: center;">0%</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif; text-align: justify;">During 2012, the Company granted 2,075,000 options to employees and consultants having an approximate fair value of $4.5 million based upon the Black-Scholes option pricing model.&#160; During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.</p>
<table style="font: 10pt times new roman, times, serif; width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Weighted</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Remaining</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Aggregate</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap" colspan="2">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Average&#160;Exercise</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Contractual</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; text-align: center;" nowrap="nowrap" colspan="2">Intrinsic</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2">Options</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2">Price</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2">Life</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold; border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap" colspan="2">Value</td>
<td style="font-weight: bold; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt; width: 48%;">Balance &#8211; December 31, 2010</td>
<td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">&#160;</td>
<td style="width: 10%; text-align: right;">2,539,091</td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">1.32</td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td>
<td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="width: 10%; border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">6.97 years</font></td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt; width: 1%;">&#160;</td>
<td style="width: 1%; border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="width: 10%; border-bottom: black 2.5pt double; text-align: right;">1,028,000</td>
<td style="padding-bottom: 2.5pt; width: 1%; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">557,002</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.26</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(23,333</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.57</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(93,750</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">0.59</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; December 31, 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,979,010</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.34</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">6.01 years</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">-</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,075,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.21</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(374,851</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.34</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1pt;">Forfeited</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(225,413</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2.37</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: right;">&#160;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; December 31, 2012 &#8211; outstanding</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,453,746</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.78</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">6.43 years</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,308,000</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt;">Balance &#8211; December 31, 2012 &#8211; exercisable</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,891,877</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.60</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">5.71 years</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,160,000</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt; text-align: left;">Grant date fair value of options granted &#8211; 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,467,984</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Weighted average grant date fair value &#8211; 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.15</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 2.5pt; text-align: left;">Grant date fair value of options granted &#8211; 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">609,000</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #ccffcc;">
<td style="padding-bottom: 2.5pt;">Weighted average grant date fair value &#8211; 2011</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.09</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The options outstanding and exercisable at December 31, 2012 are as follows:</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap">Options&#160;Outstanding</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap">Options&#160;Exercisable</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">Range&#160;of</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap">Contractual&#160;Life</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 14%;">$0.09 - $2.00</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 12%;">2,162,362</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">1.78</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 13%;">5.76 years</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 11%;">1,801,187</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 11%;">1.14</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 13%;">5.52 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;">$2.01 - $3.00</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,212,227</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.26</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">7.15 years</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,011,533</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.17</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: right;">6.14 years</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;">$3.01 - $6.00</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">79,157</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4.87</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4.49 years</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">79,157</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td
 style="border-bottom: black 1pt solid; text-align: right;">4.87</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">4.49 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;">$0.09 - $6.00</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">4,453,746</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.78</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">6.43 years</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,891,877</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.60</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5.71 years</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The options outstanding and exercisable at December 31, 2011 are as follows:</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap">Options&#160;Outstanding</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap">Options&#160;Exercisable</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Weighted</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Weighted&#160;Average</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap">Range&#160;of</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">Average</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" nowrap="nowrap">Remaining</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Options</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap">Contractual&#160;Life</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 14%;">$0.09 - $4.57</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 12%;">2,889,011</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 12%;">1.20</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 13%;">6.11 years</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 11%;">2,364,608</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 11%;">1.29</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: right; width: 13%;">5.72 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;">$4.58 - $9.05</td>
<td style="padding-bottom:
 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2.76 years</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">2.76 years</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;">$0.09 - $9.05</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,979,010</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.34</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">6.01 years</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2,454,607</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1.46</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">5.62 years</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock', window );">Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested and Expected To Vest Exercisable [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following is a summary of the Company&#8217;s non-vested stock options at December 31, 2012:</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"></td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted&#160;Average</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unvested</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Grant</td>
<td style="font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Stock&#160;Options</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Date&#160;Fair&#160;Value</td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 74%;">Non-vested&#160;&#8211;&#160;December&#160;31,&#160;2011</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="text-align: right; width: 10%;">524,403</td>
<td style="text-align: left; width: 1%;">&#160;</td>
<td style="width: 1%;">&#160;</td>
<td style="text-align: left; width: 1%;">$</td>
<td style="text-align: right; width: 10%;">0.82</td>
<td style="text-align: left; width: 1%;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,075,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2.21</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td>Vested/Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(891,332</td>
<td style="text-align: left;">)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.81</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;">Forfeited/Cancelled</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">(146,202</td>
<td style="text-align: left; padding-bottom: 1pt;">)</td>
<td style="padding-bottom: 1pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right;">1.79</td>
<td style="text-align: left; padding-bottom: 1pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Non-vested &#8211; December 31, 2012</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">1,561,869</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right;">2.11</td>
<td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;">Weighted average remaining period for vesting</td>
<td style="padding-bottom: 2.5pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">2.09 years</font></td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The assumptions used by the Company are summarized in the following table:</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="width: 87%; color: black;">Exercise price</td><td style="width: 1%; color: black;">&#160;</td><td style="text-align: left; width: 1%; color: black;">$</td><td style="text-align: right; width: 10%; color: black;">2.20</td><td style="text-align: left; width: 1%; color: black;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; color: black;">Expected dividends</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;">0</td><td style="text-align: left; color: black;">%</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; color: black;">Expected volatility</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;">110</td><td style="text-align: left; color: black;">%</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; color: black;">Risk free interest rate</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;">0.26</td><td style="text-align: left; color: black;">%</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; color: black;">Expected life of warrant</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;"><font style="font: 10pt times new roman, times, serif; color: black;">2 years</font></td><td style="text-align: left; color: black;">&#160;</td></tr></table><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The assumptions used by the Company are summarized in the following table:</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="width: 87%; color: black;">Exercise price</td><td style="width: 1%; color: black;">&#160;</td><td style="text-align: left; width: 1%; color: black;">$</td><td style="text-align: right; width: 10%; color: black;">1.14</td><td style="text-align: left; width: 1%; color: black;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; color: black;">Expected dividends</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;">0</td><td style="text-align: left; color: black;">%</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; color: black;">Expected volatility</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;">174</td><td style="text-align: left; color: black;">%</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; color: black;">Risk free interest rate</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;">0.71</td><td style="text-align: left; color: black;">%</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; color: black;">Expected life of warrant</td><td style="color: black;">&#160;</td><td style="text-align: left; color: black;">&#160;</td><td style="text-align: right; color: black;"><font style="font: 10pt times new roman, times, serif; color: black;">5 years</font></td><td style="text-align: left; color: black;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">Schedule Of Share Based Payment Award Warrants Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><div><font size="2" style="font-family:times new roman,times">On April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000. The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</font></div>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap">Remeasurement</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap">Commitment</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap">Date</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap">Date</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap">April&#160;6,&#160;2011</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 74%; color: black;">Closing stock price</td>
<td style="width: 1%; color: black;">&#160;</td>
<td style="text-align: left; width: 1%; color: black;">$</td>
<td style="text-align: right; width: 10%; color: black;">1.39</td>
<td style="text-align: left; width: 1%; color: black;">&#160;</td>
<td style="width: 1%; color: black;">&#160;</td>
<td style="text-align: left; width: 1%; color: black;">$</td>
<td style="text-align: right; width: 10%; color: black;">2.08</td>
<td style="text-align: left; width: 1%; color: black;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;">Expected dividend rate</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0</td>
<td style="text-align: left; color: black;">%</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0</td>
<td style="text-align: left; color: black;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;">Expected stock price volatility</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">117.1</td>
<td style="text-align: left; color: black;">%</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">104.6</td>
<td style="text-align: left; color: black;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;">Risk free interest rate</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0.28</td>
<td style="text-align: left; color: black;">%</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0.29</td>
<td style="text-align: left; color: black;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;">Expected life (years)</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">1.08</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0.85</td>
<td style="text-align: left; color: black;">&#160;</td>
</tr>
</table>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap">Remeasurement</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap">Commitment</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap">Date</td>
<td style="color: black;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap">Date</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap">July&#160;28,&#160;2011</td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-indent: -13.2pt; padding-left: 13.2pt; width: 74%; color: black;">Closing stock price</td>
<td style="width: 1%; color: black;">&#160;</td>
<td style="text-align: left; width: 1%; color: black;">$</td>
<td style="text-align: right; width: 10%; color: black;">2.08</td>
<td style="text-align: left; width: 1%; color: black;">&#160;</td>
<td style="width: 1%; color: black;">&#160;</td>
<td style="text-align: left; width: 1%; color: black;">$</td>
<td style="text-align: right; width: 10%; color: black;">0.84</td>
<td style="text-align: left; width: 1%; color: black;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;">Expected dividend rate</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0</td>
<td style="text-align: left; color: black;">%</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0</td>
<td style="text-align: left; color: black;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;">Expected stock price volatility</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">112.1</td>
<td style="text-align: left; color: black;">%</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">105.6</td>
<td style="text-align: left; color: black;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;">Risk free interest rate</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0.29</td>
<td style="text-align: left; color: black;">%</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">0.21</td>
<td style="text-align: left; color: black;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;">Expected life (years)</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">1.08</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="color: black;">&#160;</td>
<td style="text-align: left; color: black;">&#160;</td>
<td style="text-align: right; color: black;">1.04</td>
<td style="text-align: left; color: black;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The following table summarizes the estimated fair value of the warrant liabilities at December 31, 2011<i>(in thousands):</i></p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-indent: -0.25in; padding-left: 0.25in;">Balance at December 31, 2010</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 87%;">Warrant liability</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 10%;">1,492</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">Change in fair value of warrant liability</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">242</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;">Reclassification to additional paid-in capital</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(1,734</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in;">Balance at December 31, 2011</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">-</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule Of Warrant Activity [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of warrant activity for the Company for the year ended December 31, 2011 and for the year ended December 31, 2012 is as follows:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.75in;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="font-weight: bold;" nowrap="nowrap">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted&#160;Average</td><td style="font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Number&#160;of&#160;Warrants</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise&#160;Price</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="width: 74%;">Balance at December 31, 2010</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">&#160;</td><td style="text-align: right; width: 10%;">1,131,078</td><td style="text-align: left; width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 10%;">3.49</td><td style="text-align: left; width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,272,963</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.25</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(15,615</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.03</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Forfeited</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(129,240</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">2.08</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td>Balance as December 31, 2011</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,259,186</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.95</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">985,855</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.71</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,768,167</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.11</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 1pt;">Forfeited</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(844,373</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">3.32</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="padding-bottom: 2.5pt;">Balance as December 31, 2012</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: right;">1,632,501</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">1.99</td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock', window );">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of all outstanding and exercisable warrants as of December 31, 2012 is as follows:</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;">Exercise</font><br /><font style="font: 10pt times new roman, times, serif;">Price</font></td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;">Warrants</font><br /><font style="font: 10pt times new roman, times, serif;">Outstanding</font></td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;">Warrants</font><br /><font style="font: 10pt times new roman, times, serif;">Exercisable</font></td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;">Weighted&#160;Average</font><br /><font style="font: 10pt times new roman, times, serif;">Remaining</font><br /><font style="font: 10pt times new roman, times, serif;">Contractual&#160;Life</font></td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;">Aggregate </font><br /><font style="font: 10pt times new roman, times, serif;">Intrinsic Value</font></td><td nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right; width: 17%;"><font style="font: 10pt times new roman, times, serif;">1.14</font></td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: right; width: 17%;"><font style="font: 10pt times new roman, times, serif;">100,000</font></td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: right; width: 17%;"><font style="font: 10pt times new roman, times, serif;">100,000</font></td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: right; width: 20%;"><font style="font: 10pt times new roman, times, serif;">4.09 years</font></td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right; width: 15%;"><font style="font: 10pt times new roman, times, serif;">62,000</font></td><td style="width: 1%;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">1.32</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">18,182</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">18,182</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.00 years</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">8,000</font></td><td>&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">1.60</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">635,855</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">635,855</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">4.83 years</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">102,000</font></td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">2.20</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">250,000</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">50,000</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">1.20 years</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;">&#160;</td><td>&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">2.22</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">517,257</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">517,257</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.91 years</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: left;"><font style="font: 10pt times new roman,
 times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">-</font></td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.30</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">61,207</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">61,207</font></td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.30 years</font></td><td>&#160;</td><td>&#160;</td><td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;">-</font></td><td>&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="border-bottom: black 1pt solid;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.75</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 1pt solid;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">50,000</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 1pt solid;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">50,000</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 1pt solid;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.13 years</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;">-</font></td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">1.99</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 2.25pt double;">&#160;</td><td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">1,632,501</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 2.25pt double;">&#160;</td><td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">1,432,501</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 2.25pt double;">&#160;</td><td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">3.80 years</font></td><td>&#160;</td><td>&#160;</td><td style="border-bottom: black 2.25pt double; text-align: left;"><font style="font: 10pt times new roman, times, serif;">$</font></td><td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;">172,000</font></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrant activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfWarrantActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to warrant outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure relates to share based compensation arrangement by share based payment award non vested stock options and expected to vest outstanding and exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedAndExpectedToVestExercisableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of derivative liabilities at fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number of fully vested share options (or share units) and share options expected to vest at the date of the latest statement of financial position, weighted-average exercise price (or conversion ratio), aggregate intrinsic value (except for nonpublic entities), and weighted-average remaining contractual term for both options (or share units) currently outstanding and options (or share units) exercisable (or convertible).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Principles of Consolidation</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">All inter-company transactions and accounts have been eliminated in consolidation.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EmergingFromDevelopmentStagePolicyTextBlock', window );">Emerging From Development Stage [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Emerging from the Development Stage</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the second quarter of 2010, the Company emerged from the development stage.&#160;&#160;&#160;A development-stage enterprise is one in which planned principle operations have not commenced or if its operations have commenced, there has been no significant revenue.&#160;On May 6, 2010, the Company entered into a Sublicense Agreement (the &#8220;Meda Agreement&#8221;) with Meda&#160;AB of Sweden (&#8220;Meda&#8221;) and received an up-front payment of $2.5 million. The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement of principal operations, and therefore development-stage reporting was no longer required.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Use of Estimates</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy', window );">Premiums Receivable, Allowance for Doubtful Accounts, Estimation Methodology, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Accounts Receivable and Allowance for Doubtful Accounts</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Revenue Recognition</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;For the year ended December 31, 2012 and 2011, the Company&#8217;s only stream of revenue was laboratory revenue.&#160;&#160;Laboratory revenues are a component of discontinued operations for the years ended December 31, 2012 and 2011. See Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>License Revenues</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&#160;&#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Laboratory Revenues</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which was the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior period multiplied by the period&#8217;s actual gross sales to determine the actual sales allowance for each period. See Note 3 - Discontinued Operations of Adeona Clinical Laboratory.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Risks and Uncertainties</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock', window );">Marketable Securities Held To Maturity Trading Available For Sale Securities Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Classification of Marketable Securities as Held to Maturity, Trading, and Available for Sale</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading, are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&#8217; equity. At December 31, 2012 and 2011, respectively, the Company had no debt and marketable equity securities.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows <i>(in thousands)</i> :</p><p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31, 2011</td><td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; width: 72%;">Purchase of short-term investments</td><td style="width: 1%;">&#160;</td><td style="text-align: left; width: 1%;">$</td><td style="text-align: right; width: 25%;">(4,370</td><td style="text-align: left; width: 1%;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Amortization of premium on investments</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">57</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify;">Proceeds from short-term investments</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4,293</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 1pt;">Loss on sale of short-term investments</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">20</td><td style="text-align: left; padding-bottom: 1pt;">&#160;</td></tr><tr style="background-color: #ccffcc; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2.5pt;">Fair value</td><td style="padding-bottom: 2.5pt;">&#160;</td><td style="border-bottom: black 2.5pt double; text-align: left;">$</td><td style="border-bottom: black 2.5pt double; text-align: right;">-</td><td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Property and Equipment</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="border-bottom: black 1pt solid; text-align: center; width: 49%;" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;"><b>Asset&#160;Description</b></font></td>
<td style="text-align: center; width: 4%;" nowrap="nowrap">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 47%;" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;"><b>Estimated&#160;Useful&#160;Life</b></font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;">Office equipment and furniture</font></td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;">3-5&#160;&#160;years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;">Laboratory equipment</font></td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;">7-10 years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;">Manufacturing equipment</font></td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;">10 years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;">Leasehold improvements and fixtures</font></td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;">Lesser of estimated useful or life of lease</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Depreciation expense was approximately $63,000 and $144,000 for the years ended December 31, 2012 and 2011, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During 2012, the Company reviewed property and equipment for impairment and determined that certain items were impaired due to obsolescence. As a result of this review, the Company recorded an impairment loss of approximately $47,000. For the year ended December 31, 2011, there were no significant events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Long-Lived Assets</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Goodwill</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">ASC No. 350, &#8220;Intangibles &#8211; Goodwill and Others,&#8221; requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. See Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivatives, Reporting of Derivative Activity [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Derivative Liabilities</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In&#160;addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option pricing model.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Net Income (Loss) per Share</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive, at December 31, 2012 and December 31, 2011, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the year ended December 31, 2012 were 4,453,746 and 1,632,501, respectively, and for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and Development Costs</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Fair Value of Financial Instruments</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;">&#160;</td>
<td style="width: 3%;"><font style="font: 10pt symbol;">&#183;</font></td>
<td style="text-align: justify; width: 94%;"><font style="font: 10pt times new roman, times, serif;">Level 1 inputs: Quoted prices (unadjusted)&#160;for identical assets or liabilities in active markets;</font></td>
</tr>
</table>
<p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;">&#160;</td>
<td style="width: 3%;"><font style="font: 10pt symbol;">&#183;</font></td>
<td style="text-align: justify; width: 94%;"><font style="font: 10pt times new roman, times, serif;">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</font></td>
</tr>
</table>
<p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;">&#160;</td>
<td style="width: 3%;"><font style="font: 10pt symbol;">&#183;</font></td>
<td style="text-align: justify; width: 94%;"><font style="font: 10pt times new roman, times, serif;">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cash and cash equivalents include money market accounts and mutual funds of $8.6 million and $5.0 million as of December 31, 2012 and December 31, 2011, respectively, that are measured using Level 1 inputs.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockBasedPaymentArrangementsPolicyTextBlock', window );">Stock Based Payment Arrangements [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock-Based Payment Arrangements</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Income Taxes</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC Topic 740, &#8220;<i>Income Taxes</i>,&#8221; which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In addition, accounting guidance now codified as FASB ASC Topic 740-20, <i>&#8220;Income Taxes &#8211; Intraperiod Tax Allocation&#8221; </i>requires<i> </i>management to assess the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The accounting guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December 31, 2012 and 2011, respectively, the Company did not record any liabilities for uncertain tax positions.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Recent Accounting Pronouncements</i></b></p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">There were no accounting standards or interpretations issued or recently adopted that are expected to have a material impact on the Company&#8217;s financial position, operations, or cash flows.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EmergingFromDevelopmentStagePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for emerging from development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EmergingFromDevelopmentStagePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for investments in debt securities (which may include mandatorily redeemable preferred shares or preferred shares redeemable at the investing Company's option) that are classified as held-to-maturity. This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of held-to-maturity securities are other than temporary, and how the fair values of such securities are determined, This policy also may describe the entity's accounting treatment for transfers between investment categories and how the fair values of such securities are determined,This policy also may describe the entity's accounting treatment for transfers between investment categories, how the entity determines whether impairments of available-for-sale securities are other than temporary, and how the fair values of such securities are determined.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_MarketableSecuritiesHeldToMaturityTradingAvailableForSaleSecuritiesPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_RisksAndUncertaintiesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding risk and uncertainties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_RisksAndUncertaintiesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockBasedPaymentArrangementsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding stock based payment arrangements for various stocks.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockBasedPaymentArrangementsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 8, 9, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 2110<br><br> -Paragraph 6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 325<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197087<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 20<br><br> -Subparagraph a(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 2-6<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2196966<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 40<br><br> -Section 45<br><br> -URI http://asc.fasb.org/section&amp;trid=2197723<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 5, 6, 16-19<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16385135&amp;loc=d3e33801-111570<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 14, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 46R<br><br> -Paragraph 4<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 140<br><br> -Paragraph 46<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959686&amp;loc=d3e355033-122828<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 96-16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 97-2<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -URI http://asc.fasb.org/section&amp;trid=2229173<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n)(7))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 133<br><br> -Paragraph 44<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesReportingOfDerivativeActivity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 107<br><br> -Paragraph 8, 10, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144439<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 18-23, 26, 34<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7-15, 26, 30-37<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 48<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32247-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 4<br><br> -Paragraph 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 6-34, 43, 47, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32280-109318<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144749<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144681<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the estimated allowance for doubtful accounts for premium amounts due from policyholders, insureds, and other insurance entities. May include factors that management considered, such as historical loss experience and current economic and competitive conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 310<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=4738109<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7512638&amp;loc=d3e5144-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PremiumsReceivableAllowanceForDoubtfulAccountsEstimationMethodologyPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 34<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section C<br><br> -Paragraph 5<br><br> -Chapter 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 7<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 6<br><br> -Paragraph 5, 6, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 42<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8, 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 94-6<br><br> -Paragraph 11, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract', window );"><strong>Disclosure Of License Collaborative and Employment Agreements and Commitments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock', window );">License Collaborative and Employment Agreements and Commitments [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="text-align: left; width: 0.5in;"><font size="2" style="font-family:times new roman,times"><b>7.</b></font></td>
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times"><b>License, Collaborative and Employment Agreements and Commitments</b></font></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><i>License and Collaborative Agreements</i></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">As described below, the Company has entered into several license and collaborative agreements for the right to use research, technology and patents. Some of these license and collaborative agreements may contain milestones.&#160; The specific timing of such milestones cannot be predicted and are dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which may never occur).&#160; Further, under the terms of certain licensing agreements, the Company may have the obligation to pay certain milestones contingent upon the achievement of specific levels of sales.&#160; Due to the long-range nature of such commercial milestone amounts, they are neither probable at this time nor predictable and consequently are not included in this disclosure.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On December 19, 2012, the Company entered into a License Agreement with The University of Texas at Austin (the &#8220;University&#8221;) for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to pertussis antibodies. The License Agreement provides that the University is entitled to payment of past patent expenses, an annual payment of $50,000 per year commencing on the effective date through December 31, 2014 and a $25,000 payment on December 31, 2015 and milestone payments of $50,000 upon commencement of Phase I clinical trials, $100,000 upon commencement of Phase III clinical trials, $250,000 upon NDA submission in the U.S., $100,000 upon European Medicines Agency approval and $100,000 upon regulatory approval in an Asian country. In addition, the University is entitled to a running royalty upon net sales (as defined in the License Agreement). The License Agreement terminates upon the expiration of the patent rights (as defined in the License Agreement); provided, however that the License Agreement is subject to early termination by the Company in its discretion and by the University for a breach of the License Agreement by the Company.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In connection with the License Agreement, the Company and the University also entered into a Sponsored Research Agreement pursuant to which the University will perform certain research work related to pertussis. The Sponsored Research Agreement may be renewed annually, in the sole discretion of the Company, after the first year for two additional one year terms with a fixed fee for the first year of $303,287 and for the second and third years, if renewed, a fixed fee of $316,438 and $328,758 respectively, all payable in quarterly installments. If renewed by the Company after the first year for the remaining two years, the research shall be performed from the effective date of the Sponsored Research Agreement until December 31, 2015; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Research Agreement which remain uncured for sixty days after receipt of notice, automatically upon the Company&#8217;s bankruptcy or insolvency and by the Company in its sole discretion at any time after the one year anniversary of the date of execution thereof upon no less than 90 days notice. Upon termination prior to December 31, 2014, the Company shall only be responsible for payment of expenses that do not exceed the fixed annual amount and are incurred prior to the termination date and non-cancellable expenses committed to be expended by the University prior to the termination date for the lesser of the remainder of their appointment in the case of salaries and December 31, 2014. Upon a termination after December 31, 2014 or due to a breach by the University, the Company shall only be responsible for all reasonable expenses that do not exceed the fixed annual amount and that are incurred by the University prior to the termination date for services performed prior to the termination date.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On November 28, 2012, a closing was held for the transaction contemplated by the Prev Agreement the Company entered into with Prev ABR LLC (&#8220;Prev&#8221;), pursuant to which it acquired the<i> C. diff</i> program assets of Prev, including pre-Investigational New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents.&#160; Pursuant to the Prev Agreement, the Company paid Prev an initial cash payment of $100,000 upon execution of the Prev Agreement and at closing paid an additional cash payment of $135,000 and issued 625,000 unregistered shares of our common stock to Prev. See Note 6. In addition, upon the achievement of the milestones set forth below, Prev may be entitled to receive additional consideration payable 50% in cash and 50% in our stock, subject to Prev&#8217;s option to receive the entire payment in shares of our stock, with the exception of the first milestone payments to be paid in cash: (i) upon commencement of an IND; (ii) upon commencement of a Phase I clinical trial; (iii) upon commencement of a Phase II clinical trial; (iv) upon commencement of a Phase III clinical trial; (v) upon Biologic License Application (BLA) filing in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi) upon BLA approval in the U.S. and upon approval in territories outside the-U.S. The Prev Agreement also provides that Prev has a right to the return to it of all assets acquired by the Company under the Prev Agreement if on or prior to the date that is (i) thirty (30) months after the execution of the Prev Agreement, the Company has not initiated toxicology studies in non-rodent models or (ii) thirty six (36) months have not filed an IND under the program related to the assets and such failure is not due to action or inaction of Prev or breach of its representations or warranties or covenants or if there is a change of control as defined in the Prev Agreement and after such change of control the assets are not further developed; provided however that such thirty (30) and thirty six (36) month periods can be extended by the Company for an additional twelve (12) months upon payment of a cash milestone payment.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On August 6, 2012, the Company expanded its relationship with Intrexon and entered into the Second Channel Agreement with Intrexon that governs an &#8220;exclusive channel collaboration&#8221; arrangement in which the Company will use Intrexon&#8217;s technology relating to the identification, design and production of human antibodies and DNA vectors for the development and commercialization of a series of monoclonal antibody therapies for the treatment of certain serious infectious diseases. Pursuant to the terms of the Second Stock Issuance Agreement with Intrexon, which was approved by the Company&#8217;s stockholders on October 5, 2012, the Company issued 3,552,210 shares of its common stock, $0.001 par value, which issuance is also deemed paid in consideration for the execution and delivery of the Second Channel Agreement, dated August 6, 2012, between the Company and Intrexon. The fair value of this transaction was $7.8 million and was charged to research and development expense for the year ended December 31, 2012, in accordance with the Company&#8217;s accounting policy. In connection with the transactions contemplated by the Second Stock Issuance Agreement, and pursuant to the First Amendment to Registration Rights Agreement (the &#8220;First Amendment to Registration Rights Agreement&#8221;) executed and delivered by the parties at the closing, the Company agreed to file a &#8220;resale&#8221; registration statement registering the resale of certain of the shares issued under the Second Stock Issuance Agreement. None of the shares to be issued under the Second Stock Issuance Agreement need to be registered until April 30, 2013. Under that agreement, the Company is obligated to use its reasonable best efforts to cause the &#8220;resale&#8221; registration statement to be declared effective as promptly as practicable after filing and to maintain the effectiveness of the registration statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Subject to certain expense allocations and other offsets provided in the Second Channel Agreement, the Company will pay Intrexon royalties on annual net sales of the Synthetic Products, calculated on a Synthetic Product-by-Synthetic Product basis. The Company has likewise agreed to pay Intrexon a percentage of quarterly revenue obtained from a sublicensor in the event of a sublicensing arrangement.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company also agreed upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the &#8220;IND Milestone Event&#8221;), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares of Common Stock (the &#8220;IND Milestone Shares&#8221;) having a fair market value equaling two million dollars ($2M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the &#8220;Approval Milestone Event&#8221;), the Company agreed to pay to Intrexon either (i) three million dollars ($3M) in cash, or (ii) that number of shares of Common Stock (the &#8220;Approval Milestone Shares&#8221;) having a fair market value equaling three million dollars ($3M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company also agreed that it will pay an optional and varying fee whereby the Company remits a payment, in cash or equity at our sole discretion, to Intrexon calculated as a multiple of the number of targets in excess of three (3) total that the Company desires to elect (the &#8220;Field Expansion Fee&#8221;). The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for each target in excess of three (3) total that the Company elects, or (ii) that number of shares of Common Stock (the &#8220;Field Expansion Fee Shares&#8221;) having a fair market value equaling two million dollars ($2M) for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field Expansion Fee Closing.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On November 18, 2011, the Company entered into the Initial Channel Agreement with Intrexon that governs an &#8220;exclusive channel collaboration&#8221; arrangement in which the Company initially intended to use Intrexon&#8217;s technology directed towards the production of PGIS. As consideration for execution of the Initial Channel Agreement, the Company entered into the Initial Stock Purchase Agreement with Intrexon pursuant to which the Company issued to Intrexon a number of shares of our common stock equal to 9.995% of the number of shares of the Company&#8217;s common stock issued and outstanding following and giving effect to such issuance at a purchase price equal to the $0.001 par value of such shares, which issuance was deemed paid in consideration for the execution and delivery of the Initial Channel Agreement. The Company also agreed to issue additional shares of its common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored by the Company in the U.S., or similar study as the parties may agree in a country other than the U.S. The program under this Initial Channel Agreement is in the discovery stage. In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a &#8220;resale&#8221; registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance. The registration statement registering such shares was declared effective on April 13, 2012, but is not currently valid due to certain issues regarding the failure of the Company&#8217;s prior auditor to follow proper partner rotation. Intrexon has agreed not to require the Company to file a post effective registration statement on Form S-1 with respect to the First Tranche Shares and instead has agreed to wait until the Company is once again S-3 eligible for registration of such shares.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company paid Intrexon a prepayment of research and development expenses of $2.5 million for research and development goods and services to be provided in the future and has been recorded on the Company&#8217;s balance sheet in prepaid expenses and other current assets.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In September&#160;of 2005, the Company entered into a three-year research agreement with the University of Michigan. Pursuant to that agreement, the Company sponsored research of approximately $460,000 per year.&#160;&#160;On March 20, 2008, the Company terminated the agreement.&#160;&#160;On March 24, 2009, the Company entered into a payment plan with the University of Michigan to pay the outstanding balance of $197,000.&#160;&#160;The Company agreed to pay $5,000 per month, the balance was paid in full July 2012.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><i>Employment Agreements</i></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Effective February 3, 2012, Dr. Kuo resigned from his positions as President and Chief Executive Officer. In connection with his resignation, Dr. Kuo entered into a nine-month consulting agreement with the Company (the &#8220;Consulting Agreement&#8221;). Pursuant to the Consulting Agreement, Dr. Kuo will be entitled to a consulting fee of $17,000 per month and retain the right to exercise the stock options held by him that have vested (324,999) as of the effective date of the Consulting Agreement for a period expiring on the date that is one year from the effective date of the Consulting Agreement.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Effective February 3, 2012, Jeffrey Riley was appointed to serve as the Company&#8217;s Chief Executive Officer and President. In connection with his appointment, Mr. Riley entered into a three-year employment agreement with the Company (the &#8220;Riley Employment Agreement&#8221;). Pursuant to the Riley Employment Agreement, Mr. Riley will be entitled to an annual base salary of $348,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Riley was granted options to purchase 750,000 shares of the Company&#8217;s common stock with an exercise price equal to the per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1.7 million using a Black-Scholes valuation model.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Effective February 6, 2012, C. Evan Ballantyne was appointed the Company&#8217;s Chief Financial Officer. In connection with his appointment, Mr. Ballantyne entered into a three-year employment agreement with the Company (the &#8220;Ballantyne Employment Agreement&#8221;). Pursuant to the Ballantyne Employment Agreement, Mr. Ballantyne will be entitled to an annual base salary of $298,000 and will be eligible for discretionary performance and transactional bonus payments. Additionally, Mr. Ballantyne was granted options to purchase 425,000 shares of our common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, on a monthly basis, over thirty-six months. The Company measured the fair value of the stock options at approximately $1 million using a Black-Scholes valuation model.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><i>Other Commitments</i></font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">As of December 31, 2012, amounts due for license and sponsored research agreements are as follows <i>(in thousands)</i>:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 50%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-weight: bold;"><font size="2" style="font-family:times new roman,times">Year&#160;Ending&#160;December&#160;31,</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 17.3pt; width: 85%;"><font size="2" style="font-family:times new roman,times">2013</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 12%;"><font size="2" style="font-family:times new roman,times">287</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 17.3pt;"><font size="2" style="font-family:times new roman,times">2014</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">60</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 17.3pt;"><font size="2" style="font-family:times new roman,times">2015</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">35</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 17.3pt;"><font size="2" style="font-family:times new roman,times">2016</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">10</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 17.3pt;"><font size="2" style="font-family:times new roman,times">2017</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">10</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 8.65pt;"><font size="2" style="font-family:times new roman,times">Total</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">402</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><i>Operating Lease</i></font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During 2012, the Company entered into a one year operating lease for office space in Ann Arbor, Michigan.&#160; In March 2013, this lease was amended to extend the term of the lease to December 31, 2014, for annual lease payments of $33,000. In March 2012, the Company also entered into a one year operating lease that may be renewed for two additional terms of one year, for office space in Rockville, Maryland, for annual lease payments of $35,000. The Maryland office lease may be terminated with 60 days written notice.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During the years ended December 31, 2012 and 2011, the Company recognized rent expense of $123,000 and $64,000, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of license, collaborative and employment agreement and commitments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0in;"></td>
<td style="width: 0.5in;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>5.</b></font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>Stock-Based Compensation</b></font></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Stock Incentive Plan</i></b></font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During 2001, the Company&#8217;s Board of Directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 Stock Plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of December 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of December 31, 2012, there are 872,739 options issued and outstanding under the 2007 Stock Plan.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various period from the date of grant, and generally expire ten years after the grant date. As of December 31, 2012, there are 2,515,000 options issued and outstanding under the 2010 Stock Plan.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company has applied fair value accounting for all share based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes assumptions used in the years ended December 31, 2012 and 2011 are as follows:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="3"><font size="2" style="font-family:times new roman,times">Year&#160;ended&#160;December&#160;31,</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"><font size="2" style="font-family:times new roman,times">2012</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;"><font size="2" style="font-family:times new roman,times">2011</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Exercise price</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">$1.69 - $2.47</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">$0.49 - $2.22</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; width: 74%;"><font size="2" style="font-family:times new roman,times">Expected dividends</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; width: 12%;"><font size="2" style="font-family:times new roman,times">0%</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; width: 12%;"><font size="2" style="font-family:times new roman,times">0%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Expected volatility</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">108% - 174%</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">175% - 188%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Risk fee interest rate</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">0.37% - 1.98%</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">1.30% - 3.58%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Expected life of option</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">5 - 10 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">5 - 7 years</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Expected forfeitures</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">0%</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">0%</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company records stock-based compensation based upon the stated vested provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 9%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 3%;"><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td style="width: 88%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">immediate vesting,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">half vesting immediately and the remainder over three years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">quarterly over three years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">annually over three years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">one-third immediate vesting and remaining annually over two years,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">one half immediate vesting with remaining vesting over nine months,</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">one quarter immediate vesting with the remaining over three years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">one quarter immediate vesting with the remaining over 33 months; and</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">monthly over three years.</font></td>
</tr>
</table>
<p style="text-indent: -0.25in; margin: 0pt 0px 0pt 1in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During 2012, the Company granted 2,075,000 options to employees and consultants having an approximate fair value of $4.5 million based upon the Black-Scholes option pricing model.&#160; During 2011, the Company granted 557,002 options to employees and consultants having an approximate fair value of $609,000 based upon the Black-Scholes option pricing model.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued employees for the years ended December 31, 2012 and 2011 were $1.4 million and $268,000, respectively. Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to consultants for the years ended December 31, 2012 and 2011 were $216,000 and $705,000, respectively.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Average</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remaining</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Aggregate</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Average&#160;Exercise</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Contractual</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Intrinsic</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Price</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Life</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Value</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; width: 48%;"><font size="2" style="font-family:times new roman,times">Balance &#8211; December 31, 2010</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">2,539,091</font></td>
<td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">1.32</font></td>
<td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right; width: 10%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">6.97 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">1,028,000</font></td>
<td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Granted</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">557,002</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.26</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Exercised</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(23,333</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">0.57</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Forfeited</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(93,750</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">0.59</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Balance &#8211; December 31, 2011</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,979,010</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.34</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">6.01 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Granted</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,075,000</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2.21</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Exercised</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(374,851</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">0.34</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Forfeited</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(225,413</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">2.37</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Balance &#8211; December 31, 2012 &#8211; outstanding</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">4,453,746</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.78</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">6.43 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1,308,000</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Balance &#8211; December 31, 2012 &#8211; exercisable</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2,891,877</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.60</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">5.71 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1,160,000</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Grant date fair value of options granted &#8211; 2012</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">4,467,984</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Weighted average grant date fair value &#8211; 2012</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2.15</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Grant date fair value of options granted &#8211; 2011</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">609,000</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Weighted average grant date fair value &#8211; 2011</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.09</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="margin: 0px;"><font size="2" style="font-family:times new roman,times">&#160;&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The options outstanding and exercisable at December 31, 2012 are as follows:</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options&#160;Outstanding</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options&#160;Exercisable</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted&#160;Average</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted&#160;Average</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Range&#160;of</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Average</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remaining</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Average</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remaining</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Contractual&#160;Life</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Contractual&#160;Life</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 14%;"><font size="2" style="font-family:times new roman,times">$0.09 - $2.00</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 12%;"><font size="2" style="font-family:times new roman,times">2,162,362</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 12%;"><font size="2" style="font-family:times new roman,times">1.78</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 13%;"><font size="2" style="font-family:times new roman,times">5.76 years</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 11%;"><font size="2" style="font-family:times new roman,times">1,801,187</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 11%;"><font size="2" style="font-family:times new roman,times">1.14</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 13%;"><font size="2" style="font-family:times new roman,times">5.52 years</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">$2.01 - $3.00</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,212,227</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2.26</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">7.15 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1,011,533</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2.17</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">6.14 years</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">$3.01 - $6.00</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">79,157</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">4.87</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">4.49 years</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">79,157</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">4.87</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">4.49 years</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">$0.09 - $6.00</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">4,453,746</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.78</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">6.43 years</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2,891,877</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.60</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">5.71 years</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The options outstanding and exercisable at December 31, 2011 are as follows:</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="11" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options&#160;Outstanding</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="9" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options&#160;Exercisable</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted&#160;Average</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted&#160;Average</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Range&#160;of</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Average</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remaining</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Average</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remaining</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Contractual&#160;Life</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Options</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Contractual&#160;Life</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; width: 14%;"><font size="2" style="font-family:times new roman,times">$0.09 - $4.57</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 12%;"><font size="2" style="font-family:times new roman,times">2,889,011</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 12%;"><font size="2" style="font-family:times new roman,times">1.20</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 13%;"><font size="2" style="font-family:times new roman,times">6.11 years</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 11%;"><font size="2" style="font-family:times new roman,times">2,364,608</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 11%;"><font size="2" style="font-family:times new roman,times">1.29</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 13%;"><font size="2" style="font-family:times new roman,times">5.72 years</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">$4.58 - $9.05</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">89,999</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">5.93</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">2.76 years</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">89,999</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">5.93</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">2.76 years</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: center; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">$0.09 - $9.05</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2,979,010</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.34</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">6.01 years</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2,454,607</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.46</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">5.62 years</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The following is a summary of the Company&#8217;s non-vested stock options at December 31, 2012:</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted&#160;Average</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Unvested</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Grant</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Stock&#160;Options</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Date&#160;Fair&#160;Value</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 74%;"><font size="2" style="font-family:times new roman,times">Non-vested&#160;&#8211;&#160;December&#160;31,&#160;2011</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">524,403</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">0.82</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Granted</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,075,000</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2.21</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Vested/Exercised</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(891,332</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">0.81</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Forfeited/Cancelled</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(146,202</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">1.79</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Non-vested &#8211; December 31, 2012</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1,561,869</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">2.11</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Weighted average remaining period for vesting</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">2.09 years</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b>&#160;</b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">As of December 31, 2012, total unrecognized stock-based compensation expense related to stock options was $3.2 million, which is expected to be expensed through September 2015.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">FASB&#8217;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from financing activities.&#160; Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options.&#160; The Company did not record any excess tax benefits in 2012 or 2011.&#160; Cash received from option exercises under the Company&#8217;s stock-based compensation plans for the years ended December 31, 2012 and 2011 was $127,000 and $15,000, respectively.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Stock Warrants and Derivative Liabilities</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On October 25, 2012, the Company entered into a Common Stock Purchase Agreement with certain accredited investors. As part of this agreement, the Company issued warrants to purchase 635,855 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.60 and a life of five years. The warrants vested immediately and expire October 25, 2017. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of December 31, 2012, all the warrants were outstanding.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company&#8217;s common stock based on achievement of certain stock price milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date of issuance for an exercise price equal to the price ($2.20 per share) of the Company&#8217;s common stock on the date of execution (March 15, 2012). The expense recorded for the year ended December 31, 2012 approximated $63,000 and was estimated using the Monte Carlo valuation model. The assumptions used by the Company are summarized in the following table:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 87%; color: black;"><font size="2" style="font-family:times new roman,times">Exercise price</font></td>
<td style="width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%; color: black;"><font size="2" style="font-family:times new roman,times">2.20</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected dividends</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected volatility</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">110</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Risk free interest rate</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.26</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected life of warrant</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font style="font: 10pt times new roman, times, serif; color: black;; font-family:times new roman,times" size="2">2 years</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&#8217;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. All of this expense was recorded in the year ended December 31, 2012. The assumptions used by the Company are summarized in the following table:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 87%; color: black;"><font size="2" style="font-family:times new roman,times">Exercise price</font></td>
<td style="width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%; color: black;"><font size="2" style="font-family:times new roman,times">1.14</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected dividends</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected volatility</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">174</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Risk free interest rate</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.71</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected life of warrant</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font style="font: 10pt times new roman, times, serif; color: black;; font-family:times new roman,times" size="2">5 years</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. Each warrant was exercisable&#160;for thirteen months&#160;at $2.00 per share and subsequently exchanged for new warrants with substantially the same&#160;terms as the original warrants except that the expiration date was extended for two months. The original warrants had an anti-dilution price protection feature; if the Company issues securities at a price per share that is less than $2.00 per share, the warrant holders will be ratcheted down to the lower offering price. However, the Company had instituted a floor price of $1.40 per share in connection with the price protection.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40 per share. Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2012, all of these warrants have been exercised.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The warrants were initially recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent reporting period. On April 6, 2011, the fair value of the warrant liability was $1.5 million, which represented an increase in fair value of $765,000. The fair value was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remeasurement</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Commitment</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Date</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Date</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">April&#160;6,&#160;2011</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 74%; color: black;"><font size="2" style="font-family:times new roman,times">Closing stock price</font></td>
<td style="width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%; color: black;"><font size="2" style="font-family:times new roman,times">1.39</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%; color: black;"><font size="2" style="font-family:times new roman,times">2.08</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected dividend rate</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected stock price volatility</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">117.1</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">104.6</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Risk free interest rate</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.28</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.29</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">Expected life (years)</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">1.08</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.85</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date was&#160;extended by two months.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrant was initially exercisable&#160;for thirteen months&#160;at $2.0725 per share. The warrant had an anti-dilution price protection feature; that provided if the Company issues securities at a price per share that is less than $2.0725 per share,&#160;the&#160;exercise price of the warrant&#160;will be ratcheted down to the lower offering price.&#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&#160;three months to August 12, 2012,&#160;and (iv) the warrant&#8217;s initial exercise date was changed to January 2012. Due to this warrant exchange, the warrant liability was marked-to-market and reclassified to additional paid-in capital since it ceased to contain the provisions of a derivative liability. As of December 31, 2012, all of these warrants have been exercised.</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The warrant is&#160;initially recorded as a liability at&#160;its estimated fair value on the commitment date, which was $776,000 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent period. On July 28, 2011, the fair value of the warrant liability was $253,000, which represented a decrease in fair value of $523,000. The fair value is measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Remeasurement</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Commitment</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Date</font></td>
<td style="color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Date</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">July&#160;28,&#160;2011</font></td>
<td style="padding-bottom: 1pt; color: black;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-indent: -13.2pt; padding-left: 13.2pt; width: 74%; color: black;"><font size="2" style="font-family:times new roman,times">Closing stock price</font></td>
<td style="width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%; color: black;"><font size="2" style="font-family:times new roman,times">2.08</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%; color: black;"><font size="2" style="font-family:times new roman,times">0.84</font></td>
<td style="text-align: left; width: 1%; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"><font size="2" style="font-family:times new roman,times">Expected dividend rate</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"><font size="2" style="font-family:times new roman,times">Expected stock price volatility</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">112.1</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">105.6</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"><font size="2" style="font-family:times new roman,times">Risk free interest rate</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.29</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">0.21</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">%</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -13.2pt; padding-left: 13.2pt; color: black;"><font size="2" style="font-family:times new roman,times">Expected life (years)</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">1.08</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; color: black;"><font size="2" style="font-family:times new roman,times">1.04</font></td>
<td style="text-align: left; color: black;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The following table summarizes the estimated fair value of the warrant liabilities at December 31, 2011<i>(in thousands):</i></font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-indent: -0.25in; padding-left: 0.25in;"><font size="2" style="font-family:times new roman,times">Balance at December 31, 2010</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in; width: 87%;"><font size="2" style="font-family:times new roman,times">Warrant liability</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">1,492</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;"><font size="2" style="font-family:times new roman,times">Change in fair value of warrant liability</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">242</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; text-indent: -0.25in; padding-left: 0.25in;"><font size="2" style="font-family:times new roman,times">Reclassification to additional paid-in capital</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(1,734</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; text-indent: -0.25in; padding-left: 0.25in;"><font size="2" style="font-family:times new roman,times">Balance at December 31, 2011</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">A summary of warrant activity for the Company for the year ended December 31, 2011 and for the year ended December 31, 2012 is as follows:</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 95%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Weighted&#160;Average</font></td>
<td style="font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Number&#160;of&#160;Warrants</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">Exercise&#160;Price</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 74%;"><font size="2" style="font-family:times new roman,times">Balance at December 31, 2010</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">1,131,078</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">3.49</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Granted</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">2,272,963</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.25</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Exercised</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(15,615</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.03</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Forfeited</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(129,240</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">2.08</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Balance as December 31, 2011</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">3,259,186</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.95</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Granted</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">985,855</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.71</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Exercised</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(1,768,167</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">1.11</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Forfeited</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">(844,373</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">3.32</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Balance as December 31, 2012</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1,632,501</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">1.99</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Stock-based compensation expense included in general and administrative expenses relating to warrants issued to consultants for the year ended December 31, 2012 was $271,000. There was no stock-based compensation for warrants for the year ended December 31, 2011.</font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><!-- Field: /Page --></font></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: center; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="margin: 0px;"><font size="2" style="font-family:times new roman,times">A summary of all outstanding and exercisable warrants as of December 31, 2012 is as follows:</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Exercise</font><br  /><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Price</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Warrants</font><br  /><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Outstanding</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Warrants</font><br  /><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Exercisable</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Weighted&#160;Average</font><br  /><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Remaining</font><br  /><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Contractual&#160;Life</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Aggregate </font><br  /><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Intrinsic Value</font></td>
<td nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right; width: 17%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1.14</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 17%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">100,000</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 17%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">100,000</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right; width: 20%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">4.09 years</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right; width: 15%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">62,000</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1.32</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">18,182</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">18,182</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.00 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">8,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1.60</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">635,855</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">635,855</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">4.83 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">102,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">2.20</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">250,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">50,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1.20 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">2.22</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">517,257</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">517,257</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.91 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.30</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">61,207</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">61,207</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.30 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="border-bottom: black 1pt solid;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.75</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">50,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">50,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.13 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">-</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="border-bottom: black 2.25pt double;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1.99</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1,632,501</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">1,432,501</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3.80 years</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.25pt double; text-align: left;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">$</font></td>
<td style="border-bottom: black 2.25pt double; text-align: right;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">172,000</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"></font>&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Options of Subsidiary</i></b></font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">As of December 31, 2012, Epitope, a majority-owned subsidiary of Synthetic Biologics, has 50,000 stock options outstanding and 40,000 stock options exercisable. These stock options have an exercise price of $0.001 and a remaining contractual life of 5.50 years.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="text-align: left; width: 0.5in;"><b>6.</b></td>
<td style="text-align: justify;"><b>Stockholders&#8217; Equity</b></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Year Ended December 31, 2011</i></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the year ended December 31, 2011, the Company issued 28,333 shares of common stock in connection with the exercise of stock options and warrants for proceeds of $15,000 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company issued 73,585 shares of common stock for employment service, having a fair value of $94,000 ($1.29 average per share) and 171,796 shares of common stock for consulting services, having a fair value of $165,000 ($0.96 average per share), based on the quoted closing trading prices. The Company also issued 3,123,558 shares of common stock as consideration for the Exclusive Channel Collaboration Agreement with Intrexon, having a fair value of $1.7 million ($0.54 per share), based on the quoted closing trading price.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&#160;1,428,572 shares of common stock&#160;for $4 million. Direct offering costs were approximately $296,000.</p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 6, 2011, the Company sold 1,688,782 shares of common stock and a warrant exercisable for 844,391 shares of common stock&#160;for $3.5 million. Direct offering costs were approximately $243,000.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; text-indent: 0px; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Year Ended December 31, 2012</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">On October 31, 2012, the Company completed a private placement financing of </font>6,750,000 shares of the Company&#8217;s common stock at a closing price of $1.60 for gross proceeds of $10.8 million.&#160;&#160;The Company paid direct offering costs of $680,000.&#160;&#160;See Note 5 regarding warrants granted with this offering.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="color: black;">During the year ended December 31, 2012, the Company issued 374,851 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $127,000. The Company also issued 1,768,167 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $2.0 million.</font> The Company also issued 3,552,210 shares of common stock as consideration for a second Exclusive Channel Collaboration Agreement with Intrexon, having a fair value of $7.8 million ($2.20 per share), based on the quoted closing trading price. These shares are subject to the registration rights agreement as described in Note 7. In connection with the private placement that was completed on October 31, 2012, the Company also entered into an agreement with NRM VII Holdings I, LLC, an affiliate of Intrexon that acquired 3,125,000 shares of the Company&#8217;s common stock in the private placement, pursuant to which NRM VII Holdings I, LLC agreed to be bound by the terms of and join Intrexon as a party to its registration rights agreement as described in Note 7. In addition, the Company issued 625,000 shares of common stock as consideration for the acquisition of the <i>C. diff</i> program assets of Prev ABR LLC, having a fair value of $1.2 million ($1.87 per share), based on the quoted closing trading price.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Repurchase Program<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockRepurchaseProgramAbstract', window );"><strong>Stock Repurchase Program [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockRepurchaseProgramTextBlock', window );">Stock Repurchase Program [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="text-align: left; width: 0.5in;"><b>8.</b></td>
<td style="text-align: justify;"><b>Stock Repurchase Program</b></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 3, 2009, the Company&#8217;s Board of Directors approved a Stock Repurchase Program authorizing the Company to repurchase, from time-to-time and through December 31, 2009, up to $1 million of its common stock, up to a maximum of four million shares at prices of up to $5 per share. As of December 31, 2012, the Company had repurchased 81,482 shares for approximately $50,000 ($0.61 per share), based upon the quoted closing trading price.&#160;&#160;These treasury shares are not included in the computation of earnings (loss) per share and are deemed to be canceled and retired.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockRepurchaseProgramAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockRepurchaseProgramAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockRepurchaseProgramTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of stock repurchase program.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockRepurchaseProgramTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information (Details 1) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidExpensesResearchAndDevelopment', window );">Intrexon prepaid research and development expenses</a></td>
        <td class="nump">$ 2,412<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other receivables</a></td>
        <td class="nump">17<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">80<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
        <td class="nump">$ 2,509<span></span></td>
        <td class="nump">$ 16<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidExpensesResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for research and development expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_PrepaidExpensesResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amounts of other receivables due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesGrossCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6787-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 4<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKNAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Computed ''expected" tax benefit - Federal</a></td>
        <td class="num">$ (5,803)<span></span></td>
        <td class="num">$ (2,618)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Computed "expected" tax benefit - State</a></td>
        <td class="num">(676)<span></span></td>
        <td class="num">(448)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals, entertainment and other</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible stock-based compensation</a></td>
        <td class="nump">518<span></span></td>
        <td class="nump">366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpensesForIncomeTax', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">562<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantExpenses', window );">Change in fair value of warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">91<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_RealizedLossOnDebtSecurities', window );">Realized loss on debt securities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">7<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
        <td class="nump">5,956<span></span></td>
        <td class="nump">2,035<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Expected tax expense</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as expenses that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_RealizedLossOnDebtSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_RealizedLossOnDebtSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpensesForIncomeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrants during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpensesForIncomeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted federal tax law to the domestic taxable Income or Loss from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Paragraph Question 1-7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentFederalTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted state and local tax law to relevant amounts of taxable Income or Loss from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6889476&amp;loc=d3e330036-122817<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 289<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentStateAndLocalTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 45<br><br> -Subparagraph a, b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to nondeductible meal and entertainment expenses under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to differences in the deductibility of incentive stock options and other equity-based compensation costs in accordance with generally accepted accounting principles and enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the change in the period in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=21917399&amp;loc=d3e32123-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock', window );">Schedule of Disposal Groups Including Discontinued Operations Balance Sheet and Additional Disclosures [Table Text Block]</a></td>
        <td class="text"><div><font size="2" style="font-family:times new roman,times">The assets of the discontinued operations are presented separately under the caption &#8220;Assets of discontinued operations&#8221; in the accompanying Consolidated Balance Sheets at December 31, 2012, and December 31, 2011, and consist of the following <i>(in thousands):</i></font></div>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font size="2" style="font-family:times new roman,times">December 31,</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2012</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2011</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">Assets of discontinued operations:</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 74%;"><font size="2" style="font-family:times new roman,times">Property and equipment, net</font></td>
<td style="padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt; width: 10%;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">23</font></td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Total assets</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">23</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock', window );">Schedule of Disposal Groups Including Discontinued Operations Income Statement and Additional Disclosures [Table Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The summarized statement of operations data for Adeona Clinical Laboratory for the years ended December 31, 2012 and December 31, 2011 are as follows <i>(in thousands):</i></font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 93%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6"><font size="2" style="font-family:times new roman,times">December 31,</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2012</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><font size="2" style="font-family:times new roman,times">2011</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 74%;"><font size="2" style="font-family:times new roman,times">Laboratory fees, net</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">115</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 10%;"><font size="2" style="font-family:times new roman,times">1,169</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Operating Costs and Expenses:</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">General and administrative</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">466</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">539</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Cost of&#160; laboratory services</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">110</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">975</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Impairment loss on goodwill</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">178</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt;"><font size="2" style="font-family:times new roman,times">Total operating costs and expenses</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">576</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">1,692</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Loss from discontinued operations</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(461</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">(523</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">Other Income:</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in;"><font size="2" style="font-family:times new roman,times">Gain on sale of Adeona Clinical Laboratory</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">677</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Income (loss) from discontinued operations</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">216</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">(523</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The tabular disclosure of disposal groups, which may include the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsBalanceSheetAndAdditionalDisclosuresTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementAndAdditionalDisclosuresTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EGD">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Organization and Nature of Operations and Basis of Presentation (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable</a></td>
        <td class="nump">$ 700,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13, 16<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EYYGK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="3"></th>
        <th class="th" colspan="8">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1">24 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>First Year [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Second Year [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Third Year [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Ind Milestone Event [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Approval Milestone Event [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Field Expansion Fee [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Phase I Clinical Trials [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Phase Iii Clinical Trials [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Nda Submission In Us [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>European Medicines Agency Approval [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Regulatory Approval In Asian Country [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>December 31, 2014 [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>December 31, 2015 [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Office Space In Ann Arbor [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Office Space In Rockville [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2012

</div>
          <div>Intrexon [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Prev Abr Llc [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2005

</div>
          <div>Research and Development Arrangement [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>Dr.Kuo [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>Jeffrey Riley [Member]</div>
        </th>
        <th class="th">
          <div>Feb. 29, 2012

</div>
          <div>C. Evan Ballantyne [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Ann Arbor, Michigan [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">$ 12,287,000<span></span></td>
        <td class="nump">$ 3,340,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 460,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPayment', window );">Line of Credit Facility, Periodic Payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">197,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest', window );">Line of Credit Facility, Periodic Payment, Interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(324,999)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,700,000<span></span></td>
        <td class="nump">1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConsultingFees', window );">Consulting Fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">348,000<span></span></td>
        <td class="nump">298,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="nump">425,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
        <td class="nump">123,000<span></span></td>
        <td class="nump">64,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
        <td class="text">May 31,
         2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Operating Leases, Future Minimum Payments, Due in Two Years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OperatingLeaseLeasingTerm', window );">Operating Lease Leasing Term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">extend the term of the lease to December 31, 2014<span></span></td>
        <td class="text">one year operating lease that may be renewed for two additional terms of one year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Operating Leases, Future Minimum Payments Due, Next Twelve Months</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">35,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MilestonePayment', window );">Milestone Payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ResearchAgreementFixedFee', window );">Research Agreement Fixed Fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">303,287<span></span></td>
        <td class="nump">316,438<span></span></td>
        <td class="nump">328,758<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_CashPaymentForLicenseAgreement', window );">Cash Payment For License Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalCashPaymentForLicenseAgreement', window );">Additional Cash Payment For License Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">135,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_UnregisteredSharesIssuedToLicenseAgreement', window );">Unregistered Shares Issued To License Agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">625,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalConsiderationPayable', window );">Additional Consideration Payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">50% in cash and 50% in our stock<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition of program assets (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,552,210<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">625,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Equity Issuance, Per Share Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PartialConsiderationForExecution', window );">Partial Consideration For Execution</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Intrexon a number of shares of our common stock equal to 9.995% of the number of shares of our common stock issued<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">Other Commitment, Due In Second Year</a></td>
        <td class="nump">60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementSettlementAlternatives', window );">Registration Payment Arrangement, Settlement Alternatives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Company also agreed upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the "IND Milestone Event"), to pay Intrexon either (i) two million dollars ($2M) in cash, or (ii) that number of shares of Common Stock (the "IND Milestone Shares") having a fair market value equaling two million dollars ($2M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event.<span></span></td>
        <td class="text">Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the "Approval Milestone Event"), the Company agreed to pay to Intrexon either (i) three million dollars ($3M) in cash, or (ii) that number of shares of Common Stock (the "Approval Milestone Shares") having a fair market value equaling three million dollars ($3M) where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.<span></span></td>
        <td class="text">The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two million dollars ($2M) in cash for each target in excess of three (3) total that the Company elects, or (ii) that number of shares of Common Stock (the "Field Expansion Fee Shares") having a fair market value equaling two million dollars ($2M) for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the thirty (30) day period immediately preceding the date of the Field Expansion Fee Closing.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementTerm', window );">Registration Payment Arrangement, Term</a></td>
        <td class="text">In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a "resale" registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid Expense and Other Assets, Current</a></td>
        <td class="nump">$ 2,509,000<span></span></td>
        <td class="nump">$ 16,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalCashPaymentForLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of additional cash payment for license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AdditionalCashPaymentForLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalConsiderationPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description related to additional consideration payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AdditionalConsiderationPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_CashPaymentForLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of initial cash payment upon execution of the license Agreement during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_CashPaymentForLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense in the period for consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A Milestone Payment is an Authority payment made to a Contractor which is linked to the Contractor delivering a service or commodity such that, should the Agreement be terminated at the point of payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_OperatingLeaseLeasingTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The period at which the operating lease arrangements made.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_OperatingLeaseLeasingTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PartialConsiderationForExecution">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description related to partial consideration for the execution and delivery of the Initial Channel Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_PartialConsiderationForExecution</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ResearchAgreementFixedFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ResearchAgreementFixedFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_UnregisteredSharesIssuedToLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued during the period for license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_UnregisteredSharesIssuedToLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share assigned to the consideration received for shares issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityIssuancePerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense incurred for leased assets including furniture and equipment which has not been recognized in costs and expenses applicable to sales and revenues; for example, cost of goods sold or other operating costs and expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payments of both interest and principal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityPeriodicPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the required periodic payment applied to interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCreditFacilityPeriodicPaymentInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OfficersCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 16<br><br> -Subparagraph b(i)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 13<br><br> -Paragraph 122<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum amount of other commitment maturing in the second fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherCommitmentDueInSecondYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 4<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementSettlementAlternatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the settlement alternatives, if any, contained in the terms of the registration payment arrangement and indicates the party that controls the settlement alternatives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number EITF00-19-2<br><br> -Paragraph 12<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RegistrationPaymentArrangementSettlementAlternatives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the term of the registration payment arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number EITF00-19-2<br><br> -Paragraph 12<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RegistrationPaymentArrangementTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 4) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="nump">$ 2.20<span></span></td>
        <td class="nump">$ 1.14<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">110.00%<span></span></td>
        <td class="nump">174.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">0.26%<span></span></td>
        <td class="nump">0.71%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of warrant</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph e(2)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP2AI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Retained Earnings [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">$ 23<span></span></td>
        <td class="nump">$ 47,280<span></span></td>
        <td class="num">$ (43,724)<span></span></td>
        <td class="nump">$ 3,579<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="nump">23,338,707<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">973<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">973<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock for employee compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for employee compensation (in shares)</a></td>
        <td class="nump">73,585<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">1,684<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,687<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement (in shares)</a></td>
        <td class="nump">3,123,558<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueConsultingFees', window );">Issuance of common stock for consulting fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">165<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">165<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesConsultingFees', window );">Issuance of common stock for consulting fees (in shares)</a></td>
        <td class="nump">171,796<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Issuance of common stock for stock options and warrants exercised</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">15<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">15<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Issuance of common stock for stock options and warrants exercised (in shares)</a></td>
        <td class="nump">38,948<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">6,956<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">6,961<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
        <td class="nump">4,545,926<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified', window );">Warrant liability reclassified to stockholders' equity</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,734<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,734<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(8,149)<span></span></td>
        <td class="num">(8,149)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">31<span></span></td>
        <td class="nump">58,901<span></span></td>
        <td class="num">(51,873)<span></span></td>
        <td class="nump">7,059<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="nump">31,292,520<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,852<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,852<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement</a></td>
        <td class="nump">3<span></span></td>
        <td class="nump">7,811<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">7,814<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement', window );">Issuance of common stock for exclusive channel collaboration agreement (in shares)</a></td>
        <td class="nump">3,552,210<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for acquisition of program assets</a></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,168<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,169<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for acquisition of program assets (in shares)</a></td>
        <td class="nump">625,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Issuance of common stock for stock options and warrants exercised</a></td>
        <td class="nump">2<span></span></td>
        <td class="nump">2,080<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,082<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Issuance of common stock for stock options and warrants exercised (in shares)</a></td>
        <td class="nump">2,143,018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
        <td class="nump">7<span></span></td>
        <td class="nump">10,113<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10,120<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
        <td class="nump">6,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(17,068)<span></span></td>
        <td class="num">(17,068)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
        <td class="nump">$ 44<span></span></td>
        <td class="nump">$ 81,925<span></span></td>
        <td class="num">$ (68,941)<span></span></td>
        <td class="nump">$ 13,028<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2012</a></td>
        <td class="nump">44,362,748<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants liability reclassified to stockholders equity during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_AdjustmentsToAdditionalPaidInCapitalWarrantsLiabilityReclassified</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of consulting fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period For Exclusive Channel Collaboration Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options and warrants exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period as a result of consulting fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued during the period For Exclusive Channel Collaboration Agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueForExclusiveChannelCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the stock options and warrants exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 0in;"></td>
<td style="width: 0.5in;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>2.</b></font></td>
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>Summary of Significant Accounting Policies</b></font></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Principles of Consolidation</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">All inter-company transactions and accounts have been eliminated in consolidation.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Emerging from the Development Stage</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During the second quarter of 2010, the Company emerged from the development stage.&#160;&#160;&#160;A development-stage enterprise is one in which planned principle operations have not commenced or if its operations have commenced, there has been no significant revenue.&#160;On May 6, 2010, the Company entered into a Sublicense Agreement (the &#8220;Meda Agreement&#8221;) with Meda&#160;AB of Sweden (&#8220;Meda&#8221;) and received an up-front payment of $2.5 million. The execution of the Meda Agreement combined with revenues from Adeona Clinical Laboratory were an indication of the commencement of principal operations, and therefore development-stage reporting was no longer required.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Use of Estimates</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Accounts Receivable and Allowance for Doubtful Accounts</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Revenue Recognition</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;For the year ended December 31, 2012 and 2011, the Company&#8217;s only stream of revenue was laboratory revenue.&#160;&#160;Laboratory revenues are a component of discontinued operations for the years ended December 31, 2012 and 2011. See Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><i>License Revenues</i></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&#160;&#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><i>Laboratory Revenues</i></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which was the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior period multiplied by the period&#8217;s actual gross sales to determine the actual sales allowance for each period. See Note 3 - Discontinued Operations of Adeona Clinical Laboratory.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>&#160;</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Risks and Uncertainties</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Cash and Cash Equivalents</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Classification of Marketable Securities as Held to Maturity, Trading, and Available for Sale</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such determinations at each balance sheet date. Debt securities are classified as held to maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held to maturity securities are recorded as either short-term or long-term on the balance sheet, based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held to maturity or as trading, are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders&#8217; equity. At December 31, 2012 and 2011, respectively, the Company had no debt and marketable equity securities.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows <i>(in thousands)</i> :</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">December 31, 2011</font></td>
<td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 72%;"><font size="2" style="font-family:times new roman,times">Purchase of short-term investments</font></td>
<td style="width: 1%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="text-align: right; width: 25%;"><font size="2" style="font-family:times new roman,times">(4,370</font></td>
<td style="text-align: left; width: 1%;"><font size="2" style="font-family:times new roman,times">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">Amortization of premium on investments</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">57</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify;"><font size="2" style="font-family:times new roman,times">Proceeds from short-term investments</font></td>
<td><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: right;"><font size="2" style="font-family:times new roman,times">4,293</font></td>
<td style="text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">Loss on sale of short-term investments</font></td>
<td style="padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: left;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: right;"><font size="2" style="font-family:times new roman,times">20</font></td>
<td style="text-align: left; padding-bottom: 1pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">Fair value</font></td>
<td style="padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 2.5pt double; text-align: left;"><font size="2" style="font-family:times new roman,times">$</font></td>
<td style="border-bottom: black 2.5pt double; text-align: right;"><font size="2" style="font-family:times new roman,times">-</font></td>
<td style="text-align: left; padding-bottom: 2.5pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Property and Equipment</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</font></p>
<p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table align="center" style="width: 70%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="border-bottom: black 1pt solid; text-align: center; width: 49%;" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>Asset&#160;Description</b></font></td>
<td style="text-align: center; width: 4%;" nowrap="nowrap"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 47%;" nowrap="nowrap"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2"><b>Estimated&#160;Useful&#160;Life</b></font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Office equipment and furniture</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">3-5&#160;&#160;years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Laboratory equipment</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">7-10 years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Manufacturing equipment</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">10 years</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Leasehold improvements and fixtures</font></td>
<td style="text-align: center;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="text-align: center;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Lesser of estimated useful or life of lease</font></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Depreciation expense was approximately $63,000 and $144,000 for the years ended December 31, 2012 and 2011, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts. Repairs and maintenance are charged to expense as incurred.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">During 2012, the Company reviewed property and equipment for impairment and determined that certain items were impaired due to obsolescence. As a result of this review, the Company recorded an impairment loss of approximately $47,000. For the year ended December 31, 2011, there were no significant events or changes in circumstances identified by the Company that would indicate that the carrying value of an asset was not recoverable.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>&#160;</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Long-Lived Assets</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Goodwill</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">ASC No. 350, &#8220;Intangibles &#8211; Goodwill and Others,&#8221; requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. See Note 3 &#8211; Discontinued Operations of Adeona Clinical Laboratory.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Derivative Liabilities</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In&#160;addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option pricing model.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Net Income (Loss) per Share</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding. Diluted income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding including the effect of common share equivalents. All common equivalent shares were anti-dilutive, at December 31, 2012 and December 31, 2011, as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the year ended December 31, 2012 were 4,453,746 and 1,632,501, respectively, and for the year ended December 31, 2011 were 2,979,010 and 3,259,186, respectively.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Research and Development Costs</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Fair Value of Financial Instruments</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 3%;"><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td style="text-align: justify; width: 94%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Level 1 inputs: Quoted prices (unadjusted)&#160;for identical assets or liabilities in active markets;</font></td>
</tr>
</table>
<p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 3%;"><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td style="text-align: justify; width: 94%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Level 2 inputs: Inputs, other than quoted prices included in Level 1 that are observable either directly or indirectly; and</font></td>
</tr>
</table>
<p style="text-align: justify; text-indent: -0.25in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%;"><font size="2" style="font-family:times new roman,times">&#160;</font></td>
<td style="width: 3%;"><font style="font: 10pt symbol;; font-family:times new roman,times" size="2">&#183;</font></td>
<td style="text-align: justify; width: 94%;"><font style="font: 10pt times new roman, times, serif;; font-family:times new roman,times" size="2">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, accounts receivable, other current assets, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Cash and cash equivalents include money market accounts and mutual funds of $8.6 million and $5.0 million as of December 31, 2012 and December 31, 2011, respectively, that are measured using Level 1 inputs.&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Stock-Based Payment Arrangements</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable and are re-measured over the corresponding vesting period. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Income Taxes</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC Topic 740, &#8220;<i>Income Taxes</i>,&#8221; which requires that the Company recognize deferred tax liabilities and assets based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">In addition, accounting guidance now codified as FASB ASC Topic 740-20, <i>&#8220;Income Taxes &#8211; Intraperiod Tax Allocation&#8221; </i>requires<i> </i>management to assess the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The accounting guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December 31, 2012 and 2011, respectively, the Company did not record any liabilities for uncertain tax positions.</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times"><b><i>Recent Accounting Pronouncements</i></b></font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2" style="font-family:times new roman,times">There were no accounting standards or interpretations issued or recently adopted that are expected to have a material impact on the Company&#8217;s financial position, operations, or cash flows.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of short-term investments</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="num">$ (4,370)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of premium on investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">57<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from short-term investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,293<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Loss on sale of short-term investments</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">20<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Fair value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentForAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the gain (loss) realized on the sale of held-to-maturity securities disposed of during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents investment securities as of the balance sheet date which may include marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Trading Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7534914&amp;loc=d3e22054-111558<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a, f, g<br><br> -Article 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Available-for-Sale Securities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 12<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=16383099&amp;loc=d3e24584-111560<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow from purchases of trading, available-for-sale securities and held-to-maturity securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireMarketableSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 31<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>176</ContextCount>
  <ElementCount>332</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Organization and Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Organization and Nature of Operations and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - License, Collaborative and Employment Agreements and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitments</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Stock Repurchase Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockRepurchaseProgram</Role>
      <ShortName>Stock Repurchase Program</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableTables</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Organization and Nature of Operations and Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/OrganizationAndNatureOfOperationsAndBasisOfPresentationDetailsTextual</Role>
      <ShortName>Organization and Nature of Operations and Basis of Presentation (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetails1</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivableDetailsTextual</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Selected Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails</Role>
      <ShortName>Selected Balance Sheet Information (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Selected Balance Sheet Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails1</Role>
      <ShortName>Selected Balance Sheet Information (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Selected Balance Sheet Information (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails2</Role>
      <ShortName>Selected Balance Sheet Information (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Selected Balance Sheet Information (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/SelectedBalanceSheetInformationDetails3</Role>
      <ShortName>Selected Balance Sheet Information (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Stock-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails3</Role>
      <ShortName>Stock-Based Compensation (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stock-Based Compensation (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails4</Role>
      <ShortName>Stock-Based Compensation (Details 4)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Stock-Based Compensation (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails5</Role>
      <ShortName>Stock-Based Compensation (Details 5)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Stock-Based Compensation (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails6</Role>
      <ShortName>Stock-Based Compensation (Details 6)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Stock-Based Compensation (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails7</Role>
      <ShortName>Stock-Based Compensation (Details 7)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Stock-Based Compensation (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetails8</Role>
      <ShortName>Stock-Based Compensation (Details 8)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockBasedCompensationDetailsTextual</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetails</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsDetailsTextual</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>050 - Disclosure - Stock Repurchase Program (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StockRepurchaseProgramDetailsTextual</Role>
      <ShortName>Stock Repurchase Program (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>051 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>052 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>053 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>054 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element syn_WarrantsFairValue1 had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_CommonStockParOrStatedValuePerShare had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_CommonStockValue had a mix of decimals attribute values: -4 -3.</Log>
    <Log type="Info">Element us-gaap_DerivativeFairValueOfDerivativeLiability had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes had a mix of decimals attribute values: 3 4.</Log>
    <Log type="Info">Element us-gaap_OtherCommitmentDueInSecondYear had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Element us-gaap_PrepaidExpenseAndOtherAssetsCurrent had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice had a mix of decimals attribute values: 2 3.</Log>
    <Log type="Info">'Monetary' elements on report '029 - Disclosure - Summary of Significant Accounting Policies (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '047 - Disclosure - Stockholders' Equity (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '049 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '050 - Disclosure - Stock Repurchase Program (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '053 - Disclosure - Income Taxes (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">	Process Flow-Through: Removing column '0 Months Ended
Apr. 06, 2011'</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - Consolidated Statements of Cash Flows</Log>
    <Log type="Info">Process Flow-Through: 008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</Log>
  </Logs>
  <InputFiles>
    <File>syn-20121231.xml</File>
    <File>syn-20121231.xsd</File>
    <File>syn-20121231_cal.xml</File>
    <File>syn-20121231_def.xml</File>
    <File>syn-20121231_lab.xml</File>
    <File>syn-20121231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001144204-13-022048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-13-022048-xbrl.zip
M4$L#!!0````(`.-SD$([0?5.ZP<!`(+K#0`0`!P`<WEN+3(P,3(Q,C,Q+GAM
M;%54"0`#Z9AM4>F8;5%U>`L``00E#@``!#D!``#L76ESVSB:_CY5\Q\T_MRT
M>>CTICTE'TK<\:&UG.Y.[6ZY8!*2,$V1:I!4K)ZJ^>T+D)1$4A0/B10/(95R
M8A[`>SSO`1!X\>F?'S.UL8#80+KV\YEPSI\UH";K"M(F/Y]]>QUPW;-_7OW]
M;Y_^P7&-SU"#&)A0:5@&N=^X^XO[_?KE8?5ZHWW.GPOG4N-_>.E"[%V(O"`U
M>.&2[U[RG<;P\?\:[\O&+3#!*P;R'T:#XU8-7P.#-$I:L)L3SX7-/?O*K2Y;
M,ZB9C4="V!B19W\@<TK[OU.0J>/&KRX%A/YS\;P7Z(C<&&"D@.5/C?X<([4A
MB#\U'.J:EWSKLD6I<[O\>,<JNJ0_&T0RFG%I+(E<IJ8YO[RX^/'CQSGYW9Q"
M$\GO2%?U"9*-<UF?469%092$,_<U%6E_^-ZC39[K>$*>).*AM]\)UZO'Z5T%
MK5_P/MR^<&ZN']UJ^H=D/ROT>KT+^^[Z40.%/4@:%2Y^?WP8R5,X`QS2#!-H
MLH\6%$%[\'EDZ$U1Z$2]X3RQ>D&!<PQE"J2=[_0N`):QKL*+,9!-#G[,5:`!
MHNKE@/R^:DC6+<W$2[_8#"B?3_3%A7O3U@S'"]Q&-[*%,0'YKO?<NR$O*A"%
MOT-NA#P./^1I^//T3L@+2%M`PPQ_Q;D7\I(&"`;#W[%OT5<$_RL&DL-?(#?"
M'C?G>,?SY$[("Y;!30"8K]\9`^/=UJQ[(X2+#S4"/[\_>$!MF3@"-N3N&;5C
M:@:7A@WP%SANV&9QZ6(JVG@NYEB?0VPB:'C-U&[`7,[)VP::S=7UM2F&8W)M
MJ7$K'W#^82AG%ROG=J-K)OPP&R,HF]1'^1R-[-Y$Q!3<!]\&W^_>)(&[A3)'
M+?5M9+T;\$^+^+^[!?GQ2FCH?R#C;63J\A]#8A?TJ4<X>X<.ZT[+Y$ED+C>_
M(X5>(<X3-VRQ^*6P4NC-_=>S*Y[\Z?::0JO[Z2+X\J9!`TZH3UY=4$B7Q$J1
MC$R'EH:"R'TGKKAZO]S!RMD5$=]E"#^?+D*;IGU>;%%Q$<XXT272%0_=)L`F
MB0Z07*(]<?9?3XN>^VM9*MX7"'8EP=OAZN[JRJ;+"Y^:R95(S=]8AJG/WB2>
M&\$Y57[K[4'7)J\0SX86EJ<$B3?Z;(9,RO+U\H;T.B$N\7E\;\+U$XH-CA=H
M0`+W:9\0!Q=0U>?TG3[&0)M`^M]J`&9/]L^N5@TDE,,1@-;B^%XJH-DO2/R>
M0(N`6=]X>QZ_B3SW"#!%6>>-6MT3F&W[E4XU8.*E?]N9=/+3L9,+F8[".APO
M$7ENWM[</4QA_HC0.XXV]D-Y+ZT[[1WD3F-17E:Q^8"S)8-4P$D24GB1^\52
M:8;"N_;MNLO?`'6%IM&?3#"T':)A.P'J:'7-]VA_]<1O9/`U(@-`%=[;2:F.
MC7*[B8U#B.;:<1U[L9Y_`!%XCF]S8BNQ:=$7B$L2\S(M@JDG?>%@:E<`$?AR
M(R-1`%DQD7<`(0JC(REQ3S^0-(`(?*D\X3;*4P40*K1\`DA`:&\/<`+4.YL;
M&^:/L@J!]D4WYL@$:KEQKD!T&:#?@7D8$\?Q9571,E3`VOU75<G;/)R4C@.I
M8,D<8#`$')`*II'!6Y_0I2#5,M$"CJ!L843GO.X^9-52H#+`^HQD0G/+!'3:
MZGE\![!&,A]C"/%H"C"\7H8W8%N-FV"5VUY6P3]'06PF(GP2.48F<2P8C8A<
M;,=R]Z=%"*2BTK6P<40UP!#)SD:=6WR=CDK[BH*H)0!U")!RK]V`"B1`*=4;
MR>/IJ/H%F@!I4%FYO%KI.)RYJBM7['*_`/M;E)!LIF?W1,?KE/QR3ZA#IN48
M0RWG>PX00.Y@L;].B=WLP>+."WK04JJ<.#"4L,4@])(/);;DEM508EMN;#ZU
MHO.IY0&5.Y_:YOIS7#Y;##JD)L>W\XI>'AED8U?U#U^'2.`8\>MX<(G*9"LU
M(9$P@3WNE$)NJEQ]HBRI^]N.&E*JKW!;<LLX%<G<9;)4I(A4I.*@8J/(<HTB
M:P<PENB5+=&K%L02)X=O0[O3]3+KS9)32ERY`953`ID(R'ZQ;2`;E!V#XMY0
M?"'O`</"D*%Q'S3N$!\#9*+PJQF6:I+\>!US!CH>(`UH,@)J7UD@0\?+$<0+
M),.:Q=T]6#\I4&V^/#EKC-EDS!$F8SIY?Q=R=5GRR9@V)Z:;PN_D_5UH#QM@
M.6<=<LY:0I'EG-7-.4L"2'?5$;_:+B*\7=,"$M`P^C+1CF&OM++!=J^9&'[H
M6C4PMH,+1_%^5HZ0$)"_4MY[#TN?#:1;<'[85N[D0F-+K>NUU+HRN&-KLQD&
MV&+NHR_FK@DVV.KOTT+#"ZV)XFQZ!!]H9LVJH?`UV1OE^NAG.G5TBK1JZ]1+
M_VGK%*JD665(R%F^DDS7`'9E,>-ZZ;UC*_UN-E?U)209LJ:XWS'H=XZ*@"`Q
MG\Z0.Y+9DT;,O2;K,[B.C-=`I04<1U,(32*K37YTBPQ9U>ET%1$R^66N&T#]
MC'5K;I`FR!B-1$KZ#.D&:194GN>T("C5B9M,0M+*C4HL50;J`WC7L5VSL1IP
M.XZ0'*A&2^JDL<H^'9ZN[A_!OW1,)]"-Y_$M?*=VYX@N,.?U/*?V5`T0).1I
M`P<O<R>-!F?*C]9TI)9#Y&I[4?NJT;?,J8[17U#YIBD0VY,]CN!HS2;BF.\^
M():1`8<8R7"3!=O_>Q[[[O)\K]FJ2*7#'&3B?JB*$0Q#XA&0V&QU>WR+(3%2
M,`R)Q_&)#(EQ@F%(/')TKNH491FC=O)I&#:_6EXKJ-*D;NVL@,U(%Y@?LUB0
M7=[,8D$=K(#%@@*M@,6"`D>H+!9D-W)EL:`.5L!B08%64.]8$&D'P0JSY=HP
M$-PR<9PJNVS]?\W6_Q<%([:<_\14RE;GGXRJV6+[:BN7K54I/*_/=:U*W8'%
MEIX4M/2D[L!B*TD*6DE2%+"&6"=-F4LJEM5J5_O4[>OENJK(^EHU<)&`I4VR
M$^#MU%2[V<Q01R538][)X:FIVIFK@9C<?AZ/B4NKJ\;C&"VYXE.J_@4:)@E0
M)HF"P)C2S73D'\KQ`JAT;!=^U?GN0$9_RT>`_X!F7Y9UBU[7E$?+M(`ZL#2E
M(L/:_27@'KB:3`PEATTL:'B1&\!W"AJ1;=O*694BQXNYG`V^J@C+='G$+7BB
M??94BMJM6^K/NEI@;Z/^6SB&&/O'0'TJGXFGUKR"%D@A[LSY=H.TR6;L-`3+
M&71<WE`GCA2:R*E_=PTU.$8F&2N](E,EXZ%-,S:R;O%72Z\&KHJ2D1-?/((Z
M#EC%5-^7[1>\I0?K"-9?X'B,X?(%J;`B&]R+Q>RVO!AT"X+NS=T":-=`I<.>
MI5:1BJ[%HC=49"<%8"?E%UH<&=>P-/%(*;_D2Q(S3OF9+H^<\HN<T$YER7[U
M9UZ/^1?+/L)8+.\:/9$6L<ZCK/%ZUJMO31P+8#6I<_!?W3Q/NF]QS[+)W-=Q
M5"GPOK-FLCYOA.GRJ*&(:#-=4AE0?W8+QET`$$^\`8#U;B`%`;P<`9J/VY_:
M;>4/,5J0;H<JD&%U/C/MY&>#@'#&2@N%/';0A``A1:'+1_P5:']!7`U$I*UL
MZ>?NI&#1>_1NK&*8*!(3]/BX=)@XQF:[<@U?PC[TE%%H;$]2O?8D509W;!,3
MPP#;]53TF215Q0;;)G5::*AH88\2U,:HA$ZK5*:B!)4>2JQ3=B9)*<\D*2]B
MV)DD[$R2JF"5?9(Z7=VS,TF.?R9)>=%PQ%W3(L]7`TW'WC6]%@Q#XA&02#J3
M&!)C!,.0>`0D2KS09DB,$0Q#XI&C<U6GL\H8M9-/P["YN/):094FZFMG!>PK
M0X'Y,8L%V>7-+!;4P0I8+"C0"E@L*'"$RF)!=B-7%@OJ8`4L%A1H!2P6''O=
MNP?Z/FT+U;"`4BV+WP?Z]O*;$,$S]!>*?HG!OR#X2PS_Q>-?ZE2D%GK]#&`M
M>F8!A4:`)C.`@B)`D^&_>/Q+4D76,-3/`-:B/VD+>(`3H-[9W#CHG"-3GY>\
M#*0"T66`<%?!7NI/6J^%>S91%,L-HOIZMK7HF044:P$LMA=F`2RVBX>=T%35
MCS6YGMRT#SC95Y=]</D(-&L,9)/X$FU2UZ.DHIAD",G"<U5IL45Y/1=;-9$"
MEX%#X<A3`XLD3,3(X8E$UE@)L`A;-9S6TH\6AE/F3X^_.X7M%HP3#$/BD9%8
MU42@C`AE>4,=K*!*:4;MK(!E)3([_8=I>Z7M(8:+_CM^4.4:Z#O(3/TTGH.%
MOXV(,A6+'M.R*MTX@GB!:-&],-_?5U5==C^2O4!9GV@T`@QMFF]TP[0+0\YU
M;#Z0SMT*Q@8$6*;GQ]_"!51U>R!Z]T&;+/D:C&S=3/*HF[-*O`688W53/RM*
M84/.VIOKY8,K8,^DTF@.9'BO]36MC]_UDI^Y0A<3A?'BG2,*98AI/U+[+R3G
M72!5+;D?2Z'^`$<GK7]ZCAG\TZ(><4%^K&>5`]?+K7OOH6PAS&QB02A7)ZW_
M&UU5G<^0:`$]1V_3VM9/NB;ON.TMD^UDV5,2LN]7A89?,0)J1:I_9R0!-S_?
M*0:&LLQ0AA##680@&-(R0-J3`DBPF"&#*O%>^W:*(-LA`X:O#/!U9]&OVX",
MJ!4B0C+P[D^@)B_[\SG6%U4Y%RM3M"62",->!MA[@1-+M=>=K81+AL0&`MJ-
M;FEF58[1R!1\R41R4NCKTWF`TA[)&CS)WB^#K$ZRWY+![O$R_31(/PJ*/%^1
M8C`[1\O4($+XR0/]1:F1<O8$9MNZZU1#=U[ZMQ76J83",E*94)'U8)$J$W)<
MNU64C;'#J,NX+Z]R,&)G2Y^82ME1T2>C:G;R<Z65FV1[2AWW?*X>/L)6SS*K
M=N?^Q5HH>=\=FK54M9.@0DQN!W9;U4SC<8S62?'LW,OB=P/D>NYEW8$ELF,L
MBSG&LN[`8J=2%G0J9>WG*MD!`B4K,5;#CUO%@YF=!U##\P!.%LZLO'\]R_N?
M+*!9M?XZ5NL_63BSXOOU++Y?%*!9+?U*J*EPO\-*X]>S-/X)`YH%TCI6NJ_[
M=#TK"UE06<BB@/5,&B)RTR8/NF$,=/P#8+<8C(V15_`!WE5XK\GZ#-Y]S!&M
MR_XZQ;HUF8J\5/*H;=>KB&3047@R+DNN]I2*?X&&28!M$NL!!BWI0_^A2S06
M0*4K\,*O.D4)=0TN'P'^`YI]6:;;NNA.L4?+M(`ZL#2E(HL/]Y>`>U9!,C&4
M'#:I0..,B%B%HQ-1)BM85"%U$J!:=!'\TEY//1Y#F:;DGEA.GK2YDP3R?,GG
MK:GBXAARU!O&U>FJM>2?U_94:PV_7/VW!;`)L;J\IUVHJKW?WA6*1[D#A`WS
M.P0ECZ=48\DX<K0;8.L$%3N"I#FE?IH-\G6"JGV=(EQ#S0;8JI-B;^$88ARH
MD[LI=/(;,J?WFH(62"&1RYD;1=ID,__D2HP._X8Z&51"$V'[S6NHP3&B-75?
MD4E+]&Z:<39HK@872)ZB":A('?6BQ.7@,%QF58>CV.$>`:9PE,I;'4;B>(D3
M._O*X!\<U_BF(;,Q@G;5H$:#XU;7__ZW^_\(_SOX=?@%?L#;5KO3_?X"_T17
MOW^[_P^]_/T'6LC-9E-NM5KRZ[^G5^U/7^X^-3]_%@9?/ET*W4&[)0P&7_Y+
MN/SY2^OGSY_:GWOM>[=]AQ"+]DP%;]@SQ&=7[O49!(:%X96+$OOFBOC5O=7O
MM(V0%K^-;K>:0X;>%(7.);F7OK6W.:VU3DE9MVL;`KSR//QDS:"]I6[/KK?>
MIQ=OH:;/D!;6;%(!^9JX\%,?S?G<\C#L[Y;>BI,CQ=&=:GL2'\0^;28(7N`$
M$8]#,$L+B#1<<+[`\<Y:86=7HZ5F3HF/DAO72%?U"9*-GQKWFGS^Z6)7PY2:
MS;T;0A"F=;`4^/$5+I/UZK7?G4VM^KFQB#_6S`$R9*#2&'WGE*Y*UA7GN#:G
MGUU-^5D:(!7B&W)YHN.$#(UF),$@CLNI+D\"0H/&#Z`MO?SYVEUU^8J!'4"6
MLW==3=89"11.L[YW`VK9%(9P/AH]6R9U9_3YT%ZV/76#0L]^QG4J#07*B#!J
M_'S&GUTUF^U6LRDT?1J,Z'5%WZTN6Q3%=$-E,GX%GOOJ].)]=]5>GUQ0Z,6!
M"L)9VVIP3'B`3HN^MX,D.EEB*KAM@JF?8E]3P7X</#J/#,@U(UE?@^_^/K::
M">^'XCY%+_1G6#_K9OS`^PVJZE=-_Z&-B"/3-:C<&X9%+"-17T^Z%TT[FO+W
M]ZNN6IH)L&-="7GR]Q-H(F!(CLM8&S:MZI!4=-]I+(EKRM_=T'HG&=Y`U8$9
M8:82S_UB:4XO&S.ED3IHH[UVC_A:+Q6>'FC7ZTHRP)A&];CBB^_M[I$CZ9W8
M$5IVC]Z&]^E(X&,Z:C=[V70D1'?4)OE:-AU%*(MVU.NUFI$=K;[$O4`9H@7]
MJOL$31=567#:Y/VJB^HO4[IB!+,'2<\DJ\%]PX"FD:&`Z*Y&#S';G61`0HPL
MQ!;?2T&$<^-Y?(N,N6X`]3/6K3G)[YQA*[E*24*:!15W+8&N92@O4?+C:6]B
MCLA2"BQFR$Z&0N\(HA@B]DRZCA&.(#;;82H/Z7MGJ0UBSUE(00I@+ZJ_3.F*
ML]\]Z7K234@GE1YTH/F]'ZUBG!UZ/*0EZ3(7$F-$V*'#QSWH=#Z]$5-%]O2<
MQW%F*T))L,E+TEVF9,6(3>JD(LMOP9DXIF:G'>(<]NPLSA5)S=#H$Y:W#,&2
M`B9#'RQUNZ&9E+^GC&B)TWLO/*N+I`63J/6`P#M2[27/6>8$O2`UX7UE1U"J
M[#*>F'S$TA0Z/KGD0D-*I"2F(6<!'-+K_BS[LP+WLY`]M_4K4*WP^:#]@VU(
M#UD0D!S[,01XIO9B>^>Y)WUALY_T<.7=1#:)*P\&_"`M^]*9,J!GWWW?FJ0Z
M@WHWE2T27KMYBRD&3,UFXNYW%+;UO)*%WEK='N]777R_.5`9([:NT!-;!U`9
M+"!+@I@UH\>40.46CNGGXBQDR;6$;L>?4,5WG`.9,<+DVO2[T@%DVN*=ZJH"
ML>$4[LUBLE)J=?QISW8W61"1N@IZFMF;0DB.KO(=[8XZ8I<OGH,=Q:NC4=R4
M.F(S?]KC!FQ\ZPBH%;)%;2!8%T+R`:C=CEF%<+`7:K=#1"ZTQX[\>;%[!"JR
MA6WS".9^V)$**9.80CC8"[;;*4,T[9XQ8E]3<G*]P;FRN$XS)S#U_%H:"OV#
MS2'`S]A6K&*/%%8;\/<1I&=UF8=B.M0]YWEAUW!W%P4YT2P60W-P^WAJ^88N
M!!)X/C#PC.XU8_K$8]-GKT+)2'8Q1#E=94A0K+`R(2C96K/LQ!18998E:8<*
M;`=IGN1@'T=RX`1;N+^AZS+/6\W0"9PDON9`G@YUZ,>F]J"YNW"F!#+F/A?3
MLI2#"O:,3_NK(-_(%#XI&>7W#R4M<5#*@+1X]W^(NPBE7A)$J447;\<0=2#=
MR34M"5*'#*#";2=3BO8W^W#"6RU1%*)0D*TD8X'9I'](9G\819EG``1Q9(`I
M1I$5'VIS2@&:3:DM=II1YK"#ML]0@QBH9+C45V9(LS=9T`WC=Q]T[UF2)>=Q
M']M;@84(,3UF3-R;4W5H/6:_!BK09#B:0FC:[:[F&^AB.56G&U^,ZZ5O/9T1
MO:!N-7$!22LW*J%2!NKF.*Y$$VY2KS@)Q0RR6^2)`HFK@OJ:[?:^$GJ!!@18
MIG60;N$"JKJ][BY*/C>68>HS&E!'<$X7P[?>'G1M\@KQ;&B1EH`!J>DCTY;6
M<K77YWE\3P2X>D)Q9ZK".O?L-$W&O#^%B.3H,-93N1U):A9$6.P"5;';V8^R
M=:TU]UZ2/2!QWZ=[@8GJK3X.)2!.'!VQUTM.@>,.[%IS=NU,VYK)LQMSOH9C
M';NUYE[!!RVV2>Q/Q\0!`+RD5F"O,B1O8ETE]CXAV1(D7B/\VV\J87);TLR1
MW/)()>Y[^+:*<Q8+75_JUD2-!*KK2_DVUY_C1,O:V^OUJX'VTW2;"E-"LR=F
MWVG\FJQLNWL;6>\&_-.B?FWA[IYTZK3XKR>).)U.K!9NIC2$W6L#@+`]]G\>
MNT^NOA`DV50;E]@V-XI)T&&VM"538$*R-F:Y(!9$@X]C>-EY1J$9L/_PCC(B
M)F[!I92:&'N).G$X^BHVK6N99C1(\N?8T=UE2EBL\^[N25F.TN*$=L]/5NX4
MQ64QK?3DQ`?!#"35:8OME*$W<QH3Y`?=H'_8G\CP0=X3-)_'))'HFR9&[Y9)
MMQV\ZNM]T,Z^Y"PR0#'H7#*BK3"&JS`"KY_8X[;P"5%6745^JP"SHTB=O+!I
M-P./U!4"10I\'1S4<[;+SXH@\8#E9D60N]?:LOP`$!_8^78WIZ[+C[T<ESH6
M0>Y>V$N!@/B<;PCQ-3"03.=)Z8DX4-F]G"#21^Y<?,+QYV(G31JZ@Z1C\95H
MD83#5RM5>IV:K^C@=Q3->3^]9T#<\7E-JDW"JI`;JULG4/F?S]C8>AL^8CK.
MEL84AM/<C\;?()I,R;7^@BAA`I\LZBV?Q_9KGD_QAXDW="V`V.D(?%/TK`78
MCY:C<!.[LD%J=GOM5D_,DIO]%F$<LK4M7%&2)'4[O"?@1*[4V'-92]94;R^#
MR8'J0]*[A`MD(JGN*_^RG#EAXU7?D:CM.!]M<Q2:\0*==5EP!/$"R>XA#"_P
M_]E[]R>UD611^/<3L?^#KH_G?'8$S2#Q'I^9B/9KUWO]NK9G-_:G"0%%M]9"
M8O3H-OO7?YE955))")!`@`2Z-\Y.&Y`J*S,K*]\Y=>\<>N/AYMTX5>UT(L`K
MBJNC&04-6H]CR#3L>V3KO\%MOOC-J&\TC'A\YTJ#UN/(T89_C^W*.B]NZ4&>
M]/XZQ.FI_->4TY&]5`FJ948Y>"$0CK^!H\FI&F[V$"VL]I0^\$0?9<?<P#P+
M<V>:P,-N?]3?N>=M4,L4MFWH>NMZ-)+(MQX8II\YS'[EVC:/LV*!TIW'^`B1
MPY/*!J.XGV@I,)U\@R7WG;EL;!RB'PU$AM'%(F=/"5A;?.QJT#S2:T[PDHVP
MFLN&(]I.P"KZ29'#K]BJW"/;JZO+V\;)D5)Z#"$JE"X5*3E59Z7&^PSY,1F]
MJ7+`F=<L*'EOA^@)^B"C;UN^K>8AI>BJ<#I:9C+R(*M/6AY@<UL]A7=XI%8&
M%=[99X\]W$Z\]_;T!$3;=;4!\'YH8T+J6U9*U=J@G^M*3:Y['$A+=Q+58%,'
MF4JU(=V1;)Y".^/G[:1<F=W-9Z@/QX,<NDEQNJE>ZUMG)BH(_3<_F#>U_'UR
MPC:43QT*R*DV<W*)4I.-'R)U+HH#CB28*K+[7;5)G9%1)V*6;"I=U-X/.-'`
M!IU3H$($+,XKUK.MD=&XE\>%4A4$E&YG&GJOV]'+0D$>D_PC>Z1O2C!A!N-!
M?J]'M.Y1`"U70.4R(\^_JP-$SV#<']1CDT>,6Q]U7[O2Z7C3N$I`6N[A&=9C
M5X=HXL"U&1,T2M@E%_7;MRE:,AFCF[^;3KYREU%_J/=Z.1UC1X(WNX54MJ$^
M&(V&(^-,\!Y9Y>GU>_VQ,3@O,6!_GZ9!W'?*FEFFM_IJVNS3G-XN_*_6`^S]
MLVU.LYL=9GMAA_U<@NT4U"L_+K#_YE##RY,7*36[J/_4%S:U3=^WYE8ICJ1A
M-P[['PS/23=V%*?21:'@D$OM8OGB`%=3:7B(Q`1V;'GE;NC1MO5JSYS2/%CW
M'\@5]EHZ=Z-'HY>1+K/?TL6ZL8I&T*6ONT-?'V2Y:M1U$T63Q\@U3P]MVYUT
MNR\DNRN!])R@I+P:M_Y1\N^WKE(&&/E:218!X:WKG2B@O+922=`4QLE&0.AK
MH7>>,#?Z)I'QNA<0Q][!KNY!PY$2%#IH!TDZJ;D1G^:?/??.,Q>WOL^"$O@T
MDS.VK'@,$'>V9=('&==,'DBE3'S-EAZ\LR1!IZ<&3ZIO/V#577=>-]>B@(,'
MP(CK`'9>N^$DF(?V[73JADX9[-)+-<;=MEJ)4.V<HF[L!56L4"(K+;##W7]*
MXI%^TO&V<:6RP-E]`10"Y6_,GH$&:@9@10>KKVR*_[68_]6U9^)?H%F;-DY:
M^BOH\]C.AV0<-J:@GKO?0-!]8Z#Z>]C_?+$T+8\T]Q*NBI2K]GBP5@8C^:E[
M&F3()S\YO*$E"6"2OTOFE=*7-C6A9/MZY8*6']DYP,(K"^U@&I$18[.<7IGB
M2MSP_L.7WR5VXVJV+2"L(XM[-J5`!@.=60_89K2$&&AW`]ML6K)T`/=AGCS`
MO7.F'@.C#I:A_[YSCH&_WB@I6O.L>@0H=RJ$:]VW\T!)^>ZDFZ_]'I0I/+T8
MRB<96)9V?3.(_11Y5_VM?"AW:98EPLB__S1/-#K>WN>X!(5\K&_9PAX@)<M<
M-O/79W-5SL'3^VO]P+<OF>_4Y8=O5WEBR=!Y@&UE^'D9_H.1OAO&U+)'`'.7
MZ#+6!@OE@C*;LY4?G?C$&;TM!VY?L,ZRT7R>LW(WJ?06?F7Z]V2NSMCLY>IW
MG\W>.=%`L=MI8#V4=4",T3`U]"/WZD>#>==I&8U3'>SW@QFDDHP:H;_(8Q],
M[SNCUO:QA52"]M0=)M6G7.L>`]#\6FAQ$#UWRMB,FO>BXOI!F)J@(*!3DTV%
M+RZ>4E0&9HUQ-^WA*0K%\3=1`.L'@I\FFK0X/]NF@],G(G.L%!NS^+)'`W9G
M'M_V\Y</X!1Q8H/^".A=<USF7?IX$._/QCG!W2#$.;.7?>WEN_0RUCX:Q#NM
MV\X!$*.RHI)%!L8_S96$G+>NIR:PRZSU,L*><01L;RA.L8TB)4$GV<BIXJS=
M0MLJ%K8\Z3[SZ>UUW^2.9"J1[;0SAZK/+YHCT3[K.LA\ZQ&*7':N63:`A2L)
M\D"8<#=M$/AO+0<>+?EZ'(R':[.6<BZ>XW[<#^3=\\@[1@DPTR.4'IPV[DNP
M5SHI/\_FQ4H#:=<066,XV`,D.5P6DRQ+-2;4%Q^P8'YE=?."4SFS^PB;3+S[
ML&6+;'5M693Z<2KLU.21RM>,B@I`R$?YLALS:TM.=C\,F)-M*9^:<?AF).D^
M>7>F(Q(R,$'/M:T9OW&=V6=@7[ARQ0I"O)EVI"+X\:C);["3EW;>&^VW_[&#
M%^3ST?Q@9;-?G\SAE[]H>F<9_.RX'NQ7"ZP%2&^'/6IPCYE.BW_0TGS8Z/R%
M]FC-@GM\HO/3"PVTA!GS;J:H,2Q]]HLF_WJAX8MO?.L_[,:D/)1?-`?T&?EY
MX+%@>H^?X9HOGFA39MO^TD0ICA4?].^E.9N)?__/7?#B+_]%T'L2]`>P/W%4
MYHUI6W?.+UK@+E^H/YS)'PJ0.Y;#O_\?<[%\\=_ZH/,"?_=S,-OV4+L?/0;?
M(_1[HZX82N22$_Q#;Q.H$_GAS_A,](_D#LX-J\K9FNG,M(_H]&*:.]>4Z<SX
M!4Y"\O%SE>'S;O3GP%/_@4P=_WNY]\87IG=G`3?!$_!_/_A_B0DT/%(WEC-C
M^,H;\>$>B$JRW_((4`M8Q<%`L*SYZB"BXA\6_O&:^5//(@,8*2>;B-%6K(A0
M,?TJO[V*0U@C9OFZ<H)[!C)9>VFYMGMG36%-4%':VC/X7.-;&8%6_P*M6]-9
M19_H+S374W^0\2KEQ\\U$!MF6L;!W>-ZOV@3VYQ^YP!I$\L-V/3>P5=@1ABM
M"CN8AMAX`C@8X9JQ!V:[W&D*'#V1"\+O//K!TH-?.)$X@ZV;@?PUHM0-?<UR
MYN3,AS]GEH_*M=_6OL'#8JL(L5@(KC1X#VP8*,6<_ZP6+&LE=QX=.>U5&UXZ
M!YW#`AD7';1H30?0C("9!`TCB0HVIPLJ`F@@\%5@3=S9"E?P0!%A\<X26P$;
M(0A]E,CXLFCU6[B36>!.S"FHU9FKMX'(FBE4GA:]>,.NM9D7WFE3'&L&R@[+
MAL-CJ$+`[V\\MK`"='UJ"ZQ?6*+:,K69YTH@Q4B*!R#BRI^'#L$#D&7\GJ/H
MWO2UI>D%#E@(LRSJFPHL"-W<FL`96IGVG66VUR^D2I_'S;+C4E1`>M/<7%CV
MZI==4!=5%XWA3TE*3!D:E@+\G(L*[$S<('`7-PD)E?I.(G49I+\AL'[1R$(X
MOR;ZC80("U$VW\)1R:^7IO%[.'HW(J/0\\E34F`##8-D,<AGSYV%TT![):7\
M]7)(KX0=7""'H!\C]/>R\XXL^NO);0W4#=27`_4EG/<C2](O&1;2AZ^7R`PQ
MU$57.*I1ED!;X4OP$,1]\_"CP#R'*7J^73_CSA)XM^7:S[?N_:*8OJ;RZ;,9
M6)1*.P]M>Z4QQ\-<UQDZ9C[?8Y#[W3MM:EL.RF@-:`K/K6'D($2CINEIVL_D
MJ,I\&^Z'8X$_,G-][I>;H>O,"EQL*J:%#BC1C^9JG5X7?7W5DZD;J!NH&W6U
M@M?!JTU>^D9G;736B]UUH[/62D@)G54HJQ3_D]J?JK>>6T]-JLV-7EH#QFV@
M;J!N]-(*BGQ<DG)9=N77*'DYE\@JM2?DUW]]O.ET>N>^FY]E)%UE*'X7RSV-
MN<.Y,4K"4U/\HJ0W']:V/#_0[I@3=2^),N*>S0$2YMDK[;OC/CJ:Z6N?]5M*
M>%2TT`R27+(IY0`4F>AJ:>+HMS(1UXT0ARU4A>:<WQ*[A"NTGO=%`W4#=:,R
M5U#3BG+$+Y'^M:<.OPS[C1[<<,\^9SO6D5YHB280OO9H!??:.P<>^R&J8+"V
MY7?'`H'G6\$*M=UO[`<H76:@W6+)P@Y+^1)D;3VYJ(&Z@;K1K2HH?R-W9*+B
M3HL=DI$_\A(9I/;DX\J7WBA?#??LP3W40A@DW"JE>B4UK\N7L?5DCGI`W2"E
M47ZJ*O_>*G7VE\@"M2?0F_G<@G^=7;VAF-K<#I<6'`B'-:I-Y3GG<]1O@W29
M#VQF:K<O"TC,HS5WNLHN/=]<;>E9+C;\_P]3F[7\CVBPHP]?^+Q'CNB0D^:9
MC$8[J2XJ2]$#(`YZ']I,IZ59@39S$6%N`#\(&#X,6PD]/V0)9M+FH8>M;M)`
MR=7QO?8*5G?<T)D"6R[Y-%$"<1G:8$"9'GSOP0&S@$[W*^QTSAR<,]G6_N8^
MPFN]5KK-S33T/%C(IFQ1@'J*89)UURF`[(<3(%X0!HA]>%(N3S\T`2TV+.Q@
M,H#\9L("]`3XH14PVK451`MJ[N3?B*P'QEOB$.':U6?#.AV9=]BM:084`-1+
MYLI[AHAQL>T0PVD/G'RS>%[,)F:]??,1^\-KF1V2S,7*#3QW>6]--1L8!:_$
MJ-%1'A;U&?N.]6WJHJ(M$C^IR&#_L9SIS03GB]-YHVD5(:RTE!,6J><4'TUF
MR5$X+0EY'5BP^A#6Z)"0,I?P8V:V=R2N>>5Z.'841-S7P(.+(O24O$OZ:](0
MJ&Q8;XD6K]F4FLAK7;VE85/8I)BX-T'=Q!N:KBEK9IF8S-;2/EM+]D-3FC_Y
MLK6?%'E&Y\7ZCZ(O]1?/6QK8$/RJPD0V`&Q*/S+MK'>]^?PN^?!7T#H>S!\9
M/Q7?)'_^ZG4/>P?Z4XO!)9^U`OPB!=[2`K,Z%W#\E\G'_\;@YKY?@%&2\43\
MI?H0'8;/(<C=E?8:6^/AP4CAE+Y5'VIK&RF9125`I`J;NJ3I,>WQWL4:;??1
M`3F/WT5X1@SB!Q(M^.N%^6^\]58W]/LZR/@:'="WU&]0-'O6/+;$D=UP2X..
MNW1)!\:3ZH:!'Z!>#=],:;@`;`0;0`L55[GP@WN3](7-C3EO;=`<HK;2E+,:
MM>AM\?<"?X#JXRN:C<9H1`7OP&CZ]V".NX]<;V#F]%X"@EH^30)`QEGR*P!Y
MC$8#B'[7P$,<!D78:(]@+&J4SCGC-5CT.MM\].6KJ1,V/P/P,;X?L/!WTPE1
M<1_A:>C`F6`_IFS)VSC2(7@$?>E>>S1)79$W$'4E4%\3'2L\4#A_(!8,.5Y@
MQ7``>/`XGDI^VO(]_=%]X,OSQP>$9>7XQF\1&$H]'X'/GQ\>\XQ>]G'\Y&@?
M3`^0/<JZ*(&!@9>!=0'/%FG`?.H`TN!VQL"&U%[)6KWW/)SC>JN6]O[]J[5V
MN/!]XE8`$^%OH(W;YH1^CZU+^6GB4\U%-XT)=735E(>%U8%YT"30P02P:#0F
MG"V9.XVGX9GUG!ZU%L!`%AXE[&E_YZB6<OJUJM@QQ1!8D%'1L.=P"8]Y;GAW
MS]NJB@.*;>K)+%C:8,T_LV#EIT,X4W"NP.+@0VO)AC=A:=@WV3K,6_BB&>NC
M>[-BIH?$NH'57/@IV<4+R_<!G^@-8,`(8-IPC"!%\!W"+HDW`W(&H/80?GO5
MXI;W1#2O)OMLPIBCB"F+-P=6194BG!69:?JJ/3=3!"@V`$8I[)F.;XJB=^R'
MBPVT)WR)A>MA"]K`M&Q^^&$WW8@U=/V%ILX65?NGHXVXD<V40Q\/BRA[XH`Z
MS8!4?9P*%[\&WOH5>(I&)3B!F!L,V/\,ZX)2YA\ZN:!(%UHN3W;Y1T\[A&"S
MG[?(Z($=>THZB-._I7\_T5`J_OK$2%IQ1FD3!XX&XM=PL1`7K<)I6LQJFN2U
MO%O)YW;.G`.P96Y`?@Y,(E+L.2O`D(VF76&%K.LV\[+,O.E/MX4U3\)G#U0F
M[.=-<B\AO#;Z#6JY\_H3#[5YTH5N9+M]Y?[C+NI(?;@W'QB_=YEM@78K]>&I
M2N"<7=<KB(H+H.;Z47P#RN4=RM8Y_)94I->*$QD4AKO-KKQ:8J#^1'P=4C,[
MI!5HRBZ<P#]#BFYQ&U'O)"T;AA1&;5<26(T2^$C@MH*4C+]NU2=NZ`F-PM5+
MSP+M'7W"#MFJW)9=VCAV$L-P0L@K*C07$1CR0U<'HW`=AB>XS97^7?0;VA!H
MUI%>[[B:KZ@(%(,,U7V0L;?2!JTLA)!I1U$0%VR2K^$$M`KFP%;B$9]IDXY'
MN>77">LNBH(K&'M)2LPC`YTBX?V+?Z8X#+G51>XZ,+MN@$X4OEE)\^VIT>YK
MP!,V!2RQ4(/]``M)CNQ!2)/@(>(FEB,C]`([/N>`S58&=]28V,IK)N:AR?=+
M2L0!8:(M/*[ZER@`C(2:<S,HS32Q"PS]'4!#VW7N@&T]1D.^9\W54*FKX7>?
M3/XW`-X"8_[-/5"M+7SC"1!+TXO.ZF[W!E?'T*F$[B>>HQ`;6,M8,>?U^1A+
M@._94O&A_-[^VKYMRU/K`Q8<.-TD&D"@+LSO#-ND<9Z10>5PP6=L<Q^V28$C
M>AF7"2C\%M(')3[([[$1.BA)=]P%.I'\-@AVN(TV0V+![Z=!"Q>&9UP47,(E
M/W=MVWV$-_W"?4\$&;JBW*DI0OYWKCM[!)','Y"+S+309_/0UFS*WZ`$%#6Z
MCA@C@=C2YJ;E:0^F'=(9>^3SH#F0POTOP+S#+W#K\#+@G0>XJGR\,W&_<&F9
M?$@3T&')8W'H#8LW'>7)N!,QS9*66`*&@.*`QX6)S1S#&1/L@VR`E+3%]$N*
M%@K!3O"*J"]B""<B$UPS-F<>36`R?TA7W0QV!H@2SB[9C)?]6/*TB7G(APCR
MZP.^M5T?AVS5]C1>@$#Y8%(62<P]&XXXJ!_>%%4_50?[=SB[PQ^TM7<!S7,#
M'F*FC\J9Z8/&,0%)L@0:6^CS(RF@GIPHR,0E`SF+4;45,\A\8%$AY/`4T`^F
MEC<-%^C$QA-!;V0_+)]D29!P6N<2(S*>I&Q5>MJY,$*9&=J<65%;C4`'Z6G/
MM.F]"2='2BT'G=SH^);G`%5D@)T<Q(+W40Y;((<1Y9A#YZ=\VB;/SP'\AS8F
MB-$RV-@*5":AS+N^(FN;LU,I]>E6ND6^Q%$5%(&W"='YV@TG`5X9\N>-EE6M
M+=QF!,?(4(HU%Y)QMO4?^H[N]!:\BDLQ26RN#<PDM:7/+(IBXQMC-4*8A1@%
MB12A)6;3SH329-//A&5'YI3\>7),9?J5#Q9[%),2,:0"LE:J!2+N&>\23&U3
MC-4T-2>40>@YB"47-:4H1S`%G;`CE0!C6_L;R&77(WM3+"M3Q\#.)0O06DPP
M%DAR%Y4$C_)\:&=DD0;L#M,B,:LQNBOXWGA#/W>*@3^)&#3L=V`>]11W:M'/
M20W>$G[;/!#38W=P)V";*E1[?%_@UI<)#8C2"9KNJ&+&[@U+R4"U,/``C`Z7
MIA^RB".X>KJ15O"ISQ+4<A&-J"&J5P((GP>+)RZ+:.Q.O,37OV!SP8:<$CS:
M+C6!B0DW$IMPDCD^:RO"#D.CC.=\2)I'9P<N2_))F7>FY?A!$K!LN)K;K5*W
MVQ<A>H#>O!U\$[JIVA:^)>04GF(_OC'NF2/371(F+_>\NE-*+I_]HCW3GZ-L
M]T/3QT1/D"8S$LQXM\$;T&R]DU(;A#QLX)GQ7/BFR5BE3'6`PF92TL+-$*7)
MNQ-`F;!AGW7%@R8*CZ6'#PNA-06,NI@&`R^;6S^XUWC&4,&VT+1@W$9]UGN>
M%I66KQH@:/^3HS'#S9U&%W#U?]#TL0":`-5WX9(E21LN$VY:87\([W9L1T\I
M7RZ%=NG:M?S(]9L)T%M1*T`),\Q!&;R6(TK;AC_TQ+64S/1QL$(`"PX6?!QS
MK#/8L>]WW84>__5^[6<\"=`DP@)JN%-X0]I,5/.`^_!W;J2M?66LY,R9.I[>
M"Q!`T67Q7L17Q*61MG%JN;?ZD^?;!H'!HV'DL9,1)?0`\61%4YW&SFSI._'1
MUTI!'<SKFX?.3&01BG#6G"'LD;14]'12_:;W%K!&%%TR,0D+]>I8^G+7J.>N
M3!M]DFWM+6/K.CS5XF&;%)##:)99_G>\O=!U@YJE*']27RHT7!+V,U54ATOL
M3,LO+B421@4(`3J]N,*-ZC])1G+A:.B%A2]CJRU"85O[)PK_9'&&GX!8\94J
M0"MWI"_RIY,W;RN"F=\H<C/8?T3:9M'+A)TF=I-X-2<Y\9E`%#JO,6)'W6?4
MMYA+^`JHUM9^CQ*ZE><6#&[YV4ZXE#TD&#`V6C,@CXQ2,@$I*7!&:Q.Q3"_F
MJL`-^,26C2]K2XF4X(%`0^(L7<NA[%]ZMX7'8F&I/,NC`H!(Y'G%<ZXPN8CK
MHJX"5VLV`SAN.3Q@!:K6(C%O^@F'`1Y#;0(_@RTA2+6571<@?K\DPO*19..L
M;7FS&Q2#*Z$-`YN))`5@0#:]=ZCN0PBP.%2GL#%PKDG>9.(?DH["#QYX)@;?
M*"O[4;)DO/X4.&M"+&.1SBS5;.%#BFSY;?JU]LW5>$/O=78/U(2'E5@XUBP;
MGCSC%MXYN_)E,K)-I'ZOYA5Q3EDL,%!$KE%YAXJ^(]I:XP]ZS5QI&Z.8(E@A
MMU[V0-=QE+R3]LOESZGA5_V.G!J1_"]?H7I<4<C*#*+HQN.(;&N?4\40FQ4N
M15<0.473]PS`_YOK+RVXR9(;7)K63-/[/TEH$QN24#Y[VAWVL3;C>8L;J)1W
M@]T'DJZWR*J+T$8R2;3V2'J4,;1G^RXO8+&%KU7X1C&>G&$N`[I3R)Y;W"-*
M3H2/KV]C^83)!=I;^`0IG.*1-18A-GNJ=Y(OAR/TG5&8CM24!]/F.TBQ+>T"
MOP>N\N.(I+)/=8L",^375V3U7!L2"?#C2%*GP>9@B!C^6O5_8D/4-(Z7OI`[
M&!WD`<4B;=-:^&H*!FW^[R8`VTXZ,5+[3&Y1T%3#Y`6>#D&>5QF35,_PU/6#
MV'K//,V["+3._U$QT*;#4.008.HA5XPXD8#EX)*QYR+R(C<5TRM#1/C9OA?^
M9`8W$^(F2;_X+O>.4,,\7G3KN#&V,5'$(V\Y]V!9]%S2BFINQ$KX,&(G6./&
MJ-(6U,MIZ8&MYUE)35B>SD0&E8=^2)2T&^S\`.U&RHBCR&);>RFB>*FWB+BE
M*-^,U7:*:R:BI"!YK2FY3>&<\W]88".O!=GD9;PQADP9(-0%`3L)/6(^M$R>
MPU"CT-.3>6DDB9:!,#;(6\,A;(1+15AW`>H8>M>0?$*5B".BE$@G\OU8K'!'
MG(!Z@1IJ7J*)1QQ*EXH#5AF]9QK=?4J\W:?XMC3S>$#?4E9/WKFVZW[G7A+L
M*T+WO\P(P)\M0&E(Y(5A=F-4XTZ.$WSJ+@&]9&/%KQ)%B`4KBX^3!T[9F.EY
M%G8[BIU>V-!)TPV`R`GN`3K*\'S$M+5HHI2,2J#E*J!2XMM\2:X[*J0POP.D
MJ<W,=KY&$LV7D`EWEO"E6G$!./\BJ1/Q3+`[S_5]P1O8=DH:YL*'2K])<T[4
MQ4%ZO)3HRLW5Q536PM@I(7(QT>OU>+WE?^?2X'=@"P\E36`U.?U5VX)R(_Q_
MB8(HGOTY(8_'OREY/E4"%=$W5.FKZ!]1TFLK?B\UE9^I88SX/22+HCQQ"J6`
M6(AZ+,Q-RP8;AHO'.]N=H*\=A(F[L*;:%'YN\3X,4S/TZ4X37DK`V=T]O)72
M:$6*/^AA8/APNQW0";(+A+B-IJCP?/X96O"+%:E3'C60E,]Z,LU]QN8FR%("
M?6(ZW[UP&4Q7+9%U#A8W&+H/+N;O<K^E(Y9MJ>UO>&X!]G-9,`D/[=!G<3HR
M#X:A(Y-"ZQ07T-S0HT()GT3SU!36ZB04C@8JB\">ES28%@$E!P<\)7,;\(J"
M?X+R-X/;E).27F9B,@9L$];"PJHI)E53ZIP-AK&P)".RX+W_0&G[-1;3]3_'
MZP+X%796HF9Y^,<;X+D'N*J;A-_*;2$B%/7"8C&AA"QE_`O\Q3V(,I(`*)\T
M_][U@AM*^K><!\;5/]$PUO4LV!+5V\!YM:3S,+CW&!,:*H8);30U:XNY"R!^
MQKFUL9G27"F(_4#W`N4W?,5.1:(KFJ_]C=GDAOS`:0R7SS?/Y%U4*?'_`:Y,
M>@Q%_U?3;BKK*[8%U1Z/K"MAZ*$/'RPW*OA98PG>,2P^\]@S&M.B9=$?QG$5
M5@FBA`E*=PF]*0V"YJH8XU5VS.=NFBC+433<"+@Y!^H6V7?^/6,!Q5K;VFM<
M4EW'BV'EOJ5[P:%""JWB^*\:H^6:GV]10@+UYN8[D3F5\`+L(B@[$,CEE/>N
MPX(LS_T`ZFI1!W#*G*0>9GPY^/7::@K8ZSLS$X<+K>!V=!ZCQU*X4;UNS*)\
M5$6&HSAVG3OQ#XZE!-9;<2Z*C*J'L81?\?(SPILG*@)X<LD"4VK0,8D!EK8J
M3E1D4ITL:G;8@XWCGZ@7E=YS=9`3BW>4Y#W7N0<(/EZL%Z.MXRW@$BJ!&@&R
M6N`2EZNV^(46.KSF!;ZF0"(]Q6LX4UD(L#@J^[[@"?S=(M[R^NF@[A#;N1:Y
M(P*]E8L;6M&VN*LHWA4')K$Y1-J6#4:>V0#[J@JM(,KX2AQ87E6[6'KL'G/J
MZ#R1<<'/>ESJ[-\#;!M[<[:UVV!K\F^R_C=YH&<8<9KEP7VC>E2CK<N6C&\]
M15T\&JF;9[%9H/#BF^V'BZ=N`+-2*2WQK^SN/0$3F!\$=#'P&U!:WW1AD!K$
M:PE\+5*AGM')<$,?GO2?QTJ/]LL!Q$IT;<MNVE9-'LSJ>CBL5-/#B1L$[B*[
M[V$6+9Z`@'GTS.6O3_A_CXW,[#:+8I,W''K`UC(0O0@?&;J<<%_VK"+`"EI+
M6&GV"D*L49%ZLN=M8C90:B_`(D!LAT`N?U]KPN>":+%AB-L$"''GN:$SNQ%S
M<?Y[.IW/I]/UF6U%CXDF#[OQ4RGRYK.T&U#MR_0]Y"67[+U:#ES%3X.*+9O-
M@PA5)4'T=!]`/&34"!*C7PXHSWJM[K!3%<1DC%O;ZXR`91>PPT](*?7ZW+R*
MM&]0O1=62!9<@9-1C6-P_M/(#T$9</2'M4##Z:^%4JX"S%)B,YG>L]=E<'9>
MNSB6[[6,<;<6F#BUH->R%,0R-OP>,V1PA(IIEZ`7'0O*X]H+9SQ'1<`L[YP9
M!^A3YR;Q&<R0]):-=K^D3;^-O,3[GK#R8"F)>0D@ZD9CLR,=L]S624$`RSM@
M-^6=K],3.-\0B%JX#JOLOL;'DY'SSVKKTS>R]2GMJ8EY5V8+GS,;U,J2?1X>
MY;5@](L9`X-:M%S`,%P4S.3M`WCS,\]$T7-C8VXR[P40YV5G],J=1UTZJ7>L
M)J*:5.=N4T=?["3*:\<HH$?_I*"PM:#2.K6#)V:E(_BD^C%/=$S/7'6R$BOR
M(4Y+.=,)&PA'\;RX-5)0M!JKON$)XM%?GW#7<[10):,5&T<T[>-C%SOLC7_:
MY9R.47_DL4BWR*$Q\5['K+I-@.Z^G]-;WKGC"MH0Z3T,JT,VV39_%F/@=Q(]
M2E\MD$%Y:;C!3MAY&$Z[^T^8W,R4:X22JD,/6XQ[N8V"#`J?WRV4#<BQ$=J]
MZ6>5)U,KM4M@&*6JEB4TQ(9-BJ!Q>*-WM(MAB@^F$V)1(4^(:?AB?TQ>$E>\
MSU3Z9=D.WB^Y_;H-ARA8!?62&GNOF4AH:`G;C`RNQLU2`7/]M;2_+>I91%VW
M>9=T3%#_012T5]K309=F,O,&.;T>_:-8(]9D4JGH7B>&NV`>[<SR,>D84P1;
MHD.,\!%@P1J-RF"*OX`:OE-6\<*-.@SQPF71X%O[PI:F)4K?J!R>.;S;H-(Q
MG,:/\%WSR>O4I[A)7#U_XNKZ3/5HW$#V$"3B1VQS;WF1K:`TFZ.$55'*JED!
M6XB&]/P)9"TQ664"AB$8Q=A)H(V=PDPQ,H4[E<B1A7"L-0@3SBU'A<&F^.$\
M?9IZ0SQ`;2U'2V9=#BLD8%.#"OF<%QK?1.-B^#RNQ"`;,0Y`:0@@0>89O%0'
M+";T*8-T,*N=7&713"E3G%8Q;(^WAQ3=AFI\7M;<S%=3PO\>JU'>4S\I\@DU
ME:,5V\*W-=GG4V48E1'9HA$8W9\IR8=56.2VSB,?-A_]N"5M=/9EI;IH6":/
MO_9N+EHV.Z)Q<;3D^HHT#,!/S8U3H+=BH+!#`17\9\@DT#A^8))2*@H@"MA#
MA]K'AS3KC@ILYU1$H`8&DA*<&K$M0#'%QZET+"7&98L6CI7)2JD_6Y>6<?2!
M0\DI%Y<]U5ABUO]@K<O"OXKYBXT(K-86)%TBI2,*$/("/.J;Q'PYT%+5_M1Y
MH'@T0\<*>!,0>-()J>"1=[/B`^FMA>AIY./\:*DH2@F*,BL:9$R!R8V*TIT*
ML]0N09-,PR)F4<4C*WUV%^FQ7+:@#/,8MNB*)@Q:-&R5VS^/B=)$B8]XAE2D
M,$]6RAS"9/]5K.?#AI1)X%I;^C6U4$OF\"6VBE5@=TYC/)UWO-S75]I'MZUU
M^YV6.G#\G0.W[YU%<[2B>E#]A18=,.2>3P$-K8T>@^^CD9VF%CRZ-W#2EE&W
M?NK!"H<O9H/4&8R:A269BS/@'$QS=$C!"_$E:TH,!M.72QZOC^]-,1&`/T'S
MUK/>+>;8X\M;>)K%Y#"'84,=$UE87/1^^J;/MZH8RS"-_!=8RQM/N*6J7]E0
M*`7>+;P]-0T]0I\"!U]*8#\:AJKV?Y2&7?RNY%+8`99.I&P,O`%6]("LTRC]
M<`3CQI\KUG9B=\G)Q!O98>U9Y3GDC#2AXPY6J/=Y%I?G-.Z5"SQ%X^5]\C:.
M;FX$UCD%UGHANMX28\4=,=@Q*J*7EY8H.:93NOFB0HU]PQ"I%M;Q/%ANZ-N*
M[R9QG:G3>J-+O)DE=2%LMVX"O(9W/YC4H^1]+!X;@Z!:6_B$#OS8J]N"OR.R
MJ;<:-4:FIJFRW_X<QXRHMXIL?1/?*Z*'*G-FHG$'-847+0+YB$#QM\SEB]\V
M8?@&=<BN'+2-?>UCD9`U]C1Y1<8[HDZZ,=&2(V.3#\T]QN1\7!4G.)/!"WEH
M4P[5>J1!/Z0@():PG2"]1TVZ?(EI4C=?I_<N#2%8BK&X%F;6:0MWQNQ&?%5*
M?'UD`3`+]8)YAE5+-&93^XIM8!H95JTM(*E$VYYG=D0JZM@CIYN&0HF=60\6
M'6EG[1D1S>$-$-`5+%I%QZ.U<<2&*UH!^<D!VJ\M.PSBUJ3G`2,U\IN1\IY^
M0NV8V,9A]_+;^'/Y:HJ0X=RSFQEN#\1?"X5\=D@Z0^DTA8CD\3;*VP:J+TWJ
M5</1$4\+F@D,DFLX0ARW9>*]<\'I"]\,%[MJFZVHX8+<<N!.O\OA.C3#_8?H
M!A7%MQ5`?#DJ)@(B@;GY[NBBP5?IM7K];FO8&Q"@>FO0-5K]SEH?*,J-R1&R
MY"\U6N/AN-71>=9`MV7TQRU]-$CE`=3V%%^`(%J_1;Z`H6QZTWMQ1.+A/:]P
M>$]SD51K"ZH?5V2QH,]((>'Z_*7TB%/E%SB4TW-GX33@OO852)9HUI20\SA*
MB]3I#8MD)=-H7[:#)+J#*=-6XO&$?,3DL_BF2$_*?M[*F*K40G>WDO-)Z[2P
MBAO>3S1`.2N\>M$D#$HIHCYZMASPZ:,3PI;/$RPT*8T&:#BHWYLR:1`O-FL6
MSRD7<[(\+N^5T=@*`EJ:S>ZPT;E"/!S@@,Y'E/<8F*#QB"&G#<]Z@3]\.5R.
M5J96D\H[;!&C<$4#073DM9+KRGDTE$'CW&-D5KKZ-DW2$KR!`QUG%C:C;!QG
MU1+>5"[]#VD1OHU"1N]B&["1X-7:PK>D(2]R%RD8B$JRZ<U\G$1`L_"4GR4R
M$90\+IZ6P6?$89B"46`G+H.4LBL`1=2?X]3?R&E"(PPP'.E1E23_B<G]KW*>
MCFAMRN=I6TN3J^1<:VZI`%J^FGG'Q2P-QE*\[ASNC%>*O83<S2)]#NHV(IC;
M6MPB0(9T1!JWQV<Y4#M=DS=&OPDLV/(]_`]>1BNEMV33.%+V`>O4HQ93@-L]
M5X>YC>NOY=?[J\7$M?<H_.,PC;I[)?^G>P2.>[LAW4[//2H!,-5"AS,,YJK_
MB_;_0JJ"QO.,&EWH2/?L\QC]%`*FN":&2D3`4CGP?`(-'TH2#539@:!\A02[
MC_9-IVUD'6[^7W[NFV/>'/.K/.9&=,S?T7_%>#R\XQWMS\3)5_N;2QD1=:=W
M)V@^\6[BO(/^S`*-)K"I23OF7_%_O4##I3GWS;EOSOU9SWTW.O>_.\K9Y1\F
MAW1PESI<XH%-L53'E<K_S`Q,T6PERGA*ID[1Y/05'U))3@S*IN93-[>E\90D
M#VJASE=Y"^_0=L2\'9/&79@:GTF#MF7`IO>.]2?8;S37#R<'B!Q\U9[D=X8?
M,18ZQ\2H4Z9,]DO%Q6-3CS?DF6!\:N(^B#`-S@7T94XP-G=4*JMHH?30GJ5M
M)MUDR)=)2!4C5"8)1%`T[K(S>UI2E2W^-F^GTNE33;Z./&EJ*N9TTXBW5E2-
M*OPR*'6D;D3><<Q4)S-'^>G27$4)W?"AAYD9B@744JL)5=X3!8Q<=-HF#[#Q
MC<C4%G4P1SQ!6-E6PZ.5'A6X<!VVDO=FQ#!4X!Q2D&`>XD@5X.NGH_8`(R.V
MC!(\[;<[\0?TF]R1\?0X(*&M"V$G\X:2%G_[`@A2E2W4!E]K,8FO%&A[21[@
MSSPZI]UB'@2O16D"$A7;PE_Y5&7*]N`%'0L2%6K`-(ZRQE<@?2_S!.]$>F&<
M:`@")`#S']T`_)?\)R1O^`=XIT6-':C5K)^4,;S>"BX[-?&1:UCF(P9*E.N;
MOYY/S`M62[0YX2;D4LI,Y38FDAJ5&7S)LM(XI8<O%@M!U$)%73^&8*<BX12;
M@[>UKQOCS/PM%I@O_/>.Z]RPQ=)V5QADIC%S/)",JH/#\]"30P8#Z2)9SP;E
MDQ33C[L;?[I.W%3SRX5+2YLSC,Y'I1J1DD)?WD2DBIIS`JAX=;@\W>M!Q)RY
M+B(::8I\@53@.XO=$CU$>7[M]AP$V*\<$DY0S@!F"[N)DO=8_DH.#0<+$AL"
MFIQ'X3]2T5>K!F8,'J+-"`YQ3"HW3N-<!/^;6KAJW48B0?:;^:/)[*_:%M1D
MIDBSI8`0)UJ`1./1'Y0!U,F')^G'0?.[T.)?..XCG.A9-)7P[>W7EQK61GYS
MX3;0AKUD=>0.!DE41";\5'Y<"*QV@J%II1BX9Y@`A:`GBQ.<J'-#XKH!>.$)
M1ET29,R=)'9D@,:":<V6Q9?2&&!8#-_J;Z[Y:XFKD#DFOZ[@$8\JX[#BF:?A
M"K'(>SNE@:.\7.6R\_">\&EDL-AR3#38B</F5J`]$Q+W>509$>>T1JTB'.J>
MK.`M#@)N0B>65L?^)!,#^L0#ZG5!<XFM(+K*;.L[7M@4GL!4-Z*BCQ!CJ2$H
M/EDP4&E8U/V"#W-M!/RUV#;OL&I'%N#L)W-N#!0[=J+1D*C.CL5.HK#P'<Z!
M%KX;^!;SWUU>\*N*I%A22;$4+:)\%W<`H,)IG#SLBWG._!1S7Q,=-<N?VC@!
M.G1D(P0\!WR(-^;NH%S&?$1JV!9W<8G+FL3A?C`]+++4YFP6Z6$DPS0S#.Y=
M,4OV\=Y5NA:88%$D1:J<.XV-#S`9,_1XTOP$Q1CL`LND@#N^BTH"GXG=Q;F@
M<N,+``^>#+#UG&/:J__P?'J;_>!2Q>0M8B+7\K]#S_)GUI0'&$ACS2(]F"[<
MO\R[A=$%P+W;]_`--9DD'XWB'#8#,(@F81"GZ6=)>?5=Z3>@>$^0!?[QG6$&
M5T(V3YCXW'+$[ST&.JN3;`/!):4?.P])AH.>CQ[R**D76_;`I6'S2\3"QD`K
MJIO`UZ84:H(,U6`?0#M@X/3,FD7MQKP9E>2I=REB;P.7-K*Y4LKW%S8E[T]\
M?CY[KN.&(O6X4<@KMH5OB;:#F:FII)V#D`#Y)RN2A$<#OO&(WBC09^XRD!T8
MTZKCO0FVN!DU<:!:>ZP"<S9&9F(Y*4]Z*V&C8^NQJ.'7)AGPOS^'_LV=:2Y_
M>6GZEO]I_AG="0[?Q:TS^QK'`F.&_>S:UA2$SC<@UDNXB+__]I?_^E_YGM?4
MO]2T_^JYX=)_)SUC:FN`N#/`:W[!@BB/WH4>".2"+VS^ZY-7_.\_WO[KS1]=
M_08DYPT*S">_74AF!\^;.7'*0B22NNUM$F;;&,N3@;A71PFZ3ZD]Q9<HVIAW
MIP72(Y3,J#HF1E59YGYRM`_DTQRU,AK@^J1(VI2L8%%44"AHH/ELZ]?U_OTK
M[1F^2#$YX'O%A'B.HOAOIA?8YH1^WZ)6CCSM!AG1`T$25X$I#W.1#)HY>L<?
M'1R0]"Z[>8N<H2E>T(K<KE@E)?S^LG@!&[`\LYZ+[DP+-K/(9DBT),H"1*TN
MS@B]:^$257(WO.,@48``JV]!%L,C+6UIA[@PK/QTV.E0EVL9C5^"U1&:W'@B
M_9:)T`COC$7UL*#O+N`"Q*.(,Y]`]S8]7N@L"`478+\]_(EJ=;$+W0);59'/
M'!M/<<I&K2-]99>BL!A?2MXC^&GH4#E'_&Z/IP"XDH>XEMW+J08W^E()#H*4
M:S*V_HU.'V[P3)^CJGDD"[>^2CLPCFT9FVX&17M6/`//$`*^]O.4697JC(T<
M10<2;'+4Q,BPBC/PS`V=E*A_X(2*@QAV-R,$P`/2B@/6A9_X_">B;9/PCVQ\
M)75E#'PMLX%**T/_BW,F>)-7/`FR<)_Z.^$N1(M(W*?L\[CDF&<B%I4\=!LZ
M1]'+HP?596B^G.@)R>.@"K5OHW=O>*]*-6%!(S<1L9``K]3XU$O3)B;[>L_(
MO9MA6[<V=CE`7(F*6YDR%XVDBYCR&<'@AC[\W'_^2\HVRW<\:ZXGY)A<-^I7
M2>G.FMQ[9'3EGW/--6'>)@1!M6=GRNW>9QY<!NQ(9:`7L,:@C'VH![7&:,XY
M^J?AU+-PJE'&/O!RN0CT5AJXRM)>KS%Z-TBG">#V#HQ"9X:7N.O]HOWW=#J?
M3Z<OM!,)KIW:84:!^C8WU1G&C8GI\"4S7'Z8+G>Q*\=V[D/[>`^6:[XCFX52
MF\U!0&5*+?DA_N07;8P?R='5ZX5W)4Y-;V$ZS$'R5D8'SE5(6>0:XP0H%^*G
MQP"4'[YL5HG",>7`?[./<-C"R>?FATH"=<E,6C(_&MV+8,CC*(+YMVZT^]GW
M2BEQ>S>(FJ?L>RXY@!4ZC@20-G/#B<TR3N3YC^%F`(6N5JW;X)P$KA(L#;.=
M0M2?GL)7T^WA[#EBFA\NL&WK?S;735&'#XJ^;<E=R3]->KW?-,TQB+KY'2>*
M5??6?N-N2;$J@0*AM8A,KB9^545KI8E?-?&K"^+4)GY5&^`J2_LF?I7?;5&R
MDUM5]ACJ$P6\V^?V$5;&!WA\'Y^N]ZN"E>)T.O?ZU\0G+7TPK@I>SAE-/"FC
M58.KSW^XRG-TU0X=U[CGA@7.IP>6L351J$")[+[H2/)&3"RJ?G)3P_#G1L<U
M[KEA@;.G@94;F?_KQFYT#?N?FOU[@T%-\'!VI%\<[?O=_>W62LJ\DM.4RI5Z
MJ/!I[CS>M#H,4W;,;`[!J0^!KG=J@H>S(_WB:#\>[N_BK:0`/&7N?QD(>+=8
MFI9'F3(TNQV;9KON##M,YB5,%K35C_6=\2@5SYXN`\Z2,_BK$VJN/A&OCM?T
MX:B^W';NG/PC2GN>D>]&+M!IY`*50]N;@U@!,$LT,(?[.Q?.?A`;;JL9M^FM
MP3AW2EOU^.VD2GXI>4RHL5-[ZTV]G!J#]L0&[;/>('=BWU$0\;RA^<EIWC^@
M1.D$-*]LMY'&\]9$71L6:%C@0M6S3S04CX]4:5*+&O9N6*!A@3,H:@=Y'CMM
MW<B8D+!?UA$.QG&=J/_ZYAKLO-0ZM\>@\0OE@G,P'.Y]_L[N%6JXK6;<5N-`
MYWG3#,IKCB+&"#[#E(+G!WDH-YV]IE5/>0"6V*I'+S'<U'2&:MCMB([7(_);
M$7]LW!(JG@1WZ`2WW_[R7\EY<.('G^8X=(4Y/CWYA4_7I#*HK_>FQU[B".C/
M8LC]E8Z#4TV=[97=YYT<UZ_^Y+BO`7#/#3&5IO)=7L"O<!!<U2:E$@G1@XD#
MV!Z8]MDV.?GVFHY:BXYE56[)]SJD(6Y&IZ.W-DXE?>F:W@S=*Z\MCTT#U_/%
ML&L@)0Z`9OA!-`B5T=NT+$*O3>I3?DF,H$SMXW.K`DHO<T+JOP40^'BKT#0!
M6IV/(A,#EG%Z'5@QTWOQG;L44ZTDK)JY7,(&+#&0#Y4&'_"_PCG2=Y[IB+&M
M.$+,=9C&%DO;7;%HL)\<+X:3MC0_G/C6S#*]E3;C.!2/B6EY?*YY/#<KM5/<
MB&W3\&?V8XI#RHT^S>1KXQQTS7RD&;3IN7S9+^'#SG#<7[@4LV7E1V+L&G[$
M-\@2A.4[I%1MFA]&P[)-GV9:<P@LTA28Q"4-LPX\BR;<<EJT-N.VA6C`^8DT
MT$N03LXSNYF0&!<[33,&7WZ='](80$W"M(#(<DHV;-*ZF5EV2'!$0[I].7B,
M/43SQ3G<_M*V`KF)F?5@@=RG&;\NQ5JFYM(*$N/?:2CXC,UIOIQXZQ)@R0:0
M()@QGR,8>6AA!4',5/QL`7V)/A(=B"3X+!IDQT'_P;RIY>.(-FO*6F"J^Y1R
MB;]I8;JE)8;,T>A'.4J1;X-/=!3ST696-'"59K'1FBU!:S%>DMER9)WXE5P-
M4>?P9W`X&_(,BA/@&'IAQK"V(!ZVK+<Z@P&P^3`ZG&*F,D*F#KC<>'#J._@\
MFG]J=!`SG6$Q@;M$3HH%[#"W@!UN$+!15U(D`9U06!"'B+J:T>J+":&QO)T"
MYZ*GG=X%OU%EIA@[:D6P)`1P"\2<\V<(U*#QB*GOMDB/Z#3BU(@'T\:3*[]3
MY1"^8?T3X"%+I"+S,T"?)L4.[,.=S^$T>3A<FWXEI3ZMKUYW.%@PM(%!XSF*
M\D:04QVC2\%B/HH#RR?)0"-?(P).5LF;$S;\$;Z@0V-PSN"B)'G>XSM/'IW$
M&5&I#!159V"*P;9316$F:F;((97E^#A%<3TRI!^ARP.R,YQHCK,UN?2;FY:'
MA^L["S0@4YB^,1.\G>`C<5V1P,(_^-80?L%;EZ<%##E+;+[_/PF`)XP\GH(+
MR!`&-O$`P_#2T(\F?9(O5)WX2YO@U+OC5?GVBE\/J!@XH@NQ.0\$4/SFP:=W
M"G%L1CP:&JUA=UQ(@@\O0H)?@+[_*2UL]$YKP_G?I>/KG0U74.+ZB7Y5X/KI
MXD%HKI^#KY]B5TB"4A=UA123J"<7J*!MZ7UB]P(B-4&M1J2>=S9ZTK!THD.<
MX%K%)D^.*\?*:+!?03#@Z8"CX]XY`$GRM(EJ.B$UP?"2:]!!]U",@IQ#NY1Y
M'ILE'\9W>CAT@!P$%@@F'#$>LRG:?G[`S%DK/HR)4ZC*KB5WY^."$:PS#8Q%
M.%`K?J#X(S3.6YJ-_&PUC'KF@1:2Y^ZY16+CC:B0&\>RAPX13`Z4IRM82Y)>
M7%\^WKAT[9+<XE=.DGF8"8JX$,GP0GB.F$Y>W<!#R!\+8A55DDNIJX4^N3CP
M>L$@X,W7*6@CJ!(LA8/'PN"-MG!GS.8`)']G@BA=R-O.CSTVNT=Q9$S?R$BY
MS4W[F@_<H.TTL^*;+O8;N]AWR]C'O^!8QGNAXQG_4Y[3^).=$SF:H1?58YDR
MLH(N9=!%I5"ZH\RTLD5_;Q)6;K'<A3,4`0@ZEI)0I;<'8^U&>VJT>SL3HB]J
MXYUV3VS<V"$)3IL!6_)<$>PC33XEZ8S*G=Y:I6D14G))F(QR@.K\U"`C-S)J
MV%@]8OX'US8#R[:"G64\5:%N&=O7.Z.?0,3I($NN:MO#/FU[-"J+HZM2O?O%
M\K_C>"C-0F0Q/T"O67WT%<UQ'SUS^>L3_M]2A%:[.R1BM\>[J'W9B-#;W0XB
MHMONE\;V%13DMC5G?'YNE+9;!X*7`$@?N;S#W8[7MN]AGFW73II'3#UWO3FS
M@M"K0:OO$BF[6_N^IMWF*RVHA<._+C$L'M7T$\')1-B3?Q0E12L128QEK:4&
M>[QZ23/O/$:3WD42113"C)\0N2L^4WZLW9L/+,HE$`FW3>BHYN5;XS-/^^RN
MK;]6;>6O%A/7WJ.LBL,TZA:%"2RS4U>I68L%FUD8&1:GL9RXSQKU3TKJL]/U
MM#2\-^UY)$PC@MH\?XT+X(5I48Z3R"(!T<I5QX;:M:/VGZ'IP248IP0UQ*PO
M,4W'"2GKL:%E[6F)U0G!O>7-M+5+E20QE\+\7PFJ/[H-S>M+<XVNWW62B]H9
M2?.HS`])[F#IX0*6NF^(7D^BBUMX$]UCK2NBN2+<&Y)?!\F[77'(7^`%T%"]
M;E0GXF4H9QG9]H=W0S$VMD/1*]\,I8(.S:@!AZ@)BKR;,D7>:'6&R>J@P(VK
MQ-9*P^[-!ZZZ\8+C'Y1;GTK*?]IK]S6`R\YPDN;(LH^QKL70Z]G0]_M#@-TH
M$?9!9TS8V`/N_7FDMA[8*K/^UTU^>UGK))J/4,W&W<;YXM&@,6&]^(RZ+.`_
M9NR!V>Z2:E:B7Y&;GXI*7"U9#2G*[F(&E26J.8M%J,7%4[W=BPX7?O74&(RH
MH%56J`/,]JJM577[\+EZ*/?"@:$/Z)#2_H>=?L;^+_4T7DQD)#.@7G[F2X'(
MR%D7WY8/%-7`&,?(#:H+AAKRU`%#]-Y4#5<5X"I<;W848OZ3%F,[C.`*8[.B
MI&P.87[?27/Q-DQ5G\4;\M3UJJC4Q7L+4M"\VUD,45ED5I22S1EL[MV&J1K!
MWEA4#96/2>4O,J)<=W16%:YJD/GV[LYC=SF*5JN)SD81:!2!1G:<V<*+P)=M
M>^J.WJK"50VRXWPOSYP&H6G7':%5A:L:A'X'=+8<WYK6$YVUU0W$>_.VN:L$
ML*4WGSP*1XN^X1=)@5H!6P]V^9RG^V`M\5\K8.O!+.^M><,K9P>V'KSR#TQ^
MOB#\'[>#5?809MENL;?>NV"OO;XT;1I:\S]RQ(/^8BTMMK,OS9(@5Z)K9:*[
M:24@XD._(Y`ZY<!DM/K=<:LSWM$+N?@4\+/CKJ)@'9O)<L^</SYOZ>UN[J[E
M#5L=X68GV+29&TYLEKS<JR'>"@*]DTMC:(]3>#AHCW/U]FO8^H+8.K=`+9N;
M]Y.YK8Y!Y5<7PJ'':)-9`OA_Y?6>NY!<#0WC_(H.Y_4RX!`%MC7!Q=D17]J>
M#U`KRU$EC4%#\\KN^;C$KQTZKG'/#0L<W>-7P@9D#DJCN9R<A9\9W5:WVSTK
M+IY?#]G/K+!TVOV=`\HJPO:70_.J'/7:H>,:]]RPP)'=+-LBM&7L[2V?0Y*_
MU.98@!PW#G_&HU$$S!(5I7&W->R7Z,`LB\X[M:>&T4KPF!^=OT`U&U>/N<K)
M/+K"JZL&-WG#-`W3U(]ISI&V5L;^\J2JY4YW.AZ8S8E)):*-A^-6@23"O('K
M:LC9B^.;LP<$N[V&4ZJ0;E,+2#,9+X;P6.EB'?TXZ6(-IYZ+4X^;#58&A#=U
M9K8FW:L:MWMUM$(Q#:(FV#@[ZB]%OS/:QOXE*0W-ZWWJ:X>.:]QSPP)-PE>M
M:7;TA*_NL-<:]<][C3497Z?+^#K`(]5<5_4^Z[5#QS7NN6&!)N.K4O[*)N-+
MIL8;_59/WS\WODGY:E*^MGN3NOMGXY\]$:/ALC(;Z%0'APVGU1U+#7M5P$MV
M_/!TGHPR(_&M&P9^8#JS`A,BSA]\/7]T_3QY('N!VFOU^MW6L+=_6X(*A-L;
M[JM7;H?>'HX:?KL4?KO4K+=>M\EZJP3]KTDRMKJ=H_0]JZ1^7()/]IS:,>-!
M:1/XH3F%%8*TS+R]T5AOC88E>MV:.Z"Y`W9IQX-:B_^&W\XO[8ZM'??;PZ8F
MI!KTOR;)V`(\7HUV?.H<RR;KILFZ:5B@88&&!1H6:%B@88%SN_I.J;Q19:PV
M,P.FS4W+TQYP=IOFSC67#Q/5[GCI;,+_AP[!.AH8S0&JO)%03<9I+-,M:12#
M86L\:IJY--*JD5;5@*5AG,HS3ETS*?]),WE!'30!'O..<?5P37]LE,7F%%VM
M^&V4Q8U9!6V]W_!;(Z@:054)6!K&J3SC7+N;L>GSW)RKZQ'(C>:X"<)!9USW
M])=JLEPCJQK&:1CG,AGGNIR,C:K8G*+K$;^-JK@)0KW=*7$\7,-OC:!J&*=A
MG$MFG(2>^'-`9;W1OY=RS87IW5D`=6?YHVSHML"YW`I)0-!0#5>N<J\RX/YV
MSR*OI=(F2(/_J(71FAED5%&;'GSA`\"V[3[ZO^3;+_&,Y<P8[K+3[EO."^V\
M.,A),6(E^>9':Q;<(X2=GUYH0CL`^\,VES[[19-_%=F(-F6V[2_-*:#_UR<=
M_F]QG/#?6<9/$0NG2(^\*1"'>:*<\)$,&'RY/4,P7832^?6)KC_1'/?1,Y>_
M/N'_+8,8GS@SQC3Y='CS*NPLEKF7\L$O2?<]A"[CDY#E3=ZN"1OL]GUC.P(%
M9Z9=%1@G$RL1%QC7C*$K)8]T-54;/Y4ESA$)$@%XRYV`]452(V#.OG@C8"J\
M>"T$3'UTLB^F`YN)=N?.ZTO]1G*>??'SD:<6]WYE:7,$N<(6IN7D\2E4%BF-
M/#G[XHT\J>[BE90G)2A>>_@+C[%A.<HSILAGSYKNW4&5AC]4@F'VPN]Q#[MT
MOM8>M]6%K()4O]@35EW(*B);7\&O/',:A*8=[^&]-;\`VE?PG#72]1JIWDC7
M>G!!9:3K<?//LZ+\,L>D]U,YR:Z==F>LW6A/C7;^VB,)0SD@E)%A5B6(Q)0]
M"9)1#DQ&2Q\8K>X@=Z.1ZB'IW.L?&R.Y$\>/SRV'3>$Z-Z'.O?X6^G3+@:G?
M'@Z*]=BO$DZJP25;J%023'IKU-%;^NB`$3'G1M*YUZ^#S"V+6]KZ`2TBSTVH
M<Z]_"IG;-_+(W%,U))'63!FG`+1W';7X;@XM_NSDO;@:&:-EZ/!_QO[WQ&FQ
M<7;47QX'M(W]IRQ?&?'+P_JPK??S:=%GW_3%<;S>ZNAZJ]_MU@0;9T?]Q7&`
MT=:;"^_D6!^`E5&J%EN:9SHSQE"&<ML5RNV@@(OZ6,`<-\!1M<F4&\`L\08?
MM_1^B1-XST?FZD#2,-P6.'OM0[QYU2%R=2`Y%QU[XV(.]'IB[.H.:',C-`S7
MW`A7PVZGOQ%.[-X_8O.C*'?G$,/H&CO\'1W24H?/];NM86]_[W(%NF\UW+=7
MR/J,_24/R1ZJ$HVK!,OY.LNW>]W#;*4:H>T:+PFC-1KKK=&P1#VV.;3-);'K
MDA@TPRK.S6_ED;/?'NJ%S:<<G50KW+NS(M`>T&U5;[JM-MU6FVZK9ZA!:[JM
MGIMV56"<I@5/-1<_'WF:9H@'$:<RS1"KC*1&P)Q]\4;`5'CQ6@B8^NAD3;?5
M"SL?5TJ>6MS[E:5-TVVUD2=57+R1)]5=O)+RI.FVNBUAL!(,4\'.<$T_P&ND
M^L6>L.I"5A'9VG1;;:1K<ZX:Z=IP086DZ^5T6^VU\]>X5:DS5S5ZE9VBV^IH
M-,8.)_5%TKG7KT/GO]*ZK1H'I,*>FU#G7O_XG?\&;3U7;FLU<5(-+CE^_TSL
M;MUK#3I-X^+*LDVENJT:XZJ@I=Z,<K0.UU7LMGJ\+E6@TH]0M1^W._V##,7*
M&X95*[$[>FL!,`7&XP.D377(7!U(&H;;*CS'^_?5;-BM,G0T"H]YJ"?&KNZ`
M-C="PW#-C7`U[';Z&^'\[7N/T*?J$-.H1D7Y51-.IVE!,AYBP*1I"7%NFEY5
M"Y+N`1.7JD3C*L%RQCY5G8)AFAJC[3HOB5X?(SQ-GZIST_2J+HFF>>;9^:U,
M0WA0/*[4]*DJ`5KL4\7[3&%W*LO73,T/%P#32G/G6@#?OG(72]-9\6V-#'WX
M`M[D.C</S`\8LHX+3");766TLS*NL7_5J%_Y]E5-!5M3_+D#0_3>"K;V*MRZ
MZ[A-.PHWH:DD>@\IH:P"4U0+FU5CUM\=?E_7'9M5A:L:5/ZK9P*DM41EW<7/
M=??&/`HW?T73(MY<"?6$E25(K8"M!_>\-@.E"/&M:7GQO_YAVN%!)8D5H\UQ
M`\O"IAV65"_W,7(>*-N3W@5=V;/T),2?=/56_`^C0"57E5*SJY&LOB59O%-2
MLKC1:_4Z!R2XG!M%YUZ_#H4?)?%*ISTRJH*6TH5N@2*'LFR`W89>-3CZ_`>K
MS$!H9]AO=?)/[3LS-LZ.^LOC@+:Q?VUY)457(7VQA`W\@_3"GV43D4:*G9R'
MG^'4L6YW_]NX#"">-W0_-=U!`[LPV;5';>FQ$MG?NMZ<62C97ID.!G#S.^+K
MF5M?M42XHY<`/--[@Y;1.<"(.1:A=\K2AM-JQ6EZ>UCC&K7C>BJ/ETP7.RTU
MQ5>YGNRT[V&K4=I?U4[<2?)-6_V!WAH-2CQY3=+I>;FO^DG.1ON05G7GI_$I
M-?7R=B?3NC239W-IGFQ!KRV99[DS;>YZ&MX%!TS.O,8#=QYQ'T.8*]]61':W
M;B;:/S^DG7&Q^J8J'M5J<FJU,941%:LJ>%5!7K[Z#17R?X<@9^>KLY<"P..3
MC)U.HFTF]KRQOJ%:N[KUL<ACS8:!E=S`M+70\=C4O7/@W:+.XV9B^O#WU%TL
MF>.;F(^EL1_X-UZ3MHG79N!JR9J01]/7GG;;A@;0V/!)"^_[Z3T6F^"S4_'0
MA,E7P3_O03^XN]>^LF7`80.X^NW:(GK;^:C)%M[>?GT96;Y8`W076C-T9I(Z
MI'+'TEPMF!/XP!%_AI8'[YN:_KTVQUGVVAS>"W2>,M_7`O,'4-UA<PM^S#E@
M:IN^;\TM5+^P%FEI>@'R:/H-<\N!M5$G,Z>!]6`%%O/;,9:U-QDKF!XR*6`5
MV3GQ#;T2/YFQ63CE7(N[8C(,%?&RY4C@1774C,V9YXD7`NPLT,P@\*Q)R,N"
MHM.0.#-3UP_X$GX()T&\7=W`M[CR2IM9F.(::'@:/4`,?)2%08`-3Z_FTFG1
MU;>]0O3!X\QZ`%!INWS-:(L^G';0M396?&T\_DO;%-C"1TD1TAB\:K8N5P#R
M&8'&18)N##%:3I\^U2ERW@(@?10)`*>]:LY[)6X\^,/"/R@=5_NGZ6&"B4]D
M>PW+/9A(+>V]94XLFPXB;=.*-ESO._("2/G)T3Y-`Y>NT7YTQ2L"AG)TX<1:
M#H@K$S]>P,GF]/X<>M-[./;:[9W'&`IV[=$*[K4I&.M@%H/\G<*C&-N"Q]$J
M=CV_K8%F(45W<(]5I?+AY,*6[X?PX*/D*5A^*=<;=/NM4;^O^?<FWB%X"7"X
MN#R%G^*;0/Q,.51@JN/K01"A,`13?6$%9,;#A7('PI5$:K32/5CWP,*1_-.6
M.*4$5WFJMP=<*)F:;<WILSER.,FVU&N$2]A:+``'H/[8*WH2%!FX^-)8'[:U
MKQ;>F`"XK[SD$9"OW?&T+;SV).80/+A!@Y7FF0!B$G6`(RV`ZXRTIWNVX/?E
M#):=XL-P*^'MB!<-!QEP&-J!O+8"6,TWZ:JC-SE`=W@&'@6\\D6)B-GJH6G;
M]);D#MPP\`/8/:Q[3LF=/*_U.:(?3&!\3<]S0*>@+``Q2?V)3B5>P:94C$![
MQ],2.M;4Y)K+TG.!Q18M\3OARD)V>&0V<#><K.`>6.K>#$"EN`/>`]9XRR9>
MB+7@1H>#14R1N/\C)29:``$7$`)SH)J_-"T\3;0$G)`Y8W1*'L$>0*5/2`$"
M"EZW(*U2\)8\H*1,X5I&OT-:0RP6-JDL"7'!-1<7Y=6]Q1XXRE"F"#'&?\6%
M`-`*Y9@#*J7V^Q*>L1RXU_AVQ7K19@4T\N/U#4@9P4]AU@[)#DIN,DD?5ZA5
M7$U%I1-./7Z%B(M4\'5A!N<8^$`*2OKHV5.C;73P[1R!SW,C$/Y0EX:EIB%A
MY%F2<9_SC<96(>JL;);0$#<KB$M`[`]K05+MZ:`;Z8>H,*+'E7\3^LCZ^+8/
MP%(`O.G9KO9@VB$GTL*=,9O#`=(_7`CE/406F*P2)PN-`M[P@,P"B^\R[HA`
M6GR1#@9IN7)9;0TZYVQK4&XYRV@(>Q'O(<]R*<A]DSB">7UU<0)[^1"56W=0
M/GPE52&4#YA1T@"@\Y'T5&,8^(Z/<):$=W!F/5@@0&>Y0RR5/$05`TH<H=*A
M.N#,E`[+3R6=CX/[\1[[A#RX-J@^-IAMS1&I_A'1#^FH6]E#4LU+Y(OE?P?+
M"4Q.BXQH/]`\K`QOCDGECTFG;1S0Y+&RYZ3REXGT>@H'17-43GI4"B8L)=]5
M/'WIT-RE:A@WM<HEN8B(4N2\$ZYA?3^/=>RO-F</EN]Z*P3SP9HBP%M=U5M<
MT?$;<ONB$\YNZ8)'KV/DG-[DD-8[^SBD$W&DM`LX)*=SPKFK8"$.1F5[A!EV
M8<WE#=[3]TN+\`W,3<LCQVOT,KFEI"O7$$B2OMP%,_W02[AR7Z($N?DZO7=M
M0..:,_?6MJ-HHG0NXYLB![-PW6[S+S<NX<8EW+B$&Y?P`;5W^@&S2:I`TII;
M\XU+N):&?(4P=#56?.,2KM,1T8<'7"R5/235O$0:EW!MCTFG/3R@)+:RYZ3R
METGC$KX>EW"_<0E7U/]2Y2U\<K2_FP[WGXYR>(1S%1D$]_R6AAT&E&UJVB57
M&>BM'H#;'QH;Z@S:VAMS>A]Y-2D/-?;4QG3CZ:V6%S#F"`=U_*49:$^-=D?)
MNR5'J!].?/9G"/#:5-%U;SIW(E,6,1QGUR,J\,?HP[9,V^;^2M]<*```<A<^
M%@'@5RX(%0N1%;T#"\:0#S"].^#YN9;'':SDUN4;"[CCE#;SZ$:.]F^9K[PW
ML19-0YAN9I;-LX&Y8WGIN0'CU05S9@:A!TJ@-5\GB@\,.`T]JAHBK[5\/L(3
M`0RDM:G<#3"4QF0KX76^=^T9\_PHM1RV.+UGY#!P'QWI_;;=1W@\*I*@-=O:
MW^!3N'_391:SB/\H##"W7<".6BW24^EJ87&?XXC-"R9F:VAI2MO.*ZIN@2"V
M-M@MIQP7OO-V2BM^KN"(W-&S^#[!>DCT!\M';L`S[[$;K!%-QV#4<B!8-L55
M;>UUR"3SRC?P?RGLF#P)MJC'6_%XB^E]9[.;P+VAOP(!BU)NBYN=S2PA9#%*
M=H.\;"XM+`7WJ6[)"K0IHT(*^#6P.55.B'((OD>2GZ8VB^L"(SAVU!.MXX%*
MM"8H3Z,ZW$..36VC+E4^2HEB.*H"X[4R>$=%D3G@/SNN#M7X#61Y2D&'&D9T
M1-!VL;`".EMX/\F>`50X/-0'%$R,[D5^B6K\`N5%VEFO5@%2X[D43(R)(7@Z
MNPH:WBE+AUPXGV8T]I*AFJ``X[&EZP5QUZ"VEBUV-D=0DR<81$(_W4$!U@"5
MA?&Z02Q3FGIX/!$!R=<^'0ZHOGHM:+M?++:)HI8=11TW\T*WVII5&'O4S`LM
MYNZI!$A9LZA28!Z7A%^8D*]X;=0.D76?RE<91%:((U]%JE6-L5A!D,Y.V-=[
M![$:"5-:OT2:#E@9[!XVM+&RW%L7I-<%SLHS!QG.\;X&>XZ!K#8]3C;%L_P(
MW2O;)>>!TD8E+TVJD!79)+JN);IV#VAU7RV25@N:AL'H<:/=&5439=>:2=WD
MP-4E!ZY"&-J1`-<P3,,P5YHQJ384;%+QZW1<='W8KE&2<<,TE6":3J]]B<U*
MJJF\-A4<M3THG;9Q@.'7"-<KY9D#O%&5E:V5UV&IZN<958/DGB)<,9:\JG.B
M'^14JP"2*@!")?%R&B$[ZM<0205JONJ8+%KEY&],:`[O`!98,$<EA=+Y"X>,
MB'JGY"`14:JUH8HF76"FC`$K4C2E%:B5$GG+B5=OJ)^**1H54F%.=%Q'=0"A
M&_X]<QU0OGI%2L+/*E8L6JL8ER>HQ8JC7J_5'>L;2Q75EG+4NRZJQ=B[9G%H
M]-4Z)'6%@O5_=)RH4(BZM958#9B`4<D,@074,YD>]*0(GOAG>Q0.Q@]C#6QH
MIPM@D[6C:I6GJ<J5+(GE6\#"IB<$UG:YI#VSGM-G.PA"8-CP8@?K8UKPF'@N
MA2'\'>V7EWL]!>6R0[^.?KZC@A1Y(ZHH4ZF"?ALY;LB-KA#9=5%A06<&ZST\
M7Z>4*,<1_!U#'@$BL0SOCRX-:@`8%=)9OE(!Q'_>%-`U=]`9"^A`L,4;RBZC
M,Q6N-!6IA1/O]JZF&]:@FDZIH<N0L+EKZ(Q^EX\9S:B?@S.WL7RN;W0SR^>L
MIGJNJ9ZK?JIZ%5*,F^JYVI1D5*BDI:F>:SBR6AS95,]=*&&;ZKDS4+W:!3DU
M*I!JJN<:YMBX)329XVV![:S\HZF>RY]V(>WE&[W;-G#S$B,8`P5\B$^;2KOJ
M5?4TA5!-I=UU,EBG/6IFEA1(IRLBZ9NJO`IG!C5%5@W#-`Q3!L.<.J.Y&B*X
MJ>"KZ]'2=:.IX&N8IB#3=/I-!5\E)7)3[5?;0U6ORJV&9RK",S6ZO*]3-VXJ
M`^MUIIK*P(9Y#F&>*@TGW<MMO+$RL!9)KV5">]+,^&-MX@"4?UM/I(Y3K45Q
M7V8J?79FN:A52A=ED`9CX7K/*'G;#7W3F?G/><ZV%>%G)\4O*E%[U#EGHO91
M4@%`6R6:)#4P\6D9Z'YIVB;6#F4PV4X7\MFO)+H"SAQ>+6/YF[-NO@Z!TJWG
M0(:11\.?2D'(/]/E/7G)$X>SSZ^NI0/LYX=H/1VA%/6QU1L;=4/0><WZHU\J
MKWCOA;5*M[6ZN>NY8<HX.J4DA/7V/RR5/"&E7#:9N:<G/C1?HG+O*2_HW%KR
MG9>(63L[#S\7R6,^X[$K`F9YQ_*9WAIV#W"#'(O,.]ROQ[W'TILRVOTSG,LM
M%M+>N>U\)Q5B<`)(F[DA6-5'.HJY;:R"`%;!#%L[?Z<G<(%.9=7J45'425G!
M+=P*%]]*57+-:6`]8&\(W@@I[KX@_XWQ+8TWM%D3+-0`)L</#6P28?K"Y>@7
MZ=EP*5Z_ICU#]9L/-.T9=F&(WOO(\"Y#)K)G%:D^S*HNS(+UN,3\)RW&9C'\
MMW#PS+O<65K50N]%UE57"\6'U<^>GL,_AGBMQ[MSY_'?PA_M7R1Y:@5L/7CI
MC>C'%^_O<Y%"WAI0Y&2S3,\=8FTB2^>,+.E`ILZPE`+J\R#IW.L?&R,EE467
M`4JWW2MEIFTEQ6B!($L)X/\5M1U0]G=@LQH<??Z#56)PL&4,C=9XT*T)-LZ.
M^HOC`+UM[#^FHY*BJY`&6*+RW8BODS/O,[W?&NCGY=^=]2IGQ_?%D5UO=^IQ
M81TSI^58"0!O76_.K!S:6)-P4K.$$V/<,GH'M`DY4\I)PVDUX[3#6M"=F\B5
MU3,CKZ)?/"WI[)?_Q>D@W9;1'[?TT?XM/AK+N=X<H+?'%V8Y-TZ_2M#KV(P[
M'O5;HWX]>+>A_S$$UW#_ABB5%%R-RZ\R-#N^RZ\U'(Q:^F!X5G0T7K\SB*W\
MY1?U$%N-UZ_QQ1S;ZT<SGH?[N\L;KU_#:?D<(NWN`57YYR;R.>H:R]C?%J=@
M;FJ<OY3M_+6*1X>T1#VH->@:K7[G@*:65:)XE6!I*F6W.#L/2'8\/XTOL7E?
M!>MBO^*,@YN)B2/(I^X"9[?SUA9BCKMF.5,[G/$1Y'?,89YI4^6K.5M8CN4'
M.+/]@<F?^YK'<%`"-M9S99VMKUF^'\(KX*.IZ_BA'="GN8IG^=CVH1Z-7_<8
M?>:XFK\)=GQQM':>6MYV/OJ=F=O@\?]S<Z.]M9@]^T7[^;-YQ[2;FPCB4X"_
MDZUE2<WQ6T?^*+\NW+1MS0T#']@3I1_Q.>.>0ZIJCG@*^`]^WE1Z`TZ([K\^
MX72/%JI$N\<B"O\>96,%:L1B[.?:K:CEVDJHB+:X4E1.EJ;7Q-.TGT\+2[Y"
MMJNO)J\WPVVL=ST#PWV*)7:U*=^PW26QW9M8,:@VY1NV.YCM<O>V.`,??F$+
M$RRQ#.%W!F!>P<\]<QJ$IATCZ[TU;X[(A1^1V[L[C]V9`=.JP(;O@`LMQ[>F
MVC^PL6V%Z7^2-@GK-<O')D`95=_KK<*/#;7>UG,W^#QWW?ZUKU\MQNETT#]9
M%]Q=^_H-[]27=N=>?S/O&.MM2H[-.[UV9TR!C=R-Q\Z-OG.O7Z"O2QUTI/[)
MH1X8U9=6QZ^?J3!OG%QGWIU%=M*3?KF+58?FHY8^:JC>4/W<N+G<Q2I#]6Z[
MT\FG8EX7,;)2"1NM0$(ZRJ,D5E$C/*`PL:%^K!,.JD3\2UZL,C0?='/5J%\N
M)1JR5P4YE[M89<C>:X^ZC5;8:(4%]8).+N=A%?7"QE-X,*1&VZ@2Z2]YL>K0
MO)\KN'FYE+A.LC=4OT:JZR#@&Z7PTI3"RZ%.XP0\L;K7!(NN[`;HZ\.6T=_9
MZ.UR*=&0O2K(N=S%*D/V;GNL-_K>I>E[QX;TID+T:]Q_IY06W<8C<&4WQ$!O
M&9U&+VBH?F[<7.YBE:$ZRO=&&VRTP2O0!O>JQ=Y1WU]5#CFX-_'QY<[PBM./
M]N.N:@!U?MZY]CAEPST-]S3<<ZY[2V]2*/<@5J7UZ<IS72WU[3W&[FSHNVXH
MC==KQ4-)T,_/1WG:RU^IW-K*9=4!K`(\E'<N1L-(#2-M9Z1>PT@-(Y6ADX\:
M'_:>!*N?7EXU[M.'E2Z/JNH0GL0.DANKYA"7B?S#PC\^+7%F#0T4^1I.?&MF
MF=Z*H+>B[4W6-[II>[4=)U+E*4FWV?->6MJ;I16X2];23(#PWZYG!:L;]]%A
M('@B6A)E5TYPS\!ZU5Y:8-/>65.`[][T->Y#U&B4D>9*5DC-H.EE_4@93$-S
MD7R6^L&]^<#@<?E#IBUQ,@="\[33[G1T/L9)\V3_<)S-))MW:[8UIY_VVWUQ
M(VZ:D?2_/X?^S9UI+G]Y;?E3V_5#CWV:OU+F,7W!D5!L]LKU`__KO>FQESBR
MZ;.Y6@"3^M^`W"]M`/RWO_S7_\I7T5BJ>]<&H>V_^3,$M'YT`Q8O$#U$0,,_
MOK#YKT]>\;__>/NO-W]T]1N@UPV2Z<EO)#AI7$U""-P`[7XIR$Z"$Z.KA`81
M[3.=)I/-TRX.`##;O[&QCR$_\DE9,VBGI,CN8+"$*/DBE2S\6(\,??A"XR3:
MLDB^BR0ANVZRA1?_+_^JH`S8?3<<2_20)/\7#B![DSV`+"7O<\-V#&E_'C2]
M#CV:&K=C4EN+?H'2Q716<JZ<,6IUNUW-1]E"DGKJ+A:N(^2AY:"0<-B49L,]
M6L$]O2,2B_#[I.!$N9@8'[?TW"EC,WKU4[U/PAA_I'=:`[V_:5V/BSV<>F=J
M4]._MYGO)Y:5BY#\3F]JV&WU1QM?CF"QQ=)V28@B(A]`N..=\D"WAC8W+4][
MP.[W!/6X1U`_>ZJWC;%F\O$5VA(P2PL\Y_L9ZJWA>+!M33&_#]<0:_J;%]4'
M?;%JIPVO75^UI?'I?;`$DN3/T$6$H8PG7O!,N@+IWDHAR;1]5V*JV](-0%9_
MM`EPN&<1;@O$5CP@$!=\\V-JAS[.+WQU;P*+V/!^VS;!6N"_N[WS&",$$]O@
M6`'VPW6V[+@]U$"7L/%AW'6_M]]NV]<J!CXYVM]-)T2U"4YUQI'WX?;1C-:H
M/VSIO=Y&BJM'6!WA!Y2/=Z:W>K!(?VAL>$W\2V28ISU)VK;VVO)`GL#OY\SC
MJA/H-MHC#J<TER`N?E@+./OV2GMJC`<TNO**"7H++&UK@XW4U%N#T:@U'&TB
M@U!4!3W3Y-1&O5ZK.];ST;#;[N]%Q5YW#RJ>B6))YL%U3Z#"&/NJ,/5DZ[17
M2$0JR;$4,?ZG:>`F[465]W%DK<WP"C!1Z#_@\)PE/,\OG+GEF`[:$\C0"=-K
MT!I*JS'B>.6]BE[NIXY1@(J(N&YB8Q"[]=%!NO-<4%"2RDZG/8K.BX+JZ"_U
M3EZ:UDR;99XI?-=@U.%G*.,U7QG3T,+3^AJ.$?+H)HP$^!W^!_`D=#?+CUY?
MCP-Y=%[+ISP;F<IS=]B#VW23^&P55I];:RIS2I;JQC`:YIRISX$2.ABU],'P
M`(U>\LY.:(QV)V9P]9AM43?[?:-EZ)U"ZJ8)%(5/9^7KG,/XB(+.B5V6]M0Y
MI1>)[PK^!YU8_\;3#"8,/@U'4TS\AM>1BQQ^%H$+VYXQ?^I9$SXMG,[SL`T[
MR*36NL@+[D%"/1+VI&1T=PE1(@Q-0Z-%T=9R%)AHM8]?/FC_>/=.^QLH&[!;
M7WO7TMZ_?]6BG\[GEFTA'(!*B6L.B3G],[0\85_T]Q&XEI.]TY:V##T_1&4&
MIZ3?6].-0/*]D!$Y8=H$LV*TR8I>"WM><(Z&S_[MPF(1_(!#N%-,+UCA@U;@
M[T\Z=&+A0YFR8["&EWQV%Z'6I_=*9$8ZQJLVW"'S>:Q.X.F%&V`!K_,9OTL^
M>^Q!NWWYA9-QLS%F*`=#;X^&!QMCL;,SMX<2W9K^ROGE/;S)\9ERV!_8K3-[
M$QGQT<'WX6-`],(*D@[2QM>YW==91EAFF':5Y@@N;O6;E@&48)V6EF`>.O<Q
M^\07!_=@*1R4=TN5\-)>?;`IDH2"[(*:*N5C4J>LKOWVV\0,CQ,SC._4";/=
MQ^05BM&_A.+B,_2/8N@M)OLT>>#C$RYO4KK*\9(/?=3/?-#^I_>P$)O>.QAH
M7-%KEJ!^D)_YJ[M@XL:%W^=::6&NZ.(Q02^`+3.XVAWF*U8<*<K^DDVMN35%
M/`JCU0]!K8F?T*:@[;H!JC%+V+,U)<L7/3N@:,[8DA'_X7T\#X.0/GL`K"V%
M1$._C&WC?T&5"6TS<#W8VY1[[+D*E;4`*8!3N&D`?-"&GED.:-\\L)IX%G?I
M(`$T=SH-O>?J_MZ&'N#+:VF@?#$OJ7N)5PM4TGLCU"7IC2M02!8_="?`JUPG
M`MHM$<7B12K"`.OP1L1*N!1ZBCF]MP!,$OB(8XEV&Y%%$/FFG23/:U"'A`)O
MN\[=#=A%=TQS3$*RI!/J;6@]`?]%$&CF`O1-L8\5T<EA%J("5;()Z1AFP`UR
MY'O-(5.+4,^_)+X"#OLS!'AM\0H@$:<"US7I\5FD-VT*,U?_P%^`S/KDQ$X#
M?9QE;R5-+4U>42FC%27"[PX($@^4?$J``"46C1+04G"GH(^3SB\L)Z/S(OYU
M]*'^XGDDYEAD-$N9)<P&5?ZUI,AH`1J=<(ZI#![#?WC?62"X4;(YX"<Z<U)N
MJK)2#=^!U1"$OF^A8A58$W=FR7#4^O[A9#R`P>-S&S)((L(BD6\%MG@O3X'`
MO2Q-/Q!+PV8Q=0(IBP:JXV`^AO+3I\+[A[8,>7MH4\)7R*4$F\_1W`9TS=#P
M#.X]-[R[7W,(]81G_:DPXZ)%G+6?]NFGL6@0/_55@$A("6`B"?49[CFFO0/+
MRG)0VP?3"K`/>WLJ!I]N?>Q=UH.&NM['U[?HIEB`18K25)C<O[>_MM-+O`D]
M=\D`I1]00EDH86]!N$Y7W"4$=B/M,?F0>MG(7UE(%>W6MTR$&R2DM\HPE3>3
MW=2\T*&,&\]=F3;\@)9R@$=)>&O/R!Z?6XZ4D!F,]GP3`^+59(%TA_=$MP9P
ME"5,<'%N!*L)3T"N!5](WIZ!R>T^TF49,?DZ'+!IQ7T$?`KR7\*&@`@O1N11
M<,A/@1>!Q^@'9NSJ4'#)?6D3C\%-*#>SOGCRY<V=<L8M;'#_K=$LY=<#XJ<H
MG^'JT[X"A_LN?O!%RG!%%*\YV5)O?+1`HP0Q"CRU6+\,'EWO>^8MP$_>UJ51
MV9N@0@X8(347A;B]:LG3Y;N@'BF\GO0H@N"?!T+3G%L>W`PDY^DR?'0C.0.B
M"$4Q?<<54L*N"<_\@$7GC$7WI_(6%-C=3K=EC(:$9?D3X9[FB+>\&<_Z`XCG
M<ANMQ*OI/?J@U>N.N-SL&J/6L#]"!"[Y[8,;-FVZO$@?A,W_&9H>P&KC@?<#
M^'+!#9-WT2IIP;`9%>21ELF+B!@!,?]"T,2_1P@F3-(9H0<6S;HF!1&V$A:D
MO66OWXX9LK&U^V6[1&0DOQ\]*P!YK7AL(S'N!19I"BB_S=`.)(=A?`,O3,74
M\!4#)@,:?D0X1N&78`4QSAV^]0,.R\Q<^8(8'FS?6A(0H,U3WI$9!G#NR9]G
MKV+`LUSD$]/Y[H7+`"Y>>#FP@6L_\&O862.^N!72QP6]\_`M&1TQ?T2'`8X;
MG7&1?(O?20*S'VP:<KL+[!@&G_"[U]4H.PON,T<;=_AF^=[:VN^T&X4N2\]"
M_G/7%:I4=@/QGNO80ACXR`R6S%M05#JI\?'[=.:2D00Z+WG^B?-_1%)$6&61
MZ6PAI9!4$5320)7@TM[QYX[KW("1C`Y;.H_1LE/R%091G(&^F+&L^W?[*O)<
M(C*9%RGIQ%.SZ`/+0V7*!1G.CP'GE:DIHHFF;7H6XU[,-0P+<IB)M3D/K*NW
M`,V,6[^1RK"VHR(DP^_@-3[(W@3^"I*-AY=4VNV#9YE_ITBVK0\U6M!Y+>N/
M[@-G3Y'89K24=`P,>]XS.[Z.`\]T?.ZCXG&?Q9)K(H)5>`@LUOHWV>BD$JCQ
M,NV98G;C%ZK!G169M)10*"P3N:>UO)&ZEA9[W98>NWGG/(`5*2XE.!D?`5^O
MO?!.>_;NX^OG(!>GW\T[N%.DZ8A'1MJ#L3D(+&VJACY_NSM%,8[?<0$)!U;$
M*LFV9[RH`LU#^L!"5#D2$.DF59QGGQ5TK*,]*3LH_X5^8*(A"CH:O!,3?Q/6
M>\*\C*\C(2I39*4]!''2#JY@.JH&N/[^;IR@G`K3A@X/`Q-WQ#%;-_22<5O8
M*\+1UJ*TG$'*P-WDCR3-(_9@`A<@0P,'"@<X;4\HQZI)3!H%^IV5C24BQU*%
M['=^HO0/W#7N4/P;MR#R512-2N5N4CUXBHJZ(*F!`(@7N33P=4G<B!<K>293
MME2)QA73#.<(OTV):@+H7[1GUO-LEP?0%?C_!?Q@XR\V>%/HF9T/93WUL/.A
MC*?D0[*4*;;EEDL;?DFH>?;R_>US#9,K@&\5KTQL<S`/M%J7;GHL>`):2WS2
M[S)\$LG#\?P%O>O9@]PYK)APTB26I%\DOLU8'YZXH2>^91Q%-#^3WCWZQ3TE
M6T1^2*[O@#QR>.H%89,"%R02(TF:4G1CS3RU+)A?R&A>\FX7;CV3;`CD*#39
M,+[1[3S7X"`'][ZB&.^0,NMQ*>ZC1P'&=<(?UI0'D_P@1.<GX@^52<^EF,T"
M_H/!!X_SKH`%S`:`9Q#!0\$/?#,P!<EC9'=EX_+R4$QNDC`"<<Z,1RKFIF5C
MY,+B8$K]CM^49%#(OT6>"'P6NXMX+LP2S4,G$%81_$"DBQ$OH#`$@X0R#_%]
M<VXJX()P7]]3](0R79S`<VUM%YMR&4ZTX)&6M3>HNQ0!DCD/.4F'-IO%!F;2
M]T:O5(DO[?<U`J"::+DSBL-Q'3](Z/B2_J3G)JZ8X)&!A:8]TXV(EG2:E%N'
M%[BLB\!SZISG3M;<5T^\#>\`%I$OGPZ__(#_4.!,1BB0@^^M93)9D+@@H0:2
M+X)[>&3:X89$0\Y7=W`$/*J%4J,T<1AF*EXR57,7%4U2HP-UQ^2-&OO?Y%;(
M^891:[EPXJ96`MA\F^CBX=NP4.9@T-/DN@B(8Z`@U^]`((71Z;\/%Q1`D2$;
M;E!^O-4>0#]PO3B(KD2:UZ)$D=?<)"ISK0!.@0LZF4,A`WH]G2'/7.(/8A6>
MF8$\(=*]B"]Q0Y2@Y'O"/V>6#S8EAI32VF849E;(1XEGVCL??SA=B[S%Z:(<
MXVA7\%MO[:0G\.TKZ6QJUF5_6^9P1B(L\F4R?U@4&R]-D9HG(;/D#E"NXMTZ
MPWW,8FTI,W,POLJ04'#MH,&\2J%HC<-;=&'.UH[6A(%L8PE7%;U78I$K`LFT
M0A[N5JPS1'$B"9<7'_EX1KP[J=\J$4:5W80+(=K?]O1MC#Q-IZXW(\1%"FD6
M0?%W(>4/:$L7M++5QD1<92]^IJFY@_%:_.BE6/<MZ<2W\(,9-U!=[8N:@_J%
M1YYB]DU'A(N^(!$WYFPBK#[!)?&&A-=4$[$K85VE`A!1WBVJ*W#Z%="`FJ;-
M5&F72*_U0;'@>Y+FEDS.YP^JXD`PKCA`XF#%.M$.U+?!.G-8ZB7<Z"CZ*KB-
M(O>?8B5R?S>OX.IVB`^[;>UW\59T8V5KD5BCP1W/_*THZ/F=%7G/)J`JH`L>
M[$,">FKBCU)<D!O5'/(9F]HFPAV[]DTJ:5DL*?\$_T96G_+\%-+*A(U"BI.K
MH:>2*),($#CH58B\F9D`<$RAJN\#[X%I89&9`%C$4^LQ7NN&RA6FW>`7CUBK
M(+0Q^E(]0U]"`%#O];C="08*>;P!'6"%\;/:^//.N(6OL9=!'F4IRH$%W*D9
MEY(3K;%BB33\2(T7++;YREI3EC!-+-+2>.H`Z2-1DDB<02#OPZCMR&>N&0$.
MP)*?AER^DQ]][3<WD]7-VH>8+6^E:K#14K2M[XSX.):7"3!--#NF:&MQFR>.
M_X&1Q!R\4B>(/1F6,]%_PW-\R);CQ_`A,C.B;^G(QCIF<QC.N`65*4B5$\P0
M>0F%B!5.KDWN7U-Q'T7:";ECWKHNO\KI=[>SA>7$(IAGA*QQ;(MDK2W\NQB,
M3H$2>^[8GZ$%^IVXL66^C_BEC*F[(,COD@E!/'OHV<3%7_@2?KA96NEK##T=
M'R+C^,U#2E]IK9T;D6=)KIU'-U(M9VAN@8;^[*GQX;GT*;84SPO<R$Y(6B-&
MTB*U_!57R?GEG]:TDL!1AQX_H4TE"VQ$.AU7B`%UIBWC[]E0/I+W1/IN4L]C
M[B?CD2ID&.[EQC/NW\._Q4_)G:\J.:)Z%2F?V)FBT)&T$<\++IS@ZWEX`!04
M,/%F%B\"7*(W>":5-!DJ)C"F*%M!D59<HP'**]7AG4'<1AR=<0N_QV('3S<<
M+<KIID`[/U;\"R7G6:KE&7*$C"Z9YZ<),XTJDA4YDI4F2%\!1ZZ_,8_$N)6O
MV2XV,BT6E"3PGTQA<@\_RCBHW?+$20;D^\J4+<!>O%39Q`"-:*F@IL-#,4&L
MIX.>PX.-(JOXP?16R`J8.4>LF_*Z>VR!YK$I'>>M*,J)C9ZHOA3YD,*1R62H
M5N*H*]H]Q:46V*QI:4<^@O@T!^B<"BB4@P%-:=_BB7O6A;/O!NCZE_F]$DYT
MM@HG`[/1`%IWVV`6PQOT4U-"]ENF6N\B:SGC1P"I'T314ED!3GF"4GXE#B6&
M:4A8D;<-T8[/>&B*%-&=>",M#`YQ?!1$!^'`/U1B9J&C=#4LVB@/&?'=;MA0
M%A9*$K@@RDSZ7`K&!]<.%^SFD:$_#]E6=@F+A+$IQ',:C>Z#K,92XE\HA7FD
M*X<P#C;PXBON$6Q$;44RIO3,5F!K`:YW(N>F(A$ND0)$,DS$6H4G=%?(BS?1
MH=\_FM[,E_%Q);CU^:_OP#"^S>JPL!;NWXB7G/CDQ^USZ$TI*6036K/S[5-!
M(_6R,C-%Y5HZ$@DW?'#<'H_[/ZU?947;<L0)86JGW3D0VGV4KN`[BX0M]P#C
MXB3YHJ`5]5):2HQP617!B5"DPUY1I24'=BT*]DAY!`='P#:2.J/=3FPP$$;4
MD/_F@%Z"@.3@F?'<M(1'90DPBW.Q,?](\Z/<^/6L;^GZH:O5MT!6F!YEGY`3
M7PWB8#89[21EJ)$.0/G<D1OIFY)E(@,C<'-M%AN6+V%!?<LE1/OHRCP@F+;A
M+&5'T;:'S+9'N20V%8*=-,051P&_`5*F]U*G(60!6G5#Y-F+W\HD1WDY)PX<
M)UX.&)0S)L[46D3(E2T)]6X4"`X#F5!$&=E4K0SG%AN:\00CZ>6GH^(K7<H"
M'B&V137U)@G$T[?,<(8Y9X1S$C?(CUC(B=SL8&F%R[.2VO$AHP0S3BJ$CZ+)
ME$26IK*@XM+E<36QVPTX0TT'RYZ^WNB<>T793C)^FZ(<3YD%5)LS%2R4]Z8E
M0V#I,"")RSO$W=>;+BB8UEV43Y^`+2D@&]VK(F8NW49J/,=C2N+7KL0&7B!L
MQ%TW!=TW/'7G8H8:Y?K)Z@:10YL*FXD>$?A+9,0)9G&`SH1C/J*>3MG%1S9=
MMV"7<&./M@,[C."-0W9"$HC<O(M@R/JS)MR[7]DR(+L@W@XPF='I]+?V*B`S
M]H82;&+^2ZJRI"DD^A9\`"7-NC.==&[6YLR'6*N)5EGO.M@;)&OX,YMB@@7T
M@9XW*/&B,THN%!5Z\V*C")P=[^K1N\9;424/.*@NSB[,1`YG^(6J3LN31C4)
MX^'&UI_?,C42?./3?H0C2COE(,OWXN4N->5Y:-O:WT/`+%[GAYS4IA72,3M:
M978K:UI8595N;R(E\BV;>-24/=*87WMM[?^&E-D((,OT#32G0/^T1/:+C[GP
M/B7L\BYF]Q:;:V^X!0NO_32?PQWO95I3^"K^<I'G*U=,R2K'<M@-SW!7AA-D
M"'8I9-+>UU?Q4YG)A.MIN5E/Q/"1,SI5WV2JL,GJ>7V8E&^$(H]%V6=134G4
MV)9"5<DA/^B\!(/OWEKP6XFJ+##!`A9^U@5I/QZ/GR,EA&V27?.>M2/A>Q7.
M5&HAHK28252@1)77.TKKLY9II'6-3OW?@:X>6VE?P-1<R>1R+.3F;(Y*.Y,.
MFBSU>X,`X"6>4E1L%`=*T7A+^P#'C8.Q6<]3)J04$`C\K5EWU7:QL/DY%=I,
M\1"E\&%36EX!O^(=-GJCJ)HS>E(UH>-`(#XB2L&YBQ(36F-W%+[<=4(_JDYL
M:[>1PP\[=2@@FG'/=2EH4">33JL]^\_S3*JU@60)MVG4H%<&C42?>D7HH%,2
MG3"R7[6$D-"#D@^-1<VC\F"R6$FX8D$_IC"V9-@(0T8W6"+%2YJ2_M$%,_W0
MDV7\J?S_M`Q&6R#5XEP9`\.#8:;V$MNUWWR=WKN8H(FOXVX/*IZ["..RKEO(
M$'A1A<BKMO;F`7CV)9P1.!`KAZ6EWE9)]Y9/<0#^WJ7JK,DV9<6R!9SRZN)2
M;L?#:\`7DW?&^*3R+D76;4*OM];K?"U0M4O`X0,7(N!.)]X:'>^8%OFG*+-&
M[17>6.,5I-G&(;2B32]%JE!$JFV=,[R12F]G%$.F+T)1?CR#X1E9H&[HPRO\
MYS%+_'*-/"%Z&>-V?GTRI;LX6D@,(NAW?GJAB1GCE"^R]-DOFORKR+;VF:XP
M`<E[Y^%HD!LQ&NB_I]/Y?#I=G['`)SGD';-`:.2)6?BH/2L%[3A$+$;]&_(6
MQ_^6_!U_`HR^3I^SC43?@J]C\^1N,#+'UE\#.A*3*[:=C,=[*V"'G@MQ'F_P
M7W"LA^WN,AY*,NK_5,K6L=(V+^[%TGHY*Y=`>ZU<B)[N?Q@B2(R2R#(:5@4K
MI1^.DJZ-S.-1TI'H-5?!J:^"0:<6:*C`%5`2C_<;'C\UCW=WXKP2:+@D23YH
MN/S47*XWDGPSC\LAA_KRR(R?6W_,@NP\["A<&Q(0FCR,X&`MHC43OIWSGYHB
M8%;B5&4R7R6/6LD7BMROT>ZO'[=1>]`O"0_?L&QSW_/&@:L0*Q-`VLP-)S8[
MTJ'+;6D7!+"\X];K&.6=M].3>(\9JU5SEA<,I50ETK6D2CKG3GN/W38)W*)Q
MKJI2)/\.JA72>LW;]N\<,QCE%[H1$6TD(H6[7,JLT#!H0C6`MP[\GP?RJ15G
M[\>XPOP+F56/]5]4`<A?1HD=BZA0ES=(YE5]S%O(T#C_;?;P%]X[F1(;^,\2
M8_*Z74J"3T"P>YS]YLU3]F5JTE3&C*BHB:Q\42L3;5_<Z?<'R\96-`#=RC:=
MV<X-]?F&,+%`/B/?RW\NH%-*%2A'8B`J_^1<(S%IYP`^;H[G\8XG,BB-UMK4
MF)8BS>OU^5B/=>?`RAA\5GK=4NZST8WR?)X.>OAW*S$Y;!,S_._/_LKY14P<
M2$S%OG5F<4)27%X`'ROI#=\`RR]M8/7?_O)?_XMOHGK<+TRF^7SFY<'1SW@-
M[X_@"YO_^N05__N/M_]Z\T=7OP$\W.#VG_Q&:@>%B1-WWDW@+G\I2#=!\DA#
MP:?WB@IG\E-:>P<`\ZKN(G;!SU;$71/\8\2)-2F@CDF(DB_BQ=$Q-31!CBVO
MK\3,^O.TFO\DZYB[&25=B63$EZ[IS2A[A!I+8._SJ"FXJ6W".@YUNW<]ZS]2
M""BUQE[TZY9(^@?P@-]O\+]B"$'FT%D$,USB*Y0DLLS&X?Q7)F#IA[4(Z?Z=
M8P:=?$@DXIDBA8ZN)/'F?IQF1STRLO-FU"W=FS-E3S-MI+=Z(T.N0==@,@-.
MI$`_>]II#_1XN><M2FE4>E_^&;IX[\GJ]L`SQ2`DNO&R"^)\WCS>#[U5M,W,
MT=F,NAZ%051!#6(:QR'ZVC-8SW^NI!O&H]:IR00OJ^73X$0'`4RK!+VCG1:V
M.T0D2M+0O[DSS>4O[QR`AWTS?[R.!GI?O2B5@E,5FT4CQBFI>Z`]1))TG!;:
M!0WJ-0E>!E"<?S1@(.;G!:\2-\#A^X\W6,O!)=^H/=@C#0]"(85D#,P?F0,.
M=BN2LNO&I@L-.UVC@#NL3T1C-!RW=T2"9"HSX-A`'#02E0LJQ0GX&^Q]I50A
M[,%(S_B]R+OA8)O5E51BWC)LJ60#C-X2+0?.IIY(O._V?D*^0]Z"^Q&;/N/7
MHBU$MST>_$0`1,7O7[&A2O)=3(P@!CE$P-'G(>H$>#JZ0WS)\\SAIO"_>\-M
MM/7N%M#[[7X)D`^Z/X&"LSMC^)>]O&L7<SQS9`QCEN#Y,H;S!'%.&O:H3HQE
M0[B04Q&Q[2*R'80O"70,:RZZB>SJK=N*,)'0D5"^Y5?=&C)6EXQZ)<EXW)BP
MD'^#P5H.[+$Q_TK>K#F4C0ESV-P*M!MY[>9EQG-G8F]<_]C8+2-%NU<.UI[U
M6Z/.F7+GGS>,<A9&.3;4SXS60!]5'KD[V.\8F75U$.)DZU3HBJU`<FMY"3G/
M!L-3Y/+NE*P-_8XO!7N]G3*PG@*OD"Y[VBU^8*8-3Y/E$@V)B;J45HI1JWDJ
M]H(C=Q%.@^]32Z$JU4?57Z/ZZ#HW,T:3)7C4U9U^O^$Q;/1%,\?GDR^J@_.J
M\OU^<F:W57&YJ*TF'8]]XKJ#*M6^78**]$^:Q1-E&%8(NU7E\;W@N*G47B]W
ML<I(JOY@9ZU-%255974MG#!T1]GVR99[CXW\:N37Y2Q6&?DUUBN$ETM0M+XP
M``4+.BC+"(>_L0DLRZ:A9^$TM@JANZH\WTBN"B]6&<FULTE$%057#?2NN#&Q
MB1F,6/Y0(4SG3FHZ3\[`>?IK]%OC?I4<)@U'E,@1QS[Y1JNSN[=7%67I`4K@
MU7"_T3:4?B-5S6/*`?KYS\D5*Y@-BUT?BQ6H&;R8JI2J%XWQD7%\G!1;8%62
MMQ*58LRA2<#8[^0.Y]MY%F_!@M,!K3G<CK`P/,"GE<#S,P8/T703\X<8WXMU
MXEOJ#?--0FCJFBZMKNEDY1ZO!4O&J`;>C/_!F93SUR2;OZIZ1=:BU*:IF+H(
M,C854Z?$/&\,0[/(>&<QG.^)K5;R,EI3Y'+^:JCN064K#6$OH7JI:^P,A)X=
MLR6)V,K&(%Z:,QXM_1_9%4-_H4VCP$0UPQ%G.=Q':M/=ZHS'>??;X/SDCOI.
M03=]3>31J?WX:SJ;.?TSM'Q+-HA;BMY^E>+":K+\?M%*(W?HOL'XQ>7&U%]-
M^<@"M=$TIGE-3<];W8`L>32]6860?>FQ\?W4G%YK/,@]):\A7ET3&_1.JV?L
M5Z1Z"8FH--A%`W!!/F5$>RHEI2[HKM4'K7$G=\%B@_0S2(5QOV#2>TT,J<IJ
M3.\9R*`FK[1VFM*S8L+L@)6JU;KFLEGAV*?]V3XB]AA<<PE:'!J;5=?>FO3`
M$ZD)60/FHK^JY.1I&/`B&;!*+'8!4R+7]E>35-3;C#S1]*P@7S,U9X>C%(,M
MJ9E!W7%[&(TO,A],RZ:$RL#%H7EP\6GS,`AYVW[Z0HS18#^6EAC$QD<J&9VN
MT=;^YCXRN-);6AA8MO6?:`100/.#UL&#_8IQ?+:UL+"'IABRL70#X"#+M#7W
MT6&>?V\M16#:UT"/`#Q\Q:EL\/;NR)!C$-]A6AB.%_P"0#@A8F?63/"K&C-C
M7G6&:9J5#*WS^9=)CM7U=D=R+)_SB'PUW59."5R5F!JX<40'+><@DWLT*W+]
MO`S4Q=\YI!WZOGRY1[7HY@28/UAMR/IN`?X=\XXF`>+\*=^:X=R1QWN&O1,U
M*]`L.!4X*L.VON.:`6R-YFQ1LKF/QT\DEFL82[5MR?_18LJL&Y%I_@@@TSLF
M$D@VX\@+[8`V)V&71W;+RRST;RX9G8MXJ-@=<^AH\\>SQ89"!Y`#ECOSD6*/
M]];T'E/:,8,^,\U^POCC44^XMO8A"XGX8G]Z#S^S:<(CR"+?M#=MQ[8XI2QD
M<*#ROZEE;S;H+3Y`#IY:VJ:#\\R`ZW$8R1T\C9M8F-_YU@`[G"D0MK;VDMK6
M`5(DE"FA"%)OD>0)E.4SQN>3(N<@U9E#4C8$;%##3>`N]L/R@1@>LVG4I!Q-
ME"+C5K[0)J9M\CH&-VKX@D_@E!<PR^1+3,`)\$_FJ<V>9'>(U&TD[*'JPM=7
MVK#7N=$[:DMJ?"F5B=Q.IV"+TQV,R1B_2Y["$6?:9Y?G97"#UXHQPGM8+SWF
M3SUKPE#=$,-4B2-`#V#^O6OSL7T+&A3(V=D,`G@@#.(Q27/+`=[!R]W')MCT
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M[!(DA0TP_>Z0:4`=\WUM+H:.X1,/)IRVT.=R1(6*G_R#)O$UQZH$15\2$I0B
ML!.!*5&A]<,)JEI\H+U)4]B)L28KI!T*5#'E-Q"Z%=>4)+'_#4JD/[/(_/,W
MGXK?VU_;Q`N@W08TV2_!D0:.RHVM5V!!N&V0V;.A(^"R;,ROO/YDUW3(CY_>
M<UM<F.);`==2D.^$+'D.\&38[A2`Q)<DT"7!Q*'%ZR"5QVKT7Z/7[O670<5/
M3OJ0E,WZ,Q=_Y**\!2%M+6FP(>KTW-)#0]-UP-)8H8CUJ>$U?;WE7MEU7Y&U
MIQ0BP[N%??QH@8'"[34'R*C!CQ>PH_N-M/_?G_/,45;G+;\"-L/`&#'G9_AK
MNMICWO+1!5M4L$<Z[F>P2X$V>-L`:A-;4!1A_&N2Q,_Q8<T8O7OT16^!?TA/
MN)G*^>JHOII"B)!"S=5?']0@,#XG#/1NADX\A]0'B]N[$1+;61RUC5.0HW#0
M]YL%PYW<O0587X/(M=TE:E*@"]RQNC"7W$,\6U;9B49;N48F>QT[@WR0=,!3
M?X:F!TR'1Q"(U4FJVPRQB.X9B<29@D0?D9@YNC[^ZU9]XH:>X!-,EM2[P<+F
MD2SV1Y&?!]9;2M&@JNK$]"C4X7PLT$<U0UW>FFLHG]._BWY#&P(='ST\=&*<
M9+\(C^L4RCX^.=H'<Z4-6ED((44>SQI<Z*;V-9S`<:!YQ+=W'N.F\[/4).,/
M;&;&7RN6_7.Z&C3\7L'82R3%UT?0N!WM6>HUB8=1(L!UQ:P'AAX`+5S>`)VP
M!8:YDC;\4Z/=3SINV0\V#55/51(\1-R$?&`$F\".&-%\.V-P;6JO;,O!!`+M
MO3G!H<&NM^)V%+EQ9XH3"]\O*2%!$K1%%V%$,V&N(Z%H8/$ZTWB,_*_`NV*V
MN.W"W>I%IEM"V!448NI-^KO//LW?^-P_ZU=6O/W.'>41H-<HRY";E\`79NS>
MC>\_%%KK+B]?7)+`9`N,%A"/*TZE9:R2<->Z#6H<?,^6XH)%AD8CY[8M.<]7
MW<@@%!;F=SAD$0/1M>W[X6+)A1.IF2:UN!&N8^1K/,`+?K5''XC5=F]):@8D
MH7`7(",9V#I?0Y"HFR&QX/?3H(4+PS,T1$K,_>;=;^!-OW#'-$%&_N>I]%/<
MN>X,-5[^@%QDAE/"YZ&MV2"3N/&W]/"4`ZIQ><08G<)6=N-S#B2-G@'AP,&\
MPR]2?0=0[JM#:5J`-1^=DK"LO6HIFQ8R"*"8R`@1N6"B4.?"1"=D.&."?9`-
MD)*).(403IG.>(0KJ\^0,/J$6X@,;,2`])V*@$<Z--N^]$/[@8=L8@IM.$9P
M37E35!'4N_K?X>R.1WC>D1T'1\D&4R[8;-"IW"F9@3>8XAYN5(&$#]H'-C!E
MA`\#-<@0EC<-%W#6XL93%`+"\\I?/E->O/.H2H==1C"2'WB42Z'-&0*UF@AT
MD%#V3`FX<F/2]#0,644.!E"E`':*8PK^0EEG85`+4/Z`(+0U#$5XV#T)3PI(
M@!!`!/R'=N"+97@44"I]&"&,R)5I4R3O3/4V_>RQA04(_$)J"H;V;N7!>>MZ
MK]UP$H"X$,$17[P"2/"!P;HSUW;O5ORNKNQ%+&'7XBW20;]-"`BY4TW^?/M]
M?0H_8\;A/\&R$;J\&%W"!2_OP2"*Z-M<XK(6SV*9QU*7WRTSB55I%T<.<7QC
M?"D)11F3SZ)KE<>,Q!7,W>]"UR4%4_X\Z1I/O_+!8H]L)LZ^;8-44=(0K,0N
MP?B006E3<T(*W&+('@Z@B_<NZ!UV.$L&ZO%/H5F[88!2"'_0UOX&$LCU2`,7
MR\H('FC^I!-;BTGH^5S"X)7C6:B!QZD6`;M#=SZH3D$D%:/#A[?E%(L9E+C$
M+LSCK>>"M`NDX;#95.`I'#,I=E7KRF-W(/T\U+DHFB]PRSVL`J43-&9088D-
M/@M%-@9N`%`+PW3`J;ST/>((KNQLI!5W=JO4<A&-J&^HP@\=T);/]3CN=MZ)
ME_BB$VPNV)!3(@Y34=1(M@81\9VV(E0P/0'HB2$J2?/H[,"U0%:Z>6=:CA\D
M`<N&*U..ER:MU2M`^.R_Q.'>NKB09+1!`?U:Q?:WQ"%%%O9C<7G/'#4C*K(>
MN"/&G4Y#U(U_T9[ISU&P^:'I8^X,P[0`R@>8TU%`"^!.BBQ,LVEISXSGPE7%
MXSV63VJ_S:28`;$(FHY'25SN!/8LS(%G7?&@B2<'K+II%"B:`DK<!29]P9&U
M?G`GDDS]09[GZOZSWO.TG$@&#M"4(K]#AM<KC2X**/CHAP%Q@%J:\-"0F`F7
M":^-4#.%LRLV2:88ES-3:)>>'LN//$&9`+U5PG`;$_$R(^Z)*)GK8"0Q`"PL
MD&KJA6G'KJ!UCUK\U_NUG_F\YRH1%E##?428R"'BZ3-5TF\+<*]O!$Q@QK2/
M8.MIW42[I=?JZS_%KX>5M]Q;UW#0(^'W7K@UA1!,*ZP7CH9-86+N["5C7CI,
M>38ULA.&BQ>8VHE^:V9+D\]'-PSY+)T;C\U#9T::;>2MG3-*A92G7U&ZZ!Z?
MWEM`@LAY:F+M%BI)L33A7A//7?$LJ;;VEK%UA<P/)ZA!4MHBZMB6_QVE,5J<
M>,&+4;_J2X6Z(J*ABNBA]%,AB!5'KP\B"G4O:\JU)]3EZ*23Y:FA@P:^C%7P
M"(5M[9\HS-*Y]2K$BAM%`5J1^3)%/7F3M"*8N824FW$?F"<5[>AE0ND6NTF\
MFI.<&$4@"OU:/"$8]6CE+92[#%1K:[\30/@NY;D%Z4H[X5+VD&#`V`+)@#RR
M,$B?IT[+,UJ;B&5Z,5<%U#9AV\O:4;*%R@,84$<7BX5WCL/?;?E1(8'D6>XP
M!$0BSRM.-87)1=@"[UZX*K(9`",U9?"`%:BWL,2\Z2>L/SR&4<YSR*Y"VG])
M1'<B"<)9R/)F-RAN5D*+`G**6!<0FDWO'53X+2$H8F^YPBZ8$TK.)J(322'A
M)@LP>XY\5SY79(@2T?I3H"`ES:,7%MZI9&;S5#MA`&W3R[1O+CGGUFMV,(2H
MQ,U68N%8([D*VH,1OB.\F1$<E/J7&@;F%%DLT%^;2(-_,T?7HZD]<]'7,+?#
MI841//:<7C.W)@`;(/[.,A554;OU4UG[<DT_BK6FG0;Y0Z#\ZMH1`D6?#_"4
M?(7J#D*A(0.^D03GB&QKGT.T;;@IOTF#E@]'=Y\(`4_?,P#_;ZZ_M$`R)S>X
M-*V9IO=_DM`F-B2A?/:T.^RW.IW.\Q8W("A,RH(@Y1>(M.X(;73V.09>)MU=
MZ&''%&Z\U0-;.(*$XP9#)QGF#*`[A>RYQ=TU9.1]?'T;RP%*%GP+GR"%4SRR
MQB+$9D_U3O+E<`:^,_*6T[7[8-I\!RFV32:B1X$!99_J%@5FR.FHR,2Y-B02
MX,>11$R#S<$0X2JZ:4$T!9(5$QN:XF4/OYRL9)M&3%/#D(!M6@M?C3;2YO]N
M`K#MI)&9VF=RBX*F/#.-(G_D%I*A`?4,3UTL:Y$P9Y[F701:YW\NW@739AV&
M(H<`,T7X1<^)!"P'PMR>"[>PW%1,KPP1X6?;QOS)#&XFQ$V23KM=YK=0*]"D
M]<B`C["-,5&/7'G<P\!3$9-6P57</+&-&3L#KM[,1"<5O,U*:E"2VQ+!;P_]
M'E2MD&V'!:C74S(#N?';VDOA,D^]100)9CS-.E;W*(B0"$F`)+&FY*8!ON7_
ML,"&6?-HR\ME8\`F45X8/&(ZELQ[0+^^T.^2*05TLI:!4%+)FN807L5A45D$
M$]+1RX!H$E=0[.:G7`.1$A&7?<48IQ(2)7XB"UBX]P#T@]"C]TPCF:D$D7P*
MVD@U/*ZYE*LG9;7MNM^YM>AC-2C>&S+,A3];P&63".MC`DA4R$(&)#YUEX!>
MLHMB7T9A#\$RXN,D8RL;`YO0PLS^V/@'0]>+T[%;/`GF$;,.OCONHR--1/0V
MHF4AH%*"-GQ)KG,HI*"*N-1F9CM?(XGF2\B$62]\2I8\J=)$3]ZE/)#/.R%R
MW@".B`PGX4NBWZ0Y!Y=E)AXK8?DK7M.;@WVE<7AI9R1(YA]_L?SO_JTSBZHD
M\4*O3=0(@2>>3(!_K0EZ0B;\?XD,79YF,F%J=4TB)S?"8:CB4+F1HNR:5OQ>
M49^F.![C]]"IB9*^R/D)##Q!QQY&NN>F98.6Q@_RG>U.T#L&'.8NK*DVA9];
M/KD.IF;HD_05_@[8]-T]O%44I)+R##<SJ';<,@%\P"D#<6.CLBU\*'^&%OQB
MU8I:'D2ZOB=SUF9L;L*I)]`GIO/="Y?!=-42*60!UNAJ#RXF"G$/B".6;5&*
MG4ARX]$M4:`GX*$=^BS.>^+N:W2)4'"'/'E4J819CSX)D:DI]/%)*$PIRG&$
MWZ%\1F\T%UWXE(RNH3"%?\*!GX'<YZ2DEYD8#N1]'3#3=VK*HD@;5'^A*T=D
MP1OJ@7+PUM)[\\B(1(6,Z=_#S_$_;P!%8"GBM587H8)@$YKH#V4#UQJ0CA`R
MQ3]8C!`A(QC_`G]Q#T>4.!O/G>;?NUYP0UESE@,F82!-/3!`7<\"F"@I%/C0
MDF8_EMDSH2.@P]I&I3JSMB8/C\E+[@,=2#3ZOK*I6.UOS)Y]<S_PU5??/!-E
MW:UL$/36];Z:ZL_YFVO#PXD:?T1LC`(MWA0J78@'%!82$RU-X()+P`@C)'80
M)U=^N\9ZGB];B7@NZ)"4.;J&=HM.2<S[EL.SCF2&-GK\%7($40B+`I"A!WJW
MS\15RWA*-/.Y81;E48B:M8`KEJ+E"1P^AIT>X?=M[34NJ:[CQ;!R:_)><($X
MC:LX4J!Z\_G-CG7R#[S.7KBD9=8&O(!:9(B2)[F<\MYU6)"M9(.<C*)2RLW`
M;\1RV!$HO9H"]OK.S`0#HS[>CG@^>BR%&]7.9A9EO"BR#,62Z]R)?W`L);#>
MBJ.#,OX2QI)NQ?.8"6^>2+CCX;X%!CG1%8$NPK9Z9%5D4E$#WMQ8V<WQ3]2+
M:GWX=<^)%7I+EY>O^(S;HO#Q8CVK>1UO`9<""=0(D-7\T;BVH,4%.Y;U\OY+
M&KG"1;6VSYLOJ/$J6!R5.5_P!'5%B;>\?CJH'&T[UR)W1*"W<G%#*]H6-UKC
M77%@$IM#I&W98.2+"<P?TJ<3Q^`3!Y:70"R6'KO'+(>'J+L#/^MQ78H/EC=#
M/@=%3[%"!7[:6E;O/"6]*%FLD3S0U+UCE@?W%U\J\3I7`[5T@Q1DOY1T7VP^
MM#Q_=#L#B^XF/J][(![QL%]8@.?=F8GV)]A4F&X9:<&04/9S3-..+V_MER+H
M/49?G@UT%LCCP(C1B,/.*4=<$Q2Y!ES3+S-'$4C,/8$S]NB9RU^?\/]F;3UN
M<QJ_2X`4]6_599^)FT>&=C#"8<_V?OT>XX@S5U<F%&=!LG:`3KM?T=(U2<\]
MNW7O)K4<-CHTQ"#/SU)_P^LWTQ;:B([T2-#=%%4ALME<F7TJWO$TUZ/)N:E&
M7SS\K-?J#CO[+_Y\/\KD&$"1XPA2,0Q7KJ*[=\GS[U%'VT:/?9&_#]64#LS]
M85E+G?8(<+;'6!B;R2!2/L8_$Z)[+6/</3&N2V%J+4M@TK/O,2H!;(W*[1Z2
M9^-[2[Y5"E%OSQ$51A&)57SC)[Y>T@`:[;X$\6UDA>6FJ_+TO@2@5V0VDX^)
MN_G6*?A*A:PW!U`US[85NL9]X+DK_%B>Q&0A+R_C_VR;3G#KS-[(2OZZ>!\_
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MM,-W]`ECVTR1CA13#SUL%^/MG.JWA0/RDWGCPP=MK'O3S\J#I9K*JA)#215E
MB<N[GB088I_X2B/\@^F$F+7'?="7@/.J8_Q]IGXC,WE0YNP<B%=A[.-T5-[R
M9$TK0]U.J(.DXQ4@T,:16/54RU]+/=NB*B5J`I(UCF?0Q4H?41+3Z]$_BI7&
M)X-PHOY2="[#N./,\C%(B^&>EJ@)$;8`)G!1CRJFV`74?X:BL`LWJBGB*:>B
MWXCVA2U-2Z2"42(S<WB]K-+`A/I^\5V;E,E#G2.N(L];!/O6IXQ%78:R.^D1
MW;&[C>5%2DIZD(T<*4!C;WC(CS_!HME?[@0T1]!T,=>ZC35XIN@)QHTT,@P1
MCK72.V$L.BH,-`1M?8Q3;XB,VM9R-*/09==6`C;5L94W,J,>@&(Z&>8_)CJU
MB2Y`2LJT!)E'/2G_5+0J53K%46=V)$/4F-`4IT)T'>6%Q**.9T,/G7R.$M6Y
M\BY"W2?O-1T\T_XT?^\Z=^^QI(@,DMJD*B+8-P2W=AM/<;WBW"Q^<'Q*NZ(<
M'5O4B9&P31U?3'$B7T8>)M_,OW$%?L3`,LU7U+-)'M;>S46'"D?T:8B67%^1
M>OGXJ0Z:"O16#!2F=U.V=,;!@NOI!T9C4JXAD?T;.M3]):2NGY3%.:?L`=5;
ME!1#5*<GAA?QO*R4+)*5&!PKDY62W+5^Y&.7%(>24R[.*<H\]OL<854$_%7T
M4P6)\<X!;-]A=R_^E/RJXHT0)9C7>-SEWJ-;(O*0\DPN*@5BOFQCJU[7:A=@
M9,/0L0)>+0!/.B%O0$P%6NEQ5]CY7-[L4EK@^8Q:<)-G=N/-=J?"+-4!N/K3
ML(B>@7&C6I_=18H'/T=X7CT6J$/&+&JQS!7#QT2.F\1'W.LOTG`F*Z4S:K(4
M'1/#L#8W"5QK2PE2B^;K$7R)K6*JTYV3T"HODREQBM5'MZUU^YV6VHX^EB]^
MHBE6Q,1(H4\!M8-6Q]!%C7I-+7AT;X";EU&S&RKYQOE6$:I3?![5F"4)R(D\
M![L`S4IX(;YD[5)$C_URR8,"L1P6#77X$]2-/^O=8LH!OKR%)T9T47085K>8
MR";BXO#3-T>^5457HVED/&'BI3)M3!G^D@;O-CGP$7\2H4^!@R\EL!^U0%;+
M<Z6V&[\KN106G!/71Y/]LF%%\VN=1NF'(Q@W_EPQ01*[2_;\WL@.:\\JSR%G
MI`D=EY.A'N%97&92DV<N5!0-BI=7;FR*?OE"(6/@;TLTQ7=$(]DHJU@*7Y$?
M2B=ARP@('*&:W;</)[V"D'=#WU:,QH185OM@1Y?1D=KWQ6I;;K4+=#5%6WL-
M"'V@";#^%\F*G^;QI[>\;JU*RMHAP[W6=+UXI]K[6'YLU/SJ.$CO`F8!?J(I
MW)$OJ`5_1V13Q3XU=J!B=-G_9H[MM52Q*PMY8L$K:M.9,Q-E"-2D)9KAC2U5
MQ=\RHAZ_;<+P#6I';ME_'OO,Q.<YJT=R\@Z)=T0="F*B)?M+)Q^:>XS)9MHJ
M3K!'DA=RK[MLVB@'4_"Z#2I^I?>HJ0\O,?IZ\W5Z[U)3H*7HH6UAX%Q;N#-F
M[Q[TEE>BJ#;C&U&K\IEY7[$@HRX>HH]@6O/!=MHS3`RDKL`:;6&[\7BYWE]$
MB:BU>69'**$R&]GT.!3*S`SX@#C767M&N#IY<CJZF$2GB;C=/'9V<D7]CI]L
M*O_:LL,@KA<_#QBI-OCQI`[U";7<MXV#%N2W\>?RU6(J56#=S'![<)!:*,NR
MXR(9BI$I)`%W1EN\)26?.,0$.N(F=3.!07(Y18CC.FV\=SG7AMO!8NR-4AL7
M9>?++>,T'-G3C>8:_!`E7%&010'$EQW*(B`2F)OO=KT;?)5>J]?OMH:]`0&J
MMP9=H]7OK!5O470RAS^?O]1HC8?C5D?GH:MNR^B/6_IHD`I&9<G'';(NV7#>
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MH>`-;$([HUE.V<T><H@952IA-OP_4'/\-'\KO:3O8H6SXG*)<OG_(17H:`.:
MLH-K%DZJI10/$R2E!F=\8SL?:IFI_"P1D5*"TA,YAH;;8E@A'\?PL">8.)8T
M&QBG=)F1+4=]@$PQ"\=.C`^.VJ>)^G'>1MY:FER%XEI.8BB?Y:MI!%R"4+_!
MM6&&&:\4>PFY]2=-(74;$<QM+:X3D:Y8D?CD\89(8F82=6&Y`8/5T^[A?_#H
MK93BXE^*$?T,:=NI*LI./1*U!;C=;46?NY[9G#CFKQ83UTZ\>M3=*[LZ7?`Z
M[NU>/5?:&D;B=&!CT+#]7[3_%U*5`$V4@?LZ=*3CY'F,&8I>D$L>/9#"UZ[P
M/.]DQIM;18VYBJ1!;\QZV\WJ-YVVD<7L_+_\'#1LW[`]L;T1L?T[^J]HD(EB
MW]'^3)P$M:^(/#-15QAW@LHB[^+!.]?,++CD`IN:HV"XFO_K!:IIS3EHSD'%
MSD$W.@>_.PHO\P^3S:(\,0\E"&SR@CNNU(_`DC#E-$(9S$U&A:D'_8JW;26#
M@@^V?W36(Y3'.!_U5+_?H4Z+,4J3>AV9RHQF&E)B_8D#BWRN3<L<,57/Y8++
MCZB)]F@TQ2ENVYD*(\0J**\BG*"?<^(^"'<?-OWT91X/UKLKZ:NT4+ICV](V
MDY8I,D,24D4YEC&5"(JK2)'^MI[AN'6\@-)D0$U,BBQ6-85BNJF?9"L>Y1F/
M!Y47(3E^,(N+=#SEITMS%24[P8<>!HR2$\7CU&B5QB(;.Y!SB<@ARC<2S815
M.C/%#:.5;5T%+^SN_[EP';:2PC<>4XO5!R'YF7#F`I]8,FH/HK$B5%/1;\=S
M1DSZ3>Z(0;JWF5"!Q.&58<.D69'I7\KE,)+-1+^BG^\E&NF?N6OP-IY_59O,
M<=K$#>U"$]O0U'U<96:IG*O5XE-.7#%2177LQM[@6)[1]S(6?2="V'$P&[@T
M`,4=%7C^2_X38FK^`0JHJ+2'^ESX24;FB:4@N=3@NNC/_XA>+[4Q(+V>]Y@,
M5DO4/$&LR:EZR?AY(G#>2LVTBW+%XW@:7RP^:7AUBXH3=!5/15(#-IEI:U\W
M^L/Y6\0@'O@]SF5ABZ7MKIAH"+H^?R/9EC.0QLUZQ@'O/9I^W-WXTW7BIMH<
M+%Q:VIQ9RG0TGL]/C0]$="+E9L]BFD3/!YZ)L3WB`5#+YN=TN\UP(`1V?R!O
MAOR5;(8.&BM6I)N<T^`_4L=1D\-F#!XBMA5T=DRJ!$AC3H0:9FO-P(N(OT3A
M#<6MOYD_ZB(B1=H$0+QKHL#E7OUJ-#"ZU\GGQI$3('*R9@\JKOF[T.)?..XC
M$'L6-;]\>_OUI8:9T]]<$%/:L)?,G=Y!B$2^=,+4RY@Z%C6>Q?``\V@ZI_DC
MF9GE1'5""3F8-4>'1$FDYL9G;4UCEN,0<+$)31_8F!'<$C*:.2:7H_`(GU&`
M-0<\.4.<=%YVF@:.LC44*8P#@CR?NC^++<=$@YTX;&X%VC,A1)Y':6%QID-4
MF.10`Q<%;[&?=1,ZL;@AM@[C^2>J!*06TWPR%\E8V_J.-PEYO#!63%3T$6),
M1(8;.0L&2FJ-:JUX7]ZKT,K?.5J<>+??<0/9VHH;Q2;*%N(3E\@&?H?=K(5Q
M!-]B0I#+,^'5TQ@?4GDBHT64[^+R$ZHHP/[)ONA*S1F8&W/$998_M;&/=32B
MA%B`MR*7L\II2C!=MU&Y7)S.*/CZP?0P,UJ;LUETJ]+QU<PP`,M/U!'<NTK)
MC!GBC!%5FLCNV5AU@X%\'("DCCBA`4X+\[M(K?*9V%V<1R`WO@#PX,D`"\(=
MTU[]AXD98S_X@3)Y+5[D(_DWV*+^S)IR]Q0?A91!>E`GN:.$UQ9',X`HL.=3
MWP,RSA0OAQF`DCH)E7%660).?5?Z#2C9$F01LYE<+R&6)G)FD^6(WWL,-!`G
M68/$A41R:C#59*&K)TH(P=I(D)<VEY\65F"N*)$,7YM2CP@R5&I\`.V`MMDS
M:Q85)WM\IJUZC2#V-G!I=C'C!K5(59T^LL?;B,J?/==Q0Y%;4;.Q%%_8E`S-
MF&63N[E&J_-;HO8^,Z6!]"W@?3C6,O-0&$\T^QUQBG)J!B:H;$.05@9HC((9
M%>U0W0=F>R9F/"0\>O'QEPS<2A@26+H<%0QGLG91MDW6?22[*L;M$X_'Y7!>
MZ?^B_I#V024!5]M2?K_ZC:U9(B63)F?!R3Z=Z!>^>[.:!]9-,+%Q-B,(`GW4
MXY_+7J1P82E[XO^'L46DXZ]/X)=<LZ#EGXC%HFACP>AC!(_EN8^PJ@(AE8+2
MIROF9X<DQ<M_$1`^B':(O!=>9F>['*1>W^D):;HAOIG9?EY^B)UD.0JBCSS>
MDS[Q6>`N]T#447`1W;Q)I.PN$]NS!Z+XGB-JP6;86=UQ'19]0[C)^D(@,O'5
M#J[;,7-`(C:[=6=6QZWCTB![!L+>I&@X-0,]&SK)I82?OC7O`L<V:''W;J5O
M]PY^I.=_?0+/GU<"YAPW49#?XD$.AR!'_^GXK'30!5";;3X]8'<XSN.0[<'S
M62*61$RFA!5-VX^""&4DR:72^GG9$M#(EH`J%L1TBNTX.*N<*S#*I:B:<P@>
MJB?3FNU41%2)<3[72+Y\<JF[6R[EE,[GU<#R3CXZ@!/VP$-5>*'94"6E4SP#
MZSJIF$]$];9ZR/8RQS<+^"T6^ED%7('98B=T:QR,QZIP8BD.MW5DE.^#:Y!7
M$O+.*OB-O:SGYJ3FOC/Z2K0%`,\7;$F-JML'M>G+N*K726ILX8&,>')\5849
M=\Y4--2ABOFD7X22^ET>>WE(#\+<7_[K'+@[Z]UQTYS8LJX/=<9H[NP768T4
MC8#C@]]PW-NG.>^J^@U?6YMTF69,YCYC,O/EVE0KK69F/:2"\XJLN/J4F_V-
M%V5F9YDW#[PCBGG!NVN1<['?7-'<D</>3_FP56UDG<G&5F:C'HU-A]7&O%W>
M_-:C9,1L0?&QM:FBDV!S*YV[-G-NGB@C?;'B>RPV#/<HF0YGY.Q\8W4OA=;7
MP,_;)@L?)1Y^1N[-/:/X4HA[#0Q\+/;M[>/W/HM,WF<.]*50_QHX_*!1V`6]
M=^+?,^N!^_(*N>>B[D+3>S8+;?B5'&WY5\\-E_X[V6Y&'<@4SV-Z:=I8^?OU
MGC&<A'LK*L--^S4OG49.WM<?*#9T("6^2;=:U$=LPP`KJEW$"F9&4TGE"`AL
M8H...#%BD?O(E)KUV^C=&]ZK5J@+EQI66U+='=YIK]3^*0*?&B'4SYQCT=HX
MR"(NN(NZV46^.\1B1A$=KYR+2U\3?"@(L,VS=Y/=5_F`%ILGD2W<W9<M(X2?
M8-2O4O-.[N](WF-'1E>!*#PMQF?!(*CV[.BTW,\YE"'^LV"/*[T&9>Q#/:HU
M1O,&%:SAU$IPJE%.8HYN7`1Z*PU<96FOUQB]&Z13'+O'2]SUE`C^B0373OTP
MHWE!$NMG8=+,?(Y2&2X_3)>[V)5C._>A%3F;>8YL%DHQ&ABG[&Q)(!WC1S+\
MO]Y>OL0$DQ9VMSM(WL;5I-6_QC@!RH4X(]WN<$#YX<MFE6BL0SGP9V2R[18.
M6SCYW/Q02:`NF4E+YD<CHQ:KA@QY'$4P_]8S<TO')66Z?7.#:-S4ON>2`UBA
MXT@`1<G.:Q@^_S'<#*#0U:IU&YR3P%6"I6&V4XCZTU-X8Q+[2>-8!P;.>/_5
MK[+#;=FQLRA:4T(OU0.#;WZXP%'(_]D\'8#F9E%B^^V,`0*T5[;ET&!%)7=)
MG4#N;YQKGAD:H\C>[H:26V-AA7/<SX+O0N&O9+QKW"TIWB50(*MJ""U-#*R2
M%D\3`VMB8!?$J4T,K#;`59;V30PLO^NC9$>YJNPQU"<*>,C/[6>LC!_Q^'Y"
M7>]7!2O%Z73N]:^)3UKZ8%P5O)PS(GE21JL&5Y__<)7G+*L=.JYQSPT+G$\/
M+&-KPC%*Z?"^J(1YPP=IU2!!JF'X<Z/C&O?<L,#94\G*C>[_=>/,Y8;]3\W^
MO<&@)G@X.](OCO;][OYV:R5E7LFI3N5*/53X-'<>;UJS8T>@G`O?'()3'P)=
MS^C26TD\G!WI%T?[\7!_%V\E!>`IZP?*0,"[Q=*T/,J4L47K^SO7G>'0^;R$
MR8*V^K&^,QZEXAG89<!9<A5`=4+-U2?BU?&:/AS5E]O.G==_1&G/L_K=R`4Z
MC5R@3+A`FX-8`3!+-#"'^SL7SGX0&VZK&;?IK<$X=TI;]?CMI$I^*7E,J+'3
M)+Y-':$:@_;$!NVSWB!W8M]1$)$Q4;>A^9%IWC^@S.D$-*]LQY+&\]9$71L6
M:%C@0M6S3\$]\S1>?]FD%C7LW;!`PP)G4-0.\CQVVKI!=;4EH.&OIN6HLY4W
MUV#GI=:Y/0:-7R@7G(/A<._S=W:O4,-M->.V&@<ZSYMF4%Z#%:[S:L\PI>#Y
M01[*36>O:?=3'H`EMOO12PPW-=VE&G8[HN/UB/Q6Q!];4ENIO;H\86<I.8\Y
M7O=V.H6K)O`_N@'SW[NFX\/;WEJ.Z6!/G2]LRJR'XPY>WK^C$?54DAO`N<H"
M5BW9@(D0'_=?VMARJ6P(DV=_1Y^D85ES0;+[)!TV`GA?S4.B,G-Z:0H_A[7#
MV'N!(_0URH)EK5'12;=[0'^AAJRR$4P6+%%7GS-M\X+PJ%?F6!S!`Q?=*>G>
M-AFWUQ8\I)M7Y*'@SA883PLY:M?:>0Q&VT[`[@8<>?90R7V/C[7O\Y<?T*,O
MS9DV8Y-`,[&])8V/N]&FP,B@>GI[.<[*%CB*\5/VJQ6SY5E1#M^(@.?7A#5C
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M(LG:N($:-]`1W$`?3"><F],@]+#94G2IU,SC88R+A6TOQ=/3ZQ0S[JKGZTD$
M9EZYBV4(1Y@'MN9S:\JVLN09_27=0B'12KM^]'XA&ZB"0FVCV:U,4<LCVB[.
M>]'M-KZ?`[!W><Z?2@NBWN!RA.I@7.I>*N-(?\]\7S.GTW`1VF;`,%*X]-C4
MHA*?*Q(.SXQ>DU]9'&O=X=&PUOC1S^='-P[3,Z[<B]X]"?IVNM%W.\31?8X%
MH+?3J1>RF9Q)=W#69(E5E0B79EOFQ+*MP&)KJ9"-=_P429%'N4=R>K]QF9*]
MW?LI9PU9TA/I2_)67R)>RO`^5\:&V%8X2`+Z@3DSUX.+;(7W2]TR"X^57U?M
M76_CT*IZFC>:#^AI!MWEVJS6P\J@KML=:(R.CKP*N,ZOUXAM2@0/\0"<(HUN
M:U.BK3:I-%R_WIL>>VGZ;*9>`+>>9SIWU)3HY2K^R6>NG=P^FM[LTY):&(%5
M_$\3?QWX_V!^P&9H)L.*4_CSFXL??0H#/P!3$W9'WS%O:OD$2Q5+"[_=,PTQ
M83HK[=[T-7.YM"W0S^:FY6D/IATR]/5BK25F!\Q!93-M6_,11=H$<215.,U$
M+/F:;V'%/?X/(:RMX0K*V]RYQLSIO>;2UQJ\\)'C4[O#_X476KX&:+06Y%QV
MT79GV@S^@8_2;[301V#P\Y?(H#=?I_>N#3L5[UQZ%AK/VL*=,9L#D/R=Z?OA
M@M,3WH5+\E56S/1@<6<&'ZD&I(;$H)`TZND:[AU0-7>QP8#_2]I[L)U>]*$%
M2SB1]7_LCDT$PJ]/N#GR)*5ACLKR:QS-<7%!QEZ7UOX7L%F\/K%;_$_)=_$G
M61Z,`QP.M4?G.?P(Y8*^;D@=;_J)N(`82<6L)CU[F9=BCUR?T-N#L7:C/37:
MO:PDK,,7Z+1[8@%CG>JG;3N3]F?(NU^;60\6"/79,5T9DK/D>PSQHLY/U5CT
MQ#'J)`$>7!MT.=L*5L?@0;TS^@E84`?"'^7UPSZ]?C0Z`*NE%5U^L?SOVIRA
M&@<0@C*F>:!_E;WOK%393KL[)$2TQQF8.,*">KO;P06[[?XAJ#\&0]O6G'1>
MKM4>@^OZB.D.5WN/]?[AAM>?GJLCQ((5,V=6@*UFC['K3&E\C+=N;]%;%4,W
MN_-.-GA?`WA``C`-X$H-5F>,+6M9%AP/+_)L>5RM1::CM*&E$6NT.L-^J]/I
MB./K:X&KL<72=E=,].V!G?BA'2"&P?1^P/>9#AK@GON#K-^4V?RTU^YK"\NV
MT<;EMG>X%/9Q#CLXYCXMAE[/AK[?'P+L1HFP#SICPL8><&?:M(*V^4D9!3,Z
M6^W=XX7?"]>_[%LPD^?J2\<?2X:DQJ`KC%56!=/ZN[+LQ9T;_2>]@<V.#75=
MB7=($L;5(*G>H%?W<-X"FYEWVYH@-V>S.9LU9O!3W3[5Q<`7MC`M!]3`ZT7!
M[=V=Q^ZR?4'E@=T(B]KSB;@-HR5E%.)ZCP[Z*CPLL]^:47/A2,"6DY;C6]/+
MD1^;$929_U7F`GL$)7=22#C?*K;36J+R\X:`:X/(@HA\;\T;/):`QW^@-_;T
M^RPFCK7-P;5<"=X\D5"Z>WLC$:U^:=HT"H;#.3)T_<5:BM>V3BK;E]DSM?^0
M'&8E.7]+<\/NN-49%ZDL6=O7(3">$FG;LEISX$IO=XLD%-4`3?M/9"W*?F6,
M5BT8SJ&G!^VQ&EW>>V+N99(Q[X$XH/=GJV.,,*IW6HP??)_PC(*U3+F_\N!G
MQF;V<@J4TT5$1&++7?/`_10K(Q/BU2C42N?H>SB$)L=:]N*V=!S-#_^6_J2*
MG=9G1K?5+=9RBY[+Z@!S^D/::?>;<097MZ5C7*?;\O#IAV]Y"M[6<-*EE8\^
M&W=;PWX198G*%O)+C',BKG!1X6Y\@3C:5E-8`%DGJ%8^TVEOD%`:$L[AILKM
MFBKNPCDGU8S6>#AN[>50*]W^/A0/>QD[W5ZM=GY<5]'YW$,=O13W4!TI<_H.
M"64A[ZK<.U&90*6,E#UDGM$V"K4'ND)#ZP*W='T.GNZPUQKUB[-Z53P\6S63
MAJ4O<DN-A^=D+<&-?JNG;_/_-BZ>I-;0W>9QKI9WXXC\MG.C]?8+G0*:"J"K
MTAXD(_&M&]=N5]%Z/;)?H=?J];NM86];2+KQ!>S*_F@/M_7#O"#\5=S+U>LV
M7JYR.;O5[>R9UU1IW?R@&X/%_3VJR`E'/J-&:S366Z-A$6VU.5=K-\:@7A&A
MJG+C83=&OSULXB)EWQ@`;UUNC(T^U^ORBC5;:K9T\>[8K4*&(J*\M7:R6Y=L
M^R7;@:EZ8,'.N^=/1CG@/FIN.-5E,ABVQJ-Z);8TW'09B#B;9U5VO=%,WM%"
M#"!(R\Q&0%Z]@#3:^K9YS]7#7\-(EX&(VJN3]<IMKBF35TQ:BG;`M4)APTN7
M@8B:*9.->+P^\:BW.T5*W\Z/OX:1+@,1&T=*E#?!(3$/XL`A%2<?P5C"M$6I
M#2LI6#1200FP:V:0-7^PR-C!TTX8%"OGG+%0@9F"6T7T(1/^=#VS/9ILJQCA
M\=->"7B;YMCMW7FN]/V/\VW_S99LDD/:=V:(TFW3G[;CJ-36P$HOOA-`<DK0
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M_C0_.'9FM`P=_L^XG+;&1C4:J2L0#=MZ?Z,D/".F]!:.-^_OT8V[NK37J\#(
M:AH72-%#)5%I&N+&'B4HF$A`#;:KBI5M#[-G=YWAN*47Z^B^&8?[6S4U1F"O
M75`[J@OZ$GOLC7<JLI=&V.9D_.6_FK-QR-DXL:*]ACTE+RWRA!2\WBZE&T*>
M;DZ[V;$H-BXNX[2@+Z9F^$LHK8F.294`KU*-;&I/[#,WLJD]_M3Y<\EF,1NO
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M^UQBQTU_Y1P,Q4?7V0!(Q5IL\G0\3.*S?,W4_'`!+UUA*_H`OL7-F\Z*L\O(
MT(<OX)6N<_-`>P,P$&Z9$9C5B;-2:7[$J+\^X=K1DY278]2O?-)?EG\]X_C6
M./`N("DS1;!P"N".)*$\B5>E;>.0L/H%(?]WAPN<$T%=00S0P)"+8[7ZY0=G
M4X<Z>2O)T7O%JTO=^*5@]K49*$'NMZ;EQ?_Z!XZ`.#T.CNO&$=K(4,:)/T;:
ME@*25,=T!4ZI>L6?@`X6_V/'=(Q*AOHZ,F!D]%J]3C'78=T#?7+OG?;H6!VO
MCA%LB^ZJS,MZ?ZP>PD_"A=$9]G?,4:I;BQ.C4-[%>>0:_LTMX9]ETE+%..,9
M5GEVNX5.&3WXO%K[`$EQ'G[8(Q:_,33SUO7FS$)N>64Z:#=O5?HO+4#V3.\-
M6D:GF,#?B(0L_KQ4S.GMX?$CL\?5_+:X:V,E,#'Q;,W;5H#@EQ*:T%O]@=X:
M#0ZC?L5=ZR<8R%LLA7.__9_R1MDV2]"392S:DGF6.P.CT-/P?!6K9KZ4(X3O
M0;-8]27E=[H;F$<0QWKP8?G2?(&?,X5;$K/5,B:UJ:NHD]K0Z\"A\_UPP3\[
M.)"C4N;?(3#B?'5P-`2C.V8,HQ;"IK3)2HWK4$\&'O*Q_@/?6@Y]&\>$B$Q*
M#&<WT"<*ZQ#O9_1N&)VT=4,I>D"F#V(TA'V(M]!1YK^5)I2V3)5[;')D9+PC
M4YKD]RIDO/%IKA>M.S@R7F4D<^H/`FOC1H4H*N$6V@5?%@6Y=-)FUH,%IV3F
M;]QN2:0[^#6"<.OO*4*I]:=_VH\J>YRI0G1Y<&T0[[85K.I+&%T_"VF.<F"^
M6/YW;>XQ!K=3P#RXTC4/@P*U)4XGV9;Z8@Z.;<T9YHV`PI0*5M:,0'OKPUGW
MV7;5N,1-*EP0:]='5S(WZ6:-9MMHMHUFF[B3DU,T&LVVRE=`H]E6E##ZL,@A
M:C3;$VNV0_T2#TZCV6:\JW]>S58I&"C5>9OM%GX-6'B`!Q_8>\N<H`RUF'\;
M8#X:9:%5*Y-?J(]2^_5)]<7PQL)$=IX#U-H#@BW3_`5C`Z-'F\OLX8L@6[C>
M,]*GW=`WX9I_SM5H*R+2!H7ZC+IS6;G]`N@;Y&'<R!!W<BZ%.H'4FT[;(+3*
M*)4$D3ZEIU^:-N949%%V7=_95WH55IOI@9N""U1``2Z`?4TQ?7A$,G7>-BMD
M>;+Y\IL2!UPFZ;Q$O=4;&T<`XI17?M$#].H>PY'H2TB*T+3X7"?G0:=I+X)Q
M[U.O`(FJ<K`RT[:+DNH+F]JF[UMS@`)O>2UP-?PQ_FW:\*`U@]=I4W-I!::]
M$4G%LH22SY:8)+7_BQ/)9:UAMXCUE"NQ[+AG-COEHC`W;+GY-ALL1=,]<A"I
M:(;/0:_<[WHMG-I32$,OID='Q;C1\^+BO)W"*T#.5C+OXE8MHI57@RD@IE0C
MU4\M_XW&E,:`I6=9HS.<69X?&E3#FS5BHU'&MRCC.<11W@JA_7Z>P8P'U=\>
M!,4A!5([]W.LRMMRMY!YGY7/)5MTC(/*U/;7%@Z@TL<P67SFSN._A=3>'`\X
M,@HN`\.[>_Z>8-?'4_72A8^%O!4U,)=U`+Z3&!Q8/B!'V/Z^$5!ZN-ONC8^P
MX;)M4?QKO6CQO)9[RQ@:K?&@6]Z*9]J)#G;8B9T0!:2/*E@K0_QG>K\UT(MB
M+6V5GY'BG=+8]EANI]T%B%?B$S+&+:-7)-TAMU?H,C%FM#M%[O#B6S^.C(NT
M*3^'!^Q,<J/;,OKCECXJD!U;V3MO?.H[K\[*SGC4;XWZI6'LC&0ODO_2J#IW
M/"@Q&+7TP;#@DA72=K;$$!IMITIW][-1K]?J#@LHI]>N[73;W2)!_BIH.SG"
M=UN4H<V[/5,XL/QW)YHG#+I&J]\IDK5Y&!XN**@*2E[:N;4A#EH@AKDQY)FS
M?_'I4P\3X4[3MC4WAI0"ERR&589#*4H)/Z]^`+,L+&T/D!)S;6Q,?,;"G_SB
M]AA3#G&%_1M31/$21+B:H3SQM)\/?WT<?-F<_7R2@&WU,)^(]Y6/>444-O@_
M`_Z5RZ?!?R;^MV8LE$^0Y%CN\M^_?:YJ0_ZT1G1WY[$[,V#:D>CQ#LAA.;XU
MU>(6R.50X>CA_2BV>Q`"GN[8\NX(];`4.**:WIV@G"*67VKB0DD(ZG2BGKL-
MCJX01T:G%!SU=C:9.^^FL_-7SBSC^J7`,3#*Y\YCQ+3.A.U2;A'A9-VX_`Z.
M/.SKX^YMU-)'S>YJN;MNN]/)(W3+WX+B_J[MJ1[M%ILG5L7KC4^]/3@$G94^
M:8-NG`#1;*]NV^NU1]U&3NYO_N10,!MMLD`_;N-BY:31SV$JUW=[E[T['1CS
MJL7DGGMJ%,$U`7>Q)E=?'[:,_K#97BVWUVV/]1I)N+_\5\5.]DVC!);&B=V+
MU2,&>LOH7*P,N>S=(5_62$)6[%2?0#[N$=G?D8!Q.ISOF>-^*$</C^K8*H3E
MH]4!'*CV'=VN;;!T+5CJMO43.EOWK,>Y6&E7)0U]*R*,MJ&4<)R9*DE@CD.9
MJ!KE'"<B"]NEO.I(N$J4/34(RX&P7H.P8K?4Z(1V3M%M5N&F.@G;#G>&%HM4
M[.4LP9,E?*]#]M;UWEM3YOCL]LYC-,CV\%FQ^U>B);`LVYT2IFZSR_%:FKF`
MNSGPM5G(J`.IS;=#A7W^TG5\UV,SS6,^\/KT7C.C;=(`KKB4CU+A,T8'$.+I
M<Z78C\\(+FW#J4K!C4C(JM$34Y:W5.GE!T9D1_:WU_/EJM)+C]#>H"UIFPU\
M]34S=2_)[H`;Y,:_@-PQNM[P6JSHWY*/XD^`H92#)Y?=*-YV#B#??`%L>W17
M,.[@93<,.,]/':[\9M(FV=U:'[:[RSC7EWKJ9H,+Y[B[98]Y4G8W/[/'E'KY
ML/'3YAY+H^$AJQ^30%N/3S:)-I*E5ZTC,>C4^RALQ'._6GCN9L%S/CR7R=&#
M:F%:KSE';YZ$D87\;3*S6&.6]-,E=J4YY-5Y*5L`;14Y6*/VH)]%<'7<Q1KL
MW]SDY))=:-C5:B47:8HV6SGPI0K)>QVC\&8/I'K:(LQET64/D,-Q#ZZ#O_XT
M?^=,W048C3]PP""\Z25SV-P**CG,XEL\JH)C;63HPQ>^%I@_-,;!UV;6?,X\
M,/7@+32B0O[2Z+Q@8H9B])'^(O&L.M7"WSC6XAD@;!D&?,JSN5S:*QIS!\^]
M9<!.I@TP>DL7IV?2V^D/,&B[O9]P\(_M^KXV8;`6?8W#[<!\[;;'@Y\(@`_6
M]-ZZ,QWM:X`/)MZ%^,"%@#8$''U.`Z<?P;KM#O$ES^E]:WTU6_O#;;3U[A;0
M^^U^"9`/NC\];^6PT3/'^Z5L]$S>.U&?GMTV>MF31\JTT1/7PT[A?)2+-:LM
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M"S?'V?GGY@*YIS_86`98:YFT:\IXPU/'XZGQQ@RWF@ND+Z`G6?^!:XT<BJZC
MS=@$7L6FH4<SF!MN.@(W;2SCNA#YA**)]"/L^^X^XDR%@_GHX!J%DB*,_=:X
MOU<XNS8[/(P+C%:G>S*;H+BP/!Z%3E=9L`<X)Z[Z:%!>591OC&.7$)K.CG"_
M9G/F>6P&#]_Z/@O\6V?VWC(GEDT*1F6CVVP^9].`\I\#ML#PJ;<2(6T&%YJO
M!?=FH-V9#PRHZS,,ROH`A#4'.034A0?P!J3G9P(%Y!0U"0E9XZL-<E!A2"AG
MDG03@#UM`/:@DXM/4Y1/'H@88\`6\3\X?W#2EA,8K6;<LPG]7FGH]RLZ4S7+
M]T.0B)BL`M\]6-/=MN9%1B^[F1[<+6!?`U(.@Z1K[/36'`4#VQ>MIM'^TIQQ
MET^4Q:>_T*:1)5^>_9Z;*3=E]K8ZB;%Z]8Z:&9U\-G(5^+&PD;TFX,WIGZ'E
M6^01`G5XZ;EWGKDX!]7Z1E8V_+EX:`_?9C6ER$<6:.Z2>6:`>:SD2IZ:GK>Z
M`>H_FM[L5"KL\>L+>JWQ8&-]5HTW=AC]]4ZK9^26:+4(C%`5A08@`"]GV._G
MOP\'K7%G8_"_=A<B<-"XGR_(5H4[\:32]3T#'KSDF,JSK<R\5VI>5;9V&.6?
MY3\6ZUBJJF1%9>$8$K4)%6STR&;\U<1N+CEV4RCHHL9M/KH!\S^;*_+99P5C
M;OT_/LT3X1@M="S^F]^_OGX"1WMJ+4S;1V_[;\,._K\80O7UOR47_<*FS'K`
M+U!`;%ZZ,[KY8'JT]!]?F&T&;/;9](+5-\]T?'-*09>7*_6;VQ^6_\?MC+F.
M^<JV')1P[\T)UL.YWNJ]/?U`49@_7@&^K."M.44D\8=>N8L%=O,Q[<\FF#?\
MA\4WG-@:8%O!]SOG@?D!E8N^-2V/YK:^MOPIV%"AEX\"^F:`;KI/?E.`V;Z8
MR@:?/33G@M5GVW0";&H$!OP2'_S=9_/0QAF_>4)U?VQ\S\O5M]62$9)C6D3?
M"HI\03<4_>:#^<-:A`M!@-\^ZYU_Q=O*`>RY]O;!=,(Y3DCVP#!.;:]&V\A%
M(CA9*HF&]=C:I_G<FK+H&_C5V]"#XP0'8B<7]B]PBRDJ=H^PQ3<^W(THG>5S
M()7R!?[1$F(>^A"9?`=6+L-+-.I!-J>$6)N9/LL!=A8<Z@9$03^([P?FA'GH
MT?GC/;LS[3=.(&^0#U.`QOF;ZR^MP+1S7"`WW6$_<8.DH"@=0#8SHY8%N^##
M^\3HIZZX#`"Q*8+X6'SZ&:Y16,"\.PH:E\#**IS`*IVVWN?=&38!(@&]G<W(
M-0WOM6S@*]=AH*'P9G4Y8-V"K<&3WSBR.AR2+2NI9`7UYCM#3ZI(MCD<"KW3
M21$MO89$QA=W9=K!:B^J[2)(9\C1L&D-%0=_==W9HV7;[Q9+T%001>_)JYQ#
M2FP[7;UA`@O9JZAPW`(/SBP[#$`X?(VRHM_\F-KAC,W>@J[/"R+)-?-I_L8$
MP>K<^;"IK_>FQVZI36(.L/4_J$22Q!+(IV`59U_1`1"%(VN<[^,J?FJ77:,_
MUD>#>)^E[.(\:/E@_MOU\"KST:J92`$>K.)E^26WQ*7RX<<8#\?`KQ>`'Z-,
MMM$'P#@=_2+0<@RVZ?7ZW6'OF,<*C+&EZYOV7STW7+YS\#WP`)IHL$T+A.7L
M$X^RN<Y&K6:[]9S;;#2Z"4E9$F3GVNR66R%E(Y>X45(^(LOI+6/^)G#30H^G
MVT9'^Z5IH[__ZSUCN$ZL1L3&N_]RE8#<WPZZO]4GDD<-U/7!.%)LUG9YR/:-
M>FR_OWOW!7@I?L=7D0WWRO5S*:"UX);Q,$;7X5@Y*7YKPHZ=\^(WJ4%_<J1F
M?2D,K`]'^R!X$UI.B^%:L'"YR-WC.O\D$YCRF]WU8-W!V-A7ETOCY'2HK07/
M]H>#JF"68RNGDZ06?'O3W]\&R4#+21%<"^Z]Z0WTXR%X_9F_FI;#);5<"&SS
MK!^""OUI_LW\<2F<G$1Q"8@Y"ZIKP=.#X3#-TB7C^[WKW'UCW@*]2K'O^B4S
M,<3[#_A?C/._P](QY@=?L+=N/7(9TB[[+KGL^T,ET%-TYPG7WW1*$X/B7(B_
M8F[MJ]#SV`:?7D&/55K-V;YBR;#M<#`-1GO#)K,]W[K>:S><!//07G^Z1#0:
MH^0)*@3`<2$OBN2BD*/]\=EC8%7,A%8&O^,3K$"^O68/S';)P5=27D[N]<H'
M;@<JC9YN1/9N;A`EXC]AC\48PW[9ITE/<NBVY9()">H^2CPR>M(*R%RG'$!V
M(&;4*0K(!@\VH;`<H=Q/@;1MQ;)ARY4>DT[+VKJ?7B>-XLKM9V.RU@XF[J:Y
MN'([$[V'/?@ZE=.4:X/]\?DVN./@]@9G/";YLL@*X=H8#ZN^G[V/2;?J.SOL
MF'3WY410K<)%2*;*:[;TX*5D0\'?-L,_T$1<8%><_VR/GI9Q[72':_IV*;"=
M;;\[];7C[9<RUZ93#PSC?S!GYGI;L^.*JDYQ<ES6$H>OOSORGW?Q5TKCYW(,
MK?3>U14.7;S0OK,6IA25E]CR6OWV%O.)[KC[9Q7_1*#L%HN]H]*"6]\/%Y1?
MXXNAR.RS!^+HDY,OMK(I\3JQL3^`<?\@0%+YAD;;,,3`YF/NI)+H2B1QYT-7
MI]T;7Q&ZC(.YJS>\5G3MP5UZ>W`J[HJ*X<I=B$\X>6T]6#.X)#;Z=5^%?N`N
M_N@,;FZ77N'$WC\^,\]R9ZHFM["H8.LUO"-?VKNJ!AP=!Y>&\"_PG(F!BP;G
MNW%NC&[^'MH-D]<-X0V3Y\%Y2KUJL).SZ.8*L/,/%RQKBJQ64P]`N[JM#_4C
MXSR)ALO#>G$Y28COJ"4BUX7X\V@$G-V-JV7WLZD%G-W[U\?NA70#O3WL73N&
M<GA;,C$W&C68V^EXR>:Y_I5C;H=."C?&L772RF-HWU-Y]?(LCSLT$W.="Y%G
M7RS_^UN/[<YS/:L=U..FIW$LI&=AX=)07EPKE%@?7R/6SV,!-2@_A_DCL7XL
MP[.:6,]O^PC\',T/50O\[*%C<;QU^]=U;1UN]W"\Z=UCZ?5UP-LVJT?*JV/Y
M:VJ!G[W/HSZ^YO.XC\4C^*T[/"?>)KL7FQ0QL+``3C^7J?/;9_U?QOAU"I]'
MV>+%('*37H?==S\,K@27QS1+KHHICVQL("[U_J7C,FU")#LI7\.6MS25'EXQ
M*E+-IZ^,*PS8LG%E6\[;X__:<'&VDW!0CO:GY$O?NMZ<49]Y5,W?.?P2+"O;
M[OB05@8?N?+K3H*/,LQ2L=:G,/`#T\%F,!]#Y/,M=4U&1S1*Z0S_P"*UC^:"
M'Q2:-8J?X%<YNS^G&]B7OI%2C/<]L-0Q;CZZ#[R#_B8L@=&3KX=XNF/\Q6`I
MNV/]!E;ICCOC,OS7U46"OA,)Z6[IEXB$/[+7I4_]VS"X=SWK/VSVNS-C'ITF
MOAR>*?_E*E&'%-_B]->G>>+;3F?<Z^>55*,18/["V>]DF._U`9O]?)@?C>'_
M-7@OB^-SX_T:9(VQ"PEK<P8N$0E_?`TG/OLS1/?9`_Q/Y!I3-3H]Y^"*SF#0
MZ9019J@RP@[5>T=#8]B];*&V&4EYU5ZCK_<O7>TU3BGZ@3]S8EX?&-V!T6"^
M%,P;F`>1%_.&;AC&I8O/4V&^V\%V@/DP/QSK_4O'>WJ4WYNE%;C+]>RZ3`3U
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MCE(;+/T=4U6.$Q5N*+6'9V`;I7KM,CUB#:4.,Y7K+?W\0A'^PM3:'`G>86<4
M$47E[:&ZJ,NK&8$4+U)54E'4R3>?FO$Z[4*>UU*W46D$YF6_3C%KIFP$EEK%
MNC-+XG1,66+D^Z!=G31SYF02LY0V5E5#K^);KY<#90^GY'$20QI*5=HIV5#J
MF$[),C/$:TZI_$[)P7&BTK5$6K6=DGJ)/O>&4L=T2NK'R3=H*%5IIV3M*94W
MP6DC2KN\^5.)+4)JC]-*.WJK</=/=B\Y*>Q;_L(6IN7`YT@8SYP&H6EC3SDC
MAPW>>?+;Y\&_=/V#7DH7V?UAK3ZJ=$)5YT.O0=2NMJ)G<480(W_0.PUYJD*>
MA`<"^ZN.F\-3'>HDO`Z-:,M%'8,0U?]02IOPBT;4>;P+V*VW$3(5HD["HX`-
MUO4/1D.>RI`GX4;X[7,/1)M1RER.RR;/=M\!"J'^AP:)%>'QA+/@XJ[OS9Z(
M3<OGFPQQ)A.N_Z]1N:Z(/?#3D.=D)EQ#G3)-N/Z_AA_T;D.>W38<B9DR%9W+
MQ-3YC+C!AV%#G:I0)V7$H9O5*-/-VI"GTD9<0YXR[8]*7CT'A$(5^^<=K&(Y
MOC6E25?[]&U8:W%CC([5A#8);'4PHF_&R`VF'%P5,HSM[-'MG(L]RCFOR46R
MQ59!E.!5L(:2HT!;UH2V9`43_0NGLD83\XH7:J1P,NB,.V4-:=L%;(60LIU1
M>KW!<#SJG0XKQ^EHG+KQRN">+2E$G1+K&`KNH]HHS%_*H_?/B4+Y_^F,IDK8
M<E>%G<4WNG%8:][D3ZR;W+3KW^J.D<3(UKQ%>WB::X\1U4%[((^,VYW^!6-D
M#QZ!4S.Z`(RH;N*&1[9AI&IRY#P>V`8CVS"RQZDQHB'1M<:(Z@<^D$<`(_H%
M8V0/'NE>!H^HSN@#>:1[&3RR"2-[\,C@,GA$]8@W&-F&D:/=OGN;WF_^#*U@
M]<[Q`R_$#WVQRD?7>6`^F-]ECC_O&[U>IWN@CRHGQ)7"S,Z!%WI_H(\&XYJC
MYH@#U$X`[]'0\@_"?9EHN1F-]2YV/C\!O$=#B^C<4S)F]-[`Z!P+,VL@'U/*
M<#+LY\[=MS5\ISTZ%N[R[Z@N2"W@)=<O%ZGGC#X8Q\+K'M&<8\"1E,2GQ"T(
M@B/AMN">CGW]8..X4R)6;P^/I>85V5&9&1"<HKS['IO"G]]<_*AX)47>=%\#
M,Q9+3+DJ;P.EA'4C(MWZ?KC(:^ON/PVFE-Y,.X&N$&H*7#!E9"/E0@U*A'^:
M'MT[Q=20+3EW(L,L\]V'+;H[K>T(BVY)@=FUZ,%$7!>ZP3WSOMV;S@%^@<X?
MMTY@S2P[#*P']I5-0\\*+`;<,;7#&9N]]=P%PAD&!.:G^1O30['CP^7)P5QE
MOX#<30(1.<</ZEV]4TKS]**8JBYY].J0IVOTQ_JHC!Z1ET,>HSKDT0=`H%)Z
MAU63/(4]>Q4Z.H8Q-,:#,AKA%D1314E3H6,S'O5'_3(R"/>@S&&)LJG72W6N
MID<$PP_]0W.'=Z&D$DBO$//KP\%('PRO!.U?`:&T##^J"(/KX$FM-.*.+YCV
MB8)427(88Z-7AI%<'%'5I4^%A,RHU^L.3Z+[G(D^D3I<3DSG/!;Y]K2I7AEE
M*B4BLI:$/8_,W.YX'9]$];U(PAK]FT_3X!#5X@3=I:^3-.>^!W><N:L4ID>H
MLJP@;8TSN!(NEL!5/+S#DWA83YW\L=,2O=3S>G`N\.&8JP?QJG@6#\YI*X=X
M)S-LRTH4JMY!--J=D\1]#\I/.CM$M3RFW39FB5<+D>D<D,)E/(5T_8TK'0S&
MZ8BME!`EH-3W&,)WT?CH%D2(+*&X5(1TA\7&D';;P_YE8T3O[>$(NF2$=+O%
M!J_!C7+A&#$,HZ#Z9%RX&#&,HD-$C5T\<K!*\M$5NL>Z;A*G;9=:HEE:BE<!
MT*N)JO-SY+KFDTVS3D;WQ(9D55'.LFDVTD=EV"P-R8ZB/F;2K-\<LZK0+$/!
MS239H%M2ZF5#LZ/HX-E$TXU.&4._&YH=Q4K(EHWZT.@W1*L(T7(>-.-,-]I!
M`97-:Z7,,.S^7:IIU!.FT:G!KR[*SL_K!4VDAG05(ETQ4ZDA775(5]1D:FA7
M'=H5-9T:VE6'=D5-J(9VU:%=85.J(5Z5B)?SX)WQPCM^_DOQ5D%^)H%?A7[@
M+OXP1C=_-QW10Q\;T7X.O>D]0"6W>7MWYS$"F9,*]K-PG<1/;^4O_FD%]U\!
M`)SXA$GIKN='T^OTM<'F54%/+>G6&=S<+KV&;E4$;.MYV[.:",<_-G0H@0[K
M/=ZZ_QI_T$?I)F]5V42ML7M^I4&/SD\OJY5?59#94+D<-Q:>YH;$ETCBV-V%
M--8_Z&MCWJN"SX;0Y?C&4&2//QCCALX72>?8CX8'NMNH8)=*Z-CI1I*[\\%H
M*'VIE(Z/M/XOXX-^Y?IVU)OA\`'VV1GPU*+,*"=_9-_=U`"5YS\9!>KG,'+4
MD+0&)"U0`HCMT1J25IZDA8H8.]0&OB%HE0E:I`:3,M0:P5M]HA:J(VU.:?4)
M6J@,]A((FMG]Z:^>Z^>P\SKZ'U_#B<_^##%P^`#_\VVUY$CEP5W;=/!7)\X^
MW[RELV-,U__XPFPSP#=ZP>H;O,,'4Q#?]W*E?L,Y<[&TW14#_G4`2,</[0#7
MS)EYTA]V.F64%&Y%YQD0*J/7XYNW;,+%QFLV9YZW<6',*7@'-OF#-0.CFTL3
M$!MKT"">/[MP#%E@>1QDYK"Y%0!QOEF!S3[-X]<0A?[.YG./K;Y8-EOE(\OP
M,KF\2D1Y]>;!=%Z:-DB?8.6P?'3I&?U+I$O:+W<JZ1.-,#ZZ^#FL&UO6RXOU
M-3L"1E-3OM`+TQD?GD>X?;.']P0\%)='X<[TQ+0^'/5^&=4_.[$I\/G.]T/3
MF8*8DNEPWUR9]?9IKJ3";>O[7#0S<G-NW;=[^`?JFE80X@9,.YUGM[/LS1CU
MAZ(`)_?F?BL1&TJ^89Y!`&.]&K"6DQMY".G.CHW#^Y=G[DLM32FRKVT]BJ1)
M67+B*PDJ4',BFKYUO;>6`Q!;H+W,'BS?]59?F?<`(&0*LRU-NWK;V@_)_6QM
MS)1GTRB+0KO8K-7.:2`[07?\W+MX;\T5'MS*189$:.>XZ=.8M;L.VCK:EY9'
MER#VKZP"X+!`_T8W;KIZ&O\JI.OG^:WMNM[Q#G,Y=VRQ([V^I;79LL?==$G7
M4S%QD;UKB][^"U^$UB_,P7MGP,,3PQN]<X.]]W/"<;!^O4_1%!S1R!XO<Q99
M&0KT\0K/]L$4B)@/IE<ZIHPR"L".CZG=L^#/A<`R\9=WEYM57GS0\9G_A4W=
M.\?Z#SOF&,`,-T`W0D8>V(YQD+8.A(L5@[VD3JRB'`/B<V%CWX/QVV?C!-B(
M[ECIN=#S>+WV&TFO'[1H><?(4*ZO;""EU_*SYTX9F_D8>22E)S6U(=?QWPJ+
M;@P3?M*=*TH<1@!_FM/O4""PV>O0`S'&24S?QB;G6\9R1:BVTU8?]"/<[05"
M=`Q-6SX'-G#R-[OUU[5!=SF5RTY[/!"'*N_Z$<#96Z3?X"@`22'Q4D$WN&VV
M&H&;D9^M3XRZ73D_YE!XLBG!':MXRH0;XGC$T-O&.(L8VT'8=#[7;\2<Q>9;
M&'[PY+=>)]5.=_N:Y4"7[>+,\&5W^Z>$+K>DH.G:Q>#*<\KHRU>F?V\S/]W\
M()<LWGF^]$X\$WQ_2#;(N'O3<9@=V<M['*P_7H:^Y<"2MU.X`GV+]`"\_#`S
MA/UPG4*6=J?=[V4*PVV`YA*']&4^`FT]C[LC$'N`<:0=[!F6V',#V\\54.P!
M=*7/MCDE"FZ#&]@K=H*$$]^:6::W4CB"&"S]QCR!-KTSRB6=TN]6]_?1=2P`
M%W`1"`/GTWS./*JC\,^P+[3"1LE-;0=1W0PE=J$+S2)'T>L0U/&/`/*W1V8_
ML`\`_WVVX-U1D9%6THQ14JG,L^XN.+^"6>G,_L7,XNTS,R`<='8"&"]8-FCG
M2TVY=6"=B>M]L*;WUIV9*:Y3W-;MEHBI;_>65QH-N_V=D$7K[0+LK1MZP7U9
MD.F[N2M><"=HUORTD,GU\N$,>+!4"'NIQ/-\*R=3`=^#CO)I_@I.F!6\-:>6
M#=8ZO]:LJ3@[.;)+Q]OURW%2QN58\[=B(+X30OU@4/M%`94KGR9E^Q\BMWBW
M*ZL2Z7VOO?\;NOF<QUVC-S[-Z.LD#LO,]$N^>7L^597(M#4U-DM9')8UMF8[
MXAK:[,Z0S=3E3T<>-(MR^"VKA-%LH91Q:PTC[^FZ6S2Z<N=S,+@]7]U%Y3%0
MY+RC:.XEJU"S]EQ[G!0\9^C?'1=#RWN&&1C.[`M`@["3^7FP[V[02VHL68N4
M`<6NT$AW#S"261>Y`DN4S]&]Z?0IQ6C;VQ*>%\$5;UWO"UOFSH3,K3BB\WE-
MZNY>-'&_16Z/3QY783ZPX-Z=\5P55MRUGX9W8UV<.F.I"!`)Z'$[\2X_>^Z=
M9RZB/AH\5O]ISCUEMR&\T\.H]S?W)8N?RM9G"P_[&.F]Q'RV4D`KL-GX'?%O
M;A=NF,>0VG',T@5)^P*2]$H*D2O>-F,+NO6+N[SSSKWNM`>ZZF?,L;X*\*L0
M?NT$;^&7GFE_,W\(\2(D_.%QTQMCH"=%^XXERX5NA]%_TQ]UN@="1]%Y$,_O
MW>EQ,-CK92)P^[K'`'07,@?#P6&`OG.F[H+!3S"7QT$7`5U!'UUGQF;A-+`F
M-A-/?V"P+J8TH<L@@#.:S[FR"]E)E\6A\)QX;SOH4XF]99M/&V,:A8C7'0SV
MW>)FL,ZQSUV$3$G4TO:I)`;)K#I0N*+7EW"\1%NE'0N5`\L.+.8'`^/"=^C^
MC?-^4D\=CIFQ'AO(.Y<K%;!\:,H/U!>0%J@GO7=]_Y/SFDV"N"'%/FDT:8!B
M3\*VE4J#)A]Z=H$BCRJBCMOAMNT^8AA8&NG`;[>^SP*)Z-Q:[@YT&9U4O*HH
M"$<&?Y>L&_<'I8$?G>RR=;0L89Q#S2E;`\L'!O)K&F<\X\+G^1@@`V4I7AD'
MMFO$LBWOND>!<U=<5URKI<#YTIRA%"@%@4:GOQDPN5`YD.P,XX['^4"1?+CV
MHT]@R9KH_451^0JND-7<]=`_7@JJ]$ZZH44!`(X)]R[$]L8IYV-9<&_ND5$8
MM>.^OAW$M78?!T"S"V&#<6=4$)KUJV/++74P=C:M5AI$A3&4!Z(U++ZWS`G&
MZD&1^<A*0=4VFB57*QNP_-=G`<#>S.=LBGW78C/,#%C2%+N5#B7TA82!ZZT2
M/RZH@"S#I!NPAVY`N&6[,?PE`'7Z/1I;]DBNSF[OK#M,.+*BWQ6V_M);0\YK
M=_K]8GO;!,P)-[6-7L23G2Y6G9QC5](&>..85/!8XCD;#@J>LVQ83K:CG53J
M#HM2:?>.#M66_DB\X"U_EJ=,4(09EN15?0@C!2OAI]_N/3>\NP>+-[.9Y5H-
MR3B=>K-5Q4ID^L'"'L9)`5[Z[SOGL\>6IC63%X<PNX"5*66*7R(E!`.ZJ;JY
M_0#Y[11;V96LW>_U2MK*9HLM,MB4PA%,O*?@7DG*S)ZK'QOP78X58[C#VMT)
MO23<IO9EKRU_:KL^R)QO`.!+.U=J`*8E_(\=O%AJ?K"RV:]/\"<WIFW=.;]H
M_P[]P)JO7F@+T[NSX(/.,H#_^_%"F\.[?M%T_'=@+>#Z<MBCYKD+TVGQ#UJ:
M#^)C_N+)_]P%+W"!"?ZA=]J:`%\C^#5U`_BSGR?R@9^7^-=?_NOXT)F+Y8O_
MU@>=TR[[SM'>LHD7FMY*0SK`;^Z9AG$"TUEIC')S9YKE!*YF(AU%%I=FRGHI
M[=$*[K777EO[NXFK_=_0;<%/9Y8'-XKK:>Y<?6/[&G"*!3^`#8<CM45X!230
M/:5]9<N`[BFMVVD)E'\-V`/3_M;6_J_I_`>^>31]0/V=>0>HAS\5_/$=C0Q]
M^,+7*'/:6FBO%5Q;(*5?6J[MWEE3'[YY@#/L.FWX+5+/8<3CG&;WEJ^9RZ4+
MQ$5"MK0/7@1!BO"^]4-;``[N-1:5JZ99(/0U>+.IS4/;)J1H$].')9XA^!)N
MH_-"K!#7O6I1[5WT*_W%\Y;V>&]-[X$6*VW"-"`3P\@6D,+33%AG-K-XXQW$
M+&/:L^YS#J*OA4N>+N?CRP7_+>&<@QG7UCZ''I9B`2%=^F(+.`F,/%JP+03$
M"3#];:818F"+3/--&RD-*ST==UH@8`E(?#D@<='2[IEI!_=3G@7"!^1HRQ08
M6?15GK/@X'EHO&M+&YG.8]9B`J_@^,?EICQ*"]^`R.49@TS&@TQGIF%07G[2
MUKYMW[D&-X8+BU(K<KKVY]8,=VYB`K_F3N#`T!K\W=@5R!'_]'TX2Y2VI4U6
M"@+;\6%4T0H,XKA!`JL^0QS17H'V1$S$H^7P70&:D7-C1FQKGQSM$QP`/%1Z
M2Q%CVW:(9PP$%O%4FD5OQ><Y695PD-Q3]NG5WEM3P#_*3[ARW2DHUBSS:`8%
MSF;PZ&HKK(?9<!Z1\Q/GT6CWM9FY\K4ELC5CWY^OGXH<&-CC=.C]]>-!R"O]
MA/A7<=$`Y]R&=_"RG5>WHU&JKP\FGB8JGM6S@/PBJZKYB28U4.NV^GVC9>@=
MC2<*(A6GE'X)VT+-SB3AX%LSQA-'0=B9#Z0?:'/3\K0'*A%`V@_;(VT!7((\
M_NRIT38ZQ'_T7A#V$TI?Q*,.>_@S=%$W0ST2WQ5X)N8H:TM,:,/?R,/>YX<=
M\8R(DZB>PO7G_:)-;'/ZG2.JK1%=\$<";Q^!S>@61FW_*)C3#<3>Z'#,Z>VA
M@CFL8]\/<WG0E"F+6!);M$V%[Y*XW8(M/XEGM/(4W"V7GOL#;)6`V2L-&&0<
M;7I&I>*"Q_FEQ!&U1%.1BR5`%&`9Q""H#`C?#"X1VUTNE%N/:/`4I9]\,<JA
MC4_=N>Z,7V^^C#<"/X",`S@?K!DQ".UG'@9@[0AUY1[H.F$,[^&IZ\UBRF2)
MKPF(1I18_CUC`;YNR6U?"3$R"=R_4\^:\.4^`G6U'I%)GH'UDT]:^F)!YLVF
ME=6G-5$6KL45]+CKM`I(7"NS8-.7#;^S;<V271!50GW\\D'[Q[MWVM]<&_\-
MBFM+>__^50L/%UT8*\V<S\G/!.LECA08:@`+O/CO<-58WO>6,"R`11!&J51+
MY2=ZC=\B2CRXW%A!TEK^TD5[%CASZ3["WO&B@8TMS'^['FDU7%-TXPYIVM1<
M6@&L#E]%C/K*]9:N/+/X9K1N/=?V-^VSS2]*@!Z!F-JFM4`>P=`\-L+5W$>'
M>?Z]M900"(EQS^P9ZE!9*]/"&_'*?DS9,KHX276F$T*GCDU#!Q/4-5G'CS\"
M?=)1KLS8/U/`S)>^C5A9B$[^:V3BY:XR%K6)08'NZ!\\KH3(5F+'596X\V3K
M'O='Q/C#WCWB\V/A8&/NR1:M\,FQ#+=\>)?_?TM+#6DM^[MJ[<IAQYUM@[8V
MUT@`N[U5R.Y]E<==VS8UWGM/F)'JBXZ5O+EC#,6!KN<^5INE'/_;EBL3K)Q]
MC/[X.KUGLQ`KZ^2\!Y%PM*'ZU):&_J=YW`:3ATL(9"0CW!<!UN#3>E^$J@-[
M>1TK.E&^]^[@B9%NP)4;A::/J^)_L"H*=%LJ,0PHW`)75_ZQ:3B#Q`]`G85E
MLM^Z82WB8M=AJP^F]YT%M],I9D$@\!]"'$_\-G1FN29J]--E:KDV=QQL&&?'
MQFBP+S90G,>Q-XS]X/]@1`^]`GG.U1O2'5^NWHMS0+OB1:1?EZ#*OG.B%C3B
M4N274>Q[$'>,C:NCN@2O%KY9[D<2'<,V@GFJ?7P!]>H!C!9Y2G\#TG%-QI4K
MRTW<FX&\>CW0,1_%S8NJCWKUTG!SV+Y\48Z-K@=,\4?^6S)_/EB.M0@7LF23
M-\1Y=+%=2M[H;V%R%NDD5!3F/38L*I]*VVV:Z%NWV]]GNP+BH^\5Z`8R13P>
MY1HHD7UY[KHZ'KH<^^UOBN'7<+^9LX^S6JL?LM^#6BM']1^WOA_RXE+_%7<Q
M\>D(Y)C;HDHG1R_D;FS\!T=9-&A3Z<P$[R@X:*$[/K#!="XL7`RNO\!S)MKW
M>Z';:'=&UX%N9430F5B[P?5)6;O3'O5.A>XH/R^/01A-3J8U_&]N8-KI@L^/
M;O`O%L3FHMHM^^`$(TRO,U+FP$D@3Z:,DS<;[ENE:C'^4*9T9UON67/L2FC#
M3SVETK9S7D!+WMR>9VB'=M+=>VLTW\.1R7_KE:;;]U2DA3@.)%8:^N=:M*PY
M&LI0BB(7>!Z1U*,;8&CT#Q1*&R`]!@9V#U514/#;9[W[H?R])0:#W((Q]MJR
MP[AMBN<&/`@J&U+O,V9L#_(5A21.*#WP"&T<=9BVO(QX+D^N126$'RP;0X,.
MR]T4%2RI5ZYMFQ,*>CTPA=#HJ8);8[KA:]6;S3M?8]#RW2L;3"3L1^)9L)W\
M9F86^!7:EF45WI@ZU*R2._LX,[^&DX7E8_KB.^?W/)LRJDZN-Z'G+AEVPIY9
M4PP)W-XQ9[JZQ=2'!].^!+I]87>A;6+5E=S5.^?6MTS0X4(G\/)T2\RSQRB4
M$8V6M7ZPV5N6UVW^_T+3"YAG4YM;T[9IJV(-Q4_SUO+\`/V!>5QPG:XQ&LK.
M$!O`.S'\<;/T/!O0![WNJ%H;B'JJYX$?T-_/"S_&)\1R;UV/YV7&TST/"NM]
M]MC#[<1[;T\+,OMVF")=)?+B5V8/W5BKS@N=W,WOCL?N+)\2%'@'05Z!\LT]
MU7XR6R`.C'A+^4',()&:X@?80-6SW(V`CO(3IH9-`=V4%23^[88>S]E:HTL&
M2!)P#-Q:J9_PZ5K3<&/2BFXD\@IRS^WY+<[]TQP^<=.=*^F2N(-$RB3[,\30
ME:N-V^-Q_R<9O<OU+$_+Y+C8M<N$YX4W0Q?C6Z36G;_138E#C'C)<$?I_+@-
M.#ZDX/_<W&AO73=P,''PJTCKO+G!'8+*^/V7N?CN/?Q#^T$?!:LE^_6)3-MY
M(C[U7$P9O0^"Y2\___SX^-C^,?'LMNO=_6QT.MV?\>N?\8=/\-4_K[T[V:AU
MN;3IO)CV2YX!^143(..4,G^/TK&`CI9(;7VT9L$]YE%W?GJA33`/T[LA%6;I
MLU\T^5>1=&MMRFS;7YJ@MMVAA*!_+S&BRO\=9WP'GH3B@0&?@58NT[X#=_E"
M_>$L!6ZGW;><N%9-S=7=L]*MUTY5L\DL7?I',%.!*7'9K\RFD;.:(*]&]-7>
M.7/76]!QRPO6SX&G_@-IO"FWWG*P0N47[8:C,9U;S__+OZI%<C\N8.$?,CD#
M4XJ9]4!\_HQRC]W0!XGO/R>XK`J5+&8=QG&WI+,HP+ZQV3R(#DT9YW/B!H&[
MR#ZB6?A[HCGNHV<N?WW"_YN%E.09DV\3@-WP%6'7RX`CX.:167?W`<)BSPY8
M0.!9OI]R_'$5S7=M:_9"4[<SI?S0[/6!/(!4Y]<G@TQ8U'R9TV\W(1P:LNY#
M5B,3%EE4<ZYM7A`>]<H<BPGL\<Z#FV1V(RI__GLZG<^GTQ?:H2=&$R)^V/N)
M/Y1Q96W!@]36?LJ\5K*?4<'`BR""0;[E:<Z'/<1T_'1'/#X8;3L!.U?/M8=*
M[GM\K'WG9LO'>RM@^S,EAROK;-&C+TTL\YI@B;/HAZ;=:%.*@3"OX&$]CL"A
M#1SGU9SH].YG13E\(P*>7Q/6C-'P6%@[@]Q.0V>T^Q(^2L(H0%GET?T)0"_1
M9FX(%\8F\FX3<`5?JA#VYB"J%MW\A2&OU^F?`'T%?`'',L53T)W!Y):0?$Y6
M"O-"91<K.>$RX[G*)N_9E==5<"4V^P4;(8V-?I%D;6STQD8_@HT>1=]DTXG=
M_3-NM*^,\284>J=FAJW1ZFT],)=KTA=3;2MJT-.OJ`.HXE/R,W:V/]KWHYBB
M!NN%3,/=RYUQ*X5XICK";H?-G5::K\AQ,=HFKPN@<&_=H,[(TP='1]ZIA&GC
M^EFCKM'J=\:-^V=_!!YX/!KO3W%(SK,^=HW=PVR@@AD;.\/.+=X3U4PZJ7@_
M6MF_#KM7R(:OC#+\S#CA7#,#:F-&/:EX7UO4!AF^$C,@/38/T1/&4P,].<DY
M:K4';PU]>H.YX"%*]Y&W*XU;SJG`F`Z(66N)+>5X;PU\;;IEG$2%[()J+I>V
MQ=]:I+U@W.>P>^+VI2==[,SI5)^Q!@-;-U&3PS]#B],CY2;-<=2OQ&%Z11ZB
MQH%ZD61M'*B-`_4(#M0/IA/.S6G`;^WH)JF9=]`8%TMHN!2O:*]3S"-2/;]H
M(J2)^FH88$-CTGZQC=A6ECRC;[%;*%F@TFY2O5_(<5!!H;;15_6>E_NZWBJ7
M:+LXEU^WVSA,#\#>Y7E,*RV(>H/+$:J#<:E[J4STZ3WS?<V<3L-%R&?/S=C2
M8U,K+HB[#N'PS.@UF<?%L=8='@UK3?#I?,$GXS`]X\I#3]V3H*]NL:<2*X\]
M'&9EBUY>%EM+)V[\Y$=++#[*C9+3#X[+E.SWWD]-:\BB^E_IQBC';WV)>"G#
M#UT9:V);<2U)Y0?FS%Q/$Q/PMB6S5='_>JRLU&KO>AN'5M7GO-&04)NP7I$E
M=EBIX'4[!HW1T9%7`2?Z]9JS31GM(;Z`4V2A;K!EXZ9R1=JS1<W!L<<>[XKX
MFL+AO(4G=82FSGIB)K`8":PTFW6=8@T>M[>L_\)P#"R;O3$]S/K;/<$,>^J)
MWN)E;"'1YF[+"Y5F@-EC%TZR[:*0YJ&V.I;AUI&-UWW1>9UE=WVO!)%W09Z7
MMA_9(WU3<<)&8$94C<9/;NVA[^/3G.OCX27?4(Q$4B%_T\:9]2`]1KSMH/4?
M1GE&0NB1?38W%Y:]^B7M!Z)_D[3[Y&BW2\^RM4%+&>>>G**.GSSR'43NK!5\
MXN-\]6@BN)Q=ZV%D!J?08KJR@Z.LJ<\]]E5-C[4?]%N=3H<G#2O?X9O%E)F9
M%O)A[/"+EW@;W`"J71LV\R!1J2W<&;/Y2\P8K?`@HQ'0ZGAOS*:F^=X>CD&)
MAI"[V,Z&ED%:_$+2/=%64>`ZC].2/I3]%+/;*9:7]<O=@P3"KT^XO?\D9<*-
M^U5JXYFI'A9.TMLWJR_#.[(S1>\XD`@UFA2<`](4L]P]J5?OV%YBGM.Q`#[$
M/UE[#,?3R8X/;64VC9/!+HF;,CV@)6%['Y]NJ=0XYN;JC3A2C6)8!JWX[WU<
MYL=@^Y)\,XJC/`4FR3`^8$_C_>"7.$0IE_,XXU4'NY(SWKF_8SGC93CMM#S0
M"GK;ZX@PG*%Y$H2=M@OF.FAO?BQY:W8P!ZP9#D/WBEQS!Q"SA!<)4JZ_J5@J
M__KS/S4(.)\;?2>K*A);>W!ML)C1>*\[R71]V"X6#KQ`OM4[O7:Q5/%2>?=(
M0O:+Y7_7YAY#AQ&.#?*#RY"R[8+ANPMD6,!!,<VJ9K+6MN9,>[9BIN=ORZZN
M!:WTHDK=GL#4`AF=]JA8D][]U=I\<WJ.[5<^:E[N)T?[>VBO-&.T5\C!Z'<Q
M:I`9;L!PSJ9H0]_H9D8;K`H$&W*COHDN--&%&KF!F^A"$UUHH@L7[B1OH@M[
M(@ZU("6@,+K<Z$)";;G1NVUCJ23A\?HC^6D3B3BY8_U2$`9V6N\D"#NMDZS(
MZ6FB%M?B3*N])ZTDMK[4"(?11#CT3K_V$8[#N/QRHR'E1P+JAX/R#WA-97@3
M.;G0R`D@HYA&?H3(R1'\XZ(BIK2JCQW506]-RRN]'DS?43^#GD7W_V_ORGH3
M1X+P\_P+"^U#(DT23(9`1KM(Y&#$;C)!.;2/D3$=:*VQ4=LFX=]O51\^P)AV
M,#.$$$4(X[:[SJ_ZJ.YV.44KE\[4*RVS4<6_W+5"Q?E0@NG*5217<GZGB[(D
M@7_W<D7]B>=;S@^`MPD4<T*$'EQP!UQ3%RBXFQ#Q5JVU-3I+H4JA)KDF2EH-
MO""2'*X=O/3\0&LI5#[59TVA&9W:2J3*S*>J?GI>B*JW/G/H=UFM00=QM=7;
MZ^=:\^AORU5V#<_W0F:/0#?*"=M#95/"O%.%(GO[EP:CQQ%<=%T_H$&(BK*<
MKCN%EI?'U!JREB0&'@"_45?8N0[PF`8(NX`,8X">41!,OI^<O+Z^'OO$/AYZ
MTY/+[C]@1_#7//]FUIM_GLP_K%[GDR'W`'XY@,K>)@ZU:2!H@-X\W/6!O+\J
MD<>MX+G26BA9C'%![`(M+<5$1/))EGPF'`,B]@*+!3ATW$*='57-(_,\>D]T
M+Q+T(%6TUHRK$'?4M:KD)&4N8#]?.([,KTSL8;<1P(D#>*9-_W+C2CG-,_#S
MS(E+ND^MTJH=*ZS-94GAIRK4<3R/?5BFS>-O<TPO\J.QU)27\U>N([[D!]LC
MH-W9@5QQ&O9].J`6FSU8/.YC!9QYH&$*=MB#=@MG>X$OGU>:9*A::9V:M7H*
M!+4I!C83C-Z3(?4#$5=4"R0^]^61L+'>NM(NCY$N-,HQ7+Z"ZGC.`KS9]2T[
M(:KQ1&S#*5,>.-F&TKT1*?\KWU)[$C+$\@#/=,'226J->VPZ^O$C!GDC=B@6
MC^(VGPXT$=AB<D7BT)FOZ:P+?!$_/N:%8O:"40')@;(J!DM6ZZNVC_R9,)7Y
M(8JK))0.9=#G?@0!V,@GUP,7#'4-LU8U!M;,5V5M.3<QP+-WX#<_M$<&E7'L
M.%;R:FWEQSNS=IM>")W_PHM9XH(;:]<=W()PP+Q=<CV-K77+XIJ>O!;8$V%N
M"8\;"V$UC$M54R>$U8[@_]1\1PC3D\@#"0*Q"T7;`<-VH=ATR9+ZS9E2ZB`H
MQ_>48X;0QQ")4-1!9P$_L5Q#Q`,ZM$1X,'Y"C^R*A4-Q')1MI?'HZ?CAV.AX
MGL`(7JX]&%,W=N\7CX'K/\Q<*!Y0V^@Q;Q#:@$?X>RP49S9'BKA"E\>-VZ<`
M!`(A<-=AW,Y=EN246%@+@;YKLH`U)*X],P[Z'I;P%?W0V1,P5>G^O#(BB1E<
M9)7#KXA7$VL6GQ!&*#^O]8`>&L&KI];8&P/L)3'?./BC=GN(*65X<!?GZH!B
M43QERPVY(R$`";B";Z(S)W'Z((,0@6R50V-D39%#2Z3(0=_Y/Q+(3#D0B<79
M7T[1*Q!-!/`M/D]]P'-Q.EF4:S<)^P[UH1^MB@)X6DH3G'XYM(\:37$ASQ-#
MT.5H*Y^7UM7'U^.FT0#0!AV/"43M`/6-VT:3@0)[!=6<#!O,R?5"5T1P;ID!
M[B&AKO"!#/5I(WNV7VX8Z]N3"?-`_CL/^'F,[E&_7-3/-ZJG&.(120':/-L.
M.2))6!,W;'!G[+,`WJLF5P9F(\I94#8$:)PATN&;A]CZ3V!V$H$E;>(6H,3B
M&Y>CLV(L$Z(S6YF(VHG&:`JXL=N3`92GZT)W!I7%\#N'L)U'\&4JWFX8[U#B
M#*[?P/@0*CN$["""+^%Q#][E@O=24WKD_5VX:41WC0X"10A@W0<WQG-:`;0G
M#N&.2".T2[DUN+F`-FR<\V-=\1E&P<F+M&HY7A`+<`CT,B0\#I`W&Q&!>S)"
MV,$IO`AWB8S/EU4(31QB!_[[\#5+""4UD".F.,)*SI80G\5Q2?`,P&?QWQ6,
M3CTG'!.YGS,.ODP)@[Y,`KHM">;S(O.@I!@E&E$\&O;@M'K(,5LXA09T!TOL
M3N9ZE@#,B"X_(`[<>+Y_YXJQN\Q)F3)F6QJ-:!Y,K\[2*5PQ\U*8."7^._3>
M>WYH-+:9_!\,'K^4IU%GD=7VG^]>"A&F4U6A4&L^7\B&1&+X5`Y=B";;=D?2
M)=2K0:XD"YN=GM$+E.;:@;+,O3_SS<TTS\YU1M\S-_-<;H`+1K^WP/=8('7!
MSJ#LHE&I.P6,2F0X"-5V7<41Q+$^=3G.1:D)\5:]>HBFJUR]Y(EUZ"UFE;6]
M5:YIE;7MM4IMY>9:9:.Y15;98V3:[K,;Q_[`=CG/Q-XR<Q2<CYBUDFR3I\3$
MD_D=C\F$M&A&>G6Z1#GNEY/K45-Y=?J$_GK>\A68D]31;+R;NT22HNPMKN:H
MW+R.?-;.I.)6T*D#DM7FT:W%U)`/3[_H03M\]IA(SKB8)>^(H?H!\5SKTJ$N
M9GG')U-':GJ^9-`E#SJ6S1?.1+F?8F2^9P%SVXVX^L*0$T6K)+(4E;5)6A1I
MI17=RY+MQ@)!]?2HVEPC$#RYC-C>T,4M3!ZMMPOBDA>Z)/US`2JT>_M+:DF.
M/:Q#B/ZP@P8AB\F_5^2%,-#X3>*HQS)2C0O5N`D2]>56(HGW9$K<,!NZRY>@
MK*ULTLJ07`9I2I@SB(]/KDT83FZ!G?8\.3)19#!.7WRZU6Z,5'UQ%B$U(WL6
MQQJU6Q!F/8[(^6LI9"WO;/6MHI'G@G[!#_GE2_0M^9'3PJC5Y^:4]F,#OW#,
MM(S)19]8S!ZUX5%`#<>;<%-\PR,&LTWXO1HO-F"02U<2+:['$\>;$?)`V)3B
MH5EJ/57RG,1+RQ^)*0$RZ#!OK#+>97M=GC^T7N"H8M>RD>Y9ED?;[V,Y!T&1
MY?HF.2Z0%E$`1I_CY7=:]+8=QQ.)I'<O]U$C3XSP\T5&V%^8>"RX`3_@U?V`
MUA^S'##>9';IE$C[Q9.N<@U\NT$R5]1Q=R4E\_5[1IM6FL#X<C2W&XDG4H1D
MD"WAO"#Q*=PS#Q=K#3,%C'JR+)P*ICV8HR3YP42\I0A8=.`H+?T]%GYN+-Q]
MM\V?@/DVU];_W=@([_!#)_AX`6A'T'%>_GM\W./CKKMN;MO1/-LT/IJ?(`CM
M"#KJM1VE\C\-.@*_<_@8_[*=V:GE(>1G<-Y<?.3;$FT//G[8(+0C"+EO/_[N
M>:@/BXX?UG7S\+%1K9>.C]&\NMS9:3_16T*&E;E>JFV/$5Q8*?4'UL*7/HD-
M!;5R)(KJ,G=8A^]'E=J6;S5YJ3T#U^5&+SD%R#S?!C)7)*;,=0$UB93&@I]P
M^3]02P,$%`````@`XW.00D3=92=?#```2:D``!0`'`!S>6XM,C`Q,C$R,S%?
M8V%L+GAM;%54"0`#Z9AM4>F8;5%U>`L``00E#@``!#D!``#M76USVS82_MZ9
M_@>>^[6R++NY2SQ).XIDYS1CQQ[;R?4^92!R9>%"$2I`RE9^_0$0:;T0!$&*
M(D'?36>:Q,8"N\^S!):+!?C^C^>9[RR`,DR"#T>]XY,C!P*7>#AX_'#TY>&R
M\_;HC]]__NG]WSJ=/S_>73E#XD8S"$+GFK>98/"<)QQ.G8L?G0L/AX0Z7U=]
M.;RKX]/C=\YXZ0Q1B!XH<K\SA__BDF(/+7]U^G.*?:=W^JMS>M([<TY^.S]Y
M<_[FK7-[[70Z8D@?!]_'B('#50S8AZ-I&,[/N]VGIZ?CYS'UCPE][)Z>G)QU
MDX9'JY;GSPQOM7XZ2]KVNG]>7]V[4YBA#@Y8B`)W+26Z4<GUWKU[UY6_Y4T9
M/F=2_HJX*)2@Y>KE9+80_^HDS3KB1YW>:>>L=_S,O".!`24^W,'$D<.?A\LY
M?#AB>#;WA=KR9U,*$_ZS9<#%>Z>]TY7P+P,2,.)SI$/P/B)?&'H_!0C9D2/Z
M_'(WVE*<RX=3"+$[QL0GC]AEQRZ9=473;G977:&BBWPW\B465URA+57A.83`
M`R]15O17P;C2.XB[-90O^"!T&Y9X)`GZ!+&Q1#YBG4>$YEV!5Q?\D"4_D0AV
M3GHQ`;_$/_[69XR/.H@HY8Z?#."C,?ARV&_J=MV:M1P@-M4H)W^]2UB?;JN'
MJ)MTP?^:8FO;>>,671;-9K*W#@YAELA/*)GIX$G&)0HU'4(]H'PZXK-1Q+@.
M9"[Z1_Z1\P3X<1KR7]6.;]]U212$[`Y<P`LT]N$SA`9.H1.SGP^]U3%/IS;Q
M=$MACK!W\3R'@$$_\&[X#$--GV$3:?M9,\(@)N_,)O)6*MY,AIC-"4/^)TJB
M^2AP_4A$)/RG+@E"'$3@W<R!2KQ,Y^52G=I/]3Z(Q1[PFWT>D,LFUZMA7O2$
M[&*<LY35.T$2[@GA\I:'5"&?&R[^BO!<Q/1\9M?.C!HQ:]G0&VNV?M5)SF<2
M`N-Z7A$4;"^ZGTG@YDYU1N+6DF5FO-FZ949:ZKV)_^#;$/A,BD.VO6YJ\3<2
MLPYW,V/-5HDZ'Y(KC,;8QR$&@XA.T;A>;9,0^A8MA3>;OS+L"#3H/MF`9[TO
M[!IKWS+(-:4\*BKD2]DR;2$GRV3[5L(-+<V>;DLXR`)?@[I%3\5]2-SO4^)S
MO9B(E<*E!GQ%X[I#69@`Q]*3FGQ%?@0:=56M&_29;*@5K_-I,^WSG0&9S4A@
M1$6J:2MX2!MHW[39]SR\TN$686\4#-`<A\C?4%VWON4+MX(H$Q"J?(VHAKH[
M"!$.P+M`-,#!(^/+=3030(,WA`EVL2XT,1!N!74F(%C]1L)?I`HMHKFB=H0U
M6K,TL8[Q0M4V&U4M#9>#[LZ>Z>\__[3^KYH]W_N0_U_DN=C-Y"7QN^?F;T:?
M]>T"9RA0<X8Z'CEXC+=7=*\GZ;9UY],_0<!5\+EK][T9#C`+A4(+B!72Z)XG
MV>C>2"8)NX]IKOTV[C7?`0..R)1K/80%^$2FK/,IT\NU@[`<VVW<<AX%?+J"
M*\+8);=[L-IPXZ:NYZB/,"$45NT>T#.PBV?NA]P6'""Z'''D9,J52W)0N7Z/
MHR`$"DP7\1URU`;7XQK`W'4YA6_FSPJ=^K>&`I(HNC(^?T+(EMEKA^1?B%+T
M\E"J%D!5JP:=*A>[S2V1E'65.H,2T,$4!8_<I2\1IC*U<#.)M4C"4]4KA*ED
M6X`W0B%_`:C]R1P%"SZ[B&5J9:+1Y)TAT@:N\NVV+[DB-S?+3*$Y@FWB*P\#
M^_(JGR%<QP.Z=6ZK7=U/?U[`LE<0UZB'J>!/SP+Y]MNW6;&MM;).CG'S;R8\
MPNR'(<7C*!0[V@_D#N:$RFB1"VA3>]6-T2X?V`M-^[94DE3T+=#[*:+P$3'L
MBM=3[$?A.JVE<(`\2=LF*J[GCHI2[;WFKZP^&W1I0T*+3W29^+5[_MO7+<KU
MWG8'*8GI_GL(U>\@B%,YESYYJG`#8=UE,_L'Z_%K3A:*\S-\[%M*%I@;]7'Y
MA8$W"EYR4'TWQ(N\LJ<"G70W/:/.2J+XP0%O0&;B!4.2JZLF4@LTFK4N3E9J
MFS`#AFI/WRB32G*'<L08GW_Z+(<$??N6<I`#0K7'7_(HN"14S$61+W2^A,RL
MJ5;D=1"A@"+FXLT!N9!CWTRD'ER#BV?7CQA>@,@Z!N`/B,^9(*MENO](0:X4
M&225ZZO%[)4$+Z;U[SG)V@J?L;[[5X29K/[BJSRW]I&B6>:ALF+R+>:O`$@Q
M9_\X)&=E-Y!:BW_6GM+;`TYXA]Y4:BT91?:9WME4:#"$.047YT726\U:RI/:
MY)<\BDVL2.O$I3=\9AV2:!Q.(C\Y!Z5A22O6<M;TD"0L6E5SU??^$ZTV,\4"
M.1-)Z1]Y#UJV3,OYTX"1D&=5!=8_P?="PL&)*)^\[\$5?W+[[HGOQ?]:W@'R
M\0_P/B$<B!R=C&'%)0ER6_2!KPD/,)OS&)8N1[,Y7QIDIDC#_@$';;G[')*.
MQ/\TF9-"\6E%9;:Q%3?!ZB(.&5O+T%I>/Z`KL\V1;+DKY`*3\*E)P^S_OO%R
M[</:E3(J"G2M6TJ%%H`$_HHR+U4_3??(Y]%Y^A8JHP<J4[BE1!:!)^&UJM1+
M9;N.%!"#(:S^'`6%J#42;SFY9A`E]%:5I3D4O?%-9,/X`+/R1K)"A!MU^.I<
MP`S&Q"DT224KG$+>\[/VYF(.D!)^=62GX4F(U22C]H^1THJH[P;*VA(Q%6\I
M7\4@>JGBJ)>Q$K<!&M-9IN]7Q74I<!-'L"K7E1UCQ/<VE8K!$MF6DEX`G(14
MJW)@2KUW[GLJRNNN^&ND-@51PNXA:W/2FFRH<)CYN_0`+26]:I@3MZ@J4770
M<L+5T:P]RPE5G=1\P1=:RK3O`Y$E"Q2N$?T.\NC`.JNLVV,SDF_V=$5!^E);
M;68067B@F1OM`GBR6%HDLJ[C_0(>2XMZ(G#C^I3U,<.<[=3"O;6;^#+PV7>Z
M)N6_F5<V%WG.LSMI-^<%P,JO,&[\B5_O`Q4BNT`O[6:["%Q6'MY5`7")`Q2X
M>X8FJD[VNH%A$VM1)RD^-W0SV;@Q\))0^>>-Q)5=/`-U<7;M8OG^['-9#6.;
MP?8>$%9Y/JXTO7M5A%<XP*MV@(*5XS8%*GG6&2Y9:ME6DEX`&OMN!+D#ERR`
M+D4:@/)H>4"8]@5#W;[5O&5`D!]*U!XY2D.!8N+MIG0TC&F$&J0MWY34=U$*
MY,`LOVVU,N.58;3AHM%ZXY6/^,&_B[-;=J0^X)X1'QD*MSC7;`I/XJ2:BKMF
M\LBE;EIJ)5T91B?,:&KF8F(R;U\H?_>"VEUN)GT/N`H#+HKYH%>K6)E0D>83
MA2+K.I&AN#G=+W%%0V4C'_8FA\K4_/\W+>L]M&:N8LE/$U8U@@5?^]S'35)'
MYZH"WL8KL@L8]XD0[PG[?C4>]-+;_ZZWK`$UOHU;L6"67RKO0>QN;7\5?A1,
M"%U!5WHA-.SWL,N<H1*OY>OG==K@^^1)8*HXE+I6T,"H0OTT.TT8T)8Z^UD,
M)L/"@J;=E4]KS.P+CSK!]I&9`X3-$WCO4#-XSXHIO%?[AVO6!>KY#X*B\9XE
MC_$9EN0*%/5W/C)WUTQDF_W`22:ZVUMD1B#8&'%OJY[O0>KVEG.48ZR-7Y^1
M1FT<%S)<Z;1B+6%);[KQ%8L-K&UGAUK;SJQ8V\X:>#^I]&O>>ZUT<<=?.<J$
M)B5[&2N;NFW3<:8>R\T%+</6:A<P'<H&%YNJ6K8.8>7=I37'[5?8E<OANF9G
M(0XA7W!1(IE_*>!AL@IY-L.KPN/2*9F]1SSL;+BW>DW$"FLUAI&X!8]$-!01
MZ"6>A--_\W@T+VK([Z"1&&A'K<^<V8<G\!=P33B#VL]TFH@W'Q,9$Z>,DW+A
ML?&E0Z7Y/;@D\$HXZH;@*R-S$Q)KWU%V='Z88EJ&Q;7<*R-Q`Y!J;X<_]-I1
M>LUXC2QN0E+M#?,'I+'LRK^]X+\B$M="QC?35QII;WS=MGPV7-7)8>-AU8BU
MWY&\NB-)?&E,YI!D4DBW]Z\6V//M--6KK(-G+U>PWP-=\)>'K+2`L7BC#YX>
MZ\V76',X:L@<I)3YB+PAC#-S--GMVXK^VN!JH\4"CX+J8P0OWR(H]%3H>VHK
M128@V1@FI@QYJ<<51;8#1.ER0N@3HEZA25G32PL8+@6.C=%CRH"-'&9.D6:.
M9(/G,@R-RB4SIMZ^CSV*CURL8$UJ>_HS41:BH2M3I'T\95MO^BUY9;G_^ZX8
M;8P8\'_^%U!+`P04````"`#C<Y!"R6N\,@)#``"\S00`%``<`'-Y;BTR,#$R
M,3(S,5]D968N>&UL550)``/IF&U1Z9AM475X"P`!!"4.```$.0$``.U]67/C
MN);F^T3,?\C)?NU<Y*6JLJ*K.^0MVW.=EL=V574_,6@2DM%%D;H@Z;3JUP]`
MBA0E$@M)@#AT*BKB7J<-@&?#=L[!=_[M/UZ7P;L71&(<A;^]GWS\_/X="KW(
MQ^'BM_>_/UY]^.7]?_S[__Y?__9_/GSXK[/[FW<7D9<N49B\^T;;S#'RWWW'
MR?.[R[\_7/HXB<B[/_*QWM&A/AY]_/+N:?WNPDW<1^)Z?\7OZ!^N"/;=];^^
MFZX(#MY-CO[UW='GR?&[SR>_?C[]]?27=W??WGWXP#X9X/"O)S=&[RB)8?S;
M^^<D6?WZZ=/W[]\_OCZ1X&-$%I^./G\^_E0T?)^W_/4UQCNMOQ\7;2>?_NO;
MS8/WC);N!QS&B1MZVUYLF*9^DR]?OGS*_DJ;QOC7..M_$WEND@E-2M<[;@OV
MKP]%LP_L5Q\F1Q^.)Q]?8[^DB[;QD_(SU0%./^5_?,_$Y1*/1`&Z1_-WFQ]_
MO[^N=\-A\LG'RT^;-I_<(*!?8C3\FJQ7Z+?W,5ZN`E3\[IF@.9?%XON,\E-&
M\[^PT3[UH(;^C$)F/Q]\-'?3(-%(6WUL391&2Q>'9@C-A^Y%9S;$AR5:/B&B
MD\B=<?M0^$R)(5[ZA#Z4C&NDLVGT/M2&43+5.F4V`V8T%03)!H_7(1U@<C0Y
MRM>*?RF6Y6GH7X8)3M;7X3PBRVR%>O]NGSE&%!TB>48)]IYP%$0+[,4?O6CY
M*>-1.%H_0L^C,(X"N@,DR#]S`[8`/SPCE,3MJ>0/98C$.Y>@#3ENH)'>W7'U
M$?^0T/]E>HQG\QF=!9G^>@J:,Z89HL^?W7"!XNOP(8F\OYZCP*>'B\M_IM0B
M]7$A^LC@;&DTL4Y?-,2P&S]?!=%WC;:W';(?R3.R<$/\=V;&=+F[=9.4H*II
MTU^>N3&FG[PC**8?SWY]@1(7!_$C>DW2+HK2\]E^K#^DRZ5+UK/Y`UZ$]"SO
MN73%][PHI4M^N+BC4O<PBC>?;,]BN^$'9&5BF)?)D,QTML!.7^EY2,&Q%['A
M4^1O+7TVG_HH"MUSVI6M03?N4T3_%)$UFQA10K_E(?SB/@6HLRUJ^S(,`72P
M8'V?AB&"SG:OFX"><QT%R-L[#U8.V]T77[5QAR"^RW*K./`0Y!^9(O]H$/*/
M39%_W)=\=A*E1QSDGT?+%;V8]S1XX7`&2>UBWN+Q#!+;Q9C%XQDDMHOIBL<S
M2.R)9F)/3!)[JIG84Y/$_J29V)],$ONS9F)_-DGL+YJ)_<4DL=TO.BJC:B!\
MQZNBA6C1B/T(OL$>%00ZCX(@/^CB%\2<O;1KM,X\OPN"<E<+_365VQ(GV;\Z
M[\^]OVB7X<Z*U/5A#09ZCU8I\9[I3+@CT8*X2RU&*ANU'^'7(?T:>G1?>SBB
M&L;0352'0V#3(+K)ZJQ9_E#]2+Q'`7/DWKDD63\2EZ[%7G;][DNOXK@9\3Z:
MTSL^^_,-I72'!]H,A3[R"R[8V'J"9ED^0^3M?"U@&001V159-?PX=^.G+&Z8
MQA\6KKOZQ&3Y"05)7/PFD^Z'SY--RL"_;'[ME)YRRB*ZIC_&Q5?H*H2"[-L.
MO['S.1>5#8H?F8]%A=JLH3/95^J4[-+L$J\8;1/";943,2?14D%<Q2<C";'O
M(D*W]-_>TQYI3"F)5HQF9O)Y6/A7YINB9G@99-WH%$(+]L/V[T%$3S*_O4](
MBCHJ*4;>QT7T\LE'.-</_6%?+?173F[%]VB!XX3.J>36738IAM?4.3*AFL9T
MAFY*$A!>J&E2T],0(C^G=!,WN*9+T>L_T%HH\[VVSO%HA%ZGO)#ZT<!2/T\)
MBX%>X=AS@_]&+KD,_0O*"D?PO.;.R0AD+R"^$/^Q%:._P@$BYY22143$)K_3
MTCD=@=";Z2[D?3*PO.D!B:5W/JR73U'`D?1.&^>G$<AXG^)"NJ=VEG!ZD8OR
M;(N'9Y>@>)8F+-V4D2A>SP4=G9]'H`<E-@KE_#2P<HHS^B,=EJ.&:A/GEQ$(
M?(_@0K0_#RS:*:7!9W1<!2[/Q'?:.%]&(-Q]B@OI_F+)<.\0P9$O/I\TMG4F
MGT<@;B[IA=R_6))[?E[*R;JBOVNZ3PO;.Q,C-U5#\F\D?WLILJH$=FA55T'9
MVIF,X3XJ(+X4OYU+Z9\H"/X11M_#!^3&48C\ZSA.MRPW'F8X?9S)>&ZI`A9*
MA0Q]7\TI^R,*TC!Q27ZOX,V&QK;.9`Q752[II>#MW%0W5^A[M(H(RY5D_'!7
M(U$79S*>RRN?@U(;0]]C<\+NTJ<`>U=!Y"9"%53:.9,Q7&@;R2Z%S;G6?MJ-
M;IB,=_"?WQR"'8=@!Y1@1W<E3>.8&O/TB04&O*:UI;DA^+`'EVS=08_NHF>/
M>P0"9W^V&NBHBZY9Q!M"N?-@<)/.WW?$VV3V6Y1L=G:1@0NZ60UZJ.I!P@`<
MP[\C:.5B__*5Y:FQ/*$9W7Y)SJ9<3PJ]K89+5-6EQH?N:&'?G6(VO\#Q*HK=
MX"N)TM5UZ`4I<W<W/CA1F'2=![4:KE&>DGW8TQVI[*MZ56T6'-B,X[13T)9B
MW='*/HMD1$V"7HT"-\^V^F>*5^S00Q=UX>K([V8UT*.^+`H9T!WP[*X@]EZ.
M9;/>1&ZXN^?>1J$GG2LJW:T&CU05ILB(CF!H+=.2_L*Y0'1IQ5EB<64'%>I`
MI9O=4)),^*H<Z(Z3]MU#I)N'W0A2NVVC&B[2%2KM+N`;[#[A@$HLFXWUIQ4*
M=WS5(>!'F;IP!.BHO;G)W;EKMI2JWUUW.]B-0+42O?A&6V<+DK.!T.-[A5DE
M;37WL1NQTJ,P/F=P'!"MM-7$C$W_@@8U-;,$9_VKT*>F&+NQ+KT:J0;`[%_]
M.YTC1"*`GMVIQ@,<!=W1L1"=P[G=_>$&J2C4UM#:F=C-_Q2*F>LZ;>("S*&@
MDA<L4\A^4V=B-V&T@S::6("SUT]]'^>?OG.Q?QV>NRN<N$&%:-%)3=K9.;*;
M<=I!7VI,P3D-W+/GK2'R+UT2XG`1TT-FNDRSI[`75.@>%FU%\L[.D=V<U0X:
M5&,*SA[5!&S:XO#@'-EU-W304#,3<*(+LB-K#R>1<V0W[[6#ME18D@0>(*2D
M[8+<'O+35"D^Y*?!S4_;/>I3"Y^1C$,_.VK>(9(]O%.^\?`&&$T^FS([<$[@
MNR3G#R6G:?(<$?SW=@F4JFZ_(W@0`&4VX!RUFTC-GH*T55/>"3Q6@!(+<,[1
M362*GUPK]@2/+Z#.!YPS=N5"W6'?4N@-'K&@'2]P4GMJ[_J5MBM!+_"8!FH\
MZ`8TT*@AZ2[%Z0$>_$!./YP<GY9X("K=P.,G*#(AR1.RY#[@U#DZN`X.KH/Q
MNPXV!ATN-D\L5%ZY<?N,QD$@X@".3^`K"BF9P33TI_Z2"I21R$"#-T0+-"3I
M:=4K()1]L[KD[("):M^C&%&!/%-:+]`+"J(L+5^N,6$_JRZ"#OJ2,0-GBM68
M:[/L674(=%!+$P-PW&HYT/1-%,=7E-GS_,T7)79[Y#I#\XB@"B#UY2OEF#*`
M0Y>LLR6?)?;3GE20E+[%-=UXZ2%3M)<9_*I5ST,'\S`K"C@.0DIB5$@GYZ5X
M7BH_^DC[CL:)H<*)CL6A\3G2GRYA$,N"1;>AE54OA)*X=B7=S(*&DTJC2/.Z
MKM?AE8M)YC2<S3<?+P+W3?D*BCVM.A@ZBEZ-+3A'D>OPA:Z4;/;F3"IM7LU=
M[#[+ZZ`O%8;@G%2RAX1<+D4G2&%'NZ_Z>FA-SM8(-O\NF[[=)WX]-";D"$YP
M4'XB[76RM_OTK]<RJ<(:G%#A+KW-97=O43*;TTO%-$D(?DH3YEU]C$J0P1P"
M3UG=/;YA]WVA-JOH*0$X4<Q;E&PY$ZW2U79V7Q_V69GWN8`3N"P2Z8MLA#,W
MQAYS\>$@39"O<'M6'`$^*&<'AN`<@>2[!V5GCQ-9(D[G,>V^=6RCOZY;L8!Q
M,%&+-EM'7^/H-+K=]Y>ZS:2S".!X*R0BZ;X)V'[;J6WQK[[PM'^5^A/AQ3.S
MU1=J;@MTFS(YS.89X94D''4U=AO0]DM0=>UVYP_F(ZAJ%E/N&HVOPX8W;8>T
MID-:T_C3FDIV<JMFY=ZCD!G_]!4K65A3/S/I3<^T)_'2)_2!_I9>$NFP"BHM
MU211)X</,"?//?HNLH5<='IH:F\HTEZHXX._0Y5`*SQI<PX0'%[>FG*<"S1W
MTR`QK*3-1P;24LD4&&WM`QY\VSD-*<`^Y!VL9C5QIT2S;K@<@%$*!T=$JAMA
M/ZOY@"U5)&,$SI6V\CA!JIY:6ZLIM2U5TD0\G.AZ7QR4L21@-9(.9S:T>9M4
M?\LSE@=C393#F0I3_W_2/!TF?HPX"VGA>D(^F__T+)0Y$S/CFF5TQ_>(6E>,
M$_2`R`OV4%[+\QYYT2+7C7`;&H2"T3Q@&TX><.)%&>7Y0\J+E-`YDI.;Y=0U
M\RI;L%L-!K]<<3_>X/B(.?3G:Z0N38M&@U\9N2=S.E)R&K-_1:9W%9'+5R](
M8_R"F.<W1,%Y%%"-17G@:;H@""WY12"TC`T?#5\KJ\8*>0@-SY"F6PX.OZ:S
M7E[A9.B(S'?JY6<.2=:DZA#PZT9WX0A.H1*A>?;397T,^-6G.[%4://+D+OM
M#3W/AS&Z0MQG38J]X6?!M61FZ]L8=%/LK)!:=_BX_&VY*572Q]_4>HJPM(0T
M8,FQ'6?)[@"VL?G[3Y0Z/Z5BM#^]%)I''\TTC0`_F:L#0Z5N^KAF6D^:JO]H
M&OJ;IXSQY2LB'HX;4[7Z#@D_64L'AZ4Z^SA@VD\UO?I4&],VBK^&Z:C"8JE1
M^R^?1,9YB[YG?^EZ'2O[VX;^UW,7VV&G5*']]T="<^RAP[T!;%<$T'0'V^&G
MU&(?UTCCTJH2ARG6AO*Y_SWR`C>.\1QSE]?>XSI'T/TBVM@LM6O?6]+MC>#1
M6+P>-;)+T7-<&[!SS`\E.`X)YW`2SL5'=U8XYCQJ1&%I;`<>`I-'M23S",**
MXL;/5T'T_0"]>U@RWL(;%;JK,Y.^(]$+IG/E;/T[I>4Z+)'[IEZ"7_)Z6PK`
M=*T'`[]2]6)-O)P5_UE+YF.Y7J&'`[1SM'N,]!F$B<]9?1K0S0R:3<J0<.!D
MCK;/UFK.6;(9@C2E),[FPA.`*<#&BAME&DNT)&QO->-]&"7)^->1-B]3TE5$
MVH;':EVLYL5;4563"(S!RF:?G,VSS_?-A>LTEM4\]N'TVU4V.G+:%:9I-0]H
M-J?<+HB[G,8Q2M3FK*"_W61T6S-8(A`=&>P:8:*M)I$/IZ(&MHVEEYL%E[::
M&CZ<PA1%`0=Y\0*M"/*P[.I0;68W]WO8&\,^WW#RP#/V&"@"7;LOHO0IF:?!
MU/.B-&S<`56ZV<WW'E:Q,CG`R1+?RH7MTDL&XOJW;+IR^]C-`A]6Q4(AZ,@;
MUZ/?_T2!GU#Y)2FAN\,#\MC_4P8?HL#?_&M]C]R`E1[]2J7,I)2=QME3Y@R6
M_9%N.H]HN:*G<;*^7J[HWI/)6&`@YCYJ-Z5]6`LS*T4MN?2:JM1MB)^%%SA>
M1?DU(;LE4+$)P1LD/>VFVP]K+0JB,)>KS[(RL@IM6R/CY-$(6MO-PA_N%"]@
M7TO2ONY)^>`&]*)1'%^H:!!^D02%Y9WMYO7;FIHB:6AY%*`-S)D@-T87*/__
M"M^;U#Z%\*'Z('9?"0QK"^VDHN5E@2F;:+4BJ'2W^[B@I694U=O,)AATN3K!
M=P31;<F_0'-$"/*+NA.AGQTIN4[P?@/:?8!@2/6JC,.![*KS<!LEJ&*[[32_
MW]GN"P5#6FYBTEQ\LO;Y"Y0=]F/I!&W3W>X;A%Z*:LNFL8ABPU:0?70VSR]H
M;O"51.F*-LMO[(TE'93UV&%LNZ\7#"BYHPS@P&?Q3P]W[KKS`6O3USFRZ3HS
M?+JJ\`BJ:%V=7$+-KXC6X9;[:;V[<V33PV5.J0UL&@/$JA-0^;*9U;KK!YPC
MFRXR`TMV'T'`B9:J)Q9KR;]WCGX<WUD[J0!ZM\\A/*]/K>EMAF`PYQ@Z\D8_
MWN`DRM.C1_$,FB6Y$?3-)7^AK"[J-F8GRIE0Z>\<6ZWLW4U%G-P(57[!^,@H
MWQY"?E9XCWGPOVU"LO0RR1)5D;=):]S6GI?DR+0=S3FV6B5<J_:[<0_'158S
MWR+">A>X84+9*,-[;>8\=Q#GV&J%<:,37\@TH`5^SV2W0?56*E<?Q3FV6C_<
MY'27<`T'LEY="EJ.;<XQP(>1W53>CFDXSC<.W5<X=.D-1\^!73"8<PP=K+4?
M;\;\[-4EID"DF,TK%8JN(E+%?"N`WG@QDL[C.<<V?7$=M5)WTO3BW]135Q6B
M>CW6T_<!Y]BFCVY0,U`7"*#SNXPOQ3-<8U_GV*9G3HON6_$*YY#.')$OB*R9
M%YG06R3#)!(=S1K;.R<VG69:U<?E#_P1NX%?+0<MYP2@"ZV;<MLQ#>>(G1&=
M07WN1X($&N9W<D[&`D`DY@&6@B2J<$[&@C);4`LG(>`A7:UR(#$W*+#HKL-Y
M1);YB4E^KU0<P3F!CB';@2$XSYJOPP01%"<,[5:8P+%MYIQ8A8IM(65>EL8N
M+V"",WG4^=%]1;%4'3LMG1.K#A<-&JFQ`^>65;!T&X4>_7'K_`O]AE,*2_$(
MHC@E2&$)[#NT<P*]!H].3G4DR31Z9+98WIZ;/S6\H`><%_KS"RK1*+C0X!PO
M3+]!G1.;GA<MVJK[8?J+Q)1/;O]96V.B%L_+JMCYK:<YM9$CG((6G<#RX5V^
M.P%_[O$N]J8,B'D](PLWW$!0T"7GEN554&/:&A#]Y9D;XPQ^"\7LX,%^?8$2
M%P?Q(_UV>H#2/^!BOPU<;/8D2_YDHMIL/%C6NT3#`=U_2)=+ESF<'_`BS(XK
M8;)YGL$J_$0!]MBY)U]O#@O-8:%Y`PO-,+F_8UF:5+F!XZ;0BWXV%L>XB`,X
M$5W[6==C\:%WXPU.(/BM8=2-I2B<41'`"6I6S+X$SMVZWX0!`U%'JY4MVJA9
MRH8D0`KU#C$Y7"(.EXBW<(G@O8@X6S_2;T]?L>1@(^MMY@+Q3'L2+WU"'^AO
M41A73LT"]98JXQYE%+@!$WSFDLN(O<B6\BZJV_8V=*<H%/;!WZ&QKC=%?;14
MY@Y_/Y(RG0LT=],@,:S4S4<L:K5DU%3P<3:GIP-4?IL%65-"A4E/--]VSDY[
M<4=I/ZNW/L494X\AJK!E2A4W><I_1-;E]X4JX+:W>G'J+'H1.\:JBGUSPW3N
M>NSF%B[4Q"[J8O4NTUGR$H[@N++N6=D6R3FN;&.F&)^1TUJ59CA.W8PJ[E1H
M:&6HII[R(6M'C`))E]2".3)U$#60(U!;F>L\T.B1_3?W%2_3I53Z.^VLEA?<
M,^)FJ>^3"T?>5&!*\JZVLUOM3TW@^_3"6<FY)X/?8S1/@QL\%_FT%'K;K?37
M,L:CPLP(='<9)WA)&?<+RE_$(?(VX]@M!*A%GSRV)*=9J$[Z0V+AP54/S54?
M(^_C(GJA4P;G^J$_[*N%_LJY00LWN*16G:PYE[>&5B-PMC=3K?F@I2KDG`:N
M>W6_B2V'.$=F=<'N$3L6J5J^EG44KW$W\S<O0&[XGU&<O:81^]<:FEIQ)C=9
M88/SK)E<8X)$OELBPHCE6&]IQ3&L*,9&:N$<P[^Y_Q,1YDAE^-KHJ3AJ5M-]
M)(Y)Q1',N)"-N"W5.1J5'J4A2N4QS+B@U1VB+1346<,EIW`<3,.J&(@C=DA=
MPW/BYAAZ4I]BM9FA:(6:BZ/5Q&K6UQXO8%11[AXY0^?1<A6%+&E2LC\*^YGQ
MMQO9%65\P`FG[A$H710;VYORS"MO<E)Y-ZN)RPR8B:1+/4`V*,UZ@K<'_>D2
MX@HN98WM[$9.^).@61DUTL$(_Q[%"<%>@GR&4,!>[-#_8^R]N`$SLN;?RG))
M.@]J*(!B)OND%Y=PGC]UXT.>==%C6&=B.>^XIVYU&LQ6(B-?-$Q;#)#]&J+I
MF/=3TWUPG3^W+DIB4G*^I2SV>I6&/E_Y+7H[$YNYT;UG;X/S5IUO,'/_!GNL
MBGA\CUY0F(H"Q7LMG<E8WJ4V$&XLD7KSK<VG[N@IA=+H+IKD*FKN3*"_!I51
M;ZQD^1:9[AL.Z!RF<ZX`BN`(6=##F4`';U1@`,[1,U_[6/;\ZXI9AM"SO-O4
MF=CT0[993IHHU_$ZO1D6,UJ[`7LVK[:>\)H[$YN)NJIV+J(>#NKV!5H1Y&$9
MKDNU&:M?#%O\/*KA@&1_C2+_.PZ"+2R$!"VRN8-S-)8473[]<"I53\,$^SA(
M&7KL-F23@WH@GP'(,*=:FFR@9B]=$M*%,Z93^^'9)6BZ9(=D@0ZUC.\<C26+
M5QN[A87\8MU".-?CY-PE9$V)S^!#!!:@U-\Y&@M6EC([A0:_6,_/;L8/GLVG
M/J+TG-,!L><&VV>K#"TV2NBMP$.4OZ<`'3`:#SG;T'*V>VQY<8R2.(/57D6Q
M&WPE4;JZ#C<P5HV31:$*08]11X/GV(]'.+ES+>CG/LNY12)KT/0%JPB2/;7-
MN9YH$PP8!VP+EHH;@1[+*4:SBE!BVTHJ0H"SP'00RGE*"!)?I3H/:A5'Q8B!
M])(%G)>3ND[F!^3#P]'\+1S-\T(J)5-G;L"J##\\(\0.`-LHRA:M-#Y;[ZP!
ML7@1D"5*#4/`")Z$#BX0F,<Y&?&W[E*.!-AQ1-M0C\.I7N$0V$IL!UNJ"P5(
M,M9HC<IXQA;OS"=,U!)WLGHQ[#%]FQ(H)'R:Q[*\0BAN=OHTM@,/^L^C&LXM
MNBS'M\G3B!7<L-P^HT'G%W$`Y\G55Q12,H-LS5Y2@3(26=!3GC<DZ6GHJ;&:
MGH2RYP3YI>R86II:^#ZV\_P!D1?LH?@\BKGI=OT'MOHDM842M7%K+!VU!76[
M:28SD;-9T\A6P2/-J5G`+IP%N`4_^Y+2$WW8']4NLF6'E;LGKW"2=KLPHE2N
MN=_`X\'2[,^G#F/@K?\-"U3Y[4UQ\+1^"^8?E74,"Q]74Q>7<,J6-8<_RUKQ
MA1%SZL73R]UL_NB^BJ>[A@^8>BHJ-@UMZN:N$)I$`\8WN14,2TOEN&4VA$^3
MA."G-*O<^AC=HQ4K$4IWPPP-31I.T?`-.R\-#1N55NG`J?NM*ZA]0`H^A+;?
M3FC[G"`?)U>NAP,^?#"_\8A"QHW$@]GV=JF3QMN:FML.S#8+6$49\"*D6M0!
M)+;97R_PL*#.H^62+A'8#>Y<NE9((4,:VUN-0_)F`$<O'/K!*.0>!:P8Q)U+
MDO4C<</8S:NYGZVK?Y'B0:D.8B:,:0C^J053<**<5>*DZU^]L:&X9@M@IC92
MEVNNY`KDC.ND("#;DRE-6<N,N0F\3LDQ93^KL>9FHZ\[,56X`#-7V$4^WM[D
MQ8^DZHVMQHW;7$X;28>SI]Q$X>(1D25#9-ZB<)PAEV0OE`EF1%_3VS)!<7)/
MV19HJ?585J/"K6"E.G`&Y^W(`PH0`S^KIE!>A_.(+#.'V^'-]L%[]G:\9P4:
MWW;)_4JB.%9X-"?L.)Z7US(VX.P]TR"(OK,5Z2HB%U'ZE,S3H$Z^@N;:C&/U
MH70K1;;D"D["49U*>NKI,@&WW:SZA?I-OQTF)-D?X`X%A^>BAU.!W5-!XSW_
MCJ"5B_TB@^\>Q?0H[C&TI0OT@H)HM6Q>:I3[@M_NVW`"9\>?T>6(;)?&6/%H
M)NHVFOU<P@2<[7O7K.3::6P_F@V;1SV<I-W,<'(8"\6ILM,8_/,R(>F2I$IP
M!Z:CPX'I<&!Z`VX4+J36V?J1?EL2-5;H/:(T)35NP$16N.0R8J5A287>MK.:
M%/714ID[_/U(R@02=#:O57@Y4R69TFRIO996C]>*4ZA94W5&3"4#Y/C9]$@9
M^K/Y''M(+FV5;E;/TYU$K\B5N4(Y92:"F@:X[:TB,W06O8@=2+=^#GN9GZ++
M'I-UM)HXT\X/(&$#CA=MZGGI,LUR@JHU/.C/`<HD'/K3)7OU\[<8'5<<B]'R
MB=&DZ6AD>`1S6IQM)813'DO*CH2)L07BC@]^I8-?"5X@CBZ;=!3_#VK^$9'5
MYFMJ.XI`&X]R8R?FS0?9H9U>GWGEQS@MP4?$^'3#V3HW]-U@]XF]!L)(+8.L
MN<]H@F$B#@#MF$GD_77FQKOF<TAC/>R3$/9)34^)W'`AB[*4;4842ZG2#,8-
MFQ$EKW&_;64[`K(C18&@2VK'+&H@\8FV,H<7;?A&!;=,EU+I[[2S>G;9,^)F
MJ>^3"T?>[JN:O*OMK(87U.2]1ZZQ6U!6Z+1VSIL2PJC,(X/;)IMKV?2[2_PK
M%Y.LNN8TCM-E1DU\^<H>Z\?HCF`/S4)>56VCWP2/+#V$!.#XT35SNLK<>!?X
M!?OT;B-Y*VG\VZ,)O`PA"3A^!2/<_A$%=!@&6F+#ZG:_/IJ(SS"R@)-&K)7?
M>QS_=460ZLMPX]\>35AJ"$G``:+-6'F2<_O49HZQA_@3F;$9^:A=X/+69F9,
M!H6!G8(Y\<]V*;V*R!SA)"6(38GK\`X1'/FZC_Q*'X6/;3Z,#`J;^0EV^.#P
MX/40/W@+\8.^$WJ6)G'BAJRZP6TJ\5]I_Q;XI`"3G+\!_\B&NZ^T81(+=E\S
M'P*?_V",;4!N#K;'7M,C)/(O4@:2E=.8L1-G?YSM.@B%YM%ZL-$D7'1B[0WX
M%#9<;8^+,4O1?%WA30V``18-Z;='\W!Z"$D`\RGTNJID,RF#YC%]LJE]"WP$
MR"3G.MP&,&RH<F[[$^'%,[WY3E\0<1=H)^`US)E91,';CP*UEH?$$0')"N-6
M!T!3EJB/BK<3&](JD\(B?QZ_11:L63?*5H2\G>B1;K$4IOD+?-/L>\BUM)'W
MHFMD`2F;8BHL^<OH+;ERM+9DLXH4P`]]61#(UKT+PQ"[!(FE9^Y[Q%1$?W\>
MA5EMR]0-6/3X2&:4PU(#OS:Q9>&4Q@HD&-%#`OPIRI.`D1R3[M38J99LPU@[
M"J<T5@#A#WW>C&O**`YC[&59.<-XE':_::>BLF4G4ET$I7D!";OHF6"[?`ZT
MY.U]U)F,*M)B3`:EA?4)LAC)J]MU9V7_NJ!2*Y,%#676R3[K3*"'4X:20FDZ
MXX^M"%VG2J9GB1)G\J,$6SH(IC30/F$7R=KF]=WT_Q,%_DZ-2XQX8#:&O^I,
MH(=*!A)":3=]@B.&<LW+O;R3W1CYJC.!'LH82`BEW7`B%U#RS0_U`@[YYF\W
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M&L-K"C\W440YG)U28VJN!3PJ\'F&1ED'!"OTP^`V_#"YA"T$`@SWZ,=^.0<]
M/]&R<`YX27I0@\#G,QIE_>T@)HWGT?K1CP*IT$(@<#R<AV?`1Z,"51A>.!(T
M)2B)WX>"WH?$;X`%O3MO*I?_3'&RO@YC2@7[9;R9Q;=1^()B.G>YA\<A/@L>
M47P@(<"KU<>C70H>/L!7P2.)#R,#8UE<VDG_([/VH8UF]ZO@L<>'D8&Q##+M
MI&^@Y8:WF]J'P2..#R8&8VEL)O;8W/:[(!58I@@\&KE]^<`K=::V;8.QQK98
M$=#C7D"$I,,C-XA=[AX,H)AE2ZK``Y?#D)$.(/-!SWP,3AB*2;:B"3QB.00)
M`0,O[^$*SZ=B#GR=EV*-V*_:QZ9-!C/T$3DR6',P,I-@G$,)?9P<0A^'T,>;
MQ;SI6,O=>!J$]*/@8R2#B.`-I$R+:KA?X!?LTW6=E><>SLKJWP8?6AE2$F\@
MP5K$[1]10(<)Z)'>AM7M?AU\=&9860!+J=;%[SV._[HBB(%L(WI93(:TNZ9O
M@P_L#"D)8*G176YOHCEF[)HM_2CX<,X@(I!$;*!<@D\/E^##)?@M7((+=G*G
M+;/T*&0^6QF$JZC?F,!8)7R`>4N^1Y\4B[*QO75H4YFTFY7$X^6M*0<(VH5>
M+<%#POC394>51`K+L-/.ZLV3.P&:-;%/N"G@S#RT_$A[<7:+>B,S5RFM6T,C
MT<8RK[=?XJX:3<T,71:D*WFS<$0"+.DU;X4M)6AYN>TN2N-(QG2E6>*$S1$6
ME!<"S34UM9(%QK.ZND`Y)!N#%Z:+C1NG!"G)D]/:2@J3NDCY5,-[LM+DA3BG
M=S`<+K(KOPACR.Q'WW9:D*H(#B&\80)7X\K2,2V*0Q!ON,"5&>32L5A>71B'
M,-XPP2M#Z*W`[8XGBD,@SU04RRIH*I!(7@6'%7@H[Z=#*.\0RH,'Y;%QXL:R
MARRU=N`307E4&W,5;#[&%J@PYM;VW6L%/L6QF69C:`_GSVQ3N`Y+C<WFFZ_?
M8/<I.\_R7(3RGN#S^M3Y,%=[!WF!&\=XCKUL^YK-+Q#!+_3G%U02\!A-?1_G
M'[QSL7\=GKLKG+@!1S?]!@6?&*>%1<E!&<HYYN?#.>9PCGD#*4G3,,$^#E(V
M/Q^0EQ+,JL)?OGI!2N?-%145,_XTV4SF2Y>P!W7Q'2+YG7C=/(`DH<G@5T>4
M#F56"F`R0)JIO'67\AJ_LJZV4ZP,:["-V>P(Y<?0/9`,+J!&<$@%ZW_J59EJ
MS?HQD!5F.>A0!YJ@)V?R2*]IRNBE@],`_LID0R)O(.0OY5J*B#HT">-Z;S2,
M0.!AI>Z37#QX-X:M*_W@V\9X4V'_#<3KI5-#!5;5`A7@H=SLR`18+-_LL:$+
MY!LD\L"G>0(3UALHH]3R)`+3PMO"G+[]!%,3(H,'#2L]$@V.P=F?(O@YJ``$
MI`,0%OK"VQ-*%A:!/T"&JW9Y26!FH43W?SE$]P_1_4-T_Q#=/T3W#]%]:('=
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MMZTS@9[K+20=SJ6V<[#P-MI$!>M1PVV)/G-O`UI\WIF\^6SLEM*`EXK-9V!O
M#C''$=>JAB;!F;SI?.V.$OD14KC;ER$5AO@AT>E,#GG@'<7V0Z6*7U/^<1AC
M#T!>^"XMSN20!2X0S4BPXQ[IT'1R'7*S#KE9;R`WZRYP0Q9KED1KJ\U&E/VT
M1S:8.&)!ES1!9;>A[52D?7&*A0XO4ZBSV($$<;O)WW@H-X?RIU\]^OSY9Z$?
MLJ&EU=R;NJDV7%,;:1Y`EA-Q]*&AI56@B9:RK-`,Q^N8G6&+TCRBO,%J.S/I
M-&:R@??HAB-YZ8TCYETYMCR%OO(";^)SAE)2U!.%]Y7;\6[7C74PF_R;L"0@
M!PZK)C7,N67CEZ#?S_XY7:T(\G#&P#WSL,4/+HGE&W&+8>SB61B:_9R]OIU8
MP*PA]RB@&RIEGR3K1RJ:V/4R/L[6U;_(,IR5!S&3+F8F!;H-4W`*+%6)DR[I
M]<:FLL_44Z9;B5VNNBU;(.=<-Q4!V32-Z<I\3O9R%41KA-AZ?4XIIM]BT51Q
M:I&HC^4$PV:#KV]54A[,WO93XCW3W;8(7D\7"X+RO5A08UFEJZ%41.VEEU5Y
M,99+*R-`6&58K;.I#$:E\LW*`FZOFRUWMB:)'N4`J`P]A)8&J2,=A3OT3`LR
M_L3)\P,.%P&ZSJ+`D>1FU6DL.UFM+:=*78.=>1UDVNV0\OB<E1:,$YRD^;?4
MU-EC1#MYM;V5VI-C8P^<9,;60;E]AK23"6M\RLI8-E>W*S_#TA6CI.<J(E<X
M=$,/N\'4?\%Q1-8/B+Q@#\GTVF$L.PFH&A3:D5?=J:4Q\CXNHI=//L+Y!9K^
ML']OIK]R;M#"#2Y#:F4\9U1#*T.)E%IO!1RR=2<RJLHYIX)[T-QO8BK13WK6
MYXFM+MQ]<C6[@<P)UO(YO;.$S1^\_7F4DC,<Q1Y&H<=P'SWQRL[MX!S9>&S;
M:)8-B[20;&.NL15.HA4?^Z'6QCFRX?I2E&&-4D")`,7.D*<2LRA5%`I\84K]
MG"/XCC!E1N!@8^]1*/7:-[9WCBQG-<H%WJPH+C=@0BJZ]`,DL*);46\%O>S(
M9@HE?Q8T*Z-&.ACA/Z1/,?IGRNSKA2W3\C1`3@_G:#R09@(6=$`7&-.,/"^+
MU\<YL@Q_)A*YLI*VO$">/[VT!&77T:JN09/QQ;!J#2V=(ZL/QX5FSO.NUQB`
M.B&DNWIC>^?(:KI@"Y5(V0!TR>Q<9*/V#ML<E`CO6\[1FW]&+&+][5C1;J6@
MKR2*C8`Q\+_F'+_Y<DUBYN$!SC32:ZZHDO!KSO';+I@D9=Y8OMEU'*=NZ*'9
MO`A1/D9%T'(VK\25.0I7[N\<0Z\.U)H=8]B/C:AH!8(^1Q'"/LZQ3=#"7F!P
M51:,X4+>X'E%Y1P)[S9RCFWZNE1%6J?9&`SD5GLK3'*8$DJCU%JKC9WC<6$6
M[M,.IV3=>>#&<:GX&<F>.%4.L8+3G:RK<SP6L$`53B0%V/I/AZL@BDB;!;S>
MP3D>`XB>F/Y"SE\,R9E.1GK@0KRU>Z^5<PP=P8U#]/;*J3UIXYF=4J_#\MA9
M3IP;[#[A`"=K7O:&O*=S#-U1T(*14@?CO_=7T"GW4/QDN,,#4^"<_"C^@18"
M*0W1_JO6C*4G.==/<O^:(ISDD<PHAZ7&.8'NH;`LG-)81PQZ6Y^BQGWN=?S@
M$^A^%*.LEV;T0R#(PBP*KDZ><P+=[P1-6J5]V\^I!`4>;<70NX!<GT!W"X(5
M6VGZNM*\BJ<?.)N`N>'G/^^;?/Y;)W\9ESV:4W5F*O9T3J![-ELP4BI*>]6;
MSC8Y6`T,?EV'$^AN47-\EP:AW8O:F]X_LJUW&OK,B^;1'Q\C]BN5M)E!O^^<
MC,''.Z@X2JOJXS.VC>2X>Y=!973?E+M-*R'."70WN3VY;!-VS*=D%!&`>^1%
MBQ#_O2TF(<W&J'=U3L;@BU?EI%2#=F0*G5ME850#G$:*3SFGT#WF)CDOS4)[
M/ET9YBQN[1..4NL-G5/H/F(^W:5`[;MO"XR\#?A%LPF57I?,6N+'*'&#ZM_/
MHSBYC9+_1LEV/:GBQ`KVX$&^[YR.Q<T[F#A*$[3O^KV@"\T+)?P%56+%VU^*
M(N9MAW!.Q^)";<-1J4OMJ7S7H4<0-;\NF0Q*?9U3Z!Z^5JR4FM">$-AW;Z]L
M[:+JQ[H_XYQ"=]69XKHT!7!^O2JU)@_2M>\XIS^"5Z^1[=(:M#OUIF&"+W"0
MP='EB8(D2E`&35T</E42)ML.XYR.P<76A:M25=JS*R]0]]U4J:]S"MW%U(J5
M[3L=PV]"RH6[W;.0>C?XPI=S7@C=?D+F-,@&IY>7QB5YX\,27`L4!X"MM;;2
M*/1G/X]1Z3)[[L;/])J*Z*7&OZ("*GS#L[E.#X+B5\9A"5KE6IB+]L>0!95*
M928VC4945*)@JXBKF<'Z%:%&-38;@03KK!4G+ML+UH/WC/PTH'-$:8IM5F3Z
MTVR^];3EAW[F@\M*PZPBDLUI&>:4Z4^/!KG*N`[`O"O4P^"6/3D0H)D/VH7=
M&FC.=MJ$.RC/$'[45Q0BX@;3T)_Z2ZJH."&9([D(!-,_W*,84?D_TQ\OT`L*
MHA6;KIL&PEU(T^`6T0Z-SL3JYJ=+#T(S^;05(J7FKUVQLM_LR!6])BCTMVD0
M.Y+]_OW[1TIW\HP2[#WA*(@6V(L_>M'R4R;@[##Y'`64FCC/9;U`B8N#^)$.
MFU*";.$,E^=HT:;;=.BVAHR<;8PJU!8[J('YX@:!IARBVG;/L]AWC!@_^=6+
MPH3:S&60=:/+&%JP'[9_#R(Z(7][GY`4O17XZO&<RB1\@`'GTX.-#!NZFGLD
MX?#RUI0#!4%4JY;@H597`)JD&)>UM@X\\&HN=G43\6"TT`T[W&;4O:7T]PD'
M!`29/L78QRY9/[A!X3A5P`YO[.,8B7T;`P_G\0!(.UO:6,WZV;Q2E%D.4"WM
M[)B);[>"$^<J@:,W%:;`+&S&]0?EF&!&D?#."W=9<B*Z"UPO6V6D6U9S!\=J
M#H/2%&K6&I<=,!HZ2V-Z<X_CJ4>WZ#B7K7@[X_1PC+QZ,;*9\3G0@1)L3B_L
M1X+D/GUI7Q:%L[J3"32@KK(:2Z`GE4[E`=G&C&C1>-F,ZS`AZ#4*A>&+W4;.
MQ.;#(C7;K\<5ZCR8$ND=02_3)W(3B,M0[C=C%>[')]8F+@!=@=@YA3WN1/Y%
M2G"XR(-16?@JOD7?LS^)W=,J`["RRN/(C%+GQU@-]I($]N"6A04Y\Z/6SIF,
MX2E,(]EP3E)"`Z@FOA7I<$V/'[H/YDR@/W?IQYON@NA]+IN1AY`?L]3&MGJ5
M]G4FT!^JM&+%6&D%H1%MTOSH;Z\0%TJZQ0C.9`PO3EHR9*P(0^5I!8>D[*]*
M2NHT%BN?#E]=G5DS5OFAXH&ZBLCNAU7>J"CW9S7$X2NH%3LZ4CO;+W24KN;D
M^FE8(FMT6?Y4QG6.1@%,HH--'<4EACAD-N8.=CYE-H[F'$''/NG)G(X"%T9U
MG>T*NE0M&(R5/Q^UIB6\F2O!L;MQY`F^C)5-BF_[K50\!"N-#EM173@"5)VC
M>M.IXYDIWO;J'5FI>MAZ4^=#2PF+]N>?[(_LN6&`XGB_[!P77*+[B*Q$-VR5
M:6!02X6'CF=9+TAC_()8!9\0!>=10'47Y:C%TP5!:).6W>U`JS(XJT(]<@VW
MXE5+'0:5VV1.2/GM#O=)T0B6R\QWNU'*&-)20Z#CHJIO,6U88\;@GNG(F`3\
MGOUGI0CT'K1_#2:7IUYC'X1?*=P\_^;PUIM/;)5L\[Z[K;X/C*,FN%Y^(4&B
MB]:Y2LY"YUA^=0SXQ<,[L23!$"_^LW]GW<\3;7UWW1\`?J7G]OP`@DB^C4(J
M&D1-KGB$/9O/$<D*[S2F=ZAU'$_I9SD?6M"$VQR2R[B=H0MKA_%AZU*S+,6(
MPS;6VDTAK8R[Z[#(]Z-G@R<<9M27;%[@F+TE3QNOO+V&@VT"_21E#-FX<GP[
MIQ]C9JG@EI#U@JT*);XE`,(#@GS<4+KHJE]9#%X0*SM4Q@_*E8$%;1EC.*MZ
M%F^P0`X@(`<0D#<``I*Y$[;6?9&BZ_"64OOX'04OZ!LE_5ED:"K=S4""&-A$
M%)F!DRO?1/`#HO;F_S=R1:\4Q1T-084,H[`=-N`D<3>1^OB,21=-E?VL`E+T
M5525"S@YV$V47D4I29X[*&K;T2IX15]-[;"A(_':H*KPO)NFBGYF("V&4E2%
M"QU9V*:G%#U8=U98;0!#X!9#3K$]=B3YV".Z+!V`$P]W)K-W)ME_0RKQ)@H7
MK&C]74J\9Y=-FV(^G*W/J206$5G/YDQF10M?`EG1<<0105ITYQ#.=8S/`X<#
M*99"QQ&MPV/TT&9;\Y`*`@RH!B3S``+``<A.X&%/-6-F5U*$I&!4BB/810?I
M,[6;C:`%VV"4;0:,V0P^B04TY@I$B7U?GA[(7T,`))H`F2<ML7XG;PZ2>3(.
M3.;VBH*WTW7#`[:*+<.?!<W*J)$.1OAZ$8'-@,4,#`D,"A7&-*:L(5P8#:#`
M3`T<U2FQ!6>*&5<AE*W*E"[A[5GZ<&?-8``-"CQ;0?VQ'Q<T#%YJ!F&F-_+L
MA(OAK,03Z'FE4WM`5DHS:@2)/6L5SD?-^'<EWLP#-.Q9JW@Y7<7:Q`6<`(XN
MM'^K,'%=5"/G1[?W+4;>QT7T\LE'.-</_6%?+?17SF68T'OVV?IF4Z:2<\;B
M-36$-:3U<"6B77<6CZK8"SJX6VZ]D2FT(.G)2"B_NJCK5&L^^YB5L>7S2U]A
M&S^AS.9S5NUV15>PZW`:4KD\142XLPIZV$%2XEAI?3>54#Z(B._IO?T%!X&X
MFK*HBQWLHVY";B#=&.HZ56CJ!AOLA\OY''DL[2Y_W\C9!E6Z&0(BTKHEJO)A
M#+%6]''N>JW6T12BD'2?5!9J.UULN3*UWIA5AN4-U;16C&^X%\C+UL+C"?W3
MB7`7:&IJ![2IA5'7Y<YC8Q`)GZI+^+0@S08HMCX)5]B`XRK8387?IA:Q_/?;
M*/0X?Z[$-F29/9J^8`@.RTAX02/+.F#3P5B*0JEJ3=\PA9FE'-[0:0+&C&PK
M*S!AD[%9&9`PS+C,S?A9[HXEV%Z?TV;8<X-'@MV`;Q;B#G81V?1.\H8XAI!O
ML^K!N+6"FKLXQS8?^@^C(C[GQOPVM[[[D#XM<<R6H.OP=[&".*V=8YO9C:9U
M(V!:1Z"I42V7*8E6R`V_(1][+$(V7:#06T]7*Q*]N(%024I][4(6FE:9L@AT
M9$XV*O`>+=*`M2T_>AU.8^R&YU$:)F0MU*!:9[OXA:95J"X#8]7U_E_JD@21
M8'T=QHD;!!E[&P>!U+.MUMDYAI]/UXX;'56B.FI#Z%Y5[>X<FW'Q*7F\6XBY
MBXZV')HZ]`VG)`">\*&T9?PF=85)G#`<#^&NM-?*.;;EJ6UEZ'7)-_!A2K!;
M?"^A9/>;.2<VLA`UB+:)$6-7EQ*32RC;O5;.B8U,1`VB;>`#SB/3YD?,&ZQJ
M@9-.V,\Y&0L6HY0-.*$@QLUL?D[HQ2BY<CT<X&2=6Q_V-L8HT)=";^=D+(",
MBLS`F64*!%]O8.+[Z;`8Q3D9"V9C2Z8`/9CL6EIG`R).]Q*29EO)?JV=/RBO
M#%^<6]EH:!*<D['@2@XI$3A/T;I7>6KBK<2P-V%YXB\Z)V/!Q30H`!W)^)QR
M`=42\)Q3]VXCYP0ZW&4SS3HR-C7!DF9YO216K'/=U-PY@5YP4$8]G#29OO/V
M:U8RL9BW7TD4"P$L]'_-.;'AO+&Q1'*8U^&FUG2J1Y1R>G.\IX2[@?S.W-C>
M.85>1U)*?J$1^\4`,Q(I93BONG1!F9O(%++7W#F%7LY11OW696%='[,58L2%
MBXS6^"I-4H*^4;$NT^5FQL<Y2O_WB'G(A#5`VH[EG([%"]6)M5+-VMVSN^2P
M_\$Y=B+GR,AM[YQ"]RA)R2^E;-^)I&@EYRDA8E]@NX&<T[&XDMKS56I7>Q;)
MSIN$JXC<N7%R1UDIG<M*[^H:.SJGT+TQZGR4"M">`O(-!_2*'86([QMO:N:<
M0O=`\*@N1:G=;U`&28KJ"U?X%?GTJLU-@N*T=T['X$T0DE]*67\Q1S=^WDZ7
M32D,60U6<2?G%+KC0(V'4NA]_`?-R[3OXWRD3N)7[>Z<0K^TM^6F5(GV;+'?
M0X(6.&8AGTVY\KS>ZF.DJ!3U`9R?H-^]V_-3*J;/;5PV5Z(PQC[*[YW43CA%
M9.2=G)^@7[;5>-A&FJW?$CB5JG/#J8`UB='>%<=P?AK+%;L52Z4Z[6=];"M.
MN^&VPO%TR5*I!1H4=7-^@GXK5^6BU)/V5QQW+DGPWGS/:KPC+^5$<%2Z.3]!
MOTNK<E&*WGXBAJGRM#]!OV:K\U%JJ_F:/73ELOOL/%/NHEG@9QL6>D!)DA=D
MFP;TT!-F#U%$VU6GX<:AVFZ2*K1M/_HMIO]L7?F'!*>B[4C0W^9TEA"88)N8
M\LJ/4D#EMB-9A8[H:-+M]-X@/6-0RW[I3;Q\00(T6E%K>ZMI1RO<!6'FB,`4
MT%CQF%5=[L(NHQ:^6!B%,T/[LRD4^)>O*S>;\E=(C"K):SUJN7-%4!P>;&\O
M94[DE-[_EGE*$`L=>0GR.<%HY:[C./S))5#HRGY>G=@B)?I2Z#P.C:E(H="9
M_?PU:P<X(*A,=DYRM3?!D_(.;K.:.*4*$<+-U?P3)\_TG(1?L)^RY#\O2'T<
M+FH)G`Q$XBZBXD`))KD<44@5G,1GZT><L!I,VV$D5SYK)(WE[FA/9^+<,ULV
M?$?0RL7^)L&$<I5YQNCNB9)8GA:ETGL<VY"2'(I]R+XCH69CS'#O49#9<_R,
M5X_1958+0+H/M1W)JB/!]HJ[;S6MU6`*AYC\(XW$\,.5%O9F9$>SW0$@KK)J
M2)S_%\WG!*WOZ?U:C%W5T'#4PFUBW)`_X?SRQ0W/W"!PPV0=BKT)S6U'+6D.
M^_T]";S4VKP""?:>\<(5%XGC-!ZUN'D"*)[&ZT[_+(N1N&1-5>R+$?`XK4<M
M<:X(BB?@/^P1RC$-Y"V[Q(_\%.5,))O2IZUDZ<G_KUU9L]_L"!N])BCT40D:
ML2/N[]^_?Z363.\""?:><!1$"^S%'[UH^2F3>I8C=8]6*?$8J.T=B1;$75Z@
MQ,5!_$B'IMR\'SR=;?_:(\Q;:[@C#9^`5[V\JU!;W/(-3"2Z)^O*G]MW2?".
MJ^\8,7[RJQ>%";69RSQ!@>XM:+%)VMW\/8CH]/OM?4)2-+B2BEE_%9&MP<_F
M+(DF"K-Y('(42#L[8TF+5&(%#@;6MO#[C.3)@=]0\ASYU^$+P].@2Q;>Y@F*
MIEZ;<9RQI$NVY0H./E;SSG./F(CH;GV;,B'-YIMLW90R1?#?+`/^#&U["9&2
MM'S`@9Z]J9U=0'!;8I:V3&S;2+.D.X_IC"4UM`^'</"M[LCFD+]AQT=Y-%QU
MN5?J[T!_^-F6&PF.U(`7B^N0_H@>W5<4;VX3AVO$X1KQ!JX1FV#:%6+/)`)J
MX)N0V\9W(-":I.=H+A!R/N#<'C:T9NQ-0_\F\CKI3-Q_-+<%56[@W!+*;>2>
M/6YA4+&94^TV8AM3ZB68+BD;\K\A-V`NO4L&'4MWG)#S7EC7T*.Y&6A@%,Z=
MH`4SS6!TYY$0<%G+^*.Y*^CBUEA5GS]=YM<O\6.N(E*2S`E&"7J`/^[+Z3<'
M%/O,PB?789F`/)OO4<*+;4L[.F-`@%%B0P?$+`=NQPW8E?PFBN-9>(&>D@?D
MI80*BRMW41=G#!@P$@;@X,<R<\ACC$$0?6?/THL`))V3689=83Q2[U/;H1SH
M&#(]&(,#ZEHNL,K7`DX/9P(=7$:!`<EK4ZL^I,G!B71P(KT%)Q(]0D<AB\+.
MYOL+93Q]8D]+/*%;0J7_>!Q*BMP8*TY6^VCF9M]@;M$3^`,B+]CC'L54NUOU
M$RD+N7Y2:\&?L03Q?1+.7)\=&9554K2WZK71J8,*0P//BU+O%0RMV7P39VPU
M180C676B:)\M,E;AN%QK]&\QENE-[9Q>BM?SB+"B#2H/^11&L>J6Z:CH;FS"
M<:/6Z):5-6GN8-6UHUMU!4=PDB#JM^H.'H;-A1NZ2TB!`<!KY`UVGU@=0XSB
M6R32CZ3G:!P^<CXDBYU5/\(AL_W@38#@39#48J'[T55^>MA6J.<<L,6=S+@"
MM`(<*#%AZGK)_S#W\91*-T,7?NES<S59MI%_R<_H-&`9>,:<*FJ@,KI50C=,
M-E7SW3,K.L:*)#V3*%T\'WT^/A*^"57K;,4;HVKI=:4H,Z5!)9JPQ.=SY#&(
MV&VF!UV&=[,]ID4J'UNB4TK(>J>Q8-/7,/IH4F7T\`HG,U*%GYU$P<HINJ=)
M\(8%GY^CB4DX]U@51HK`_67H9BB$6E:%YD'!9PII81&.%["39U?@X1R+CTG(
MPMMT_XW%KR1@0$?NX_@SPD:38M2%,QT)EGI4S"IP>=$BS-[(NJ\%,HA`D[P>
MX]`6EU\P:9ATJR6LR.L%RO__.BSLJ>)Z%N?L*?0?A[8490$IPY)#[SUZ06$J
M.D[*^XY=9Z4,P-3Y**QH?161W^G*G;T%HLO"7;0IF2:'5E4>8AS:4Y=(><.W
M'O?*(*@8W!5)UH_$#6-Z$6&D'H)@AR`8H""8!3#S.A:<8:ARY0^.(%)G7`!@
MO.?V(!8M!0[-J[;9E-J+YV`CUD.;HS$6XY'2L\@E_FQ^@>D=FO9@+^AG\SFF
MI\18&"25]K.:K=YA4M9#IBHL@IG+O`/SV;KZ%VG52M5!S,0^#96L;,$4G"!G
ME3B%BD;[C0T%)%O4G6PC=;GF2JY`SKA."@*R!YK2E/&MZQOYAQO^C8APG]IM
M9#5*VVS.]7VG1C(8DS]+8WHYC^/*0R#)CL+I82;<:F3[X',`)Q>BB4;V(T%(
MNC))^QJ*ORKO)`(%J&MLGR/04TJCZH#L,29T:'Q_N0X3@EXC<<66W49V0]Q*
MAE_?;^HL@)D=#]XS\E-VE;M<KH)HC=#FP78SI!<+UWMN_C[UOHP)Y\FQ#.XK
M.].L(I+YF"4[E^E/.Q,C/G8C>^`0LH"36J:'QRV'TG7<S`>=B1D0#>6->Q"K
M:398<Q(%LS2^'2L%<D9YB^:J\XRDRVL2(ZJ<YVGH7Z`7%$0KMO^4&*Z<DU:+
MWL[$)E2-P86'YWE1D@@8_7,D4BUD7HNS3%E^\RRC./[*<"WCZS"7E@SZP<#7
MG,E8P),-,0_'1=Z7P3]8G2&?84;3Z9(]=(C8KV9I$B=NZ)>E9PP:F"H)SF0L
MC\V&E`@<#]QF24=^,_N;]5A@2&H#.).QO#-3YT?'Q:_1?Y/OQ9E]+0C*"+]`
ML4>RX3GN'&$?9P+]D9<2"W!>"=U&(69P_71^;PRB#+9?(6%&O*2G,QG+>RX%
M1N`\'JH46LR+L>70<`(]<7HXD[$\ZA(P`.?%3X7(#`!>32%94^=H+(^RFBB'
M\\2G0MV=2V8DX\S/"%4H^:;0VSDR4[O:J*)$S,!YXI/=N3<G3E8NH1JH%RJ-
MW\TY&@^"L9B+]ICJC-)[--]A-L;T5((DA[9S>OR/`NQGQ\:"A7@V/W?CYZL@
M^AY3HM#FS0C+[6<?^OW^6OE12<OQ]_3'V-OAJ=<#EY:T_/N(GKF,Y9$+@"<N
MW$OT'D>C?MY29$O/YB6<,'M2G2T\`F4)NT%:6WE*%/-=>-%45]5/[!M/]!Y-
M__'_`5!+`P04````"`#C<Y!"T&&+F?N(``!'`0@`%``<`'-Y;BTR,#$R,3(S
M,5]L86(N>&UL550)``/IF&U1Z9AM475X"P`!!"4.```$.0$``.V]:W/EN+$@
M^'TC]C]@O1/AZHBCZGITVV[OW#LAJ4I]M;>JI*U2VS/1,>&@2!R)MWG(8Y)'
M5<>_?I$`'^`+!/A(X,B.F>M624@P,Y&92"02F?_]?WS;1>2)IEF8Q/_VN]<O
M7_V.T-A/@C!^^+??_7)W=?:GW_V/?_\__X___G^=G?W/B\\?R+O$/^QHG)./
M;,PVI`'Y&N:/Y/T_SMX'89ZDY"]B+L*F>OGFY4_D_DC>>;EWEWK^;QEA?[A*
MP\`[;LCY/@TC\OK-AKQY]?HM>?7#GU_]^.<?_T1N/Y*S,_AD%,:_W7L9)0S%
M./NWWSWF^?[/WW__]>O7E]_NT^AEDCY\_^;5J[??EP-_)T;^^5L6-D9_?5N.
M??W]__SXX8O_2'?>61AGN1?[-11,TP?W^J>??OJ>_Y4-S<(_9QS^0^)[.6?:
M*%YD<`3\ZZP<=@:_.GO]YNSMZY??LN!WP(,TB>AGNB7\\W_.CWOZ;[_+PMT^
M`K3Y[QY3NNW'(4K3[P'^^Y@^>#D-8/X_G;%/B/G_[^+7OR,PZ)?/U]4L?(9#
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ME/X2*/WW-,HK#XJ;@;-7KTO/J_CUW]@&FE/`ZLZ[KZVDI/8#`Q&4?!#%MIQ4
M`\BO?`BZYBZ'*88,JY>^E%CENEN03[9[TFOV8Z8CH_5@&W(JHZJ0`!A&^#C[
M`CL?92N2VQ&*0>EM2X2I!&?4?_F0/'T?T%`(+_NA+;/L5W\3EOTS?0C!H,?Y
M)V_79U4'AR+(JP+-]M(7FVX]CL!`;&E='&$,61T3AE)21R1A73F]9)J1>M$U
M.X5\^T]Z5`IJ>RRJI'81'5CY8B#A(PD;:D]8E\,95UX'A*(KL/T2L9;$7A[2
ME'WP*LQ\+_I?U$O?Q\$[9MT'A'9P.)+<*M!MBT$QE(BQ!`:SXTX`06LKMG8E
MU+&D>$Q09$$>D9)UK>]5&-'TDGWM(4G5MK<Y$M7RMI$<L&%\&"G'V3.ZBZ"+
M:V][Q:!K;?MD8"WYO$L]N'[[<MS=)QU^%\@WQR#)9!NQ]O(6?R=B@`TQG(<A
MEN3U+K`L<WVKN[(OFNQV2?PE3_S?OCQZ;'5N#CE<CP(::L=4!8CKI:I)&'+_
M.!3A8!LB`(D$:=&#1:$'V;O5$+,>5W=<QM;2CC)L?,>F'="#QA`DB6^A-1B[
MA[_;D.`Y^&%)9-_2RK+7LZYK2=DY^TX`W[J*O"%SVQR#)&=MQ-H+6?V=P``;
MDC8/0RQ9ZUU@6=CZ5G=MFU:EGB@.\OUCD:U<&]%!<R(&6CV^+XTSMC7L%8H^
ML]@G$6M+K(@4B"]?L=_U74>IQR-+;A_"@Y)0A'$*@>##;4KPTKAC2_*@L/1)
M\Y"DX$@TQ+[TY;D>;46:963'Y(&')!V1Y&7PMB/%'0$9EN&V=*P;-_@KC:+_
MC).O\1?J94E,@^LL.]!T0([5,*C1@F'$!P[6`'#&(4@)0@2,O1#!-")^TR$"
M-RXP(D;=D(!:AM:5^;\DT2'.O50$A8=L=O]85!GO(CH@%M5`$9JW8JP71AE7
M?@=$HBNW_?*P<FQ77+-]IOLDS2&LG'OYH*NA!,&-YPZA/13Y+&Y#*P`B("Q&
M<%>B`#EFJQ2?GFBM2G;6E?3;PWT4^E=1XO7ET/>/0Y7I)H(#8B`&$3[*GO#.
M1A572GN6OBN:W76WD$M[L[T*8R_V0W;>3+)PY.&'$;B-?%LU.</IK#=;4@&2
M$M+B`Y#3)2R7'L6Y0Y:5E&0-W1I,4AY7+#QC<9YE-,\TS$)K(*(!Z*#8N7GA
M`QS0:$U,;0IP_WJW1;5WL?&$\M++'A6BR/^,*(`%.IVD2/9K6Y*&B=*^\X1[
M"EK$R\D]?0CC&(X;R98<J;=\0&O?>B(_%5,:!T,X8FJKK`AM'96T`'&[\/WD
M$.?99^K3\`F>BGVB>7$.4VT>*C#,K42-?L=<%\-)/7Y#&,2F/$`O[V%)3^27
MHH(7)+"V)4[D>%J-)V<DIBMP6L>778+3J+N[AGIV]OIQW<2S+[<IW7MA\/[;
MGL89/8^#F_R1IL(=&3<S.M"(UD:/F+80%5"D`..OXCD@$9"6C<\\HJ@`RSA5
M":?*+V*17J]OC&6GII'%!RU?:X%NPY@?"W\^A$%1.0H!<4Q+9:#H;8.EK^78
MQ^B;[;LPVR>9%_V<)H?]=>Q'!T@=9K]E;,G#^$"#&^:B\EH0&E[3]$G1C^<3
M21\XRM]L23D=X?-M2#4CD:<DU9SKF46CP_^R?&!'D$"F-BDAE[>3>O[0DC1R
M;VG`[..'1.;H;G_X9(;B8ALN75MDS;R,:8HCVC\F[.6]:W\<$%.'YV&*KYY:
M&F?OU`*&.3_>,D;RND]_/X1[B/2SDY3RN*(`0SVG*-'O^O)B^(9P`%&VJP3A
M\1%;)Y-)9'#\:8W_&L$&[4.(LQ1HF1:'\3<(8B^N#AMR406^+[P(#G3V`M\K
M4/>>OX\<(@WW5#ENB+O'R5$KC+>3?$IRFC$D/B1>W(S(?6(<&/72M,`1=Q9-
M<MI"Q\$VA$-QB2ONRYF0=2+Q]42VK/9$(C\D\<,9V]AV)&832`%OFPID(G]M
M13(0ONE%;>D>,B:R9M1'J1M:8%C%;,?1[SP8*4`Z<6"+DK\$*2+XNU+05^FM
M.(^]5JU=<P(NO30]@@U]\J(#A=B2MQ.7;5"-+MM2!AB0/"'Y8Y@&9,]<I9!F
M9)ND)*-L6DC#W!]2]EWVV_S18\Y`2GE$W\\%X#V8L?R0PF,/!N7M]U'(__+5
M2X.,S7@4=7ZWS.R1)*;\?AU&WM-CPKC*""E#7`Q-_^B#E0^W)&*F$MC-AGA1
MEI"0AU+@%N'A(>45PHE?$B=HVK"U`0IAQGOAEY#LD=*<!&ST!OX45[PJUA'L
M,*.4T<V&1$<>>8L8L0'[7M]$C(>,YAT;G(9>!-QA1C8+@S)$]U+2T/(3O1QC
MP/\0'(,)V-(';1:]8'\##&(H)!PI>/3=2VOEDC4M<Z-4LIY9QHZ&C8;!\.-?
M@X$ON_&NP?"1_0"7(6KX$2UU*`M=]#^$WGW(K%C(?3A>`N<QB9@QR^!`E!\U
M4D2UIT!4'P.R.@YZ#<JW'AF8"&@'<DY7(O#W!84V]<14)-N:9"B/^%ETM]X1
M3DCZ^7,M``N9<QV4!S.XBI'V;V:,,=^+D793SJ8S>D.<R4/K%_"A#+1>Z4;5
MRO1``\EJ:"GF``RN;@XBWB,U,)9(@UW04&/\HWJP-3W51MH%?52+=H]**N7:
MBE\ZKHYV]5!+%EQ2/'WAK?(!/MC6NV5QMN3.CFB?6VJGIV^6%$VM80XHUJ!T
MNJ1)4Y"TI#H:.F/AQ?V$:(D;\1&C@$%?!.0\S]/P_I#SISIW"3N-<)MK/S`R
MF;(R]/%GNP_-3:,=#L4W;ME<_#:)X_07N&Y2*$+?:-Q7.CW(]CQ@*2[(BH+G
M?.!&U#0+++Y:,<(]$[C_MU<O7[UZ#3=\XB[P_R&O7VU>O>+_1S)1R=T[Y(])
M"A=3&[@JHR3DE(K;SQ6KUFLFFLU?LX$PR6P"C#+-EB##J>2R)0AR*9]LT)#U
MO$H:L&*(=1/J]@5C1K<S%+.>0A?-3JY"H[G$NK96*[E8'V>%C54:V3=_VKQ^
M\\?-'W[X03:U[+=O7OW$_O('V>J*/[W=_/#FU>;UGWYJ`+S=O'W[I\T?7_UQ
M53.M6Z=B=;;]\,/F!_9_;]Z^DKG`?O/V#V\V?_SA3QVVO7V]>?O'']AT;V0`
M]MLW/[W9_/CFE?W=;9Y^.+"OS27`H1UM+BGN[&5#FT.GKDC_SH!X#Q,$_/&S
M%]UZ87`=7WK[D`FTA)?J0F8<&/-F1H>4SA5'!40`BES'I(#;-)HN6;NNF4D4
M/-X^"V/B"SA+US>.$V%@;1<1LG!`R)PRQBM3JK;5T\G\29`9\TS5U8D<D4S4
M:T=M2]ZY?]0UXWC;TF>:>V%,@_=>"MJ0G?O^87>(8$G?T6WHAZI@KP8PXK:D
M14I;Q$H@4D*1%Q(<*0"_L[4K3:)))B`0H^QL1\YB;[`/K2E53FU#ZQ+JQBZT
MED!B;C_Z%KN]_6B;:YMWC$9WBW;O%#5OW`8N$]VY0>RAH]#3#=-@G^[N:0JA
M)`+Z9JO\M@;2XG)?)]\;<P,QX;<]ZS\'2[LWR/HWQ\Z]/E'8NE%0AUZ;]$B*
MQBL3![*8=*GI9`UI/RS!L8ZH)+GT5F9(]S6U9_*#_<(0?H$GLV(W?Z1YZ'N1
M(D-*#P[IR;X.`0/6GW`@TH"RF!AU8M3HO()?F!Q;;Z>UE41^/*VK(;;2OAA.
M-RGO>1+P>Z1;FGZ!ZUO%5JXY@;7D,`5)HSDN#);<I$1`BUM":&),^`1NY(]-
M(J^XMZ\N[,F+,"9!$D4>\U^84RWN[#MA07M9/&-RJ4[L&1%*6\K&<<C.J[P(
M;27K`%I3KAX21I5*P)`:R`U%,B*E4*!.:HL[&C,D7&I-&9`LNQHBTC(,M:,`
MLJP9%>JZ6N%2:K(V"4UM"'M)L*T)32'2T8*&!-G5@)LZN\U0#61(R[K0)$)7
M(6[LYT/.(::I&FMF*4Y.85]H=9RZ[5N)0G<2`S6MA(Z=ZYH(*\GO$XZ>.M!V
M4N0-3F7-=";<$Z=I%OTLLA+7#M*S"#N!([2!<BGRB9TY/$LX&9R<55!V;(/&
M0;.I/,X<F"<1X>)164.4%!IA_9#<P67TA#P$85,#!@^6?=)O^]&N,?8-L=\,
M'(IQ[D^7X;P#%<I&Y'Y492V=Z#MXZ!WGE6`V%5=]D.J7(0>.\=/H</(`O_22
M.'5V7YXX=X[M.J9@U(S9/+!?QWZRH_PX`/?\&B5SAB`0+=@PTFUA$B-)-=2!
MDCBK((\I\R,BTQ9WM;S@2?I-6:^_Z%F;:<CZ,`RBM*L0[[04KIH2E(,=D/AI
M!%PF6='GHP2S6@MJ5'S:<C\F.WB2_S.-&2K1>1R<![LP#@&-/'RB!6(*^1^#
M1-2"<2+:HE1`<!%JPI0294LAYM'B-6#L'$'7I`!3JS55HZW;>GJ!^2PVHXSR
M1X;0._I$HX3WSAO7;S4<ZF-8-0'=AWQB/!<G"6(US=:Z67&>"NUGO#/H"&H(
M6\]XEUT%!P)E6OK=?3\YKMP6W6\3M]NJNZWE9COC6_=@*Q[/2/W**L^:KH6]
MEJ+JX[XFO\V>9$_!N7N2<>H@HWV`L12<^I!DV14CXS*)&38'AE"!61)G%W2;
MI%2,N_.^T>S]-^:*)6D0QEYZO,[ICG>R8Y",10R_A^N8[>0T&P]PK?-5]"#9
M6LP;B%6]@.]]1^"+I/XDJ;])Q$=),9Y_=D,:'R;\RZ*I</UM4G[<;MP.BY_P
M';(=9*,=@VV+!<-TX\<]5[5&_;'3-4T19E?UN')!!+[%OJ(1AQV'1>VG/DY(
MMYEZ#5/:OA<%V'<.A&BGT"3Z8+>)L1JDU9:Q;MMT/0&;_`3[KUZ:>M7IJ^_P
MTS<*Z7EU%[GV6A<CUCON*.,K9CB67<G02S:8H4E7BO'H/-D>Q_+ND19=O*%-
M=WE.A*;?!YY4#PW)OQ:4!(<4S!KTQA9)`9W^UVN?SA;A/-9#\P%3(#\K[[<#
MDXW/Y2-C`W,2KKPPY3F_-]OB"V7EB;[:+KJ02$9*CXA.-@F'@O*]`%=DJM]L
M22D+'U8S%J,6;19!84RV0)#(56<J^M4%ZW=J).G8RFDT@?UDQC*E7L:<HX"*
MG[[KVDH@&_[ELSF/\*>*_(#]_4G<5X8Q\T(XIAE)Z3Y)X=6%E\D-.-DD7DX\
M=K0.&'B>D'OV4YCMV8H%G)EA_L@^!4UDCM1+R0MFP.&[<9+NFM'!HP]];,,M
MB1)&>/J=%6N.+$E8MM_`$LO[@;X9Q@S./;%C),BD<)BU(FL#(*AAL4&TNS&M
M<FAQRMDX$(0RP%[\"<P0&VDW<J(6E6[80RDGB)=6<,0=/!NJ;K#4@)C766,D
M]!_KE0$+:Y==TV@)"_3I`/JHMR]:$M6YBM$1)P=">5-">$Z$[DQ#=L[%Z8:O
M(;D*5*D,,;64E3$5\S;G>TEP(L9H'%MT\#YUUK6H6[>;<RXID4I@:R653:(4
M^_IPL3O4'EI^]MAY[D7$UXR3Q(ZUO@"%HZWS=Z)]>PO-"=H2F26X.$'/5+ST
M`S]T&\:\N<W/AS"`5V1*)?)KBH;ES:V[Z.E7RI:WI7>2=M=(,0F[V=YYWV3+
M?)=\YK$P2%%B`,H"Y<M]P]HF-X\Q&GNA_`%)<S<$U/MF"\DZ&X>WQF7Y8VW7
MF;25KBD;6X5LN+#GKD,[YLK/V:&7I;[>\C2)MK?I+;!/J/?&^9L$8D2&YC7R
MJBA,8QQFY*6%8)\'V30[+FTT.MC#GZR%A33PB];`3R_TH\D]GB)_F>SV*7VD
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M/=!/!VA7?;/EN$F%(/5-Q,0)$2W'9)([#WB*B4@Q$Q%3@2?0V[_$%5NS/`.\
M@@&Q8$"R[2EHV_/6H"\\P%5=0%NR7!CL\8OJOVMP"=,*SC,?;>,XRW;@V<RJ
M>"A#K=,<62/`J0>/:!%U"6H+>%T*%DQ>3_=K!P*;\VE+C&G#U$`C86PKG(DD
M6M`O@0=<P20Q/#8[_Q:J;A/5<#;T:8"`SLE$"%0]CLD6&VE?9Q;&WXI>J(1H
M4!\4$F2EL<-'"ENA0O:[8^VT<*@05=71)[^*858%9)"[B@+Y#=;B"<)Y$/#D
M4"^Z]<+@.K[T]B%S9$>%0@V'*"!C!+2%I1Y/`.#L.B8%B!.BH[4>;3'260S,
M$KVY%\8T*.,1H[(T`(!:E'<`Y6X%53&05!$_%X1&S?%NM50%NQ%#Q<U]\%VR
M8UBI`L2]XS'#P@,(C[DLY%<QU%X"QM*(HP9#56+2"8$J9`3QD&'0*LMJ?RR=
M)D4.M<'20;=3&HNDU(^\+`NW(3/;>2+:8A6G44*YP-ALB*5#5-'^:=7XY5ZW
MR=5""*,>V'0;5MGO4G4>_-=!%(3([I(!OZZ\W:$!6#H:9_PNF)\B;O;\6O@S
MR'46YO0+39]"'SK?LL7]3/WD0;P%4WKV.!B@GA&PF-H];51?ALSNUN&#U(>/
MHO_;&<>`R"ALBH-M@<6&5'B0`A$B,"$2*K9,M#U.<_BS>\X^7YK7[F$.59F[
MQT),3<8,XC+L1$?4=_Q*2Z#$RT7UTZ.,[!I/AAKNG4!JKVH4O7")F*8P&1M1
M)E!E?(K\LZLDW=(P/Z3V&D`LP@N`YZZ)=%/*V0-E/NEN'R5'2ITQ(-,EO1M^
MGBCFUM5:^&1+Z;5R-ON*/4*LB6:7![<35FU#;ICKMC,'E.FBKZGH&G(_N>BN
MRK8PX7K_S8\.\,8-:CO&-+J$9+O[1&2PGC^DE%^+]:CR<G,C%>Y=BA'Z:EZ4
M^663DVIV4DQ/&O.3Z@,VRN6NQ1FURE<<\0N.^`V.>*MQ1*?:[EHL^4M9"E8P
M(A12T\W],I*93F5<K#*RB]H6N=#LDH9E:<LIC/5*IM-T<KNVTYP5!L:S2*4]
M5>LYGS?+F,]5X](S3.E\_GQJ)QT_3VLZT=YHF--IQL;ZF9/O`N>^"'R-5(O4
MGL+^Z;*/K`G!(GD&QTZ,.A0JC9Y7P\+?]VGRD'H[XF49S:W509J]G(79*@G4
MI<^!(_"@)IH$N'K4T+J)$99QGHWIF<.^D>DE;$K@RF$SHT7C=#MS$F&I&4HY
M*+>KA*`^A#[4H+ZB@\WH=*$="",UB3$.%!7@!.`=.LEHD*;4IJ@@:[L&67.#
M.6JZ=,,U7D8\PM`_1/S9D$RQ:\>)(:W3#;]T56Z=`,MDP]`%=R%(,MDT%&$0
M1VV##G':QL'M4(6:2/U@Q`G9BD%-U`XNK&\MN%&Z9%X*XR?[Y41'HC6!`[Y$
MAR1C=Z*>P36KH4>@TF[X-7%.^A6CU$UT+9ITNV8P%,JHZU_T:N(Z+L8<J]$[
M@PN.QAR[4?@:[AH.31)-+(?;3L<HJ9/]#K<-B4I!M9T/%%,BDO2DE-SS."C>
MN63OO]'4#[/>NDFSIW3`1]$@V]AK:>33\]HWY;2DFM<ABS25#TH3)7Y*)!Y\
M+7E`5^/!7(]G`A/$BILY0/`7'?ZX9M&,[(2NLZ1I)-9QGY8U>IISNN!B+6OV
M"J?KQ.S>9$[,-GQN.VP3.-)RX<;(ERRD?TBA&4EA*5VS>&960MNK6]#FK9^F
M\HE^Y7^9FJ-2P]N_.^X0-"$[A8&+`:Y=&H\2-V2W>"-@^&58#O"3S-ULC8Y`
MFJ1JM*71NHX)BS!#R=H3V->R+DE3TC.<U;-Q\@P5[232,:9J7;]X3G;G==X<
ME_OIA[)&QV>I1,>`2S]_7B2W?@D&3*XB4#OTU=1$GMN&=[\&0\RJO/Q^K3(O
M.J[\&N1?QWY*O8P29I>\6ACV(`SL5WXA#,&!`BLJ!]^H)DXW3&+-^5_,IL@'
M@*4,ROS`!VPTEVR?&0MF5..P`Q02@L..`M\N8935"()E5(W.]F:X.J2/@Y+;
M>\!NB:V56NJ77O9X%25?,[,2ZETP.Y73^]!7%DP'`,(AW"J3;D9(HDF(I9KH
M@T*E*(4^)%&H_9,!B=LT>0H#&EP<?\DHV_&*EE+QP[F?AT]L,Z0ZNC)A,MQ.
MS.:D]K4.XE)83D,NCN0%S,3\[N](-1FI9W-`YQ8A75(^WJ.NCU:K+5>GRW)/
M8^-I@FRI,B"4WXK],**-CLQWR7*JO<KG;-7\6XY=(T?SZD.DVW*,_?GT#(D%
M-K+S:%JQ,2[ZN<-OX6<?.'@`IK&#;E+QS'/#(*VIH\KJ?LLJ*'*I9*.R7O8K
M=VD7YQHHO&6U?+)V53&-4IJS$=?JF6;([_N>0F=W\!WK!8CU2WBM7:7K/!O1
M-O5X_`29#L+*"ZOSS*J^3<.]2$[SLG55SC#[9!3YNT>V1S,E@&V9?MOS=T;Y
MHY>S'=E/#K"=0](-!*V>FJ\1RA24(&1;3WC/.UFWB+<?X!I2E8%,DEX]64)A
MKY+4]"5!%P1?;?O05FHN5-%QZVF`/@E2C0W'7@[IT`!ZO/7"M%93AAA33!_T
MLM#8=O+<`UR.B`LD9@+*`IL9J/'>._(07@\W7-#J07T:4.PA99JLVWS:HC/B
MW#IOT^9"L@93">U+V:!5+U#W2[8M17?'MKA=U-(^V1KW9-,YH5>VR0U&V#*S
MLTR;;'_GV+6%G"ZY1,W-]E84Z3GG-7JT/#`5O!5W3$W0J&\F@X,Q+B8@YPN7
M1YOJJIF1IWPG@%0(;K)'9T;J7?<`5GIOH\1:L9_SQ5:RF49K:<<=U;`TP[[I
MN)G!B^B^H_N4^N%8'+<Q##%ZVT*O+3KRGVW%:6VBJ!61-4#0@=AKGT"V(ZX]
MTHBG,?Q^)F-?9IK\+CG<Y]M#=%Y$SQ0:I`1#U*@1]-O240WG#D4)0$H(6THW
MF0K87PXQ^.#4S\/[B-:13R92-'SRV.]L%8Z=1=7HVF!JL8Z2M+5:0T-LI&_`
MAKU+TCS\Q]@F.0QC)9&BBWCG&E_ZL_V,!3-\A6=(=^%A1]B_POB)%M?K;F04
M#(C-<%I`O\S@2?Q_T"C(DYV7'](P/WZA/OPWI-F7)`J*?QT_4R\*_T&#G[TP
MAHP%?LB'QJLW^2--[]A)_X[N]NR0GQZO=WLO3/F"*%1FQ8\BZMRJK&LK`7SL
M["XY^UA\CM3?VQ#X8OF+(_0>%1\E\-4BL6E#JD\3_FT"'R?5UXGT>5M&`96A
M``PF)/,B<=Y^9%IXEM-T)UD56RZ!>YRP:E_7-U)M`[VZA<*S\"5Z-_&[,-LG
M(@+!`Q![FN9'A9D>@T2TM>-$M*5:LGWD)B826!$3Y8"V3)TY/2\`Y#N19BDI
M*[P#W-LT5>:4M.W-(`F8)D932]IV0D]%)E]TO"]94QL0^-K`M<;0:*1+C&%D
MVQ)0C92\#@)C;5Q.Z*,M(<O$5VCB*AIH<-\P"?O2B%2H.W(?NPPQMNX*1I15
MOAE0:ZH-W^`+,\8WVS+P\KD*BFFY!X/`5CP$!2DC3@)`@G=0PI+/*P0'ISH*
MIF0QE>`U$FF>1]53S2KLN?>.-F.>R&39\23&=&K8F1A1*#P#41:Q>$?%?Z6'
M*47Y!8U7:@:3(!H,(](&BWN\*,&_@PHO]?NPLM:+_<=AL^B$-)X'J";=>,<E
M^E]!7<*R6HGM-UWF<MI6/F,AM:F$1ONT%KA5Q=.R_@,JY]!>/9&P<W>N(M>C
MP*XQT-^##93%I@&X32D4DGI'MS1-:?!>/.HYCP,>>QQ,?IPYH54CH4FRIMDH
M9B/%-'PS$_<B=M(D%Z=;$%-6!K;;&G<QHLI5*QZQ"1\DT:#4KODQT=9Q@V2@
MJC9-U*<DIY+1-#-''6"KIJ>'%$TSPR$EU\0ANZ)!%`QQTBN9C[M=@S"D&^/*
M/Z`8T]^X=;[PCO)[C&S4F3`"QWK)ID_.H`:7L*"_);1U_V`F<0TZQ(9I\9'$
M#$+@C83W\)!RRR&*S?`0A7R#P?9'R*AB_RI:QX0QV24Q/6;D(7RB,;Q]S:IL
M&?XR*V='_6@#KV=W7OK`Q@<%0B_)>90E;`:XVX=<&^F3$!3AK.R$1N(D%W_Z
M&C(Y"N@VC$4Q'$`O][XE<;([VGGRAB!#:(_8#&U7X]V:F>%:T+Z*>6^VXL+8
MBWY.D\/^.BYR1]AO&>5,E@XT*`)0@\4_EIG;FF6>Q@@MLRVFAJN<<G+"9R?5
M]$2>GU0?<,.L+\.9@@G)%LIWU+0F)8@KMG\9:F%C""LG/*B<\)%]P1MCDK5*
M"(M:#K7IFVXV7`B"WXH[OTD1\!+6B?!W38AI[/MVZ=O<I0+?PR2=KW83;?)*
M;JG%"+N+X<"K.FV=T8^"-Q7&LOJGS")]J&\@32U`&]RV$>B2HV\'`)9(P$Z9
M@G'"2@JB%2F8;A`LX[_`'=XB%%@W70/ZKF6]^I5]P7.=-/DZA[O)'[!VPIO!
M$JUCGC3_R9[U%N21S`[G3WT+TCWQZ!=IL<N1*)UU,;%W[)UK6-5GWYE6U<6>
M(`H_V&`2)WN`]%WTF??^<+_AAXK.@C0<RK2<9GRZW&Q@,N20&FN==:MRS1_^
M+M1I2#69?2NC)M70VE23N=4@9!'2VYV&^FAUL=.0ABQK*NRX(",6I!+%FZ$O
M)A262^E'+_V-YA"<JY^K*W15#QZS1)4F09V<P`*.-]T5D*0&)36LM:I54PEC
M^#S"D4:[)@-6B`F/(M3J528:U2EC9:!.J%7K?$J##.PUO"DKJ\><Q\%E40R-
M5Z.\KE=`93(FS(9;XVX"L3WEU?@L8H^#>3:D*KH#F2_U7!!SNEY#&XVKXBU)
M-RB&:_;&&H7(U?.F*FM/4;V)FFK1@2F+9MRR5<L9IM4C>1,O9G@2FZZ,BC0=
M?Z:$WQ`^PX8;HO>K%9Z8ZM@8D2GY`G[Q6-9Z,9O%*-H7<'RAG"AP8ZYNHR[.
MF*[9\W/J"CQ&QL1@%HM^C9JX<7]&KG_EF$%9AE*^O_,B$>L5R3()CZ*39=-K
MT5"],6]E7.]<C(\N$A=U,QZZ3!S4_>"GHW3.N8,QI+*\@]&AR\W0[OR0KBLV
MYBJ,O=A?Z`Y&-9E]FZ,FU5`GJ\E.X@[&C/3V'4P?K2[>P6C(LJ;"C@ORY)P^
MV0\IVT[=;"]YTZFRP1G_[XWHK?G^&TW],!ML]#I]/J2,O3D$J\\95=<N=M80
M\TD](<5/Q9RDFM1&/MXJ'.".>JCJ6R:W:.5'KZ]>"IV^"%V-&3I9>DMR`Y+R
M>,/I,-XR>U6?7KP@X%5RO:B*^T!V%6\O#>S($SZ,H0H1]PZW2@YU*Y1B9:C-
M-A-R0MI<&[&JL9O5\7;!#SAD#B?W"#6PC_9ZYN8TG6\OY[-HW(#::["[T*8R
MF4FKU619>)^83.#DC<.L`W%CFW%Z+YG>G'=Q$VPGHM^+NF8<OQ_64O1^B)!I
M>X4+47ICBBIM'C+OHL(*^V4UP$\R\4+_O_WA3Z^XM_S??GS[TX89P6P/-]E/
M-.KT\;`5`5>*JBKNK9)3/*W[3/V$2<$17D*P/2:_!-8K-*U_/*)V#2'<EK]R
MG'@F!B,)'VI+AW3QYO$>7O+0RT@@$$^V6\H?-OG+4F!V5;X>!9BZJQ3XMKZJ
MI-W%:/$B46(WH\/+1(7=#P7KTHE"W9Q[J)5I<S/$/3^TC6Y=.%[\B6S[J:3"
MFBB`$*V'$O7>;4F,)IVWY;;L@A$%H"M]KY[#F!^?[6C_=`H&T,94[''9;ROR
MJ.#C*>Z7PWXO&N)X$:`%EX37\39)=^(D/WYSK#L#HDKK$]66+1F25+>F1`)V
MX$IX(?+@!7^49(=4/.CGP3,>.@OKN:Q>"AO*9EO+S`03LR953AG/\UMVNE'H
M56,8:HVI!GK=BBKBSP3^;J]<E!+'^O`(P=VP&&RK,M0"J.*64.J*9[=44D<V
M46NZ)3MZYWVCV:@*-4?B5FIK(=E3FHB-('R(964:0[4II#F,M%9F;3ZJR/7(
M^F2UI_18CZ#B'M]@>_S$J&(_UMF-<=!SNGQ7.0X:[N'LJ9&/@C/9,)AYMR'%
MK%*2+%Q*]*8=UE,[X&ZNP!65'QHG\5EQD2OS:5OQR7,C97$IG>D['"Z@,),S
M?#Y3/_*R+-R&OB?:DK]C1]4G#V[,RJI7Q[ODO+I6!XMU'1?=#@>R>F9.BI3)
M,YOTGONCQH3\'JF:LBI$>.2/-NL\!9@6TNF+B?'S==9G!%/T,GDQJKB0)W*V
M!NSB9SR^LPX7-%)R7.+#V5I\T$G=69P1GQB)A_PQ2<-<Z$(*?<DH7-Q[3UX8
M09*2E1J*+BWYD.ACI1DMLQ7(J46+[`-X?O%-^N#%X3\XJI=)G"51&(C@41S<
M,@$LM>9F6VS-7O2%_89[-CJO;I:9']%#7HHAG;:3TKP;TIB9>W_RW+")5K.3
M>GH'7&4GV),8LP?3;5Y4I=J^\Y+Z=")6ICX`W-%O^46DSG%<_%.G8GOZV;2*
M&9(/[_`QPK]VFC9I!;8-F2=-MIV,K5(HYJ)F:U@K\2Q8T>8EC!]N&>Z^WI-C
M!1"B55&B/M!]"*)0Y>@UO0[E.?T4"-`T42N2@&DNQK6@K?BC*H"GPA=>%F90
M0J4V-\SZ?`D?8GY8B_,NKCH.QZQI$<W`3/+;0LJG$Q63I*T/]D)I2M(KR@ZX
M#*LP(UF8&9B:O81RM'5_`<W`LPZ]O2R@YVVC]87.KF\Z$Z(-,">RT^NXMV.0
M:'W<;#/DPK;K"KV8FCQ1D-O*.TV*4?550D/=DL8PA#![:ER-GLN&'I&7Q7HS
MVB^,#7$L(G!:7$&V#HNH38^Y6$)G[*2%7W@1/#']\DAI7N.FY?T;36,I05R#
M/&7Z2@%/^`224+OARMNGU%;&N*[8JM+&-646UP\72/`7WWL:9]QH?*817&SS
MIZ5?'KV4WGL9#<K2RYIN^8R)D;WT62SH<V*+?4B42JBF),6<XM'WAO!ISRY@
M7E+56W?#CU^+(XD.1^YU.8+MZ<]7E3['?[:>.&@O+F1T-8\!LV9VT6(,,F%I
MD^&`8[`J4R99#4=\B(549K+A4.H+X@D`*LD\)E%`TPSJJ.='*"&F\QY4#8CI
MY8^1T/%V)8#?$P%">.4T^YL\"C&HOKJ6@'6\<QWILJTE9@$U_3FLZXY>,$B&
M;0B>8W&PI6C\_10B[:N:0?S*5$0G/SZ1=\D/H<\V22I5%GRBT-1CMX\2OCM6
M908SWJ!LMPOSL>/N\M]`>IJR-&/4'FWQ!=+XA&CV4WVDKB>;%0T.J^]8W"Z?
M$Z^PTOQ743HYZW\-C9ML8B8CH-K+%YH8R9@LPH*V5LS6`XL>P3\G4W0>?JW"
ME;NB@C(SH$$C:!")KVWD\LL%OVC-K[H:,_S!K[]IK1[S<C9%-IN+&93)MI+[
M?9_IOFA1>9LF#ZFW&_&O1H"0;-PHZKT>/:DA2`%BV9G!H`-+3?3$258!+5E:
M6+S']ODQ**L"/GIF[94,RUOOJ9"BLV&:TS*X&XJ^%6E-Y%Y,9FV;T]27<06V
M%]:N*NT8%;%10=DH*J559*4N,.56/1DS*MY!78"4!E#+B7A91G.[95\T!&BP
MNM.L8BVKR;].C%H)9E<#5*9U0`4<B#VO3HAEG1@-*6M(%&8#"WX)>^NE^?$N
M]>(,:DQ!0O?XUC`*BMK68I2,;G42<3//88@,Y,!.@44/;NL(/5'K=I'0DC/[
M.F.VL9C,XH`FZ5EKA1`ZM@W9IM,%S3/8M,RE%;&&IUPX@+\8/.HHH!(,L_:F
M&OU.74UY^$:\&#V27XO_.J!96/2@EKS4$+%..<MQ^9H<OWN_H^E#&#]`)[1W
M](E&R1[",U]R[X&.:X#I#$AQ/3.BVG)40HL>@!(\X1.XH"'/@TB=6.`\*IOY
MM%[]/'XOJ..-2TM.\`:)@<2)##YB+5(X03/EJ*&Y6N+ML[]D]&;[/LO#'7,%
M5,W26@,1]](.BFW18@,@=:4:XN(&JD5$,I$(S%VS7V#:^V2OM&`VSJ6[\+#+
M/E<MHL^C*/D*K]^NDO1=<KC/MX>H*$F1%7@RR_>1YH])D$3)PU%P7:$0RWT#
MM1'O<HSIMK<5<Y-Z\@VIIN=-W<L/E.51F)37WR#21UQ488N\VZ[%.]P6P0LK
M9;>5\+(:B1E]>J+Q@4)OU8<X-#ORCL.B1IK&">G&73@,D8!<5'\+I.'&DS1%
ML!M%TI._Z2T<PNPW2`G[A=&1YEX80Z<(O0.Q%BA6.P8],CHB!&`\-;`!Z()F
MG"A56AT"II$U=LA-Z8.7\CHR*?L`I_\@?\':"==$QQH5\/45#+?_$Z20LO_`
M\YXG+X(T4H,@LA8\<B<G'8)ZVS7Q)&SX00)U<7^U2B1VJR5M\>SKIZ0KFY-W
MW(]>^AO-P8'^0OU#RELS_0>-@KODHY?#O^&Z",S8>=G<A/G77SQYN,!(;Y=>
M[7-(._N*[&H+>_TI4@,3^!@T72H_1XKOD>J#_/0-GY3!W+$!_^+B8IX+(AMU
M0OJB[9UX_A/&)*#W.<EJYKWX^ACZCV3G':$)>G0(*/LY#L!.A1'X2P&E.\[Z
M?5JF3F905R(C;/+.[Z3Q7D[R1RJUW8,R%5Y\_#V#W`/_OF-_9X,8'"F[^+")
MO(P\,FZ=Y<G9KN#72W+W&&8E45Z4)1S?@&9^&MY3_AG(>,YA;HD+>4H]3KEH
MW@D7[%MX0WY/\Z^4QA)K"#/,](&1#&'?Q^2K-"7[3$[371@SZKX^4O8'QE-&
M2)@*GC+&M_&5^0O4)1R($1N3G.[V2>JEQPW?,<M/;=ETA&TE!]&S,#NP)6E-
M4J$1;##9,0--MQ>M:@MVQKYSEH%-67?9K!TMUG8FY./(RIX$Y@5&LF<'JN-M
M!*6SXP!\/7YIJ'^*T9X"]?I!FZQNA%R`,J\>@,6KTQ+<Q?.,"[3BAO?-1+8;
MO3>25\1'!I7EODG+TK<WVP])_/`A?*+!.7_%H:^7DZ;#?)0PC=Q.CG\U#;E)
MZ_+I4&*"377&YR)B,A>U=WDN)!(7DIE<0'T.,4/\.\\DILL^GK[_G"3!US"*
MF`VZ9F>M^"&$FT2.6OFGT>0`_3D0-=N$L+8@EP/X7E1#5[);_MU%77:-;DSM
M-1;FMLJ:2O+DH.,%C>DVA&YPEPD[9*49.Z-?47#;-;-?#29`"@P:D=3I,U0!
MDQJ:%.`NJ-<SH%`GH#:+1/T+P?N:&7[-C*WXD+7#N[E2RL=Q8XU$+"5=->K.
M/M-]DL*BR.V[SWWVOV&NVN.UI\`L#JU/5O=I>@6Z(14P..SU7T@)[X+]68_F
M9#+-J*6=#46X4\/93'XQ=?/>(,[5-QI5X_J0[0K:O9-!JG6PQ]6"06'I"OR0
MI$QV6F_2\"&,O>@ZRPZ\@BSL[WKNJA8HDJ.J24:W4[8`(QR.E(`N"/B)4J7C
MD$XD2^NVEE/,_LSO:9G_&93$YXGXG2B;;,T?-=$WV1,U4#:\?>Z]E\9L`;);
MFO)>"?I[WA@DXOXW3D3GO6,!01B(:)[AXLZ(31?FGJDI>.W]4T_J,%]-9)11
M#OEPTK/*]]^@&PD=#='J0*.^G-`AIOO`0$")'K72@]D"T$7-LD\I[KL*;2'M
MOJS0E5`\G;ORPO0OD')RL[UB&VH,P9WK.,M3[K9DHUJG!X^H=[H$M>41X`@'
MA!!)!4HD6!>5;P%RDP7(Q=1`(Y%MZZ")O,ZKW"MWRCI/4\9\*GUB[#1I-`5F
M35]]LOJKXC::S1%Y!A?4ZKF0J5T+>#J=^E<AHE*P:*BW+SCBR1R!H^J3EX;)
M(1.#[3V<FJ*ZG8K"9GIKH;RJ07;3$(B-LJH:^3E5)5(7-^O5";%25E4W5T@M
M27A:\(E^/:^LU6V:Q`F\V9045%\[C*="U)H)9+:%D$U!ZCE(<Q(7%<PEFC%U
M<:I(MW5THCQCYM&'27I+V?\&GVGYS,?G7LYY\%\'\9+C'7\4LN]S?1KYS893
MH>;5&Y/9C:\TX5Q45\MDXF;33Q/<;E;])*G%T]#F\YSZ'8[.=CH.BZB#.H2T
MI1%@SNZ2L^K)J?2N]-<[_H[1`;6;3)G\*-&(,DQ-TQ;`MFKI2M_T@K!%_;S@
MEXQN#]&'<$MOMB+UEG-P+":D#X]5#-:`H,[M6@E+!#`!:`B]"G@'U.494*A5
M!G8&B6S`(?+25F<H6A%^$(1'0#@$B?BL]LJ^FNI?H^BKH?)-#Q[[CS0X1&SV
M\D7-SVERV&?7_#T]\\MYN@-XZ`<:W.QIRA<WN_`B*(SWY9%2>&UW'@2\=I<7
MU7$Z/2N#]WVLL#4B0SO!X.+;/.VV?"TF/D^J[Q,9`5)C0`H4",>!7Y366$@]
M#%PQEDXP.CEU1FN%[BUR&AH"YKUV/RCY_L"1V9!N,1`H<]`\M8@NN5Z:'F&!
MGLH;21@HM@L^(`J]^S`2[J:?[/9IF/'J#H^T]55140%^G]$'?M,0Q@4>W<'D
MJP<U1B!7VF)!!72#W[BO0+;VV-NBB#I_8=K$PU@V=L9I*+B].4YEZ[+[8W%)
M4J'Q;+?(Q=D]:9=TC-TK;I1+\;O_?*2Y3SYX;.MZP<"R[]@FQ:OQ_H,M"/NE
M*(3%%R-K+$;O'WR/1P)%>:SB`YGXE_0)MG'N>!UMP#`5-8#%WKM/*70WW:?)
M-N1E#V!\M6WR*F"RP"05%T]M1YVU5RRPJ<[9*/`"O#5Q9>7U3TE.LP^)%T/E
MV"*K*GZHJ[;KA'[GS(H8%)Y'O&KWJ[L`\!DWA,_)%;":5>HFX,!^MC)/DC5X
M@AF(7D!1VB'J^5IBPT[<0.6[RT.:@E'3"W=/F,2*%=`@3:7T')P4\.Y$OI>E
M,YE,IQUMU1778>74E%4'R@_JZ*`&L`LE!U6RJ"S`YY#"62'.B:*"H]JE+863
M(TQL2TV9/UZ\Q]$+":EAD&(X8XBW!:887[ZT<F''.14R=&(.IG3T!PF\@CI:
M3&/M,*VE%O+I5T<GIH>!X:$JSZ^'^M_L`R+UJ4ZROSC60\H4_*]>RH[9HB%]
M'/R5OSW(L[_0+*<!F!*&J<]^O$O@5S>'/,N9#86JPO`WFOIAQFG0BA$[@Q]6
M`-D9@GM<4/AP\11'QDY^CT,NCD0>5SW9`1Q)@23?4TLTB<!3[+,%IM!G`'Y-
M)&2+`16ZCIA9YQ?L[%Z]8/?%@A7C)BY8[L:":06Q'5ZQGLTKI1$TB04.\S8.
MQ<LO7UY/K[F>\KCJA1A?ST1:SZ_E>C[5ZTFE]81?DZ2UGK0FQEX\VJ$%[`:K
MG4'.7H2JGP?\+5])95$\;4+D:O+D5B):,UBABG0)B]W=BC=$O)<MYMY(U?FL
M[Y8XS$FV9&C;F\,<.[&SN8HT'%.;J46(5F6F/5W\6.((8IC6S/82]/NUF@>1
MLYZ#R*:V`8K3Q\:V-ZMK4-U<GQGGCI'UR9=9'U2;;GN-^O<#%VR8M>#5IR0>
M(``[3#4%DQ,)2$UC\GJA)X:/,N+DEHG_UPH\BY#1,DNP=G`H9H.+6)"H,21'
MB_XI(D,S=H0E8T#3MP.[T1Z9%/DH"17B!`NR[+`3OYL5^9GQ(<M1H%DLTHT(
MM7SI5M2C^A21ON7`7H?/ME:L:!VVV8X<S5=*G2C2;(VT8;GJ9AX?Z@=QYWE5
MU'*"C3*<THHU,B9;^<RH[@0CS4;.<R+51'71N"S'A620"YXA%^S8BFEJ,&P5
M)NG``B\9BWLS[;LE$VCT]X-CQ*ATLH!UZ?+GM(DS>QMG2EU_QEIQ/4^\8AH'
MGG]I*5C_RRT=[5K.!,Q,.ILZG2TC,2-2WZ-8;E]Z/'\&3#(V:Z4<E5;(R6C/
M3+576BJD.XQW!WJ5I!]"'Y)[SQ]2*LJ#:MDI/5@DHZ1+2*?N.7.,&2`I($D-
MZHBQ.4W"=(S(5,KZ_96HH-.KZ0P.]HR#D6+)EL!$JVP$+2"DG,2`TLVV*@)>
MO`X0'87S"7$+\UFMA"ZF$*_:\NOYX%]UE?CR%0QY4<SZG0/6:&5V)`UV)+/9
M82>8,5D]AN,94W7#3DAS2].4!@Q#\526.2]2%&921--D1DL!33.BU?%,,1<7
M^_.Z9)H<UG/1%"S&@V0I'M@*9DY0`%4LTUSZ$7MO0+F*6^\(6"B4N3$,LV=&
M$[U.;PCX,RG^;JW'Q0P<47M2]"QUI]]$=YTQNR%!6@CWE:M(?UUF22&=(X"H
MG9%&2.BV%:H`-O)-3PUDKS>2(2D<>UXO='&4\R3W(D2$<=LVZ4A]MWF3AL@[
M4,_DXGC'OGW^+<P4^JL#[4)%DP8Q1E4_-@0@R:\`ZUXQDY7H<J*.25<`M0N9
M=*3/`7T"C-XE.R]4=U(:AW9!GQK$3)([`>V>1JU&F1,ZU15"_>)`;0F<?.]Q
ML]V&/JTF9A^Y.J1QF+/M[R/=W=.T1T'TX)#N.W0(:(N.@)&J28'L5&#D5P%H
M16J,UD0.E^LNR&1)85J<I##V6'U$*2'#XY$D0X5P6R+JL7*-L0$YP+CMFH@\
M'44>2XA'Q446WC%9F2RT'[WXL/5\Z'T5/^C)K1($271'T&X+0&.X(P(\BX1*
MC&U)KX[<R`*L(31X;N]G>-XR<EBLQR"ZL#)BG8Z7\#?+1[NI^&&ZDYW%;3N-
M[95%EKM!V]HW"EOV!LU/L;J6#T)S<$27P7YC.+S*>'+XT?L6[@Z[44ELCD.4
MQ3:"W<V0_]VJ#Z=D9GNU^SB)N-YAK+?>C7&8Z]U"L+/>XN]NK'<?,SOKW<-)
M!\)Z=0_+*6$]"=J%L%Z#&,/@E]29U;F@GI*NWN:R3D;ONK*F';WK")H#JM/I
M`_M$)]TU]<[C@CH-$&BH6#WRR>9Q3L<TB?U`O8P^)E%`PMT^39Z*=&&@>1M^
M@]!AAS0G=$\EK-I:J)!44WW,J/_R(7GZ/J"A4$7V0UL#V:_^]H$^>-'[.`_S
MX\#QO&\4@O;T(]<5%S:"B"&63NJ+(8HAQXHE+Z5T>+W7DD'QH<'+S\X0).EK
MH=7Q"XJUM'1`GX\AEKSU+:\L;#UK.SVX[D?4B_\CR?9A[D7JH'K?4*Q@>C^:
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MT"Q/0ZCE>NEEC\SNP'_`]CQY$<0_^W\[ED\S?5+,)(@YI'?R$:K)"`#PS8K_
M((':3NAQA%[4Y(S9XMW)Y9@KVZ[K]GC.TIQIG=?OP8U%(>:V,Z5L$^J^1H_D
M9\V7Z.G1Q22FQX]>^AO-SWT_.<3\-?_'0W[PHJM#'`SKHPDT5A12FYC.@0\@
MB0`E)2R70@%-.+C]B*79:C6BF$9+A;=+%$6ELL_TB<8'5;)0>R2B+>\BV;GF
M+$:08H@M8ZR-*4G%B`V):2>U?S:V6L_;E\$5T_H/"&O;H/=+ZO377F*Z8K9;
MRM8BSKV'/EU1#L=ZZS6,[M#Z%F-)/=C*.R\G$=>I6FB`^=TC)?MJ@%RD,.VW
M7&B/U$:DO/%&32WBDS7M/`A"8+,7?0PCYI6Q/;-HXM`7;QB#0-(W-=+M]:]'
MDVIXV>4#/7G.=?1U=,\,?U`_;P?N%ZB>5U.SJZ@I&U!MD[3426L50S440M;+
M<6W`O+X#7Q>>`(JJA,I;NM90U,NX#IK=VZAB2%ERTMZ5VGQ<<2_&^D6@>__5
MN_Z3MY'/R=&+\J.NPS8X'&D#4:#;B;N*H8XX;&XBKK-I&&`..P8[]I"TH*#8
M$F0G#B2?9!ZSN-8VBC&1EW>)$7G'VR)^3I+@:QA%U[N]%Z:P9A^23'6S-`"`
MN%T,HMP6FW+@AM1#"8RUM7EH8R[A&[$1)(G)0P%K<S-1"TM[2U%*"IZ$G\=Y
M&(31`1I/U<D<[[_YT2&@P14C$@HY'X2MNMF^]]*8;8,9TTG>QNZ<>ZH*A5AF
M?D3]68HAG7.)-*^<'U3.3&!J(LT-V5/E[+`;B:Z+&R*^8$M)K;%GVV9/8L(>
M3#NPJ$JUS<:2^H1G908NG?-++TV/##]>RU-A1?3@$:V$+D':=Y<;:/Y80HN"
MN+94?`7:O#':,/732!C;^F<BB8B[.*^R?K-]%V;[A/GY/Z?)87\=@U%@.$&1
MW(39#>9+!S?L5"!:R]YG>>KYRKU[QJR8._8LXCL;D:C<#ZG+Q7R$3[@AU91$
MGI-4DY)?RVFM95JLP@JVT08RP4D)FOW9ZC8[7^8[F^ML@<=3>0,<!U]5?Z(J
M]5_J"XBF8#FF=!J3&1J##6D5)]BTJQ-\6N%67=-,K,>F<KAH=U@3:_E:?F%E
M:=N-937%21M2ABN6L1?5;&[:!HG8^7;@YX'0E(/*KJ![B`I'M;@MKC,TMB6K
MF+UAH&O:%W:4YP^++SRV(#[]\D@I&([Z)K7N@9%='!N$96K*QIY)("&`VJL&
MB:5JLT$^>3O;Y5-/@!68M@57V;JM;1`US9)_,88A",+H<^FI,]KR,XR(5FM*
M-NYLL"%"G2P_^'"8!=;\%7/Q5_HLQK(_(^61,M-SR8:%/D_9+HK_*]]]C`"A
M)3Z.H-Y-'@0`4D*0&L3ZRPZ]96CFVFFLP0(=1JXHS?HC2?WCT#N*U`@JFG'`
M(!LQF0FH;MF@=5YE:*62:R#;3&*E11]LJ%H9PEUN&)-<9)F'2<#36*.:.C_)
M\HP-\0^\FR[<]*;DGK)1E$/="^>(9.`=D8"Y3-9RF@9UH+]=2E,!)FN>P=FU
M_O87FCZ%/LTN@;L#JKK`Q$BZO0@+1@XFH]<]DD:64Q,^MPT3L@I'X/?\`4A-
M:5:`6#$]JQ!Y!R_1"JN3THC7"\Z3/IK9G^.`@E&ZAP`WH:**9"#:X(!M2ND^
M27ERL[!MUBS3<C9"-F6+&0@,V]=,K+M11;"7FMD]ZZ=@PESSU\H:)3>QM5#W
M>DPQ2#5US0(:4"FY:^$PP;7_QLP?6+NN_3L=JS=F'2::O1'3X.357O&#SCNH
M.;.Z>=770_S\*[]J4MOOL99EA/"4DHHXX3/QFWX!L[Q7J%4FP#:5CMZ!#NGU
MC+O0`:5VVZR)RY61ASLS)W;<N#58L*1]$Q.3%S#U=Z=DY90<X?XL?W`PD/AX
M:A:@JP)+&(&._,\YUO7X4M7T/".3ER1JWVH.)S$O,BW>@6XN^3U*W7MH$_HJ
M#FQ;TIA7ND2SF,J\$C]NV/$D+<BWDK:\I)BW#B=+R#CJ%MZ39.6%L3@QE8:H
M0+P]\!/-;[9WWC?U5K[$!W"W]&58HF<%-@3F+C9MB-M4'D!I$GI`V%?@S^P[
M%K?Y=;C$N<&,(SR0AW#W\"VPY7U_0;WIV?^74QK$AX4I#<+\RO/#:+A/FV(P
MYI/!/E0[-RY\$"E'6<X17!!EU`=^@T+1><TW)!&V)'@T`:YWN#4I'LS;Z@B%
MY8RTA=&V)\WJ%#&%="!*=++;T=0/O>C68QO$:+WN_O&8,CV`</<ZO!Q'^,#!
MG#`TJ=9$_)8)59AE<)?]*<FI$[TGE%+2D6N%B&#6J^?9`;=>FA_O4B_.V/$)
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MI`>/?%>A0U#?582`(P!(."2I01VHGF2!-.P+!&U1[+L?T)5#Q+IG1:.BS]2G
MX1,H^\]IDF67\'1(7994#8A9O6R,A(Y+5C:?JB$VA,-L2`%EK?S89%K2"L)J
M23$M<>I4#=.1)42=B*+D*[R0NTK2=\GA/M\>HBZ*&BIB-`^FQA@2V!&Z$IZP
M"4@Y`^G5*]L*-9/4"R\@`>]-7M%\1OQ#EB<[FBY'U$^"J)@^P)G;*:)0S<<4
MS>M8DPEJ-SFF<9O2O1<&138OFS]CKK,/!4[?T2<:);PRV4!<0P\6*;:A2TCW
M9H3#E7GZH/P"DB=\2[`VTN"F$L4./"G]EL1D7U"7RD0%->QZ>?LZ;YFFDO?E
ML(,LG;QZM)013F48$R]XXO9`=$8:(=K:,R4CK9,#5R8JA^=P\-3*VC1EFBZX
M$@S1G1A!OS^15!KOBO,]B8[:[[::TZXC0NV-4D-^\'2@J9GCPM\_'E'JAQ`>
MV2"M2[DIWBZ\V5(*1UNL59*!;--%.6Q-2]X<C&V_VZCV6SLQRKH,ZV-LYSVE
M%G[\F:3U/:-71'MWBC[YQ-.GJLSS:#9<>R2B)G61;"]Z-<)ZZMLXKA^]^+#U
M_%Q4)Z"CF&/*[H`XM`6W7Q8FG_9%9R"F"G%PL]V&/AV72BTPI#.^!OH]&9L<
MA)\!!1`9EV&L<Z#N>LA'0,W%P/1\!PK:<W]<Z0(K`5%]X1$2AKH<%*T=VIT=
M.)@]!QF!&%SO64?`NFZTAG2A7E0>=@>>DO:.[MFI.^21,?9S1'D;F3@XWT'I
ML'^HNT2HKS27^03NY>=2;.FY6BRG)O+<&U+-SD5=GG^L:8O%>]6UV/2!9AGQ
M)%X%T@>LW1`Y0B_RW?.B%J+GEGI)\S`]C=;WTP,-_D+C($EOO2/,.520M'\L
M5KKL`*(]A@;&$3&0E"-M7!B9HOPD4-ZOA;+.+9`NSE7_R"?HL$B\K+P#ZM8#
MAK\D]U'X4!2S`!O.:.118BA1EWMAS"O6)6T.6+L24FI%(W=9H1)S=1+.%C3.
M>E>KB6=C)*X^MI`<$FUYF$55',%V52P-M&\,S>FZ5]7QEI1PTU)"7_JZ;0WL
MTX$>_>M1@,G:QQLS7WA9<];S-&5+(-K!'.LAA<J??_72X,H+4]YO]CS+#KL]
M9_C[;_!.,J.W:>C3F[COH<#ZWT2R"&LSKI-X`),1/EO#OA#ID^3B2.1QQ6<)
M_^Z&P)=%!V0B?7M#RJ\3_GG"OF_#:&$SM*)Z#V.L&$!LDL\?4DJ#L\.>I^>$
M1:X*KZ;[S7^$CY:V]0"UQB-N=CVXNQ#%R0N3"0,RP.OLGHM9X<`0#U"S9D-1
M+)ELC3',&%Z0:&%J]M2'PUX(-9OC8.35V/K?1@PK83"R=W,XT]P<S@PW!X$!
M*5%8YP5;3M/Q4)0-UE;T!R7]J<47?$YP8(6S>O7`Y^=#&(!7[SH/>J4`,V2'
M9J_;L3PL8WWB6]]?$G"8H!*2C<VO]?53W_XZS+2Q`=9(/+<M<)2]%0^R'%Z7
MBK/#4P7UK'9#?6:LR`#[&^+2,G'R>V._04?9'7NM^8GNCY_#[+>KE.H6%%G_
MVZ>Z-PXP$G%G!`P(H%`5^G@N&Z,F;SD#MHS^L*3_V9P-C3B0KLX">_OALHPX
MV5U09;97W0,5-AMY![P?I^C>9%>'VD&OQ[:^=3Z*O>>MQ3H;QT#XML4M#HN5
M%;U1N!47ZQR.O`AC<J1>:J_CD@ML6"$$2K=A',+<NCN<-1:PB=B'5F@`;[S)
MVV'!BW[Y1]_;5]V0>C?U-7<C_!26FR8R5TFZI6'.Q`]\C.OXEO>373J'1>^C
MKB>QZ+)N\2P64GRYWH_K;_/3)SN+$O'YDTIBF<K0B@W;"L).*BTZY=`W.C[`
MLS/8DW@^2B;R5LH]FN2/7DZ^LF,#?XG/V90GY)X2'S:7*(+[O+I_=$KWD(+.
M_B4Z24.JH0>57`Y1SG=^GV<30LHA^Y='H`AJ&(NL&/H$$IJQCX3;D/)R,-"H
M".H2'KR(>)!XP[-E6]F'/)6&QT\+]VK/:#R]%!HC2[I(#HV)&3V!2&E!SLTA
MSW(OANZ7GPXC;[67_]8I1$(5C%KA,'A3GOZD[VV(^.*)A3D-&(=*]=K!37.Z
MFV3?K'3>$WO,E]Q+<Q=H_U3MI'U<N*`/8LNZ$#GW*W'C?3SZ.L\^+][S_ZS&
M"?,X`(H9O5>;T?O2C-[/-:,G$2$?VZX7BXB/[-6GX]G\#!&C3'&H7NE#)^33
M=%BTID,C/E8?EJL>NU<KGB-1/)Q1-G;,>\$-BAXQ0):<96QX(3EA4W(2I>2<
MDE'OMU1+6_1>,X5HSB'F<)UE!QJ\XQ$0@0='.>-_K`[8XEV*TF2;3X9IEJ>0
MNJ;I+;^3V0M5+LH;@/>*J)B?[';0S)R'M.!Q61F*H^4$_`)11.MFW"!RD@^5
MF$N24);YP)&(94QJ+1'A\A)A5OUD$=[T[+#5\+4(N]/R+4YPY5'WSLG;0F=_
MG+HGG,Z11O)WH$;-MWV8BKH#"*><\6^?T,%'AY%K;LC2]T7)K1J#%;=HE,/0
M%-:JPU\EMQ@_V?9.8<;3/3A-E[QES+]*\NR[`B[(GB1OIWRHU-XKECYGZFX4
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MB7RMS7<#0_O^F[]X2@#RGK2,E*Z626`LI">UR4VRPHOO<U-,L$-;W=S;(TMA
MOWEXN;01KKP`UM,F3G6C1%X7@WWSGRK_PI"-?;PY[5T0PT"CYQP\JSU2NL:S
MM!OJ8G!"^YX^4]$R&I[E/C:=S[T)$*<:?'2:2Z>T'QD:PQ53*MS;8^['Z;HW
MOJ;Z3'>BFLQE76X&JFJ]&=MOD+$YA8J3LYAM+QFCPHI(:*U3IG+M"HV+KH!>
MDD8_]SZ$6_MVV([!6*SPWVQK<3KV>7C?&:)QE<*_,[`Y(?L\C=GVS@F(]GG=
M,L(K\'_1NP_[_$?:'Y=9`;VSB?[^.)M[."60G>;A*?D8,S:]I7V,Z3O>Z<09
M)3_JFI$2QEGH\[K*..GUK6^>4"Q1Q3BT4UOU9=%;X%0C82:\/']X2/E+TS;Q
M6DG,)YH>/YTKS[_@XD*\41=@/*5HZ:A)7S'=O=>>G^2)NTD)TL&Z_='3/#]W
M68=V3'9I0\1BYK!]>__-E9>SJ^KDBGY_OT)::RK2S'_G_WK'%KYJAM)CI5`^
M>R*-1338MUYKD?:C&O$+`@A([<%.L;W(!+8*V@.@?0NT/W%[53?"(@_]#V;F
M1X,0FHY,X,=5@PFBT.$+*'28/]*4`+GP>_KW0Y@?ORN9([<9Z6\NXL7'`JB(
M=?JR"$-7D/(+C^Q']O_I;A\E1UJU#_D:TS1[#/=B[(OW7VYNOSO91B*ZUG/)
M5B*:IO-T`D;*)UA:.Y(M3$XHN&3.9-RJWIU8M!-[F3O<K_CC%?QYZ-OOK'OE
M^&9@W8+7NC9@`?_=GQLI^0\:!1?'SS2"HGFW7IJ'-!MUW]?Y*KKWOA;S%,Z[
M/\MWESY-X-L`57R=%)^WZ[AC<51F1.FJ/P)#[H_,[10,V:_$$#/7'8LCEX\P
M-3R/!#>\Y(ET!3'$'P?<Z%6-6+\7O:8%L]CKM0H833+KZWSU1((RX\Q;L]UK
M]6TW[3H62V5&E,S!8@A.'UA3CO3;=9E/[MKU5:W8LHU6=4R8[>`(_VUV?L@?
MDS3\!PU^@7;`4K>!6R8XV<6Q\1CD,W#@_%O89_S7_)KU(,=<9@U8IO+),A]*
M?H7!_]NM^()%PNT'#A91$;W@P!+Z<1(6I4O!NP32#M>Q*(-?.PV+HF"6;FAT
M(QS&C-2?(OQ;A'^L\(L(_]RF74JA4$_QT5.T3,8,[";9]S'PL`P#3\3"C:GL
M@A9N1%\GGX7Y5#?;QO2O7OW$&/F1#O1%T`)#.HUJH-\69R%Y-]NV1`HP\JL`
M1-?II:EY^>JGLS<O%01AG5-T)4P^:&B*UZ)2SP:]G2#U#3"+4M]"7U=.!-AZ
M4J]\3+8T+2_!(7-5YOOD:TSF>X1K49E_^^KU'R;(?`/,HLRWT->5$P'FG*6?
M2@U(/?F#JV+?)V)C8M\C7TL[.%/$O@%FU\&9(B@"S#%3/Y46<&^<E?D^^=)P
M;]:6^1]^_.,4F:_![,J\C+Z!S#,PYTS]5&I`ZG]XJ2#(LM1W)$Q#ZMOBM:C4
M__#CGWYZ]:.QU#?`+$I]"WU=.1%@CEGZJ;2\_/%/9S^]5)!C4^;[Y&M,YGN$
M:VE+/T7F&V!V+?T4.1%@CLG\5%K`SCLK\WWRI6'G%Y/Y5M'TH<*H@T.19'L`
MS9'B'Y:*7!H@+(0V:0NME3P1390K3/=<O1CN4I*'M00.E1S+^J008OP4N/?\
M>=%UG.4I7YVLP.Y3$C_1+*?!8#MEE,^ZG@2GS[[EL^#$MXGT\2KWJ_J\E9;+
MECC*1IP55+^C/EV%[C6S_Q:A_&P]VC5JI]C2)>E^.MN07G:0MZ\W<#OR&K]J
MR@EPY<UII85.9\H=<Q3BJEUY7/.D\<YV7QC:L/["AOW#CP[\24#]P/<0A_EW
MI>>Q@7>X.3P."X/H2.BW,,MY$Q2PX/*3`B\K?9;[HN91]DBI>&!V>OFGAB[$
M(@FH9OZ#.VY5\\$;EE?5^NJI.E4=YJ'Z5.UGM,_`IQIG:',+&6B#>I)>U3,7
M)BO;[RA/F[OO@V#"S@MH3RV,L>V6U[3(R(LM[^KD[?900&K_R*9,=F7]"P'!
M1VY:O_/V^Y3ZH5C2%!X>9\4X]GTVYX[OR\S9?:!B@A,LG&&V"ZVZ,?=N0>[L
MRW_A3@/VOMSZZJGNRQWFH9I2\?5GM2^/,[2Y+XOQWY<1Q>>Q03]SJ;*R08_R
MM+E!+W@F%NR4=OF4[I,TAW^)_?[Y[*[]>\FJNVOO1N+.[EIUX,3>8+L?/M4]
MMH^%J`:Q[J*ZGDVTL<UH,;:YW58@WU_"(2&*3JW0X1Q>K+5#?*5,)K>5D/U3
M[!2#=G'5S6+(*+JS7WQ*8K&C3:E/:!NC4]UAC)B.?9M=^N-N5BYT;SV>_8WP
M=-;HB=`_SRVR94X^GYOGZ8P$G^IKN^9HL[!V7&7T>(!&1IA-;#I?/!I>>ULK
M!\E3^D1C0"TE^S39PEC_,62_Y"9=S,(Q%;%S\.S(U\?0?^0N75&G.B5A1ICC
M!<X=`XN.)+F/P@=>CBE/V!\S]@5!I>Q4PD=SQM=LRV;PLHRR7['A<OWKKX\)
M>?0RQK:<'"E#B)&0;4,V;T;3)YXTF#8"_7[*/*(T]$C,Y#/+O/0(4SYX4$`J
MS",*_V*$^I0RWH-;R.G(O*A*/Q34<LX%-(V.W.45!14*=IY@;:GE/+2UK_W-
MW#-W?-WY!;F=0.M4O=Z%2G5CW1/_,SG`"];Q'G%0ULIK<.`2?@UWQ,L;!='9
M[E9[)PV?I'!5^#[>U^[B7U?\SMAO_!R`D]NJFY<LKNS4IEB=Z$9MSGS$?;IS
M6_Q/M$W/7QC=77KU+`<;V_5\]HWNUEF5:R<V;+;YY47G\>+4W-FS1;\HK>VY
M=;(7O:TH/SG#*1[N;P`WU87.!LHPBQ.Z.#471W1(G9=WZA0036EQL<1P9[L[
M#9_X63ZE0%/[P+TI^F,U;J38'WTO>X3:T)[O)REO*D^^AKF@(*?IKLK/]^J%
M?3:^P<1];$W78-HFYHQG4%ZI'9CLN>(7F.%THEZ!*>-M9$P`;O]$_L#<)='U
M!IY[$L9L_@VZ`M4V+=R!=A9'[0!D70^@YW1>9V]`L)V6WAD/L!\@&81MU'2[
MI7[>;F_)'^W[_B%-:2R>\7M\]PUCCWL'<,7P?+;=29L$1B*(R0YQ.KW@A4MQ
M'@?OO^V9[-'@+H%?2:V(6C1_ICOA%5\F<9YZ?G[PHCLFC6OVCE\0R1/J-;_H
MTJS9.;,XUL,YI$25W"7\UQNYJ5Q/1\T*92+A3`!IW/<))[%FEMX5G@1O6KFG
MG>T]K02M"*K#>1R"\>Q7ULOPN\+4QE[J((9NM#71<"4J?^`\RPX[O<)="!^U
MWN1D(=:ML)G59R8B?;C=O\/BIH3%RV;1,+=:O*Q$\F649/7AK9=N^YU9EK0Z
MB_6GUC4YDT.0(M)YQZ`&NLSU#$(*TG50:XM5<<<%(RRU<EL(3:Q00O]BRV?[
MWI5>0+@&6X[U#D,7L,$>58VUL]25:T%4\06MOW&58M4G"QNSK+LP!\L)`2-E
MF>+>H4A"-X!F9\NLAHF0L^V"O2KNRJNJ8.WT8M1LB_2R@[AQ'5W<H=%8I:<'
MD>T4O)5'NK'*(YQN5&-6LAG_2K3/4RK\3AZZ4)5S7OFCKE]JZK)N^5O+_D,A
M*<\+(N9DK7`U.D,USDENWR4N2#A<P_$LFM:C;GXM>'J7<4;F:9';-A/;--E<
M_Y4G)N796%9)=QR24>Q#L'-578Q9,P-BM'B3*XAJV$574-5\]JN#[D51_];+
M.P]#7]EY8CL3Z^4?!NML'#I(0YYH\TWIUP+*FE4?M&*R(1XR87BW)>=Q'@9A
M=,C#)_J%^H<TS$.:O?\&N3$TN&(DP19Q$"MTLWWOI7#)D[&#MM@ACOT3#`3^
M,+Z*>%^R+O/:0BX/)O5H4GZ/P`>)]$7>K:?X)B3O"Z=Y`^[ST%QV0IZ.\G/;
MYF?2S\][4WYB7DP@*'C[9F)][;9M'S]YN^'PLS:H=4O5($-3/38$H*P%KM$)
MLJ^K76'34[B.I)U`#D8WG1/>N-P]>K%V[R9\'$XA0V,"8U=(V.A[4<`?,0$B
MC78N`I?-6CV>ULYH6(S=]VIVWY?LOC=B=X[,;HU3M0LL_U35?BP/9LQ9I@]A
MS',0BY,Q_M'=5=:\%QU_!OAR$MDW4_>;Q9)Q)FXVSV$K'^T7A(["L]C(]9J_
MH.SC=ML*.<#J/JOIPH,`FX*'X=$4@A<."=[SV)O4K6XL64_\+(TV6F4NZVJM
MZ,8_Z'IVA@[+EL_,Z&X15:;^:?:>F\)&R7T^R98V_U2BLVIBRQ1.U@X%SV.I
MKCFEM^F=4G2=*]#Y;`DS/TH@4>_G0\A+S+C`F].3LI\$.V/*RP([HZZ]9_TA
M8^5\EI2V>[!(AI2N;_`<#O`ZK8]L8/$LCO':39%03O(8'9(L'^9U&%[;PVKT
M\SO'ZTL>QE&^EKS!T_Q\?X9NPSB$#RK\&3<8OZH$ZODC;C"BSTD99,GSB/>,
MMM2RM]D^!W>FNFF94N;0*?2>A0-DM!Q.Y"JX60CQ)%8*.<W!TDJYE0:Q2`7+
M9JF5?[9TB558^$^55F%<+=(IW)Z/\S._59-[.#X+-VBA)DY6\CW^>5VBI5;-
M1K*$M55S)`RS0F^N]A8_D`/T//;VF>V9W$/0V<06]'X,"V!T\JDQ=GHQZ%U-
MV[+<%E-LUCF"/<_4G"F\^@Q?Y2]?URVJ:C?5QGHWBJ1VS(;;48!Q*!-]P%\;
MR.\Y_90,W!X2B^UJSR$0,+/=DV,(/HL0P!*-H#"S1`!1:X=(-[)(%NL0U?9,
MGG_>B5O]SKIN]_S69\_CF#^GY9-CV,T]X//2=TS?'AF:93;*^7W&^V`,'<&5
M,%B'Y!'$^_NUE`!5X@WYM82Q4L=Z?2K0'&H=06JXO!I2-%FL&ST!7BOK(_<.
M11+B`30'6V3P<>3U8%UD#)&=B//+US]8+^>LD@I9-!4BL9!$OC40R;<V9?*M
M]@*_=4@J];%^^?:-8V+Y5E<NWZXAF#\8".8/-@7S!^TE'K8[Z\>.I^+\\@^O
M'!/+'W3%\H<5Q/+-FU?Z<ED/MB&8,JHCJ\R&NF,S3?!^J4#<BG1VY&-0/-O"
ML91\OC&1SS=6Y?.-]CHS"75)0/41?ZE`W)*`OM$6T#<K".C;MP8&M!YL0T!E
M5$?6^2UYZY`%-4'\I0)Q*P+:$9!!`6U+QT("^L<?#02T&FQ%0"541P7TCS\Z
M)*`&B+]4(&Y'0-L",BR@+>E8Z&3TTT\&1Z-JL)6SD83JV$'CIY_<D4\3O%\J
M$+=S0&K+Q_`)J24<LYO-C#5Z'AZ+W'1FK"]N%<Y>.5_'H*>+=O=B>YE%QJA6
M_:0@Q\>99B/*QL%C(GP"V2N?DN)^KWO_5W>F7Z\RN,GG3R'SQ(R=*^25,`3.
M!`8]E^\;(F&Q6FGJ=?-%YG&XLN72X)/+^UA`R&9E=7Q*RMR-W@2/&H>U)`SG
M6<L2NCSKM=%\73Z)O)@)6]!B62_F^P_^HY5A'%N^AW<?T<&M&AT%UY^E3&,K
MMC5M'SX`&2L;MP.\[N/%23TG^9?(H;Y168;=T`FS_03EOFCIF3U26CQ%\7+R
M]3'T'\7S%$HSXGLQ\7SV:;8*`)0!DAEA_T?3)VB&EZ0DS+(#GXDMA2B10/9)
M*M)BV;>2(D,VD7PJ]A_B']*4T1$=R\<K?(T.<<!?O-!V*5MXZW)Z;UIF['N+
M/&*9ONF=P+E_--U7\G]:Z;Z?*71`8[^_3&*>%GGPHCN:[E3M2=W"\Q0B"2LM
MD+VG+(WC2B?-O\*92$@3CO6)!2B0%DZ3@Q_"[3,L!K*@[".\;Y$C(G,$_R1.
M\VMN+'B/7:;O*L]A[Z_J=5TS$L,X"WT'BG2V<'D6>_@PHYTHOUEA]5R+2NGS
M__SA(>5%G"6F/#W?IX@C%L!"Z<!>]<<SMK=,&J#]L]REO<<.-H8AFJ@6>FWI
MA3\73;EAA+4>XS/1Q-2MO@5OBWW/:N-+9+.1N4(F&YW+4:5RL(&\M.`#S>*Q
M)7,&JC:D4]W%OG?E9S[*9E,RA/^HS#KL&XGZ`+N-Y,"#95A2&&<UV5`/8XZF
MA+;M+$.%,'2?4_=)PA)B^%K]?*!O)+X8OA[.OV^(X6N[CP;T,.9HNBF&;6$8
M$,/7YN\$EMFON;][Q[XRXD(VQR'NUFT$.T<@'O*"`9:]R-F(8N[4O<O>WJC[
MUMRA0%(V='RK\8X#;7]TE<^Y%`Z:QBZ5%%MVCI$HUDF9RT9RYB2NP46Y6U[[
MFHIF')*9KF7S7+<BL,,FY_\\W^]3ZH<<N\\0:<^^>&DV[M>93(/I])F1U^\1
MEA='(,'B-_(T1,Q#8"(W'+`)2]KQSLS7<_H+NMT^2HZ4PL<NV3</40[9'.J'
M=$H8K/=T(XAWWM:4X[DD21#6Q49K"1IOU33XOW"Y.8CX"TLYX+%K@UHM/M<A
M0[=ZFP1IR>&W0I3=TG3]0C=>H:Y7XE93B$$?WP#8$:48]D9U),B28WZZA&DE
M_$ZE3-1YWY>4>0#"(>PEOQHIDHF:+^.1L[/!+HD;WSHO/_'7,'_\$L8/$;WF
M=[#)B%L^;2XD,S"5T+:(B7E(2X>JJ0C,1<1DI)K-NKLU:YEEJ9RSQLOL1HW/
MW3$H"MD#87X`@^)%>J(Z9T8;^Y8QT2,VOR6O?$;2F-(AX5U@^0<-ZZ2U7\W:
M3I#D65,Z8GL-95G+!+LJS$N(@(E!7E><^3F<F?SJDU=)>A7&7NR'7G0>/(59
MDAZ_T/0I].F8'$^9"TV`IQ':E=QR'DE<V4RDFHJ4<Y%R,@<D=L8J-T5U^A)/
ME]%@RT3A(DPR/Z2,UNPZ]M6".`R`)6TJE#LBQ0<3:30S=KY]H1EE>T,RQG@^
M/=2[#_-D3]6AW<88K%!N"[%.Z%;\W?I"]C*P$9CMX1[BU?7A/J-_/S!3\OZ)
M_8]&>L40!.8%\B#2';>]&DGX4!>R+];!'O4:5BTTG9M4I<18E?7Q7(M!&+OR
M/AR<[)<9VPD0JU%@6>Y'<@A&I&>15&)U'YR^D192B8<[RC13B>TVP='#F*/I
M9@YG6QB&4HG-N]^L8H(')5<]WI[I'9;BMM&R*11:W!ZQ5;8$9'+'7)'^PEOI
M55UR?TZ3;)6J&HJON91(.8E9*[R<K=[&BB_6W>'A-^RKSN9E+LC`694,VPP,
M1QCH5%+F=)5=[)GLJ+[B5R7L14G5QWK-K[E>:W"46<N7)BES2-LF:\U.T6O6
MSOLG8>&J!?&,><@)%<7ODBT1Z34ODI0DO&X$4`F_I_P1_W=%Y;N`!(<4KCB@
M$-U>,,S+B`>%[PY1#@!>?"R`BNW"E]<'JM657X#*%.S_TR+[LT`A^1K3-'L,
M]V+LB_=?;FZ_.[T"=WHF=)%:=EKV<_(F<EU4,;S9EHE*=TEY&WFSE:XH![8%
M?7@D0V]"4%MG2EARLZUSZ^Z2^J::_5Z^PK9AA4^:/AT3.8?`BB@HSLF,4Y[4
M*86^((R;(6L&QUC=9!-BJFO+]H%AAH<;J`%#H(:QV1=&0ERS/PPX"\*Y<*93
MC%-$3&XBHZ""N1M%[5MOEQSBO-5.QJUN,FU=&.TJTU*$R9H)-2%K]1]0Q=8@
M)-WKH-9>81@@[SPV=,L^DCJZHX=E4T&*+<^:GO1+IJP8O6*YP!ZU#U/.S'=>
M/KXY-0:C[THM5!66O!Q)8*C=7<@5I,UVG1&L)61Y#7BWE$DMW/V[38]DXUV>
M7$9>EE7*?9/R=[]2)5;%3<@H*.*UA@89G2P^`)%V#'*3BE?>&Q<:54TF**D)
M2G0(P@S[ZPI;.X:O*6FSMZ2K*$E2DS-3#P#RUM2+\J"EYZ-=.BJYB+[)=J6%
MOT!;]-H<.2W9;[XYK`-]N]>@`ICN8!GU7SXD3]^'_+F$V+_$S^V=2_SV;^)=
M!7]RH>M0ZD(BJ+`^$9U08`5"7/$Z48G!T`=#$2L5PTR^\*^/6P&.]5K7#7_(
M]4MC%8N6O^QL!P#7[/JUYCWQ\^7:JE?#)FR#CF@Q_R.__94H;_4=RQ^]G.R\
M([F'FQ-FBE*X'E:U43N]2]Q10[;(_>V8%;-GP/_"J_.?QP';6*C/?KQ+X%<Z
MW<-QOW\JYMZ`H2O:,X$%KQM6X@&7O/!KC`[/&#O$OQB-M:G,X/2Y8K/8\-_7
M.U%]<1_G2=&-<WN(HF/96A.83$LFLR'PZS*EJ*?3)C3P;.Q<=8--,?Q$&VM.
M-=V+[F2&=GO!W"3X8)S1[#/UDX<X_`<-M-.2>D"M923UDJ&5K%-"DAK4C20D
M;9)B*S1-2SS2(JI"/ZU&$=!VJ4'PUGY<SD27U#E'@XKD1"2B3)!$B$54GSH5
M][2?34@GZRH%^R0=SF?*.NRXA()W,L$Y37=.6,TU+=-:P86669I_FUFFFK\>
MN\6L!V+?7LHH#E_[54\_R&NKEY6&V-J]F50AVWQC8EU;AR6V]\ZQ+:YXV3)E
M1?2B7E:_]E?M,[FB9W=)[D7RWR^3+/^4Y/^+YK4G)I?C5Z3<X'P?,6\'BZ%#
M5?K+DF^-E\CRW%)O7K'39QO"$6CZ"8`"&YD3AH1T'-J01G,)6\E$CG&Y^ZS9
ME,M'$RYC9CBA&HAVFA2F=<"SN>^84_3$4'NBE>&_V=:__!!Z]V$4YD>%V=2>
M`M'R&9#55JMZ%*F&;22_HWC@7__1EMVQ22.FUIN*:%MQ#>5S>EPV]E/*#,)U
M+'VG<*M4>J0/BQ69U22DFV\DX.!D+ITJI"3@]71&*Y(YD2[(#@A+VKI/P<.8
M_VO;\/J#6L/"NA<\2>D^*5,&HN*3(2WR"B#Z$3#P/(%+FB#,]@ELY7"&"/-'
M]IDDIFQS]E+^8IW?%"7ICFWC"</$XT5X_:,?,>T-MR1*V!DY[;XA1XF#XPL0
M6L#81,D;$6,##;<6,I;B)3SM=*5P<><S)Q(J[F'/XK'.327K<NB/?^XDXYP:
M/),)!9LZ<C=T"I%QQR3E5`+#0_9GR:#P@/%QPN:N>4?7_<X)6MW5KI@&E.ET
M[Y=TN-8VO$GPK`RO$\)RBJ9WM0NY(1LTV?B>QWGX+HQX-QCQ4"I-<NK#/\L+
M#9T7A\;3()G.">1UT@W9%*2<HWS=5\U2WZR[\.YO`7)OJQ>`U5'<`PX$)0>*
MAX(U![;L+&W5Y+FSR%BV:JK6RJ9HHLI.MC3OZ/3HGAXLDDW1):0;,W8[NC>5
M+HCN!?1?T3UM>V5!@+`,DY&2R];(1,-QB_N'0>BEQR]>Q!#B-XT:W83Z89"+
M_`\AWE?H7XS=$!@-`B5NK.UW%9I,0Z*F`;MG@5*(^OH6J"0(4?[K[W_R=NS'
M.Z:/F<>=A/%&0^/`F!JA0TI'K&1UV!``A']*H/;[$$VF*VG2E>C1A:HYVN+7
M42%=V</3I5ON\=#;R//Y27^T4\P``*+.#*+<.32*@:0:Z42S&#7'VR*C9#>>
MF%P<LC"F67;N__T09B$/#ZD=CB$(1$$91KHM*>5((@VU[&>L@CRFG(^(3%O0
MU?)B5]+AQY2.-S$<A[4L_6U"=$1I0THPZUX%(DFV-:57Y'1TID_>9N2^Y2G]
MEL3*SH>M06C9;"W4NEE'8H#UMH']3&PF$?5P</*BW:;TZ?P^_1"I^X=WAB$M
M7`]Z7<>-/A$VAK!!UI=OB)WR`@[P$M.-3WQ*@^R*H2XGGI=EV?NR#_1A49W[
M<4*ZXB)@"``UGS5470+0'^(N0M#6@"#<,XRFN'6/,WJR-MGX27%:/O\U+VW]
MCL?_Q=TT_^LE^^8A@NC[%:5#G06FS85D1J<2VONJL0K9"UD3<Q$Q6=E+3(RI
MYR,PH8V+BF=*N<YEV**DM]JE%4V$1GNB^34?MM1>';Q9BB[OW7.T?'IV81T)
MO$K2YMPZF2WZ\%C9@`8$*>/9A(&W=<V%XMNG3:!6:N(,"F_;%;I3ZM/PB=F3
M^R/)JILCJ*XO^BD24?>7G<`A48=Z_F,!SRU,W;NL-$ML4)9$`1\M6:!,O-JT
M5S+#5(\;:7>&2CS=VO3;-3YWQCY=>E\%,H5/=AY7!3>&K-#L>;&LTP(,Z"CU
ML,,@YN6*7G4IJ]2_=.2AQE\YO16#YB!/SM?DB98-7($IGZJZCYG@P:"G%<9@
MV^(BO0_RA_A?:<FORE=+)!FR7HAD,>O2L(T+F9:%/#11)0"DIZ@38.ZDC4QA
MQ4\;)6O<DZFGJ`I6..>MG2:9YCZ;,9VH;IO$0K?<-CWE'O;<M#3;3BRX6]!2
M,Q#<`V@I"MQ+@CH$W%=,UH7XKQDIG;*J#063WC=4#H+5*CYZ8J<*"`_*W#H'
M'_['2R][C&B6M4H+#I9:GC.C"X>=4:+-77HQHIRS4]333LWFY\^$V<<98R[4
M!QF_I%/8HO((4AFBQN'&/Z0I;/KBD./F,47/%F@?4+0,P5+!XT>/'1FC\X>4
M\@S!">%CY0QV`L@C1&E$6,4,I)K"O6/)*1(Y(9!L2"7JF:3+0!YU*1-R'#F@
M:*FX(K*LH=\KNEC+N58.NU1+>A&GXD&=&,W+.$QFCM*S\H\6\HOF^$-K1DC:
M3RV,(R6=":Q'3'I(TH^<=)[/N!5",:%MVZ`MT:#-?N1D2!SU(B@#LHBG8Y^2
M.(QSRL0B+WKHW&RW%`P"%$M6Z-8((*).C9+0L?LU0-GGB90@O`ZW+0U:GQ),
M?=$3K;:>:,D5GG[<L*T_O63'DY!WO7YWH-?Q)_HMO_M*HR?Z,8GS1U6L7@L<
M45<TR6G+&0<C-=R&^8B\D@3`$@%,!+0MW9E(&5OVMS:5Q$2^VJIB(%QV%>8+
M9=P(_A?U5"^61P`M*TF#!&WU$%`$P%S2"R4Q;%U_<$TCN@*DHPL=Z;&K!7>/
M83I%"6HXRSH@$Z"M`AS(.0U0D<*6]$?7%*`C.SKRWQ8<N^)_Q=8W?YP@_Q*@
M905HD*"M`0+*.150$L/6]0^NZ4!7@'24H",]EK4@W$Y3@@K.M@Y(!.BK``"Y
MIP$*4MB2_M$Y!6C+CI;\MP3'A4W@/`XFZT%W`ML*T4>2Z>8`&>*.*HD.>;S3
MVN)8YS`K+L[657Q0/_3WNA[EP.QHMZ5I.EBA_*]A_G@=!^%3&!R\Z/TW/SH$
M8?S0*5L.3P1NDRQ/:1ZFHK8YC>DVS+.+XUV8P[5Y/<U(B2MK**%VW+/&]FZA
M68$*N4CB@WC[<ILF;`Y^D\POEMEXJ/#/9X0KK'I.R]6\3H^-]R4;$PTVXO8-
MM&L(NGT(K5H!/`O<P0)(^TPC3G'V&.[ODO=Q'N;'T3IIIC,AVCMS(CO;?X_Q
M@4F(/`NY2XB8QWI1M:4H;MJ)KQV*\U&*,:W(1&%N*_\T29[>K2#]ST.BK.HE
MC\#J/-!`JK/=I(3]>;"*U]I2KH/@2Q6":#7JNTO;J$3?6=?)0O3_TNTVI<?/
M842/2EGJ&8@D4KTHMA>N&$3X*.OK-\Q5>1D'63IY-2_?/WGQA1<QUN3'F"H7
MM'\LTIH.(=I>UDL"`TD]TJKMT,;ZI3;:6!*IE`Q9*%5B,:.%%_."[Y/T8^@_
MA@^>NH3HP&"T=EP#J';[,4$S.39R0\JQUE=9S>=F:R4%DR>O\^?$_^TIC"+Z
MT4N/C%N!<J&'1B.M]#"R[:6N1K*E+L9:7^H15LMKK>8SWIGQ0Q(_W-%T=\M6
M\9&==NNXXL7QTLOI0Y(>F?N<TVI$,!)TFSHCXAER.M&=7:48S8^3;#RI`"S'
MLU8@,=$D$?.4.%-\VZ?%>;+K@M8.8#D:\9DZHQ-:.T9T6Z1AIC.8JI+EQ@6=
M2JDMQX(6YD$^SH,>K7<@.C13`?3U7D?Z\?3^,\THXQ1<]+VC3S1*]KS3;QW,
M'NT.I#L#HE[K$]7Q`0M(?D<BP38:2KO04LAPW=KB:;9HIN*84?_E0_+T?4!#
M(8GLA[8`LE_]3<1)+XX?8,+A_D*#0Q%$2H%FIP>["'5?'$DYT)+'9H[S_2C.
M&+(])A*E$(_(PUK26GYJT//I&80DH1W4NGMSN;J6W(UEL,22POZEEN6O=YTG
M1U1NMMO0IU_VGD^OXRIHHXJJJ""0(BMJI#M9:WPTX<,A6:T*K%F/L6@P7XZS
MC'-^&3&HXSG:<M`&L2$(7;3')*&"<$L2!O@_*`K]S)\33#]X49$I\GZ[A0K!
M3U145ACPD[3`\`+L8^CWA-HAC:"`(15063S$CC.%2@SB#8*6<+7N$G0D:Q6!
M'W2Y-`$=$/I!IV=44BQY;.@$N2#\_0Z?D91-S_2A/M\YWKZ&9[/JE)^^H5BY
M/_UH=G-.Q3#R]O6&P$CKN[N*OXV\FV'F+K.V/^JO[8\6U_9'[;7]T:VU_5%S
M;7^T=$-ZF40,GR3UP()(,3?(!_[$:!WXL]0Y/ANY,5WJ"X@QV^68TKENE$'E
M0*[(A&>3GRF&V+UTM<H5WY0KF`'PA96H'2!?5H-.RK:,WO@L]XW3LB_#F8`S
M+`R1OV#]-M@REP8MCAZ73LS^J*_HEM:RZ<W%X7[Z^I(-"WTONDM#+QJV$2,`
M6`W'52AW2D;R5(5K4@XG8KQUGW:<[XU^Y&-,G[G^86@L`0,@J#(PB/:`%(2A
MHW*@YG]7$I3,GRP+GP+OR^%^%V89LR_7\2]J,1@:C20!P\AV:E\&'JF'PJ7$
M+_;7?837\I*K&3UYM=\?TF1/(6T\"/TPIMGY`XW]X_E^GR9/7J1<>SU8)$G0
M):23'E'`D0J0"$A2@EJ7$J,UDF7&9(&F/Q6@#X<(QE;S7L?G6>C%E]#G(54_
M1M,$QGI(H$M*-Z>L!*RE!B[``984P-;%R&RA&N\.3%9ILB#]?P<OS6D:':_C
M+/>BB'O"131^]%)4$QA)D+1):0M2!4ADR.JBQ?HUJ17"L!3$3`!E!3&2OA45
M1'F)J@WNC)(,WC]J2I/%:U5KQ+FC+,,7K8:2.%EAKL(TRZ&NE=(':8]"$O\N
M<FU!X"-XA3?KOL,`)^5%[6?C]`Y4535FY>)UAF'UCNJBUVF25%?SMKY^0]QL
M]/CI9^7D%:SJ"2L7L#T*:?VZR'7JWU25J*VOW@`GY<7K9R/BXT)VO+S97J;L
MI)E?>7X8A?E1F/+0+RR[XKI)!QKST:`6,9W4=@8%K_\$'"D!-Z0$+;=P:^\`
MIY.53"`+]6F?OOAUGO%IRYY3VG1==+V9IU75+&YIET3<9"W;D'(6A_5MC%`=
MO1LFU#$-;(OL!$ULR2N>1M:5'0<J0EX<.\4?S[]Z:?">=[.%@T[*^U1FO!+O
MW:,7W^SY#>Y?H,MM<!T+2A7JC(8"HBU`9&O'/8=YS_C$1/YX(R?AXDCD<>49
MG*.P(0()(F%!1.5NP(,4B&R(0`4"P@(96_;(.K/OU<R^+YE];\3LO(_9X6K,
M#N@VC$/XVL^',("^C"ZS_+3E^R?!\I@^>.P+_Y)O#?G&W/.Q-\6VPX"\(YZ`
MM]&+_I47IG_QHD/'4"VQE"-?/`5?8I1I*YC60>.Y(?!EPC]]<H["1$[.LIN#
MEE'%R9.PDGK*O)A1U-+DZ15MV=2'*`_CARM*AV[Q6X.P:MBV4>NF-9<#"(RP
M4K'6-HY!XO.MDDO35"3O'BGQ=I`T`I$-6K2@9AK+ME^R%Q>;VR0E?DW,ELWT
MTEJQW5ZA;539[9-8Q*99O#Q!FLFJKMCE>X=C-L3J1[>_?$2:_;ZQ)UAK<[4D
MTI@;CTHX.OVAAB4#,>Q-V9YT'@>?P<Y$13]W58"[=SQF*'L`X8YL,-OF<7/&
M(9BS`A"D`+`6GUX%>]2@LTI@.N%EA;0@RSC[>)B*XE)>3E^/B7A[.+:$=]'M
M7%;`,%*/(S#0JEPOA#.Z-`^(1J\P]\L%HO=1&@9A%ZX.^2&E'\,XW!UV90,L
MT5KZ:P*Y":KW[.9S8?HM$P@=MZ)B&E+,4YYKL[H7^M>$YY^@'S@LDATJR$;U
MG::*=L>QFBC7TRO,-3X(_Q.*.L4#9^[A\5BUY10(CT@3*483&&[ER&N"_%U]
MR/5R\O4Q]!_YP3>IB(HX49[\;GKG!;1S_L6(.*RU+&B5_L;TH%'F;T0)G-M3
M+P]IJLZI,YS(O=VT)G'RG@);RH9\HM]RMJO0Z(F-2.+\T?4-%9%R!_?4EFA/
MW%";<KU,R<*K)+WULOR6.=MQ7AP@M:IT]@/:*%DX1,)(A3\&1@".",#R[&\G
MS#R)("GT[`G:]@5M*=TS3+G2P&[\(?1Y5/K\(:7B_@F>/(8!A3^S?1O&_!*'
M3.,SN*\/,T*A4'E$`VB&6DZ:;-F/C%][P:\BU-V-9&/LY)@"8*7"HU(O!RL\
MJI1RLKWX&$8TRY.8#B>]]PY#L@4]Z+47OAJR6KJZCHYK('I..JB"-GHQ.3_D
MCTD*VEFJ(WC1H)X>N63;8.KY;#4+#YR!``)"?4&YI1$!C4#18;_U2$;3)ZAJ
MS>^G=KLD@`]D!^[$>_F&9(_)(0KX%+7MN&>?96YD&$,"$RG,QSX)2Q/!T;-B
M%980!2QM'](J6;<'5&I&78.B?TJYEE?A-QI<T;X+"?5XM.H%PP@/-L&I)96/
MAKMC*_IN@GSS%CF5^_D$4C\?/\G8EA[&/GB"XE[9(UN8]FR?,D7>$"_B7H!W
M'_'`T]^KA[>A]"[5BG*NM99XM29&E*=97D*M.=-S3KSLL=[L"\>N^LI0#HH:
M""LG90SU;L?%[+'AK77\6#LI(:9T-)6;9UHS-]0'ZLK-_+!/8N914__`KVW8
M,-A4HX[?'ASXSEWGEEA198251$N'T=*G1GJ,CC)-/YP'`4_$]Z))FJX-CG50
MUR>GXPM7H,110S"#N*9)\&I2&U8!]O?2!GCE;';.VY;6$>WL;:AVC1.XF<Y-
M-@V_Q"E]"#-X+1CP=-?L.LL.-+A+-(V#P01(YL&(I+9@R<`BFSHC`IS<)8Z8
MB%D$@I&(#[QE`3,2F:`P%!1V'`&'C(7-5<4R&.;**)L,8TU<PI](XBP,J$BN
MN15'Q'$OH@\(WW?H1UVUT\@0I`"Q[23H4?&.9GX:\H<+)*41#[)!F$_R$1K$
M%:=]VV[!.DMD8?]7J,G`KC^L(WAW[,7S/V9%X/GN+4VY63GG+J;B1ET)AGA_
M/H)^I\)M\;"T&,\+2(C-@@@86[?A:].!>;>M(U+MFVP->9I>T=U+(7#24#?F
M9K\OHR8#F]D8V-]0DH\U">C4=Q<@+6,)1Z<*JA813,N_*"W@Z/;0HT&-.5;:
M3&#.6<V"A6A!*[X_+O,]6]HH][[_=T3':8*$#;A.^V*QFGX3G)?@^%1'7<5M
M"[\>/98AV.LB6GOYZ,4QH_R\YV0E-`]OKR]3@A@W/M,]XSVT3KC97L(-;OPE
M3_S?%#N^!C#BOJ]%2E?YBH0PT+<:C)?0XH"$0]KR`>;1M&W2E*AIPO0'],6N
M[15HRQQB.8K#/;,%H9<>;U+AM'RD^6,27,=/\%B<WL)U:NF_*-3);![,TA&&
M!';*&%3PY"8M*[F(*4@Y!_-7898S-LT9G\=:=8?EB$TF$XM:@&&*^';**DR0
M740-!;M0FXO;-'E(O=UG"E6TP_CA$P^,WFQ%^*Q(C_H'A-`N:`VE+#ZWS`<P
M=7HIEG3D'R:6MYUB:G@66TQ.Q.RPR191V?H#$)F]H!*\O7IP#G`HZ>,0<T/O
ME1Q"M1Z+JE;'K"RI5\[8FQK1>LQH>&WZG.Y8%27A4]1$T@IIH-VXG<L\<,@R
MC"N!H3$8U0#$4S6;BT):98%R0'<\DJ![$M"#QSQ;:Q+4.8J6<.+("6);@@H7
MN(Y26SMBXY.&>M(V$<7.8=M`#A$[?(NW:U<4XF_1G?>M>)UR06.Z#55[Z!@D
M9C?N42(ZB8\"@A0@A,&4[XS(BP+L.VMML\W)27;[`T15?_][>/[EY^`%YHRF
M>P%"SDI*K3:YUI.U3NMJ+4%#5YDON9=#C9\/B3])<4;@\=5GE*`A)>*`/$K/
M09U4)G/B2I7ZW9!&\2D=T"<]01S0*BTIQ-.MZ]A/=I3A\1DZ1$%?!GXI]"F)
M`QH<_#R\CVB!XD?J1="]_CWT:<B9VSJ08;G8U(@:N0`;VO(LIN2ZV9QT0QK3
MEIJ[(7QFKM:-N6TI\@H\X>,V\*BZ'L8)3J!&MTW57DH/VEJ_D!(X:1#ZJQ%?
M)LK&1<O,[Z9I4#)DOGT8+$T.7S@!*V'$'C;!F<2$#,YP19%PWY$:K(NJR@S#
M,:HGDS/-_LK+554%%*Z2M$)K(,E,!8&47:9&NBUGQ>BJZ`7/I:AUTT8R\30"
MZ$H%9W52E,PP[JT4WGK-_57,F&D\],3*)=-0!CF);%P3IK]]?H0:<M=Q5<#_
M9MOZVH!V:@!BO8'6(:%S1.1`4#ZS[OX`][!M';;R%'@&06%,MD#0$R>(Z<17
M!W1Z$D&@VDR/4UXI\$5`Q4_?];S2*AH#^&S*(_RIHCU@?W]BB#U17JJA[)>4
MTGV2\CHK66TR>-$F2!(/#K2X60[";)^`EP!L#/-']ATH<G*$7K\OBDS'.$EW
M7B359O2/?L0<K'!+HH01G7YGKRN!MFHWGF+KZO6,BBE>!+=3'Y(LNXG?T?O\
M"V7F.LS#06.C!$&KFZ)$NUMN0PPG,)[<Q`0@2`UBIUS(-!(B(($=#@(@(5N/
M!+T*,$8T#%B1#=2#*5J',+7V.(F;TI($X79+4\HTC)F!_"NEXM>2885`0]?F
M;"#3K;1&S'_V4F%\:D#V#7AV6F%,'FG$ZSU1SW\D]UX$3SQ(]DAI3@(O9S-R
MN_35XSY-=`A$YR)F@>"F-ZL2KBW[,SHJW2SE,JK/>&$*L'*B^5$4)5]A`=X5
MMWW,OSK/,IJ7-G$T-\5X*L3@PP0RV\I434&J.3:DG(6''_@\&U)[5W934!:@
MN?:KGBKJO7(VFR&#J6+;C@Y,E%D+843M6[HA"!NAOM'+*BEXY\S%FS[V[XL+
M-GZ_MM89(T]R+\+%V4KP3^_V3RW=B'?IS,-AYR%HB[IMFXSL_#[CU3%5=^E:
M\)AWZ9H$]5TW"SB(('3WPXS\6D+_;VM7Z1-IJZ@!7?'XZ#];O3<W$;K.O;F!
MQ$T^WG8FYCEC13&2JR3](NK##AUUM<&1CKT&Y`S*CJ0)`KJL/@,!\G("&P?B
M&<2)C.2B<A`<P[*UZ-`Y%<\@1'AU[*#+B*#<M?6]LF!BC\N;B<!:VRJP,VR>
MAO>'G%=)S1,B7;CEE*E="@_!ZH,U.[HRW19W<5D?&Q>LO:+7'AY+'K#.Y*9V
M2#Z?&QJAY6SEA1=`-$#;.%;C;5E#"6$=\\>&\T"@&]9.@3P@RL-]9\2O3L"#
MYUX[-DZ!OE6C=E_PSA$;MM@J6[-<;:N@-%4MD["P'U>9P'/_[X<PX^6J;K;%
M$QPCETX]DU7O;HQ(;4=/]O.DN>"85,SFA!V<1'1GP_<D`J%IPTH$3G<'32FT
M:D0UV;N:B?U$\V<H0TT:[^1R3*=%Y2*(3MUV%R+0[DE`BSGCAP*=;0PO)MG!
ML6X#EV39)=S6LO7YZJ6!JLFPR2R(\4DSXCI9L,P42RU$X4J?WUZ?%3"V(I.G
M0I6>!VZ'*LP([`05:\=AS?7+H@7Y.64XF1@+`6#3+I0H:_CI&\('.Z/\0ZC?
MP14@>8"_]OB8R^.O=>7H'O8SC91C^-\YNP@F>,PX><PDP>JVT"!_=`>0C:;-
MU*\)*5XNI'*9I6RME)25JXZ3$W#_0)F8:V1=86U6V*B;H;#48587=;NY;J8Y
M;99RUSIV[D/HW8<13W1E=M[$K6Q!VO0O.T1H.9ILJ#-NYB@%<`)SU\]<"GVK
M#D*_*HQZ"KUZ,/F6IW'RO!*'SEN>3'_^+1RZAAX!0KJ[&46]+105@'B34H`0
M`4-^!2CT_#0T0K""K7H")<=5M:1I!0%_ET#!0&,1+\"L"WF%OJ%T"#C'!-TU
M8G0N&2=0<\<0@@N15FRS"/;9?L6DJRIZRMO0D\GJR[8]N#<5.=_OO^U#>/QZ
M]Y@FAX?'-Z_>OOE(H?+O@!)K`B.ILC8I':D1@&4IA1*4%+`$@,FO`MR:W3=;
M*%F$C%8)L?O9=DM]>+Y8EP]AQ\9F"9'SLK(?E"([,$2.C<&*X\T2LV/V4EN$
M&9V'*.6L4I40`F,[97S.ZW*7U>QM(&O]V2SSQIO`&]2>;\LI4J<UW&):Y)9=
M:50VK,;UOIE89%K'+(F"_.EJTJ[T68_'?WMQ4LQPS5:,*<<4(S&B&6Y9A_(]
M\OO8@V><RS@;`Y,Z9AD&29^N"O5;_6+2DW`HUF-$.,X(URR"6B&FV`.E-N!9
M@TG9>VXDZQGE>[6B/(WAMK1P-0(PM<<\-\W!5#2Y%.<YE.)ZX-U2_QKFC]=Q
M$#Z%P8%Y]U7ESK(SY,7Q+LPC>K.M!PW<::S\00M7E8NSK!.3@G'PCJ4>:>D&
MQ1+IB0;I-JX7UU&6H5O)531E<K#X(F%VZF;[+DS9!I^D4`'\9KL-?9IFRCCQ
M.!Q2B%B'@,X;1H#AA3=**'ZN*^&L!X:U%T6.">NNR&11^9C^IQ?_@Z9*N6@-
M0A*"#FJ=TO\I$2.LKVT_%^6%[&4A8@-&_Y$&![`T[W?[*#E26CS=[R_T?5Z]
M\;O9PH'@(88J?>(^"XJ`,\/UF1=/_1#&=,296/W3F.T<UV=CYTU9\4FP;.5'
MRUHI@^7[-Z3^-`#6'R]OC/GG-^3B2`0&!%"P[+G8Y&XRR-U[-7<3!7?O=;B+
MVH(2R0QT.E7BV`#$\.0B9-1$#.;@K/Q!S+#F6BSK1/H6MY(-);:4-^0*&V>8
M0QTVHH945U7B3KAU30W&LWR?:489GQ_92>0=?:)1LH>3;-5O:N`480*-:)/T
MB.G60Q=0_'PIP55U6VT>1R:L4UM2]1<)\0#3KRYUJ.7BV`FOG$.X]H8WZ,W^
M0K.<!M`*K2CZ>I?`KVX.>9:S90SCAT^'$=E%0P'S0(/'UH[K/=1Z3/HZG$_D
M<04&A*.P(042&R+0$'T.RZ*^=PG_-1M5([,A`AUK)QS;[.[NW@UVWQ\;N[P)
MNW,#=J,>>9`-1^?H@VLU\"QRX:K0H)_"8KM0V%/-"1"MH39)G0I9)>!P0\7W
M*]5$U[0\BY'68T$&2,/4<C-A;.NHD21.#K6+`P#7[X>4<MU_1S,_W?>]K2@"
MRVH8I$#\&.+])T>Q<Y0`I(:P\DC%E`;H%Q3`@)"/@/8`$3MN9<2[3PXY[[5#
M:S*]BDRY3Q!O_1,?^3Z9TH@KT=Y+\Z-&!\*U[0+"NF)=OFCIE7P7HZ-4>/OH
MIR0.H3TSV]0+0U/=]EU19:KS&"3BSCE.1$\SWA*B.C?7-[<`9&NKQ*`%<V_4
M%+#VIJ@G79AM1K(\*_Q@:#_X65C46S"H"B51@J$V%5&BW^TEPH97)RP`@/BI
MV$,XC+T&(NO2@=M$9%RDNKU#1N5ILH=87Y/U'PF+!IQ97=8DRPX[<4Z\@[>#
M=_1;?L&^]]N`.[G<!_[V6E=Y6D['\C2::*?J=IWC0WH"364SX(Q(591JK,BO
M'"\"B!&.F;4\E$77M\=S6G#QOO]W1.]_4:'K/DN^/T1>"FV"_2C)#BG/)@#?
M/@L?XG`;^M!WV9,$Y@`B)IT!>"?A/"%LJPUW\"2AU66T;M_,>Y-"_T\>7;MG
M)Y$XR4D4[D(1@_LS>>%]QWN9B:`<37>\T2@7[:3X/%CCC($`TE(_Y`UY<2_!
M/B7,L$&!E6-)#AO$_O7[3$P'XWUI/$]@I'$`OP^^(VF8_7:V9>XU21E%+[+O
M-OR[+Z!S,V,4KR@.)9+WS)Z>/0'EC!G@;*2AS]&4CD3SC&I=G?@=9[FX3:OZ
M&E\EZ?MOC*59^$3AN4-,H\LD8I].4B$*Y1EAR*8N-?]TD[HTA;,LJESO7Z!3
M7@-+'=:A$4"%$RF0(@VLZC.F-6NZX,KV&=/%E@W7EBXH;6WAD20$K)9<3KW;
M[MU(AB98DV6.+66J-]MZ2L9!'3KN1BJ.+4HP<S-A@LT<[2_GA^6K+0%O9LV_
M8=/;UZ&][>UK+`.>*%4J)GDGU:T0V^D5XC0*.EVD=+&:(U:279"^LI$N>]F'
M;,J6+A/:\J6Y+ICI/0\A]+\$3$H/N;ZK')$R#>#I<J:/V1Q)D[]2GP+K[VRL
MBYH^'[IY/9K+XXJX?:%Y'O&?SB-VE(D]>*VLVC4G3;>62*JQ7U=(ZV\3^>/N
MRJV:66:2K%QG5V3[XBC]8^0)C>E,:TGT(,YK"C,D)<G_M/^*8B*3S(1X:%5=
MD5_IQ]''"Z8SK26_@SBO:XP;TNM`WOM$)IG)[]"J3H[C7<?!QS"B69[$]/T3
MFU;Y9'5H]+0(V\BWYX@/FYI4<Q,^N?7GK"/DRD$L-9\G+_;Y?I\F3UYDL.)*
MD&G+KH/%G+4OYW=.`'0(EZ5`@_>31>$JI!'<MGIQQ@S-%1U^9*(:/4T`1KX]
M*Z0!4Y-J;L@2L;[L(^3**Z[F\^3%_IEM%%!PYR;^XL%UW3NX*HKS,#[0H*C(
MD\1#Y?CU@"=?LYCA-D<VX$NB@-)-3.!CHJQ%_3E2?V].M]3E*6HED?02QH0]
M\\23ZT"F*7&-)KT^.1-IPM)I;:7H47)-7J)>/VFO;^\Z\3+SXXNE3-!%?FG^
M]T.8'\5]VW5\<<C"F&;99;*[#V..;!5"?E?E'RB.8I.FFWX>FX/]'`LJOEM>
M0[.%+S]-I&]OY!OI^OM6GR3/X%?GP?'TI9Z\?[/9=U!%-O%_NV0SPNUP&OKT
MEJ8\\69@XQZ!FKQC:V(S1]#$)XJ[SN(CA'\%LAY$3IDMTS_.UAZ;/\8S5&,_
MOH`#ZR%2!_QB/?9\/9@A%YE+UFSYIR2'A%&?AD^05*9N_-8S>+H='O[RO#-,
M[,4^<+B>FO=WVQ#>H;3)9WR\1[Q1/KF$NMTD_2%"NWGY`W*!)\>_Q&E5F^+.
M^W9!8[H-E>DL0Q#3)7H$ASEB+4_-:S^7D]L4D!%ZVU*B9CB>J%S'?DJ]C+ZC
MXK_7<5DR4^K?IQ`</?CI8F2$W[PXK_@`>5%^ZCOP2ZL.F=+G;(J9$3_:0F>R
M6"Z(X&?Z1-G);Y+XE;!KB%X+KS7%KOB4FR+7XH.^N#47!T_42C$_7B7I+XSX
M-/?"F)G?6^:'\L#"Y8&AI^PKKCW%=,$SQ7*._%7?XLG^U=?XMEI];T.*+]H4
M0U.NM*71<.$F'['+MRKOO]'4#S/P`77.V&-@DP_9NOC,D:+J`9;T$5=.V1J,
M[3EFCW(-]9RML8:#2T*E)5$=M(?^GW-E.R^][%&<KVAPQ9:Z8`HM<L"+NCRJ
M&.N"7YD1>EV>UED16?URDH`4*;$BH&VEWM/Z74&!FO/U(\TX/*EHI)$HS2Q?
M,W+]WAHT;4?I_](BPF?[AKV?M&YQDJ7NTR_9PA^BW!O)G>D,FQIO[__:O`![
M.:?UQ1LBKQD^[^7D](0(&D//SO,X.`]V85PDW#W1LOP`^\.TBJP+3CXQG6)1
MRF:E6PA,"/L,:>)2%:W@?ZOJOIX[6/=U>98V,@$6E!3!G`_L$__.?F;_`1^`
M_>'_!U!+`P04````"`#C<Y!"KN,DSDI0``#-\P4`%``<`'-Y;BTR,#$R,3(S
M,5]P<F4N>&UL550)``/IF&U1Z9AM475X"P`!!"4.```$.0$``.U]:7/C1I;@
M]XW8_U#K^3IV%2G)=G5,SP1UU6A;5=1*LCWS"0&122K'(*#&H2KYUV\F0(`@
MD2>0P,M$,1S1K9(R$^_*X]W_]A_?-L&[5Q0G.`K__L/DIP\_O$/A(EKB</WW
M'WY[O/[QUQ_^X]__]__ZM__SXX__=7Y_^^XR6F0;%*;O/I,Q*XR6[[[B]/G=
MU5\_7BUQ&L7O?B_6>D>6^FGZT\=W3V_O+OW4?XS]Q9_)._*'ZQ@O_;=_?3=[
MB7'P;C+]UW?3#Y.3=Q].__;A[&]GO[Z[^_SNQQ_I)P,<_OGD)^@=`3%,_O[#
M<YJ^_.W]^Z]?O_[T[2D.?HKB]?OIAP\G[\N!/Q0C__8MP7NCOYZ48R?O_^OS
M[</B&6W\'W&8I'ZXV,VBR[#F33Y^_/@^_RL9FN"_)?G\VVCAISG1I'"]XXZ@
M__JQ'/8C_=6/D^F/)Y.?OB7+'R@-XBA`]VCU+O_\W]*W%_3W'Q*\>0DHV/GO
MGF.T(K]["\GTR70R+2;_2\FG6;B\"E.<OMV$JRC>Y"#_\(XN^]O]S1[L9(GT
M&:5X\82C(%KC1?+3(MJ\IT/?"U=[WPG0BRA,HH"(1(J6YWY`.?+PC%":Z$/)
M7ZHG$._\&&W!\0.#\.ZO:P[XAY3\+^5C,E_-7U"<\Z\CH3EK]@/TQ;,?KE%R
M$SZDT>+/YRA8DM/FZI\9D4AS6(@^,CA:!D6LU1=[0MA/GJ^#Z*M!V=LMV0WD
M>;SV0_Q7+L;DN/OBIUF,ZJ)-?GGN)YA\\BY&"?EXRS.U[8>ZH?>0;39^_#9?
M/>!U2"[PA4].]<4BRLBQ'J[O"&47&+5@B^*ZW8"_Q,DBH@MF:+FCTWPU6Z(H
M]"_(5"JSM_Y31/X4Q6^4K%%*OK5`^-5_HNMKWWR=/]F17RA`BX/[H=-5+ENP
M([CT."%2BY87T>8%A4E;*-GK&`"NXZ5A_$ZXQ0N"'KJ(@J`0(OR*Z#.+3(W>
M\C?7.D;%(4=^3:BQP6G^+WW8VW_*`-WOT4L6+YX)2^_B:!W[FY:T;Z[3#;@;
MHNULT*/_K<VI5Y_<#8Q[%-`;C5R^Z1O1E8C`+UH^SK@K#7%Q]'V!&+I(U#[V
M2,_OWE#9K@Y\([;%T=2'>[T=6S-0:=D^;LK6$(M6`[J@VN+2]8/&[H.V"#27
M`%%)+E'JXR!Y1-_2K(WN:.:S0QS4VT_V=5*7RP^(RJ1G7"9#(M-:`EM]!?A"
M;2V+QKYL!P%:2+"Y3]M!@M9R;QJ`7A]9[0]?M76'`+[-<:NX\!#@3_L"?SH(
M^"=]@7_2RQN]O<`+E^L1U#;B+5ZO1V#;"+-XO1Z!;2.ZXO5Z!/;4,+"G?0)[
M9AC8LSZ!_=DPL#_W">POAH']I4]@?S4,[*]]`MM>T5%9U;3SPPC0HA6![$ZM
M[^?.7X1%N#4C37VX#R^1$2&5K6K,8MA:]!AKF`:JQ2.0M8AIL%ISEK]4/YZX
MKO`JKJL%/"NP,(CCXH,A6M,/TK#"CS2L</)SCM_VU[?^$^)@48]1_+BW5C'I
M_;^_&P+".Q3C:'D5M@/U8/:@,#^DA,D=H*[-'PCNQRC-#4KZ$-=F#@3K%]2.
MMM6\H6A*WD6H'4UW,PW"FC;AU";DCH+DE'JI>7UN"1A[`)+C#(5+M"Q!I`N8
MB3?.8\.CQ=[7`AJ-'<62HYW\PA,M/7M*TI@<R^4R`44V7]Q3G>I]*$YP)0"W
MU,@IO?*3IYS<6?+CVO=?WE/(WZ,@3<K?Y+C\^&&RC0__E^VOO2H*\K$(<6O`
MSA[H;>_R.A=G\3[4?KPHUR,_-EBX'\R^'?'^)0\@_7'QC(.*^ZLXVF@3L@0E
MDJ#Q+HJ)#O+W'\B,+"$01B]T(7I'$]Q6*(ZW%Y<`]ASP8"O;0.PC6PC=D!\3
M%196@[TI"!OYS)`PK0ZX#8Q+T.*G=?3Z?HEPP3/RPR&KR*^\0E#OT1I3^0S3
M+_Z&M==X0[T3.]BT1_Y]5@E`YS)J")I?$+!C/[@AM\FW?Z`W(=$/QGJG#E&]
M"7M)]LG`=+_(8HK>-4X6?O#?R(_),_J2H,(A/6^X=^8$]07@EPR8@@C^-0Y0
M?$$@64>Q6.SW1GH_.T%V-N0EQ4\&ICC1R&G.X\/;YBD*.+3>&^/]X@25#V$N
MZ7L*<Y1'FTU4Y!P]/!,\DWF6TBQ,"J+X7!=,]'YU@A-*B)3L.1N8/>6+_)$L
MRV%$?8CWT0F2'X!<$O?G@8D[(S`L*1S7@<\3\[TQWN2#$_1M`%U2^!<@\:V,
M?H+7"G.L-X'1AMM*=`/XDO*_`E&^>#T58%V3W[&46.%X;V*)(JO(`28")1<^
M@G*!OF'5>5"-]B9NZ*@"\'<*$\CSY@\4!/\(HZ_A`_*3*$3+FR3)4"Q\V7#F
M>!.75%<!$A5+AE9B"\A^CX*,4"\N%`W>CF".]29NZ*]<X"O2PZBO6[WZ'KU$
M,8W7I_APSR31%&_BDD;+QZ'BQ]#*;0'87?84X,5U$/DL!P=SG#=Q0\ME`EZ1
MFZ/KOC_T7QTB>FO4I\6O3@/E<)BOKG%(X,#D'1,E6.(!TYE^](+I"KB8F$=/
MV-$39C'C9DE"SC&%LV-_H`,^,2[@IACVBN*G:!?L,2S?:,TD`;?HGX$]:$VZ
ML_FS!7447-EFN":[=+XO*-V^*D5[2S`-V!.GRD4)"GQWJ$OLO8O1BX^75]]H
MG#^-LYZ3)V-<D$C.9879P/X_56:K8<+WP&KR/*W'U$%<C_/5)4Y>HL0//L51
M]G(3+H*,>GV8R;X*V[WUHL">2^7#H`N"?#>R2T>%ZJ&POVE@W:%Z[-W!S'=,
MZV[T>D#RT$=[1$0Q?;L+_"*X\9\9?J$O3'*-"<]T_C1@3ZOZ82Y$@>_6=FD[
MTAH+-`/J-O+#_3?*ERA<2'>IRG1HSZ\JOU5QX;O<AV$\.P0<O5`32[+_YA#R
M4&4:M`]9QCM5'/A.?)<V:X&9]-*$=COK79=U'W/3T^_.17F+_2<<X!3GAT@S
MD5C!E*2ZA`M>[38XC4,9+C7^._^-WA_J5H[]"=#><BW&B6T?3<3&8M2*B:I6
M(Y02K]ESH#WS9MC-QVT<>UN+URQ"P-JQ##"9C90YDY85%[@:4Z$C"<QRLQY>
MT-G$!,C&5B\O$?'L#\57P\+8'H5V-12@YLC^[@>9*#"",=J;0`?Z"YG$=2RP
M\!C%,ZJ6/B)CY^%0;PJ=5-""ERPDQO$ZFBV7N`#[SL?+F_#"?\'D'J@A+'H9
M2R=[4^C`IA;<5D-K'&?S/2W[$Z+EE1^'.%PG1"'(-EE>(N@2K?`"BZY@^61O
M"AT-U8+_:FB-P[?':D:D\>3RIM!FK1;\9:,Q!L^?3+WH8,CTIM"9("TXK8*4
M,:?@(=]M">S>[Z38S6=57WAO74G-(NF\8ZBV0L$B%2IRS[QCC/8Q1AN><?M:
M,1'B>9QCN<SUJCL4Y^4(E,T#O`4<BNE61F@4EH-];(O:$[,L?8YB_-?NXI/R
M_7"B`Q66E!$9AV&!A6:>CJO+Y&*2`T6<E)`8A]6`A:*XAH[B3`>*1JEC,@X+
M0<WLU>*Z5ICM0`DK/6R,61)LX;O&-2V8Y4"!+#4LQA%&W,!1>CMS9CA0A4N.
M`72$<$\\5;N4A=7@'"@"IHI'CR'%@,:^BD))O2ONT.4<BCX8%2P*`1R<&4=+
MH.+.X-/O:`,\V@`M9MSVD`K7VZ1;E9(-W#D.6?I$.(S"N/<)A03#8!8N9\L-
M#O/B[;2+UQ9?`7LE,X'->T+&L7DM1V@4'+\G_""T?"9X7J)7%$1YMJ6<W\)Y
MP+:^%MR6H3,.DVZ#,#KG-;!EKP5362B,(6B^>#?>1DER3<AT490O(&CN=(=S
MM(IB5.ML=_6-T(J@CD,_?LMO.9JK26827`A\ZYLP182O\M=^+U\%-B"V$*U^
MB3&&E`""7%32M:!"6:%%_E:4SG7($JF""_3MPHP4^L./:><>P57!&`5L2E0B
M]CZ?V$AT?MNQ^UUV8LC%LQ^NR8ER[>,X]UC,5UO`RR@Y5GB@XDQH*V%+SBEB
MUGV#=>.GJ7O_E=P/]-PI**1T:;.G0->8:,%N%93&X9S/*VIP*21ZLPLG0I>H
MZ,!S.6+C<-6W8;J`++"6M0[\%N(TACA_N?[021.#KF/1Z7A70<Y<S#]<.<=]
M3)F%"),O*)VOB/HX2],8/V4I=34\1E5/@*N\7KVRJ'3X!G2I#&,2U9$&XP@S
M(.CNJ"*Z6^KCH`MI=+E/#O$P%D@`>(>4V8UEX-JYG^`%-6#C(",ZBH*=17$%
MZ)H;.N86#93&H2S([TM"B@,JR&(^6Z\)7;A#A_MMGQ\"U$?A$=2Y+KN*5JO5
MH8N)F!:RUD2`-AL/<HVUO[[@"Y48N[;JY4I<=@K]@?#ZF>X1(G'^&GW)-D\H
MGJ]RE&NAGNHBT&Y!^*(FZI+1'L,>LQ@L"98MK/_)3<@HE`#7#*UE,32%^<?(
M6OUV:$)J<O;<6.-L"_POHLU+%-(=-/N&E4)N6?-<B[[EX.`V9VOY$I\1O1C4
M<D2*L;8$WO(XPV8H"PVWF<BI5B9EJ'">+?GT>LR5H61,XX'A]&%=,BF+V1-L
M2:77XRT7%V-V.!BF'E#A,MH0-$5:*VN\+6GS>BSEH6),574S+\D2:[E^7M(O
MKA^P78LA6A=6RC4A,H$W]0YZ03&.J*8=IT!%+35RGYN)PM:EL_.YR(#=V!8$
MY^)L^3]9$:F7/$:<IUUI[41+>HV@,,G9E4OW/,<[N4=$O!.<H@<4O^(%K=-!
MT+I'BV@=YBL*G\B#0``=/*LC<@.29!P.UASMHLS$91:3/5K@FD<;LPDENW.T
M%H..U-6^E+2Q&T?H)@?WXH0W)2>BU:##>PT(B@P]Z+I,S+0,D=!?1_'5MT60
M)?@546=%B(*+*"#\C@HO[VP=HYQFG,0-(VM#QP&K"(919*'+.^F(22'R/<F)
MYN+04<,=!:4%MN.(YA1MG-FB>*A)0LI5EX`.`S;U&CG$:1R]:H4;HYLD-->`
M#@<V]MXX1,I88]RA7AFW1`$+$W2-N%FZBK,M#/35?BD<H%,R\Z,#S"S$L34W
M&].AHW&-W.<'^.RL8PXP-!=(&KR4!31IH>4&W5\`.OK5Q!YM8E2QU:H2"$+!
M[,)7U@H6AJOJ[]8F2A5GH:R`VANV;N><A<MM/8'DZAN*%SAAAJ-V7=+"@%3M
M3:V"8R4,4+8^_6UN5AK4UH1ONF?@*%!!LI('MRNMB[;%%_0U_TM;[;N:#]^I
MSXSJO8=0)0!NEV(7;H0.$G"P`'P+/T,J]QY&E0Q`6>&8EX**G[0\TZI:0_=H
M$?A)@E>8>S%T7M>;VF^",X9H)1MN&^;:Y=M/W3&P-0"O&`=E1;,CH&QJOT%-
M#'W%Q\X&M"(<Z2H$*I[6+:1L:K\E30C\+A2G#S;:GP[8LH7N,3?PF!OXG>0&
MWK:+=;?$4.%2#PZQ#8KVA[Z(F$4]F>-LR>*[Y:>R\^#NKUR*+1>2GSQ?!]'7
MP7LYU<ZX"@:]BZ8Q[7B_Z-\O+"(>KY7CM6(QXX@B3Z7V+HY>,3D.S]]^2]#R
M)JQ:),P6*7[%*5;J^:2_F`.W62?D>KORRO_`\GMH[D>XP`':,P4]1N:DJ8_/
M`>?=MI,AMCSV1![H`"J#UA^M!`QV$@*L.:\O%@L,22P20->=DSGQ9XF$R<+Q
MP$G`P_!81@'HU#T9BZ^C6#?^JC$%.$\8A-$L(D#GWS%YG8.[M=!US8YIM19T
M3N]PXM&:/-W3\7KHDK0O[/78_OF*D&H=^YM9DJ!4[<00S(=.S(4Z/R0DZ9Y\
MUX-0M.ME!IQ0.QR#&8A#9\9!=$"#M3T,QVY%8HPC)^X2$6`76*;OU8=!Y\$.
MJ^8=8@Z=_F:&[3EI$@(WN;$NH^PI767!;+&(LI!Y\ZM,@\Y]'58L9)08AUUH
M1U/ZLMG0;C]_R8X*[ASHC-AA!41(!O!\+C/B\9\H6*;1QD^SF%R*#VA!_Y]0
MYR$*EMM_O=TC/\!_H>4G'X>4Q+G^1..N\J:%C^2N?42;%Z(_Q6\WFQ=RY>8,
M$LA7?Q^%SN\=5D#[I:.!O#8;>LJ6B,_#2YR\1(5>EZMUA.3":%?)3.CDXV%E
M38$8!G+?>M",:=C;2]Y,MQ)O3HRZ8#1T3O)PJI.``"/)9=M)\H,?$,VP?/,1
MLB+\*@G$D4^&SG*&.A9$]#"0!&?#54(H&",_09>H^/\:S;;I/@I.?O5%H'.F
MAY4D/;J`I]3U)5%:IY'*=.A4:TV^J@H'&]'.T4=V'C-W,2*7\?)RBT+9%39<
MYH]XKK>GVX+0Z=@]"8XJZMUC0.R4I2]1BFJ[1D]N#B=#YVOW)",L-+L'C/2@
MW#1!OT2Y<I9(#P>=Z=`9V9W8K(MH]VB101A=`#Q?%>JX'WR*H^R%#"NL.\R6
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MHX4M]&5D1BBHJ9P`\$:])#%:I+34IN@QRQSOG<(:9XTRGXLA="3+T(]4(X]3
M[]1*4VT[T=!#>PPJ38YN7L']T,<JD`[^)._4G7J-8BR,V3>`F2MAHW=J70<A
M(<,HO,;V7=&Z@(`0IQ8SR+KN/A(&G9F+XH)N$9*]O`0Y\GY0EFZ^"5=1O"FX
MH%!`6VT%[]2ZSCY<)FN@!!VW92J:C^AT*$EIHRIAU-YNF'<*;*G3X!&;RX?8
M`%M=C,5E1AOTZ']#B929>R.]4^!V/P;XV4!H'$[BDAQ?HG!!?MQY'\(EX]E.
M8P*#*,EBI'!X=UW:.[6N,[?PZNZ**W1],*9I=M=`<.$7-1@NR:/BE?S\BJKJ
M9MQ^A!QS;+=%O3-84YH17C<-LMV)8J-I_S!CGQE5S'/U*$X>?URM#B6K:\EU
M,YQ^AT\;+6FM>@\<8-^7<V7@MD[S>.V'VZ)FY+#\0H/QB"#OA)?\\MQ/<%X&
M=P?$T,V>ZF#N.E$5,-?AFJ^VQ[T?[)I4*;R+C*P/T#ZJ$]R[:_"1R-!Y(':G
MF?X4<`LK4QSGG!8]4&LTK>0>LLW&I\ZJ![P.\[=5F&X3)VD/=4*J!77E#%TF
MLP&!2K\>[B2`PX!Q3A-I$Q)99>-W619XDPO9P]FY'=$=S2YEOV7GJ]D2$7PN
MR(*TS_!M$7L2Q31^GQ;-J%4M&KH*-A-@`M9>+J7*KM9<"6"K[P,BS@_5O.>[
M+@V\Y?5YQSD'#-!A-&?!`Z)Y.42!\@,:5_3PC*@R5!EKC]J`'=I`W:9>9]5.
M.I4N?)UEQOV*UZ3$>/8[#1ALMA($N-`+*N>!C!4<]RB@1K`\R"UOX/=$(2W3
MPQ3O]_8+PUSW:@"?UP%6O.V[K&S!9=^)D?R[OR-5QG44/$<!P2:AV7+IV_"-
MW@\AH'J&4JMWT4209N\L@/2>Y\IK@+>(EQ"?=^5JX#>:37:+%[0$:2V7XY76
M([W:O`11?K94B1U)GB:_V>!MG8%NGL#Z.=<:!L%.-/X-K4W+1+DU"*+-:69A
MH!W;!Y,8OE(C]!G-CL^/N7OTDL6+9_*&V+:8[+B=V8M*]J=X4O<-QUY?MILD
MLP"WBI1>#-F78S,:P:Y%Y0W]4*P^K142)Y@%\$1D0*/R*A1-`WX(BNG+>05*
M\!G-;MDJE'=^G+X]QCY1,XOR1T-O'1X<"OM'-A5@$_%`TMM3&JL`;S$%%G#V
MF1Z.H]EV:A$(QTB$UA'L=5-\#L^;RHX337,PDD""CHVAP5<;%*\)DK2*P"5Z
M14&45\=Z2/TUDO-1<P4/N/>\!DOU,1M'*LIO"9JOKI(4;\@U(8KYW1_H`;>9
M;[%9&PB,HU;&78PV.-O46MG,@B#Z2CV9C*;76_P)FI]1^APMZ<7Y5LBV@/?&
MON$!]Z1O(38F<1]'_<%[<C2&&8T#B\C;2N\!()WK`;>G;R$A*CA!-XQAIYGA
MY$]JBOV-R'*<^CA,RS>Q]!&@,M4#;B2O>?LKHC2.;B\T:88:X<G_41_<JQ]0
M0[S&0UYEO@?<J+W-BUX1+^@J`<S]S*K13OO'/T9E">['V*<ACK-7'P=T'*U9
MZ->'%YBJG0%]?<X#[KFN>6[T2`;HY&1C)?[8)9G5CQO5)3S@%NZMWI?*J)7B
M\*O3XK!K.C^/RQ#L^>HV"M>W^!4MBXY\ZJ+19CEO`MP7J(6<M,6S%)J/3@O-
MIRA:?L5!0#;(#>%7N,94$<MQ+O\DU6*5U_`F[IDBM9`SD*[>P_/E'(5HA6D$
M]T44DH43`M$URO.5U1XDZ@MX$[<LDWJ85>QUVS2YJ\21W*.7**;DJM?GV.;V
MB[:\ZA+>Q#U[I@YNE42X;>N\1$\:CT;&:&_BG@&2@T;%4BAC(O,,G\=XC0D,
MM$!U'M-+T54[O56F>A-WS(,Z.%7,=+NA])4?AX0VR1V*\^0)];TJF>E-W+$E
M:J!4L=UM8^(]X0FA)S6<U=RF5]]H5@V2/LL59GL3]RR)BFA5(N!VO=%KHIO^
M[@<9JN5AWH2$1MEF9T`5"('2?&_BCF50&S%S_7A-WN>[/-%M#MPLCHERB6K`
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M2H.0UU8@`%]9D"+;EE[CN0HE92IA+KICL4I.,:Q*RLOL&/HL26XC/]\P5=N6
MVD-%I3Q6^U5'7LJR$V%&T2MM1X(Y.4+BBRRF?%%4G/07`;Z*!I,G!3J,(QF6
M&XO=*49]1R?8(+.>Y44)?^B<6^8+FIR7,7EH;7WS:D]>X1S@-->>&*V"=H\9
MKE942(8SI;A>)YFMNU8E=NM?KSG1S]\:57AG7_V8*$6EWO6'3T>GR>\H(1#3
M<X?()M41'B/ZJWF6)JD?+HM6@5??4+S`2644DRJVML!G@:'&9!EFVV@[CN?+
M[L7&IFU^I)74VT:'MW@6MUW<`LM-'Z7$C1`&^EUD2``[;FGC9[@=@`&_^WL3
M?&BB0I=3Z>5)\R4*.809^O'2`A)@Q<?&9TH[*D+7B^GO05(G4?UJI$'2!6F3
M)-L4O^OT.&G_(>`:1$,^5#H1:1RE<&K.N$;K=QJ1DE8A_"W$46])X(I)_0N>
M-CF@*Z!(/.Y;!519F=*8#5P\J9>K5!ESZ$HG:FSO:%MJN1QP>:1!!$.=%-#E
M3222PKYI*[M5FS>/X0^,5Y:ZTYY;Y,VI%E*Z/HMC(ZDMRAFMU+8%9/<YI0VJ
M-'?<[:!423":G@.UQC@P;L(QM,?9'=_T0HA"*C+S507CUO%<U$-*6RADVJNZ
MV%RG&[HC"P6[W,),$"^"E\@A5M,^6RGU&BL">[TZRH\NJN,)-:X'T=",FKS8
MVGRU%_--'I>8;*QZ3,TE2GT<Y!EF&<'Z&(IL1RAR"40NL*)-OC=PY`'#A[B:
M.O@#F!._1(><`^B&_"CJ9M(<#'Q.-YDA85H=<+<9EX>I$Q5=LC7KPX`]ZFPF
ML!EV`/9HM!VU3/[M=7A,Y?\^;JPV2?K':^AX#=G`N-*\_!C-%O_,<(Q8C1U$
M^1\J\QVZN%3QZ<SUCP770[2F1G\8<\&N]LYU%,\VM)IR\>X6W1>\.<!14#I,
M%N$PCJ#HNSA:(+1,:%-'VG6EK`:3F[(#FDZ,\VH:-^$K*B@AW.3ZJP%'$VEM
M^5;8C2-VF=8*2J--HU;00Q0LM_]ZNT=^@/]"RT\^#F^C)+GZMLW7SS,D'Y_]
M\!%M7J*8O(MW[3I$XM3?1X%#B72DKE<B=(\1MN%ZJFVX*E9J9]`5.G=$$X%C
MC'2$1(I(CQ&S-FO6DZ-J?52MOQ/5FIMA?O[V2+X]^X8E3S?9;$>4;S5,1LIK
MBN$E>2U@<259Z6Q@35R1AYH"L(<>E`"P&\.LR$6&*D!I09HL#C%UJGY&FR<4
M,[BI-`]8V59DQ3X?51&SBH.[`I,5T$+.<<<#*\2M.29"R)BMQ`BK/OMAMB(O
M`Z(ZA6LU;HFF`.N2K1DFP<F8W0+FAKRG"8B2-T\UQA9-3_*RJ<,+MJ4,LH>[
MY1BC@/,Z]D@OX$X%K-OOR\_^-[S)-E(&[8T#;B]]0'\VDPX!=IQ-.%1C4WT<
M='MG-3X=0NSX>=?5[PW<<[F#XWLR<?TIP7UA[>KLMU&V=[.A^RUSN*:I7>_C
M,XHP>2ZNC58+K^+@!YUUH+LMFY$&'F;C"8'7<D0`1;P?W1%'=T2G6S-!BY_6
MT>O[)<(%S\@/AZPBO_)NT=H/K@C&Z1M'Z6:,LMRAP(:8RY5^"5S`P#7M'PX!
MLM]S2-:DZP&L!HC*-O4M`N2'_QDE+SCU`[&)CS$4R'K.(A##?L<&V"JK^&>T
M]*OD9C'YFR.!+.&*U&?"Z[B6^MG_GRBF=N.$YC8^E0^Z>MB1Q*2JN((M\5<2
M=58=F_$S7NI55EX#V-JNP=364E$A:L,;KD/";`ZMU+Q8'P9LI]?B#9N]!]BX
MS<'JI"NHL"MX(#G'A?.`#?W:QD@.#HZ;)0^PDI[/S/'0S@`IC]BLY>+B]F[=
M5M^2'KA[XZ!]`WQ>L'G7`-YMGMVC)(TQK5M\X2?/-!>$_!^ER:L?4$%F_U86
MF=!Z46M\";)8ADX8&JMM[I+,R,,E.BP+[77H*`\FA6Q'$+ML*>1X?2NR3,L6
MA@3VSQGU*UQGX9(O'QJSO0ELP&AGCC$L->J8NWT3=8XQL"05LT6,P9FY!"<8
MWFT+02;WZ!6%F<C/=3#2FUAB2MOG!IMU#-AM[!F^!7,+Y1V*%Y2P:Q971,.]
MB25AI2+6R!"`3G-GMZ2L&GM_Q@&Y,<@)7]9CX/!(,,.;P)JLE-DDP6$<B>;%
M14TCTHLRG$*#\_Y0;V*)74KE*&0!;V7'IOOHS0]HBKG:8<@;[DTM,33)=ID(
M@7'T';I$!-@%EA5PJ0_SII;$GZILK4/`Q]&(YU,4+;_B(-@5<*"5'@3\8T_P
MII;8AU0XR4>!WWS`)9[.PA0O<9#1FO([!U51O0,M:9T9:E;-RCJF5WX<DALC
M(8=2WKUAMJ':K"B2S\3ZWM2^>%2NQ!C#&+JUDAD!XUC-T@L_CM\(XGFA$($`
M*<WWIM95].(+B#)&/399&CA0F1:"B6@P:H:6NP+=\]5LB0@^%V1!O/"#7?XN
MK><=I40=7"!"GZ<``94I9<--H"-_>(D2/_@41]F+:B-WC96.8<X:'8KTZ"JS
MZ=D4^WRL<OK=53DMNCC,5WOR>Q-NJZDQQ5TEH:+]J@Y51.V&Y2CRQ310YR9.
M?4&2F\S$%X#+PG04%8[:;XPTWYLLEFJV&;DK5P,N9`,M8S4R0/M0P.[&BRRF
MK#)[-6X7!4XAZ$6\.E'#F/\GC=)<'71<71V\]N=17SWJJVZJ/44;O`JI<Y^\
MBQ;HX1DA^CK:^9UW)863\[=]FHE/*5F\ZS``.*)7#T8,MX56"^,O_D9>%[7E
MBL`Z^G#BHO`FUJ*:5>&UO.>%,*I6/`E8R^[`&%;PD013MP^3KA9;9T-G;2O.
MNI.L:X02MC&,.<Z6E/(]TC;W$0ON4=B;MD=)%="FU#"7-\>6@JP"9JK@,`[#
MSR<4$A2#_#&Q(><_18_&5\@C-"4S@7/%A9SC!"1)$;(QGEW#G+0[GAY0_(H7
M*+F($FY4=?>%@5/)-43`&+[0AT)7$=D/QIN+O`>&5H9.4N]/2D08CR.>7X,8
MAV0VXXXZ7!4Z7;[%K=,16V-I!8>.`<O%J#",2**DNRUL3;:]PD.U.Z;0)Q+O
MYF*<JQ7<N3-M6XQSWZC%5T],+`N=3Z^JCYK`$SIOJ4?W7=E1<QZ6VV=+D<.!
M1).?KQ[];[I>/>T/0&7H&Q,6[NEDB#BCL*;LB$IS%C@FVRW2LS2-\5.6]QY_
MC.[1"^U335X`>0U+J=/-P#>@*@?T+))&Z6-,ZQM)=`900?1CC,8Q1L--#]4%
M`0^GU_X"!_PBZ_S!CL0^,`$?$^.D00BLX<`1!FRFJ#`0W-5OB(719H/B!?:#
M.Y\<2=)";,SQP-$`/,9PV,C!8!2/ZWL4T,XT=WZ<OCW&?IB0>X1>,N=O];](
M2S2J+N)(<(`60H[7.Z]C)#V1FX.!8PWT."7G=H64$P%9M\&B54Q6-0\XN(!-
M^:9E3@4/MZ_5KD%7EM3MT@^Z,EBL"X9S5*5/=CJ].&>Q.=B6`O)['&%SCPG\
M*%Y!MU&X?D3QAK9)V)6Y.D=^G)?!B#'%]R9,$6%2>D\H)F"Q]EK0+GT=$6B%
MW(CZ'*(`T8*\]<#RFW`5Q9O\8X#%08IH=FI)/"=?^O,A>WD)<J8JFN^D\X]&
M.PVCG0HUOP]3W;'\AZ.,*^N#[^[[3W&4)`IIS,*)+A7QD"$RBJ?/+`BBK_0R
MNX[BRRA[2E=9T,1<@>TZZP#;_[2D0!.O[H^=CX54A&A-=6,@J6A@2%[[;?;^
M;IHMIK]6.W\/C;%4%U![S0Y>.V`>K_T0_U64=(C")`KPLI"6<'E7(\9\=8U#
M`CCV@XJY2IDV)M8_/H=58WP-4?OX7#X^EX<SN!/)?/'QLHQ+OR?D)*2@U5(O
MT2L*HKQ"%L?HKC37@7>P#BZC>`K/R4T9[^[\1%'A$4USZ*$K00,Z5<L,B_?E
M6<Y;YGB'7K(\^*'3%PQNV*)0F.(VW1ML7YJ\>',>`M];,I.5>LCT:%;_GO6(
MHUE]_Q[C5&T]?WLDWY;$:RG,=D234,-DI+RF&$HCMA1F`^LBBCS4%(`]]-P6
M@`HG:;#MP4A@[4.1-VS&-E&QL9Q(T4&'/,W"Y7RUP@LDYY7*-&`-HQ7C%/&R
MM<26&N.XXX%UB=8<$R'D>&!>5UNJ)76W]&VI!HMM6?;BR6U2;1X[^41;@F3W
M.*7YK"D1&87!=;989)LL#P&O-ZHD/P=HZR*:;6CV<.$^XA)%[)$V\@G[PG2Y
MLF,0Y7$$,[3L+R/LC&)?S*[^6;+%HT=;L)6&Q)-C0,,QH.$8T.#&(]P-,Z3]
M`0WD41!G:/D[.5RC^,Y_RZ61H^0RQSH2L,"#W4;CT196:C1!89)35,R1^D@'
M(@OXD(\CF&"+VRWVGV@A`8S4HN/9<QP**A#A,)K8V#1:_'GN)_NB"Y[@-5_5
MP=FF3^?5E/.>[4\4X/+4TW)1MUGX^&34]EVW)//W\5:\]\.US'5=C7'D95B'
M=P3<D7H@:Z.`7XQ[E!<PIP+6;?9\QB'>9!LI@_;&`3\B#^C/9M(AP(ZSR?^F
MQJ;Z.."WH1J;#@!VW`75U6YA26BIOMWB9\L\]/F[J/$0G\4Q%<HB2F@W9/MT
MFGWUX^6UC^/?_2!#LR3)-CD*R=4W6L@M07<Q7J!YR'I`]OY-6_S*>RQO*NY]
MTV`4#DS#1'K)O1>7^!4OB>8JJ3/3^[?M<Y<W!'5(6HS#9M4+I7Z/B!Z;U]*$
MD-G]K]OGJ!]6:AO4&$>JCU%:W>/DS^L8J5;TZOW;%D83#".T/&*8RVQ",:C$
M/LD)]:2SNVGMM8E,5'OY*'2O,&T9[8T*I7">@@BG625IOH_C=12O$$ZS&-&=
M>!/>H1A'2]-:DM)'+6PG9E9/4J9"*6]G[L=GB9QJ@]>9.7K5CEZU[\"K=HS`
M<I5Q'6^6>98FJ1_2SI9?,HF[P?BW'`@7ZQ-W4Y+WDK\""#9QZIC>O27.)S(P
M300OR7X^Y$!T7&^(FVNO!Z@\TY?B#5'"T/(RH[7%"^QR0B3Y'^?[G@6A:&DO
MYE`P7BODNML$;<CKZ;IS=BH7[:E'%#&\[;`WP'$E_;8M'N0!3C`56G2W"(Y!
M8F&?=-8YK@=\TOUBSNQ7O.FN0D=E<'N/Y%61^Y;!QK?L\TGW)H,LW'LT!3HD
M@;7=^0?"ZV=RG,\(0OX:[<69#',VBB"PSQ<]Q(DIH4@IPS^/7S=.M%2WOF39
M'!06^JG;"[19LI12_<NX3V89T4JZ@`NU%B`6^K;[DVMMRI2B_:O+]J2^552@
MAT@GN"QTL</9&&2$*G?!Q^]X%[CS\)Y\E^XG&4EVGH&C#:/4K8$$61$";_+]
M.+(T2%()\@B"\=O$*4JW_CVB)3_)[R^B,`]WR?R`!C!.92(]+#3>Q"%'&PQY
M*E$?0?Q^!^KQ#P<>]7H)DVX/C3=QS*$W/'DJ4>\<]@\OZF8>=#>$2#A,\"(/
M2A_F7;W_36_R77K]FD2HA-.0_\]FN[5;`OK]N`2%1*@$M+-ST`;ESLSMLT^E
M@5X$!Q_U)HYY`7NC0B6AG5U_)JLPFHV_S/]U22A>I9+UE#TE^ZPWM=]7-Q0=
M*L$;N7>NBT=327"!(/&F(_+/F2=-)=Z=/73]G*N+KH^=_T3!\OQMF]=U1][-
M&/%J%_?\56]JO\ML(#)44M?9(V;3;5Y[P;22NEZ^ZDWM=V<-1(9=YL*XLZ$!
MN]T>LZ&/V=#CS89F'E%%MM0L2Y^C&/^%EK^131W7DJ=HZYSD_&W/#ZE2K;B'
MK[F2C]T+YM^M[#4I(FW\V\/7H).Z^Y$IXP(L()]5/6%RT.:K/7`_?/A(OB+L
M@2J;!IU[W0_CFJ]=!3K8V'6&!389=-*"Z_5IT"G3D%P_H`-L`KXRTT\^3'YN
MP?3Z-.@D94BF']`!NLRFS@G?ANWU:="9P,`G?)T.L)4J=9A^>O9+&Z97TZ!3
M;X&97J>#L53POO?ZZ=FO'S^<:;.]/@TZAQ62[0=T,)9]W?M>;\/T^C3P1$_@
MS;Y'"&,)RX"9/RK&JIU2;$LZI')OK5J6HJ/]9NZUNVL!)^_M$U_`H!VX;EOO
MVG5N`DY$.^0`FT\-D!WG5*M6:,"95HJ<.@39\6.O:W%:6_*']*O33@SVRC5B
M#3XH#\!+@.0-M3"_A9*X^>3C`?]]-Z2RHL"<?;DF31'J%?OOO,>4>V4&K,L]
M&41@932!MH7;D8<R@NQLZS)7).(]/'V,V?_A1=UDK<H>S^9F74S[,EWZ.X69
MV,-VI+).!"TOZ6)?,LL@XBJCR8AJVW[7=2[LRY#I[]'0DC[&/$IVYS"<'',8
MCCD,QQP&ZXSFEAS0+G5T,YMK>/7/#*=O-R&1VRP7X>UU\B4*7U%"))VK1`WQ
M6>@H_[Z3#=7)8$$7MV$$3]JE;8"O0J<-0(F=9?W;AA&XW_.--K3`[7\5.F,!
M2N`:5#!FKK=8X+;UOX>7N<:'H7,FH,2.10AHZ_EW]:RSSKD.\ZRSH9/;8')7
MG/5M2CT!0P2=;0(HK>H4,F8R=TQ!L4:>=8MU6>=/AU!Q5,C4HX7<'JG>?XC;
M(M2:4(&G"@$)=0LR0?>(&U33HIV6;!%I+9BLR7X"4M"4B62L+YS5XNST(]J!
M!F\6D,A8:S?'"Z<7)"O:XZ$%^?$QHK_2CXSL,R3%')#0N7E#%F8W2S5S?>3L
M#F`Y/0:P'`-8C@$LQP`6]P-8@(.TJ_?6+$FRC5JF:?\?=2#291`BF!)*%],'
MV/0I'DF7^!4OR=OBGO!I.`%M?MN!T)@A:?&=9\F**/5[1!X:."!*,83,[G_=
M@?B:8:DQHK184[2ZQ\F?US&BW<(0$9-T2*EE?=N!X)PA:0$=GP-L%Q/M[M[L
M7-*/.A#(,P@1C(7Q+-$*AYC._93AI1\2;<0Z4]39T11U-$4=35'],;=P)5%*
M16%."4EG%]$\UPQ4'!S<YNP!4M)^*<SQMEB(>!QB,Y:'BML,_<.G[X946M9Q
M;QRPZ83+"3;C#D&W*MVQB'1Z)+,X9V-SD"TF`,Y!R`08K**FA.C<`XPU#$B/
M91-41/0*7*M$G6S8#4ZIY-!@$6$I==90(`V-1]DF_3E`6\6#>[)S??I^56(#
M9S10&H$Z)_AP?^>5?2T)E=?W\7XT9^>%K5+`LL%<$)42A^O<5"&J$-SO1RV,
M.?]H-*Y1F0K?=]%B)WRW]H63-V1U4&(8N]>6E85KWVSKNN1:Y<.U+X)\6.EM
MDL/8[3XV^;7.EVM??/<PLLLCAC%OKBV2.R*?+G#W&6U9[8T*YKRZ'"&UR:O[
M\]&K>_3J'KVZUAF?+'GTNI1@P+0];?U9B2Q'MC'.%K_KK3AQE06WK44CM[#2
M"S=,$,]_=S#*@<AS-M06%E&\>*8/I)NP$I;Y:@OW+?:?<AV3YV.2S[3%TRIA
ME!HFT('2''_4(O"3!*_P(J?N?'5)=N@K^?D55<`_1K/E$A?`WOEX>1->^"\X
MI9!SW%9=%G4@6MD(DMT5UX^%/(1H39]))L_3%G>;_?&[/+A[K9QGDV+VRU$Q
M.RIF1\7,.'-G88J7.,CHT?^`%EE,3GR47'U;!!G9Q]>$K)1X6;J])Z[\F-:@
M2.Y07)@_W]@+2()U>_RJ(ZIBOQ08HTQ^\3?\D#O5J<!J;,]<UQ&U/9JX+2\N
MQB&K,(7-3EM"DNTP#%JB9>L;!@'CFH%=U<T:<40EB!^?_5"Y//O@,-BGV)OO
M$-F")A:85FT79FDGGZ%!L,_:`2#*#9)8:)YNC?TALF5UH=[Z24D_:%_S`&86
M3*\$Z&Y#[V8SM?V@5&D(!`"%+7D/H,<EBRK0/@#;Y=G&5ZQ]:1H6/&-K61MP
M#8B<D>8V5==M`L_"]`_(/:#56`"RK9'M&Z1[0R3K8+0PUP1<5=3J7]"Y61*O
M$):-2N7@[3BZ0V1A0LK`>JD2B8RU27*Q'+&J;M2VO9)=`%J8]@*G[BI3S%CC
MI5%ND!&I#I9X&YU1'79.SEY:.=D4H/BK>H`B^V&6EY'(XL4S^4`9ZBD()Y3.
M.48**M0$DE'P&`1X#`(\!@':(Y/'(,!C$.`Q"'!L08#W]%$JN2VJ,8Z$_-7A
M=3S2+T=%NK%JHX"CY?9(+^!.!:Q5*=I[O<`FPAJ;K*'`X5T'A&W:,CDP`]?-
M4^#$B08K3D"+G;;DQ8GY2J?]<>-4@QO;L<"1/)K<V`%M+/G:7&CB'JC3Z0=U
M9E2#H6-1]-BQ!S9T$R85EDQU6#(M<8,-C=!E20UL8P$\O;'DY$1CEU2#H5WP
M>BS9`]M8T$A_+/GE3(,EY6!HI[$F2^I@&XM+Z.]>__A1XV(O!T-[+36O]CK8
MQGSKL`6C.V;QV>)8TT_CFQ@LCF.TPI>LF3=WK#>Q+M=MPHR*X4+_?==@_Q)M
M/;5-3VZ6)JD?+G&X[B\F7>/SWL2Z5+2FI`U-D#$EHO%1/]B[]-CEBN30('@3
MZ[+5V`?@T$2!-438'N94V\T'D3'WB#ISR.\OHC`/+,C\@)97%CZ2;(+3FUB7
M!-?#0=T7Y8R9BT:Y;:IPLAM".1PF>&%!*.`^+-[4NK0Y"/$74*='\YM-,7Z/
M9&FRLX^E"(\!AL=2A,:9>Q?X(8U]D02"U(<Y$N=W`++CX2`E-M(XO/V!P%%W
MASP0<PH\*$X0(TY`).O^(K23,T8"Q[HU*<M0:)E0VQ@:4H-T(O;K,48"1[!I
M<J(&-71<B*'(8OK:+=MAB\*(Z^-L*0`GBR@_@!G,-S&0VIGPM)D=(<*E\H75
MQ^>`X_$:`M%2:VR'N7VWYU:7)<#F_YR]$$`6N'B.4Y-.\N#'B?Q`UU@&NO99
M3YSEW!EZA'%;8=GJ;W=^G+X]$GHF1%NCR)^_U?\BBVM77L262F2RP'<=A(S9
M1N$E0'J[-`>#QT!JL4K.[AU65AW\5YN7('I#B)Y*%P2]+$BICTL<:"2:`QXH
MR:8Y(^Y(AH55?&(GXZ[7,2HN*LY)JCH5.I92=H#JX&',X#X(X[A'H_IDJ*A+
M+:;H\W.'G%4[D3P5-U&X!_RLA/D/G#X_X'`=H)O<'Q1)WLNMUH**Z-3D69/A
MK;&UBO]\^!^?\S[F28K3K`!030HZK`@5'=I9%CKB#.8F:'4DM)")+DM"1:GV
M?D#(D+8KVGC[J"2'6H7$=11?X]`/B=8?S):O.(GBMP<4O^(%DHE#B[6@8D@-
MR$%+;*U0F1.T^&D=O;Y?(EQHR^2'0R69_,J[16L_N`J)1//L((Q1U@1@<A[J
M')#Y"4_]TKB`@OO&/AP"%<S'HUJ3MH?0<I]&70^OY2K*XG,<)0N,P@6MBKD0
MGU#<"5`A8DQR,0X;(>!6/3VO7G`:O?#+333&>%,88XPBZ1NP.A[]41V.1;P@
M=2I$H<`ZHS3/F]IMFE%&PEB&)0QS#]"2FK29X[VI)565N4QB,Y>+C-M>JG:%
ML::PT4)\7K!YUP#>;9X]9$\)^F=&9?B5GDKR8!7.#&_J2&8M'WQC&=+6L%(>
MA\*;XTV!PY`$;%)F[`X5JQZ>]>!#<=DMQDAO"IS**B0SSS390&$<F=/[M)!>
M?,SQWA38!J'!4"DB8U$Y;MM5EYBZ$3C#AMQ8`75+(SBYK4L:.9?]U2S@?<L[
ML2[Q;\H-Q.D%>V,G1Z=.1G:(XGXCJ$]QE/22P,W_FG=B7>NZ_L21@[\Q]Y?1
M;!"CN/;7,$OX->_$$AN<2+IZQM_*RHXW29+1`W.^*GV,CU'I=<P32DM_,D=>
ME.=[)Y88[F02H(61E:4AF;6KR@K_'#X*YW@GUC7N8O-.BH65=2-O\:HF;1P&
M[0_R3BPQO<DXT@3;RCJ1.\%YP7%1E8$@*-TK]<'>B259?.J;Y!#\<=2+O`C\
M)*ED;A[GJ4$U!43PKI9-]4ZL*RK'?R2K(&.LN6`?F_$ZB*)8Y_)J3O!.+(GV
M4=V4;!2,V6EZ8!,Y1L@S&?'NK8-1WHDE]C)%AM3AWMDK;&+#Q3-536["2M>H
MMOPM]I]P@-,W7L21?*9WZH"12@.7BH4P%3#ML#75ZB\>E)J3U?4=&`+O]#NR
M26G0I))B*$.503E^DE/L26Y45BR9.)7)]+#0>*<.6,6`Z5/).I39S+HSNW=7
M5;,^[ZD#MKM>L:^D$,K0YTRE5>?[L)\Z8.NTC6#5]H"RJ]J^/<9<O_O4`5.T
MM92K=@Z4.9R5%(;SO5_LF^+GPQU3_-8K4DCS[%)5`[KB3._4`6NZ!BX5GZ%L
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M5`O,V/U2%*&BNX1WYI#A7@>I2A2LBIB]"1<Q(I+?)O!(::YWYH!=60N;BI&C
ML@'6GD2B=N"F/^.=.6`@[@OQ2I)&9?VK8]JG"M/XCG?VG=B2F9A7PF15=/$L
M3/$E#O):I44\=!RE*&\A4+[Y54+#=9?QSAPQ[+9!;)>!:!.G+U'[EX327._,
M`<.F%C85(ZVR8C&,)"U2#YO3G."='/GRF&T&,@[>I"[(%R=:)_,^V5I.!3J9
MX@+6,TZ7(.6V:YKYK#0-7?C)\SU:(*)1+J\)A4J?QGQET@"D^!5GA,$H:4N)
M&;R@MK!9D5)WHNT@IWH1E8B5CFC319VK-D<JQ>9WPYR@81.Y\L:"/NP>%L]H
MF05D<RGMS>UI3GZ:KW86UD+AR?NATQ9D+U&<GP:RTI=]?]J*8U%6/*QW^G/3
MD*V\5Z4([M"35SGNYX.@8C70=FUU<;?@74\=`CZA$,5^,`N7L^4&ASA)X]SX
M7P8ND#_<$_X1VC^3'R_1*PJB%[I;MP.$5Y"AQ4'+-/>Z%>LWGRE."`7E?9V,
M!)X_#TE+?[='6_0M1>%R%[_3H"Z!/7U&*5X\X2B(UGB1_+2(-L5[,7^&/D<!
M@2@I@M<O4>KC('DDRV8$J,'K;!["\R5*T>PIR4/B13>P<*+W`:YB:'YK"B$_
MN%YA[WH)&7EW?^.-X';Q\WXZ3+CQC)/@X#9GS;27L"06A<<ASL.'@XK;#*V5
MVI.6V6Z,]6QL,<'M,,$"WVWFM6L,`AOQH<FT0]!=+X2>/25XB?WX[<$/2CNF
M0F,0YAS/DN`,A<X@//A=9^<.H2_^AOSX2(0U\7,'L;Q'B'2R!]^2@LLX#J]5
M<'+[T+W+XP?17>`O<NF7GK[L"1YP"(02H]A,YB+D-F//LP2'*$EF"W)%)7FE
M>\G)S)GA61()(3F7^="#=2CNCY'TQQC)+<72N=2O`\E=`=?4V=S`R*H^3C=A
M&J-O42BTO>X/\B:PAA\U(C>-HDTLK.+$78Q>9T_Q;2#NJGLXS)O`VFK:<H.%
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MCPA.[(2!65B5FFES=JNLZTVA`Y%,G.BJF$)WSAGB><\,C&S]OF>NYDTM"7'J
M_L#GXF>N-XR-LI+?AZ9$1;"8-[7$+-=!4B3H@;=?47A$%,'3E`[;\&G]=X1X
M"6_J@&FN#5(C:3A2UV^;Q1$5U?SF1&_J@+%/'17POA[Z;\?\CS3]-$!)<MCP
MEELRI?V*WM0!VYX!',%[6+14(Q9!EN!71!O@A2BXB`+"^J@H/C];QR@G76M=
M0F5Q;^J`V<\LNN!=&U3,"`42%=PM#`FB%;RI*X9!/9S,%=8W$N8@/]3,70&,
M8]$1<V!+W'JL5T__@RBE=MB6IE'FG"<=O7W0.W'%WM0K"<R5CU_B9!%$21:C
M3QE>TC=M]U@JUCNYEI32]:%A[@/>B0.&*/,HFRM;;V&\4"T6KG7(4'T-[\1]
M$Q0;*W-UYH.]FTK]MNK3.'$8O*]MI#A<P#MQ0'751TE02<XE"]67*,1AB@AK
MRCH*\Q6!/6^4QXP^4YOHG3B@CJJC`M[*0$<MJ=SR/5DF6JQOO2@8)F<56LJL
M0E+_;_CD_`+#F[`,@B>OH2<<YAA4J%Y6KUO!"=!J.>LEH1NQ^`TF.Q>]J]ZL
M%^1C5#H53$FR6=9S0PEU;C8:1,F?6P(:N4%J)\,KHHW[*I=7=4S0*`F*&\Z[
MEB;;RD#J)8'8=9PK89RO6H,B*`AD_!O'VD&2_=('Q;EJT#C+#-VVRVVRQ,BA
MG]KD>A6AW):WD]S+#-V$7\BI_/@5!:_H<T1.7Q$K5:;;4F-HCVEL!BNB8XKE
MH.HH"]<'M(C"Y7\C7U1$03P1N!!15V[O(0*=M]8?HQ^?<=R&S]4\X-)%7=E<
MQ\-8B07KN'P=97'ZW(+-NXFV%#9JR><]1,:1^LA$$Z_:\;F<!UW>J"N;:WB,
M(W&1+\Q$TVC-[L8"T*6/C&SO`X2,)3&FM)%IC?V.F3>T"Q\?K1Q'*\?1RB'@
M\^461$Z\S!\X?;X)E_@5+\F^RQT82QRN&T$TE(QW$:$=V?AQ$6F#0K3"M/+_
M(TYI^-YN&4G=,RB0'+'8`)+'\6I%#;0HK?+>.C0XXQF_/$9788K+'CL"$=5<
M"=A<!"DQ;!G6IQ]8T4#V"R+^1Q8)BY;51@";CUK0NNE%VT<'V%C(9,G_1:M5
MC-[N<8#>A)QI#@0V_!AA$!,KL/.:[82^>O7#<Y\\R<+T+13WOF&.!3;<&.$3
M#S%HBQVG@3.A+WD_?\:$-&M?7#*3/1C8"F.$9US,P"H`,KEU'RW^?,5!@#[[
M\1N1KZ6079S1P-83(_SBHV;,D`;S@+V-PO4CBC=W6;QX]JE^6RJNYV\71'M8
M1_$;(1Y1(\H12XFNU7)%1VI0M\?.\1K5?,0Y:$LUGI8K0M>S[B`!NB(EI8/;
MAB)V][R:&BGM5*"X`G2Q[2X<9LN,!N)NRT@_G=F`RWV;:<U6J_7M:+UH,\W9
M;*GXS642F[E<9-S>L.U:?`%7].;S@LV[!O!N\\QLDR];"G^W[O)5J__MJ%;7
M=YLOZ,+>0M9QV*V$E=O[V%Q#*%MJ=K?L"&6R2#<,*TTU;0,NU"UB$)NE?#S&
MMS<-]OB"M9[ILUD));N<36VZ?`%7UE:C<M/<W<1B%%V^@&M<M^4&"P\KXF82
MM/AI';V^7R)<'(3DA\/SC_S**_PKYV^W=$'^HX0WU)HRTYS7B`AN?D>)?DE>
MPL&]6YJ#H&HT"\G7I'03:.[9U/&8F:]6>($>7LA+Y":L/+:B$T<P`ZHR,H=D
MS5-&`KM5%\`>K#O?K#)K#J9`E2]NQQL&\'8]E(CP9'ZP#?&[6JW0@@9+%\5+
M.$>_RC1K2@YSK@%5'(PUF^F=6=S+0VTB5`E@94;H\6^'E%5GX25:Y.?`R83\
MZ50<0<H8"E6Q5X/:33;Q$+&7,6?JC#DK\8'1Z<TQIH:(%>I*>^/-?M;/SLM.
MX]>_1.&"\^>:B5GFKS;T!>_$DE9>$L.M072-]?ER5K2DMF%CWX"NVFQ2;'H3
MS!VIK+J.[FADT<T%&887?O`88S_@2XYX`G2Y9;-,8AC<A)A;R%6,M?G*G@)=
M)'D8SO)QMTN1_K+T'[*G#4X2`L--^)N8KYS1W@EL;$W?+!6@;5>&WU461R^(
MYGHL\8(Z`F9K%"[>9B\O<?3J!T+>*LWU3F`C;_KFM#(1+$NB0>LLH&,K2&_"
M68+]\"+*PC06IQ:J388N:=XWY]6I`!:XQ63]_\O\.$5Q\'83)JD?!#E-MFJU
MU!ZJ-MF:PN8"JZ@Z)H)"U7;R3V@B59WNG<#9X#1XTX:Q.P2M>C9?XSA):24D
MX>%[,,H[@;/(:5&ZR2@&)E;Q8U=04LB0PV'>*8RYRP!'6*C8I7U4U1^%+#D8
MY9W"E6OJR!$&)H[G;':M-WUJ=]R-&')S'9MMRH[<]H,1\%$XSSNU)%EJGU5L
MODHQ&46%:4J)^>J"P(K3:W^!`YR^%:<57FP/+P&W%69[I]85F^;S7!&?<=2<
M5D#V9ML'JIL(E*MXIY;D9AD2A3I>T.5N#%W9;=N-;ML#D9=/G.4/G\/^H[\3
M.M'.0=R&KT.#X)U:$L^E(HQ#$J6[^?)C(<DA6A,4EXY),I,N57.K/@17_$7O
MU!(+6Z]R*J<!=,EP3ANR,,F"%(?K:X1XEM3]0=ZI=>6\F_QD@VTLJ1&V:GL>
MS1PG=0D5;&O6<._4DG)1*GN2AP`_-\0E;G8]<3[12@I54_1/<90(K13FO^:=
M61(S-\3YSL'?6$PZK#Z%"-:S<'E/N1C(327,\=X9;(R;GH[$P\!85"0\0PE6
MN&AH>TDH,Y'Q\V"X=V:)$5.9G0P$2FY^=)J;\Q=$\0K7.9K)=99F,?J,0[S)
M-F5!\*+OU->(VN&%+?5TU_+.'+)\ML+.G._<Y`-]'Q7Z/[@HAL=YJW/'>V<.
MF#&E&%1,<MMRJ2B@%UD<B^W7>@MY9P[9+_51JX3#MI+=NV2@ZRB^\Y/TCM"A
M<L4H)70R)WIG#I@`U5&!<SDR&?<9!RA)HQ#QW4BL8=Z9`_8N'N`5"ZRR4E6>
MS+)'U#7^AI;7B*6<",=[9X[8KH085$R"LF.Q38E^\KS;X=M^7Q7\/-.B<))W
MYH"92@V-BF=0UBKVW;1<X@**5MQ3G>[][(")2!>ABJ-01A\F1W\+8[3&"?7K
M+G-+5G*3)!E:/D:*/%5?P/O9`4N//DH57Z%L/[*=&H4)7J+"Q$%$E-,-4C[)
M^]D!TXX:&A7/W+;PY.55"]F\S&*B^A1FYD)F:V7/Q'&(BFMX/SMDT='":A?*
MXK0T;$,?"-)^N*#5(W)L9QN:LR,0`-$T[V<'C$"JB%1LAK(%L3.*_3C%!R<5
M>4%<?4.+C..I59GF_>R`Z485D8ISC@:&L[J$[Q(21.8ZX43O9P?,.>JH5%PV
M:,ZA_PT;14X?CM5[(W<'[YS%#RA-@_RG64!>EV&>H"FZG%LMYXQ(M"-6*25-
M8\;P*0,B^,_?:O^0E"/27<D*%DO21+2IPW6ZVL77VH_22N*Z*T'RM:4TZ[&=
M0;R>JLG>A,O*8'WUB@0E_46C[64(5PSW"XMSB-`3T:O:$.J4%TYQG/QB<I0V
M",,\N,8H6%Y]>_%#6J'E&HGK]/)&.TYY+A'*UP/T'5.%>L^(OKHI@@6I;W.1
MHB4G7$-YJA6O`Y4'H)P();M,U7/OZU$@89G"9&>8ID*(DFU-5T>IE.G\-VPC
M(/3BX^4VS&`6+G.]E<@G2A-Y>(W*;&<8K42*DM--YT>.Y_LZHN2C?QXB3W^W
MASWZEJ)PB2HD&OB3XYW`D>+%$XZ":(T7R4^+:%,H_KG9]QZ];!N[WL71.O8W
MERCU<9`\DJ4S`EC'TAG,3\R>Z)98\)QDXDG>![A2!8\<=Q!7VX.J-B$E(=<3
M<*BN.MW7JFN-"4M<>/HE)N`*@1JZ6+8AB-=1O)/B^8I:1*,P%V[1O2*=[%GG
MG./?*RK(C*+6Q*YQYCPNO%.?4?H<+6_"5YKW20XQO'-4B?:QSCJ>=2X[OI=6
M$Z]QE*%@WV3WB.JR.%Q_R:BF.E]M?=49(4B,_Z+1)^=H-TM84<#(!SSK'(AB
M;[\)A$=2U$),CAT!=F.D40*MU_2L\U&V%2,ACL9JX()*SET)ZI842U18950O
M*J7YGG7Q[B(56`F?'FLU#*Q!WX3D1_3H?T/)5FU6UY?-R&`%P25.%D&49#$2
M:-<*LX[JM>+.$-/PJ%\?]6N+&;>U2%XC&D06$"'>VBW/48A66'1T2&8ZI%G+
M,1F%6KU%,Z?,+%S>1HM6#!?/=TB-5L5G'.IS=4O=T^A!6J<PY\V7B+YYLD6*
MR<FW1?TS\@/:$^&*UBTDCYF0D\=B:FF'5&8#J(Y#6=8@!+L8T$4D+!=J9'V'
ME&A3^$(KU$SGWQ\^]7172>C745RAR_'\"68XH`?+,;"S2N$S#4>X":OXDOGJ
M``L.M^03/>L2PMD)QBJ(0)<WY.3N^P&UL=U&23(/+]%3^H`668Q3S.6::(IG
M748X)W]?B,(X2A=202P8$`315YJD=;F%G9PE>5Q)*;92<[3N4M[$NHQR[@W:
M!K=Q%!2L+A9E58XSPYM8EVHN?S`U43!653"-4C^PR:@\.5J5CU;EHU7Y:%6V
MG'%4,8U"&JTT7QW>PHG"`:(TWR4+LR(^P'9FIF;1@#=WZFYKNQ"U]@'%KWC!
MU3)4IP,;CI4YU%1"-#!T@K_G_I)J4LH,+<<#FW%-<K"&$K3U7V-/5A)7J]0R
M7VWC<;2VIW`E8*NJ\9TJ0W8<!OL&[KO"KU&27/AQ_+:*8EJ#7_3(TE@%V$[;
M4DS:(0K6RKTGV9#UMV!/`#;RFN9XB9,Q6_VA.0'4AMC"5KBUF]EO&E9`H?NU
M;D/WLH;,WF+_B;8@Q"CY@D3<E<QTR?"K@(JQ*]PZBZ!V=N;1+GBT"\+9!27-
M-\B%>UV\JHK"DYSZ3_))EIO^E!!PA$?<:DXJTX!L>&KTU^%9A8Y57"/'!!7`
MXLS(.S;1)B_/<92MGZ<?3J;"&C=JDX'L=JK<:/)0&2VW3?!=?2>6Q&3J^TX,
MFNQ@.'>U6J$%K=JXBPDD2.['!<[*:'5*@(P`\K8W6,!J`ZO;%U9YQI,/,]BZ
M?1*HT&`O"+ZF9704)-ZR]L5P=I(@`9K?P5E4AE5=A7Y>@<S($<1>U+XPTDYR
MPT72F+T"J'!W&]>"P,!NG<61RW4A$HY["4S:D.TS+W)9*L+!F&O`%HX.&%EL
M7:BIA@3(<3.6)``C&;27TR):AWF]%__;-KA6='SS9KC"9"[&W!P"@##OF/9H
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M)G<X&-B!K<<I.;<KI*PZI#_'__##OU`L/)'W!P&[A=DT;9ZP#:#=/D[/LX0H
M_DF]O[?D[.3,L,4[*SDH^=`[[G9E(49_C!&2'I+2N<!.6`'3U+E\B)!5Y^5-
MF,;H6Q1*&F[6!T&[495HW#P_FTBX?8`^+)[1,J,O]ZO-2Q"](;1-^697ZJ->
MQ(5?9)G>5SZG(G"55O'+WP$O49S;8R4G<=^?ML9-*XL#'8`.CH=OF"',CBS2
M*Z6?#WH38`O?$)+&%O+^".KV^7M/!($P\7D6+B_1*PJB%WIB5&5X.=>IQFQO
M`FL>[)'Q/.U2B29NBTW7#(F)):7.]5,D)J>N1ZYQML#.9'[^UC"3SV@<YKQH
ME_R)UG1-;L)B>\C*'?3P-6]BB55Q7RHX(M0/_J/HJM"5-K_3EGU+6B>^[.`=
MT5_-LS1)_7!9]6'K43Q50?`FUB7^]">S.D2!KA%E1I*W#PBT9)-N>_L+Y%!M
M`6]B7?(/7XK448*N$L6T*14/QURTUS'*L;Y$R2+.0>.8F(1SO(DE-EX1\Y2P
M@&Z48&;/?HE"3/N+D)-I*XN5W_<:":.!)3.]B75)-_Q=JH`+=,,%8W55RV;/
M15?6HG:=@,V<&=[4N@0</GL%.$#W8C#.UKSKA!H_\Z'>U!(#K28C*^#'T:.A
MAMF='\_CG"S+'$F%_J\*L[VI)8&-FGP6X3..[@NY;6VK)]`.,?4H`B'/^=.\
MJ76EK47,%B-BK!N#8I-?.O8>K?9HE6#R'$22!_,%T?JB`"_SYWY)@62^NO"3
MY^L@^IK<Y<3+<PPH]/1#O]W?*"<A:*[?$`"*X!Y6G5(B-*'Y=Q#+;`T<A:0(
MX31'TB'LV/<"NHO3(/@V/<>L^W;P84]VY(9]>ZA?1J;/5U6);9HWG=\5`CX(
MIUG!D88T'7)%C+F0/\SK[#W]RI.?(/*/_P]02P,$%`````@`XW.00MO?$CT7
M%P``K"8!`!``'`!S>6XM,C`Q,C$R,S$N>'-D550)``/IF&U1Z9AM475X"P`!
M!"4.```$.0$``.U=6W/;N))^WZKS'[A^V=FJ<6Q)=A*[)G-*ON5XCQWYV,[,
M[-,IF(0D;"A``Y"*/;]^`?!.@"0D40YHJ:8J(Q/=#71_N'7C]LO?GV>^LX"4
M(8(_[?7>'>XY$+O$0WCR:>_KX]7^Q[V___JW__CE/_?W_SB[OW$NB!O.(`Z<
M6TXS1M!SOJ-@ZES^M7_IH8!0Y[=(EL-%O>N_.W&>7IP+$(!'"MQOS.$)5Q1Y
MX.5G9SBGR'=Z_9^=_F%OX!P>G1X>GQY_<.YNG?U]D25SIW`&G`#0"0R^@!ED
M<^#"3WO3()B?'AQ\__[]'7O!P10&R'U"Q"<3Y+)W+ID=<(']7G_0X[KX4)3V
MBM#9!1R#T`\^[?T9`E\6?<_ARF-VRJ4L)U6R%5B^#]X1.N$DA[V#/VYO'F31
M$_D^PM\*U,]/U$_H!P<B^0DPF)"+5"](&?+$QP=18DKJU\C]XX8+S@M%-<0(
MLP!@-RN$4NA8Q=[)R<F!3$U(,9R``'J5PD\.*/'A04R6<(5L?P+`/.4:`_8D
M.>($:>[]P]Y^:O!3EX0XH"]%RS#HOIN0Q4&<J&,+*>5UNHHO3M4P>A#I>7B"
MAAP^NU,]O4C1,""\@"S0LT1I&B8,>'W4\\@DP=(KLC#DZAEX@H:<`Q"\S"'3
M0B-3-,5BP9Q69,)3-+EX<$ZAVU!Q`'5EW1D#-]B'SW,?8,`[F9<K_G=J$()Q
M.-,+\0)Z($I\P(GV.16DR$WYFIEB!M$9`8Q)``+>L_WZ"YC/$1X3\5FT@U-1
MQ$?.X(@?7^^O33H3J5;2F0ZQ=XD#%+Q<<[%T)K/9<Q"W3"U%6@`/CA%&LG"\
M`W+VLUXZ]Q-@SXED.#DAOQR4)21"0P:]$?Y5_N90,2Y#<HA>)>:*270<F4`S
M>A?X;NA79W!0L/3ZIC\GF!&?CT2\`IX!7W1]#U,(`Q;9O3I9;_0^M_0#MP^,
MK9[G=V(!3B1A9_&22>\`[X`C-N`WF+](J\=B8(Z%\U-!X'_OL(%>:CHV&H_F
MD,I2:)I%!9T>DZ,Z3#))#AD[F:P=&D4KGT\!GD!VC1\"XGZ;$M_C<^W+/T/>
MI=?#4\>HQ^O8'*]8N(.PDQ?_7TZ4P0Y$8RP:.L*5I.CA?=\:O+L>M`%NP*97
M/OG>T(%F9'K`/BP!&!?E2%G;BL6(3@!&?\D,^<3Y"PA""O.#%/]X!ACB=K_+
M*1\AM"JS'K<3,0-'S/4)XV+X'WGQ<DH>95`<^&2"S$1\SV>SK9`^A+,9H"^C
M\0.:8#3F70WWB5SI\R,\N>--P44P;F.&M%K`>H=EP&)I`HB</"<3Z"02MQ4;
M82XB3!'R'-(Z/!H//4@P..?"Q<AP`YX(E<Z[:%4D@/?0A6@!GGP8N[IKB]$C
MVBLCFL\HW^@XPE%>3I*9D^46M56>GY-EN*V`/T`?NB7/3(E<-!'IP>HKS2\6
M4W3<=A$,CH*8C?%!`GKG9#:'F.6-KT_3VWR@V%QP[TMV)\^_U9;6N%NFWE3O
M2&OAG:,DK7N#7%[!X#GQ_:BW10LHPIVSN4]>9.QS0F$TO>6?>7V<H4#^%8&P
M.KL>J^,R5G$&/SN%+*)P:IJ)D^4B4W+Y;"NNLH[?PWE(W2GO2NXHF5`PR[4<
M-4V/R'MMZW$R=B?FWU9+7V/^$SZ"YV0&G/^@M^F'LDTC%D?R;*L=[Z$O_.D[
M0(.71PKXJ.?F8I^5J7H+?RQ;..9WI``G+V%;[6WFJ*WBW#4X>8I7;N[D.3\E
MO[8VU&4&P:/PD)8"+>;00M9?PR]W?HHD;RU@:WO6>2S;$J:'>7/.^M;7@@:'
MO-!>C4CU"*[@P>^@T;KK!43J*/1`&+OU6V_^E5W(/$+K"M&#J$0.UO5&MQ[L
MG&^4AT_]K`=$"0_D':>M-^Z*BV<7,`#(9X_P.0B3E>]V1.E!5"(*:Z[*.3_%
MV3IQOEM;`<QF^K&UEG$.$A8]H$HX8QGO(!:]P\P$@-X*H/4J4%-")"N@YO1V
MN)E@4.A;5^+48[A6*&77:[;DH!<ZU-:D:1$?*)&8%EWT;>^*VX*NUVY-J.C`
M!YN,UNSZ][;0*W3];0O55PPE"+2!BK'M@T9#D*XXQS:CU8.I!I(,(GK;WI.;
M6;RW##Q5O;"ZN\0<GRWN7LV,WE\&H7X%0DK0:!F$^CN$:HT^6`:A005"ZAZ3
M)1`:;"]"VF6)XM!32Z)'0PWG5"Y=;/TX4V?>G@$$5:.*&IQIPF";QY(Z"_<-
M4*@:.=3P2B,*6SQ>U%EX8(!"Q>API&X^:41A-R9H+7QD@,)1!0I*M*$9A:,=
M"CH+'QN@<%R!@KJ_HQ&%XQT*.@N_-T#A?04*2VSN2%!XOT-!9^$/!BA\J$!!
M?ZZC%H4/.Q1T%OYH@,+'"A14[[H1A8\[%'06+BX2FE#J$=&?V*A%9.NCN<I9
MLDI,ZJCT>.C]:>4FAQT6:^X'+`0^UI:BQU+QR]??$;CM,91UD2HTT;:$Z=%7
MX@&MH;_UK5Y_)K&R%VZBU.)WK(\D:,XR[G#1;-@M]*^:[WJ;*W&#XI;=;>_]
M5#OVJ@Q<$2L^5F("6@MO<7Q8-66A0ZE.UMM;\?[U]M[VGJ/JQ*X.`D-:/1Y*
M'*#ZK.^;0T?\(VZOOH=C1UX+?2KNSOVTQQ"??HCKI.6W*85C_NT%[R>W:/^;
M:_3N>>8G%$)PS?W4$M"R$>)\$Q'Q;<'UMU9S(60.:8`@.TC*OG>POCK<W,NJ
M4T3()F7X3')993@+]&W3@]?I9?4H-8,-:+-R?]9X>>`R%TCJ>7Y5>[?#CZO<
M/?AV[H4\2*[[YK^R2\!Y`J]\A`8.UKY,4'6[?O2HP0UQI9@:%O'7?L*W+S[M
M]_K[@]Z[9^9%E6F)_--:N&3^"=]R^>M?+##,.6$061X;9%;[;D!%GC(_+>,!
M]`.6?-G/1)EJ77-]?UU9-&SQ[S7*H'L1P:00>;[DCW6*H7M@P:@<><;TKS5*
MHCS#8%**E$G^6B-W]74&D^PSKNCG?B9@V0*47WLPR3[A$3_6R;K\!H11W@F3
M_+5<[DUOD)AT1CZE!2[1(YV(3K#W?IT2&':%N=R#=7.N?T;#M#1Y*9>9D.4*
M5_N.BDFM2'C$C^5:8_TC'T9F*'.M`8S^:9+E"D'PEU7*4?^>R^ICII2EQ21^
MADF6I?Y1D^$3"ZBLEF+VRF?#_S:CCAP"^<K1*?^&\.2:STO%'&[/`3'5I[V`
MAL)=D%1\AHZ(]RCYO#`ZD++G8"3"Z&*&']&RD#.C(!2IGRD)YTDFB(OGRCFJ
M=G!.&)+1_1&?_M(A8S!@7PB.1K"\9HV4>:UFA/<$@+[H]!H#GVD5BR:009+T
M%&UFY@K#)Q2TH6U^NW5AQJ\":4!J#XJ_`TJYX7@_)Y976*:%DK`V1EFQ-P52
M=(?_-;X"B/X&_!".QK$:-P@\(3^]T50H:$3<`:7ERLHU8R'T+D)1E>YD]E*E
M*T(OGUT_9&@!A;X8^KGU,]ZO).MEF5E:$K<YP[D4>ANUW,.4-UK6GNF6EE?H
M'23SBI;;;.6*EV2O8+[;,&;H?`591GT-1T=`%D&PT!?W&9CC7.;I/-1+&D'/
MU!'`9=IH+A=Q^(0M'A+9Y3.D+F+"IS2I`LU2.E\IUC:4J1B+*L[0^[^0Q=>Y
MD:'GR8`T\.\`\J[Q.9BC`/B)!NDLZAZZ/F`L?HHV,4H+HCI5A83@<\)TTX4L
MJ5,:06_(U"<92A6^3-*M"36?M!GT_1JJ#J@IRSX:2SU6F.RNR-ZQ&LXU&[I_
MAHC)[DG>P2>WK44AC*K:4,O2!0N(G=)S\??U;,[=8_'KAK"<OI4$7:CXF!L*
M,'@!H_]?8WV`*E?7C3FZ`*ZJ353ZT?@",:X6\*4<3N:''N_1M%?IU!EG)7&=
MK#C)Q`3!]JRWNLPN5#[>&;H0>NR*DEDR]QF-Q49M@I.Q)#\E3N;!N=:XAH@.
M5#(3[98=J]N4V0$39EY"M+;#FQ'/?R%/#*2N1*73D9EM73E=:(_9=L[1>.4C
M'9K%K';%VK->LOKUY_`Y./-Y6\N,U(:LR#*88!S.3H/D^X^-+"E'1M3ZT41G
M#^#ZDFK0;"2T#*K+&:03X;#R0>$"+J!/Y(3^(0`3**^N?=$HN12390K?(_9-
M-*2OO`NE`4`X2%Y0TFEJ1FV9BK>`?N/##)?Q`-V0RDGD/Z#O/9);<=$[DGO^
MQ0QRN`!(YB7F2B!/'JE8:9;-Y6"9*<\@AGS@1X#/A/`"4L8YKZ"\+K_2.,OP
M6*;NB"+>KH$O8QC2OPAQ4*FH&;5E*F8'_>]`-+R*Z/(D&F`K55V.RS*5+SG]
M3.SI^\K@./1OT)C/QR+W7+[@H>OAS5DL4_;!G4(O]&'):V;U;C/+;]?A_7TV
MF\_FL)7&>L4LWX:QHP-\Z6&*5[+WBKE:9O*AZW).+]F1566C!C++E)*+H,KM
M*[D^]NPE(TEZX.^`>NJ2Z6^0\6Y+.%!<=7&GZ2,1GT9A(/8&RCF)2)/!H/2!
M/ETELZ=(;PRL+P176.058%DI<]L`2/N_N(8-W0`MQ*2[L<-L8+!=T>5;\<H2
M+#/%A=QW&<>*LHA0E=Z&Y)8I.1ISOPFFJXH<H*N08B0\IULX>X(TYWLTDQ:4
M\\B,>^\_+%Z8OO*0EKBL4`V)18K<`AR*$S%R`U.E+O54-JGC^A#@?Q`F8_6*
M&MI4FXH//9`V;J7TND2;"D\P?(D"2?%S66+.=!N*:R*N0NPQ12%3!HN4C'O@
M>[B`W!FYXZ.-./`]@4KX7T,1J\%UF$=??^"&O\1/ND4^GRIQ(.*I56Y!MI:H
M"^N%Y`7X8G-A)535%#9!!;4O&Y4;4Q.=36TH+9S85?<%!KI!,TWJR'*KZ7Z.
M3,,'2!>\KV!BCR@KK+&N+:L#K7,)-8N;T4;X,R'>=UZ`E6Q6+:P;1M-H),-@
M4IMQ$K0O1<KT*_GK2;)G+;>JZ[OQ7=->,D=J44=Y1R&OK&G,[QXR"*@[Y9.D
MW")M?C^0$?G:]7SCIW)%)"@,(!7;,(MN81G/9DJ+X(Q#N+]![!&JF6_IDS<&
M5WO#7UQR_:D!;6('E%HY,)F>/!XR%LZ*FQ7O**^C(PQ;B'^:95.8R$I!G0TS
M)]'=*T+'4`:&[D$`KW%T[*J]B')3/O;X!NMJ^EFN9B2:R;\NN*IIS6K/ILTY
M=6&:GZGHKF2%7*Q:;*XY>\E=VXD*IY`VG5&WK+UJ.T[7`DRMO:&,NF#M>Z'L
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M^1]`G-*ITJ"2P"(E6EW"._<)XPU"GD\L^>B;SL>BGB0Y::/I;C5);WDU6=Y#
M]3@%N'SM39L+G\UYO`5WI5'-UQCTVRB$10TUZC_BRS&2IEEQ,4@UF3U[R0H!
MT%YY--*G6C04%0LXJ"__P'H%CNH5.+)=@7Y?6;BJ2K=7A7Z#"GW;51@,ZE'(
MI5NKP@=E\:DJW585>B<G]:TY2[=(A?+%W:4I>46R30/TJA.5+R2>HBAABI+2
MHGRMK:&ME*M%ZVERGL.]A_[AH;*XKTVTJ*[GRM=3>DQMHFV%SZYJD'\.YW,*
M723SN!>S:O8`J'(,<7E.B]2.;A6$,+I*4-Y6+AJ)TM/6DUFDD-Y3F&17)A8B
MBV;4-L8;FTI>CD*:TEL$9>XFVJ3@Z?GEWU$P?>!`^/!:;HX@:KM<D=TB`U27
M_7'*_Q"#6RP/^)5F6$N(1<9H@M/,&NM)L<H<R=,2:?FO"+U"&&!QT^#06R"6
M.]BIVF$E=IL,X(U)2,\082Z"V!4!,.6X7AV-1:I<SE%`YLK:1>FS107.ST25
M()<VT:;"MWH69>.'73IVQB6[2#Z99#R2I*<M7"Y??#/&D,4>3TWKN=_%WGJ#
M@Y^16>3H1U=Z)N7-WT=2_)Z'(,G_AZ_S73[/4215+'7HS%],+R@A3N?]:`6N
M?$)H0QW2T5A4@5;N]C89#^I&U&==[9HOE&S=H.99VF-G=:#)[CIPR02CO_)/
M$9I1;VY,;N_ENA8;3XN[!FJE6SG*I%.Q7LUVDEXGZD3RP)3AJ^B&Y!U0?-WJ
MFJNM;6VOJI3\A@;WO'(M=R`:T5;U'D,<H`OD2XYH]D9)P(=,_F?2>51,_);G
MM*C&9$_7&?4PAN2=<(%Q0.$SP>7`2/F[13&1.PH7PR>JN?%*3;&HV+FJLLIK
M]2NR=Z$.BK=ULF=XBQI4]#9+L*S9S;2]8%[UB+I\OS"*N\2*J7?Q&[[';B9J
M35>GU0&[@&;V>%P<T3>J`TU<':D&,O$<L*D/67D;2-[A6TN(M=#'#W>FRSQF
MK;^>J4O`KP6XW4!?T'^&I#Q@%SY:-%;_#QR/*7RY1SY4+A_6I5E4]//+!<!G
M@(O!P0M63TGIDRU28(BY/_5$Z"URIV@"E)EI5;I%*MSSUKC@4N`MGVUQ2WO*
M2:\J`HN4B.X8?9@#5[R'GAA=^Y)%!9&MRF36K]-&H;)('6[I4+S5+.<[E^.Q
M\+,7<42AN&FLF=+&#6-UI2YO%C.AM0BZ"^C*^C3H]0_5,Q_Z5%N+K^S3UZ=:
M5/P[L4Y_G=R)_4@1G_HH480:&NM40<A$F2HJB]3YXH&'\&F&F.P8\%=%DTH"
MBY2X#"F90S$G\9"+,&3#"<3NB]AA31;J&SV&Y!8I>`\GH2]OD4\*R8=]A@`^
M%_?GJR]UF-);I.*_0D`#2'UY'H-/E.6.XWAXT8VPIO0VCK/-92^/MN8<%D%Z
MA2@+_A<"9?JJ)%A4Z`?H$NSI2JVF6%3LQRFBVE(K"185NBKH_GK1]-;6C./G
M2_#D1JQ0B7_X[T=(9_G[+RM)S#JI5UJ*S,WKK\0K$2RX`X&8Y,=;6RI\@`K:
M#F!7?GLL]WR<DM(!==)'6=)=^^@9>KPEY><'E21K*[CYBTY$B#VK=.4'2W/=
M2`-=![#,'L@S5=J<HP/J?\443A#C,Q\8A]RC4/PCJ3;`,CP6!>ISN/'1#WGQ
M:U@<0"%7BZ^6SJ*A1#Y.4"IGM$CJAE$>J;O<2&F16NF>HFB(X^6,'C5[!,_*
MGC\]40=:GEC=FVAWVJC3`!/:#JA\#X$O-NQ&C_9=P*>`S_A#BHHO>=13=6#T
MO(!C2+DT7A.'C,$@6L6,.TE>3Y/S?/GPHBG'QM1O[WG#LBYGP!,@UJF;D710
MO]P"-H=JZ/X9(B8'D-'XCI()!;,FH!N8[;=)YGCQ-LOU$!M#=2&E)CH;0TG5
M92Z'D)HI+8H,\!H8;?878Z8\F25\Y2GGG4S[AP/EOBA3>HM4/"/B..?X`E'H
MB@/DZ?N2ZHET`U*+%+NE_P3X+ZA$HLK?+2IRMHLM=0XN('/IO#A-;2"S:([Z
MX$ZA%\KM6O5'M/AT+=I+GUW;^BBR?H3/P9E?.(/;ILP"]D'R/3-7O<:UQE,L
M7;+FP:^F.\32^:QT15P_9&@!XVUOYT0()5&F&B^T19'U`^P&+54Q!]48\!I[
M::CL<@'51W0K"6H[@59TBU1IK@3I\E^M(O54]FASA:`OSET".7VX@LJFFTH"
M>W3XS+..W*QHYZGV0?'<_,V4O@,-*G>C07R+=L6>W$;"&$[M/MS7[64UASG-
M;D304/Y`K:+_*NY(J[H4S;[&E5W15G'O#["Q6_L,,6_'/I\`#[T9PDCPBWUG
M2:"))^C?I(\)RKJV)>]'6NB`\8G9#/"?_P]02P$"'@,4````"`#C<Y!".T'U
M3NL'`0""ZPT`$``8```````!````I($`````<WEN+3(P,3(Q,C,Q+GAM;%54
M!0`#Z9AM475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.-SD$)$W64G7PP`
M`$FI```4`!@```````$```"D@34(`0!S>6XM,C`Q,C$R,S%?8V%L+GAM;%54
M!0`#Z9AM475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.-SD$+):[PR`D,`
M`+S-!``4`!@```````$```"D@>(4`0!S>6XM,C`Q,C$R,S%?9&5F+GAM;%54
M!0`#Z9AM475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.-SD$+088N9^X@`
M`$<!"``4`!@```````$```"D@3)8`0!S>6XM,C`Q,C$R,S%?;&%B+GAM;%54
M!0`#Z9AM475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.-SD$*NXR3.2E``
M`,WS!0`4`!@```````$```"D@7OA`0!S>6XM,C`Q,C$R,S%?<')E+GAM;%54
M!0`#Z9AM475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.-SD$+;WQ(]%Q<`
M`*PF`0`0`!@```````$```"D@1,R`@!S>6XM,C`Q,C$R,S$N>'-D550%``/I
HF&U1=7@+``$$)0X```0Y`0``4$L%!@`````&``8`%`(``'1)`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EK6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding,Begining Balance</a></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="nump">2,539,091<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
        <td class="nump">2,075,000<span></span></td>
        <td class="nump">557,002<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
        <td class="num">(374,851)<span></span></td>
        <td class="num">(23,333)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited</a></td>
        <td class="num">(225,413)<span></span></td>
        <td class="num">(93,750)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding,Ending Balance</a></td>
        <td class="nump">4,453,746<span></span></td>
        <td class="nump">2,979,010<span></span></td>
        <td class="nump">2,539,091<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Balance exercisable</a></td>
        <td class="nump">2,891,877<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Balance</a></td>
        <td class="nump">$ 1.34<span></span></td>
        <td class="nump">$ 1.32<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Granted</a></td>
        <td class="nump">$ 2.21<span></span></td>
        <td class="nump">$ 1.26<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Excercised</a></td>
        <td class="nump">$ 0.34<span></span></td>
        <td class="nump">$ 0.57<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Forfeited or expired</a></td>
        <td class="nump">$ 2.37<span></span></td>
        <td class="nump">$ 0.59<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price per Share, Balance outstanding</a></td>
        <td class="nump">$ 1.78<span></span></td>
        <td class="nump">$ 1.34<span></span></td>
        <td class="nump">$ 1.32<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
        <td class="nump">$ 1.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">6 years 5 months 5 days<span></span></td>
        <td class="text">6 years 0 months 4 days<span></span></td>
        <td class="text">6 years 11 months 19 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
        <td class="text">5 years 8 months 16 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding,Begining Balance</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 1,028,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding,Ending Balance</a></td>
        <td class="nump">1,308,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,028,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Excisable</a></td>
        <td class="nump">1,160,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value of options granted</a></td>
        <td class="nump">$ 4,467,984<span></span></td>
        <td class="nump">$ 609,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
        <td class="nump">$ 2.15<span></span></td>
        <td class="nump">$ 1.09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c), d(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(d)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph c(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph d(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(b)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(1)(a)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Held-to-maturity Securities [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0in 0in 0pt;"><font size="2" style="font-family:times new roman,times">During the year ended December 31, 2011, the Company held investments in marketable securities that were classified as held to maturity and consisted of corporate bonds and certificates of deposits as follows <i>(in thousands)</i> :</font></p>
<p style="text-align: justify; text-indent: 0.5in; margin: 0in 0in 0pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<table style="width: 70%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0">
<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;">
<td style="padding: 0in;" valign="bottom" nowrap="nowrap">
<p style="text-align: justify;" class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; padding-top: 0in;" valign="bottom" nowrap="nowrap">
<p class="msonormal"><font size="2" style="font-family:times new roman,times"><b>&#160;</b></font></p>
</td>
<td style="border-bottom: black 1pt solid; border-left: medium none; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom" colspan="2" nowrap="nowrap">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times"><b>December 31, 2011</b></font></p>
</td>
<td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; padding-top: 0in;" valign="bottom" nowrap="nowrap">
<p class="msonormal"><font size="2" style="font-family:times new roman,times"><b>&#160;</b></font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 1;">
<td style="width: 72%; background: #ccffcc; padding: 0in;" valign="bottom" width="72%">
<p style="text-align: justify;" class="msonormal"><font size="2" style="font-family:times new roman,times">Purchase of short-term investments</font></p>
</td>
<td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">$</font></p>
</td>
<td style="width: 25%; background: #ccffcc; padding: 0in;" valign="bottom" width="25%">
<p align="right" style="text-align: right;" class="msonormal"><font size="2" style="font-family:times new roman,times">(4,370</font></p>
</td>
<td style="width: 1%; background: #ccffcc; padding: 0in;" valign="bottom" width="1%">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">)</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 2;">
<td style="background: white; padding: 0in;" valign="bottom">
<p style="text-align: justify;" class="msonormal"><font size="2" style="font-family:times new roman,times">Amortization of premium on investments</font></p>
</td>
<td style="background: white; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="background: white; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="background: white; padding: 0in;" valign="bottom">
<p align="right" style="text-align: right;" class="msonormal"><font size="2" style="font-family:times new roman,times">57</font></p>
</td>
<td style="background: white; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 3;">
<td style="background: #ccffcc; padding: 0in;" valign="bottom">
<p style="text-align: justify;" class="msonormal"><font size="2" style="font-family:times new roman,times">Proceeds from short-term investments</font></p>
</td>
<td style="background: #ccffcc; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="background: #ccffcc; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="background: #ccffcc; padding: 0in;" valign="bottom">
<p align="right" style="text-align: right;" class="msonormal"><font size="2" style="font-family:times new roman,times">4,293</font></p>
</td>
<td style="background: #ccffcc; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 4;">
<td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom">
<p style="text-align: justify;" class="msonormal"><font size="2" style="font-family:times new roman,times">Loss on sale of short-term investments</font></p>
</td>
<td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="border-bottom: black 1pt solid; border-left: medium none; background: white; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="border-bottom: black 1pt solid; border-left: medium none; background: white; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom">
<p align="right" style="text-align: right;" class="msonormal"><font size="2" style="font-family:times new roman,times">20</font></p>
</td>
<td style="padding-bottom: 1pt; padding-left: 0in; padding-right: 0in; background: white; padding-top: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 5; mso-yfti-lastrow: yes;">
<td style="padding-bottom: 2.5pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom">
<p style="text-align: justify;" class="msonormal"><font size="2" style="font-family:times new roman,times">Fair value</font></p>
</td>
<td style="padding-bottom: 2.5pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="border-bottom: black 2.25pt double; border-left: medium none; background: #ccffcc; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">$</font></p>
</td>
<td style="border-bottom: black 2.25pt double; border-left: medium none;
 background: #ccffcc; border-top: medium none; border-right: medium none; padding: 0in;" valign="bottom">
<p align="right" style="text-align: right;" class="msonormal"><font size="2" style="font-family:times new roman,times">-</font></p>
</td>
<td style="padding-bottom: 2.5pt; padding-left: 0in; padding-right: 0in; background: #ccffcc; padding-top: 0in;" valign="bottom">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
</tr>
</table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EstimatedUsefulLifeOfAssetsTableTextBlock', window );">Estimated Useful Life Of Assets [Table Text Block]</a></td>
        <td class="text"><p style="text-align: justify; margin: 0in 0in 0pt;"><font size="2" style="font-family:times new roman,times">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</font></p>
<p style="text-indent: 0.5in; margin: 0in 0in 0pt;"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
<div align="center">
<table style="width: 70%; border-collapse: collapse; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;" class="msonormaltable" border="0" cellspacing="0" cellpadding="0">
<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;">
<td style="border-bottom: black 1pt solid; border-left: medium none; width: 49%; border-top: medium none; border-right: medium none; padding: 0in;" valign="top" width="49%" nowrap="nowrap">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times"><b>Asset&#160;Description</b></font></p>
</td>
<td style="width: 4%; padding: 0in;" valign="top" width="4%" nowrap="nowrap">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="border-bottom: black 1pt solid; border-left: medium none; width: 47%; border-top: medium none; border-right: medium none; padding: 0in;" valign="top" width="47%" nowrap="nowrap">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times"><b>Estimated&#160;Useful&#160;Life</b></font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 1;">
<td style="padding: 0in;" valign="top">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">Office equipment and furniture</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">3-5&#160;&#160;years</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 2;">
<td style="padding: 0in;" valign="top">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">Laboratory equipment</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">7-10 years</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 3;">
<td style="padding: 0in;" valign="top">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">Manufacturing equipment</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">10 years</font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 4; mso-yfti-lastrow: yes;">
<td style="padding: 0in;" valign="top">
<p class="msonormal"><font size="2" style="font-family:times new roman,times">Leasehold improvements and fixtures</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">&#160;</font></p>
</td>
<td style="padding: 0in;" valign="top">
<p align="center" style="text-align: center;" class="msonormal"><font size="2" style="font-family:times new roman,times">Lesser of estimated useful or life of lease</font></p>
</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EstimatedUsefulLifeOfAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of estimated useful life of assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_EstimatedUsefulLifeOfAssetsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6435544&amp;loc=d3e41834-113960<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7512638&amp;loc=d3e5086-111524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 137<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27232-111563<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27337-111563<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27405-111563<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 320<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6872113&amp;loc=d3e27290-111563<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_HeldToMaturitySecuritiesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
